<SEC-DOCUMENT>0000950123-21-015753.txt : 20220114
<SEC-HEADER>0000950123-21-015753.hdr.sgml : 20220114
<ACCEPTANCE-DATETIME>20211119152256
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-21-015753
CONFORMED SUBMISSION TYPE:	DRS/A
PUBLIC DOCUMENT COUNT:		33
FILED AS OF DATE:		20211119
<PUBLIC-REL-DATE>20220114
DATE AS OF CHANGE:		20211119

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arcellx, Inc.
		CENTRAL INDEX KEY:			0001786205
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				472855917
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-03146
		FILM NUMBER:		211428141

	BUSINESS ADDRESS:	
		STREET 1:		25 WEST WATKINS MILL ROAD
		STREET 2:		SUITE A
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
		BUSINESS PHONE:		240-723-6641

	MAIL ADDRESS:	
		STREET 1:		25 WEST WATKINS MILL ROAD
		STREET 2:		SUITE A
		CITY:			GAITHERSBURG
		STATE:			MD
		ZIP:			20878
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS/A
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS/A</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Amendment No. 2 to Draft Registration Statement, as confidentially submitted to the Securities and
Exchange Commission on November&nbsp;19, 2021. </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>This draft registration statement has not been publicly filed with the Securities and
Exchange Commission </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>and all information herein remains strictly confidential. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right"><B>Registration No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B><I>THE SECURITIES ACT OF 1933
</I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>ARCELLX, INC. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Exact name of Registrant as
specified in its charter) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2836</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">47-2855917</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7.5pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction of<BR>incorporation or organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Primary Standard Industrial<BR>Classification Code Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification Number)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>25 West Watkins Mill Road, Suite A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Gaithersburg, MD 20878 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(240) <FONT
STYLE="white-space:nowrap">327-0603</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of Registrant&#146;s
principal executive offices) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Rami Elghandour </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>President, Chief Executive
Officer and Chairman of the Board of Directors </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Arcellx, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>25 West Watkins Mill Road, Suite A </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Gaithersburg, MD 20878 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(240) <FONT
STYLE="white-space:nowrap">327-0603</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7.5pt; font-family:ARIAL" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for
service) </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Dan Koeppen <BR>Megan J. Baier</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Jennifer Fang</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Wilson Sonsini
Goodrich&nbsp;&amp; Rosati, P.C.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>1301 Avenue of the Americas</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>40<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> Floor</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>New York, New York 10019</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(212) <FONT
STYLE="white-space:nowrap">999-5800</FONT></B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Lisa Firenze</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Jeffries L. <FONT STYLE="white-space:nowrap">Oliver-Li</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Wilmer Cutler Pickering Hale and Dorr LLP</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>7
World Trade Center</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>250 Greenwich Street</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>New York, New York 10007</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(212) <FONT
STYLE="white-space:nowrap">230-8800</FONT><BR></B></P></TD></TR>
</TABLE>  <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Approximate date of commencement of proposed sale to the public:</B> As soon as practicable after the effective date of this
registration statement. </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If any of the securities being registered on this form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the
Securities Act of 1933, check the following box.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this form is filed to register additional
securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the
Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this form is a post-effective amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration
statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, smaller reporting company, or an emerging growth company. See the definitions of &#147;large
accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and &#147;emerging growth company&#148; in <FONT STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Exchange Act. </P>
<P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="16%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9744;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated</FONT> filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging growth company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-family:Times New Roman">&#9746;</FONT></TD></TR>
</TABLE>  <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman">&#9744;</FONT> </P>
<P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>CALCULATION OF REGISTRATION FEE </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>TITLE OF EACH CLASS OF</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES TO BE REGISTERED</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>PROPOSED<BR>MAXIMUM&nbsp;AGGREGATE</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>OFFERING&nbsp;PRICE<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>AMOUNT&nbsp;OF</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION&nbsp;FEE</B></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Common Stock, $0.001 par value per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Includes offering price of any additional shares of common stock that the underwriters have the option to purchase.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:ARIAL; " ALIGN="left">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of
1933, as amended. </P></TD></TR></TABLE> <P STYLE="margin-top:3pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>The Registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date
until the Registrant shall file a further amendment, which specifically states that this registration statement shall thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933, as amended, or until the
registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P> <P STYLE="font-size:3pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#c21128"><B>The information in this preliminary prospectus is not complete and may be changed. These
securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction
where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><FONT COLOR="#c21128">SUBJECT TO COMPLETION, DATED &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022 </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Shares </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g96c25.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are
offering &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock. This is our initial public offering of shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Prior to this offering, there has been no public market for our common stock. We estimate that the initial public offering price of our common stock will be between
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We intend to apply to list our common stock on the Nasdaq Global Market under the symbol
&#147;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; and a
&#147;smaller reporting company&#148; as defined under the federal securities laws and, as such, have elected to comply with certain reduced reporting requirements for this prospectus and may elect to do so in future filings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investing in our common stock involves a high degree of risk. Before buying any shares, you should read carefully the discussion of the material risks of investing
in our common stock under the heading &#147;Risk Factors&#148; starting on page&nbsp;12 of this prospectus. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities, or passed upon the accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER&nbsp;SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Initial Public Offering Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting Discounts and Commissions<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL; " ALIGN="left">See the section titled &#147;Underwriting&#148; beginning on page&nbsp;175 additional information regarding underwriter
compensation. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">Delivery of the shares of common stock is expected to be made on or about
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2022. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We have granted the underwriters an option for a period of 30 days to
purchase up to an additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock. If the underwriters exercise the option in full, the total underwriting discounts and commissions payable by us will be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and the total proceeds to us, before expenses, will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Joint Book-Running Managers </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="18%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:16pt">
<TD VALIGN="top"><B>Jefferies</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>SVB&nbsp;Leerink</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Barclays </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>William&nbsp;Blair</B></TD></TR>
</TABLE>   <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Prospectus dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. </P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_1">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_2">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_3">SUMMARY FINANCIAL DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_5">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_6">MARKET, INDUSTRY AND OTHER DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_7">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_8">DIVIDEND POLICY</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_9">CAPITALIZATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_10">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_12">MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_13">BUSINESS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_14">MANAGEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_15">EXECUTIVE COMPENSATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">149</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_16">CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">161</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_17">PRINCIPAL STOCKHOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_18">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">164</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_19">SHARES ELIGIBLE FOR FUTURE SALE</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">169</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_20">MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF OUR COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_21">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_22">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_23">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_24">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc129231_25">INDEX TO FINANCIAL STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Through and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022 (the 25th day after the date of this prospectus), all dealers
effecting transactions in these securities, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&#146;s obligation to deliver a prospectus when acting as an underwriter and with
respect to an unsold allotment or subscription. </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We and the underwriters have not authorized anyone to provide you any information other than that
contained in this prospectus, any amendment or supplement to this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no
assurance as to the reliability of, any other information that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the
information appearing in this prospectus is accurate only as of the date on the front cover of this prospectus. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">For investors outside of the United States: we have not and the underwriters have not done anything that would permit this offering or possession or distribution of
this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions
relating to, the offering of the shares of common stock and the distribution of this prospectus outside of the United States. </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>This summary highlights selected information contained elsewhere in this prospectus and is qualified in its entirety by the more detailed information and financial
statements included elsewhere in this prospectus. This summary does not contain all of the information that may be important to you and your investment decision. You should carefully read this entire prospectus, including the sections titled
&#147;Risk Factors,&#148; &#147;Special Note Regarding Forward-Looking Statements,&#148; &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations&#148; and our financial statements and related notes before
deciding to buy shares of our common stock. In this prospectus, unless context requires otherwise, references to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; &#147;Arcellx,&#148; or &#147;the company&#148; refer to Arcellx, Inc. and, where
appropriate, our subsidiary Subdomain, LLC. </I></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a
clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. We believe cell therapies are one of the forward pillars of medicine, and our
mission is to advance humanity by engineering cell therapies that are safer, more effective and more broadly accessible. Though cell therapies have shown benefits to date, cell therapies have historically been constrained to existing biologic
structures, which has limited their impact and opportunity. Our novel synthetic binding scaffold, the D-Domain, was engineered to overcome the limitations of traditional Chimeric Antigen Receptor T cells (CAR-Ts). Existing cell therapy solutions,
most of which use a biologic-based, single chain variable fragment (scFv) binding domain, tend to be beneficial to a limited segment of patients, often result in high toxicity, and have narrow applicability in treatable indications. We believe we
can overcome these limitations by engineering a new class of D-Domain powered autologous and allogeneic CAR-Ts, including classical single infusion CAR-Ts called ddCARs and dosable and controllable universal CAR-Ts called ARC-SparX, to address
hematologic cancers, solid tumors, and indications outside of oncology, such as autoimmune diseases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At the 2021 Annual Meeting of the American Society of
Hematology, we recently announced positive preliminary clinical results from our lead ddCAR product candidate, CART-ddBCMA, which is in Phase 1 development in relapsed or refractory (r/r) multiple myeloma (MM). Of the 24 patients who have been
dosed, 22 are evaluable for safety analysis and 19 are evaluable for efficacy analysis, based on follow-up of at least 1 and 3 months, respectively, following treatment. These evaluable patients comprised the dose escalation cohorts for the first
dose level (DL1) (n=6) and the second dose level (DL2) (n=6) and a dose expansion cohort of DL1 (safety n=10, efficacy n=7). The enrolled population has poor prognostic indicators. 19 patients were evaluable for cytogenetics and 17 (89%) had
high-risk features. The population received an average of five prior lines of therapy (with all patients having completed at least three prior lines). 9 out of 24 patients (38%) had extramedullary disease, and 10 of 24 (42%) had greater than 50%
bone marrow blasts. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Key highlights from our data are as follows: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">All 19 patients responded for a 100% overall response rate (ORR); </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">13 of 19 patients (68%) achieved complete response (CR) or stringent complete response (sCR), and an additional 3 patients
(16%) achieved very good partial response (VGPR); </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">16 of 19 patients (84%) have ongoing responses with the longest response over 21 months; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Only 1 of 22 patients (5%) and 2 of 22 patients (9%) patients have experienced grade 3 cytokine release syndrome (CRS) or
immune effector cell-associated neurotoxicity syndrome (ICANS), respectively; no patients experienced greater than grade 3 CRS or ICANS; and all CRS and ICANS incidents resolved using standard interventions. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">1 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe our clinical data validates that D-Domains can provide meaningful clinical benefits. Our D-Domain
platform consists of structurally unique binders that are small and stable. They can be consistently manufactured and easily modified to generate diverse libraries of proprietary target-binding domains. The small size and structure of our D-Domain
binders compared to other antigen binding domains used in CAR constructs, such as scFvs, are illustrated below. The unique properties of our D-Domain translate to a higher transduction efficiency, high surface expression, and low tonic signaling
properties which we believe will lead to cell therapies with improved lasting therapeutic benefit and reduced toxicity. Our D-Domain platform enables us to make a range of CAR-T therapies, including ddCARs and ARC-SparX, tailored to the complexities
of cancer. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g43p97.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe the preliminary results from our ongoing Phase 1 clinical trial of CART-ddBCMA demonstrate the potential for CART-ddBCMA
to be a best-in-class treatment for patients suffering from r/r MM. MM is the third most common hematological malignancy in the United States and Europe, with approximately 35,000 new cases diagnosed per year in the United States. There is currently
no cure for MM and patients typically have a life expectancy of approximately five years. In 2020, the size of the global MM market was approximately $18 billion. We estimate the current total addressable CAR-T market for r/r MM to be approximately
$10 billion based on the number of patients who are receiving third line treatments and beyond. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are preparing to initiate our iMMagine pivotal trial of
CART-ddBCMA in r/r MM in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; to provide safety and efficacy data to support a potential Biologics License Application (BLA) to the U.S. Food and Drug
Administration (FDA). We also intend to rapidly pursue clinical development of&nbsp;CART-ddBCMA in earlier lines of therapy through our iMMagine-2 clinical trial. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are also advancing our novel ARC-SparX programs, ACLX-001 in r/r MM and ACLX-002 in r/r acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS).
ARC-SparX are adaptable versions of ddCARs where the antigen-targeting region is located on a SparX protein that can be dosed separately from the ARC-T cells, our proprietary D-Domain based universal CAR-T cells that are designed to activate only
when bound to a SparX protein that is bound to an antigen on a cell. We believe that controlling ARC-T activation with SparX protein effectively separates the antigen-recognition and killing functions, which allows us to reduce toxicities.
Additionally, ARC-T cells can be dosed with different SparX proteins that target different antigens which can potentially address antigen heterogeneity, and thereby address harder to treat indications. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to initiate a Phase 1 clinical trial of ACLX-001, the first product candidate developed under our ARC-SparX platform, for the treatment of r/r MM in
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. ACLX-001 is immunotherapeutic combination composed of our ARC-T cells and SparX proteins that target BCMA. This trial is intended to establish an
ARC-SparX dosing regimen and prepare for ARC-SparX trials in expanded indications. Our lead ARC-SparX indication is AML/MDS, for which we have multiple SparX in development targeting different antigens. We plan to initiate the Phase 1 clinical trial
for ACLX-002, an ARC-SparX product candidate targeting CD123, for the treatment of AML/MDS in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and plan to initiate a Phase 1 clinical trial for another
ARC-SparX product candidate directed at another antigen associated with AML/MDS in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">2 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have built a broad and scalable pipeline that has positioned us to capitalize on the potential of our
proprietary platform technologies and achieve long-term growth and sustainability within the field of cell therapy. We believe our therapeutic approaches, ddCAR and ARC-SparX, will enable us to select mechanisms that are most appropriate for each
target and indication we may choose to pursue based on underlying disease biology and patient need, such as in solid tumors, including small cell lung cancer (SCLC) and hepatocellular carcinoma (HCC). We are also integrating AI-powered discovery and
computational tools to expand the applicability of our platforms. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have worldwide rights to all of our programs which are summarized in the pipeline chart below:
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g129231g03e76.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our D-Domain platform has broad potential utility for additional cell modalities, targets, therapeutic areas and applications and we
plan to expand our pipeline beyond hematologic and solid cancers to autoimmune disease, as well as to allogeneic cell types. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The recent availability of cell
therapy products, such as <FONT STYLE="white-space:nowrap">CAR-T</FONT> cells, introduced an unprecedented &#147;living therapeutic&#148; modality that offers benefits well beyond what previous oncology modalities offered. For the first time, these
therapeutics directly harness the strength of the patient&#146;s own immune system to significantly reduce, even potentially eradicate, tumors. While <FONT STYLE="white-space:nowrap">CAR-T</FONT> and other genetically modified cell therapies have
shown significant progress in extending the lives of patients who often have no other treatment options, there are limitations to their broader use, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Limited Long Term Efficacy</B>: FDA approved <FONT STYLE="white-space:nowrap">CAR-Ts</FONT> may offer higher response
rates compared to other available therapies, but efficacy as measured by the duration of response is highly variable. For example, of the patients with <FONT STYLE="white-space:nowrap">B-cell</FONT> lymphoma with high response rates, approximately
40% or fewer patients were in ongoing response at 18 months. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Significant Adverse Effects:</B> These cell therapies also have the potential to cause several adverse effects.
Uncontrolled cellular expansion and resulting side effects such as CRS, neurotoxicity and <FONT STYLE="white-space:nowrap">&#147;on-target,</FONT> <FONT STYLE="white-space:nowrap">off-tumor&#148;</FONT> toxicities stifle the broader use of these
therapies in several key ways. Specifically, they limit the number of patients that are eligible for treatment, relegate these therapies to later lines of treatment, preclude the use of these therapies in the
<FONT STYLE="white-space:nowrap">non-academic</FONT> and outpatient settings, and increase costs to patients, payers and providers due to the need for intensive care unit access when they are used. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">3 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Narrow Applicability:</B> Currently, <FONT STYLE="white-space:nowrap">CAR-T</FONT> and other genetically modified cell
therapies are utilized in only a few hematological oncology indications. Their activity in most tumors is primarily driven by a limited number of tumor specific antigen targets. Their utility is further limited by secondary resistance mechanisms
arising in the r/r settings, as well as the antigen heterogeneity that is characteristic of some of these diseases. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our mission is to advance
humanity by engineering cell therapies that are safer, more effective, and broadly accessible. We plan to achieve this goal by maximizing the impact of our proprietary <FONT STYLE="white-space:nowrap">D-Domain</FONT> binders, which enable <FONT
STYLE="white-space:nowrap">CAR-Ts</FONT> to have distinct advantages including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Promising Clinical Data</B><B>&#151;High ORR and Durable Responses</B>: In our ongoing Phase 1 clinical trial of
CART-ddBCMA, the ORR was 100% and the duration of response was promising with more than half of patients with r/r MM having ongoing responses for at least one year following treatment. We believe these results demonstrate the capability of <FONT
STYLE="white-space:nowrap">D-Domains</FONT> to not only effectively bind target antigens and drive <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell proliferation but also to efficiently kill substantial proportion of tumor cells. High cell surface
expression and low propensity for tonic signaling of D-Domains may enable more effective interactions between the CAR and the antigen as well as reduced T-cell exhaustion, which may explain the rapid and long-term responses observed in our Phase 1
clinical trial. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Potential Differentiated Safety Profile</B>: We believe the small and stable structure of the <FONT
STYLE="white-space:nowrap">D-Domain</FONT> enables a high transduction rate, resulting in a high proportion of cells expressing the CAR construct on the cell surface (CAR+ cells). A high proportion of CAR+ cells lowers the total number of T cells
required to be administered which we believe may yield a therapy with an improved toxicity profile, consistent with observations in the Phase 1 trial of CART-ddBCMA. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Opportunity to Treat a Broader Group of Cancer Patients</B>: We believe our Phase 1 clinical trial of CART-ddBCMA
underscores the capability to apply D-Domains across a wide variety of tumor antigen targets in the future. Based on the differentiation of the <FONT STYLE="white-space:nowrap">D-Domain,</FONT> and the breadth and depth of our <FONT
STYLE="white-space:nowrap">D-Domain</FONT> libraries, we believe we can expand to a broader group of patients, including those with heterogeneously expressed tumor antigen and antigen targets that might be difficult to target. We are currently
developing therapies within both our ddCAR and ARC-SparX platforms to treat a broad variety of indications, starting with r/r MM and AML/MDS, and, in the future, including solid tumors. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The foundation of our competitive advantage is our proprietary technology, clinical evidence, track record of execution, manufacturing success, and assembly of a proven
management team. We believe these advantages position us to achieve significant market share in a large and attractive market and to ultimately transform the cell therapy market, contributing to a significant advancement in medicine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Strategy </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our strategy to achieve our mission is as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Advance CART-ddBCMA to treat r/r MM patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Develop comprehensive ARC-SparX AML/MDS program; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Expand our pipeline to select solid tumor indications; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Apply our <FONT STYLE="white-space:nowrap">D-Domain</FONT> technology outside of autologous
<FONT STYLE="white-space:nowrap">CAR-T</FONT> solutions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Enable greater access to CAR-T therapy through clinical studies in broader patient populations that support improved
market access; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Invest in technologies that lower customer friction, increase capacity and improve responsiveness; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Leverage novel AI and machine learning technologies to drive our discovery efforts; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Opportunistically pursue strategic partnerships and collaborations to maximize the full potential of our platform.
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">4 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Team </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our team and
culture are critical to realizing our vision of reimagining cell therapy as one of the future pillars of medicine. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are led by a diverse team of executives with
significant experience in business, discovery, development, manufacturing, and commercialization of differentiated and novel therapies specifically in the fields of oncology, cell therapy and rare diseases. Rami Elghandour, our Chairman and Chief
Executive Officer, previously served as President and Chief Executive Officer at Nevro where he grew the company from a small private company to a publicly traded commercial organization with nearly $400&nbsp;million in revenue. Prior to Nevro,
Mr.&nbsp;Elghandour was an investor with Johnson&nbsp;&amp; Johnson Development Corporation where he led several investments, including Nevro&#146;s Series&nbsp;B financing. Our Chief Medical Officer, Dr.&nbsp;Chris Heery, an oncologist by training,
was the former Head of Clinical Trials Group for the Laboratory of Tumor Immunology and Biology at the National Cancer Institute, and previously served as Chief Medical Officer at Precision Biosciences and Bavarian Nordic. Our Chief Scientific
Officer, David Tice, PhD., has over 20 years of biopharmaceutical research and drug development experience in oncology including 18 years at MedImmune, the global biologics research and development unit of AstraZeneca. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have attracted a diverse and talented group of innovators and company builders to help us execute our strategy and to build a transformative cell therapy platform
company. Collectively, we are driven by our shared purpose and our values. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, we had &nbsp;&nbsp;&nbsp;&nbsp; employees and are committed to continuing to build and maintain a diverse and inclusive
organization. We believe focusing on diversity and inclusion is not only the right thing to do but is also a competitive advantage. We are purposeful in our efforts to seek and retain top diverse talent from underrepresented groups as reflected
throughout our organization: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Executives: &nbsp;&nbsp;&nbsp;&nbsp;% female; &nbsp;&nbsp;&nbsp;&nbsp;% diverse (defined as racial&nbsp;&amp; ethnic
representation); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Managers and Senior Scientists with managerial responsibilities: &nbsp;&nbsp;&nbsp;&nbsp;% female;
&nbsp;&nbsp;&nbsp;&nbsp;% diverse; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Professionals and Individual Contributor Scientific roles: &nbsp;&nbsp;&nbsp;&nbsp;% female; &nbsp;&nbsp;&nbsp;&nbsp;%
diverse. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commitment to diversity doesn&#146;t stop within the walls of our organization. With our mission of advancing humanity, we believe
in equitable access to healthcare. Inclusive research programs that encompass real-world patient populations can contribute to addressing racial inequality in healthcare. We are dedicated to expanding representation within our clinical trials. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also believe deeply in corporate social responsibility and being conscious stewards in our society. We are devoted to leveraging our science to make a positive
impact for the patient and local communities we serve. As our organization expands, we intend to grow our community involvement and outreach efforts, and establish our corporate brand as a force for good through corporate philanthropic, patient
advocacy, and employee volunteerism. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Key Investors and Our Financing History </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our team is further supported by a strong group of investors that share our commitment to reimaging cell therapy. Since our formation in December 2014, we have funded
our operations primarily with approximately $234.8&nbsp;million in gross cash proceeds from the sale and issuance of redeemable convertible preferred stock and convertible promissory notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Associated with Our Business </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ability to execute our business
strategy is subject to numerous risks, as more fully described in the section entitled &#147;Risk Factors&#148; immediately following this prospectus summary. These risks include, among others: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We have a limited operating history and have incurred significant losses since our inception, and we anticipate that we
will continue to incur losses for the foreseeable future, which makes it difficult to assess our future viability. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">5 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Even if this offering is successful, we will need substantial additional funding. If we are unable to raise capital when
needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and development programs, future commercialization efforts or employee headcount. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We currently generate no revenues from sales of any products and may never generate revenue or be profitable. Our product
candidates are in the early stages of development. We only recently began a clinical trial to test our first product candidate in humans. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our ddCAR and ARC-SparX platforms represent novel and unproven approaches to treatment, which makes it difficult to
predict the timing, results and costs of product candidate development and the likelihood of obtaining regulatory approval. In addition, we may experience difficulty in identifying appropriate target binding domains and fail to capitalize on product
candidates or indications that may be more profitable or for which there is a greater likelihood of success. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our ARC-SparX platform is highly dependent on the success of ACLX-001. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We rely on third parties to conduct our clinical trials and manufacture our product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Clinical development is a lengthy, expensive and uncertain process. Our clinical trials may fail to demonstrate adequate
safety and/or efficacy of any of our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may encounter substantial delays, including difficulties enrolling patients, in our clinical trials.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our product candidates may cause undesirable side effects or have other properties that could halt their clinical
development, prevent their regulatory approval, require expansion of the trial size, limit their commercial potential, or result in significant negative consequences. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Interim, preliminary or topline data from our clinical trials that we announce or publish from time to time may change as
more patient data become available. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Manufacturing genetically engineered products is complex and subject to both human and systemic risks. We or our
third-party manufacturers may encounter difficulties in production and sourcing and may be subject to variations and supply constraints of key components. Modifications in manufacturing may require additional studies and regulatory filings,
resulting in additional costs or delay. </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may receive unexpected or unfavorable feedback from FDA or foreign health authorities regarding satisfaction of safety,
purity and potency (including clinical efficacy), amongst other factors, all of which would prevent or delay regulatory approval and commercialization and potentially impact the development of our other product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will
suffer if we fail to compete effectively. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We expect to significantly expand our organization, including creating additional infrastructure to support our operations
as a public company and our growth as we advance our product candidates through clinical trials, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If we are unable to obtain and maintain sufficient intellectual property protection for our platform and our product
candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitive position may be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The price of our stock may be volatile, and you could lose all or part of your investment. Unstable market and economic
conditions may have serious adverse consequences on our business, financial condition and stock price. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our business is affected by the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and may be significantly
adversely affected as the pandemic continues or if other events out of our control disrupt our business or that of our third-party providers. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">6 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate Information </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
were incorporated in Delaware in December 2014 under the name &#147;Encarta Therapeutics, Inc.&#148; In January&nbsp;2016, we filed a certificate of amendment to change our name to &#147;Arcellx, Inc.&#148; Our principal executive offices are
located at 25 West Watkins Mill Road, Suite A, Gaithersburg, Maryland 20878. Our telephone number is (240) <FONT STYLE="white-space:nowrap">327-0603.</FONT> Our website address is www.arcellx.com. Information contained on, or that can be accessible
through, our website is not a part of this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We use the
name Arcellx, the Arcellx logo and other marks as trademarks in the United States and other countries. This prospectus contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience,
trademarks and trade names referred to in this prospectus, including logos, artwork and other visual displays, may appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or TM symbols, but such references are not intended to
indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#146; trade
names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Emerging Growth Company and
Smaller Reporting Company Status </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS
Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time that those standards apply to private companies. We have elected to use this extended transition
period for complying with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that we (i)&nbsp;are no longer an emerging growth company or (ii)&nbsp;affirmatively and
irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective
dates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act, we will remain an emerging growth company until
the earliest of (i)&nbsp;the last day of our first fiscal year in which we have total annual gross revenues of $1.07&nbsp;billion or more, (ii)&nbsp;the date on which we are deemed to be a &#147;large accelerated filer&#148; under the rules of the
SEC, (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the previous three years, or (iv)&nbsp;the last day of our fiscal year following the fifth
anniversary of the date of the completion of this offering. An emerging growth company may take advantage of specified reduced reporting requirements and is relieved of certain other significant requirements that are otherwise generally applicable
to public companies. As an emerging growth company, </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may present only two years of audited financial statements, plus unaudited condensed financial statements for any
interim period, and related Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations in this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the
assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may provide reduced disclosure about our executive compensation arrangements; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may not require <FONT STYLE="white-space:nowrap">stockholder&nbsp;non-binding&nbsp;advisory</FONT> votes on executive
compensation or golden parachute arrangements. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have elected to take advantage of certain of the reduced disclosure obligations in the
registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different than you might
receive from other public reporting companies in which you hold equity interests. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">7 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are also a &#147;smaller reporting company,&#148; meaning that the market value of our stock held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700.0&nbsp;million and our annual revenue is less than $100.0&nbsp;million during the most
recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (1)&nbsp;the market value of our stock held by non-affiliates is less than $250.0&nbsp;million or (2)&nbsp;our annual revenue is less
than $100.0&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million. If we are a smaller reporting company at the
time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only
the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations
regarding executive compensation. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">8 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_2"></A>THE OFFERING </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Underwriters&#146; option to purchase additional shares </P></TD>
<TD>We have granted the underwriters an option for a period of 30 days to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Common stock to be outstanding immediately after this offering </P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:0%; font-size:9.5pt; font-family:ARIAL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares (or
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares if the underwriters exercise their option to purchase additional shares in full). </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Use of proceeds </P></TD>
<TD>We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, as follows: (1)&nbsp;to fund the development of our product candidates CART-ddBCMA, <FONT STYLE="white-space:nowrap">ACLX-001</FONT> and <FONT
STYLE="white-space:nowrap">ACLX-002</FONT> and (2)&nbsp;for other research and development activities, working capital and other general corporate purposes. See the section titled &#147;Use of Proceeds&#148; for more information. </TD></TR></TABLE>
 <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Risk factors </P></TD>
<TD>See the section of this prospectus titled &#147;Risk Factors&#148; beginning on page&nbsp;12 and other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in shares of our
common stock. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Proposed Nasdaq trading symbol </P></TD>
<TD></TD></TR></TABLE>   <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of shares of our common stock to be outstanding after this offering is based on the 139,218,480 shares of our common stock
outstanding as of September 30, 2021 (including an aggregate of 136,422,468 shares of common stock issuable upon conversion of our outstanding redeemable convertible preferred stock as of September 30, 2021), and excludes the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">28,795,570 shares of common stock issuable upon exercise of options to purchase shares of our common stock outstanding as
of September 30, 2021, at a weighted-average exercise price of $0.95 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">An award of restricted stock units covering 5,244,329 shares of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock issuable upon exercise of
options to purchase shares of our common stock that we granted after September 30, 2021, at a weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock reserved for future
issuance under our 2017 Equity Incentive Plan, as amended (2017 Plan), which shares will be added to the shares to be reserved under our 2022 Equity Incentive Plan (2022 Plan) upon its effectiveness; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock reserved for future
issuance under our 2022 Plan, which will become effective on the business day immediately prior to the date of effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of
shares of common stock reserved for future issuance under this plan; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock reserved for issuance
under our 2022 Employee Stock Purchase Plan (2022 ESPP), which will become effective on the business day immediately prior to the date of effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic
increases in the number of shares of common stock reserved for future issuance under this plan. </P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise indicated, this prospectus
reflects and assumes the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">No exercise of outstanding options after September 30, 2021; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">No exercise by the underwriters of their option to purchase additional shares of common stock from us in this offering;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The conversion of all outstanding shares of our redeemable convertible preferred stock into shares of our common stock,
which will occur upon the closing of this offering; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The filing and effectiveness of our amended and restated certificate of incorporation and the effectiveness of our amended
and restated bylaws, which will occur immediately after the closing of this offering. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">9 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_3"></A>SUMMARY FINANCIAL DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following tables summarize our financial data for the periods and as of the dates indicated. We have derived the consolidated statement of operations data for the
years ended December&nbsp;31, 2019 and 2020 from our audited consolidated financial statements included elsewhere in this prospectus. We have derived the condensed consolidated statement of operations data for the nine months ended September 30,
2020 and 2021 and the condensed consolidated balance sheet data as of September&nbsp;30, 2021 from our unaudited condensed consolidated financial statements included elsewhere in this prospectus. We have prepared the unaudited condensed consolidated
financial statements on the same basis as the audited consolidated financial statements and have included all adjustments that, in management&#146;s opinion, are necessary to state fairly the information set forth in those condensed consolidated
financial statements. Our historical results are not necessarily indicative of results that may be expected in the future and our results for the nine months ended September&nbsp;30, 2021 are not necessarily indicative of the results that may be
expected for the full year ending December&nbsp;31, 2021 or any other period. You should read the following summary financial data together with our financial statements and the related notes included elsewhere in this prospectus and the information
in the section titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; The summary financial data in this section are not intended to replace, and are qualified in their entirety by, our
consolidated financial statements and related notes thereto included elsewhere in this prospectus. </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">(in thousands, except share and per share<BR>amounts)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Statement of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;23,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;44,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;17,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;32,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,002</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,096</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,002</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(44,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other comprehensive loss:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unrealized loss on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,002</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(44,304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15.39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20.38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted-average common shares outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,508,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,327,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,167,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,574,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net loss per share, basic and diluted
(unaudited)<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.37</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.54</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted-average shares used in computing pro forma net loss per share, basic and diluted (unaudited)<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,860,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,354,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR></TABLE>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The unaudited pro forma net loss per share for the year ended December 31, 2020 and the nine months ended September 30, 2021 was computed using the weighted-average number of shares of common stock outstanding,
including the pro forma effect of the conversion of all outstanding shares of our redeemable convertible preferred stock into shares of common stock, as if such conversion had occurred on the later of the beginning of each period or the issuance
date of the convertible preferred stock. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">10 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF SEPTEMBER 30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO<BR>FORMA <SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA&nbsp;AS<BR>ADJUSTED&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(in&nbsp;thousands)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">61,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">61,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">233,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(109,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(109,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(103,795</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">129,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The pro forma balance sheet data gives effect to (a)&nbsp;the conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate of 136,422,468 shares of common stock, and (b)&nbsp;the
filing of our amended and restated certificate of incorporation, each of which will occur upon the closing of this offering. </TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Reflects the pro forma adjustments described in footnote (1)&nbsp;above and the issuance and sale of shares of common stock in this offering at the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and
estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the price range set forth on
the cover page of this prospectus, would increase (decrease) the pro forma as adjusted amount of each of cash and cash equivalents, total assets, and total stockholders&#146; (deficit) equity by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting estimated underwriting
discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1.0&nbsp;million shares in the number of shares offered by us at the assumed initial public offering price after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us would increase (decrease) each of cash and cash equivalents, total assets, and total stockholders&#146; (deficit) equity by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. The pro forma information discussed above is illustrative only and will be adjusted based on the actual initial public offering price and other terms of our initial
public offering determined at pricing. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">11 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information in this
prospectus, including our financial statements and the related notes and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations,&#148; before deciding whether to invest in our common stock. The occurrence of
any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our common stock could decline and you may lose all or part of your
investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks
Related to Our Limited Operating History, Financial Condition and Capital Requirements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have a limited operating history and have incurred significant
losses since our inception, and we anticipate that we will continue to incur losses for the foreseeable future, which makes it difficult to assess our future viability. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical-stage biopharmaceutical company with a limited operating history. Our operations to date have been limited to organizing and staffing our company,
business planning, raising capital, establishing and protecting our intellectual property portfolio, developing our D-Domain, ddCAR and ARC-SparX technologies, identifying potential new target antigens, developing product candidates and undertaking
research and development, including preclinical studies and clinical trials of our product candidates, all of which are biologics or biopharmaceuticals and require approval under a Biologics License Application (BLA). We have not yet demonstrated
our ability to successfully initiate and complete any large-scale or pivotal clinical trials, obtain marketing approvals, manufacture commercial-scale product, or conduct sales and marketing activities necessary for successful product
commercialization. As a result, it may be more difficult for you to accurately predict our future success or viability than it could be if we had a longer operating history or were closer to commercialization. In addition, as a young business, we
may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown challenges that may adversely affect our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have no
products approved for commercial sale and have not generated any revenue to date, and we continue to incur significant research and development and other expenses related to our ongoing operations. We have incurred losses in each period since our
inception in December 2014. Our net losses were $18.0&nbsp;million and $32.1&nbsp;million for the years ended December&nbsp;31, 2019 and 2020, respectively, and $23.0&nbsp;million and $44.3&nbsp;million for the nine months ended September&nbsp;30,
2020 and 2021, respectively. As of September&nbsp;30, 2021, we had an accumulated deficit of $109.4&nbsp;million. We expect to continue to incur significant losses for the foreseeable future, and we expect these losses to increase as we advance our
product candidates through preclinical studies and clinical trials; continue to discover and develop additional product candidates and expand our pipeline; continue to develop our D-Domain, ddCAR and ARC-SparX platforms; maintain, expand, protect
and enforce our intellectual property portfolio; and hire additional personnel. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue, which we do not expect will
occur in the foreseeable future, as our product candidates are in preclinical or Phase 1 clinical development. Our prior and expected future losses have had and will continue to have an adverse effect on our stockholders&#146; equity and working
capital. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if this offering is successful, we will need to obtain substantial additional funding to complete the development of our product
candidates. </I></B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Investment in biopharmaceutical product development is highly risky because it entails substantial upfront capital expenditures and
significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. As our product candidates enter and advance through preclinical
studies and clinical trials, we will need substantial additional funds to expand our clinical, regulatory, quality and manufacturing capabilities, whether internally or with third-party partners and collaborators, and advance our product candidates
through preclinical studies and clinical trials in order to obtain marketing approval. If we obtain marketing approval for any of our product candidates, we also expect to incur significant commercialization expenses related to marketing, sales,
manufacturing and distribution. Furthermore, upon the completion of this offering, we expect to incur additional costs associated with operating as a public company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">12 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate that our net proceeds from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;million, based on
an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp; per share of our common stock, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. We intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, to fund the development of our product candidates
CART-ddBCMA, <FONT STYLE="white-space:nowrap">ACLX-001</FONT> and <FONT STYLE="white-space:nowrap">ACLX-002</FONT> and for other research and development activities, expanding manufacturing capacity, working capital and other general corporate
purposes. Based on our current operating plan, we believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our planned operations for at least the next twelve months without the proceeds from this
offering, but our assumptions could prove to be wrong, and we could consume capital significantly faster than we expect, requiring us to seek additional funding sources sooner than planned, through public or private financings or other sources, such
as strategic collaborations. Such financing may result in dilution to stockholders, the imposition of burdensome debt covenants and repayment obligations or other restrictions that may affect our business. Our future capital requirements will depend
on many factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The scope, progress, timing, results and costs of developing and manufacturing our product candidates, and their
components, and conducting preclinical studies and clinical trials and other testing of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our ability to continue our business operations and product candidate research and development, and to adapt to any
changes in the regulatory approval process, manufacturing supply, or clinical trial requirements and timing due to the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and otherwise, including our ability to comply with new
regulatory guidance or requirements on conducting clinical trials during and after the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The costs, timing and outcome of regulatory review of any of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual
property rights and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our ability to establish and maintain strategic collaborations, licensing or other arrangements and the financial terms of
any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution,
for any of our product candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The extent to which our product candidates, if approved, can be offered by prescribers in various clinical settings,
including academic hospitals and community practices, the acceptance of our products, if and when approved, by patients, the medical community and third-party payors, and the revenue received from commercial sale of any products for which we receive
marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The effect of competing technologies and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The extent to which we acquire or invest in other businesses, products and technologies and any other licensing or
collaboration arrangements for any of our product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot be certain that additional funding will be available on acceptable terms,
or at all, especially in view of the widespread impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic (as further described under &#147;&#151;Risks Related to Our Business&#148;). If we are unable to raise additional capital in
sufficient amounts or on terms acceptable to us, we may have to decrease headcount and/or significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. We
could be required to seek collaborators for our product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable to us than might otherwise be available or relinquish or license on unfavorable terms our
rights to our product candidates in markets where we otherwise would seek to pursue development or commercialization ourselves. Any of the foregoing events could significantly harm our business, prospects, financial condition and results of
operations and cause the price of our common stock to decline. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we may seek additional capital due to strategic considerations even if we believe we
have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities,
which may adversely affect our ability to develop our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">13 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Development of Our Product Candidates </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our product candidates are in the early stages of development. We have no products approved for commercial sale and have only recently began clinical trials to
test our first product candidate in humans, which may make it difficult for you to evaluate our current business and predict our future success and viability. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are early in our development efforts. We are still developing our D-Domain, ddCAR and <FONT STYLE="white-space:nowrap">ARC-SparX</FONT> platforms, and conducting
drug discovery and preclinical studies for a number of product candidates while advancing our ongoing Phase 1 clinical trial for CART-ddBCMA. We have treated a small number of patients as of the date hereof and our clinical experience with our
initial product candidate is limited. We have not initiated clinical testing of any product candidates based on our <FONT STYLE="white-space:nowrap">ARC-SparX</FONT> platform. Because our product candidates are in an early stage of development,
there is a high risk of failure and we may never succeed in developing marketable products. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is a high failure rate for biopharmaceutical products
proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in later stage clinical trials even after achieving promising results in earlier stage clinical trials.
Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, regulatory delays or rejections may be encountered as a result of many factors,
including changes in regulatory policy during the period of product development. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because of the early stage of development of our product candidates, our ability
to eventually generate significant revenues from product sales will depend on a number of factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Identification of additional target antigens for desired indications; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Identification and development of D-Domain-based binding regions that bind to the desired target antigens;
</P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Successful completion of preclinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Submission of INDs or other regulatory applications for our planned clinical trials or future clinical trials and
authorizations from regulators to initiate clinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Successful enrollment in, and completion of, clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Achieving favorable results from clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Receipt of marketing approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Establishing and maintaining sufficient manufacturing capabilities, whether internally or with third parties, for clinical
and commercial supply; </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Establishing sales, marketing and distribution capabilities and launching commercial sales of our products, if and when
approved, whether alone or in combination with other products; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials and
commercialization activities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Effectively competing with other therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Developing and implementing successful marketing and reimbursement strategies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity for
our product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Maintaining a continued acceptable safety profile of any product following approval, if any. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we do not achieve one or more of these requirements in a timely manner, we could experience significant delays or an inability to successfully commercialize our
product candidates, which would materially harm our business. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot be certain that our clinical trials will be initiated and completed on time, if at all,
or whether our planned clinical strategy will be acceptable to the FDA or foreign health authorities. In addition, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic is still evolving, and it is impossible to predict the impact this
pandemic may have on the development of our product candidates, our preclinical studies and clinical trials, and our business. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To become and remain
profitable, we must develop, obtain approval for and eventually commercialize products, if approved, that generate significant revenue. We do not expect to receive approval of any product candidates for
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">14 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
many years and may never succeed in these activities. In addition, it is not uncommon for product candidates to exhibit unforeseen safety issues or inadequate efficacy when tested in humans
despite promising results in preclinical animal models or earlier trials, and we may ultimately be unable to demonstrate adequate safety and efficacy of our product candidates to obtain marketing approval. Even if we obtain approval and begin
commercializing one or more of our product candidates, we may never generate revenue that is significant or large enough to achieve profitability. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if we
succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development, manufacturing and other expenditures to develop and market additional product candidates. Our failure to become or
remain profitable would decrease the value of the company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our ddCAR and <FONT STYLE="white-space:nowrap">ARC-SparX</FONT> platforms represent novel and unproven approaches to treatment, which makes it difficult to
predict the timing, results and costs of product candidate development and the likelihood of obtaining regulatory approval. In addition, we may experience difficulty in identifying appropriate target binding domains. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have concentrated our research and development efforts on our ddCAR and <FONT STYLE="white-space:nowrap">ARC-SparX</FONT> platforms, and our future success depends
on the successful development of these platforms. Although there are other cell therapies and adapter platforms in clinical development, our platform technologies, including our D-Domain technology, have not been extensively tested over any
significant period of time. In addition, while we believe that&nbsp;our platforms may be capable of overcoming certain challenges faced by <FONT STYLE="white-space:nowrap">conventional&nbsp;CAR-T</FONT> therapies, we cannot be certain that our
approach will result in the intended benefits or will not result in unforeseen negative consequences over time. As an example, we may not be able to identify D-Domain binders that can recognize certain antigen targets that we would like to pursue,
or the development of the applicable D-Domain, ddCAR or SparX protein targeting such antigens may be too challenging or expensive to be commercially viable. We do not currently have any approved or commercialized products. As with other targeted
therapies, off-tumor or off-target activity could delay development or require us to reengineer or abandon a particular product candidate. There can be no assurance that any problems we experience in the future related to preclinical and clinical
development of our novel platforms and our product candidates will not cause significant delays or unanticipated costs or that such problems can be solved. We may also experience delays in developing sustainable, reproducible and scalable
manufacturing processes or transferring those processes to manufacturing partners or developing our own internal manufacturing capabilities, which may prevent us from completing our clinical trials or commercializing our product candidates on a
timely or profitable basis, if at all. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because cell therapies represent a relatively new field of cellular immunotherapy and cancer treatment generally, developing
and commercializing our product candidates subjects us to a number of risks and challenges, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Developing and deploying consistent and reliable processes for procuring a patient&#146;s apheresis material, engineering
a patient&#146;s T&nbsp;cells <I>ex vivo</I> and infusing the engineered T&nbsp;cells back into the patient; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Developing protocols for the safe administration of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Establishing integrated solutions in collaboration with specialty treatment centers and other clinical settings in order
to reduce the burdens and complex logistics commonly associated with the administration of T&nbsp;cell therapies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Conditioning patients with chemotherapy in conjunction with delivering each of our products, which may increase the risk
of adverse side effects of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Educating medical personnel about the administration of our product candidates, particularly if our clinical trials permit
expansion of participating physicians to those in various clinical settings; </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Educating medical personnel regarding the potential efficacy and safety profiles of our product candidates, as well as the
challenges, of incorporating our product candidates, if approved, into treatment regimens; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Sourcing, supplies for the materials used to manufacture and process our product candidates for clinical trials and, in
the future, commercial sale, if our product candidates are approved; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Developing reliable and scalable manufacturing processes; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Establishing adequate manufacturing capacity suitable for the manufacture of our product candidates in line with expanding
enrollment in our clinical studies and our projected commercial requirements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">15 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Achieving cost efficiencies in the scale-up of our manufacturing capacity; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Obtaining and maintaining regulatory approval from the FDA or other health authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Establishing sales and marketing capabilities to successfully launch and commercialize our product candidates if and when
we obtain any required regulatory approvals, and risks associated with gaining market acceptance of novel therapies if we receive approval; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Obtaining coverage and adequate reimbursement from third-party payors for our novel therapies in connection with
commercialization of any approved product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may not be able to successfully develop our product candidates, our technology or our
other product candidates in a manner that will yield products that are safe, effective, scalable or profitable. Additionally, because our technology involves the genetic modification of patient cells <I>ex vivo</I>, we are subject to additional
regulatory challenges and risks, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Regulatory requirements governing gene and cell therapy products have changed frequently and may continue to change in the
future; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Genetically modified products in the event of improper insertion of a gene sequence into a patient&#146;s chromosome could
lead to lymphoma, leukemia or other cancers, or other aberrantly functioning cells; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Although our viral vectors are not able to replicate, there is a risk with the use of lentiviral vectors that they could
lead to new or reactivated pathogenic strains of virus or other infectious diseases; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The FDA recommends a 15-year follow-up observation period for all patients who receive treatment using gene therapies, and
we may need to adopt such an observation period for our product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, public perception and awareness of cell therapy safety
issues may adversely influence the willingness of subjects to participate in clinical trials of our product candidates, or if approved, of physicians to prescribe our products. Physicians, hospitals and third-party payors often are slow to adopt new
products, technologies and treatment practices that require additional upfront costs and training. Treatment centers may not be willing or able to devote the personnel and establish other infrastructure required for the administration of CAR-T cell
therapies. Physicians may not be willing to undergo training to adopt this novel and personalized therapy, may decide the therapy is too complex to adopt without appropriate training and may choose not to administer the therapy. Based on these and
other factors, hospitals and payors may decide that the benefits of this new therapy do not or will not outweigh its costs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, in developing our product
candidates, we have not exhaustively explored different options in the design and method for manufacturing ddCARs, <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells and SparX proteins. Although we do not currently plan to change the structure of
our ddCARs, <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells or SparX proteins in the near term, we may in the future find our ddCARs, <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells or SparX proteins, or any manufacturing process thereof,
may be substantially improved with future design or process changes. Changes in product design and changes in the manufacturing process, equipment, or facilities may require further comparability analysis and approval by FDA before implementation,
which could delay our clinical trials and product candidate development, and could require additional clinical trials, including bridging studies, to demonstrate consistent and continued safety, identity, purity and efficacy. For example, we have
used a lentiviral vector to transduce the gene for the ddCAR and ARC constructs into patient T&nbsp;cells. In the future, we may find that another type of vector or other means of genetically modifying T&nbsp;cells may offer advantages, particularly
as we consider inserting our ddCARs and ARC-T&nbsp;cells into other immune cells. Changing how we genetically modify the immune cells would necessitate additional process development, comparability studies, regulatory filings and clinical testing
and delay existing product candidates. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the clinical trial requirements of the FDA and foreign health authorities and the criteria these
regulators use to determine whether a product candidate is acceptable for approval, can vary substantially according to the type, complexity, novelty and intended use and market of the potential products.
<FONT STYLE="white-space:nowrap">While&nbsp;CAR-T&nbsp;and</FONT> other cell therapy products have made progress in recent years, only a small number of products have been approved in the United States or other markets, which makes it difficult to
determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">16 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our ARC-SparX platform is highly dependent on the success of ACLX-001. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ARC-SparX platform, including our AML/MDS program, is highly dependent on the success of ACLX-001, the first product candidate based on our ARC-SparX platform.
ACLX-001 is an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA, or SPRX001, for the treatment of r/r MM. The ARC-T cells and the SparX proteins comprising ACLX-001 are entirely novel and neither has
been tested in humans. All SparX proteins are comprised of one or more antigen-specific binding domains fused to a protein that we refer to as the TAG. The TAG is a novel protein sequence derived from the 26kDA C-terminal fragment of human alpha
fetoprotein (hAFP) and also has never been tested in humans. The ARC-T cells are designed to have a binding domain that recognizes the TAG, which we refer to as anti-TAG. The anti-TAG has also never been tested in humans. There can be no assurance
that the ARC-T cells, the SparX proteins, the TAG, anti-TAG and other parts of ACLX-001 will not trigger an adverse response, cause unintended off-target recognition, limit the expected activity of the product candidates or result in other negative
outcomes. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, because all product candidates in our ARC-SparX platform use the ARC-T cells, a failure with ACLX-001 will increase the actual or perceived
likelihood that our other product candidates in the ARC-SparX platform will experience similar failures. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our Phase 1 trial of ACLX-001 is intended to serve as
clinical validation of our ARC-SparX platform as we seek to understand the pharmacokinetics, safety profile, and dosing strategy for future clinical development. Upon completion of the Phase&nbsp;1 trial, we will leverage the learnings from this
trial to advance our AML/MDS programs utilizing ARC-SparX and consider developing additional SparX for r/r MM for a broader pipeline in this disease area. If we do not successfully complete the Phase 1 trial for ACLX-001 in a timely manner or fail
to achieve favorable results from the trial, we may experience significant delays or other issues in advancing our other ARC-SparX product candidates including ACLX-002, AML-2, AML-3 and AML-4. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical development is a lengthy, expensive and uncertain process. Our clinical trials may fail to demonstrate adequate safety and/or efficacy of any of our
product candidates, which would prevent or delay regulatory approval and commercialization and potentially impact the development of our other product candidates. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before obtaining regulatory approvals for the commercial sale of our product candidates, including CART-ddBCMA, we must demonstrate through lengthy, complex and
expensive preclinical testing and clinical trials that our product candidates have adequate safety and efficacy profiles, and the manufactured drug product has quality attributes that are appropriate for use in humans. Clinical testing is expensive
and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during clinical development, and, because our product candidates are in an early stage of development, there is a high risk of failure and we
may never succeed in developing marketable products. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The results of preclinical studies and early clinical trials of our product candidates may not be
predictive of the results of later-stage clinical trials, particularly because early trials have smaller numbers of subjects tested. In addition, it is not uncommon for product candidates to exhibit unforeseen safety or efficacy issues, such as
immunogenicity, when tested in humans despite promising results in preclinical animal models. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any clinical trials that we may conduct may not demonstrate the
safety and efficacy profiles necessary to obtain regulatory approval to market our product candidates. As we continue developing our product candidates, serious adverse events, undesirable side effects, or unexpected characteristics may emerge,
causing us to abandon these product candidates or limit their development to more narrow uses or subpopulations in which the risk-benefit ratio is more acceptable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Treatment with our product candidates may cause side effects or adverse events that are unrelated to our product candidate but may still impact the success of our
clinical trials. The inclusion of patients with significant <FONT STYLE="white-space:nowrap">co-morbidities</FONT> in our clinical trials may result in deaths or other adverse medical events due to an underlying condition or other therapies or
medications that such patients may be using. As described above, any of these events could prevent us from obtaining regulatory approval or achieving or maintaining market acceptance and impair our ability to commercialize our product candidates.
Because the product candidates in our platforms share similar components, such as the D-Domain, a failure of one of our clinical trials may also increase the actual or perceived likelihood that our other product candidates will experience similar
failures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">17 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In some instances, there can be significant variability in safety and efficacy results between different clinical trials
of the same product candidate due to a variety of factors, including, but not limited to, changes in trial procedures set forth in protocols, differences in the size and type of the patient populations, changes in and adherence to the clinical trial
protocols and the rate of dropout among clinical trial participants. If our ongoing or future clinical trials are inconclusive with respect to the safety and efficacy of our product candidates, or if we encounter safety concerns associated with our
product candidates, we may: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Incur unplanned costs; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Be delayed in or prevented from obtaining marketing approval for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Obtain approval for indications or patient populations that are not as broad as intended or desired;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Obtain approval with labeling that includes significant restrictions on use or distribution or safety warnings including
boxed warnings; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Be subject to changes in the way the product is administered; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Be required to perform additional clinical trials to support approval or be subject to additional post-marketing
requirements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Have regulatory authorities withdraw their approval of the product or impose restrictions on its distribution in the form
of a modified Risk Evaluation and Mitigation Strategy (REMS); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Be subject to the addition of labeling statements, such as warnings or contraindications; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Be sued; and/or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Experience damage to our reputation. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, even if the trials are successfully completed, clinical data are often susceptible to varying interpretations and analyses, and we cannot guarantee that
the FDA or foreign health authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. We cannot guarantee that the FDA or foreign health authorities will view any of our
product candidates as having adequate safety and efficacy profiles even if favorable results are observed in these clinical trials, and we may receive unexpected or unfavorable feedback from the FDA or foreign health authorities regarding
satisfaction of safety, purity and potency (including clinical efficacy), amongst other factors. To the extent that the results of the trials are not satisfactory to the FDA or foreign health authorities for support of a marketing application,
approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product
candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may encounter substantial delays in our clinical trials. </I></B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. Events that may prevent successful or timely completion
of clinical development include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Delays associated with the <FONT STYLE="white-space:nowrap">COVID-19</FONT> global pandemic, as further described under
&#147;&#151;Risks Related to Our Business&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Delays in reaching a consensus with regulatory agencies on trial design; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Delays in reaching agreement on acceptable terms with prospective clinical research organizations (CROs), and clinical
trial sites and obtaining required institutional review board (IRB), approval at each clinical trial site; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Delays in recruiting and enrolling suitable patients to participate in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Failure to collect sufficiently viable white blood cells from patients, adequately expand or successfully transduce
sufficient number of patient T cells for infusion or otherwise manufacture product candidates, or infuse patients in a timely manner with product candidate; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Failure by our CROs, other third parties or us to adhere the trial protocol or the FDA&#146;s good clinical practices
(GCPs) or applicable regulatory guidelines in other countries; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or foreign health authorities for
violations of applicable regulatory requirements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical trial
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">18 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
sites, including due to a facility manufacturing any of our product candidates or any of their components being ordered by the FDA or foreign health authorities to temporarily or permanently shut
down due to violations of current good manufacturing practices (cGMPs) regulations or other applicable requirements, or infections or cross-contaminations of product candidates in the manufacturing process; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Delays in having patients complete participation in a trial or return for post-treatment
<FONT STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Clinical trial sites or patients dropping out of a trial or experiencing changing health or other conditions that require
removing them from the trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Discovering that product candidates have unforeseen safety issues, undesirable side effects or other unexpected
characteristics; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">To the extent that we conduct clinical trials in foreign countries, the failure of enrolled patients in foreign countries
to adhere to clinical protocol as a result of differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such
foreign countries; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Receiving untimely or unfavorable feedback from applicable regulatory authorities regarding the trial or requests from
regulatory authorities to modify the design of a trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Suspensions or terminations by IRBs or Data Safety Monitoring Boards (DSMBs) or internal clinical holds and/or clinical
holds from or by regulatory authorities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Lack of adequate funding to continue operations; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Changes in regulatory requirements and guidance that require amending or submitting new clinical protocols and/or
amendments to INDs. </P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any inability to successfully complete our clinical trials could result in additional costs to us or impair our ability
to raise capital, generate revenues from product sales and enter into or maintain collaboration arrangements. In addition, if we make material manufacturing changes to our product candidates or change manufacturers, we may need to conduct additional
bridging or comparability studies. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which
could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we encounter
delays or difficulties enrolling patients in our clinical trials and/or retention of patients in clinical trials, our clinical development activities could be delayed or otherwise adversely affected. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. The timely completion of clinical trials in accordance with their
protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the trial until completion of treatment and adequate <FONT STYLE="white-space:nowrap">follow-up.</FONT> The enrollment of patients depends
on many factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Inability to enroll, or delay in enrollment of, patients due to outbreaks and public health crises, such as the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> global pandemic, as further described under &#147;&#151;Risks Related to Our Business&#148;; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The patient eligibility criteria defined in the protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The perceived risks and benefits of the product candidate being studied; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The size of the patient population required for analysis of the trial&#146;s primary endpoints; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The proximity of patients to trial sites; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The design of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our ability to recruit clinical trial investigators with the appropriate competencies and experience;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our ability to obtain and maintain patient consent; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Reporting of the preliminary results of any of our clinical trials; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The risk that patients enrolled in clinical trials will drop out of the trials before completion of treatment and adequate
<FONT STYLE="white-space:nowrap">follow-up.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, our clinical trials will compete with other clinical trials for product
candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to
enroll in a trial </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">19 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
being conducted by one of our competitors. Since the number of qualified clinical investigation sites is limited, we expect to conduct some of our clinical trials at the same clinical trial sites
that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such clinical trial sites. Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our
ongoing and planned clinical trials, which could prevent completion or commencement of these trials and adversely affect our ability to advance the development of our product candidates. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interim, preliminary or topline data from our clinical trials that we announce or publish from time to time may change as more patient data become available and
are subject to audit and verification procedures that could result in material changes in the final data. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, we may publish interim,
preliminary or topline data from clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data
become available. Preliminary or topline data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary or topline data previously published. As a result, interim,
preliminary and topline data should be viewed with caution until the final data are available. Adverse differences between interim, preliminary or topline data and final data could significantly harm our reputation and business prospects. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, preliminary, interim and top-line data are subject to the risk that one or more of the clinical outcomes may materially change as more patient data become
available when patients mature on study, patient enrollment continues or as other ongoing or future clinical trials with a product candidate further develop. Past results of clinical trials may not be predictive of future results. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically more extensive information, and
you or others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed significant with respect to future decisions,
conclusions, views, activities or otherwise regarding a particular product candidate or our business. Similarly, even if we are able to complete our planned and ongoing preclinical studies and clinical trials of our product candidates according to
our current development timeline, the positive results from such preclinical studies and clinical trials of our product candidates may not be replicated in subsequent preclinical studies or clinical trial results. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in
early-stage development and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical and other nonclinical findings made while clinical trials were underway or safety or
efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical, nonclinical and clinical data are often susceptible to varying interpretations and analyses and many
companies that believed their product candidates performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or other regulatory approval. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our product candidates may cause undesirable side effects or have other properties that could halt their clinical development, prevent their regulatory approval,
require expansion of the trial size, limit their commercial potential, or result in significant negative consequences. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our product candidates involve
genetically modified T cell-based immunotherapies. A number of genetically modified cell therapies, such as <FONT STYLE="white-space:nowrap">CAR-based</FONT> products, have potentially severe side effects, including CRS and neurotoxicity, that can
escalate and require intensive medical intervention and result in injury or death to the patients. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is no guarantee that our product candidates will not
have side effects similar to those seen in other genetically modified cell therapies or that we will be able to prevent side effects from escalating to an unsafe level for our patients. Additionally, our initial product candidates are directed at
treating patients with r/r MM. These patients are often elderly and/or have significant <FONT STYLE="white-space:nowrap">co-morbidities,</FONT> and we expect they will receive our product candidate as a last line of therapy after most others
therapies have failed, and these patients may be particularly susceptible to safety and toxicity risks. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff, as toxicities resulting from T cell
therapy may be complicated and difficult to manage, which could </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">20 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
result in patient death or other significant issues. Additionally, it can be difficult to determine if the serious adverse or unexpected side effects were caused by the product candidate or
another factor, especially in oncology subjects who may suffer from other medical conditions and be taking other medications. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have designed a new binding
domain that we believe should have low immunogenicity because we also removed potentially immunogenic sequences from their binding domains, which we refer to as &#147;deimmunization.&#148; However, it has never been tested in humans outside of our
current Phase 1 trial and we cannot guarantee that there will not be any unexpected side effects from this binding domain or the SparX proteins that we plan to test as part of our product candidates. Although we have completed
multiple&nbsp;preclinical&nbsp;studies designed to screen for&nbsp;toxicity&nbsp;caused by unintended <FONT STYLE="white-space:nowrap">off-target</FONT> recognition <I>in vivo </I>by our novel binding domains, our product candidates may still cause
unintended <FONT STYLE="white-space:nowrap">off-target</FONT> recognition in patients. Additionally, our genetically modified <FONT STYLE="white-space:nowrap">T-cells,</FONT> the ddCARs and the ARC-T&nbsp;cells, may still bind targets other than the
target antigens or the TAG on our SparX proteins, respectively. If significant unexpected binding or <FONT STYLE="white-space:nowrap">off-target</FONT> binding occurs in normal tissue, our product candidates may target and kill the normal tissue in
a patient, leading to serious and potentially fatal adverse events, undesirable side effects,&nbsp;toxicities&nbsp;or other unexpected characteristics. Detection of any significant unexpected or <FONT STYLE="white-space:nowrap">off-target</FONT>
binding may halt or delay any ongoing clinical trials for our product candidates and prevent or delay regulatory approval. While we have developed a&nbsp;preclinical&nbsp;screening process to identify cross-reactivity of our product candidates, we
cannot be certain that this process will identify all potential <FONT STYLE="white-space:nowrap">off-target</FONT> tissue that our product candidates may interact with. Any unexpected or <FONT STYLE="white-space:nowrap">off-target</FONT> binding
that impacts patient&nbsp;safety&nbsp;could materially impact our ability to advance our product candidates into clinical trials and ability to proceed to marketing approval and commercialization. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If serious adverse events or undesirable side effects arise, we could be required to suspend, delay, or halt our clinical trials and regulatory authorities could deny
approval or require us to limit development of that product candidate to certain uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit
perspective. Undesirable side effects could also result in an expansion in the size of our clinical trials, increasing the expected costs and timeline of our clinical trials. Side effects that are observed during the trial, whether treatment related
or not, could also affect patient recruitment for future trials or the ability of enrolled patients to complete the trial or result in potential product liability claims. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, if serious adverse events or undesirable side effects are identified during development or after approval and are determined to be attributed to any of our
product candidates, we may be required to develop REMS to ensure that the benefits of treatment with such product candidate outweigh the risks for each potential patient, which may include, among other things, a communication plan to health care
practitioners, patient education, extensive patient monitoring or distribution systems and processes that are highly controlled, restrictive and more costly than what is typical for the industry. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any of these occurrences may harm our business, financial condition and prospects significantly. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Manufacturing genetically engineered products is complex and subject to both human and systemic risks. We or our third-party manufacturers may encounter
difficulties in production and sourcing and may be subject to variations and supply constraints of key components. If we or any of our third-party manufacturers encounter such difficulties, our ability to provide supply of our product candidates for
clinical trials or our products for patients, if approved, could be delayed or prevented. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The manufacture of biological drug products, such as ddCARs and
ARC-SparX, the components thereof, and the viral vectors used to manufacture these product candidates and components, is complex and requires significant expertise and capital investment, including the development of advanced manufacturing
techniques and process controls. Manufacturers of biologic products often encounter difficulties in production and sourcing, particularly in scaling up or out, validating the production process and assuring high reliability of the manufacturing
processes (including the absence of contamination), in light of variations and supply constraints of key components. These problems include logistics and shipping, difficulties with production costs and yields, quality control, including
consistency, stability, purity and efficacy of the product, product testing, operator error and availability of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if contaminants
are discovered in our supply of our product candidates or in the manufacturing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">21 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability, purity, and
efficacy failures, deficiencies, or other issues relating to the manufacture of our product candidates will not occur in the future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, our product
candidates are derived from cells collected from our patients and such cells may vary in type and quality as the patients may vary in age, stage of disease, and history of treatment among many other factors. We have strict specifications for the
patient cell material and the product candidates we manufacture, including certain specifications that are reviewed and approved by regulatory authorities. The patient cell material variability may exceed our manufacturing process capability or
deviate from the specified ranges, and result in failure in production of the patient therapy, lower quality batches, or even require adjustments to the specifications approved by authorities. The patient cell material may also be variable in
factors that we currently may not be detecting with the analytical methods used or may not know how to measure and we may discover failures with the material after production. We may not be able to deliver the quality and consistency of our cell
therapy products that we need or may need to re-collect cell material which can increase costs and/or cause delay, adversely impact patient outcomes and otherwise harm our clinical trials, reputation, business and prospects. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may fail to manage the logistics of collecting and shipping patient material to the manufacturing site and shipping the product candidate back to the relevant
parties and experience delays or shortages of certain clinical or commercial grade supplies and components. Logistical and shipment delays and problems caused by us, our vendors or other factors not in our control, including the pandemic, business
interruptions, global supply chain issues, and weather, could prevent or delay the delivery of product candidates to patients. Additionally, we have to maintain a complex chain of identity and chain of custody with respect to patient material as it
moves to the manufacturing facility, through the manufacturing processes and back to the patient. Failure to maintain chain of identity and chain of custody could result in patient death, loss of product or regulatory action. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Material modifications in the methods of product candidate manufacturing may result in additional costs or delay. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As product candidates progress from preclinical studies to late-stage clinical trials to marketing approval and commercialization, it is common that various aspects of
the development program, such as manufacturing methods, materials and processes, are altered along the way in an effort to optimize yield, manufacturing batch size, minimize costs and achieve consistent purity, identity, potency, quality and
results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and could affect planned or other clinical trials conducted with product
candidates produced using the modified manufacturing methods, materials, and processes. This could delay completion of clinical trials and could require <FONT STYLE="white-space:nowrap">non-clinical</FONT> or clinical bridging and comparability
studies, which could increase costs, delay approval of our product candidates and jeopardize our ability to commercialize our product candidates, if approved. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we or our third-party manufacturers use hazardous and biological materials in a manner that causes injury or violates applicable law, we may be liable for
damages. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological
materials, by our third-party manufacturers. We currently outsource all manufacturing to third parties, but we and our manufacturers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture,
storage, handling and disposal of medical and hazardous materials. Although we believe that our manufacturers&#146; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we cannot
completely eliminate the risk of contamination or injury resulting from medical or hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these
materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. We do not currently have any insurance for liabilities arising
from medical or hazardous materials. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our
business, prospects, financial condition or results of operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The process for treating cancer patients using T&nbsp;cell therapy is subject to human and
systemic risks. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;vein-to-vein&#148;</FONT></FONT> cycle for treating cancer
patients using T&nbsp;cell therapy typically takes approximately four to six weeks and involves a large number of steps and human participants. First, the patient&#146;s lymphocytes are isolated by </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">22 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
apheresis at the clinical site and shipped to the manufacturing site. Under cGMP conditions at the manufacturing site, the patient&#146;s lymphocytes are washed, and then enriched for <FONT
STYLE="white-space:nowrap">CD3-positive</FONT> T&nbsp;cells using specialized reagents. After overnight culture and T cell activation, the T&nbsp;cells are transduced using lentiviral vector transduction technology to introduce the CAR and ARC
genetic construct into the enriched T&nbsp;cell population. At the completion of T&nbsp;cell transduction, the T&nbsp;cells are expanded for several days, harvested, formulated into the final drug product and then cryopreserved for delivery to
patients. In the United States, samples of the final product are subjected to several release tests which must fulfill specified criteria for the drug product to be released for infusion. These include sterility, identity, purity, potency and other
tests. We are subject to stringent regulatory and quality standards in the course of a T&nbsp;cell therapy treatment process, and we cannot assure you that our quality control and assurance efforts will be successful or that the risk of human or
systemic errors in these processes can be eliminated. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Prior treatments can alter the cancer and negatively impact chances for achieving clinical activity
with our product candidates. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patients with hematological cancers typically receive highly toxic chemotherapy as their initial treatments that can impact
the viability of the T cells collected from the patient and may contribute to highly variable responses to <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell therapies. Patients could also have received prior therapies that target the same target
antigen on the cancer cells as our intended product candidate and thereby these patients may have cancer cells with low or no expression of the target antigen. As a result, our product candidates may not recognize the cancer cell and may fail to
achieve clinical activity. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be able to file additional INDs to commence additional clinical trials on the timelines we expect, and even if we
are able to, the FDA may not permit us to proceed. </I></B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to submit additional INDs for our current and future product candidates. However, our
timing for submitting these INDs is dependent on the results of further research. Additionally, we cannot be sure that submission of an IND will result in the FDA allowing further clinical trials to begin, or that, once clinical trials have begun,
issues will not arise that suspend or terminate such clinical trials. Additionally, even if the FDA agrees with the design and implementation of the clinical trials set forth in an IND, we cannot guarantee that the FDA will not change its
requirements in the future. These risks also apply to other clinical trials we may seek to commence under other INDs or amendments to existing INDs. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The
market opportunities for certain of our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small, and our projections regarding the size of the addressable market may be incorrect.
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are initially developing CART-ddBCMA as a last line therapy for patients with r/r MM with plans to pursue label expansion into earlier lines of therapy.
However, there is no guarantee that it, or any of our product candidates, even if approved, would be approved for earlier lines of therapy and any approved products may end up having a smaller market opportunity than we anticipated. Additionally,
our projections of both the number of people who have the cancers we are targeting, as well as the size of the subset patient population who have the potential to benefit from treatment with our product candidates, are based on our beliefs and
estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, or market research and may prove to be incorrect. Further, new studies may change the estimated
incidence or prevalence of these cancers. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. As a result, the number of patients may
turn out to be fewer than expected. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on
product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </I></B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because we have limited financial
and operational resources, we must prioritize our research programs and will need to focus our discovery and development on select product candidates and indications. Correctly prioritizing our research and development activities is particularly
important for us due to the breadth of potential product candidates and indications that we intend to utilize with our clinical development strategy. As a result, we may forego or delay pursuit of opportunities with other product candidates or for
other indications that later prove to have greater commercial potential. As an example, although we believe that targeting BCMA initially before targeting other antigens will help us validate our platforms more easily, the risks associated with MM
patients and the competition in cell therapies targeting BCMA, among others, could outweigh the benefits. Our resource allocation decisions may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">23 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
cause us to fail to capitalize on viable commercial products or profitable market opportunities. Our spending on current and future research and development programs and product candidates for
specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may also relinquish valuable rights to that product candidate
through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biopharmaceutical industry is characterized by intense competition and rapid innovation. Our competitors may be able to develop other products or drugs
that are able to achieve similar or better results or make it difficult for us to develop our product candidates on a timely basis by limiting our access to patients, clinical trial sites, manufacturers and other resources. Our competitors include
large and specialty pharmaceutical companies and biotechnology companies, academic research institutions and governmental agencies, and public and private research institutions. We believe the key competitive factors that will affect the development
and commercial success of our product candidates are safety, efficacy, ensuring consistent quality and purity of the product candidates, delivery, price and the availability of reimbursement from government and other third-party payors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We anticipate substantial direct competition from other organizations developing advanced <FONT STYLE="white-space:nowrap">CAR-T</FONT> or other types of genetically
modified cell therapies due to their promising clinical therapeutic effect in clinical trials, including 2seventy, Abbvie, Allogene, Amgen, Autolus, Bristol-Myers Squibb, Caribou Biosciences, Carsgen, Cellectis, Crispr, GSK, Innovent,
Johnson&nbsp;&amp; Johnson, Legend, Novartis, Pfizer, Poseida Therapeutics, Precision BioSciences, and Regeneron. In addition, we expect to also compete with companies developing: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">T cells with CARs that are reactive to tumor associated antigens; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">T cells with <FONT STYLE="white-space:nowrap">T-cell</FONT> receptors (TCRs) that are reactive to tumor associated
antigens; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">T-cells</FONT> with adapter platforms; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Bispecifics that bring T cells and diseased cells into close proximity with each other; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Other immune cells that can be targeted using antibodies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Natural killer (NK)-based cell therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><I>In vivo</I> CAR-T therapeutics; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Allogeneic cell therapies. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff, greater access to clinical
sites and patients, experienced regulatory, marketing and manufacturing teams and well-established sales forces. In addition, many of these competitors are active in seeking patent protection and licensing arrangements in anticipation of collecting
royalties for use of technology that they have developed. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Mergers and acquisitions in
the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater
availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective,
safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if we obtain regulatory approval of our product candidates, the availability and price of our competitors&#146; products could limit the demand and the price we
are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is inhibited by price competition or the reluctance of physicians to switch from existing methods of
treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances. For additional information regarding our competition, see
&#147;Business&#151;Competition.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">24 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Business </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our business is affected by the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and may be significantly adversely affected as the pandemic
continues or if other events out of our control disrupt our business or that of our third party providers. </I></B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While the extent of the impact of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business and financial results is uncertain, a continued and prolonged public health crisis such as the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic could have a material
negative impact on our business, financial condition and operating results. We have experienced and may in the future experience disruptions from <FONT STYLE="white-space:nowrap">COVID-19</FONT> to our business in a number of ways, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Delays in supply chain and manufacturing, including the closure of apheresis collection centers, suspension of cell
transport, limitations on transfer of technology, shutdown of manufacturing facilities and delays in delivery of supplies and reagents; </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Delays in discovery and preclinical efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Changes to procedures or shut down, or reduction in capacity, of clinical trial sites due to limited availability of
clinical trial staff, reduced number of inpatient intensive care unit beds for patients receiving cell therapies, diversion of healthcare resources away from clinical trials and other business considerations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Limited patient access, enrollment and participation due to travel restrictions and safety concerns, as well as housing
and travel difficulties for out of town patients and relatives; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Changes in regulatory and other requirements for conducting preclinical studies and clinical trials during the pandemic.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may be required to develop and implement additional clinical trial policies and procedures designed to help protect subjects from the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> virus. For example, in March 2020, the FDA issued a guidance on conducting clinical trials during the pandemic, which was updated in July 2020, January 2021 and August 2021. The guidance describes a number
of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical trial report (or as a separate document) contingency measures implemented to manage the trial and any disruption of the
trial as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; a list of all subjects affected by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic-related trial disruptions by unique subject identifier and by
investigational site and a description of how the individual&#146;s participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from
investigational product and/or trial, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the trial. In its most recent update to this guidance, the FDA addressed questions
received from clinical practitioners who are adapting their operations in a pandemic environment. These questions focused on, among other things, when to suspend, continue or initiate a trial and how to submit changes to protocols for INDs and
handle remote site monitoring visits. There is no assurance that this guidance governing clinical trials during the pandemic will remain in effect or, even if it does, that it will help address the risks and challenges enumerated above. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other potential impacts of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our ongoing clinical trial include patient dosing and trial monitoring,
which may be paused or delayed due to changes in policies at various clinical sites, federal, state, local or foreign laws, rules and regulations, including quarantines or other travel restrictions, prioritization of healthcare resources toward
pandemic efforts, including diminished attention of physicians serving as our clinical trial investigators and reduced availability of site staff supporting the conduct of our clinical trial, interruption or delays in the operations of the FDA, or
other reasons related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic
continues, other aspects of our ongoing clinical trial and future planned clinical trials may be adversely affected, delayed or interrupted, including, for example, site initiation, patient recruitment and enrollment, availability of clinical trial
materials, clinical trial site data monitoring and efficacy, safety and translational data collection, and data analysis. Some patients and clinical investigators may not be able to comply with clinical trial protocols and patients may choose to
withdraw from our trials or we may have to pause enrollment or we may choose to or be required to pause enrollment and/or patient dosing in our ongoing or planned clinical trials in order to preserve health resources and protect trial participants.
It is unknown how long these pauses or disruptions could continue. Patients may need to withdraw due to COVID-19 infections or experience increased adverse events and deaths in our clinical trials due to COVID-19 related infections, which may result
in increased complications due to immune suppression from our lymphodepletion regimen. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">25 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we currently rely on third parties to, among other things, manufacture raw materials, manufacture our
product candidates for our ongoing clinical trial, ship investigation drugs and clinical trial samples, perform quality testing and supply other goods and services to run our business. If any such third party in our supply chain for materials is
adversely impacted by effects from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, including staffing shortages, production slowdowns and disruptions in delivery systems, our supply chain may be disrupted and our costs could be
increased, limiting our ability to manufacture our product candidates for our ongoing clinical trial and planned future clinical trials and conduct our research and development operations as planned. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We previously closed our offices and requested that most of our personnel, including all of our administrative employees, work remotely, restricted <FONT
STYLE="white-space:nowrap">on-site</FONT> staff to only those personnel and contractors who must perform essential activities that must be completed <FONT STYLE="white-space:nowrap">on-site</FONT> and limited the number of staff in any given
research and development laboratory. Our increased reliance on personnel working from home may negatively impact productivity, or disrupt, delay, or otherwise adversely impact our business. In addition, this could increase our cyber security risk,
create data accessibility concerns, and make us more susceptible to communication disruptions, any of which could adversely impact our business operations or delay necessary interactions with local and federal regulators, ethics committees,
manufacturing sites, research or clinical trial sites and other important agencies and contractors. Further, we and our third-party service providers, including our CROs, the clinical trial sites, our manufacturers and suppliers, may experience
staffing shortages. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our employees and contractors conducting research and development activities may not be able to access our laboratory for an extended period of
time as a result of the closure of our offices and the possibility that governmental authorities further modify current restrictions. In addition, when our facilities are open, we could encounter delays in connection with implementing precautionary
measures to mitigate the risk of exposing our facilities and employees to COVID-19 or otherwise in connection with addressing an actual or potential exposure to COVID-19 (for example, temporarily closing all or a portion of a facility or
disinfecting all or a portion of a facility that may have been exposed to COVID-19). As a result, this could delay timely completion of preclinical activities, including completing IND/Clinical Trial Application (CTA)-enabling studies or our ability
to select future development candidates, and initiation of additional clinical trials for our other development programs. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Health regulatory agencies globally
may experience disruptions in their operations as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The FDA or foreign health authorities may have slower response times or be under-resourced to continue to monitor our
ongoing clinical trial and, as a result, review, inspection, and other timelines may be materially delayed. It is unknown how long these disruptions could continue, were they to occur. Any elongation or
<FONT STYLE="white-space:nowrap">de-prioritization</FONT> of our clinical trial or delay in regulatory review resulting from such disruptions could materially affect the development of our product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trading prices for shares of other biopharmaceutical companies have been highly volatile as a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic and following this offering the trading prices for shares of our common stock could also experience high volatility. As a result, we may face difficulties raising capital through sales of our common stock or such sales may be on unfavorable
terms. In addition, a recession, depression or other sustained adverse market event resulting from the spread of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> could materially and adversely affect our business and the value of our common
stock. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to evolve. The ultimate impact of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business operations is highly uncertain and subject to change and will depend on future developments, which cannot be accurately predicted, including the duration of the pandemic,
additional or modified government actions, and the actions taken to contain <FONT STYLE="white-space:nowrap">COVID-19</FONT> or address its impact, among others. We do not yet know the full extent of potential delays or impacts on our business, our
clinical trials, our research programs, healthcare systems or the global economy. We will continue to monitor the situation closely. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, our business
could be significantly adversely affected by other business disruptions to us or our third-party providers that could seriously harm our potential future revenue and financial condition and increase our costs and expenses. Our operations, and those
of our CROs, contract manufacturing organizations (CMOs) and other contractors, consultants, and third parties could be subject to other global pandemics, earthquakes, power shortages, telecommunications failures, water shortages, floods,
hurricanes, typhoons, fires, extreme weather </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">26 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
conditions, medical epidemics and other natural or <FONT STYLE="white-space:nowrap">man-made</FONT> disasters or business interruptions, for which we are predominantly self-insured. The
occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses. We rely on third-party manufacturers to produce and process our product candidates. Our ability to
obtain clinical supplies of our product candidates could be disrupted if the operations of these suppliers are affected by a <FONT STYLE="white-space:nowrap">man-made</FONT> or natural disaster or other business interruption. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As widely reported, global credit and financial markets have experienced volatility and disruptions recently including severely diminished liquidity and credit
availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability, and increased inflationary risk. There can be no assurance that further deterioration in credit and
financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions.
If the current equity and credit markets deteriorate, or do not improve, it may make any necessary equity or debt financing more difficult, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable
terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service
providers, manufacturers and other partners may not survive these difficult economic times, which could directly affect our ability to attain our operating goals on schedule and on budget. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of September&nbsp;30, 2021, we had cash, cash equivalents and marketable securities of $131.2&nbsp;million. While we are not aware of any downgrades, material
losses, or other significant deterioration in the fair value of our cash equivalents and marketable securities since September&nbsp;30, 2021, no assurance can be given that further deterioration of the global credit and financial markets would not
negatively impact our current portfolio of cash equivalents and marketable securities or our ability to meet our financing objectives. Furthermore, our stock price may decline due in part to the volatility of the stock market and the general
economic downturn. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we
may not be able to successfully implement our business strategy. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ability to compete in the highly competitive biotechnology and pharmaceutical
industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel. The loss of the services of any of our executive
officers, other key employees and other scientific and medical advisors, and an inability to find suitable replacements could result in delays in product development and harm our business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To induce valuable employees to remain at our company, in addition to salary and cash incentives, we have provided stock options that vest over time. The value to
employees of stock options that vest over time may be significantly affected by movements in our stock price that are beyond our control, and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our
efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements
provide for <FONT STYLE="white-space:nowrap">at-will</FONT> employment, which means that any of our employees could leave our employment at any time, with or without notice. Our success also depends on our ability to continue to attract, retain and
motivate highly skilled junior, <FONT STYLE="white-space:nowrap">mid-level</FONT> and senior managers as well as junior, <FONT STYLE="white-space:nowrap">mid-level</FONT> and senior scientific and medical personnel. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We expect to grow the size of our organization, and we may experience difficulties in managing this growth. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, we had &nbsp;&nbsp;&nbsp;&nbsp;
employees. As our development and commercialization plans and strategies develop, and as we transition into operating as a public company, we expect to need additional research, development, clinical, quality assurance, statistical analysis,
managerial, operational, sales, marketing, financial and other personnel, as well as additional facilities to expand our operations, including for in-house manufacturing capabilities. Future growth would impose significant added responsibilities on
members of management, including: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Identifying, recruiting, integrating, maintaining and motivating additional employees; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">27 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Managing our internal development efforts effectively, including the clinical and FDA review process for our product
candidates, while complying with our contractual obligations to contractors and other third parties; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Improving our operational, financial and management controls, reporting systems and procedures. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage any future growth,
and our management may have to divert a disproportionate amount of its attention away from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities in order to devote a substantial amount of time to
managing these growth activities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently rely and for the foreseeable future will continue to rely on certain independent organizations, advisors and/or
consultants to provide certain services, including regulatory advice, clinical trial support and drug product manufacturing. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be
available to us on a timely basis when needed and at a reasonable cost, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided
by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise advance our business. There can be no assurance
that we will be able to manage our existing consultants or find other competent contractors and consultants on economically reasonable terms, or at all. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do
intend to transition some regulatory, clinical trial execution, and manufacturing capabilities in-house, but in order to do so, will need to identify, recruit and build experienced teams. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, or we are not able to
effectively build out new facilities to accommodate this expansion, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research,
development and commercialization goals. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our internal computer systems, or those used by our third-party CROs or other contractors or consultants, may fail
or suffer security breaches, which could result in a material disruption of the development programs of our product candidates. </I></B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Despite the
implementation of security measures, our internal computer systems and those of our current and future CROs and other contractors and consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, and
telecommunication and electrical failures. While we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption
of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover
or reproduce the data. Likewise, we currently rely on third parties to manufacture our product candidates and to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our
business. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the development
and commercialization of our product candidates could be delayed. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our employees, independent contractors, consultants, commercial partners and vendors
may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business operations and
current and future relationships with investigators, health care professionals, consultants, third-party payors and customers will be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health
information privacy and security laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties. We are exposed to the risk of employee fraud or other
illegal activity by our employees, independent contractors, consultants, commercial partners, vendors and agents acting on behalf of us or our affiliates. Misconduct by these parties could include intentional, reckless and/or negligent conduct that
fails to: comply with the regulations of the FDA or foreign health authorities; provide true, complete and accurate information to the FDA or foreign health authorities; comply with manufacturing standards we have established; comply with healthcare
fraud and abuse laws in the United States and similar foreign fraudulent misconduct laws; or report financial information or data accurately or to disclose unauthorized activities to us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">28 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We will face increasing regulation as we advance our product candidates through clinical trials and pursue
commercialization, if approved. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we obtain FDA approval of any of our product candidates and begin commercializing those products in the United States,
our potential exposure under such laws and regulations will increase significantly, and our costs associated with compliance with such laws and regulations are also likely to increase. These laws may impact, among other things, our current
activities with principal investigators and research patients, as well as proposed and future sales, marketing and education programs. In particular, the promotion, sales and marketing of healthcare items and services, as well as certain business
arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting,
marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient
recruitment for clinical trials. The laws that may affect our ability to operate include, but are not limited to the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving,
offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or
recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The federal civil and criminal false claims laws, including the civil False Claims Act (FCA), that can be enforced by
private citizens through civil whistleblower or qui tam actions, prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent
or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government. No specific intent to defraud is required under the civil FCA. The criminal FCA provides for criminal penalties for submitting false
claims, including imprisonment and criminal fines. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Civil Monetary Penalty Act of 1981 and implementing regulations, which impose penalties against any person or entity
that, among other things, is determined to have presented or caused to be presented a claim to a federal healthcare program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent, or
offered or transferred remuneration to a federal healthcare beneficiary that a person knows or should know is likely to influence the beneficiary&#146;s decision to order or receive items or services reimbursable by the government from a particular
provider or supplier. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The federal Health Insurance Portability and Accountability Act of 1996 (HIPAA), which created new federal criminal
statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property
owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any
materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH), and their
respective implementing regulations, which impose requirements on certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates that perform services for them that involve the use,
or disclosure of, individually identifiable health information, relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The federal Physician Payment Sunshine Act, created under the Patient Protection and Affordable Care Act as amended by the
Health Care and Education Reconciliation Act of 2010, collectively, the Affordable Care Act (ACA), and its implementing regulations, which require applicable manufacturers of covered drugs, devices, biologicals and medical supplies for which payment
is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with certain exceptions) to report annually to the Centers for Medicare&nbsp;&amp; Medicaid Services (CMS) of the U.S. Department of Health and Human Services
(HHS) information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by
physicians and their immediate family members. Additionally, effective </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">29 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
January&nbsp;1, 2022, for data collected in 2021 and reported to CMS in 2022, such reporting obligations with respect to payments and transfers of value made in the previous year are expanded to
include the following <FONT STYLE="white-space:nowrap">non-physician</FONT> covered recipients: physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and anesthesiologist assistants, and
certified nurse-midwives. </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Additional requirements and regulations applicable to the distribution of pharmaceutical products, including extensive
record-keeping, licensing, price reporting, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. Pricing and rebate programs must also comply with the Medicaid rebate requirements of the U.S.
Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the ACA. If products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply.
Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that
potentially harm consumers. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, we are subject to state and foreign equivalents of each of the healthcare laws described above, among
others, some of which may be broader in scope and may apply regardless of the payor. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Effective upon the closing of this offering, we will adopt a code of business
conduct and ethics, but it is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in
protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Efforts to
ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or
future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those
actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal
healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In
addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not realize the benefits of any <FONT STYLE="white-space:nowrap">acquisitions,&nbsp;in-licenses&nbsp;or</FONT> strategic alliances that we enter into.
</I></B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the future, we may seek and form strategic alliances, create joint ventures or collaborations, or enter into acquisitions or additional licensing
arrangements with third parties that we believe will complement or augment our existing technologies and product candidates, including artificial intelligence, machine learning and other technology-based platforms that may supplement our discovery
efforts. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These transactions can entail numerous operational and financial risks, including exposure to unknown liabilities, disruption of our business and
diversion of our management&#146;s time and attention in order to manage a collaboration or develop acquired products, product candidates or technologies, incurrence of substantial debt or dilutive issuances of equity securities to pay transaction
consideration or costs, higher than expected collaboration, acquisition or integration costs, write-downs of assets or goodwill or impairment charges, increased amortization expenses, difficulty and cost in facilitating the collaboration or
combining the operations and personnel of any acquired business, impairment of relationships with key suppliers, manufacturers or customers of any acquired business due to changes in management and ownership and the inability to retain key employees
of any acquired business. As a result, if we enter into acquisition or <FONT STYLE="white-space:nowrap">in-license</FONT> agreements or strategic partnerships, we may not be able to realize the benefit of such transactions if we are unable to
successfully integrate them with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve
the revenue or specific net income that justifies such transaction or such other benefits that led us to enter into the arrangement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">30 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may become exposed to costly and damaging product liability claims, either when testing our product candidates in
the clinic or at the commercial stage, and our product liability insurance may not cover all damages from such claims. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We face an inherent risk of product
liability as a result of the clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to
be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product,
negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be
required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Decreased demand for our product candidates or products that we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Impairment of our business reputation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Withdrawal of clinical trial participants; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Initiation of investigations by regulators; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Costs to defend the related litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A diversion of management&#146;s time and our resources; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Substantial monetary awards to trial participants or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Product recalls, withdrawals or labeling, marketing or promotional restrictions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Loss of revenue; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Exhaustion of any available insurance and our capital resources; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The inability to commercialize any product candidate; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A decline in our share price. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Failure to obtain or retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit
the commercialization of products we develop, alone or with corporate collaborators. We may have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and
we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle us to indemnification against losses, such indemnification may not be available or adequate should
any claim arise. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patients with cancer and other diseases targeted by our product candidates are often already in severe and advanced stages of disease and have
both known and unknown <FONT STYLE="white-space:nowrap">significant&nbsp;pre-existing&nbsp;and</FONT> potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that
may be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact or end our opportunity to receive or maintain regulatory
approval to market our product candidates, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which we do not believe that an adverse event is related to our product candidates, the investigation into the
circumstance may be time-consuming or inconclusive. These investigations may interrupt our sales efforts, delay our regulatory approval process in other countries, or impact and limit the type of regulatory approvals our product candidates receive
or maintain. As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition or results of operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We may need to increase our
insurance coverage each time we commence a clinical trial and if we successfully commercialize any product candidate. As the expense of insurance coverage is increasing, we may not be able to maintain insurance coverage at a reasonable cost or in an
amount adequate to satisfy any liability that may arise. If a successful product liability claim or series of claims is brought against us for uninsured liabilities or in excess of insured liabilities, our assets may not be sufficient to cover such
claims and our business operations could be impaired. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">31 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial
condition. </I></B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Recent changes in tax law may adversely affect our business or financial condition. For example, in 2021, there have been numerous changes
proposed to U.S. federal income tax law, including an increase to the U.S. corporate tax rate, international business operations reform and the imposition of a global minimum tax. Many countries, including the United States, and organizations such
as the Organization for Economic Cooperation and Development are also actively considering changes to existing tax laws or have proposed or enacted new laws that could increase our tax obligations in countries where we do business or cause us to
change the way we operate our business. Any of these developments or changes in federal, state, or international tax laws or tax rulings could adversely affect our effective tax rate and our operating results. We urge prospective investors in our
common stock to consult with their legal and tax advisors with respect to any recently enacted tax legislation, or proposed changes in law, and the potential tax consequences of investing in or holding our common stock. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Sections&nbsp;382 and 383 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#147;ownership change&#148; (generally defined as a
greater than 50% change (by value) by 5-percent shareholders in its equity ownership over a three-year period), the corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> net operating loss carryforwards and other <FONT
STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset its post-change taxable income may be limited. As a result of our most recent private placements and other transactions that have occurred over the past three years, we may have
experienced, and, upon closing of this offering, may experience, an &#147;ownership change.&#148; We may also experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As of December&nbsp;31, 2020, we had
U.S. federal and state net operating loss carryforwards of $61.1&nbsp;million and $59.2 million, respectively, and U.S. federal research and development tax credit carryforwards of $1.9&nbsp;million, which could be limited if we experience an
&#147;ownership change.&#148; We also have net operating loss carryforwards and credits for state tax purposes, which may be impaired or otherwise subject to limitation. In addition, we will be unable to use our net operating loss carryforwards and
credits if we do not attain profitability sufficient to offset our available net operating loss carryforwards and credits prior to their expiration. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks
Related to Reliance on Third Parties </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We rely and will rely on third parties to conduct our clinical trials. If these third parties do not properly and
successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not have the ability to conduct all aspects of our preclinical testing or clinical trials ourselves. We depend and will depend upon independent investigators and
collaborators, such as medical institutions, CROs, CMOs and strategic partners to conduct our preclinical studies and clinical trials under agreements with us. We expect to negotiate budgets and contracts with CROs, trial sites and CMOs, which may
result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. As a result, we have less direct control
over the conduct, timing and completion of these clinical trials and the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Nevertheless, we are responsible for ensuring that
each of our studies is conducted in accordance with applicable protocol, legal and regulatory requirements and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties
are required to comply with GCPs, which are regulations and guidelines enforced by the FDA or foreign health authorities for product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial
sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or foreign health
authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP
regulations. In addition, our clinical trials must be conducted with biologic product produced under cGMP regulations and may require a significant number of test patients. Our failure or any failure by these third parties to comply with these
regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">32 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any third parties conducting our clinical trials are not and will not be our employees and, except for remedies available to us pursuant to our agreements with such
third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing product candidates. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may
also be conducting clinical trials or other development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they
need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or
terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be
harmed, our costs could increase and our ability to generate revenue could be delayed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of our relationships with these third parties terminate, we may not
be able to enter into arrangements with alternative providers or do so on commercially reasonable terms. Switching or adding third parties to conduct our clinical trials involves substantial cost and requires extensive management time and focus. In
addition, there is a natural transition period when a new third party commences work. As a result, delays may occur, which can materially impact our ability to meet our desired clinical development timelines. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We rely and expect to continue to rely on third parties to manufacture our clinical product supplies, and we may rely on third parties for at least a portion of
the manufacturing process of our product candidates, if approved. Our business could be harmed if those third parties fail to provide us with sufficient quantities of product supplies or product candidates or fail to do so at acceptable quality
levels or prices. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not currently own any facility that may be used as a clinical-scale manufacturing and processing facility, and we rely on outside
vendors to manufacture supplies and process our product candidates. For certain of our components or product candidates, we rely on single suppliers or manufacturers to supply or manufacture, but we plan to expand the number of suppliers and
manufacturers as we advance our product candidates through clinical development. Our product candidates are not yet manufactured or processed on a commercial scale and we may remain unable to do so for any of our product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although in the future we may develop our own manufacturing facilities, we may also continue to use third parties as part of our manufacturing processes and may, in any
event, never be successful in developing our own manufacturing facilities. Our anticipated reliance on third-party manufacturers exposes us to the following risks: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is
limited and the FDA must inspect any manufacturers for current cGMP. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">Non-compliance</FONT> of our third-party manufacturers with requirements of our marketing
application(s). In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, the production of our product candidates. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Third-party manufacturers may have little or no experience with our product candidates, and therefore may require a
significant amount of support from us in order to implement and maintain the infrastructure and processes required to manufacture our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Third-party manufacturers might be unable to timely manufacture our product candidates or produce the quantity and quality
required to meet our clinical and commercial needs, if any. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Third-party manufacturers may not be able to execute our manufacturing procedures and other logistical support
requirements appropriately. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Third-party manufacturers may not perform as agreed, may not devote sufficient resources to our product candidates or may
not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store, and distribute our products, if any. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure
strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#146; compliance with these regulations and standards. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">33 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party
manufacturers in the manufacturing processes for our product candidates. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our third-party manufacturers could breach or terminate their agreements with us, and we may be required to pay fees upon
suspension or termination of the agreement even if the manufacturers do not deliver adequate supply of the product candidates or their components. </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Raw materials and components used in the manufacturing processes, particularly those for which we have no other source or
supplier, may not be available or may not be suitable or acceptable for use due to </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our third-party manufacturers may have unacceptable or inconsistent product quality success rates and yields, and we have
no direct control over their ability to maintain adequate quality control, quality assurance and qualified personnel. </P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each of these risks
could delay or prevent the completion of our clinical trials or the approval of any of our product candidates by the FDA, result in higher costs or adversely impact commercialization of our product candidates. In addition, we will rely on third
parties to perform certain specification tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm and the FDA could place
significant restrictions on our company until deficiencies are remedied. Furthermore, our or a third party&#146;s failure to execute on our manufacturing requirements, to do so on commercially reasonable terms or to comply with cGMP could adversely
affect our business in a number of ways, including: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">An inability to initiate or continue clinical trials of our product candidates under development; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Delay in submitting regulatory applications, or receiving marketing approvals, for our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Loss of the cooperation of future collaborators; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Subjecting third-party manufacturing facilities or our manufacturing facilities to additional inspections by regulatory
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Requirements to cease development or to recall batches of our product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">In the event of approval to market and commercialize our product candidates, an inability to meet commercial demands for
our product or any other future product candidates. </P></TD></TR></TABLE>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any CMO with whom we contract fails to perform its obligations, we may be forced to
enter into an agreement with a different CMO, which we may not be able to do on reasonable terms, if at all. In such scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some cases, the
technical skills required to manufacture our products or product candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a
back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with
quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidate according to the specifications previously
submitted to the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. In
addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer.
We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our
reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because we rely on third parties to research and develop and to manufacture our product candidates, we must share trade secrets with them. We seek to protect our
proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants
prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. Despite the contractual provisions
employed when working with third parties, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or
are disclosed or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">34 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
used in violation of these agreements. Given that our proprietary position is based, in part, on <FONT STYLE="white-space:nowrap">our&nbsp;know-how&nbsp;and</FONT> trade secrets, a
competitor&#146;s independent discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have a material adverse effect on our business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to
our trade secrets, although our agreements may contain certain limited publication rights. For example, any academic institution that we may collaborate with will likely expect to be granted rights to publish data arising out of such collaboration
and any joint research and development programs may require us to share trade secrets under the terms of our research and development or similar agreements. Despite our efforts to protect our trade secrets, our competitors may discover our trade
secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. A competitor&#146;s discovery of our trade secrets would impair our competitive
position and have an adverse impact on our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may in the future seek to establish collaborations, and, if we are not able to establish them on
commercially reasonable terms, we may have to alter our development and commercialization plans. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may in the future seek collaboration arrangements with
other parties for the development or commercialization of our product candidates. The success of any collaboration arrangements may depend on the efforts and activities of our collaborators. Collaborators generally have significant discretion in
determining the efforts and resources that they will apply to these arrangements. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the development process
or commercializing the applicable product candidate and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither of the parties has final decision making authority. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Collaborations with biopharmaceutical companies and other third parties often are terminated or are allowed to expire by the other party. Any such termination or
expiration could adversely affect us financially and could harm our business reputation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any future collaborations we might enter into may pose a number of risks,
including the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Collaborators may not perform their obligations as expected; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Collaborators may not pursue development and commercialization of product candidates that achieve regulatory approval or
may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#146; strategic focus or available funding or external factors, such as an acquisition, that divert resources
or create competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial
or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Collaborators could fail to make timely regulatory submissions for a product candidate; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Collaborators may not comply with all applicable regulatory requirements or may fail to report safety data in accordance
with all applicable regulatory requirements, which could subject them or us to regulatory enforcement actions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Collaborators could independently develop, or develop with third parties, products that compete directly or indirectly
with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own
product candidates or products, which may cause collaborators to cease to devote resources to the commercialization of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory
approval may not commit sufficient resources to the marketing and distribution of such product candidate or product; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the
preferred course of development, might cause delays or termination of the research, development or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">35 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be
time consuming and expensive; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Collaborators may not properly maintain or defend our intellectual property rights or may use our proprietary information
in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and
potential liability. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, if we establish one or more collaborations, all of the risks relating to product development, regulatory
approval and commercialization described in this prospectus would also apply to the activities of any such future collaborators. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any collaborations we might
enter into in the future do not result in the successful development and commercialization of products or if one of our future collaborators subsequently terminates its agreement with us, we may not receive any future research funding or milestone
or royalty payments under such potential future collaboration. If we do not receive the funding we expect under the agreements, our development of our product candidates could be delayed and we may need additional resources to develop our product
candidates and our platforms. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, if any future collaborator of ours is involved in a business combination, the collaborator might deemphasize or
terminate development or commercialization of any product candidate licensed to it by us. If one of our future collaborators terminates its agreement with us, we may find it more difficult to attract new collaborators and our reputation in the
business and financial communities could be adversely affected. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We face significant competition in seeking appropriate collaborators. Our ability to reach a
definitive agreement for any collaboration will depend upon, among other things, our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#146;s
evaluation of a number of factors. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may
have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or
increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and
additional capital, which may not be available to us on acceptable terms, or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we
may not be able to further develop our product candidates or bring them to market or continue to develop our platforms and our business may be materially and adversely affected. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Intellectual Property </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to
obtain and maintain sufficient intellectual property protection for our platforms and our product candidates, or if the scope of the intellectual property protection is not sufficiently broad, our competitors could develop and commercialize products
similar or identical to ours, and our ability to successfully commercialize our products may be adversely affected. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our success depends in large part on
our ability to obtain and maintain patent protection in the United States and other countries with respect to our platforms, product candidates and research programs. We seek to protect our proprietary position by filing patent applications in the
United States and abroad related to our novel discoveries and technologies that are important to our business. Our pending and future patent applications may not result in patents being issued that protect our product candidates or their intended
uses or that effectively prevent others from commercializing competitive technologies, products or product candidates. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Obtaining and enforcing patents is
expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications or maintain and/or enforce patents that may issue based on our patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">36 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
applications, at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development results before it is too late to
obtain patent protection. Although we enter <FONT STYLE="white-space:nowrap">into&nbsp;non-disclosure&nbsp;and</FONT> confidentiality agreements with parties who have access to patentable aspects of our research and development output, such as our
employees, corporate collaborators, outside scientific collaborators, contract research organizations, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach these agreements and disclose such results
before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, for example with respect to
proper priority claims, inventorship, etc., although we are unaware of any such defects that we believe are of material import. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we, or any future licensors or
licensees, fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If any future licensors or licensees, are not fully cooperative or disagree with us as to the
prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and
unenforceable. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. In addition, given the amount of time required for the development, testing and regulatory
review of new product candidates, patents protecting such product candidates might expire before or shortly after such product candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude
others from commercializing products similar or identical to ours. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Composition of matter patents for biological and pharmaceutical products such as proprietary
binding domains and <FONT STYLE="white-space:nowrap">CAR-based</FONT> product candidates often provide a strong form of intellectual property protection for these types of products without regard to any method of use. We cannot be certain that the
claims in our pending patent applications covering composition of matter of our product candidates will be considered patentable by the U.S. Patent and Trademark Office (USPTO), or by patent offices in foreign countries, or that the claims in any of
our issued patents will be considered valid and enforceable by courts or administrative tribunals in the United States or foreign countries. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent position of
biopharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and in recent years has been the subject of much litigation, resulting in court decisions, including Supreme Court decisions, that have increased
uncertainties as to the ability to enforce patent rights in the future. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States, or vice versa. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, we may not be aware of all third-party intellectual property rights potentially relating to our product candidates or their intended uses, and as a result the
impact of such third-party intellectual property rights upon the patentability of our own patents and patent applications, as well as the impact of such third-party intellectual property upon our freedom to operate, is highly uncertain. Patent
applications in the United States and other jurisdictions are typically not published until 18 months after filing or, in some cases, not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in
our patents or pending patent applications, or that we were the first to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our
patents or pending patent applications may be challenged in the courts or patent offices in the United States and abroad. For example, we may be subject to a <FONT STYLE="white-space:nowrap">third-party&nbsp;pre-issuance&nbsp;submission</FONT> of
prior art to the USPTO or become involved in post-grant review procedures, derivations, reexaminations, or <I>inter partes</I> review proceedings, in the United States or elsewhere, challenging our patent rights or the patent rights of others. An
adverse determination in any such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated, or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing
similar or identical technology and products, or limit the duration of the patent protection of our technology and products. In addition, given the amount of time required for the development, testing and regulatory review of new product candidates,
patents protecting such candidates might expire before or shortly after such candidates are commercialized. Any failure to obtain or maintain patent protection with respect to our product candidates could have a material adverse effect on our
business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">37 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The patent application process is subject to numerous risks and there can be no assurance that we will be successful
in obtaining patents for which we have applied. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pending patent applications cannot be enforced against third parties practicing the technology claimed in
such applications unless and until a patent issues from such applications. The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future development partners will
be successful in protecting our product candidates by obtaining and defending patents. These risks and uncertainties include the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary,
fee payment and other provisions during the patent process. There are situations in which noncompliance can result in abandonment or lapse of a patent or patent application, resulting in partial or complete loss of patent rights in the relevant
jurisdiction. In such an event, competitors might be able to enter the market earlier than would otherwise have been the case; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can
be reinterpreted after issuance; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Patent applications may not result in any patents being issued; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Patents that may be issued or <FONT STYLE="white-space:nowrap">in-licensed</FONT> may be challenged, invalidated,
modified, revoked, circumvented, narrowed, found to be unenforceable or otherwise may not provide any competitive advantage; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our competitors, many of whom have substantially greater resources and many of whom have made significant investments in
competing technologies, may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to make, use, and sell our potential product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">There may be significant pressure on the U.S. government and international governmental bodies to limit the scope of
patent protection both in the United States and abroad for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts,
allowing foreign competitors a better opportunity to create, develop and market competing product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any of the foregoing events could
have a material adverse effect on our business, financial condition, results of operations, and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not identify relevant third-party patents
or may incorrectly interpret the relevance, scope or expiration of a third-party patent, which might adversely affect our ability to develop and market our products. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot guarantee that any of our patent searches or analyses, including the identification of relevant patents, the scope of patent claims or the expiration of
relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States and abroad that is relevant to or necessary for the commercialization of our
product candidates in any jurisdiction. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the
patent&#146;s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our products. We may incorrectly determine that our products
are not covered by a third-party patent or may incorrectly predict whether a third-party&#146;s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States or abroad that
we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our
products. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to
compete effectively in our market. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We rely upon a combination of patents, confidentiality agreements, trade secret protection and intellectual property and
confidentiality agreements to protect the intellectual property related to our technologies. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass
our technological achievements, thus eroding our competitive position in our market. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">38 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have pending U.S. and foreign patent applications in our portfolio; however, we cannot predict: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">If and when patents will issue based on our patent applications; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The scope of protection of any patent issuing based on our patent applications; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The degree and range of protection any issued patents will afford us against competitors including whether third parties
will find ways to invalidate or otherwise circumvent our patents; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Whether any of our intellectual property will provide any competitive advantage; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent
applications; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Whether we will need to initiate or defend litigation or administrative proceedings to enforce and/or defend our patent
rights, which may be costly whether we win or lose; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Whether the patent applications that we own or may <FONT STYLE="white-space:nowrap">in-license</FONT> will result in
issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot be
certain that the claims in our pending patent applications directed to our product candidates and/or technologies will be considered patentable by the USPTO or by patent offices in foreign countries. There can be no assurance that any such patent
applications will issue as granted patents. One aspect of the determination of patentability of our inventions depends on the scope and content of the &#147;prior art,&#148; information that was or is deemed available to a person of skill in the
relevant art prior to the priority date of the claimed invention. There may be prior art of which we are not aware that may affect the patentability of our patent claims or, if issued, affect the validity or enforceability of a patent claim. Even if
the patents do issue based on our patent applications, third parties may challenge the validity, enforceability or scope thereof, which may result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are
unchallenged, patents in our portfolio may not adequately exclude third parties from practicing relevant technology or prevent others from designing around our claims. If the breadth or strength of our intellectual property position with respect to
our product candidates is threatened, it could dissuade companies from collaborating with us to develop and threaten our ability to commercialize our product candidates. In the event of litigation or administrative proceedings, we cannot be certain
that the claims in any of our issued patents will be considered valid by courts or administrative tribunals in the United States or foreign countries. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The strength
of patents in the biotechnology and cell therapy fields involve complex legal and scientific questions and can be uncertain. The patent applications that we own or may <FONT STYLE="white-space:nowrap">in-license</FONT> may fail to result in issued
patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the validity, enforceability or scope thereof, which may
result in such patents being narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around
our claims. If the breadth or strength of protection provided by the patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to
commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. Since patent applications in the United
States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to file any patent application related to our product candidates. Furthermore, for U.S. applications in which all claims
are entitled to a priority date before March&nbsp;16, 2013, an interference proceeding can be provoked by a third party or instituted by the USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of
our applications. Various post grant review proceedings, such as <I>inter partes </I>review and post grant review, are available for any interested third party to challenge the patentability of claims issued in patents to us. While these post grant
review proceedings have been used less frequently to invalidate biotech patents, they have been successful regarding other technologies, and these relatively new procedures are still changing, and those changes might affect future results. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to the protection afforded by patents, we seek to rely on trade secret protection, confidentiality agreements, and other agreements to protect proprietary <FONT
STYLE="white-space:nowrap">know-how</FONT> that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary
<FONT STYLE="white-space:nowrap">know-how,</FONT> information, or technology that is not covered by patents. Although we require all of our employees to assign their inventions to us, and require all of our employees, consultants, advisors and any
third </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">39 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
parties who have access to our proprietary <FONT STYLE="white-space:nowrap">know-how,</FONT> information, or technology to enter into confidentiality agreements, we cannot be certain that our
trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the
laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both
in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially
adversely affect our business, operating results and financial condition. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Numerous factors may limit any potential competitive advantage provided by our
intellectual property rights. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The degree of future protection afforded by our intellectual property rights, whether owned or
<FONT STYLE="white-space:nowrap">in-licensed,</FONT> is uncertain because intellectual property rights have limitations, and may not adequately protect our business, provide a barrier to entry against our competitors or potential competitors, or
permit us to maintain our competitive advantage. Moreover, if a third party has intellectual property rights that cover the practice of our technology, we may not be able to fully exercise or extract value from our intellectual property rights. The
following examples are illustrative: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Pending patent applications that we own or may license may not lead to issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Patents, should they issue, that we own or may license, may not provide us with any competitive advantages, or may be
challenged and held invalid or unenforceable; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Others may be able to develop and/or practice technology that is similar to our technology or aspects of our technology
but that is not covered by the claims of any patents that we own or may license, should any such patents issue; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Third parties may compete with us in jurisdictions where we do not pursue and obtain patent protection;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We (or any licensors) might not have been the first to make the inventions covered by a pending patent application that we
own or may license; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We (or any licensors) might not have been the first to file patent applications covering a particular invention;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Others may independently develop similar or alternative technologies without infringing our intellectual property rights;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may not be able to obtain necessary licenses on reasonable terms or at all; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Third parties may assert an ownership interest in our intellectual property and, if successful, such disputes may preclude
us from exercising exclusive rights, or any rights at all, over that intellectual property; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may need to initiate litigation or administrative proceedings to enforce and/or defend our patent rights, which will be
costly whether we win or lose; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may not be able to maintain the confidentiality of our trade secrets or other proprietary information;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may not develop or <FONT STYLE="white-space:nowrap">in-license</FONT> additional proprietary technologies that are
patentable; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The patents of others may have an adverse effect on our business. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Should any of these events occur, they could significantly harm our business and results of operation. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation
involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, reexamination, and post grant review proceedings
before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our
product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Third parties may assert that we are employing their proprietary technology without authorization. Generally, conducting clinical trials and other development
activities in the United States is not considered an act of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">40 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
infringement. If and when one of our product candidates is approved by the FDA, a third party may then seek to enforce its patent by filing a patent infringement lawsuit against us. While we do
not believe that any claims that could otherwise materially adversely affect commercialization of our product candidates, if approved, are valid and enforceable, we may be incorrect in this belief, or we may not be able to prove it in a litigation.
In this regard, patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#147;clear and convincing,&#148; a heightened standard of proof. There may be third-party patents of which we
are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be
currently pending patent applications, which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these
patents. Moreover, we may fail to identify relevant patents or incorrectly conclude that a patent is invalid, not enforceable, exhausted, or not infringed by our activities. If any third-party patents were held by a court of competent jurisdiction
to cover the manufacturing processes of our product candidates, constructs or molecules used in or formed during the manufacturing processes, or any final product itself, the holders of any such patents may be able to block our ability to
commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held invalid or unenforceable. Similarly, if any third-party patent were held by a court
of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a
license or until such patent expires or is finally determined to be held invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a
third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and
commercialize our product candidates. Defense of these claims, regardless of their merit, could involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim
of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#146; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which
may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of
litigation, we may need or may choose to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at
all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may
become involved in lawsuits to protect or enforce our patents, which could be expensive, time-consuming and unsuccessful. </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Competitors or other third
parties may infringe our patents, trademarks, copyrights or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an
infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in
question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable, or interpreted narrowly and could put our patent applications at risk of not issuing. Defense
of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful infringement claim against us, we may have to pay
substantial damages, including treble damages and attorneys&#146; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time
and monetary expenditure. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Post-grant proceedings, including interference proceedings, provoked by third parties or brought by the USPTO may be necessary to
determine the validity or priority of inventions with respect to our patents or those of any licensors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">41 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing
party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or post-grant proceedings may result in a decision adverse to our interests and, even if we are successful, may
result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with any licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may
not protect those rights as fully as in the United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, because of the substantial amount of discovery required in connection with intellectual
property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim
proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because of the expense and uncertainty of litigation, we may conclude that even if a third-party is infringing our issued patent, any patents that may be issued as a
result of our pending or future patent applications or other intellectual property rights, the risk-adjusted cost of bringing and enforcing such a claim or action may be too high or not in the best interest of our company or our stockholders, or it
may be otherwise impractical or undesirable to enforce our intellectual property against some third parties. Our competitors or other third parties may be able to sustain the costs of complex patent litigation or proceedings more effectively than we
can because of their greater financial resources and more mature and developed intellectual property portfolios. In such cases, we may decide that the more prudent course of action is to simply monitor the situation or initiate or seek some <FONT
STYLE="white-space:nowrap">other&nbsp;non-litigious&nbsp;action</FONT> or solution. In addition, the uncertainties associated with litigation could compromise our ability to raise the funds necessary to continue our clinical trials, continue our
internal research programs, <FONT STYLE="white-space:nowrap">in-license</FONT> needed technology or other product candidates, or enter into development partnerships that would help us bring our product candidates to market. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by
governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO
and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by
payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent
rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, <FONT
STYLE="white-space:nowrap">non-payment</FONT> of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.
Failure by us or any licensor to maintain protection of our patent portfolio could have a material adverse effect on our business, financial condition, results of operations, and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time. </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patent rights are of limited duration. In the United States, if all maintenance fees are paid timely, the natural expiration of a patent is generally 20 years after its
first effective filing date. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such product candidates are
commercialized. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic products. As a result, our patent portfolio may not provide us
with sufficient rights to exclude others from commercializing product candidates similar or identical to ours. Upon issuance in the United States, a patent&#146;s life can be increased based on certain delays caused by the USPTO, but this increase
can be reduced or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">42 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
eliminated based on certain delays caused by the patent applicant during patent prosecution. A patent term extension based on regulatory delay may be available in the United States. However, only
a single patent can be extended for each marketing approval, and any patent can be extended only once, for a single product. Moreover, the scope of protection during the period of the patent term extension does not extend to the full scope of the
claim, but instead only to the scope of the product as approved. Laws governing analogous patent term extensions in foreign jurisdictions vary widely, as do laws governing the ability to obtain multiple patents from a single patent family.
Additionally, we may not receive an extension if we fail to exercise due diligence during the testing phase or regulatory review process, apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to
satisfy applicable requirements. If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product will be
shortened and our competitors may obtain approval of competing products following our patent expiration to launch their product earlier than might otherwise be the case, and our revenue could be reduced, possibly materially. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court or the USPTO. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we or a licensing partner initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could
counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there
are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation.
Such mechanisms include <FONT STYLE="white-space:nowrap">re-examination,</FONT> <I>inter parties</I> review, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in
revocation or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we
cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would
lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents
in the biopharmaceutical industry involves both technological and legal complexity and is therefore costly, time consuming and inherently uncertain. Changes in either the patent laws or interpretation of the patent laws in the United States could
increase the uncertainties and costs, and may diminish our ability to protect our inventions, obtain, maintain, and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope
of our owned and any licensed patents. Patent reform legislation in the United States and other countries, including the Leahy-Smith America Invents Act (the Leahy-Smith Act), signed into law on September&nbsp;16, 2011, could increase those
uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the patent
positions of companies in the development and commercialization of pharmaceuticals are particularly uncertain. The U.S. Supreme Court has ruled on several patent cases in recent years, either narrowing the scope of patent protection available in
certain circumstances or weakening the rights of patent owners in certain situations. Depending on future actions by the U.S. Congress, the U.S. courts, the USPTO and the <FONT STYLE="white-space:nowrap">relevant&nbsp;law-making&nbsp;bodies</FONT>
in other countries, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be able to protect our intellectual property and proprietary rights throughout the world. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and the laws of foreign
countries may not protect our rights to the same extent as the laws of the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or
importing products made using our inventions in and into the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">43 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export
otherwise infringing products to territories where we have patent protection or licenses but enforcement is not as strong as that in the United States. These products may compete with our products, and our patents or other intellectual property
rights may not be effective or sufficient to prevent them from competing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many companies have encountered significant problems in protecting and defending
intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection,
particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally.
Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being
invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies
awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property
that we develop or may license. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In
addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or
any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations, and prospects may be
adversely affected.<B><I> </I></B> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we are not currently aware of any claims challenging the inventorship of our patents or ownership of our intellectual property, we may in the
future be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or <FONT STYLE="white-space:nowrap">co-inventor.</FONT> We generally enter into
confidentiality and intellectual property assignment agreements with our employees, consultants, and contractors. These agreements generally provide that inventions conceived by the party in the course of rendering services to us will be our
exclusive property. However, those agreements may not be honored and may not effectively assign intellectual property rights to us. Moreover, there may be some circumstances, where we are unable to negotiate for such ownership rights. Disputes
regarding ownership or inventorship of intellectual property can also arise in other contexts, such as collaborations and sponsored research. If we are subject to a dispute challenging our rights in or to patents or other intellectual property, such
a dispute could be expensive and time consuming. If we were unsuccessful, we could lose valuable rights in intellectual property that we regard as our own, which could have a material adverse effect on our business, financial condition, results of
operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed
confidential information of third parties. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may receive confidential and proprietary information from third parties. In addition, we employ individuals
who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed alleged trade secrets or
other confidential information of these third parties or our employees&#146; former employers or our consultants&#146; or contractors&#146; current or former clients or customers. Although we try to ensure that our employees and consultants do not
use intellectual property, proprietary <FONT STYLE="white-space:nowrap">information,&nbsp;know-how&nbsp;or</FONT> trade secrets of others in their work for us, we may become subject to claims that we caused an employee to breach the terms of his or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">her&nbsp;non-competition&nbsp;or&nbsp;non-solicitation&nbsp;agreement,</FONT></FONT> or that we or these individuals have, inadvertently or otherwise, used or disclosed the alleged trade
secrets or other proprietary information of a former employer or competitor. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be
a distraction to our management and employees. If we are not successful, we could lose access or exclusive access to valuable intellectual property. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">44 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be
harmed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to seeking patents for our technology and product candidates, we also rely on trade secrets, including unpatented <FONT
STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into <FONT STYLE="white-space:nowrap">non-disclosure</FONT>
and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into
confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may
not be able to obtain adequate remedies for such breaches. Detecting the disclosure or misappropriation of a trade secret and enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and
time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently
developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by
a competitor, our competitive position would be harmed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If our trademarks and trade names are not adequately protected, then we may not be able to build name
recognition in our markets of interest and our business may be adversely affected. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our current or future trademarks or trade names may be challenged,
infringed, circumvented or declared generic or descriptive determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names or may be forced to stop using these names, which we need for name
recognition by potential partners or customers in our markets of interest. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we would be given an
opportunity to respond to those rejections, we may be unable to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark
applications and to seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademarks may not survive such proceedings. If we are unable to establish name recognition based on our
trademarks and trade names, we may not be able to compete effectively and our business may be adversely affected. We may license our trademarks and trade names to third parties, such as distributors. Though these license agreements may provide
guidelines for how our trademarks and trade names may be used, a breach of these agreements or misuse of our trademarks and tradenames by our licensees may jeopardize our rights in or diminish the goodwill associated with our trademarks and trade
names. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, any name we may propose to use with our product candidate in the United States must be approved by the FDA, regardless of whether we have
registered it, or applied to register it, as a trademark. Similar requirements exist in Europe. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA
(or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, it may be required to expend significant additional resources in an effort to identify a suitable substitute name that would
qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a
subsequent infringement claim asserted by the owner of a senior trademark. At times, competitors or other third parties may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to
market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade
names. If we assert trademark infringement claims, a court may determine that the marks we have asserted are invalid or unenforceable, or that the party against whom we have asserted trademark infringement has superior rights to the marks in
question. In this case, we could ultimately be forced to cease use of such trademarks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">45 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Government Regulation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be unable to obtain regulatory approval for our product candidates. The denial or delay of any such approval would delay commercialization and have a
material adverse effect on our potential to generate revenue, our business and our results of operations. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The research, development, testing,
manufacturing, labeling, packaging, approval, promotion, advertising, storage, recordkeeping, marketing, distribution, post-approval monitoring and reporting, and export and import of drug products are subject to extensive regulation by the FDA, and
by foreign health authorities in other countries. These regulations differ from country to country. In the United States, we are not permitted to market our product candidates until we receive regulatory approval from the FDA. The process of
obtaining regulatory approval is expensive, often takes many years following the commencement of clinical trials and can vary substantially based upon the type, complexity and novelty of the product candidates involved, as well as the target
indications and patient population. Despite the time and expense invested in clinical development of product candidates, regulatory approval is never guaranteed. To gain approval to market our product candidates, we must provide clinical data that
adequately demonstrate the safety and efficacy of the product for the intended indication. We have not yet obtained regulatory approval to market any of our product candidates in the United States or any other country. Our business depends upon
obtaining these regulatory approvals. The FDA can delay, limit or deny approval of our product candidates for many reasons, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our inability to satisfactorily demonstrate that the product candidates have acceptable safety and efficacy profiles for
the requested indication; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The FDA&#146;s disagreement with our trial designs or the interpretation of data from preclinical studies or clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The population studied in the clinical trial may not be sufficiently broad or representative to assess safety in the full
population for which we seek approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our inability to demonstrate that clinical or other benefits of our product candidates outweigh any safety or other
perceived risks; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The FDA&#146;s determination that additional preclinical or clinical trials are required; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The FDA&#146;s <FONT STYLE="white-space:nowrap">non-approval</FONT> of the formulation, labeling or the specifications of
our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The FDA&#146;s failure to accept the manufacturing processes, drug product characteristics or facilities of third-party
manufacturers with which we contract; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The potential for approval policies or regulations of the FDA to significantly change in a manner rendering our clinical
data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if we eventually complete clinical testing and receive approval of any regulatory filing for our product
candidates, the FDA may grant approval contingent on the performance of costly additional post-approval clinical trials. The FDA may also approve our product candidates for a more limited indication or a narrower patient population than we
originally requested, and the FDA may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates. If FDA requires us to narrow our indications to smaller patient subsets, our
market opportunities for our product candidates, if approved, and our ability to generate revenues may be materially limited. To the extent we seek regulatory approval in foreign countries, we may face challenges similar to those described above
with regulatory authorities in applicable jurisdictions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any delay in obtaining, or inability to obtain, applicable regulatory approval for any of our product
candidates would delay or prevent commercialization of our product candidates and would materially adversely impact our business, results of operations and prospects. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The FDA regulatory approval process is lengthy, time-consuming and inherently unpredictable, and we may experience significant delays in the clinical development
and regulatory approval of our product candidates or be unable to generate product revenue. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have not previously submitted a BLA to the FDA or similar
marketing applications to foreign health authorities. A BLA must include extensive preclinical and clinical data and supporting information to establish the product candidate&#146;s safety, purity and efficacy for each desired indication. The BLA
must also include significant information regarding the manufacturing controls for the product. The novel nature of our product candidates may introduce </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">46 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
uncertain, complex, expensive and lengthy challenges that could impact regulatory approval. Even if we eventually complete clinical testing and receive approval of any regulatory filing for our
product candidates, the FDA or foreign health authorities may approve our product candidates for a more limited indication or a narrower patient population than we originally requested. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may also experience delays in completing planned clinical trials for a variety of reasons, including delays related to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The availability of financial resources to commence and complete the planned trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject
to extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Obtaining approval at each clinical trial site by an IRB or ethics committee; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Recruiting suitable patients to participate in a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Enrolling and retaining sufficient number of patients to complete a trial, including post-treatment <FONT
STYLE="white-space:nowrap">follow-ups;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Clinical trial sites deviating from trial protocol or dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Adding new clinical trial sites; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Manufacturing sufficient quantities of qualified materials under cGMPs and applying them on a subject by subject basis for
use in clinical trials. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We could also experience delays in physicians enrolling patients in clinical trials of our product candidates in lieu of
prescribing existing treatments or other clinical trials. Furthermore, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted, the Data Monitoring Committee for such trial, or by
the FDA or foreign health authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the
FDA or foreign health authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or
administrative actions or lack of adequate funding to continue the clinical trial. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates
will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to
commence product sales and generate revenue. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Securing regulatory approval also requires the submission of information about the manufacturing processes and
inspection of manufacturing facilities by the relevant regulatory authority. The FDA or foreign health authorities may fail to approve our manufacturing processes or facilities, whether run by us or our CMOs. In addition, if we make manufacturing
changes to our product candidates in the future, we may need to conduct additional preclinical and/or clinical studies to bridge our modified product candidates to earlier versions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our
product candidates. Applications for our product candidates could fail to receive regulatory approval for many reasons, including but not limited to the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The FDA or foreign health authorities may disagree with the design, implementation or data analyses of our clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The FDA or foreign health authorities may determine that our product candidate(s) do not have adequate risk-benefit ratio
or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The population studied in the clinical program may not be sufficiently broad or representative to assure efficacy and
safety in the full population for which we seek approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The FDA or foreign health authorities may disagree with our interpretation of data from preclinical studies or clinical
trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA
or other submission or to obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">47 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The FDA or foreign health authorities may fail to approve the manufacturing processes, test procedures and specifications
or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The approval policies or regulations of the FDA or foreign health authorities may significantly change in a manner
rendering our clinical data insufficient for approval. </P></TD></TR></TABLE>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have or may pursue Fast Track, orphan drug, and/or RMAT designations from the
FDA for one or more of our product candidates. Even if one or more of our product candidates receive Fast Track, orphan drug, and/or RMAT designations, we may be unable to obtain and maintain the benefits associated with such designations. These
designations may not lead to a faster development or regulatory review or approval process, and will not increase the likelihood that such product candidates will receive marketing approval. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, CART-ddBCMA has been granted Fast Track, orphan drug, and Regenerative Medicine Advanced Therapy (RMAT) designations by the FDA. In the future, we may pursue
one or more similar designations for other product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Fast Track designation is designed to facilitate the development and expedite the review of
therapies for serious conditions with an unmet medical need. Programs with Fast Track designation may benefit from early and frequent communications with the FDA, potential priority review and the ability to submit a rolling application for
regulatory review. Fast Track designation applies to both the product candidate and the specific indication for which it is being studied. However, if we do not continue to meet the criteria of the Fast Track designation, or if our clinical trials
are delayed, suspended or terminated, or put on clinical hold due to unexpected adverse events or issues with clinical supply, we will not receive the benefits associated with the Fast Track program. Furthermore, Fast Track designation does not
change the standards for approval. Fast Track designation alone does not guarantee qualification for the FDA&#146;s priority review procedures. Fast track designation also does not guarantee our product candidate will be approved in a timely manner,
if at all. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regulatory authorities in some jurisdictions, including the United States and Europe, may designate drugs for relatively small patient populations as
orphan drugs. Under the Orphan Drug Act, the FDA may designate a product as an orphan drug if it is a drug intended to treat a rare disease or condition, which is generally defined as a patient population of fewer than 200,000 individuals annually
in the United States. In the European Union, the prevalence of the condition must not be more than 5 in 10,000. Orphan drug designation neither shortens the development time or regulatory review time of a drug nor gives the drug any advantage in the
regulatory review or approval process. If a product that has orphan drug designation from the FDA subsequently receives the first FDA approval for a particular active ingredient for the disease for which it has such designation, the product is
entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic for the same indication, for seven years, except in limited circumstances such as a showing of
clinical superiority to the product with orphan product exclusivity or if FDA finds that the holder of the orphan exclusivity has not shown that it can ensure the availability of sufficient quantities of the orphan product to meet the needs of
patients with the disease or condition for which the product was designated. Even if we or our collaborators obtain orphan designation to a product candidate, we may not be the first to obtain marketing approval for any particular orphan indication
due to the uncertainties associated with developing pharmaceutical products. The scope of exclusivity is limited to the scope of any approved indication, even if the scope of the orphan designation is broader than the approved indication.
Additionally, exclusive marketing rights may be limited if we or our collaborators seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was
materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition. Further, even if a product obtains orphan drug exclusivity, that exclusivity may
not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve a product with the same
active moiety for the same condition if the FDA concludes that the later product is safer, more effective, or makes a major contribution to patient care. Furthermore, the FDA can waive orphan exclusivity if we or our collaborators are unable to
manufacture sufficient supply of the product. If we or our collaborators do not receive or maintain orphan drug designation to product candidates for which we seek such designation, it could limit our ability to realize revenues from such product
candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">48 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A company may request RMAT designation of its product candidate, which designation may be granted if the product meets
the following criteria: (1)&nbsp;it is a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2)&nbsp;it is intended to treat,
modify, reverse, or cure a serious or life-threatening disease or condition; and (3)&nbsp;preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. RMAT designation
provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate, and potential eligibility for rolling review and priority review. Products granted RMAT designation may also be
eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to
additional sites post-approval, if appropriate. RMAT-designated products that receive accelerated approval may, as appropriate, fulfill their post-approval requirements through the submission of clinical evidence, clinical studies, patient
registries, or other sources of real world evidence (such as electronic health records); through the collection of larger confirmatory data sets; or via post-approval monitoring of all patients treated with such therapy prior to approval of the
therapy. RMAT designation does not change the standards for product approval, and there is no assurance that any such designation or eligibility will result in expedited review or approval or that the approved indication will not be narrower than
the indication covered by the RMAT designation. Additionally, RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may pursue Breakthrough Therapy designation for one or more of our product candidates in the future. Even if granted by the FDA, such designation may not lead
to a faster development or regulatory review or approval process, and it does not increase the likelihood that the product candidate will receive marketing approval. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or
condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical
development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number
of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA are also eligible for priority review if supported by clinical data at the time of the submission of the BLA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although Breakthrough Designation or access to any other expedited program may expedite the development or approval process, it does not change the standards for
approval. We may not experience faster development timelines or achieve faster review or approval compared to conventional FDA procedures. For example, the time required to identify and resolve issues relating to manufacturing and controls, the
acquisition of a sufficient supply of our product for clinical trial purposes or the need to conduct additional nonclinical or clinical studies may delay approval by the FDA, even if the product qualifies for breakthrough designation or access to
any other expedited program. Access to an expedited program may also be withdrawn by the FDA if it believes that the designation is no longer supported by data from our clinical development program. Additionally, qualification for any expedited
review procedure does not ensure that we will ultimately obtain regulatory approval for such product candidate. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If approved, our investigational products
regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ACA includes a subtitle called the
Biologics Price Competition and Innovation Act of 2009 (BPCIA), which created an abbreviated approval pathway for biologic products that are biosimilar to or interchangeable with an FDA-licensed reference biologic product. Under the BPCIA, an
application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA
until 12 years from the date on which the reference product was first licensed. During this 12-year period of exclusivity, another company may still market a competing version of the reference product if the FDA approves a BLA for the competing
product containing the sponsor&#146;s own preclinical data and data from adequate and well-controlled clinical trials to demonstrate the safety, purity, and potency of the other company&#146;s product. The law is complex and is still being
interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">49 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that any of our product candidates approved as a biologic product under a BLA should qualify for the
12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our investigational medicines to be reference products for competing
products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent litigation. Moreover, the
extent to which a biosimilar, once licensed, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for non-biologic products is not yet clear, and will depend on a number of
marketplace and regulatory factors that are still developing. If competitors are able to obtain regulatory approval for biosimilars referencing our products, our products may become subject to competition from such biosimilars, with the attendant
competitive pressure and consequences. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory
obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any regulatory approvals that we receive for our product candidates will require surveillance to monitor the safety of the product candidate. The FDA may
also require REMS as a condition of approving our product candidates, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient
registries and other risk minimization tools. In addition, if the FDA or foreign health authorities approve our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising,
promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration,
as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency,
or with our third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements, may result in, among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or
voluntary or mandatory product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Fines, warning letters or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or
revocation of license approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Withdrawal of the drug from the market or voluntary or mandatory product recalls; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Adverse publicity, fines, warning letters or holds on clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Product seizure or detention, or refusal to permit the import or export of our product candidates; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA&#146;s and other regulatory authorities&#146; policies may change and additional government regulations may be enacted that could prevent, limit or delay
regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or
unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or
sustain profitability. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA strictly regulates manufacturers&#146; promotional claims of drug products. In particular, a drug product may not be promoted by
manufacturers for uses that are not approved by the FDA, as reflected in the <FONT STYLE="white-space:nowrap">FDA-approved</FONT> labeling, although healthcare professionals are permitted to use drug products for
<FONT STYLE="white-space:nowrap">off-label</FONT> uses. The FDA, the Department of Justice, the Inspector General of the Department of Health and Human Services, among other government agencies, actively enforce the laws and regulations prohibiting
manufacturers&#146; promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and a company that is found to have improperly promoted <FONT STYLE="white-space:nowrap">off-label</FONT> uses may be subject to significant liability,
including large civil and criminal fines, penalties, and enforcement actions. The FDA has also imposed consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed for companies that engaged in such
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">50 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
prohibited activities. If we cannot successfully manage the promotion of our approved product candidates, we could become subject to significant liability, which would materially adversely affect
our business and financial condition. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we
will be successful in obtaining regulatory approval of our product candidates in other jurisdictions. Failure to obtain regulatory approval in foreign jurisdictions would prevent our product candidates from being marketed abroad. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to regulations in the United States, to market and sell our products in the European Union, many Asian countries and other jurisdictions, we must obtain
separate regulatory approvals and comply with numerous and varying regulatory requirements, both from a clinical and manufacturing perspective. Approval by the FDA does not ensure approval by regulatory or payor authorities in other countries or
jurisdictions, and approval by one regulatory or payor authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. However, a failure or delay in obtaining regulatory
approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also
approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in
the United States, including additional preclinical studies or clinical trials as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a
product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. A product candidate that has been approved
for sale in a particular country may not receive reimbursement approval in that country. We may not be able to obtain approvals from regulatory authorities or payor authorities outside the United States on a timely basis, if at all. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may also submit marketing applications in other countries, such as countries in Europe or Asia. We may not be able to file for regulatory approvals and may not
receive necessary approvals to commercialize our products in any jurisdiction. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in
those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain
countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do not have experience in obtaining regulatory approval in international markets. If we are unable to obtain approval of
any of our product candidates by regulatory or payor authorities in the European Union, Asia or elsewhere, or if we fail to comply with the regulatory requirements in foreign jurisdictions, the commercial prospects of that product candidate may be
significantly diminished, and our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we obtain FDA approval of any of our product candidates, we may never obtain approval or commercialize such products outside of the United States, which
would limit our ability to realize their full market potential. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order to market any product outside of the United States, we must establish and comply
with numerous and varying regulatory requirements of other countries regarding safety and efficacy. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country
does not mean that regulatory approval will be obtained in any other country. Approval procedures vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory
approvals could result in significant delays, difficulties and costs for us and may require additional preclinical studies or clinical trials, which would be costly and time consuming. Regulatory requirements can vary widely from country to country
and could delay or prevent the introduction of our products in those countries. Satisfying these and other regulatory requirements is costly, time consuming, uncertain and subject to unanticipated delays. In addition, our failure to obtain
regulatory approval in any country may delay or have negative effects on the process for regulatory approval in other countries. We do not have any product candidates approved for sale in any jurisdiction, including international markets, and we do
not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or fail to obtain and maintain required approvals, our ability to realize the full market
potential of our products will be harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">51 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The impact of recent healthcare reform legislation and other changes in the healthcare industry and in healthcare
spending on us is currently unknown, and may adversely affect our business model. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our revenue prospects could be affected by changes in healthcare spending
and policy in the United States and abroad. We operate in a highly regulated industry and new laws, regulations or judicial decisions, or new interpretations of existing laws, regulations or decisions, related to healthcare availability, the method
of delivery or payment for healthcare products and services could negatively impact our business, operations and financial condition. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There have been, and
likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare, including proposals aimed at lowering
prescription drug prices and increasing competition for prescription drugs, as well as additional regulation on pharmaceutical transparency and reporting requirements, any of which could negatively impact our future profitability and increase our
compliance burden. We cannot predict the initiatives that may be adopted in the future, including future challenges or significant revisions to the ACA. The continuing efforts of the government, insurance companies, managed care organizations and
other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The demand for our product candidates, if we obtain regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our ability to set a price that we believe is fair for our products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our ability to obtain coverage and reimbursement approval for a product; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our ability to generate revenue and achieve or maintain profitability; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The level of taxes that we are required to pay; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The availability of capital. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect
our future profitability. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Commercialization of Our Product Candidates </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer
treatment centers and others in the medical community. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of our product candidates receive marketing approval, they may nonetheless fail to gain
sufficient market acceptance by physicians, patients, healthcare payors and others in the medical community. For example, existing cell therapies are currently offered only in tertiary academic hospitals that have intensive care units that can
support the safety and toxicity issues associated with cell therapies. If we are unable to demonstrate sufficient safety to permit a broader use of our product candidates, we may not generate significant product revenue and we may not become
profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The clinical indications for which our product candidates are approved; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe, pure and
effective treatment; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The potential and perceived advantages of our product candidates over alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our ability to demonstrate the advantages of our product candidates over other conventional
<FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The perceived prevalence and severity of any side effects for our product candidates compared to the prevalence and
severity of any side effects for conventional <FONT STYLE="white-space:nowrap">CAR-T</FONT> products and other cell therapies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Product labeling, limitations, warnings or product insert requirements of the FDA or foreign health authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The timing of market introduction of our product candidates as well as competitive products; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The cost of treatment in relation to alternative treatments; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">52 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The availability of adequate coverage, reimbursement and pricing by third-party payors and government authorities;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The willingness of patients to pay
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> in the absence of coverage by third-party payors and government authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Relative convenience and ease of administration, including as compared to alternative treatments and competitive
therapies; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The effectiveness of our sales and marketing efforts. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical
community, we will not be able to generate significant revenue. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if our products achieve market acceptance, we may not be able to maintain that market
acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may face difficulties from changes to current regulations and future legislation. Current and future legislation may increase the difficulty and cost for us to
commercialize our drugs, if approved, and affect the prices we may obtain, including changes in coverage and reimbursement policies in certain market segments for our product candidates, which could make it difficult for us to sell our product
candidates, if approved, profitably. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Existing regulatory policies may change, and additional government regulations may be enacted that could prevent,
limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we
are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not
achieve or sustain profitability. In both domestic and foreign markets, successful sales of our product candidates, if approved, will depend on the availability of adequate coverage and reimbursement from third-party payors. In addition, because our
product candidates represent novel approaches to the treatment of cancer and autoimmune diseases, we cannot accurately estimate the potential revenue from our product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patients who receive medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment.
Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs and treatments they will cover
and the amount of reimbursement. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#146;s determination that use of a product is: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A covered benefit under its health plan; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Medically necessary and has acceptable risk-benefit ratio; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Appropriate for the specific patient; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Cost-effective; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to
provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or
sustain profitability or may require <FONT STYLE="white-space:nowrap">co-payments</FONT> that patients find unacceptably high. Due to the high costs associated with cell therapies, patients are unlikely to use our product candidates unless coverage
is provided or reimbursement is adequate to cover a significant portion of the cost of our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, no uniform policy of coverage
and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly
process that will require us to provide scientific </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">53 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. If we obtain approval in one or more
foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in the European Union, the pricing of biologics is subject to governmental control.
In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of our product candidates will depend significantly
on the availability of adequate coverage and reimbursement from third-party payors for our product candidates and may be affected by existing and future healthcare reform measures. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ACA made extensive changes to the delivery of health care in the United States. We expect that the rebates, discounts, taxes and other costs resulting from the ACA
over time will have a negative effect on our expenses and profitability in the future. The ACA contains provisions that may reduce the profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of
Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part D beneficiaries and annual fees based on pharmaceutical companies&#146; share of sales to federal health care programs. For example, the ACA made several
changes to the Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#146; rebate liability by increasing the minimum basic Medicaid rebate on most branded prescription drugs. Additionally, for a drug product to receive
federal reimbursement under the Medicaid or Medicare Part B programs or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since the enactment of the ACA, there have been judicial and Congressional challenges to certain aspects of the ACA. In June 2021, the United States Supreme Court held
that Texas and other challengers had no legal standing to challenge the ACA, dismissing the case without specifically ruling on the constitutionality of the ACA. Accordingly, the ACA remains in effect in its current form. It is unclear how this
Supreme Court decision, future litigation, or healthcare measures promulgated by the Biden administration will impact our business, financial condition and results of operations. Complying with any new legislation or changes in healthcare regulation
could be time-intensive and expensive, resulting in material adverse effect on our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other legislative changes have been proposed and adopted in the United
States since the ACA was enacted. For example, the Budget Control Act of 2011, among other things, included reductions to CMS payments to providers of 2% per fiscal year, which went into effect in 2013 and, due to subsequent legislative amendments
to the statute, will remain in effect through 2030, with the exception of a temporary suspension implemented under various COVID-19 relief legislation from May 1, 2020 through March 31, 2021, unless additional Congressional action is taken. In
January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012 (the ATRA), which, among other things, reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers, and
increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Legislators, regulators and third-party payers may continue to put forth proposals to reduce costs while expanding
individual healthcare benefits, including proposals that impose additional limitations on the rates we will be able to charge for our product candidates, if approved, or the amount of reimbursement available for such approved products from
governmental agencies or third-party payers. Current and future healthcare reform legislation and policies could have a material adverse effect on our business and financial condition. We cannot predict what other health care programs and
regulations will ultimately be implemented at the federal or state level or the effect of any future legislation or regulation in the United States may have on our business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There has been heightened governmental scrutiny recently over the manner in which drug manufacturers set prices for their marketed products, which has resulted in
several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform
government program reimbursement methodologies for drug products. For example, in 2020, HHS and CMS issued various rules that are expected to impact, among others, price reductions from pharmaceutical manufacturers to plan sponsors under Part D, fee
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">54 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
arrangements between pharmacy benefit managers and manufacturers, manufacturer price reporting requirements under the Medicaid Drug Rebate Program, including regulations that affect
manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements, and manufacturer price reporting under Medicare Part B.
Multiple lawsuits have been brought against HHS challenging various aspects of the rules. In January 2021, the Biden administration issued a &#147;regulatory freeze&#148; memorandum that directs department and agency heads to review new or pending
rules of the prior administration. Under the American Rescue Plan Act of 2021, effective January 1, 2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid programs will be eliminated. Elimination of
this cap may require pharmaceutical manufacturers to pay more in rebates than it receives on the sale of products, which could have a material impact on our business. Further, in July 2021, the Biden administration released an executive order,
&#147;Promoting Competition in the American Economy,&#148; with multiple provisions aimed at increasing competition for prescription drugs. In response to this executive order, HHS released a Comprehensive Plan for Addressing High Drug Prices that
outlines principles for drug pricing reform and potential legislative policies that Congress could pursue to advance these principles. In addition, Congress is considering legislation that, if passed, could have significant impact on prices of
prescription drugs covered by Medicare, including limitations on drug price increases. The impact of these regulations and any future healthcare measures and agency rules implemented by the Biden administration on us and the pharmaceutical industry
as a whole is currently unknown. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our product candidates if approved. Complying
with any new legislation and regulatory changes could be time-intensive and expensive, resulting in a material adverse effect on our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At the state level,
individual states are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including discounts, restrictions on certain product access and marketing cost disclosure and
transparency measures. For example, a number of states are considering or have recently enacted state drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under such
state laws once we begin commercialization after obtaining regulatory approval for any of our products. These measures could reduce the demand for our products, if approved, or impose additional pricing pressures on how much we can charge for our
products if approved. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for
pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our
product candidates, if any, may be. In addition, increased scrutiny by the U.S. Congress of the FDA&#146;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and
post-approval testing and other requirements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or
administrative action, either in the United States or in other jurisdictions. If we or our collaborators are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or our collaborators
are not able to maintain regulatory compliance, our product candidates may lose any marketing approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We currently have no marketing and sales organization and have limited experience in marketing cell therapy products. If we are unable to establish marketing and
sales capabilities or enter into agreements with third parties to market and sell our product candidates, if approved, we may not be able to generate product revenue. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently have no sales, marketing or distribution capabilities and have limited experience in marketing cell therapy products. To achieve commercial success for any
approved product for which we retain sales and marketing responsibilities, we must either develop a sales and marketing organization, which would be expensive and time consuming, or outsource these functions to other third parties. In the future, we
may choose to build a focused sales and marketing infrastructure to sell, or participate in sales activities with our collaborators for, some of our product candidates if and when they are approved. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are risks involved with both establishing our own sales and marketing capabilities and entering into arrangements with third parties to perform these services.
For example, recruiting and training a sales force is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">55 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed
or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. We may
have little or no control over the marketing and sales efforts of third parties conducting such activities on our behalf and our revenue from product sales may be lower than if we had commercialized our product candidates <FONT
STYLE="white-space:nowrap">in-house.</FONT> We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There can be no assurance that we will be able to develop adequate <FONT STYLE="white-space:nowrap">in-house</FONT> sales and distribution capabilities or establish or
maintain relationships with third-party collaborators to commercialize any product in the United States or abroad. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Failure to comply with health and
data protection laws and regulations could lead to government enforcement actions (which could include civil or criminal penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may be subject to or affected by data protection laws and regulations, such as laws and regulations that address privacy and data security. In the
United States, numerous federal and state laws and regulations, including federal and state health information privacy laws, state data breach notification laws, and federal and state consumer protection laws, such as Section&nbsp;5 of the Federal
Trade Commission Act, govern the collection, use, disclosure and protection of health information and other personal information could apply to our operations. In addition, we may obtain health information from third parties, including research
institutions from which we obtain clinical trial data, that are subject to privacy and security requirements under HIPAA, as amended by HITECH, and its implementing rules and regulations. Depending on the facts and circumstances, we could be subject
to criminal penalties if we knowingly obtain, use, or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the California Consumer Privacy Act (CCPA) took effect in January 2020 and became enforceable in July 2020. The CCPA created new individual privacy rights
for California consumers (as the word is broadly defined in the law) and placed increased privacy and security obligations on many organizations that handle personal information of consumers or households. The CCPA requires covered companies to
provide new disclosure to consumers about such companies&#146; data collection, use and sharing practices, provide such consumers a new right to <FONT STYLE="white-space:nowrap">opt-out</FONT> of certain sales or transfers of personal information,
and provides consumers with a new cause of action for certain data breaches. Additionally, California voters voted to approve the California Privacy Rights Act (CPRA) in November 2020, which modifies the CCPA significantly, potentially resulting in
further uncertainty and requiring us to incur additional costs and expenses in an effort to comply. The CCPA and CPRA may impact our business activities and increase our compliance costs and potential liability. Many similar privacy laws have been
proposed at the federal level and in other states. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Compliance with data protection laws and regulations could require us to take on more onerous obligations
in our contracts, increase our costs of legal compliance, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. Failure to comply with data protection laws and regulations
could result in government investigations and/or enforcement actions (which could include civil, criminal, and administrative penalties), private litigation and/or adverse publicity and could negatively affect our operating results and business.
Moreover, clinical trial subjects about whom we or our potential collaborators obtain information, as well as the providers who share this information with us, may contractually limit our ability to use and disclose the information. Claims that we
have violated individuals&#146; privacy rights, failed to comply with data protection laws, or breached our contractual obligations, even if we are not found liable, could be expensive and time consuming to defend and could result in adverse
publicity that could harm our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">56 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>A variety of risks associated with seeking regulatory approval for and marketing our product candidates
internationally could materially adversely affect our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to seek regulatory approval of our product candidates outside of the United States
and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Differing regulatory requirements in foreign countries, including constraints on manufacturing; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Additional trials in foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Requirement to secure and validate region-specific manufacturing and clinical and commercial supply;
</P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Economic weakness, including inflation, or political instability in particular foreign economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Foreign taxes, including withholding of payroll taxes; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other
obligations incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Difficulties staffing and managing foreign operations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Workforce uncertainty in countries where labor unrest is more common than in the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Potential liability under the Foreign Corrupt Practices Act of 1977 or comparable foreign regulations;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not
respect and protect intellectual property rights to the same extent as the United States; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including war, global
pandemics and terrorism. </P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These and other risks associated with our international operations, including relating to data privacy and security,
may materially adversely affect our ability to attain or maintain profitable operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The European Union system for authorization of medicinal products for
human use offers several routes: the centralized procedure, the decentralized procedure, and the mutual recognition procedure, as well as domestic national routes. The centralized procedure provides for the grant of a single marketing authorization
that is valid for all European Union Member States as well as the European Economic Area (EEA) countries of Iceland, Liechtenstein and Norway. The centralized procedure is mandatory for certain categories of investigational products, including human
products containing a new active substance indicated for the treatment of certain diseases, including cancer, AIDS, diabetes and neurodegenerative illness; orphan medicinal products; and medicinal products manufactured using biotechnological
processes. Applications for marketing authorization for such medicines must be submitted to the European Medicines Agency (EMA), in which the Committee for Medicinal Products for Human Use (CHMP) is generally responsible for conducting the initial
assessment of a product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The decentralized and mutual recognition procedures are applicable to the majority of conventional medicinal products and are both based
on the principle of recognition of a marketing authorization by one or more Member States. Any national marketing authorization granted by a European Union Member State&#146;s national authority can be used to support an application for its mutual
recognition by other Member States. Marketing authorization applications can also be submitted directly to the Member State&#146;s national competent authority under the national route (if the centralized route is not compulsory). Following Brexit,
there are now multiple routes to obtain a marketing authorization in the United Kingdom, Great Britain or Northern Ireland, including national routes and international routes. The application procedure will depend on the relevant procedure chosen.
Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us to restrict or delay efforts to seek regulatory approval in the United Kingdom for our product candidates, which could
significantly and materially harm our business. Further, even after obtaining market authorization, differences in GMP, pharmacovigilance, and other regulatory requirements in different jurisdictions can increase our compliance costs and exposure to
potential liability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">57 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

   <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Inadequate funding for the FDA, the SEC and other government agencies could hinder their ability to hire
and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our
business may rely, which could negatively impact our business. </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ability of the FDA to review and approve new products can be affected by a variety
of factors, including government budget and funding levels and the ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes and other events that may otherwise affect the FDA&#146;s
ability to perform routine functions. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the Securities and Exchange Commission (SEC) and other government agencies on which our
operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. Disruptions at the FDA and other agencies, such as recent furloughs or government
shutdowns, may also increase the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Separately, in response to the COVID-19 pandemic, since March 2020 when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been
working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. The FDA has developed a rating system to assist in determining when and where it is safest to conduct prioritized domestic
inspections. As of May 2021, certain inspections, such as foreign preapproval, surveillance, and for-cause inspections that are not deemed mission-critical, remain temporarily postponed. In April 2021, the FDA issued guidance for industry formally
announcing plans to employ remote interactive evaluations, using risk management methods, to meet user fee commitments and goal dates and in May 2021 announced plans to continue progress toward resuming standard operational levels. Should FDA
determine that an inspection is necessary for approval and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, the FDA has stated
that it generally intends to issue a complete response letter or defer action on the application until an inspection can be completed. In 2020 and 2021, a number of companies announced receipt of complete response letters due to the FDA&#146;s
inability to complete required inspections for their applications. As of May&nbsp;26, 2021, the FDA noted it was continuing to ensure timely reviews of applications for medical products during the ongoing COVID-19 pandemic in line with its user fee
performance goals and conducting mission critical domestic and foreign inspections to ensure compliance of manufacturing facilities with FDA quality standards. However, the FDA may not be able to continue its current pace and review timelines could
be extended, including where a pre-approval inspection or an inspection of clinical sites is required and due to the ongoing COVID-19 pandemic and travel restrictions, the FDA is unable to complete such required inspections during the review period.
Regulatory authorities outside the U.S. may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown or other disruption
occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Future shutdowns or other disruptions could also affect other
government agencies such as the SEC, which may also impact our business by delaying review of our public filings, to the extent such review is necessary, and our ability to access the public markets. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regulatory authorities outside the United States may also impose similar restrictions or other policy measures in response to the COVID-19 pandemic. If a prolonged
government shutdown occurs, or if global health concerns continue to prevent the FDA or other regulatory authorities from conducting their regular inspections, reviews, or other regulatory activities, it could significantly impact the ability of the
FDA or other regulatory authorities to timely review and process our regulatory submissions, which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our business activities may be subject to the Foreign Corrupt Practices Act and similar anti-bribery and anti-corruption laws, as well as U.S. and certain foreign
export controls, trade sanctions, and import laws and regulations, all of which can subject us to criminal liability and other serious consequences for violations. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business activities may be subject to the U.S. Foreign Corrupt Practices Act (the FCPA), and similar anti-bribery or anti-corruption laws, regulations or rules of
other countries in which we operate. These laws generally prohibit companies and their employees and third party business partners, representatives and agents from engaging in corruption and bribery, including offering, promising, giving or
authorizing the provision of anything of value, either </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">58 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
directly or indirectly, to a government official or commercial party in order to influence official action, direct business to any person, gain any improper advantage, or obtain or retain
business. The FCPA also requires public companies to make and keep books and records that accurately and fairly reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. Our business
is heavily regulated and therefore involves significant interaction with government officials, including potentially officials of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governments. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, in many countries, healthcare providers are employed by the government, and the purchasers of biopharmaceuticals are government entities. As a result, our
dealings with these providers and purchasers are subject to regulation and such healthcare providers and employees of such purchasers may be considered &#147;foreign officials&#148; as defined in the FCPA. Recently, the SEC and Department of Justice
have increased their FCPA enforcement activities with respect to biotechnology companies. In addition to our own employees, we may in the future leverage third parties to conduct our business abroad, such as obtaining government licenses and
approvals. We and our third-party business partners, representatives and agents may have direct or indirect interactions with officials and employees of government agencies, state-owned or affiliated entities and we may be held liable for the
corrupt or other illegal activities of our employees, our third-party business partners, representatives and agents, even if we do not explicitly authorize such activities. There is no certainty that our employees or the employees of our third-party
business partners, representatives and agents will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in whistleblower complaints,
adverse media coverage, investigations, loss of export privileges, debarment from U.S. government contracts, substantial diversion of management&#146;s attention, significant legal fees and fines, severe criminal or civil sanctions against us, our
officers, or our employees, disgorgement and other sanctions and remedial measures, and prohibitions on the conduct of our business. Any such violations could include prohibitions on our ability to offer our products in one or more countries and
could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees, and our business, prospects, operating results, financial condition and stock price. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, our products may be subject to U.S. and foreign export controls, trade sanctions and import laws and regulations. Governmental regulation of the import or
export of our products, or our failure to obtain any required import or export authorization for our products, when applicable, could harm our business. Furthermore, U.S. export control laws and economic sanctions prohibit the provision of certain
products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export
privileges. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to this Offering and Ownership of our Common Stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We do not know whether an active, liquid, and orderly trading market will develop for our common stock or what the market price of our common stock will be and,
as a result, it may be difficult for you to sell your shares of our common stock. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, there was no public trading market for shares of
our common stock. Although we have applied to list our common stock on the Nasdaq Global Market, an active trading market for our shares may never develop or be sustained following this offering. You may not be able to sell your shares quickly or at
the market price if trading in shares of our common stock is not active. The initial public offering price for our common stock will be determined through negotiations with the underwriters and may bear no relationship to the price at which our
common stock will trade after this offering. As a result of these and other factors, you may be unable to resell your shares of our common stock at or above the initial public offering price, at the time you wish to sell them or at a price that you
consider reasonable, or at all. The lack of an active market may also reduce the fair market value of your shares. Further, an inactive market may also impair our ability to raise capital by selling shares of our common stock and may impair our
ability to enter into strategic partnerships or acquire companies or products by using our shares of our common stock as consideration. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The price of shares
of our common stock may be volatile and may be adversely impacted by future events, and you could lose all or part of your investment. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trading price of
our common stock following this offering is likely to be highly volatile and could be subject to wide fluctuations in response to various factors, many of which are beyond our control, including limited trading
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">59 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
volume. In addition to the factors discussed in this &#147;Risk Factors&#148; section and elsewhere in this prospectus, these factors include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our decision to initiate a clinical trial, not to initiate a clinical trial, or to terminate an existing clinical trial;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The commencement, enrollment, or results of the clinical trials of our product candidates or any future clinical trials we
may conduct, or changes in the development status of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Results from ongoing clinical trials and future clinical trials of our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse
development with respect to the applicable regulatory authority&#146;s review of such filings, including without limitation the FDA&#146;s issuance of a &#147;refusal to file&#148; letter or a request for additional information;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our failure to achieve product development goals in the timeframes we announce; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Adverse results or delays in clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Changes in laws or regulations applicable to our product candidates, including, but not limited to, clinical trial
requirements for approvals; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Adverse developments concerning our manufacturers; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our inability to obtain adequate supply for any product candidate, or any component thereof, or approved product or
inability to do so at acceptable prices; </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our inability to establish collaborations if needed; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our failure to commercialize our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Unanticipated serious safety concerns related to the use of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Introduction of new products or other therapies offered by us or our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Announcements of significant acquisitions, strategic partnerships, joint ventures, or capital commitments by us or our
competitors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Additions or departures of key scientific or management personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our ability to effectively manage our growth; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The size and growth of our initial cancer target markets; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our ability to successfully treat additional types of cancers or at different stages; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Actual or anticipated variations in quarterly operating results; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our cash position; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our failure to meet the estimates and projections of the investment community or that we may otherwise provide to the
public; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Publication of research reports about us or our industry, or positive or negative recommendations or withdrawal of
research coverage by securities analysts; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Changes in the market valuations of similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our operating performance and the performance of other similar companies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Overall performance of the equity markets; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The expiration of market <FONT STYLE="white-space:nowrap">stand-off</FONT> or contractual
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Sales of our common stock by us or our stockholders in the future; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Trading volume of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Changes in accounting practices; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Ineffectiveness of our internal controls; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to
obtain patent protection for our technologies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Significant lawsuits, including patent or stockholder litigation; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">General political and economic conditions, including the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
global pandemic; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Other events or factors, many of which are beyond our control. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">60 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the stock market in general, and biopharmaceutical companies in particular, have experienced extreme price
and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual
operating performance. If the market price of our common stock after this offering does not exceed the initial public offering price, you may not realize any return on your investment in us and may lose some or all of your investment. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume
could decline. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about
us or our business. Securities and industry analysts do not currently, and may never, publish research on our company. If no, or very few, securities or industry analysts commence coverage of our company, the trading price for our stock would likely
be negatively impacted. In the event securities or industry analysts initiate coverage, if one or more of the analysts who covers us downgrades our stock or publishes inaccurate or unfavorable research about our business, our stock price may
decline. If one or more of these analysts ceases coverage of our company or fails to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant influence over matters subject to
stockholder approval. </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, our executive officers, directors, and 5% stockholders beneficially owned approximately 60.7% of our
voting stock as of September&nbsp;30, 2021, and, assuming the sale by us of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock in this offering, based on an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, that same group will hold approximately
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding voting stock immediately after this offering (assuming no exercise of the underwriters&#146; option to purchase additional shares). Therefore, even after
this offering, these stockholders will have the ability to influence us through this ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control
elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that
you may feel are in your best interests as one of our stockholders. Further, the significant concentration of stock ownership may adversely affect the market price of our common stock due to investors&#146; perception that conflicts of interest may
exist or arise. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If you purchase our common stock in this offering, you will incur immediate and substantial dilution in the book value of your shares.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The initial public offering price will be substantially higher than the net tangible book value per share of our common stock. Investors purchasing common
stock in this offering will pay a price per share that substantially exceeds the book value of our tangible assets after subtracting our liabilities. As a result, investors purchasing common stock in this offering will incur immediate dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, based on the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of our common stock, which
is the midpoint of the price range set forth on the cover page of this prospectus. Further, investors purchasing common stock in this offering will contribute approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of
the total amount invested by stockholders since our inception, but will own only approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding after this
offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This dilution is due to our investors who purchased shares prior to this offering having paid substantially less when they purchased their shares than
the price offered to the public in this offering and the exercise of stock options granted to our employees. To the extent that outstanding stock options are exercised, we issue restricted stock to our employees under our equity incentive plans or
if we otherwise issue additional shares of our common stock in each case at per share prices below the price to the public in this offering, there will be further dilution to new investors. As a result of the dilution to investors purchasing common
stock in this offering, investors may receive significantly less than the purchase price paid in this offering, if anything, in the event of our liquidation. For a further description of the dilution that you will experience immediately after this
offering, see &#147;Dilution.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">61 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are an emerging growth company and a smaller reporting company, and we cannot be certain if the reduced
reporting requirements applicable to emerging growth companies and smaller reporting companies will make our common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an emerging growth company, as defined in the Jumpstart Our Business Startups Act (JOBS Act) enacted in April 2012. For as long as we continue to be an emerging
growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation
requirements of Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as amended (Sarbanes-Oxley Act), reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements, and exemptions
from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an emerging growth company for up to five years following the year in
which we complete this offering, although circumstances could cause us to lose that status earlier. We will remain an emerging growth company until the earlier of (1)&nbsp;the last day of the fiscal year (a)&nbsp;following the fifth anniversary of
the closing of this offering, (b)&nbsp;in which we have total annual gross revenue of at least $1.07&nbsp;billion, or (c)&nbsp;in which we are deemed to be a large accelerated filer, which requires, among other things, that the market value of our
common stock that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> to exceed $700&nbsp;million as of the prior June&nbsp;30th, and (2)&nbsp;the date on which we have issued more than $1&nbsp;billion in
<FONT STYLE="white-space:nowrap">non-convertible</FONT> debt during the prior three-year period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even after we no longer qualify as an emerging growth company, we
may still qualify as a &#147;smaller reporting company,&#148; which would allow us to take advantage of many of the same exemptions from disclosure requirements, including not being required to comply with the auditor attestation requirements of
Section&nbsp;404 of the Sarbanes-Oxley Act and reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy statements. We cannot predict if investors will find our common stock less
attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies.
We have elected to use this extended transition period under the JOBS Act. As a result, our consolidated financial statements may not be comparable to the financial statements of issuers who are required to comply with the effective dates for new or
revised accounting standards that are applicable to public companies, which may make comparison of our financials to those of other public companies more difficult. As a result, changes in rules of U.S. generally accepted accounting principles or
their interpretation, the adoption of new guidance, or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time and
resources to new compliance initiatives. </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a public company, and particularly after we are no longer an emerging growth company or a smaller reporting
company, we will incur significant legal, accounting, and other expenses that we did not incur as a private company. We will be subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (Exchange Act), which will
require, among other things, that we file with the SEC annual, quarterly, and current reports with respect to our business and financial condition. Compliance with the various reporting and other requirements applicable to public companies requires
considerable time and attention of management. We cannot assure you that we will satisfy our obligations as a public company on a timely basis. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition,
the Sarbanes-Oxley Act, as well as rules subsequently adopted by the SEC and the Nasdaq Stock Market (Nasdaq) to implement provisions of the Sarbanes-Oxley Act, impose significant requirements on public companies, including requiring establishment
and maintenance of effective disclosure and financial controls and changes in corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act (Dodd-Frank Act) was enacted. There are significant
corporate governance and executive compensation related provisions in the Dodd-Frank Act that require the SEC to adopt additional rules and regulations in these areas, such as &#147;say on pay&#148; and proxy access. Recent legislation permits
emerging growth companies to implement many of these requirements over a longer period and up to five years from the pricing of this offering. We intend to take advantage of this new legislation but cannot guarantee that we will not be required to
implement these requirements </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">62 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment, and the current high level of government intervention and
regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Changing laws, regulations and standards relating to corporate governance and public disclosure, including the Sarbanes-Oxley Act and regulations implemented by the SEC
and Nasdaq may increase legal and financial compliance costs and make some activities more time consuming. These laws, regulations and standards are subject to varying interpretations and, as a result, their application in practice may evolve over
time as new guidance is provided by regulatory and governing bodies. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a
diversion of management&#146;s time and attention from revenue-generating activities to compliance activities. We expect the rules and regulations applicable to public companies to substantially increase our legal and financial compliance costs and
to make some activities more time-consuming and costly. If these requirements divert the attention of our management and personnel from other business concerns, they could have a material adverse effect on our business, financial condition, and
results of operations. The increased costs will decrease our net income or increase our net loss and may require us to reduce costs in other areas of our business or increase the prices of our products or services. For example, we expect these rules
and regulations to make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to incur substantial costs to maintain the same or similar coverage. We cannot predict or estimate the
amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board
committees, or as executive officers. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Substantial amounts of our outstanding shares may be sold into the market when
<FONT STYLE="white-space:nowrap">lock-up</FONT> or market standoff periods pertaining to this offering end. Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to
fall. </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after the <FONT
STYLE="white-space:nowrap">lock-up</FONT> and other legal restrictions on resale discussed in this prospectus lapse, the trading price of our common stock could decline. Based on the number of shares of common stock outstanding as of
September&nbsp;30, 2021, upon the closing of this offering, we will have outstanding a total of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock. Of these shares, only the shares of common stock
sold in this offering by us, plus any shares sold upon exercise of the underwriters&#146; option to purchase additional shares, will be freely tradable without restriction in the public market immediately following this offering, unless purchased by
our affiliates. The underwriters, however, may, in their discretion, permit our officers, directors, and other stockholders who are subject to these <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements to sell shares prior to the expiration of
the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements pertaining to this offering will
expire 180 days from the date of this prospectus. In addition, upon completion of this offering, approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock that are either subject to
outstanding equity awards or reserved for future issuance under our equity incentive plans will become eligible for sale in the public market to the extent permitted by the provisions of various vesting schedules, the
<FONT STYLE="white-space:nowrap">lock-up</FONT> and <FONT STYLE="white-space:nowrap">stand-off</FONT> agreements described above and applicable securities laws. We plan to register under the Securities Act of 1933, as amended (the Securities Act),
all &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock that we may issue under our equity incentive plans. Once we register these shares, they can be freely sold in the public market upon
issuance and once vested, subject to volume limitations applicable to affiliates and the <FONT STYLE="white-space:nowrap">lock-up</FONT> and <FONT STYLE="white-space:nowrap">stand-off</FONT> agreements described above. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After this offering, the holders of up to 136,422,468 shares of our common stock will be entitled to rights with respect to the registration of their shares under the
Securities Act, subject to the <FONT STYLE="white-space:nowrap">180-day</FONT> <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements described above. See &#147;Description of Capital Stock&#151;Registration Rights.&#148; Registration of these
shares under the Securities Act would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule&nbsp;144 under the Securities Act. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The market price of the shares of our common stock could decline as a result of the sale of a substantial number of our shares of common stock in the public market or
the perception in the market that the holders of a large number of shares intend to sell their shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">63 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity
incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect
that significant additional capital may be needed in the future to continue our planned operations, which include conducting clinical trials, pursuing commercialization efforts, expanding research and development activities, and operating as a
public company. To raise capital, we may sell common stock, convertible securities, or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities, or
other equity securities, investors may be materially diluted by subsequent sales. Such sales may also result in material dilution to our existing stockholders, and new investors could gain rights, preferences, and privileges senior to the holders of
our common stock, including shares of common stock sold in this offering. If we raise additional funds through <FONT STYLE="white-space:nowrap">up-front</FONT> payments or milestone payments pursuant to strategic collaborations with third parties,
we may have to relinquish valuable rights to our drug candidates, or grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe
we have sufficient funds for our current or future operating plans. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the 2022 Plan, which will become effective upon the business day immediately
prior to the date of effectiveness of the registration statement of which this prospectus is a part, our management is authorized to grant equity awards to our employees, directors, and consultants. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Initially, the aggregate number of shares of our common stock that may be issued pursuant to equity awards under the 2022 Plan will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares, plus (i)&nbsp;the shares of common stock remaining available for issuance under our 2017 Plan and (ii)&nbsp;shares subject to awards granted under our 2017 Plan
that, after the date of stockholder approval of the 2022 Plan, expire or otherwise terminate without having been exercised in full or are forfeited to or repurchased by us (provided that the maximum number of shares that may be added to the 2022
Plan pursuant to (i)&nbsp;and (ii) is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares). The number of shares of our common stock reserved for issuance under the 2022 Plan shall be cumulatively increased on the first
day of each fiscal year, beginning with our 2023 fiscal year and ending on our &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fiscal year equal to the least of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding as of the last day of the
immediately preceding fiscal year, and a lesser number of shares determined by our board of directors. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience
additional dilution, which could cause our stock price to fall. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, we expect to adopt our 2022 ESPP, which will become effective upon the business day
immediately prior to the date of effectiveness of the registration statement of which this prospectus is a part, and pursuant to which our management is authorized to grant rights to our employees to purchase shares of our common stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Initially, the aggregate number of shares of our common stock available for sale under our 2022 ESPP will be
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares. The number of shares of our common stock available for sale under our 2022 ESPP shall be cumulatively increased on the first day of each fiscal year, beginning
with our 2023 fiscal year and ending on our &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fiscal year equal to the lesser of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
shares,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the total number of shares of our common stock outstanding as of the last day of the immediately preceding fiscal year, or a lesser number of shares determined by
our board of directors. Unless our board of directors elects not to increase the number of shares available for future grant each year, our stockholders may experience additional dilution, which could cause our stock price to fall. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business
could be harmed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate
financial statements on a timely basis is a costly and time-consuming effort that needs to be evaluated frequently. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements in accordance with generally accepted accounting principles. In connection with this offering, we intend to begin the process of documenting, reviewing, and improving our internal
controls and procedures for compliance with Section&nbsp;404 of the Sarbanes-Oxley Act, which will require annual management assessment of the effectiveness of our internal control </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">64 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
over financial reporting. We have begun recruiting additional finance and accounting personnel with certain skill sets that we will need as a public company. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Implementing any appropriate changes to our internal controls may distract our officers and employees, entail substantial costs to modify our existing processes, and
take significant time to complete. These changes may not, however, be effective in maintaining the adequacy of our internal controls, and any failure to maintain that adequacy, or consequent inability to produce accurate financial statements on a
timely basis, could increase our operating costs and harm our business. We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our consolidated financial
statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control
system&#146;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and
instances of fraud will be detected. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are not able to comply with the requirements of Section&nbsp;404 of the Sarbanes-Oxley Act in a timely manner, or if we
are unable to maintain proper and effective internal controls over financial reporting, we may not be able to produce timely and accurate financial statements. If that were to happen, our investors could lose confidence in our reported financial
information, the market price of our stock could decline, and we could be subject to sanctions or investigations by the SEC or other regulatory authorities. In addition, investors&#146; perceptions that our internal controls are inadequate or that
we are unable to produce accurate financial statements on a timely basis may harm our stock price and make it more difficult for us to effectively market and sell our service to new and existing customers. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to maintain effective internal controls, our business, financial position and results of operations could be adversely affected. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the closing of this offering, we will become subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures
to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules
and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control
system are met. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These inherent limitations include the facts that judgments in decision-making can be faulty and that breakdowns can occur because of simple error
or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system,
misstatements due to error or fraud may occur and not be detected. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have broad discretion in the use of the net proceeds from this offering and may not use
them effectively or in ways that increase the value of our share price. </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our management will have broad discretion in the application of the net
proceeds from this offering, including for any of the purposes described in the section entitled &#147;Use of Proceeds,&#148; and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used
appropriately. Because of the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management might not apply our net
proceeds in ways that ultimately increase or maintain the value of your investment. We intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, to fund the development of our
product candidates CART-ddBCMA, <FONT STYLE="white-space:nowrap">ACLX-001</FONT> and <FONT STYLE="white-space:nowrap">ACLX-002</FONT> and for other research and development activities, working capital and other general corporate purposes. However,
we cannot specify with certainty all of the particular uses of the net proceeds that we will receive from this offering and our existing cash, or the amounts that we will actually spend on the uses set forth above. The amounts and timing of our
actual expenditures will depend on numerous factors, including the ongoing status of and results from clinical trials and other studies, the product approval process with the FDA, and the scope of our commercialization efforts, as well as any
strategic collaborations that we may enter into with third parties for our product candidates, any unforeseen cash needs, and our investments and acquisitions. The failure by our management to apply these funds effectively could harm our business,
result in financial losses that could cause the price of our common stock to decline and delay the development of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">65 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pending their use, we may invest the net proceeds from this offering in short-term, interest-bearing, investment-grade
instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government in a manner that does not produce income or that loses value. These investments may not yield a favorable return to our stockholders. If we do not invest
or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We do not intend to pay dividends on our common stock, so any returns will be limited to the capital appreciation of our stock. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You should not rely on an investment in our common stock to provide dividend income. We have never declared or paid any cash dividends on our common stock. We currently
anticipate that we will retain future earnings for the development, operation, and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of any future debt
agreements may preclude us from paying dividends. Any return to stockholders will therefore be limited to the appreciation of their stock, which may never occur. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Certain provisions under our charter documents and Delaware law could delay or prevent a change of control, which could limit the market price of our common stock
and may prevent or frustrate attempts by our stockholders to replace or remove our current management. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of
incorporation and amended and restated bylaws, which are to become effective upon the closing of this offering, will contain provisions that could discourage, delay or prevent a change of control of our company or changes in our board of directors
that our stockholders might consider favorable. Some of these provisions include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A board of directors divided into three classes serving staggered three-year terms, such that not all members of the board
will be elected at one time, which could delay the ability of stockholders to change the membership of a majority of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The exclusive right of our board of directors to elect a director to fill a vacancy created by the expansion of our board
of directors or the resignation, death, disqualification or removal of a director, which prevents stockholders from being able to fill vacancies on our board of directors; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at an
annual or special meeting of our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A requirement that special meetings of stockholders be called only by the chairperson of our board of directors, our Chief
Executive Officer, our President, or our board of directors acting pursuant to a resolution adopted by a majority of our board of directors, which could delay the ability of our stockholders to force consideration of a proposal or to take action,
including the removal of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Advance notice requirements for stockholder proposals and nominations for election to our board of directors, which may
discourage or deter a potential acquirer from conducting a solicitation of proxies to elect the acquirer&#146;s own slate of directors or otherwise attempting to obtain control of us; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A requirement that no member of our board of directors may be removed from office by our stockholders except for cause
and, in addition to any other vote required by law, upon the approval of not less than a majority of the shares present in person or by proxy at the meeting and entitled to vote, which could delay the ability of stockholders to change the membership
of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A requirement of approval of not less than <FONT STYLE="white-space:nowrap">two-thirds</FONT> of all outstanding shares of
our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation, which may inhibit the ability of an acquirer to affect such amendments to facilitate an unsolicited takeover attempt; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The authority of the board of directors to issue preferred stock on terms determined by the board of directors without
stockholder approval, which preferred stock may include rights superior to the rights of the holders of common stock and could be used to significantly dilute the ownership of a hostile acquirer. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporate Law, which may prohibit
certain business combinations with stockholders owning 15% or more of our outstanding voting stock. A Delaware corporation may opt out of this provision by express provision in its original certificate of incorporation or by amendment to its
certificate of incorporation or bylaws approved by its stockholders. However, we have not opted out of this provision. These anti-takeover provisions and other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">66 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirers to obtain control of our
board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer, or proxy contest involving our company. These provisions could also discourage proxy contests and
make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could
cause the market price of our common stock to decline and limit opportunities for you to realize value in a corporate transaction. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our amended and restated
bylaws that will become effective upon the closing of this offering provide that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all
disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated bylaws that will become effective upon the closing of this offering provide that the Court of Chancery of the State of Delaware (or, if the
Court of Chancery does not have jurisdiction, another state court in Delaware) is the exclusive forum for the following (except for any claim as to which such court determines that there is an indispensable party not subject to the jurisdiction of
such court (and the indispensable party does not consent to the personal jurisdiction of such court within 10&nbsp;days following such determination), which is vested in the exclusive jurisdiction of a court or forum other than such court or for
which such court does not have subject matter jurisdiction): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Any derivative action or proceeding brought on our behalf; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Any action asserting a claim of breach of fiduciary duty; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Any action asserting a claim against us arising under the Delaware General Corporation Law (DGCL), our amended and
restated certificate of incorporation or our amended and restated bylaws; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Any action asserting a claim against us that is governed by the internal-affairs doctrine. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have
exclusive jurisdiction. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated bylaws further provide that the federal district courts of the United States of America will be the exclusive
forum for resolving any complaint asserting a cause of action arising under the Securities Act. For the avoidance of doubt, this provision shall not apply to any claim brought to enforce a duty or liability created by the Exchange Act. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These exclusive-forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our
directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. Any person or entity purchasing or otherwise acquiring any interest in any of our securities shall be deemed to have
notice of and consented to these provisions. There is uncertainty as to whether a court would enforce such provisions, and the enforceability of similar choice of forum provisions in other companies&#146; charter documents has been challenged in
legal proceedings. It is possible that a court could find these types of provisions to be inapplicable or unenforceable, and if a court were to find either exclusive-forum provision in our amended and restated bylaws to be inapplicable or
unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We could be subject to securities class action litigation. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the
past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because pharmaceutical companies have experienced significant stock
price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management&#146;s attention and resources, which could harm our business, operating results, or financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">67 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_5"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus contains forward-looking statements. All statements other than statements of historical facts contained in this prospectus, including statements
regarding our future results of operations and financial position, business strategy, plans for our product candidates, planned preclinical studies and clinical trials, results of clinical trials, future research and development costs, regulatory
approvals, timing and likelihood of success, as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in
some cases beyond our control and may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In some cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;should,&#148; &#147;would,&#148; &#147;expect,&#148;
&#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148; &#147;project,&#148; &#147;contemplate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential&#148; or
&#147;continue&#148; or the negative of these terms or other similar expressions. Forward-looking statements contained in this prospectus include, but are not limited to, statements about: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The impact of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or other related disruptions on our
business; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other favorable
results; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our plans relating to the clinical development of our product candidates, including the disease areas to be evaluated;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The timing and focus of our clinical trials, and the reporting of data from those trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our ability to take advantage of expedited regulatory pathways for our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and
sales strategy; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The expected benefits of potential strategic collaborations with third parties and our ability to attract collaborators
with development, regulatory and commercialization expertise; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The size of the market opportunity for our product candidates and our ability to maximize those opportunities;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The success of competing therapies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our estimates of the number of patients who suffer from the diseases we are targeting and the number of participants that
will enroll in our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The timing or likelihood of regulatory filings and approvals, including our expectation to seek special designations, such
as orphan drug designation, for our product candidates for various diseases; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our ability to obtain and maintain regulatory approval of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our ability to adequately secure our information technology systems and the regulated data stored therein, as required by
law; </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The pricing and reimbursement of our product candidates, if approved; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our plans relating to the further development and manufacturing of our product candidates, including for additional
indications that we may pursue; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Existing regulations and regulatory developments in the United States and other jurisdictions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms
where available; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our reliance on third parties to conduct clinical trials of our product candidates and manufacture of our product
candidates for preclinical studies and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The need to hire additional personnel and our ability to attract and retain such personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The accuracy of our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our financial performance; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The sufficiency of our existing cash and cash equivalents to fund our future operating expenses and capital expenditure
requirements; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">68 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our anticipated use of our existing resources and the proceeds from this offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we operate and financial
trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking statements speak only as of
the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described in the section titled &#147;Risk Factors&#148; and elsewhere in this prospectus. Because forward-looking statements are inherently subject to
risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be
achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein
until after we distribute this prospectus, whether as a result of any new information, future events or otherwise. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, statements that &#147;we
believe&#148; and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable
basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These
statements are inherently uncertain and you are cautioned not to unduly rely upon these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">69 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_6"></A>MARKET, INDUSTRY AND OTHER DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus contains estimates, projections and other information concerning our industry, our business and the potential markets for our product candidates,
including data regarding the estimated size of such markets and the incidence of certain medical conditions. We obtained the industry, market and similar data set forth in this prospectus from our internal estimates and research and from academic
and industry research, publications, surveys and studies conducted by third parties, including governmental agencies. Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to
uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information. While we believe that the data we use from third parties are reliable, we have not separately verified these
data. Further, while we believe our internal research is reliable, such research has not been verified by any third party. You are cautioned not to give undue weight to any such information, projections and estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">70 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate that the net proceeds to us from the sale of the shares of our common stock in this offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to purchase additional shares in full, based upon the assumed initial
public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and
commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share would increase (decrease) the net proceeds to us from this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the number of shares offered by us,
as set forth on the cover page of this prospectus, remains the same, and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. Similarly, each increase (decrease) of 1.0&nbsp;million shares
in the number of shares offered by us would increase (decrease) the net proceeds to us from this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the assumed initial public offering price remains the
same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. We do not expect that a change in the initial public offering price or the number of shares by these amounts would have a
material effect on our uses of the proceeds from this offering, although it may accelerate the time at which we will need to seek additional capital. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The principal
purposes of this offering are to obtain additional capital to support our operations, establish a public market for our common stock and facilitate our future access to the public capital markets. We currently anticipate that we will use the net
proceeds from this offering, together with our existing cash and cash equivalents, as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Approximately $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million to fund the development of CART-ddBCMA, our first
product candidate based on our ddCAR platform, as a treatment for r/r MM through iMMagine, our planned pivotal Phase&nbsp;2 clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to fund the development of
product candidates under our ARC-SparX platform, including our planned Phase 1 clinical trials of ACLX-001 as a treatment for r/r MM and ACLX-002 as a treatment for r/r AML and high risk MDS; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The remaining proceeds, if any, for other research and development opportunities, developing our manufacturing capacity,
working capital and general corporate purposes. </P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe opportunities may exist from time to time to expand our current business through
license or acquisitions of, or investments in, complementary businesses, products or technologies. While we have no current agreements, commitments or understandings for any specific licenses, acquisitions or investments at this time, we may use a
portion of the net proceeds for these purposes. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we believe that our available cash and cash equivalents, will be sufficient to fund our planned operations
for at least twelve months following the date of this offering without the proceeds from this offering, this belief is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we currently expect.
Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than planned. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our management will have broad discretion over the use of the net proceeds from this offering. The amounts and timing of our expenditures will depend upon numerous
factors including the results of our research and development efforts, the timing and success of preclinical studies and any ongoing clinical trials or clinical trials we may commence in the future, the timing of regulatory submissions, any funding
we may obtain through future collaborations, if any, and any unforeseen cash needs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pending their uses, we plan to invest the net proceeds of this offering in
short-term, interest-bearing, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">71 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_8"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have not declared or paid any cash dividends on our capital stock since our inception. We intend to retain future earnings, if any, to finance the operation and
expansion of our business and do not anticipate paying any cash dividends in the foreseeable future. Payment of future cash dividends, if any, will be at the discretion of our board of directors after taking into account various factors, including
our financial condition, operating results, current and anticipated cash needs, the requirements and contractual restrictions of then-existing debt instruments and other factors that our board of directors deems relevant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">72 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_9"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth our cash and cash equivalents, marketable securities and capitalization as of September&nbsp;30, 2021, as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">On an actual basis; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">On a pro forma basis to reflect the conversion of all outstanding shares of our redeemable convertible preferred stock as
of September&nbsp;30, 2021 into an aggregate of 136,422,468 shares of common stock upon the closing of this offering and the filing and effectiveness of our amended and restated certificate of incorporation; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">On a pro forma as adjusted basis to further reflect our issuance and sale of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the estimated offering price
range set forth on the cover page of this prospectus, after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You should read this information in conjunction with our financial statements and the related notes appearing elsewhere in this prospectus, as well as the section of
this prospectus titled &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="69%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF SEPTEMBER 30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA&nbsp;AS<BR>ADJUSTED&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>(in thousands, except per share data) </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(unaudited) </B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents and marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">131,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">131,182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred stock, $0.001 par value per share; 136,422,468 shares authorized, issued
and outstanding, actual; no shares authorized, issued or outstanding pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">233,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stockholders&#146; equity (deficit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Preferred stock, $0.001 par value; no shares authorized, issued or outstanding, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized and no shares issued or outstanding, pro forma and pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common stock, $0.001 par value per share; 185,000,000 shares authorized, 2,796,012 shares issued and
outstanding, actual; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma
(unaudited);&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">238,891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(109,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(109,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total stockholders&#146; (deficit) equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(103,795</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">129,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total capitalization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">129,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">129,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the estimated offering price
range set forth on the cover page of this prospectus, would increase (decrease) our pro forma as adjusted cash and cash equivalents and marketable securities, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total
stockholders&#146; equity (deficit) and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares of common stock offered by us, as set forth on the
cover page of this prospectus, remains the same, and after deducting the estimated underwriting discounts and commissions and estimated offering expenses payable by us. Each increase (decrease) of 1.0&nbsp;million shares in the number of shares of
common stock offered by us would increase (decrease) our pro forma as adjusted cash and cash equivalents and marketable securities, additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital, total stockholders&#146; equity (deficit) and
total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, assuming the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, remains the same, and after deducting estimated
underwriting discounts and commissions and estimated offering expenses payable by us. The pro forma as adjusted information discussed above is illustrative only and will be adjusted based on the actual public offering price and other terms of this
offering determined at pricing. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">73 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of shares of our common stock to be outstanding after this offering is based on the 139,218,480 shares of
our common stock outstanding as of September 30, 2021 (including an aggregate of 136,422,468 shares of common stock issuable upon conversion of our outstanding redeemable convertible preferred stock as of September&nbsp;30, 2021), and excludes the
following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">28,795,570 shares of common stock issuable upon exercise of options to purchase shares of our common stock outstanding as
of September 30, 2021, at a weighted-average exercise price of $0.95 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">An award of restricted stock units covering 5,244,329 shares of our common stock; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon exercise of
options to purchase shares of our common stock that we granted after September 30, 2021, at a weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future
issuance under our 2017 Plan, as amended, which shares will be added to the shares to be reserved under our 2022 Plan upon its effectiveness; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future
issuance under our 2022 Plan, which will become effective on the business day immediately prior to the date of effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of
shares of common stock reserved for future issuance under this plan; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for issuance under
our 2022 ESPP, which will become effective on the business day immediately prior to the date of effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common
stock reserved for future issuance under this plan. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">74 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_10"></A>DILUTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you invest in our common stock in this offering, your ownership interest will be diluted immediately to the extent of the difference between the initial public
offering price per share of our common stock and the pro forma as adjusted net tangible book value per share of our common stock immediately after this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our historical net tangible book value (deficit) as of September 30, 2021 was approximately $(105.6) million, or $(37.79) per share of our common stock. Our historical
net tangible book value (deficit) is the amount of our total tangible assets, adjusted to remove capitalized deferred offering costs we expect to recognize as an offset to the proceeds from this offering, less our total liabilities and redeemable
convertible preferred stock, which is not included within our stockholders&#146; (deficit) equity. Historical net tangible book value per share represents historical net tangible book value (deficit) divided by the number of shares of our common
stock outstanding as of September 30, 2021. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our pro forma net tangible book value (deficit) as of September 30, 2021 was approximately $127.7 million, or $0.92 per
share of our common stock. Pro forma net tangible book value (deficit) represents the amount of our total historical net tangible book value (deficit) as of September 30, 2021, after giving effect to the conversion of all outstanding shares of our
redeemable convertible preferred stock into an aggregate of 136,422,468 shares of common stock upon the closing of this offering. Pro forma net tangible book value per share represents pro forma net tangible book value divided by the total number of
shares outstanding as of September 30, 2021, after giving effect to the conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate of 136,422,468 shares of our common stock upon the closing of this offering.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After giving further effect to our sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock in this offering at the assumed initial public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, and after deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us, our pro forma as adjusted net tangible book value as of September 30, 2021 would have been approximately $ &nbsp;&nbsp;&nbsp;&nbsp;million, or $&nbsp;&nbsp;&nbsp;&nbsp;per share. This represents an immediate increase
in pro forma as adjusted net tangible book value per share of $&nbsp;&nbsp;&nbsp;&nbsp;to our existing stockholders and an immediate dilution in pro forma as adjusted net tangible book value per share of $&nbsp;&nbsp;&nbsp;&nbsp;to new investors
purchasing common stock in this offering. Dilution per share to new investors purchasing common stock in this offering is determined by subtracting pro forma as adjusted net tangible book value per share after this offering from the assumed initial
public offering price per share paid by new investors. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table illustrates this dilution on a per share basis: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Assumed initial public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Historical net tangible book value (deficit) per share as of September 30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(37.79</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma increase in net tangible book value (deficit) per share as of September 30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38.71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net tangible book value (deficit) per share as of September 30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in pro forma as adjusted net tangible book value per share attributable to new investors
purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma as adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dilution per share to new investors purchasing shares in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the
estimated offering price range set forth on the cover page of this prospectus, would increase (decrease) the pro forma as adjusted net tangible book value per share after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;per share and the dilution to new
investors purchasing common stock in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us. An increase of 1.0&nbsp;million shares in the number of shares offered by us would increase the pro forma as adjusted net tangible book value per share
after this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and decrease the dilution per share to new investors participating in this </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">75 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming no change in the assumed initial public offering price and after deducting estimated underwriting discounts and commissions
and estimated offering expenses payable by us. A decrease of 1.0&nbsp;million shares in the number of shares offered by us would decrease the pro forma as adjusted net tangible book value per share after this offering by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and increase the dilution per share to new investors participating in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming no change in the assumed initial public offering
price and after deducting estimated underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the underwriters exercise their option
to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional shares of common stock in this offering in full at the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
share, which is the midpoint of the estimated offering price range set forth on the cover of this prospectus and assuming the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same, and after deducting
estimated underwriting discounts and commissions and estimated offering expenses payable by us, the pro forma as adjusted net tangible book value per share after this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;per share, and the dilution in pro
forma as adjusted net tangible book value per share to new investors purchasing common stock in this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes, on a pro forma as adjusted basis, as of September 30, 2021, the number of shares of common stock purchased from us on an as converted to
common stock basis, the total consideration paid, or to be paid and the weighted-average price per share paid, or to be paid, by existing stockholders and by new investors in this offering at the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, before deducting estimated underwriting discounts and commissions and estimated
offering expenses payable by us. </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES PURCHASED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>CONSIDERATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED-<BR>AVERAGE<BR>PRICE PER<BR>SHARE</B></TD>
<TD VALIGN="bottom" ROWSPAN="2">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Existing stockholders before this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,218,480</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">$</FONT></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="font-size:9.5pt">100</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">%&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The table above assumes no exercise of the underwriters&#146; option to purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional
shares in this offering. If the underwriters&#146; option to purchase additional shares is exercised in full, the number of shares of our common stock held by existing stockholders would be reduced to approximately&nbsp;&nbsp;&nbsp;&nbsp;% of the
total number of shares of our common stock outstanding after this offering, and the number of shares of common stock held by new investors participating in the offering would be increased to approximately&nbsp;&nbsp;&nbsp;&nbsp;% of the total number
of shares outstanding after this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each $1.00 increase (decrease) in the assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus, would increase (decrease) the total consideration paid by new investors by
approximately $&nbsp;&nbsp;&nbsp;&nbsp;million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. An increase (decrease) of 1.0&nbsp;million shares in the number of shares offered
by us would increase (decrease) the total consideration paid by new investors by approximately $&nbsp;&nbsp;&nbsp;&nbsp;million, assuming no change in the assumed initial public offering price. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of shares of our common stock to be outstanding after this offering is based on the 139,218,480 shares of our common stock outstanding as of September 30,
2021 (including an aggregate of 136,422,468 shares of common stock issuable upon conversion of our outstanding redeemable convertible preferred stock as of September&nbsp;30, 2021), and excludes the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">28,795,570 shares of common stock issuable upon exercise of options to purchase shares of our common stock outstanding as
of September 30, 2021, at a weighted-average exercise price of $0.95 per share; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">An award of restricted stock units covering 5,244,329 shares of our common stock; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">76 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock issuable upon exercise of
options to purchase shares of our common stock that we granted after September 30, 2021, at a weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future
issuance under our 2017 Plan, as amended, which shares will be added to the shares to be reserved under our 2022 Plan upon its effectiveness; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for future
issuance under our 2022 Plan, which will become effective on the business day immediately prior to the date of effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of
shares of common stock reserved for future issuance under this plan; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock reserved for issuance under
our 2022 ESPP, which will become effective on the business day immediately prior to the date of effectiveness of the registration statement of which this prospectus forms a part, as well as any automatic increases in the number of shares of common
stock reserved for future issuance under this plan. </P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that any outstanding options are exercised or new options are issued under
the equity benefit plans, or we issue additional shares of common stock or other securities convertible into or exercisable or exchangeable for shares of our capital stock in the future, in each case at per share prices below the price to the public
in this offering, there will be further dilution to investors participating in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">77 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_12"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>You should read the following discussion and analysis of our financial condition and results of operations together with our
financial statements and the related notes thereto included elsewhere in this prospectus. Some of the information contained in this discussion and analysis or set forth elsewhere in this prospectus, including information with respect to our plans
and strategy for our business, include forward-looking statements that involve risks and uncertainties. You should review &#147;Risk Factors&#148; for a discussion of important factors that could cause our actual results to differ materially from
the results described in or implied by the forward-looking statements contained in the following discussion and analysis. For convenience of presentation, some of the numbers have been rounded in the text below. Our historical results are not
necessarily indicative of the results that may be expected for any period in the future. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical-stage biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other
incurable diseases. We believe cell therapies are one of the forward pillars of medicine and our mission is to advance humanity by engineering cell therapies that are safer, more effective and more broadly accessible. Though cell therapies have
shown benefits to date, cell therapies have historically been constrained to existing biologic structures, which has limited their impact and opportunity. Our novel synthetic binding scaffold, the <FONT STYLE="white-space:nowrap">D-Domain,</FONT>
was engineered to overcome the limitations of traditional Chimeric Antigen Receptor <FONT STYLE="white-space:nowrap">T-cells</FONT> <FONT STYLE="white-space:nowrap">(CAR-Ts).</FONT> Existing cell therapy solutions, most of which use a
biologic-based, single chain variable fragment (scFv) binding domain, tend to be beneficial to a limited segment of patients, often result in high toxicity, and have narrow applicability in treatable indications. We believe we can overcome these
limitations by engineering a new class of <FONT STYLE="white-space:nowrap">D-Domain</FONT> powered autologous and allogeneic <FONT STYLE="white-space:nowrap">CAR-Ts,</FONT> including classical single infusion
<FONT STYLE="white-space:nowrap">CAR-Ts</FONT> called ddCARs and dosable and controllable universal <FONT STYLE="white-space:nowrap">CAR-Ts</FONT> called ARC-SparX, to address hematologic cancers, solid tumors, or indications outside of oncology
such as autoimmune diseases. Our lead product candidate CART-ddBCMA, which is in Phase&nbsp;1 development in relapsed or refractory (r/r) Multiple Myeloma (MM), has demonstrated that <FONT STYLE="white-space:nowrap">D-Domains</FONT> can provide
meaningful clinical benefits. We plan to initiate several additional trials with CART-ddBCMA including our iMMAgine pivotal trial in r/r MM in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as well as expansion studies to earlier lines
of therapy. We are also advancing our novel ARC-SparX programs, <FONT STYLE="white-space:nowrap">ACLX-001</FONT> in r/r MM and <FONT STYLE="white-space:nowrap">ACLX-002</FONT> in r/r acute myeloid leukemia (AML) and high risk myelodysplastic
syndrome (MDS), and plan to initiate Phase&nbsp;1 clinical trials for both programs in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We are also exploring indications in solid tumors, as well as integrating <FONT
STYLE="white-space:nowrap">AI-powered</FONT> discovery and computational tools to expand the applicability of our platforms. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since our formation, we have devoted
substantially all our resources to discovering and developing our product candidates. We have incurred significant operating losses to date. Our net losses were $18.0&nbsp;million and $32.1&nbsp;million for the years ended December&nbsp;31,<B><SUB
STYLE="font-size:85%; vertical-align:bottom"> </SUB></B>2019 and 2020, respectively, and $23.0&nbsp;million and $44.3&nbsp;million for the nine months ended September&nbsp;30, 2020 and 2021, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of September&nbsp;30,<B><SUB STYLE="font-size:85%; vertical-align:bottom"> </SUB></B>2021, we had an accumulated deficit of $109.4&nbsp;million. These losses have
resulted primarily from costs incurred in connection with research and development activities and general and administrative costs associated with our operations. We expect to continue to incur significant expenses and increasing operating losses
for the foreseeable future, and our net losses may fluctuate significantly from period to period, depending on the timing of and expenditures on our planned research and development activities. We expect our operating expenses and capital
requirements will increase substantially in connection with our ongoing activities, as we: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>Expand the clinical program for CART-ddBCMA to include expanded enrollment of the Phase&nbsp;1
clinical trial, the initiation of the planned pivotal trial and subsequent clinical trials focused on earlier lines of therapy; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>Grow our supply and contract manufacturing infrastructure to support the continued development
of CART-ddBCMA; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>Initiate clinical trials to evaluate our ARC-SparX product candidates, <FONT
STYLE="white-space:nowrap">ACLX-001</FONT> and <FONT STYLE="white-space:nowrap">ACLX-002;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>Expand our pipeline of product candidates, including through our own product discovery and
development efforts or through acquisition or <FONT STYLE="white-space:nowrap">in-licensing;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>Continue to develop our proprietary platforms to extend their use; </P></TD></TR></TABLE>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">78 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>Attract, hire and retain additional clinical, scientific, manufacturing, management and
administrative personnel; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>Add operational, financial, and management information systems and personnel, including
personnel to support our product development, as well as to support our transition to a public reporting company; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>Require increased manufacturing capabilities with third parties for our preclinical studies
and clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>Determine and execute our long-term manufacturing strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>Pursue regulatory approval of product candidates that successfully complete clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>Establish a sales, marketing and distribution infrastructure to commercialize any product
candidate for which we may obtain regulatory approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>Obtain, maintain, expand and protect our intellectual property portfolio, and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>Incur costs associated with being a public company, including legal, accounting and auditing,
investor relations, and compliance. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result, we will require substantial additional funding to develop our product candidates and our
platforms and to support our continuing operations. Our ability to generate product revenue will depend on the successful development, regulatory approval, and eventual commercialization of one or more of our product candidates. Until such time that
we can generate significant revenue from product sales, if ever, we expect to finance our operations through public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances and
licensing arrangements. We may be unable to raise additional funds or to enter into such agreements or arrangements on favorable terms, if at all. Our failure to obtain sufficient funds on acceptable terms when needed could have a material adverse
effect on our business, results of operations or financial condition, and could force us to delay, reduce or eliminate our product development or future commercialization efforts. We may also be required to grant rights to develop and market product
candidates that we would otherwise prefer to develop and market ourselves. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our development efforts. We cannot assure you that we
will ever be profitable or generate positive cash flow from operating activities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, we have not had any products approved for sale and have not generated
any revenue from product sales and we have accumulated significant losses. Since our formation in December 2014 through September&nbsp;30,<B><SUB STYLE="font-size:85%; vertical-align:bottom"> </SUB></B>2021, we have funded our operations primarily
with an aggregate of $234.8&nbsp;million in gross cash proceeds from the sale and issuance of redeemable convertible preferred stock and convertible promissory notes. As of September&nbsp;30,<B><SUB STYLE="font-size:85%; vertical-align:bottom">
</SUB></B>2021, we had cash and cash equivalents and marketable securities of $131.2&nbsp;million. Based on our expected operating cash requirements and capital expenditures, we believe our cash and cash equivalents and marketable securities as of
September 30, 2021 are adequate to fund operations for at least twelve months from the date that the condensed consolidated financial statements are issued without the proceeds from this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> Pandemic </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to present substantial public health and economic challenges around the world, and to date has led to the implementation of various responses, including government-imposed
quarantines, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">stay-at-home</FONT></FONT> orders, travel restrictions, mandated business closures and other public health safety measures. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We continue to closely monitor the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on all aspects of our business, including how it has and will
continue to impact our operations and the operations of our suppliers, vendors and business partners, and may take further precautionary and preemptive actions as may be required by federal, state or local authorities. In addition, we have taken
steps to minimize the current environment&#146;s impact on our business and strategy, including devising contingency plans and securing additional resources from third party service providers. For the safety of our employees and families, we have
introduced enhanced safety measures in our facilities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Beyond the impact on our pipeline, the extent to which <FONT STYLE="white-space:nowrap">COVID-19</FONT>
ultimately impacts our business, results of operations and financial condition will depend on future developments, which remain highly uncertain and cannot be predicted with confidence, such as the duration of the outbreak, the emergence of new
variants, new information that may emerge concerning the severity of <FONT STYLE="white-space:nowrap">COVID-19</FONT> or the effectiveness of actions taken to contain <FONT STYLE="white-space:nowrap">COVID-19</FONT> or treat its impact, including
vaccination campaigns, among others. If we or any of the third parties with whom we engage, however, were to experience any additional shutdowns or other prolonged business disruptions, our ability to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">79 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
conduct our business in the manner and on the timelines presently planned could be materially or negatively affected, which could have a material adverse impact on our business, financial
condition and results of operations. Although to date, our business has not been materially impacted by <FONT STYLE="white-space:nowrap">COVID-19,</FONT> it is possible that our clinical development timelines could be negatively affected by <FONT
STYLE="white-space:nowrap">COVID-19,</FONT> which could materially and adversely affect our business, financial condition and results of operations. See &#147;Risk Factors&#148; for additional discussion of the potential adverse impact of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business, financial condition and results of operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Components of Results of Operations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenue </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have not generated any revenue from product sales and do
not expect to do so in the near future. In the future, we may generate, revenue from payments received under collaboration agreements, which could include payments of upfront fees, license fees, milestone-based payments, and reimbursements for
research and development efforts. However, there can be no assurance as to when we will generate such revenue, if at all. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Operating Expenses </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and Development Expenses </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses account
for a significant portion of our operating expenses and consist primarily of external and internal costs incurred in connection with our CART-ddBCMA program, the development of our ARC-SparX product candidates and the ongoing discovery and
development efforts for additional product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">External expenses include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Payments to third parties in connection with the clinical development of our product candidates, including CROs and
consultants; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The cost of manufacturing products for use in our preclinical studies and clinical trials, including payments to CMOs and
consultants; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Payments to third parties in connection with the preclinical development of our product candidates, including outsourced
professional scientific development services, consulting research fees and for sponsored research arrangements with third parties; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Laboratory supplies used in the preclinical development of our product candidates; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Allocated facilities, depreciation, and other expenses, which include direct or allocated expenses for IT, rent and
maintenance of facilities. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Internal expenses include employee-related costs, including salaries, related benefits and share-based compensation
expense for employees engaged in research and development functions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expense research and development costs in the periods in which they are incurred. We track
external costs on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">program-by-program</FONT></FONT> basis beginning with lead candidate selection. External costs that are not allocated to a program are classified as preclinical
and discovery costs. We do not track internal costs by program because these costs are deployed across multiple programs, and as such, are not separately classified. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages, primarily due to the increased size and
duration of later-stage clinical trials. As a result, we expect that our research and development expenses will increase substantially in the foreseeable future as we advance CART-ddBCMA into a pivotal trial; initiate ARC-SparX clinical trials in
our <FONT STYLE="white-space:nowrap">ACLX-001</FONT> and <FONT STYLE="white-space:nowrap">ACLX-002</FONT> programs; continue to discover and develop additional product candidates to expand our pipeline; maintain, expand, protect and enforce our
intellectual property portfolio; and hire additional personnel. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The successful development of our product candidates is highly uncertain, and we do not believe it
is possible at this time to accurately project the nature, timing and estimated costs of the efforts necessary to complete the development of, and obtain regulatory approval for, any of our product candidates. To the extent our product candidates
continue to advance into clinical trials, as well as advance into larger and later-stage clinical trials, our expenses will increase substantially and may become more variable. We are also unable to predict when, if ever, we
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">80 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
will generate revenue from our product candidates to offset these expenses. Because of the early stage of development of our product candidates, our ability to eventually generate significant
revenues from product sales will depend on a number of factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Identification of additional target antigens for desired indications; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Identification and development of D-Domain-based binding regions that bind to the desired target antigens;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Successful completion of preclinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Submission of INDs or other regulatory applications for our planned clinical trials or future clinical trials and
authorizations from regulators to initiate clinical studies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Successful enrollment in, and completion of, clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Achieving favorable results from clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Receipt of marketing approvals from applicable regulatory authorities; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Establishing and maintaining sufficient manufacturing capabilities, whether internally or with third parties, or
arrangements for clinical supplies; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Effectively competing with other therapies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Developing and implementing successful marketing and reimbursement strategies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Obtaining and maintaining patent, trade secret and other intellectual property protection and regulatory exclusivity for
our product candidates; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Maintaining a continued acceptable safety profile of any product following approval, if any. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any changes in the outcome of any of these factors could significantly impact the costs, timing and viability associated with the development of our product candidates
and our ability to generate significant revenues from product sales. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses consist primarily of salaries, related benefits, and share-based compensation expense for personnel in executive, finance and
administrative functions. General and administrative expenses also include allocated facilities, depreciation and other expenses, which include direct or allocated expenses for rent and maintenance of facilities and insurance, not otherwise included
in research and development expenses, as well as professional fees for legal, patent, consulting, investor and public relations, accounting and audit services. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
anticipate that our general and administrative expenses will increase as we increase our headcount to support the growth of the company. We further expect that our general and administrative expenses will increase substantially following the
completion of this offering, as we will incur substantially higher expenses relating to accounting, audit, legal, regulatory, compliance, director and officer insurance and investor and public relations as a result of being a public company. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Other Income, net </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other income, net consists primarily of interest earned
on our cash and cash equivalents, restricted cash and marketable securities. As a condition of our lease agreement for our company headquarters, we are required to maintain cash collateral on deposit in a segregated money market bank account equal
to the required security deposit, which is presented as part of restricted cash. The bank may restrict withdrawals or transfers by or on our behalf, but we are entitled to retain any and all interest earned on this account. Our interest income has
not been significant to date due to low interest earned on invested balances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">81 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Results of Operations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comparison of the Nine Months Ended September&nbsp;30, 2020 and 2021 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our results of operations for the nine months ended September&nbsp;30, 2020 and 2021:<U></U> </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE MONTHS ENDED<BR>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 18,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 33,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 15,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,002</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,318</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,002</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(44,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21,297</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and Development Expenses </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses were
$18.1&nbsp;million for the nine months ended September&nbsp;30,<SUB STYLE="font-size:85%; vertical-align:bottom"> </SUB>2020 compared to $33.5&nbsp;million for the nine months ended
September&nbsp;30,<SUB STYLE="font-size:85%; vertical-align:bottom"> </SUB>2021, an increase of $15.4&nbsp;million. This increase was driven primarily by $9.7&nbsp;million of higher external costs associated with our CART-ddBCMA clinical trial and,
$2.3&nbsp;million of higher external costs related to preclinical development of our other product candidates. Additionally, there was an increase of $3.4&nbsp;million in personnel costs related to the addition of research and development, clinical,
and regulatory employees. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The break-down of our external and internal research and development costs is as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE MONTHS ENDED<BR>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">External costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">CART-ddBCMA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,703</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,413</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 9,710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Preclinical and discovery costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,684</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,228</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total external costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,097</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,938</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Internal costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and Administrative Expenses</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses were
$4.9&nbsp;million for the nine months ended September&nbsp;30, 2020 compared to $10.8&nbsp;million for the nine months ended September&nbsp;30, 2021, an increase of $5.9&nbsp;million. This increase was driven primarily by an increase of
$4.6&nbsp;million in personnel related costs due to an increase in headcount coupled with increases of $0.5&nbsp;million in professional fees related to legal, consultants and accounting and audit services, and $0.6&nbsp;million in other expenses.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">82 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comparison of the Years Ended December&nbsp;31, 2019 and 2020 </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our results of operations for the years ended December&nbsp;31, 2019 and 2020: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEARS ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 15,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 25,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 9,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,832</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,096</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,122</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,123</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and Development Expenses </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses were
$15.8&nbsp;million for the year ended December&nbsp;31, 2019 compared to $25.1&nbsp;million for the year ended December&nbsp;31, 2020, an increase of $9.3&nbsp;million. This increase was driven by $1.5&nbsp;million of higher external costs
associated with our CART-ddBCMA clinical trial and $4.5&nbsp;million of higher external costs related to preclinical development of our other product candidates. Additionally, there was an increase of $3.3&nbsp;million in personnel costs related to
the addition of research and development, clinical, and regulatory employees. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The break-down of our external and internal research and development costs is as
follows: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEARS ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CHANGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">External costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">CART-ddBCMA</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,499</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Preclinical and discovery costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,857</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,365</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total external costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Internal costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,422</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,705</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">25,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and Administrative Expenses </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses
were $2.2&nbsp;million for the year ended December&nbsp;31, 2019 compared to $7.0&nbsp;million for the year ended December&nbsp;31, 2020, an increase of $4.8&nbsp;million. This increase was driven primarily by an increase of $2.4&nbsp;million in
personnel related costs due to an increase in headcount coupled with increases of $1.9&nbsp;million in professional fees related to legal, consultants and accounting and audit services. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of September&nbsp;30,<SUB
STYLE="font-size:85%; vertical-align:bottom"> </SUB>2021, we had cash and cash equivalents and marketable securities of $131.2&nbsp;million. Since inception, we have incurred net losses and negative cash flows from operations. For the nine months
ended September&nbsp;30, 2020 and 2021, we had net losses of $23.0&nbsp;million and $44.3&nbsp;million, respectively, and we expect to incur substantial additional losses in future periods. As of September&nbsp;30,<SUB
STYLE="font-size:85%; vertical-align:bottom"> </SUB>2021, we had an accumulated deficit of $109.4&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">83 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have historically financed our operations primarily through the sale of redeemable convertible preferred stock.
Through September&nbsp;30, 2021, we have financed our operations with an aggregate of $234.8&nbsp;million in gross cash proceeds from the sale of redeemable convertible preferred stock and convertible promissory notes. Based on our expected
operating cash requirements and capital expenditures, we believe our cash and cash equivalents and marketable securities as of September 30, 2021 are adequate to fund operations for at least twelve months from the date that the condensed
consolidated financial statements are issued without the proceeds from this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, we have not generated any revenue. We do not expect to generate any
meaningful revenue unless and until we obtain regulatory approval of, and commercialize any of, our product candidates or enter into collaborative agreements with third parties, and we do not know when, or if, either will occur. We expect to
continue to incur significant losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates and begin to commercialize any approved products. We
are subject to all of the risks typically related to the development of new product candidates, and we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. Moreover,
following the completion of this offering, we expect to incur additional costs associated with operating as a public company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will continue to require
additional capital to develop our product candidates and to fund operations for the foreseeable future. We may seek to raise capital through public or private equity offerings, debt financings, marketing and distribution arrangements, other
collaborations, strategic alliances and licensing arrangements. We anticipate that we will need to raise substantial additional capital, for which the requirements will depend on many factors, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>The scope, progress, timing, results and costs of developing and manufacturing our product
candidates, and their components, and conducting preclinical studies and clinical trials and other testing of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>Our ability to continue our business operations and product candidate research and
development, and to adapt to any changes in the regulatory approval process, manufacturing supply, or clinical trial requirements and timing due to the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and otherwise, including our
ability to comply with new regulatory guidance or requirements on conducting clinical trials during and after the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>The costs, timing and outcome of regulatory review of any of our product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>The costs and timing of preparing, filing and prosecuting patent applications, maintaining and
enforcing our intellectual property rights, and defending any intellectual property-related claims, including any claims by third parties that we are infringing upon their intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>Our ability to establish and maintain strategic collaborations, licensing or other
arrangements and the financial terms of any such agreements, including the timing and amount of any future milestone, royalty or other payments due under any such agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>The costs and timing of future commercialization activities, including manufacturing,
marketing, sales and distribution, for any of our product candidates for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>The extent to which our product candidates, if approved, can be offered by prescribers in
various clinical settings, including academic hospitals and community practices, the acceptance of our products, if and when approved, by patients, the medical community and third-party payors, and the revenue received from commercial sale of any
products for which we receive marketing approval; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>The effect of competing technologies and market developments; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B>The extent to which we acquire or invest in other businesses, products and technologies and
any other licensing or collaboration arrangements for any of our product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A change in the outcome of any of these or other variables
with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will
continue to require additional capital to meet operational needs and capital requirements associated with such operating plans. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt
financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">84 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
or engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Adequate funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed could have a negative impact on our
financial condition and our ability to pursue our business strategies. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials or we may
also be required to sell or license to others rights to our product candidates in certain territories or indications that we would prefer to develop and commercialize ourselves. If we are required to enter into collaborations and other arrangements
to supplement our funds, we may have to give up certain rights that limit our ability to develop and commercialize our product candidates or we may have to accept other terms that are not favorable to us or our stockholders, which could materially
affect our business and financial condition. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">See the section of this prospectus titled &#147;Risk Factors&#148; for additional risks associated with our
substantial capital requirements. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Cash Flows </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets
forth a summary of the primary sources and uses of cash for each of the periods presented below: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEARS ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE MONTHS ENDED<BR>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,772</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(28,662</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(21,382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(888</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net increase (decrease) in cash, cash equivalents, and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 20,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 12,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(22,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 23,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Operating Activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities during the year
ended December&nbsp;31, 2019 of $18.8&nbsp;million was primarily attributable to our net loss of $18.0&nbsp;million and net changes in operating assets and liabilities of $1.3&nbsp;million, partially offset by
<FONT STYLE="white-space:nowrap">non-cash</FONT> charges for depreciation and share-based compensation of $0.5&nbsp;million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities
during the year ended December&nbsp;31, 2020 of $28.7&nbsp;million was primarily attributable to our net loss of $32.1&nbsp;million partially offset by net changes in operating assets and liabilities of $1.7&nbsp;million and <FONT
STYLE="white-space:nowrap">non-cash</FONT> charges for depreciation and share-based compensation of $1.7&nbsp;million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities during
the nine months ended September&nbsp;30, 2020 of $21.4&nbsp;million was primarily attributable to our net loss of $23.0&nbsp;million partially offset by net changes in operating assets and liabilities of $0.4&nbsp;million and <FONT
STYLE="white-space:nowrap">non-cash</FONT> charges for depreciation and share-based compensation of $1.2&nbsp;million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities during
the nine months ended September&nbsp;30, 2021 of $32.7&nbsp;million was primarily attributable to our net loss of $44.3&nbsp;million, partially offset by net changes in operating assets and liabilities of $7.0&nbsp;million and <FONT
STYLE="white-space:nowrap">non-cash</FONT> charges for depreciation and amortization and share-based compensation of $4.6&nbsp;million. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Investing Activities
</I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities of $3.8&nbsp;million and $0.9&nbsp;million during the years ended December&nbsp;31,<B><SUB
STYLE="font-size:85%; vertical-align:bottom"> </SUB></B>2019 and 2020, respectively, was attributable to purchases of property and equipment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in
investing activities of $0.3&nbsp;million during the nine months ended September&nbsp;30, 2020 was attributable to purchases of property and equipment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash
used in investing activities of $62.3&nbsp;million during the nine months ended September&nbsp;30,<B><SUB STYLE="font-size:85%; vertical-align:bottom"> </SUB></B>2021 was attributable to $1.0&nbsp;million of property and equipment purchases and
$61.3&nbsp;million of purchases of marketable securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">85 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Financing Activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net
cash provided by financing activities of $42.7&nbsp;million during the year ended December&nbsp;31, 2019 primarily consisted of proceeds of $42.6&nbsp;million from the sale of shares of our Series&nbsp;B redeemable convertible preferred stock, net
of transaction costs, and proceeds of $0.1&nbsp;million from the issuance of restricted stock purchase awards upon the early exercise of stock options. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash
provided by financing activities of $41.7&nbsp;million during the year ended December&nbsp;31, 2020 primarily consisted of proceeds of $42.8&nbsp;million from the sale of shares of our Series&nbsp;B redeemable convertible preferred stock, net of
transaction costs, proceeds of $0.1&nbsp;million from the issuance of common stock upon the exercise of stock options, partially offset by the payment of deferred offering costs of $1.2&nbsp;million. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in financing activities of $1.2&nbsp;million during the nine months ended September&nbsp;30, 2020 consisted almost entirely of payments made for deferred
offering costs related to the initial public offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities of $118.4&nbsp;million during the nine months ended
September&nbsp;30, 2021 primarily consisted of proceeds of $119.1&nbsp;million from the sale of shares of Series&nbsp;C redeemable convertible preferred stock, net of transaction costs, and $0.4&nbsp;million from the exercise of stock options. These
proceeds were partially offset by payments under the capital leases for equipment used in our product development of $0.4&nbsp;million and payments of deferred offering costs of $0.7&nbsp;million. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Contractual Obligations</B> </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our <FONT
STYLE="white-space:nowrap">non-cancelable</FONT> contractual obligations as of September&nbsp;30, 2021: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="55%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(in thousands):</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAYMENT DUE BY PERIOD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>CONTRACTUAL OBLIGATIONS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LESS&nbsp;THAN</B><br><B>1 YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">1-3&nbsp;YEARS</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B><FONT STYLE="white-space:nowrap">3-5&nbsp;YEARS</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MORE&nbsp;THAN</B><br><B>5 YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease obligations<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1) </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Capital lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">344</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Payments due for our lease of office, laboratory and manufacturing space in Gaithersburg, Maryland. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We lease certain
office and lab space in Gaithersburg, Maryland under a <FONT STYLE="white-space:nowrap">non-cancelable</FONT> operating lease that has a term that expires in 2030 unless renewed. Rent expense is recorded on a straight-line basis over the terms of
the respective leases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we have entered into contracts in the normal course of business with CROs, CMOs and other third parties for preclinical
research studies and testing, clinical trials and manufacturing services. These contracts do not contain any minimum purchase commitments and are cancelable by us upon prior notice and, as a result, are not included in the table of contractual
obligations and commitments above. Payments due upon cancellation consist only of payments for services provided and expenses incurred, including <FONT STYLE="white-space:nowrap">non-cancelable</FONT> obligations of our service providers, up to the
date of cancellation. We have entered into agreements with certain vendors for the provision of goods and services, which include manufacturing services with CMOs and development services with CROs. These agreements may include certain provisions
for purchase obligations and termination obligations that could require payments for the cancellation of committed purchase obligations or for early termination of the agreements. The amount of the cancellation or termination payments vary and are
based on the timing of the cancellation or termination and the specific terms of the agreement. In addition, certain agreements with our CMOs and third-party vendors contain milestone payments and low single-digit royalties on worldwide net sales
for certain products we sell that incorporate certain goods provided by our manufacturers and suppliers. Certain of these agreements contain one-time commercial milestone and royalty buyout provisions. We have not included any contingent payment
obligations, such as milestones or royalties, in the table above as the amount, timing and likelihood of such payments are not known. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT
STYLE="white-space:nowrap">Off-Balance</FONT> Sheet Arrangements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have not entered into any <FONT STYLE="white-space:nowrap">off-balance</FONT> sheet
arrangements and do not have any holdings in variable interest entities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">86 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Critical Accounting Policies and Estimates </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our financial statements are prepared in accordance with generally accepted accounting principles (GAAP) in the United States. The preparation of our financial
statements and related disclosures requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, costs and expenses, and the disclosure of contingent assets and liabilities in our financial statements. We base
our estimates on historical experience, known trends and events, and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and
liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on a periodic basis. Our actual results may differ from these estimates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While our significant accounting policies are described in more detail in the notes to our financial statements appearing at the end of this prospectus, we believe that
the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and
development expenses, including clinical trial accruals and related expenses </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development costs are charged to expense as incurred. Research and
development costs consist primarily of salaries and benefits of research and development personnel, costs related to research activities, preclinical studies, and overhead and facility-related costs. We account for advanced payments, including <FONT
STYLE="white-space:nowrap">non-refundable</FONT> amounts, for goods or services that will be used in future research and development activities as expenses when the related goods have been received or when the service has been performed, or such a
time when we do not expect the goods to be delivered or services to be performed, rather than when the payment is made. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Expenses related to clinical trials are
accrued based on estimates and/or representations from service providers regarding work performed, including actual level of patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to
patient enrollment or treatment are accrued when reasonably certain. Similarly, we accrue expenses related to the work performed by contract manufacturing organizations based on the progress of the work performed. If the amounts that we are
obligated to pay under clinical trial agreements and manufacturing agreements are modified (for instance, as a result of changes in the clinical trial protocol or scope of work to be performed), the accruals are adjusted accordingly. Revisions to
contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision become reasonably certain.<I> </I> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Share-based compensation </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We account for share-based compensation in
accordance with ASC Topic 718, Compensation&#151;<I>Stock Compensation </I>(ASC 718). ASC 718 requires all share-based payments to employees, and directors, including grants of incentive stock options, nonqualified stock options, restricted stock
awards, unrestricted stock awards or restricted stock units to employees, and directors of the company, to be recognized as expense in the statement of operations and comprehensive loss based on their grant date fair values ratably over the
requisite service period. Our policy is to account for forfeitures as they occur. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate the fair value of options granted using the Black-Scholes-Merton
option pricing (Black-Scholes) model for stock option grants to both employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> and the fair value of common stock to determine the fair value of restricted stock. We will reconsider the use
of the Black-Scholes model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in future periods have characteristics that prevent their value from being reasonably
estimated using this model. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions. Our methodology for developing the
assumptions used in the valuation model are as follows: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Fair Value of Common Stock</I>&#151;See the subsection titled &#147;Determination of the
fair value of our common stock and fair value of total equity&#148; below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Expected Dividend Yield</I>&#151;We have never declared or paid
dividends and have no plans to do so in the foreseeable future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Expected Volatility</I>&#151;Due to the lack of a public market for our common
stock and lack of company-specific historical and implied volatility data, we have based our computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to us (e.g.,
public entities of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">87 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">
similar size, complexity, stage of development and industry focus). The historical volatility is calculated based on a period of time commensurate with expected term assumption. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Risk-Free Interest Rate</I>&#151;The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the
stock options. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Expected Term</I>&#151;We use the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&nbsp;107, Share-Based
Payment, to calculate the expected term for options granted to employees as we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of restricted stock awards, unrestricted stock awards, and restricted stock units (collectively, awards) without a market condition (e.g., certain market
capitalization thresholds) is determined based on the fair value of our common stock on the grant date. Vesting of awards is accelerated for certain employees in the event of a change in control or in the event that we remove the employee with or
without cause from their position. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate the fair value of awards subject to both a market condition and a performance condition on the grant date using a
Monte Carlo simulation model. For awards with vesting subject to the fulfillment of both market and performance conditions, share-based compensation expense is recognized using the accelerated attribution method at the time the achievement of the
performance condition becomes probable. The amount of share-based compensation expense is dependent on our periodic assessment of the probability of the performance condition being satisfied and our estimate, which may vary over time, of the number
of shares that will ultimately be issued. If the performance condition is not met, no compensation expense is recognized, and any previously recognized compensation cost is reversed. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In applying the Monte Carlo simulation model, we simulated our total equity value as of an expected change in control event that achieves certain market capitalization
thresholds as established in the agreement. For each simulated value, the total equity value is allocated to the various classes of equity in our capital structure according to the characteristics of that capital structure, such as the number of
shares of each class of equity, seniority levels, liquidation preferences and conversion values for redeemable convertible preferred stock, and participation thresholds for common stock and each series of redeemable convertible preferred stock. The
fair value of the restricted stock units (RSUs) is the average of the discounted proceeds to the common stock across all simulated paths. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Monte Carlo
simulation model requires various subjective assumptions that represent our best estimates of the fair value of common stock, expected equity volatility, risk-free interest rate, discount period, expected dividend yield, and time to change in
control event that achieves certain market capitalization thresholds as established in the agreement: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Fair Value of Total Equity</I>&#151;See
the subsection titled &#147;Determination of the fair value of our common stock and fair value of total equity&#148; below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Expected Equity
Volatility&#151;</I>Due to the lack of a public market for our common stock and the lack of company-specific historical and implied volatility data, we have based our computation of expected volatility on the historical volatility of a
representative group of public companies with similar characteristics to us (e.g., public entities of similar size, complexity, stage of development, and industry focus). The historical volatility is calculated based on a period of time commensurate
with expected change in control event that achieves certain market capitalization thresholds as established in the agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Risk-Free Interest
Rate and Discount Period</I>&#151;The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected time to change in control event that achieves certain market capitalization thresholds as established in the
agreement. The discount period is the period between the valuation date and the assumed change in control event date, with the assumption that all equity shares in the capital structure are paid out in cash. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Expected Dividend Yield</I>&#151;We have never declared or paid dividends and have no plans to do so in the foreseeable future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">88 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL"><I>Time to Change in Control Event&#151;</I>The time to change in control event is based on our best
estimate of a change in control event that achieves certain market capitalization thresholds as established in the agreement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Determination of the fair value of
our common stock and fair value of total equity </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Given the lack of an active public market for our common stock and other equity instruments, we have from time
to time engaged an independent valuation firm to assist us in determining the fair value of the common stock, which has also been used to determine the fair value of our total equity. In the absence of a public trading market, and as a
clinical-stage company with no significant revenues, we believe that it is appropriate to consider a range of factors to determine the fair market value of the common stock at each grant date and resulting total equity value. In determining the fair
value of our common stock and total equity value, we use methodologies, approaches, and assumptions consistent with the American Institute of Certified Public Accountants&#146; (AICPA) Audit and Accounting Practice Aid Series: Valuation of Privately
Held Company Equity Securities Issued as Compensation. In addition, we considered various objective and subjective factors, along with input from the independent third-party valuation firm. The factors included (1)&nbsp;our achievement of clinical
and operational milestones; (2)&nbsp;the significant risks associated with our stage of development; (3)&nbsp;capital market conditions for life science companies, particularly similarly situated, privately held, early-stage life science companies;
(4)&nbsp;our available cash, financial condition, and results of operations; (5)&nbsp;the most recent sales of our redeemable convertible preferred stock; and (6)&nbsp;the preferential rights of the outstanding preferred stock. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Practice Aid identifies various available methods for allocating enterprise value across classes and series of capital stock to determine the estimated fair value
of common stock at each valuation date. In accordance with the Practice Aid, our board of directors considered the following methods: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B><I>Probability-weighted expected return method</I>. The PWERM is a scenario-based analysis
that estimates the fair value of common stock based upon an analysis of future values for the business, assuming various outcomes. The common stock value is based on the probability-weighted present value of expected future investment returns
considering each of the possible forecasted outcomes as well as the rights of each class of stock. The future value of the common stock under each outcome is discounted back to the valuation date at an appropriate risk-adjusted discount rate and
probability weighted to arrive at a <FONT STYLE="white-space:nowrap">non-marketable</FONT> indication of value for the common stock. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B><I>Option pricing method</I>. Under the OPM, shares are valued by creating a series of call
options, representing the present value of the expected future returns to the stockholders, with exercise prices based on the liquidation preferences and conversion terms of each equity class. The estimated fair values of the preferred and common
stock are inferred by analyzing these options. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I></I></B><B><I></I></B><I>Hybrid return method</I>. The hybrid return method is a blended approach using aspects of
both the PWERM and OPM, in which the equity value in one of the scenarios is calculated using an OPM. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on our early stage of development and
other relevant factors, for valuations performed prior to May 2020, we determined that an OPM was the most appropriate method for allocating our enterprise value to determine the estimated fair value of our common stock and total equity value.
Starting in May 2020, we determined that the hybrid return method was the most appropriate method for determining the fair value of our common stock and total equity value. Using the hybrid return method, we determined the common stock fair value
and total equity value based on aspects of both PWERM and OPM models. We applied a discount back to for lack of marketability to account for a lack of access to an active public market and a discount for a liquidation scenario in which common
stockholders do not receive their return. Following the closing of this offering, the fair value of our common stock will be determined based on the quoted market price of our common stock on the date of grant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Emerging Growth Company and Smaller Reporting Company Status </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an
emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS
Act until such time that those standards apply to private companies. We have elected to use this extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies
until the earlier of the date that we (i)&nbsp;are no longer an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">89 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
emerging growth company or (ii)&nbsp;affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable
to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless we affirmatively and irrevocably opt out of
the extended transition period provided in the JOBS Act, we will remain an emerging growth company until the earliest of (i)&nbsp;the last day of our first fiscal year in which we have total annual gross revenues of $1.07&nbsp;billion or more,
(ii)&nbsp;the date on which we are deemed to be a &#147;large accelerated filer&#148; under the rules of the SEC, (iii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt
securities during the previous three years, or (iv)&nbsp;the last day of our fiscal year following the fifth anniversary of the date of the completion of this offering. An emerging growth company may take advantage of specified reduced reporting
requirements and is relieved of certain other significant requirements that are otherwise generally applicable to public companies. As an emerging growth company, </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may present only two years of audited financial statements, plus unaudited condensed financial statements for any
interim period, and related Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations in this prospectus; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may avail ourselves of the exemption from the requirement to obtain an attestation and report from our auditors on the
assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may provide reduced disclosure about our executive compensation arrangements; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We may not require <FONT STYLE="white-space:nowrap">stockholder&nbsp;non-binding&nbsp;advisory</FONT> votes on executive
compensation or golden parachute arrangements. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have elected to take advantage of certain of the reduced disclosure obligations in the
registration statement of which this prospectus is a part and may elect to take advantage of other reduced reporting requirements in future filings. As a result, the information that we provide to our stockholders may be different than you might
receive from other public reporting companies in which you hold equity interests. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are also a &#147;smaller reporting company,&#148; meaning that the market
value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> plus the proposed aggregate amount of gross proceeds to us as a result of this offering is less than $700.0&nbsp;million and our annual revenue is less than
$100.0&nbsp;million during the most recently completed fiscal year. We may continue to be a smaller reporting company after this offering if either (1)&nbsp;the market value of our stock held by non-affiliates is less than $250.0&nbsp;million or
(2)&nbsp;our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million. If we are
a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting
company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and, similar to emerging growth companies, smaller reporting companies
have reduced disclosure obligations regarding executive compensation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recent Accounting Pronouncements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A description of recently issued and recently adopted accounting pronouncements that may potentially impact our financial position and results of operations is
disclosed in Note 2 to our annual consolidated financial statements appearing at the end of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Quantitative and Qualitative Disclosures about
Market Risk </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. As of
September&nbsp;30, 2021, we held cash and cash equivalents of $70.0&nbsp;million and restricted cash of $0.2&nbsp;million. We generally hold our cash in a checking account and restricted cash in interest-bearing money market accounts. Additionally,
as part of our treasury management strategy, we invest in highly rated debt securities consisting entirely of corporate bonds, which we have the ability to liquidate within <FONT STYLE="white-space:nowrap">one-day</FONT> should the need for
additional cash arise. Accordingly, we believe our exposure to credit risk on our marketable securities portfolio is low. As of September&nbsp;30, 2021, we held marketable securities of $61.2&nbsp;million. Our primary exposure to market risk is
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">90 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
interest rate sensitivity, which is affected by changes in the general level of U.S. interest rates. Due to the low risk profile of our investments, an immediate 100 basis point change in
interest rates would not have a material effect on the fair market value of our cash equivalents, restricted cash, and marketable securities. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Effects of
Inflation </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Inflation generally affects us by increasing our cost of labor and research, manufacturing and development costs. We believe that inflation has not
had a material effect on our financial statements included elsewhere in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">91 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_13"></A>BUSINESS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical-stage biotechnology company reimagining cell
therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases. We believe cell therapies are one of the forward pillars of medicine, and our mission is to advance humanity by engineering cell
therapies that are safer, more effective and more broadly accessible. Though cell therapies have shown benefits to date, cell therapies have historically been constrained to existing biologic structures, which has limited their impact and
opportunity. Our novel synthetic binding scaffold, the <FONT STYLE="white-space:nowrap">D-Domain,</FONT> was engineered to overcome the limitations of traditional Chimeric Antigen Receptor T cells <FONT STYLE="white-space:nowrap">(CAR-Ts).</FONT>
Existing cell therapy solutions, most of which use a biologic-based, single chain variable fragment (scFv) binding domain, tend to be beneficial to a limited segment of patients, often result in high toxicity, and have narrow applicability in
treatable indications. We believe we can overcome these limitations by engineering a new class of <FONT STYLE="white-space:nowrap">D-Domain</FONT> powered autologous and allogeneic <FONT STYLE="white-space:nowrap">CAR-Ts,</FONT> including classical
single infusion <FONT STYLE="white-space:nowrap">CAR-Ts</FONT> called ddCARs and dosable and controllable universal CAR-Ts called ARC-SparX, to address hematologic cancers, solid tumors, and indications outside of oncology, such as autoimmune
diseases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our lead product candidate CART-ddBCMA, which is in Phase 1 development in relapsed or refractory (r/r) multiple myeloma (MM), has demonstrated that <FONT
STYLE="white-space:nowrap">D-Domains</FONT> can provide meaningful clinical benefits. We plan to initiate several additional trials of CART-ddBCMA, including iMMagine, our pivotal trial for treatment of r/r MM,
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;as well as expansion trials for earlier lines of therapy thereafter. We are also advancing our novel ARC-SparX programs,
<FONT STYLE="white-space:nowrap">ACLX-001</FONT> in r/r MM and <FONT STYLE="white-space:nowrap">ACLX-002</FONT> in r/r acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS), and plan to initiate Phase 1 clinical trials for both
programs in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We are also exploring indications in solid tumors, as well as integrating <FONT STYLE="white-space:nowrap">AI-powered</FONT> discovery and
computational tools to expand the applicability of our platforms. </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="50%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">Our <FONT STYLE="white-space:nowrap">D-Domain</FONT> platform consists of structurally unique binders that are small and stable. They can be consistently manufactured and easily modified to generate diverse libraries of proprietary
target-binding domains. The small size and structure of our <FONT STYLE="white-space:nowrap">D-Domain</FONT> binders compared to other antigen binding domains used in CAR constructs, such as scFvs, are illustrated below. The <FONT
STYLE="white-space:nowrap">D-Domain</FONT> platform enables us to make a range of <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies, including ddCARs and ARC-SparX, tailored to the complexities of cancer. The unique properties of our <FONT
STYLE="white-space:nowrap">D-Domain</FONT> translate to a higher transduction efficiency, high surface expression, and low tonic signaling properties which we believe will lead to cell therapies with improved lasting therapeutic benefit and reduced
toxicity.</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt;margin-bottom:1pt" ALIGN="right">


<IMG SRC="g129231g69b02.jpg" ALT="LOGO">
</P></TD></TR>
</TABLE>   <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At the 2021 Annual Meeting of the American Society of Hematology, we recently announced positive clinical results from our
ongoing Phase 1 clinical trial for CART-ddBCMA for the treatment of r/r MM. Of the 24 patients who have been dosed, 22 are evaluable for safety analysis and 19 are evaluable for efficacy analysis, based on
<FONT STYLE="white-space:nowrap">follow-up</FONT> of at least 1 and 3 months, respectively, following treatment. These evaluable patients comprised the dose escalation cohorts for the first dose level (DL1) (n=6) and the second dose level (DL2)
(n=6) and a dose expansion cohort of DL1 (safety n=10, efficacy n=7). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Key highlights from our data are as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">All 19 patients responded for a 100% overall response rate (ORR); </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">13 of 19 patients (68%) achieved complete response (CR) or stringent complete response (sCR), and an additional 3 patients
(16%) achieved very good partial response (VGPR); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">16 of 19 patients (84%) have ongoing responses with the longest response over 21 months; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">92 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Only 1 of 22 patients (5%) and 2 of 22 patients (9%) patients have experienced grade 3 cytokine release syndrome (CRS) or
immune effector cell-associated neurotoxicity syndrome (ICANS), respectively; no patients experienced greater than grade 3 CRS or ICANS; and all CRS and ICANS incidents resolved using standard interventions. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The enrolled population has poor prognostic indicators. 19 patients were evaluable for cytogenetics and 17 (89%) had high-risk features. The population received an
average of five prior lines of therapy (with all patients having completed at least three prior lines). 9 out of 24 patients (38%) had extramedullary disease, and 10 of 24 (42%) had greater than 50% bone marrow blasts. We believe these results not
only reflect the advantages of the <FONT STYLE="white-space:nowrap">D-Domain,</FONT> but also demonstrate the potential for CART-ddBCMA to be a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> treatment
for patients suffering from r/r&nbsp;MM. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MM is the third most common hematological malignancy in the United States and Europe, with approximately 35,000 new cases
diagnosed per year in the United States. There is currently no cure for MM and patients typically have a life expectancy of approximately five years. In 2020, the size of the global MM market was approximately $18&nbsp;billion. We estimate the
current total addressable <FONT STYLE="white-space:nowrap">CAR-T</FONT> market for r/r MM to be approximately $10&nbsp;billion based on the number of patients who are receiving third line treatments and beyond. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are preparing to initiate our iMMagine pivotal trial of CART-ddBCMA in r/r MM in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to provide safety and efficacy data
to support a potential Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA). We also intend to rapidly pursue clinical development of&nbsp;CART-ddBCMA in earlier lines of therapy through our <FONT
STYLE="white-space:nowrap">iMMagine-2</FONT> clinical trial. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">ARC-SparX are adaptable versions of ddCARs where the antigen-targeting region is located on a SparX
protein that can be dosed separately from the <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells, our proprietary <FONT STYLE="white-space:nowrap">D-Domain</FONT> based universal <FONT STYLE="white-space:nowrap">CAR-T</FONT> cells that are designed
to activate only when bound to a SparX protein that is bound to an antigen on a cell. We believe that controlling <FONT STYLE="white-space:nowrap">ARC-T</FONT> activation with SparX protein effectively separates the antigen-recognition and killing
functions, which allows us to reduce toxicities. Additionally, <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells can be dosed with different SparX proteins that target different antigens which can potentially address antigen heterogeneity, and
thereby address harder to treat indications. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to initiate a Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">ACLX-001,</FONT> the first product
candidate developed under our ARC-SparX platform, for the treatment of r/r MM in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . <FONT STYLE="white-space:nowrap">ACLX-001</FONT> is immunotherapeutic
combination composed of our <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells and SparX proteins that target BCMA. This trial is intended to establish an ARC-SparX dosing regimen and prepare for ARC-SparX trials in expanded indications. Our lead
ARC-SparX indication is AML/MDS, for which we have multiple SparX in development targeting different antigens. We plan to initiate the Phase 1 clinical trial for <FONT STYLE="white-space:nowrap">ACLX-002,</FONT> an ARC-SparX product candidate
targeting CD123, for the treatment of AML/MDS in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and plan to initiate a Phase 1 clinical trial for another ARC-SparX product candidate directed at another
antigen associated with AML/MDS in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have built a broad and
scalable pipeline that has positioned us to capitalize on the potential of our proprietary platform technologies and achieve long-term growth and sustainability within the field of cell therapy. We believe our therapeutic approaches, ddCAR and
ARC-SparX, will enable us to select mechanisms that are most appropriate for each target and indication we may choose to pursue based on underlying disease biology and patient need, such as in solid tumors, including small cell lung cancer (SCLC)
and hepatocellular carcinoma (HCC). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">93 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have worldwide rights to all of our programs which are summarized in the pipeline chart below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g03e76.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our <FONT STYLE="white-space:nowrap">D-Domain</FONT> platform has broad potential utility for additional cell modalities, targets,
therapeutic areas and applications and we plan to expand our pipeline beyond hematologic and solid cancers to autoimmune disease, as well as to allogeneic cell types. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The foundation of our competitive advantage is our proprietary technology, clinical evidence, track record of execution, manufacturing success, and assembly of a proven
management team. We believe these advantages position us to achieve significant market share in a large and attractive market and to ultimately transform the cell therapy market, contributing to a significant advancement in medicine. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Team </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our team and culture are critical to realizing our vision
of reimagining cell therapy as one of the future pillars of medicine. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are led by a diverse team of executives with significant experience in business,
discovery, development, manufacturing, and commercialization of differentiated and novel therapies specifically in the fields of oncology, cell therapy and rare diseases. Rami Elghandour, our Chairman and Chief Executive Officer, previously served
as President and Chief Executive Officer at Nevro where he grew the company from a small private company to a publicly traded commercial organization with nearly $400&nbsp;million in revenue. Prior to Nevro, Mr.&nbsp;Elghandour was an investor with
Johnson&nbsp;&amp; Johnson Development Corporation where he led several investments, including Nevro&#146;s Series B financing. Our Chief Medical Officer, Dr.&nbsp;Chris Heery, an oncologist by training, was the former Head of Clinical Trials Group
for the Laboratory of Tumor Immunology and Biology at the National Cancer Institute, and previously served as Chief Medical Officer at Precision Biosciences and Bavarian Nordic. Our Chief Scientific Officer, David Tice, PhD., has over 20 years of
biopharmaceutical research and drug development experience in oncology including 18 years at MedImmune, the global biologics research and development unit of AstraZeneca. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have attracted a diverse and talented group of innovators and company builders to help us execute our strategy and to build a transformative cell therapy platform
company. Collectively, we are driven by our shared purpose and our values. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">94 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, we had &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; employees and are committed to continuing to
build and maintain a diverse and inclusive organization. We believe focusing on diversity and inclusion is not only the right thing to do but is also a competitive advantage. We are purposeful in our efforts to seek and retain top diverse talent
from underrepresented groups as reflected throughout our organization: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Executives: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% female; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;%
diverse (defined as racial&nbsp;&amp; ethnic representation); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Managers and Senior Scientists with managerial responsibilities: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% female;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% diverse; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Professionals and Individual Contributor Scientific roles: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% female;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% diverse. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commitment to diversity doesn&#146;t stop within the walls of our organization.
With our mission of advancing humanity, we believe in equitable access to healthcare. Inclusive research programs that encompass real-world patient populations can contribute to addressing racial inequality in healthcare. We are dedicated to
expanding representation within our clinical trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also believe deeply in corporate social responsibility and being conscious stewards in our society. We are
devoted to leveraging our science to make a positive impact for the patient and local communities we serve. As our organization expands, we intend to grow our community involvement and outreach efforts, and establish our corporate brand as a force
for good through corporate philanthropic, patient advocacy, and employee volunteerism. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Key Investors and Our Financing History </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our team is further supported by a strong group of investors that share our commitment to reimaging cell therapy. Since our formation in December 2014, we have funded
our operations primarily with approximately $234.8&nbsp;million in gross cash proceeds from the sale and issuance of redeemable convertible preferred stock and convertible promissory notes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Strategy </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our mission is to advance humanity by engineering cell
therapies that are safer, more effective, and more broadly accessible. Our strategy to achieve this patient-centric goal is as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Advance CART-ddBCMA to treat r/r MM patients: </B>Based on the current results of our Phase 1 trial, we believe we have
demonstrated that&nbsp;CART-ddBCMA&nbsp;can deliver deep and durable anti-tumor responses for r/r MM patients. We plan to initiate a pivotal trial in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
We also intend to rapidly pursue clinical development of&nbsp;CART-ddBCMA in earlier lines of therapy and plan to initiate clinical trials of CART-ddBCMA in other key geographies, such as Europe and Asia, and gain significant market share in the
existing $18&nbsp;billion global MM market. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Develop comprehensive ARC-SparX AML/MDS program:</B> Our strategy is to build a comprehensive AML/MDS <FONT
STYLE="white-space:nowrap">CAR-T</FONT> solution with development of various SparX proteins for personalized therapy tailored to the molecular profile of each AML/MDS patient&#146;s disease. We believe AML/MDS is particularly well suited to the
ARC-SparX approach given the heterogeneity of AML/MDS antigen targets and the high unmet need of the indication. We plan to initiate the Phase 1 clinical trial for <FONT STYLE="white-space:nowrap">ACLX-002,</FONT> an ARC-SparX product candidate
targeting CD123, for the treatment of AML/MDS in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; d plan to initiate a Phase 1 clinical trial for another ARC-SparX product candidate directed at another
antigen associated with AML/MDS in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Expand our pipeline to select solid tumor indications: </B>As we validate the benefits of our <FONT
STYLE="white-space:nowrap">D-Domain</FONT> technology through our ddCAR and ARC-SparX platforms, we plan to diversify development programs beyond hematologic tumors to solid tumors. We believe this combination of therapeutic platforms will allow us
to select mechanisms that are most appropriate for each target and indication we choose to pursue based on underlying disease biology and patient need. We continue to invest in solid tumor programs, including SCLC and HCC. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Apply our <FONT STYLE="white-space:nowrap">D-Domain</FONT> technology outside of autologous <FONT
STYLE="white-space:nowrap">CAR-T</FONT> solutions: </B>Since <FONT STYLE="white-space:nowrap">D-Domain</FONT> binders can be applied across cell modalities, we plan to expand beyond autologous T cells into healthy donor- and/or iPSC-derived
allogeneic T cells, as well as other cell types such as natural killer (NK) cells. At the same time, we intend to expand our discovery efforts to generate <FONT STYLE="white-space:nowrap">D-Domain</FONT> binders against additional targets which can
then be deployed across either or both of our ddCAR or ARC-SparX platforms as well as any of the cell types </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">95 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
we are pursuing. Ultimately, we hope to develop multiple therapeutic options incorporating different mechanisms, cell modalities, and targets to treat hematologic cancers, solid tumors, and
indications outside of oncology, such as autoimmune diseases. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Enable greater access to CAR-T therapy through clinical studies in broader patient populations that support improved
market access:</B> Initial studies in CAR-T have focused on demonstrating efficacy in patients refractory to multiple lines of therapies, resulting in approval and utilization in a limited segment of patients with late-stage disease. We intend to
run clinical trials demonstrating the benefit of CAR-T as an earlier therapy option, supporting increased market access to broaden the number of patients eligible for the therapy. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Invest in technologies that enable access:</B> As demand for <FONT STYLE="white-space:nowrap">CAR-Ts</FONT> continues
to increase, we plan to invest in technologies ranging from manufacturing to logistics and demand planning that enable lower customer friction and improved responsiveness. We believe these investments can help us provide much needed access to
patients and clinicians and differentiate us in the marketplace. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Leverage novel technologies to drive our discovery efforts:</B> We intend to invest in applications of artificial
intelligence (AI) and machine learning (ML)&nbsp;to help accelerate our discovery pipeline by mining our <FONT STYLE="white-space:nowrap">D-Domain</FONT> libraries to identify indication-specific SparX proteins. We believe this investment has the
potential to improve the efficiency of our drug development efforts by accelerating clinical trial timelines and increasing the probability of success of the programs that we advance. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Opportunistically pursue strategic partnerships and collaborations to maximize the full potential of our platform:</B>
Our versatile platforms have broad potential applicability in areas outside of oncology, including autoimmune diseases. We intend to evaluate strategic partners with proven clinical development and commercialization capabilities for certain targets
or assets that do not overlap with our internal programs or our core focus. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Cell Therapy Background&nbsp;&amp; Current Limitations </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Background </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">T cells are a key component of the immune system that can
target diseased cells for elimination through the recognition of cell surface antigens. A growing understanding of the immune system over the years and advances in cell, gene and protein engineering have led to approved genetically modified cell
therapy products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Genetically modified cell therapy involves isolating immune cells, modifying them outside of the patient&#146;s body and then reintroducing them
into the patient to destroy diseased cells. Such cell therapies have largely focused on using the patient&#146;s own T cells (autologous approach) to express engineered antigen receptor complexes, such as TCRs or CARs. The extracellular binding
domain of the TCR or CAR recognizes the antigen, and, after the T cell binds with the cell expressing the antigen, the intracellular signaling domain induces cell killing and activates pathways specific for the T cell&#146;s proliferation and
survival. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The recent availability of cell therapy products introduced an unprecedented &#147;living therapeutic&#148; modality that offers benefits well beyond
what previous oncology modalities offered. For the first time, these therapeutics directly harness the strength of the patient&#146;s own immune system to significantly reduce, even potentially eradicate, tumors. Initially evaluated in indications
where patients were refractory to multiple lines of therapy and had generally exhausted their therapeutic options, adoptive cell therapies have shown response rates that exceed many other available modalities. Particularly striking is that these
responses are achieved with a single, personalized administration of the cell therapy, generally achieving rapid responses and resolving toxicities in days to weeks. This transformative therapy results in extended quality of life benefits without
maintenance or additional treatment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of November&nbsp;19, 2021, there are five FDA approved <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell therapies: Abecma
(idecabtagene vicleucel), which has been approved by the FDA for treatment of adult patients with r/r MM after four or more prior lines of therapy, Breyanzi&nbsp;(lisocabtagene maraleucel), which has been approved by the FDA for treatment of adult
patients with r/r large <FONT STYLE="white-space:nowrap">B-cell</FONT> lymphoma (LBCL) after two or more lines of systemic therapy, Kymriah (tisagenlecleucel), which has been approved by the FDA for treatment of patients up to 25 years of age with
r/r <FONT STYLE="white-space:nowrap">B-cell</FONT> precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse and adult patients with r/r LBCL after two or more lines of systemic therapy, Tecartus (brexucabtagene
autoleucel), which has been approved by the FDA </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">96 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
for treatment of adult patients with r/r mantle cell lymphoma and adult patients with r/r ALL, and Yescarta (axicabtagene ciloleucel), which has been approved by the FDA for treatment of adult
patients with r/r LBCL after two or more lines of systemic therapy and adult patients with r/r follicular lymphoma after two or more lines of systemic therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Current Limitations </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While
<FONT STYLE="white-space:nowrap">CAR-T</FONT> and other genetically modified cell therapies have shown significant progress in extending the lives of patients who often have no other treatment options, there are limitations to their broader use,
including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Limited Long-Term Efficacy:</B> FDA approved <FONT STYLE="white-space:nowrap">CAR-Ts</FONT> may offer higher response
rates compared to other available therapies, but efficacy as measured by the duration of response is highly variable. For example, according to published results for Yescarta in the <FONT STYLE="white-space:nowrap">Zuma-1</FONT> clinical trial,
Kymriah in the JULIET clinical trial, and Abecma in the KarMMa clinical trial, approximately 40% or fewer patients were in ongoing response at 18 months. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Significant Adverse Effects:</B> These cell therapies also have the potential to cause several adverse effects.
Uncontrolled cellular expansion and resulting side effects such as CRS, neurotoxicity and <FONT STYLE="white-space:nowrap">&#147;on-target,</FONT> <FONT STYLE="white-space:nowrap">off-tumor&#148;</FONT> toxicities stifle the broader use of these
therapies in several key ways. Specifically, they limit the number of patients that are eligible for treatment, relegate these therapies to later lines of treatment, preclude the use of these therapies in the
<FONT STYLE="white-space:nowrap">non-academic</FONT> and outpatient settings, and increase costs to patients, payers and providers due to the need for intensive care unit access when they are used. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Narrow Applicability:</B> Currently, <FONT STYLE="white-space:nowrap">CAR-T</FONT> and other genetically modified cell
therapies are utilized in only a few hematological oncology indications. Their activity in most tumors is primarily driven by a limited number of tumor specific antigen targets. Their utility is further limited by secondary resistance mechanisms
arising in the r/r settings, as well as the antigen heterogeneity that is characteristic of some of these diseases. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Solution </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our mission is to advance humanity by engineering cell therapies that are safer, more effective, and broadly accessible. We plan to achieve this goal by maximizing the
impact of our proprietary <FONT STYLE="white-space:nowrap">D-Domain</FONT> binders, which enable <FONT STYLE="white-space:nowrap">CAR-Ts</FONT> to have distinct advantages including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Promising Clinical Data &#150; High ORR and Durable Responses</B>: In our ongoing Phase&nbsp;1 clinical trial of
CART-ddBCMA, the ORR was 100% and the duration of response was promising with more than half of patients with r/r MM having ongoing responses for at least one year following treatment. We believe these results demonstrate the capability of <FONT
STYLE="white-space:nowrap">D-Domains</FONT> to not only effectively bind target antigens and drive <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell proliferation, but also to efficiently kill substantial proportion of tumor cells. High cell
surface expression and low propensity for tonic signaling of <FONT STYLE="white-space:nowrap">D-Domains</FONT> may enable more effective interactions between the CAR and the antigen as well as reduced <FONT STYLE="white-space:nowrap">T-cell</FONT>
exhaustion, which may explain the rapid and long term responses observed in our Phase&nbsp;1 clinical trial. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Potential Differentiated Safety Profile:</B>&nbsp;We believe the small and stable structure of the <FONT
STYLE="white-space:nowrap">D-Domain</FONT> enables a high transduction rate, resulting in a high proportion of cells expressing the CAR construct on the cell surface (CAR+ cells). A high proportion of CAR+ cells lowers the total number of T cells
required to be administered which we believe may yield a therapy with an improved toxicity profile, consistent with observations in the Phase 1 trial of CART-ddBCMA. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B>Opportunity to Treat a Broader Group of Patients:</B>&nbsp;We believe our Phase 1 clinical trial of CART-ddBCMA
underscore the capability to apply <FONT STYLE="white-space:nowrap">D-Domains</FONT> across a wide variety of tumor antigen targets in the future. Based on the differentiation of the <FONT STYLE="white-space:nowrap">D-Domain,</FONT> and the breadth
and depth of our <FONT STYLE="white-space:nowrap">D-Domain</FONT> libraries, we believe we can expand to a broader group of patients, including those with heterogeneously expressed tumor antigens and antigen targets that might be difficult to
target. We are currently developing therapies within both our ddCAR and ARC-SparX platforms to treat a broad variety of indications, starting with r/r MM and AML/MDS, and, in the future, including solid tumors. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">97 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The foundation of our proprietary platforms is our <FONT STYLE="white-space:nowrap">D-Domain</FONT> technology, that
has generated promising initial clinical data. We believe our <FONT STYLE="white-space:nowrap">D-Domain</FONT> technology is a transformational platform that enables us to take the right approach for the right indication within cell therapy. The
strengths of the <FONT STYLE="white-space:nowrap">D-Domains</FONT> are its size, stability, and structure which make it a unique and essential building block for making next generation <FONT STYLE="white-space:nowrap">CAR-Ts</FONT> to deliver on the
promise of this therapeutic category which is poised to be one of the forward pillars of medicine. Our method of generating <FONT STYLE="white-space:nowrap">D-Domains,</FONT> and the individual binders themselves are protected in our patent
portfolio, which consists of over 60 U.S. and international patents and over 50 U.S. and international pending applications. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are generating <FONT
STYLE="white-space:nowrap">D-Domains</FONT> against multiple targets which can then be deployed to create a new class of <FONT STYLE="white-space:nowrap">D-Domain</FONT> powered autologous and allogeneic
<FONT STYLE="white-space:nowrap">CAR-Ts,</FONT> including ddCARs and ARC-SparX, to address hematologic cancers, solid tumors, and indications outside of oncology such as autoimmune diseases. ddCARs are single infusion
<FONT STYLE="white-space:nowrap">CAR-Ts</FONT> enhanced with our <FONT STYLE="white-space:nowrap">D-Domains</FONT> as the antigen recognition motif. ARC-SparX are adaptable versions of ddCARs where the SparX protein is dosed separately from the <FONT
STYLE="white-space:nowrap">ARC-T</FONT> cell. Our <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells are dosable and controllable, universal <FONT STYLE="white-space:nowrap">CAR-Ts</FONT> designed to activate only when combined with a SparX protein
that is bound to an antigen on a cell. </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g22s63.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">98 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>ddCAR Platform </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
use our ddCAR platform to generate single infusion therapies where our <FONT STYLE="white-space:nowrap">D-Domain</FONT> binder replaces the scFvs. The ddCAR is composed of an intracellular T cell signaling domain similar to traditional CARs fused to
our <FONT STYLE="white-space:nowrap">D-Domain,</FONT> which functions as the extracellular antigen binding region. Upon engagement with the antigen on a target cell, the ddCAR signals to activate the T cell to kill the target cell. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g11i49.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <FONT STYLE="white-space:nowrap">D-Domain</FONT> was developed to overcome limitations of existing
<FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies by employing a novel synthetic binding domain as a replacement to the traditionally used antigen binding domains for conventional <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies, known
as scFvs. The result is a structurally unique binder that is small, stable, and can be modified to generate a diverse library of proprietary target-binding domains. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Structurally Unique <FONT STYLE="white-space:nowrap">D-Domains</FONT></I></B>: <FONT STYLE="white-space:nowrap">D-Domains</FONT> are short polypeptides that
spontaneously fold into a stable triple alpha-helical structure.&nbsp;The <FONT STYLE="white-space:nowrap">D-Domain</FONT> is derived from a 73 amino acid synthetic protein,
<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT><FONT STYLE="white-space:nowrap">-3D,</FONT> that has no known homolog in nature or apparent function as first described in a paper by Walsh,&nbsp;et
al.&nbsp;that appeared in the Proceedings of the National Academy of Sciences in 1999. This domain is devoid of post-translational glycosylation or disulfide bonds leading to consistent manufacturability via microbial, fungal or mammalian protein
expression. Additional key structural features of the <FONT STYLE="white-space:nowrap">D-Domain</FONT> are as follows:</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">99 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I>Small Size</I></B><I>:</I> The figure below showcases the small size of the 8kDa
<FONT STYLE="white-space:nowrap">D-Domain</FONT> compared to other antigen binding domains used in CAR constructs such as the scFv and bi-valent camelid VHh structure of approximately 25kDa. A smaller antigen binding domain will decrease the overall
lentiviral construct size which may improve transduction efficiency. The small antigen binding domain may also function to improve the immunological synapse formation and thus <FONT STYLE="white-space:nowrap">CAR-T</FONT> cell killing.
</P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g94t84.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I>Hydrophobic Core</I></B>: The figure below depicts the three-dimensional structure of the <FONT
STYLE="white-space:nowrap">D-Domain</FONT> highlighting the triple alpha helical bundle with the tight hydrophobic core (in red). The hydrophobic core results in ultrafast folding kinetics of the <FONT STYLE="white-space:nowrap">D-Domain</FONT>
creating a stable structure when expressed in cells. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g32y64.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I>Stability</I></B><I>:</I> <FONT STYLE="white-space:nowrap">D-Domains</FONT> are highly stable proteins compared to
scFvs which facilitates expression of CARs on T cells and manufacturing of SparX proteins. As shown in the middle panels of the figure below, using size exclusion chromatography, we have demonstrated that a higher level of monomeric protein content
can be purified from human embryonic kidney (HEK) 293 cells expressing <FONT STYLE="white-space:nowrap">D-Domain-based</FONT> SparX proteins compared to scFv, indicating lower levels of aggregation of the
<FONT STYLE="white-space:nowrap">D-Domain</FONT> based SparX proteins and thus greater stability. In addition, we have tested the thermal stability of <FONT STYLE="white-space:nowrap">D-Domains</FONT> as compared to a
<FONT STYLE="white-space:nowrap">PD-L1</FONT> binding scFv by heating them to temperatures about 100 degrees Celsius and measuring the retention of </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">100 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
<FONT STYLE="white-space:nowrap">PD-L1</FONT> binding. As shown in the panels on the far right, <FONT STYLE="white-space:nowrap">D-Domains</FONT> that were heated to the indicated temperatures
retained greater <FONT STYLE="white-space:nowrap">PD-L1</FONT> binding as compared to the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">PD-L1-binding</FONT></FONT> scFv, demonstrating the thermal stability of the <FONT
STYLE="white-space:nowrap">D-Domains.</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g24b13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When utilized in CARs, we believe the structural properties of the <FONT STYLE="white-space:nowrap">D-Domain</FONT> translate into
unique benefits of high transduction rates, high cell surface expression, and low tonic signaling. In the context of ddCARs, we believe the <FONT STYLE="white-space:nowrap">D-Domain</FONT> structure creates an efficient and scalable cell
manufacturing process, as demonstrated by our high CAR+ rate, yield, and viability of cell product made to date. See &#147;&#151;Manufacturing and Delivery&#151;CART-ddBCMA Cell and <FONT STYLE="white-space:nowrap">ARC-T</FONT> Cell.&#148; </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I>High Transduction Rate</I></B><B>: </B>In the manufacturing of CART-ddBCMA, we have achieved transduction rates
ranging from approximately 60% to 85% in over 20 lots tested. We believe this high transduction efficiency may improve product consistency and reduce the number of untransduced T cells administered to patients that do not contribute to efficacy but
may contribute to toxicity. Our high transduction rate compares favorably with previously published Phase 1 data regarding the transduction rates for Abecma (then known as bb2121) and <FONT STYLE="white-space:nowrap">JNJ-4528,</FONT> a <FONT
STYLE="white-space:nowrap">CAR-T</FONT> therapy being developed by Janssen, as shown in the left panel of the figure below. While we believe these data suggest that CART-ddBCMA has a meaningful advantage in transduction efficiency over existing <FONT
STYLE="white-space:nowrap">CAR-T</FONT> therapies, these data are based on a cross-trial comparison and not a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> clinical trial and may not be directly
comparable due to differences in trial designs and methodologies. As manufacturing processes and vectors can also be vastly different across cell products, we also engineered a vector where the <FONT STYLE="white-space:nowrap">D-Domain</FONT> was
replaced by an scFv targeting BCMA while leaving all other conditions identical to isolate the effects on transduction from using a <FONT STYLE="white-space:nowrap">D-Domain</FONT> as compared to scFv.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">101 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
As shown in the right panel of the figure below, our CART-ddBCMA transduced T cells demonstrated superior transduction efficiency when compared to scFv transduced T cells derived from multiple
normal human donors. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g03i03.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I>High Cell Surface Expression</I></B><B>:</B> Coincident with higher transduction rates, the expression of the CAR on
the surface of the T cell is higher with CARs employing a D domain compared with an scFv. In Exhibit E, using transduced T cells from multiple normal human donors, CAR expression on the surface of T cells was uniformly higher using a BCMA-binding D
domain as compared to a BCMA-binding scFv. We believe that higher CAR cell surface density may help drive activation against low antigen-expressing target cells. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g91e20.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">102 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I>Low Tonic Signaling</I></B><B>:</B> Tonic signaling occurs in <FONT STYLE="white-space:nowrap">CAR-T</FONT> cells
when the CAR construct signals without engaging an antigen on a target cell, which can exhaust a T cell prematurely. Tonic signaling has been described in the literature for several scFv-based CARs. To determine the percentage of <FONT
STYLE="white-space:nowrap">D-Domains</FONT> that induce tonic signaling, we examined 42 <FONT STYLE="white-space:nowrap">D-Domains</FONT> isolated from two different screening campaigns for their ability to signal without antigen stimulation when
incorporated into a CAR construct. Pooled data indicated that only 3 out of the 42 <FONT STYLE="white-space:nowrap">D-Domains</FONT> exhibited a level of tonic signaling above background, as measured by relative luciferase units, a signal detecting
CAR activation, as represented by the blue dots in the left hand column of the figure below. In contrast, the 42 <FONT STYLE="white-space:nowrap">D-Domains</FONT> exhibited a much higher level of CAR activation in the presence of the CAR antigen, as
illustrated by the right hand column of the figure below. We believe the low propensity for tonic signaling of <FONT STYLE="white-space:nowrap">D-Domain-based</FONT> CARs may lower T cell exhaustion. </P></TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g26a01.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I>Engineered <FONT STYLE="white-space:nowrap">D-Domain</FONT> Scaffolds</I></B><B>: </B>The structural features of the
<FONT STYLE="white-space:nowrap">D-Domain</FONT> make it particularly well suited as a scaffold protein that can be modified by inserting selected amino acids to generate diverse libraries of proprietary target-binding domains. We create highly
diverse libraries of variants of&nbsp;<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT><FONT STYLE="white-space:nowrap">-3D</FONT> by randomly replacing <FONT STYLE="white-space:nowrap">12-14</FONT>
amino acid residues (blue regions in the figure below) on the outward facing surface of&nbsp;<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT><FONT STYLE="white-space:nowrap">-3D</FONT> with one of 18
amino acids. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g18g60.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We screen the resulting libraries for potential target-binding domains and engineer further variants with the appropriate target
binding profiles to enhance target specificity, optimize binding affinity, and remove potentially immunogenic sequences, a process we refer to as &#147;deimmunization&#148;. We use rigorous target selection criteria applied to genomic and proteomic
datasets generated from public, collaborator, and internal sources. We internally validate expression profiles for all antigens under evaluation to select the best targets. At the same time, all the reagents needed to screen our proprietary <FONT
STYLE="white-space:nowrap">D-Domain</FONT> libraries for specific binders to the antigen are generated and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">103 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
qualified. Over a dozen <FONT STYLE="white-space:nowrap">D-Domain</FONT> binders to a variety of tumor antigens have already been generated to date. We have also identified and characterized
several target-binding domains for certain therapeutic targets, such as BCMA, CD123, CS1, HER2, and <FONT STYLE="white-space:nowrap">PD-L1.</FONT> <FONT STYLE="white-space:nowrap">AI-based</FONT> approaches are employed to assist in optimization and
continue to be developed to enhance our discovery process. Applying all these discovery methods, the engineered <FONT STYLE="white-space:nowrap">D-Domains</FONT> are incorporated into our genetically modified T cells in our ddCAR and ARC-SparX
platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>ARC-SparX Platform </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ARC-SparX platform is a controllable
and adaptable modular therapy that builds on ddCARs by replacing the antigen binding domain of the T cell with a novel synthetic binding domain that recognizes only SparX proteins, which contain the antigen binding domain. When the SparX
protein&#146;s antigen binding domain recognizes and binds to the antigen on a diseased cell, it recruits the <FONT STYLE="white-space:nowrap">ARC-T</FONT> cell to kill the diseased cell. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g67w08.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells are designed to remain in an inactive state, or silenced, and activate only
when combined with a SparX protein that is bound to an antigen on a cell. We believe that controlling <FONT STYLE="white-space:nowrap">ARC-T</FONT> activation with SparX protein effectively separates the antigen-recognition and killing functions. By
separating these functions, our approach renders the killing function of the <FONT STYLE="white-space:nowrap">ARC-T</FONT> cell dependent on the antigen specificity and dose of the SparX protein rather than on uncontrolled <FONT
STYLE="white-space:nowrap">CAR-T</FONT> proliferation as is the case with conventional <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy. We believe unregulated killing, which induces severe toxicities, can be mitigated with our approach by
adjusting the dose and schedule of SparX protein administration. Additionally, stopping the dose of the SparX protein periodically can allow the <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells to rest after activation lowering the risk of <FONT
STYLE="white-space:nowrap">T-cell</FONT> exhaustion, which is a common cause of rapid decline of genetically modified T cells. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Soluble Protein Antigen
Receptor <FONT STYLE="white-space:nowrap">X-linkers</FONT> (SparX protein) </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All SparX proteins are comprised of one or more antigen-specific binding domains
from our <FONT STYLE="white-space:nowrap">D-Domain</FONT> library, fused to a protein that we refer to as the TAG. The TAG is a protein designed to be recognized by our <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells, which have a <FONT
STYLE="white-space:nowrap">D-Domain-based</FONT> binding moiety that is specific to the TAG, which we call the <FONT STYLE="white-space:nowrap">anti-TAG.</FONT> This <FONT STYLE="white-space:nowrap">TAG/anti-TAG</FONT> design is critical to the
universality of our <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells as it allows such cells to bind any SparX protein, because each SparX protein contains the same TAG. As SparX proteins bind their target antigen on diseased cells, they display
the TAG thereby &#147;tagging&#148; such cell as one that should be killed by an <FONT STYLE="white-space:nowrap">ARC-T</FONT> cell. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">104 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The TAG we have built into our SparX proteins is a ~26 kDa <FONT STYLE="white-space:nowrap">C-terminal</FONT> fragment
of human alpha fetoprotein (hAFP). We selected and engineered the TAG for our SparX proteins for the following reasons: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Humans have a <FONT STYLE="white-space:nowrap">pre-established</FONT> tolerance to hAFP from experiencing high levels in
utero and as pregnant mothers. We believe that creating our TAG from a normal human protein will reduce the likelihood of immunogenicity of the TAG and by extension, the SparX protein containing the TAG. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We believe the small size of the SparX protein will allow it to penetrate complex tumor microenvironments with a half-life
short enough (estimated to be several hours in humans) that physicians could manage an emerging toxicity by withholding or decreasing the next SparX protein dose thereby causing the ARC-T cells to deactivate. Such control is not possible with most
mAb-based adapters due to their half-life of several weeks. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The TAG can also be readily fused to multiple binding regions, enabling SparX proteins to be multi-valent or
multi-specific. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Because the antigen-specific binding domains on the SparX protein differ by only <FONT STYLE="white-space:nowrap">12-14</FONT>
amino acids on the outer faces of the scaffold, the manufacturing process for each SparX protein is substantially similar regardless of specificity. SparX proteins can be readily produced in microbial, yeast and mammalian expression systems, and
development is underway on subcutaneous formulations. We also expect the pharmacokinetics of all SparX proteins to be similar and believe that we can leverage the learnings from clinical trials of one SparX protein to inform the design of later
trials for other SparX proteins. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Antigen Receptor Complex (ARC) </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ARC is similar to CARs in that both are engineered chimeric transmembrane receptors, where the engagement of the extracellular antigen binding domain induces
activation of the intracellular domain resulting in the T cell&#146;s proliferative and cytolytic activity. However, in lieu of the scFv extracellular binding domain of conventional <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies, the
extracellular domain of the ARC is comprised of our proprietary binding <FONT STYLE="white-space:nowrap">D-Domain</FONT> that is designed to exclusively bind the TAG and not hAFP or any other known proteins or antigens. Thus the <FONT
STYLE="white-space:nowrap">ARC-T</FONT> remains in an inactive state, or silenced, in the absence of our proprietary SparX protein. The ARC signals through a similar mechanism as traditional second-generation CARs since they share the same
intracellular signaling regions of <FONT STYLE="white-space:nowrap">4-1BB</FONT> and <FONT STYLE="white-space:nowrap">CD3-zeta</FONT> with the only difference arising from when the T cells are activated. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, because all <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells are intended to express a <FONT STYLE="white-space:nowrap">TAG-specific</FONT> binding
domain rather than a cell surface antigen-specific binding domain, the manufacturing of <FONT STYLE="white-space:nowrap">ARC-T</FONT> is more scalable than in conventional <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies in that <FONT
STYLE="white-space:nowrap">ARC-T&#146;s</FONT> comprise the same drug product irrespective of clinical indication. The same lentiviral vector comprising the universal ARC and a similar <FONT STYLE="white-space:nowrap">T-cell</FONT> transduction
process can be used for every patient regardless of disease or target antigen. With conventional <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy, different viral vectors, each with a different <FONT STYLE="white-space:nowrap">T-cell</FONT>
transduction process, need to be used to make new <FONT STYLE="white-space:nowrap">CAR-T</FONT> cells when physicians want to target a new antigen. This represents a significant manufacturing and regulatory advantage. In the longer term, engineering
an allogeneic <FONT STYLE="white-space:nowrap">ARC-T</FONT> cell presents the opportunity for a truly universal cell therapy that could be manufactured to be an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;off-the-shelf&#148;</FONT></FONT> option that physicians can use regardless of disease or target antigen. Moreover, <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells could be
redirected to kill cells expressing different antigens just by changing the SparX protein. This universal nature of the <FONT STYLE="white-space:nowrap">ARC-T</FONT> cell can provide substantial flexibility to the physician and allow for dynamic
treatments that can respond quickly to the changing profile of a disease such as cancer, unlike a conventional <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Benefits of the ARC-SparX Platform </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe the key benefits to
our ARC-SparX platform are driven by the controllable and adaptable characteristics and present an opportunity in indications where toxicities, heterogeneity, or on target off tumor effects represent a challenge: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Limiting Severe T Cell-Associated Toxicity through Dose Regulation of SparX Protein.</I></B> Our <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells do not bind
directly to the diseased cell. Rather, the SparX protein is designed to recognize and bind one or more specific antigens on the diseased cells and then flag such cells for destruction. The <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells bind the
SparX protein and once the triple complex of <FONT STYLE="white-space:nowrap">ARC-T</FONT> cell plus SparX protein plus antigen-expressing cell is formed, the <FONT STYLE="white-space:nowrap">ARC-T</FONT> cell is
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">105 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
activated to kill the antigen-expressing cell. The <FONT STYLE="white-space:nowrap">ARC-T</FONT> cell remains in an inactive state, or silenced, in the absence of our proprietary SparX proteins
as it is designed to only bind the TAG. Our <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells are activated only when combined with a SparX protein that is bound to an antigen on a cell. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Conventional <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-D-Domain</FONT></FONT> based <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies
bind directly to the target cell and kill it in a rapid and unregulated manner that often induces severe toxicities including CRS and neurotoxicity. In contrast, our preclinical <I>in vitro </I>and <I>in vivo </I>data support the view that the
killing function and expansion of the <FONT STYLE="white-space:nowrap">ARC-T</FONT> cell can be controlled by the dose of SparX protein administered. More SparX protein leads to more tumor killing and T cell activity while less SparX protein results
in less killing and expansion. By varying SparX protein dose and/or its schedule of administration, physicians can control the <FONT STYLE="white-space:nowrap">ARC-T</FONT> killing function and expansion and thus control the corresponding potential
toxicities in a manner analogous to that used for other therapeutics such as small molecules and antibodies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have conducted<I> </I>preclinical studies in which
we have observed the ability of SparX proteins to control the killing function of <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells in a dose-dependent manner, as exemplified in the figure below. In this study, mice were given a BCMA-expressing
tumor followed by a constant number of <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells. In the first group of five mice (left), a SparX protein that could not bind the tumor was injected daily (3 mg/kg of SparX- <FONT
STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>3D). Because the SparX-<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>3D could not bind the tumor, the tumor
grew as evidenced by the intense blue, green and red colors. The second, third and fourth groups (left to right) of mice received a low (0.03 mg/kg), medium (0.3 mg/kg) or high (3 mg/kg), dose respectively of a mono-valent BCMA-binding SparX
protein. The low dose had little to no impact on tumor growth, the medium dose almost cleared the tumor as shown by the near absence of color and the high dose cleared the tumor as shown by the complete absence of color, indicating that SparX
protein targeting a tumor can modulate the extent of tumor killing <I>in vivo</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Tumor Killing is Dose Dependent </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g28a04.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We anticipate that SparX proteins will be available in intravenous and potentially subcutaneous formulations and that physicians will
be able to routinely utilize both forms of administration in the outpatient setting while patients may periodically (<I>e.g.</I>, weekly) self-administer subcutaneous formulations in the home setting. In follow up visits, the physician can assess
the patient for adverse events (AEs) and disease response and then accordingly dose-modify or change the SparX protein(s) with the objective of limiting toxicity. Physicians are already well versed in managing the treatment of patients with an
arsenal of anticancer therapies such as small molecules and mAbs, where dose modification is common. The ARC-SparX platform follows a similar paradigm, where the physician can control toxicities by dose modifying or switch to a different SparX
protein in the case of r/r disease. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, intermittent dosing of SparX protein can allow <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells to rest
between doses because the predicted half-life of SparX proteins of a few hours allows the SparX to naturally decay and limit constant <FONT STYLE="white-space:nowrap">ARC-T</FONT> stimulation. The periods of rest may lower the risk of <FONT
STYLE="white-space:nowrap">T-cell</FONT> exhaustion. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Should we demonstrate the ability for <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells to be activated in a
dose dependent manner we believe physicians would be able to better manage toxicities such as CRS and neurotoxicity as they emerge and before they escalate to unsafe levels, which should lead to an improved safety profile for our ARC-SparX platform.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Expanded Access to Treatment</I></B><B>. </B>Due to the potential for severe toxicities, patients with <FONT STYLE="white-space:nowrap">co-morbidities</FONT>
or advanced age are often not eligible or not encouraged to pursue currently available <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies. We believe SparX-mediated control of the <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells may improve
upon the safety profile of current <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies thereby expanding patient eligibility criteria. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">106 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, less than 7% of oncology/hematology practices in the United States currently are authorized to administer
and manage <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies. If physicians are better able to control toxicities associated with cell therapies through dosing and thus reduce the need for intensive care support, we envision enabling community
practices to treat their patients with such therapies, including in the outpatient setting, rather than referring them to one of the few authorized sites. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
figure below shows the general treatment plan, which consists of a single initial infusion of <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells in the outpatient setting followed by periodic administration of the SparX protein. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g29a01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Increased Adaptability of Treatment Regimen. </I></B>Because <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells are not
antigen-specific, they can be adapted to changing disease conditions. Due to tumor heterogeneity and downregulation or loss of the target antigen, r/r disease remains a significant issue for <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy. On
our ARC-SparX platform, physicians can administer different SparX proteins to redirect the same <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells to new antigens. This is particularly important in the relapse and refractory settings where tumors
may be heterogeneous or downregulate expression of the antigen(s) targeted by the initial SparX proteins. We believe our platform can address refractory disease caused by tumor heterogeneity by using different SparX proteins that target different
antigens. This will be particularly important as we move beyond B cell malignancies into indications like AML/MDS or solid tumors. We believe that our ARC-SparX platform can address these issues because the same
<FONT STYLE="white-space:nowrap">ARC-T</FONT> cells can be redirected <I>in vivo </I>to target different antigens through the administration of different SparX proteins for personalized therapy tailored to the molecular profile for each
patient&#146;s disease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">107 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our preclinical studies support the ability of <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells to kill
heterogeneous tumors through sequential administration of SparX proteins with different target specificity. We used an <I>in vivo </I>model in which NSG mice were injected with
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">NALM-6-GFP/Luc</FONT></FONT> expressing either BCMA (97%) or CD123 (3%). We chose this approach as it mimics the antigen heterogeneity often observed in many patient&#146;s tumors.
With only 3% of the tumor cells positive for CD123, daily dosing with SparX&nbsp;B had little effect on tumor growth compared to mice which received a <FONT STYLE="white-space:nowrap">non-binding</FONT> control SparX. In contrast, SparX&nbsp;A had
significant anti-tumor activity by day 7 following <FONT STYLE="white-space:nowrap">ARC-T</FONT> and SparX administration, but tumors rapidly regrew. As shown in the figure below, the tumor cells that regrew were characterized to be completely CD123
positive. However, all the measurable tumor cells could be eliminated by redirecting <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells through sequential administration of SparX&nbsp;A followed by SparX&nbsp;B. Taken together, these data support
the ability of <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells to be redirected <I>in vivo </I>to kill heterogenous tumors that are refractory to single antigen targeting. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g05h31.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g77g82.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">108 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Custom Logic-Gated Therapeutics to Enable Selectivity. </I></B>The unique properties of <FONT
STYLE="white-space:nowrap">D-Domains</FONT> and our ability to engineer them allow us to create mono-valent, multi-valent, or multi-specific SparX to optimize antigen binding affinity and improve efficacy.
<FONT STYLE="white-space:nowrap">Bi-specific</FONT> SparX proteins can be designed as an &#145;OR&#146; gate to target two different antigens for broader tumor cell recognition when faced with antigen heterogeneity or an &#145;AND&#146; gate to more
specifically identify diseased cells that uniquely <FONT STYLE="white-space:nowrap">co-express</FONT> two antigens but spare healthy cells that express only one antigen. We believe an <FONT STYLE="white-space:nowrap">AND-gated</FONT> SparX may be
well suited for targeting solid tumors where it has been challenging to kill the tumor while preserving normal cells that also express the antigen. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g50a54.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a general matter, SparX proteins do not permanently bind antigens. When both binding domains of a
<FONT STYLE="white-space:nowrap">bi-specific</FONT> antigen are bound to a cell, each binding domain may unbind, but the likelihood of both unbinding at the same time is lower, and therefore, <FONT STYLE="white-space:nowrap">bi-specific</FONT> SparX
proteins are more likely to stay attached to the cells. Through affinity engineering, we believe that if we decrease the affinity of each single antigen binding <FONT STYLE="white-space:nowrap">D-Domain</FONT> to its target, then the SparX protein
will not bind or stay bound long enough for an <FONT STYLE="white-space:nowrap">ARC-T</FONT> cell to engage and kill the cell bearing only a single antigen. Thus, through engineering and controlled dosing, the
<FONT STYLE="white-space:nowrap">AND-gated</FONT> bispecific SparX proteins can drive greater specificity for dual-antigen expressing tumor cells over single antigen expressing normal cells to avoid the typical
<FONT STYLE="white-space:nowrap">on-target</FONT> <FONT STYLE="white-space:nowrap">off-tumor</FONT> related toxicities observed with so many conventional <FONT STYLE="white-space:nowrap">CAR-T</FONT> products targeting solid tumor antigens. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Efficient and Streamlined Manufacturing Across All Programs. </I></B><FONT STYLE="white-space:nowrap">ARC-T</FONT> cells are genetically modified to express the
same <FONT STYLE="white-space:nowrap">anti-TAG</FONT> binding receptor to be used in every patient, regardless of disease or the target-specificity of the SparX protein. We believe this feature may enable use of the same lentiviral vector and
similar cell processing, resulting in a scalable manufacturing process that is applicable to every patient across all programs. We have also established manufacturing processes for SparX proteins utilizing a cost-effective microbial-based expression
system and purification process. Because each SparX protein is substantially similar regardless of specificity, the manufacturing and purification processes for each SparX protein is substantially similar regardless of specificity. For more details,
see &#147;&#151;Manufacturing and Delivery.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Efficient Regulatory Process. </I></B>Because the <FONT STYLE="white-space:nowrap">ARC-T</FONT> cell
manufacturing process is identical across all ARC-SparX programs, the regulatory requirements will be shared across the platform. This has distinct advantages that will span global regulatory filings from IND through post BLA requirements. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">109 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Pipeline Approach </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
are leveraging the full breadth of our platform by matching ddCARs and ARC-SparX with the indications in which they would be most effective based on the biology, patients, and market dynamics. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In MM, we plan to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Evaluate the efficacy of our lead asset, CART-ddBCMA, in our iMMagine pivotal trial in r/r MM and seek regulatory
approval; </P></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Pursue expanded access to CART-ddBCMA through label expansion clinical trials, which we refer to as <FONT
STYLE="white-space:nowrap">iMMagine-2;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Pursue clinical development of&nbsp;CART-ddBCMA in other key geographies, such as Europe and Asia; and
</P></TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Evaluate the potential of our ARC-SparX technology through our planned Phase 1 clinical trial of <FONT
STYLE="white-space:nowrap">ACLX-001</FONT> in r/r MM. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In AML/MDS, we plan to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Pursue AML/MDS with a library of SparX proteins beginning with <FONT STYLE="white-space:nowrap">ACLX-002;</FONT> and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Explore trials that evaluate the use of a single administration of <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells
together with a combination of SparX proteins engineered to target different AML and MDS antigens to extend the power of the platform. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
additional indications, including solid tumors, we plan to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Extend benefits of our <FONT STYLE="white-space:nowrap">D-Domain</FONT> platform by applying ddCARs and ARC-SparXs to new
indications, including SCLC and HCC. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Pipeline </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
have built a broad and scalable pipeline that has positioned us to capitalize on the potential of our proprietary platform technologies and achieve long-term growth and sustainability within the field of cell therapy. We have worldwide rights to all
of our programs which are summarized in the pipeline chart below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g03e76.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">110 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Multiple Myeloma Program </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our MM program is led by our CART-ddBCMA product candidate, which is an autologous cell therapy comprised of <FONT STYLE="white-space:nowrap">D-Domain</FONT> powered T
cells that have been genetically modified to recognize and kill specific cells expressing BCMA, a target antigen for multiple myeloma. We are advancing our CART-ddBCMA product through our iMMagine pivotal trial in patients with r/r MM, which we plan
to initiate in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and thereafter pursue U.S. regulatory approval. CART-ddBCMA has been granted Fast Track and Orphan Drug by the FDA.&nbsp;In May 2021, we
also received Regenerative Medicine Advanced Therapy (RMAT) designation for CART-ddBCMA for the treatment of multiple myeloma. Following completion of enrollment for our iMMagine pivotal trial, we plan to continue to enroll more patients into
additional clinical trials, to support label expansion to enter into earlier lines of therapy and include patients who have had prior BCMA-targeted. We also plan to pursue international clinical trials to expand into geographic locations in Europe
and Asia-Pacific. We are also advancing our initial ARC-SparX program, <FONT STYLE="white-space:nowrap">ACLX-001,</FONT> an immunotherapeutic combination composed of <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells and bi-valent SparX proteins
targeting BCMA, to treat r/r MM. This program is designed to lay the foundation for our ARC-SparX platform. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Market Opportunity </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MM<B> </B>is a type of hematological cancer in which diseased plasma cells proliferate and<B> </B>accumulate in the bone marrow, crowding out healthy blood cells and
causing bone lesions, loss of bone density and bone fractures. These abnormal plasma cells also produce excessive quantities of an abnormal immunoglobulin fragment called a myeloma protein (M protein) causing kidney damage and impairing the
patient&#146;s immune function. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MM is the third most common hematological malignancy in the United States and Europe, representing approximately 10% of all
hematological cancer cases and 20% of deaths due to hematological malignancies. The Surveillance, Epidemiology, and End Results (SEER) Program database projects that approximately 35,000 new cases of MM in the United States and over 35,000 new cases
in six select markets within Europe and Asia. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The median age of MM patients at diagnosis is 69 years with <FONT STYLE="white-space:nowrap">one-third</FONT> of
patients diagnosed at an age of at least 75 years. Because MM tends to afflict patients at an advanced stage of life, patients often have multiple <FONT STYLE="white-space:nowrap">co-morbidities</FONT> and toxicities that can quickly escalate and
become life-endangering. Despite the development and use of multiple new therapies, including second generation proteasome inhibitors (PI) and immunomodulatory drugs (IMiD), stem cell transplantation and CD38-binding monoclonal antibodies, the
five-year survival rate is still approximately 50% and MM remains incurable in most patients. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Most patients eventually relapse after treatment, and those who
relapse following treatment with second generation PIs and IMiDs have a median event-free-survival of only 5 months and median overall survival of only 9 months. The outcomes of patients following treatment with CD38-binding antibodies are also poor
with response rates of approximately 30%, median progression-free-survival of 3.4 months and median overall survival of 9 months. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Currently, multiple
BCMA-targeting therapies are in development or under regulatory review, including T cell engagers (TCEs), antibody drug conjugates (ADCs) and <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies. Along similar lines, TCEs and <FONT
STYLE="white-space:nowrap">CAR-T</FONT> therapies targeting CD19 and BCMA have been developed and approved for the treatment of certain CD19 and BCMA positive hematological malignancies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In 2020, the size of the global MM market was approximately $18&nbsp;billion. We estimate the current total addressable <FONT STYLE="white-space:nowrap">CAR-T</FONT>
market for r/r MM to be approximately $10&nbsp;billion based on the number of patients who are receiving third line treatments and beyond. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of November&nbsp;19,
2021, the only <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy targeting BCMA that has been approved by the FDA is Abecma. Bristol Myers Squib is currently enrolling clinical trials targeting expansion of Abecma, currently approved only as a
fifth line of therapy, into earlier lines of treatment. The BCMA-targeting ADC, Blenrep is also an approved product and has reported an ORR of 31%, which is considerably lower than the 72% ORR for Abecma. Additionally, Abecma has shown a greater
median progression free survival of 11.1 months, compared with the median PFS of approximately 3 months with Blenrep. Although such responses are a step forward, there remains a need for improved overall response and durability. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">111 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>CART-ddBCMA: Phase 1 Trial Preliminary Results </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The CART-ddBCMA Phase 1 multi-center, open label, trial is the first involving one of our proprietary <FONT STYLE="white-space:nowrap">D-Domains</FONT> and was designed
to test CART-ddBCMA in r/r MM patients to evaluate the safety profile of escalating dose levels (DL) and to expand enrollment at a selected dose to further characterize the efficacy and safety profile of that dose. To be eligible, patients must have
had at least 3 prior lines of treatment, which had to include an immunomodulatory drug (IMiD), a proteosome inhibitor (PI), and an anti-CD38 antibody, be refractory to the most recent line of therapy, have an ECOG performance status of 0 or 1, have
measurable disease, and have adequate function of vital organs. If eligible, patients were enrolled, underwent leukapheresis (apheresis), and could receive bridging therapy while cell manufacturing occurred. When CART-ddBCMA cell manufacturing was
complete, patients received lymphodepleting chemotherapy with fludarabine (Flu) and cyclophosphamide (Cy) on days <FONT STYLE="white-space:nowrap">-5,</FONT> <FONT STYLE="white-space:nowrap">-4,</FONT> and <FONT STYLE="white-space:nowrap">-3.</FONT>
On day 0, patients received an intravenous infusion of CART-ddBCMA. After infusion, patients were evaluated at fixed intervals for assessment of AEs and evidence of objective response. Safety data are assessed for dose limiting toxicity in the first
28 days following infusion and will be collected throughout the trial. Long-term safety data will be collected for up to 15 years per health authority guidelines. Efficacy data are assessed pursuant to the International Myeloma Working Group (IMWG)
criteria on a monthly basis for the first 6 months and then quarterly for up to two years, or upon symptomatic relapse. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g33v00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The clinical trial began enrollment in December 2019 and the first patient was dosed in February 2020. Three clinical trial sites
have participated to date. Additional sites are planned for initiation in &nbsp;&nbsp;&nbsp;&nbsp; . We have completed the dose escalation component with 6 patients each enrolled in DL1 (100 x 10<SUP STYLE="font-size:85%; vertical-align:top">6</SUP>
cells) and DL2 (300 x 10<SUP STYLE="font-size:85%; vertical-align:top">6</SUP> cells). The preliminary data from the dose escalation were presented at the 2021 Annual Meeting of the American Society of Clinical Oncology. Based on the nearly
identical ORR in each DL and the observed potential for increased toxicity in DL2, we are currently expanding enrollment at DL1. As of the data <FONT STYLE="white-space:nowrap">cut-off</FONT> date of November&nbsp;4, 2021, we have enrolled and dosed
an aggregate of 18 patients at DL1. Data were presented at the 2021 Annual Meeting of the American Society of Hematology. In the efficacy analysis, 19 patients with at least 3 months follow up were included. For the safety analysis, 22 patients were
included based on having more than 1 month of follow up. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">112 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g34h85.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The median age of enrolled patients was 66 years (range <FONT STYLE="white-space:nowrap">44-76).</FONT> Thirteen (54%) patients were
male and 11 were female (46%). Bone marrow replacement of &gt;50% with malignant plasma cells was present in 10 (42%) of patients and 9 (38%) had extramedullary disease. Of those for whom cytogenetic evaluation had been performed (n=19), 17 (89%)
had high-risk cytogenetics. The median number of prior lines of therapy was 5 (range <FONT STYLE="white-space:nowrap">3-16).</FONT> Twenty (83%) patients had triple class refractory disease and 17 (71%) had penta-refractory disease. Taken together,
these demographic data indicate the patient population enrolled in this study had poor prognosis with expected median overall survival in the range of <FONT STYLE="white-space:nowrap">6-8</FONT> months based on published analyses of patients with
similar characteristics. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g34n66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Of the efficacy evaluable population (n=19), the objective response rate (ORR) was 100%. The complete response rate (complete or
stringent complete response; CR/sCR) was 68% (13/19), with 3 additional responses being VGPR (16%), resulting in a rate of response at depth of VGPR or better of 84% (16/19). We have observed deepening of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">113 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
responses over time, with an increasing proportion of patients who reach sCR/CR with each month on study, which is suggestive that patients treated more recently may still reach deeper responses.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>sCR/CR Rate by Month of Follow Up After Treatment with CART-ddBCMA in Phase 1 Trial </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g35f55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Responses are ongoing for 16 patients (84%), making calculation of median duration of response challenging. However, at the time of
the analysis, amongst the patients who were dosed in DL1 at least 12 months prior with a median follow up of 539 days, 4 of 6 (67%) were in ongoing response, with a median progression-free survival that exceeds 489 days (~16 months) and may continue
to lengthen with further follow up. In the 6 patients enrolled in DL2, with a median follow up of 311 days (~10 months), 5 of 6 patients have ongoing response and a median duration of response exceeds 269 days (~9 months) and may continue to
lengthen with further follow up. These data are summarized in the table below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g99g99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:8pt; font-family:ARIAL">In DL1 (100m, n=6 patients), median follow up 539&nbsp;days, median duration of response is 489+ days
(i.e. 16+ months), and 4&nbsp;of 6 patients continue to respond. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:8pt; font-family:ARIAL">In DL2 (300m, n=6 patients), median follow up 311&nbsp;days, median
duration of response is 269+ days (i.e. ~9+ months) and 5&nbsp;of 6 patients continue to respond. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">114 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A plot of each patient&#146;s response and duration of response with minimal residual disease (MRD) response is
presented below. Three patients have had disease progression; two of which have been <FONT STYLE="white-space:nowrap">re-treated.</FONT> One of the <FONT STYLE="white-space:nowrap">re-treated</FONT> patients did not benefit from <FONT
STYLE="white-space:nowrap">re-treatment</FONT> and the other is in early <FONT STYLE="white-space:nowrap">follow-up.</FONT> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g48w84.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Of the dosed patients, 22 were evaluable for safety analysis. The rate of AEs of grade 3 or higher CRS and ICANS are of special
interest (AESIs). A potential difference was observed in the incidence of these events in DL2 compared with DL1. In DL2 (n=6), 1 patient had a grade 3 CRS event and another had a grade 3 ICANS event. No events of grade 3 or higher CRS or ICANS
occurred in the 6-patient dose escalation cohort of DL1, but 1 out of 10 patients had a grade 3 ICANS event in the dose expansion cohort. In combined analysis of all patients in DL1, 100% had a grade 1 or 2 CRS event but 0% had grade 3 or higher
CRS. The median time to onset of CRS was 1 (range 0-6) day(s) and median duration was 6.5 (range 2-8) days. The median time to ICANS onset was 3 days (range 2-4 days) with a median duration of 8 days (4-9 days). Only 1 (~6%) grade 3 (or higher)
ICANS event occurred in DL1. All cases of ICANS and CRS resolved with standard interventions, such as tocilizumab and dexamethasone. We are conducting analyses to determine whether any patients may be treated as an outpatient. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g36a20.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">115 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical samples have been analyzed to demonstrate mechanism of action and characterize the cell expansion kinetics of
CART-ddBCMA in the phase 1 trial. We have measured CAR <FONT STYLE="white-space:nowrap">T-cell</FONT> number using polymerase chain reaction (PCR) to quantify the number of gene copies, i.e. vector copy number (VCN), of the CAR from the peripheral
blood cells of patients. The pattern of cell expansion is consistent between patients and dose levels. The peak expansion of CART-ddBCMA most commonly occurs on day 9 (range <FONT STYLE="white-space:nowrap">7-14).</FONT> There has been no obvious
correlation between peak CART-ddBCMA quantity in the peripheral blood and the best overall response (BORR). A graph demonstrating CART-ddBCMA quantification in peripheral blood over time is shown below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>CART-ddBCMA cell quantification using PCR to quantify VCN at sequential timepoints (n=21 patients) </B></P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g37a20.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>iMMagine: Planned Pivotal Phase 2 Trial of CART-ddBCMA </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our planned pivotal trial of CART-ddBCMA in r/r MM, the iMMagine trial, is scheduled to begin enrollment in &nbsp;&nbsp;&nbsp;&nbsp; . We expect the trial will be a <FONT
STYLE="white-space:nowrap">single-arm,</FONT> open-label, evaluation of the efficacy of CART-ddBCMA, as measured by the primary endpoint of ORR. Secondary endpoints will include sCR/CR rate and duration of response of a single infusion of
CART-ddBCMA after lymphodepleting chemotherapy. The primary endpoint was selected based on historical precedent of the primary endpoint used in other <FONT STYLE="white-space:nowrap">CAR-T</FONT> pivotal trials and the selection of this primary
endpoint has been reviewed and agreed with the FDA. Based upon feedback from regulatory authorities, we plan to include a total of approximately 110 patients in an integrated analysis of efficacy and safety, which may include patients from the Phase
1 trial, provided all requirements of the pivotal trial apply to those patients. We plan to enroll approximately 80 patients in the pivotal trial and expect a median <FONT STYLE="white-space:nowrap">follow-up</FONT> requirement of approximately 12
months. This trial will be conducted at institutions in the United States only. Secondary and/or exploratory endpoints will include duration of response, progression free survival (PFS), overall survival (OS), CR/sCR rate, assessment of minimal
residual disease, further characterization of the safety profile of CART-ddBCMA in a larger patient population, and confirmatory correlative biomarker analysis for pharmacology, predictive biomarkers of depth and duration of response, and
manufactured CART-ddBCMA cell phenotyping. Assuming positive data from this clinical trial, we plan to file a BLA in . </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>CART-ddBCMA: Earlier Lines of Therapy
<FONT STYLE="white-space:nowrap">(iMMagine-2)</FONT> and Post-BCMA Targeted Therapy </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Ultimately, we believe the use of CART-ddBCMA will move to earlier
lines of therapy in MM so following completing enrollment of the iMMagine trial, we plan to initiate enrollment of a clinical trial designed to evaluate efficacy of CART-ddBCMA in additional populations, which we refer to as the <FONT
STYLE="white-space:nowrap">iMMagine-2</FONT> program. Similar to other <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapies targeting BCMA, we plan to focus on enrollment of patients in earlier lines of therapy that have high risk of recurrence
and/or presence of MRD. Additionally, we will enroll a cohort of patients who have been treated with prior BCMA-targeting therapy to determine efficacy and safety in this population. We will seek to demonstrate in the iMMagine trial that CART-ddBCMA
can provide clinical benefit in patients in earlier line populations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">116 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>CART-ddBCMA: Future Clinical Plans </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also plan to initiate clinical trials of CART-ddBCMA in other key geographies, such as Europe and Asia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">ACLX-001</FONT> (BCMA): Planned Clinical Development </B></P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our first ARC-SparX program is <FONT STYLE="white-space:nowrap">ACLX-001,</FONT> an immunotherapeutic combination composed of
<FONT STYLE="white-space:nowrap">ARC-T</FONT> cells and bi-valent SparX proteins targeting BCMA, or SPRX001, for the treatment of r/r MM. We have received FDA clearance for our IND application to advance
<FONT STYLE="white-space:nowrap">ACLX-001</FONT> into clinical development, where we will use our <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells for the first time in combination with SPRX001. We are currently preparing applications for Fast
Track, Orphan Drug and RMAT designations. We plan to initiate our Phase 1 dose-escalation clinical trial of <FONT STYLE="white-space:nowrap">ACLX-001</FONT>
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , utilizing the same antigen binding domain as CART-ddBCMA. This trial is intended to serve as clinical validation of our ARC-SparX platform as we
seek to understand PK, safety profile, and dosing strategy for future clinical development. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Escalation of the <FONT STYLE="white-space:nowrap">ARC-T</FONT> cell
dose and escalation of the SPRX001 dose may happen in parallel and/or in series depending on observations of safety and efficacy in each combination dose level. In addition, the clinical trial is designed to allow flexibility in the frequency of
SPRX001 administration based on observed pharmacokinetics of SPRX001 and <FONT STYLE="white-space:nowrap">ARC-T</FONT> cell expansion kinetics. Preclinical data suggest that frequency of dosing may be a key factor for the efficacy and safety of <FONT
STYLE="white-space:nowrap">ACLX-001</FONT> due to the ability to control ARC T interaction with tumor cells (via antigen binding) through SPRX001. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The clinical
trial design is intended to accelerate the timeline to meaningful clinical data as compared with more standard dose evaluation approaches. The primary objective of the trial is to identify a dosing regimen that does not exceed the maximally
tolerated dose (MTD) and achieves clinical benefit comparable to what has been observed in our Phase 1 clinical trial of CART-ddBCMA. The primary endpoint of the trial will be to determine the incidence of treatment-emergent adverse events (TEAEs),
including dose limiting toxicities (DLTs). Upon completion of the Phase 1 trial, we will leverage the learnings from this trial to advance our AML/MDS programs utilizing ARC-SparX and consider developing additional SparX for r/r MM for a broader
pipeline in this disease area. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our AML/MDS Programs </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">With the ARC-SparX
platform we are developing a comprehensive solution for personalized therapy tailored to the molecular profile of an AML/MDS patient&#146;s disease. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Diseased cells
from AML and high risk MDS patients often have a complex cytogenetic profile that leads to significant clonal heterogeneity. This heterogeneity exists not only between patients but also within an individual&#146;s disease. Traditional targeted
therapies including <FONT STYLE="white-space:nowrap">CAR-Ts</FONT> have struggled to drive deep and durable responses because they target only a fraction of the patient&#146;s diseased cells. In addition, traditional
<FONT STYLE="white-space:nowrap">CAR-T</FONT> targets in AML/MDS such as CD33, CD123 and CLL1 are expressed on normal myeloid cells, including progenitor cell populations, which may lead to prolonged myelosuppression. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to build a library of SparX proteins targeting different AML and MDS antigens that can be used in any combination depending on the molecular profile of a
patient&#146;s diseased cells to combat disease heterogeneity. Furthermore, we believe the controllability of the ARC-SparX platform will give physicians the ability to turn off the therapy once disease is controlled to allow for faster recovery of
the normal myeloid compartment and thus less toxicity. We plan to initiate the Phase 1 clinical trial for <FONT STYLE="white-space:nowrap">ACLX-002</FONT> for AML/MDS in &nbsp;&nbsp;&nbsp;&nbsp; and plan to initiate a Phase 1 clinical trial for
another ARC-SparX product candidate directed at another antigen associated with AML/MDS in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Background, Current Treatments and Limitations </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Acute myeloid
leukemia (AML)</B>, also referred to as acute myelogenous leukemia, arises from healthy bone marrow stem cells that have accumulated multiple genetic mutations causing the mutated stem cells to grow uncontrollably. The aggressive growth of AML cells
in the bone marrow disrupts the development of healthy blood cells including white cells, red cells and platelets. The net result is that AML patients often present with anemia (too few red blood cells), infections (caused by too few functioning
white blood cells) or frequent bleeding and bruising (caused by too few platelets). The aggressive growth of AML in the bone marrow and blood, its disruption of normal blood cell production and the lack of durable treatments leave AML patients with
a 28.7% five-year survival rate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">117 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According to the National Cancer Institute SEER database, there were estimated to be 64,512 people living with AML in
the USA in 2017. In 2020, new cases were estimated to have been approximately 19,940, with 11,180 deaths. The disease accounts for approximately 1.1% of all new cancers, but is the most common acute leukemia affecting adults. AML also represents
approximately 20% of childhood leukemia. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The standard of care for the majority of AML patients consists of induction chemotherapy (cytarabine and anthracycline)
followed by additional rounds of chemotherapy with or without stem cell transplant. Although approximately <FONT STYLE="white-space:nowrap">two-thirds</FONT> of patients achieve remission, relapse often occurs within the first 18 months following
treatment. The high relapse rate points to the need for new therapies capable of extending disease free survival. We believe there is a critical need to develop new therapeutic modalities with greater safety and efficacy, especially for patients
with r/r AML. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Currently, new therapies for AML have many limitations. The lead candidates of small molecule inhibitors of proteins that are over-expressed or
otherwise dysregulated in AML show only modest efficacy with short duration of response. Antibody-based therapeutics, including antibody-drug conjugates and bispecifics, have thus far shown limited efficacy and in some cases, significant toxicities.
Additionally, <FONT STYLE="white-space:nowrap">CAR-T</FONT> therapy is being deployed with specificity for various targets including CD33, CD123, FLT3, CLL1, CD19, IL1RAP and NKG2DL. Many of these therapies are in the early stages of clinical
development. The common theme across the various therapeutic modalities described above is the need for new therapies with enhanced efficacy and improved safety. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>Myelodysplastic syndrome (MDS) </B>is a closely related disease in which a population of abnormal myeloid stem cells develop in the bone marrow. Depending on the
type of abnormal, or dysplastic cell that emerges, patients may experience a specific decrease in red blood cells, or one of the disease-fighting cell populations referred to as monocytes, neutrophils and dendritic cells. Like AML, MDS impacts the
elderly with patients often diagnosed in their 70s. The incidence of MDS has been estimated to be as low as 10,000 new cases per year in the United States. MDS is considered to be a type of cancer because about
<FONT STYLE="white-space:nowrap">one-third</FONT> of MDS patients progress to AML. Standard therapy for MDS is cytarabine alone or in combination with idarubicin or daunorubicin. Stem cell transplant can cure MDS but the advanced age of onset and <FONT
STYLE="white-space:nowrap">co-morbidities</FONT> often limit MDS patient transplant eligibility due to the toxicity of typical transplant conditioning regimens, especially for those patients characterized with high risk MDS. Thus, new therapies are
needed for MDS patients as well. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">ACLX-002</FONT> (CD123): Preclinical Development </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our first AML/MDS product candidate is <FONT STYLE="white-space:nowrap">ACLX-002,</FONT> which is be an immunotherapeutic combination agent composed of the same <FONT
STYLE="white-space:nowrap">ARC-T</FONT> cells used in <FONT STYLE="white-space:nowrap">ACLX-001,</FONT> together with mono-valent SparX proteins that each contain a binding domain directed at CD123. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on the potential validation of our ARC-SparX platform in our planned Phase 1 clinical trial of <FONT STYLE="white-space:nowrap">ACLX-001,</FONT> we intend to
advance our ARC-SparX platform into myeloid diseases by initiating our Phase 1 clinical trial for <FONT STYLE="white-space:nowrap">ACLX-002</FONT> in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
for the treatment of r/r AML and high-risk MDS. We are currently preparing applications for Fast Track, Orphan Drug and RMAT designations after IND review is complete. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have also identified a group of high priority antigen targets associated with AML/MDS through internal analyses and extensive conversations with key opinion leaders.
We are in the process of isolating binding domains that bind these targets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <I>in vitro </I>cytolytic activity of
<FONT STYLE="white-space:nowrap">ACLX-002</FONT> was assessed by <FONT STYLE="white-space:nowrap">co-culturing</FONT> a CD123-expressing human AML tumor,
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">MOLM-14-GFP/Luc.</FONT></FONT> For the negative control, we used <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells together with SparX-<FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>3D. As shown in the figure below, <FONT STYLE="white-space:nowrap">ACLX-002</FONT> exhibited dose-dependent <FONT STYLE="white-space:nowrap">MOLM-14</FONT> killing across a broad range of SparX protein
concentrations (10<SUP STYLE="font-size:85%; vertical-align:top">-4</SUP>nM to 10<SUP STYLE="font-size:85%; vertical-align:top">2</SUP>nM); p&lt;0.0001). In contrast, the same <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells failed to kill <FONT
STYLE="white-space:nowrap">MOLM-14</FONT> cells in the presence of the negative control SparX-<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>3D. Each data point shows the mean standard deviation for
triple replicates where the significance of the comparison of the dose response curves for <FONT STYLE="white-space:nowrap">ACLX-002</FONT> and <FONT STYLE="white-space:nowrap">ARC-T</FONT> + SparX-<FONT STYLE="font-family:Times New Roman"><FONT
STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>3D has a <FONT STYLE="white-space:nowrap">p-value</FONT> less than 0.0001. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">118 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B></B><B><I>In Vitro </I></B><B>Cell Killing of Human <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">MOLM-14-GFP/Luc</FONT></FONT> Tumors by <FONT STYLE="white-space:nowrap">ACLX-002</FONT> is Dependent on SPRX002 Dose </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g39b76.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The <I>in vivo </I>anti-tumor activity of <FONT STYLE="white-space:nowrap">ACLX-002</FONT> was compared to that of a <FONT
STYLE="white-space:nowrap">CAR-T</FONT> cell with a scFv-based binding domain directed at CD123 (CART-CD123). NSG mice were injected on Day 0 with <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">MOLM-14-GFP/Luc,</FONT></FONT> a
CD123 expressing human AML cell line, the presence of which can be quantitated by a co-expressed GFP and Luc. We monitored tumor growth by using BLI to measure bioluminescence produced by diseased cells. Six days after
<FONT STYLE="white-space:nowrap">MOLM-14</FONT> injection, the first group of mice received 5&nbsp;million CART-CD123 cells, the second group received 5&nbsp;million <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells with 1 mg/kg daily (q.d.) of
negative control SparX-<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#097;</FONT></FONT>3D that does not bind the tumor. Mice in the third, fourth and fifth groups each received 5&nbsp;million <FONT
STYLE="white-space:nowrap">ARC-T</FONT> cells along with doses of 1 mg/kg bi-valent SparX proteins targeting CD123 (SPRX002) q.d., 1 mg/kg SPRX002 dosed every other day (q.o.d.) and 0.3 mg/kg q.o.d. respectively. Each treatment group contained 4 or
5 mice. Mice were imaged weekly for four weeks with an additional imaging on the third day following treatment because this cell line grows quickly. As expected, tumors in mice receiving the negative control SparX protein grew quickly while tumors
in mice receiving the CART-CD123 were largely eliminated within 28 days of CART-CD123 administration. The CART-CD123 treatment group as well as all three <FONT STYLE="white-space:nowrap">ACLX-002</FONT> treatment groups of mice were observed to have
significant anti-tumor activity on days 3, 7 and 14 after receiving treatment (p&lt;0.001). Among mice receiving 1 mg/kg of SPRX002 q.d. or q.o.d., tumors were also mostly cleared within 28 days. Mice treated with 0.3 mg/kg SPRX002 q.o.d displayed
robust anti-tumor activity but did not fully clear the tumors by Day 28. These results demonstrate tumor killing that is comparable to that observed with the CART-CD123 and dependent on SPRX002 dose and schedule. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">119 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">ACLX-002</FONT> Clearance of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">MOLM-14-GFP/Luc</FONT></FONT> Tumors is Dependent on Both Dose and Schedule of SPRX002 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g40f82.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">ACLX-002</FONT> (CD123): Planned Clinical Development </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to begin clinical development of <FONT STYLE="white-space:nowrap">ACLX-002</FONT>
in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;with initiation of a Phase 1, dose escalation trial of both <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells and SPRX002 in advanced AML and/or MDS.
Escalation of the <FONT STYLE="white-space:nowrap">ARC-T</FONT> cell dose and escalation of the SPRX002 dose may happen in parallel and/or in series depending on observations of safety and efficacy in each combination dose level. In addition, the
clinical trial is designed for flexibility in the frequency of SPRX002 administration based on observed pharmacokinetics of SPRX002 and <FONT STYLE="white-space:nowrap">ARC-T</FONT> cell expansion kinetics. Preclinical data suggest that frequency of
dosing may be a key factor for the efficacy and safety of <FONT STYLE="white-space:nowrap">ACLX-002</FONT> due to the ability to control <FONT STYLE="white-space:nowrap">ARC-T</FONT> interaction with tumor cells (via antigen binding) through
SPRX002. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The clinical trial design is intended to accelerate the timeline to meaningful clinical data as compared with more standard dose evaluation approaches.
The primary objective of the trial is to identify a recommended phase 2 dose (RP2D) that does not exceed the MTD and achieves evidence of clear clinical benefit. The primary endpoint of the trial will be to determine the incidence of TEAEs,
including DLTs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Assuming positive data from the planned Phase 1 trial of <FONT STYLE="white-space:nowrap">ACLX-002,</FONT> we expect that we will likely conduct
Phase 2 trial of <FONT STYLE="white-space:nowrap">ACLX-002</FONT> to further study its potential efficacy. Depending on observed efficacy, this trial has the potential to be a pivotal trial from which data could support the filing of a BLA with FDA.
We plan to develop <FONT STYLE="white-space:nowrap">ACLX-002</FONT> in combination with additional SparX proteins against additional target antigens with the goal of overcoming tumor antigen heterogeneity in AML/MDS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other Preclinical AML/MDS Product Candidates </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have also
identified a group of high priority antigen targets associated with AML/MDS through internal analyses and conversations with key opinion leaders and are developing additional SparX proteins against such target antigens. We anticipate initiating our
Phase 1 clinical trial for our next most advanced AML/MDS product candidate, which we refer to as <FONT STYLE="white-space:nowrap">AML-2,</FONT> in&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . We
have also isolated <FONT STYLE="white-space:nowrap">D-Domain</FONT> binders to several other targets (which we refer to as <FONT STYLE="white-space:nowrap">AML-3</FONT> and <FONT STYLE="white-space:nowrap">AML-4)</FONT> and plan to progress them in
our pipeline to add to our AML/MDS SparX library. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">120 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Solid Tumor Program </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
intend to develop multiple assets and novel technology to combat a variety of solid tumor indications while leveraging the strengths of each of our existing therapeutic platforms. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">ddCARs may be best suited for&nbsp;targets&nbsp;that have high homogeneous tumor cell expression with little to no normal cell expression&nbsp;with&nbsp;potential for a
wide therapeutic window.&nbsp;We&nbsp;are continuing to build ddCARs where&nbsp;the target biology&nbsp;supports this approach.&nbsp;To this end,&nbsp;we have&nbsp;selected <FONT STYLE="white-space:nowrap">D-Domain</FONT> binders to an attractive
target that we are evaluating as a&nbsp;ddCAR&nbsp;to potentially treat patients with HCC.</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Some solid tumors have been shown to contain a high level of
heterogeneity within an individual&#146;s tumor. Where this heterogeneity exists, we believe a library of SparX proteins targeting a specific solid tumor patient population has the potential to drive deep and durable responses beyond those produced
by any single targeting therapeutic. We currently have engineered novel SparX proteins for various solid tumor-associated antigens, some with overlapping expression in specific patient populations such as SCLC, that together may allow ARC-SparX
product candidates to overcome antigen heterogeneity of the disease. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Targeting solid tumors with cellular therapy presents additional hurdles such as <FONT
STYLE="white-space:nowrap">on-target</FONT> <FONT STYLE="white-space:nowrap">off-tumor</FONT> toxicity as well as physical and immunological barriers. We intend to use a multi-pronged approach employing innovative technological solutions such as <FONT
STYLE="white-space:nowrap">AND-gated</FONT> SparX proteins as well as technologies designed to enhance the persistence and function of ddCAR or <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells in the tumor environment. We also intend to employ
clinical and translational strategies such as combinations with checkpoint inhibitors to boost activity of ddCAR or <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells to further overcome some common immunological barriers to successful <FONT
STYLE="white-space:nowrap">CAR-T</FONT> therapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Additional Indications and Applications of Our Technology </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe our platform technologies lend themselves to a broad array of potential applications, including: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Novel Targets</I></B><I>. </I>We believe our platforms are well suited to safely and rapidly explore targeting of novel antigens that would be otherwise
challenging to target with a conventional <FONT STYLE="white-space:nowrap">CAR-Ts.</FONT> We have successfully generated <FONT STYLE="white-space:nowrap">D-Domain</FONT> binders to over a dozen tumor antigens and are employing sophisticated tools,
such as AI and ML, to optimize these assets. We employ <FONT STYLE="white-space:nowrap">AI-based</FONT> approaches to assist in the optimization of <FONT STYLE="white-space:nowrap">D-Domain</FONT> properties and continue to develop <FONT
STYLE="white-space:nowrap">AI-based</FONT> approaches to enhance our discovery process. We currently use an in-silico immunogenicity risk assessment and deimmunization platform using an ML algorithm for predicting potential immunogenic epitopes. We
also use <FONT STYLE="white-space:nowrap">AI-based</FONT> protein structure determination programs to analyze the surface chemistry of our <FONT STYLE="white-space:nowrap">D-Domains</FONT> to better determine aspects such as library design and hit
optimization. We believe further implementation of AI and ML can assist in other areas of the discovery process such as <FONT STYLE="white-space:nowrap">D-Domain</FONT> affinity optimization from deep learning of analysis of thousands of <FONT
STYLE="white-space:nowrap">D-Domain</FONT> sequences from our panning and screening campaigns. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Allogeneic Cell Therapy Products and Other Immune Cell
Therapies</I></B><I>. </I>We believe it will be important for patients to have both autologous and allogeneic cell therapy options as both therapeutic options mature, including therapies derived from T cells and NK cells. We believe allogeneic cell
therapies may not be a fit for all indications and as such we expect to develop them where applicable as another tool in our fight against cancer that includes our autologous ddCARs and ARC-SparX. While our initial clinical programs utilize
autologous <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells, we also anticipate developing allogeneic cell therapy technologies to target the broadest indications and/or create an
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">off-the-shelf</FONT></FONT> universal cell therapy. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Indications Beyond Oncology</I></B><I>.
</I>As the field of adoptive cell therapy looks to apply the technology beyond oncology, so too do we seek to explore such opportunities. We envision expanding into treatments for antibody-mediated autoimmune diseases, such as refractory systemic
lupus erythematosus, refractory primary Sjogren&#146;s syndrome, or thrombotic thrombocytopenic purpura. For example, published scientific studies have shown that clearance of plasma cells within patients that have antibody-mediated autoimmune
diseases have resulted in improvement in clinical symptoms. We can test CART-ddBCMA or <FONT STYLE="white-space:nowrap">ACLX-001</FONT> in these settings to eliminate normal plasma cells for patients with these severe autoimmune diseases. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Diagnostics. </I></B>Our <FONT STYLE="white-space:nowrap">D-Domains</FONT> or SparX proteins may be used in various diagnostic settings much like monoclonal
antibodies or antibody fragments. As an example, we can envision labeling SparX proteins with a radiotracer for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">121 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
imaging tumors in patients as a patient selection tool prior to starting therapy with that same SparX together with <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Antibody Alternatives. </I></B>Our binding domains have many positive attributes over scFv binding domains that we believe could allow them to be used as an scFv
alternative in <FONT STYLE="white-space:nowrap">non-cell</FONT> therapy applications and serve as the foundation to creating a new class of therapeutic antibody alternatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Manufacturing and Delivery </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our manufacturing process is consistent across
CART-ddBCMA cells and <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells. This consistent process enables flexibility of cell product production within a site using the same equipment and consistent protocols, utilizing product specific viral
vector input. As we advance clinical development of multiple product candidates across our ddCAR and ARC-SparX platforms, we have secured key components, including lentiviral vector, and capacity from our manufacturing partners to ensure we are able
to complete enrollment for our planned CART-ddBCMA pivotal trial, earlier line clinical trial of CART-ddBCMA, and our planned Phase 1 trial of <FONT STYLE="white-space:nowrap">ACLX-001.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>CART-ddBCMA Cell and <FONT STYLE="white-space:nowrap">ARC-T</FONT> Cell </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently rely on third parties for the manufacture and release testing of viral vectors and product candidates for clinical testing. We also currently rely on third
parties for patient apheresis material logistics, as well as to package, label, store and distribute our product candidates. As we progress through development to commercialization, we will leverage our <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">best-in-class</FONT></FONT> vendors and evaluate other options to secure commercial-scale capacity. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our current cell manufacturing
supplier has proven to be a reliable partner for the CART-ddBCMA Phase 1 trial, releasing 100% of initiated cell product runs to date, and will continue to deliver cell product for CART-ddBCMA Phase 1 expansion trial. Of the first 20 lots, cell
product for CART-ddBCMA has thus far had a mean viability of 98%, a mean CAR+ rate of 74%, and a mean yield of nearly one billion cells, more than sufficient for our intended therapeutic dose of 100&nbsp;million cells. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Viability by Lot: Viability is reported as the percentage of viable cells in the drug product with an acceptance limit of 70%. Based on over 20 lots of CART-ddBCMA run
to date, we have achieved a mean of 98%, well above the acceptance level. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g41x63.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">%CAR+ by Lot: CAR positive, as defined by proportion of cells expressing the CAR construct on the cell surface, is well above
acceptance levels, as well as published competitor reports. A high proportion of CAR+ cells lowers the total number of T cells required to be administered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">122 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g42b83.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Yield (million of cells): Based on our CART-ddBCMA process, our mean yield is nearly one billion cells, surpassing the levels needed
for both our low dose of 100&nbsp;million cells and our high dose of 300&nbsp;million cells. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g43n80.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are continuing to invest in process improvements to reduce the overall process time and improve costs. Our <FONT
STYLE="white-space:nowrap">D-Domain,</FONT> due to its stability, has demonstrated a high transduction rate resulting in a more efficient manufacturing process. We believe this will translate to improved processes that will reduce the time to
intervention for patients. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have established partnerships with established and experienced cell therapy contract manufacturers to supply clinical materials and
manufacturing capabilities for our clinical trials. As we scale to commercialization, we will increase capacity with our current suppliers and evaluate other options to secure commercial-scale capacity. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The manufacturing process for our <FONT STYLE="white-space:nowrap">ARC-T</FONT> cells is consistent with the CART-ddBCMA process. However, cells are transduced with a
lentiviral vector encoding our universal ARC, which is a CAR with an <FONT STYLE="white-space:nowrap">anti-TAG</FONT> binding domain, in lieu of a lentiviral vector encoding the CAR construct with a ddBCMA binding domain. Because our <FONT
STYLE="white-space:nowrap">ARC-T</FONT> cells are designed to express the same <FONT STYLE="white-space:nowrap">TAG-specific</FONT> binding domain rather than a cell surface antigen-specific binding domain, the same lentiviral vector encoding the
universal ARC can be used for every patient regardless of disease or target antigen. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">123 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>SparX Protein </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
manufacture SparX proteins <FONT STYLE="white-space:nowrap">in-house</FONT> for most research activities, but we use a third-party CMO for most preclinical studies, and all clinical trials. We produce research SparX proteins in mammalian and
microbial systems using fermentation and protein purification strategies that we believe can be scaled for commercial purposes. The purified SparX protein is formulated to the desired concentration and then put into the desired formulation buffer.
Every SparX protein is monitored throughout the purification process and afterwards using an array of analytical tests that assess SparX protein size, binding activity and potential biophysical changes in the SparX protein. We anticipate the process
will evolve over time to improve yields, quality and quantity of recovered SparX protein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Competition</B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biotechnology and pharmaceutical industries, including the oncology subsector, are characterized by rapidly advancing technologies, intense competition and a strong
emphasis on intellectual property. Any candidate that we successfully develop and commercialize will have to compete with existing therapies as well as therapies that may be developed in the future. While we believe our <FONT
STYLE="white-space:nowrap">D-Domain,</FONT> ddCAR and ARC-SparX platforms and scientific expertise provide us with&nbsp;a number of&nbsp;key advantages, we face substantial competition from many different sources, including large pharmaceutical
companies and biotechnology companies, academic research institutions and governmental agencies, and public and private research institutions.</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We anticipate
substantial direct competition from other organizations developing advanced <FONT STYLE="white-space:nowrap">CAR-Ts,</FONT> other types of genetically modified cell therapies, or other anti-BCMA biologics due to their promising clinical therapeutic
effect in clinical trials including: 2seventy, Abbvie, Allogene, Amgen, Autolus, Bristol-Myers Squibb, Carsgen, GSK, Innovent, Johnson&nbsp;&amp; Johnson, Legend, Novartis, Pfizer, Poseida Therapeutics, Precision BioSciences and Regeneron. In
addition, some companies, such as&nbsp;Allogene, Caribou Biosciences, Cellectis&nbsp;and&nbsp;Crispr, are developing allogeneic cell therapies that could compete with our product candidate.</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot predict whether other types of <FONT STYLE="white-space:nowrap">CAR-T</FONT> or other genetically modified cell therapies may be developed and demonstrate
greater efficacy, and we may have direct and substantial competition from such therapies in the future. Further, despite the unique approach that we have developed to address the limitations of <FONT STYLE="white-space:nowrap">CAR-T</FONT> and other
types of genetically modified cell therapies, we expect to face increasing competition as new, more effective treatments for cancer enter the market and further advancements in technologies are made. We expect market adoption of any treatments that
we develop and commercialize to be dependent on, among other things, efficacy, safety, delivery, price and the availability of reimbursement from government and other third-party payors.</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in
research and development, manufacturing, preclinical testing, conducting clinical trials and marketing approved products than we do. Mergers and acquisitions in the pharmaceutical, biotechnology, gene therapy and cell therapy industries may result
in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.
These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary
to, or necessary for, our product candidates.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Commercialization </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In
light of our stage of development, we have not yet established a commercial organization or distribution capabilities. Prior to approval of any of our product candidates, we intend to develop a commercialization infrastructure for those products. We
will initially focus on the United States and be prepared to expand to other key markets as subsequent regulatory approvals are received. While we are preparing to launch on our own we will continue to evaluate partnership opportunities to provide
commercialization infrastructure, including sales and marketing and commercial distribution. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Development, Evaluation and License Agreement with Pfenex Inc.
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2018, we entered into a Development, Evaluation and License Agreement with Pfenex Inc. pursuant to which we obtained the option to obtain
worldwide, sublicensable, exclusive licenses to incorporate certain </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">124 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
proprietary SparX proteins into our ARC-SparX platform. Under the terms of the agreement, Pfenex is eligible to receive development funding in addition to development, regulatory and commercial
milestones up to an aggregate of $19.3125 million for each product incorporating a SparX protein expressed using a production strain based on the technology licensed from Pfenex, as well as low single-digit royalties during the royalty term on
worldwide net sales of any such products. The royalty term is on a licensed SparX protein-by-licensed SparX protein and country-by-country basis and the shorter of (i) ten years from the date of first commercial sale and (ii) three months after the
launch of a generic drug in such country. Such royalties for combination product are subject to certain net sales adjustments. Arcellx may terminate its licenses to individual proprietary SparX proteins at any time upon prior written notice. Either
party may terminate for a materially uncured breach subject to a disputed breach resolution mechanism. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Intellectual Property </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Developing intellectual property is a vital component of our business plan for maximizing return on our investments. We actively develop intellectual property that we
believe is important to our business, including seeking, maintaining, enforcing and defending United States and international patent rights for our product candidates, processes, and our discovery, development, and therapeutic platforms. We pursue,
maintain and defend patent rights in strategic areas to protect the technology, inventions and improvements that are important to the commercial development of our business and our competitive position. We also rely on trade secrets to protect
aspects of the technology, inventions and improvements that cannot be patented but are important to the development of our business and competitive position. We have spent considerable effort securing intellectual property rights, including patent
rights related to our proprietary D-Domain binding domain, ARC and SparX protein technologies and to our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We own three patent families directed
to the proprietary D-Domain binding domain technology. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The first patent family includes three pending U.S. non-provisional applications, and several pending foreign patent
applications covering commercially important jurisdictions in Europe, Asia, Australia and the Americas. The family further includes three issued U.S. patents, two granted European patents (validated in 37 and 13 countries covered by the European
Patent Organisation, respectively) and nine patents granted (or applications allowed) in other commercially significant jurisdictions. The U.S. patents broadly cover libraries of our proprietary D-Domain binding domains, compositions comprising our
proprietary D-Domain binding domains and methods of using our proprietary D-Domain binding domains. Compositions covered by the issued claims include fusion polypeptides comprising our proprietary D-Domain binding domain and CARs comprising our
proprietary D-Domain binding domains. Methods covered by the issued claims include the use of CARs comprising our proprietary D-Domain binding domain in the treatment of cancer. Any patent issuing from the first family is expected to expire in 2036,
not including any patent term adjustment and patent term extension. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The second patent family is directed to proprietary D-Domain binding domains that bind commercially relevant target
antigens and fusion polypeptides containing these domains. The second family includes an international application, three pending U.S. non-provisional applications, and pending foreign patent applications in 17 commercially significant foreign
jurisdictions in Europe, Asia, Australia and the Americas. Any patent issuing from the second family is expected to expire in 2038, not including any patent term adjustment and patent term extension. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The third patent family is directed to proprietary D-Domain binding domains that bind commercially relevant target
antigens and fusion polypeptides containing these domains. The family includes a pending U.S. provisional patent application. We plan to convert the pending application into an international application. Any patent issuing from the family is
expected to expire in 2042, not including any patent term adjustment and patent term extension. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We also own two patent families directed to the
proprietary ARC-SparX platform technology. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">One patent family is directed to our ARC construct and SparX protein technologies, and to methods of using them in T
cell-based and other therapeutic applications. The family includes a pending U.S. non-provisional application, and pending foreign patent applications in 17 commercially significant foreign jurisdictions in Europe, Asia, Australia and the Americas.
Any patent issuing from the family is expected to expire in 2038, not including any patent term adjustment and patent term extension. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">125 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A second patent family is directed to dosing regimens for employing the proprietary ARC-SparX platform technology in
therapeutic methods. The family includes a U.S. provisional patent application. We plan to convert the pending application into an international application. Any patent issuing from the family is expected to expire in 2042, not including any patent
term adjustment and patent term extension. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to patent protection, we also rely on trademark registration, trade secrets, know how,
other proprietary information and continuing technological innovation to develop and maintain our competitive position. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our trademark portfolio currently contains
pending U.S. trademark applications for the ARCELLX, ARC-T, SPARX, SPARX PROTEINS and SPARX PROTEIN trademarks. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We seek to protect and maintain the confidentiality
of proprietary information to protect aspects of our business that are not amenable to, or that we do not consider appropriate for, patent protection. Although we take steps to protect our proprietary information and trade secrets, including through
contractual means with our employees and consultants, third parties may independently develop substantially equivalent proprietary information and techniques or otherwise gain access to our trade secrets or disclose our technology. Therefore, we may
not be able to meaningfully protect our trade secrets. It is our policy to require our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to execute confidentiality agreements upon the commencement of
employment or consulting relationships with us. These agreements provide that all confidential information concerning our business or financial affairs developed or made known to the individual during the course of the individual&#146;s relationship
with us is to be kept confidential and not disclosed to third parties except in specified circumstances. Our agreements with employees also provide that all inventions conceived by the employee in the course of employment with us or from the
employee&#146;s use of our confidential information are our exclusive property. However, such confidentiality agreements and invention assignment agreements can be breached and we may not have adequate remedies for any such breach. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent and other intellectual property positions of biotechnology companies like ours are generally uncertain and involve complex legal, scientific and factual
questions. Our commercial success will also depend in part on not infringing upon the proprietary rights of third parties. It is uncertain whether the issuance of any third-party patent would require us to alter our development, commercial
strategies, drugs or processes, or to obtain licenses or cease certain activities. Our breach of any license agreements or our failure to obtain a license to proprietary rights required to develop or commercialize our future products may have a
material adverse impact on us. If third parties prepare and file patent applications in the United States that also claim technology to which we have rights, we may have to participate in interference or derivation proceedings in the USPTO to
determine priority of invention. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For more information on these risks and other comprehensive risks related to our intellectual property, see &#147;Risks Relating
to Our Intellectual Property.&#148; </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Government Regulation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the research, development,
testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biopharmaceutical products. Generally,
before a new biopharmaceutical product can be marketed, considerable data demonstrating its quality, safety, purity and potency must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by
the regulatory authority. Potency is interpreted to mean the specific ability or capacity of the product, as indicated by appropriate laboratory tests or by adequately controlled clinical data obtained through the administration of the product in
the manner intended, to effect a given result. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>U.S. Biopharmaceutical Development </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, the FDA regulates biopharmaceuticals under the Food, Drug and Cosmetic Act (FDCA) and the Public Health Service Act (PHSA). Biopharmaceuticals
also are subject to other federal, state and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations requires the
expenditure of substantial time and financial resources. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or post-market may subject an applicant to administrative or
judicial sanctions. These sanctions could include, among other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">126 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
actions, the FDA&#146;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, untitled or warning letters, product recalls or market withdrawals, product seizures,
total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse
effect on us. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Biologics must be licensed by the FDA under the PHSA through the submission of a BLA before they may be legally marketed in the United States.
The process generally involves the following: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Completion of extensive preclinical studies in accordance with applicable regulations, including studies conducted in
accordance with good laboratory practice (GLP) requirements; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Submission to the FDA of an IND, which must become effective before human clinical trials may begin;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Approval by an independent institutional review board (IRB), or ethics committee at each clinical trial site before each
trial may be initiated; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, GCP
requirements and other clinical trial-related regulations to establish the potency, purity and safety of the investigational product for each proposed indication; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Submission to the FDA of a BLA; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A determination by the FDA within 60 days of its receipt of a BLA to accept the filing for review; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Satisfactory completion of a FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing
facility or facilities where the biologic will be produced to assess compliance with cGMP, requirements to assure that the facilities, methods and controls are adequate to preserve the biologic&#146;s identity, strength, quality and purity;
</P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Potential FDA audit of the preclinical study and/or clinical trial sites that generated the data in support of the BLA;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">FDA review and approval of the BLA, including consideration of the views of any FDA advisory committee, prior to any
commercial marketing or sale of the biologic in the United States; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Compliance with any post-approval requirements, including the potential requirement to implement a REMS, and the potential
requirement to conduct post-approval studies. </P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The data required to support a BLA are generated in two distinct developmental stages:
preclinical and clinical. The preclinical and clinical testing and approval process requires substantial time, effort and financial resources. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Preclinical Studies and IND </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Preclinical studies include laboratory
evaluation of product biochemistry, formulation and stability, as well as<I>&nbsp;in vitro</I>&nbsp;and animal studies to assess the potential for toxicity and to establish a rationale for therapeutic use for supporting subsequent clinical testing.
The conduct of preclinical studies is subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information,
analytical data, any available clinical data or literature and a proposed clinical protocol, among other things, to the FDA as part of an IND. An IND is a request for authorization from the FDA to administer an investigational product to humans and
must become effective before human clinical trials may begin. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, may continue after the IND is submitted. An IND automatically becomes
effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve
any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical Trials </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The clinical stage of development involves the
administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#146;s control, in accordance with GCP requirements,
which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial,
dosing procedures, subject selection and exclusion </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">127 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
criteria and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the
IND. Furthermore, each clinical trial must be reviewed and approved by an IRB for each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are
reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. There also
are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A sponsor who wishes to conduct a
clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the
FDA in support of a BLA. The FDA will accept a well-designed and well-conducted foreign clinical trial not conducted under an IND if the trial was conducted in accordance with GCP requirements and the FDA is able to validate the data through an
onsite inspection if deemed necessary. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical trials in the United States generally are conducted in three sequential phases, known as Phase&nbsp;1, Phase&nbsp;2
and Phase&nbsp;3, and may overlap. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are
initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, tolerability and safety of the drug. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 2 clinical trials involve studies in disease-affected patients to determine the dose required to produce the desired
benefits. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified and a preliminary evaluation of efficacy is conducted. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the
data necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product approval. These trials may include
comparisons with placebo and/or other comparator treatments. The duration of treatment is often extended to mimic the actual use of a product during marketing. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Post-approval trials, sometimes referred to as Phase&nbsp;4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional
experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase&nbsp;4 clinical trials as a condition of approval of a BLA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and written IND safety reports
must be submitted to the FDA and the investigators for serious and unexpected suspected adverse events, findings from other studies suggesting a significant risk to humans exposed to the investigational product, findings from animal or<I>&nbsp;in
vitro</I>&nbsp;testing that suggest a significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Phase&nbsp;1, Phase&nbsp;2 and Phase&nbsp;3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend
or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its
institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the investigational product has been associated with unexpected serious harm to patients. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring
board (DSMB) or committee. This group provides authorization for whether a trial may move forward at designated check-points based on access to certain data from the trial. Concurrent with clinical trials, companies usually complete additional
animal studies and also must develop additional information about the biochemical and physical characteristics of the investigational product as well as finalize a process for manufacturing the product in commercial quantities in accordance with
cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the product and, among </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">128 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
other things, companies must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested and
stability studies must be conducted to demonstrate that the product candidates do not undergo unacceptable deterioration over their shelf life. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, as a
result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, the extent and length of which are uncertain, we will be required to develop and implement additional clinical trial policies and procedures designed to help protect trial
participants from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> virus, which may include using telemedicine visits and remote monitoring of patients and clinical sites. We will also need to ensure data from our clinical studies that may be
disrupted as a result of the pandemic is collected pursuant to the trial protocol and is consistent with GCPs, with any material protocol deviation reviewed and approved by the site IRB. Patients who may miss scheduled appoints, any interruption in
trial drug supply, or other consequence that may result in incomplete data being generated during a trial as a result of the pandemic must be adequately documented and justified. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, on March&nbsp;18, 2020 and in subsequent updates, the FDA issued a guidance on conducting clinical trials during the pandemic. The guidance describes a
number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical trial report (or as a separate document) contingency measures implemented to manage the trial and any disruption
of the trial as a result of <FONT STYLE="white-space:nowrap">COVID-19;</FONT> a list of all trial participants affected by <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">COVID-19-related</FONT></FONT> trial disruption by unique
subject identifier and by investigational site, and a description of how the individual&#146;s participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant
discontinuation from investigational product and/or trial, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the trial. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Compliance with cGMP and GTP Requirements </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before approving a BLA,
the FDA typically will inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in full compliance with cGMP requirements
and adequate to assure consistent production of the product within required specifications. The PHSA emphasizes the importance of manufacturing control for products like biologics whose attributes cannot be precisely defined. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA also will not approve the product if the manufacturer is not in compliance with GTP. These standards are found in FDA regulations and guidances that govern the
methods used in, and the facilities and controls used for, the manufacture of human cells, tissues, and cellular and tissue-based products (HCT/Ps), which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a
human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission, and spread of communicable disease. FDA regulations also
require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Manufacturers
and others involved in the manufacture and distribution of products must also register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional
information to the FDA upon their initial participation in the manufacturing process. Any product manufactured by or imported from a facility that has not registered, whether foreign or domestic, is deemed misbranded under the FDCA. Establishments
may be subject to periodic unannounced inspections by government authorities to ensure compliance with cGMPs and other laws. Inspection that follow a &#147;risk based schedule&#148; may result in certain establishments being inspected more
frequently. Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrent with clinical trials, companies usually complete additional preclinical studies and must also develop additional information about the physical
characteristics of the biologic product candidate as well as finalize a process for manufacturing the product candidate in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents
or of causing other adverse events with the use of biologic products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently
producing quality batches </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">129 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
of the product candidate and, among other requirements, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biologic product.
Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biologic product candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>BLA Review Process </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following completion of the clinical trials,
data is analyzed to assess whether the investigational product is safe and effective for the proposed indicated use or uses. The results of preclinical studies and clinical trials are then submitted to the FDA as part of a BLA, along with proposed
labeling, biochemistry and manufacturing information to ensure product quality, identity, purity and other relevant data. In short, the BLA is a request for approval to market the biologic for one or more specified indications and must contain proof
of safety, purity and potency for a biologic. The application may include both negative and ambiguous results of preclinical studies and clinical trials, as well as positive findings. Data may come from company-sponsored clinical trials intended to
test the safety and efficacy of a product&#146;s use or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the
safety and efficacy of the investigational product to the satisfaction of the FDA. FDA approval of a BLA must be obtained before a biologic may be marketed in the United States. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Prescription Drug User Fee Act (PDUFA), as amended, each BLA must be accompanied by a user fee. FDA adjusts the PDUFA user fees on an annual basis. According
to the FDA&#146;s FY 2022 fee schedule, effective through September&nbsp;30, 2022, the user fee for an application requiring clinical data, such as a BLA, is approximately $3.1&nbsp;million. PDUFA also imposes an annual program fee for each marketed
human biologic ($369,413 in FY&nbsp;2022) and an annual establishment fee on facilities used to manufacture prescription biologics. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the
first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes <FONT STYLE="white-space:nowrap">a&nbsp;non-orphan&nbsp;indication.</FONT> </P>
 <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA reviews all submitted BLAs before it accepts them for filing and may request additional information rather than accepting the BLA for filing. The FDA must
make a decision on accepting a BLA for filing within 60 days of receipt. Once the submission is accepted for filing, the FDA begins <FONT STYLE="white-space:nowrap">an&nbsp;in-depth&nbsp;review</FONT> of the BLA. Under the goals and policies agreed
to by the FDA under PDUFA, the FDA has 10 months, from the filing date, in which to complete its initial review of an original BLA and respond to the applicant, and six months from the filing date of an original BLA designated for priority review.
The FDA does not always meet its PDUFA goal dates for standard and priority BLAs, and the review process is often extended by FDA requests for additional information or clarification. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before approving a BLA, the FDA will conduct <FONT STYLE="white-space:nowrap">a&nbsp;pre-approval&nbsp;inspection</FONT> of the manufacturing facilities for the new
product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent
production of the product within required specifications. The FDA also may audit data from clinical trials to ensure compliance with GCP requirements. Additionally, the FDA may refer applications for novel drug products or drug products which
present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes physicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what
conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it considers such recommendations when making decisions on approval. The FDA likely will reanalyze the clinical trial data, which could result in extensive
discussions between the FDA and the applicant during the review process. After the FDA evaluates a BLA, it will issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific
prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter usually describes
all of the specific deficiencies in the BLA identified by the FDA. The Complete Response Letter may require additional clinical data, additional pivotal Phase&nbsp;3 clinical trial(s) and/or other significant and time-consuming requirements related
to clinical trials, preclinical studies or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application. Even if such data
and information are submitted, the FDA may decide that the BLA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">130 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Orphan Drugs </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the
Orphan Drug Act, the FDA may grant orphan designation to a drug product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000
individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For biologic drug products, an orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the
therapeutic agent and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is
entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing
of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety or providing a major contribution to patient care or in instances of drug supply issues. However, competitors may receive approval of
either a different product for the same indication or the same product for a different indication but that could be <FONT STYLE="white-space:nowrap">used&nbsp;off-label&nbsp;in</FONT> the orphan indication. Orphan drug exclusivity also could block
the approval of one of our products for seven years if a competitor obtains approval before we do for the same product, as defined by the FDA, for the same indication we are seeking approval, or if a product candidate is determined to be contained
within the scope of the competitor&#146;s product for the same indication or disease. If one of our products designated as an orphan drug receives marketing approval for an indication broader than the indication for which it is designated, it may
not be entitled to orphan drug exclusivity. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The period of exclusivity begins on the date that the marketing application is approved by the FDA and has
historically been interpreted by FDA to apply to the indication for which the product has been designated. In September 2021, however, the Court of Appeals for the 11th Circuit held that, for the purpose of determining the scope of exclusivity, the
term &#147;same disease or condition&#148; means the designated &#147;rare disease or condition&#148; and could not be interpreted by the Agency to mean the &#147;indication or use.&#148; Thus, the court concluded, orphan drug exclusivity applies to
the entire designated disease or condition rather than the &#147;indication or use.&#148; It is unclear how this court decision will be implemented by FDA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Orphan
drug exclusivity will not bar approval of another product under certain circumstances, including if the company with orphan drug exclusivity is not able to meet market demand or the subsequent product with the same drug for the same condition is
shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care. This is the case despite an earlier court opinion holding that the Orphan Drug Act unambiguously
required the FDA to recognize orphan drug exclusivity regardless of a showing of clinical superiority. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Orphan drug status in the European Union has similar,
but not identical, requirements and benefits. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Expedited Development and Review Programs </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new drug products that meet certain criteria. Specifically, new
drug products are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track
designation applies to both the product and the specific indication for which it is being studied. For biologics, the sponsor can request the FDA to designate the product for fast track status any time before receiving a BLA approval, but ideally no
later than the <FONT STYLE="white-space:nowrap">pre-BLA&nbsp;meeting.</FONT> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any product submitted to the FDA for marketing, including under a fast track program,
may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it treats a serious or life-threatening condition and, if
approved, would provide a significant improvement in safety and effectiveness compared to available therapies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">131 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A product may also be eligible for accelerated approval, if it treats a serious or life-threatening condition and
generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than
irreversible morbidity or mortality (IMM), which is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a biologic receiving accelerated approval perform adequate
and well-controlled post-marketing clinical trials. If the FDA concludes that a biologic shown to be potent can be safely used only if distribution or use is restricted, it may require such post-marketing restrictions as it deems necessary to assure
safe use of the product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, a drug product may be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination
with one or more other drug products, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically
significant endpoints. The benefits of breakthrough therapy designation include the same benefits as fast track designation, plus intensive guidance from the FDA to ensure an efficient drug development program. Fast track designation, priority
review, accelerated approval and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval process. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>RMAT Designation </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of the 21st Century Cures Act, Congress
created the Regenerative Medicine Advanced Therapy (RMAT) designation to facilitate an efficient development program for, and expedite review of, a product candidate that meets the following criteria: (1)&nbsp;it qualifies as a RMAT, which is
defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2)&nbsp;it is intended to treat, modify, reverse, or cure a
serious or life-threatening disease or condition; and (3)&nbsp;preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. A sponsor may request that the FDA designate a
drug as a RMAT concurrently with or at any time after submission of an IND. The FDA has 60 calendar days to determine whether the drug meets the criteria. A BLA for a regenerative medicine therapy that has received RMAT designation may be eligible
for priority review or accelerated approval through use of surrogate or intermediate endpoints reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites. Benefits of RMAT designation
also include early interactions with FDA to discuss any potential surrogate or intermediate endpoint to be used to support accelerated approval. A regenerative medicine therapy with RMAT designation that is granted accelerated approval and is
subject to post-approval requirements may, as appropriate, fulfill such requirements through the submission of clinical evidence from clinical trials, patient registries, or other sources of real world evidence, such as electronic health records;
the collection of larger confirmatory data sets; or post-approval monitoring of all patients treated with such therapy prior to its approval. Like some of FDA&#146;s other expedited development programs, RMAT designation does not change the
standards for approval but may help expedite the development or approval process. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Abbreviated Licensure Pathway of Biological Products as Biosimilars
or Interchangeable Biosimilars </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Patient Protection and Affordable Care Act, or Affordable Care Act (ACA), signed into law in 2010, includes the
Biologics Price Competition and Innovation Act of 2009 (BPCIA), which created an abbreviated approval pathway for biological products shown to be highly similar to <FONT STYLE="white-space:nowrap">an&nbsp;FDA-licensed&nbsp;reference</FONT>
biological product. The BPCIA attempts to minimize duplicative testing, and thereby lower development costs and increase patient access to affordable treatments. An application for licensure of a biosimilar product must include information
demonstrating biosimilarity based upon the following, unless the FDA determines otherwise: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Analytical studies demonstrating that the proposed biosimilar product is highly similar to the approved product
notwithstanding minor differences in clinically inactive components; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Animal studies (including the assessment of toxicity); and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A clinical trial or trials (including the assessment of immunogenicity and pharmacokinetic or pharmacodynamic) sufficient
to demonstrate safety, purity and potency in one or more conditions for which the reference product is licensed and intended to be used. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">132 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, an application must include information demonstrating that: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The proposed biosimilar product and reference product utilize the same mechanism of action for the condition(s) of use
prescribed, recommended or suggested in the proposed labeling, but only to the extent the mechanism(s) of action are known for the reference product; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The condition or conditions of use prescribed, recommended or suggested in the labeling for the proposed biosimilar
product have been previously approved for the reference product; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The route of administration, the dosage form and the strength of the proposed biosimilar product are the same as those for
the reference product; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The facility in which the biological product is manufactured, processed, packed or held meets standards designed to assure
that the biological product continues to be safe, pure and potent. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Biosimilarity means that the biological product is highly similar to the
reference product notwithstanding minor differences in clinically inactive components, and that there are no clinically meaningful differences between the biological product and the reference product in terms of the safety, purity and potency of the
product. In addition, the law provides for a designation of &#147;interchangeability&#148; between the reference and biosimilar products, whereby the biosimilar may be substituted for the reference product without the intervention of the healthcare
provider who prescribed the reference product. The higher standard of interchangeability must be demonstrated by information sufficient to show that: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The proposed product is biosimilar to the reference product; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The proposed product is expected to produce the same clinical result as the reference product in any given patient; and
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">For a product that is administered more than once to an individual, the risk to the patient in terms of safety or
diminished efficacy of alternating or switching between the biosimilar and the reference product is no greater than the risk of using the reference product without such alternation or switch. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">FDA approval is required before a biosimilar may be marketed in the United States. However, complexities associated with the large and intricate structures of
biological products and the process by which such products are manufactured pose significant hurdles to the FDA&#146;s implementation of the law that are still being worked out by the FDA. For example, the FDA has discretion over the kind and amount
of scientific evidence&#151;laboratory, preclinical and/or clinical&#151;required to demonstrate biosimilarity to a licensed biological product. </P>   <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
timing of final FDA approval of a biosimilar for commercial distribution depends on a variety of factors, including whether the manufacturer of the branded product is entitled to one or more statutory exclusivity periods, during which time the FDA
is prohibited from approving any products that are biosimilar to the branded product. The FDA cannot approve a biosimilar application for twelve&nbsp;years from the date of first licensure of the reference product. Additionally, a biosimilar product
sponsor may not submit an application for four years from the date of first licensure of the reference product. A reference product may also be entitled to exclusivity under other statutory provisions. For example, a reference product designated for
a rare disease or condition (an orphan drug) may be entitled to seven years of exclusivity, in which case no product that is biosimilar to the reference product may be approved until either the end of the twelve-year period provided under the
biosimilarity statute or the end of the seven-year orphan drug exclusivity period, whichever occurs later. In certain circumstances, a regulatory exclusivity period can extend beyond the life of a patent, and thus block biosimilarity applications
from being approved on or after the patent expiration date. In addition, the FDA may under certain circumstances extend the exclusivity period for the reference product by an additional six months if the FDA requests, and the manufacturer
undertakes, studies on the effect of its product in children, <FONT STYLE="white-space:nowrap">a&nbsp;so-called&nbsp;pediatric</FONT> extension. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Post-Approval Requirements </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following approval of a new product, the
manufacturer and the approved product are subject to continuing regulation by the FDA, including, among other things, monitoring and record-keeping requirements, requirements to report adverse experiences and comply with promotion and advertising
requirements, which include restrictions on promoting drugs for unapproved uses or patient populations, known <FONT STYLE="white-space:nowrap">as&nbsp;&#147;off-label&nbsp;use,&#148;</FONT> and limitations on industry-sponsored scientific and
educational activities. Although physicians may prescribe legally available drugs </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">133 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
<FONT STYLE="white-space:nowrap">for&nbsp;off-label&nbsp;uses,</FONT> manufacturers may not market or promote such uses. Prescription drug promotional materials must be submitted to the FDA in
conjunction with their first use. Further, if there are any modifications to the drug product, including changes in indications, labeling or manufacturing processes or facilities, the applicant may be required to submit and obtain FDA approval of a
new application or supplement, which may require the development of additional data or preclinical studies and clinical trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may also place other
conditions on approvals including the requirement for REMS, to assure the safe use of the product. A REMS could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient
registries and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn <FONT
STYLE="white-space:nowrap">for&nbsp;non-compliance&nbsp;with</FONT> regulatory standards or if problems occur following initial marketing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may withdraw
approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated
severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to
assess new safety risks or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market, or
product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Warning letters, or holds on post-approval clinical studies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Refusal of the FDA to approve pending applications or supplements to approved applications; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Applications, or suspension or revocation of product license approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Product seizure or detention, or refusal to permit the import or export of products; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs and biologics may be promoted only for the
approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion <FONT STYLE="white-space:nowrap">of&nbsp;off-label&nbsp;uses,</FONT> and
a company that is found to have improperly <FONT STYLE="white-space:nowrap">promoted&nbsp;off-label&nbsp;uses</FONT> may be subject to significant liability. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other U.S. Regulatory Matters </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Manufacturing, sales, promotion and
other activities following product approval are also subject to regulation by numerous regulatory authorities in the United States in addition to the FDA, including the Centers for Medicare&nbsp;&amp; Medicaid Services (CMS), other divisions of the
Department of Health and Human Services, the Department of Justice, the Drug Enforcement Administration, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety&nbsp;&amp; Health Administration, the
Environmental Protection Agency, and state and local governments. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, in the United States, sales, marketing and scientific and educational programs must
also comply with state and federal fraud and abuse laws. These laws include the federal Anti-Kickback Statute, which makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and
willfully solicit, receive, offer or pay any remuneration that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug, for which payment may be made under a federal healthcare
program, such as Medicare or Medicaid. Violations of this law are punishable by up to five years in prison, criminal fines, administrative civil money penalties and exclusion from participation in federal healthcare programs. Moreover, the ACA
provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the
ACA. If products are made available to authorized </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">134 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the
U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The distribution of biologic and pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage
and security requirements intended to prevent the unauthorized sale of pharmaceutical products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The failure to comply with any of these laws or regulatory
requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, requests for recall,
seizure of products, total or partial suspension of production, denial or withdrawal of product approvals or refusal to allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws,
even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#146;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products
marketed by us could materially affect our business in an adverse way. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Changes in regulations, statutes or the interpretation of existing regulations could impact
our business in the future by requiring, for example: changes to our manufacturing arrangements; additions or modifications to product labeling; the recall or discontinuation of our products; or additional record-keeping requirements. If any such
changes were to be imposed, they could adversely affect the operation of our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>U.S. Patent-Term Restoration and Marketing Exclusivity </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depending upon the timing, duration and specifics of FDA approval of any future product candidates, some of our U.S. patents may be eligible for limited patent term
extension under the Hatch-Waxman Act. The Hatch-Waxman Act permits restoration of the patent term of up to five years as compensation for patent term lost during product development and FDA regulatory review process. Patent-term restoration,
however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#146;s approval date. The patent-term restoration period is <FONT STYLE="white-space:nowrap">generally&nbsp;one-half&nbsp;the</FONT> time between the
effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due
diligence. Only one patent applicable to an approved drug is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the
application for any patent term extension or restoration. In the future, we may apply for restoration of patent term for our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length
of the clinical trials and other factors involved in the filing of the relevant BLA. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Government Regulation Outside of the United States </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to regulations in the United States, we are subject to a variety of regulations in other jurisdictions where we seek to commercialize any of our product
candidates, including countries in Europe and Asia. Such foreign regulations govern, among other things, research and development, clinical trials, testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution,
reporting, advertising and other promotional practices involving biological products as well as authorization and approval of our product candidates. Because biologically sourced raw materials are subject to unique contamination risks, their use may
be restricted in some countries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Whether or not we obtain FDA approval for a product candidate, we must obtain the requisite approvals from regulatory authorities
in foreign countries prior to the commencement of a clinical trial or marketing of a product in those countries. Certain countries outside of the United States have a similar approval process that requires the submission of a clinical trial
application, or CTA, much like the IND prior to the commencement of human clinical trials. In the European Union, for example, a CTA must be submitted for each clinical trial to each country&#146;s national health authority and an independent ethics
committee, much like the FDA and an IRB, respectively. Once the CTA is approved in accordance with a country&#146;s requirements, the corresponding clinical trial may proceed. The requirements and process governing the conduct of clinical trials,
product licensing, pricing and reimbursement vary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">135 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
from country to country. In all cases, the clinical trials must be conducted in accordance with GCP requirements, applicable regulatory requirements and the ethical principles that have their
origin in the Declaration of Helsinki. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>European Union Drug Development </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similar to the United States, the various phases of preclinical and clinical research in the European Union are subject to significant regulatory controls. Although the
E.U. Clinical Trials Directive 2001/20/EC has sought to harmonize the E.U. clinical trials regulatory framework, setting out common rules for the control and authorization of clinical trials in the European Union, the E.U. Member States have
transposed and applied the provisions of the Directive differently. This has led to significant variations in the member state regimes. Under the current regime, before a clinical trial can be initiated, it must be approved in each of the E.U.
countries where the trial is to be conducted by two distinct bodies: the National Competent Authority (NCA) and one or more Ethics Committees (ECs). Under the current regime, all suspected unexpected serious adverse reactions to the investigated
drug that occur during the clinical trial have to be reported to the NCA and ECs of the Member State where they occurred. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The E.U. clinical trials legislation
currently is undergoing a transition process mainly aimed at harmonizing and streamlining clinical-trial authorization, simplifying adverse-event reporting procedures, improving the supervision of clinical trials and increasing their transparency.
Recently enacted Clinical Trials Regulation EU No&nbsp;536/2014 ensures that the rules for conducting clinical trials in the European Union will be identical. In the meantime, Clinical Trials Directive 2001/20/EC continues to govern all clinical
trials performed in the European Union. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>E.U. Drug Review and Approval </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the European Economic Area (EEA), which is comprised of the 27 Member States of the European Union (including Norway and excluding Croatia), Iceland and
Liechtenstein, medicinal products can only be commercialized after obtaining a Marketing Authorization (MA). There are two types of Marketing Authorizations: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Community MA is issued by the European Commission through the Centralized Procedure, based on the opinion of the
Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMA), and is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology
medicinal products, orphan medicinal products, advanced-therapy medicines such as gene-therapy, somatic cell-therapy or tissue-engineered medicines and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS,
cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that
constitute a significant therapeutic, scientific or technical innovation or for products that are in the interest of public health in the European Union. </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their
respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in
another Member States through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized
Procedure. Under the Decentralized Procedure an identical dossier is submitted to the competent authorities of each of the Member States in which the MA is sought, one of which is selected by the applicant as the Reference Member State (RMS). The
competent authority of the RMS prepares a draft assessment report, a draft summary of the product characteristics (SPC) and a draft of the labeling and package leaflet, which are sent to the other Member States (referred to as the Member States
Concerned) for their approval. If the Member States Concerned raise no objections, based on a potential serious risk to public health, to the assessment, SPC, labeling or packaging proposed by the RMS, the product is subsequently granted a national
MA in all the Member States (i.e., in the RMS and the Member States Concerned). </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the above described procedures, before granting the MA, the
EMA or the competent authorities of the member states of the EEA make an assessment of the risk-benefit balance of the product on the basis of scientific criteria concerning its quality, safety and efficacy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">136 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>PRIME Designation in the EU </I></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist.
The PRIority Medicines (PRIME) scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products
from small- and medium-sized enterprises may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive
regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated EMA
contact and rapporteur from CHMP or Committee for Advanced Therapies are appointed early in the PRIME scheme facilitating increased understanding of the product at the EMA&#146;s Committee level. A kick-off meeting initiates these relationships and
includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Orphan Drug Designation and
Exclusivity </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Regulation (EC) No 141/2000 and Regulation (EC) No. 847/2000 provide that a product can be designated as an orphan drug by the European Commission
if its sponsor can establish: that the product is intended for the diagnosis, prevention or treatment of (1) a life threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the European Union when the
application is made, or (2) a life threatening, seriously debilitating or serious and chronic condition in the European Union and that without incentives it is unlikely that the marketing of the drug in the European Union would generate sufficient
return to justify the necessary investment. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention, or treatment of the condition in question that has been authorized in the
European Union or, if such method exists, the drug will be of significant benefit to those affected by that condition. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An orphan drug designation provides a number
of benefits, including fee reductions, regulatory assistance, and the possibility to apply for a centralized European Union marketing authorization. Marketing authorization for an orphan drug leads to a ten year period of market exclusivity. During
this market exclusivity period, neither the EMA nor the European Commission or the member states can accept an application or grant a marketing authorization for a &#147;similar medicinal product.&#148; A &#147;similar medicinal product&#148; is
defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. The market exclusivity period for the authorized
therapeutic indication may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation because, for example, the product is sufficiently profitable
not to justify market exclusivity. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Sales of our products will depend, in part, on the extent to which our products will be covered by third-party payors, such as government health programs, commercial
insurance and managed healthcare organizations. In the United States, no uniform policy of coverage and reimbursement for drug products exists. Accordingly, decisions regarding the extent of coverage and amount of reimbursement to be provided for
any of our products will be made on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">a&nbsp;payor-by-payor&nbsp;basis.</FONT></FONT> As a result, the coverage determination process is often a time-consuming and costly process that
will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be obtained. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The United States government, state legislatures, and foreign governments have shown significant interest in implementing cost containment programs to limit the growth
of government-paid healthcare costs, including price-controls, restrictions on reimbursement and requirements for substitution of generic products for branded prescription drugs. For example, the ACA contains provisions that may reduce the
profitability of drug products through increased rebates for drugs reimbursed by Medicaid programs, extension of Medicaid rebates to Medicaid managed care plans, mandatory discounts for certain Medicare Part&nbsp;D beneficiaries and annual fees
based on pharmaceutical companies&#146; share of sales to federal health care programs. Adoption of general controls and measures, coupled with the tightening of restrictive policies in jurisdictions with existing controls and measures, could limit
payments for pharmaceutical drugs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">137 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Medicaid Drug Rebate Program requires pharmaceutical manufacturers to enter into and have in effect a national rebate
agreement with the Secretary of the Department of Health and Human Services as a condition for states to receive federal matching funds for the manufacturer&#146;s outpatient drugs furnished to Medicaid patients. The ACA made several changes to the
Medicaid Drug Rebate Program, including increasing pharmaceutical manufacturers&#146; rebate liability by raising the minimum basic Medicaid rebate on most branded prescription drugs from 15.1% of average manufacturer price (AMP), to 23.1% of AMP
and adding a new rebate calculation for &#147;line extensions&#148; (i.e., new formulations, such as extended release formulations) of solid oral dosage forms of branded products, as well as potentially impacting their rebate liability by modifying
the statutory definition of AMP. The ACA also expanded the universe of Medicaid utilization subject to drug rebates by requiring pharmaceutical manufacturers to pay rebates on Medicaid managed care utilization and by enlarging the population
potentially eligible for Medicaid drug benefits. The CMS has proposed to expand Medicaid rebate liability to the territories of the United States as well. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Medicare Prescription Drug, Improvement and Modernization Act of 2003 (MMA), established the Medicare Part&nbsp;D program to provide a voluntary prescription drug benefit to Medicare beneficiaries. Under Part&nbsp;D, Medicare beneficiaries may
enroll in prescription drug plans offered by private entities that provide coverage of outpatient prescription drugs. Unlike Medicare Part&nbsp;A and B, Part&nbsp;D coverage is not standardized. While all Medicare drug plans must give at least a
standard level of coverage set by Medicare, Part&nbsp;D prescription drug plan sponsors are not required to pay for all covered Part&nbsp;D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at
what tier or level. However, Part&nbsp;D prescription drug formularies must include drugs within each therapeutic category and class of covered Part&nbsp;D drugs, though not necessarily all the drugs in each category or class. Any formulary used by
a Part&nbsp;D prescription drug plan must be developed and reviewed by a pharmacy and therapeutic committee. Government payment for some of the costs of prescription drugs may increase demand for products for which we receive marketing approval.
However, any negotiated prices for our products covered by a Part&nbsp;D prescription drug plan likely will be lower than the prices we might otherwise obtain. Moreover, while the MMA applies only to drug benefits for Medicare beneficiaries, private
payors often follow Medicare coverage policy and payment limitations in setting their own payment rates. Any reduction in payment that results from the MMA may result in a similar reduction in payments
<FONT STYLE="white-space:nowrap">from&nbsp;non-governmental&nbsp;payors.</FONT> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For a drug product to receive federal reimbursement under the Medicaid or Medicare
Part&nbsp;B programs, or to be sold directly to U.S. government agencies, the manufacturer must extend discounts to entities eligible to participate in the 340B drug pricing program. The required 340B discount on a given product is calculated based
on the AMP and Medicaid rebate amounts reported by the manufacturer. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There has been heightened governmental scrutiny recently over the manner in which drug
manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review
the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drug products. For example, in 2020, the HHS and the CMS issued various rules that are expected to impact, among
others, price reductions from pharmaceutical manufacturers to plan sponsors under Part D, fee arrangements between pharmacy benefit managers and manufacturers, manufacturer price reporting requirements under the Medicaid Drug Rebate Program,
including regulations that affect manufacturer-sponsored patient assistance programs subject to pharmacy benefit manager accumulator programs and Best Price reporting related to certain value-based purchasing arrangements, and manufacturer price
reporting under Medicare Part B. Multiple lawsuits have been brought against the HHS challenging various aspects of the rules. In January 2021, the Biden administration issued a &#147;regulatory freeze&#148; memorandum that directs department and
agency heads to review new or pending rules of the prior administration. Under the American Rescue Plan Act of 2021, effective January&nbsp;1, 2024, the statutory cap on Medicaid Drug Rebate Program rebates that manufacturers pay to state Medicaid
programs will be eliminated. Elimination of this cap may require pharmaceutical manufacturers to pay more in rebates than it receives on the sale of products, which could have a material impact on our business. Further, in July&nbsp;2021, the Biden
administration released an executive order, &#147;Promoting Competition in the American Economy,&#148; with multiple provisions aimed at increasing competition for prescription drugs. In response to this executive order, the HHS released a
Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and potential legislative policies that Congress could pursue to advance these principles. In addition, Congress is considering legislation that, if
passed, could have significant impact on prices of prescription </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">138 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
drugs covered by Medicare, including limitations on drug price increases. The impact of these regulations and any future healthcare measures and agency rules implemented by the Biden
administration on us and the pharmaceutical industry as a whole is currently unknown. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or
commercialize our product candidates if approved. Complying with any new legislation and regulatory changes could be time-intensive and expensive, resulting in a material adverse effect on our business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing,
including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk
purchasing. For example, a number of states are considering or have recently enacted state drug price transparency and reporting laws that could substantially increase our compliance burdens and expose us to greater liability under such state laws
once we begin commercialization. These and other health reform measures that are implemented may have a material adverse effect on our operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As noted above,
the marketability of any products for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. There is an increasing emphasis on cost
containment measures in the United States with respect to healthcare costs and prescription drug prices and we expect it will continue to increase and exert greater pressure on pharmaceutical pricing. Coverage policies and third-party reimbursement
rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the
future. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are unable to predict the future course of federal or state healthcare legislation in the United States directed at broadening the availability of
healthcare and containing or lowering the cost of healthcare. These and any further changes in the law or regulatory framework could reduce our ability to generate revenue in the future or increase our costs, either of which could have a material
and adverse effect on our business, financial condition and results of operations. It is also possible that additional governmental action will be taken to address the COVID-19 pandemic. The continuing efforts of the government, insurance companies,
managed care organizations, and other payers of healthcare services and medical products to contain or reduce costs of healthcare and/or impose price controls may adversely affect the demand for our product candidates, if approved, and our ability
to achieve or maintain profitability. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, in most foreign countries, the proposed pricing for a drug must be approved before it may be lawfully
marketed. The requirements governing drug pricing and reimbursement vary widely from country to country. For example, the European Union provides options for its member states to restrict the range of medicinal products for which their national
health insurance systems provide reimbursement, in order to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls
on the profitability of the company placing the medicinal product in the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and
pricing arrangements for any of our products. Historically, products launched in the European Union do not follow price structures of the United States and generally, prices tend to be significantly lower. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employees and Human Capital </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, we had &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; full-time employees,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of whom were engaged in research and development activities. None of our employees are represented by a labor union or covered under a collective bargaining agreement. Our human capital resources
objectives include, as applicable, identifying, recruiting, retaining, incentivizing and integrating our existing and new employees, advisors and consultants. The principal purposes of our equity and cash incentive plans are to attract, retain and
reward personnel through the granting of stock-based and cash-based compensation awards, in order to increase stockholder value and the success of our company by motivating such individuals to perform to the best of their abilities and achieve our
objectives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">139 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Facilities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our corporate
headquarters are located in Gaithersburg, Maryland, where we lease 13,571 square feet of office and laboratory space pursuant to a lease agreement that expires on January 31, 2030. We believe that our existing facilities are adequate for our
near-term needs but expect to need additional space as we grow. We believe that suitable additional or alternative space would be available as required in the future on commercially reasonable terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal Proceedings </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, we may become involved in litigation
or other legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are likely to have a material adverse effect on our business. Regardless of outcome, litigation can have an
adverse impact on us because of defense and settlement costs, diversion of management resources and other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">140 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_14"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers and Directors </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the
names, ages and positions of our executive officers and directors as of November&nbsp;19, 2021: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="68%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>NAME</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>POSITION</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><I>Executive&nbsp;Officers:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rami&nbsp;Elghandour</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Chairman of the Board of Directors</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Christopher Heery, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Chief Medical Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B></B><B><I>Key Employees:</I></B><B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Neeraj P. Teotia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Commercial Officer</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">David Tice, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Chief Scientific Officer</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Narinder Singh, M.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-size:9.5pt">49</FONT></TD>
<TD NOWRAP VALIGN="bottom"><FONT STYLE="font-size:9.5pt">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL">Chief Technical Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors:</I></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ali&nbsp;Behbahani,&nbsp;M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Raymond Camahort, Ph.D.*</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jill Carroll, M.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">David Lubner, M.S., C.P.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lewis&nbsp;T.&nbsp;Williams,&nbsp;M.D.,&nbsp;Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">72</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Derek Yoon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr. Camahort has notified us that he will resign from our board of directors contingent upon and effective immediately prior to the effectiveness of the registration statement of which this prospectus forms a part.
</TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the audit committee </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(2)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the compensation committee </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(3)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the corporate governance and nominating committee </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I></I><B></B><B><I>Rami Elghandour</I></B><B></B><I></I> has served as our President, Chief Executive Officer and Chairman of the Board of Directors since January
2021. Previously, Mr.&nbsp;Elghandour served in various roles at Nevro Corp., a medical device company, from October 2012 to March 2019 including President, Chief Business Officer and most recently Chief Executive Officer and as a member of the
board of Nevro Corp. from May 2016 to March 2019. From September 2008 to October 2012, Mr.&nbsp;Elghandour managed investments for Johnson&nbsp;&amp; Johnson Development Corporation (JJDC), the venture investing arm of Johnson &amp; Johnson
(NYSE:JNJ), where he led several investments and served on the board of directors of a number of private companies, including Nevro&#146;s board of directors. Additionally, he led strategic initiatives in the development and management of
JJDC&#146;s portfolio. From 2001 to 2006, Mr.&nbsp;Elghandour worked for Advanced Neuromodulation Systems, Inc. (acquired by St.&nbsp;Jude Medical), a medical device company, where he led firmware design and development on several implantable
neurostimulators. Mr.&nbsp;Elghandour received an M.B.A. from the Wharton School of the University of Pennsylvania and a B.S. in Electrical and Computer Engineering from Rutgers University School of Engineering. We believe that Mr.&nbsp;Elghandour
is qualified to serve on our board due to his investment and engineering experience, strategic track record, and his service as our President and Chief Executive Officer. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Christopher Heery</I></B><B><I>, M.D.</I></B> has served as our Chief Medical Officer since April 2021. Previously, Dr.&nbsp;Heery, served as Chief Medical
Officer of Precision BioSciences, Inc., a genome editing company, from May 2019 to April 2021, where he oversaw the clinical development of one of the first allogeneic CAR-T cell platforms and provided clinical insight into clinical efforts for gene
editing therapeutics. Dr.&nbsp;Heery also served as Chief Medical Officer at Bavarian Nordic A/S, a biotechnology company, from October 2016 to April 2019, where he oversaw clinical development programs for its immune-oncology and infectious disease
portfolios. Prior to that, he was a Staff Clinician and then an Associate Research Physician and Head of the Clinical Trials Group of the Laboratory of Tumor Immunology and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">141 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Biology at the National Cancer Institute (NCI), a U.S. government health agency, from April 2012 to November 2013 and November 2013 to September 2016, respectively, where he was part of a larger
effort to create new immunotherapies for the treatment of cancer. He joined the NCI Medical Oncology Branch as a Medical Oncology Fellow in 2009 and also served as an Adjunct Appointment in the Genitourinary Malignancies Branch. Dr.&nbsp;Heery is
board certified in Medical Oncology and Internal Medicine. He received a B.A. from Duke University and a M.D. from East Carolina University Brody School of Medicine, and completed his internal medicine residency at the University of Illinois at
Chicago. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Key Employees </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Neeraj Teotia</I></B> has served as our
Chief Commercial Officer since April 2021. Previously, Mr.&nbsp;Teotia served as Vice President, Marketing of Nevro Corp. (NYSE:NVRO), a medical device company, from May 2016 to April 2021, having held roles of increasing responsibility in marketing
since joining Nevro as Director, Marketing in April 2014. From July 2012 to April 2014 Mr.&nbsp;Teotia served as a Director, New Business Development in the Global Surgery Group at Johnson&nbsp;&amp; Johnson (NYSE:JNJ), a diversified healthcare
company, where he was responsible for assessing various licensing and acquisition opportunities. Prior to his role in New Business Development, Mr.&nbsp;Teotia worked in various marketing, licensing &amp; acquisitions and research&nbsp;&amp;
development roles within the medical device group at Johnson&nbsp;&amp; Johnson. Mr.&nbsp;Teotia received a M.B.A. from the Kellogg School of Management at Northwestern University and holds a B.S. in Electrical Engineering from the University of
Illinois at Urbana-Champaign. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>David Tice, Ph.D.</I></B> has served as our Chief Scientific Officer since July 2021 and previously served as our Vice
President, Research and Translational Sciences after joining our company in April 2020. Previously, Dr. Tice served as Senior Director at MedImmune, the global biologics research and development unit of AstraZeneca (Nasdaq:AZN), from 2002 to April
2020. While serving as the head of the antibody drug conjugate strategic area at AstraZeneca, Dr. Tice managed a portfolio of over 20 pipeline projects spanning discovery to Phase&nbsp;1. Prior to this experience, Dr. Tice worked at Genentech from
1999 to 2002 where he focused on genomics-based target discovery and monoclonal antibody targeting in cancer. Dr. Tice received his B.S. in Biology from Virginia Tech before receiving his Ph.D. in Molecular Medicine from the University of Virginia.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Narinder Singh</I></B><B><I>, M.S.</I></B> has served as our Chief Technical Officer since October 2021. Prior to joining us, Mr.&nbsp;Singh was Chief
Technical Officer at Forte Biosciences (Nasdaq:FBRX), a clinical-stage, biopharmaceutical company focused on dermatology, from August 2021 to October 2021. Prior to that, Mr.&nbsp;Singh was Head of Technical Operations at Aimmune, Inc., a
biopharmaceutical company, from July 2020 to July 2021. Prior to that, Mr.&nbsp;Singh served as Senior Vice President, Pharmaceutical Sciences and Manufacturing at Genocea Biosciences, a biopharmaceutical company, from March 2018 to July 2020, and
as Vice President, Drug Product Development&nbsp;&amp; Manufacturing at Momenta Pharmaceuticals, a biotechnology company, from July 2015 to March 2018. From May 1997 to July 2015, Mr.&nbsp;Singh served in a variety of technical leadership roles in
drug product development and commercialization at Amgen Inc., a biopharmaceutical company. Mr.&nbsp;Singh holds an Integrated M. Tech in Biochemical Engineering and Biotechnology from the Indian Institute of Technology in Delhi, India; an M.S. in
Chemical Engineering from the University of Houston; and an M.B.A. from the UCLA Anderson School of Management. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Ali
Behbahani, M.D.</I></B>&nbsp;has served as a member of our board of directors since January 2015. Dr.&nbsp;Behbahani joined New Enterprise Associates (NEA), a venture capital firm, in 2007 and is currently a general partner on the healthcare team.
Prior to joining NEA, he worked as an intern and later as a consultant in business development at The Medicines Company, a specialty pharmaceutical company developing acute care cardiovascular products. He previously held positions as a Venture
Associate at Morgan Stanley Venture Partners from 2000 to 2002 and as a Healthcare Investment Banking Analyst at Lehman Brothers from 1998 to 2000. He has been a member of the board of directors of Genocea Biosciences (Nasdaq:GNCA) since February
2018, Oyster Point Pharma (Nasdaq:OYST) since July 2017, Monte Rosa Therapeutics, Inc. (Nasdaq:GLUE) since April 2020, Nkarta, Inc. (Nasdaq:NKTX) since August 2019, Black Diamond Therapeutics (Nasdaq:BDTX) since December 2018, CRISPR Therapeutics AG
(Nasdaq:CRSP) since April 2015, Adaptimmune Therapeutics Plc (Nasdaq:ADAP) since September 2014, CVRx, Inc. (Nasdaq: CVRX) since July 2013, Minerva Surgical, Inc. (Nasdaq: UTRS) since May 2011, and was on the board of Nevro Corp. (NYSE:NVRO) from
August 2014 to March 2019. Dr.&nbsp;Behbahani received a B.S. in biomedical engineering, electrical engineering and chemistry from Duke University, an M.B.A. from the Wharton School of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">142 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
University of Pennsylvania and an M.D. from the University of Pennsylvania School of Medicine. We believe that Dr.&nbsp;Behbahani is qualified to serve on our board due to his experience in life
sciences and his experience as a member of the boards of directors of multiple companies in the life science industry. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Raymond Camahort, Ph.D.</I></B> has
served as a member of our board of directors since November 2021. Dr.&nbsp;Camahort has been employed at Novo Ventures (US) Inc. in Boston, Massachusetts since 2015, where he served as an associate from 2015 to 2019 and a principal from January 2020
to present. Dr.&nbsp;Camahort has also served on the board of directors of Inspirna, Inc. since October 2021, and has served as a Board Observer at Checkmate Pharmaceuticals and Stride Bio. He has over 15&nbsp;years of combined research, business
development, and venture capital experience, with expertise in biochemistry, molecular biology, and genetics. Dr.&nbsp;Camahort was an associate at the Harvard University Office of Technology Development from September 2013 to October 2015 where he
worked to commercialize technologies developed in both chemistry and stem cell/regenerative biology. Dr.&nbsp;Camahort completed a National Institute of Health (NIH) post-doctoral training fellowship at Harvard University from July 2009 to September
2013 while concurrently holding a business development position at Partners Healthcare Research Ventures and Licensing from February 2013 to August 2013. Dr.&nbsp;Camahort holds a Ph.D. from the University of Kansas in biochemistry and molecular
biology, and a BS in biological sciences from the University of California Santa Barbara. We believe Dr. Camahort is qualified to serve on our board due to his experience as an investor and his extensive experience in life sciences. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Jill Carroll, M.S.</I></B> has served as a member of our board of directors since September 2017. Ms.&nbsp;Carroll has served as partner of SR One Capital
Management, LP (S.R. One), an entity affiliated with SR One Capital Fund I Aggregator, LP since September 2020. Prior to S.R. One, Ms. Carroll was principal at S.R. One, Limited, initially joining as a Senior Associate in September 2011. From August
2010 to August 2011, Ms.&nbsp;Carroll served as a VP, Corporate Development at Limerick Biopharma. Between May 2004 and August 2010, Ms.&nbsp;Carroll was served as the Senior Director, Strategic Planning&nbsp;&amp; Corporate Development at Dynavax
Technologies (Nasdaq:DVAX), where she was involved in multiple pharma-partnering deals, as well as substantial private and public financings. Ms.&nbsp;Carroll also served as a director at Clearview Projects from Sept 2001 to May 2004 and as a
consultant specializing in health care at Mercer Management Consulting from March 1999 to July 2001. Ms.&nbsp;Carroll is a member of the board of directors of HotSpot Therapeutics and Odyssey Therapeutics. Ms.&nbsp;Carroll received her B.S. in
Chemistry from Duke University and her M.S. in Biochemistry, Cellular and Molecular Biology from Johns Hopkins University. We believe that Ms.&nbsp;Carroll is qualified to serve our board of directors because of her substantial experience as an
investor and her prior management experience as a consultant and as an executive. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>David C. Lubner</I></B><B><I>, M.S., C.P.A.</I></B> has served as a
director of our company since August 2020. Mr.&nbsp;Lubner served as Executive Vice President and Chief Financial Officer of Ra Pharmaceuticals Inc., a biotechnology company acquired by UCB S.A. in April 2020, from January 2016 until June 2020.
Before joining Ra Pharmaceuticals, Mr.&nbsp;Lubner served as Chief Financial Officer of Tetraphase Pharmaceuticals from its inception in 2006 to 2016, as Chief Financial Officer of PharMetrics from 1999 until it was acquired by IMS Health in 2005
and as Vice President and Chief Financial Officer of ProScript from 1996 to 1999, where Velcade<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> (bortezomib), a therapy widely used for the treatment of the blood cancer multiple myeloma, was
discovered. Mr.&nbsp;Lubner serves as a member of the board of directors of Dyne Therapeutics Inc. (Nasdaq:DYNE), Gemini Therapeutics, Inc. (Nasdaq:GMTX), Vor Biopharma Inc. (Nasdaq:VOR), Point Biopharma, Inc. (Nasdaq:PNT) and several other private
companies, and Mr.&nbsp;Lubner previously served on the board of directors of Nightstar Therapeutics plc from 2017 until it was acquired by Biogen in June 2019 and Therapeutics Acquisition Corporation (d/b/a as Research Alliance Corp. I.), a blank
check company focused on the healthcare industry. Mr.&nbsp;Lubner is a Certified Public Accountant and is a member of the American Institute of CPAs. He received his B.S. in business administration from Northeastern University and an M.S. in
taxation from Bentley University. We believe that Mr.&nbsp;Lubner is qualified to serve on our board based on his financial and senior executive leadership experience and his biotechnology company board experience, including serving as an audit
committee chair. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Lewis T. Williams, M.D., Ph.D.</I></B> has served as a member of our board of directors since August 2019. Dr.&nbsp;Williams is currently
President and CEO of a private cell therapy company, Walking Fish Therapeutics, and has been venture partner at Quan Capital, a life sciences venture fund, since August 2018. Dr.&nbsp;Williams founded Five Prime Therapeutics (Nasdaq:FPRX), a
biotechnology company, in December 2001, served as Five Prime&#146;s Executive Chairman from July 2003 to January 2012 and January 2018 to December 2018, as President and Chief Executive </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">143 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Officer from August 2011 to December 2017 and as a member of Five Prime&#146;s board of directors from January 2002 until December 2019. Previously, Dr.&nbsp;Williams spent seven years at Chiron
Corporation, a biopharmaceutical company, now Novartis Vaccines and Diagnostics, Inc., most recently as its Chief Scientific Officer. Prior to joining Chiron, Dr.&nbsp;Williams was a professor of medicine at the University of California, San
Francisco and served as Director of the University Cardiovascular Research Institution and Daiichi Research Center. Dr.&nbsp;Williams has also served on the faculties of Harvard Medical School and Massachusetts General Hospital and <FONT
STYLE="white-space:nowrap">co-founded</FONT> COR Therapeutics, Inc., a biotechnology company focused on cardiovascular disease. He is a member of the National Academy of Sciences and a fellow of the American Academy of Arts and Sciences.
Dr.&nbsp;Williams is currently on the board of directors of Protagonist Therapeutics, Inc. (Nasdaq:PTGX) and Neoleukin Therapeutics (Nasdaq:NLTX) and was previously a member of the board of directors of Chiron, COR Therapeutics and Beckman Coulter,
Inc., each of which was a public company during his service as a director. Dr.&nbsp;Williams received a B.S. from Rice University and an M.D. and a Ph.D. from Duke University. We believe that Dr.&nbsp;Williams&#146; experience in drug discovery and
development and in executive positions at several pharmaceutical companies, his experience as a founder of a publicly traded healthcare company and his service as a director of other publicly traded healthcare companies give him the qualifications,
skills and financial expertise to serve on our board of directors. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Derek Yoon </I></B>has served as a member of our board of directors since April 2020.
Mr.&nbsp;Yoon has been employed as President&nbsp;&amp; CEO at Solasta Ventures (previously known as Aju IB Investment) (Solasta), a venture capital firm, since November 2013 and a member of the board of directors of Solasta since July 2019. Since
December 2017, Mr.&nbsp;Yoon has served as member of the board of directors of Trefoil Therapeutics, and between December 2015 and August 2017, Mr.&nbsp;Yoon served on the board of directors of Clearside Biomedical (Nasdaq:CLSD). Prior to Solasta,
Mr.&nbsp;Yoon was a Portfolio Manager with RBS Citizens from April 2011 to November 2013. From July 2009 to April 2011, Mr.&nbsp;Yoon was an Investment Manager at Berwind Private Equity. From October 1999 to July 2007, Mr.&nbsp;Yoon was Investment
Manager at Kibo Capital in South Korea. Mr.&nbsp;Yoon received a Master of Finance from Boston College and a M.B.A. from Babson College. Mr.&nbsp;Yoon also received a B.S. in Chemical Engineering from Yonsei University in South Korea. We believe
Mr.&nbsp;Yoon is qualified to serve on our board of directors due to his experience in life sciences and his experience as a member of the boards of directors of multiple companies in the life science industry. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Composition </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors currently consists of seven
members, with one vacancy. After the completion of this offering, the number of directors will be fixed by our board of directors, subject to the terms of our amended and restated certificate of incorporation and amended and restated bylaws. Each of
our current directors will continue to serve as a director until the election and qualification of his or her successor, or until his or her earlier death, resignation or removal. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation will provide that our board of directors will be divided into three classes with staggered three-year terms. Only
one class of directors will be elected at each annual meeting of stockholders, with the other classes continuing for the remainder of their respective three-year terms. Our directors will be divided among the three classes as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Class&nbsp;I directors will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their
terms will expire at the annual meeting of stockholders to be held in 2023; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Class&nbsp;II directors will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their
terms will expire at the annual meeting of stockholders to be held in 2024; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The Class&nbsp;III directors will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and their
terms will expire at the annual meeting of stockholders to be held in 2025. </P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At each annual meeting of stockholders, upon the expiration of
the term of a class of directors, the successor to each such director in the class will be elected to serve from the time of election and qualification until the third annual meeting following his or her election and until his or her successor is
duly elected and qualified, in accordance with our amended and restated certificate of incorporation and amended and restated bylaws. Any additional directorships resulting from an increase in the number of directors will be distributed among the
three classes so that, as nearly as possible, each class will consist of one third of our directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">144 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This classification of our board of directors may have the effect of delaying or preventing changes in control of our
company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director Independence </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the completion of this offering,
we anticipate that our common stock will be listed on the Nasdaq Global Market. Under the rules of Nasdaq, independent directors must comprise a majority of a listed company&#146;s board of directors within one year of the completion of this
offering. In addition, the rules of Nasdaq require that, subject to specified exceptions, each member of a listed company&#146;s audit, compensation and corporate governance and nominating committees be independent. Audit committee members and
compensation committee members must also satisfy the independence criteria set forth in <FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> and <FONT STYLE="white-space:nowrap">Rule&nbsp;10C-1,</FONT> respectively, under the Exchange Act. Under
the rules of Nasdaq, a director will only qualify as an &#147;independent director&#148; if, in the opinion of that company&#146;s board of directors, that person does not have a relationship that would interfere with the exercise of independent
judgment in carrying out the responsibilities of a director. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To be considered to be independent for purposes of
<FONT STYLE="white-space:nowrap">Rule&nbsp;10A-3</FONT> and under the rules of Nasdaq, a member of an audit committee of a listed company may not, other than in his or her capacity as a member of the audit committee, the board of directors or any
other board committee: (1)&nbsp;accept, directly or indirectly, any consulting, advisory or other compensatory fee from the listed company or any of its subsidiaries or (2)&nbsp;be an affiliated person of the listed company or any of its
subsidiaries. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To be considered independent for purposes of <FONT STYLE="white-space:nowrap">Rule&nbsp;10C-1</FONT> and under the rules of Nasdaq, the board of
directors of a listed company must affirmatively determine that each member of the compensation committee is independent, including a consideration of all factors specifically relevant to determining whether the director has a relationship to the
company that is material to that director&#146;s ability to be independent from management in connection with the duties of a compensation committee member, including, but not limited to: (i)&nbsp;the source of compensation of such director,
including any consulting, advisory or other compensatory fee paid by the company to such director and (ii)&nbsp;whether such director is affiliated with the company, a subsidiary of the company or an affiliate of a subsidiary of the company. </P>
 <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors undertook a review of its composition, the composition of its committees and the independence of our directors and considered whether any
director has a material relationship with us that could compromise his or her ability to exercise independent judgment in carrying out his or her responsibilities. Based upon information requested from and provided by each director concerning his or
her background, employment and affiliations, including family relationships, our board of directors has determined that&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;representing&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of our seven directors, do not have a relationship that would interfere with the exercise of
independent judgment in carrying out the responsibilities of a director and that each of these directors is &#147;independent&#148; as that term is defined under the rules of Nasdaq. Mr.&nbsp;Elghandour is not an independent director because he is
our President and Chief Executive Officer. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In making these determinations, our board of directors considered the current and prior relationships that each <FONT
STYLE="white-space:nowrap">non-employee</FONT> director has with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our capital stock by
each <FONT STYLE="white-space:nowrap">non-employee</FONT> director, and the transactions involving them described in the section titled &#147;Certain Relationships and Related Party Transactions.&#148; There are no family relationships among any of
our directors or executive officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Leadership Structure </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Mr.&nbsp;Elghandour serves as both our Chief Executive Officer and Chairman of the Board. In addition, our board does not have a lead independent director at this time,
but will continue to monitor and evaluate the appropriateness of our board leadership structure. Our board believes that Mr.&nbsp;Elghandour&#146;s service as both Chairman of the Board and Chief Executive Officer is in the best interest of the
Company and its stockholders. Mr.&nbsp;Elghandour possesses detailed and in-depth knowledge of the issues, opportunities and challenges facing us and our business and is thus best positioned to develop agendas that ensure that the Board&#146;s time
and attention are focused on the most critical matters. Specifically, his combined role enables decisive leadership, ensures clear accountability, and enhances our ability to communicate our message and strategy clearly and consistently to our
stockholders, employees, customers and manufacturers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">145 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

   <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Role of the Board in Risk Oversight </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors has an active role, as a whole and also at the committee level, in overseeing the management of our risks. Our board of directors is responsible
for general oversight of risks and regular review of information regarding our risks, including credit risks, liquidity risks and operational risks. The compensation committee is responsible for overseeing the management of risks relating to our
executive compensation plans and arrangements. The audit committee is responsible for overseeing the management of risks relating to accounting matters and financial reporting. The corporate governance and nominating committee is responsible for
overseeing the management of risks associated with the independence of our board of directors and potential conflicts of interest. Although each committee is responsible for evaluating certain risks and overseeing the management of such risks, our
entire board of directors is regularly informed through discussions from committee members about such risks. Our board of directors believes its administration of its risk oversight function has not negatively affected the board of directors&#146;
leadership structure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Committees </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors has an
audit committee, a compensation committee and a corporate governance and nominating committee, each of which has the composition and the responsibilities described below. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the effectiveness of the registration statement
of which this prospectus forms a part, the members of our audit committee will be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will be the chair of
our audit committee and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will be our audit committee financial expert, as that term is defined under the SEC rules implementing Section&nbsp;407 of the Sarbanes-Oxley Act, and
possesses financial sophistication, as defined under the rules of Nasdaq. Our audit committee will oversee our corporate accounting and financial reporting process and assist our board of directors in monitoring our financial systems. Our audit
committee will also: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Select and hire the independent registered public accounting firm to audit our financial statements;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Help to ensure the independence and performance of the independent registered public accounting firm;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Approve audit and <FONT STYLE="white-space:nowrap">non-audit</FONT> services and fees; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Review financial statements and discuss with management and the independent registered public accounting firm our annual
audited and quarterly financial statements, the results of the independent audit and the quarterly reviews and the reports and certifications regarding internal controls over financial reporting and disclosure controls; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Prepare the audit committee report that the SEC requires to be included in our annual proxy statement;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Review reports and communications from the independent registered public accounting firm; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Review the adequacy and effectiveness of our internal controls and disclosure controls and procedures;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Review our policies on risk assessment and risk management; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Review and monitor conflicts of interest situations, and approve or prohibit any involvement in matters that may involve a
conflict of interest or taking of a corporate opportunity; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Review related party transactions; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Establish and oversee procedures for the receipt, retention and treatment of accounting related complaints and the
confidential submission by our employees of concerns regarding questionable accounting or auditing matters. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our audit committee will operate
under a written charter, to be effective prior to the completion of this offering, which will satisfy the applicable rules of the SEC and the listing standards of Nasdaq. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Compensation Committee </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the effectiveness of the registration
statement of which this prospectus forms a part, the members of our compensation committee will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; .&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will
be the chair of our compensation committee. Our compensation committee will oversee our compensation policies, plans and benefits programs. The compensation committee will also: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Oversee our overall compensation philosophy and compensation policies, plans and benefit programs; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">146 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Review and approve or recommend to the board of directors for approval compensation for our executive officers and
directors; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Prepare the compensation committee report that the SEC will require to be included in our annual proxy statement; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Administer our equity compensation plans. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our compensation committee will operate under a written charter, to be effective prior to the completion of this offering, which will satisfy the applicable rules of
the SEC and the listing standards of Nasdaq. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Corporate Governance and Nominating Committee </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the effectiveness of the registration statement of which this prospectus forms a part, the members of our corporate governance and nominating committee will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; .&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; will be the chair of our corporate governance and nominating committee. Our corporate governance and
nominating committee will oversee and assist our board of directors in reviewing and recommending nominees for election as directors. Specifically, the corporate governance and nominating committee will: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Identify, evaluate and make recommendations to our board of directors regarding nominees for election to our board of
directors and its committees; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Consider and make recommendations to our board of directors regarding the composition of our board of directors and its
committees; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Review developments in corporate governance practices; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Evaluate the adequacy of our corporate governance practices and reporting; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Evaluate the performance of our board of directors and of individual directors. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our corporate governance and nominating committee will operate under a written charter, to be effective prior to the completion of this offering, which will satisfy the
applicable rules of the SEC and the listing standards of Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Director Compensation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, we have not implemented a formal policy with respect to compensation payable to our <FONT STYLE="white-space:nowrap">non-employee</FONT>
directors. We reimburse our directors for expenses associated with attending meetings of our board of directors and its committees. Following the completion of this offering, we expect to implement an annual cash and equity compensation program for
our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table presents the total compensation that each of our then <FONT
STYLE="white-space:nowrap">non-employee</FONT> directors received during the year ended December&nbsp;31, 2021. </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FEES&nbsp;EARNED<BR>OR&nbsp;PAID IN<BR>CASH&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION<BR>AWARDS&nbsp;($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ALL OTHER<BR>COMPENSATION<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Tiba Aynechi, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ali Behbahani, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Raymond Camahort, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jill Carroll, M.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">David Lubner, M.S., C.P.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lewis T. Williams, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Derek Yoon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr. Ayenchi resigned from our board of directors on November 8, 2021. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Directors who are also our employees receive no
additional compensation for their service as directors. Mr.&nbsp;Elghandour was an employee director during 2021. See the section titled &#147;Executive Compensation&#148; for additional information about Mr.&nbsp;Elghandour&#146;s compensation.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">147 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Compensation Committee Interlocks and Inside Participation </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">None of the members of our compensation committee is or has been an officer or employee of our company. None of our executive officers currently serves, or in the past
fiscal year has served, as a member of the board of directors or compensation committee (or other board committee performing equivalent functions or, in the absence of any such committee, the entire board of directors) of any entity that has one or
more executive officers serving on our board of directors or compensation committee. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; text-indent:4%; font-size:9.5pt; font-family:ARIAL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;have or may be deemed to have an interest in certain transactions requiring disclosure under Item&nbsp;404 of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the
Securities Act. These transactions between us and members of our compensation committee and affiliates of such members are disclosed in &#147;Certain Relationships and Related Party Transactions,&#148; and such disclosure is incorporated by
reference herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Code of Business Conduct and Ethics </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to the
completion of this offering, we intend to adopt a written code of business conduct and ethics that will apply to our directors, officers and employees, including our principal executive officer, principal financial officer, principal accounting
officer or controller or persons performing similar functions. Following this offering, the code of business conduct and ethics will be available on our website at www.arcellx.com. We intend to disclose future amendments to such code, or any waivers
of its requirements, applicable to any principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions or our directors on our website identified above. Information
contained on, or that can be accessible through, our website is not a part of this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">148 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_15"></A>EXECUTIVE COMPENSATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our named executive officers for 2021, who consist of our principal executive officer and the next two most highly compensated executive officers, are: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Rami Elghandour, our President and Chief Executive Officer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"> </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"> </P></TD></TR></TABLE>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Summary
Compensation Table </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth information regarding the compensation of our named executive officers for the year ended
December&nbsp;31, 2021. </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Name and Principal Position</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SALARY</B><br><B>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>BONUS</B><br><B>($)&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION<BR>AWARDS<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NONEQUITY<BR>INCENTIVE&nbsp;PLAN<BR>COMPENSATION<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ALL OTHER<BR>COMPENSATION<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Rami Elghandour</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; font-size:9.5pt; font-family:ARIAL"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;<BR></TD>
<TD VALIGN="top" ALIGN="right">&#151;<BR></TD>
<TD NOWRAP VALIGN="top">&nbsp;<BR></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2021</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts reported represent bonuses based upon the achievement of company goals for the year ended December&nbsp;31, 2021. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Outstanding Equity Awards at Fiscal <FONT STYLE="white-space:nowrap">Year-End</FONT> </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth information concerning outstanding equity awards held by each of our named executive officers as of December&nbsp;31, 2021: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION AWARDS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCK AWARDS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>GRANT<BR>DATE<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SECURITIES<BR>UNDERLYING<BR>UNEXERCISED<BR>OPTIONS (#)<BR>EXERCISABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SECURITIES<BR>UNDERLYING<BR>UNEXERCISED<BR>OPTIONS (#)<BR>UNEXERCISABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION<BR>EXERCISE<BR>PRICE<BR>($)&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTION<BR>EXPIRATION<BR>DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER<BR>OF<BR>SHARES<BR>OF STOCK<BR>THAT<BR>HAVE&nbsp;NOT<BR>VESTED<BR>(#)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>MARKET<BR>VALUE&nbsp;OF<BR>SHARES<BR>OF&nbsp;STOCK<BR>THAT<BR>HAVE&nbsp;NOT<BR>VESTED<BR>($)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each of the outstanding options to purchase shares of our common stock was granted pursuant to our 2017 Plan. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">This column represents the fair market value of a share of our common stock on the date of grant, as determined by our board of directors. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employment Arrangements with Our Named Executive Officers </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered
into an employment offer letter agreement with each of our named executive officers in connection with his or her employment with us. These offer letters provide for &#147;at will&#148; employment. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rami Elghandour </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On January&nbsp;22, 2021, we entered enter into an
employment agreement with Rami Elghandour, our Chief Executive Officer. Pursuant to the agreement, Mr.&nbsp;Elghandour will serve as our Chief Executive Officer on an &#147;at will&#148; basis. Mr.&nbsp;Elghandour&#146;s employment agreement
provides for a base salary of $500,000, eligibility to receive an annual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">149 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
performance bonus with the target amount determined as 50% of Mr.&nbsp;Elghandour&#146;s annual base salary, and eligibility to participate in employee benefit or group insurance plans maintained
from time to time by us. Mr.&nbsp;Elghandour will also be eligible to receive reimbursement for reasonable temporary housing and travel between San Francisco, California and Gaithersburg, Maryland, and we will provide an additional amount or amounts
as necessary to make such reimbursements tax neutral to Mr.&nbsp;Elghandour based on the highest marginal rates actually in effect for Mr.&nbsp;Elghandour at the time or times applicable taxes related to the reimbursements are due. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the employment agreement of Mr.&nbsp;Elghandour, we agreed to grant the following equity awards to Mr.&nbsp;Elghandour: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I>Initial Option</I></B>: We agreed to grant Mr.&nbsp;Elghandour, at the first general meeting of our board of
directors following the effective date in which our board approved a third party valuation report determining the value per share of our common stock, a stock option (the Initial Option) to purchase a number of shares of our common stock equal to 6%
of our outstanding shares, calculated on a fully diluted-as converted basis as of the date of grant of such option. The Initial Option will be subject to the terms and conditions of our 2017 Plan and a form of stock option agreement approved by our
board of directors for awards thereunder allowing early exercise. The Initial Option will vest as to 1/36th of the shares subject to the Initial Option on each monthly anniversary of January&nbsp;22, 2021, subject to Mr.&nbsp;Elghandour continuing
to be a service provider through each vesting date. The Initial Option will, to the extent vested, be exercisable through the earlier of February&nbsp;6, 2031 or the 36 month anniversary of the date Mr.&nbsp;Elghandour ceases to be a service
provider, subject to the terms of our 2017 Plan. Mr.&nbsp;Elghandour will be permitted to exercise the initial option through the issuance of a full recourse promissory note and security agreement in a reasonable form provided by us.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I>Antidilution Option</I></B>: If, following the grant of the Initial Option and prior to the consummation of a
&#147;liquidity event,&#148; as such term is defined in the employment agreement, we issue shares of equity securities in exchange for capital as part of a bona fide financing transaction (a Financing Event) we agreed to grant to Mr.&nbsp;Elghandour
additional options to purchase a number of shares of our common stock, or an anti-dilution option, such that the number of shares subject to the Initial Option and all outstanding anti-dilution options will be equal to 6% of our outstanding shares
of common stock on a fully diluted-as converted basis as of the date of grant of the applicable antidilution option; provided that no antidilution option will be issued with respect to a liquidity event. Each antidilution option will be subject to
the terms and conditions of our 2017 Plan and a form of stock option agreement (the Initial Option) early exercise. Each antidilution option will have the same general terms and conditions and vesting schedule as the Initial Option.
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I>Initial RSU Award</I></B>: We agreed to grant Mr.&nbsp;Elghandour, at the first general meeting of our board of
directors following January&nbsp;22, 2021, an award of restricted stock units (the Initial RSU Award), covering a number of shares of our common stock equal to 3% of our outstanding shares of common stock calculated on a fully diluted-as converted
basis. The Initial RSU Award will be subject to the terms and conditions of our 2017 Plan and a form of restricted stock unit agreement thereunder. The Initial RSU Award will vest pursuant to a service component and a performance component. The
service component will be satisfied if Mr.&nbsp;Elghandour remains a service provider through the effective date of our change in control, as defined in the 2017 Plan. The performance component will be satisfied upon a change in control depending on
our market capitalization, as defined in the employment agreement, achieved in such change in control as follows: upon achievement of a market capitalization that is equal to $2,500,000,000, or the minimum threshold, 1/6th of the shares subject to
the Initial RSU Award will vest; upon achievement of a market capitalization that is equal to or greater than $5,000,000,000, or the maximum threshold, 100% of the shares subject to the Initial RSU Award will vest; and upon achievement of a market
capitalization that is between the minimum threshold and the maximum threshold, a portion of the shares subject the Initial RSU Award will vest between 1/6th and 100% based on straight line linear interpolation. </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><B><I>Antidilution RSU Award</I></B>: If, following the grant of the Initial RSU Award and prior to the consummation of a
liquidity event, we issue shares of equity securities in exchange for capital as part of a Financing Event, we agreed to grant to Mr.&nbsp;Elghandour additional restricted stock unit awards covering a number of shares of our common stock (an
Anti-Dilution RSU Award), such that the number of shares subject to the Initial RSU Award and all outstanding Anti-Dilution RSU Awards will be equal to 50% of the total number of shares of our common stock subject to any stock options to purchase
shares of our common stock granted to </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">150 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">
Mr.&nbsp;Elghandour on or prior to the date of grant of the applicable Antidilution RSU Award. Each Antidilution RSU Award will be subject to the same general terms and conditions and vesting
schedule as the Initial RSU Award. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the employment agreement of Mr.&nbsp;Elghandour, if we terminate the employment of Mr. Elghandour
other than for death, &#147;disability,&#148; or &#147;cause&#148; or Mr.&nbsp;Elghandour resigns for &#147;good reason&#148; (as such terms are defined in Mr.&nbsp;Elghandour&#146;s employment agreement), and Mr.&nbsp;Elghandour executes a waiver
and release of claims in our favor that becomes effective and irrevocable within 60 days following his termination and resigns from all positions he may hold as an officer or director, Mr.&nbsp;Elghandour is entitled to receive (i) an amount equal
to 100% of Mr.&nbsp;Elghandour&#146;s annual base salary and annual target bonus for the year of termination, payable in equal installments on our regular payroll schedule over the 12 month period immediately following Mr. Elghandour&#146;s date of
termination, (ii) reimbursement of premiums to maintain group health insurance continuation benefits pursuant to &#147;COBRA&#148; for Mr.&nbsp;Elghandour and his respective dependents for up to 12 months and (iii) vesting acceleration with respect
to any outstanding equity awards held by Mr. Elghandour subject to time-based vesting on the date of his termination such that each applicable equity award will be treated as vesting for an additional 24 months following Mr.&nbsp;Elghandour&#146;s
date of termination. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the employment agreement of Mr. Elghandour, if, within the 3 month period prior to or the 12 month period following a &#147;change
of control&#148; (as defined in Mr.&nbsp;Elghandour&#146;s employment agreement), the employment of Mr. Elghandour is terminated under the circumstances described in the above paragraph, and Mr.&nbsp;Elghandour executes a waiver and release of
claims in our favor that becomes effective and irrevocable within 60 days following his termination and resigns from all positions he may hold as an officer or director, Mr.&nbsp;Elghandour is entitled to receive (i) a lump sum payment equal to 100%
of Mr. Elghandour&#146;s annual base salary and annual target bonus for the year of termination, payable pursuant to our regular payroll procedures, (ii) reimbursement of premiums to maintain group health insurance continuation benefits pursuant to
&#147;COBRA&#148; for Mr.&nbsp;Elghandour and his respective dependents for up to 18 months, and (iii) vesting acceleration of 100% with respect to any outstanding equity awards held by Mr. Elghandour on the date of his termination (with
performance-based awards vesting based on achievement of target levels of performance). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event any payment to Mr. Elghandour pursuant to his employment
agreement would be subject to the excise tax imposed by Section 4999 of the Internal Revenue Code, as amended (the Code) (as a result of a payment being classified as a parachute payment under Section 280G of the Code), Mr. Elghandour will receive
such payment as would entitle him to receive the greatest after-tax benefit, even if it means that we pay him a lower aggregate payment so as to minimize or eliminate the potential excise tax imposed by Section 4999 of the Code. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Executive Equity Awards </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On February&nbsp;6, 2021, we granted Mr.
Elghandour an initial option to purchase 5,878,407 shares of our common stock at an exercise price of $1.57 per share pursuant to the terms and conditions discussed above under <I>Employment Agreements with Our Named Executive Officers&#151;Rami
Elghandour&#151;Initial Option</I>. On June 9, 2021, we amended Mr. Elghandour&#146;s option to reduce the exercise price to $1.14 per share. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June&nbsp;9, 2021,
we granted Mr. Elghandour an option to purchase 4,610,250 shares of our common stock at an exercise price of $1.14 per share pursuant to the terms and conditions discussed above under <I>Employment Agreements with Our Named Executive
Officers&#151;Rami Elghandour&#151;Antidilution Option.</I> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On June&nbsp;9, 2021, we granted Mr. Elghandour an initial RSU award covering 5,244,329 shares of our
common stock pursuant to the terms and conditions discussed above under <I>Employment Agreements with Our Named Executive</I><I> </I><I>Officer</I><I></I>s&#151;<I></I><I>R</I><I>a</I><I>mi</I><I>
</I><I>Elg</I><I>h</I><I>a</I><I>nd</I><I>o</I><I>u</I><I>r</I><I></I><I>&#151;Initi</I><I>a</I><I>l</I><I> </I><I>R</I><I>S</I><I>U </I><I>A</I><I>ward</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Potential Payments upon Termination or Change in Control </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently
expect that, prior to the completion of this offering, we will adopt arrangements for our executive officers that provide for payments and benefits on termination or change of control, which arrangements may be included in the anticipated
confirmatory offer letters or separate plans or agreements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">151 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employee Benefit and Stock Plans </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2022 Equity Incentive Plan (2022 Plan) </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to the effectiveness of
this offering, we expect that our board of directors will adopt, and our stockholders will approve, our 2022 Plan. The 2022 Plan will be effective on the business day immediately prior to the effective date of the registration statement of which
this prospectus forms a part. Our 2022 Plan will provide for the grant of incentive stock options, within the meaning of Section&nbsp;422 of the Code, to our employees and any of our parent and subsidiary corporations&#146; employees, and for the
grant of nonstatutory stock options, restricted stock, restricted stock units, stock appreciation rights, performance units, and performance shares to our employees, directors, and consultants and our subsidiary corporations&#146; employees and
consultants. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Authorized Shares</I>. A total of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock are reserved
for issuance pursuant to our 2022 Plan. In addition, the shares reserved for issuance under our 2022 Plan will also include (1)&nbsp;those shares reserved but unissued under our 2017 Plan as of the date of stockholder approval of the 2022 Plan and
(2)&nbsp;shares of our common stock subject to awards granted under our 2017 Plan that, after the date of stockholder approval of the 2022 Plan, expire or otherwise terminate without having been exercised in full or are forfeited to or repurchased
by us (provided that the maximum number of shares that may be added to the 2022 Plan pursuant to (1)&nbsp;and (2) is &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares). The number of shares available for issuance under
our 2022 Plan will also include an annual increase on the first day of each fiscal year beginning with our 2023 fiscal year, equal to the lesser of: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the outstanding shares of our common stock as of the last day of the
immediately preceding fiscal year; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Such other amount as our board of directors may determine. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If an award expires or becomes unexercisable without having been exercised in full, is surrendered pursuant to an exchange program, or, with respect to restricted
stock, restricted stock units, performance units or performance shares, is forfeited to or repurchased by us due to failure to vest, the unpurchased shares (or for awards other than stock options or stock appreciation rights, the forfeited or
repurchased shares) will become available for future grant or sale under the 2022 Plan (unless the 2022 Plan has terminated). With respect to stock appreciation rights, only the net shares actually issued will cease to be available under the 2022
Plan and all remaining shares under stock appreciation rights will remain available for future grant or sale under the 2022 Plan (unless the 2022 Plan has terminated). Shares that have actually been issued under the 2022 Plan will not be returned to
the 2022 Plan except if shares issued pursuant to awards of restricted stock, restricted stock units, performance shares, or performance units are repurchased by or forfeited to us, such shares will become available for future grant under the 2022
Plan. Shares used to pay the exercise price of an award or satisfy the tax withholding obligations related to an award will become available for future grant or sale under the 2022 Plan. To the extent an award is paid out in cash rather than shares,
such cash payment will not result in a reduction in the number of shares available for issuance under the 2022 Plan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Plan Administration</I>. Our board of
directors or one or more committees appointed by our board of directors will administer our 2022 Plan. The compensation committee of our board of directors will initially administer our 2022 Plan. In addition, if we determine it is desirable to
qualify transactions under our 2022 Plan as exempt under Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> of the Exchange Act, such transactions will be structured to satisfy the requirements for exemption under Rule
<FONT STYLE="white-space:nowrap">16b-3.</FONT> Subject to the provisions of our 2022 Plan, the administrator has the power to administer our 2022 Plan and make all determinations deemed necessary or advisable for administering the 2022 Plan,
including but not limited to, the power to determine the fair market value of our common stock, select the service providers to whom awards may be granted, determine the number of shares covered by each award, approve forms of award agreements for
use under the 2022 Plan, determine the terms and conditions of awards (including, but not limited to, the exercise price, the time or times at which awards may be exercised, any vesting acceleration or waiver or forfeiture restrictions and any
restriction or limitation regarding any award or the shares relating thereto), construe and interpret the terms of our 2022 Plan and awards granted under it, prescribe, amend and rescind rules relating to our 2022 Plan, including creating <FONT
STYLE="white-space:nowrap">sub-plans,</FONT> modify or amend each award, including but not limited to the discretionary authority to extend the post-termination exercisability period of awards (except no option or stock appreciation right will be
extended past its original maximum term), and allow a participant to defer the receipt of payment of cash or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">152 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the delivery of shares that would otherwise be due to such participant under an award. The administrator also has the authority to allow participants the opportunity to transfer outstanding
awards to a financial institution or other person or entity selected by the administrator and to institute an exchange program by which outstanding awards may be surrendered or cancelled in exchange for awards of the same type, which may have a
higher or lower exercise price and/or different terms, awards of a different type, and/or cash or by which the exercise price of an outstanding award is increased or reduced. The administrator&#146;s decisions, interpretations, and other actions are
final and binding on all participants. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stock Options</I>. Stock options may be granted under our 2022 Plan. The exercise price of options granted under our
2022 Plan must at least be equal to the fair market value of our common stock on the date of grant. The term of an option may not exceed ten years. With respect to any participant who owns more than 10% of the voting power of all classes of our (or
any parent or subsidiary of ours) outstanding stock, the term of an incentive stock option granted to such participant must not exceed five years and the exercise price must equal at least 110% of the fair market value on the grant date. The
administrator will determine the methods of payment of the exercise price of an option, which may include cash, shares or other property acceptable to the administrator, as well as other types of consideration permitted by applicable law. After the
termination of service of an employee, director, or consultant, he or she may exercise his or her option for the period of time stated in his or her option agreement. In the absence of a specified time in an award agreement, if termination is due to
death or disability, the option will remain exercisable for twelve months following the termination of service. In all other cases, in the absence of a specified time in an award agreement, the option will remain exercisable for three months
following the termination of service. An option, however, may not be exercised later than the expiration of its term. Subject to the provisions of our 2022 Plan, the administrator determines the other terms of options. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stock Appreciation Rights</I>. Stock appreciation rights may be granted under our 2022 Plan. Stock appreciation rights allow the recipient to receive the
appreciation in the fair market value of our common stock between the exercise date and the date of grant. Stock appreciation rights may not have a term exceeding ten years. After the termination of service of an employee, director or consultant, he
or she may exercise his or her stock appreciation right for the period of time stated in his or her stock appreciation rights agreement. In the absence of a specified time in an award agreement, if termination is due to death or disability, the
stock appreciation rights will remain exercisable for twelve months following the termination of service. In all other cases, in the absence of a specified time in an award agreement, the stock appreciation rights will remain exercisable for three
months following the termination of service. However, in no event may a stock appreciation right be exercised later than the expiration of its term. Subject to the provisions of our 2022 Plan, the administrator determines the other terms of stock
appreciation rights, including when such rights become exercisable and whether to pay any increased appreciation in cash or with shares of our common stock, or a combination thereof, except that the per share exercise price for the shares to be
issued pursuant to the exercise of a stock appreciation right will be no less than 100% of the fair market value per share on the date of grant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restricted
Stock</I>. Restricted stock may be granted under our 2022 Plan. Restricted stock awards are grants of shares of our common stock that vest in accordance with terms and conditions established by the administrator. The administrator will determine the
number of shares of restricted stock granted to any employee, director, or consultant and, subject to the provisions of our 2022 Plan, will determine the terms and conditions of such awards. The administrator may impose whatever vesting conditions
it determines to be appropriate (for example, the administrator may set restrictions based on the achievement of specific performance goals or continued service to us), except the administrator, in its sole discretion, may accelerate the time at
which any restrictions will lapse or be removed. Recipients of restricted stock awards generally will have voting and dividend rights with respect to such shares upon grant without regard to vesting, unless the administrator provides otherwise.
Shares of restricted stock that do not vest are subject to our right of repurchase or forfeiture. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Restricted Stock Units</I>. Restricted stock units may be
granted under our 2022 Plan. Restricted stock units are bookkeeping entries representing an amount equal to the fair market value of one share of our common stock. Subject to the provisions of our 2022 Plan, the administrator determines the terms
and conditions of restricted stock units, including the vesting criteria and the form and timing of payment. The administrator may set vesting criteria based upon the achievement of company-wide, divisional, business unit or individual goals
(including, but not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">153 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
limited to, continued employment or service), applicable federal or state securities laws or any other basis determined by the administrator in its discretion. The administrator, in its sole
discretion, may pay earned restricted stock units in the form of cash, in shares or in some combination thereof. In addition, the administrator, in its sole discretion, may accelerate the time at which any restrictions will lapse or be removed. </P>
 <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Performance Units and Performance Shares</I>. Performance units and performance shares may be granted under our 2022 Plan. Performance units and performance
shares are awards that will result in a payment to a participant only if performance objectives established by the administrator are achieved or the awards otherwise vest. The administrator will establish performance objectives or other vesting
criteria in its discretion, which, depending on the extent to which they are met, will determine the number or the value of performance units and performance shares to be paid out to participants. The administrator may set performance objectives
based on the achievement of company-wide, divisional, business unit or individual goals (including, but not limited to, continued employment or service), applicable federal or state securities laws or any other basis determined by the administrator
in its discretion. After the grant of a performance unit or performance share, the administrator, in its sole discretion, may reduce or waive any performance objectives or other vesting provisions for such performance units or performance shares.
Performance units will have an initial value established by the administrator on or prior to the grant date. Performance shares will have an initial value equal to the fair market value of our common stock on the grant date. The administrator, in
its sole discretion, may pay out earned performance units or performance shares in cash, shares, or in some combination thereof. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Outside Directors</I>. All
outside <FONT STYLE="white-space:nowrap">(non-employee)</FONT> directors will be eligible to receive all types of awards (except for incentive stock options) under our 2022 Plan. To provide a maximum limit on the cash compensation and equity awards
that can be made to our outside directors, our 2022 Plan provides that in any given fiscal year, an outside director will not be granted cash compensation and equity awards with an aggregate value greater than
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (increased to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; in the fiscal year of his or her initial service as an outside director), with the
value of each equity award based on its grant date fair value as determined according to GAAP for purposes of this limit. Any cash compensation paid or awards granted to an individual for his or her services as an employee or consultant (other than
as an outside director) will not count toward this limit. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Non-Transferability</FONT> of Awards</I>. Unless the administrator
provides otherwise, our 2022 Plan generally does not allow for the transfer of awards and only the recipient of an award may exercise an award during his or her lifetime. If the administrator makes an award transferrable, such award will contain
such additional terms and conditions as the administrator deems appropriate. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Certain Adjustments</I>. In the event of certain changes in our capitalization, to
prevent diminution or enlargement of the benefits or potential benefits available under our 2022 Plan, the administrator will adjust the number and class of shares that may be delivered under our 2022 Plan and/or the number, class and price of
shares covered by each outstanding award and the numerical share limits set forth in our 2022 Plan. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Dissolution or Liquidation</I>. In the event of our
proposed liquidation or dissolution, the administrator will notify participants as soon as practicable and, to the extent not exercised, all awards will terminate immediately prior to the consummation of such proposed transaction. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Merger or Change in Control</I>. Our 2022 Plan provides that in the event of a merger or change in control, as defined under our 2022 Plan, each outstanding award
will be treated as the administrator determines, without a participant&#146;s consent. The administrator is not required to treat all awards, all awards held by a participant or all awards of the same type similarly. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a successor corporation does not assume or substitute for any outstanding award, then the participant will fully vest in and have the right to exercise all of his or
her outstanding options and stock appreciation rights, all restrictions on restricted stock and restricted stock units will lapse, and for awards with performance-based vesting, unless specifically provided for otherwise under the applicable award
agreement or other agreement or policy applicable to the participant, all performance goals or other vesting criteria will be deemed achieved at 100% of target levels and all other terms and conditions met. If an option or stock appreciation right
is not assumed or substituted in the event of a change in control, the administrator will notify the participant in writing or electronically </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">154 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
that such option or stock appreciation right will be exercisable for a period of time determined by the administrator in its sole discretion and the option or stock appreciation right will
terminate upon the expiration of such period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For awards granted to an outside director, in the event of a change in control, the outside director will fully vest
in and have the right to exercise all of his or her outstanding options and stock appreciation rights, all restrictions on restricted stock and restricted stock units will lapse and, for awards with performance-based vesting, unless specifically
provided for otherwise under the applicable award agreement or other agreement or policy applicable to the participant, all performance goals or other vesting criteria will be deemed achieved at 100% of target levels and all other terms and
conditions met. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Clawback</I>. Awards will be subject to any clawback policy of ours, and the administrator also may specify in an award agreement that the
participant&#146;s rights, payments and/or benefits with respect to an award will be subject to reduction, cancellation, forfeiture and/or recoupment upon the occurrence of certain specified events. Our board of directors may require a participant
to forfeit, return or reimburse us all or a portion of the award and/or shares issued under the award, any amounts paid under the award, and any payments or proceeds paid or provided upon disposition of the shares issued under the award in order to
comply with such clawback policy or applicable laws. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Amendment; Termination</I>. The administrator has the authority to amend, alter, suspend or terminate
our 2022 Plan, provided such action does not materially impair the rights of any participant. Our 2022 Plan automatically will terminate in 2030, unless we terminate it sooner. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2017 Equity Incentive Plan, as amended (2017 Plan) </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our 2017 Plan
was originally adopted by our board of directors and approved by our stockholders in January 2017. Our 2017 Plan was most recently amended in June 2021 and approved by stockholders in June 2021. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our 2017 Plan allows us to provide incentive stock options, within the meaning of Section&nbsp;422 of the Code, nonstatutory stock options, stock appreciation rights,
restricted stock awards and restricted stock units (each, an &#147;award&#148; and the recipient of such award, a &#147;participant&#148;)&nbsp;to eligible employees, directors, and consultants of ours and any parent or subsidiary of ours. It is
expected that as of one business day prior to the effectiveness of the registration statement of which this prospectus forms a part, our 2017 Plan will be terminated and we will not grant any additional awards under our 2017 Plan thereafter.
However, our 2017 Plan will continue to govern the terms and conditions of the outstanding awards previously granted under our 2017 Plan. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of
September&nbsp;30, 2021, the following awards were outstanding under our 2017 Plan: stock options covering 28,795,570 shares of our common stock and an award of restricted stock units covering 5,244,329 shares of our common stock.<B><I> </I></B>
</P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Plan Administration</I>. Our 2017 Plan is administered by our board of directors or one or more committees appointed by our board of directors. Different
committees may administer our 2017 Plan with respect to different service providers. The administrator has all authority and discretion necessary or appropriate to administer our 2017 Plan and to control its operation, including the authority to
construe and interpret the terms of our 2017 Plan and the awards granted under our 2017 Plan. The administrator&#146;s decisions are final and binding on all participants and any other persons holding awards. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The administrator&#146;s powers include the power to institute an exchange program under which (i)&nbsp;outstanding awards are surrendered or cancelled in exchange for
awards of the same type (which may have higher or lower exercise prices and different terms), awards of a different type or cash, (ii)&nbsp;participants would have the opportunity to transfer any outstanding awards to a financial institution or
other person or entity selected by the administrator or (iii)&nbsp;the exercise price of an outstanding award is increased or reduced. The administrator&#146;s powers also include the power to prescribe, amend and rescind rules and regulations
relating to our 2017 Plan, to modify or amend each award and to make all other determinations deemed necessary or advisable for administering our 2017 Plan. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Eligibility</I>. Employees, directors and consultants of ours or our parent or subsidiary companies are eligible to receive awards, provided such consultants render
bona fide services not in connection with the offer and sale of securities in a capital-raising transaction and do not directly promote or maintain a market for our securities. Only our employees or employees of our parent or subsidiary companies
are eligible to receive incentive stock options. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">155 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stock Options</I>. Stock options have been granted under our 2017 Plan. Subject to the provisions of our 2017 Plan, the
administrator determines the term of an option, the number of shares subject to an option, and the time period in which an option may be exercised. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The term of an
option is stated in the applicable award agreement, but the term of an option may not exceed 10&nbsp;years from the grant date. The administrator determines the exercise price of options, which generally may not be less than 100% of the fair market
value of our common stock on the grant date, unless expressly determined in writing by the administrator on the option&#146;s grant date. However, an incentive stock option granted to an individual who directly or by attribution owns more than 10%
of the total combined voting power of all of our classes of stock or of any our parent or subsidiary may have a term of no longer than 5 years from the grant date and will have an exercise price of at least 110% of the fair market value of our
common stock on the grant date. In addition, to the extent that the aggregate fair market value of the shares with respect to which incentive stock options are exercisable for the first time by an employee during any calendar year (under all our
plans and any parent or subsidiary) exceeds $100,000, such options will be treated as nonstatutory stock options. Certain of the company&#146;s outstanding options under our 2017 Plan have an early exercise provisions pursuant to which the
participate may exercise the option prior to the shares being fully vested. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The administrator determines how a participant may pay the exercise price of an option,
and the permissible methods are generally set forth in the applicable award agreement. If a participant&#146;s status as a &#147;service provider&#148; (as defined in our 2017 Plan) terminates, that participant may exercise the vested portion of his
or her option for the period of time stated in the applicable award agreement. Vested options generally will remain exercisable for three months or such longer period of time as set forth in the applicable award agreement if a participant&#146;s
status as a service provider terminates for a reason other than death or disability. If a participant&#146;s status as a service provider terminates due to death or disability, vested options generally will remain exercisable for twelve months from
the date of termination (or such other longer period as set forth in the applicable award agreement). In no event will an option remain exercisable beyond its original term. If a participant does not exercise his or her option within the time
specified in the award agreement, the option will terminate. Except as described above, the administrator has the discretion to determine the post-termination exercisability periods for an option. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Non-transferability</FONT> of Awards</I>. Unless determined otherwise by the administrator, awards may not be sold, pledged,
assigned, hypothecated or otherwise transferred in any manner other than by will or by the laws of descent and distribution. In addition, during an applicable participant&#146;s lifetime, only that participant may exercise their award. If the
administrator makes an award transferable, such award may only be transferred (i)&nbsp;by will, (ii)&nbsp;by the laws of descent and distribution or (iii)&nbsp;as permitted by Rule 701 of the Securities Act. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Certain Adjustments</I>. If there is a dividend or other distribution (whether in the form of cash, shares, other securities or other property), recapitalization,
stock split, reverse stock split, reorganization, merger, consolidation, <FONT STYLE="white-space:nowrap">split-up,</FONT> <FONT STYLE="white-space:nowrap">spin-off,</FONT> combination, repurchase, exchange of shares or our other securities or other
change in our corporate structure affecting the shares, the administrator will make proportionate adjustments to the number and type of shares that may be delivered under our 2017 Plan or the number, type and price of shares covered by each
outstanding award. The administrator&#146;s determination regarding such adjustments will be final, binding and conclusive. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Dissolution or Liquidation</I>. In
the event of our proposed dissolution or liquidation, the administrator will notify each participant as soon as practicable prior to the effective date of such proposed transaction. To the extent it has not been previously exercised, an award will
terminate immediately prior to the consummation of such proposed action. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Merger and Change of Control</I>. In the event of our merger with or into another
corporation or entity or a &#147;change in control&#148; (as defined in our 2017 Plan), each outstanding award will be treated as the administrator determines, including, without limitation, that (i)&nbsp;awards will be assumed, or substantially
equivalent awards will be substituted, by the acquiring or succeeding corporation (or an affiliate thereof) with appropriate adjustments as to the number and kind of shares and prices; (ii)&nbsp;upon written notice to a participant, the
participant&#146;s awards will terminate upon or immediately prior to the consummation of such merger or change in control; (iii)&nbsp;outstanding awards will vest and become exercisable, realizable or payable, or restrictions applicable to an award
will lapse, in whole or in part, prior to or upon consummation of such merger or change in control, and, to the extent the administrator determines, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">156 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
terminate upon or immediately prior to the effectiveness of such merger or change in control; (iv)&nbsp;(A) the termination of an award in exchange for an amount of cash or property, if any,
equal to the amount that would have been attained upon the exercise of such award or realization of the participant&#146;s rights as of the date of the occurrence of the transaction (and, for the avoidance of doubt, if as of the date of the
occurrence of the transaction the administrator determines in good faith that no amount would have been attained upon the exercise of such award or realization of the participant&#146;s rights, then such award may be terminated by us without
payment) or (B)&nbsp;the replacement of such award with other rights or property selected by the administrator in its sole discretion; or (v)&nbsp;any combination of the foregoing. The administrator will not be obligated to treat all awards, all
awards a participant holds or all awards of the same type, similarly. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event that the successor corporation does not assume or substitute for an award (or
portion thereof), the participant will fully vest in and have the right to exercise all of his or her outstanding options and stock appreciation rights, including shares as to which such awards would not otherwise be vested or exercisable, all
restrictions on restricted stock and restricted stock units will lapse, and, with respect to awards with performance-based vesting, all performance goals or other vesting criteria will be deemed achieved at one hundred percent (100%) of target
levels and all other terms and conditions met. In addition, if an option or stock appreciation right is not assumed or substituted in the event of a merger or change in control, the administrator will notify the participant in writing or
electronically that the option or stock appreciation right will be exercisable for a period of time determined by the administrator in its sole discretion, and the option or stock appreciation right will terminate upon the expiration of such period.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Amendment and Termination</I>. Our board of directors may, at any time, terminate or amend our 2017 Plan in any respect, including, without limitation,
amendment of any form of award agreement or instrument to be executed pursuant to our 2017 Plan. To the extent necessary and desirable to comply with applicable laws, we will obtain stockholder approval of any amendment to our 2017 Plan. No
amendment or alteration of our 2017 Plan will impair the rights of a participant, unless mutually agreed otherwise between the participant and the administrator in writing. As noted above, it is expected that as of one business day prior to the
effectiveness of the registration statement of which this prospectus forms a part, our 2017 Plan will be terminated and we will not grant any additional awards under our 2017 Plan thereafter. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>2022 Employee Stock Purchase Plan (2022 ESPP) </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to the
effectiveness of this offering, we expect that our board of directors will adopt, and our stockholders will approve, our 2022 ESPP. Our 2022 ESPP will be effective on the business day immediately prior to the effective date of the registration
statement of which this prospectus forms a part. We believe that allowing our employees to participate in our 2022 ESPP will provide them with a further incentive towards promoting our success and accomplishing our corporate goals. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Authorized Shares</I>. A total of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock will be available for sale
under our 2022 ESPP. The number of shares of our common stock that will be available for sale under our 2022 ESPP also includes an annual increase on the first day of each fiscal year beginning with our 2023 fiscal year, equal to the lesser of: </P>
 <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of the outstanding shares of our common stock as of the last day of the
immediately preceding fiscal year; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Such other amount as the administrator may determine. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>2022 ESPP Administration</I>. We expect that the compensation committee of our board of directors will administer our 2022 ESPP and will have full and exclusive
discretionary authority to construe, interpret, and apply the terms of the 2022 ESPP, delegate ministerial duties to any of our employees, designate separate offerings under the 2022 ESPP, designate our subsidiaries and affiliates as participating
in the 2022 ESPP, determine eligibility, adjudicate all disputed claims filed under the 2022 ESPP, and establish procedures that it deems necessary for the administration of the 2022 ESPP, including, but not limited to, adopting such procedures and <FONT
STYLE="white-space:nowrap">sub-plans</FONT> as are necessary or appropriate to permit participation in the 2022 ESPP by employees who are foreign nationals or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">157 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
employed outside the United States. The administrator&#146;s findings, decisions and determinations are final and binding on all participants to the full extent permitted by law. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Eligibility</I>. Generally, all of our employees will be eligible to participate if they are customarily employed by us, or any participating subsidiary or
affiliate, for at least 20 hours per week and more than five months in any calendar year. The administrator, in its discretion, may, prior to an enrollment date, for all options to be granted on such enrollment date in an offering, determine that an
employee who (i)&nbsp;has not completed at least two years of service (or a lesser period of time determined by the administrator) since his or her last hire date, (ii)&nbsp;customarily works not more than 20 hours per week (or a lesser period of
time determined by the administrator), (iii) customarily works not more than five months per calendar year (or a lesser period of time determined by the administrator), (iv) is a highly compensated employee within the meaning of Section&nbsp;414(q)
of the Code, or (v)&nbsp;is a highly compensated employee within the meaning of Section&nbsp;414(q) of the Code with compensation above a certain level or is an officer or subject to disclosure requirements under Section&nbsp;16(a) of the Exchange
Act, is or is not eligible to participate in such offering period. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">However, an employee may not be granted rights to purchase shares of our common stock under
our 2022 ESPP if such employee: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Immediately after the grant would own capital stock and/or hold outstanding options to purchase such stock possessing 5%
or more of the total combined voting power or value of all classes of capital stock of ours or of any parent or subsidiary of ours; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Holds rights to purchase shares of our common stock under all employee stock purchase plans of ours or any parent or
subsidiary of ours that accrue at a rate that exceeds $25,000 worth of shares of our common stock for each calendar year in which such rights are outstanding at any time. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Offering Periods</I>. Our 2022 ESPP will include a component that allows us to make offerings intended to qualify under Section&nbsp;423 of the Code and a component
that allows us to make offerings not intended to qualify under Section&nbsp;423 of the Code to designated companies, as described in our 2022 ESPP. Our 2022 ESPP will provide for consecutive, overlapping
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; -month offering periods. The offering periods will be scheduled to start on the first trading day on or after
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; of each year, except the first offering period will commence on the first trading day on or after
the effective date of the registration statement of which this prospectus forms a part and will end on the first trading day on or before &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and the second offering period will
commence on the last trading day on or after &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Contributions</I>. Our 2022 ESPP will
permit participants to purchase shares of our common stock through contributions (in the form of payroll deductions or otherwise to the extent permitted by the administrator) of up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% of their
eligible compensation, which includes a participant&#146;s base straight time gross earnings but excludes payments for incentive compensation, bonuses, payments for overtime and shift premium, equity compensation income and other similar
compensation. Unless otherwise determined by the administrator, a participant may make a <FONT STYLE="white-space:nowrap">one-time</FONT> decrease (but not increase) to the rate of his or her contributions to 0% during an offering period. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Exercise of Purchase Right</I>. Amounts contributed and accumulated by the participant will be used to purchase shares of our common stock at the end of each
offering. A participant may purchase a maximum of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock during an offering period. The purchase price of the shares will be 85% of the lower of the fair
market value of our common stock on the first trading day of the offering period or on the exercise date. Participants may end their participation at any time during an offering period and will be paid their accrued contributions that have not yet
been used to purchase shares of our common stock. Participation ends automatically upon termination of employment with us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I><FONT STYLE="white-space:nowrap">Non-Transferability</FONT></I>. A participant may not transfer contributions credited to his or her account nor any rights granted
under our 2022 ESPP other than by will, the laws of descent and distribution or as otherwise provided under our 2022 ESPP. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Merger or Change in Control</I>. Our
2022 ESPP provides that in the event of a merger or change in control, as defined under our 2022 ESPP, a successor corporation (or a parent or subsidiary of the successor corporation) will assume or </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">158 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
substitute each outstanding purchase right. If the successor corporation refuses to assume or substitute for the outstanding purchase right, the offering period with respect to which the purchase
right relates will be shortened, and a new exercise date will be set that will be before the date of the proposed merger or change in control. The administrator will notify each participant that the exercise date has been changed and that the
participant&#146;s option will be exercised automatically on the new exercise date unless prior to such date the participant has withdrawn from the offering period. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Amendment; Termination</I>. The administrator will have the authority to amend, suspend or terminate our 2022 ESPP. Our 2022 ESPP automatically will terminate in
2041, unless we terminate it sooner. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>401(k) Plan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
maintain a 401(k) retirement savings plan for the benefit of our employees, including our named executive officers, who satisfy certain eligibility requirements. Under the 401(k) plan, eligible employees may elect to defer a portion of their
compensation, within the limits prescribed by the Code, on a <FONT STYLE="white-space:nowrap">pre-tax</FONT> or <FONT STYLE="white-space:nowrap">after-tax</FONT> (Roth) basis, through contributions to the 401(k) plan. The 401(k) plan authorizes
employer safe harbor contributions. The 401(k) plan is intended to qualify under Sections&nbsp;401(a) and 501(a) of the Code. As a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan, <FONT STYLE="white-space:nowrap">pre-tax</FONT>
contributions to the 401(k) plan and earnings on those <FONT STYLE="white-space:nowrap">pre-tax</FONT> contributions are not taxable to the employees until distributed from the 401(k) plan, and earnings on Roth contributions are not taxable when
distributed from the 401(k) plan. We contribute 3% of an employee&#146;s annual compensation, regardless of the amount of the employee&#146;s contributions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Limitation of Liability and Indemnification </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated
certificate of incorporation and amended and restated bylaws, each to be effective immediately after the closing of this offering, will provide that we will indemnify our directors and officers, and may indemnify our employees and other agents, to
the fullest extent permitted by Delaware law. Delaware law prohibits our amended and restated certificate of incorporation from limiting the liability of our directors for the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Any breach of the director&#146;s duty of loyalty to us or to our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Unlawful payment of dividends or unlawful stock repurchases or redemptions; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If Delaware law is amended to authorize corporate action further eliminating or limiting the personal liability of a director, then the liability of our directors will
be eliminated or limited to the fullest extent permitted by Delaware law, as so amended. Our amended and restated certificate of incorporation does not eliminate a director&#146;s duty of care and, in appropriate circumstances, equitable remedies,
such as injunctive or other forms of <FONT STYLE="white-space:nowrap">non-monetary</FONT> relief, remain available under Delaware law. This provision also does not affect a director&#146;s responsibilities under any other laws, such as the federal
securities laws or other state or federal laws. Under our amended and restated bylaws, we will also be empowered to purchase insurance on behalf of any person whom we are required or permitted to indemnify. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to the indemnification required in our amended and restated certificate of incorporation and amended and restated bylaws, we have entered, and intend to
continue to enter, into an indemnification agreement with each member of our board of directors and each of our officers prior to the completion of the offering. These agreements provide for the indemnification of our directors and officers for
certain expenses and liabilities incurred in connection with any action, suit, proceeding or alternative dispute resolution mechanism or hearing, inquiry or investigation that may lead to the foregoing, to which they are a party, or are threatened
to be made a party, by reason of the fact that they are or were a director, officer, employee, agent or fiduciary of our company, or any of our subsidiaries, by reason of any action or inaction by them while serving as an officer, director, agent or
fiduciary, or by reason of the fact that they were serving at our request as a director, officer, employee, agent or fiduciary of another entity. In the case of an action or proceeding by or in the right of our company or any of our subsidiaries, no
indemnification will be provided for any claim where a court determines that the indemnified party is prohibited from receiving indemnification. We believe that these charter and bylaw provisions and indemnification agreements are necessary to
attract and retain qualified persons as directors and officers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">159 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The limitation of liability and indemnification provisions in our amended and restated certificate of incorporation and
amended and restated bylaws may discourage stockholders from bringing a lawsuit against directors for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even though an
action, if successful, might benefit us and our stockholders. Moreover, a stockholder&#146;s investment may be harmed to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification
provisions. Insofar as indemnification for liabilities arising under the Securities Act, may be permitted to our directors, officers and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the
opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act, and is, therefore, unenforceable. There is no pending litigation or proceeding naming any of our directors or officers as to which indemnification
is being sought, nor are we aware of any pending or threatened litigation that may result in claims for indemnification by any director or officer. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">160 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_16"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other than compensation arrangements, including employment, termination of employment and change in control arrangements, with our directors and executive officers,
including those discussed in the sections titled &#147;Management&#148; and &#147;Executive Compensation,&#148; and the registration rights described in the section titled &#147;Description of Capital Stock&#151;Registration Rights,&#148; the
following is a description of each transaction since January&nbsp;1, 2019 and each currently proposed transaction in which: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">We have been or are to be a participant; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The amount involved exceeded or exceeds $120,000; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Any of our directors, executive officers or holders of more than 5% of our outstanding capital stock, or any immediate
family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Sales of Securities </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Series B Preferred Stock Financing </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August and September 2019 we
issued and sold an aggregate of 27,444,339 shares of our Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred stock (Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock) at a purchase price of $1.561 per
share for an aggregate purchase price of approximately $42.8&nbsp;million. These shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock will convert into an aggregate of 27,44,339 shares of common stock upon the completion of
this offering. The table below sets forth the number of shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> Preferred Stock sold to our directors, executive officers and holders of more than 5% of our capital stock: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="22%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>INVESTOR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>AFFILIATED DIRECTOR(S)<BR>OR OFFICER(S)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES OF<BR><FONT STYLE="white-space:nowrap">SERIES&nbsp;B-1</FONT><BR>PREFERRED<BR>STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>PURCHASE<BR>PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Quan Venture Fund II, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Lewis T. Williams</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,406,150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">New Enterprise Associates 15, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Ali Behbahani</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,804,613</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,500,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Novo Holdings A/S</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Raymond Camahort</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,669,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,727,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">SR One Capital Fund I Aggregator, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Jill Carroll</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,669,318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,727,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Aju Life Science 3.0 Venture Fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Derek Yoon</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,203,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Takeda Ventures, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,720,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,684,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2020 we issued and sold an aggregate of 21,958,284 shares of our Series <FONT STYLE="white-space:nowrap">B-2</FONT> redeemable convertible preferred stock
(Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Stock) at a purchase price of $1.951 per share for an aggregate purchase price of approximately $42.8&nbsp;million. These shares of Series <FONT STYLE="white-space:nowrap">B-2</FONT>
Preferred Stock will convert into an aggregate of 21,958,284 shares of common stock upon the completion of this offering. The table below sets forth the number of shares of Series <FONT STYLE="white-space:nowrap">B-2</FONT> Preferred Stock sold to
our directors, executive officers and holders of more than 5% of our capital stock: </P>  <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="54%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>INVESTOR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>AFFILIATED&nbsp;DIRECTOR(S)<BR>OR OFFICER(S)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES OF<BR><FONT STYLE="white-space:nowrap">SERIES&nbsp;B-2</FONT><BR>PREFERRED<BR>STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>PURCHASE&nbsp;PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Quan Venture Fund II, L.P</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Lewis&nbsp;T.&nbsp;Williams</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,125,577</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">New Enterprise Associates 15, L.P</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Ali Behbahani</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,844,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,500,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Novo Holdings A/S</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Raymond Camahort</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,935,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,727,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">SR One Capital Fund I Aggregator, LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Jill Carroll</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,935,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,727,804</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Aju Life Science 3.0 Venture Fund</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Derek Yoon</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,562,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Takeda Ventures, Inc</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,376,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,684,995</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">161 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Series C Preferred Stock Financing </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March, April and June 2021 we issued and sold an aggregate of 57,224,618 shares of our Series C redeemable convertible preferred stock (Series C Preferred Stock) at
a purchase price of $2.097 per share for an aggregate purchase price of approximately $120 million. These shares of Series C Preferred Stock will convert into an aggregate of 57,224,618 shares of common stock upon the completion of this offering.
The table below sets forth the number of shares of Series C Preferred Stock sold to our directors, executive officers and holders of more than 5% of our capital stock: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>INVESTOR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>AFFILIATED&nbsp;DIRECTOR(S)<BR>OR OFFICER(S)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES OF<BR>SERIES&nbsp;C<BR>PREFERRED<BR>STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B><br><B>PURCHASE</B><br><B>PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">New Enterprise Associates 15, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Ali Behbahani</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,537,435</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">20,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Novo Holdings A/S</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Raymond Camahort</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,384,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">SR One Capital Fund I Aggregator, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Jill Carroll</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,576,538</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">SR One Co-Invest II, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Jill Carroll</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,384,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Takeda Ventures, Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&#151;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">476,872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">David Lubner</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,218</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investors&#146; Rights Agreement </B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are party to an amended and restated
investors&#146; rights agreement with certain holders of our capital stock, including New Enterprise Associates 15, L.P., NEA Ventures 2016, L.P., Novo Holdings A/S, SR One Capital Fund I Aggregator, L.P., SR One Co-Invest II, LLC, Quan Venture Fund
II, L.P., Takeda Ventures, Inc. and Aju Life Science 3.0 Venture Fund. Under our investors&#146; rights agreement, certain holders of our capital stock have the right to demand that we file a registration statement or request that their shares of
our capital stock be covered by a registration statement that we are otherwise filing. See the section titled &#147;Description of Capital Stock&#151;Registration Rights&#148; for additional information regarding these registration rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Indemnification Agreements </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered, and intend to continue to
enter, into separate indemnification agreements with each of our directors and executive officers, in addition to the indemnification provided for in our amended and restated certificate of incorporation and bylaws. The indemnification agreements
and our amended restated certificate of incorporation and amended and restated bylaws that will be in effect upon the completion of this offering require us to indemnify our directors, executive officers and certain controlling persons to the
fullest extent permitted by Delaware law. See the section titled &#147;Executive Compensation&#151;Limitation of Liability and Indemnification&#148; for additional information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Related Party Transaction Policy </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our audit committee will have the primary
responsibility for reviewing and approving or disapproving &#147;related party transactions,&#148; which are transactions between us and related persons in which the aggregate amount involved exceeds or may be expected to exceed $120,000 and in
which a related person has or will have a direct or indirect material interest. The charter of our audit committee will provide that our audit committee shall review and approve in advance any related party transaction. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to the completion of this offering, we intend to adopt a formal written policy providing that we are not permitted to enter into any transaction that exceeds
$120,000 and in which any related person has a direct or indirect material interest without the consent of our audit committee. In approving or rejecting any such transaction, our audit committee is to consider the relevant facts and circumstances
available and deemed relevant to our audit committee, including whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and the extent of the related
person&#146;s interest in the transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">162 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_17"></A>PRINCIPAL STOCKHOLDERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the beneficial ownership of our common stock as of December&nbsp;31, 2021 by: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Each person, or group of affiliated persons, who is known by us to beneficially own more than 5% of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Each of our named executive officers; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Each of our directors, as of December&nbsp;31, 2021; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">All of our current executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have determined beneficial ownership in accordance with the rules of the SEC, and thus it represents sole or shared voting or investment power with respect to our
securities. Unless otherwise indicated below, to our knowledge, the persons and entities named in the table have sole voting and sole investment power with respect to all shares that they beneficially owned, subject to community property laws where
applicable. The information does not necessarily indicate beneficial ownership for any other purpose, including for purposes of Sections&nbsp;13(d) and 13(g) of the Exchange Act. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have based our calculation of the percentage of beneficial ownership prior to this offering on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock outstanding as of December&nbsp;31, 2021, which includes 136,422,468 shares of our common stock resulting from the conversion of all 136,422,468
outstanding shares of our redeemable convertible preferred stock into our common stock upon the closing of this offering, as if this conversion had occurred as of December&nbsp;31, 2021. We have based our calculation of the percentage of beneficial
ownership after this offering on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock outstanding immediately after the completion of this offering, assuming no exercise by the underwriters of their
option to purchase additional shares. We have deemed shares of our common stock subject to stock options that are currently exercisable or exercisable within 60 days of December&nbsp;31, 2021, to be outstanding and to be beneficially owned by the
person holding the stock option for the purpose of computing the percentage ownership of that person. We did not deem these shares outstanding, however, for the purpose of computing the percentage ownership of any other person. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise indicated, the address of each beneficial owner listed in the table below is c/o&nbsp;Arcellx, Inc., 25&nbsp;West Watkins Mill Road, Suite&nbsp;A,
Gaithersburg, Maryland 20878. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="56%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES&nbsp;BENEFICIALLY&nbsp;OWNED<BR>PRIOR TO THIS OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES&nbsp;BENEFICIALLY&nbsp;OWNED<BR>AFTER THIS OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>NAME OF BENEFICIAL OWNER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENTAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENTAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>5% Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Named Executive Officers and Directors:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">All executive officers and directors as a group (&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;persons)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than one percent (1%) of the outstanding shares of our common stock. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">163 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_18"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following descriptions of our capital stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws are
summaries and are qualified by reference to the amended and restated certificate of incorporation and the amended and restated bylaws that will be in effect upon completion of this offering. Copies of these documents will be filed with the SEC as
exhibits to our registration statement, of which this prospectus forms a part. The descriptions of the common stock and preferred stock reflect changes to our capital structure that will occur upon the completion of this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the completion of this offering and the filing of our amended and restated certificate of incorporation in connection with this offering, our authorized capital
stock will consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock, par value $0.001 per share, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of redeemable
convertible preferred stock, par value $0.001 per share. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the closing of this offering, all the outstanding shares of our redeemable convertible preferred
stock will automatically convert into an aggregate of&nbsp;136,422,468 shares of our common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on 139,218,480 shares of common stock outstanding as of
September 30, 2021, and after giving effect to the conversion of all of our outstanding redeemable convertible preferred stock into an aggregate of 136,422,468 shares of common stock upon the closing of this offering and the issuance of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock in this offering, there will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock outstanding upon the
completion of this offering. As of September 30, 2021, we had 60 stockholders of record. As of September 30, 2021, there were 28,795,570 shares of common stock subject to outstanding options and an award of restricted stock units covering 5,244,329
shares of our common stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common Stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Voting Rights
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each holder of common stock is entitled to one vote for each share on all matters submitted to a vote of the stockholders, including the election of
directors. Our certificate of incorporation and bylaws to be in effect immediately after the closing of this offering do not provide for cumulative voting rights. Because of this, the holders of a plurality of the shares of common stock entitled to
vote in any election of directors can elect all of the directors standing for election, if they should so choose. With respect to matters other than the election of directors, at any meeting of the stockholders at which a quorum is present or
represented, the affirmative vote of a majority of the voting power of the shares present in person or represented by proxy at such meeting and entitled to vote on the subject matter shall be the act of the stockholders, except as otherwise required
by law. The holders of a majority of the stock issued and outstanding and entitled to vote, present in person or represented by proxy, shall constitute a quorum for the transaction of business at all meetings of the stockholders. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Dividends </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to preferences that may be applicable to any
then-outstanding redeemable convertible preferred stock, holders of our common stock are entitled to receive dividends, if any, as may be declared from time to time by our board of directors out of legally available funds. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of our liquidation, dissolution or winding
up, holders of our common stock will be entitled to share ratably in the net assets legally available for distribution to stockholders after the payment of all of our debts and other liabilities and the satisfaction of any liquidation preference
granted to the holders of any then-outstanding shares of redeemable convertible preferred stock. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Rights and Preferences </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Holders of our common stock have no preemptive, conversion, subscription or other rights, and there are no redemption or sinking fund provisions applicable to our
common stock. The rights, preferences and privileges of the holders of our common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our redeemable convertible preferred stock that we may
designate in the future. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fully Paid and Nonassessable </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of
our outstanding shares of common stock are, and the shares of common stock to be issued in this offering, upon payment and delivery in accordance with the underwriting agreement, will be fully paid and nonassessable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">164 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preferred Stock </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the
completion of this offering, our board of directors will have the authority, without further action by the stockholders, to issue up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of preferred stock in one or more
series and to fix the rights, preferences, privileges and restrictions thereof. These rights, preferences and privileges could include dividend rights, conversion rights, voting rights, redemption rights, liquidation preferences, sinking fund terms
and the number of shares constituting any series or the designation of such series, any or all of which may be greater than the rights of common stock. The issuance of preferred stock could adversely affect the voting power of holders of common
stock and the likelihood that such holders will receive dividend payments and payments upon liquidation. In addition, the issuance of preferred stock could have the effect of delaying, deferring or preventing change in our control or other corporate
action. Upon completion of this offering, no shares of preferred stock will be outstanding, and we have no present plan to issue any shares of preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Common Stock Options </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of September 30, 2021, we had outstanding
options to purchase an aggregate of 28,795,570 shares of our common stock, with a weighted-average exercise price of $0.95 per share, under our 2017 Plan. After September&nbsp;30, 2021, we issued options to purchase an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock, with a weighted-average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, under our 2017 Plan.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Restricted Stock Units </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of September&nbsp;30, 2021, we had
outstanding an award of restricted stock units covering 5,244,329 shares of our common stock. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the completion of this offering, under our amended and restated investors&#146; rights agreement, the holders&nbsp;of up to&nbsp;136,422,468 shares of common
stock or their transferees, have the right to require us to register the offer and sale of their shares, or to include their shares in any registration statement we file, in each case as described below. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Demand Registration Rights </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the completion of this
offering, the holders of up to 136,422,468 shares of our common stock will be entitled to certain demand registration rights. At any time beginning after 180 days following the completion of this offering, the holders of a majority of the shares
having registration rights then outstanding can request that we file a registration statement to register the offer and sale of their shares. We are only obligated to effect up to two such registrations. Each such request for registration must cover
securities the anticipated aggregate gross proceeds of which, before deducting underwriting discounts and expenses, is at least $5&nbsp;million. These demand registration rights are subject to specified conditions and limitations, including the
right of the underwriters to limit the number of shares included in any such registration under certain circumstances. If we determine that it would be materially detrimental to us and our stockholders to effect such a demand registration, we have
the right to defer such registration, not more than once in any twelve-month period, for a period of up to 60 days. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Form
<FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the completion of this offering, the holders of up to 136,422,468 shares of our
common stock will be entitled to certain Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights. At any time when we are eligible to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> the holders of the
shares having these rights then outstanding can request that we register the offer and sale of their shares of our common stock on a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> so long as the request covers securities
the anticipated aggregate public offering price of which, net of selling expenses, is at least $1&nbsp;million. These stockholders may make an unlimited number of requests for registration on a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3.</FONT> However, we will not be required to effect a registration on Form <FONT STYLE="white-space:nowrap">S-3</FONT> if we have effected two such registrations within the twelve-month period preceding the date of the
request. These Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights are subject to specified conditions and limitations, including the right of the underwriters to limit the number of shares included in any such registration under
certain circumstances. Additionally, if we determine that it would be seriously detrimental to us and our stockholders to effect such a demand registration, we have the right to defer such registration, not more than once in any twelve-month period,
for a period of up to 60 days. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">165 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Piggyback Registration Rights </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the completion of this offering, the holders of up to 136,422,468 shares of our common stock will be entitled to certain &#147;piggyback&#148; registration
rights. If we propose to register the offer and sale of shares of our common stock under the Securities Act, all holders of these shares then outstanding can request that we include their shares in such registration, subject to certain marketing and
other limitations, including the right of the underwriters to limit the number of shares included in any such registration statement under certain circumstances. As a result, whenever we propose to file a registration statement under the Securities
Act, other than with respect to (1)&nbsp;a registration related to any employee benefit plan or a corporate reorganization or other transaction covered by Rule 145 promulgated under the Securities Act, (2)&nbsp;a registration relating to the offer
and sale of debt securities, (3)&nbsp;a registration on any registration form that does not permit secondary sales or (4)&nbsp;a registration pursuant to the demand or Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights described in
the preceding two paragraphs above, the holders of these shares are entitled to notice of the registration and have the right, subject to certain limitations, to include their shares in the registration. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Expenses of Registration </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will pay all expenses relating to any
demand registrations, Form <FONT STYLE="white-space:nowrap">S-3</FONT> registrations and piggyback registrations, subject to specified limitations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Termination </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The registration rights terminate upon the earliest of
(1)&nbsp;the date that is five years after the completion of this offering, (2)&nbsp;immediately prior to the completion of certain liquidation events and (3)&nbsp;as to a given holder of registration rights, the date after the completion of this
offering when such holder of registration rights can sell all of such holder&#146;s registrable securities during any three-month period pursuant to Rule 144 promulgated under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Anti-Takeover Effects of Certain Provisions of Delaware Law, Our Amended and Restated Certificate of Incorporation and Our Amended and Restated Bylaws </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain provisions of Delaware law and certain provisions that will be included in our amended and restated certificate of incorporation and amended and restated bylaws
summarized below may be deemed to have an anti-takeover effect and may delay, deter or prevent a tender offer or takeover attempt that a stockholder might consider to be in its best interests, including attempts that might result in a premium being
paid over the market price for the shares held by stockholders. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Preferred Stock </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation will contain provisions that permit our board of directors to issue, without any further vote or action by the
stockholders, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of preferred stock in one or more series and, with respect to each such series, to fix the number of shares constituting the series and the designation of
the series, the voting rights (if any) of the shares of the series and the powers, preferences or relative, participation, optional and other special rights, if any, and any qualifications, limitations or restrictions, of the shares of such series.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Classified Board </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of
incorporation will provide that our board of directors is divided into three classes, designated Class&nbsp;I, Class&nbsp;II and Class&nbsp;III. Each class will be an equal number of directors, as nearly as possible, consisting of one third of the
total number of directors constituting the entire board of directors. The term of initial Class&nbsp;I directors shall terminate on the date of the 2023 annual meeting, the term of the initial Class&nbsp;II directors shall terminate on the date of
the 2024 annual meeting, and the term of the initial Class&nbsp;III directors shall terminate on the date of the 2025 annual meeting. At each annual meeting of stockholders beginning in 2023, successors to the class of directors whose term expires
at that annual meeting will be elected for a three-year term. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Removal of Directors </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation will provide that stockholders may only remove a director for cause by a vote of no less than a majority of the
shares present in person or by proxy at the meeting and entitled to vote. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">166 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Director Vacancies </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
amended and restated certificate of incorporation will authorize only our board of directors to fill vacant directorships. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>No Cumulative Voting </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation will provide that stockholders do not have the right to cumulate votes in the election of directors. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Special Meetings of Stockholders </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated
certificate of incorporation and amended and restated bylaws will provide that, except as otherwise required by law, special meetings of the stockholders may be called only by the chairperson of our board of directors, our Chief Executive Officer,
our President, or our board of directors acting pursuant to a resolution adopted by a majority of our board of directors. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Advance Notice Procedures for
Director Nominations </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our bylaws will provide that stockholders seeking to nominate candidates for election as directors at an annual or special meeting of
stockholders or seeking to propose matters that can be acted upon by stockholders at annual stockholder meetings must provide timely notice thereof in writing. To be timely, a stockholder&#146;s notice generally will have to be delivered to and
received at our principal executive offices before notice of the meeting is issued by the secretary of the company, with such notice being served not less than 90 nor more than 120 days before the meeting. Although the amended and restated bylaws
will not give the board of directors the power to approve or disapprove stockholder nominations of candidates to be elected at an annual meeting, the amended and restated bylaws may have the effect of precluding the conduct of certain business at a
meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of the company. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Action by Written Consent </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of
incorporation and amended and restated bylaws will provide that any action to be taken by the stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by written consent. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Amending our Certificate of Incorporation and Bylaws </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and
restated certificate of incorporation may be amended or altered in any manner provided by the DGCL except that amendment of certain provisions would require the approval of a <FONT STYLE="white-space:nowrap">two-thirds</FONT> majority of our then
outstanding common stock. Our amended and restated bylaws may be adopted, amended, altered or repealed by stockholders only upon approval of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> of the voting power of all the then outstanding
shares of the common stock. Additionally, our amended and restated certificate of incorporation will provide that our bylaws may be amended, altered or repealed by the board of directors. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Authorized but Unissued Shares </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our authorized but unissued shares of
common stock and preferred stock will be available for future issuances without stockholder approval, except as required by the listing standards of Nasdaq, and could be utilized for a variety of corporate purposes, including future offerings to
raise additional capital, acquisitions and employee benefit plans. The existence of authorized but unissued and unreserved common stock and preferred stock could render more difficult or discourage an attempt to obtain control of the company by
means of a proxy contest, tender offer, merger or otherwise. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Exclusive Jurisdiction </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated bylaws will provide that, unless we consent to the selection of an alternative forum, the Court of Chancery of the State of Delaware shall be
the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a claim of breach of fiduciary duty, any action asserting a claim arising pursuant to the DGCL, any action regarding our amended and
restated certificate of incorporation or amended and restated bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. Our amended and restated bylaws further provide that the federal district courts of
the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. Any person or entity purchasing or otherwise acquiring any interest in our securities shall be deemed
to have notice of and consented to these provisions. Although we believe these provisions benefit us by providing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">167 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
increased consistency in the application of law for the specified types of actions and proceedings, the provisions may have the effect of discouraging lawsuits against us or our directors and
officers. Please also see the section titled &#147;Risk Factors&#151;Our amended and restated bylaws that will become effective upon the closing of this offering provide that the Court of Chancery of the State of Delaware and the federal district
courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our
directors, officers or employees.&#148; </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Business Combinations with Interested Stockholders </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are governed by Section&nbsp;203 of the DGCL, which, subject to certain exceptions, prohibits a public Delaware corporation from engaging in a business combination
(as defined in such section) with an &#147;interested stockholder&#148; (defined generally as any person who beneficially owns 15% or more of the outstanding voting stock of such corporation or any person affiliated with such person) for a period of
three years following the time that such stockholder became an interested stockholder, unless (i)&nbsp;prior to such time the board of directors of such corporation approved either the business combination or the transaction that resulted in the
stockholder becoming an interested stockholder; (ii)&nbsp;upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of such corporation
at the time the transaction commenced (excluding for purposes of determining the voting stock of such corporation outstanding (but not the outstanding voting stock owned by the interested stockholder) those shares owned (A)&nbsp;by persons who are
directors and also officers of such corporation and (B)&nbsp;by employee stock plans in which employee participants do not have the right to determine confidentially whether shares held subject to the plan will be tendered in a tender or exchange
offer); or (iii)&nbsp;at or subsequent to such time the business combination is approved by the board of directors of such corporation and authorized at a meeting of stockholders (and not by written consent) by the affirmative vote of at least 66
2/3% of the outstanding voting stock of such corporation not owned by the interested stockholder. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated certificate of incorporation and our
amended and restated bylaws will provide that we must indemnify our directors and officers to the fullest extent authorized by the DGCL. We are expressly authorized to, and do, carry directors&#146; and officers&#146; insurance providing coverage
for our directors, officers and certain employees for some liabilities. We believe that these indemnification provisions and insurance are useful to attract and retain qualified directors and executive directors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The limitation on liability and indemnification provisions in our certificate of incorporation and bylaws may discourage stockholders from bringing a lawsuit against
directors for breach of their fiduciary duties. These provisions may also have the effect of reducing the likelihood of derivative litigation against directors and officers, even though such an action, if successful, might otherwise benefit us and
our stockholders. In addition, your investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Listing </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to apply to list our common stock on the
Nasdaq Global Market under the symbol &#147;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#148;. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Transfer Agent and Registrar </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The transfer agent and registrar for our common stock is
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. The transfer agent and registrar&#146;s address
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">168 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_19"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, there has been no public market for our common stock, and although we expect that our common stock will be approved for listing on the Nasdaq
Global Market, we cannot assure investors that there will be an active public market for our common stock following this offering. We cannot predict what effect, if any, sales of our shares in the public market or the availability of shares for sale
will have on the market price of our common stock. Future sales of substantial amounts of common stock in the public market, including shares issued upon exercise of outstanding options, or the perception that such sales may occur, however, could
adversely affect the market price of our common stock and also could adversely affect our future ability to raise capital through the sale of our common stock or other equity-related securities of ours at times and prices we believe appropriate.
</P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon completion of this offering, based on our shares outstanding as of September 30, 2021 and after giving effect to the conversion of all the 136,422,468
shares of our redeemable convertible preferred stock outstanding at September 30, 2021,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of our common stock will be outstanding, or
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares of common stock if the underwriters exercise their option to purchase additional shares in full. All of the shares of common stock expected to be sold in this offering
will be freely tradable without restriction or further registration under the Securities Act unless held by our &#147;affiliates,&#148; as that term is defined in Rule&nbsp;144 under the Securities Act. The remaining outstanding shares of our common
stock will be deemed &#147;restricted securities&#148; as that term is defined under Rule&nbsp;144. Restricted securities may be sold in the public market only if their offer and sale is registered under the Securities Act or if the offer and sale
of those securities qualify for an exemption from registration, including exemptions provided by Rules 144 and 701 under the Securities Act, which are summarized below. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a result of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions described below
and the provisions of Rules 144 or 701 and no exercise of the underwriters&#146; option to purchase additional shares, the shares of our common stock that will be deemed &#147;restricted securities&#148; will be available for sale in the public
market following the completion of this offering as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares will be eligible for sale on the date of
this prospectus; and </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares will be eligible for sale upon expiration
of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements and market <FONT STYLE="white-space:nowrap">stand-off</FONT> provisions described below, beginning more than 180 days after the date of this prospectus. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements and Market <FONT STYLE="white-space:nowrap">Stand-off</FONT> Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our officers, directors and the holders of substantially all of our capital stock and options have entered into market <FONT STYLE="white-space:nowrap">stand-off</FONT>
agreements with us and have entered into or will enter into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters, subject to certain exceptions, not to dispose of or hedge any of their common stock or securities
convertible into or exchangeable for shares of common stock during the period from the date of this prospectus continuing through the date 180 days after the date of this prospectus, except with the prior consent of&nbsp;Jefferies LLC and SVB
Leerink LLC. See the section titled &#147;Underwriting&#148; for additional information. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule&nbsp;144 </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rule&nbsp;144, as currently in effect, generally provides that, once we have been subject to the public company reporting requirements of Section&nbsp;13 or
Section&nbsp;15(d) of the Exchange Act for at least 90 days, a stockholder who is not deemed to have been one of our affiliates at any time during the preceding three months and who has beneficially owned the shares of our capital stock proposed to
be sold for at least six months is entitled to sell such shares in reliance upon Rule&nbsp;144 without complying with the volume limitation, manner of sale or notice conditions of Rule&nbsp;144. If such stockholder has beneficially owned the shares
of our capital stock proposed to be sold for at least one year, then such person is entitled to sell such shares in reliance upon Rule&nbsp;144 without complying with any of the conditions of Rule&nbsp;144. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rule&nbsp;144 also provides that a stockholder who is deemed to have been one of our affiliates at any time during the preceding 90 days and who has beneficially owned
the shares of our common stock proposed to be sold for at least </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">169 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
six months is entitled to sell such shares in reliance upon Rule&nbsp;144 within any three-month period beginning 90 days after the date of this prospectus a number of shares that does not exceed
the greater of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">1% of the number of shares of our capital stock then outstanding, which will equal shares immediately after the completion
of this offering, assuming no exercise by the underwriters of their option to purchase additional shares; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The average weekly trading volume of our common stock during the four calendar weeks preceding the filing of a notice on
Form 144 with respect to such sale. </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Sales of our capital stock made in reliance upon Rule&nbsp;144 by a stockholder who is deemed to have been
one of our affiliates at any time during the preceding 90 days are also subject to the current public information, manner of sale and notice conditions of Rule&nbsp;144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule&nbsp;701 </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Rule&nbsp;701 generally provides that, once we have been
subject to the public company reporting requirements of Section&nbsp;13 or Section&nbsp;15(d) of the Exchange Act for at least 90 days, a stockholder who purchased shares of our common stock pursuant to a written compensatory benefit plan or
contract and who is not deemed to have been one of our affiliates at any time during the preceding three months may sell such shares&nbsp;(to the extent such shares are not subject to
<FONT STYLE="white-space:nowrap">a&nbsp;lock-up&nbsp;agreement)</FONT> in reliance upon Rule&nbsp;144 without complying with the current public information or holding period conditions of Rule&nbsp;144. Rule&nbsp;701 also provides that a stockholder
who purchased shares of our common stock pursuant to a written compensatory benefit plan or contract and who is deemed to have been one of our affiliates during the preceding 90 days may sell such shares under Rule&nbsp;144 without complying with
the holding period condition of Rule&nbsp;144&nbsp;(subject to <FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;agreement</FONT> referred to above, if applicable). However, all stockholders who purchased shares of our common stock pursuant to
a written compensatory benefit plan or contract are required to wait until 90 days after the date of this prospectus before selling such shares pursuant to Rule&nbsp;701&nbsp;(subject to
<FONT STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;agreements</FONT> and market <FONT STYLE="white-space:nowrap">stand-off</FONT> agreements referred to above, if applicable). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the completion of this offering, the holders
of up to 136,422,468 shares of our common stock will be entitled to certain rights with respect to the registration of such shares under the Securities Act. The registration of these shares of our common stock under the Securities Act would result
in these shares becoming eligible for sale in the public market without restriction under the Securities Act immediately upon the effectiveness of such registration, subject to the Rule&nbsp;144 limitations applicable to affiliates. See the section
titled &#147;Description of Capital Stock&#151;Registration Rights&#148; for a description of these registration rights. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Statement </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After the completion of this offering, we intend to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> under the Securities Act to
register all of the shares of our common stock subject to equity awards outstanding or reserved for issuance under our equity compensation plans. The shares of our common stock covered by such registration statement will be eligible for sale in the
public market without restriction under the Securities Act immediately upon the effectiveness of such registration statement, subject to vesting restrictions, the conditions of Rule&nbsp;144 applicable to affiliates, and any applicable market <FONT
STYLE="white-space:nowrap">stand-off</FONT> agreements and <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements. See the section titled &#147;Executive Compensation&#151;Employee Benefit and Stock Plans&#148; for a description of our equity
compensation plans. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">170 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_20"></A>MATERIAL U.S. FEDERAL INCOME TAX CONSIDERATIONS FOR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> HOLDERS OF OUR&nbsp;COMMON&nbsp;STOCK </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a summary of the material U.S. federal income tax
consequences of the ownership and disposition of our common stock acquired in this offering by a <FONT STYLE="white-space:nowrap">&#147;non-U.S.</FONT> holder&#148; (as defined below), but does not purport to be a complete analysis of all the
potential tax considerations relating thereto. This summary is based upon the provisions of the U.S. Internal Revenue Code of 1986, as amended (the Code), Treasury Regulations promulgated thereunder, administrative rulings and judicial decisions,
all as of the date hereof. These authorities may be changed, possibly retroactively, so as to result in U.S. federal income tax consequences different from those set forth below. We have not sought, and do not intend to seek, any ruling from the
Internal Revenue Service (IRS), with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements and conclusions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This summary also does not address the tax considerations arising under the laws of any <FONT STYLE="white-space:nowrap">non-U.S.,</FONT> state or local jurisdiction or
under U.S. federal gift and estate tax laws. In addition, this discussion does not address tax considerations applicable to an investor&#146;s particular circumstances or to investors that may be subject to special tax rules, including, without
limitation: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Banks, insurance companies or other financial institutions (except to the extent specifically set forth below), regulated
investment companies, real estate investment trusts or other financial institutions; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Persons subject to the alternative minimum tax or the tax on net investment income; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt"><FONT STYLE="white-space:nowrap">Tax-exempt</FONT> organizations or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Pension plans and <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Controlled foreign corporations, passive foreign investment companies and corporations that accumulate earnings to avoid
U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Brokers or dealers in securities or currencies; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Traders in securities or other persons that elect to use a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">mark-to-market</FONT></FONT> method of accounting for their securities holdings; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Persons that own, or are deemed to own, more than five percent of our capital stock (except to the extent specifically set
forth below); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">U.S. expatriates or certain former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Persons who hold our common stock as a position in a hedging transaction, &#147;straddle,&#148; &#147;conversion
transaction&#148; or other risk reduction transaction or integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Persons who hold or receive our common stock pursuant to the exercise of any option or otherwise as compensation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Persons who do not hold our common stock as a capital asset within the meaning of Section&nbsp;1221 of the Code
(generally, property held for investment); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Persons subject to special tax accounting rules as a result of any item of gross income with respect to our common stock
being taken into account in an &#147;applicable financial statement&#148; as defined in Section&nbsp;451(b) of the Code; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Persons deemed to sell our common stock under the constructive sale provisions of the Code. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, if a partnership, entity or arrangement classified as a partnership or flow-through entity for U.S. federal income tax purposes holds our common stock, the
tax treatment of a partner generally will depend on the status of the partner and upon the activities of the partnership or other entity. A partner in a partnership or other such entity that will hold our common stock should consult his, her or its
own tax advisor regarding the tax consequences of the ownership and disposition of our common stock through a partnership or other such entity, as applicable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>You are urged to consult your tax advisor with respect to the application of the U.S. federal income tax laws to your particular situation, as well as any tax
consequences of the purchase, ownership and disposition of our common stock arising under the U.S. federal gift or estate tax rules or under the laws of any state, local, <FONT STYLE="white-space:nowrap">non-U.S.</FONT> or other taxing jurisdiction
or under any applicable tax treaty. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">171 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder Defined </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For purposes of this discussion, you are a <FONT STYLE="white-space:nowrap">&#147;non-U.S.</FONT> holder&#148; if you are a beneficial owner of our common stock that,
for U.S. federal income tax purposes, is not a partnership and is not: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">An individual who is a citizen or resident of the United States (for U.S. federal income tax purposes);
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A corporation or other entity taxable as a corporation created or organized in the United States or under the laws of the
United States or any political subdivision thereof, or otherwise treated as such for U.S. federal income tax purposes; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">An estate whose income is subject to U.S. federal income tax regardless of its source; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A trust (x)&nbsp;whose administration is subject to the primary supervision of a U.S. court and that has one or more U.S.
persons who have the authority to control all substantial decisions of the trust or (y)&nbsp;that has made a valid election under applicable Treasury Regulations to be treated as a U.S. person. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Distributions </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As described in the section titled &#147;Dividend
Policy,&#148; we have never declared or paid cash dividends on our common stock, and we do not anticipate paying any dividends on our common stock following the completion of this offering. However, if we do make distributions on our common stock,
those payments will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. To the extent those distributions exceed
both our current and our accumulated earnings and profits, the excess will constitute a return of capital and will first reduce your basis in our common stock, but not below zero, and then will be treated as gain from the sale of stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the discussions below on effectively connected income, Foreign Account Tax Compliance Act (FATCA), and backup withholding, any dividend paid to you generally
will be subject to U.S. federal withholding tax either at a rate of 30% of the gross amount of the dividend or such lower rate as may be specified by an applicable income tax treaty between the United States and your country of residence. In order
to receive a reduced treaty rate, you must provide us with an IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or other appropriate version of IRS
Form <FONT STYLE="white-space:nowrap">W-8,</FONT> including any required attachments and your taxpayer identification number, certifying qualification for the reduced rate. Under applicable Treasury Regulations, we may withhold up to 30% of the
gross amount of the entire distribution even if the amount constituting a dividend, as described above, is less than the gross amount. If you are eligible for a reduced rate of U.S. federal withholding tax pursuant to an income tax treaty, you may
obtain a refund of any excess amounts withheld by filing an appropriate claim for refund with the IRS. If you hold our common stock through a financial institution or other agent acting on your behalf, you will be required to provide appropriate
documentation to the agent, which then will be required to provide certification to us or our paying agent, either directly or through other intermediaries. You should consult your tax advisors regarding your entitlement to benefits under an
applicable tax treaty. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Dividends received by you that are treated as effectively connected with your conduct of a U.S. trade&nbsp;or&nbsp;business (and, if
required by an applicable income tax treaty, such dividends are attributable to a&nbsp;permanent establishment or fixed base maintained by you in the United States) are generally exempt from&nbsp;the 30% U.S. federal withholding tax, subject to the
discussions below on backup withholding and FATCA&nbsp;withholding. In order to obtain this exemption, you must provide us with a properly executed <FONT STYLE="white-space:nowrap">IRS&nbsp;Form&nbsp;W-8ECI</FONT> or other applicable IRS Form <FONT
STYLE="white-space:nowrap">W-8</FONT> properly certifying such exemption. Such effectively connected dividends, although not subject to U.S. federal withholding tax, are taxed at the same graduated rates applicable to U.S. persons, net of certain
deductions and credits, subject to an applicable income tax treaty providing otherwise. In addition, if you are a corporate <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder, dividends you receive that are effectively connected with your
conduct of a U.S. trade or business may also be subject to a branch profits tax at a rate of 30% or such lower rate as may be specified by an applicable income tax treaty between the United States and your country of residence. You should consult
your tax advisor regarding the tax consequences of the ownership and disposition of our common stock, including any applicable tax treaties that may provide for different rules. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">172 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Gain on Disposition of Common Stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the discussions below regarding backup withholding and FATCA withholding, you generally will not be required to pay U.S. federal income tax on any gain
realized upon the sale or other disposition of our common stock unless: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The gain is effectively connected with your conduct of a U.S. trade or business (and, if an applicable income tax treaty
so provides, the gain is attributable to a permanent establishment or fixed base maintained by you in the United States); </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">You are a <FONT STYLE="white-space:nowrap">non-resident</FONT> alien individual who is present in the United States for a
period or periods aggregating 183 days or more during the calendar year in which the sale or disposition occurs and certain other conditions are met; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Our common stock constitutes a United States real property interest by reason of our status as a &#147;United States real
property holding corporation&#148; (USRPHC) for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding your disposition of, or your holding period for, our common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that we are not currently and will not become a USRPHC for U.S. federal income tax purposes, and the remainder of this discussion so assumes. However,
because the determination of whether we are a USRPHC depends on the fair market value of our U.S. real property interests relative to the fair market value of our U.S. and worldwide real property interests plus our other business assets, there can
be no assurance that we will not become a USRPHC in the future. Even if we become a USRPHC, however, as long as our common stock is regularly traded on an established securities market, your common stock will be treated as U.S. real property
interests only if you actually (directly or indirectly) or constructively hold more than five percent of such regularly traded common stock at any time during the shorter of the five-year period preceding your disposition of, or your holding period
for, our common stock. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you are a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder described in the first bullet above, you will be required to pay
tax on the gain derived from the sale (net of certain deductions and credits) under regular graduated U.S. federal income tax rates, and a corporate <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder described in the first bullet above also may
be subject to the branch profits tax at a 30% rate, or such lower rate as may be specified by an applicable income tax treaty. If you are an individual <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder described in the second bullet above, you
will be subject to tax at 30% (or such lower rate specified by an applicable income tax treaty) on the gain derived from the sale, which gain may be offset by U.S. source capital losses for the year, provided you have timely filed U.S. federal
income tax returns with respect to such losses. You should consult your tax advisor regarding any applicable income tax or other treaties that may provide for different rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Backup Withholding and Information Reporting </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Generally, we must report
annually to the IRS the amount of dividends paid to you, your name and address and the amount of tax withheld, if any. A similar report will be sent to you. Pursuant to applicable income tax treaties or other agreements, the IRS may make these
reports available to tax authorities in your country of residence. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Payments of dividends on or of proceeds from the disposition of our common stock made to you may
be subject to information reporting and backup withholding at a current rate of 24% unless you establish an exemption, for example, by properly certifying your <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status on a properly completed IRS Form <FONT
STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or another appropriate version of IRS Form <FONT STYLE="white-space:nowrap">W-8.</FONT> Notwithstanding the
foregoing, backup withholding and information reporting may apply if either we or our paying agent has actual knowledge, or reason to know, that you are a U.S. person. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Backup withholding is not an additional tax; rather, the U.S. federal income tax liability of persons subject to backup withholding will be reduced by the amount of tax
withheld. If withholding results in an overpayment of taxes, a refund or credit may generally be obtained from the IRS, provided that the required information is furnished to the IRS in a timely manner. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">173 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Foreign Account Tax Compliance Act (FATCA) </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the following paragraph, provisions of the Code commonly referred to as FATCA, Treasury Regulations issued thereunder and official IRS guidance generally
impose a U.S. federal withholding tax of 30% on dividends on, and the gross proceeds from a sale or other disposition of, our common stock paid to a &#147;foreign financial institution&#148; (as specially defined under these rules), unless otherwise
provided by the Treasury Secretary or such institution enters into an agreement with the U.S. government to, among other things, withhold on certain payments and to collect and provide to the U.S. tax authorities certain information regarding the
U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or otherwise establishes an exemption. Subject to the
following paragraph, FATCA also generally imposes a U.S. federal withholding tax of 30% on dividends on and the gross proceeds from a sale or other disposition of our common stock paid to a <FONT STYLE="white-space:nowrap">&#147;non-financial</FONT>
foreign entity&#148; (as specially defined under these rules) unless otherwise provided by the Tresury Secretary or such entity provides the withholding agent with a certification identifying the substantial direct and indirect U.S. owners of the
entity, certifies that it does not have any substantial U.S. owners, or otherwise establishes an exemption. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The withholding obligations under FATCA generally apply
to dividends on our common stock. The withholding tax will apply regardless of whether the payment otherwise would be exempt from U.S. nonresident and backup withholding tax, including under the other exemptions described above. Under certain
circumstances, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder might be eligible for refunds or credits of such taxes. The Treasury Secretary has issued proposed Treasury Regulations which, if finalized in their present form, would
eliminate withholding under FATCA with respect to payment of gross proceeds from a sale or other disposition of our common stock. In the preamble to such proposed Treasury Regulations, the Treasury Secretary stated that taxpayers (including
applicable withholding agents) may generally rely on the proposed regulations until final Treasury Regulations are issued. An intergovernmental agreement between the United States and an applicable foreign country may modify the requirements
described in this section. Prospective investors should consult with their own tax advisors regarding the application of FATCA withholding to their investment in, and ownership and disposition of, our common stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>The preceding discussion of U.S. federal tax considerations is for general information only. It is not tax advice to investors in their particular circumstances.
Each prospective investor should consult his, her or its own tax advisor regarding the particular U.S. federal, state and local and <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax consequences of purchasing, holding and disposing of our common
stock, including the consequences of any proposed change in applicable laws. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">174 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_21"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the terms and conditions set forth in the underwriting agreement, dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022, among us, Jefferies LLC, SVB Leerink LLC, Barclays Capital Inc. and William Blair &amp; Company, L.L.C. as the
representatives of the underwriters named below and the joint book-running managers of this offering, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the respective
number of shares of common stock shown opposite its name below: </P>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>UNDERWRITER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">SVB Leerink LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Barclays Capital Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">William Blair &amp; Company, L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters
of officers&#146; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the shares of common stock if any of them are purchased. If an
underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be terminated. We have agreed to indemnify the underwriters and certain of
their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the common stock as permitted by applicable
laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no assurance can be given as to the
liquidity of the trading market for the common stock, that you will be able to sell any of the common stock held by you at a particular time or that the prices that you receive when you sell will be favorable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters are offering the shares of common stock subject to their acceptance of the shares of common stock from us and subject to prior sale. The underwriters
reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. In addition, the underwriters have advised us that they do not intend to confirm sales to any account over which they exercise
discretionary authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Commission and Expenses </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have
advised us that they propose to offer the shares of common stock to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers, which may include the underwriters, at that price less a
concession not in excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock. The underwriters may allow, and certain dealers may reallow, a discount from the concession not in excess of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share of common stock to certain brokers and dealers. After the offering, the initial public offering price, concession and reallowance to dealers may be reduced by the
representatives. No such reduction will change the amount of proceeds to be received by us as set forth on the cover page of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">175 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table shows the public offering price, the underwriting discounts and commissions that we are to pay the
underwriters and the proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional shares. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER&nbsp;SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT&nbsp;OPTION<BR>TO&nbsp;PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH&nbsp;OPTION&nbsp;TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT&nbsp;OPTION<BR>TO&nbsp;PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH&nbsp;OPTION&nbsp;TO<BR>PURCHASE<BR>ADDITIONAL<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Underwriting discounts and commissions paid by&nbsp;us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We will reimburse the underwriters for their expenses related to the review of this offering by the Financial Industry Regulatory Authority, Inc. (FINRA) in an amount up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Determination of Offering Price </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, there has not been a public market for our common stock. Consequently, the initial public offering price for our common stock will be determined
by negotiations between us and the representatives. Among the factors to be considered in these negotiations will be prevailing market conditions, our financial information, market valuations of other companies that we and the underwriters believe
to be comparable to us, estimates of our business potential, the present state of our development and other factors deemed relevant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We offer no assurances that
the initial public offering price will correspond to the price at which the common stock will trade in the public market subsequent to the offering or that an active trading market for the common stock will develop and continue after the offering.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to apply to have our common stock listed on the
Nasdaq Global Market under the trading symbol &#147;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#148;. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stamp Taxes </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you purchase shares of common stock offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws and practices of the country
of purchase, in addition to the offering price listed on the cover page of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Option to Purchase Additional Shares </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase, from time to time, in whole or in part, up to an
aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares from us at the public offering price set forth on the cover page of this prospectus, less underwriting discounts and commissions. If the underwriters
exercise this option, each underwriter will be obligated, subject to specified conditions, to purchase a number of additional shares proportionate to that underwriter&#146;s initial purchase commitment as indicated in the table above. This option
may be exercised only if the underwriters sell more shares than the total number set forth on the cover page of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>No Sales of Similar Securities
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, our officers, directors and holders of all or substantially all our outstanding capital stock and other securities have agreed, subject to specified
exceptions, not to directly or indirectly: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open
&#147;put equivalent position&#148; within the meaning of Rule <FONT STYLE="white-space:nowrap">16a-l(h)</FONT> under the Exchange Act, or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">176 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Otherwise dispose of any shares of common stock, options or warrants to acquire shares of common stock, or securities
exchangeable or exercisable for or convertible into shares of common stock currently or hereafter owned either of record or beneficially, or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Publicly announce an intention to do any of the foregoing for a period of 180 days after the date of this prospectus
without the prior written consent of Jefferies LLC and SVB Leerink LLC. </P></TD></TR></TABLE>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This restriction terminates after the close of trading of the common
stock on and including the 180th&nbsp;day after the date of this prospectus. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Jefferies LLC and SVB Leerink LLC may, in their sole discretion and at any time or
from time to time before the termination of <FONT STYLE="white-space:nowrap">the&nbsp;180-day&nbsp;period</FONT> release all or any portion of the securities subject <FONT STYLE="white-space:nowrap">to&nbsp;lock-up&nbsp;agreements.</FONT> There are
no existing agreements between the underwriters and any of our stockholders who will execute <FONT STYLE="white-space:nowrap">a&nbsp;lock-up&nbsp;agreement</FONT> providing consent to the sale of shares prior to the expiration of <FONT
STYLE="white-space:nowrap">the&nbsp;lock-up&nbsp;period.</FONT> </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stabilization </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that they, pursuant to Regulation&nbsp;M under the Exchange Act, certain persons participating in the offering may engage in short sale
transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of the common stock at a
level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either &#147;covered&#148; short sales or &#147;naked&#148; short sales. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional shares of our common stock in this
offering. The underwriters may close out any covered short position by either exercising their option to purchase additional shares of our common stock or purchasing shares of our common stock in the open market. In determining the source of shares
to close out the covered short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase shares through the option to purchase
additional shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Naked&#148; short sales are sales in excess of the option to purchase additional shares of our common stock. The underwriters must close
out any naked short position by purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the shares of our common stock in the
open market after pricing that could adversely affect investors who purchase in this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A stabilizing bid is a bid for the purchase of shares of common
stock on behalf of the underwriters for the purpose of fixing or maintaining the price of the common stock. A syndicate covering transaction is the bid for or the purchase of shares of common stock on behalf of the underwriters to reduce a short
position incurred by the underwriters in connection with the offering. Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our
common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common stock may be higher than the price that might otherwise exist in the open market. A penalty bid is an arrangement
permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the common stock originally sold by such syndicate member are purchased in a syndicate covering transaction and
therefore have not been effectively placed by such syndicate member. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither we nor any of the underwriters make any representation or prediction as to the
direction or magnitude of any effect that the transactions described above may have on the price of our common stock. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued at
any time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters may also engage in passive market making transactions in our common stock on&nbsp;the Nasdaq Global Market&nbsp;in accordance with
Rule&nbsp;103 of Regulation&nbsp;M during a period before the commencement of offers or sales of shares of our common stock in this offering and extending through the completion of distribution. A passive market maker must display its bid at a price
not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must then be lowered when specified purchase limits are exceeded. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">177 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Electronic Distribution </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A
prospectus in electronic format may be made available <FONT STYLE="white-space:nowrap">by&nbsp;e-mail&nbsp;or</FONT> on the web sites or through online services maintained by one or more of the underwriters or their affiliates. In those cases,
prospective investors may view offering terms online and may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of shares of common stock for sale to online brokerage account holders. Any such
allocation for online distributions will be made by the underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#146; web sites and any information contained in any
other web site maintained by any of the underwriters is not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Activities and Relationships </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters and certain of their
respective affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal
investment, hedging, financing and brokerage activities. The underwriters and certain of their respective affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory
services for us and our affiliates, for which they received or will receive customary fees and expenses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the ordinary course of their various business
activities, the underwriters and certain of their respective affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans)
for their own accounts and for the accounts of their respective customers, and such investment and securities activities may involve securities and/or instruments issued by us and our affiliates. If the underwriters or their respective affiliates
have a lending relationship with us, they routinely hedge their credit exposure to us consistent with their customary risk management policies. The underwriters and their respective affiliates may hedge such exposure by entering into transactions
that consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the common stock offered hereby. Any such short positions could adversely
affect future trading prices of the common stock offered hereby. The underwriters and certain of their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express
independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Disclaimers <FONT STYLE="white-space:nowrap">About&nbsp;Non-U.S.&nbsp;Jurisdictions</FONT> </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Canada </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Resale Restrictions </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The distribution of shares of our common stock in Canada is being made only in the provinces of Ontario, Quebec, Alberta and British Columbia on a private placement
basis exempt from the requirement that we prepare and file a prospectus with the securities regulatory authorities in each province where trades of these securities are made. Any resale of the shares of common stock in Canada must be made under
applicable securities laws, which may vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary exemption granted by the applicable Canadian securities
regulatory authority. Purchasers are advised to seek legal advice prior to any resale of the securities. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Representations of Canadian Purchasers </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">By purchasing shares of common stock in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us and the dealer from whom the
purchase confirmation is received that: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The purchaser is entitled under applicable provincial securities laws to purchase the shares of common stock without the
benefit of a prospectus qualified under those securities laws as it is an &#147;accredited investor&#148; as defined under National <FONT STYLE="white-space:nowrap">Instrument&nbsp;45-106&#151;Prospectus</FONT> Exemptions; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The purchaser is a &#147;permitted client&#148; as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103&#151;Registration</FONT> Requirements, Exemptions and Ongoing Registrant Obligations; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">178 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Where required by law, the purchaser is purchasing as principal and not as agent; and </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">The purchaser has reviewed the text above under Resale Restrictions. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Conflicts of Interest </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian purchasers are hereby notified that the
underwriters are relying on the exemption set out in section 3A.3 or 3A.4, if applicable, of National <FONT STYLE="white-space:nowrap">Instrument&nbsp;33-105&#151;</FONT><I>Underwriting Conflicts</I>&nbsp;from having to provide certain conflict of
interest disclosure in this document. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Statutory Rights of Action </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the prospectus (including any
amendment thereto) such as this document contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s
province or territory. The purchaser of these securities in Canada should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Enforcement of Legal Rights </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our directors and officers as well
as the experts named herein may be located outside of Canada and, as a result, it may not be possible for Canadian purchasers to effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and the
assets of those persons may be located outside of Canada and, as a result, it may not be possible to satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of
Canada. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Taxation and Eligibility for Investment </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian purchasers of
shares of common stock should consult their own legal and tax advisors with respect to the tax consequences of an investment in the shares of common stock in their particular circumstances and about the eligibility of the shares of common stock for
investment by the purchaser under relevant Canadian legislation. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Australia </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This Offering Memorandum is not a disclosure document for the purposes of Australia&#146;s Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not been
lodged with the Australian Securities&nbsp;&amp; Investments Commission and is only directed to the categories of exempt persons set out below. Accordingly, if you receive this Offering Memorandum in Australia: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You confirm and warrant that you are either: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A &#147;sophisticated investor&#148; under section 708(8)(a) or (b)&nbsp;of the Corporations Act; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A &#147;sophisticated investor&#148; under section 708(8)(c) or (d)&nbsp;of the Corporations Act and that you have
provided an accountant&#146;s certificate to the company, which complies with the requirements of section 708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A person associated with the company under section 708(12) of the Corporations Act; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A &#147;professional investor&#148; within the meaning of section 708(11)(a) or (b)&nbsp;of the Corporations Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor
under the Corporations Act any offer made to you under this Offering Memorandum is void and incapable of acceptance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You warrant and agree that you will not offer
any of the securities issued to you pursuant to this Offering Memorandum for resale in Australia within 12 months of those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under
section 708 of the Corporations Act. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>European Economic Area </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In relation to each member state of the European Economic Area (each, a &#147;Relevant State&#148;), no shares have been offered or will be offered pursuant to the
offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which have been approved by the competent authority in that Relevant State or, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">179 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that the shares may
be offered to the public in that Relevant State at any time: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">To any legal entity that is a &#147;qualified investor&#148; as defined under Article 2(e) of the Prospectus Regulation;
</P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">To fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2(e) of the Prospectus
Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P></TD></TR></TABLE>  <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">In any other circumstances falling within Article 1(4) of the Prospectus Regulation, </P></TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">provided that no such offer of securities shall require the Company or any of the representatives to publish a prospectus pursuant to Article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the purposes of this provision, the expression &#147;offer to the
public&#148; in relation to any securities in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to
purchase or subscribe the securities and the expression &#147;Prospectus Regulation&#148; means Regulation EU 2017/1129 (as amended). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This European Economic Area
selling restriction is in addition to any other selling restrictions set out below. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No securities have been offered or sold, and no securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary business
is to buy or sell shares or debentures, whether as principal or agent; or to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong (&#147;SFO&#148;) and any rules made under that Ordinance; or
in other circumstances that do not result in the document being a &#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong (&#147;CO&#148;) or do not constitute an offer or invitation to the public for the purpose of the
CO or the SFO. No document, invitation or advertisement relating to the securities has been issued or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is
directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities, which are or are intended to be disposed of only
to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any rules made under that Ordinance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not
been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus may not be issued, circulated or distributed in Hong Kong, and the securities may not be offered for subscription to members of the public in Hong Kong. Each
person acquiring the securities will be required, and is deemed by the acquisition of the securities, to confirm that he is aware of the restriction on offers of the securities described in this prospectus and the relevant offering documents and
that he is not acquiring, and has not been offered any securities in circumstances that contravene any such restrictions. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Israel </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel
Securities Authority. In Israel, this prospectus is being distributed only to, and is directed only at, and any offer of the shares is directed only at, (i)&nbsp;a limited number of persons in accordance with the Israeli Securities Law and
(ii)&nbsp;investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members
of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50&nbsp;million and &#147;qualified individuals,&#148; each as defined in the Addendum (as it may be amended from time to time), collectively
referred to as qualified investors (in each case, purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors are required to submit
written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Japan </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offering has not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948 of Japan, as amended), or FIEL,
and the Initial Purchaser will not offer or sell any securities, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">180 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity
organized under the laws of Japan), or to others <FONT STYLE="white-space:nowrap">for&nbsp;re-offering&nbsp;or</FONT> resale, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan, except pursuant to an exemption from
the registration requirements of, and otherwise in compliance with, the FIEL and any other applicable laws, regulations and ministerial guidelines of Japan. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Singapore </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not been and will not be lodged or
registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be
circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor under
Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;), (ii)&nbsp;to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to Section&nbsp;275(1A), and in accordance with the conditions
specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person that is: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which
is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">A trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary
of the trust is an individual who is an accredited investor, </P></TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the
beneficiaries&#146; rights and interest (howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the shares pursuant to an offer made under Section&nbsp;275 of the SFA except:
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">To an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising
from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA; </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Where no consideration is or will be given for the transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">Where the transfer is by operation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">As specified in Section&nbsp;276(7) of the SFA; or </P></TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt">&#8718;</FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:9.5pt">As specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations
2005 of Singapore. </P></TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Switzerland </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The securities
may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange (&#147;SIX&#148;) or on any other stock exchange or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the
disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock
exchange or regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither this prospectus nor any other offering or marketing material relating to the offering, the company or the securities have been or will be filed with or
approved by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, and the offer of securities has not
been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (&#147;CISA&#148;). The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers
of securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">181 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>United Kingdom </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No
shares have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the Shares which has been approved by the Financial Conduct Authority, except that the
shares may be offered to the public in the United Kingdom at any time: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(a) to any legal entity which is a qualified investor as defined under Article 2 of the UK
Prospectus Regulation; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(b) to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus Regulation),
subject to obtaining the prior consent of the representatives for any such offer; or </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(c) in any other circumstances falling within Section 86 of the FSMA, </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">provided that no such offer of the shares shall require the Issuer or any Manager to publish a prospectus pursuant to Section 85 of the FSMA or supplement a prospectus
pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to the shares in the United Kingdom means the communication in any form and by any means of
sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or subscribe for any shares and the expression &#147;UK Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it
forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">182 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_22"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The validity of the issuance of our common stock offered in this prospectus will be passed upon for us by Wilson Sonsini Goodrich&nbsp;&amp; Rosati, Professional
Corporation, New York, New York. Wilmer Cutler Pickering Hale and Dorr LLP, New York, New York is acting as counsel for the underwriters. Certain members of, and investment partnerships comprised of members of, and persons associated with, Wilson
Sonsini Goodrich&nbsp;&amp; Rosati, Professional Corporation, own an interest representing less than one percent of the shares of our common stock. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_23"></A>EXPERTS </B></P>  <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Ernst&nbsp;&amp;
Young LLP, independent registered public accounting firm, has audited our consolidated financial statements as of December&nbsp;31, 2019 and 2020, and for the years then ended, as set forth in their report. We have included our consolidated
financial statements in the prospectus and elsewhere in the registration statement in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_24"></A>WHERE YOU CAN FIND ADDITIONAL INFORMATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act with respect to the shares of our
common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement, as permitted by the rules and regulations of the SEC.
For further information with respect to us and our common stock, we refer you to the registration statement, including the exhibits filed as a part of the registration statement. Statements contained in this prospectus concerning the contents of any
contract or any other document is not necessarily complete. If a contract or document has been filed as an exhibit to the registration statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus
relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC maintains an Internet website that contains the registration statement of which this prospectus forms a part, as well as the exhibits
thereto. These documents, along with future reports, proxy statements and other information about us, are available at the SEC&#146;s website, www.sec.gov. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a
result of this offering, we will become subject to the information and reporting requirements of the Exchange Act, and, in accordance with this law, will file periodic reports, proxy statements and other information with the SEC. We also maintain a
website at www.arcellx.com where these materials are available. Upon the completion of this offering, you may access these materials free of charge as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC.
Information contained on, or that can be accessible through, our website is not a part of this prospectus and the inclusion of our website address in this prospectus is an inactive textual reference only. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">183 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc129231_25"></A>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Audited Consolidated Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin129231_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-2</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin129231_2">Consolidated Balance Sheets as of December&nbsp;31, 2019 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin129231_3">Consolidated Statements of Operations and Comprehensive Loss for the Years Ended December&nbsp;31,
 2019 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-4</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin129231_4">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146;
 Deficit for the Years Ended December&nbsp;31, 2019 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-5</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin129231_5">Consolidated Statements of Cash Flows for the Years Ended December&nbsp;
31, 2019 and 2020</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-6</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin129231_6">Notes to the Consolidated Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-7</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Unaudited Condensed Consolidated Financial Statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin129231_7">Condensed Consolidated Balance Sheets as of December&nbsp;
31, 2020 and September&nbsp;30, 2021 (unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-22</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin129231_8">Condensed Consolidated Statements of Operations and Comprehensive Loss for the Nine Months
 Ended September&nbsp;30, 2020 and 2021 (unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-23</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin129231_9">Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146;
 Deficit for the Nine Months Ended September&nbsp;30, 2020 and 2021 (unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-24</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin129231_10">Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September&nbsp;30,
 2020 and 2021 (unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-26</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin129231_11">Notes to Condensed Consolidated Financial Statements (unaudited)</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-27</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-1 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin129231_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the Shareholders and the Board of Directors of Arcellx, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Opinion on the
Financial Statements </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have audited the accompanying consolidated balance sheets of Arcellx, Inc. (the Company) as of December&nbsp;31, 2019 and 2020, the
related consolidated statements of operations and comprehensive loss, changes in redeemable convertible preferred stock and stockholders&#146; deficit and cash flows for the years then ended, and the related notes (collectively referred to as the
consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&nbsp;31, 2019 and 2020, and the results of its operations and
its cash flows for the years then ended in conformity with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Basis for Opinion </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on the Company&#146;s financial
statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal
securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We conducted our audits in accordance with the
standards of the PCAOB and in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are
free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond
to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant
estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">/s/ Ernst&nbsp;&amp; Young LLP </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have served as the Company&#146;s auditor since
2019. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Tysons, Virginia </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">September&nbsp;27, 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-2 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>ARCELLX, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin129231_2"></A>Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands, except share and per share amounts) </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,069</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deposits and other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,078</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,746</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred rent, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred rent, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,866</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Commitments and contingencies (Note 7)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A redeemable convertible preferred stock, par value of $0.001 per share; 29,795,227 shares
authorized, issued and outstanding at December&nbsp;31, 2019 and 2020; liquidation value $29,795 at December&nbsp;31, 2019 and 2020.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series B redeemable convertible preferred stock, par value $0.001 per share; 27,444,339 and 49,402,623
shares authorized, issued and outstanding at December&nbsp;31, 2019 and 2020, respectively; liquidation value of $42,841 and $85,681 at December&nbsp;31, 2019 and 2020, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71,460</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Common stock, par value of $0.001 per share; 98,973,453 shares authorized at December&nbsp;31, 2019 and
2020; 1,407,800 and 1,836,508 shares issued and outstanding at December&nbsp;31, 2019 and 2020, respectively (Note 9)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,047</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">43,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of the consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-3 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>ARCELLX, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin129231_3"></A>Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands, except share and per share amounts) </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,766</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,056</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,040</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,974</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,096</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,974</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,096</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Other income:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15.39</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20.38</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted-average common shares outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,167,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,574,764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of the consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-4 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>ARCELLX, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin129231_4"></A>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands, except share data) </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:7pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>REDEEMABLE CONVERTIBLE PREFERRED STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCKHOLDERS&#146; DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMMON STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ADDITIONAL<BR><FONT STYLE="white-space:nowrap">PAID-IN&nbsp;CAPITAL</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED<BR>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCKHOLDERS&#146;<BR>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Balance at December&nbsp;31, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,795,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,040,865</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(14,935</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Issuance of Series&nbsp;B redeemable convertible preferred stock for cash, net of transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,444,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Issuance of common stock from vesting of restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">366,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,795,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,444,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,407,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33,047</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Issuance of Series&nbsp;B redeemable convertible preferred stock for cash, net of transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,958,284</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Issuance of common stock from vesting of restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">294,683</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:7pt; font-family:ARIAL">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,795,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,402,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,836,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(65,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of the consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-5 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>ARCELLX, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin129231_5"></A>Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands) </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED<BR>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,972</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">629</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current and <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">688</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,333</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,772</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28,662</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(888</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,832</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(888</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of restricted stock purchase awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from the exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Payments of deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,185</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of Series B redeemable convertible preferred stock, net of transaction
costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,801</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Supplemental disclosures of noncash investing and financing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchase of property and equipment included in accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">311</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred offering costs included in accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of the consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-6 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>ARCELLX, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin129231_6"></A>Notes to Consolidated Financial Statements </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1. Nature of the Business </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Organization </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Arcellx, Inc. (Arcellx or the Company) was incorporated in Delaware in December 2014 and is headquartered in Gaithersburg, Maryland. The Company is a clinical-stage
biopharmaceutical company reimagining cell therapy through the development of innovative therapies for patients with cancer and other incurable diseases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company has not commercialized any of its drug candidates and planned commercial operations have not commenced. The Company has incurred significant losses in the development of its drug candidates. The Company has not generated revenues from
product sales. As a result, the Company has consistently reported negative cash flows from operating activities and net losses, had an accumulated deficit of $63.7&nbsp;million at December&nbsp;31, 2020 and expects to continue incurring losses for
the foreseeable future. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidity </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accompanying
consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business.
The propriety of using the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations and potential other funding sources, in addition to cash
on hand, to meet its obligations as they become due. Based on the Company&#146;s expected operating cash requirements and capital expenditures, management believes the Company&#146;s cash on hand as of the date these financial statements are issued,
is adequate to fund operations for at least twelve months from the date that these consolidated financial statements are issued. The Company expects to incur substantial operating losses to continue development of drug candidates, including
preclinical and clinical testing and regulatory approval prior to commercialization. Even if drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company plans to seek additional funding through public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations,
strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all.
The terms of any financing may adversely affect the holdings or the rights of the Company&#146;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs,
product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although management continues to pursue these
funding plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company, if at all, to fund continuing operations past twelve months from the issuance date of these consolidated
financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Basis of Presentation and Consolidation </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accompanying consolidated
financial statements were prepared based on the accrual method of accounting in accordance with U.S. generally accepted accounting principles (GAAP). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as
found in the Accounting Standards Codification (ASC) and Accounting Standards Update (ASU) of the Financial Accounting Standards Board (FASB). The accompanying consolidated financial statements include the accounts of Arcellx and its wholly owned
subsidiary. All significant inter-company accounts and transactions have been eliminated in consolidation. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Use of Accounting Estimates </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of
assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant estimates used in preparing
the accompanying consolidated financial statements include, but are not limited to, estimates related to recoverability of long-lived assets, share-</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-7 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
based compensation, and the valuation of deferred tax assets and liabilities. Although actual results could differ from those estimates, management does not believe that such differences would be
material. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Segment and Geographic Information </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Operating segments
are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The
Company views its operations as and manages its business in one operating segment operating exclusively in the United States. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cash and Cash Equivalents
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company considers all highly liquid investments with an original maturity of three months or less at the date of purchase to be cash equivalents. The
Company deposits its cash primarily in checking and sweep accounts with commercial banks and financial institutions. Cash equivalents consist of money market funds. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Restricted Cash </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is required to maintain cash
collateral on deposit in a segregated money market bank account, as a condition of its lease agreement equal to the required security deposit amount. The bank may restrict withdrawals or transfers by, or on behalf of, the Company. The required
restricted cash reserve totaled $111&nbsp;thousand and $199&nbsp;thousand as of December&nbsp;31, 2019 and 2020, respectively. This amount is presented as <FONT STYLE="white-space:nowrap">non-current</FONT> restricted cash on the accompanying
balance sheets. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table reconciles cash and cash equivalents and restricted cash per the balance sheets to the statements of cash flows (in
thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Concentration of Credit Risk </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Financial instruments that potentially
expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at one accredited financial institution in amounts that exceed federally insured limits. The
Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fair Value
of Financial Instruments </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s financial instruments consist of cash and cash equivalents, accounts payable and accrued expenses.&nbsp;The
fair values of financial instruments approximated their carrying values at December&nbsp;31, 2019 and 2020, due to their short-term nature.&nbsp;The Company accounts for recurring and <FONT STYLE="white-space:nowrap">non-recurring</FONT> fair value
measurements in accordance with FASB ASC 820,<I>&nbsp;Fair Value Measurements and Disclosures</I>&nbsp;(ASC 820). ASC 820 defines fair value, establishes a fair value hierarchy for assets and liabilities measured at fair value, and requires expanded
disclosures about fair value measurements. The ASC 820 hierarchy ranks the quality of reliability of inputs, or assumptions, used in the determination of fair value and requires assets and liabilities carried at fair value to be classified and
disclosed in one of the following three categories: </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Level&nbsp;1&#151;Fair value is determined by using unadjusted quoted prices that are
available in active markets for identical assets and liabilities. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Level&nbsp;2&#151;Fair value is determined by using inputs other than
Level&nbsp;1 quoted prices that are directly or indirectly observable. Inputs can include quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets and liabilities in inactive markets. Related inputs
can also include those used in valuation or other pricing models, such as interest rates and yield curves that can be corroborated by observable market data. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-8 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:ARIAL">Level&nbsp;3&#151;Fair value is determined by inputs that are unobservable and not corroborated by market
data. Use of these inputs involves significant and subjective judgments to be made by a reporting entity&#151;e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more
judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&nbsp;3. A financial instrument&#146;s level within the fair value hierarchy is based on the lowest
level of any input that is significant to the fair value measurement. Refer to related disclosures in Note 3-<I>Fair Value of Financial Instruments.</I> </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Property and Equipment, Net </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Property and equipment are recorded at
cost and depreciated over its estimated useful life using the straight-line method over the estimated useful lives of the related assets or lease term, whichever is shorter. Upon retirement or disposal, the cost and related accumulated depreciation
are removed from the balance sheet and the resulting gain or loss is recognized within operating expenses. Routine expenditures for maintenance and repairs are expensed as incurred. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Estimated useful lives for property and equipment are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>ESTIMATED&nbsp;USEFUL&nbsp;LIFE</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">7 years</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Lesser of estimated useful life or remaining lease term</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Impairment of Long-Lived Assets </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company reviews the
recoverability of its long-lived asset group when events or changes in circumstances occur that indicate that the carrying value of the asset group may not be recoverable. Recoverability of the long-lived asset group is measured by a comparison of
the carrying amount of the asset to future undiscounted net cash flows expected to be generated by the asset group. If these cash flows are less than the carrying value of such asset group, the Company then determines the fair value of the
underlying asset group. Any impairment loss to be recognized is measured by the amount by which the carrying amount of the asset group exceeds the estimated fair value of the asset group. There were no impairment losses recognized during the years
ended December&nbsp;31, 2019 or 2020. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Redeemable Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s redeemable convertible preferred stock is classified outside of stockholders&#146; deficit because the shares contain deemed liquidation rights that
are a contingent redemption feature not solely within the control of the Company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s policy is to not accrete the carrying value and related
issuance costs of the redeemable convertible preferred stock to its redemption value until such redemption becomes probable. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and Development
Expenses </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development costs are expensed as they are incurred. Research and development expenses consist primarily of salaries and benefits
of research and development personnel, costs related to research activities, preclinical studies, and overhead and facility-related costs. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company may be
obligated to make upfront payments upon execution of certain research and development agreements. Advance payments, including nonrefundable amounts, for goods or services that will be used or rendered for future research and development activities
are deferred. Such amounts are recognized as expense as the related goods are delivered or the related services are performed, or such time when the Company does not expect the goods to be delivered or services to be performed. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Deferred Offering Costs </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company capitalized certain legal,
professional accounting and other third-party fees that were directly associated with <FONT STYLE="white-space:nowrap">in-process</FONT> equity financing as deferred offering costs. Upon consummation of the equity financing, these costs will be
recorded in shareholders&#146; equity (deficit) as a reduction of proceeds. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-9 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical Trial Accrual and Expenses </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company makes payments in connection with clinical trials under contracts with contract research organizations that support conducting and managing clinical trials.
The financial terms of these agreements are subject to negotiation and vary from contract to contract and may result in uneven payment flows. Generally, these agreements set forth the scope of work to be performed at a fixed fee, unit price or on a
time and materials basis. A portion of the obligation to make payments under these contracts depends on factors such as the successful enrollment or treatment of patients or the completion of other clinical trial milestones. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Expenses related to clinical trials are accrued based on estimates and/or representations from service providers regarding work performed, including actual level of
patient enrollment, completion of patient studies and progress of the clinical trials. Other incidental costs related to patient enrollment or treatment are accrued when reasonably certain. Similarly, the Company accrues expenses related to the work
performed by contract manufacturing organizations based on the progress of the work performed. If the amounts the Company is obligated to pay under clinical trial agreements and manufacturing agreements are modified (for instance, as a result of
changes in the clinical trial protocol or scope of work to be performed), the accruals are adjusted accordingly. Revisions to contractual payment obligations are charged to expense in the period in which the facts that give rise to the revision
become reasonably certain. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Share-Based Compensation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company accounts for its share-based compensation in accordance with ASC Topic 718, <I>Compensation&#151;Stock Compensation </I>(ASC 718). ASC 718 requires all share-based payments to employees, and directors, including grants of incentive stock
options, nonqualified stock options, restricted stock awards, unrestricted stock awards or restricted stock units to employees, and directors of the Company, to be recognized as expense in the statement of operations and comprehensive loss based on
their grant date fair values ratably over the requisite service period. The Company has elected to account for forfeitures as they occur. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company estimates the
fair value of options granted using the Black-Scholes-Merton (Black-Scholes) option pricing model for stock option grants to both employees and <FONT STYLE="white-space:nowrap">non-employees</FONT> and the fair value of common stock to determine the
fair value of restricted stock. The Company will reconsider the use of the Black-Scholes option pricing model if additional information becomes available in the future that indicates another model would be more appropriate or if grants issued in
future periods have characteristics that prevent their value from being reasonably estimated using this model. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Black-Scholes option pricing model requires
inputs based on certain subjective assumptions. A discussion of management&#146;s methodology for developing the assumptions used in the valuation model follow: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Fair Value of Common Stock -</I> Given the lack of an active public market for the common stock, the Company has from time to time engaged an independent valuation
firm to assist management in determining the fair value of the common stock. In the absence of a public trading market, and as a clinical-stage company with no significant revenues, the Company believes that it is appropriate to consider a range of
factors to determine the fair market value of the common stock at each grant date. In determining the fair value of its common stock, the Company uses methodologies, approaches, and assumptions consistent with the American Institute of Certified
Public Accountants&#146; (AICPA) Audit and Accounting Practice Aid Series: Valuation of Privately Held Company Equity Securities Issued as Compensation. In addition, the Company considered various objective and subjective factors, along with input
from the independent third-party valuation firm. The factors included (1)&nbsp;the achievement of clinical and operational milestones by the Company; (2)&nbsp;the significant risks associated with the Company&#146;s stage of development;
(3)&nbsp;capital market conditions for life science companies, particularly similarly situated, privately held, early-stage life science companies; (4)&nbsp;the Company&#146;s available cash, financial condition, and results of operations;
(5)&nbsp;the most recent sales of the Company&#146;s redeemable convertible preferred stock; and (6)&nbsp;the preferential rights of the outstanding redeemable convertible preferred stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Expected Dividend Yield&#151;</I>The Company has never declared or paid dividends and has no plans to do so in the foreseeable future. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Expected Volatility&#151;</I>Due to the lack of a public market for the Company&#146;s common stock and lack of company-specific historical and implied volatility
data, the Company has based its computation of expected volatility on the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-10 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
historical volatility of a representative group of public companies with similar characteristics to the Company (e.g., public entities of similar size, complexity, stage of development and
industry focus). The historical volatility is calculated based on a period of time commensurate with expected term assumption. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Risk-Free Interest
Rate&#151;</I>The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Expected
Term&#151; </I>The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&nbsp;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical
exercise data to provide a reasonable basis upon which to estimate the expected term. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Income Taxes </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax
consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities are measured using enacted tax rates expected
to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are
established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> that the deferred tax assets will not be realized. In
evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">jurisdiction-by-jurisdiction</FONT></FONT> basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a valuation allowance against its net
deferred tax assets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Liabilities are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax
position is considered <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax
positions are recognized in the provision of income taxes. As of December&nbsp;31, 2019 and 2020, the Company had no interest or penalties related to uncertain income tax benefits. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenue Recognition </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company accounts for contracts with
customers in accordance with Accounting Standards Codification, or ASC, Topic 605,<I>&nbsp;Revenue Recognition</I> (ASC 605), and created a new Topic 606,<I>&nbsp;Revenue from Contracts with Customers </I>(ASC 606). Under ASC 606, the Company will
recognize revenue when it transfers control of promised goods or services to customers in an amount that reflects what the Company expects to receive in exchange for the goods or services, and the performance obligation(s) under the related
contracts are satisfied. To determine revenue recognition for contracts with customers the Company performs the following five steps: (i)&nbsp;identify the promised goods or services in the contract; (ii)&nbsp;identify the performance obligations in
the contract, including whether they are distinct in the context of the contract; (iii)&nbsp;determine the transaction price, including the constraint on variable consideration; (iv)&nbsp;allocate the transaction price to the performance obligations
in the contract; and (v)&nbsp;recognize revenue when (or as) the Company satisfies each performance obligation. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comprehensive Loss </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Comprehensive loss comprises net loss and other changes in equity that are excluded from net loss. For the years ended December&nbsp;31, 2019 and 2020, the
Company&#146;s net loss was equal to comprehensive loss and, accordingly, no additional disclosure is presented. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Emerging Growth Company Status </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is an emerging growth company, as defined in the Jumpstart Our Business Startups Act of 2012 (the JOBS Act). Under the JOBS Act, emerging growth companies
can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying
with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it is (i)&nbsp;no longer an emerging growth company or (ii)&nbsp;affirmatively and irrevocably opts out
of the extended transition period provided in the JOBS Act. As a result, these consolidated financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-11 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Recently Issued Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In February 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-02,</FONT> <I>Leases (Topic</I><I></I><I>&nbsp;842)</I>. The guidance in this ASU supersedes
the leasing guidance in Topic 840, <I>Leases</I>. Under the new guidance, lessees are required to recognize lease assets and lease liabilities on the balance sheet for all leases with terms longer than 12&nbsp;months. Leases will be classified as
either finance or operating, with classification affecting the pattern of expense recognition in the income statement. The new standard is effective for fiscal years beginning after December&nbsp;15, 2019 and early adoption is permitted. In November
2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">2019-10</FONT> deferring the effective date for private entities for fiscal years beginning after December&nbsp;15, 2020, and interim periods within fiscal years beginning after
December&nbsp;15, 2021. In June 2020, the FASB issued ASU <FONT STYLE="white-space:nowrap">2020-05</FONT> deferring the effective date for private entities for fiscal years beginning after December&nbsp;15, 2021, and interim periods within fiscal
years beginning after December&nbsp;15, 2022. The Company is currently reviewing its leases and other contracts to determine if the adoption of this guidance will have a material impact on its consolidated financial statements. The Company expects
that the adoption of this guidance will change the way it accounts for its operating leases and will result in recording the future benefits of those leases and the related minimum lease payments on the Company&#146;s balance sheet. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-13,</FONT> <I>Financial Instruments&#151;Credit Losses (Topic 326) (ASU <FONT
STYLE="white-space:nowrap">2016-13)</FONT></I>, which modifies the measurement of expected credit losses on certain financial instruments. In addition, for
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities, the standard eliminates the concept of other-than-temporary impairment and requires the recognition of an allowance for credit losses
rather than reductions in the amortized cost of the securities. The standard is effective for interim and annual periods beginning after December&nbsp;15, 2022 and requires a modified-retrospective approach with a cumulative-effect adjustment to
retained earnings as of the beginning of the first reporting period. Early adoption is permitted. Based on the composition of the Company&#146;s investment portfolio, current market conditions and historical credit loss activity, the adoption of ASU
<FONT STYLE="white-space:nowrap">2016-13</FONT> is not expected to have any impact on its financial position, results of operations or the related disclosures. The Company will continue monitoring through the effective date of the standard. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has evaluated all other ASUs issued through the date the consolidated financial statements were issued and believes that the adoption of these will not have
a material impact on the Company&#146;s consolidated financial statements. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Recently Adopted Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">2018-07,</FONT><I> Compensation&#151;Stock Compensation: Improvements to Nonemployee Share-Based
Payment Accounting.</I> The update expands the scope of ASC Topic&nbsp;718, <I>Compensation&#151;Stock Compensation</I> (ASC&nbsp;718), to include share-based payment transactions for acquiring goods and services from nonemployees. The ASU
simplifies the accounting for nonemployee stock-based compensation awards. The guidance aligns the measurement and classification for employee stock-based compensation awards to nonemployee stock-based compensation awards. Under the guidance,
nonemployee awards will be measured at their grant date fair value. Upon transition, the existing nonemployee awards will be measured at fair value as of the adoption date. The guidance is effective for reporting periods beginning after
December&nbsp;15, 2019 and early adoption is permitted. The Company adopted this standard as of January&nbsp;1, 2020 using the modified retrospective method of adoption. The adoption of
<FONT STYLE="white-space:nowrap">ASU&nbsp;2018-07&nbsp;did</FONT> not have any impact on the Company&#146;s consolidated financial statements and related disclosures. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13,</FONT> <I>Fair Value Measurement</I> (Topic&nbsp;820): <I>Disclosure
Framework-Changes to the Disclosure Requirements for Fair Value Measurement</I> (ASU <FONT STYLE="white-space:nowrap">2018-13),</FONT> which eliminates, adds and modifies certain disclosure requirements for fair value measurements. ASU <FONT
STYLE="white-space:nowrap">2018-13</FONT> is effective for interim and annual reporting periods beginning after December&nbsp;15, 2019. Early adoption is permitted. The Company adopted this standard as of January&nbsp;1, 2020 using the modified
retrospective method of adoption. The adoption of <FONT STYLE="white-space:nowrap">ASU&nbsp;No.&nbsp;2018-13&nbsp;did</FONT> not have any impact on the Company&#146;s consolidated financial statements and related disclosures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-12 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. Fair Value of Financial Instruments </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the fair value of the Company&#146;s financial assets by level within the fair value hierarchy (in thousands): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31, 2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FAIR VALUE MEASUREMENT BASED ON</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>QUOTED<BR>PRICES<BR>IN&nbsp;ACTIVE<BR>MARKETS<BR>(LEVEL 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIGNIFICANT<BR>OTHER<BR>OBSERVABLE<BR>INPUTS<BR>(LEVEL 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIGNIFICANT<BR>UNOBSERVABLE<BR>INPUTS<BR>(LEVEL 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Money market fund (long-term restricted cash)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>FAIR VALUE MEASUREMENT BASED ON</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>QUOTED<BR>PRICES<BR>IN&nbsp;ACTIVE<BR>MARKETS<BR>(LEVEL 1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIGNIFICANT<BR>OTHER<BR>OBSERVABLE<BR>INPUTS<BR>(LEVEL 2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SIGNIFICANT<BR>UNOBSERVABLE<BR>INPUTS<BR>(LEVEL 3)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Money market fund (long-term restricted cash)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company did not transfer any assets measured at fair value on a recurring basis to or from Level&nbsp;1 during the years ended December&nbsp;31, 2019 and 2020. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. Prepaid Expenses and Other Current Assets </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other
current assets consist of the following (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other prepaid expense and current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">621</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,491</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. Property and Equipment, Net </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Property and equipment consist of the
following (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less: accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(497</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,330</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-13 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depreciation expense was $0.3&nbsp;million and $0.6&nbsp;million for the years ended December&nbsp;31, 2019 and 2020,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. Accrued Liabilities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accrued liabilities consist of
the following (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued bonus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued vacation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. Commitments and Contingencies </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Operating Leases </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company leases office and laboratory space in Gaithersburg, Maryland under one lease that has a term that expires in 2030 unless renewed. The Company received a
tenant improvement allowance from the landlord totaling $1.7&nbsp;million. The tenant improvement allowance has been recorded as deferred rent and is being recognized over the lease term. In July 2020 the Company signed the first amendment to lease
to expand the leased space by an additional 9,359 rentable square feet to a total of 22,930 rented square feet. The lease term for the additional space expires concurrently with the original lease agreement. The Company received a tenant improvement
allowance from the landlord totaling $0.1&nbsp;million which was recorded as deferred rent and will be recognized over the lease term. The landlord completed all renovations and delivered the premises to the Company in December 2020. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The lease agreements contain rent escalation and rent abatement clauses. For financial reporting purposes, rent expense is charged to operations on a straight-line
basis over the term of the lease. As of December&nbsp;31, 2019 and 2020, the Company had recorded deferred rent liability of $1.9 and $2.0&nbsp;million, respectively. Rent expense for the years ended December&nbsp;31, 2019 and 2020 was
$0.4&nbsp;million and $0.6&nbsp;million, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Future minimum lease payments under noncancelable operating leases as of December&nbsp;31, 2020 are as </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">follows (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">608</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">872</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Thereafter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Capital Leases </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company signed a capital lease agreement for
equipment in December 2020. The lease term is for <FONT STYLE="white-space:nowrap">thirty-six</FONT> months with an option to purchase the equipment for $1 dollar at the end of the lease term. The Company has a total contractual obligation of
$520&nbsp;thousand under this lease, $205&nbsp;thousand of which will be due in 2021, $130&nbsp;thousand will be due in 2022 and 2023 and $54&nbsp;thousand will be due in 2024. The lease commences at the time the equipment is delivered.&nbsp;As of
December&nbsp;31, 2020, the equipment had not been delivered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-14 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Contingencies </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From
time to time, the Company may be subject to various litigation and related matters arising in the ordinary course of business. The Company records a provision for a liability when it believes that it is both probable that a liability has been
incurred and the amount can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount. As of December&nbsp;31, 2019 and 2020, the Company was not involved in any material legal proceedings. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has 29,795,227 authorized shares of $0.001 par value Series A redeemable convertible preferred stock (Series A preferred stock) all of which were issued and
outstanding as of December&nbsp;31, 2019 and December&nbsp;31, 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In July 2018, the Company issued the second tranche of Series A preferred stock in exchange
for $12.5&nbsp;million in cash. The Company incurred $21&nbsp;thousand in transaction costs related to the issuance. The Series A preferred stock is classified as temporary equity as a result of certain redemption rights that are outside of the
Company&#146;s control. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has 49,402,623 authorized shares of $0.001 par value Series B redeemable convertible preferred stock (Series B preferred stock)
27,444,339 of which were issued and outstanding as of December&nbsp;31, 2019 and all of which were issued and outstanding as of December&nbsp;31, 2020 from the issuance of Series <FONT STYLE="white-space:nowrap">B-1</FONT> and Series <FONT
STYLE="white-space:nowrap">B-2</FONT> redeemable convertible preferred stock discussed below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2019, the Company authorized 26,803,724 shares of $0.001
par value Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred stock (Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred stock) and in October 2019 the Company authorized an additional 640,615 shares of
$0.001 par value Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred stock. All 27,444,339 shares of Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred stock are issued and outstanding as of December&nbsp;31, 2019. This first
tranche, consisting of 27,444,339 shares at $1.561 per share was issued for net proceeds of $42.6&nbsp;million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company also authorized 21,445,726 shares of
$0.001 par value Series <FONT STYLE="white-space:nowrap">B-2</FONT> redeemable convertible preferred stock (Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred stock and with the Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred
stock, the Series B preferred stock) at a price of $1.951 per share. In October 2019, the Company authorized an additional 512,558 shares of Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred stock. The Company concluded that the
investors&#146; rights to purchase Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred stock upon achieving certain clinical activities (i.e. clinically significant and meaningful biological activity with manageable toxicities from a phase
1 clinical trial, approval by the board of an acceptable clinical development plan, IND filling by a specified date and completion of other key analysis) (the Milestone closing) did not meet the definition of a freestanding financial instrument, as
they were legally attached and assigned together with the issuance of Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred stock. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, after
weighing the substantive and implied terms and features of the Series B preferred stock instrument, the Company concluded that the conversion option is clearly and closely related to the redeemable convertible preferred stock host contract and
therefore would not need to be bifurcated. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2020, the Company issued the second tranche of Series <FONT STYLE="white-space:nowrap">B-2</FONT>
preferred stock in exchange for $42.8&nbsp;million in cash. The Company incurred $40&nbsp;thousand in transaction costs related to the issuance. All authorized shares of Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred stock are issued
and outstanding as of December&nbsp;31, 2020. The Series B preferred stock is classified as temporary equity as a result of certain redemption rights that are outside of the Company&#146;s control. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s Series A preferred stock and Series B preferred stock (collectively, the Preferred Stock) have the following rights and preferences, privileges and
restrictions: </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Dividends </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The holders of Preferred Stock are
entitled to receive annual noncumulative dividends at an annual rate of 8% in preference to any declaration or payment of any dividend on the common stock, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis when, as and if declared by
the board of directors. As of December&nbsp;31, 2019 and 2020, no dividends have been declared. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-15 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Voting Rights </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each
share of Preferred Stock represents such number of votes as is equal to the number of shares of common stock into which such share is convertible. The holders of Preferred Stock vote together with the holders of common stock on an <FONT
STYLE="white-space:nowrap">as-converted</FONT> basis on all matters in which stockholders are entitled to vote. The holders of Series A preferred stock, exclusively and as a separate class, are entitled to elect three directors, the holders of the
Series B preferred stock, exclusively and as a separate class, are entitled to elect two directors of the Company as of December&nbsp;31, 2020. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Conversion
Rights </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each share of Preferred Stock is convertible into shares of common stock determined by dividing the original issuance price by the conversion price.
The conversion price is equal to the original issuance price, which is $1.00 for Series A preferred stock, $1.561 for Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred stock and $1.951 for Series
<FONT STYLE="white-space:nowrap">B-2</FONT> preferred stock. All series of Preferred Stock will convert into shares of common stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> basis. Conversion can
occur at any time at the option of each holder. In addition, all shares of Preferred Stock are mandatorily convertible in certain events, including upon the closing of a qualified initial public offering. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidation Preference </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of any voluntary or
involuntary liquidation, dissolution or winding up of the Company, the holders of Series&nbsp;B-1 and Series&nbsp;B-2 preferred stock are entitled to receive, before any payment of any of the assets of the Company to the holders of the Series A
preferred stock and holders of common stock, $1.561 per share and $1.951 per share, respectively (as adjusted for any stock dividend, stock split, combination or other similar transactions, plus any declared but unpaid dividends). After payment of
the above but before any payment of any of the assets of the Company to the holders of common stock, the holders of Series A preferred stock are entitled to receive $1.00 per share with respect to shares of Series A preferred stock. The Company has
not adjusted the carrying values of the Preferred Stock to the liquidation preferences of such shares because it is uncertain whether or when an event would occur that would obligate the Company to pay the liquidation preferences to holders of
shares of Preferred Stock, and at the balance sheet dates these circumstances were not probable. Subsequent adjustments to the carrying values of the liquidation preferences will be made only when it becomes probable that such a liquidation event
will occur. </P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Redemption Rights </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The preferred stock is not
currently redeemable. Upon certain change in control events that are outside of the Company&#146;s control, including liquidation, sale or transfer of control of the Company, the preferred stock is contingently redeemable. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Anti-dilution Protection </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The holders of the Preferred Stock have
proportional anti-dilution protection for splits, dividends and similar recapitalizations. Subject to certain exclusions, anti-dilution price protection for additional sales of securities by the Company for consideration per unit less than the
applicable conversion price per unit of any series of Preferred Stock, shall be on a broad-based weighted average basis. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. Common Stock </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has 98,973,453 authorized shares of $0.001 par value common stock as of December&nbsp;31, 2019 and 2020, of which 1,407,800 and 1,836,508 shares were issued
and outstanding as of December&nbsp;31, 2019 and 2020, respectively. The shares issued and outstanding represent shares issued to executives of the Company pursuant to the early exercise of existing stock options as well as shares issued to
employees pursuant to exercises of vested stock options. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The early exercises were performed by three executives of the Company. One officer of the Company
satisfied the exercise price of the options exercised by the issuance of a seven-year full recourse note in the amount of $79&nbsp;thousand. The note accrues interest at the applicable Federal rate (approximately 0.39% at December&nbsp;31, 2020) and
is fully secured by the shares of common stock and the personal assets of the officer. The note is recorded as an offset to additional <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">paid-in-capital.</FONT></FONT> The other two
executives satisfied the exercise price of the options exercised by making cash payments to the Company. In order to execute the early exercises, the executives signed a Restricted Stock Purchase Agreement (RSPA) granting the Company, in the case of
termination of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-16 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
employment of the executive, the rights to repurchase all of the unvested shares at the price paid by the executive for such shares. Based on the share repurchase rights outlined in the RSPA, the
Company recorded the proceeds from the early exercises as a liability on the balance sheet. At December&nbsp;31, 2019, there was a balance of $20&nbsp;thousand recorded as other current liabilities and $32 thousand recorded as other long-term
liabilities related to the unvested balance of the restricted shares exercised. At December&nbsp;31, 2020, there was a balance of $20&nbsp;thousand recorded as other current liabilities and $12&nbsp;thousand recorded as other long-term liabilities
related to the unvested balance of the restricted shares exercised. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All shares that were early exercised by the executives of the Company are considered
legally issued, however, for accounting purposes, only vested shares are considered issued. Below is a reconciliation of shares issued and outstanding: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total shares of common stock legally issued and outstanding (including shares early exercised)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,805,524</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,066,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less: (unvested early exercised shares of common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(397,724</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(230,215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total shares issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,407,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,836,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#146;s stockholders. Common stockholders are entitled to
receive dividends, as may be declared by the board of directors, if any, subject to the preferential dividend rights of the Preferred Stock. When dividends are declared on shares of common stock, the Company must declare at the same time a dividend
payable to the holders of Preferred Stock equivalent to the dividend amount they would receive if each share of Preferred Stock was converted into common stock. The Company may not pay dividends to common stockholders until all dividends accrued or
declared but unpaid on the Preferred Stock have been paid in full. No dividends have been declared or paid by the Company through December&nbsp;31, 2020. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the
event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the remaining assets of the Company legally available for distribution after the payment of the full liquidation preference for the Preferred Stock.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>10. Share-Based Compensation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In January 2017, the Company implemented
the Company&#146;s 2017 Equity Incentive Plan (the 2017 Plan). The 2017 Plan provides for the grant of Stock Options, Stock Appreciation Rights, Restricted Stocks or Restricted Stock Units. The aggregate number of shares of common stock initially
available for issuance pursuant to awards under the 2017 Plan was 6,540,416 shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2019, the board of directors approved Amendment No.&nbsp;1 to the
2017 Plan, increasing the number of shares of common stock available for issuance under the plan by (i) 6,290,000 to a total shares available for issuance of 13,735,603 immediately following the closing of the Series B financing, and (ii)&nbsp;by up
to 4,775,000 shares to a new total of 18,510,603 shares immediately following the Milestone closing under the Series B financing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2019, the board of
directors approved Amendment No.&nbsp;2 to the 2017 Plan, increasing the number of shares of common stock available for issuance under the 2017 Plan by (i)&nbsp;156,770 to a total shares available for issuance of 13,892,373 immediately following the
closing of the Series B financing, and (ii)&nbsp;by up to 4,883,230 shares to a new total of 18,775,603 shares immediately following the Milestone closing under the Series B financing agreement. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2020, the board of directors approved Amendment No.&nbsp;3 to the 2017 Plan increasing the number of shares of common stock available for issuance under the
plan to 18,775,603 shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stock options granted under the 2017 Plan generally vest over four years and expire after 10 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-17 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The exercise price for stock options granted is not less than the fair value of common shares as determined by the board
of directors as of the date of grant. The board of directors determines the value the Company&#146;s common stock taking into consideration the most recently available third-party valuation of common shares, as well as additional factors, which may
have changed since the date of the most recent contemporaneous valuation through the date of grant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A summary of stock option activity for awards under the 2017
Plan is presented below: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTIONS OUTSTANDING AND EXERCISABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED<BR>AVERAGE<BR>EXERCISE<BR>PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED<BR>AVERAGE<BR>REMAINING<BR>CONTRACTUAL<BR>LIFE (YEARS)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE<BR>INTRINSIC<BR>VALUE <SUP STYLE="font-size:85%; vertical-align:top">(1)<BR></SUP>(IN&nbsp;THOUSANDS)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of January&nbsp;1, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,635,542</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Forfeitures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(90,840</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(366,935</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,560,767</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,889,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.76</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Forfeitures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(276,227</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(428,708</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,744,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercisable as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,508,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money at
December&nbsp;31, 2019 and 2020. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The weighted average grant date fair value per share of stock options granted during the years ended
December&nbsp;31, 2019 and 2020 was $0.47 and $0.58, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The aggregate grant date fair value of stock options vested during the years ended
December&nbsp;31, 2019 and 2020 was approximately $0.3&nbsp;million and $1.7&nbsp;million, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company recorded share-based compensation expense of
$0.1&nbsp;million and $1.1&nbsp;million during the years ended December&nbsp;31, 2019 and 2020, respectively. As of December&nbsp;31, 2020, there was $2.9&nbsp;million of unrecognized compensation cost related to unvested share-based compensation
arrangements granted under the 2017 Plan. This remaining compensation expense is expected to be recognized over a weighted average period of three years as of December&nbsp;31, 2020. The intrinsic value of the options exercised for the years ended
December&nbsp;31, 2019 and 2020 was $0.1&nbsp;million and $0.5&nbsp;million, respectively. Share-based compensation cost is measured at fair value and is recognized as expense on a straight-line basis over the requisite service period. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Share-based compensation expense included in the statement of operations for the years ended December&nbsp;31, 2019 and 2020 was as follows in thousands: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2019&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-18 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The assumptions used in the Black-Scholes option pricing model for stock options granted were as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95&#151;100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.84%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.42&#151;1.42%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>11. Net Loss Per Share Attributable to Common Stockholders </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company&#146;s potential dilutive securities, which include redeemable convertible preferred stock, options to purchase common stock and unvested shares of restricted common stock, have been excluded from the computation of diluted net loss per
share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the
following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an
anti-dilutive effect: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,239,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,197,850</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,163,043</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,514,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unvested shares of restricted common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">397,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,800,333</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,942,802</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shares of redeemable convertible preferred stock also participate in dividends with shares of common stock (if and when declared) and therefore are deemed participating
securities. The holders of redeemable convertible preferred stock do not contractually share in losses and therefore no additional net loss per share has been disclosed under the <FONT STYLE="white-space:nowrap">two-class</FONT> method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>12. Income Taxes </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s provision for income taxes consists of
the following for the years ended December&nbsp;31, 2019 and 2020 (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Current income tax provision (benefit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">U.S. federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred income tax provision (benefit):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">U.S. federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,774</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,671</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,187</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,954</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,625</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,625</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total provision (benefit) for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-19 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A reconciliation of the statutory U.S. federal rate and effective rate is as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">U.S. federal tax</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">State tax, net of federal benefit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33.2</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(29.9</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Payroll tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in tax rates and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.4</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(0.8</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Income tax expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The significant components of the Company&#146;s deferred income tax assets (liabilities) were as follows (in thousands): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred income tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">U.S. federal net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,352</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12,826</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">State net operating loss carryforward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,862</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,935</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gross deferred income tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,074</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,724</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less: Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,010</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total deferred income tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred income tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net deferred income tax assets (liabilities)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company recognizes valuation allowances to reduce deferred tax assets to the amount that is more likely than not to be realized. In assessing the likelihood of
realization, management considers (i)&nbsp;future reversals of existing taxable temporary differences; (ii)&nbsp;future taxable income exclusive of reversing temporary difference and carryforwards; (iii)&nbsp;taxable income in prior carryback years
if carryback is permitted under applicable tax law; and (iv)&nbsp;tax planning strategies. The Company&#146;s net deferred income tax assets are not more likely than not to be utilized due to the lack of sufficient sources of future taxable income
and cumulative book losses which have resulted over the years. The net change in valuation allowance for the years ended December&nbsp;31, 2019 and 2020 was an increase of $5.9&nbsp;million and $9.6&nbsp;million, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On March&nbsp;27, 2020, Congress enacted the Coronavirus Aid, Relief and Economic Security Act (CARES Act) to provide certain relief as a result of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The Company did not apply for any relief offered by the government during the year ended December&nbsp;31, 2020. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company had Federal and State net operating loss (NOL) carryforwards of approximately $61.1&nbsp;million and $59.2&nbsp;million, respectively, as of
December&nbsp;31, 2020. As of December&nbsp;31, 2020, the Company also had federal research and development tax credit carryforwards of approximately $1.9&nbsp;million, available to potentially offset future federal income taxes. Approximately
$6.4&nbsp;million of the Federal NOL was generated prior to 2018 and will begin expiring in 2035 while the remaining $54.7&nbsp;million will be carried forward indefinitely. The State NOL will begin expiring in 2035. The federal research and
development tax carryforwards, if not utilized, will expire beginning in 2038. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-20 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">However, the deductibility of such federal net operating losses may be limited. Under Section&nbsp;382 of the Internal
Revenue Code of 1986, as amended (the Code), and corresponding provisions of state law, if a corporation undergoes an &#147;ownership change,&#148; which generally occurs if the percentage of the corporation&#146;s stock owned by 5% stockholders
increases by more than 50% over a three-year period, the corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOL carryforwards and other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset
its post-change income may be limited. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has not determined if it has experienced Section&nbsp;382 ownership changes in the past and if a portion of its
NOL and tax credit carryforwards are subject to an annual limitation under Section&nbsp;382. In addition, the Company may experience ownership changes in the future as a result of subsequent shifts in its stock ownership, some of which may be
outside of its control. If the Company determines that an ownership change has occurred and its ability to use its historical NOL and tax credit carryforwards is materially limited, it would harm the Company&#146;s future operating results by
effectively increasing the Company&#146;s future tax obligations. The Company has not identified any uncertain tax positions and did not recognize any adjustments for unrecognized tax benefits. The Company&#146;s tax returns for all years remain
subject to examination by taxing authorities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>13. Employee Benefit Plan </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company sponsors a tax deferred retirement plan under the Code to provide retirement benefits for all eligible employees. Participating employees may voluntarily
contribute up to limits provided by Internal Revenue Service regulations. The Company made contributions to the plan of $0.09&nbsp;million and $0.2&nbsp;million for the years ended December&nbsp;31, 2019 and 2020, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>14. Subsequent Events </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company issued 57,224,618 shares of $0.001 par
value Series C redeemable convertible preferred stock (Series C preferred stock) at a price of $2.097 per share for a total cash consideration of $120.0&nbsp;million. This financing was completed in multiple rounds in March 2021 through June 2021.
The Company incurred $0.9&nbsp;million in transaction costs related to the issuance. The Series C preferred stock will be classified as temporary equity as a result of certain redemption rights that are outside of the Company&#146;s control. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subsequent events have been evaluated through September&nbsp;27, 2021, which is the date that the consolidated financial statements were available to be issued. Other
than as described above, there were no material subsequent events that occurred during this period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-21 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>ARCELLX, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin129231_7"></A>Condensed Consolidated Balance Sheets </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands, except share and per share amounts) </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,&nbsp;2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SEPTEMBER&nbsp;30,&nbsp;2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.25em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,357</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134,139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,853</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Deposits and other <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,991</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>Total assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>Liabilities, Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,583</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Deferred rent, current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">171</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.25em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,271</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Deferred rent, net of current portion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,863</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Other long-term liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>Total liabilities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Commitments and contingencies</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Redeemable convertible preferred stock:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Series A redeemable convertible preferred stock, par value of $0.001 per share; 29,795,227 shares authorized,
issued and outstanding at December&nbsp;31, 2020 and September&nbsp;30, 2021; liquidation value $29,795 at December&nbsp;31, 2020 and September&nbsp;30, 2021.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Series B redeemable convertible preferred stock, par value $0.001 per share; 49,402,623 shares authorized,
issued and outstanding at December&nbsp;31, 2020 and September&nbsp;30, 2021; liquidation value of $85,681 at December&nbsp;31, 2020 and September&nbsp;30, 2021.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Series C redeemable convertible preferred stock, par value $0.001 per share; 0 and 57,224,618 shares
authorized at December&nbsp;31, 2020 and September&nbsp;30, 2021, respectively; 0 and 57,224,618 shares issued and outstanding at December&nbsp;31, 2020 and September&nbsp;30, 2021, respectively; liquidation value of $0 and $120,000 at
December&nbsp;31, 2020 and September&nbsp;30, 2021, respectively.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Total redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">233,379</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Stockholders&#146; deficit:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Common stock, par value of $0.001 per share; 98,973,453 and 185,000,000 shares authorized at
December&nbsp;31, 2020 and September&nbsp;30, 2021, respectively; 1,836,508 and 2,796,012 shares issued and outstanding at December&nbsp;31, 2020 and September&nbsp;30, 2021, respectively (Note 11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Accumulated other comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.50em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(65,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(109,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:5.25em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(103,795</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL"><B>Total liabilities, redeemable convertible preferred stock and stockholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">144,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of the condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-22 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>ARCELLX, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin129231_8"></A>Condensed Consolidated Statements of Operations and Comprehensive Loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands, except share and
per share amounts) </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE MONTHS ENDED<BR>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Revenue</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Operating expenses:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,868</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,831</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,002</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,002</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,320</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other income, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,002</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other comprehensive loss:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unrealized loss on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,002</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(44,304</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss per share attributable to common stockholders&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15.24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(19.03</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted-average common shares outstanding&#151;basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,508,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,327,309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of the condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-23 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>ARCELLX, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin129231_9"></A>Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands, except share data)
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6.5pt" ALIGN="center">


<TR>

<TD WIDTH="27%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>REDEEMABLE CONVERTIBLE PREFERRED STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCKHOLDERS&#146; DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES C</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMMON STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:7pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ADDITIONAL<BR><FONT STYLE="white-space:nowrap">PAID-IN</FONT><BR>CAPITAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED<BR>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCKHOLDERS&#146;<BR>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.15em; text-indent:-2.15em; font-size:6.5pt; font-family:ARIAL">Balance at December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,795,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,444,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,407,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 307</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(33,047</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(32,738</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.15em; text-indent:-2.15em; font-size:6.5pt; font-family:ARIAL">Issuance of common stock from vesting of restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">252,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.15em; text-indent:-2.15em; font-size:6.5pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.15em; text-indent:-2.15em; font-size:6.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,002</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23,002</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.15em; text-indent:-2.15em; font-size:6.5pt; font-family:ARIAL">Balance at September&nbsp;30, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,795,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,444,339</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">42,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,660,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(56,049</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(54,999</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>    <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of the condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-24 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>ARCELLX, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(unaudited) </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands, except share data)
</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:6pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:5.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>REDEEMABLE CONVERTIBLE PREFERRED STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="22" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCKHOLDERS&#146; DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:5.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES A</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES B</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SERIES C</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>COMMON STOCK</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:5.5pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ADDITIONAL<BR><FONT STYLE="white-space:nowrap">PAID-IN</FONT><BR>CAPITAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED<BR>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED<BR>OTHER<BR>COMPREHENSIVE<BR>LOSS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>STOCKHOLDERS&#146;<BR>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.33em; text-indent:-2.33em; font-size:6pt; font-family:ARIAL">Balance at December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,795,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,402,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,836,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,420</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(65,142</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(63,720</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.33em; text-indent:-2.33em; font-size:6pt; font-family:ARIAL">Issuance of Series C redeemable convertible preferred stock for cash, net of transaction costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,224,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.33em; text-indent:-2.33em; font-size:6pt; font-family:ARIAL">Issuance of common stock from vesting of restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.33em; text-indent:-2.33em; font-size:6pt; font-family:ARIAL">Exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">902,015</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.33em; text-indent:-2.33em; font-size:6pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.33em; text-indent:-2.33em; font-size:6pt; font-family:ARIAL">Unrealized loss on investment</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.33em; text-indent:-2.33em; font-size:6pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(44,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:6pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.33em; text-indent:-2.33em; font-size:6pt; font-family:ARIAL">Balance at September&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,795,227</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">28,894</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,402,623</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">85,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,224,618</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">119,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,796,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,648</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(109,441</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(103,795</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>    <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of the condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-25 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>ARCELLX, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin129231_10"></A>Condensed Consolidated Statements of Cash Flows </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(unaudited) </B></P>  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(in thousands) </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE MONTHS ENDED<BR>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(23,002</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(44,299</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">710</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Amortization of premiums and discounts on marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current and <FONT STYLE="white-space:nowrap">non-current</FONT> assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">522</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(649</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,110</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,079</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,046</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,494</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Deferred rent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,382</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32,692</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,030</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchases of marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(61,283</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(62,313</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Payments under capital leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from the exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Payments of deferred offering costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,248</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(668</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Payment for repurchase of restricted stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of Series C redeemable convertible preferred stock, net of transaction
costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119,118</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash (used in) provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,232</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">118,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net (decrease) increase in cash, cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(22,894</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,689</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash, cash equivalents and restricted cash, end of the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Supplemental disclosures of noncash investing activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchase of property and equipment included in accrued liabilities and accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(850</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of the condensed consolidated financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-26 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>ARCELLX, INC. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin129231_11"></A>Notes to Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(unaudited) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>1. Nature of the Business </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Organization </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Arcellx, Inc. (Arcellx or the Company) was incorporated
in Delaware in December 2014 and is headquartered in Gaithersburg, Maryland. The Company is a clinical-stage biopharmaceutical company reimagining cell therapy through the development of innovative therapies for patients with cancer and other
incurable diseases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has not commercialized any of its drug candidates and planned commercial operations have not commenced. The Company has incurred
significant losses in the development of its drug candidates. The Company has not generated revenues from product sales. As a result, the Company has consistently reported negative cash flows from operating activities and net losses, had a
stockholder&#146;s deficit of $103.8&nbsp;million as of September&nbsp;30, 2021 and expects to continue incurring losses for the foreseeable future. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidity </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The accompanying condensed consolidated financial
statements have been prepared assuming that the Company will continue as a going concern, which contemplates continuity of operations, realization of assets, and satisfaction of liabilities in the ordinary course of business. The propriety of using
the going-concern basis is dependent upon, among other things, the achievement of future profitable operations, the ability to generate sufficient cash from operations and potential other funding sources, in addition to cash on hand, to meet its
obligations as they become due. Based on the Company&#146;s expected operating cash requirements and capital expenditures, management believes the Company&#146;s cash on hand and marketable securities as of September&nbsp;30, 2021 are adequate to
fund operations for at least twelve months from the date that these condensed consolidated financial statements are issued. The Company expects to incur substantial operating losses to continue development of drug candidates, including preclinical
and clinical testing and regulatory approval prior to commercialization. Even if drug development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company plans to seek additional funding through public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations,
strategic alliances and licensing arrangements. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all.
The terms of any financing may adversely affect the holdings or the rights of the Company&#146;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs,
product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although management continues to pursue
these funding plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company, if at all, to fund continuing operations past twelve months from the issuance date of these condensed
consolidated financial statements. </P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>2. Summary of Significant Accounting Policies </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There have been no material changes to the significant accounting policies disclosed in the Company&#146;s audited financial statements for the year ended
December&nbsp;31, 2020, included elsewhere in this Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> other than the addition of the marketable securities accounting policy and updates to the share-based compensation expense
accounting policy during the nine months ended September&nbsp;30, 2021 as discussed below: </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Marketable Securities </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company carries marketable securities classified as <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> at fair value
as determined by prices for identical or similar securities at the balance sheet date. The inputs used to determine the fair value of marketable securities are considered Level&nbsp;2 within the fair-value hierarchy. The Company records unrealized
gains and losses as a component of other comprehensive loss within the statements of operations and comprehensive loss and as accumulated other comprehensive loss in stockholders&#146; deficit. Realized gains or losses on <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-27 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
securities are determined using the specific identification method and the Company includes net realized gains and losses in other income, net. Marketable securities are classified as either
current or <FONT STYLE="white-space:nowrap">non-current</FONT> assets based on their contractual maturity dates. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">At each reporting date, or more frequently if
circumstances warrant, the Company evaluates individual <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt securities for impairment.&nbsp;In the event that the carrying value of an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt security exceeds its fair value and the decline in fair value is determined to be other-than-temporary, the Company records an impairment charge in
earnings attributable to the estimated credit loss.&nbsp;In determining whether a decline in the value of an <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> debt security is other-than-temporary,
the Company evaluates various factors including, but not limited to, the nature of the investments, changes in credit ratings, interest rate fluctuations, industry analyst reports, the duration and extent to which fair value has been less than
carrying value, the Company&#146;s assessment as to whether it is more likely than not that the Company will be required to sell the security prior to recovery of its amortized cost basis, and the severity of the impairment. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Share-Based Compensation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of restricted stock awards,
unrestricted stock awards, and restricted stock units (collectively, awards) without a market condition is determined based on the fair value of the Company&#146;s common stock on the grant date.&nbsp;The Company recognizes share-based compensation
expense for awards with only a service condition ratably over the requisite service period.&nbsp;Vesting of awards is accelerated for certain employees in the event of a change in control or in the event that the Company removes the employee with or
without cause from their position. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company estimates the fair value of awards subject to both a market condition (e.g., certain market capitalization
thresholds) and a performance condition on the grant date using a <I>Monte Carlo</I> simulation model. For awards with vesting subject to the fulfillment of both market and performance conditions, share-based compensation expense is recognized using
the accelerated attribution method at the time the achievement of the performance condition becomes probable. The amount of share-based compensation expense is dependent on the Company&#146;s periodic assessment of the probability of the performance
condition being satisfied and the Company&#146;s estimate, which may vary over time, of the number of shares that will ultimately be issued.&nbsp;If the performance condition is not met, no compensation expense is recognized, and any previously
recognized compensation cost is reversed. Refer to Note 12 for further discussion regarding the terms of awards granted during the nine months ended September&nbsp;30, 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>3. Restricted Cash</B><B><I> </I></B><B> </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is required to
maintain cash collateral on deposit in a segregated money market bank account, as a condition of a lease agreement. The bank may restrict withdrawals or transfers by, or on behalf of, the Company. The required restricted cash reserve totaled
$199&nbsp;thousand at each of December&nbsp;31, 2020 and September&nbsp;30, 2021. This amount is presented as <FONT STYLE="white-space:nowrap">non-current</FONT> restricted cash on the accompanying balance sheets. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table reconciles cash and cash equivalents and restricted cash per the balance sheets to the statements of cash flows (in thousands): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SEPTEMBER&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70,027</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">46,795</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70,226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-28 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>4. Fair Value of Financial Instruments </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the fair value of the Company&#146;s financial assets by level within the fair value hierarchy (in thousands): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31, 2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LEVEL&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LEVEL&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LEVEL&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Money market fund (long-term restricted cash)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SEPTEMBER&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LEVEL&nbsp;1</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LEVEL&nbsp;2</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LEVEL&nbsp;3</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Money market fund (cash equivalent)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Money market fund (long-term restricted cash)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">199</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Marketable securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets measured at fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">65,324</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">61,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company did not transfer any assets measured at fair value on a recurring basis between levels during the year ended December&nbsp;31, 2020 or the nine months ended
September&nbsp;30, 2021. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>5. Marketable Securities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Available-for-sale</FONT></FONT> marketable securities, which consisted entirely of corporate bonds, were as follows (in thousands): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="86%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SEPTEMBER&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Amortized costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">61,160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gross unrealized gains</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gross unrealized loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">61,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of the Company&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities held at
September&nbsp;30, 2021 had contractual maturities of less than one year. All of the Company&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities in an unrealized loss
position at September 30, 2021 were in a loss position for less than twelve months. Unrealized losses on <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities at September 30, 2021
were not significant and were primarily due to changes in interest rates, including market credit spreads, and not due to increased credit risks associated with specific securities. Accordingly, no allowance for credit losses related to the
Company&#146;s <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">available-for-sale</FONT></FONT> marketable securities was recorded for the nine months ended September 30, 2021. The Company does not intend to sell these securities
and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be at maturity. The Company recorded interest income of $77 thousand for the nine months ended
September&nbsp;30, 2021, which is included in other income, net on the condensed consolidated statements of operations and comprehensive loss. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-29 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>6. Prepaid Expenses and Other Current Assets </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current assets consist of the following (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SEPTEMBER&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid research and development costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,308</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other prepaid expense and current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,761</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,957</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>7. Property and Equipment, Net </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Property and equipment consist of the
following (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SEPTEMBER&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lab equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,514</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,371</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,355</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Lab equipment under capital leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Computer equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, gross</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,617</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less: accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,126</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,836</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,900</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,781</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depreciation and amortization expense was $464&nbsp;thousand and $710&nbsp;thousand for the nine months ended September&nbsp;30, 2020 and 2021, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>8. Capital Lease Obligations </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company signed a capital lease
agreement for equipment in December 2020. The lease term is for <FONT STYLE="white-space:nowrap">thirty-six</FONT> months with an option to purchase the equipment for $1 dollar at the end of the lease term. The lease commencement date is
commensurate with the date the equipment was placed into service which was in June 2021. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company signed a capital lease agreement for equipment in March
2021. The lease term is for seventeen months and ownership of the asset will be transferred to the Company at the end of the lease term. The lease commencement date is commensurate with the date the equipment was placed into service which was in
March 2021. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of September&nbsp;30, 2021, the remaining future lease obligations under these capital lease agreements are as follows (in thousands): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="94%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">377</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less: amount representing interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Present value of net minimum lease payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">353</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-30 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The capital lease obligation balance was $353&nbsp;thousand as of September&nbsp;30, 2021, of which $147&nbsp;thousand is
included in other current liabilities and $206&nbsp;thousand is included in the other long-term liabilities. The implied interest rate used to reduce the minimum lease payments to present value was 5.0%. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company made payments with respect to capital lease obligations of $0 and $359&nbsp;thousand for the nine months ended September&nbsp;30, 2020 and 2021,
respectively. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Interest expense in connection with the Company&#146;s capital leases were immaterial for the nine months ended September&nbsp;30, 2020 and 2021.
</P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>9. Accrued Liabilities </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Accrued liabilities consist of the
following (in thousands): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SEPTEMBER&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,897</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued bonus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,113</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,393</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accrued vacation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">249</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">415</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,154</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">646</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total accrued liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>10. Redeemable Convertible Preferred Stock and Stockholders&#146; Deficit </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has 29,795,227 authorized shares of $0.001 par value Series A redeemable convertible preferred stock (Series A preferred stock) all of which is issued and
outstanding at December&nbsp;31, 2020 and September&nbsp;30, 2021. The Series A preferred stock is classified as temporary equity as a result of certain redemption rights that are outside of the Company&#146;s control. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has 49,402,623 authorized shares of $0.001 par value Series B redeemable convertible preferred stock (Series B preferred stock) all of which is issued and
outstanding at December&nbsp;31, 2020 and September&nbsp;30, 2021 from the issuance of Series <FONT STYLE="white-space:nowrap">B-1</FONT> and Series <FONT STYLE="white-space:nowrap">B-2</FONT> redeemable convertible preferred stock discussed below.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has 27,444,339 authorized shares of $0.001 par value Series <FONT STYLE="white-space:nowrap">B-1</FONT> redeemable convertible preferred stock (Series <FONT
STYLE="white-space:nowrap">B-1</FONT> preferred stock) all of which is issued and outstanding at December&nbsp;31, 2020 and September&nbsp;30, 2021. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company
has authorized 21,958,284 shares of $0.001 par value Series <FONT STYLE="white-space:nowrap">B-2</FONT> redeemable convertible preferred stock (Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred stock and with the Series <FONT
STYLE="white-space:nowrap">B-1</FONT> preferred stock, the Series B preferred stock).&nbsp;The Company concluded that the investors&#146; rights to purchase Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred stock upon achieving certain
clinical activities (i.e., clinically significant and meaningful biological activity with manageable toxicities from a phase 1 clinical trial, approval by the board of an acceptable clinical development plan, IND filling by a specified date and
completion of other key analysis) (the Milestone closing) did not meet the definition of a freestanding financial instrument, as they were legally attached and assigned together with the issuance of Series <FONT STYLE="white-space:nowrap">B-1</FONT>
preferred stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, after weighing the substantive and implied terms and features of the Series B preferred stock instrument, the Company concluded that
the conversion option is clearly and closely related to the preferred stock host contract and therefore would not need to be bifurcated. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In December 2020, the
Company issued the second tranche of Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred stock in exchange for $42.8&nbsp;million in cash. The Company incurred $40&nbsp;thousand in transaction costs related to the issuance. All authorized
shares of Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred stock are issued and outstanding as of December&nbsp;31, 2020 and September&nbsp;30, 2021. The Series B preferred stock is classified as temporary equity as a result of certain
redemption rights that are outside of the Company&#146;s control. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-31 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the nine months ended September&nbsp;30, 2021, the Company authorized 57,224,618 shares of $0.001 par value
Series C redeemable convertible preferred stock (the Series C preferred stock) and issued all authorized shares in exchange for $120.0&nbsp;million in cash. The Company incurred $0.9&nbsp;million in transaction costs related to the Series C
preferred stock issuance. The Series C preferred stock is classified as temporary equity as a result of certain redemption rights that are outside of the Company&#146;s control. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s Series A preferred stock, Series B preferred stock and Series C preferred stock (collectively, the Preferred Stock) have the following rights and
preferences, privileges and restrictions: </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Dividends </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The holders
of Preferred Stock are entitled to receive annual noncumulative dividends at an annual rate of 8% in preference to any declaration or payment of any dividend on the common stock, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis when,
as and if declared by the board of directors. As of December&nbsp;31, 2020 and September&nbsp;30, 2021, no dividends have been declared. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Voting Rights
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each share of Preferred Stock represents such number of votes as is equal to the number of shares of common stock into which such share is convertible. The
holders of Preferred Stock vote together with the holders of common stock on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis on all matters in which stockholders are entitled to vote. The holders of Series&nbsp;A preferred stock,
exclusively and as a separate class, are entitled to elect three directors, the holders of the Series&nbsp;B preferred stock, exclusively and as a separate class, are entitled to elect two directors, and the holders of Series&nbsp;C preferred stock,
exclusively and as a separate class, are entitled to elect one director of the Company as of September&nbsp;30, 2021. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Conversion Rights </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each share of Preferred Stock is convertible into shares of common stock determined by dividing the original issuance price by the conversion price. The conversion
price is equal to the original issuance price, which is $1.00 for Series A preferred stock, $1.561 for Series <FONT STYLE="white-space:nowrap">B-1</FONT> preferred stock, $1.951 for Series <FONT STYLE="white-space:nowrap">B-2</FONT> preferred stock,
and $2.097 for Series C preferred stock. All series of preferred stock will convert into shares of common stock on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">one-to-one</FONT></FONT> basis. Conversion can occur at any time
at the option of each holder. In addition, all shares of Preferred Stock are mandatorily convertible in certain events, including upon the closing of a qualified initial public offering. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidation Preference </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of any voluntary or
involuntary liquidation, dissolution or winding up of the Company, the holders of Series C preferred stock are entitled to receive, before any payment of any of the assets of the Company to the holders of the Series B preferred stock, the holders of
the Series A preferred stock, or the holders of common stock, $2.097 per share (as adjusted for any stock dividend, stock split, combination or other similar transactions, plus any declared but unpaid dividends). After payment of the above but
before any payment of any of the assets of the Company to the holders of Series A preferred stock or the holders of common stock, the holders of <FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> and
<FONT STYLE="white-space:nowrap">Series&nbsp;B-2</FONT> preferred stock are entitled to receive, before any payment of any of the assets of the Company to the holders of the Series&nbsp;A preferred stock or the holders of common stock, $1.561 per
share and $1.951 per share, respectively (as adjusted for any stock dividend, stock split, combination or other similar transactions, plus any declared but unpaid dividends). After payment of the above but before any payment of any of the assets of
the Company to the holders of common stock, the holders of Series A preferred stock are entitled to receive $1.00 per share with respect to shares of Series&nbsp;A preferred stock. The Company has not adjusted the carrying values of the preferred
stock to the liquidation preferences of such shares because it is uncertain whether or when an event would occur that would obligate the Company to pay the liquidation preferences to holders of shares of Preferred Stock, and at the balance sheet
dates these circumstances were not probable. Subsequent adjustments to the carrying values of the liquidation preferences will be made only when it becomes probable that such a liquidation event will occur. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Redemption Rights </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Preferred Stock is not currently redeemable.
Upon certain change in control events that are outside of the Company&#146;s control, including liquidation, sale or transfer of control of the Company, the preferred stock is contingently redeemable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-32 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Anti-dilution Protection </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The holders of the Preferred Stock have proportional anti-dilution protection for splits, dividends and similar recapitalizations. Subject to certain exclusions,
anti-dilution price protection for additional sales of securities by the Company for consideration per unit less than the applicable conversion price per unit of any series of Preferred Stock, shall be on a broad-based weighted average basis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>11. Common Stock </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2021, the board of directors approved an
amendment to the Amended and Restated Certificate of Incorporation of the Company, which increased the number of authorized shares of common stock. The Company has 98,973,453 and 185,000,000 authorized shares of $0.001 par value common stock at
December&nbsp;31, 2020 and September&nbsp;30, 2021, respectively, of which 1,836,508 and 2,796,012 shares were issued and outstanding at December&nbsp;31, 2020 and September&nbsp;30, 2021, respectively. The shares issued and outstanding represent
shares issued to employees of the Company, pursuant to the early exercise of existing stock options as well as shares issued to employees pursuant to the exercise of vested stock options. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">One employee of the Company satisfied the exercise price of the options exercised by the issuance of a seven-year full recourse note in the amount of $79&nbsp;thousand.
The note accrued interest at the applicable rate (approximately 0.4% at December&nbsp;31, 2020) and was fully secured by the shares of common stock and the personal assets of the employee. The note was recorded as an offset to additional <FONT
STYLE="white-space:nowrap">paid-in</FONT> capital. In June 2021, the Company approved the forgiveness of this loan and related accrued interest resulting in compensation expense of $84&nbsp;thousand. Other employees satisfied the exercise price of
the options exercised by making cash payments to the Company. In order to execute the early exercises, the employees signed a Restricted Stock Purchase Agreement (RSPA) granting the Company, in the case of termination of employment of the executive,
the rights to repurchase all of the unvested shares at the price paid by the employee for such shares. Based on the share repurchase rights outlined in the RSPA, the Company recorded the proceeds from the early exercises as a liability on the
balance sheet. During the nine months ended September&nbsp;30, 2021, two employees resigned and the Company bought back 172,726 shares representing all unvested shares that had been early exercised at the price paid by the employee for such shares.
The repurchased shares are not considered legally issued and outstanding; however, are available to be reissued in the future.&nbsp;As such, they are excluded from the legally issued and outstanding shares in the reconciliation below. At
December&nbsp;31, 2020 and September&nbsp;30, 2021, there was a balance of $20&nbsp;thousand and $0 recorded as other current liabilities and $12&nbsp;thousand and $0 recorded as other long-term liabilities, respectively, related to the unvested
balance of the restricted shares exercised. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All shares that were early exercised by the employees of the Company are considered legally issued. However, for
accounting purposes, only vested shares are considered issued. Below is a reconciliation of shares issued and outstanding: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SEPTEMBER&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total shares of common stock legally issued and outstanding (including shares early exercised)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,066,723</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,796,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less: (unvested early exercised shares of common stock)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(230,215</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total shares issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,836,508</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,796,012</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#146;s stockholders. Common stockholders are entitled to
receive dividends, as may be declared by the board of directors, if any, subject to the preferential dividend rights of the preferred stock. When dividends are declared on shares of common stock, the Company must declare at the same time a dividend
payable to the holders of preferred stock equivalent to the dividend amount they would receive if each share of preferred stock was converted into common stock. The Company may not pay dividends to common stockholders until all dividends accrued or
declared but unpaid on the preferred stock have been paid in full. No dividends have been declared or paid by the Company through September&nbsp;30, 2021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-33 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the remaining
assets of the Company legally available for distribution after the payment of the full liquidation preference for the preferred stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>12. Share-Based
Compensation </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In March, April, and June 2021, the board of directors approved Amendments No.&nbsp;4, No.&nbsp;5, and No.&nbsp;6 to the 2017 Plan, increasing
the number of shares of common stock available for issuance under the 2017 Plan by 24,857,211 shares to 43,632,814 total shares available for issuance. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Stock
options granted under the 2017 Plan generally vest over four years and expire after 10 years. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The exercise price for stock options granted is not less than the
fair value of common shares as determined by the board of directors as of the date of grant. The board of directors determines the value the Company&#146;s common stock taking into consideration the most recently available third-party valuation of
common shares, as well as additional factors, which may have changed since the date of the most recent contemporaneous valuation through the date of grant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A
summary of stock option activity for awards under the 2017 Plan is presented below: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="53%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTIONS OUTSTANDING AND EXERCISABLE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED<BR>AVERAGE<BR>EXERCISE<BR>PRICE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED<BR>AVERAGE<BR>REMAINING<BR>CONTRACTUAL<BR>LIFE (YEARS)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGGREGATE<BR>INTRINSIC<BR>VALUE (1)<BR>(IN&nbsp;THOUSANDS)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,744,952</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8,143</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,327,157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.05</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Forfeitures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,317,035</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(959,504</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Outstanding as of September&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,795,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.95</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,758</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exercisable as of September&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,264,983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,285</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the estimated fair value of the common stock for the options that were in the money as of
September&nbsp;30, 2021. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The aggregate grant date fair value of stock options vested during the nine months ended September&nbsp;30, 2020 and 2021
was approximately $1.6&nbsp;million and $6.5&nbsp;million, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company recorded share-based compensation expense related to stock options of
$0.7&nbsp;million and $3.9&nbsp;million during the nine months ended September&nbsp;30, 2020 and 2021, respectively. As of September&nbsp;30, 2021, there was $20.7&nbsp;million of unrecognized compensation cost related to unvested share-based
options granted under the 2017 Plan, expected to be recognized over a weighted average period of 2.9 years. The intrinsic value of the options exercised for the nine months ended September&nbsp;30, 2020 and 2021 was $0.3&nbsp;million and
$0.7&nbsp;million, respectively. Share-based compensation cost is measured at fair value and is recognized as expense on a straight-line basis over the requisite service period. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The assumptions used in the Black-Scholes model for stock options granted were as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE MONTHS ENDED<BR>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7&nbsp;years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">95%&#151;100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">105%&#151;110%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.42%&#151;1.42%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.83%&#151;1.17%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-34 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Given the lack of an active public market for the common stock, the Company has from time to time engaged an independent
valuation firm to assist management in determining the fair value of its common stock. A discussion of the Company&#146;s determination of the fair value of common stock is included within the <I>Restricted Stock Units </I>section below. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Restricted Stock Units </I></B></P>  <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During the nine months ended
September&nbsp;30, 2021, the Company granted 5,244,329&nbsp;restricted stock units (RSU) to an executive officer subject to service, performance, and market conditions. Each RSU entitles the recipient to one share of common stock upon vesting. The
service condition requires the executive officer&#146;s continued employment with the Company through the achievement of the performance and market condition which can occur at any point in time. The performance condition requires the consummation
of a change in control event as defined in the 2017 Plan and the&nbsp;market&nbsp;condition&nbsp;requires that the aforementioned change in control meets defined market capitalization thresholds (a minimum market capitalization of $2.5&nbsp;billion
must be achieved for any of the RSUs to vest, all of the RSUs will vest if a $5.0&nbsp;billion market capitalization is achieved, and a portion of the RSUs will vest if a market capitalization of between $2.5&nbsp;billion and $5.0&nbsp;billion is
achieved). As the performance condition is a change in control event, the performance condition will only become probable once a change in control is consummated. Accordingly, as a change in control did not occur during the nine months ended
September&nbsp;30, 2021, the Company did not record any share-based compensation expense related to this RSU&nbsp;award. The Company estimated the grant date fair value of the RSUs using a <I>Monte&nbsp;Carlo</I> simulation model of approximately
$1.6&nbsp;million. </P>  <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company used the<I>&nbsp;Monte</I><I>&nbsp;Carlo</I>&nbsp;simulation model approach to estimate the fair value of the RSUs on the date
of grant. In applying the<I>&nbsp;Monte</I><I>&nbsp;Carlo</I>&nbsp;simulation model, the total equity value of the Company was simulated as of an expected change in control event that achieves certain market capitalization thresholds as established
in the agreement. For each simulated value, the total equity value is allocated to the various classes of equity in the Company&#146;s capital structure according to the characteristics of that capital structure, such as the number of shares of each
class of equity, seniority levels, liquidation preferences and conversion values for redeemable convertible preferred stock, and participation thresholds for common stock and each series of redeemable convertible preferred stock. The fair value of
the RSUs is the average of the discounted proceeds to the common stock across all simulated paths. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The<I>&nbsp;Monte</I><I>&nbsp;Carlo</I>&nbsp;simulation model
requires various subjective assumptions that represent management&#146;s best estimates of the fair value of common stock, expected equity volatility, risk-free interest rate, discount period, expected dividend yield, and time to change in control
event that achieves certain market capitalization thresholds as established in the agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Fair Value of Common Stock and Fair Value of Total
Equity</I>&#151;Given the lack of an active public market for the common stock and other equity instruments, the Company has from time to time engaged an independent valuation firm to assist management in determining the fair value of the common
stock, which has also been used to determine the fair value of the Company&#146;s total equity. In the absence of a public trading market, and as a clinical-stage company with no significant revenues, the Company believes that it is appropriate to
consider a range of factors to determine the fair market value of the common stock at grant date and resulting total equity value. In determining the fair value of its common stock and total equity value, the Company uses methodologies, approaches,
and assumptions consistent with the American Institute of Certified Public Accountants&#146; (AICPA) Audit and Accounting Practice Aid Series: Valuation of Privately Held Company Equity Securities Issued as Compensation. In addition, the Company
considered various objective and subjective factors, along with input from the independent third-party valuation firm. The factors included (1)&nbsp;the achievement of clinical and operational milestones by the Company; (2)&nbsp;the significant
risks associated with the Company&#146;s stage of development; (3)&nbsp;capital market conditions for life science companies, particularly similarly situated, privately held, early-stage life science companies; (4)&nbsp;the Company&#146;s available
cash, financial condition, and results of operations; (5)&nbsp;the most recent sales of the Company&#146;s preferred stock; and (6)&nbsp;the preferential rights of the outstanding preferred stock. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Expected Equity Volatility</I>&#151;Due to the lack of a public market for the Company&#146;s common stock and the lack of company-specific historical and implied
volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company (e.g., public entities of similar size, complexity,
stage of development, and industry focus). The historical volatility is </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-35 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
calculated based on a period of time commensurate with expected change in control event that achieves certain market capitalization thresholds as established in the agreement.</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Risk-Free Interest Rate</I><I></I><I>&nbsp;and Discount Period&#151;</I>The risk-free interest rate is based on a treasury instrument whose term is consistent with
the expected time to change in control event that achieves certain market capitalization thresholds as established in the agreement. The discount period is the period between the valuation date and the assumed change in control event date, with the
assumption that all equity shares in the capital structure are paid out in cash. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Expected</I> <I>Dividend Yield</I>&#151;The expected dividend yield is based on
the Company&#146;s historical and expected dividend payouts. The expected dividend yield is zero as the Company has historically paid no dividends and does not anticipate dividends to be paid in the future. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Time to Change in Control Event&#151;</I>The time to change in control event is based on the Company&#146;s best estimate of a change in control event that achieves
certain market capitalization thresholds as established in the agreement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company engaged an independent valuation specialist to determine the fair value of
the RSUs. The independent valuation specialist considers a number of objective and subjective factors, including weighted probability of various liquidation event scenarios, operating and financial performance, discount for lack of marketability of
the Company&#146;s equity, and general and industry-specific economic outlook, among other factors. The discount for lack of marketability is applied to reflect the increased risk arising from the inability to readily sell the RSUs. The assumptions
used in the<I> Monte</I><I> Carlo</I> simulation model to determine the grant date fair value of the RSUs during the nine months ended September&nbsp;30, 2021 are presented below: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Time to liquidity event (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.56&#151;3.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Equity volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%&#151;110%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.11%&#151;0.31%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Discount for lack of marketability</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26%&#151;32%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of September&nbsp;30, 2021, there was $1.6&nbsp;million of unrecognized compensation cost related to unvested RSUs. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Share-based compensation expense included in the statement of operations for the nine months ended September&nbsp;30, 2020 and 2021 was as follows (in thousands): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE MONTHS<BR>ENDED<BR>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">303</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">708</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,852</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-36 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>13. Net Loss Per Share Attributable to Common Stockholders </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s potential dilutive securities, which include redeemable convertible preferred stock, options to purchase common stock, and unvested shares of
restricted common stock, have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net
loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to
common stockholders for the period indicated because including them would have had an anti-dilutive effect: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57,239,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">136,422,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Options to purchase common stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,656,562</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,795,570</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Unvested shares of restricted common stock from early exercises</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272,093</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restricted stock units</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,244,329</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,168,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">170,462,367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shares of redeemable convertible preferred stock also participate in dividends with shares of common stock (if and when declared) and therefore are deemed participating
securities. The holders of redeemable convertible preferred stock do not contractually share in losses and therefore no additional net loss per share has been disclosed under the <FONT STYLE="white-space:nowrap">two-class</FONT> method. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>14. Subsequent Events </B></P>  <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subsequent events have been evaluated through
November&nbsp;19, 2021, which is the date that the condensed consolidated financial statements were available to be issued. There were no material subsequent events that occurred during this period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-37 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:50pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Shares </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g129231g96c25.jpg" ALT="LOGO">
 </P>  <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>PRELIMINARY PROSPECTUS
</B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:32%">&nbsp;</P></center>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Jefferies </B></P>  <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>SVB Leerink </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Barclays </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>William Blair </B></P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022 </P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>INFORMATION NOT REQUIRED IN THE PROSPECTUS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;13. Other Expenses
of Issuance and Distribution </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the expenses to be incurred in connection with the offering described in this Registration
Statement, other than underwriting discounts and commissions, all of which will be paid by us. All amounts are estimates except the SEC registration fee, the FINRA filing fee and the exchange listing fee. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>

<TD WIDTH="87%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT&nbsp;TO&nbsp;BE<BR>PAID</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Exchange listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Transfer agent and registrar fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be provided by amendment. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;14. Indemnification of Directors and Officers </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section&nbsp;145 of the Delaware General Corporation Law (DGCL) empowers a corporation to indemnify its directors and officers and to purchase insurance with respect to
liability arising out of their capacity or status as directors and officers, provided that the person acted in good faith and in a manner the person reasonably believed to be in our best interests, and, with respect to any criminal action, had no
reasonable cause to believe the person&#146;s actions were unlawful. The DGCL further provides that the indemnification permitted thereunder shall not be deemed exclusive of any other rights to which the directors and officers may be entitled under
the corporation&#146;s bylaws, any agreement, a vote of stockholders or otherwise. The certificate of incorporation of the registrant to be in effect upon the completion of this offering provides for the indemnification of the registrant&#146;s
directors and officers to the fullest extent permitted under the DGCL. In addition, the bylaws of the registrant to be in effect upon the completion of this offering require the registrant to fully indemnify any person who was or is a party or is
threatened to be made a party to any threatened, pending or completed action, suit or proceeding (whether civil, criminal, administrative or investigative) by reason of the fact that such person is or was a director or officer of the registrant, or
is or was a director or officer of the registrant serving at the registrant&#146;s request as a director, officer, employee or agent of another corporation, partnership, joint venture, trust or other enterprise, against expenses (including
attorney&#146;s fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding, to the fullest extent permitted by applicable law. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section&nbsp;102(b)(7) of the DGCL permits a corporation to provide in its certificate of incorporation that a director of the corporation shall not be personally
liable to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except (1)&nbsp;for any breach of the director&#146;s duty of loyalty to the corporation or its stockholders, (2)&nbsp;for acts or
omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (3)&nbsp;for payments of unlawful dividends or unlawful stock repurchases or redemptions or (4)&nbsp;for any transaction from which the director
derived an improper personal benefit. The registrant&#146;s certificate of incorporation to be in effect upon the completion of this offering provides that the registrant&#146;s directors shall not be personally liable to it or its stockholders for
monetary damages for breach of fiduciary duty as a director and that if the DGCL is amended to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of the registrant&#146;s directors
shall be eliminated or limited to the fullest extent permitted by the DGCL, as so amended. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section&nbsp;174 of the DGCL provides, among other things, that a
director who willfully or negligently approves of an unlawful payment of dividends or an unlawful stock purchase or redemption may be held liable for such actions. A </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-1 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
director who was either absent when the unlawful actions were approved, or dissented at the time, may avoid liability by causing his or her dissent to such actions to be entered in the books
containing minutes of the meetings of the board of directors at the time such action occurred or immediately after such absent director receives notice of the unlawful acts. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As permitted by the DGCL, the registrant has entered, and intends to continue to enter, into separate indemnification agreements with each of the registrant&#146;s
directors and certain of the registrant&#146;s officers that require the registrant, among other things, to indemnify them against certain liabilities that may arise by reason of their status as directors, officers or certain other employees. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The registrant expects to obtain and maintain insurance policies under which its directors and officers are insured, within the limits and subject to the limitations of
those policies, against certain expenses in connection with the defense of, and certain liabilities that might be imposed as a result of, actions, suits or proceedings to which they are parties by reason of being or having been directors or
officers. The coverage provided by these policies may apply whether or not the registrant would have the power to indemnify such person against such liability under the provisions of the DGCL. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These indemnification provisions and the indemnification agreements entered, and intended to be entered, into between the registrant and the registrant&#146;s officers
and directors may be sufficiently broad to permit indemnification of the registrant&#146;s officers and directors for liabilities (including reimbursement of expenses incurred) arising under the Securities Act. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriting agreement between the registrant and the underwriters to be filed as Exhibit&nbsp;1.1 to this registration statement provides for the indemnification
by the underwriters of the registrant&#146;s directors and officers and certain controlling persons against specified liabilities, including liabilities under the Securities Act with respect to information provided by the underwriters specifically
for inclusion in the registration statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;15. Recent Sales of Unregistered Securities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following list sets forth information regarding all unregistered securities sold by us since January&nbsp;1, 2018. No underwriters were involved in the sales and
the certificates representing the securities sold and issued contain legends restricting transfer of the securities without registration under the Securities Act or an applicable exemption from registration. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(a) In July 2018, we issued and sold an aggregate of 12,500,000 shares of our Series&nbsp;A redeemable convertible preferred stock at a purchase price of $1.00 per
share for aggregate proceeds of $12.5&nbsp;million to a total of six&nbsp;(6)&nbsp;accredited investors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(b) Between August 2019 and October 2019, we issued and
sold an aggregate of 27,444,339 shares of our <FONT STYLE="white-space:nowrap">Series&nbsp;B-1</FONT> redeemable convertible preferred stock at a purchase price of $1.561 per share for aggregate proceeds of approximately $42.8&nbsp;million to
eighteen (18)&nbsp;accredited investors. Additionally, in December 2020 we issued and sold an aggregate of 21,958,284 shares of our Series&nbsp;B-2 redeemable convertible preferred stock at a purchase price of $1.951 per share for aggregate proceeds
of approximately $42.8&nbsp;million to eighteen (18) accredited investors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(c) Between March 2021 and June 2021, we issued and sold an aggregate of 57,224,618
shares of our Series&nbsp;C redeemable convertible preferred stock at a purchase price of $2.097 per share for aggregate proceeds of approximately $120.0&nbsp;million to thirty-two (32) accredited investors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(d) From January 2018 through November&nbsp;19, 2021, we granted stock options to purchase an aggregate of 34,015,684 shares of common stock upon the exercise of
options under our 2017 Plan at exercise prices per share ranging from $0.07 to $1.57, for an aggregate exercise price of approximately $29.3&nbsp;million. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(e) In
June 2021, we granted an award of restricted stock units covering 5,244,329 shares of our common stock. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(f) From January 2018 through November&nbsp;19, 2021, we
issued and sold to certain service providers of ours an aggregate of 1,863,248 shares of common stock upon the exercise of options under our 2017 Plan at exercise prices per share ranging from $0.07 to $1.24, for an aggregate exercise price of
approximately $515,290. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-2 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

  <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offers, sales and issuances of the securities described in Items&nbsp;15(a), 15(b) and 15(c) were exempt from
registration under the Securities Act under Section&nbsp;4(a)(2) of the Securities Act or Regulation&nbsp;D promulgated thereunder as transactions by an issuer not involving a public offering. The recipients of securities in each of these
transactions acquired the securities for investment only and not with a view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions. Each of the recipients of
securities in these transactions was an accredited person and had adequate access, through employment, business or other relationships, to information about the registrant. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offers, sales and issuances of the securities described in Items&nbsp;15(d), 15(e) and 15(f) were exempt from registration under the Securities Act under either
(1)&nbsp;Rule&nbsp;701 in that the transactions were under compensatory benefit plans and contracts relating to compensation as provided under Rule&nbsp;701 or (2)&nbsp;Section&nbsp;4(a)(2) of the Securities Act as transactions by an issuer not
involving any public offering. The recipients of such securities were the registrant&#146;s employees, consultants or directors and received the securities under our 2017 Plan. The recipients of securities in each of these transactions represented
their intention to acquire the securities for investment only and not with view to or for sale in connection with any distribution thereof and appropriate legends were affixed to the securities issued in these transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;16. Exhibit&nbsp;and Financial Statement Schedules </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>(a)
Exhibits. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">See the Exhibit Index immediately preceding the signature page hereto for a list of exhibits filed as part of this registration statement on Form
<FONT STYLE="white-space:nowrap">S-1,</FONT> which Exhibit Index is incorporated herein by reference. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>(b) Financial Statement Schedules. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Schedules have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;17. Undertakings </B></P>   <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Insofar as indemnification for
liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the SEC, such
indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or
paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the
registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the
Securities Act and will be governed by the final adjudication of such issue. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The undersigned hereby undertakes that: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(1) For purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this registration statement
in reliance upon Rule&nbsp;430A and contained in a form of prospectus filed by the registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it
was declared effective. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(2) For the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus
shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-3 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>EXHIBIT<BR>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>DESCRIPTION</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;1.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement, including Form of <FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;3.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;3.2*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Certificate of Incorporation of the Registrant, to be in effect upon the completion of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;3.3*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Bylaws of the Registrant, as currently in effect.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;3.4*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Bylaws of the Registrant, to be in effect upon the completion of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;4.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Investors&#146; Rights Agreement among the Registrant and certain of its stockholders, dated March&nbsp;26, 2021.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;4.2*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Specimen common stock certificate of the Registrant.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;5.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Wilson Sonsini Goodrich&nbsp;&amp; Rosati, Professional Corporation.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.1+*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.2+*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2017 Equity Incentive Plan, as amended, and forms of agreement thereunder.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.3+*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2022 Equity Incentive Plan and forms of agreements thereunder, to be in effect upon the completion of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.4+*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2022 Employee Stock Purchase Plan, to be in effect upon the completion of this offering.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.5+*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Employment Offer Letter between the Registrant and Rami Elghandour.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.6*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Lease Agreement between TPG West Watkins Property, LLC and the Registrant, dated October&nbsp;5, 2018.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.7*&#134;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Development, Evaluation and License Agreement between the Registrant and Pfenex Inc. dated December&nbsp;24, 2018.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">23.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Independent Registered Public Accounting Firm.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">23.2*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Wilson Sonsini Goodrich&nbsp;&amp; Rosati, Professional Corporation (included in Exhibit&nbsp;5.1).</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">24.1</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (see <FONT STYLE="white-space:nowrap">page&nbsp;II-5</FONT> to this <FONT STYLE="white-space:nowrap">Form&nbsp;S-1).</FONT></TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be filed by amendment. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">**</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Filed previously. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">+</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Indicated management contract or compensatory plan. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="right">&#134;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Portions of this exhibit have been omitted in accordance with Item 601 of Regulation S-K. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-4 </P>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this registration statement to be signed on its behalf by the
undersigned, thereunto duly authorized, in the City of Gaithersburg, Maryland, on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>  <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-size:9.5pt"><B>ARCELLX, INC.</B></FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Rami Elghandour</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><I>President, Chief Executive Officer and Chairman of the Board of Directors</I></TD></TR>
</TABLE></DIV>  <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Rami Elghandour and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; as his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT>
and agents, each with the full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities (including his or her capacity as a director and/or officer of registrant) to sign any or all amendments
(including post-effective amendments) to this registration statement and any and all additional registration statements pursuant to Rule&nbsp;462(b) of the Securities Act of 1933, as amended, and to file the same, with all exhibits thereto, and all
other documents in connection therewith, with the Securities and Exchange Commission, granting unto said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorneys-in-fact</FONT></FONT> and agents, and each of them, full power and
authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as they, he or she might or could do in person, hereby ratifying and confirming all that said
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agents or any of them, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on
the dates indicated. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>

<TD WIDTH="42%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>DATE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL" align="left">Rami Elghandour</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL" ALIGN="center">President, Chief Executive Officer and Chairman of the Board of Directors
<I></I></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><I>(Principal Executive Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Chief Financial Officer<BR><I>(Principal Financial and Accounting
Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL" align="left">Ali Behbahani, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL" align="left">Raymond Camahort, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL" align="left">Jill Carroll, M.S.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL" align="left">David Lubner, M.S., C.P.A.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL" align="left">Lewis T. Williams, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9.5pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL" align="left">Derek Yoon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Director</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2022</TD></TR>
</TABLE>  <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-5 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g129231g03e76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g03e76.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X6 -:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(Q+3$Q+3$W5#$T.C0W.C$Q*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3$Q+3$W5#$T.C0W.C$Q*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,2TQ,2TQ-U0Q-#HT-SHQ,2LP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C$R.#PO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14%304))04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04%304%!04%%028C>$$[05%"24%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T%G045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$T;G%M<6%K=7!8648S34%*
M<$%!2B8C>$$[2&]">E!V:6Q$9G!85E X06QS;B]!3U)J+W="8U4P-SE+-G O
M>3)4+T%027@O=T-U2S W.4LV<"]Y,E0O05!)>"]W0W5+,#<Y2S9P+R8C>$$[
M>3)4+T%027@O=T-U2S W.4LV<"]Y,E0O05!)>"]W0W5+,#<Y2S9P+WDR5"]!
M4$EX+W=#=4LP-SE+-G O>3)4+T%027@O=T-U2S W.28C>$$[2S9P+WDR5"]!
M4$EX+W=#=4LP-SE+-G O>3)4+T%027@O=T-U2S W.4LV<"]Y,E0O05!)>"]W
M0W5+,#<Y2S9P+WDR5"]!4$EX+W=#=28C>$$[2S W.4LV<"]Y,E0O05!)>"]W
M0W5+,'5J,6)54DEH:W4U>6=)-6HQ2#-&9"\R:&ET4%%6,5 X;C=X-VEE4R\X
M04U/;7)'>D]L<D<V3B8C>$$[-G-:;E1H2$1Y3GA2,6=,,4UK9T91=2]81D9*
M6F)E679)359M,$UQ879.33%Q=RMS>5-N;70P-E)B;T5U26LT231K-$9L3WA(
M2E<W1B8C>$$[85)S1W$O;$4X.&M$6&YM94]#4V-E;F144U<O3T]!4$@Q15I9
M8VEH;'(X1&)H2U4K3$%T25<R,6HX<T9:1VYU4$TW065N>6I%,7%19B8C>$$[
M:&8Q1%=Q:V9(-F9%94A,9G!I=$U-+U-U<68X04Q:4"]!36I(+W)I;6YF<%A6
M4#A!;'-N+T%/4FHO=T)C5G S-E8Q5"]!2F)*+W=$:R8C>$$[62\X05A&860K
M;&15+W=#5WEF.$$U1U O049X5VYF<%A64#A!;'-N+T%/4FHO=T)C5G S-E8Q
M5"]!2F)*+W=$:UDO.$%81F%D*VQD528C>$$[+W=#5WEF.$$U1U O049X5VYF
M<%A64#A!;'-N+T%/4FHO=T)C5G S-E8Q5"]!2F)*+W=$:UDO.$%81F%D*VQD
M52]W0U=Y9CA!-4=0+R8C>$$[049X5VYF<%A64#A!;'-N+T%/4FHO=T)C5G S
M-E8Q5"]!2F)*+W=$:UDO.$%81F%D*VQD52]W0U=Y9CA!-4=0+T%&>%=K5'!E
M<6%K,B8C>$$[<%=G3C--45IO=U%:2&]2>DAV:6A7=3EA,6=88W=&+V-F,VIF
M-W1F>%!V;3='2TYC9S%P;&]55W!A='E6=DUA861)2D510SEU6DEL2R8C>$$[
M=7=5<T=Q,S)E5E1556]$=C)-6E)I4#1F<U-M=&PU8C%#-V%Q*V1.4&=J85-'
M3TTS1BLP8F9V,UI/5$M#,T99*TA+43%.1DE/*U)00R8C>$$[4#10<U=M4&%P
M9&%X65A+=T175&5":U-4,6)7-&MK46-H6&E395!X3#!/,E=2>'=0.% R2V]7
M,G,V=5I#1&980DA#43=Y=C%#16IV:28C>$$[8U5E-$E5=C Q<E O04,S,T@O
M23$O=T-U2'=O9'=6:T]J5V-M<&%:-GIE8D9S=%(O,&AH63-5<VMA96YB>$-1
M2#%Y+TAN2V%O:55Q5R8C>$$[+T-U55EG+U-L13-79U@X2VAO+T]D:$Q717I"
M9G)S;TI:6&1$1T])8T)V9W%/4E=O25!404](*V(Y:3!X6#E.87HO>3,S2"])
M,2\V-28C>$$[8C153S1)6DXU43%#+VYT<C1Z6$US<%(T07!D,EEG15,Q<%4Y
M-D1,35='0E!)9DI)6E9O<T%V-SEB835V>EIX37)-6C-:84%Q<$E(-R8C>$$[
M>#1L,R]W0F(W*VU7-4U526EX14@T9G-62'DK6' P4FY'=39E-F=Q06]U:GE)
M84@Q<3AA9'9S2"]!0SES9T)$*UHO<U5O6%AD3'9.228C>$$[;6IJ8E593#%:
M95IJ;7,U5VMJ64DU47-'25=O3$MA2$I9-%DU9G<Q-W=%24)B:68V=34Y4G%H
M,$%023EW,E0X0T8O4U!K<4HP;4I,>28C>$$[-&5+-C%%,E5A>',V>7969UA(
M,D4K,'8R:65V8G)K6C1O06)20BM#<&TS;'=P1W!K.'<R2FMC8V=K9'=805@P
M,6LK23!&1RM09T(O328C>$$[0T14<FQD42]M9EE%;U!59$YL<W)&3&XY2S(Y
M>3=Y*VU)3&5B,4A!.4Y:3V)$66=F2'@K65!H:S1W9U180CEI<&9&8U1L2F%Y
M3G-G228C>$$[*TDO>G)K>F=H+TY(>5$V,VQM;&YJ:F4T84Y(9%9A47-A2T-A
M1FIU3VU*=U%R-E(X;%I&2#564S5U:$AA95IT3T9U-VA5;74W:')99R8C>$$[
M15-%339%4'A&22]%,#5,;$(T04XX9GE!2U5J=DDU3&5',V1B>C%M;$0K;VE/
M1'=+4T9/>D4P64%-2V=F>'DV3TM"+VA(>5%O>%A%-28C>$$[4U=S:F))0U!I
M4#A!3W5%-$EF>E(X;%104G10='(K>G4U8FI7,# K-FA&8E<S;C4P;E!&;4DU
M9R]".6UG<4M63U9Z>'AI4E5!9F=%;R8C>$$[=6)Y=SEV=V%4>D)P.'%39E=A
M9E9R;U--<'1G849L8C V0U=N=V1Z-%8R>4E%1"]",V9W.39T5U=G,G0U1$-&
M.'A7,$8W339Q67)L,B8C>$$[:6E25$=R;&YM<3%/3$U5<'@W67EJ168U4&(S
M0E5,<D=K=G Q=C9Q-GIB6'A->&A63%-9>45G4G$U:V]E3$)$>C1I;S9G*T=3
M:$-%:B8C>$$[.49F0E=!*V).5#%+1R]G5T<W;6I5=T%K2DEY9VXQ2$9D:C=:
M6&MX479K4&MG;S<Y4"M41&(R5F)N6%)C0S-29%%+>6]%3GA696)2028C>$$[
M>4UA8V560V4Y4&A&1%A(.$DY,%9T;#)M*U1D3G9.4#!Q-D8Y<D9X3')5='-T
M;F)7=#-"-FQ(;7!/=D=5<G=B,#5)>$=:1S0X9S%4>"8C>$$[;V-Q2D%*,FIT
M-4IP=6)Y5&-09#9V1D9"<D5D=%EM.&5!<F97>C-(<#)K4VMP25)C4$=:15HQ
M37%O=E1L>$Y244YX,BMN-69S5%1'9"8C>$$[6G5F3%=L87)C-EIC5"M963=M
M,&Y%3GEK='IB:W!W045Q9WA&;$QC=S-&<6M5-UI:2$A9=6\O2D-583-Q3G1B
M95EK9SAV-C%E,RMM3"8C>$$[-DA'-FUE4D=E46]P;&]P15I#:51K1G%/;51J
M:DA$=D57:#E+3B]Z:7(K5W-R1U9R;E9!,&@U14-E1VQ7,R\S>FU$*V-N-4IP
M<B]O5B8C>$$[1#AS+RM7<E90*U(X4"]61$@X-U!Y5VYF.4-O9FQN+WDQ87 O
M>5!H+S9O62]N6BM3,#<O;U9$.',O=T1L<3%4+T%*2'<O=T161$@X-R8C>$$[
M4'E7;3$O-7A6+TQ733AL=6152DE+-WIW.4A(12]W0S9F030O;DHK4S Q+S!+
M:"M79B],5G%N+TDK2"]Q:&HK9&XU3%1V*VA54'EZ+R8C>$$[04]7<E90.$%K
M9D0O04Y5369Z<R]*860O,$MH*U=F.$%Y,6%P+W=!:C1F.$%Q:&HK9&XU3%1V
M.$%O5D0X<R\X06QQ,50O:V9$+W="528C>$$[369Z<R]*85%M<"]K>"M5;FMQ
M,U9R-CDQ3T]'+V-"5'I343AO9V%F66@R,FM/6%ED5&QK9E146FIW;69*3&8P
M2BM24"]!1F-T52LW+R8C>$$[04LX-6ME3G%/-DQD*U1Y9'IV,$HK4E O049C
M=%4K-R]!2S@T*TYQ3S9++VLX;F,W.4-F:U0O,6-T52LW+W)Z:C0R;S=O<BM4
M>61Z9B8C>$$[-D<O27-+52]35W%C5TE*3DXV:EEF-W Y.&9',4AD1F9Y951U
M82]1;C5%+SE83%90=2\V.#0K3G%/-DLO:SAN8S<Y0V9K5"\Q8W15*R8C>$$[
M-R]R>FHT,F\W;W(K5'ED>G8P2BM24#A!,6-T52LW+W)Z:C0R;S=O<BM4>61Z
M63!B.&DQ0D$Q3%9+3TM.=#)R6&(Y>C1J2'AT4C-26"8C>$$[.&YK-VUV,$HK
M4E O049C=%4K-R]!2S@T*TYQ3S9++VLX;F,W.4-F:U0O,6-T52LW+W)Z:C0R
M;S=O<BM4>61Z=C!**U)0+U9Y,50W=B8C>$$[*W9/4&IA:G5I=C502C--;#AV
M9FQ,*U='=E="=DY*=F(V94)M34UL6D56;%IF:6]635%)-D$O3$M-;71Z4DY%
M0G!Y66I!,%5Z+W=#:"8C>$$[9F9)+RLO-R]!4#5'>"\X059,22]Y;&LX;75N
M9CE#*RM2+SA!9CDO+T%-:EDO=T1Q;&HO2U=4>5=N9CA!479V:V8O9CDO=T0X
M:EDO*R8C>$$[<5=0.'!:4$IA9"\P3#<U2"]W0B\S+SA!>4YJ+T%/<5=0.'!:
M4$IA4S=54"MC62]Y.#%'8U-Z,T]P0F\Q16$X2F]G2U9,8C%H4&1S<B8C>$$[
M3W5M5&5Y,&AF*VA54'EZ+T%/5W)64#A!:V9$+T%.54U(-3)F:W1/+S9&42],
M4#A!-6%T52]W0U(X4#A!,5%X+T]Z.&QP,R]1<4@U6B8C>$$[+W=$3%9Q;B]!
M0U!H+W=#<4=0-3)F:W1/+W=#:%50>7HO=T-7<E90*U(X4"]!1E%X+T]Z.&QP
M=&8K8U9F>3%I65-R8S9O5VI024%Z=R8C>$$[,'%U+RLK8V9Z:R]*865Y4B]W
M0C)V>4@V<WA%<G-69&ER<U97>69:2'I8.5EX5F1I<G-64TAZ3#5/<W9-1GA:
M5%A6-V57-'-M1'!&828C>$$[>6E.2$EK:FMQ-#1S5"]D8V%G:C17660X5E,O
M>70K5V5I95A.4T=O,G0Q95A.=W%44E)I-65);VMC>&I*4E5J:FE!5F9254E"
M,$<R2R8C>$$[;TPX,'1,,4\X1VM4864Q<TIR4U=6-EAC;VA8-&M#:FEX6D15
M9%)X3E(Q>DLP,&=,='ED3DE#-S9S274Y33@W,TQ19DAO.$-123!A>"8C>$$[
M=UA34F=H-'A#>%IL:S5K;4UC83AS>5)+02]N9DIY4DQ'4#5Y<3%L-7HK<DIB
M4E)A1&)W<DEK;$E*-#1Y5$=N0D)Y16Y+:2]A1D18;"8C>$$[=EA"8TQV,4DT
M;UAF<54Y4S S>G!F=VE+4F1#:#0X3T1W>E%O>2MK<G)(43AZ=79Q:V<K3E!$
M1$=50B]/5$=7369Z:U)B>&5D;TE)-R8C>$$[6DEF3"]O2D<X46I-:T)(0GE#
M=TY83F9P=T5W4#@U0D]--RMP0C,S;'I76B]R161V<#)G5SEV37)*1W!U25AE
M3&MN1&MJ.&PK261A."8C>$$[974U<FMO-4EJ<DIL2$I%8WI*:B]!4'ER2'I"
M+WDP-F8O=T)*:U X05A,9GI-9E U3C,U<5!N.&YF.'%X.'=F.'1/;B]!4%-:
M1"]82"8C>$$[.'I(>BM3+VUO*V9Y8V9Y>3AW8F8V5' K+W=$>2M1+S%X+TUX
M."]K=C5Q4&XX;F8X<7@X=V8X=$]N+SA!4UI$+T%&>"]->#@O:W8U<28C>$$[
M4&XX;F8X<7@X=V8X=$]N+T%04UI$+UA(.'I(>BM3+VUO*V9Y9"]Y<DAZ0B]Y
M,#9F+W="2FM0.$%82#AZ2'HK4R]M;RMF>65P9FQ.-28C>$$[26TX=C)C,3ED
M6$M3,U8X,T0P-$I056A622M61%94>%IQ,3,W9%!(34A66G5-,$]J9S9R3GAM
M:#!E:#5I3TDW1EA9<3=&5G$O868U+R8C>$$[=T=+<G-69&ER<U9D:7$R5"LW
M8C5(.5=+=6HO=3$K42]6:7)W2"]N25159DMD>C4R.'9A9'%N;4LK.',S=6UW
M=&1*9E=T;S%Y;D-D*R8C>$$[85!Z:6U35D1(2EI$<$<R-TME>$E5:&<R=#)0
M;&Q&<TQ:4'I7=3=A,FUS2FAF,S<R=#A5=C1,;2MV4')-:4Q(3DDP<FUD4DA*
M1S1!9"8C>$$[9FI$3G5-5F916#5987IO,3=&<3ET665:2E!-5&DV1V\Q;&IL
M:DYP839M9W5,4S)8,6%K;W-F,F0Y='A286-1;UIR2CEK9DYF,6I&5B8C>$$[
M,DMU>%9)9DUU9S8U<71X6E!P,G5Y-E)"8G-'=4EO;V<U;2]E4G1U>%IA9G4P
M9$]H2'A6-UEQ;"]L8GEB-6@P;E5H96%L-6UU9%=I4B8C>$$[2F]K=$A74DEW
M<VAJ35I03V%9<S!9:DE$3G5E4G%A-'%L6#5V-EAF,S!7:G1A-EI,<7%15%-V
M3F)1:&IS54%(27%'249C>3E,24,W3B8C>$$[3UAP6D%86G!H8S)N>C-:.4LT
M+TQY93-G955/.&QQ<W%Y2W9%2U%V=W)8*V%H4%@R>DI%<2]J8V=3<FQ.3$Y3
M.'(S='=33%AY6'%&<28C>$$[0DE716MB>3AJ2%)G131U:VEJ8W)V=G-+9%-7
M>6-C;TA/66))-5%/8W=U='9,,G)*8GAW,U!K<3=U06M#>$9W2&IC>6-M6G!/
M4U)6,R8C>$$[<71!83!!<%5J135",&U%2$E,,FUU=71",4-51#!V26QZ0DER
M;U5O,#=+15=G6E-#=%=,539S5'8W8EE"369Z,45X+U!B+U%&*T5:;"8C>$$[
M.&E86#%J:5%K:DY/54)+<T]2:D-+<&]70DA4;U!E<GAJ*V5&-'@O4%DO.$$T
M1#@V9CE74SDO-450+U1,9DAH,VAU.&5(94AF-$0X-B8C>$$[9CE74SDO-450
M+U1(>#1D-%AX-&0T9"]G5'IN+T%.5U,Y,R\T<&8X07!J-#A/.$PT.$\X3R]W
M04(K9% K<DIE+SAI2"]!2UDK4$1V0R8C>$$[*U!$=D1V.$%!9FY4+W%Y6'8O
M26@O=T-M4&IW-W=V:G<W=S<O04%(-3 O-G-L-R]Y268X07!J-#A/.$PT.$\X
M4%=V>5HX=F5:.4IS<B8C>$$[<#E61#)T;DY)4'$K;GEQ431C03AP84@W24DR
M<#,V*T9C1%=:27E)<FTV+U=:27E)<#98;4<T8G-69&ER<U97<CEP+VXO05EQ
M=7A6,B8C>$$[2W5X5C)+<EI0-W1V:V8Q67$V4"LW6#5$.5=+<%)R9FMZ>7!R
M:WDS1W$V5&)89#)G4E5U,VI56$-Q:CAW9VU7:V=3=E9E5D-#46%G:R8C>$$[
M67%S;3AI95(U=T)0-64P>55"5VI!97IT,F]J>4=6;#-4;S!J1GE0-6I8<FEQ
M33!N>34U93!B,68P4G!D<'!V<FA"4#E59VEG-6E)128C>$$[4F@O5%9E6$%%
M:&$Y3592,&XR4C@Q+U=-5EA9<6PK=C-'<U<R:UA-,FI7<3-U<&]".5=T6%I5
M5GE704Y76FM!;W14.7)&5TMN6&9Z528C>$$[:&DU>C9$8GE-<#5S24=1<C9A
M,U)6:%4S0FLY4G)9:&Q#>'-/44\U2D-95E10>79R6&YF53=L2DYB,$)D0W,R
M9UIM9V$T:75P4DU*828C>$$[25!5:6-#:E)F15(V97@O87=+:VXU=6%J3%IN
M47@K;$QN4V)3831K5SAU8E8U1F8P=V]*,FHS62M(=FU8<%DS93%U6'!9,V4Q
M;6YN9R8C>$$[.'=7-&UB;#5Z,5(T45!G-#-&,DA99V=B,6IO9UEB+W1C96YX
M9%1L*T@O4D@R3UAW2"M94'-1=7 K6G!K84%A9#5S,5=25VY+5$=7-"8C>$$[
M=6%I1VDP:V]!=$0Y<7%J;#1D<6U58V9F14UO-"LK369S5%8Y9#!)>4YW.#<V
M,G%C-'=L6F)H:55Q4%9,9D-T0T)52T)8<%4Y84-V9R8C>$$[;"]-:3$X178U
M:V9S66<O;DAZ84A02%AT45I14T9B-C%/2VHO04E036IW661W*U1K*T1$*V%0
M:S$O:E!Z:"\Q9F11+S93<"\K83AF0B8C>$$[:#-$-4PT34\T9DHS*TTO3T@O
M5CDQ1"]P2VXO-7)X.$=(8U!K=F=W-V@X;F8T>C@T9CE8,U50.$%P2VXO04]A
M.&9":#-$-4PT34\T9B8C>$$[2C9P*U-U=BMA=%-.-49Q36MT-W!S4D1*93-$
M<S=R35(O9'%Z5DQ!<G94.6XV8W=D6D-!<71I-$=S>'=J5F)&-G1M0S1,<U9D
M:7$Q=B8C>$$[=$HX+S1(1E8R2W5X5C)+=7A6878R;BMF.$)I<3=&6%EQ-T98
M67%T:R]U,BM2+U9I<3)*>5EK25$P2VIW.%!N:7$W:S,X:"]$*W5+=28C>$$[
M-4XO269W+W)I<G549GE(.% V-'%T:V-H4CA"*S!V:"]-4&9&5C-*=C5$*T@Y
M8U9D>6(K42]H+UA&6&-M+VM0-&8Q>%8S2G8U1"M(.28C>$$[8U91.3%B5VPP
M-DID5W%4:%%X55-+:F=D3VY+=45%:FMK16A3+U%U:F8Y5WDS+S5%>&8P=SAC
M=3E01V4Y,S9&,&(O<3)7+SA!>4II+R8C>$$[<&IX>3<Q-'HS=2]1=6IF.5=Y
M,R]!3U)-6#E-94]8979'93E99$<P6#%62#9-=#DQ62\S35A9:C)X-#5D-CA:
M-S$O-D8P8B]Q,E<O+R8C>$$[04-*:2]P:GAY-S$T>C-U+U%U:F8Y5WDS+W=#
M4DU8.4UE3UAE=D=E.3,V1C!B+W$R5R\X07E*:2]P:GAY-S$T>C-Q,%5-1G-S
M8U9V8B8C>$$[<D1'5TI#4G%Q<E5Q97=P9TI*451A=GEB*U$O:"]806@S2G8U
M1"M(.6-69'EB*U$O:"]81E9R=5%Y9D%D,CEV-50W-'%U-4XO269W+R8C>$$[
M<FER=51F>4@X4#8T<3=K,SAH+T0K=4MU-4XO269W+W)I<3%(2EHO9T]Z93,X
M;SDX5EAC;2]K4#1F,7A6,TIV-40K2#EC5F1Y8BM1+R8C>$$[:"]81EAC;2]K
M4#1F,7A68DLU151K;V%"5#1E2'IX5F1(+V1R.&@K<D96,DMU>%8R2W):4'-J
M-7(K<UEQ=7A63#EF,7EX,$Q33&Y6<B8C>$$[-'-,4S%!85AG3U1F17=154))
M-W1I<D8T+W=!,R]+<D)42DAC=T9M0VA*5FE6>41D1S!,:5 Q1$EY2R]%;&Q5
M:6I#;%=Q;TY+;5AL;B8C>$$[.'AV2S-M93=71%%R:#<R2C1(=49U=VAJ:7!(
M3#9,3%-4:$IY-41B-$M%9$1G5E4X,V%T<DYJ2G P3VMR13%Z97ET1"LK0DMG
M8V565"8C>$$[46EL2V(U;6%41$-F15HS55(P9%8R;G%C,E!G:FER:6Y+="]C
M:U$Q+SAW9E5:1U=Y5&E+<WI2>3AD:E%G169A22]W06UT93%2;5HK6"8C>$$[
M,#,Y3#=(5VI6.6]86#=V-5,O2'DK0VAQ2&UZ>C%9*V@V;W-73GA+24DK0WE5
M-6UN9&EO<'8Q0B]$2C0Y2G U,UA&<TQA=%(R;')S5B8C>$$[6#1F<6QW.65A
M22]4=C5G57%0<4IP,4AP>C%!-'-W2D)&845,.35P,7)3=G=.3B]3*WAU+TYD
M;V8W6#AP92\X04@Y<5-8,S5L96%R3R8C>$$[.6QT<%!Q:GE133!B36E/5DI"
M,V]3=SA->3AF6FU'55%F5G4V=E W4F%R2$UW4$%42'5"+U=O+SAR6#AZ+W=!
M;'0O>4QB+VUV2F9Y5"8C>$$[:3@R;B]24'%E-DAY4#8S9CAR6#AZ+WE7,R])
M='8K83AF-4IX96$O-DHY5#-1*U(O5S<O;&$O;68K4S(O-49T+WI8:B]!0U1I
M.#$O,"8C>$$[5#9N=6@X:BMT;'9K6'IR8V$X.&QR97A+=#-$*SA6-&Q):DM%
M53-Q5%)G5#E/83-8-DE984UE4F5H-T4W66QQ<FI-97-B-V-Q6FQM="8C>$$[
M9"LW1EA9<71B-U-F4"M">%9D:7)S5F1I<G-65W(Y<"]N+T%9<75X5C)+=7A6
M,DMR6E W='9K9C%9<390*S=8-40Y5TMR<U9D:7)S5B8C>$$[5WEF6DAZ6#E9
M>%9D:7%',5!5-TA43$=7+W8U:$)A44%'5U9Q:TM#46\V06YQ8U933F90+T%*
M2W4W6GHY95=7,61X8GES.$TS<&-N;28C>$$[83(T3U=4:B]!2&EL5T(V1&,O
M0U%C5E(K;"MA4$QE<%A+,F5L6#A&-B]P3DUH=%<Y5TPP-#,Y2G%3>#AO<7$R
M>%AL565'2W!6-3EJ,"8C>$$[>5I.3W0W,GIM=E=N;5I,94M"=VIC>4(Q2GI9
M84%Z0FM9:U)O8C(V6'1M3TM565)N1U4K2U=W0G)D:&UO,EAL8E164G(W43<V
M05-!1B8C>$$[3U9W;%-$=4YG83ES,F5/96%F,'II9F<X-W%-1VMW9TA*:'E2
M=BMK4#%O939F>51A4TQ(8V%294DW2W-G2#%H1#A,0V]/,6-N05HU0R8C>$$[
M>$]0>6%S>#!/33%,1DU'<BMR.7%J.68X9R\X059R=E K4C1Y9F@V;BMD2#5.
M6&HY;B\V;E O5$YF6"])3F8X06IL,VQ0*TTT>#A0528C>$$[+W=!-E!Y6'@K
M>B\Y5&XO<&TO<B]!2D(O-G1D-2]W06IX:C1E<"]N4BM3*U R9CA!-FY0+T%%
M>DPY0SAL95)T83 V3RMT16TT3CA,;R8C>$$[6E1Y4G@Q5G9F3F)N,75O>%,T
M6E8X;F8V3'-J439J1TIW0G(S;EDY>5EF.$%+<B]+9BLK-78K4G!Y;BM633-E
M4&LU6"MH>E-D>"M:5"8C>$$[;E)F3#)L-DI$-D=N>$9&:V9L27I%<WI%2U%+
M:RM(8DU84'%*-51C:3=(4C9(1G!O;4]-5F%A6E$U:G-69&EQ,79T2C@O=T-"
M>%9D:28C>$$[<G-69&ER<U97<CEP+VXO05EQ=7A6,DMU>%8R2W):4#=T=FMF
M,5EQ-E K-U@U1#E72W9%+TYT>B]!335.=G%&-FYL>3!73S O4TXV3"8C>$$[
M4U)N,'AG8D%E:4Q19U-(;4-E17)F1G8X9$0P1D9+9F5E-2]Z=FTP>#=N>69B
M;3%V1VYT;V\W1V,V97I#,TYM>C-%>DTW3VY-6$UW5"8C>$$[:4A)+V1604MS
M95-H1F9L>B]W07)H+U-S6"M-=U1P>'-P3U)B-FE'1C)$8B]!1W9Q=35Q,W(K
M;GAO;VHT.#9U9&Q8;VMN,E(X,2]7328C>$$[5EA9<6\S;&Q:,S%S.7)E=U(S
M5G),45-15$ES:V)53E)Y5F=19'A81E5U;CAO959*+W=#.3!E>4QC1$5S9V=J
M1'%J3TI31F-+1U@Y-"8C>$$[02MX*S%V,7A65C!N>3$U9#!D5EA39$QT3E!#
M2C9A+U9O231I14HU1F%O0G-73F9N:7%39FU$1EE00EEV9#9Q,FMM3U)Z1&-*
M1DI+>"8C>$$[67)19V5M458R>EDY;FU12G%02'0S9V9E-DQT,DU$0TIL:SA+
M<&)%06YP-4U*:V<P1U%!4V5D2C-!3E)Y=&)O-VM&93<K0DEZ84-7428C>$$[
M8W-)+S P6&UP4G=(;G$U2"]-;BMT4FXP<GEP8U-M5S0X,E!.2S%/56ML;&--
M>&]+0W!,5C9:3T]834)1>%8O;D)Q;G!T3$TS3%5K;B8C>$$[>GAY+U=P+V],
M>5HO,4Y(+T%%-'HO=T)C4&HU+SE4+S)1669K=$@O>6MF.$%3=5-E,FXU53(Q
M-6)X6$YR<EEL=#5L-7AY3&(W168X028C>$$[23--4V9A>&EA34YX-2]S9')I
M.6PT-4EI56-T>% Y2"]!23AR+W=$2VY0.$%T8B\Y3R\X03$Y>5 X<R\P4'0O
M63)F-D4O=T1B9CEJ+R8C>$$[04UE6G(U8SAV,FUH85EL;&(O1S,R<'!I2T=2
M>C%9:F5N<TTQ97 Q17-S*TEV4V%$47<P,DE1:CA4,VQ.37@S3E=T.7!0;B]!
M-'%U>"8C>$$[5C)+=7A683,R:RMF.$1I<3=&6%EQ-T9867%T6#=4+U K07A6
M9&ER<U9D:7)S5E=Y9C-B9DDO<7A6,&8Y,G9Y2#9S5EA9<3=&6%EQ="8C>$$[
M:RMY4&UV-GAI<3=&578Q+U)93F(P:34P=65A83-H=5%&95<S64Q+07)"=FA,
M0GAV>' P>%9I<"]+3%))-'5&<'%&-V)K2&UH-5%T4R8C>$$[5F)O,V%/5TU8
M<2]$2WI55EA684UF,G9I=S)Q6BM6+TED=F].>6PT*W)A:G$Y.&M$5WAU=%-M
M4V51;SAV<6XT=4-T<S)Y:71!34-T928C>$$[9#=++VYB5$HW3#9U6G)36G!1
M=#)W5TUN:E%D4TLP3RM:,FEN16-1;&1%9$A59')98VLK0U5/2&EH2R]6>35-
M5#%84B]-;7%*1VQY;28C>$$[;$)9<6-"2$XV66]&2491<CEU5F,R3TQ.:7@X
M=5 U3VDQ5VLQ5V-!5$=':#-%:CE+03%$>68U9W9R9U13>E=+;%533E93-%AI
M1FI52R8C>$$[;T93>#9$>'DW2')-8T)1179K-&UO-TDQ3U=81DDT*U%(,61Y
M1R\U5B]R6"LO=T-Z+W=#:VA-<R]L1$@S4RM44B])1V9V:"]P;G!V:R8C>$$[
M,U%7,%A2-&)6-797;&LU5%-%1W%!=G@R5#(O6#%Z438S565,:TIQ;G,K>61%
M9$YG14-B4%!Y,S=V2E X>$A:=7A6,DMR5RLP;GHO9R8C>$$[8U9867$W1EA9
M<71B-U-F4"M">%9D:7)S5F1I<G-65W(Y<"]N+T%9<75X5C)+=7A6,DMR6E W
M='9K9C%9<390*S=8-40Y5TMR<U9D:28C>$$[<G-65WEF6DAZ6#E9>%9D:7%8
M-B]P.3EQ3VM83FQ9,WIA8F1Z04-+*U)E8E(P645K2T=4<4)4-U=+<U90:U1Z
M9$1&4S,X,EA%:VEN,28C>$$[1DTV>D9I-C-2=454:TIY9VHT35EM<D=X2S!Q
M4T9#-%944'EV-6,X,3)&>6PS<B]M3G1A;D5$475I,C1T26EZ4RMO2#E+3U%X
M,5)F9R8C>$$[0C0X:4]P=TMH=GI$=#=I46%63$AP,&UP<$)/,&MT<D=R34=!
M6&)L>%8Y<2LR8DQS-E%(141,:'-C,U$Y=7=K4FI)9V-O:DMZ164W<B8C>$$[
M<U=%87):6'0X:V%W*U9,<7DT57%9635+=%)33GE9:65P2"ME*V)81D]-9655
M4SDU+V$X,7%S53AO04=M;D-U-$@O:45V,411=&-U3"8C>$$[;C%,9E%B=3%H
M0TEI=W)"2S%/2VA34S-!5DQ%5D]863@K3TEO>FE4-W<T96\P965C<FIH;D55
M3G5%+W%1,RM'9DUN+U9Q=E K:V58+R8C>$$[04IP>68U<D8O3VHX=S!F>61Q
M9CE4;B]P5"MP-CDU1C O5G)$46)A1%5N2FQO>E)235!I:6I02&EJ930V*S-4
M3V(Q*U-%.'!-4#=8,"8C>$$[2'-B0FQX86-2>6YF;T\T9#,T.7I)<W<S875X
M5C)+<E<K,&YZ+V=C5EA9<3=&6%EQ=&(W4V90.$%G8U9867$W1EA9<3=&5G$O
M868U+R8C>$$[=T=+<G-69&ER<U9D:7$R5"LW8C5(.5=+<EEZ2C9A+T-/9S=N
M=RM72W)Q>69Y:C=Z+U1&6%9K+VQ(,VXK;4MU<DHO2U!V4#A!5$96<R8C>$$[
M:&LT:C12,5AU9D5E,DMR<7EF>6HW>B]41EA6:R]L2#-N*VU+=7)*+TM0=E Y
M359D5U0K569E9C99<71*:SE29FA(43EZ-&HR>%9D5R8C>$$[5"M59F5F-EEQ
M-G-N.&\K."]W0DU69%=4*U5F968V67%T2FLY4F9H2%$Y>C1J,GA69%=4*U5F
M968V67$V<VXX;RLX+S!X5C%:4#52.28C>$$[-2]P:7$Q:DIY5#12,3A4-$@R
M>%9D5U0K569E9C99<39S;CAO*S@O,'A6,5I0-5(Y-2]P:7$Q:DIY5#12,3A4
M-$@R>%9D5U0K569E9B8C>$$[-EEQ-G-N.&\K."\P>%8Q6E U4CDU+W!I<G%Y
M9GEJ-WHO5$96<6U4:R]W04DV*THX0C=9<75R2B]+4'90.4U69%=4*U5F968V
M67$V<R8C>$$[;CAO*S@O,'A6,5I0-5(Y-2]P:7$R47EE;3-W:F]E-3A0;&EQ
M>31U-V5Z<TI,>35F,#=A,FEA86519VYI:V$X;6%G<61G3599,64O;28C>$$[
M=BM89&E)4')E=5%1=&-7<'95:5E0-F=H5T9,:7-K9DAN1S5I;%9L:F-",G)S
M1&EQ26LO369Y3D)E,V1L96%X0G Y>%I30TM96#5A>28C>$$[5759,6PT>%-8
M26E35VMB<3=E;5=O1U5N-U%Q<6E*4%!8:VE.;S!K.'<V66I48U!25G)Y,T)F
M,5534U!I0RLO3DI56F%D47=08UEQ;B8C>$$[56XR4C@Q+U=-5EA9<6PK=G@V
M,TIP1GEM:'EW=S9Q=T@Q85<T<C93;FM/6$MI=CA!<S$O6D]+<U9/;B]M-41&
M56%L6EAC:6XQ4#)5<28C>$$[1G5I+W!"4'$T<GIT;31&+U588T198G9H5DTO
M2SA8-6ET8W!C96%:=$]337=-<C)E;6U1>&E9>3%2-GI*-FTP6'=T.&1+.4(T
M:%=%+R8C>$$[.#5">5<X8V9L=5,W:6UM<U9U<&ID4E<O3&UY0TYF:"M&;RMP
M+W=!;UIS97IX.59C-F)S4%8T<G%&,6]"=%IX65=U;VDU6D%S2'%Q-"8C>$$[
M5E-#4&E*13=686<S4$AJ,2M%5DA(85)%<C-)+TAW8V=!*U1(4#EZ2"],>"]W
M*U@K;GE:-T\O,TUF.'9(+T0T*VYY6%HY5V9K<B]I<B8C>$$[+T$Q:B]I1W9+
M:F9O-S%+*W0Y56]V<"MP6#9E4"M45$]E,79"-&@T9FHW,T-Y,7AB32MZ16$S
M67$W1E9R9F%4-2]W041I<3=&6%EQ-R8C>$$[1E9R9F%4-2]W3TMR<U9D:7)S
M5F1I<3%F=% X05 K07A69&ER<U9D:7)S5E=Y9C-B9DDO<7A65&UT;V)Q>64R
M;EAL1%!'63560DLQ5B8C>$$[,31S2W%14G-E,DMS2790>4@O2V$Y9%I,;E%%
M:V1);S=D5SEE-4(Y3T="3&5.86E59EII:556-C$K3#=22GA62&5:4'EK+TPS
M>DI+6B8C>$$[=&$P9UAC<&Q--68Q-VE-*V\P359U5"LW:U0O9%9T1W10.&UV
M6&9&55 O>7!4.'-V6%<T1VI5;E-/,VA75F)M-D1E;F%,17-#:VE88R8C>$$[
M24QA3VYY<C%*<7%Z5U0W22MA+W)'2W)S5F1I<5$K6F9-,3=O.7A:45=U:3-M
M<6TV64(U3%9#>5)!>5)X,61Q140K.35B,"M&5TYD<R8C>$$[5E,O>70U,3%V
M5W131G)D95=R>E,W8TI-6DQY-45Q2C9K4FI52V]K:6E,3$IZ66]X<'-V5'=6
M4U X-E!.4&U(454P46%0<7%A4CEC;28C>$$[;5,U=359-'!50TI'2$922VHO
M.$%#-VY--U)9;WIV:48P,C1O9S-B>D174'I3+TU+=S!W6&-(;E=#.6UA5&=T
M=$9A-F9Y-"]Z:T%--"8C>$$[0D(O:S9H<3=C4RMF1%,T>6$T2RM*8FAJ:51Y
M4T0O;&4S-7$O.5AZ+T%+9&)0+W%J;#,U1$0O3BLP+W):*T1(=60O>79B.#%F
M*W(U+R8C>$$[,#8R9B]62$@X:&@O;2]A9C%R-$UE-3E"9FQ(-78Q9GI6-5)T
M=%(Q5S-A2S=2;F=A-31H575F5#0O=FM557!5+T,Q0E1K1%1W1VTQ;28C>$$[
M1T]/9$1L.7II-4EI2F]-,GI&83-9<3=&5G)F850U+W=/2W)S5F1I<G-65W0Y
M<%!N+T$T<75X5C)+=7A6,DMR5BLP+WHO9TU66%EQ-R8C>$$[1EA9<3=&5G-N
M.3(S>5 V<U9A47-%549$54%$="]81E<K5&9Y2#A0-C1Q-VLS.&@O1"MU2W4U
M3B])9G<O<FER5$9I3FM054AT,E!Z>"8C>$$[5G9K,SAH+T0K=4MU-4XO269W
M+W)I<G549GE(.% V-'$W:S,X:"]$*W5+<%(U:#AR84(U:5-#3%=T3U,K:71Y
M>E),269S<S%!4T],1"8C>$$[<TUS>#5:42MK,&M3235*3"]W07%H+TQB+W%8
M65!V8B]!2G)Y,S@U;"]N379&;#-U+W=#5E$O;'0O=T)3-T(Y-V8X,30O;DUV
M.#5F1B8C>$$[;#-U+S561"M7,R]5=7=F93,O3F50-7I,+T]8>%ID-TMB2WIT
M<D<R9W1,3S-%1G!B>"ML1$-G54MQ:6=!07(W6FIY:U-B3$%L16-M+R8C>$$[
M:U T9C%W2S=K,SAH+T0K=4MU-4XO269W+W)I<E1&:58K03='<#9E0CDX5F(U
M3B])9G<O<FER=51F>4@X4#8T<3=K,SAH+T0K=4MT328C>$$[5TI8-$1S86YP
M-$@S>%9V:S,X:"]$*W5+=35.+TEF=R]R:7)U5&9Y2#A0-C1Q-VLS.&@O1"MU
M2W1+5T)B-$1U86IP-$0S>%9V:S,X:"8C>$$[+T0K=4MU-4XO269W+W)I<G54
M9GE(.% V-'$W:S,X:"]$*W5+=$]72TU!:'%14C(O<FER+T%0+UH\+WAM<$=)
M;6<Z:6UA9V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @
M(" \+W)D9CI!;'0^"B @(" @(" @(#PO>&UP.E1H=6UB;F%I;',^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D
M9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA
M9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%D
M;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P9&8Z4')O9'5C97(^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SID8STB:'1T<#HO+W!U<FPN;W)G
M+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @(" @(" \9&,Z9F]R;6%T/F%P<&QI
M8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O<FUA=#X*(" @(" @(" @/&1C.G1I
M=&QE/@H@(" @(" @(" @(" \<F1F.D%L=#X*(" @(" @(" @(" @(" @/')D
M9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT(CXP,#$\+W)D9CIL:3X*(" @(" @
M(" @(" @/"]R9&8Z06QT/@H@(" @(" @(" \+V1C.G1I=&QE/@H@(" @(" @
M(" \9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(" @(#QR9&8Z06QT/@H@(" @
M(" @(" @(" @(" \<F1F.FQI('AM;#IL86YG/2)X+7)E<&%I<B(^1FEL92!.
M86UE.B @(" @(" @(" @(" @(# P,2YA:28C>$$[57-E<FYA;64Z(" @(" @
M(" @(" @("!24C$Q-S4W,B8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @
M,3<M3F]V+3(P,C$@,30Z,S(Z,30F(WA!.T535"!4:6UE.B @(" @(" @(" @
M(" @,3<M3F]V+3(P,C$@,#4Z,#(Z,30F(WA!.U-C<FEP="!697)S:6]N.B @
M(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP
M)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[
M(" @(" @(.* HB Q('!A=&@@;V)J96-T<R!H879E('1O=&%L(&EN:R!C;W9E
M<F%G92!O=F5R(#(X,"XF(WA!.RHJ*D9)6"!!3D0@4D5254X@4%)%1DQ)1TA4
M(%-#4DE05"HJ*B8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&9O;G1S(&%R92!P
M<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @(" @(" @("!4<F%D94=O
M=&AI8R8C>$$[(" @(" @(" @(%1R861E1V]T:&EC+4]B;&EQ=64F(WA!.R @
M(" @(" @("!4<F%D94=O=&AI8RU";VQD)B-X03LF(WA!.U1H92!F;VQL;W=I
M;F<@8V]L;W)S(&%R92!P<F5S96YT(&EN('1H92!D;V-U;65N=#HF(WA!.R @
M(" @(" @("!";&%C:R8C>$$[(" @(" @(" @($--64LF(WA!.R8C>$$[+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M)B-X03M&:6QE($YA;64Z(" @(" @(" @(" @(" @,# Q+F%I)B-X03M5<V5R
M;F%M93H@(" @(" @(" @(" @(%)2,3$W-3<R)B-X03M,;V-A;"!4:6UE.B @
M(" @(" @(" @(" Q-RU.;W8M,C R,2 Q-#HS,CHS-28C>$$[15-4(%1I;64Z
M(" @(" @(" @(" @(" Q-RU.;W8M,C R,2 P-3HP,CHS-28C>$$[4V-R:7!T
M(%9E<G-I;VXZ(" @(" @(" @,BXV)B-X03M);&QU<W1R871O<B!697)S:6]N
M.B @(" Q-BXP+C F(WA!.T=R87!H:6,@='EP93H@(" @(" @(" @07)T=V]R
M:R8C>$$[)B-X03LJ*BI4:&4@<')E9FQI9VAT(&-H96-K(&ES(&-O;7!L971E
M+B!0;&5A<V4@96YS=7)E(&UA;G5A;"!C:&5C:W,@87)E(&-O;7!L971E9"!P
M97(@<')O8V5S<RXJ*BHF(WA!.R8C>$$[5&AE(&9O;&QO=VEN9R!F;VYT<R!A
M<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @5')A
M9&5';W1H:6,F(WA!.R @(" @(" @("!4<F%D94=O=&AI8RU/8FQI<75E)B-X
M03L@(" @(" @(" @5')A9&5';W1H:6,M0F]L9"8C>$$[)B-X03M4:&4@9F]L
M;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X
M03L@(" @(" @(" @0FQA8VLF(WA!.R @(" @(" @("!#35E+)B-X03LF(WA!
M.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(# P,BYA:28C>$$[
M57-E<FYA;64Z(" @(" @(" @(" @("!24C$Q-S4W,B8C>$$[3&]C86P@5&EM
M93H@(" @(" @(" @(" @,3<M3F]V+3(P,C$@,30Z-#8Z-3DF(WA!.T535"!4
M:6UE.B @(" @(" @(" @(" @,3<M3F]V+3(P,C$@,#4Z,38Z-3DF(WA!.U-C
M<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R
M<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R
M='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP
M;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T
M960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N
M=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @
M(%1R861E1V]T:&EC)B-X03L@(" @(" @(" @5')A9&5';W1H:6,M3V)L:7%U
M928C>$$[(" @(" @(" @(%1R861E1V]T:&EC+4)O;&0F(WA!.R8C>$$[5&AE
M(&9O;&QO=VEN9R!C;VQO<G,@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT
M.B8C>$$[(" @(" @(" @($)L86-K)B-X03L@(" @(" @(" @0TU92R8C>$$[
M)B-X03LM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TF(WA!.SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^
M"B @(" @(" @(#PO9&,Z9&5S8W)I<'1I;VX^"B @(" @(" @(#QD8SIC<F5A
M=&]R/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D
M9CIL:3Y24C$Q-S4W,CPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^
M"B @(" @(" @(#PO9&,Z8W)E871O<CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I
M;VX^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @
M(" @(" @('AM;&YS.GAM<%109STB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O
M,2XP+W0O<&<O(@H@(" @(" @(" @("!X;6QN<SIS=$1I;3TB:'1T<#HO+VYS
M+F%D;V)E+F-O;2]X87 O,2XP+W-4>7!E+T1I;65N<VEO;G,C(@H@(" @(" @
M(" @("!X;6QN<SIS=$9N=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+W-4>7!E+T9O;G0C(@H@(" @(" @(" @("!X;6QN<SIX;7!'/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O9R\B/@H@(" @(" @(" \>&UP5%!G.DY0
M86=E<SXQ/"]X;7!44&<Z3E!A9V5S/@H@(" @(" @(" \>&UP5%!G.DAA<U9I
M<VEB;&54<F%N<W!A<F5N8WD^1F%L<V4\+WAM<%109SI(87-6:7-I8FQE5')A
M;G-P87)E;F-Y/@H@(" @(" @(" \>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I
M;G0^5')U93PO>&UP5%!G.DAA<U9I<VEB;&5/=F5R<')I;G0^"B @(" @(" @
M(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" \<W1$:6TZ=SXV,3(N,# P,# P/"]S=$1I;3IW/@H@
M(" @(" @(" @(" \<W1$:6TZ:#XW.3(N,# P,# P/"]S=$1I;3IH/@H@(" @
M(" @(" @(" \<W1$:6TZ=6YI=#Y0;VEN=',\+W-T1&EM.G5N:70^"B @(" @
M(" @(#PO>&UP5%!G.DUA>%!A9V53:7IE/@H@(" @(" @(" \>&UP5%!G.D9O
M;G1S/@H@(" @(" @(" @(" \<F1F.D)A9SX*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT3F%M93Y4<F%D94=O=&AI8RU";VQD/"]S=$9N=#IF
M;VYT3F%M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&86UI;'D^
M5')A9&4@1V]T:&EC/"]S=$9N=#IF;VYT1F%M:6QY/@H@(" @(" @(" @(" @
M(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&;G0Z9F]N=$9A8V4^"B @
M(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP93Y4>7!E(#$\+W-T1FYT
M.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z=F5R<VEO;E-T
M<FEN9SXP,#$N,# Q/"]S=$9N=#IV97)S:6]N4W1R:6YG/@H@(" @(" @(" @
M(" @(" @(" \<W1&;G0Z8V]M<&]S:71E/D9A;'-E/"]S=$9N=#IC;VUP;W-I
M=&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT1FEL94YA;64^5$="
M7U]?7U\N4$9".R!41T)?7U]?7RY01DT\+W-T1FYT.F9O;G1&:6QE3F%M93X*
M(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z9F]N=$YA;64^5')A9&5';W1H:6,\+W-T1FYT.F9O;G1.86UE
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y4<F%D92!'
M;W1H:6,\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @(#QS
M=$9N=#IF;VYT1F%C93Y-961I=6T\+W-T1FYT.F9O;G1&86-E/@H@(" @(" @
M(" @(" @(" @(" \<W1&;G0Z9F]N=%1Y<&4^5'EP92 Q/"]S=$9N=#IF;VYT
M5'EP93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.G9E<G-I;VY3=')I;F<^
M,# Q+C P,3PO<W1&;G0Z=F5R<VEO;E-T<FEN9SX*(" @(" @(" @(" @(" @
M(" @/'-T1FYT.F-O;7!O<VET93Y&86QS93PO<W1&;G0Z8V]M<&]S:71E/@H@
M(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9I;&5.86UE/E1'7U]?7U]?
M+E!&0CL@5$=?7U]?7U\N4$9-/"]S=$9N=#IF;VYT1FEL94YA;64^"B @(" @
M(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D
M9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T
M1FYT.F9O;G1.86UE/E1R861E1V]T:&EC+4]B;&EQ=64\+W-T1FYT.F9O;G1.
M86UE/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A;6EL>3Y4<F%D
M92!';W1H:6,\+W-T1FYT.F9O;G1&86UI;'D^"B @(" @(" @(" @(" @(" @
M(#QS=$9N=#IF;VYT1F%C93Y/8FQI<75E/"]S=$9N=#IF;VYT1F%C93X*(" @
M(" @(" @(" @(" @(" @/'-T1FYT.F9O;G14>7!E/E1Y<&4@,3PO<W1&;G0Z
M9F]N=%1Y<&4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IV97)S:6]N4W1R
M:6YG/C P,2XP,#$\+W-T1FYT.G9E<G-I;VY3=')I;F<^"B @(" @(" @(" @
M(" @(" @(#QS=$9N=#IC;VUP;W-I=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET
M93X*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1&:6QE3F%M93Y41T]?
M7U]?7RY01D([(%1'3U]?7U]?+E!&33PO<W1&;G0Z9F]N=$9I;&5.86UE/@H@
M(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z0F%G
M/@H@(" @(" @(" \+WAM<%109SI&;VYT<SX*(" @(" @(" @/'AM<%109SI0
M;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @
M(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z
M;&D^36%G96YT83PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/EEE
M;&QO=SPO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI/D)L86-K/"]R
M9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!4
M4&<Z4&QA=&5.86UE<SX*(" @(" @(" @/'AM<%109SI3=V%T8VA'<F]U<',^
M"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @(" \<F1F.FQI
M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @
M/'AM<$<Z9W)O=7!.86UE/D1E9F%U;'0@4W=A=&-H($=R;W5P/"]X;7!'.F=R
M;W5P3F%M93X*(" @(" @(" @(" @(" @(" @/'AM<$<Z9W)O=7!4>7!E/C \
M+WAM<$<Z9W)O=7!4>7!E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<%109SI3=V%T8VA'
M<F]U<',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7!-
M33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+VUM+R(*(" @(" @(" @
M(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S
M5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @('AM;&YS.G-T179T/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V5%=F5N
M=",B/@H@(" @(" @(" \>&UP34TZ1&]C=6UE;G1)1#YX;7 N9&ED.C0T,C)%
M-S)&.#,T-T5#,3$X140X13DQ03DS,4,Y1C(Y/"]X;7!-33I$;V-U;65N=$E$
M/@H@(" @(" @(" \>&UP34TZ26YS=&%N8V5)1#YX;7 N:6ED.C0T,C)%-S)&
M.#,T-T5#,3$X140X13DQ03DS,4,Y1C(Y/"]X;7!-33I);G-T86YC94E$/@H@
M(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,T0R
M,D4W,D8X,S0W14,Q,3A%1#A%.3%!.3,Q0SE&,CD\+WAM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.E)E;F1I=&EO;D-L87-S/F1E
M9F%U;'0\+WAM<$U-.E)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \>&UP34TZ
M1&5R:79E9$9R;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @
M(" @(" \<W12968Z:6YS=&%N8V5)1#YX;7 N:6ED.C0S,C)%-S)&.#,T-T5#
M,3$X140X13DQ03DS,4,Y1C(Y/"]S=%)E9CII;G-T86YC94E$/@H@(" @(" @
M(" @(" \<W12968Z9&]C=6UE;G1)1#YX;7 N9&ED.C0S,C)%-S)&.#,T-T5#
M,3$X140X13DQ03DS,4,Y1C(Y/"]S=%)E9CID;V-U;65N=$E$/@H@(" @(" @
M(" @(" \<W12968Z;W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z,T0R,D4W
M,D8X,S0W14,Q,3A%1#A%.3%!.3,Q0SE&,CD\+W-T4F5F.F]R:6=I;F%L1&]C
M=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.G)E;F1I=&EO;D-L87-S/F1E
M9F%U;'0\+W-T4F5F.G)E;F1I=&EO;D-L87-S/@H@(" @(" @(" \+WAM<$U-
M.D1E<FEV961&<F]M/@H@(" @(" @(" \>&UP34TZ2&ES=&]R>3X*(" @(" @
M(" @(" @/')D9CI397$^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A
M<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M86-T:6]N/G-A=F5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#II;G-T86YC94E$/GAM<"YI:60Z,T0R,D4W,D8X,S0W14,Q,3A%
M1#A%.3%!.3,Q0SE&,CD\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @
M(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,3$M,3=4,30Z,3@Z-3$K,#4Z,S \
M+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R
M94%G96YT/D%D;V)E($EL;'5S=')A=&]R($-3-B H5VEN9&]W<RD\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N
M8V5)1#YX;7 N:6ED.C0T,C)%-S)&.#,T-T5#,3$X140X13DQ03DS,4,Y1C(Y
M/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M=VAE;CXR,#(Q+3$Q+3$W5#$T.C0W.C$Q*S U.C,P/"]S=$5V=#IW:&5N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC
M:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DAI<W1O<GD^"B @(" @(#PO
M<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A/@H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME="!E;F0](G<B/S[_VP!#
M  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MP  1" $G ED# 1$  A$! Q$!_\0 'P !  $$ P$! 0            8%!P@)
M 00* P(+_\0 7A    4# 0 +"P@'!04%!0D  @,$!08  0<("1$2%!8955B6
ME]83%1<8&C97=I75UR$QF*6TM='4(C-6<76QV HW5'>V(R4X49$R-4%XMR9%
M<K+3)$924V63E*/!_\0 '@$! 0 " P$! 0$           $#! (%!P8("0K_
MQ !D$0 ! P(!! H*# @)"0@# 0 !  (#! 41!A(3(0<4%S%!451QT=0B4E5A
MD9.4H;'3%1884U:2E9;2U>'P"#)78H&BP>(9(S,U=9>TUN0T97-TI+*SY>8)
M)$)#1&1R\39C@B7_V@ , P$  A$#$0 _ /.]J3U)ZBVK47GUK:\^YJ;6UMS5
ME1 W-R#*DZ1H4"%'.GU.D1(DB=]+3I4B5.660F3$%EDD$E@** $ 0AL6XUK2
MUN+6_BC@'%S*ROC1:F><5G7K<G_:"BY9C.U;\4=">-%J9YQ6=>MR?]H*)F,[
M5OQ1T)XT6IGG%9UZW)_V@HF8SM6_%'0GC1:F><5G7K<G_:"B9C.U;\4=">-%
MJ9YQ6=>MR?\ :"B9C.U;\4=">-%J9YQ6=>MR?]H*)F,[5OQ1T)XT6IGG%9UZ
MW)_V@HF8SM6_%'0GC1:F><5G7K<G_:"B9C.U;\4=">-%J9YQ6=>MR?\ :"B9
MC.U;\4=">-%J9YQ6=>MR?]H*)F,[5OQ1T)XT6IGG%9UZW)_V@HF8SM6_%'0G
MC1:F><5G7K<G_:"B9C.U;\4=">-%J9YQ6=>MR?\ :"B9C.U;\4=">-%J9YQ6
M=>MR?]H*)F,[5OQ1T)XT6IGG%9UZW)_V@HF8SM6_%'0GC1:F><5G7K<G_:"B
M9C.U;\4=">-%J9YQ6=>MR?\ :"B9C.U;\4=">-%J9YQ6=>MR?]H*)F,[5OQ1
MT)XT6IGG%9UZW)_V@HF8SM6_%'0GC1:F><5G7K<G_:"B9C.U;\4=">-%J9YQ
M6=>MR?\ :"B9C.U;\4=">-%J9YQ6=>MR?]H*)F,[5OQ1T)XT6IGG%9UZW)_V
M@HF8SM6_%'0GC1:F><5G7K<G_:"B9C.U;\4=">-%J9YQ6=>MR?\ :"B9C.U;
M\4=">-%J9YQ6=>MR?]H*)F,[5OQ1T)XT6IGG%9UZW)_V@HF8SM6_%'0GC1:F
M><5G7K<G_:"B9C.U;\4=">-%J9YQ6=>MR?\ :"B9C.U;\4=">-%J9YQ6=>MR
M?]H*)F,[5OQ1T)XT6IGG%9UZW)_V@HF8SM6_%'0JLPZA=6<I?&:,QO.FH5]D
M4B=6]C86-IRCD9>ZO#R[*R4#8UMJ%,^F*%B]P6J"$B-*06,Y0H-+** (8PVN
M3,8/_"WXHZ%)I=E/6U!!K[2O+VHQI3MIL>)5.8LJSY8Q[J6H'ATBPTL@;Y&K
M9%Y$D;H\_K6)2@<%*9V3,CN:A-/ VK+DE V,[S6\/_A' <#P<!(4#\:+4SSB
MLZ];D_[045S&=JWXHZ$\:+4SSBLZ];D_[043,9VK?BCH5R6S(>N%XE#!"F[,
M&H%1*9-% 3EG9;YEEQ"HV(&199. 2%;=1+2B6=KO"T*B774/!J -HQW!^%:S
M6K2*CRA$8!.:W ' ]B-_'#BXRHO*L[:OX,_+XO,,V:B8U(6S>HES.\90R*A7
M$E+T29S;E/<3GX-S43FV+$3HUKB;F(W-L6HW% >H1*DYYA4-8=8:WXHZ%U&'
M4-JQE#XS1F/9XS^\/\B=6YB8VA#E?()ZYT>'982@;&Y&2&0;HY4M6J"$R<JW
MRF&F@#;Y;T0M8 26MP&L]B.A4GQHM3/.*SKUN3_M!1,QG:M^*.A/&BU,\XK.
MO6Y/^T%$S&=JWXHZ$\:+4SSBLZ];D_[043,9VK?BCH51=]16J]@<%#2^9WU"
M,[HDN594W.>4LC(5R:YY):DFQZ52^EG%7-3G%'E[L =V48 P.V$8;W(&L.\U
MOQ1T*G>-%J9YQ6=>MR?]H*)F,[5OQ1T)XT6IGG%9UZW)_P!H*)F,[5OQ1T)X
MT6IGG%9UZW)_V@HF8SM6_%'0GC1:F><5G7K<G_:"B9C.U;\4=">-%J9YQ6=>
MMR?]H*)F,[5OQ1T)XT6IGG%9UZW)_P!H*)F,[5OQ1T)XT6IGG%9UZW)_V@HF
M8SM6_%'0GC1:F><5G7K<G_:"B9C.U;\4=">-%J9YQ6=>MR?]H*)F,[5OQ1T)
MXT6IGG%9UZW)_P!H*)F,[5OQ1T)XT6IGG%9UZW)_V@HF8SM6_%'0GC1:F><5
MG7K<G_:"B9C.U;\4=">-%J9YQ6=>MR?]H*)F,[5OQ1T)XT6IGG%9UZW)_P!H
M*)F,[5OQ1T)XT6IGG%9UZW)_V@HF8SM6_%'0GC1:F><5G7K<G_:"B9C.U;\4
M=">-%J9YQ6=>MR?]H*)F,[5OQ1T)XT6IGG%9UZW)_P!H*)F,[5OQ1T)XT6IG
MG%9UZW)_V@HF8SM6_%'0GC1:F><5G7K<G_:"B9C.U;\4=">-%J9YQ6=>MR?]
MH*)F,[5OQ1T)XT6IGG%9UZW)_P!H*)F,[5OQ1T)XT6IGG%9UZW)_V@HF8SM6
M_%'0GC1:F><5G7K<G_:"B9C.U;\4=">-%J9YQ6=>MR?]H*)F,[5OQ1T)XT6I
MGG%9UZW)_P!H*)F,[5OQ1T)XT6IGG%9UZW)_V@HF8SM6_%'0GC1:F><5G7K<
MG_:"B9C.U;\4=">-%J9YQ6=>MR?]H*)F,[5OQ1T)XT6IGG%9UZW)_P!H*)F,
M[5OQ1T)XT6IGG%9UZW)_V@HF8SM6_%'0GC1:F><5G7K<G_:"B9C.U;\4="]T
M?"%_Y<>/::W_ .O1:*\+FJ+_ (F=17^>N7/]?R"BWF?B-_\ BWT!6*HN241*
M(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$
MHBF&/)/:$SZ$3.Y\D2VB<MCLEWS#7\$5ER;O&[HW/?$6DYK:\EQV1$[U[HRO
MAC0Z%M3B%,N&W+0D73F%'#$$<8X=Y; &K69B]J$O:$K#D!J8E;_BR7/"N%(F
M/%J.>SC'[)G]F)FS]C?%$J@T:A:YNMEJ *+-F/GUK4RT>'RURZ2QF5SE=+8_
M,-7?XQB/VX^=8\PX:\,<"-\D<& Q(Q/XN'>Q._PY)N>O# 0X6@F#.:I;I$YN
M4B=)CB&Y.1S7ET?7^53Q*CE1;@R*H=C!KE\43REGS WY):W464G>3PZ-0LN3
MQ=  ESC]4S'8\!PWB>#4!OZR=[#6","=2PI@FK"+Q;.F2\K+X[(QH9D\1!Y#
M9A&WMKU(T<0D;&^/D'F%G!<ZV,AN:B&@]#DNRMXE;N)0L3.CZLR.-*\I)27(
ML.:!B,1CPG#7P@X8XC$X:E"D6H]$]9K:<BY O-71B*TYF:?EM@.93_(V](KT
MGK=.2AY9^_:U,C,2D/3BLF:9E.7(BS2CSD1BLE6H-67+EFD-(&&.<2,=[\;.
MP.'>U*_[7KUB<9Q\DAL8Q@H"?#'N"&Q-7)5HGX4X8(,APL2SHLF63NC/']VR
MO.)WJ0,1(H;,5#2BR,Y0^.O<81LZM\E<P]./@PP]'#BN&C))Q(&...'&2> \
MXQ[XXM2J@M>F,FX$;;XIB5Y8(W LM8W?(JQF.A;@K=<<XFF&,W*#N$I<;.2.
M,6S"C@N,D4$?IFVX^[[R%,[*1II1'H_9\BLKJ9A..L:P?"00<.\2<?V'41^H
M9K2QPG9EA:Y?E2#N;%BE(UQI9%E" ;PV.@<@:/C#\28Z5%""0RX[''L%Y$D(
M5S^K;4J4O(CZU'L,A=D[@9DTA8=>\<3W]?XW9'O@D88:^Q&! /8P=7KONJ:Y
M+'2HB[-\*>8PGCS;CE$_F @C&E,T^Y+Q8[-"-D#W,D$><)]+HE/ST102C51L
M(:%2H8WYM9W!"^_W]*",XG$CAU\.MP..._J PW]>H;RE>1]?T?E+Y-%L:ADC
M86:;IFUM<FDIV,3[J*@9M4B=1C]W4K'F1+I/&VQ?GZ,)D/?!<D9UK;CANL@A
MT0;$T9B\;((SAP<.'>_%UX@ ZPTXCB.&\%A1J"RF/-65'S))SE*713(FZ,;]
M-F"NZ]X3+VR,-#0O0!<!.3F8O;$:Q">2TK33$AREN"G-.;&TT0T9)<VC 8:M
M\[W#WSW^/]JLM1<DHB41*(E$2B)1$HB41*(E$2B)1$HB41*(E$2B)1$HB41*
M(E$2B)1$HB41*(E$2B)1$HB_H 477KQ\ZFX%@0O4EJ# [96R\E= 9PRP!R2M
MV"(8Y-Z9P#/'^RPA"X*=134H7HR5%C"TRU0UMIRHD(#S4",PP2<OT2EV-;S5
MTU/51UML:RI@AJ&-?)5![631MD:'!M(X!P#@' .(QQP)&M<MN-;V)8XYO8XX
MC7AJQ5C^ NG3TO9J^CW!OZF:S[EU[Y=:O&5?4TV\SWMWA"<!=.GI>S5]'N#?
MU,TW+KWRZU>,J^IIMYGO;O"$X"Z=/2]FKZ/<&_J9IN77OEUJ\95]33;S/>W>
M$)P%TZ>E[-7T>X-_4S3<NO?+K5XRKZFFWF>]N\(3@+IT]+V:OH]P;^IFFY=>
M^76KQE7U--O,][=X0G 73IZ7LU?1[@W]3--RZ]\NM7C*OJ:;>9[V[PA. NG3
MTO9J^CW!OZF:;EU[Y=:O&5?4TV\SWMWA"<!=.GI>S5]'N#?U,TW+KWRZU>,J
M^IIMYGO;O"$X"Z=/2]FKZ/<&_J9IN77OEUJ\95]33;S/>W>$)P%TZ>E[-7T>
MX-_4S3<NO?+K5XRKZFFWF>]N\(4QF6$,#0DZ.D.69\N*126'1J:HKH=/T-&$
MEME" +@B3*M\:D4]PKB"A6 J 58T@)GR$J#@_I5@@V-;S4"4LK;8-%/+3NSI
M*H8OA=FN(PI#V)/XI.!PWP$-<P?^6[@X1PC%0[@+IT]+V:OH]P;^IFL^Y=>^
M76KQE7U--O,][=X0G 73IZ7LU?1[@W]3--RZ]\NM7C*OJ:;>9[V[PA. NG3T
MO9J^CW!OZF:;EU[Y=:O&5?4TV\SWMWA"<!=.GI>S5]'N#?U,TW+KWRZU>,J^
MIIMYGO;O"$X"Z=/2]FKZ/<&_J9IN77OEUJ\95]33;S/>W>$)P%TZ>E[-7T>X
M-_4S3<NO?+K5XRKZFFWF>]N\(3@+IT]+V:OH]P;^IFFY=>^76KQE7U--O,][
M=X0G 73IZ7LU?1[@W]3--RZ]\NM7C*OJ:;>9[V[PA. NG3TO9J^CW!OZF:;E
MU[Y=:O&5?4TV\SWMWA"<!=.GI>S5]'N#?U,TW+KWRZU>,J^IIMYGO;O"%D;C
MW19BC)&.T62F?/&0T;,NFDJ@Y2)SP)&RW,+G$6.#OZ]486EU!JTMD"A+/6LI
M&,*L2@2A(X!.3D%@3&*=FW[$E_N-154T-PL['TD-)/(Z66M#7-K'UD<8864+
MR7--%(7YP: ',S2XEP;R%6TC$,.^1OC@P[W?4E\03&WI_G'4,P_'VNVW#,I^
MZEA\=</JY7;8[0^$=">()C;T_P XZAF'X^TW#,I^ZEA\=</JY-MCM#X1T)X@
MF-O3_..H9A^/M-PS*?NI8?'7#ZN3;8[0^$=">()C;T_SCJ&8?C[3<,RG[J6'
MQUP^KDVV.T/A'0GB"8V]/\XZAF'X^TW#,I^ZEA\=</JY-MCM#X1T)X@F-O3_
M #CJ&8?C[3<,RG[J6'QUP^KDVV.T/A'0GB"8V]/\XZAF'X^TW#,I^ZEA\=</
MJY-MCM#X1T)X@F-O3_..H9A^/M-PS*?NI8?'7#ZN3;8[0^$="D40V-^!3.61
M>'MVH67IG"5R)DC:%0MP0S!1IUCZY)FM*<K$1G@\\*8H]4 P\1)!QMB@CN64
M8.U@7UJW86RDH:.KK9;E9'Q4=-/52-CFKR]S*>)\SVL#K>UI>6L(:'.:,XC%
MP&M!5 D#,.OOCH4=\03&WI_G'4,P_'VMG<,RG[J6'QUP^KDVV.T/A'0GB"8V
M]/\ ..H9A^/M-PS*?NI8?'7#ZN3;8[0^$=">()C;T_SCJ&8?C[3<,RG[J6'Q
MUP^KDVV.T/A'0GB"8V]/\XZAF'X^TW#,I^ZEA\=</JY-MCM#X1T)X@F-O3_.
M.H9A^/M-PS*?NI8?'7#ZN3;8[0^$=">()C;T_P XZAF'X^TW#,I^ZEA\=</J
MY-MCM#X1T)X@F-O3_..H9A^/M-PS*?NI8?'7#ZN3;8[0^$=">()C;T_SCJ&8
M?C[3<,RG[J6'QUP^KDVV.T/A'0GB"8V]/\XZAF'X^TW#,I^ZEA\=</JY-MCM
M#X1T*0J=C@@26)LLO'J%EXF]\D,GC:9.# [-=84LBK;$71<<>&^>+$63*")D
MW%I!%GF&B-3+;'%$@"0,_69L+92/K)Z(7*R"6GIJ2J>XS5^865DM;#&UI]C\
M[/:ZAE+P6@ /CS7.)<&MM##',/#PC@P[W?4>\03&WI_G'4,P_'VMG<,RG[J6
M'QUP^KDVV.T/A'0GB"8V]/\ ..H9A^/M-PS*?NI8?'7#ZN3;8[0^$=">()C;
MT_SCJ&8?C[3<,RG[J6'QUP^KDVV.T/A'0GB"8V]/\XZAF'X^TW#,I^ZEA\=<
M/JY-MCM#X1T)X@F-O3_..H9A^/M-PS*?NI8?'7#ZN3;8[0^$=">()C;T_P X
MZAF'X^TW#,I^ZEA\=</JY-MCM#X1T)X@F-O3_..H9A^/M-PS*?NI8?'7#ZN3
M;8[0^$=">()C;T_SCJ&8?C[3<,RG[J6'QUP^KDVV.T/A'0I!$MCA@4QE<9B+
M?J%EZ9?*9"RQQ"H6X(9@(R%CXY)FQ,<K$1G@\X*8HY4 9XB2#C;%!'<LHP=K
M OK5FPME)0T=56RW*R.BI*:>JD;'-7F1S*>)TKVL#K>UI>6L(:'.:"[#%P&M
M!5 D#,.OOCH5 %H#QL$0@WS_ #C;#>]O[AF'_P +[7I]K9&P9E.0#[*6'7_^
MZX?5R;;':'PCH7'B"8V]/\XZAF'X^TW#,I^ZEA\=</JY-MCM#X1T)X@F-O3_
M #CJ&8?C[3<,RG[J6'QUP^KDVV.T/A'0GB"8V]/\XZAF'X^TW#,I^ZEA\=</
MJY-MCM#X1T)X@F-O3_..H9A^/M-PS*?NI8?'7#ZN3;8[0^$=">()C;T_SCJ&
M8?C[3<,RG[J6'QUP^KDVV.T/A'0GB"8V]/\ ..H9A^/M-PS*?NI8?'7#ZN3;
M8[0^$=">()C;T_SCJ&8?C[3<,RG[J6'QUP^KDVV.T/A'0GB"8V]/\XZAF'X^
MTW#,I^ZEA\=</JY-MCM#X1T)X@F-O3_..H9A^/M-PS*?NI8?'7#ZN3;8[0^$
M="K$>V.K'TC?&IA1Z@YB2J=UR= G-4X'9 IRS5)EBP#.N5GDTRQ8;WM<5P%C
M%M?,&]_DK4N&PQE';J&KKY;E9'Q4=/-4R,CFKS(YD+'2.:P.M[6EQ#2&YSFC
M'?(&M-MCM#X1T+#7@+IT]+V:OH]P;^IFNKW+KWRZU>,J^IKAMYGO;O"$X"Z=
M/2]FKZ/<&_J9IN77OEUJ\95]33;S/>W>$)P%TZ>E[-7T>X-_4S3<NO?+K5XR
MKZFFWF>]N\(3@+IT]+V:OH]P;^IFFY=>^76KQE7U--O,][=X0G 73IZ7LU?1
M[@W]3--RZ]\NM7C*OJ:;>9[V[PA. NG3TO9J^CW!OZF:;EU[Y=:O&5?4TV\S
MWMWA"<!=.GI>S5]'N#?U,TW+KWRZU>,J^IIMYGO;O"$X"Z=/2]FKZ/<&_J9I
MN77OEUJ\95]33;S/>W>$)P%TZ>E[-7T>X-_4S3<NO?+K5XRKZFFWF>]N\(3@
M+IT]+V:OH]P;^IFFY=>^76KQE7U--O,][=X0G 73IZ7LU?1[@W]3--RZ]\NM
M7C*OJ:;>9[V[PA. NG3TO9J^CW!OZF:;EU[Y=:O&5?4TV\SWMWA"<!=.GI>S
M5]'N#?U,TW+KWRZU>,J^IIMYGO;O"%[RO!J5RZ9[)#[TKX3V.E[>/PN^BN*\
M-NK3_BJU,_\ F"S-_P"HTDK]/6;^9[5_1M#_ &6):+_QW?\ R=Z2L?:[)<4H
MBN_B_"\JRZE>00X2-4_(I%CF*,[ J5(FT3^^Y,D]HFPHRWAU6-[*T%A<S"+*
M5SPM1MY!1O=E2M,04:<#4JJR*D<S38B-T=1*^0!SM&RFBTKSF-:Y[^QQP:P%
MQ(P )("H&.]]]8'[5.6[2CE4=Y0<_EQ:.-T8B,FEG?$V>0!W*D9<?Q,UYE*1
M0DAFE:Q1.KK8;(X@XK%T,+?T4<1RMH72$QO3F#W.%UTI?XO,,LCI)8XLT03M
M,9?5.I"9B^)H@S9HYF@39CI'1.;&''!,#Q<!.^. 8X;^O4>#5WUU7K2OEYHE
M26)C:6%*Z.\JD,48&N1Y%Q/&9(L6,#G*VNXW6.KL@'*8\!R50M^2LZIP479I
M X)TR&+O+^8[,@W2LN=(^(RA[W-9%'+(^.GJI(P)&Q/[&1L $F:)F%X:,^-I
M+I61YC\U@<</!K&O61Q][FXB5(7W1MF6.B9&U<U-I\J>6=P<%,8;Y-"5"J'K
M6;,DRPL]M>05)TL2E1"S5(80[+5KNM <RHF\)Y[FN;DK._K&G&R[T<F>]KG"
M)CVM$KHY@)6OHX:QCH (B9L^.9C6L;@]SL UKB^-KV!^_>)'[/N H/)=-.9(
MC$WR;OT=94\:CQ:14X+4F0,=.ZDUK7VQ^)#(&=H9Y8O>9%%E@,JX\&DE<?;W
M.-J"Y8UC)=!@$>(G/'<:265D+)'F20N#08*AHSF[8#HWO?$UD<K32U ,4CFR
M Q.Q;O8L#OX><=[OZ]\:QB.^K$5NJ)1$HBO[J _[PQ/_ )!8A_TR776VS\6M
M_I*M_P"*53O_ *&^@*P5=DHE$2B+.K(FA]]@T872 ,P4EJFJ,,\A/:9S#QXZ
M%(2WJV-[IW7'SDZ2-Q;Y9 4QF1D:-QGJPV.HFY>B 0M;2"7),J!TM/>&3RB/
M1#!TCX\^&85 C+-LDLG:V-KHIR*<N;  ]SFN)#B6D&D8#'FW]6^0-7 0,=9Q
M&'$NA'="&6U"QN*G3E"<?IE+PI3*^^&0<9+G&[ DQ,\9FO*6$!D];&"0-*^(
MLBM.T+PR9O8E$@$!H<7YI&G<3D-DO=( XPMFG(:"W-IZD-TCJIM'HI"('R1O
M;,]I>W1.D#.R$;L6![-/#@-8&^.$$\?$.;'A5NT>D'4$X)]])(8TF)[ 2!/,
M,R+C%-= YK7*)M!$6=BU$S+&SSL#G.X<A5X^<[)9N@4R-K*7,">ZBVUL&[4
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M?W(8\_S5S)_I'!-=/!_/]S_H>Q_VW*%7@'.?0U6JKN%$HBKB>1.R6-NT3)/
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MB)1%M5Q+EK30T:?H,5*5D1(RS M/^?\ '+4E5103BO=I+GU_SI<+D\+1,YJ
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MLA;ESZZY];RULF034U8I:QEL3X8U(HV]N67.O/9/C,C\QO\ $,GCIF"?.DN
M:ZIS8V/C<V-M"2V)T.:'8R,#G21LG8[W&<,1CJWM['$'AUZP=\:L%U,PQS2&
M''.2!8]X",<]9BF5:R+&J3Y E!+TI4/D?1ACT-8W&?K4\<(5QOOK(G%]>';.
M 1JN^S,[I\1.0F!O(M))=ML4XJ-/) \O:\.BIXLP!DATDSVP R$29L;&,;1:
MBU[35-SRJ<W#5ACQC'7K[Y(&KG_05KQKOUQ2B)1$HB_HP5^9UV"PZR#_ &4M
MLS+/IOE\>M%>P#RK+Y+DD3$'":=P"RBG+TMDXFD*^^2$EUP6Z[I='99=*FNI
ML3W:Z<FX^YA^IH]DZ>EHZ2E%GB>*:F@IP\UCVEXAB;&'$"G(!<&XD8G#'#$K
M Z#%SCG;[B?Q>_SJ(>2!M7/G<.HA-\4*V=U6H[BP^6OZLIH/S_U?WD\D#:N?
M.X=1";XH4W5:CN+#Y:_JR:#\_P#5_>3R0-JY\[AU$)OBA3=5J.XL/EK^K)H/
MS_U?WD\D#:N?.X=1";XH4W5:CN+#Y:_JR:#\_P#5_>3R0-JY\[AU$)OBA3=5
MJ.XL/EK^K)H/S_U?WD\D#:N?.X=1";XH4W5:CN+#Y:_JR:#\_P#5_>3R0-JY
M\[AU$)OBA3=5J.XL/EK^K)H/S_U?WD\D#:N?.X=1";XH4W5:CN+#Y:_JR:#\
M_P#5_>3R0-JY\[AU$)OBA3=5J.XL/EK^K)H/S_U?WD\D#:N?.X=1";XH4W5:
MCN+#Y:_JR:#\_P#5_>4MEW]E):\DG,"F^M)>T\#8E'L<6!;"2=7O^T*0V:;.
MM[WR21W"[AN>[W2;1MD^WN.[F[6ZK7I]DV>G$P%GB=IJB:H.-:\9IF?G%HPI
MM8;O [Y5,&/_ (N #\7B&'&HEY(&U<^=PZB$WQ0K8W5:CN+#Y:_JRF@_/_5_
M>3R0-JY\[AU$)OBA3=5J.XL/EK^K)H/S_P!7]Y/) VKGSN'40F^*%-U6H[BP
M^6OZLF@_/_5_>3R0-JY\[AU$)OBA3=5J.XL/EK^K)H/S_P!7]Y/) VKGSN'4
M0F^*%-U6H[BP^6OZLF@_/_5_>3R0-JY\[AU$)OBA3=5J.XL/EK^K)H/S_P!7
M]Y/) VKGSN'40F^*%-U6H[BP^6OZLF@_/_5_>3R0-JY\[AU$)OBA3=5J.XL/
MEK^K)H/S_P!7]Y/) VKGSN'40F^*%-U6H[BP^6OZLF@_/_5_>3R0-JY\[AU$
M)OBA3=5J.XL/EK^K)H/S_P!7]Y9.XJ_LV2/&^/R\/DZL5+N%EF,CR5=]-Q*4
MB$>+(+)#XOWIL@!/%5@6;+8KLLWW=4*ZJ[S<G>Y.\NZ*-RU[,-1;:JLJ1889
MC5T]% 6&X/C#!1R5\@<#M1Y<9#6$$8#-T8()SCAS$6:W#.QUD[W>;WU//)SB
M.=.;U5@[;5W>[S4_!F#Y5DZ@KH^_YOM3R<XCG3F]58.VU-WFI^#,'RK)U!-'
MW_-]J>3G$<Z<WJK!VVIN\U/P9@^59.H)H^_YOM3R<XCG3F]58.VU-WFI^#,'
MRK)U!-'W_-]J>3G$<Z<WJK!VVIN\U/P9@^59.H)H^_YOM3R<XCG3F]58.VU-
MWFI^#,'RK)U!-'W_ #?:GDYQ'.G-ZJP=MJ;O-3\&8/E63J":/O\ F^U/)SB.
M=.;U5@[;4W>:GX,P?*LG4$T??\WVJM1O8 R,:R)@R-XS!KMP >FN:]ZO!F!)
MWSX*KB'WO?OKAB?O;?F\-[;X[@=W'NG=.Y&;G<7U+ALWU%?05M"<G(8A6TE3
M2&07.1YC%1"^$O#30M#BP/S@W.;G888C'% S @X[QQWOM5%\G.(YTYO56#MM
M6WN\U/P9@^59.H)H^_YOM3R<XCG3F]58.VU-WFI^#,'RK)U!-'W_ #?:GDYQ
M'.G-ZJP=MJ;O-3\&8/E63J":/O\ F^U/)SB.=.;U5@[;4W>:GX,P?*LG4$T?
M?\WVIY.<1SIS>JL';:F[S4_!F#Y5DZ@FC[_F^U/)SB.=.;U5@[;4W>:GX,P?
M*LG4$T??\WVIY.<1SIS>JL';:F[S4_!F#Y5DZ@FC[_F^U/)SB.=.;U5@[;4W
M>:GX,P?*LG4$T??\WVIY.<1SIS>JL';:F[S4_!F#Y5DZ@FC[_F^U5H_8 B%T
M=:\=^,P:7P6>G^:=]/!F 6_.'R&-L>\-Z\,K=Q[V^#;?&^.[&;Y[Z]S[D3O3
M=GZ;-F^H9<*FM]KD)-11T-*8_9.0!@HYKC,'AVT<29#7%I;FC-T8.)SB&W1Z
MAKX3P<W?5%\G.(YTYO56#MM6YN\U/P9@^59.H*:/O^;[4\G.(YTYO56#MM3=
MYJ?@S!\JR=031]_S?:GDYQ'.G-ZJP=MJ;O-3\&8/E63J":/O^;[4\G.(YTYO
M56#MM3=YJ?@S!\JR=031]_S?:GDYQ'.G-ZJP=MJ;O-3\&8/E63J":/O^;[4\
MG.(YTYO56#MM3=YJ?@S!\JR=031]_P WVIY.<1SIS>JL';:F[S4_!F#Y5DZ@
MFC[_ )OM3R<XCG3F]58.VU-WFI^#,'RK)U!-'W_-]JK,<V $G'$A8<A^,P:Z
M\ WEKF?>OP9 2]\N"ZXA\WAOKAD=O;?F\=[]W[B;W'NG=.Y&;G<7U+ALX5%=
M05M$<G(8Q64E32F07.1YC%1"^(O##1-#BP/S@W.;G889PQQ0,P(..\<=[[51
M[_V= @=[B\:<VVZO<6UX*P?)MWV]KSVK;&SS4@ >UF#4,/YUDZ@FC[_F^U<>
M3G$<Z<WJK!VVIN\U/P9@^59.H)H^_P";[4\G.(YTYO56#MM3=YJ?@S!\JR=0
M31]_S?:GDYQ'.G-ZJP=MJ;O-3\&8/E63J":/O^;[4\G.(YTYO56#MM3=YJ?@
MS!\JR=031]_S?:GDYQ'.G-ZJP=MJ;O-3\&8/E63J":/O^;[4\G.(YTYO56#M
MM3=YJ?@S!\JR=031]_S?:GDYQ'.G-ZJP=MJ;O-3\&8/E63J":/O^;[4\G.(Y
MTYO56#MM3=YJ?@S!\JR=031]_P WVIY.<1SIS>JL';:F[S4_!F#Y5DZ@FC[_
M )OM7?:_[/P1!G%',;ZFSG"T9/ ]70VQB!/=79OOOBZ>Q_#,WN5S=QN>Z=S'
MN=O;W-]K:K1N>S;47&W5U [)V&(5E+/3&47-[S&)HW1EX8:)H<6YV.:7-QPP
MQ&^FC[_F6"_D@;5SYW#J(3?%"NFW5:CN+#Y:_JRQZ#\_]7]Y/) VKGSN'40F
M^*%-U6H[BP^6OZLF@_/_ %?WD\D#:N?.X=1";XH4W5:CN+#Y:_JR:#\_]7]Y
M/) VKGSN'40F^*%-U6H[BP^6OZLF@_/_ %?WD\D#:N?.X=1";XH4W5:CN+#Y
M:_JR:#\_]7]Y/) VKGSN'40F^*%-U6H[BP^6OZLF@_/_ %?WD\D#:N?.X=1"
M;XH4W5:CN+#Y:_JR:#\_]7]Y/) VKGSN'40F^*%-U6H[BP^6OZLF@_/_ %?W
MD\D#:N?.X=1";XH4W5:CN+#Y:_JR:#\_]7]Y/) VKGSN'40F^*%-U6H[BP^6
MOZLF@_/_ %?WD\D#:N?.X=1";XH4W5:CN+#Y:_JR:#\_]7]Y/) VKGSN'40F
M^*%-U6H[BP^6OZLF@_/_ %?WD\D#:N?.X=1";XH4W5:CN+#Y:_JR:#\_]7]Y
M;G_%J+_:L?LH/YRO-O98>\'Q@^@MO,/&//T+<9$?-2,>KS+]VIJZUN\.8>A<
M7;YYSZ5(:JB41*(E$2B)1$HB41*(E$4=CGZMX]8GK[7>B*141*(E$2B)1$HB
M41*(E$2B+4?LBVR#RW0]/<?(8QCJ.3L&2(@M5K#'YW<VL38*+/1Y) $UF\DZ
MQP5=GXT1MS=S<NZ<NP-NPQ;7W.1N2-/E.VX/FK)J7:;J5K1%&R3/TXJ"2[/<
M,,W1###?Q.*^]R+R0I\J8[@Z>LFI#1/IFM$4;),_;#9B2[/(PS=",,-_...\
MM=O'\96YOF/>ELD_)U]MN3T/=>K\GA^FOM]R2W]V*SR>#Z2<?QE;F^8]Z6R3
M\G3<GH>Z]7Y/#]--R2W]V*SR>#Z2<?QE;F^8]Z6R3\G3<GH>Z]7Y/#]--R2W
M]V*SR>#Z2<?QE;F^8]Z6R3\G3<GH>Z]7Y/#]--R2W]V*SR>#Z2<?QE;F^8]Z
M6R3\G3<GH>Z]7Y/#]--R2W]V*SR>#Z2<?QE;F^8]Z6R3\G3<GH>Z]7Y/#]--
MR2W]V*SR>#Z2<?QE;F^8]Z6R3\G3<GH>Z]7Y/#]--R2W]V*SR>#Z2<?QE;F^
M8]Z6R3\G3<GH>Z]7Y/#]--R2W]V*SR>#Z2Z#KL].5'5K<FL>G_'Y(') L0#-
M!+)&(90%B<Q.(P(;H[6$(%C+B#:][6O>UK7OM4W)Z'NO5^3P_33<DM_=BL\G
MA^DN_P ?QE;F^8]Z6R3\G3<GH>Z]7Y/#]--R2W]V*SR>#Z2<?QE;F^8]Z6R3
M\G3<GH>Z]7Y/#]--R2W]V*SR>#Z2<?QE;F^8]Z6R3\G3<GH>Z]7Y/#]--R2W
M]V*SR>#Z2<?QE;F^8]Z6R3\G3<GH>Z]7Y/#]--R2W]V*SR>#Z2<?QE;F^8]Z
M6R3\G3<GH>Z]7Y/#]--R2W]V*SR>#Z2<?QE;F^8]Z6R3\G3<GH>Z]7Y/#]--
MR2W]V*SR>#Z2<?QE;F^8]Z6R3\G3<GH>Z]7Y/#]--R2W]V*SR>#Z2<?QE;F^
M8]Z6R3\G3<GH>Z]7Y/#]--R2W]V*SR>#Z2<?QE;F^8]Z6R3\G3<GH>Z]7Y/#
M]--R2W]V*SR>#Z2Z!>STY4+<UCG;3_C^XU:!N0"*O+)'N0!;E#JH 986\]NX
MC;N@PB#>VT&Q0;VO>XK[3<GH,<?9>KX/_3P\&/Y_?3<DM^&'LQ6</_IX>'#\
M[O+O\?QE;F^8]Z6R3\G3<GH>Z]7Y/#]--R2W]V*SR>#Z2<?QE;F^8]Z6R3\G
M3<GH>Z]7Y/#]--R2W]V*SR>#Z2<?QE;F^8]Z6R3\G3<GH>Z]7Y/#]--R2W]V
M*SR>#Z2<?QE;F^8]Z6R3\G3<GH>Z]7Y/#]--R2W]V*SR>#Z2<?QE;F^8]Z6R
M3\G3<GH>Z]7Y/#]--R2W]V*SR>#Z2<?QE;F^8]Z6R3\G3<GH>Z]7Y/#]--R2
MW]V*SR>#Z2<?QE;F^8]Z6R3\G3<GH>Z]7Y/#]--R2W]V*SR>#Z2K4;V?::CD
M#*"6X BA,7&Z(02$]@E+P<^)V8:DL+DH:"%Z4M"H<2$ES3D:96:0G4G@ 0<I
M3 ,$>7CFV**80RFGNT[IQ&\PMEIXQ$Z4-.8V0M<7-878!SF@EH)(:XC XI]B
M2E$,II[O4&<1O,(F@B$3I0TYC9"QQ<UA=@'.:"6@D@$C ^AMOG<3R=B.^08*
M]HY'$)?"%SY'WI .XDZYO6M2@98KA'8)J=02+=IUJ)264K0+"5")820J(.*!
MXW64M113U%)51.AJ*=[XIHG_ (S'MU$:L00=]KFDM<TAS26D$^,5=+44-3/1
MU<3H:FGD=%-$\=DQ[3@1JQ!!U%KFDM>TAS26D$W,#\UOW6_E6!:ZYHB41*(E
M$2B)1$HB41*(H]+?-B0?PA?]F,J.WCS'T(I#51*(E$2B)1$HB41*(E$2B)1$
MHB41:]ZUUL+.>(^:D8]7F7[M35G;O#F'H6!V^><^E2&JHE$2B)1$HB41*(E$
M2B)1%'8Y^K>/6)Z^UWHBD5$2B)1$HB418L:P'K,+/AYT*PL4_@DSTFF#0H=H
MG%W&82EC$9B[("Z(*6-H:C0+23W7)R"!QE6]%E'68VU]6N1AS&40.51\J,"=
M?W\/>Q_2L;GAUU!2#)\C-R 1FA)B!LF\<:Y<RXV8,C1=:CA;8JUA-C(H@[WC
MY:7/9B)]/#I8E4U=L;J5+F4-U.02$:"*H9'$XR5U8=\\>&K>X?T'#'O:M:C<
MB;]9CX_2 ;:V9(:,?SWP/0*-&/LZ<@Y!BZ> SS3\"1OLWCF-RHXTPTZ5H7C4
M^HGL_P <9".4SB.-\%3MPV)&V1DZY-7IX-7>[^&]J(X\5G;IR;IVTX?C39DQ
M0[J)PB<IJG?>_*MU<S4IA<[DUD+:UO3^Z/4AD<5:6S>37"I5)')3))5#T;'(
MY#8AY<UR8DN/W^_WU*]]$7F%V?K^\S3KZBS;_4#17M&Q+_)7W_26[_=K5[;L
M1?R%]_TMO_W*Q:K69NA/!J&LZ]^Q>VX[>(NV+9Z[73Q)WS >\HWM9+)>&,EG
M -E<;DR%K800>*M[POCD-D1!Z(*>ZA1+G%Q-] E?5:>ID9#7/K(ZA[*2/&HC
MMPB=$VGI].1_W>:!\DIJJA\3)JF%S78YHIV,'H,KZK;%3*R"O?6Q5$C*-@-1
M';6Q.B;3TQG((@G@?)-MJH=&R:HA<UY=FMIF,5WA3'3\VOLCE3<W0%>7*VZ(
MR*.QU1$L>HVAG%BO! 'N1PE_8'9OF_!Y-E6>NI$;"9'W8J1N+XQ'W[_C<33E
M@.N%/>'Q0T[WU3-KOJ(9IQ45CI)-OW4Q0U,4L;Z73NH*2,SD3,T+(I1_%9F:
MT]=M6\/B@IWNJV;7?4PRS"HK'2/V_=C%#50RQOI=,ZWTD9GPFCT+89A_%9@#
M3CLX/L0?8MB6".SS&XZEM%QK9))([C6$+WM-*54V?VQJ0RF1-X8])!-+?"$S
M$ZN1]G)]<0*U2@2EG=%INZ3=PR*HBGN%7''/,[3YL$$U;5,B= VFBDD?!"\S
M0:1]2Z6-@S(H\UK0V2-H.=W+(:B*HN-9%%-,_3YD$,];5,B= VEA?(^"%^FA
MTCZITL;!F1,+6MS9(VC7>EMC^"FM1%AK6['JA-"W@F1R=E59-C+J<[,"Y]F0
M'3NK\W.@B9H_M\1QI!Q-L18%2IJ')<HN*@$<2H5AS23UCYKL]L^;)6 U,9A@
MD;0SQB.5L5,681/CQIHGSUM4'U$P$FAH&-T[G-$AZN26[/;4!KZP.JHS!!*V
MAGC#)614V9A"]@-+"^HKJHOJ96MDT%"QNF+VB0R%2;A\,>CT<LFQ+PA2L,><
M6!4K=<.N#4_R]JPK*WEU4NCZR-3:MB[</,2UF1K8WEF3.;/*TW>]J(;6QJ;%
M)";$P7$S339UPT+Y9FRM$=R9)#3R7.GCC:R*:1[9WBW-D<R:@@9)3NSY"^1[
MVEV%C;CIII\;@(72S,F:V.Y,EBII+G3QQM9%+(]L[Q;6R.;-;X&24[L]Y>][
MVDTB%J,./#0:ARDZX<3R4$_B#RZN,:9&)O2.2"'IHK$VE@1F-#6W-B9G=G>?
M29RRB8QW;624LN/ELK0JWE0@8'5RYU0N4<H=01W(PFCJ8XV32RN=&^H=45#Y
M7![WO,D<=) RA$N?+!)5L@<V(.E8S)5"Y1RAU!'<S :.IBCCGEF>YCJEU142
M3.TCWO,L<5)"RA$N?+!+5MIW",/DC;;G);IA]RQ5(2XV&.ILD/.3HQD5T3-L
M=CC>@:&J;-^15ZN#PJ0('*RL<;A;>M@+>]QHB/LS8SRPMZ !4YH4C.)+O4++
MC'7PF?3NHHZ&>CC+YIWN?)2OHF-JJF%S,W35+VU;XIW2R220&/L6.=(#O4,=
MRCN$)GTSJ*.AGHF.?-,]\CZ5U$QM550N9FB>ID95OBF,TLDM.Z,YL;G2!UMT
M:2''2)6QV<F%.U0Z&.[,E>##&TDN7S-W'WB[\ <%:<XE:UH9+)+.K<I&02H3
MX^BY*RP$+F4J6AW'.J6PMFS)G25-3'*Z,"0FFIHAIM%F-(+9'P0:-[02'5DY
M;V;"UJW'FI$#9C'*Z2IJHY7Q@2$T]+%_&B+,806R.@@T;P"0ZKG+3G,+6K*F
M42#3>D=WE[C"7'"](]R'&$@[SGL;*$AFA&.(F_N*R(-B4]$ *.3S5[QVC1S-
M24 \N2VR1'4JU6>XGOZ<_H8(KTZ..*8UC710UL(E$TN,M565$+&U+W!Q+H::
M*L>ZF#CC#M*9S6AHB<.@IX;VZ..&<UK'0P5T(D$LN,M56SPL;42/!.=#315C
MWTP)!A-',0UK&Q$?=Q8-,K](DD="]P B(->3Y_(Y*]M"EA9W9X9)>_19(RD,
MQRQVBRS@W V9+)VUMCC,]*076I6V:-48?FZ0+6P7%LU\BA,VBK#4/H:2&&)[
M998XY:>&=TKI0(YFZ>JE= ]\TD0(:Z2FDGB="UZC)KY#$Z;15IJ'T-)!#%(R
M66..2GBG=*9 V.=NGJI3!(^>6-IS724SYHGQ->HO),*8PQRIB\>F%TS N7I4
M"1UE*F1MCA8U6J?<81><-1S>:N6IF]WBB:0Y4=S;B86HYM;6>$C(5BD"9^N?
MGAN=?6B>:FSI6M<]T=.V%[<&MBK:BED#PQI='4.AH8F_QT@D?)5!S=$8@,\-
MTKZX3S4^=*QA<^.G;"]A ;%75-)('M8USXZ@PT$0_CI&R/EJ@6Z(Q86Z<8SI
M^X .TH3J32Y(8P=Q#%VN4,ZT+"\JHZC=XXM3">9.TO[P:I<WUJ9986V1R5I&
MU5%9P6-MBUG5@4L>ZR>[[;C@(Q@$V.G?3R-TL39G13-=HX)(8P&0R2T^?-3N
M>VHI3GSZ.5LN\R>\[<C@< 8!-B9WT\K=-$)G1S-.C@DAC#8XI):<OG@<]L]*
M2^?,F;)B=7T"^A2B)1$HB41*(E$2B)1$HB41*(E$2B)1%Z2=A,=<^J,5YU:W
M0BY^FY"TNXXNM=S%(52')AZ2QKPVPRURQ%'LA[29==+"!&%I4+T-F4-X=^.;
M]W7Q/95CM0FHI(W87ES")V1@9KJ(-<(GU)Q!$HD&; <"YT0D#^Q9$O#]E>.T
M-J*&2,@7I[3MAL>:6OH@TB)]3KQ;*)!FTYPSGQ"0/[%D6'HV#\UOW6_E7D:\
M?7-$2B)1$HB41*(E$2B)1%'I;YL2#^$+_LQE1V\>8^A%(:J)1$HB41*(E$2B
M)1$HB41*(E$2B+7O6NMA9SQ'S4C'J\R_=J:L[=X<P]"P.WSSGTJ0U5$HB41*
M(E$2B)1$HB41*(H['/U;QZQ/7VN]$4BHB41*(E$2B)1$HB41*(E$6G#9,= .
M5M;4_P :KL:RS'L9*QU#W)([AG"V2(S%ADG>C#D0FVS!&I $P! 6)595=4)*
M((C4_<0G6$9<O[_(G*V@R99<F5E/5SFL=2NCVLV%P:(!4!V?I9HCB3*,W-!W
MCCAJ7H>0V5UOR8CN3:ZGK)S6OI71FE9"X-$#9P_/TT\.&.F;FYN=C@['#5CK
M0XAC5+Z5, ^VLB?#BONMU6R<@NOQ*3K:^\W6+#R"[^*HNNIQ#&J7TJ8!]M9$
M^'%-U6R<@NOQ*3K:;K%AY!=_%4774XAC5+Z5, ^VLB?#BFZK9.077XE)UM-U
MBP\@N_BJ+KJ<0QJE]*F ?;61/AQ3=5LG(+K\2DZVFZQ8>07?Q5%UU.(8U2^E
M3 /MK(GPXINJV3D%U^)2=;3=8L/(+OXJBZZG$,:I?2I@'VUD3X<4W5;)R"Z_
M$I.MINL6'D%W\51==3B&-4OI4P#[:R)\.*;JMDY!=?B4G6TW6+#R"[^*HNNI
MQ#&J7TJ8!]M9$^'%-U6R<@NOQ*3K:;K%AY!=_%4775TG+8)M4#6W.#F?E+ H
MR6Y$K7' *><A7-&4D(,4& +L/'0 7,$ N]@6$, ;BO;="#;;O9NJV3D%U^)2
M=;3=8L/(+OXJBZZN[Q#&J7TJ8!]M9$^'%-U6R<@NOQ*3K:;K%AY!=_%4775V
M5>P2ZL5Y@3EV7\%+#@%%D -5R')*@P))(=P42$9V.QB"44#]$LNU[  ']$-K
M6^2N+=E*PL&#+;<V DDAL5&T8G?. JP,3PG?*XMV5LGV AENNK0220V&B:"3
MOD@5HUGA.^5UN(8U2^E3 /MK(GPXKENJV3D%U^)2=;7+=8L/(+OXJBZZG$,:
MI?2I@'VUD3X<4W5;)R"Z_$I.MINL6'D%W\51==3B&-4OI4P#[:R)\.*;JMDY
M!=?B4G6TW6+#R"[^*HNNIQ#&J7TJ8!]M9$^'%-U6R<@NOQ*3K:;K%AY!=_%4
M774XAC5+Z5, ^VLB?#BFZK9.077XE)UM-UBP\@N_BJ+KJ<0QJE]*F ?;61/A
MQ3=5LG(+K\2DZVFZQ8>07?Q5%UU.(8U2^E3 /MK(GPXINJV3D%U^)2=;3=8L
M/(+OXJBZZND7L$VJ QQ5-MLI8%L<D1(%Q@[O.0NY"*<#W).2$%[8ZN.Y@!MA
M]S+" $-@C*W(A7N.P&ZK8\<-H77@_P#+I.''_P!WWDW6+#ACM"[\/_E4?!A_
M[WOKN\0QJE]*F ?;61/AQ3=5LG(+K\2DZVFZQ8>07?Q5%UU.(8U2^E3 /MK(
MGPXINJV3D%U^)2=;3=8L/(+OXJBZZG$,:I?2I@'VUD3X<4W5;)R"Z_$I.MIN
ML6'D%W\51==3B&-4OI4P#[:R)\.*;JMDY!=?B4G6TW6+#R"[^*HNNIQ#&J7T
MJ8!]M9$^'%-U6R<@NOQ*3K:;K%AY!=_%4774XAC5+Z5, ^VLB?#BFZK9.077
MXE)UM-UBP\@N_BJ+KJ<0QJE]*F ?;61/AQ3=5LG(+K\2DZVFZQ8>07?Q5%UU
M5J-[ KJ",D#("7Y<PVDBHG1#:1J8VMFSA("63?)??,;*B<X.UMRETLD[KO$I
M<X)$@E/<]\' *W58YME6TB&4T]NN+I]&_0MF%,R$RYIS!*YE2][8\[#/+&.=
MFXX#%8I]EBT"&4TUNN3JC1OT#9V4K(3+@<S2OCJI'MCSL,XL8YV&. Q7I'C>
M,H5AK"I6,,=LJ>/PV&PER9V1L(_2N$DIN5F'JUA][6,6N;DK,/<75Q/N)2XN
M2I4M4C&>>8*_BE?6U-QJJFNK)3-4U+W22O.K$D8!K0-36,: QC!@UC&M:T
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M4J8HV8;7\E/.2JLDL"92F-,3J$ZC%T#)/(/)&(LXDXDR/!,*-*,"(!A8PA&
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M@1@5ZD\.Z@X!J?T\AR_CI;W5H?HN]$N;2>:4)UBLC2-9MGF+OA1=]HES:CS
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M1RUU"7/J:P'7 V1G^1 M.#RXELLH=B(G-8UO9NE#?"ME*\6ZJJ:6UP11S5M
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MG\36]>55XAC2QZ4]0'MS'7PUINJ7[D-H\36]>3=8O_(;/XFMZ^G$,:6/2GJ
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M=<TRYEQ;L6V1?(F/L*9*4A3LC00B(NL$2C);4124D3@$X"\12<!(2B[K@*%
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M(BXBH3(W=M+&GD=VT\QR5DLB<LYZ%9OK2;+8GYP;20$C-S&FVN#IPZ1\;33
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M:TOB?B62L.^QQ+<'M8YOM(Q/DR%YC:V_)V/'I/((;,H1$7AD<T]]JXR#G*8
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M5O9()&!M1)/2NJ&2N8^.-]1(P0&-L;6T1TS@WOZ]O7R&'K'8QQ/QL;D@1DI
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MFNCH\R!XIZ6KI0^6 5.<^ID962.DJ-."YS(@6%K7-?U%-832"!\%1!%40&G
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MEUMN+R"W_P"D+_LYE0[QYBBD55$HB41*(E$2B)1$HB41*(E$2B)1%KN[A?\
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M6\>L3U]KO1%(J(E$2B)1$HB41*(E$2B)1%KTU@:)DNKJ;QE6HR.? KP.*A3
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M1$9&NS!(8XR\##$L;CO!?S>_#WV2<OL@;AL8QY%97Y09+QW2BRL?<662Y5%
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MK62F =*N&=-14@MBY@5HULG,2]]WAY<3GEW.2H@BWJVDK5 0B3-Q1HS55TI
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MF0LCC/<7 A)+US@O9'5_D^.D&-\OXV;,9'R ]D+7#;DK7F>5"43E]M),JN!
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M?9;7#+O*"HO%7G0TK,:>UT&?G,H*!KW&./5V+ZB4G2U4P TLSB&AL+(HX_\
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MI>+8,HQPAR_/5<4<WTJ8D$XQ<LDMJ-5'34!<DEED*M5$6YU3" 98IAJQQ&K
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MLKHDD@0"T]:G1(9:I4+94B$:\W2298K  M4KD">[SW%Z4J2P +4'N0%)IP
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M/6*CS1_CFY7&LN]?57*X3NJ*RMF=/43/WW/=O!HWF1L:&QQ1MP9'&UD; &-
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M\MM=.:ANDT[&-:<6%WT4TE6'RZ-A<S3@1X%^>6PT^G<W,#,,R:5CH"_/&.>
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MJ9?)C#@;FR#=VW %1%]T(-@B[IM $*X1V#,YN)U\ X#W^]WU> <Y]#56_"K
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J")X58%R]]5O/NZF>WC\QZ$6$_?=N_P 1_P#U'_\ TJPK-GMX_,>A?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g129231g03i03.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g03i03.jpg
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M?B.IBJZ+NI^U4"CE3!PQ5J23M-<H!B9699FK(MTJ*RXA+\AKY$Q+&P8Q62+
MR8ARPQA8.;&GO5*<IRQ5VO=QL5X;EKWX]^&U2+^YOU,=94TFIDY+[U]+\;I_
M4RNFX/P![@X]IL:]):>;]L=M]PRU*UJ"VA/PF/8M/HC>M:C4IZIM!7I/6D6X
MOR8YZ_7J <KPZZW.;TX27L%/J=2J\DK;)M>KS\6,>/S1RGHT0.'$RB R'(G%
MB$-IZ>4&CH/S9":Q%6D[]2<F]$[^>^3T">%SOO2XNZ^LC^V>5#<:Z>.D2D5:
MWVNF=B7;WBDZ!22SI1AH)7S3K(EB--E"I8:Q@CXIS5N$%1JY8H;'EZ>99D-[
M]ES;HIW-<=>@D[U*]-._HX=VK:2+OM52JS/9S-BM9LU#HW50E!T$8JFEE!UE
ML-)YF0 <]IT$'&=*W>8>G7(81'RWFGR"BMFFBG'6101I<>2PVIO'4WKPP+-7
M['+3B<=[R>YJ-J%TMMCC7*J*YT7J(:[52P50BQ<P+]\,"PE3E[ P?GU%Q1R4
M684/*5Z07A2M1B<5AYPD*(0([-<Y8SPE@^<9RO>$I3YY=Y>'/>QUSHARQU>*
M&N55L]8&@#T^NWNLS:N7D5FTOFXE=LL&)+4O;XHI,K9Z%['%,E!LX7)A&1HV
M5\)IPU*6%^KR/:)\=NXA+R6Z<?IO2.$4Z'V,)Q"L7UCJC]FN!N%2I#.WZD)K
M$P# :E7EI8F(N3(*3$*2A2'Y/N2E'NVVG6JE--RFU+7MU-$;O2USZMZ90.N=
M0O7(/':?<Z_TTSVPQ;;530E2Z)6:32"T"O#K9;:W59$^/#J[4>M%=1VYI)0"
M1/;(1YUIE#1,QMZ(O;.B4W)I*2FU>O+/YBX+&=^J>_!;^<T9Z_T"9Y!<@Y U
M(Z]!!,\L3=[88(\TJ+)&Z%I!*K1(R+G*V+V/JX,=$GDHME73AH"3#M<AL>Q(
M9BQ4L.)7-W8RQ?5KY]"TS).]*;PONQGIV2TZ+\24@_?*H(Y_5#LHS;^DEKI=
M+[4ZB,"TUA-TM16KVJVQ2HV#6Q*8@^*-J,&O3XDFPDI(X8H4)BDRQ%! JTF5
M)3V22;Z.W46:Z7+HXX14E]JJ]D'<I-AK#9*NS;>N/\[?!D*A\$W*LPH%=W3%
M M@XY'U-JJH<JMS)T@O"]'5O"("!TR6(,ZD24I3TW:]JOV_*,9=W?@?2_)/G
M3=J37=QK?L3N\HYAOHB:J1WS9/1W"?U"BFJM/I[-DMV3::HJ>B(JO-VY7W*N
M&D6#2AR4GLURG?*4Y\7[!/JXX^:=)G^5?,QYBP#71O0'1M/O;/.;I<(]',.4
MJI6:45&!8+)BQ*0B([&E$C UIV0(24V(8EQR%@;$#9$>8[<U[,)I34VMBXV7
MC.6V4Y3E=Q.[?CH*Q<_)#GU(L-@ D(-T*1Z3]4?LC6BN5(H;J?-]'(L8B/\
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M1M&T,RR3;"9LEI.T(VEMYY:$[0C>DZ]NO0#;9J]9CDI1EBN@F"\Z0Q+FE61
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M;;+Q$=%ENM->[X2''FDK6EOW[4OV:5O?MTI2E:UZ:VI6_MV!6\ 8 P!@# &
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M/J1(D/Z8:TAK3S[SOM][JU*!Z-J[623@@P!@# & , 8 P!@# & , 8 P!@#
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M%WT#\":M_(D#\PG +OP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M4555'0T$$-'109U2J\<6;!"E"LZ.**)R5\3;=[.VW.*'%!@# & , 8 P!@#
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MO9-/0UJTE:/FN-VA9E5KU)#2>9ZW1434%)3Q0P.&!/,2SIN;<'_UT+S _NY
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MX[S-304OB_&.H^+S\QO-S\R/-GCFQ2P9ZYLZJ.J!@# & , 8 P!@# & , 8
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MRU/^#]XU8UAY0/5=:_X54]X54[?<X:<-& , 8 P!@# & , 8 P!@# & , 8
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M_P!P?]78]#_);[PI/=E;_?#QT>SH/8M_4W7EYY&>8?CQWRZ^2'4K#U.R5KK
M:O B-@<8VH8(76$SG(D5N,RPTVEZ4ZIUU7LVMQ6D>Y6](3Z=2Y<614+%MBBJ
MEG445#01U&AIHH(J2DI7XR.EIX(HLZDBBB4X8(5).2E-*;<_[T43B@SGCG-<
MR4+[6>CK.&G]!@# & , 8 P!@# & , 8 P!@# & 4BP#IA@";$CC$RO$"@@D
M.@GQ[49^>#F38;T:,7@LS6GX;LP:\ZB;&;ELO1EO,H2^TXUM:-@8HEO#L#&I
M_#J_S'HEQY-8N"5([1:G>Z]!JQPX1K-P#"QEWCV"%:PA@.0)VD@%$VJ6;U";
M(L6F$@HT\I,B;&E <4_X2\]/TVN4%ZQ65JL<\Y*!Y=RJ$ZD81519(B5 DD;[
MO1*)*AV:W61 .OC3#QV$_ 4#AF0S$1J#;+&U/%3EV^3M>G29 \@Y@+XWS@'S
MP02GF(H9P_/?*DFX3$LB6M%B+VP],W$&QH8X?&D'#A%V",@1F88R"J./C)^#
M&1O8A7Z!^!-6_D2!^83@%WX P!@# & , 8 P#Q]^:/[Z_P @/RF6#\ZC/0/D
M,^QK8?XVT_A&LGA1X;7VQ.6'M#)G]7[/,8\[=-3A@# .Q?PL_>_?2(?\ERR?
MHU>\U$\(WU39'>U*7X0HSUU^AM>I3+S\\;&^#:,Z",Y&>\4."W+R#!1@# /8
M']"+^\HW^5V]_P#8:SFM.7_JLM3_ (/WC5C6'E ]5UK_ (54]X54[?<X:<-&
M , 8 P!@# & , 8 P!@# & , 8 P!@# & 6+:.=UVX62B68[J=*D\[(G3%>'
MZE:0'V8/5V?5'RA&#\)7SLR""+F80M:G4-P]%YSVFW']QW&!9XK7QQN+(XUX
M_P!(X<@DFIS;,37. 4^G1'[058*/ Z)SUHTS1:.&5'@#TM5^K)L9Y0]4U,XS
M(<*RG2I<B[\);0-SXZ7SEP<X_=CKGY49'Z"4/ >$.[M9*."# & , 8 P##;Z
M1%EV1X'^83##3CS[WCAU]IEEI"G'777*090VVVA&MJ6M:]Z2A"=;4I6]:UK>
M]Y]MFQ0PVC4(HFH88:[58HHFTE#"J>!MMNY)*]MW) _),_8MZ5_<#</\W2O^
MJYM%]-[*]<:E[IH?VSX<R/[F+^B^XNT;X_=2*L")4>LDFHI%Z6R0?EC2T75:
MW"4M;KIYIT>E]J.[#TB9"D0&I[9#;FAL%4@TAT:CXZ7*.R*&*F@BK="XZ.&"
M*BA@IJ&)UK/22AJ[5)FN-4DZ..&DBHW12\;29M U2NJCC<O2M3UIJ6_3U7X*
M;N+47ROI"5K2FB6YQ*5*2EQ%<,:0XG6]ZTM.G(:'-)7K7N3I:$+UK>M*2E7K
MK7V*V++:3^F%24U@ZS0S6QRC:FMC:U-DS(_N8OZ+[CWA_P!2=@C5>\6?):">
M$D0TU?; ,A$0G#D09"H[E/0A#R69+;;FVEK:<2ES2?:I2%ZUOU3OTZ/Y1ZQ0
M5FW:"DJ]-14]&K-H(7'11PTD*B5/66X6X6U-)IM8R:UGU4*:HY--//B<FI.4
MH;[]S/5OG #^@P!@# & , 8 P!@# & , 8 P"F-&1;YB?7VIK#AH8,$F2 Y*
MM_,Q19V4:A")KJ?3TTP0EUTVQ'5I6]J<&R=;TG2=;4!4\ 8 P!@'RO\ M%?X
MJO\ JW@%I4#\":M_(D#\PG +OP!@# & , 8 P!@'C[\T?WU_D!^4RP?G49Z!
M\AGV-;#_ !MI_"-9/"CPVOMB<L/:&3/ZOV>8QYVZ:G# & =B_A9^]^^D0_Y+
MED_1J]YJ)X1OJFR.]J4OPA1GKK]#:]2F7GYXV-\&T9T$9R,]XH<%N7D&"C &
M >P/Z$7]Y1O\KM[_ .PUG-:<O_59:G_!^\:L:P\H'JNM?\*J>\*J=ON<-.&C
M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , B[G'[L=<_*C(_02AX*\(=W
M:R4<$& , 8 P!@&&7TBW[PGS'_Y-G8OT&-9]UE_7*SO;U4]\48/R%,VR/SR_
M ?0C->&QPPR,,;$K<?781SD=QV-<D/J7I,:SZ4_\29$AQU:9&1HSD-L4^G98
M=J,;6LDK\^L6;05FEBIZ6*E=-"H55J51*&.I-)3BJLH901TD4XJ6*-1NFA?B
M:7/H$J(R432DI):=N.-^K"4I8J^\L5>]*4I24Z0E2M[TA.U;2C6][WI*=KVI
M6])U]FMJ4I6]:_;;WOUWGZ"PQGM<IO:Y)+H26PQ/?5_4D?[T[R8_+D$_0UG.
MA.4[U04'Y,J_]_6CZZ#_ !?^_%_TP'K,SKH_J, 8 P!@# & , 8 P!@# & ,
M Q^ <$% NMV#H[9^]OQ"%8H@P; F=:ZL3]I>M'ND%"NRXXG:Y(HH >CV\.V(
M"3DSQ<&1',KCC(/SSSDZSNEOT+9W7DE?/M>W;+==<9 Y"F.OEGU6R<4\>>E]
M)IT%LA; @T3 K4=Z,S-:;.VJR!:@*G.PI,T9&G-C)QY@DN#))#HTU,3<61/A
MLNKDM 8+USLW9;Q?:GXQP.Q=JYGT)J;V,]U&X=3H_CO(Z-77J+0N/6"H5$.W
M0A%GXY*I]B:ZK$N<@C&;-6=H?#FUYXL.<:VZP+U\:)]Q%+'F-Y9 PO/NE6ER
M)JN]FXX DTE,8-3BU(C&"5 Y DGTF)6*VJ=VJ81KG1BW2I9*ORV%5*PC"W*Z
M'5Y2KC:8CRY?Q\^_5WE*[K^3;V]?;]R.X [WS&I66O6,K;1[XC8MZPGQ+@&P
M$C-;D2*U8UV$(X.$;#V%BQ""D4Z,0+@,P2S$R,Q%98;;1JD*W0/P)JW\B0/S
M"< N_ & , 8 P!@# & >/OS1_?7^0'Y3+!^=1GH'R&?8UL/\;:?PC63PH\-K
M[8G+#VADS^K]GF,>=NFIPP!@';+]&!S]CK #R]Y?*)/!HW1./0Z3(+QXZ);X
MQFT-6P*Y/9BN.L-R78B)NWT,+>:2ZIO2%.(TK:M:?>$K2145O9*TL,LZCLZL
MTD,[UG05V&)34U-32G>KM)ZX?0X8W19&\H5)#)Q4>5EE1I/!N"RH8E.4KIJ\
MN7^L!4C^^3M7_1V(_P#%&=4^BEE#][65[GK/QP]8O14RD7_T63[EK/QT;^@"
MI/\ !Y*6K_V\Z$;_ /\ :=8]%+*'[VLKW/6?C@]%3*3_ #%D^Y:S\=-/ZP#2
M?[Y2T_\ 1T)_\4X]%+*'[VLKW/6?C@]%3*3_ #%D^Y:S\=-?ZP%2/[Y.U?\
M1V(_\48]%+*'[VLKW/6?C@]%3*3_ #%D^Y:S\=.V;PR\5AOAYQO]B 5<9UYB
M_=6<M.SA 1'"R/BFF1S*H>H4:;/;^''2.1M+OS&U.;<5ZH3[=>O"+7M2L6U:
M%8M*M0T4%/6/%Y\-!#%!1+Q5%!0PYL,<=)$IPT:;G&_3-M24DN#VO:E9MJT*
MQ:=;AHH:Q671NDAH(8H*)>*HJ.AAS88XZ2)3@HX6YQN<4VI)I++#/S3\T8 P
M!@# & , 8 P!@# & , 8 P!@# ,>^ZC.PSTU'?-R]=ACFKUSETC$F5.RFRZ=
ML7*(Z3(RIP2Y 6$U:.-^"LP/>';6N(Q/V\5:9D(U%JEIU/3LW8ZA?HY]Q.@E
M!5L9!;.R1\PPB,TDE*$PI(T8_,TG7QG8,"9/*RHD9:_7;3$@E-=;3Z)7)=WK
MW;@*A@&-?8_).N<AOW/>?D8HQ4V[1IA><8/V1%7!UX%#/5VMI>7-6*+[GFBI
M2Q,100IQL; FR(KT68=&RI0MF>*E.?DTN?&B>XT\?_(MGNCI)E=+GTUW5"YC
MUFN)F&(9C1[FG8$V[=(,R-Q(T7ZG..+I)UHY75ZG(%.(A_ +D425*9!W=N_K
M)$YQ^['7/RHR/T$H> \(=W:R4<$& , 8 P!@$%^3O)B/>?'7M_%!!6$"*=6Y
M;=N?P#1)I]Z *EVL!.#,D)C,5*I#L>(N7I]UME.W%H1M*/MWK>?WJM-YFK-7
MK&;G^(IZ*FS)YN=XJDACS9R<L[-E.3E.<F#QB?[41[;_ 'W_ "S_ #$MO^LY
MVQZ*S]8U_:+^)'\/$+[I]"+./?U*'U\!9Z+5I'EKS9^7?"!P>/DLT2S_ "\)
MP%7I]BD+F>^:EWV/1A[C#/P$.J^.M'OTEOW+T]%=SE](UI__ &+T2_\ XMH\
M0I3SGHT+3/N+Q_VHCVW^^_Y9_F);?]9QZ*S]8U_:+^)#Q"^Z?0CT1_0V?1CW
M+Z,#D75^8W#IU9ZB]T*^#+E!+5H25#MP&X@3ZI?@RXQ3:U+7M:&WFGF75)4E
M2TK0C:$[7P+*:WWE':$%?=554S*K1U;Q2IO'S\724L>?G^*HL?&RS<R[-G-S
MDOZP0YD.;.:FWTI+L.XS..F0P!@# & , 8 P!@# & , 8!"GD)=9] Y?/L ^
MPLU!QVT<[KLRWOPX,]%2"V[H=7JMALS<4I'EBER@0$P2)05EH<T2Q.C1I!2#
M.@-2(;]2F^GJ4R-R71UN1C3R+O,RZ7YRES?)KGQ0)6KUL#6?E*\!WTWM4%T8
M+-PGRQ".D?2Q YITN_6)VJ318<PU* RY\$G675NP=9-73S7-J_&2[=$[W=/2
M8J*^3>F2TM\ZNE>M"U:'/L!S S+;N%/K'0*L>I5S"0+'5+.,E!CX,FU\:"3&
MS6]M2(SZ-;2K6E)W[FW6EMOL.I0^PXV\VVXD"!I'AOXXRZS%JLCGJW(<6PD[
M5]<?=?>4W:6>.!F*V<G%.AHLR;X7T<K46+6S,4I8YD,I7HD0).COC(D:*T!>
MQ#QZXR3@$!4RABEBR'/0/*M#F7B,2"*Y_6)*YH*MUJ-$FL-52*/G;CS6I%:2
M*G+F# LIZ4X^##N0@+]IU+K'/*L,IU.%-!:X%8D-CQ[3TJ4I*I<J00G2I4V<
M_*GD2)(C+EDBA,A*E$"9&7*GSY,B7)>>6!M4#\":M_(D#\PG +OP!@# & ,
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M-HN617*X.4P,%_6A!;#'Q9;RU@W.\J/./W8ZY^5&1^@E#P5X0[NUDHX(, 8
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ME_#3NW^2])_TL?S3OPFOKUDQ^2ZY[[1ZV_0Y?43RB_G39OP2COXS6,]&Q@#
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M+X%'^RXY*O\ G1E7_P"%#]BOJ'_#P>_S7'_K3'H.<KW^L?E+^B%E?Q4?RY?
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M 8 P#K_"TJW='M-O#,B)G/1@LJ4LC 2, ZA2JJ$LPRU%A Z,R?:/ I,BS6L
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M4;G'[L=<_*C(_02AX#PAW=K)1P08 P!@# & , 8 P!@# & , 8 P!@# & ,
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M67Y+,8E"^+\M.8:DR&V933K:'W4ITXH0HM _ FK?R) _,)P"[\ 8 P!@# &
M, 8!X^_-']]?Y ?E,L'YU&>@?(9]C6P_QMI_"-9/"CPVOMB<L/:&3/ZOV>8Q
MYVZ:G# & =U'T,OX:=V_R7I/^EC^:=^$U]>LF/R77/?:/6WZ'+ZB>47\Z;-^
M"4=_&:QGHV, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8!%W
M./W8ZY^5&1^@E#P5X0[NUDHX(, 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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M5&1^@E#P'A#N[62C@@P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MC\NM._[0[G ^4[U"Y1>TX?[^B.)Y:_6*/\H63\)U4_2_S1LZ[& , 8 P!@#
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MIT%7H**&TZHHJ2FIZ6JP45%1IM)QQQ0PIM3=Y^EQFGITP, 8 P!@# & , 8
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M'0.BK-7CM.J..BI%#0PQ.&)PIN42=RO/TL<U@-=1@# & , 8 P!@# & , 8
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MW2EIUO?JK6M]F\D-:LRI9>V16+8IJG5[.@HZ^JQ2U^*BAJD.=4J>&B\:Z?\
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MCAMB<*A=$'0_J<= :@H<!ZUKXECSWZ>GLZP08 P!@# & , 8 P!@# & , 8
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MR=_-?KV7J;.5^SOE=SW:NARJ<KN?/H):(&G2R\*;)A193R9H O$2+DSP\X_
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MD-,,R34G)[)E3FIK;+I+&$==N=A+)J ,!49MCU/O'P+ HZ61138.@Q.?H,$
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M) /.N;&#8LAYV*J*7E/OO;4ESXD-B#!9FD2$.&[)34]J73/N*W)K;/FDIEO
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MWLU*6U3XO>\*=\Y8Z)]OE).R%& , 8 P!@# & , 8 P!@# & , 8 P!@# &
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M\Q<>,V*;6[#8'"8$2+J.M-S3NN<_)=NN0DKU?>I>6_?>RO7/F\"YAZT%>/6
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M)EPY$F?\>3/18IDN*] (S+% AS94UV.LA"G&YMMZ1+"5TN.-I=^0HP!@# &
E, 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g129231g05h31.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g05h31.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1U.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '3*^='0X0DE-!"4      !                      .$))300Z
M  $+    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    4 $, 80!N &\ ;@ @ %0
M4P U #$ ,  P "  <P!E '( :0!E ',       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q ;=,S0         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ ._
M_C4  @ ! [_^-0 "  $X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              *&   $J0
M   !                          $             !*D   *&
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   *&     %)G
M:'1L;VYG   $J0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   "A@    !29VAT;&]N9P  !*D    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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M'4/(.P &S0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M            _^% @6AT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"\ /#]X
M<&%C:V5T(&)E9VEN/2+ON[\B(&ED/2)7-4TP37!#96AI2'IR95-Z3E1C>FMC
M.60B/SX*/'@Z>&UP;65T82!X;6QN<SIX/2)A9&]B93IN<SIM971A+R(@>#IX
M;7!T:STB061O8F4@6$U0($-O<F4@-2XS+6,P,3$@-C8N,30U-C8Q+" R,#$R
M+S R+S V+3$T.C4V.C(W(" @(" @(" B/@H@(" \<F1F.E)$1B!X;6QN<SIR
M9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M<F1F+7-Y;G1A>"UN
M<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\B/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(Q+3$Q+3$X5#$X.C(T.C X+3 W.C P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I-;V1I9GE$871E/C(P,C$M,3$M
M,3A4,3<Z-# Z,S4M,#<Z,# \+WAM<#I-;V1I9GE$871E/@H@(" @(" @(" \
M>&UP.DUE=&%D871A1&%T93XR,#(Q+3$Q+3$X5#$W.C0P.C,U+3 W.C P/"]X
M;7 Z365T861A=&%$871E/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @
M(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @
M>&UL;G,Z9&,](FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*
M(" @(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @
M(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N
M(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIP:&]T;W-H;W ](FAT
M=' Z+R]N<RYA9&]B92YC;VTO<&AO=&]S:&]P+S$N,"\B/@H@(" @(" @(" \
M<&AO=&]S:&]P.D-O;&]R36]D93XT/"]P:&]T;W-H;W Z0V]L;W)-;V1E/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP34T](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]M;2\B"B @(" @(" @(" @('AM;&YS
M.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S
M;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(CX*(" @
M(" @(" @/'AM<$U-.DEN<W1A;F-E240^>&UP+FEI9#HS1#DS,3$T,40Q-#A%
M0S$Q.$5#04(R0C,Y13@V-CE"0CPO>&UP34TZ26YS=&%N8V5)1#X*(" @(" @
M(" @/'AM<$U-.D1O8W5M96YT240^>&UP+F1I9#HS.#DS,3$T,40Q-#A%0S$Q
M.$5#04(R0C,Y13@V-CE"0CPO>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @
M/'AM<$U-.D]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C,X.3,Q,30Q1#$T
M.$5#,3$X14-!0C)",SE%.#8V.4)"/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT
M240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \<F1F
M.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8W)E
M871E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M:6YS=&%N8V5)1#YX;7 N:6ED.C,X.3,Q,30Q1#$T.$5#,3$X14-!0C)",SE%
M.#8V.4)"/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z=VAE;CXR,#(Q+3$Q+3$X5#$X.C(T.C X+3 W.C P/"]S=$5V=#IW
M:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!
M9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!
M9V5N=#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&EM
M86=E+W!N9R!T;R!A<'!L:6-A=&EO;B]V;F0N861O8F4N<&AO=&]S:&]P/"]S
M=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#HS.3DS,3$T,40Q-#A%0S$Q.$5#04(R0C,Y13@V-CE"0CPO<W1%
M=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^
M,C R,2TQ,2TQ.%0Q-SHT,#HQ,2TP-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F
M.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @
M(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C-#.3,Q,30Q
M1#$T.$5#,3$X14-!0C)",SE%.#8V.4)"/"]S=$5V=#II;G-T86YC94E$/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3$Q+3$X5#$W.C0P
M.C,U+3 W.C P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @(" \<W1%
M=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T
M179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N
M/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP
M:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @
M(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@
M<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \
M<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P
M;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S
M=$5V=#IP87)A;65T97)S/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @
M(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^
M"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T
M.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^
M>&UP+FEI9#HS1#DS,3$T,40Q-#A%0S$Q.$5#04(R0C,Y13@V-CE"0CPO<W1%
M=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^
M,C R,2TQ,2TQ.%0Q-SHT,#HS-2TP-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S
M:&]P($-3-B H5VEN9&]W<RD\+W-T179T.G-O9G1W87)E06=E;G0^"B @(" @
M(" @(" @(" @(" @(#QS=$5V=#IC:&%N9V5D/B\\+W-T179T.F-H86YG960^
M"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI3
M97$^"B @(" @(" @(#PO>&UP34TZ2&ES=&]R>3X*(" @(" @(" @/'AM<$U-
M.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @
M(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI9#HS0SDS,3$T,40Q-#A%
M0S$Q.$5#04(R0C,Y13@V-CE"0CPO<W12968Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HS.#DS,3$T,40Q-#A%
M0S$Q.$5#04(R0C,Y13@V-CE"0CPO<W12968Z9&]C=6UE;G1)1#X*(" @(" @
M(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)1#YX;7 N9&ED.C,X.3,Q
M,30Q1#$T.$5#,3$X14-!0C)",SE%.#8V.4)"/"]S=%)E9CIO<FEG:6YA;$1O
M8W5M96YT240^"B @(" @(" @(#PO>&UP34TZ1&5R:79E9$9R;VT^"B @(" @
M(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \+W)D9CI21$8^"CPO>#IX;7!M971A
M/@H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@
M96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$!_\  $0@!! '@ P$1  (1 0,1 ?_$ !X  0 " P$! 0$!
M           '" 4&"0H$ P(!_\0 .1   @(" @$$ @$# P,!"0 # P0"!0$&
M  <($1(3% D5(18B,2,D03)181<8)C,T0E)Q@9$E5*'_Q  = 0$  04! 0$
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MG_&?X]?_ !CT]<_^/YSC'_\ <XQ_YYBU37(_\4NK^2VO*^5#?D)5]Q4%??\
M>;=GU?0]QVEE;VZ&K3'8R]:QVQ9:PTI%,M)6%<KR9K&)5(L)9^(6,8Z7\1[C
M0)WZ=70Y-*F>'1XX]1FTJ*.*)[D=M?Q%1$VL6660(XWJ)#NY-95RL";>RL(=
MV=YFB5%[CD(H9RHRS;4"@L2P50OY0!77#G-*Q:X:_F <?J[WHDFP6ONZFM"W
M?]:TYKH]4F 6OS$],K DS188C=??27%,:KC0FZ=?*02$S(4M=UN2_A:-K:\E
MBMYX^S<VRG\*2-9 [,R\#+ A<L3P-HP&8-Z#^"EQ8_L_JJW%DK:ZD$,FBW<:
M%KAKJYQ;QQ!BK!5MU2:10O;!,[&0MA"O!'L/<]5[([;M+&FTR506YF"TUX%?
M5%5I\K5ZN4["]JV(_&L$<CHL6]<H-=IB$W<!#8F32#S(TR\C22TBE4X@"-!<
M <!P01L(Y#+C(( /&5(QBN@OI.OZ9H$M_%JT;F>:6SO[3YEC?0-*"=MW%M#!
M)3NCDRYVM@2(-YJ-K^@[M[#V>SL]$J=D[.V3*4K=A<=7:;/L6RX1$0YA6+$I
MYA**R"LC9_9FF*01%5"/UQ".<K5$UB]O5^3C^<!5=K&2*+T!E0*SRLD2*NX
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M&NS/AI^36^\4>V.M.M^X+6]W'J+N.T+KC5L&(5%=0V#]I0Z\/L-U9JG'B":
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M^[[O5T6Q[)Y [$Y=4]AL5MJ]9=FUV@K"+%C&>P[*8ZZC)[EG8O7 _P!;L58
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M/_[PI4V>,?\ ZS+E)DG]H%_^J8#^>$;^F:OK::./\36)OOV=+>3^7=NK?/\
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MLB@.$"\HMSVU>5CM48 ^[#GCV.!_#GG%8?3NF76HW+)!'N7"AB3@9!#8R>/
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MG!!!&"#R#6J[YU[I/9^O'U3?]9J=KU]@ZK<JVW5@R(3J)X,HOJSSZ&3?28'
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M_(@PW+5^PA0SCU]OO+W+I'9-@:.,>F,Q(_G,L8QF4LRS*6;3::X_P=3U.#Z
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MO[67:,ZYW)/!<$L>>:^#<VCY-#?/Q6R?B3]O+*X&<!B%8*@48 'JY # X!X
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M6+L= .R4K\:#SAZ(V6PUZHK+2UE;7U_L.NF1*.DQ"B<U=33[&Y+96H[XM%8
M5JM^U*WF+5;79+"%9:E<*B(51>9K%*_#3O.CHCL48!=?L[7NUY82I&*35=9U
MV5ILEW0;%4;'?U&U+)A<^M6T;%-J.QMFAL;E)=H,5X:6QIE-@N*&IM%/_/\
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M 8E0F=5FQ]6:+BAQ*M LS'$&+V D+")<$],C'\!LVRNK>Y1FN+/NOL.S<.5
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M+O4$K]#@?E.? ^OD5.ZST#J$&GBYTK5)+L2A9+R.REF2)5*ABS.2$EC";MQ
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M8R R,9AR+F/MS&<"1C[OAEZ^Z/L)'TQG^W,98QG&:+@N$&,_8X/'\L DX]L
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MNA'^OKGUUFG&%FE%Y6@[0H@X4)@S>0SI6E##A.+N)0N:=%%-,]X58RHIA1F
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MR!I,_P!Q(P'[3%F4QLPS*986(K!8,11XR3CU<#R>26P!_$_3]:O&9".Y'C#
M9"KR#[ @9R?_ #]\9ZK> ->FIUPE7VSQWH:U<.K:QBPS&?T&-D)<6+2H9S@/
M$R_7@40C0%&>1SDI,I< #G$/J%D(;HEGW$C< K J#C&>."<$'SC//-0FK:@\
MR-'#'L#H!<.%97=(W4JI/G:KG)!Q^@!;-A::S[&6[-VJK;:5'0VS9!ZO;W+P
M1BA)1LPSTE=6J@#!B<1Q%$9LPF>&!R@4Y3%E#$,=_=*(0I)(!;\N%R>!X)\
M?R ')K,>*P.DVLSP-*T$2R7$<  D+3("KR2'+*B^IF))R"&P0./VV;Q&Z$WK
ML!+M;>M!J]F[" ! ;MTT6P"E;EK5Q*I%LZ(3N*A[ZJX K PVH?.5@B"Q(\88
MY)([I%VLA@?+%%W$_7.,C/ZUKR:G=P&1;.:2TB<G;''(QV*?82'UY^I!&3R
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M4-2WJ&6WCDQN_*7VG_#0GD*#^=_89"DLQ(_17ISI_2>C>DK*PB3YNY:R>."
M*)EWSH3<7EX0>))&=Y(8U_?(9ML: /W2_$3X]_5I-F\E=U69<VO8#M:EH[#\
M<8'6ZX"*^;QY".88]Y;1P8*^3N,XS$2+JP\1B<^)<G^,.N,U[;=/V\D?8MU%
MW>)$!S,[-\O&[#D]M-TI4^3)&Q_*M=+^&^BF&UEU>Y0F>;_=[4G "P( )) /
M=I"%7N>ZJP!(8UVVYQ*NHTXI3BE?.!1563$UEEUY-GDTU( 1BDRS.$!R88S"
M,<F/(8APD4F9$S <(YE[81QBIG=@H9F8(NU S$A5!)"KDG:H))P,#))QR:MQ
MPQ1&0Q11QF:0RS&-%0RRE50R2%0-\A5$4NV6*JH)P!7T<IJY3BE<,?S&]@"I
MJ_K^FTD^H-=AH@OK"YQ8"&WL&LU4D8?T]=( -#*^',,,6\4)2.NZM%@YU98P
M?$LZ_P!1ZC?6]BMK9/&=\QE9']1@<IVUNE7##TKE6& S#:%8#)'=/@1T)H'4
M'4EWK/44VL:=;Q6D%C'+I?X0UVW2[6ZNM"N)EDB98F9(YE>4S6<9$AN+:9^T
M%XCJ7JW:%5I&V=G5%9:;CUO0KU5/?RIZ^NL[_)9P:(WL[U1A5VS+,C&5,LEB
M$BHXR"O.$1P""'L-%@OS%=7(C>X[:K),4569L#>^1RN\[FP22F=H;: !Z*U[
MJ&ZZ=@N>G.EY;RPZ=FO;FY@TB'4+N6UM1(>RMLB3.8"([6.%7DCB07DO<N;B
M'O32%_HWG7KK>36$U-Z7:>L+9RYV%N^@>WLWEQ@&XS+$,36@*K44")90C#B4
M1K!]S>?D@;.9XZ>(+:.RM<F(R/)))(5<EI#SG<V0H\!5   \DY)UNRZE4ZBV
MH:G8)'-#8PV-A;Z<AMHHDA!5'3TR9GDE:1I&?<?6J0[8ECCCC5]SJ[2->UD4
M9LNP?=M<;%ZNTN=;N*[]:DG0O5=I7MMV1[+%WBZQ95TQ" NM&O\ BL?49I\B
MU66WF(8V[V9&%>)E;>>/ 4L  W<#>.=I!'.-L$5SU#;R/!^T(M7@[;BWE@N(
MI[5MTSSI<":.%4A-N;)X&WO))))="2*-4@,FT'V(0>F;-"APG_35$V]N*-;'
M"F0"LIUQ5',%N<I#OI0E"&57:^;<4<RPNQ)7#BHCPS#96*))>H"9^V=H9O2N
M "<*,>> ?T!&,U"'4==N=6T[0;\LD4]S;6=R41Q-- 9^Y$&0R-;L49R\,XC[
MFQWC$K0L4,6K;76JZ%:*; ;7JV;%=E4[Y7!A2LPLBD4B-2:SR>,C&A"4\B+[
M<RS 0,1(OZCG&7+ P-W"H)0\X&UQCE>1P><>_.?<UM$-IMUB(V2WQ G=8@(]
M]UIK#<([LB <F%P&!(<!=S%<C:+*_C*V_0M9\@-"Z2_;;''7JIBJVG3K.Z:L
M<:CMA+E@0[4E^:>0R;I&\N-5JL*]$=2^)<*[>,3RQ[L?2);ZRO+*TM(Y+9WF
MM[J(X>$30$L%E1\AI,LT@5ERIV*%YR*TOXKZ/I>J]-]3=8:[=Z?U 9-.UOIW
M4(@+?4[G1+N,PS7=JUFENUMIL0M[6PO=DCK+"U[>7%TZ[T>O:HFNJHHJJB,0
M4EEP@4$#&,!$L(<1@&+$?6/QP%&,8>F<X]N,>F<\W]V9W9W)9W9F=CY+,26)
M^Y))/WKPY#'%#%%%"JI#%&D<2( $2)%"QJ@' 54 "@<8 Q7T\IJY3BE.*4XI
M3BE.*5^#6"968P$L0&R V!'G'W0"3(Y8@6<?7'NB.7I.4?7'KB.<>N.*#R/?
M[?6N+GBMN-S'MW=:)^\N&]SO+6RI0[$S861JNRM%+^,VCS97.Q,@S 5:PN8B
MY 0@;ZN)B@3UQFW:$1QE&4*47 (Y' //CG'M]<^]=.[.DR].12RZ3<.]K)WI
MIH(T5A:B&5&#.7&!W6B<EAP$)!R/5VJQZ^G\_P"?^?3_ !Z\PJYC3BE?'F5A
M^PC# $_U7TY2DSEHW[#]A\T,0#%/ZGU\IY7]\Y,Y>^;!O:+"GL]3<4KY;\UF
MM173%*"+-P"ILC5*TO3VL68DS30!+W?V^TK41#S[OX])9]?XXKZN-R[L[<C=
MCSC/./OBO/5HODKM#[N_Z)Y4N;1V+576NN6$]'VD,:PT=CG<5R*'Z6!J:+&J
MNU8&+"T0)5AK!*$KXCS' R2'*1[3($DBPIR,LN/'.>,X8'P03S70SHFFW5C%
M)ICQPW221[9=Y=F7#%RZAL$E@@ Q@ D^QJU_@;OUOJ7:6S>/ ]2UY1"JS=V3
M^VN?:'O%V!0GV:7%I(#[M1\D:^Q3]E>D(2BX!MF&<IYS(6BY D1;@;L-@!?W
M5/@XX'OX.?Y8J$UJ!I(?FI;G>T!CA6!&WQHV LA0G!PS#<Q(W X4C@8Z^<P:
MU:G%*<4J*NSNJENRS:180W+<M#O>OMD>V?7-ATF6IRL@NV6J;%IKZS2VZ:GN
M5(TBS2[/90E"=1%D3.%F%VPY%*)%*A3/A!T?_5=!NV$[<VRU@D8WUO;#U;9K
M7>F:[>-I[)4L]CN]LU:]O:FV'O&[;7?XLNOK32&O?<8K,$Q1U%!5U*E?QU_X
M3=5]9,4]AJ5[N]?;TFW:UMRMN,FD+-,&UK2-EZX'562M?HR-3:)W.F;;>5.P
MVKU:?;[0[,+N>SCV$4+;"E39U]TUIO6A:(NM8M<3U[JK1.G:_P#8/1;Q_1_7
M1+@NN_/B*X?EM?==O?>>QF$6L?#B*XOCS[E*E?BE5&[\\2Z7O9/:R7&][E&R
ML-6WVETE%PU'^@Z_M^P.OKKK>XO:1VHH:GL+,24&P7&?TC6^,Z^&Q>Q;I5*M
MK74KE8I6#WOP4ZL[/!9S[#VWLG<;R^3N*G8=GO7-%<MKBAMZFEIATV$LZ#'6
M*#](E1 SKVPZAKVN[G3LV6R-K;-AC:MD):*?Q_T_Z5(-YXH]3[)7BJ[P.Q6*
M*%OV5M&N@+=R%_2.\]H[W8=BW/8FKD66 6JW^AV&Q/C1MJC,MGIM?)A2C*MF
MTNBV:E?;V?XXZ_VE<RO++=]\H&GNOG.K]D%KT=!,MM>GV#9774;>&TZ%LY$6
M6"LN1E8:N;77(#;+@1AR$I-92IWJ*I&BJ:RDK!3!6T]<E55X2&.S,*->L)10
M4V&2&98F, 1PD9@I3ESC)"DF24I94K(<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2
MG%*K9WGY?^-WC<S75?<G:^NZGLEV(1=?TR&'[[>MDRPSA)06O:5KJ=ML]R5U
MZ4$E(HU9HF:G$,9>[U]-DT/I'J/J-9)='TJXNK:%BMQ>GMV]C;[5WN9[RY>*
MVB")ZWW2@A1G'BHZ]U;3M/*I=W4<4C@%(?4\\F3@;(8PTC%F]*X7D\#FN3_Y
M+NC]Z';ZUYG]8Z+L @W^GU^O=T:HZB..STM>D(F=<V6\JZUFQC#*]8SFGOL0
M8-*DDA4X9]N,MS7VSH[58+%[O1;B\AD,4S&SGA9FMYSD]U8)'2,D!QW(VVCN
MJ6*\ $Z;U=ILMP+?4H8'"%=MS&RC?&< 1O(JE@ R@(YW$*50$@G(X@=A=2[3
MY""U6RJ6\(+(LM@N7PS#8UIEAHL&0.0*'V&H6<&Q1K/CD.1AB>&0ZT<*3QGT
M=T/U+!9Q317L9GA)S#(K 2J5YD1 Y <,I#E<^G!(R&)KQ]\9>FUUJ[TNTTJ[
MM[?7)D<I87A9+:8;91!<RO&CF/\ $BDMP1N:3.V.-FC(J%:7Q9[$L+)C6W&=
M,!%5J!E)'N&"M&$,N(LJ% *N6?@S('K(?HI#.)1F+,(YG\L=QFZLTI#O5+HQ
ML>0]N,J#D YW;&V^2-VTC@$"N;0_"#J>: 6ES-I0DC*R":WGV"88*RP$M#)-
M&K!NY&X5RK(JL"&)JT*>E=7^-6IEW+XOV]U8XDO*R>$";M.X,(9OTJ=?#U^C
M,+DB0/+.)MP'D<2LRA+&,ZU?W]YJ]]'96\8C5G8B*,EHYH,L8[ON,%_">/!4
M$85_2 '(%;7\$>F]/'S]KJ$'_OO3I8XKW4;A-IMEP(YK00EG[5W!<QS)*4RU
MW&T4T3&)B%G/P<Z0[1\Z>X*NWL=>?JNAM2MEG-RV=P9@).K*E@W_ $U3'E[1
M-W-N/$5IP3^652LQ-YJ<<1' NK];=0V/1&DRJ;F.37;N)ET^RC*DQNRE!=3K
M^80P,=Y:3:LKJ(T&2<>R-(TF#4GCM;&V9+&$HMYJ$C,T\R^EFB0$M%&TH&%5
M 716+,Q'!]>&OZ_2:K25>N:Y6)TU%2IAKZNK0#$":2:\?:( !0QZ1CC'KF4L
M^LR3E(A)2)*4L^1+FYN+RXFNKJ9Y[BXD:6::0[GD=CDLQ_H ,      "NJPP
MQ6\4<$*+'%$@2-%\*JC  ]_U)R2<DDDUF.6*NTXI3BE.*5^92C (AC3B((1S
M*4DY8C 8QQS.<YRSZ8C&$<9E*6<^F,8SG//H!8A5!))  ')))P ![DG@52[*
MBL[L%1%+.S$!5502S,3P  "23P ,U$VX]OT5+U;M'8^I0_KUBIU#8=DU[6-?
ME)F[VI^FK''%Z&O0'";\7G'%HUY!25^9,TY_.*,A2CR_<V=W:M,DUM*DD"EI
M%93@87<OJ&5.\8V;2=^1LW$C./HNI:1KDNEBUU6R^6U6YMX(;EI55$6:=87E
ME5MKQ+;DL;CNJG8V/WNWL8CR';_YA]A>6#FN[UW'3:)7D>N+Q-;6='^&[2J,
MD9KZMJLLG"L-V<SA)3U3C5-8V!&:F%@.<I@"ZNN+0V8W%UW;@(/FD*@*^Y$8
M^@*3@X9&3UH264GG'BO=FB:)::!H<VFZ+\Q(-+DB:2[N4DCN+Q466Y$L<9*P
M]N>&\F$,]K''%=HB2;I70/6"MF;;L/9MYV?5]:T_2-9US3D;/::H5Y&GDP%&
M4 3=U;#93%>OW2P,=NI%-8&( @-,?SY$!BW;2SZ9,8GS) SE28SRA^JG.> <
M[2 #DD$5LTEG8:M8V;1%UOXT8P// LR.099674!;VT*0VH39##<S([H^WYJ>
M0.T@KK9:W2;SNMCTK4]XV>LI[G62V>Y=K+B5G9U>LT<UXM06!-L4(>Y5EB9*
MHAX3=47.=51F.!B9F+7]GW]^FG3:D]M;W*L;B=6'<BBP-^T,02<'U*#DH& !
M/IK4>INH=>T?I.7JC2>AX->UW0+Z+3]/T]+&Y2PN]3G>1H(KZ33[:1EC>94B
MAOI4%M;W,\1NKB&'?-%*U%TAUC2=;*Z]3717@ZQ.^JZRV=K\+'N2V<RYF]8$
MQ$9ESMP8$6*[$816B,00%$.&<XO_ +-LK:.2RM':2")Y1;W+@AI<LQ[CJ>0'
M\D9RN0!^7%5KUCU+J5_%KVM0+9ZEJ$&GS:EH\4W>BL)((8T^3AO(AVY3:-OC
M63!6XP9&&9,KH?<?5!*?5&-2ZFVO;+2AV98(C[;<)$0(M:7-,3]Q'%42>%RH
MUMDH9.+"I!9.H*!I!&0A)SAS%=+;&*0".4E@6W9&#X.,D'W/T8'[YK>XM3TN
M]UE;V5()##"1:VT*G!,%Q*L*FZ6*"0S2P.EP59";>1V@CFE$2RM^/47C31]?
MUM2'N(=SY$6[MK'.L5^TJY3U77#)US)FH9'\]B.S7MBR0 VOZ3RM!:#B^0,P
M&66.MM)98-PZ7YD"R(K@&./ /IV9P02<G(\C<I!Q4%JU_?\ 5;26^EZA<=%V
M]DKV=Y=:1*8=1OX9)X&;-[VX[I)H5A_"990L@+1W$=Q$YC/:/\>?3-UN'DI6
M]A[4JM96_7.HJ*ZT0E%4U]+I>OL,!*S15Z2BZ<, 76M9+ZS)2+#2%D"NM'VC
M"683:RK*_P!3U35+9[EHI%T^ 10#M)$EO9J0%MXTA5!M7/X623N.]F;U9YCU
MWI'170OP\U32NG[:[LVZGU)[G591JVHWMWK.NS6]PLNL74U]<7)>YE>V@;46
M<"&2U$]I;Q1/+!+#Z(=9H :O15M J[96"U6O]9=JV9PX]($9RD(96,#%B<%X
M2B $<#C@:XQ#QZXAC.=VN9S<SR3M'%&TK;F2%.W&#@ E4R<;B-S<\L2?>O(F
MF6":78VUA%/=7,=LG;CEO)>_<,FXE5>7:NX1@B.,;1MC5%YQFL[RQ6=3BE.*
M4XI3BE.*5\[:\7%&E)RE&#2YEYRAF49QB<<A2E&4)1E&6,2SF.8RC+&<8SB6
M,^F<*^@X(/T.:YI>//BEVKU-V]&RN@:ZYI]:V^138%K2)V'E)9+]',:LHXO+
MNDA(4&?GS(8)XGF#!XXC*>=/)!)"A$C=Q<#ME#[@9._\N!CZDG/ 'MNR=50K
MH5]I1MY3+>6XA[BN%5")$?)\EE.W#+QG..!5MN]K_NJCGUX/I_7P7(K3<DD=
MT;(FO82JZ(DA1B2:YG5)@1/.9OO6 8DDF(,<Y,I@F"RQ$"'=N.,*2OW/T\&M
M7T^.QDF=;^9X8A$Y5XP2>X!Z1@*Q/V&,'W/L9_QZ^G\_Y_Y],>F/7_\ 'KGT
M_P#QZY__ #RBL"G%*<4JE#W137>?:V^O>1/6.N,ZOI=BBGTIL]39.UEY::ZT
M=IRR5MF*38\-,K1F%"95;5%/ FSM90'&$B$GD+*8E':8AF!W@@, ?'&1P?IC
MV R3G%2:7*VEO ]E<SI<R&0728 10,",H2ODY8'!)( S5NZ_6==JFL/UU'4I
MV&$EZZ5D!!:%D1%04 K*&L?C^Z< !#' <#')B,81_P"W+)9B,%B1DG&3C)\G
M'C-1S.SDEF9BS%B22<L>23]SDY-9SE-4TXI3BE.*4XI3BE.*4XI3BE.*4XI3
MBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE5L[H\@":-=UG5?5^L9[6\@-JKY
M6.N==JO_ *VHUVCR:2I.P.UMGBNX'1.OT3Q)"#K"S-YM#P"4>FTUW:X.-39-
M%Z?%]!+JNIW/[*Z?M9!'<ZBT?<FN)\;A8:5;%D:^OW7!**RP6L;">\EABVEX
MZ\OC"ZVUK&+F^D7=' &VK&F<&>ZD /9@4^Y!>0^B)';($9:CX3:K:[[I'?'D
M7?,]Z>0^F7TMHH]LL!GJ=$T%R5595BNM=6]>?:;J]8U2G_9YL%SN$L]IO=BK
M:C:=EOK&UJZK%;)7?6MU%87NA=.VZ:'T]>0?*S6J%9K^^3NQR/<ZGJ&U);FZ
MF[7;94$=K!;2S6MM!'%+*9,:+1HGGAOM0<WM_#)W4D;TP0':RB.V@R5CB3=N
M!):5Y%221V95VW>G"!83&2$2#)&4)CG'$X3A+&8RA.,L9C*,L9SB4<XSC.,Y
MQG&<<TH$@@@D$$$$'!!'(((Y!!Y!'BID@$$$ @@@@C((/!!!X((X(/FN=G>7
M@%UQOD.SM@KU7S8O];*S0==4>*_7JP&X5ZB\TF5[($EI94?=3BPR@WF,?MN-
M3$\N'"@5>A:-UY?6L.FZ=+V8XXKK%WJ4AEEFDM)9"9 \8)Q)&C!%FC]6Q%#(
MS;F;B/4_PDL[O7-;ZUM);G4=3&D%=$Z?D$$=C;:I:VABMC!.6C9;>>3>[VTK
M*BSW5Q*D\8:-8N0-#^'+R+IM[U&_K'Z=C5KBR5MK)FTW!M3:M#%DN"R7<5-$
MI76D\1C)8E9:VC!9_%]F2A,$&/I!^*>BQP7-KW;QNR#'%F'NQ7('@Q2 H0I/
MO*D?U&X<G5K#X:]67?[/U.ZM[*QFNHXYKJR%P!+82'ADEW"17;@-B-I2N[:V
M&4Y[8]3^#F@:E]>R[/LG>Y;E98RJ"NZC5L]<IPM# -J*]05: +1DV #C*QNQ
MNMXQ'U'D<I2E+F6L=?:C>;HM*#:1 Q4O+;NZ7<VS.W=*&)B09SLB89/)8^*[
M!H/1=KIJF2_D74+EN2#%&L"\8P0J(9B!D*THX!P%P!BY]/2T^O5RM/05-;1U
M*(\"2JZA%6MKE!8_P-9),05@0QG^?8(48^O\^G-&GGGN97GN9I;B:0Y>6:1Y
M97/U:1RS,?N2:W6.*.%%CAC2*->%2-51%]^%4 #GG@>:R?+55TXI3BE.*4XI
M3BE8-C6==;.9EJBJ&#L8CADIJ]4DF?9'$8?9]XLX8R..,1'DV)Y'''MAF./X
MY>%Q<*H032A1G"B1@ #Y &> ?<# /O6&^G6#RM,]E:M*Q!>1H(BSE0 K.2OK
M9  $9\E /215 ^R?QR>(]9H'<5AUYTYJ77NV;-07%ZI:T9MCKZ:LVVMJ[5FG
MM%];K+@%57IDLV8&O:Z@1K?WL!BPS@CBM>=6+FTZ":*2..(*[EGC*9RLYR0Z
MJ#@,7P7P!OP-V<#'4=(^)_5%CJ&E3ZGK,]WIMB]M;WD=R+??/I2.B2VT]V8A
M<2K%;=Q+1YYI#9EW,!0/('\SFU=>]J;%T+U4^C4=>3;"[NREX\.EO:;;;2GU
M:Y"_86AGWC7-+L3,K S5344M>NK85["Y\,D9:E!86DFYFM[J02Q[RQ*N,-A2
MG#':V0""?W<>I>=WM[+TR#1I-/9A/=VA$,%W;0M/I]P96N_F5ACEDA*7<*M!
M:P75R;A;B.47-M\K(BB0/1K0^HTL]X(7R5M;:I355&_N-R;X[U;8=\M4CMI9
MJV(M*':'K2SHBX:A" UFTEE['%:D)M9GGQ8^W>B:-FMXFA,[,5*32;W>+8 <
MGM%HSZ <$>O;ZD8YC:U)JW3CV<L5I/>V6LQ:.MI;RVUQIEE'\K::G\Q(\#*T
MFIR07D*-(Z'Y>1Y+99FD@NHTO1T_;#O5KS:+3KP]EKHJ^WUH"?[:PJGQV(\@
MDKMF2U<V,#FO'!YHCS./N^:4C_#$>!YF")[N(;)WMRK C:2"<''G.? \<>?H
M*A]0BT_1+F.)3;7T\T<=Q),(4GC0$%I;<K<)@#)V/*%[BG_ 968$X#9^P]C6
MV.NZ=U/1-LV?9[&6L6NP7,B*PU&HHF[185PLQLME$ZH75L'F,PQ>\^+6!$R$
MQ*#(!8.HZJ[O%:0P._;"AI<[$<#ASO\ !8$'@<9X\C--&T&UBCN==NM9L;-I
MFNT@TX!YKRTG>$W%HTULA!AC,;Q2L797,+I( "\8>Z>H];5VU;UHNKZS866U
M6JJ-<N;7GQ!5?U_:[.P-]M&F'78D.RJS0K21S;''@%8HMC)RFG,GQQ":BTUV
M+.,M+.2L:QKRP8G 7(X"Y_>.0N,LU2E]I<=OT_==1W<"Z=IY[UT=0:1A!=V4
M"0B6^F[D<;17!=P@M4,DL\C@QH$9<^B7QN\;JCHRI:>=)7V^^7D&,7VP)J$5
MAD+38VI5X,3++)@!PM7K89*(9YK5E>MG_;I+PAO6E:2NG]V61^[=3X$CC.Q%
M!R(XP<>G."6(#,1G@<5XMZ_Z]DZNGBM;*"2QT*RD$EI9R,CR2SB!;=KR<JOH
MD=%<B%)&CC[DA'J=C5G^3%<YIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*IMYE[3
MY#:KJ6HM] UMNVP?8\CVMO7J)/9;I1"(82K@CJ6U+">:]UK)8V#:R)"+X" 9
M#KA8)*>1;K$S,)2H])V[FVKG[GCD>PSS]#4AIJV3W2B_8K!@Y()49^Y'(^W(
MY]ZL[H9-C-I.HFW#,I;6;6Z8VR>]<"LL79:]<EG"2RL8+!E!R1H2&"$!1S'.
M(0C'TCBPV-QQXR<<YX_4UBW(A6XG6W): 2R"%CG+1!B$8YYY7!YYYYK;.?*L
MTXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3
MBE5I[L[;VA"[JNE.DUZVY[TW)#%C%JT 1[5NH=((S-%WM;L(*Y0S(DN8;">E
M:EAE2Q[!V9>56D92FK=FO:/9=%TFUD@EUK6FD@T.SD,>R)@EUJ]\$#II6GLR
ML [ H][=[6CT^V82N&FDMH9HZ]NY5=;.R"O?3+NRP+16D).UKJ< C(!R(8LA
MIY!M4A%D=-RZ7Z2U?I:DLUJQNUVC<-LL(W_8_9FU&"]O'8^T9#$$[O9;(00#
MP)4$8H4%#7 3U[5J82U)KU;7UJPP<P]:UNZUJ>)I4BM;.TC^7TW3+4%+'3;7
M.X06T9+'+M^)<7$C/<74Q::XDDD;-7K.SCLT8*SRRRMW+BXE.Z:XEQ@O(>
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M3]OE@C,."<?E! ()& ?'6_\ %/I&.Q-Q6VS;]CUP3^E),&#H$[/,]GC80R,
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MC!I()B$RVT0>(C(VZU\[C9!QB.;!RRA",,XCCRYK&HS:MJE_J4[!I+RZFG.
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MX8?O#ZD> ?K@_?WKC?5^A6FGBWU"P5X8+N5XI;5SGL3A _X1V@]IP&8 YV\
M'%='D=NU2TNK+6ZW9M?L-AIO;^WHD;BN;N*KWQA*/[&L P1U+W1)"6,,A%ZQ
MG#/^)1]:ZTDHX4.48(3@.5(4GZ!L8)_0UL/%4TXI7'3\@/;.X[CKO>W5=/J&
ML_TSU[6Z/FRL;.\RANMML=Q>Z_8)-ZNLK8K89JD:=EG[J["SF98&<DH?(. 0
M?5(# >YY\9 'W/U/[H')/V\[3H]A:;+:YGO#')/,ZQQ(F],(KAA*/*G(P&X
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MJ3]R=H_G@G^2D?>O@+2$L?7]V^9T.?7UK5/?7U<L?_:P(19N/QE'.8&"ZZ9
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M[!8VE5K=BF>,T&Q!M:M^O!)YAX&NO53 YI711QQF()_+['I-1G\:18]HP<$
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M,6XZA&+Q!J2G)?'SX#[HR'F>?0D/:26,0Q.<L#'B.:^IZC);)9O?736L9<I
MT\AB4N<MA2V,$Y.#D EB "S9C(M#T>#4;C5X=,L8M4NHHH+F_2VB6ZFB@_PD
MDE"[B$PH'.2$0$D1H%VLHAG',)H1(,D<QG"7^)8S_P#]QG'^<9QG&8YQC.,X
MSC&>80)4A@<$'(/]_P!FI0C/!K4';6PU7.268&[;7(_S^W2 5RTI1_\ :X07
M@1FPKQ>F,9N$!G;7'+$[5+X -W4LQ(8[OB)DAN?_  78)%.?_P"1(V$CD/GL
M2%48@B&3<R0"R7:+\P9X_P#. 69![;U RRC_ #C) Y<8#/6T(6"%JDM95;JE
MC7NA@PF\BP%M-H$\>L#+L@F0)A3Q_,2#G*.?^,\Q9(Y(7>*5'BD1BKQR*4=&
M'E65@&4CW! -7%974,C!E895E(((/N"."*^OE%54XI3BE.*56'R+\P.BO%JI
M:L^W=G;JC"J?VR536TUE:V5O@AR*J(5^%P?2^^\<+$5QN.J @-<YV6%P0^3,
MWIW3VJZK;R7=G KVT4HAEF>6-%1RN\Y5F#L I7.U6.64 $YQKM_U5HFG:O!H
M-U=.NJW-F]_#:I;W$@:V60Q;VF2,P1%G5PBRR(6V-CG:&\_?D#^9OL;MZI?6
MZ<2O.D]478.L,H2KN;]LL99_V1BW< 0!KRI8XQ(BNO3DZ N90E>N#]%Y](Z<
MZ.T.W@-YK#/J-P"0EDGX<.1C /.7W'.7;A5&0A;%:KKW4VKF[6TTU$L[5D5F
MOI5#L<DA\+[;"-JJ.9&/D+G%#=G\U_)[M_KV?2NX[#LMB EPC= VUO8[)>[S
M0U2K@Y:K<.*Y ULE:T\\.UF2]>>*LRJ."@@PG+&%ST]I\MX;VUMH;2%08Q:1
M*[ L22')=W&X*,>A4'@XS5^VURXA06LT\ES*ZEVN9NW'Q@ J%B2+&#R 2QX_
M-C(J(NX.Y>S=LUO5P76OZY<O:$P;&ONZQ1RH[IT;LT1'7=+5M+HLE%-(#&;$
ME?"X+,,L-6#$?A@&=Z=TBULM0CEGEE2!F225)"&0;&#$ %1^8#:!G;S@+R<Z
M1UKJ.H7F@ZDFF6ZW=]\M-!;"W5ED$MP!"LOHEC=A S"5]CK(RQD*X;!KIGXK
M?E [<\?L?KMTTJ&[]5%R.P?UVK (6UZT*4,3L&Z*]E[BVD@>XCAZS8#."/.)
MXI65;@LIYC^K>G[37[N:]M-UK-RL3,<QR(I.T2QJ BG;@;H43@+E6Q@XOPM%
MYT'TYI^A7LZZB(T[MY)L6.1+F8"2:."4EI98HI"XC^:DFE9<[I5)X[KU_G3U
MQV7H.F[3T![>PK;?(V,*RML/DJ(ZXY2KP;N:S;%_6;RUXF"6/KTR4&#6,9C;
M18,B5<['/K'I*Y::Y;5':RLK0(9)D42/.LCF.-K8G$9BW\23.0D6"K@."%W;
MJKXD1:5\AI^@6B:QK^J&86UG++V+>T^7A6XF%^R%IA.865[>SA1I[E6#QGMX
M9N1'Y NLO&C1=FJ-UV!&FUV6XZ%O&[2=MMBVS:FP=V[QNVJV;&JJ-5MA*I(*
MP;S8IL[!>9,+55K,L)L"II52=-RG7.G]&T*2XU>7NP0#4IKFYO4DN%N[\.Z1
MPP&W</FSE;\3!_$A+E8GC3U)[<^%'7WQ#Z_M--Z:M9(YK^'1](T:WT3Y'2&T
MC1;&WL+SYJ^?48^Q)'J>GQ]N-?EFBM]1DMHIIHY;MYQ=\Y*+;+7=G]ZH>Q=;
MH=5W/1T[33.O5^K]4U];7=^%J=>0@[8[6LSK:C:7C1698VG;:W'\Q9K384;+
MD\)PND:L+Q-2EN(;73[:.[7Y)DC$'>BE#%G(4*CL7VJSHHRY(8?7MNOZ .GQ
MTQ%HUWK'45Y=:>\W4,.H7<]U-IDJ2PF"*)+V6?4+&%;:8M!IUV[3JD;)Z22H
M^KH75W+E:YOS76QX3J\G8W"O(@J_ ++A15U2I2R]R7ULLNS0B8F2M255*><D
M62Q!&<\L@* 0D.QR2IP!@<>PY!P"3GW/M6FZX\D-T'N(4 E"K!.H8D)P69AR
M&PA88XRRIRO.)DIV*34-[<5L]@ND]?%6,ED]7TL)/#V+-3\WZMFD??6$9,5K
M[D6'Y''DB896  8).*N+#3:H]IW5LUAN5GV=ON!U:'P'!+*!DGD%LA<O@G"&
M12VT:.=$AO&O;6:&.42W):W*2"Z*2J6AM[AT+66+E$$#*L["RDE*)\XVP5NN
M,[[2E,LHL#6$)#V?;ML:=DEC7-=KY$PX$<CGPD1R\*8-?45WUV;&PN((+5\)
MXDT,E#6EY/>03K=RP)$CB:W4*R3%QZ2Q;U>@^-N#GWP6SER:_H^C6$]LVGV]
M]?W9,&EN^"PGD,3)*0D32,($C=F/=CA2*6=IE8B)H_CZSV& ^S]3L^O=845N
M1N14U9:Y^*\ &\S&:-1=W4;0,ZTSHC27?9CA0-6"QC\JJJH(#&/(M+2[M2RS
MW+W)>9F0N@5D0D;4P,Y"DYSC..  /%'4%SIVM:41V1IR);[=1:"0QK(,EY(X
M.V$F1"K""/=))<21J._/)(SR&>M==+3;TCL>\SKV.R,[#=8A;6:)]EJ=HMU9
M&K&+QTT\.*.6]-:E"\/#$3338E3L22BH=&!Y&&[LWN9;%GWSQ!3*IR&&_/()
M'J'!R0>"/;BM/U/1;^XT"WNK6,VVDRHD4$<<D<;QQ#=VAVXF5HH9HXF5/0JN
M(YT5F:*4+@]]>V@.T0W(FT;7LIJ!O#ZU;9VK+$4,.,P&]<)HMXFF%<!"X8L5
M!("SG$,8S$@LQE*\T446]HUQG)(_4C.#R<'CGQ@\U"P*8Q#9W4$$:R)L6>"*
M- 9$0B*.1D52<CA=Q.#QD FJ]=W==;\'7:_>-+UU9YS9K5A1_*)@VVPUJ:B#
MK;VW&HZKU:116  !26CRBX0EDL07N'*!<QHNLSB,+DD8;(S[C'CZX_KGVXVR
M%+&&PF,MW);/$(-C-&ZQ2=Z8Q&-9V(0MOR>VI/[V1SSVU_&GO_9%]H>IUNS;
MOL6\R^;:*_8R;);&NF$QUZ-:[3V*AF\F;1'AI@M;->+'U#C;%+ L$7AF,\ 0
M%'CCQCVP,'^?'Z'QQ7%>M=#TJWLKC4;:-8I6>UDCE5C^/)<3SI-"P+8=]BB<
M$*741MN.&KK3RJN3UK5_INJ;2WK[^QZ]4W;NJVF+O7&;-(#9J6VB*8,/U\RQ
MEE=G YYQB</\2B,GI\@A3@J]#<SVXE$$TD0FC,,O;8KW(F(+(V/*G'(]QD'@
MD5YL_P @KB0?*7NR>N:];MJV26EU-[LK)'8:U3;H348!9$[*<H2BP2BI 2JD
M #DHT43MAAL0!']MQ3@ _3@>/Y#W]^?UX!K>.G;=VL!(S(H+2=L%@'*AL;@,
M\@,3N)R? VGWHYUSUMKNZ@UCK6IW&OK ZY>%=<S 0Q; [J[EEAFRMK">2(B(
MQ69^2*U<FVV!CU)[R#Q#V$^N><CR1DGS@>P'GC^5;':SBUE>6[MC(K*50C:R
MJV,#!+9&20?KYX^G\=L"IM/W%,VB5>'-4G920/8(?/\ N+%1UC$",I3Q(")5
MD)>D&/:)(AA"S,N!SCG,:'<H@)&?.<^,?H1]2#] ?MXO6D'SR2F65T8LS(V1
MLQY"G)!& < CR< @#&;&;!M.F[-INEZ-K6N#SLL6)ZY^N5FJ"S:R\D"O=N9R
MI;1\XAF*S'WP?A@Q&,Q,CB<%I2A:CN!EBRX &?;&?8?7_D?IS@6I-)>$K(9>
M,Y  R3]>0<?;U9/V]SF-ZU-[0RV6Q=<O'JM@KG9Z$:VK\WI2.W50:1+I^+M\
M4_MF:V,WBI=5&NF12"DU(^V,BDPC"EW+F0;\$\$D8_0'&.3Y&,<<>:DY+^:T
MA6!0O;95VC"GRHPK''/@Y5N3DG.,8L?T#W[^0#7.J-V:Z=ZHT[N1;7K>BJ6+
M2XSFW[:/-G#;!;BY11N*:RW)=$)!5*DBD;;34'#*I65%C0!FP0PQ-VU147;N
M8KM4\DX!)&2>.#R,>#6FZY;Z?=BWN+_5+F">1Y5AM&CF>U@C7;O[3,&AA[C%
M69$VYX)7P:ZK>(WCEKG5U;:]N.:98:1VWW,H'8>S-<9NB6U;KU[8.'M;6LHH
M&R=I%!FS/.PDD[96ITID@C%SXE8PYDS2E]JC&U  I P6 '!;!()'C(Q[D\FM
M-O;J1E^169)[6WE+0RB,*[84H"7P&*@$@#@$^KD;<7.Y9J.J/^TNLM1[BT'9
MNM]YK_V6M;55M5;XADFNVOAD,Q0=KVQ9B51]64_E68%+&8RQF$\$#,HYYVG:
MC=Z5>07]E*8;BW;<C#!!!!5T=3PR.I*LI\@\8(!&'?V%KJ=I-97D0EMYUVLI
MR""#E71A@JZ, RL#D$>XR#Y!NV_PW=U4.P;;F/65SV-J]=M3E*GO>B%L+"_:
MK1K*EJW8Z2\5*];!%<HE6&*E"VK43P*!=ZV$K-B?IG2?BI9K::;"-8CTUVM&
MF:RN(XY+:)F=_0UR@D2-W=2W:=D8(4)2-G$:>3NI/A=?7L_4=S#TK<:M):7]
MM;6]\EU-9W>I$_+&Z>WMI"G<MK:SE[<%V0T<MU'+ L<L,8N)[I?CT_#;N>N;
MI6=E>3E+2ZQU[09'::?TN"R_;;3L%Z,H9J6O9KRF"U:-6L*$BXUBNL&V'SS&
M"VRBLLPE8:IUE\4K6:W6+0+BZN=:GC>*_P!9E00VMM Z,K6^E0,3(7RQ/S<B
MH4P6B5BRM'USHCX9V6A01+):):VBE)A8ENY//.NW;)>N"5(4#F(,VYOS;1N5
MO3-&,8QQ&.,1C'&(QC'&,1C'&/3&,8Q_&,8Q_&,8_C&/XQS@9))))R3R2?)/
MU-=A\>*_WBE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.
M*4XI3BE.*4XI3BE1A<];^Q]S8="OVM!V5TDFGLIJ"M-1V%S^9?+M>FL%63?(
M>?L^]<4+NL;<V$0EL[0-<<!8E(=2S&EOJ%NFH6R )&'<Q7=NGC%I>JK21A1G
MMPSI=6:$EOE2QW5BO;89I()#;R,<MM :&1OK+"<*Q/[SHT4I QW0*U5GLWL#
M1_4?9G5]U:5@_P#.\=.*V'8%3D4?2/S6NA !#LVI<//UGBNUR@["05#_ ',;
M)F6,XQE+IFGWW.F:I#%(?%CK+1V$V?.V*_+'3)D X[ES/ITCMPMM5LW-Q!Q<
MVSLO_CV8:X3'U>  7*$^=L:7"@>9*W#1^XNJ^RIL+Z+V#J>S6*7]ME25UTE+
M8Z8N/^M6^UHQ17]"Z+.,Q.A<UJ+@)XS P!RQG',.^T;5=-"M?Z?=VL;_ .'/
M) XMIA[-!<@&WG0^0\,CHPY#&KL-Y:W!(AN(I&'YD5QW$^SQ$B1#]5=5(]Q4
MD\C:R:<4KS"?D1MM5[?[O\C4>P-^I=71Z>LNNM=T&BM'%L/[(TS4U,[=1&I,
MU%VQ1K&F=CMFI5B9"#8=#]DL5\1S#L'3L4\&C:3;10NR7IN+J9E!V]QG*QN[
M!6&1&L: '& #[^>/ZXRR=3:A>M(O=M88;.!7 )6((>X%!_*!(\LC-[%OIR.,
MSO8O6&DV9J#;(76'#*#L*TM96 +5IECF.5*]K#,A,'3L%LL$P^A@D4[&(%R9
MFOALBW:M+^&6LW^G_-026B;Y53M3R.)4CX+R+VPRB13L':DP6CR1A]H/,]9^
M)>CV5_'8W33L8XCF>!-\98!MBDL5/;?:?6@<AMH.%R1@5/(;KX&PJJQJ[+Z+
M1)8F]F2'O2CF&!XA%,)9S(',HX)/,V,'])YQ ,O;B/-B'PENX[0R+=PFZ4 F
M(I(BRGR=KOSG&?W0I'!(K5S\6M)BOHK=UD>&X<J)%E@=H? !=$?=@D< $GG@
M'C-GZ*NU'<:_%U26"S",Y1S,B[ LAR?,L>F#0QGW@-_TXD(L13SZXC..9^W.
M-"U72KFPN#92H 8B4R5(SC(.TGA@&!P? Y-;W8:M9W\!O;2Y62*5@6,<BE<^
M!N /#^ 0?.,8RN!<[Q>U-&&^5C;-<H11:#T'H6B46%#5LT60VD3KSA.,EYU^
M6A3D7$19CF692R/USB&O;7M6ERSEP1"Y4HVU@Y&V/#> 2Y7CDMD #GFI[AKA
MXU51AIHU994)1DWCN;U')4H#EB!A1G(J6?Q9-;!U)V-97R-L#_TSLWZ35-YU
MJ7OE)0NXV)ZO4]V3]<Y7Q*DVF:-%:L9E H:C9V98^40LQ'IW5MI/?Z;'9LSF
M6QCN;FR0KPR1#O7< (&2SPH]P%( 9H/.0H.Y=('3;#6KO4H+2);G6WLH=4NT
M ,DDEO#\I8RR%B#LA![&Y3Z#<$A/Q)6/67\DGC^AWEX^O% "F'M&C.RV"GL+
MB.!+1JYKSALE<R_F.1IJ-HA$].;,QK%;JDPSG$A1^O"=5F2WL)YI$,J1+N*!
M=^1G!.WQP"22?IQEL ^IOAC<2Q]66%HDDD<6HL+67M.ZOOD8"!T2/+RR+,4
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:I3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g129231g11i49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g11i49.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1X"4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '>:^=E0X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0&;8FZ         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,W    !@             ",@
M Q@    ! #(    !                          $              Q@
M  (R                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  (R     %)G:'1L;VYG   #&     9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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MK^LR"8)H=@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M6!K)*I4KT*T52K$L,$"!(T7\ #]R?RS$_+,>R222=0Z21YG:21BSN;8GW/\
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M?#;22UGFMP.SK]#C;F;K#?>6W#.+=Q,=,U.9S*T\-6_=I]0V#*[%) M=0$
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MFFFFFFFFFFFL<?5=F+6'X2W0]7R'U\N.Q<[(65EK7+2B8AD'D/(((^P1_/\
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MQ9WW@>.]LI)_"MM8RAX#SADE,MZS(P/PS27I[!4]CX$94 ] NQ'8FW3I,_(
M?(RY937J'$:+]@J* >. 6%_I[0_+DQUD98,>.-!=-^=V(^6)8#[JI [[B358
MF;JW-BLM8^GD">POVA"04!!+=>UWT .CT.OQU]W9(&?"TORQ! !(]KL_KVHC
M]>QXQ9<D\<<\ ?MQWY_?GOJ<_3!MW$[N;E# 97&+D-F9+;6+QF6:= *LDTMF
M[.D'NCX6Q#$9+*>#>=4K')]G<9:'^()FQYL.6!]F3',[Q[?S   $T/8DA2.S
M D?(U)^C1"5<I95W0R1HCD\"Q9'-]P"6L?E-?KK2MRE!DMS;]Y=K[*REK*\)
M\2K-0BL3O33)WS9R*U*F1]E9A/D ;5:>K7:K%*D-4QS210/.Q'3'AGIL&!TK
MHYZDBQ];ZV#(ZA9"D:I'YQA$H7;$%C*%@S#>]J&;:!KFKQ-XDS<WKG55Z<P;
MHW1RL$0)023Y$DQB&0\1.^50050*K!$'FD#<2,$>4,WR1S3,]C(T;J[<PYDM
MXW$5,=*(*57V_:_BN5N2%(4EFB1V$V0LCP5F\4"EAK9'3<'!Z6H2 #S9+#R,
MX+2'\Y6-0M[5Y)""J'<]S"L_Q Q=3F9\2R2,(XT>14W.S!%C1 P9F+;5 Y/J
MJA>IK_2-X4Y';UO;,Y<V;L#<][9FWXLQ@=T[J.,6+;>-QU^I8AMSMG'9*4]E
MY)$BBJ599)YXU1TKA?N$'^L&9T2+PGU/&ZCU+&BZIE8:1X.$S*V5)(N2F0A6
M(7,J_P -@SL @]R.YF?T\_Q_.\6]#FZ=@9,W2L',>3J&8@9<6*.3&DQY \M+
M"33AU3<TA8@!2 ->T37$FNOM------------------------------------
M---05NT-FN?>(<#.WECMM;/Y/Y+2 @E6W%2?:''^&L,._$FOA>0-WK'Y*WB\
MX=>G52&G]_\ 7_8:G7337D\]4>/&T_U'>8(B?;CN\@;?SB ] >WNG8FU+3^/
M7R!);^J<,0 SF4%BW>NS_ #',^F?35!%CIV?CD_FYAGRHEOX.T*"O< *0*K7
M%/UE@\GKWB*UW 3XF8B#AJ"8>22!P67>')(OOV[D9_\ Z<_I_P!F[JY>W1SW
M=S$4^YN'<SNW9&"P-*Q(EBA+O:&._DLAF(TD"24[6.DBAQL#QMW:KV9O-37\
M'@?UD\23Q="Z)T 8AV=6P\;J<V>_Y"L1'_EX% H2&0+).Q/IC:-0+<E<W_X=
MO"ZY'4.J>*'SF1>G^7TR#I:I&?,<8J0+GS2,&D546.>"!8RGF/Y[2$JJ+K>)
MKFS77>L7-F;]X]XRW[S5L;=&_-G;50;YI;WPN.W'N;#8*9*>_=MXO*93Z.ME
M+]9WJS;IJ[@O,\$?M?57K!+%V8!IJ3SSKPB/SS'Q6/\ ;R%M'_\ %]--?/\
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M1-E9$K%I)\B5YI78DDEG<LQY/N:'MKJ#&Q<;#ACQL2"+&QXE"QPP1K%&B@
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M"ET;N%LVI0]AZ5-%#7,5-(3((H0\U-F=3$T 619IT/JZR%,;(;;.*$;D>F4
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M5?BN_P#F(LWVUKFWOG+5J_9E=&^7<],""/QTOW >04=@$@= =GQ4ZD"U5_%
M"K%_[\U[#X]K&L?7OW(]OM?'W7[?'N:L:CZQFJ,=:5K2QH(T8R,P6(#Q52S$
M^7R!Y'LKT/$%B?R=6TJDL%6V8F@J^HMN8E0  39^!W/W[W*$!2Q(4*#N8D*
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M#?MP#JX1S9'+,.*H'V#<7WKL-O(Y'8ZYES]O^L "6_ 8]?)_<AOZCR)/P/\
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MKT<T,G8QT5V4.DTGT3^\  :]Z%JSJ%E/D%67VV/;*W2KV6) U>0XK_A>H0E
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M0R%$=5\ )>E<#R]QF[9FZ*'6<Z;"<AY$8D(T3JVTT!V"DCD<%0/:_4#?.OC
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ME/?V)V[T_+Q<J!#C;$"* T"A5,5"@NQ:I?\ *0*([?&I7UC=7^FFFFFFH^Y
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ML"&!(!!&X'NP%$6=P-V:YX,#&#U\@DGY(!!!/1[^&Z'7D?D ]^))'P*&0:!
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M7@9V#(T69B9&-(E;EGB>,BR0+W "F*MM-T:-76OD&7C9*AL?(AF!%@QR*_%
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M+<[583L&(_#1N&L(P9I*LJAHMISQ3XXZ-+DY&)TH#+R\,[,G,!VX@(+!HHW
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M>K-(88K C=C"J^2GQ++T3R%XAS<3J/6<_-P5E7&R)C)$)E59 " /4JLX'(X
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MN.;/N2?W)-\C@77?GN>Y[]R>??74]QF8A?GH$'X9NB_V@@ ]D]L3WV?R"?$
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MIY0NYRL>Y@K$F,D=B0!ZR=<K:Z9TTTTTTTTTTTTU96^K AQ=.,GI;.5I0O\
MCY3R=R#WT.O)5[_?X_!^=7_3EN9S5E87(XOG@7_K\:PW6Y-F-"I-"3*A0_I9
M/Z5Q[ZTW^MCEK(6N1<EAL=>DK4L%3M(;%;W9[$;QB4>5>.%TDC1$B0O9C#F)
MO;^WY^W:G1<-,#HV&7]#Y0&0Y"C<6<5&O)-U9)%59[\:U+UK,_'=:S) P*P3
MG$AMB%"1'8Q%BB68< <&N>!K75M7!Y/=0OW*%B=,@;-9\?:M^4T5H,H:V]QI
M3(ZM$HA2*.LLDAFFD+A0'75EU+J$>.X5:V#>9'HL56J5A8VC:18YL]E!XNZB
MQ),A:X V@ 6$V]_32@EK^W( YXHZRCX]P.X,5F<*N:9:R06XE>S"0BEH423W
M4AB7WBTWFICD<1%VE#! JL(Z6-U.%Z*AR$" KM4![  8FU6J!\P$A@/;M>/R
MNG3([*X*AMVUCZ@5H5153=FA]S[\$ZS)_4<V10WEZ?-I[^P8BLS;-EIPV[)0
MM:CQ^1CKU9ED5O$(PM0P-)Y_E>V4^()UF_I?G2X?B'JG2L@E/QR-D0KP4,F.
MS.-K"S30R/M*G^7GFAK&?6#IT.?X5Z/UG$IST_9BS-M_B!)1&M.#55-#M-@G
M^)P"+.O.3FI![[,26)^'()_);KQ4J#TS @GQ8_!^T@C6_/+8UZ20Q )(JN2-
MPMCO (+@#DU1HD@\G9LAWVS&Z'(L^Y!'I7<+NN"?S6O/IU;,DY=O:+$!2_98
M>3?:/$A5Z#L3^Q\>U![)*CL>]C1_<J:C-CD)3$[6/H8'U&1K4DAC5\X621I2
MRAKIR":+D!155^8@M0 4,19)H+8Z5B=G\4$;)]I5%\0SOTW7B06[[!( "AB5
M/VENM4* #*'4E6)?LP JR:#43P:) 8 >HJ";LW9F"H4VU:>FV9C=53%N=UT.
M6YJ[.N!D,157D">ZOB5'9"*/(N0#'XG[NA(H!)*AOV)-JZAD#I^4!N">-UV*
M;?9Y-^FP >318CT@,; .Y&YMC<&D2SO) 4DB^0JV; /<:ILI,C>'0Z1O(L8R
MO:$$=J"%_<#OR4L02#\]:HN3RC!0."-PWL01=79% AC2G=ZSS8U52B6+,"J-
MR]%"4-+N4%>Y')'R#P&/-/<M(_P\</RY+LX!\1\#X4]G\#Q!0?(_( !U:NA%
M!0"QX *]V )JSZ;(!&Z@""+X:M7,,I)(5E46Q#E@-J@$61R2: (L#U @$*"1
M3IT$Y]Q.E\CX_)10&/P&[[+>/0^3X]]KW_-\ZMY-P6[8^7=;3P& VC9=6" Q
M/)8WR2.U5W+@N&V[B1N8 *>P]G8M=$6!W4$CWU\AJ,2GMQMY.WBK,.A(?PQ#
M,   P(Z)( !)( ZU9R2,6%]Z*@G;:A6/! L\J!M(O<;.P A]6)=VI5!WR<)N
ML@\NI-L?0.W?<"0"3W&KTQN&,LD54H6D\V4A9(Y$#(GDRH?GM).T8."5/X4=
MD>5M(U6Q'?FZ<$AF[\"@+/8?JQ%@GT(BVV(ERPD*LJ.CJ&1230&X;7W(0W"D
M\<G6;' O#[Y:S%D\I4:OBJ4GE+#*OW6K =7$([C4%"I!E![8#["?N4ZMRH=]
MY+'8WIK@4+OCFB;-_P"MU0V1X/\ #;9#?BIXVC@20EHY!ZI'W6$-J % (L\F
MO2+L-K8?5B2LL<<:JH4>*HH 550=!0/CH>(^ #TH[_'?6O<AL'FAV]_G_:S\
M=N.-;EA79P!0%?([6  ![=Q78?KKLPQ2/9E=/N<LTOW%? )T/)F^?RI/E_M'
M1_?NB:H=K]^]_P!..P%?J?WU<\&O;FZ!_4T>P'O[@^Q'N+FAI.Z1D!G#@%F!
M (_ *E@1WWUY$>)Z/B.P3V:991=FO_B^/[KO]]>@"/O]^QXOVX 'L*/^AXNK
M#;8:[,J%',;)\'Q[\2".T9F 4#Q)\OAF 'R""#JUFR0BFC1Y'ZCL"!R>]?U[
MZJ;3P3=$]AP17_P>.;[:V/<);*Q.+VRD\E.":R\@+2R(LC!E )![3P+ ]'L=
M] JOX UI;Q3U.?*Z@ZJ[+%':(H.T4"030/OS^O!_3<?@SI./%T_SY8E>>5PQ
M=EO:  0@)X]/';N#_3$+]2>[3H\ ;BIR5U>?*YNG1QQ$@B:I<,UFT;M<1K[[
M20U\?/'U&"#[S"3M%(;UT ,SN0U'R=I8W?(458NC;V+[U7N0?'B3:&C%4/Q#
M,  M$VP;@T:I*XXY(]AKS;XT1O!X*92YDD:4N\@82O%X^+ I&G2*X9#&D?V!
MON!!76S^B*66-*+%B UT.35UV]K]A?P0-0'J+@3$F@ O;D \D51-D@+NH,;[
M78U(.R<UMC96[=M[TW%%:CP>R,YB-VYR:JOE<L8?;-U,W:KUXE=!9L3)5:I6
M!*AY9%A9>G#-L3J_31EX>/TO%CADZED1F*%$H$-Y#KO9J!5-X0M?!"LP'!UA
M3U*#%3\7E35CQ2(^0WYE2,R*K*K$<OML <>I@MV1KV([ WOM_DK9.UM_;5LM
M<VYN["8_/8>Q(ACDDHY"ND\/NQDDQRJK>$B=GQ=6 )'1/)6?A9'3<S)P,I-F
M1B3/!,O>G0T:^Q[C['71F%EP9^)CYF,XDQ\F))8G'NCBQ[GD=B+-$$7J[]6F
MKK3333333334)<._XSSC_OIR_P#T7L737P?\SW_4_P!C[:FW37W333333333
M3334)>HOF+;O O#6^N4-S0Q7:.W,/,]7%RA&7,Y>T/IL3B0C_:PO7I889.P?
M&$R/T0O6LOT'I,_6^K8?3<<E7R)5#2"[BB4W))QSZ5NJ[L0/?6.ZMU"'I?3\
MG.FHI#&2%/\ .YX1!_[F_7BS1JM>'G=7(.[.4]Z\@<E<D+A(:&\<S.UW;-'&
MQ58*U%K%?(5:.&Q:+!C\?3J*D!CN/[KLX,LBR.?(=S="\/X/2.GX.)B1RM)C
MPTF3(^XRD^EI9B S,[D454@"NX7OR;U?KG4.I=1RY99XP)I07QU0VB\,L<8W
M*B(J<AR#=_E+$:B/=>_US=>GMC!TWQ&U\<\SOCL3%/.,A.K&3ZG+9&PW_BY(
M?'SB4*L,)),:Q]]ZF.'@K&SRS?QI9  -VQ=JCG;"B@!%/O[FCR30U!.OSF3$
M,*AE2-^*+D&1K):20G<]60...-H UG7Z$\UNFIN/+)5Q.43:TN/-3(Y"=&CJ
M+:B\WJJ&?I)9@6\56,R^*%R2B@DZL^J./T_\- 6E@3J,<O\ "@5P\[Q,%MF"
MV54 @VVW_*H[ZE/T>CZO!G9Q_#SOTK(B#/.$*XT<R[MJHS5O=B#N5 2.2W<:
MV7Y'+V6#>[Y10L#]S$Q,_9^ ?</17XZ[ZZ;\=]KV=)^4:^37:@:'L+YYKF@>
M#Q5'71"\4*J_R\ \<7V%]N+L>WMR,_/03QHEZ?/<N9/'>$=<R;;VI-8@*&:5
MECES>5K>:#N-8V@QM>S&>G#WXNR%.M?>)\O^(N(C61ZYJ/:B0BL0>Y-EE(X(
M4_&I9T7&X.2X(H;([!'/\S $=@. 1[EM;.=1'4ATTTU@+ZX>9\OLK%[;XVVY
M#)%FM_1VI4R$P$=)(*<B1B%IRP "3,)[( 8J@@'B3*!J5>%\>,Y0S)$6402H
MBQDCN1N9B38 J@#1_FKMJ.>(I9&QGQ(W,1FB?=)1( (I: (NC98$CL*O6B7<
M_I?MY./+7][;^N;@O9 6G>ECX8X:D1G\W(6><2.Q0OVA]@?<H(/:]:Z47ZK9
MT&.F-@]*PH%B18T:5GD*A%"@A4*#BA8NC?;DZY;QOH7T@=0DZAU#K?4\B:;(
M?(E6%8X5=Y'+$%G$IKFN*;MR"-VL@O2=Z(O07SOM).$N1\'O'&<E86\,NR'>
M,F*FWA'5CN)]5A<A7IPW"8*\[ME,$9>_LCNQ">&.1J\ Z[]5?'N#.<K'DZ<N
M,:4LF"3L:UH2!ICPQ  =0%:RM UK<'2OIKX4R<A)IYNK23Q1&&/&ESE.)Y1*
MOO2!8%1I01^>3?(!N"MM+#6P#9OZ+_Z>VS+27(>&K6X9T<2>6Z]W;CS2.P8.
M/.)[T$3J" / IXE>U(()[AF=]7/'.>&$G4H8=PHG&PX(B 17#%6(^;NP>00=
M28?3'PB9$DDPYYO+*E8Y,J41>GM<<9C5@>-P:P>Q%$C6R'8G'NQN,-NT]I<>
M[4P6SMMX]0M3#;?Q]?'4H^@%\VC@13+*P \YIFDE?KMW)UK_ #NHYW4YVRNH
M9>1FY#  S9,KRO0[*"Q.U1[*M ?&II@=.P.EXZXG3L3'PL926$./$D2;CW8A
M -S'W8V3\ZO'5GJ]TTTTTTTTTTTTU"G/.8DV]LI,VL)GCQN5IV)U [/L=LC_
M +CH=-V?G\#\'4C\+X:9_4QB-(8_/AE5& OU@;E'?['_ %[:AOC?)EPNDQY<
M2!S!EPLP-UM)(()'(OL.#SQKSX>I/"WKF_\ =F6R?FLV8R,%FJE6T!#6QLQ$
M\HF<1RQR2RP2^VM>.:*>-RLOBP5@-CYLQC?'QHMY\B%(59D-'RT"6IW!@218
M:MO;U &]:QP)8RDTKH=\[M*-CKM#2.S.K*19"J:X*FB?S$5J&<?G)L=''7K"
M6..NW4"HX">UTRA"[1HTP^WK[S*?;(!(7H:CTN#([^O:Q>RY:^7%%0J>J@":
M 8@AELU[Y%,U*(HUZ0NUAVH7?([@<D"O<6-2GM[>5QK43-9)DB,3Q,\Y#-.K
MA3U\>( +>:@!2?%6##H ^H<39LCNB0+(L N;+;N=I8=OD$$V;HT)<HN4-,VP
M$ %B:OBU[ 4!W^36WF];*>*<O+R]Q?O_ (OW-(\E#+8*:O3+>):&>:%HXV#E
M"\92<5Y5/@S _:1WUWE''^#Y?1NN0"I,7*1)2.=\+ $I7 -Q^8#9H;J["M4D
M;_&,'K70<A[@S<5VA''HR(^$-T2NZ0QDD+SMXHGGSP\A;<M[)W3G]NYB&-+^
M'R4^/L5'(63SAD>/WHW;['"  L  2C*P4@D#H['DCRH(9X7=HYXA*A4D J:9
M%V@>BEHAQO#-Q5@;N2NIX7^'Y.3#.!YL4A1XG)5]R[@KAW^+)JB"".#8N,96
M AFD#>R1W)TB'S=')Z#RCKI5("K^%9F)7\,VO;[0X 0F1E[,*)4  L :+%P2
M+#'V7=8 U')U(C=@_EN#O 'YF#$* S*#0! "@#DFQVO5*>P(QV@/10^#'KJ/
M[F\G=F[(<KT5Z/0'??1_-LZDVP+"R2M6"0?4Z&F:FMFW;N>#^8C:+#E2IX+-
M14D\K9K<X(X+"CPQKO9N]=;LS%@I\B3VA<A_@L6Z/70!+'H EF <DGKX%"0.
M>2"!:DKR0%5;"@,#0))8("#W]/\ ,/ !8D*"UGT@T>3Q1*A06/I%'G@&ZU\D
M<M&0% F!;W26960?+E0O:] ]$ ?+$_"J#\FV;N33>G< #=50-J/S!@2.>0U;
M>+LU1)8JDW [BU45'J.WGBO<#\Q/"D"[Z)^/W/3*&=?#W) I4  DDKTRC[26
M^/D?OV+9U\POM WBR0U!0Y7TEBQ"D FB21R:Y77I'KECR0+H;F -\=QQ55S2
M@CWNJG2HQRD!E\5\D\:W@7E,B_/F[J2(U/9+D@>0[!Z^"<9*31H$+1H@43R
M6*DT0:[T1RK4=7D94\"U7TCRR"6+K84N!5"B;8&@.>YYO/$XD(@C*K[;L94=
MZREG::*%F$DJ R+!W[;!$=B8RS]@]@V<G+"@WO>ZZ(.[:5);U&A1('+4*-@:
MOH8B44':%),@<QJ;W(CD/)3,(R^TA$+%HV/ ;@9+<3\07-Q78K$E85*J&-Y;
M*1.(@@[^8S*A!E([$0+>?N=.ZH@ :@UEO3ZJ(JZ!&X L#MX)_+1!;]R3J6]
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M592P)#=^([(*]#H^0\@S JQ.K3)@,D3QJ[+N4C@]KXL>WO\ !KC\OO60TX)
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MG@@@\#D'OWUMXU =2_3333334)<._P",\X_[Z<Q_T7L7_;_[_P!/QIH/^O\
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M'^GP1KX7]N:OL0>U']*)YKV]S\:^% U#F^W%?UXYX_8#V/>OT$7B5)7Y'X(
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M_M:WLNY7QLR+[4M"A=HV!$(TL5K%6.5&0#X!1BT;!"?$K\'H@&713Q9D DC
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MU!6XML[JVA3NVH)(;V+JK-/]4H$,I4R-[?U(D?I$3M/.9)?!55BL4:= _-I
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M1J$F6Z62^TTL>)!^:>=P(QV!9BP$[\1=8Q^E8#>'.CR;&CA5.H9BV4Q4D%;
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M+5,E425X)):<@#*K(R-!)&KMXO&!]O1ZJ[0?+LA.\;-1 5@"5$@KNWLPXY
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MKB[E?(8W)4+<2SU+U"]4DFJW*=J!TFKV:\LD,T3K)&[(P)::[K.BD!G520S
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M.JFP& Y5QSLD6G0DT2"RG%=6Z/A]8QC!E+3+9AG2A+ Y%%D)X(-4Z-:,.XL
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MH@ @55DA;/P18YU,?_>?RDD44&'VO>FGE/MQK:+ R$]D,(C$GD?N! ]QFZ
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M!B0-II@H %J.-9W-Z5!+TK+Z;BQQXR9$#Q@1*(Q;#W*T26K:6)NCR=>+3/\
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FTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTTU__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g129231g18g60.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g18g60.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1BV4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &)J^8I@X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0&P*'*         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,W    !@             !Q0
M N(    ! #0    !                          $              N(
M  '%                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  '%     %)G:'1L;VYG   "X@    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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ME<Y]:
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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MR:^O.E[*5W-I)):-DX1SYT.1[#^]7)XY=\>PK:UEU#>)&@O$CN.V70>4^/G
M&QCC' 5,_/SN#C[R'XOY&LV:]4WGZ;MBH3VU6\$ZOMW*)CB$2&KE?"LD:,9"
M]5\N21HF.(08T:[JKW^BW^G O-$'@SQ/$P>,@G )'#ID\>M%&>Q-6:TU&UO
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MU&L&QC41K6,:B-:UJ(C41$1.DR!)))))))))/<D\DG[DU*    #    '8 <
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M*@MKBYD9(_S%0R2<!4 ' /))))P .2,<XQ5:UD3S7$4$*LY" A%&<%B=S$9
M[!>_.,U KES2-NU$LB\_TE<U]$1S5+]W&>L0!"*BN]9D5STAE*1J.3LB--[(
MU1.*G;K#%>VDQ"P3Q3/M):-"0_!Y95(!/&=P7G'/O@1)MKF$9N8G1#PLC#*J
M?Z2P)P"1QNXR<9'&?QXOY]M:R"70RQ[?;ZO;FCU^'KEM*C6$5DZS5L,,>MED
M?$/ 4KRM$@I$E([">A6M$5JD7$O+*RE87;;H9(2TAEBPI(3UDR#8P; SS]1
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M%3$N>HK*%C'%$UQC@L"%4'ME6/)^Q''V!KW@T:[E4/+((<@84C+#MC('&/\
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MI@<>;%!8]Y*BOWS8HE$][G.3]-&4?Q(-R_RU$Z<J)^/=SE_E5R;U_FYMW/\
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MI8J,[>IV,]$5_298NDK73+[J+2K/5Y?)L+BX\J60D*BNZ.(!(QX$;3^6KDX
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MBS@1FQ?2=$/,8A)+94DKXK/B8@6/$O3E1KDRQ6TDH 0,5"Y''SGGC'QV/OG
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MF5KF,M#$TI94&V..-F"(%_+ABRQ+A5)"U[W%?%W,'DILM7KO#FB7&URY\QD
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M9IY)2^U$XV;F?;&BMG)](#<D#)J,O$D$,=C'#-DES;Q3*3+*\G\^QAN;<1M
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M;7NHRLTZXVM (KF'"Y.]U(9< %MS0#5D8<2SU26E>D8 AU]AKTIT!\8(F(T
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M1SF1@T6?1[BVGD;S;2[>6VCF,;1_FH%<+C+@[AP&#8R#G:1BI%]3@U!;BW3
MN;58YY(@^[$4FY=W !R,DXQ\$=^/SI]_9"UFGOX\\,2QAAK[2M<8S&O2?$]'
M(Q&^W9/D*QPRL1%]Q.<UWX556>DMXYH6CDP$DC*/[=QWSWRN1CYQQDU7DD>&
M</'DO&Y88&1E<G#=^&!P?W'S4T.%_(_4N:;2TH*.KO8=QKU-765\25$"M/'D
M32NCN@Q; ,DBG*TPR/"A A4P&/(U.Q$:V@WNG260WM)&Z-*R)M)W,H&Y7*D
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MTJ+^45%_E%3_ "BXI5!'U1?"[C>+'C<G:A!O]?G;A8S ;+6:N0$>OD3H[ 6
MY4:&0?VR293Q/.L1S>B%B]PG#)Z1W])>$/7^K;)M&OYXKBUL8HFMIKG>TL43
MN8MC2#)\F,E5#'&S>H?*Y(YW\5>A]&BG@URRL'%]=23&>*W$:K+)&F]GC5AM
M\]XVD8H/5*%8+ZO2U(/%W(_!WCE?FM;'5=@Y"DQ(TES]:FV(=?LK25"E 6/7
M6%P6#:'AUD@KRJ>O@0XCY8&RQ1I4%Q$*N_\ 5M-U?6K$1VU]!8M* RW21&[$
M<;@[GAA,T*/-@@QO+(41L%DD5=ITCHVMV5O?EKG2KN[ACQ&T#RK:!W4_V<\X
MB>2.("/UK"I<@J 8]RN?.D\G\I\[;!LT,EU>Z-Q->[M/W&PI+ZTF?Z&A>Y)(
MZ\M?"L_AA5]91U#FACQHP?:.D=OI8L14<SXM=-TSI^WMI1!%>:K9V0L8[M((
M?Q\T>%9U>9$#DSRJ9)"3EG/*OCG.OY+W7)9XI)VM-,O+P7;VC7$_X&%URJLL
M+R%':.,B),854X](+;MX[;RIHU;X].K=/MHWZ5J^ST,/6YYFD ^Z( ,LUM9#
M^1K'H&;(F&(![F-4K"*9&(-S4;KGJ7I[4[[4XKR:)WFFBDDDACY,0D 9 0#C
M*)'&N!SD ')P#>^F>I=-L+.2SB806L$GX>*6;T><(6*.<\#US-(W)/))X.<7
MP?29Y[MN2N/-NX[NI19K]")5V-*<AW2OMJB[0XRUK#N>Y5!%G12$CCZ:T39#
MQL3T:U$T=XH](OT]<V%]N!74ED21=A1Q-"$8LZG'J*N 3W.T$\\G<7ASU9#U
M%:W=O&,_@BKI(&#H\4K.@",,C"LA(&3PWV-6ZYJBMEU@F_:%7<@0J2%92Y40
M=%LU/L\=T5!JII5.9Q@QS(1%[ 57*A/56O3\*U?QF3:W+6K2,JJWF0R0D-D8
M60;21CW [>U>$\"SJ@9BNR1)!C')0Y /VSWK.\QJ]Z8I3%*8I3%*8I6L>5.'
M>/.9Z!NN<A:^"XA@(X]?+80D2VJ)3T:UTJJLXZLE0BO1K6E:QZ@D,:@Y(3#3
MTS(M[F:U?S(7VGL01E6'PP/<<_J/8BO&:"*X7;(H/!P>S+GX(Y'Z=C[U73R#
MX5W_  [3[#NW'W--96Z?0P)MS;5O)_\ VZNKJN$)QY)9.S5PS 08@,?T\]*'
MMR-3W]G=Y;M*UV2YN+>S:QFN+BXEC@A2T'FR2RR-L5(X3AMS,0 JLV2<X]C7
M-1TF*W@FNFNHH8((WEFDN6\J.**-2SL\@RH15!))"@ >Y)-4D\A>4_+_ "S<
M2N/N+*X.M!/);6IN,P*FM+L+#/#-G:Q63XK'5]:X3%?%N;&"J_$=AW?II!JF
M=+]/^'=C910:EU#*TS!5F?38<B*'*AA'=3AUWR#(WQ1^G<"NZ12 >=.J?$>1
M4NK70"D9Q)''J4I+.T@)7=!"$&U6((C=F:1N&$:GMY?B+N^S\2>1=SKA=]78
M6;6,VJ[/;P;$EM'E,V&*"/)AOM) 6I*5LH,0,U1M(-"Q7K&D*S]V9_B!TS9Z
MITPMW;60@73@MU;P&)8&CCMV;#"*/("LC.R@X)##<":IOAUUG?Z3U@FGZG>>
M:^M[X)+D222@W,T:-L<S^L,K!%8DD*4(!&,U;W*K=;KXRC4T0 Q#<ST5S6-8
M-&]JUK?=7?GM6]HBKWVO?Y15YQD5P,C. /OQ@\<<?L ,@<_IU,C;B,YSD?)^
M_/Q[\_;..<59+XP\;UNA<=1[$$$<6TW1[-AL'_#\1UBE8J4\<GLUI/44%R24
M8]$<PTPR.3O*'JER9[DIG*0Y10#D;OYS\9R O''I&*N.GPB*W5L>J3#$XYV]
ME'^7/ZDU([(VL^M0\Y\N4W"7'%UO5QV5\;XJ^GA(CG/L;R?[LKH;4:B]-<]K
MS%7\=!"3U[=ZHN596K7=PD*YP?4Y'<(" 2/N<@#[D5CW4XMX6D/?Z4SV+D';
MG[#!)^P-<H'DOKWE/Y![1L7(*:RZ@&D@ZP+&_O QBEK44JJ)*P+Y,\(9+B/,
M0;((U<U[&D5?B8B]@='=3])]+=.66G*[SW!7S[T6]I(SR7#=EW2+$H\L!8U)
M<8VY0<G/&W5/0_6W577%_K=R(H].0_@].2>ZMP(K5,9D"Q-,Y:>1I)&#)]+>
M6<XK/_&_Z2FZ^07%T7<5Y]TX=\4Q85_0T9+**[5K)I"O2)9/DZJ6R/(=&^V,
MUC1Q(LGY"$B6)0C:Y^)JOCEHFEWK0IH&IRPX#QR3"WC,P]((3%TZ*!ZO6=[*
M0%,0W BU0>$O5U^ ;;6-!M;9-L:M(U[=S*-J[MT$=I9K$02P55N'#HJMO!8J
MMJ?@Q](K3_$GD1.7MNY,F<J[[$!)#1,;KXZ.DH5EB^%TGVE65Q8VDX(7$$&3
M\M8%$>I'0E<C6LU-UUXQ:CU=8S:3:Z>FEZ;,PW@SF:X>-6+",[$BB16PH?"N
M2 P# ,:V;T?X5VO3E[#JM_?G4]1A!*;(/)MUE*@"3\QY9G*>HH&=0"58@LN:
MN+S3-;:IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE:KYGXCUKF_CV]X]
MVATB/#M@M?#M(*L;8TMH!5?!M8#WHK/GBE_+A/112 .+&,BB*[)KI_7+OIW5
M+?5+,1R/"2LMO,,P75NXQ+;S#OLD7C(]2,%=>5%0G4.A6O4>E7&EW321"4!H
M;F$[9[2X3F*XA;V>,^W9E+(>&S7/9R!PQQ9XI[/(K?,#AG8=]UTTZ2;6.9-$
MO+"MAV]:YQ/MX5M7MBD&&Q T;'&!^JP9@B2.D2<)K):].Z7K=_U=8";H37K3
M3+A8U%WT_JMO'</:2X =K64NK&!F)"'R9HMH&/).8ASG>:0G2MZUOUIHUYJ$
M!D)M>H-(G>!+R,9*"ZA$4VV=0!YF)('9FP!/G>:A_)CE#CSD?D78J_QUU:\J
MN/\ 8(8:FMU38Y#KA*./]O'BS;!THYY"1I!Y RSF37R'R8*.$ ,@J/,!VWNG
M=/U/3=)M5ZBN;:\U.'<]Q=6T?D+,Y<M&%50BXC0JA 0*Y&[:,UKC69+/5]8F
METJ*YT[3(Y8VM(9+@R7"JB@2K(=IWQR$,S*\C%PQ1LLJL-"[HDJ>76>/J@+I
ML'7&"//2,9'ML;DW2?IXXXVKV8#6HKWHYK@B(HOB]EZ65CV+YMY<8#RG\M2.
MR#/MW"M@  D KQP&.?N'3OQV+:$F"UME99IW&Q(A@>9.\C;5<@22,S*"K.['
M@K@=:WT=/&/9^$^#+GD;?(1JO:N9)=?;0*>4CVRZK3JZ.]*5)@B-:\$NS/*F
M6#P.:CAQGQ$>B/5S6\>>-/5<&OZ_#IUG,L]MHZ2I-*C;HWOYF'GK&V<,L"I'
M$2./,$@!( )ZC\-NGH]&TN2=;<V_XG9# 'C6.1[6W+[9V YVW$CO)'G!,6QR
M!OP+@\TQ6R*8I3%*8I3%*8I3%*8I3%*JN^J1O$&HXPJM:V*981-$E3H%CMT:
MI;!?:7YEMH0*&EKV6#FQ'2&2!R9S&R.FBEMKIS5[A]+NCP<TQY=5N-1@CA>^
MABEAL6N-_DVY,+&>XD,?K"A65/3RR^;'QOK3WB[JD<6E0Z7,\R6MQ)%->B!D
M$TL*RY$2%QL&2C%MQ  PY!"8;E"V4'*E+NM#Q3K,39;3>>03,0=5IX)]MLET
MMSTT8)4RN865-;':Y(LB+!=(#7O&L9K1JA7KUU)<6$5K-J%_)#;V-J&=I+LI
M#! D.?S&$NQ55B%*L?KW*1R0!S+HT<&K[8M'@:\N"_D(8E\YW?=M;\&J;B=^
M6(D& Z L&V8-6_\ C?\ 1P\C8-?K.^\A[-2:O9@MJ:P@\;$FJDV(-\<DB;:[
M9<UKIX4)6V'Q)'I(!)TR='*]TJ75%&^"NANMO&_2I$NM)Z>CDO(I(Y(9-2EC
M*VZY&PK:6SA'E+<D3S%8U_DCD!5QMCI'P.NY+^#J#J8K:W,5P)K>PAF\RX*(
M^Z)[FX0!( RA2]O #+QL:92&W7W<0^*^B\;(*WO53?-Q7HC[N\C,?!@%5$5S
M:2F*X\:$C7?VRS+)L%_Q)&Q?B3FV]UF[NQY8<PP\^A&(9A_ZC#!8?X>%^Q/-
M=)6NFV]MAMH>0#&XCTKV^E3GGC&XY/QCM4H41$1$1$1$3I$3\(B)_"(G^$3(
MBI&F*5KWE/C77.7-%OM"V@'R5MU&1!26,8Z35V4=Z'K;>$K_ -K9E;,8*2'O
M]A/1P#(X!2L=[VUQ):SQSQGU(P)![.N?4C?X6'!]QW'(%>4\*3Q/&XR&! /N
MI(P&'W%4X<@Z-M'%][(U/<(JH8+'.A6+&O\ TV_KFKZ"LJXBHJ/&1OJV7'55
M/"D*L:2U%]'$VKIMY!J,"36[#(QYD9/KBDP,JX_SVMC:PY'& -?WMI-93-'*
M.#ED<?3(OROZ=B#R#W]B=1<<;S=>.G-6K\@ZQ(.FK;-9Q:'=M>8]6Q+.NG2&
MC,KXS/9KID12_?UQF#4P9<=1HOP'.(OYK=E!?VDD3 "2-2\+\965%)[D=F 8
M,.!CGOC'OI-W);RJX)*L0'7G:8V8+VSW'!7[X&3DYZ+47M$5/X5$7_WS4E7Z
MO[BE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE8_L^J:UNE/+U_;:*
MJV.DG,4<JLN(0)\,S514[<&0Q[4>WOMA&^I&+^YCFJB+F3:7MW83I=65S-:W
M$9RDT$C1R*?LRD''R#D'W%8]S:VUY"]O=P17$+C#1S(KJ0?LP.#\$8([@BH;
MC^F[X=COW[ G$T12O>0JU:W%RVC^0B?ESJL<U@"M:OY8(RD"UWY^->DZO#>*
M/6[6XM_XU(   )1#")\#V\W9D9]R,-[YS527P]Z36<S_ ,+0DG)C,LOE9R#]
M <<<8P201P1C.='\<?2$\8>/^8C<L%2]V>/&MW7FOZ-<?9)K=18?,L@197P"
M27=,BE5'QQ3B_$KFM=(8=6IDGJ/B_P!6:AIAT[SH[=GA$$][%N_$R1[=K!&/
M]B7'U,AW<G##-8]GX=Z%:W(F*R2VZ2&2*Q;"VP8G</-4?VRJ?I1_3CA@PJU9
MC&"8P8V-&,;6L8-C48QC&HC6L8UJ(UK6HB(UJ(B(B(B(B9JPDDDDDDDDDG))
M/)))Y))Y)/>KX         !@ #@  <  < #M7^L_*_:8I3%*8I3%*8I3%*8I
M3%*YOOK.[5:5=R^DF21/JG7_ !G<44.?+'"KVVI*/; N*61*ZA-8)]4Z9$',
M58RW42 \B.Z5CNI? JUMI;&2X9?S56_B=AEL@7%E(@VKZB06&<9)1B .U<U^
M-3S"_MH?48)1"S@ $F-8;E9$)[[9"5! .=H8#!;%;"\ J.BUG5:KE^J2'(Y3
MFQI )1;N#%FRZ37+)T>3&H@L>\Q(4>UBQX<^REU4J*:5+11-DJ&,P607B5K1
MZAU"XT99Y!I>FW#Q*(7=4FO(ORYKEEX601R!HX@P*A4W@ R$U*^&_3\72^GP
MZJ+6%=2U2&.:9S$FY+1MTEM;A@H<8CD\Q\>I6EV'(3<UO6O^1^BG:*)N<H>D
M6KE:/VLR.=1RB+^.X=R@V@&CE_\ LV+896N7T9\Z(TC])7>A7MN2T2&YASPT
M8]8'^./N"/?;N'N<=ANFUUBUN  [>1)[K)PI^ZOV(^S;3SC&:SK6>8>-MRVR
MSTK5=KK+_8*>L;;6,>K>^5&CPW2!15_Z\;%A&.,QA--' <I0?(WYFL5>LCI;
M.Y@B6::)HT9M@W8#9P3RF=RC /U 5GI<0R.8XY S!=W&<8! )#8P<$C."<5L
MO,6O>H>^5OFIQ;XDUM9)W2!>[/;68BS6:WJI*/\ 5HU2!RC?9REO;>GA!$<Z
M.CP .E(>>84CX6?%%D%'>^B_#[6^N)+@::8+:WML*]Y>><+<S,,K IABF<OM
M]3G;M12NXY90:%UMXB:#T*MF-4,T]S?/B&SM#";CR0</<,LLL8$8;TK@EG;=
M@81RL>M*^L;X);*!B;5R1></VJL:\M+RIIFP4AQ(Y6M1RVM-$V#6R#]G)T45
MVYCFK[HOK^<F-3\&NO=-D*II<6I1CD3:?=P.A';^SN6MKC.>,>3R>V1S6)H_
MBOT5K**T.I/;2,VP0W5O)NW$$X\RW%Q >Q_O<C'J K&>=OJ0?3HWW2K*A7F"
MNY,LQA+(IH_'%18W%_5V?QJR/-K[&=$K:>*J.>UL@<JT'&E1W/!(&0:JU,CI
MSPM\16OHI(=).G1[E$T^HW$,5L8BPW"1(GFFD7&<>7$S \J01D>/4_B1T-I]
MA(;W43=L1^3!90227#28])B:410J><$R2HN#AN#4*/#)UCY6<YZQ'2@?$XUT
M:S+N%X20])+IPJ%S'5,>2]B?;C6QN"P $AB(;J,Z5[&*@O9T_P"(6FP=)6KV
MGXY;S49X8HW:--D=O+.&WQIEF9BD(9MS;3].54M@5SP\U^XZRF_&C3WT_3HI
MY?)$DHDEN8(" DK815"M*0A4;ERK89P-QZ1,T+6\:8I3%*8I3%*8I3%*8I3%
M*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*I0^M
M;X_T^_>/KN5)9(L8&C66L+LQY8II8[:V/??'3S2_8/$4(X<N[L(YSD?]NUL\
M"RF/C"*QV]/ _7X;77'T.\8"*_$DUIN) _$QHKO%D8YD$$3KGTYB8,"&-:4\
M:=,NCHL.N6-K-=26,BP7B6YC,D=G.6C-P$D(\Q83*P=$S+B0/&-R UL_D3A&
M+3\<Z%Y(\-VT6JARM T6SVVF8&3+I[BDE4%0C+N".NC2'-+\#Q&G,5@XY$1T
MY)$9[3*6@_Q*6'6=2LKG<SKJ-\BN2-V\7,NY'R1D;L[2.?8 \5?TL8YM(TZY
M@X5K"R8KCL&MXL...,#&X' [GCD5H^XN=FWL;'*-M;2*U',8)$^:4BHB.>61
MVI%[1%Z$%1A1'>KW&5$?DNTK,".0/@'W]^>.>^"?N<#/$<$CAP -S@'U'^4G
M.<#C'V/)^_->CP+<P^)N>M"LI!4B0=FG+ILU[U1C'!V!B18ONG?[1#M$@&55
M7MKF>WY[=W%:I&+BSF 'J5=ZDYR&C]9 X_F&X8XY/ ]ZD=/E*7,3$X#'8P^5
M?@9^V2I/N3[=ZMXY>WXW%O&>Z\@QM8O]SDZI03K>+J^L0#V5W=20#ZCPXD2,
MPAW->9S'2BC&1T:(T\A!D^+T=6M&TY=6U2QTY[NVL4O+B.%[N[D6*WMT8Y>1
MW; R%!"+W=RJ#!;-3>K7[:9IM[J"VMQ>O:6\DR6MJADGG=1Z8T4?+$;F[*FY
MCP*X]>:^??)O:=^O-F\CN+K?2*Z]LDN*I^\:S+K7"),1B1J2-&L!"-74@X3:
M]:P%G\GS CQVA.IDL$-W5T?IO2MKIUOIW3&I6=W':0"*5[6\BF>XF1G,LLJ*
MS.LN_?(778I$P4KA$"\']>CJB[U"XU?J*QU..^NYMT:FVN(8=/M9$41PV[%4
MBG01!8L 2R1^4\C$&8E],;!R+QH^L'$MM5I?4C5<1PBC8AFJKW*K@2CMB>KE
M=Z)\;&]HU/55<KU?:9+2[0D^;*ZL?I)R% P  0N[.>^3\X'TXK&B+)<2A[:X
M2&2$8#NC*Y)]F(/ 4$Y] &!R">^LZ:@T#E#:Z[4= T1LJ\L2HK8].4C'$:G7
MM[1]<$DZ87I[1AC E_<',]@6-5[T[Q+Z^71[&>]O[@0VT2%F:0@<+_*K.5"G
M.,,0,?U# JZPZ=?:K-'9-.EY/*P5(XXB[%O;U-N()(P51&)&. !QV(?3Z\;9
M7CUPW&!?T@Z':=E2+)EU3_5TZIJHP497P+%[7$]9Y'.++F ^4SPO*(1RNDC,
MC>'.O.I5ZDUF6>!LVL;N4(X5Y'8[G7/) 7"AC]6"1Z2M=>=!]-'IO1(+:4$7
M#1QAP2"8T4>E#C@$L69E' R!W! GIE'J[TQ2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q
M2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5A7)''VK<L<?
M[IQEN]>VUU'?M9NM2V.O<K6ND5%[ /7S4"1["(&2P1W%B2$8YT:2P1V)[C;F
M787USIE[::A9R&*ZLKB*YMY!GTRPN'0D @E25PPR-RD@\&L:]M(+^TN;*Y7?
M;W4$D$J\9*2H48@D'# '*MC*L PY%1+UCC4?#ECJ_C_PK<V>P:K5\?\ Z!L.
MM;K-=L=;K-*.'%K*B?/.K(PTE6$59!%@()GS-&QOP+ D1XXIRZU ZO)<ZOJR
MQQSS7C7'G6J"%YI'9Y)$5<MD!]H#DY7))8L"U0\%G_#5@TS36=X8[583'<-Y
MJ0QH%1').W!*Y.P<$X  #+C4X."M]UO<+#C*HUV;<UT<0)^N;><!8NMI12OP
M]EE9E0H 659+^>*^M$0]@8 @28\-X3(Y,E=6MFMA.[>6P)4P [I,CMMP.Q&/
M4<+W&<Y!QY-,N1<F.-=ZL ?.("J,XRS<G)SDX ))]@*E!QWXKZ'JUC VG:PA
MW7;X)!RH,FQC,_0Z.6-S7C-2U!/D8DJ.YK5%93WRI;"-0T5(2]#;!W>JSW(*
M)^3#R-JGUL",'>_&<_"A1C@YJ8M-.BM@&8^;+G.XCT@\_2O(&,Y![YY&*E#D
M74C4>^8*BM@[/H&VS(%?/K[2X%QYMM;8Q(\V!<T.RH5L0-A$DL)'EB@SF.($
M1AD8KY'2MZ3K)W2)Y#!>V\<LD,L4+7]I-$[1RPW%L 28Y$(9#(AP2I!]-0VI
MPQ&6TEDBCFBDE%G<Q2HLD<L$_"B2-@4?8^"H8'N?:L>E^$?B1*MY-ZWQZXNK
MK:9"+72IM#K$+7"'AF(PKPD;0-K1*GRC85C_ (T(,B?(-[7JJK(P]?=9P(L:
M=2ZNZ+C GNWNL;3E>;GS20,G )(P<=JA+SPZZ'OFWW/3&D%O-\_,5LMMF7!!
M<BV,2L6!(8,"'SZ@:SKC3QOX$X<G2K;B_B'0-)NIPU#-OJ/6ZV/L$L"HU%!)
MOGA)<' J-;V DUP5]47T[3([5NI^H== 76-9U'4(U.Y8;BZE:!6'9EMPPA5A
MDX(C!&3SR:F=*Z:T#0P!I&CV%@P4J)+>VC6;:<94SD&8JQ )!<@D D$UNO(*
MINF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4
MQ2F*4Q2F*4Q2F*4Q2F*4Q2O+A4E/73K6S@5D&'8WAH\BXG1XPA2[,T6.R)&)
M-.QJ%D.CQAL"'Y7.0;$5&(GL[O[9W951F8J@(1220H)R=H]LGDXKY"(K,RJ
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14IBE,4IBE,4IBE,4IBE?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g129231g22s63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g22s63.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1M$4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M  !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$
M8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,
M   #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M  !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RL
M    "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G
M4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M            4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN
M=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E
M8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R
M;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU  (
M 3A"24T$)@      #@             _@   .$))300-       $    6CA"
M24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M   *  $          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O
M9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M!@       3A"24T#^       <   _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H   X0DE-
M! @      !     !   "0    D      .$))300>       $     #A"24T$
M&@     #00    8              [4   4'    !@!G #( ,@!S #8 ,P
M  $                          0             %!P   [4
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   [4     4F=H
M=&QO;F<   4'    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   .U     %)G:'1L;VYG   %!P    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
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M# P,# P,# P,# P,# P,# P,# P,_\  $0@ =@"@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M/=QD%[K/3C=_P:=Q8^TCK_5^5;PY.\1IX_,V<5KFUU,>"'M8-Q,:Z1^:583
M "!H!P$ZB)ME"DDDD%*22224I))))3__T?54DDDE*22224I),YS6-+WD-:T2
MYQT  [E4V]4JN?4,*M^970
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M])ZFTAJ^5U[JZGH[BC1KNR;A-O+%-2U@L]BL-2#]'2-ED6C!@V5,LF=91NV
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M*;JG)066L!92$.VM2PO$G7O07)8O.8UW26'@T\?FJ6R<9C7B48%W<?6NI6L
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M=*G1K:>]/3"^K4[!] MVBQ' 7:%F565E[DVNV<$E<HKV(ZUW=K=^^RU1V@L
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M%V$KWK?8I)T20"222=#Z  ;=C8=&(A2I==W\;'1=]?\ $=>0-D    'VV23
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M@VNZNOL\\RYCAAUY).[N(U6Q-G2D0(Q1E&T@B/V:(L>OEA%(423/0=@;H.P
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M< =C_P ,1+2[6V6PH-(D;&L5P<1=)Q;(C5(5G"SE<X%$R"?W0[(0%#E%02D
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M?_YEQ$[6(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$VG(50IB'*!B& 2F*8
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MD/1@B;>QD&UJ=MT9=N@W"19-X<L<[;E:.CN5E$#F5<+&$46S(2^"I?,YP\1
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M'%:RFJG+(J=J\BEWN5;10[64$$V)V?.+U,N15*TA<= <>/1?S;F\4JPKU^M
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MG8"*:I#=*$$INBB(E!$]?$1B(Q$8B,1&(C$1B(Q$8B,1&(C$3@<?J$_G4_\
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MR,_%ILNS<?'?%MM;\(E6F]6UE6O:LK!2W8P))7+\-359DE[4%@I0V!"0%8[
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M/1=F;F#H2GBL[A\S&OX6NQ^+NKUR'%9.98106[/2MXY;N]*;*1W"Z@65TN@
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MT3JI@*)(:P2<O"V-H_>ILEJN6'52(3S2&47LBJY$VS./;>B9=;YEH98R@$4
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M,"!N93-';A;;+AA;OCI)V*-13%X0@^)7J(_=!ZB00]OO !5R%[ AQ 0 "&
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M5-),A0*0A"AXE(4H   4I?8  /IB)%#D9ROI_'2?I$)-U:9LLM=3*(1Q80S
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M1^FQ^7\R-?7S]Y;Z3E5'2AD$!%58X^/11[*F ]_>-W]!_$ ]_I[?B(9G&Q0
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MQ>O+Q8%R-F<7*.CG$ $C1@X'OL>NQ.!!*4 [Z[$Y2A^?T'*=W(\3A*7NR,=
M!O=U]1/@;T%5B2?H-*?IH>94IHYWD&%.)AY=A+!2N/C6?7[L5 4;^I.OK]Y+
MO5'$]=%=M*WD2M6Z9BJ_8Z*I5';D>P-XO%R"8B!!'V43()U3!V F)WV.@<_\
M0*RCX_$#U+"O9^*=2E=8\C]TA^9F^O>0%!_A'@21>F_AC?997E\^PJJ5@XP:
MW#6W:T0+[5V%0^S(I+$;'<LG>Q8M(UH@Q8H)-6C5(B+=NB0")))D "E(0A0
M * !^_\ $1$<BBRRRZQ[;79[+&+N[GN9F8[)8^=G?_B3;335CU5T45I534BU
MUUHH5$11I551X  _\^9SA^N?]Q/^[/B5)OQ$8B,1&(C$1B(Q$8B,1&(CZ8B1
MMW#,[CK<5-359E*Y&Q+>5K[2)\(AU.2RY96>BXEZ609JG;()IHH/'3LBS=8X
ME,BCYD],5!#4>>R.H<6I[L6_$HJ.=Q]%!3';*N:O*RZ<:TW5N$1?36UK%97/
ME0&&B3-MX#'Z?R[J<?+HR[KSBYMMX.0F+2'QL:_(K]&Q>]V+M6B%&0;[B%(/
MO81SR3V.20MD8LE]D12%I2:P=P=TJ3.@UJT<SFH]Z^%LJNV9RSR;L\&@V8+D
M<-F+1.?:(JG$Z9#GU@]8\L6S4<'%H7.L.-G6<7>P7CZJ,I:QV.]:9%V9EX86
MNP,M:#*1/+=F]G3H_B?3P;5;\3>V#W9&!7R-/?9GVW8U@3OK5K**L;#RF:Q3
M6]CMBV,%]Q+ZED+=<M36^T2\LQ7J]JUC)O(B+- N(678*/H%4ZAI--RZ<&(/
MWE0,U-V= 3%(*AQ()AVJY\W+X/D\R^^NS$S>&MNQJ?PKX]]*W8KLPM#6.0>U
M@"A^96![CL>=9JIP<'J#C,*BBQ<O"YO'IR+OQ296/<*LM%'HLB("-@?./#^X
M WH?-_!T8M==MI.#G5H*10*11%]$/W,:[2.4 Z,1PS.BIV AV BI^SKZ!G$N
M+AMB%+\3*MQ;D(*VX][X]@.SH]U;HWC?V]S^L[=R7JS$-&9CT95+#359%5=R
M,I]P4L5QH^Q.M_TW)=4/E7RXJ3F+KM!DY'<Z[\CIJ2%EHES:'C$J20'(]^>9
MBB^*#<3=C\VZ,@;]50>@#)'X7X@_$+$LIP^+LOZD:Q71<?*QVSK*@%\6BZH"
MP=GN199ICH'W)D;<_P##SX>Y-3YO)58_3JK8C-DX^2,.NS;:-?I./2/?KWKK
M#:W]0)*?4_%W?&\KJAL_E*^=1S @$,C5UUT0D7#8IP4)%MH]FHJTKT3V >N0
M%#/7/N!P*8XK!O/!]!=5=5<E7SG7MKTU)VLF SIZCJ"6&.E-)->'C?P^H"3;
M9]?<D:-S/7_2O2/%/P70527Y#=ROR 1O2K;7;Z]EUJBS,R""Q3P*D.O UVG+
M9'L&<4Q:1L<V19L&#=)HS:-R%20;-D" FBBDF0 *1-,A2E*4     SH&FJNB
MJNFE%KJJ1:ZZT "HB *JJ!X     G/5UUN1;;?<[6W7.UEMCDLSN[%F9B?))
M)),[>5)3C$30?I_27^\,1-<1&(C$1B(Q$8B,1&(C$1B(Q$8B!]P$/SQ$QU<G
MM-+,)!Q<(5N<T3(K"L]*DGY?9\@H(F4,8"]"5LY/VH0X@!"J"<@C[AW,O0W4
M:Y6.O%Y;K^)QU*4=Q %] &@NSK=B :T#O0V!X\0%\1.EK>/S&YS!K8XF4Y?(
M"@DXN2Q)9SK>JKB>[>@%;:DC8W#MG(JL5?0<!X*%'KW$2@?\ $!$.@$?R'W#
M]H!V.]7XP*ED^>L^"=>5]_##P?'Y:&]:UO4TW"Y!7[5L/IW#7@GY;- ?,&\>
M_GP?._IYU*T:V$2E /4]NO?[P=#[_N$/V]C^WH _#$MA^3V^/O[>-?3S_P!A
M^?U$SBY0^H^A]B!YWX&_8C]!Y]X<V(3$$!,'70]")P  #KW[Z#K_ *A[?CT
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M@?Z 3F\#_P :;^R3_P <\GU'@?\ C3?V2?\ CB)J0GCV(F$PCUV)NN_;Z?0
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M]%=7C[$JH8_S)D9Y_*\EREAMY'/R\VP^>[)OLMT?_:'8JO\ ]H$JSR4_B_\
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MRB#!-0O0]N53!Y.Q*/0@0"$2^O?EWT$?\[U]DYJOC\8C8M+@JV0Y_?LI&CV
M>*M_?9;]"))'3GPQQL%Z\KFK:\VY"&7$J4C%1@=CU6;Y[R/^$A4]]]P/B7B*
M*2"2:**9$DDB@1--,I2$(0H=%*0I0 I2E#V     /8,CLDL2S$LQ))))))/N
M23Y)/U)DK*JHJHBJB* JJH"JJCP J@   >  -"<F>3ZC$1B(Q$8B.P^G?O\
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MHXS_  EK=?Z-OJ Y&;>Y+ZWUCMGF5R,V+L'BU$7&E#J?<-&>;PFK/09!^?\
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JT'$30/J3^C_$.(FH?K_TF_ZXB;@^O](_WGQ$WXB:!]/Z3?WCB)KB)__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g129231g24b13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g24b13.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1VZ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '9Z^=8(X0DE-! 0      $(< 5H  QLE1QP"   "   < E  "')R,CDT
M,38U' (% "%-:6-R;W-O9G0@5V]R9" M($%#3%@@3F]V(#$W+F1O8W@X0DE-
M!"4      !"(I_Q8^.6%LSJ+P9N2=X]_.$))300Z      #E    $     $
M      MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP
M<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P
M  P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M    0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-
M!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M    0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N
M0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M     $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M    4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!O
MX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M            0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL
M0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G
M4',     4&=00P    !,969T56YT1B-2;'0               !4;W @56YT
M1B-2;'0               !38VP@56YT1B-0<F- 60           !!C<F]P
M5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M  QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M       +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU  (
M 0.__C4  @ !.$))300F       .             #^    X0DE-! T
M  0   !:.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@             $/@  !V,    & %, 5 !?
M #  ,@ T     0                         !              =C   $
M/@                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $
M/@    !29VAT;&]N9P  !V,    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P  !#X     4F=H=&QO;F<
M  =C     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MUSAD.#QWBVFVG]#8_P#EU,]BV,+=Z7NM]<SK< !NT;[HK]BS^ITLP^JX?6&
MASRW!RSK!IM)^SN<WZ+?1S7U^_\ T=UJ2FJ]G3+#ZK>K.I:][[0UF6UK='>F
M_:'U_P W79O:KG2ZL>K(<<;-=E-(V.J]<7-83N<'[0WV?S/IM5P]*Z62TG#H
M)9(:34S0$E[MOM_.>][TJ@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M6%EQ<['7\"6!D:&SV"8U0GBWP=$H2%)6AI*8U/'_Q  = 0$  04! 0$
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ME(./5*S %6C27D$S!4;&IR:8R&VZI@?R<7C&,X\R$2S&O&0\ZUY;1A4@R"M
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MJJ-JDZ4=C(<R9GG@+_9D;$".!; I3TJ"5##L3(DF^F8@!95C)TL_B#!5+?\
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M#!'J;E2S%E_T3DG$.O::&OR<'Q%(: ;I9#I)+(FK,70"*5(W<&OD@)/3D?5
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MU'UW7(.>2$[CTO"L2PH*3Q1WD_FOM#/M(>1YH=PM/VY>6614>)781R=?(@)
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M H-UB0LQ&!!L.33J/G_N*,I?QG'GG':O T%:L8D\%.22:I$%"K5EE=I)9(
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MB*Q)L/!GQSAYC#@CQ90XI"R$M*7Y)<SFSHL<TR(RLB2R*C*2RLJN0I4D D$
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M2LKJ@+(0+(8T9K7.//$7-YQG[XSB[7?RSC_#_=%S2YO,?D+UM_BN;_TVN_\
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M8MS52P=F55:$P.[*_4REHH*WGM310/>EB\%2K=E=%AMWY..C&V,GQ"013 =
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MTDCL=*B(I9F8GV"JH))^P&9%2K9O6JU*G#)8MW+$-6K7B7M+/8L2+%##&O\
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MI)PTR*0>J@)([]0I PJ;&:E':E.F::K6"HI97ELNZ*YT0RQ$1.^P&))1%!+
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MES2B:UZ@L=2HYOTIZ?\ 32J3LUFX.2-S;8@*)5L="%A C,>QN5]9A) 5K</
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MO#7%<!WYIBK:GEPMK]>XW=UIU2[34F+!F] VJ6NT"UJ]VQOO,9MKH4*=)O\
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M&2<A0HS2\?7NLL+F*U<ZBO7\4=B&69Y75(8G$DA5??*8_MO_ $D__G&XX_\
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MU\S/T^?AKY!MFC6Y4'$2 %PJU6DF9&RCMG0[Q&85T"+/:DH^8EHUW/TL=QT
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MP!^QL$Q4=DR&YB[3V4N&]!]DV^AV08*.B55#6DZQJU.+E(''PHZ2T09.(.-
M6M_R_7Z_QQ_C_P O^/Z^Q^^?GX,!I,COGQ9#3=R0O8$I_MS2%O;AKL?5XJ%O
M"L:1J"<28$?2RC*N,TRE.(]2(@EUA3H:UKSA]3J<,9OQXQCC&.,8XQCC&.,8
MXQCC&.,90KK!^^R\1_\ GGT5_NLZFX'_ &_\\9?7C&.,8XQGA6,*2I.?/&,I
MSC/E^GRSCRSY?R\@Z((/T(._Z?? ]B#^6:"NG?7CP]:QVVBIC2/<396U-GTF
MW7GX&H),^N%U:%L]>A-CUB6BRW8O5T%)_+HL3L6\ ,!R-K<)2H["I/$B0,*I
M%=)BE=O"/+&]0+Y&_P#D^G'53*NBH+>+C:<!T&"^-CH/V87+TKS6'-@^.0V>
MS1J!H2--:N^,CYB!Y;MB8;;?610&*  [S[C=J=KRO&VR^VFO4RKQJAD2%AM$
MP!!0H2S"60@T$R4F^,(RX680P(,VMW"WR7FF&DK=<2G-(]V1![M(ZQQK_:>1
MV"HB#ZLS,0JJ-DD@ 9;^S-]D1G<_940%G=C]E502Q/L -G,,LBL*V[JI2<X4
ME5=V4I*L9\\9QENH9QG&<?;.,X^^,X_3C@@@D$:(]B#]0?R.0-'W'N"!H_8C
MWUH_K[9+7&3CC&.,8XQCC&45[Z:/!V1J\'9L= +G]@Z#DVMCU6*;2TINSQ,:
M2&_=*5)MJ$+<+C++5QY$;###62$'H#>&PIU/H7J.3IUWEH\I+"TTO$6%M(J*
M'=HB5$X53HL\: 685#*?/!&.P4L#S/J+B:-E^-YJS5:S/Z>MB_%&D:2-)78"
M.[&$<?O'2N6L5U#*1:@A(/\ $&PCPN+6O]C>1HJ2E'9:?ZJ7J?T5\]_+BER^
MO8YH&W:,L8Y#N<K/!G=(VN@$,R.,8;)*:.0G*EL.*SO9^OE9HSN.7][&=>Q6
M3YO8@D$*25V#KVU]O?H8'[Q(W96]M=E((8#^%QK[.O5Q_)A[GZG9#RSEW'&,
M<8QQC'&,AIC]\')?S/1'^V<QQC)EXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8
MXQE3.Z5>.G]'32(&,9D[<P?&MU%!$C],9'F9 IL%LEQ]3S#2O::><6AMUUI*
MG$H\W$8PK.>T]!R51Z@ACY"<5^-DAF/(,4+]J\2&3KI59AMPH[*I(!.@3K..
M]<_%)P,L_'U7M\C%-"M**-E5C+*WC)^=DC;2EB!(P3>BQ WD9=-M7]G]3,WZ
M8[&;,$LU5.CH=5)JR) B8,J#$:R\Y)./&9$8:S@U*TIP,R\8K"F4Y2ZG"O;Y
MM_7O+^C>8?C:_I+BY*MB&69+MLUTK)=,A5(NJ>625F5E)+.$V&WK>\T?H'CO
M6?'I>N>K;:B&Q!$U>@]WXV6DZ/([DO%#%6C0QNJ>.(R'LGU UM79>Z26UKG7
M9FJ+FJ/L?$JW798F 0#-5MN3&>:]Y1WMN)^)EI:GGDO/)+;4G"D8QG&4<P;$
M2U:%&<6_'-QOA>6&*4M#.8I%?H4!4EOJ-]2/?1&;6"2.W=O0+6\D7(++$D[Q
M=9(_(C+W!8'V /OH]O8$$92#0%!U!UC[$TG3>SM.5&<OULLKRJ#L4LT>PROU
M!A+CC!PS)3A:0UA(SEME:D,%A8RG#*L+SZL]YZF]0^J/5W"\ERE&]>I<'5JJ
M;-&O$U>J8M@=)Y56)YG<Z+>[QD[U\I(SSSTSZ4]*>D>;X^MR")RG.VK)@J6;
M5IK(@FZ=W^&I*SUJR@ R@O&)P60ASU0YO?YX-GO>.,8XQCC&.,8XQCC&.,8X
MQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQFB_QJS+D%&];78G;0=/
MIF;+L-5NUHC?.[-%3^S"AJT =!RD3)=>]8[,V/+A:YP))6&<\X\6KQ()'S9M
MQ+F021H/_+W_ "_Q_EC-I?4UW#_6;11"9N.LJ"M85$IJP1&S9[<\7-,E1(Y#
M$F!M>T!1UBV *8RXA]FTS0 DE+(7@DH=IU2D8G&6%XQG4SS1+\',LA1L=,F/
M14BT)$3#WQXF5)<$>2Q&RC_Q)#V(XYW*!C7O@F^V,ZZOXA'I]E;&:+O!MCK)
M$=@O%ICK=KV@:JL0O;NC-RFOM6RN9NA5DC.CJ<O =<E<U:DY,#=:4V8XYFKQ
M&<%$D(R.O*??=8S?/QC'&,<8QQC'&,<8QQC'&,<8RA75_P#?8^(__//HK_=9
MU-R!]_K]?O\ X_X>^L9?7DXQQC'&,9_1GR^^?X,?H\^,9JAJ=M[(2?=NEZG;
MU?I;0M8A)"^]AMU#Z^V?(6FP[CI%C@+-JVES-CAL:<J\.B;-O E<F)3UW%^9
M&Q7VL.X/%0AURNJ2R3&4'QUJHA$(^9(;=ZP+$3*3U '6MR#,5W\TGS*"ZG*K
M "@>,%S/9!2P_P KM#2C2.52H+GW6Q40!B %7Y3I",N3V[ZWP';'05ZTC.O1
M,<JTC!.0EBEJ^-9DU2?C9 8Z.L0$82^+C,F![+J0B62Q215OY=8?;6G[VBO[
MRM*/9J]NI9!^A(K68YGC!'NOF1'A+#>ED.PP^4RK +.A'99ZUJNR[]O]8KR0
MJQ'T;QNZRA2-$H![?4<XNHIA=YZ\EL6.UR*I&O[)RJ+E)ITN# \FJECTQ48I
MI+8+:?/&$-H<7A*<8Q]_+SY6Q[,6UK9)^OTV?I_/ZY:1>JJOU*JJDZ^NAK]#
M[98?D95CC&.,8XQCC&?D^PT2P\,^VEU@AIQAYI>,*0XTZC+;C:TY^V4K0I25
M8S]LXSG'(8!@5(V&!!'Y@^Q']^0RAE*L 58%6!]P01H@C\B/8YIQUB,GJ)W"
MC09I2H^D;A3'=;[%*EJ>P,]8J_B=NO4VYGEJ<;$:_$%'D;IU](,('2\99J/2
M(-LU]2@V,T\5NQ7L<<RM\7Q0ZUQ_\O053(K+VT7(@[._39\L%@:(&QS7'66H
MLU";2)0L1TY692 ]:9%7B;@8K\W= E*=R0@LQ/[[WFY/E>=-CC&.,8XQCC&0
MTQ^^#DOYGHC_ &SF?X/_ #_[N,9,O&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC
M'&,HEXA-WL]7T7BO4BCE7BY;#L4=4ZV,.0D1$3)/>LI,NM]S.&L.BML.9&;(
MRD93N?60K#3:L9]%_#/B:/)<]-8Y+D$H<?Q5*6];+?6Q"I6,P[^JH2P,A3<F
MM*@[,,\^_$;E[?&</6@H4GN7>4O1T:W4,Q@D*M()%10?))\FHU;48.W=@JG<
M=:!U/V-T[IN\5G;NT2]AV+83;&*)%@D9DY:BX< 7\L%R4+<8%/##4M/N.@M^
MWA6$X9PK"T>6S]4\MZ4YSFZ$_IOC/V96XL,+\\D4=:"\!(!',D*F297?W'[]
MN[#W(#;WJ_2]#U3PW#WH_4]Q+=CDBIHU(;4E^>H=2>2)Y_%7A*=/$Q2NAC23
MNJR.O4FPNJ)G<-IUI;JO: $Q5PAX4F%A+22&_%)D"WP7V!"GV,X5C!(V,-N/
M%B9PRIQ2583A6%9SQ]Z+C:/*TK*O\54>Q'9L5DD$G[M95=XPX^H?1!4C8]P/
MMG859.0O\9>KA?@K(KR5ZUEH^K)(\16.7H=+N,D-O>CH$CZC-5_4.D:)U+VI
M%JNV8 NP=@U2AKE,NDS<W++E!<AAS+JXZ(0:^+E2TI(<1+92Z^-A;R<X;\LJ
MQZUZS]0>J_4/I^PW&5SQOII:R/:K043"KUHB HEMO&K=%(1?"HC#,!_%[D^3
M^D/3GI?T[S=,<ER+<ISC61#3EGN1,B7G$I=X:D))>:0EB9)9)_&/91'K0W^\
M^?<]]QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<
M8QQC'&,T)^-K<A:?(]4%PTY&:QV5-36WHBK;R,WA=]./TVO/5&*<N],4WKG5
MFY;/8XW8L<@00IUVC9AX J&!-58(2:?A7'V,VG=*HJMP?4GKK#4^-J,/5XK4
M=+CX&,H4U:K'3A(P2''8%;KL_>(>OW":C<MHPMJ4LL)&31REK)/#9(<6GC&6
M>XQF/6[ BJI9DR#4X^!FOS.#6:QF139'A,QQ."6J^J'<:EL3;C/K3%9BW6Y'
M!V6/A+23[2L,9H0\#AJK,[:\5%NE1FYH>KI[94G$1'=A';\]N04?\BM3RI%Z
M<V@=)7U<GE_+JV,V0U\WZ<L+"%X&PPE+&?0AQC'&,<8QQC'&,<8QQC'&,<8R
MA76#]]EXC_\ //HK_=9U-_W\@#6_ZD_K^GT_IC+Z\G&.,8XQGJOS]*O+/EGT
MJ\LY_1C/EGRS_P"K]/(;Z'WU['W_ "]OK_=@?4??^7YY\SWAF:ZLVR.TKNV:
M?-:C/E=([.W;&=C]RQMF["C[>[&US9:KY^ 69*K;'I4)2IO78=A9C#:Q/P$O
M(04>3KXD&J?&&P^V]5QY"T(Y0"()J$53HNR);J+Q]OXN82=9%EDBF:PCLI=H
MKP';HQ5;O(DF[8A,95TN_$Q=AKP5>UNN:T3+N-TC>/X:1%;225MD!P&/TQ\C
M+61-9O[[^J_\GME__#J/&1]S_0?U^_Z']^2SQDXXQCC&.,8XQCC&:Y_$SUL]
M.=7=S; @&8U5CJ.LY<PI$J0:((N.K1;%P@K&(3'N-E!6_65IBP+[191G/NBR
M\<3'>IMB8?>:BM!..5X^Y37O82:.*6$-T-FL9 SQ*Q1P)EVS0=E*LS-$^DD8
MC0\S0>4BY7>%)5B^%N"P7$,_'R.&D#% 7$U5B;%5E*_.'B+HLI=:K^%%XAFV
M^WEQV)1-QSVM'#*=1:E+5@2N1N82RV!UTPP&=G2F7[!(HD1LMHC7B<1D<**"
M0:A?FADH=I.6\<CP23BE-$@LNC3 /X(R=:K'L#U>,[!+.6/T(!'OM4DC22*$
MW(I7:$=8V:/S2%/9I@5(#!A[LJII3[@ZS>!S%S)QQC'&,<8R&F/WP<E_,]$?
M[9S'&,F7C&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&1MMRN5FR4"R,VL')T7
M&19\WE*%Y9?9>BPB"DNCO8QG+3OI0MOUXQG'H6K&<>6>;/A[5FK?@-5PCSNE
M9^X+1M',ZJRR*-$J#IO8[!4$9K>5K5[%*8V8V=8$:PG0ZD5XD9@8R?HY&U!/
MM[G>:9.F&MNWE]E:UV%-MSXE+/5*NT>DRIJB(R-C5&.BX6A"D94J+>']:&,N
MNN&$X2MQQU&/:1CW#UQ;]&\50D]*M523F:I@EY#D8%Z%Y9(_(T(&^SLH90![
M+$-'YF+9XWZ1K>J^5Y6/U1%;=.$L+8JT^.G/=0L4WC\^B52$!HY%+!6><]M@
M1JI;<%N.2EV-96J&@Y6(8ODG4Y%$2(_)"QA)KV!<-2#T8@AYMSW$-K=^.[C&
M6V7E,X<6C]./%N%1!R=6W)4FL4:UN)YE6&26,?/VACG* @*[A5()!<; WGK?
M.2H>.LTOVA!1N7*DT4+M/%#/HQE9I:RRL"7B1F<,%94(!;0S7'X?76GK7*&B
M[]A*I8E[BI)\O6I28L%J/L(8\R0PL20*CVG75AMOY'6ZSA"<*^)E:U-_G+PO
M'H_K_P!:^K+,#\)=EKUN)Y!(YUHPT4JR)'%+V1&9E$W0L%8-L>1-#Z;&<#Z'
M]'>EH&J\K2$]V_QCR1+?DN_$Q2S-&T3RGQD0M(JLZ: U&?<#MHC;]SQ[/6<<
M8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC
M-(?B37OK!,[\TUKS?0W?S7=UHT):[/JW;74BI;7>C)&/M\0P%<8<FTZHK5HD
MR766X8(*1@7!4K%<>"/+80(^*9AC-K77O->SI#5F:G,;(L-:S2H/Z'-[@;L3
M.T92-^&CXQM]:MT?%69NSO-^2I5$Y&A222<KP2,TYC*<,9,7&,ZN<R0F%EU"
M2@L&7B,/R+-',-E!1!&!7<LR9@SQ C1(H#GI*(8=*&;>::6VLAE*LN)8S1IX
M.SL\_P!BO%N=LVRJSM^=7V\H^9'8].A(^NUJT/8T=3L)-BH6+G;*  PRUA 2
MFAYR02IX5UQ;J7%K:;8S>_QC'&,<8QQC'&,<8QQC'&,<8RA75_\ ?9>(_P#H
M_OSZ*_1_]UG4W_O_ ,/('W]_N?[OY?\ 9_+_ !+\OU]S^OOE]>3C'&,<8SQG
M&,XSC.//&<9QG'^'&?MG''UQ],ICJ#P]^H>@]G%;BU#J1NC[".<DW#9B,NFP
MG@S/JZY)PMHFNGVLRM/CH=F91T 9R(4Q%.'DN1C8BW%9Y,1,$9AB^6,HJ=/X
M@%5(HUUVV0PC@BC# AO'&L>^@UE4S-8D\TS%Y.[/V.A\SO)(QTH TTDLCE==
M2[%M;).>G>CLI:NK^IH:Z4Z-IY,Q.6UVOXE=@DR(E*@1X^E7*\//3;\62$6E
M^?S3T4Z!])C",6*R12U(,]&(\O&GF,+1Z0R K8D9%.I)!7KRV/##[,/-,8Q'
M'M6&R3U8Z4W881*'VW31A0,?=4,]B*OY9/<'Q0B4R2D$'JOU'US)JGLY.R+Y
MHJ8=J5NJQLSK6T6(L*>@)$$,%^=@Z-*N1C$J4.P,>]'K*4(\MC&/-UE7FA.?
MS<9UF(06)X5<2+#-)$''MW".RAM;.NP&];.MZV<PJ\IG@AF*E#+%'(4/]DNH
M8C?WUO7]WV.QEK.6<O8XQCC&.,8XQCC&?B0..6P\*6PR4,0TMD@8AI#S#[+J
M<H<9>9<2IMUIQ&<I6VM*D+3G*58SC.<<D$J0RD@@[!!(((^A!'N"/S&01L:/
MT/\ ?_SS7/N+PM^K^R@HE^CQ<]UXNE=L9-NKFQ=$2BZ/;H2Q%^[[TF$>)A2F
M'%I<2.XR/D<<F,99@S&2H)M,;S#-:6*1IZ-VW0G8RES#*9*\QGF:>?XFG/Y*
MT_ED=V8M&'[-L.- #06?3M-Y39J23T+/=Y2T#]X)9))I)W>>I-WA=S)+*1*@
MBG3OJ.9%50-4O<W3'BQZ_NE-K5&W]V'[)086O"QV;[K>FAZN,::^N&^U&7MB
MCS;%>M%_P.AMU-E A*VIV,^(PL+)&7R7]LL]DP0['&(YN#9BAZ.SB- LDT<[
M3"*MOL66,B$OLNGL!F;!!(CRK;EGG/@"QO&LR1^,LY8+UDD?XC>@&:1G$80"
M399CLEE-D^(Q2NN#)(^B-1FGPFB?G'7*7[#6Q&SHF=C:8MQ^5E*=(:!EP9>W
MAO,?42XI4X0,;-X7'++=:4HI5Z)(I+ZK,8V[VPICK*/AW#2C01B\?2!ME=@[
M5?<>VM908)48DSQA*K,CN%>=7"'KY%)]W&ML??9]M;V<U-="^\GB:[#W1B#8
M$F>S/_%C,2CNO]IGUK0==1\>3KK2+?B[1NG9%WZZ(LM83%:4TPP</(&$8PA<
M8G"LMJ[&"\URC%02.U&(IT2;NKL7#5(U:5A)$$!<R%69>@V^Y N8T,\'Q%58
M[<]D25W+HC0O[+U*3R$B,(S.Q0*#[_0*0A.3IWC[Y^)UIRS:YCG-.4_KXF>@
MK1()C*788_LRU:E11T,A1TC+.ZUJ_P"$,P[9*FFXY*"\S31SY.7&,1WYV(\"
M"HTM6)K9%A(WEU(K1=D8I&(5;W$S>QD8'1 5?<[.4\T8LJAEDB!KR.(95B <
MJP#2"16?WB71Z; T=G8]AM:ZC7FW[,B=.[!OYBY"[7+JCKRPVDY<*BN*+G)*
M?DB)!_,"VVRW%>X0M:OA(9:0SC/H2A*<8QC%M)X[,R&$5BKD&N)#+X3_ +G=
MB6;7YDD[]M^V55W$D$;B4SAEV)B@3RC9T_50% 8:(T """!HY>KEC+V.,8XQ
MCC&.,8XQCC&.,8XQCC&.,8XQCC&<<L08\4D$QELD0P=X4H=U.%M/CD-J:>9<
M3G[*0XVM2%)S]LISG'*E9D970E71@RL/JK*05(_F" 1E+*KJR, 592K _0JP
MT0?Y$'65,I^G]J:S*A*;0;(&'J:#FG2HJ)-4THJ*A5$9)Q C^D=3SD;A3SS;
M#2WE*:3Y>G*,>G">OY'F^,YEY^1Y*!FY6U71;$D2,!)82)8A. 6"+(W16=M:
M)WKZYR?'</R/#K!Q]";_ -&5[$CPK*X9EADFDF,+,$[F-#(41=["A=DZ]X\[
M ]$Z%V2V4;9KY;=J!N9K; ,257+&U#@00^",H(A8U+ >598,SC)I33^7,O.K
M<4\MQ.6T(W7IC\2>4])\2M#C>/X5U-AY)FL5I)+$[$ K+,_E 8I_!&5 Z :'
M7>SI/47X;\7ZGYG]I\C?Y<LD*+#76>%J4*@,A2&*2%FC[;+2 /\ ,Q[$;))L
MKH/0FO>M^NHS6>M@S1X*/=>+>*E#%R$M*2).<9*D9(U:49?)?RE/J]*&VD)Q
MA+;:$X\N<AZB]0\CZHY6QR_)M&;,_4=84\<,2*-+'&FV(51^;,Q/N2<Z[T_P
M''^FN,AXKC4=:\1=RTA#22RRN7DDD*A5[,Q/LBJBC050!DT\T>;O'&,<8QQC
M'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8S6%XD_4
M79W:.+U(=1WM;VJ UK(W8RUZ<W'>]G:TUO;'K576X2"OIUMU.M5C;L>K'TF2
MU=C#PR88Q4H<_@B)EPXN3'8RZ/6W7UGU/H#3>L[IL,S;-LHFMZE5K#LN0<>=
M+N\M#0P@1EB=>))-+?Q(NM*>;(,,+-(:RAXPH@E;KRV,FSC&=18$*<@9MM$*
MS8U.1,BA->(6(V/.J4&\G$,^L]*@4,R><_"=68E0J4/JR1C+.%XXQFBOP9Q7
MPM_>+.(3J")T*^SVYHZ7-1P1=7.BJ3G.D*>K$:&72V!ZP\V\G.)!68EE#&'#
M%I<QE_#JLL9<+1WB;ZPW1M.KZV(U/N/6T;LO8.ZM6Z;V9=8ZGNZ_VI>]!35C
MB-AUB&-K-NGIJ F6&JG89B$"M\)!9GHB)/(CW''6/86QF0[$\2;KG2>SVNNK
M$=<*W9[U.V38$)M5\:?3'@Z2"U_J">V])2MM-* S#D9;BH@,67CF)A@VNMS
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M#'4MD4B6)&<.=';<<2TI[*/<<SC*U9EF59[$TR)XTDD9U3>^H8[ )  W]SH
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M"NCNOU_S_P"[\_Z??&3_ /AOQ1/XW>C'ZBMZ?^/'&,?AOQ1/XW>C'ZBMZ?\
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MUZHB],29VN]IUW:S=&G:9$[(V?%;WM&:H93:<U0[=8ZC4@:'7&]A6O8TI%P
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M)YZ@N*CK"':&0E3^[L(G>:L2 0T\(_VB(6*^Q^A4FXT3+14_%QTY!R0$S"S
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MU3QW-1VR/&DE:+E&L3!$D'D6QX)BUCOXE*5*\<1GD8I!-7BU=.O$#[,[0W'
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MNVED42QNLFT;YU8XTT+TN$FHGKY?4WJ;D4W&Q"OP-'D)N6LR=6\<GPU^1J<
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MU9PE"$)QE2E*SA*4XSG.<8QG/(9E52S$*J@EF)   ]R23[  ?4Y(!)  ))(
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M'9E(+(CU#^Y$F6'3.T=A,0,^XR2@AJ&FV@GE-)=Q[GNI2VJZ$^7L3U]M@$,
MX#!3XWUT<@G;*&#!??7UU:9P).B[<;(++H=?E+ R(Q$B!M$*2ON1K+B<HRK(
MEJ/]]7;_ /V>OO\ 4!G&0/O_ %_R&>=W:8I._=<S6L[\$LR!F%@E86.M+)H$
MC%F,GQYX)"D.>R0P0PG"LX3G#P[CXSF,M/N)S@<GQM;EJ<E*VI:*0HP*Z#HZ
M,&1T)! *D:.P0REE((8C-3SO"4?4/&S\7R"%Z\QC?:$"2.2)Q)')&Q5NK*PT
M?;W4LI]F.<W4MF>LE/':D 4Q4]5SI"F62*2A#+8<S6",QCSHK*$HPW&2HS0D
MW#?N;?KB),%ST(]?IQ/'3F>L ZB.:!Y*L\8'4)+78QD@?9)559HO8?NI$]M[
MRKAK;6J2B6,0V:DDE&U"  $GJL8BR*-:BF0)8@]AN"6,Z&]9)G,[-KFGOLUL
M>J>'EV;USO=T@F!TIV.F#:#NNO1%?D)5G-A K\S-5[84>/$"OK&E:X4 .$>R
MXA'U2MV*9PSEY^!C1,=',PY?BTMSS1"_Q8BISR32I&]B@=_!2-VTT\]=@]0D
M=Y#7^'!^6('.7IP-PO+V*5>"4\7RHDY"ND4;2)4Y+N%OPJ >M>O91HKB* L8
ML?%L/FF.MD6A]\:V[):VB=LZFE3IJDS1TU'1Y\C"RD 6X5 2I4-)H7&3(H9[
M26CPWT-.K8PV0WA+[*EM+0K.BFA:!PC-&^T1PT4B2H5=0RZ9"1O1TRG3*P*L
M 01G1Q2K,I95=>KLC+(C(P9#H@AOJ-_1AM6&BI(.\F+EG+N8#M2A";3UO>-<
M'F-QX5WK$Q623GH&N6AH1F7"=#<?=KEOBIRKS;;:7<J7&3\/(Q9B,98+$=:6
MI/+4\7FB:/87MK3%$D (8,-HX*L-J-@C^8(8 B[#)X94DZ]NI/R]F3>P0?F0
M@CZ_Y$$$@ZH-;>#Q%Z;JM.5J;M3MJ@[>I%XV9:*[L^'J.N'X&O5W;M9K]4O&
MNZ?IR6A)'7-.J)@-6@Y>-$@H\=<5:Q7YQCU(.*CW+I+[CZL5U7GJ3-LO)-7G
MLPV^@DD[-%XIH(F@Z[$05ETPD?+>P1*'57[3PV81H(D,T$,M=6\: +(9(9Y4
MG)"F0E""H0+ENNOG0G3^BKIN+94DT%MS9>X=BN;"D=E;#IE()O\ "O%:WJ.M
MY*&C;1&P89K<=*@U=^3.9$Q'BK,L$NPT$T([[:A$?@^'$:(ADO.X4$=UO6))
MWC?9)9%$AC'8MV4#M^0,SO,LS2,SI#3B3L0>IIPK$DB@ !7;J'/4 !OI],[#
MH_T:U7T/H%YU]JV1L$T#>MFV389LG9R$ER@ ,@@.*J-'"(QE64U?7=0BH:H5
M856<9'BHU"E)PZ\[E4HS+5J52>PJQ%#*WO)8D) ,\S:':9HTBB9O]R%!]LA]
M/9LV=!38D["-?:.%!MO#$O\ 9C$KRR@?9I7^VLNGR,8XQD6T;^[7</\ E= ?
M[!5;C&2EQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC(OVW/2<15F(Z!,^GV*
MWS<33H(W"4K6$9-OY00>VA6,I4['QC)YK6,XSCW6$9SCR\^;'BX(Y;)DG7O!
M4ADMS)]G2$ JA_(/(44_R)SG/5%Z>IQR04Y1#>Y6Y5XJG*?K%+<DZR3+OZO!
M66>91H_-&-@_0PQ=*C7I0RC=>*>TC(H$W7M@[)*]62#!*]791$R [+GJ2MQ^
MP6^S AX;40Y\I\0>2*\L,H3S9UK4Z+;YNT?GDAGI45T C3SQF)Q''[!8*U=G
MV%THD,:^Y+9RW+<50LR<1Z'XM$\4-RCS?/R:[RQTJ5D6X6M3:):]RO(01@-(
MWEDB2Q)O0&[;\YO/3,XIPK9P90;OJ]LIAUA>4JRE6,.HRCU)4G.,I4GS]258
MSC.,XQGE<;F-U=?JK!A_/1^A_D?H?Y91+&)8WC;Z.I4Z]C[_ '_N^N=96C'#
M80%U_.5$-(6&3E7WRHD%U8;ZL_PYRMQE2_//WSZOORN= DSJIVN]J?I\K ,/
M^!&40.7AC8_4KIO_ -)25;_B#G>\LY>QQC'&,<8QQC'&,<8QQC'&,<8QQC'&
M,<8QQC'&,<8QQC'&,<8QQC'&,<8S2AXPFC]G;P_8\0]3T#<]W42(,VE(7IW5
MNNNMMWV969G-:C$:\3%&]EF3JQ#5>7G\/)MS,''YF),<$%*RT"#.B&/U^O\
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M2Q++^7:)=@Y-:5)6E*T*PI*L84E2<XRE2<X\\9QG'VSC./OC./MGFT^OTS?
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M[Z'EI_A5^',/JV6K!9];>M)V7A5FC,MFMQ\CE$GT"TKPE>UN4(5:U)+7A.]
MC85IK95JO^OH1&DFJA-PL8*D>4N]OEB&LR<\OS(EUM5:&;(F U.R#Q"\8F7H
MYW+?EEMA:?2K/+\K5IPW99>3DGBEG/>.E2B!%>'76)7GF*1G2*NQ$K@$Z)WO
M7T!Z1YSE.6X.I!Z4BX^U6I*8+?,<Q9>)[-_9DN,.,JK+;@+V'D<?&- W4CK&
MR%3E;=V=O(Z[:_VYI89%6.V_79J,K$A%!GS D6:P0^GY,K%+DHI@YDB)D64
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M]A*O2XI/DKDMQD%2M&G(\E!4F\S2M6A[6[2CHJIV2$B.)P0P/>5678^7>]9
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M2EN.+5E:U*RI6<YSG/-#RG/\\G)\DJ\WRZJM^XJJO)70JJ+$@"J!-H
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MM_"\);I.C?\ LO"SHWWZL=$?7-/Z@X[]K<)RG' E7M4ITA=?9H["H9*TBGW
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M=@0B_4EBVMW^*_XG1^I;L/IC@))&X"K92.Y-!O\ ]*V8I.J1Q1H"STX2H,2
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MAO.80M:9:O%$\$<U@1O)LS:C,@KI_P!6[%6^?O[[51V37N#L907GU*16D'0
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MH[4E">.Y\)(H![):6%JY&C_M!L,-@J9:]?PVGXN^0Z!:Y0<5C\6('S_8XD.
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M67ZCLV_5O6E>SZAK-=B*Q<OQFK?"2QCH*DM8%HZD6M=:MA :T\1VLB2%G#.
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MBI*P0Y6#1R$^\*P46G/J0_)B"N,CR2VU9RI&3$.XQG[^6<\J+NR>,R/X]@E
M[!&(.QV4$ Z/N-_T^A(/;<1^(GJ_@^/GXWC>8EA@FA:NKO'%/9KPN.KQU+,R
M/-61@-%8G7^6CE>>SO26'VK &ET61-@YIE&'\UI9"EUV<2QC*D@^VXO"HYWU
M?GB.MN>RR3A.<(:2I:^9*7K$0!CZ]@.I)V"R[WHD$:93[JX]Q[@[!SL_P_\
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MX2A"<82E.,8QC&,8QQC/TXQCC&.,8XQCC&.,8XQCC&.,9Q3C18T(N1->0.&
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-C'&,<8QQC'&,<8S_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g129231g26a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g26a01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[15*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %2Z^5"(X0DE-! 0      $(< 5H  QLE1QP"   "&  < E  "')R,CDS
M-S0X' (% "%-:6-R;W-O9G0@5V]R9" M($%#3%@@3F]V(#$W+F1O8W@X0DE-
M!"4      ! 00;859CNK4%3/IR8'E ]0.$))300Z      #E    $     $
M      MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP
M<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P
M  P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M    0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-
M!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M    0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N
M0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M     $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M    4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!O
MX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M            0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL
M0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G
M4',     4&=00P    !,969T56YT1B-2;'0               !4;W @56YT
M1B-2;'0               !38VP@56YT1B-0<F- 60           !!C<F]P
M5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M  QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M       +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU  (
M @.__C4  @ ".$))300F       .             #^    X0DE-! T
M  0   !X.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      ,U    !@             #.P  !H           0
M                       !              :    #.P
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   #.P    !29VAT;&]N
M9P  !H     &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   SL     4F=H=&QO;F<   :      W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    $.$))300,
M  K-     0   *    !0   !X   E@    JQ !@  ?_8_^T #$%D;V)E7T--
M  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48
M$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+
M"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# S_P  1" !0 * # 2(  A$! Q$!_]T !  *_\0!
M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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M9>+RLX3#TW7C\T:4I(6TE0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M-T%7U!@C)&%Q@967U_ E,U166)&6F-4F)T*%AO_$ !P! 0 " P$! 0
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M!9-P_66M^_TGQLK$:OTOL_X+<_T>F3#D)ES 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8'J$'>V#%Z^T
MW7=[9M5W6FK7[G\2Y^X2Z5_#M_Q*[9O]^M]G[M'[]P@C]YUS]ZLEQ]KOD*V
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M^<*AL@']F=_O<U_%GN!F\!@,!@,!@,!@,"'I?_I@IS]W69_"063</UEK?O\
M2?&RL1J_2^S_ (+<_P!'IDPY"9<P& P& P& P& P& P& P& P& P& P& P&
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MO\O:MAW#[\,S17=..!GYT5Z;-N&W)@N0314=\\?C' 28!_9G?[W-?Q9[@9O
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M_)^/ZU]H?W(D_P#%\4RH/++Z V[X5K\EU"MNW7I/L[^+;Y\;9WV 9S<U@P&
MP& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P& P&
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M_%M\^-L[[ ,YN:P8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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M# 8# 8#ZZW^K?UP& P& P& P& ^NO[=8# 8# 8#ZZ_MP'UU_;K]?T_Z_[/\
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M+II*U!?(7;+F+.4R>B>^M=M^0W[S1Z>A'J:@(_Z0@0.6AZ_EG,R>1I*6,1C
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M;1GPM)9$ZZZUKI1]))&N5//U>]?;5>$5U._KUUOZAQCKOP?["I'SW\=5@0J
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MR*CG7/7;5^.=(/63GCCOI/KINZ;**H+<\J<=I]=)J=:UWQUSO?VN=ZT'O8#
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MX-TI&&T:;#%L41MFV9(C',4YIQDM:_L>/96M;SS,KZ9KS8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
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MOV56[Y:SBMV5VWIR1..W7N.?'7IO[&W5><416.)GF>:\>?JCA4"A/6OMFJ[
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M!R(%OS#>'3.)QN2.6?W9R/O6+PDS>A>W 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
M8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8# 8#
38# 8# 8# 8# 8# 8# 8# 8'_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g129231g28a04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g28a04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2BH4&AO=&]S:&]P(#,N,  X0DE-! 0
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M!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M  # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0
M    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24
MT$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P
M    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<F
MY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M      16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M    !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&
M_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M            !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&
MQ <L            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&
M=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G
M1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R;W
M!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M  #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M        MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ $L     0
M " 2P    !  (X0DE-!"8       X             /X   #A"24T$#0
M  !    '@X0DE-!!D       0    >.$))30/S       )           ! #
MA"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F
M8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0
M    $ +0    8       $X0DE- _@      '   /____________________
M________\#Z     #_____________________________ ^@     ______
M_______________________P/H     /____________________________
M\#Z   .$))300(       0     0   D    )      #A"24T$'@      !
M     X0DE-!!H      S4    &              'K   &#P         !
M                        $             !@\   'K
M        $                         $     $       !N=6QL     @
M    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M        !,969T;&]N9P          0G1O;6QO;F<   'K     %)G:'1L;V
MYG   &#P    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M 2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W
M)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M!4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P
M    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F
M<          $)T;VUL;VYG   !ZP    !29VAT;&]N9P  !@\    #=7)L5$
M585     $       !N=6QL5$585     $       !-<V=E5$585     $
M    9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6
M-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4V
MQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M 115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M        IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M         X0DE-!!$       $! #A"24T$%       !     0X0DE-! P
M  'BL    !    H    #,   '@  !?H   '@\ &  !_]C_X@Q824-#7U!23T
M9)3$4  0$   Q(3&EN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W
M-P35-&5     !)14,@<U)'0@               0  ]M8  0    #3+4A0("
M
M   !%C<')T   !4    #-D97-C   !A    &QW='!T   !\    !1B:W!T
M "!    !1R6%E:   "&    !1G6%E:   "+    !1B6%E:   "0    !1D;6
MYD   "5    '!D;61D   "Q    (AV=65D   #3    (9V:65W   #U    "
M1L=6UI   #^    !1M96%S   $#    "1T96-H   $,     QR5%)#   $/
M  " QG5%)#   $/   " QB5%)#   $/   " QT97AT     $-O<'ER:6=H="
M H8RD@,3DY."!(97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P
M 2<U)'0B!)14,V,3DV-BTR+C$              !)S4D="($E%0S8Q.38V+3
M(N,0
M          6%E:(        /-1  $    !%LQ865H@
M   %A96B        !OH@  ./4   .06%E:(        &*9  "WA0  &-I865
MH@        )*    ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+F
MEE8RYC:               %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                                    !D97-C
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M(#?@.* Y8#H@.N [H#QP/3 ^ #[ /Y! 8$$P0@!"T$.P1(!%4$8P1Q!'X$C
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M3.Q4O%R,9&QL/'0<>_R#W(O,DZP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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MFS<6$1$5555CX+DF*16.7_I" -4^YO9/DC3TQ]?O[X^_AJ(^/VK%<C[.GO\
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M&]^*=K#QC>R9GN@,QA0D\AD:U[51&N9/*D_5>?Z:E1X__P#(/I/_ -D>M_\
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M0E5"A-\1L:=J_P#MY^O(_MSX_?65Q3CMH_"K? LBQV.>%D>O+;9UU59"[*;
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MW)< ];W4NFL$UY#R;81-.IQ<V S (6S3MUTR(^FR#!;&/=2Q$R2<R;1XX.I
M^C-3D=:DFM--^LM5[#T)J7U<-?:-M^9^!\E9/J.ZQM,<LZJTWW;N-Q[S;?6F
M?L_LS"[FU#9X=DU[=0I&6-R;)8TBUR&VQJK9%RU).,PQ,<TTIW-W'-XZ*V=R
M5TO3;#]0^1F.J](:$C>DT37>1;^SRJV1LZRG6EKLNRV9E.+09^*;"R]F?2FT
MV5QMUS)-=5:W%'971A1F17M::EQ]-_%]E4W-SU7\@V5C-M26.7[&XCSDMCU$
M^#CV16]?Q:Q.#E9\5LI$<4&YK:[(&3()3UAI(8Q6)'*YA4\.FFIF^FFCIIHZ
M::TC.=9ZXV?7Q*G96 85L*K@3/K"#6YOBU'E<"%/]DD;XV)#O8,^/'E_#F,#
MXD(V&]DI!>?@]S5::3%G$?BF-R/'QFX_#<GS1S--Z[:Y%_6CFXXBI_L7IIKU
MKQ6XPK\EXY:)5/U+J/ /X?Z::_/Y*?%[]W#0_P"$6 ?P_P!--'Y*G%_]W#0_
MX18!_#_331^2IQ?_ '<-#_A%@'\/]--'Y*?%[]W#0_X18!_#_331^2GQ>_=P
MT/\ A%@'\/\ 331^2GQ>_=PT/^$6 ?P_TTT?DI\7OW<-#_A%@'\/]--'Y*?%
M[]W#0_X18!_#_331^2GQ>_=PT/\ A%@'\/\ 331^2GQ>_=PT/^$6 ?P_TTT?
MDI\7OW<-#_A%@'\/]--'Y*?%[]W#0_X18!_#_331^2GQ>_=PT/\ A%@'\/\
M331^2GQ>_=PT/^$6 ?P_TTT?DI\7OW<-#_A%@'\/]--'Y*?%[]W#0_X18!_#
M_331^2GQ>_=PT/\ A%@'\/\ 331^2GQ>_=PT/^$6 ?P_TTT?DI\7OW<-#_A%
M@'\/]--'Y*?%[]W#0_X18!_#_331^2GQ>_=PT/\ A%@'\/\ 331^2GQ>_=PT
M/^$6 ?P_TTT?DI\7OW<-#_A%@'\/]--'Y*?%[]W#0_X18!_#_331^2GQ>_=P
MT/\ A%@'\/\ 331^2GQ>_=PT/^$6 ?P_TTT?DI\7OW<-#_A%@'\/]--'Y*?%
M[]W#0_X18!_#_331^2GQ>_=PT/\ A%@'\/\ 331^2GQ>_=PT/^$6 ?P_TTT?
MDI\7OW<-#_A%@'\/]--'Y*?%[]W#0_X18!_#_331^2GQ>_=PT/\ A%@'\/\
M331^2GQ>_=PT/^$6 ?P_TTT?DI\7OW<-#_A%@'\/]--'Y*?%[]W#0_X18!_#
M_331^2GQ>_=PT/\ A%@'\/\ 331^2GQ>_=PT/^$6 ?P_TTT+Q3XO*BHO&_0R
MHJ=E1=0Z_5%1?O14^S_S1>FFEUC1HT*-'APP!BQ(@!1HL6,(8(\:, ;1
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MD'7T55B5+9"F0<KM4A1K.QR"<!JML#.F=_;B-!"?&>97%16R2O:]@O>H;?\
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MW<I-/OF</)92O':#.TDL"LLC+&]F *UF".566*22 .AEC1W>,.AD5>[G4?\
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M!ST:J_&H[OY(G9>_;LBJJ=^W:3QR> 0.? )Y('T)  )_, ?III37^IKZF@*
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MIK>7Q*D?._E"YJW,N"!4VKE)C/0;RM$/VFS>SGN\&IV:GS551&]T3IJ>/O\
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MWVKW2MEL:,?;GF"2UYKWOJR1O&LD.L"NJ6Q*'2'K+O?H[6R,TM/ 7#D]L1Y
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M45%'JC%!HBJOS[*K5;\^_P#H[JJ]< 2.>"1R"IX)'*GX@\?$$>"#X()!\$Z
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M.*1':6>=8Y?1B0?B]0H_XNU521W1&KFN&]1652>P%VX'/"@>6)'(':#SS]0
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M9C+N8OU<9CX3/;MR>G#&" /"L[N[-^%$CC5I'=O"JI)\#7%1W$\D  %F8GP
M/))/(\ ?GY^ Y) ,^^,:CP_<NLF<<ZC'88\KD5CXF&Y QLCXF7DL",I*J 0)
M988T(<P@Y#C6#$E'<=[1>R]#*U;N[LZ1';F ERL%Z>W9K10RV(Y/1BA],?\
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M&N;$*H48]I_;5;L[<L1Y' 8>\8HXGOXFA9D6L2L<?JUTE*H1VGM#'M4<*>T
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MJ7+<L;32NLS%8XZYC*F!)I<3.KGM)_\ [E?:2SF\-NTK^/V=0V_BMHX"*XB
M6\?A[F8MS3VI%54-^>WD)[:01/(M06#4,]AJY<.1^B&KWWCS(:K?![-8X&US
M?S53_P"M]@J>+FN=W^_[U7[NWWIV5*)<$.X( (9@0#R 02" >3R!\ >3S]3K
MK-\3^I_/YZCN^D>E:+U8N0#G*C5^P^EE\E1%[+_1?C"=NWZ^[D5OW?G?<J*G
MSX_IJ-.'XG\-\JS;2FOX.M7I;VUC4-EU58XC(TR8<7P%A:RV%4HF0P-/>QC,
ME%=X 42J0@VN>0=^NFV^#B\0*>3].+'XV3MJVE;\?_S9+$WH2Q!7+NLD5AQY
M!>.4*L86,%^ZU&IDZ%FO<1!&4$/J/^*.5',A,3+\FY[F#<,6'"\>02ZYWIH\
MP+K)<:9E./L^$O(X%-E^29G LJO&JLK&R"ONB%GR;6,V-[A6O@184HY)3#!"
M-Z]G]7 EZI[.J4)TK6(XDK!Q'1J4O0-ATY0)72.-(3SVCM9F1 G#<A>.*:QF
MS\+@Y2^/6K60RL[K63T^6! ]0*J1AW;M 5AY(50S <'4-,H./ZOYG9YI?452
M#$:F! F W+,]N#,?E&1XL(KV#Q1RL(*AQVTF7M//G1H4.!8F,&3'+*6$U$D6
M:V+<N97?+OBU3%T+=B7)W:$))C-:N) L:\AR29K(;TU9(D:60J"J1H*J@L/Z
MLS1MZ<78SRIR.) H*CN\<$M(X8A2J\E@/' TZ>%938%C$M*\KHUC$E@EQC!:
MQOMR0%:4+F":Q!KV(QB^WX>V[MXN8Y%5%R;D@26%X9@&B=&C96))*.I5N6![
MAR"?Q<\CR01QSKXB7EU:/E79B"%':I/CD<*%'#<\%0 O!XX^)TXW=7'O/LHX
M1\A=X[EM<[)80<8M+C#8MM.OXI8L"74ROC9,>BD%A5$>MF )$'6DAU9F+73)
MB),8(S1CQ7ZAXS;F(MQU]NO,OJF1<DGO[W8)'1TDC!,CRRET8-WB6;@/P5C[
M@SE/&8HU+=JRR,?41&;D#@$>JC%B&!^ )Y (8^=,A]#3CI%VKFFR-A_"OE7>
M/1Z+&*D#G*,21Y%?&N;3R(USF#=(7ZO$YZC_ #H[3@0G8[AOMOKID_?W_?5F
M_DGZ962<@L=PW,L9R['*3+L8H%H[^/?PY(8M[#CG69"^!E0O>,4U6LB>T+WP
M#FF1ID6&I1)7C:ZZ^P.I"[1JSX^Y4M6:LDAGADK2HTD4K*1(OIS.BA'58E4*
MZJKJ[D%I6(3Q5;L"5[:N4C?N4@"3GR3V]CLH YXX[2 .20/K7Y]4KBEI[CYI
MF[M+Z+8Y/F4N)AU1@N:QJ_W9#)<NSF2O \I)/C0TSGCR$4FK.AAN\V"&AK!
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MJS!?\SU"K!3V@<DD<$AI53.]96:>QPLLY01@J">XJJL>>X?A!8*0I/X>>.V
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M66QCYZ&/NXQIE4(HG7'6JD5A48J9HY.UR"!KR^F]$A84*ORB[,D.HKZ*\N;
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ME<O@_P"3U1/(VSE'AWKB<K)$]AYLVLK11,7D9LA,\;=A\-(Z&RQ53QZA4*P
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M*/$KN.5PJFQQ3&(PY('%\Y<N.%\)[)#6IXL>>3%<-@U5[_:(SNON*K6P?O\
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MW\J:?[2S[1E.UHC> Y+9[Y4.(V3^<T1C1)(FB0Z-9(,K@-[O(QK6H^_']O\
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MM)!'_P#&JSBA%-+W#ML3A55HW1QT<7X*DM,VG.KGD[4$6J@W$<I6V-;9V%B
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MNRW&[>:2/84AT"(HVPC#=(:'ZM. +@U;5?")&E2"0+-K6 :'U=JBOELG+O+
M9>>UCLU$M3,87).Q./EKH#&]<]TAADKMRCU/QP2+9DGAL/"8%:H]QXRAF<;)
MA<Y3]Y@*)+C9HHTECELP@QJ@@8<0RD,ZS*3Z;K(TG=X0.^?&O4JJH^:CQ#*Y
M5/F<Z62-"&YCI,$S;20Y&?"P<GKX3JQ\LIGIVCG"^"TK_88=3N<Q+8]3.G?0
M7JOFDP>X8H8=T)!%CZF;Q2S5+?)5HZU*6Y'%)3MM"SH\45KU75NR!67EX&M
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M!(XD?WMO+9>B<OPVYQ$M<"-8TZR? I9\:S6>*-7':44V :/*C 9'E0U$WWW
M,Y3#.)4:SK(_JKN:SM]Z=>>AALM@\O2N0W,5EJYM177@9#Z<D3K+7, 1T'$T
M,J,S$,%/I-J@MNXC#9G;TM/)TJ]U*^2R%<^H&6:.2*;_ /TN@'IL"7'=QR">
M058\Z;%9<KMGWN0?6LHP:^3*E(2='BME3G25(7SE&>E@^1(ERR%*8[R%D*LH
MR?UK&-:C4HNMU2R;/4K?P>&BE=X8/<ZU9W6*HAB@[*]95 )K)WBLD#0HXA6,
M11 -JX6-JT<92AQM.C%6JP+Z2Q(G(5 >SGGCGN + -XY[>57CD%[7,#/;O(M
M1Z]VCC]U82&7F)X[%GRHBRXZN'$BV6+"640?MO/Y!#33BJYH_<FVXW%41T5S
MKE;OMPX?:/\ %-O1+7KV':W&<?"T:229V62>6WZ< 1C);NWVL.6,9>S*))'5
MSSJV72^%<#?WUMSL[&QNX9[-,E@[/1R$=>>JZ*H#)'%ZK5H8^1VQ5E /IJ (
M@;>Q)8JXA%7VFD>@XZJ5&#<H_ INRN1J%(YC3$54(8KE[2#.>C5)BYF<M/EQ
M)))QZ$<C+#7*SJJ$Q"-Y@>1&LKR=MB0=LTCEPEB?N$237/FE:4,>#V@\JO#^
M.!P3SW<!N?QD<$GGAF! Y_)'NCSRJJ.8HI3G>WV1'-\2>794[=N_9%147]/S
M_0O>E_/GGD,.>>?!Y'Q)_/GXDCR>3Y^?3/R)/GGCY\^"?)YX_0?I\1QIXO'!
MZIK3<;B.4HQ5WDD,S4^%5WV?O'%>]S7,?_6HQ!$5"-3VFM[>+E[]9%=')!'M
M;>3ERXCCG>2.14$/(QQ)X(7N8R#A9.]S^%%[5C!);H9,*W\&\<M_&X&7D!N.
M%#,3YY4$* Q)(/ _"//+-RGDO[N<UGD;N]RJ16-4B^2J]S4$J?VE>U$^2]U\
MD[?-O6/LTDDA:29IF:V/>&8]D:RS!V'K&- 4_ S3Q*O:K<-ZBNH8Q:]-G)Y8
M\\R#N)':%)/Q) Y' )( ^'GG@$G3BL'Y1;6P;!,DU]73ARZC)81X4LLVQMR2
M?A2,_,C'09Q"FQ8IU?(AAEL*V(\I.R%!VCNKK'=0KU7'P4K^.H9NSCC=FP>7
MRT(O9/"6+E*2K-)0L3 R0DQO)&98I(94K2-"YEBC6,^;:Q6+R%ZCDKM/U[V-
M;NIV2[AD*R1S(L@4@3(D\44J*_\ HDCCD\LB=KQ-0%/*X&[=EN]TDFNOX+7^
MV1S#LA'H-AJ9["M()AU&XODQ2 <I1^V%9$=/)J7OVM;DEZ3799I+C<8G/.\A
M9#;6.(2'NBD[461DC=O=W:1"0J!@OE8J)S3LO5C9#2EPDVU-S*K?A+]Z6\<P
MX;@'GM4]C=Z\E06X('+8.#D@Z\T.)[2-&_W.26D/%Z$?Y"<NSL:=W=_5.\O-
M.[53R7Y/14>B-578N^\(8YUF:25IHF$4K2 /$YD$H,BE6_\ Y"&5U+>/5[A)
MVIQ)<DN"""2>X-P>02.6)\@#D GX@\D ^...3>#^E+,\_3JPEO@KU=R?UPB-
M[=U55PK9_P NWS[K\_N^?7GCX#^7W]=?#7SU8-];Q*V?3QK.='J[/V5GUP)1
M1PII D84)),9KT&=PG-_JW/:YR.1J)V[=T[<=Z[#5FHQ7+45.RP>Q4CGECKV
M'4* T\*.(Y2 B@&16X[5^@U]2[JI4,54\>%) ;D#GG@^1X^)YYX''SX<;Q08
M]^<9=(*B)'BZVR53E3S4;4+,IFI[J)XL^:-(Y$<PODC7>#45JNZNGT:4_P ?
MS$G_ .$>WK2L>#VAGN464-PW;R5C<A61B0K<$ $$@\'ZEX%'R!9ID_"#XX;C
MGY_ 'Z>6QQIUA"D1I,(JQ)<0PCQ9,62:.<!0+YB,$X6M*(PR-:YCV.:]KFHY
MKD7JTU>>:O+#8KS203PNLL,T+M#+'(OE7C="K(RGR"O!! (X('''N(;N4]I'
MD$$@@\$>./F?//R^1/!\^F78VE@<TJ:=TZ6=54TJ7+DRI!GJU&HXISL(8KD1
M$1'/>Y?%J)\D[=ILV+%N66S:GFM693W2SV)'FFE( 'XY9&9V/: H+,2!P >
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M(,'Z5[^Z1%5.Z]E3^I^:_+Y_-/E^E5[ITU&G6[&*:NXG\;*9SP^_<YINW,W
M\W?F 6QQW&PG[(U57S=7R&(JL;_P1/[7;Y--*?Z5Q)'_ )2+@_Y-$C5Y-:D3
MNBD55_\ 2ZM[N;W;V\>WS1/^Q.FFKN&W/HTO ?=&U-F;>S#->1[,IVIL',MD
M9"&HSO#(53%O,XO9N0VT6IBDUS)/'K SYYT@AD2I<D0$&,TJ0J.>YIKS:_\
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M20#D@=R$E/AQX!)\?G^Z?K]%.]/!5[_TG\K4_P!"9[K7M]_R^_42]U3Y??\
MJ[?=\NJ='@??W_O]?.N)/\OR'P^_&OV/Z*EZ>@GL>W:7*YW@YKT:_.]9JU58
MJ*B.[:A1WBJIV5$5%[*J(J=?2-S')'( I,;HX# E248, P!!X/'!X(/'P(/G
M0'@@_0\_K^7\];EGOT8S@?L?(7Y+D&S^4 I[H<2 @JW-M= ACCPQN&)HQ2-4
MRB,[HYSG]B]G/<YZ(U7+U[FY-R7]TY$9/(I6CG6M%55*J2QPK'"TC+PDLT[
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M^GU3DU_#9K?",@I=U8908[0X;AE%!J:IKH<*&5KKR\'<Y;8R;>P=+NWQ2@B
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MHZ::.FFCIIHZ::.FFCIIHZ::.FFCIIHZ::.FFCIIHZ::.FFCIIH[(GW)V_\
)';_L1$Z::__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g129231g29a01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g29a01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2#^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (.*^A!@X0DE-! 0      $(< 5H  QLE1QP"   " /\< E  "')R,CDT
M,38U' (% "%-:6-R;W-O9G0@5V]R9" M($%#3%@@3F]V(#$W+F1O8W@X0DE-
M!"4      !!V_2-9"[EW#5SS%U\GI@;R.$))300Z      #E    $     $
M      MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP
M<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P
M  P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M    0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-
M!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M    0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N
M0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M     $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M    4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!O
MX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M            0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL
M0'+ V1         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G
M4',     4&=00P    !,969T56YT1B-2;'0               !4;W @56YT
M1B-2;'0               !38VP@56YT1B-0<F- 60           !!C<F]P
M5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M  QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M       +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU  (
M @.__C4  @ ".$))300F       .             #^    X0DE-! T
M  0   !X.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      ,U    !@             !IP  !V0          0
M                       !              =D   !IP
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   !IP    !29VAT;&]N
M9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   :<     4F=H=&QO;F<   =D     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    $.$))300,
M !:!     0   *     D   !X   0X   !9E !@  ?_8_^(,6$E#0U]04D]&
M24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S
M<$U31E0     245#('-21T(               $  /;6  $     TRU(4" @
M
M   18W!R=    5     S9&5S8P   80   !L=W1P=    ?     48FMP=
M @0    4<EA96@   A@    49UA96@   BP    48EA96@   D     49&UN
M9    E0   !P9&UD9    L0   "(=G5E9    TP   "&=FEE=P   ]0    D
M;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#     ,<E120P  !#P
M  @,9U120P  !#P   @,8E120P  !#P   @,=&5X=     !#;W!Y<FEG:'0@
M*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD  &1E<V,
M$G-21T(@245#-C$Y-C8M,BXQ               2<U)'0B!)14,V,3DV-BTR
M+C$
M         %A96B        #S40 !     1;,6%E:(
M  !865H@        ;Z(  #CU   #D%A96B        !BF0  MX4  !C:6%E:
M(        "2@   /A   ML]D97-C         !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@              !9)14,@:'1T<#HO+W=W=RYI96,N8V@
M                                                    9&5S8P
M       N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@
M+2!S4D="               N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="                             &1E<V,
M        +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV
M-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@
M:6X@245#-C$Y-C8M,BXQ                                  !V:65W
M       3I/X %%\N !#/%  #[<P !!,+  -<G@    %865H@      !,"58
M4    %<?YVUE87,          0                        */     G-I
M9R      0U)4(&-U<G8        $      4 "@ / !0 &0 > ", *  M #(
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M(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG#, ,V0SS#0T-)@U
M#5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/"0\E#T$/7@]Z#Y8/
MLP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,$:H1R1'H$@<2)A)%
M$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4:A2+%*T4SA3P%1(5
M-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E%XD7KA?2%_<8&QA
M&&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:Q1KL&Q0;.QMC&XH;
MLAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY 'FH>E!Z^'ND?$Q\^
M'VD?E!^_'^H@%2!!(&P@F"#$(/ A'"%((74AH2'.(?LB)R)5(H(BKR+=(PHC
M."-F(Y0CPB/P)!\D321\)*LDVB4))3@E:"67)<<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$!_\  $0@ AP)= P$1  (1 0,1 ?_$ !\  0 !! (# 0
M           '!08("00* 0(#"__$ &40   & 0,!! 0&"@@/# L!  $" P0%
M!@< "!$)$A,4(149,4$6455AE]0*%R(R6'&!D9;6&#,T-G2AL;,C)"4W.4)2
M<G=XLK2VP? X17-U=GF%M;?1X?$F*3538F>$AH>HN,;_Q  < 0$  @,! 0$
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MJ=8#"W2CT!<'*X+V  3G('9*"8\ <>1$2ZR4(&_S[?7W_L\?N<!MR0/=OO\
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ML:#SR]&LK,T<,LY98% 0&%$<H&8YDUKN9P\:8QIC&F,C2[YCQAC:9KT#?KM
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MAS ;$D^._?P&=^E>6T[J(4CVB9N9553L"%V['N"3\^PW]^=YU/\ :T_[PO\
M(&M#-W/?3&-,8TQC3&01DK;ABO+UMB+=D*%<6%S"1 PS*,6D'+:(,V%VN].=
MVU:&04=G,JX,4Q%G!FXIE ID#<F$?E=;X,X?XBU"MJ.L5&N2U*_FT,3S2)7Z
M9D>4F2*,KU"6<C9V*\O8J=SO]9H?&O$'#FGVM-T:VE**Y8\YFF6&-['/TEA
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MTQC3&-,8TQC3&-,8TQC3&-,8TQC3&-,8TQC3&-,9I-Z[_P#N2<?_ .,!4/\
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M6!W.^W;?MW'SC.[1II7D=DL12[Q."JD<P&ZG?L6[;CYO$#?.\XG^UI_WA?\
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ML,_4IEA8ZI.S58L,4N1U%SM>E7\),QKE,P'3<,)2-<-GK-=,Y0,15NNF<I@
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M%;P#7=Q,HR41(G((R-PJ4SA2(DVT4,6+9>WFOM8E9US)@N0Z+$R4H+TTHMW
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M2I'1423[8@'!0.HNAQR(^T./=SN\9ND?"<BR@<\MFLL(/;=E9&8C?W!']G8
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M"1-C)*K,@'DT>],9TT$H"'()E.(J-A'@?NFZB7M\RF#RUF1%!)\/$]O?MO\
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M*"@&,F(_VJB8\*)&_P#A4*4WS:QF<JFF,:8S$/<3^^2#_P")3?YZXU?!XM]
M_7FO/_F?];_]<@UB8 $ ]XB//Y?_ ##^3WZL<'<GV'^S((>P^O?Z=_[\O"/.
M4# 'O]H (\?$(?G\P_'J'L]WT_MR>7Y#3+V*.59@[6;*<\F[HX@4W'WH*)\]
MA0!_N5"F#W<>W597<#8;'VC<?E/;OO\ <>.25B/G'M'M\/9W'U_5W&2G$Y:!
M$Q49UJ*A/9XUF =OV_?*-AX P<>T4C@(<>28^?$>0^'8^/A^C?Z?#YSEG./O
M[/I^_P"S>5XFP0TXD"T5(-G@< )R)J!WR7/N60-PJD/S'(7GW<ZCDLK&F,:8
MS%K<=^WU7_@I7_+8ZO@\6^@?KRB?P7Z3^K,<F)@!3@?C_P!7XOCXU:_L^_W\
M,I3Q_1^@G]F7A'G ! !$.../,?9R ?C]X<<>7F/MU4!V /N&^6_<9?<3*.HU
M0J[)TLU5#@>VBH8@CV1\NV #V5"^8_<G Q?=P(:B5[ #Q'Z?#<GV_P!GAD@2
M#OW/C])W]GY?TY*45EA5L)$IIJ#E$1 !>->R1<H>SM'0'A-3W<]V9,1]Q!$0
M#4.1AM\_W^_CL/')\X]Q_)X?IR5X:S0<^D"D7(H.3 4#'0 W8<I<_P#O6Y^R
MJ3C^Z$G9'W&'4<GN#X'?*]IC&F,QVW4Y@O&"L*V3)..\9O\ +5GAW]:9MZA'
M&E3N/ 35CBX>8L!H^OQ,_9IMM58I\\L3N!JT'+V69;1JD?"L%WJZ0!5+(4:
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MZD(58BS20C7[9N^CI!HJ@]8/6Z+MFX1<))J%@WDNXW<H6X>L$QN'0^<4@5<
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M8VE H(>FLS2+$S>N-A(T4@4^THP]F9;R%<"*L;M%JH65WCC)U#8.\:*\BK^
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M-RR4XYL$Q)F,Y7>FEGCPOARE1:1Z14X]@V:LFK=NEV+[1-<LBN$%>.9X:_3
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M1N=A5K]O.YD9:):Q$&E&.YR6K%5$BQ&9YV$42</Z)J!W(59+FL0R2*5<&0I
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MEJQ:E>SO&MCX3UG6(R%81K=UK3FTVP"%</T$B(>)%=760%C(0=LU*R)7JK2
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8F,:8QIC&F,:8QIC&F,:8QIC&F,:8S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g129231g32y64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g32y64.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1L04&AO=&]S:&]P(#,N,  X0DE-! 0
M    &O2^:0 X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0&.]!B         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,W    !@             !P@
M KL    ! #,    !                          $              KL
M  '"                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  '"     %)G:'1L;VYG   "NP    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M?W?5W9CJN;78RJ_%:PUV01N#7NJ#"YUU&.2YMFQWL].C(R5*SZQ5;/4H8+6
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M>X=@UKL?9_:=^:M51RW0_P#_T?2<ZJN/6  MC;N),1/=OYX
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                          #_X4!+:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 V+C M8S P,B Q,38N
M,38T-S8V+" R,#(Q+S R+S$Y+3(S.C$P.C W(" @(" @(" B/@H@(" \<F1F
M.E)$1B!X;6QN<SIR9&8](FAT=' Z+R]W=W<N=S,N;W)G+S$Y.3DO,#(O,C(M
M<F1F+7-Y;G1A>"UN<R,B/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA
M8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"\B"B @(" @(" @(" @('AM;&YS.F1C/2)H='1P.B\O
M<'5R;"YO<F<O9&,O96QE;65N=',O,2XQ+R(*(" @(" @(" @(" @>&UL;G,Z
M<&AO=&]S:&]P/2)H='1P.B\O;G,N861O8F4N8V]M+W!H;W1O<VAO<"\Q+C O
M(@H@(" @(" @(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O
M;2]X87 O,2XP+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W1%=G0](FAT=' Z
M+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C945V96YT(R(*
M(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B92YC;VTO
M>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B/@H@(" @(" @(" \>&UP.D-R
M96%T;W)4;V]L/D%D;V)E(%!H;W1O<VAO<" R,2XR("A7:6YD;W=S*3PO>&UP
M.D-R96%T;W)4;V]L/@H@(" @(" @(" \>&UP.D-R96%T941A=&4^,C R,2TQ
M,2TQ.%0P-3HR,3HU."TP-SHP,#PO>&UP.D-R96%T941A=&4^"B @(" @(" @
M(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3$Q+3$W5#(S.C,Y.C(T+3 W.C P/"]X
M;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A=&4^,C R
M,2TQ,2TQ-U0R,SHS.3HR-"TP-SHP,#PO>&UP.DUE=&%D871A1&%T93X*(" @
M(" @(" @/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @
M(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O<VAO<#I#;VQO<DUO
M9&4^"B @(" @(" @(#QP:&]T;W-H;W Z24-#4')O9FEL93YS4D="($E%0S8Q
M.38V+3(N,3PO<&AO=&]S:&]P.DE#0U!R;V9I;&4^"B @(" @(" @(#QX;7!-
M33I);G-T86YC94E$/GAM<"YI:60Z-S!C-F4T-F4M,6-B-BTV8C0T+6(Q9F4M
M964X860P869D.&-A/"]X;7!-33I);G-T86YC94E$/@H@(" @(" @(" \>&UP
M34TZ1&]C=6UE;G1)1#YA9&]B93ID;V-I9#IP:&]T;W-H;W Z,C)D8S Y.#DM
M,&1E.2UA,C1A+6)D9#8M.&0U,V8Q,3)D-V8S/"]X;7!-33I$;V-U;65N=$E$
M/@H@(" @(" @(" \>&UP34TZ3W)I9VEN86Q$;V-U;65N=$E$/GAM<"YD:60Z
M,S8X,S$Y,&0M,C-C,BUC-S0U+6%A9#0M838R,6$Q8C)B9#@Y/"]X;7!-33I/
M<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@
M(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$5V=#IA8W1I;VX^8W)E871E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C,V.#,Q.3!D+3(S
M8S(M8S<T-2UA860T+6$V,C%A,6(R8F0X.3PO<W1%=G0Z:6YS=&%N8V5)1#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TQ,2TQ.%0P-3HR
M,3HU."TP-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T
M179T.G-O9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(Q+C(@*%=I;F1O
M=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^8V]N
M=F5R=&5D/"]S=$5V=#IA8W1I;VX^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IP87)A;65T97)S/F9R;VT@:6UA9V4O<&YG('1O(&%P<&QI8V%T:6]N+W9N
M9"YA9&]B92YP:&]T;W-H;W \+W-T179T.G!A<F%M971E<G,^"B @(" @(" @
M(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP
M87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C-F,S%D,64P+35F86(M,68T
M,"TX,3EB+3DS-3$W,S R,S5F-SPO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @
M(" @(" @(" @(" @/'-T179T.G=H96X^,C R,2TQ,2TQ-U0R,SHS.3HQ-2TP
M-SHP,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O
M9G1W87)E06=E;G0^061O8F4@4&AO=&]S:&]P(#(Q+C(@*%=I;F1O=W,I/"]S
M=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @(" @(" @(" \+W)D
M9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^<V%V
M960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.FEN
M<W1A;F-E240^>&UP+FEI9#IC9&1A9&0U82UE.#4V+6,Y-#$M8C@Y."UC9#DW
M.69E9#8P,3,\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IW:&5N/C(P,C$M,3$M,3=4,C,Z,SDZ,C0M,#<Z,# \+W-T179T
M.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G96YT
M/D%D;V)E(%!H;W1O<VAO<" R,2XR("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A
M<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO
M<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @
M(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%
M=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R
M<SYF<F]M(&%P<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA
M9V4O97!S9CPO<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R
M9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB
M4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E
M<FEV960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.G!A<F%M971E<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D
M;V)E+G!H;W1O<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S
M/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D
M9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @
M(" @(" @(" @(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HW,&,V930V
M92TQ8V(V+39B-#0M8C%F92UE93AA9#!A9F0X8V$\+W-T179T.FEN<W1A;F-E
M240^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IW:&5N/C(P,C$M,3$M,3=4
M,C,Z,SDZ,C0M,#<Z,# \+W-T179T.G=H96X^"B @(" @(" @(" @(" @(" @
M(#QS=$5V=#IS;V9T=V%R94%G96YT/D%D;V)E(%!H;W1O<VAO<" R,2XR("A7
M:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @
M(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @
M(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @
M(" @/"]X;7!-33I(:7-T;W)Y/@H@(" @(" @(" \>&UP34TZ1&5R:79E9$9R
M;VT@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W12
M968Z:6YS=&%N8V5)1#YX;7 N:6ED.F-D9&%D9#5A+64X-38M8SDT,2UB.#DX
M+6-D.3<Y9F5D-C Q,SPO<W12968Z:6YS=&%N8V5)1#X*(" @(" @(" @(" @
M/'-T4F5F.F1O8W5M96YT240^>&UP+F1I9#HS-C@S,3DP9"TR,V,R+6,W-#4M
M86%D-"UA-C(Q83%B,F)D.#D\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @
M(" @(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^>&UP+F1I9#HS-C@S,3DP
M9"TR,V,R+6,W-#4M86%D-"UA-C(Q83%B,F)D.#D\+W-T4F5F.F]R:6=I;F%L
M1&]C=6UE;G1)1#X*(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @
M(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(#PO<F1F.E)$1CX*/"]X.GAM<&UE
M=&$^"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @"CP_>'!A8VME
M="!E;F0](G<B/S[_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_VP!# 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0'_P  1" $2 :D# 1$  A$! Q$!_\0 'P !  (" @,!
M 0            @)!@<%"@(#! $+_\0 0!   00" @(" 00! @,&!0$) P$"
M! 4&!P 1"!(3(10)%2(Q018C,E%A%R0S0G&!)5*1H<$8)S5#4V)R@I+P_\0
M'0$!  (# 0$! 0            4& P0' @$("?_$ $$1  (! P,# P$&! 4"
M!@(" P$" P $$042(08Q01,B46$'%#)Q@9%"H;'P%2-2P=$(X20S0V)R\1:B
M-%."DK+_V@ , P$  A$#$0 _ ._QQ2G%*<4K \WSNNQ",,2-6POIR.'4TL;L
MLN47Z1'N$SM[ ,<YOLY412*OH/M>U;(6&GRWKD_^7;Q\S3MPB+R2 QX+$ X'
M8=SQP<,LHCP/Q.QPJCN3]<>.1\9K(<<DW,RE@2<@A!K[8PE?+A@(I&!52/\
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MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE>+W(UCW+_36N<O_ *(BK_\
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M95<WOM?ZZ5?KMR=IVGTG^.27I"YR$5\'_4!@<?3/S\$_..]9(V],_7/;DY&
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M<G\E5554;-#4;'3<)!:&Y;;GU';9&W;M@%S@YR..X X )\(H;)!'<CY/CO\
M'[GMP2*]]=XG:S"1A[N1D>2&17.>VQM$!%>YRHJJH( (K^F]>K4<=R(WZ7M>
MU7Q)U5J; K"+>V4@ >G%N8 >-TA<?LH_I7L1*/GZ\]_S^?U[>*W-C>M<"Q!4
M?C>)TE49$1/R@01.F+ZHB)W,,A)*_P!)_P#Q?[^^0USJ%[=__P FZFF'^EG.
MS]$&%'Z"L@X&!P*\K_9&!8M>4.,Y%E]!3Y#D\T5=C]+/LHP+.UFG:1X8\2&Y
M_P [W%:(GQJK&L>K5:URNZ1<,=M/*CR1PR/'&I:1U1BB*.Y9@, #SS7M8Y'5
MF5'95&68*2%'U(&!6:\PUXK5F[=>S=K:HSG75?;BHY>6T9Z@5E(BI-C!0SQN
M(.5%56N+%E#8^+(1CFD:$SW#5'M;S<T^Z6RO;>Z9#(() ^U6V,2 <%6P<,I(
M89!&1@_-2>C7Z:7JMCJ$D/WA+2X29HL[2^W.,-X8$[E)XR!FH;X1^G-J,.FH
M6#['QW%K?/@LLE_UWCD&963("S3$4(H17G:<S(\9Z@<^2Q5(URM]$8QB)86Z
MMOXK^2>UGN!9.P+6LS(X< 8).%PK$\@J1CC)/:K#U'UE=ZOKBZO9"2U6".VC
MMX)V$ZC[LQ<%E(*A7=F8HIQDDYR34(]P^%FP_$S5^0Y/K^V'M3#OW-#9#C5[
M D3;.#$L#,CNMODCL&UU;7A1C9;&L;\(NC$1X1OZM^D]66>H7*6[PM9S,N4D
M9T$3,@SMX(VLQS@G.3W(.*VKS5(/M$U:U;J00Z5=P6K0VM[I2F+=L5F6)HWW
M;Y)7(PQ/<D*03@Q*D>0^G[&TQG$\#RO';2Q93UH<T!:R2X]783?S/C&ZL"LH
M8ULZVE1#.F2H8W1B?$V+%*KVO>DX-0N)8KEC:Y6*1PC1D2-/$H+"0A2"ID.,
M GCDMW%9K?[%)T62\U^^O+(3XGTN,P+<37L!RRAV1F2WFD]JI%(RR;F#%0N,
M2+\*_(O%[F9F]";+<4F,=ED^NILFHIBEI;*-7L;ZUO[F54C!DA%(=(8([8OY
M*O*YK?F8HQU_5()IFBN)89$Q$F(V ]C,>3MRQY*CN20!CZFQ_:-]G5MTYIFD
M1=-+>W,<6F+>:O:7:J;VWEDP#<*L:J)8-Y]-S%ZAA;:&]K9,Q?,2AHKSQ1V#
M/F7<F#/U_94.:XRR(09*^^OI\9]=55-MZM7NMLS2?C++CD9(AN;^0-7*QPC0
M5A-(FMVX2)72[@EMI=Q*F.-'+.Z-R0R;<X((8<'Y%+^RR6XM^L-.MTAF?UYC
M%=1PQQ27*VC)ON'@BG>**2:-$9UCD=0S#!89JHOP_P /V)1UNT[7-*4--D.4
M[+L+P=77R9,VKKZR534=G3I1R9)2265?X\UA(;"N882ITYC'-7NW1/ S@F0R
M(J%-S,6R0YC93[5SPGN4*%[XX.:[[_U%:KI%W_\ A5ATX9C::?TU;1-).D,5
MY+>I?Z@EW)=+;#TEN3-"1(4R"1E68%6:4F ^/U_.RNTN;#(A4M+8LZ@U$@!)
M\E5?($21(D*AQO&(RM>@4*5SV=(8@7>R-YI7&H".X9[7+B/(S^%#E3[5R",*
M2,D @Y #<5SK5.J=)DZ)TO0=2T-+C6$E%Q=:@D_I,40XA#JH),NTC< 0 !P1
MD@2IP_!<MPW',@@7,B UCIQ7T;*= ,@K 7W<T@F!1IXRJST;\<I/D[5RJYWT
M]VBETLUS&W+)@>IZF[>)#W!R=I^I3@\=L5S;JBXTF_AM)-/@F@N4A6*X:9MQ
M?:,  @X(R3@\;0>/@61:%MR6^K,8>=R.D5X)%.=4<KE]ZV26,-7*JJO;P-"3
M[_I'I_7]<H^NQB/5;P*,*\@E4'XD4/\ U)_['BJS#GTT#=P,'QR./Y]_UK</
M(FLE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE>HX62!/"_OU>BHJIUVG_ "5.T5.T_P"J<]*Q5@P[@Y_^_I7EE##!
M[5QU=2P:QBM QY'N<Y[S'?\ (5SG*J_WTC6M3OI&L:UJ(B?7^>9)9Y9?QMQC
M&T# Q^0KRD2)V'/?//\ N3_?Z5[K.T@4T(MA92&18@$12&)WZM[7I/I$555?
M^2)_]^>8HI)G"1*7<@D*,9P._?':O9(!52>78*H^2> /ID\<_P#-5S;1V#19
MMG[J.DMHMBVRMJNKD'AG:XL6"Y"2CJYJ.]A*H O5KWJQ$$KE]51$3ESTV.2*
MPC.TJ5#LP['/Z#L3P>_T)-;VK=/ZAI:0RWMK+ )P?3,J,%<J?<%8XW$<9YXY
M\'%?)>ZQR/>PS6^$XI @4T5BQZ_)+.P#6QYJ0D4/XU;7!8:P*QJC]13)0(X2
M.3W:KD7W7875H=*;[M<O)(W#.J+N*ESG<22!D9(*@GO\C%0)M?47<N 1G;@_
M0CGC^O.6R:A'GNS+;7L:PJ,K0;1T4N7733*+Y21Y$%Y F$8H/9">C@N:UR,:
MYRI]I[.Z2Q12(ZQRQ$E)4#JPXR" 0<$YR0>!^F3FLMCIEYJ4XL[6(RW+'"1#
M:I8^ "VU?C&#SGXK'ID(>88GCMV1%:"VED6.]XW,]HT@8U 9&E]7HQ1$0@_9
MG:*J?Q^T<NA<SY,PR?PXP3QGD'N,?J>_SFOD]E<6EP]O=1M#/"YCEB8<JZ=P
M<$@D'X..>_Q<YX@6<2T\<M9.B.:K8%5/J#L1?L,FJNK*"4;D[7U7_9:1J+]^
MA&*J)WTG.+]#'=S*?+!ACL0RA@?YUM)^$?3CZ_KWY^?^,5%[ROQB/0[?PO,J
M:.P=E)OL4GG:'V8\LV+8A"AD]/M#$$-J*[M/D^D5%<OW9M%F9]-N('(V".=!
MGL RD\Y\#)'TX_3X1AL@>1YXYSG^G_8C%6;<IU9*<4IQ2G%*C#E]XE#NFIEV
M2(VO=' $;R)_!J2HI(Z';[?78BN=_)OVWIRKU]\FK53+8/&I.[<QP/."& /R
M#CM6O*<'..1]">/G..#X\_'-;3N+"35&;;5:M.\340\-SU0,Z/\ :N'VW_@*
MQ/8@"HB^I/I4<-[FKYB@6=/2DRI/X'QRC'R1VP>S#R.1R,UI>N8GSR1D CMD
M$_EW!XY_>M9;SR^-E/C_ +=_TEFCL-R.)@.02VV#92P+FA-#KC2RJU1GCRHQ
M"""2,&PB%10N*V1'(KVLY]L[%X-4L8[J#U(9+J%">\4JNZKD,01@;@Q5@#X(
M%3=EZ<TT+-'))"9$$B(#OVDX(X!PQ\9!!/R*RKQLBWL30FHQY+=2<ANR8'CL
MN=<3)1ILN:^;7!F#?)F2"&/+.P)QB-)*5Y#$8XCG*KN8-8$0U2_6!%CB2ZFC
M1%&%41N4]HP, E20,=C6;4! +R<6T;Q0*^U$D_\ ,&U0&W]N2P8]AW[9J*'E
MOXRP77-[Y6X]D5J+.->5]-E8L=G/A%Q^P;A;AE>%I) VR8BGJV21LC#D- 28
M]'JWV,]'36AZR%A31+B!/NMV[Q/.FX3IZX(!XX8*Q&<C\/?L#4WTW?W"72:9
M#"DW^)M]R"E<ONN3Z:;.^&#L,-@E>X[9J(F,?J%[2NME8;E>5RH-5@M9%L&2
M\-QD?XR9Y4%+$CDOF1[1TR<6ZK_D_.A5$!X#%BI*]0/%'+*9)S=.6*6MU';B
M62<$&.YD.Y86Y81MZ>U0G&UI&RH)&><*>D7WV3PV0L[+_$6_Q6]_RI([A!%!
MI]V0Q6*>4$H8R5V>H2H+E5#$\5<QK79V&[8QB%E6&6\6R@RA#63&&8;I]5*>
M-A"5]I%:Y2PIT?W1I0&:UR+]IVU45:3=6D]G*8IXV0]U)4A74_A="1AE8<@C
MQ7'M2T^?2K^ZTZZV^O:3/#(48.A9#C<C#AE/<$?EW!K8'-:M&JROU"M_Y[I,
MF"0L1JJ_*6Y71YDT&&S.Q@R&TA#K83H5F5A6&_;I%=<2AC='1SPS4"1S'HYO
MK+Z3ILM^[-&RHD#(TKL<;4Y8$'MG*G'SY&!72.@-&M=7:\$T<J/#<60-_'[F
ML5ED(CE"Y! $R@R-Y08.!DUT,]CV&*7>9Y/?2*LQC7-C;2XPAF+%@TXI%LAX
M=2X:HAYK8-=\L0RO<UQ#%0SG>S.EZ[8VT\,29_"JJ!G_ -3C!S\ELYSWP>,=
MZ_HWTCTA+9II@U]MMI$8?O1:/>;@1PA6,1))C8NRR(1EE &0<DFR+].T>)V.
M)Y9C,F3=?LKKQ+C(:R-#=/0]G%8/_3#:N,-GR"%(4CXMBQA'$.-OLYBH@DY]
MNY'"1LR*)#(8GW,558G)8E2&(.% QW]P/;.:Y/\ ;OI*Z?K*:GHMRBVT%@+C
MIQ@J13(\$X&JIJ",&]2%5DB,*@JK*Y.05?/81\;=KX;4X3Y!KMK/Z"YUK$Q&
MDHL;PJ\+#)^86-3"_;(597RQ%MQV,1[6AEB6$=H+.6V5\S5"U6TW6+&8WFF+
MI\$JR>J[M,F_"*9/<78838PW$'(W*,8P0!^0=5=)4TWJ&VBN(==OM:EFOM4A
M]1(8U0['V"-1'B5W]0G=N.QU"D.:^[Q"-"R["2W>;5-;1W^*0(0XHFMF19]]
M4G:5E)=74668P93GU,0 85@!0LE""Q7!<T#"NPZQ.]O.]K:LS)/*6D *L(FX
MWI&R@;07.64@X\,0Q M'6VFP0:A:S6NHR:K:O"BB7"&.WN HEF@C]H=2)97=
MXW),;NWNY*CQFY<8&2RCC]G!/)(HF#1W3!(Y6M1J-541$3Z1>E_I%5%_M)ZV
MLU:T521E5&XDC))R3D\^?RSGCZ\OU-V$N&R<\<\_/!^F.X[\Y/&2-JQ<\21!
M^ K"&DD1HPB1'O>1[_X,&C6HKE<Y51&MZ555?7U7FN;':^X'"@Y8]@!Y))/@
M><C]Z@)CPW/SW^!^8XY\'%3@\9J/+Z+";0>5U;ZEEAD,FUI8IGM_)_;I<.&U
MQ#QF_P HGR2 D<,1$:16*CW#9[)W2NHIK6>_W6L@E"PI'*PSM]1"V0&/#8R!
MN&0<<$UK(, _F34C>0->Z<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4KT2I46#&/,FR00X<41#R94HHP1XX!-5Y#',5S1B$-
MB*YY'N:UK457*B)SZ 20 "2>  ,DGX '>@!)P 23P !DDGL !R2? '>ODJ;B
MIOZ^/:T=G N*R6USHUA62P384AK7*QRADQGD"1&O:YKO5Z^KD5%Z5%3GUT>-
MBCJR,,95@589&1D'!Y'-?65E)5E*L.X8$$?F#@BN2YYKY7BKFHY&JYJ.5%5&
MJJ>RHG]JB=]JB?Y5$^N*5#[RBV''QI*BE.V<=DH;Y/XD%CB.,1%>U%.C$<Y!
M#:O:+ZJGNJ(G\OKEHZ?A0)+.VT$MZ8)QD*!DXSCDGX^A-:[HTD@V=T((SP"P
M^?D#@>!^V:Z^6T+NUU!Y#X[O/%&V(<4/+ #,(WRRUB%>J2 E;-![M9'183_C
MCG42-";MSG(-ZH.W0%!&ULY#*03"<#E#@D>"61N2<\C'@5^T^DM#LOMI^S*X
MT7_$+>WZIT0A[>VN BDS)&HADC=O<([K)BD8,4#%,JQ3#2\USY+9)AEA%R77
MV0?DU,LS3DK"E>6MLXOM[-CSX;G+\1?C7XW%:@SA7M1EZZ]MNZM+#48C!>0J
MQVXBF3"RQ,2>5?';/.TY4@=L&OQ]JV@ZOTYJ=WI.JVLUCJ%G*T5Q;3J1[D."
MRMR'1ARLBDJP.5)%<UNF=K?8Y(688M#?7#V:.WD9OCTB6LH=-GH"@):MAJ9&
MM2/8BEAG!5K%"7V>3U8]"C;'Z?%<6:RV4["46S)]VG50/4MF!V$CDAU*E64\
M@C@FOD,M[;HFJ6BNDUDZ R(I]J_P[F7Y((&3DCCZ'D;:..IPC$X;S/FEAU,B
M<9WNURH<8&A@PFH/M!L&@HP&?$WU:CF_72=<T9@QEDXP"3V _7CL>1GD#/)
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M,*(5XFT8?E_WQ?AE:YTMA$9\DI5>C5&P3EI>M&=+Q[:6)H5@]J1L,$J1D/\
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M:89R&$./!]F#$IW*YY%]4$68T6R2]NF5[D6HAC,N_P!I9MI'M4,R@]^>>W/
M!(G>G])M-9O6M;V]%C"L$LWJE4;<8QNV^]XU4 99FR2 , $FJJMNZ9WOK'),
M7W/G]S48E"6FM0_G0;<'^CL$B3VJ:-4W;I[X;[&0,GPDDR) S1Y)OH;&(#U6
MY66HV%R#9V[C:LJ9]9?3DFP<.Z#W8!!88&&QW[C'2-&U7HNUZ3U[IPZ<^HR7
M$P< VTDNI:A,@*Q&Q:)7,/N_!AHBA]QR&.*Y]F_J(8A3XSF\+)MEX/F&15TX
M-'CD/7;H]M(ER>O27<S58<T2)7^K'O:A2HJ'(R*,3D_W$FC;HC@PABA\DC(
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M8?ZN\M]G_06G]8:)U#8QC=KUI%Z^GR*V I1C@..,K*PV,K#*YX&1S-?P)NL
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MRY)9E=/9;5SIK845DHS84-!2/F?,<<37F,4Z#,CPN()F.9EF1)5+A#&=H_"
M&QG@@'<, <G'T[&N@V.HB:+31HJPW+V5LDJQB,[ OM=S/&-LA .5?WAE' 88
M!'&:(H/]%;?JK.IC$W??"A0K[$\7MJR'+I+:FB=RYL.TJXO;:Z% KBR'-(",
M9RL"LA[OC:UW,+VX:SD+2&&-_P#+>5GVM&3[5*'@$EL<]SVR1@5-=;]=]4=0
M=-1Q6<]GTU86"O::A>6<DML@E;<+BX$KO)--<G_+B7#A$4%43U78&U+<.O\
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MT=AU)%!$VHP1QVES:6YQF*-69"BNW>,EMH!]\;#^)#G5&]O,61L_R&;A=;=
M+H;%7S*#/<$FX_ O2['K'I(CW<NL10$?\JC9\=:/\^.<;D:9@".0C4SV'3H3
M36GF4B\E7? ^_8L#[<QJY)R,$^\A6!Y4D9%:VC=,SP:7+J>R2'4[>59+=AN4
M1LI!59#P  <AL\ E@WMJ@C,L&QK7V5;%?J>@DXK4W=S:0,8F$"4$D54V<:9&
M0B!4/R38$>2U@A. HQ&(U"=_$]77&QMIQ A8H\BQH92OM3D8XSX[D9XX[?'>
M-,M;C71:MJDT-R4M%N7M+8AHGN63,4$A8C_SI !R2%7( R0:G#&\24M<1P>W
MS#*8F1462U^,9M(QQPDEGF'BQR/K#7UH9[S.2.(GW&BJ 9B((LD;G-]&QTUR
MTDDL8C*"-VBWGNY4C<P X"JW'?)(P .YI.H?:?IG2:W,5GI);JNV%YIS-<#T
M].L4DD(]ELF)+B96"L&DD:,C:JIC)/JPW<-OIG;-S>:EQZKEWU2^IP^Q_<L9
M$^!"QF_!-JKNT99_-#=%7Y2U40) N<WM[&(U0M(Q<TMG#>V*6\[,$9FD&QRK
M;XR&1=N#N! 9B#P",CO4=TW83=0=.3KU1JT]O832SZF&1]OJ7;2>L$6/:ZE3
MESL *KV'(&(N4^ELA+L\&"8K,G7.0YK:29?X=!8I85EG.EO:041S(1VM:]'?
M3S>C_C8Y4]W$[5NYZD,<1GDPB0IG?*@4HBY7NW(SCS@'/UQ4M:ZE'JVGR3O]
MV%IIL97[S)$J/%%"<;F8^[+=^XW$# \5=MDWZ:]SJ[QHR[)HVS;B#G ::'FN
M18Y BPA8X&UHW$F B0IS )=)$IA&(< 'RW,).#\SG=*B)45ZH6]U2&%K:-K<
MR-;Q3NS^KZ<F%8E,F,&0@+D*2$/Z"'Z=^U2UM^H[+_$M-2[TN%Y+9)R7>Y].
M4;"YC9_2*R8 (VDA#^E5Q:@V!D>J=R1'8WC==M+8Y:3'P45;ED1MN#*,MO 1
MY!98VM>V423$KRO?#<\[1QC#4IW%16<LUU:QW-A(DTK6D0DD): [###&6"KD
M\8./?Q@@XXYJ\_:%=V>N:/->Z:Z:=;OG_*A(@=;57#8<!@H# >YAQ@@=LUQM
MCH'R_3%=Z9EGM/M37FJ%RJSRRWQN$<E521,K0TZXKK05!*(9DNHBS6CAFD [
M$QA@.0S?4?/*7NBK+90V\MK<7HA2.*4A6<Q@*K*SKR'*_A5N21V[D\OM=5T1
MUTFWT]()-5B5;>-]K>JV[:KJ74<NV6VY)R3YJ5OC_IG]/W8WCA4V6:^1TW&=
MAI\]UE\F1;5E?+J+V*PC;,<2FL:F2^;&?$['$.(I#.:1R@<CU5J:%WJG4=KJ
M<BV^E)<6IVQQ#TY"'0\AO55P$;>26RN.,'COYZQUKJFQU*.PFL8[>.WC0VY"
M,S7$<D:%7=B^"03RH4>X#(X %Z'B9?Z0OM%XE3Z%RI,TUSB<)^*P[&2AUF*6
M&YQ)0;$,J+#(PQ'2'&1GXPPJ$K/A11]+SGVL17\>H3/J,/W>YF;UBBXVX;@%
M"&;@8QG.<@YYKE5])<RW,DUT,3RD,_ 4'"A1@#QM \Y\GFHK9C3.\;O)K&[W
M'&OC8GL(WK+@M:J1F%D.<*8!J-1&M:POH8;?[3M?_F3N;AE.KZ/+%,<SV@]C
M>2!RI.>>>0?T.2:T@,$X'!_KSV[<8_GQX-6?C>TC&$:O;2,:]J_\VN1'(O\
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M'HP32)<T%60#A21+\0HYB#$4D41EDM8K1N<VOZ/%!=WZ17TKA6R &D92\F0
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M\*+#(,TA/V]7,DRY*N8%S7N:JB9AUG0F>"?4TN'D?VR" H<+$< *I)SD @@
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M7U&$8)C0$F.3(",#R,'+#CGBI/HBXZ@O]/U6_7J2'1#8D7*F=8%2:5 Q";'
M! Q_  PSPQ.*BO,R'=FI[Z9I>=@-X[(*ZHFVN. R01$/08Z,19M?^YQC$@PY
M\%8RM4A5G@AP(X3J3Y&#07-K,%\OWF&YC]-FVR21X]SDXPI)&UBQ[;6)/ '.
M*TK[INRZFD37YKV-FDN$@U%X&#0RWG"[X7/8R\NRX)!/!R& GC^F%6:*S:XR
M3!<SUM(F[QIVS\TRC(9DF-88K;Q7V\5L$<:%#FGAM?#6='>%KPECD_D4)43T
M8E?ZE.HV<<<L%T$L7*P(B#9*KE&+DL1N(<*<G@@<$9YKQUSINKZ1IFG26UYM
MT)52TA@0A)1,RO([R$ %PY4\DAEX&,9Q(3S?PW6OC-E6HO*#!]<0F9/39Q74
MMW58Y5M"*^JY #M1Q8X6_@QYD1%5\>7\+"N(T37/<K6(FEH-Q=ZK'>Z1/<LR
M3V[-$\KY]-P03R?<5;L5R1\ <FN>65]?/;S:8+R2.UN 7>,L=C.!QN(YP>V"
M<=^.YJ>NT,KI[_QMS7+K%KZ6HO-76UF\-L+HT-MG1E='C2@>A%<?YCB!\2#<
MYY'-:C>W(G*Y;Q/#J44(Q))%=(GL.0Q20 [3YS@XK3M()FU"WMXD,DQN8T5$
MY+-O' _3)Y[>:IJ_20U3A=SDF8;;R>5C1[BOMSP\1J+*7&_?:^9%"YLJQAPY
MA/RVQHL4JM"<;50:$55<B(G+QUA=SQ6]M91"55DC5[API",&Y5&8#&2025)[
M<8KKOVBWMQ9Z3I.E+;3P//;JUU,8RL;HO BW 8+L_+*><8X.0:D5^H3^H[XM
MX-J?86HH>TL.O=@91&+ALBE<8AZN%'LG.B6Q9]JL=]2U8L?YA^B2G.0[FJG?
MHO*UH.GSF_MKF6-HX87$NYCL)9#E  <'!."?!'GS53T#H;JVZNK2[M=+NXRN
MRZMY-H5R5(>-E0GU/=C<,J,C'S4<OTGM5:UW[IG:6,[,UEJ/),.KK*'%Q"PJ
MZ"I#DS*S((LZ1+?*NH!"2Y:._P!DT&S(5DH1E*B.]58UEDZIO;W3+NRGL[VZ
M1Y$,C*)6:V.PKM C;V#N=RX((^"*E?M,ANK+4[&2YN+Q=3>VVWD,\TDGHR0[
M5]N\#TMQ)_RAV&"1Y-W&E=&:U\?<.'@FK:%*''FRS3R!?(+,DR9AT:UYY4HZ
MJ4ST&Q@V*Y>F#8UK43I>Z1J.IW>JW!NKV022E0HVJ$15'8*HX Y_6N822O*V
M^1BS8 R3\?WGCC-1O\K((\NV#I_$:Y['V[+G]PD-'TLB/#0B*UWLJ],:YPU<
MY%]55&HC5[=UR5T3_*MKZ=^(]A4'@ D*?GY) [\\CBL?[_M]/Z?7_?BISQA?
M!' 'OOX@B'WUUWZ,:WOK_'?7?*X3DD_))_<U\ Q\G\^]>[GROM.*4XI6'YJ"
MTL*:355#$_(F,093.5&M$!5_G_)51.W-14Z_Y+]?:IS;LFBCF66;E4.0H[LV
M./V)'^]>&)Y'CS_W\X/;N//>H%YO70L1,5I[$19K%?[A Y.OD]D1&J3V7M4[
M5/9&HJ.^D7^UY>[.1[L#;&0AP07^.Y.!V^F3@CCYSY*C!8YYSP>#]/KQSY/S
M]*U_7X=MG/WM;BV,6BPS/5&VD]JU56UB_P ?F27,4*&:BK]_ TKE3[:Q43ZW
MWO=(T_)NKF(NO_I1CU92<9P47A>/]6!X^IPM'(_8@=\<<>>2?VQ@@=^:\+KQ
M:W9$V3J:!.K*[,-=7=G_ /M+FU=@D8^.0@$:YT5[9,N >5&EA<J?F0FN,US2
MC8)'?&YVA+U992VEZEO&UM,(V6U,J[_4)'M;"AE0AL^UB1C')YJ9TNPTMK6^
MFOKQH[N"+?:0%6"7$A[*&5'Y!P=K  YY8 5:)BN)XS@]+%QK$ZB#14T/Y21Z
MV -!":\Q%(<[D[5Y3&*Y7F.1SR%(Y7/>YR]\Y[++).[2RNTCL1N=CDGC _D.
M /BM(DGO^7]_S_F:XN?LC!JO-:77-ADU9$S;(H<R?28Z8KFS[*+7B<>8^.GH
MHG/ !CSN"I&F4+'%:-PVJY/2V\[0O<+$Y@C8*\H'L5FQ@$^,D@?&3CO600S&
M(SB-S"&V&0*=@8 $C/R 1GXR,]Q7[L6ZL,=PS(;RN>(1ZNLESG'*B.2.&,%Y
M3&1J_P 7.&-CG(COKM/I%7I.>[2..6XBCDR5=@N!QDG@ GX)[UZM8_6N8(<;
MC)*B ?)9@ /W/;S7\S[?^^-F>0.^\OR3<&P-A9?AEML.8K84W*KF2.MQ-,D)
M\L>FAG/(A5[ U**V$.+#8@?4?H-4Z3G7]+T-!"OI0JHP#E47OW)) R>/)_(C
M(K][:'T9+IO35JNGV5O!>-8AH@D$<8>?TB5$C*BLV7QN=V;DY)\B0T:G\0*'
M)\,N-?4N4Y_DL)%GVHVQ;.=B](Z,<(JB;-';"8RP.[Y6%L MBJ!AP!&THB%:
M--MK)D,JLJHJX$;JRECD'<3@D*>VW!).<D<<SN@=+]87*P2W=LL5HC1J\=[-
M!"UPY&988Y$B<,#M<* ?<@+?@YJY[PRS*WR'+M=KC&87F/T'YD^'ET>\8R$E
MI6093W'C+!GJ(8!I,58L<07+-&R6.>!Q6N,H(G4D]&"68HLSDJ4V*25[ *2!
MN!VJ3N.%;M@<9YQ]KVE::ESKFF:CI%G#+:Z8+C1[2QE5@+N]CA,>H175L'68
M!,&:)]HBDCF@G19&0O;#N3:F$:AP&\U=1Y'=%WAY$5\VJPC_ $<@9-M0P7J&
MOKIME*9-C2::'82#G6'(&]LPJE^>(Q/@^9*S;V\NHZA'=3H@TW3F5KGU@54@
MC,B*NTAV&!N'X01@_!_)G3_2VH7\UQ,ML);6R<R7<COZ2M%$6+K&[<%E 9CS
MA<9)\51K^JK^E3Y!8C$H=]X*S(MS5D[!\7KMP$@K9W>6U&0XW%)$%=2XAS2[
M>WH35Z0@$EHDHU8>*Y)#!Q?A*R2TG7+&ZNY;?9'9(TS&V7*QQM&6SMR J!S[
MN#C=D?Q5^M/L*^U+IB.U;H[6;B/23:23CIZ6[<"TN(IW,CV[3-B*"YDE>612
MY"2APJMNR&VIKJ[,_P >M>A-#1) J&H852"_DQPX,=%8YKD5S2->Q4<UR>S5
M3^2=I]31&R9PIYWX...,D_MS^G?/%<C^URZC&O:MZ;@QR7!8+N!&1@?P]QD$
M*<?P]O)^61%CS8XY(V_:HBE8O_E(J?X7KM4[1?OZZ_Y_?-^&;80<\C]/VY ^
MF,?7XS^?Y90QSDYR>#\\XY\_I\8\UO#0F?YK@63Q[;!;Z?36(R"=*C@D/_!L
M@B>BK&LX#GI&L(I&H]OK(&YS$<Y1/$_^29[Z#3]4MS#>P1R94A)=F)8V/ ='
M #*P)Y[@G@@@T5L\@D?(_LC]/Z@UV3M<Y43-\%Q7+#1FPSWU+"GR8K'J08)1
M1(DD8GJUJN$T[2?$JM15'Z]_??.(7MO]TN[BVW;O0F>,-C&0K$ D>"1C(^:V
M!S6:<U:4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5';;EH&FMH$Z7
M'"]L5X)\&08 9" E1W*YCV(5KFL()S$<U>O9%Z7M%]52Q:3&LT#H6(#;D=02
M,J<=\$$]_I^I[Z,S%'.,'G/S]?(..3R/Y'-87-W#A.951JG*A-!+&SJ/9P'C
M>YID[]7N"_U(%4<U'.:UQ&I_7JG2\W8=*NK.99K*970GWPR9'!XP".&/. 2%
M/U->))DD7$BX8?A=>,8YYYX!/C/Y'-:KV-L;(B:XO,>Q'* CE'I[*OKY%BQ\
MA&&/&,**LIB$:]X6E<QIF(K%>-55JHO7)*#2HGN#+); 2[E;@>T,,'X'QGZ8
MY\FL^FW<5GJ%E/>,[6D%Q$\J(P#F-7&[!/\ %@'&?@ >*K7S7=FTM:X'H?'<
MMNXU?-69EIM@Y3,N/RQ2*Z1(=(JHZR))E(H:@/S-;(*7U6.@80&L8)&I)) L
M=S>LB*%:.(QP!0H61%"N%P />Q#>T?B]QR6-=HT_IKI7K35+O4Q=PVUJBQ+;
M6HV0R3LJ@;B"< L>7 !]Q)R<EA1-'SFP\AMU3[?&;<&;0,5V. T[-;.EF!IW
MQ9LUM9()6(=Y7D#%(Z.HG-1JM&%I!.5G7-Q(K>VC,@7#LI9P2"V0NY@#V;:.
M^ 01GCO7[+Z3TS3]%T*WM;,W<BM;R16\5O,$C^\QV[2QQ/+&P6(S^F8T=FP[
MC;G.*SW"=IYAK78L#-K_ !:)GM#JO/)N3'H%@MK5L<7Q>\5MPTQ$$_HY(\.7
M*:<PG.0@V.03VIZ+[N%%Q9R0.XB%Q&R+*#^#(/N!_B [X[%>Q'>N0/U?"W4E
M_H.@O+H\VOZ(=(><3":>/7-3MI Q,S[6"M<RQ6;8<LJEFSW O8\;/*^)%W/O
M+.L$\=C_ "Y94XKE V#O(<.+34ERUUC*GR\D_;G5]A"MS2F6D.0Q[&DCO"('
M8T[;"ZCI+W&G:3:R:FI2-I$#;&*2LH  6,-E6C0%2"/<<YP>:XYU/T>-.Z1T
M6[O];M(;B&>XM;JP=52\CFB;TS'+%ZF\20$-&XVGE23[MN8N^6F5YIY2[<PH
MX7XG:->3(ZH514[ K9T6A;3B/;6$%XF/(6OO8D2/+DN(_P")+ ,<:1$^6(5B
M2VD6]KIEK<1-NPHC#2>BP#L[; W;W@L0&Q^'C<<'(V.A[;1+#0=4O;VYECO-
MT8M5>S:2.Z1R4V*^5"[R<$C=M!PPPP-1QC;0V5X^56KL=H16E99Q9D_:[<DH
M[296WU[C<B5$^+'66KXSA38'QPI$@J%?."D@KAI&<5C@NVVLK:^:Y5B)8P#;
MM"XW1QR+G+E PPY#_P#M8[0<C(-3<N@:/?VT]XL<7H13PVCV,953)//G:WIA
MEVM@[CG!P5"D$C&V+[R1\QLXUU8TEO)EY-C>V"K045]E=;5R<KET]LPWS8M5
MW,>/#L4@RWD=$M4'[1'#"Z,C&H1S788M)T:WN$:,)'-:CU)8HY&6,.H'^9+$
M24!3&4)!P>:0Z1T?IVM6:26PMHK%HKFXM_O<LT;L &]2:$$P[D&=F27Q@G)J
M9WZ;NQ<'TIMNXU-N;$X^O=]7\''L/AI"I_GKYT>3[W$)TG(/R#D&2T9(K(PU
M<B EJ"'VT"B]&U_J:">^LX[JRF:YL8FEFD)8#8RC80L>!D)ASV!&X]QS4#]I
M#1ZZJ7'3,EQ=:!9F:9HGE),#J"K,(B%)5 KE3AF4%AD]ZMW\L]H8QIO0^;[$
MRBKJ;D=#$!^R5US7"M(<G))LH4*E:Z*49&JC)AV&(_\ AZ!$5SB-:BKRF:5;
MS75]!;PN\;2,0S1L58( 2^"/_;GCSVKD>EV3:A?V]JI91*Y#LA 98P"TA4D@
M9V@@<\G [UUX\M\K]W[>UO29+L[9L<6+R,D-CA,&QPM77Q[E3$)*K9,K&*X;
MI3*NNKPF>(IOF;\L-BO?[$8C>CPZ-86=PT<,!-QZ/JB9P[;,^TXD)VB3)Y/!
MPQ'>NYZ-H6AZ'JEHUK;-=7@07+R3AI/03)!PY&U9"3C Y;([Y)$7ZO0.3;"Q
M+86PL*RA]!C^J*N;E^69I8SY^-PXD"V%[Q(&/S(/J6==%0:A=7A]6F>>,)3(
MI%3DK>:A;V20PWJ*[W.U88E E+;1@N^XD*G&=QY&.!5FZPZGM-3U[IO3S91R
MK+*D+VR1I(S2$JJ$JV JY ))!.!\]Z#K^HG;5S&75S+.RF@?D9(52^6-[9)V
MEG*P9485K7J0B>KD]_YHU_L[^W<A9P+N>..!=D#,NYMI 8<%QD8[ 9'G@8!)
M%?MSH[HG1)=)N+N66STVX@L!<32N\:G-M;&5DRSG&/3"!4]S, %!&!5[WBQY
M![!\:)T'_LENS4C(E=$I["IF =)I[:/ 8P8F6=6][ 2/C<COC.WT.)SWJ(S/
MD<BV"YL=.U&V2UO8A(B8$4B';)$=N"8W&2/JI]IQR,#)_#7VGZ-+K&HWTSP&
M\99IIO6A]\B#N\FY<L%P,MGC/?@58CJC]0WSQS':20; .!R->K$?-+9#Q@8&
ML?\ (UH80!L.IGF>JJBM64JHU'.5_2(G*]<=)Z3$H51*P.=L@E;=^HY7@?3R
M._<<-FT#3#H4VJ1Z[91:A!=K;#0VCF-])&P;-SZA A],$;=H)8,>P YG9IS?
MFJQ;@/;[HSBOAYY<,&&J/*:@\?K"O=ZL@GG*0P:PW](#\AP@K[M;\J*B*_4U
M/0-173 FEVCR6R$F?8<S,OR(^#(#YVY88P!5.8A&"O[?@]AD9!Y[8^@)^IJU
MR/)CS !E1#AE1I VE!)CE8<!Q/3V80)A.<,@WHJ*U['.:Y%[153G.F5D8JRE
M64D,K JRD=P0<$$>01FO=>[GRE.*4XI6DLQS"UM[(^'X8UI;'U<EE/\ ?H%>
M%J*CWE*U'(-$Z5J-Z4A'J@V(OLJ\F;*VAB5;J[/M&"D6.6)[<$CDXY[<><=\
M#-AL\8S_ #';C//Z?MR:8%K'!XS4M90AY-D8G^D^9<H.42%,;_XC 0"*2/%:
MUZ*H#>CR/9T1A>E^OE]J=ZY:%6-O;G\,<.4#J>06<89\C&X9"YXVU[0HXW##
M?.<$@^1_Q],#/%<CGN[M::NRG7.#Y=>.K,BVE=.Q["JN-6SYRS9X_@:[\E\"
M,<-7":^2 7YD]T>+\A$8A.VN]=&"RNKJ.XFAB:2.V0R3OD81<$DG)R3@$X&3
MQFMJ.WFE21XXV=8@"Y X7.?]@?[(K[-J;DUYI:II[O8UZM%77V0UN+U965]C
M9$DW%J]S(@/@K(LLP@_Q<\\LS&18PVJ\Y6(K>_EK9W-X[);1-*R(9& P-J#N
M220,4@MYKE_3@C:5\9"J,L?R'DGX%17VG7SM8^5FLM\93FQV:QRNL/JU(I[.
M14T>*VUI"-/JYENKYK*B; M)D-S0290!&BR3)V4C&A]9NR].\T:]L88$%];L
MMV&"!Y)XE<*Z1G&Y73() )R,A0,D59M-A74M'OM+MM-EN-6@8W4;0H\LA@C;
M-P?25&<NBC;N&-JGQDYX_>.5Z5UAY1:(VGDF4TE9.R.-DF%V4PUI^1#C)*J"
M#HK22,;I,6M5\@B5JSW-B?,$C6DD/$!R-:>EY<Z-J=I'$[*C03H I!)60>H@
MX!;VC=@DX(X&36;3+/5K[I[6+2"VD>.SE@N6!B(=!EFF1"0&W$Q*S(#G&[(Y
M .^_([8V-4>F-HM!-BWMHN%7D4-'3S(\VT/(LJPH(8FQHQ"'&^1^0QX'.8BO
M14>/V3[Y%V%M-)=6Y",BK*C-(RD(H1@6)8C'&#G_ &KST1I+ZCU;T]:3E+6&
M75K199KK,4*HDZF3>S@#: I5_C."0<5T_,I_2I\EMG56(+ICQ\N(45:WN\O,
MF+#Q<=K(DHR4LE'W\B&=[4(9[&.&)S'"8Q$5?M$ZQ:=66&FI<1SWD;!GQ'%$
MOJ%8P&5E)0'\?!.3G.<]^/Z-Z;]LWV0],32V_56LV-\;60K:6^GQ2W[P*@,8
M#?<P8V) SMF=E5BQ*@XSJV5^FSY@Z-V7@."Y%CV&8YE&SG_A8]%E9/7V=?)"
M*?" \EB2M^9(D>-++&>]Y')TYK51'(UW-F'J+3+ZUO+A6=X;<;G/I%'5L,0$
M'&XE<@#/?@>*NTO_ %(_8/K]BD6GQ=531Z8\E[=3Z3H1B_P^&*"16DE:>XC#
MQRQ.\*KM?)+9YPPG_@_B9O6^VP#QTR*]HHVX8,.T)G%]CTTB8I3-L(4>UKA*
ME1'B15,0+H(B26QG&C$*./V1YR=Q+ZM9PZ?_ (@BR"S<JL$4@'JOL8J2-[,2
M =S8W9QD$CFOS5UG]HG0%Q?WG5W3&CW&I=$V\EE]TCUF$1:M<7(MQ%=1,)))
MI%CDE:X5E+^DZHDY0+&FW@1:_P!@Y)G,?46)X=D*[5U)<2393FV,6-Q99-*2
MKMZ^M.!L /NJ$KS(]PK%DD,:17E;ZL T*.-N&:UB@,TUU!]SO85]!&$:1?YB
ML_+@@@.,;E*ED8<Y;-<MO)V$=QU7/G2>D-5<&QL8+1($CWY86<4[@+.TC"0R
M +A@"2-BD&_#PWW_ .2.U<OSG"MS:9M,.Q3$JH'^GLUOZFRH;K("OEH&/'MZ
MJ8']M/)DU[G&*>I.X32QGJ42?D)Z<\UO3-.LHH)[*^BG>9V#P12)*L6!DE71
MB0H;@!^3D8[5P35;72PKWNG70"O<%5LF]TL:MO;*N.ZQ[0IW =UQX!BW9^,>
M7;T\M_);&$OL<PK!\0JL;?15>/4%:ZJC6U[#CSJHUC"B#K)7[A.B#G'MWMD$
M=\GPD:3U^,*S$>JQZ9HNES!9+B:Y:82"60[@L1V,48[L*"0$!&,8K<OON<G3
M=I<R7MQ<:E-.UN()0Y6*.$;W<RN6WK@QHBC&"W;VFHR[;\.][:FFB2?2P;G'
MY,G\:-?T$\!H#U>OJQTF,=T>? 5457.0L=PVI[(AG?2\FM-U>SU([(I"DO=H
MI05;'R&&48#Q@D_2J0UNY8$ D#SX\XSCD<_O^^.!I,=C:^BD*<@IN02 N85P
MU[%%9]]A G_$]ZJJ(\JHU51/XHU.^3<FV&+<6^JYS^9/TR?U^.U9$4CV@'/G
MZGX\<&NP5X]]KI'5SW)ZN+AE*9R=]].-%:5W_P!W\XYJ;F34;US_ !7$I_\
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M#+((]OJ!F"K&K!@"S<!B0>!P0*_/;=3Z-<7=U<Q6EQ)9P&0VS.(ES'O;TO\
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MHCC-%%"I&F.=1@"BM5$36N[IX4>8JSLJE@B#+,0,]@/ Y) (&/I7Y=OM2O\
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M<QZ(YJHJ(O/JL58,IP0<@_45\(# @]B,&J0?+F/E.K[6=C>3 M 8]>N.VDR
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MC[LDMMYX';-0FJ=4MI3#1X[0A(&$DN2H(=QP$('N7:0V3MY./&:N[\>M/?\
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MDF*XHXTY&'DP627(D:PEB(,K^DZ9,;BVB-Q&UI-(N1;SE$E.1P0NXDYQN4$
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M&MFN]5BN1(\ASQ/$\5*ZFZ?C(?4=/4 \O<VZ  $=S+&H['N9%\\L!P:S*2N
M?PGD$GD=N.^<<C QQSDXJT[^_P"N<_K+3BE.*4XI3BE.*4XI3BE.*4XI3BE.
M*4XI3BE.*4XI3BE.*4XI7&7-8&YK)M8?M!RXY!>R=>PWN:J,(WM%3MCNG=*B
MHO72_2\]QNT;JZG!4@BOA&1C^_\ >JL,BI]%4V5Y'A6W-4X]>OC3R2#3!Q65
MV415DJUS)L::,L1UC72V$4P5:=7C<JM1W;?7DX6FE19[:=HV(&Y03M)[=CV(
MQCL,@]AYQ<#(*@X/&>"#^F3S^PXY\UJ':6+^"-12.?28I8AED5KGQRVMHKE:
MQ'.40P/L"L1_NB,^0B*U/;M%5/I=VQEO@Y^\R!H\84<9)[Y) !P!^?('YCV7
MPI4%@#X.=OSV)Q@?WGDU&*JD8WD5P"PH,7HL.Q6N:@XT6#$^.3,^)$5I9<M[
MW29"_P#"\Y'O3Y'(]K41GTV4R<<\^?U_E_?>L6_')/<<9Y_4?7Z_OWYU'O3+
M(.;5L["H2?..R:ZO*P*]B;%*J!>O2K]*YB+]JGKZ=IZ]_?/"@EP0.S9&1Y[C
M^?\ (\\5LVMZ]E<174+;)8762-@.5:,Y4]^P8=_/Y=L#\9M"YU@NSM25&K,O
M=&.EI&QB-!M8#9\^JP^TEN=D5936(O1T.,6O/8B^:0-[Q!,@A%1414F)]2LD
MTNY@O+?U#L)C8.5'JIS$67!#;7VMM)'*@G(KH&G]=PSS73:U8"Z:Y+S22Q85
MI;D)_E2R!L@[9 C$8&>,Y/-=O  _B"$7_P#+$,?_ /HQ&_\ XYRLG))^3FJ
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MB".?Z0,4+$<]QU5R-:GLJJYR+Z]]*EGM5EO3ZCGT+.+D#.T,%\DYQMQ^>,$
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MD#SF)#)($Q[5'GDC)/@#D^ :@+:SN;R3TK6%YY,9V1C<Q^ J]V)P<  DX/&
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M48CCUGD^0S"L%'A5\4DDY3$<K6J]S&]":CNU<0I&C8G:N5$1>9'EAA4O(RJ
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MJYB#=($I0L(Y?5CWM5R*WOK-!((Y58]LX/8X!XSS_/Z5Y==RD8!_,9_;^_\
MFH$0=L9/@+B8QDL.8$<!5 Z#8A)%E 1BM:OQ(=K7*)%3V8X:/$1/Y#56JBK;
M;..*<*ZX+$#D$?!.#SSQ\X_(=JBY4.2",''D>1Q_P/\ [KDI.SJ"]B$>$[$>
MK'.5JN;[(JHOLG?2>RITJ>R?^R?XY,QVK @D'']]_CX[_M6!$.X$#/)YP/U\
M=L_/?S5<_E_J7%?(K6UUA5M$'),AGV%+*:%II-?<1_8D*;%Z3W4@BHWV:U4^
M4+BB55:]47=-N\>V5%)(7:Z@?B7C'D\YY/G('.*_0_V(]=KTGK,2W<B"RD="
MPF<")2"3G+<* 3D'(P>2<'%:$T-KWR9N\!7#=^R<>K=;8EAEGAFO\$I8<* )
M%5J1HV1SX,%/A>5Q1K>O+8J:SF6ITD/(!K5;S3;3Q#*;A5(E:19"Q!+'R0V<
MD CV[1^$'MFK]J7V@]*Q]37$^CL=5O;[61J6HZI.[2D[9,FR@F.&>!8O_#IM
M(ACC4!0QRQR/(O.&NQ; XF(;6L[C4U;J7%F4FV]NB:2YDS:&GEK4UM?B]0"O
M-);D&0Q9E)40C%(5B!D&FL8Y6(\?O_#_ $@\J*LB2REHHQ[0F_W,K-V 5@[9
M R/P@9(QXZP^RR!=7N^N=%DL]2L==,6K:+H *1NEU<C,[7,DCB-[>UNH[C=$
MHR6 #[5X>#>W_P!3#6.:88'%O'/0DG(:8$=D:#E632B5YZZ)%'\39$>BK$?,
M:5'(X_\ WNRBD)(*>4YB*557(HN(<M$GJ'/(SA2?XB20V, X[<@!0<5U7[/?
M^FKK?J".QZKZHZ[D@L&N!+<:/T];I-.BJ5=H)+B^*P2.!M3;;VT^%4 -M7C,
MO&+<EMCEGK;<$6FF#E816XW>W,2,!(]_(@W5F*).%&L$626"^PCV,:!!/8F&
M,_RA$=6#(]";-Y"MY \#'F[B]BLWMBD5 <% P#!6!8C&<C<!4C]H5GZ6C:]I
M,5_&-+GZKU7ID175O'"+E46XAL&N8)&,<=W8RV\<]W'%E-_WA58-Z9'9>\A?
MU"=5^/FI<-V-;TMK=Y+F\:DGU>J!V-969U#K+9S$/9V\(KY;X4&O]D&Z3\!1
M2SN$.,]S'O*/GVG:#=ZC<S01D)'!Z@>YV.\.Y,X52 -Q;';.5&21V!_!MYH=
M[9ZK>Z1N@NKBQG>WEELI!<VSNAP6BE08D0GR ,8(.,5L:U\S=34N=Z2US.C9
M23)MY8W39/2,K*A+2!C==?CC?M!,LEQI'M6BG2Y#H(I0P2(S31SO.0(FH]<"
MZ/=O!>W"^GZ5C))%*Q?:7:,G<(P1EN!NQP<?D:]VW3FK7::A)#;#&EI.]X))
M$B:-;97>8 2%0SJJ-B,'>YPJ*S$ ]>CR RC9<[)/(A8EM^R:/SO>N>5S(<3$
M*'*AV]B:4&JRA</R3(Z63%J99@1X[)DJJF >0<R9_L*2.$J]'TR"W:.P5M[W
MEOI\#EC,\0$8W-$L\4;AI%SO"J5P,#G#<=VTOH[I^\TGIIK'47DUV*RBEOHY
M";<6XGVNT5S$'$IC]IC0.NR1=Q!P3CB]/VF8Z@J)_CW;.D8YC^QK>)M.^Q[X
M8,N3>8T" #_2\.1:$*6V%7SYXF..*0P$4H1"(,91R&*_2U,17UW!/;XD:,-
M9!N"PG=B3V@!0_\ IQ[LD@E3Q718NG=+FDFZ]M(C.W2JG2EO'+1VLFMR1JJB
M'V;)IK))#, ARCJ0=JQ&I2Y9;S;"M!*D%C-<H6C&-CV-& 341H0C&G_ ,8_4
M;$1$3U:UO7WTLSIEN(E*JK=P22"2Q\DG'.>Y_,''FOSOKMU$]Y*/4#$L2SL<
MEF;)8[N,DL3DYR><D&H_Q,B-76/;BJ0;BJCNU_@B?:=])WTB(B_VY.__ %3K
MDU/$^TC ' ^/@$9YSG.!Q\#/!JK7$D7(' ']X[_OG Q^@J2.$WTJ[>&-155K
M>S7>B"BU4&98E(JKTUK118YWK\CO5J+_ $B]]KVG*S>NL 8R.JJO)9F"@<X
M!)&?KQS6B947G XQDY& >PSGL">W.3WSVJUSQ'U+EN( RG/,]JWT=[E:0*ZF
MH)#F/F4N/USY1U+,1JJD:;<RI(S'B+T6.&%%:;_<<Y@^=:Q>K=S@1MNCCS[A
MV9FP"1\@   ^>>2.:CIY?48? SCX^/@> *F?R(K!3BE.*4XI3BE.*4XI3BE.
M*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI
M3BE.*4XI3BE.*4XI3BE.*5A^78!AV>07U^68_7W,=S58UT@7K)"B]*JQY@5'
M+CN[1%]@F8O?,T,\T#!X9&1AV(/'SR#P?VKRRJP((!S_ /51"S+PAQ0B2[+!
MLNO,4*P+WI7S0MR"M]6(KE8QI#PYS55J*C5=*,O?JBHJ)RQV74]W$42>&*X7
M(&<F)LYQDE0P/?GVC-8S!'\8&,?..?S[#^7?-0\ML#3%3.KWR'3IX7.&:6Y/
MC:8C>VJX0O<GQ,[151J.5R)VBN=_:WVWNQ<H'VA58# [G&/+'&1R/T^:PONC
MX!(&.<>1CQC \Y[><GZ<')B/$ B.]E<Y.ND[Z1>D15Z5._M.O_Q]IS,W^9[>
M,#OYSWQR.!S\GZ?2MFRNE@D1U]I^<X[8.3SX(//TJLGS!P'&J\,G*,JQZRRG
M"[(*0\[QFFJ!WDN]J1-<_P!6U#Y<!)1?C["K_P EI@]A.'MXV^J,.@:( !9
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M&^0'D-4VE3A'C!2:VR5= 8WEN+5(($.5C4'UQK/*_''5)+:O_,.LFP@2G/\
MCE1GPHZ0F(GJ.#-MIT1T^P8/-J,ES&-0:*1SA78&2%F!"OM'#C(VD,<YY'YT
MN[31[2VL5OK_ %.;JZ_NK=]1CBE]016MS(QO&OKSU#*]U+%A?NC9=5DWS,IS
M&=&[!SK9?B1A7C'YA[.RM^:;GOR2<+V#B065L:[VKJN^%^[58'I7PP1"76&J
M85C&G. QX_S8D*29Z"0:R4$-MJL^HZ):Q"*TCQ-:S-O*VUS'[)#ER66.?LR
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M$F6).NVMKX7HXB.^E^E5W:JG]>J?UWWR1T]O2=IL E1A>W?P,_4D9K')R/\
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MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI46O*)LF-BC9S!L6,Z/,AE.Y/\
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;4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g129231g33v00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g33v00.jpg
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M @,! 0$            ("08' P0%"@(!_\0 5Q    8" 0 & PD,!P4&! <
M @,$!08'  $("1$85Y?5$A,4%189(3A8F-/7%T=55G>'E9:VM\?6(C$R.79X
MU"-167FX-4%"<G64)#:QLB4W0U)AM.'_Q  = 0$  04! 0$
M!@$" P0'!0@)_\0 7A$  0,# @(#" P)" 4+ P4  0 " P0%$08A$C$305$'
M%!87(E56D14R5&%Q@925EM+4U2,V0G:QM+7!TS4W4G6"EZ'"4W)TMO D,U=B
M<W>2D[+1UD;A\0@E-*/#_]H # ,!  (1 Q$ /P#ZRZ$H2BWBBZ7=W>EZG=79
MUJ>NG)S<W*N8>N<7)Q70]G5+5Z]:J9S5*Q:L4FFJ%2I0:8>H/,,--,&8,0ME
M: ,#8<AU!;8[.?'ON(IKPPA'D>%7 [!Z@G9SX]]Q%->&$(\CPF!V#U!.SGQ[
M[B*:\,(1Y'A,#L'J"=G/CWW$4UX80CR/"8'8/4$[.?'ON(IKPPA'D>$P.P>H
M)V<^/?<137AA"/(\)@=@]03LY\>^XBFO#"$>1X3 [!Z@G9SX]]Q%->&$(\CP
MF!V#U!.SGQ[[B*:\,(1Y'A,#L'J"=G/CWW$4UX80CR/"8'8/4$[.?'ON(IKP
MPA'D>$P.P>H)V<^/?<137AA"/(\)@=@]03LY\>^XBFO#"$>1X3 [!Z@G9SX]
M]Q%->&$(\CPF!V#U!.SGQ[[B*:\,(1Y'A,#L'J"=G/CWW$4UX80CR/"8'8/4
M$[.?'ON(IKPPA'D>$P.P>H)V<^/?<137AA"/(\)@=@]03LY\>^XBFO#"$>1X
M3 [!Z@G9SX]]Q%->&$(\CPF!V#U!.SGQ[[B*:\,(1Y'A,#L'J"=G/CWW$4UX
M80CR/"8'8/4$[.?'ON(IKPPA'D>$P.P>H)V<^/?<137AA"/(\)@=@]03LY\>
M^XBFO#"$>1X3 [!Z@G9SX]]Q%->&$(\CPF!V#U!.SGQ[[B*:\,(1Y'A,#L'J
M"=G/CWW$4UX80CR/"8'8/4$[.?'ON(IKPPA'D>$P.P>H)V<^/?<137AA"/(\
M)@=@]03LY\>^XBFO#"$>1X3 [!Z@G9SX]]Q%->&$(\CPF!V#U!.SGQ[[B*:\
M,(1Y'A,#L'J"=G/CWW$4UX80CR/"8'8/4$[.?'ON(IKPPA'D>$P.P>H)V<^/
M?<137AA"/(\)@=@]03LY\>^XBFO#"$>1X3 [!Z@G9SX]]Q%->&$(\CPF!V#U
M!.SGQ[[B*:\,(1Y'A,#L'J"=G/CWW$4UX80CR/"8'8/4$[.?'ON(IKPPA'D>
M$P.P>H)V<^/?<137AA"/(\)@=@]03LY\>^XBFO#"$>1X3 [!Z@G9SX]]Q%->
M&$(\CPF!V#U!.SGQ[[B*:\,(1Y'A,#L'J"=G/CWW$4UX80CR/"8'8/4$[.?'
MON(IKPPA'D>$P.P>H)V<^/?<137AA"/(\)@=@]03LY\>^XBFO#"$>1X3 [!Z
M@G9SX]]Q%->&$(\CPF!V#U!.SGQ[[B*:\,(1Y'A,#L'J"=G/CWW$4UX80CR/
M"8'8/4$[.?'ON(IKPPA'D>$P.P>H)V<^/?<137AA"/(\)@=@]03LY\>^XBFO
M#"$>1X3 [!Z@G9SX]]Q%->&$(\CPF!V#U!.SGQ[[B*:\,(1Y'A,#L'J"=G/C
MWW$4UX80CR/"8'8/4$[.?'ON(IKPPA'D>$P.P>H)V<^/?<137AA"/(\)@=@]
M03LY\>^XBFO#"$>1X3 [!Z@G9SX]]Q%->&$(\CPF!V#U!.SGQ[[B*:\,(1Y'
MA,#L'J"=G/CWW$4UX80CR/"8'8/4$[.?'ON(IKPPA'D>$P.P>H)V<^/?<137
MAA"/(\)@=@]03LY\>^XBFO#"$>1X3 [!Z@G9SX]]Q%->&$(\CPF!V#U!.SGQ
M[[B*:\,(1Y'A,#L'J"=G/CWW$4UX80CR/"8'8/4$[.?'ON(IKPPA'D>$P.P>
MH)V<^/?<137AA"/(\)@=@]03LY\>^XBFO#"$>1X3 [!Z@G9SX]]Q%->&$(\C
MPF!V#U!54=)O6]=P'[B7O%@4+A?NM]TGW4]Z<68XY[I>P^\'V'W0]QT*/VSV
M/VQ9[+[3ZSV?VI3ZGT/7F^GD8 <Y /+G\:P3;<.-O;<MNSL5J_'/Y/=$?D:K
M#]B&/,:SMY#X!^A;EPJIA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%3O
MTL?W@OSI_P .,R1]?Q?O6O/^1_:_RJR/CG\GNB/R-5A^Q#'F-9V\A\ _0MRX
M54PB81,(F$3")A$PB81:TG-RU/6:E(AL"QH;#UZXG:A&@?W]N;EZE-H0B]JB
MD)YX58DOK #+]IT3ZC9H1%Z,]/6PYX5VU/IVQ/CBO-[MELFE;QQ0UE9!#,^/
M);TC87O$ACX@6](&\'$"WBSLI38-$:PU3%-/IS3-[O5/3OZ.:HMUNJJFGBEP
M'=$^HCC,+9>%S7=$7])PD.X>$Y6"=K3C/WY5K^M#=];GD>,;0GI98_E\/UE(
M/$[W4_0#5/S15?43M:<9^_*M?UH;OK<>,;0GI98_E\/UD\3O=3] -4_-%5]1
M.UIQG[\JU_6AN^MQXQM">EEC^7P_63Q.]U/T U3\T57U$[6G&?ORK7]:&[ZW
M'C&T)Z66/Y?#]9/$[W4_0#5/S15?43M:<9^_*M?UH;OK<>,;0GI98_E\/UD\
M3O=3] -4_-%5]1.UIQG[\JU_6AN^MQXQM">EEC^7P_63Q.]U/T U3\T57U$[
M6G&?ORK7]:&[ZW'C&T)Z66/Y?#]9/$[W4_0#5/S15?47*1RNXU*#BB"KRK+U
MAQ@2P>LEK207Z8]Z"'TSCU!9)8>O>NL9A@ !_K$+6OCRYG=#T-(]K&ZLL7$X
MAHXKC3L;DG RY[VM:/?<0!UE62=R#NHQ,?(_0&J^%C2]W#9JQ[N%HR<,9$Y[
MC@<FM+CU K?B=00J()5)3BE*9246H3J$Y@#B#R#@!,).).+$(LTHTL01EF $
M( P""((MAWK>3!CV2,;)&YKV/:U['L<',>QP#FN:YI(<UP(+7 D$$$'!7/)(
MY(9'Q2L?%+$]T<D<C7,DCD8XM>Q[' .8]C@6N:X!S7 @@$+ERY6+23]R4X_1
MER4,[[<U;-SHC,$2L;S9<RF*T9X-^B,A820K-&E4 W\0R%&BS@_^(&NO616L
MUSHZ@G?35FI['!41DMDA=<J5TD3@<%DK&2.,;P1NQX:X=84\M_<N[HUUI8ZV
MWZ'U154DS0^&H99JYL,S'#+9(7OA8)8W#=LD?$P]3BO&[6G&?ORK7]:&[ZW-
M7QC:$]++'\OA^LMWQ.]U/T U3\T57U$[6G&?ORK7]:&[ZW'C&T)Z66/Y?#]9
M/$[W4_0#5/S15?43M:<9^_*M?UH;OK<>,;0GI98_E\/UD\3O=3] -4_-%5]1
M.UIQG[\JU_6AN^MQXQM">EEC^7P_63Q.]U/T U3\T57U$[6G&?ORK7]:&[ZW
M'C&T)Z66/Y?#]9/$[W4_0#5/S15?43M:<9^_*M?UH;OK<>,;0GI98_E\/UD\
M3O=3] -4_-%5]1.UIQG[\JU_6AN^MQXQM">EEC^7P_63Q.]U/T U3\T57U$[
M6G&?ORK7]:&[ZW'C&T)Z66/Y?#]9/$[W4_0#5/S15?43M:<9^_*M?UH;OK<>
M,;0GI98_E\/UD\3O=3] -4_-%5]1.UIQG[\JU_6AN^MQXQM">EEC^7P_63Q.
M]U/T U3\T57U$[6G&?ORK7]:&[ZW'C&T)Z66/Y?#]9/$[W4_0#5/S15?43M:
M<9^_*M?UH;OK<>,;0GI98_E\/UD\3O=3] -4_-%5]1.UIQG[\JU_6AN^MQXQ
MM">EEC^7P_63Q.]U/T U3\T57U$[6G&?ORK7]:&[ZW'C&T)Z66/Y?#]9/$[W
M4_0#5/S15?43M:<9^_*M?UH;OK<>,;0GI98_E\/UD\3O=3] -4_-%5]1.UIQ
MG[\JU_6AN^MQXQM">EEC^7P_63Q.]U/T U3\T57U$[6G&?ORK7]:&[ZW'C&T
M)Z66/Y?#]9/$[W4_0#5/S15?43M:<9^_*M?UH;OK<>,;0GI98_E\/UD\3O=3
M] -4_-%5]1.UIQG[\JU_6AN^MQXQM">EEC^7P_63Q.]U/T U3\T57U$[6G&?
MORK7]:&[ZW'C&T)Z66/Y?#]9/$[W4_0#5/S15?43M:<9^_*M?UH;OK<>,;0G
MI98_E\/UD\3O=3] -4_-%5]1;"A%N5;90U!4 L.&S%0D!ZU6DCTB:W1<E*]+
M0-'*D*528L3DB%O00FG$ +$+>M!%O>>U:M1V"^%XL]YMES=&.*2.BK:>HEC;
MG =)%'(Z6-I.P<]@!.P)4;OVC=6Z7$;M1Z:OEDCF=P0S7.V5=)!,_!)9%431
M-AE> "2QDCG ;D!;$SVE&DPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A%3OTL?W@OSI_PXS)'U_%^]:\_Y']K_ "JR
M/CG\GNB/R-5A^Q#'F-9V\A\ _0MRX54PB81,(F$3")A$PB8101I5B9I!-.1\
MP?6MO>),=?TTBNWIS2)UJ\J-Q1 P-\?8TYZ@LP2=M;$VQZ(2D[ 7LPP9AFAC
M]'8>(62FIZR\ZVN-7!%4UKM6W.W]\SQLEE;16^*DAHZ5CWAQ9! P'AC;AO$2
MX@G&/IS5%;5V[3G<SL]!4ST=L;W/K)=N\Z662"!]SN\]?4W&ND9&YHDJ:F7!
M?*_B<&M:UI#1@R%][D>_ 3-^BT/U&2;O*C]R4W_D1?44']D;A[NK/E,_UU&<
MGDUQD-Y%SSBP:[,:"W*SJD%T31"Z1\ELCK) ='LI:QS4RM:F)8PJ&I/)(^YO
M"+:L)S8T/"!R5Z+2G>LUF]BX.A;/WE3&-[^C:1!$27;X'"&9P2" >L@@;A8/
M9FJZ9]/[(U@DCCZ5P-3.&AFV3Q%^,@.:2.H.!Y+NR;DAQ8B4C@$=>9Q6A7W2
M%5@((_(R%L84PQ,Y5BD9U<P:W^7%*-L+ YH-/K6E+0.:TA4H7J@(2RO:=A+V
M%K@<U[A0P>1P$M-/&'8>2&D-X,D'!W'5NCKU4M<QIN55^$XPUPJY2S,8!<'.
M$G"TCB&Q.Y..:VBKEU)H'22,BZ3U8B>H:V)7N7M"MZB2=TBK,MT5M&[R1 <I
M K8VQ7I01M*O="DJ51HXK91H]& ]+'['TQ (HH,.)#3WM'AQ', \&Y&#D#=9
M#=:P%P-RJ06C+@:R7+1VN'29 ]\X"_"29T<O<M,R&5U0M=Q1K<S"U)'V(*'(
M4/#Z7I2O2$E4-5N-:]$76^Z*]R]>B+K5?%O'L?38SWE!CBX<][1XXOZ.>#VW
MO<T]E:S./9*ISP\>._)<\']+'29X?^MR]]8QJV*0/=HRE;E4,>(Y*8+.[$16
M,TKX,MKI+&Z[<XRU2%0NDA;SK6M%J).0,"Q$D6LZ4IM=M.[FUGE(R%UWL;38
M<31TX+7M9P&F9QESP2T ='[W(D$Y& =\6^RU9EN+A5EKF/>)!5R%@:PM#LNZ
M7M=U C9V2,+9[$5 I0SMTAC1<1D3 \)2ES2^,0&9V9W1"?KTB5C<YH-*$2Y*
M<'^D4H3'FDF:^, ]ZRPT-(TD.HZ<$;$&GC!![""S(607*N< YM?5N:1D$54Q
M!':"),$? NZKB,47I5")=&8^L1JBAD*DBIF;E"900:'8#"3R34PRS2C [V$8
M!A$$0=[UO6]9CDM]!*Q\<M#221R-+'QOIH7,>UPPYKFN80YI&Q!!!'-98KM=
M:>6.:"YW"&:)[9(I8JRHCDC>TY:]CV2!S'-.X<T@@[@K!N&VQD4N)D":<-NB
MEC6O$V(D\TP\:&/L-A2%$SMH3C1#-&0W(@EHTNC!B]2E))(!U%% "'8[ESG#
M2C:;B<Z&WWB_V^D:]SGF*CI+Q61TT <XEQ9#'B*,$^1&UC!AK0!K]W)K':]?
M6\#&U%VTYI*[U[V,;&)[C<-.VZ>MJBQ@#&R5,Y=-,6@<<KWR'+GN)Q_E ^/4
MFDU<T(S.S@Q-<^22:560Z-"DQ"[F0&*;:T@HT@6D["H1@ESR])&]S5I325)3
M4F6)P&" L,*,R:M-3>;Q8=%T]3/1TEWBN%SO]12R.AJG66V=[QF@@F80^(7.
MKJX8*B6-S9&4S)6AV)"UV+N?,HM.Z=U5W2:NCIKA7Z?GM-DTG25T+*BA9J6]
MFKF;=JFGD#HZ@V6WV^IJZ2"5CXGULD#W-!A:]O P5Y!(LVIVB.P^-M#<E+"6
M4E1,R H.] UU>F</U&S5)X_[1JE08:H.'L1AQHS!"%N84&GK%:Z:.DMUGMM'
M3Q-#6Q04<#!L,<3W<'')([F^21SY'NRY[G.))Y]==7:IOE9-<+OJ&\W"LG>Y
M\D]3<:IYRXYX8V]*(X8V\F0Q,9%&T!D;&M  ]KWOL/X$:/T:B^IS=[PH?<5)
M\FA^HO-]EKKYSN'RVI_B)[WV'\"-'Z-1?4X[PH?<5)\FA^HGLM=?.=P^6U/\
M1/>^P_@1H_1J+ZG'>%#[BI/DT/U$]EKKYSN'RVI_B)[WV'\"-'Z-1?4X[PH?
M<5)\FA^HGLM=?.=P^6U/\1/>^P_@1H_1J+ZG'>%#[BI/DT/U$]EKKYSN'RVI
M_B)[WV'\"-'Z-1?4X[PH?<5)\FA^HGLM=?.=P^6U/\1/>^P_@1H_1J+ZG'>%
M#[BI/DT/U$]EKKYSN'RVI_B+Q9$97\/8W.3RTR'1>-LJ4:YYD,B$R,C&THB]
MZT8L<W9SVE0($I>Q!T-0J4%%!V+6A#UUZQWA0>XJ3Y-#]1!=KJ=A<K@3V"LJ
M?XBQ=\G=%QB9,5=2695-'K!E!"55&8*^2*'M,RD29:K5($2ABC"]8G>W<A6N
M0K424UO0J"U"M&J3%"&<G. "G>%![CH_D\/U%7V5NQ&1<KC@<SWY4X'Q](N6
M;S6D:S-CY%D2VJJ^.EKE[C14F;OT1BALF>.LG7N5'RWY6@&\N76H3Z]A;M*5
M76>3KU7^U!Z0T% .='1CX:>'ZB"ZW8\KE<3CGBLJ3C_^Q9*T;@4@$[ 8=Q![
M&PO"J//H6C;,Y"97]"4G.7,;L%'Z[;<\(R5:0U4V+-$K4Y2I.8<0 !Q>Q5[P
MH/<5)\FA^HJ>RUU'.Y7#?<?\LJ=QV_\ .+V/>^P_@1H_1J+ZG'>%#[BI/DT/
MU$]EKKYSN'RVI_B)[WV'\"-'Z-1?4X[PH?<5)\FA^HGLM=?.=P^6U/\ $3WO
ML/X$:/T:B^IQWA0^XJ3Y-#]1/9:Z^<[A\MJ?XB>]]A_ C1^C47U..\*'W%2?
M)H?J)[+77SG</EM3_$3WOL/X$:/T:B^IQWA0^XJ3Y-#]1/9:Z^<[A\MJ?XB>
M]]A_ C1^C47U..\*'W%2?)H?J)[+77SG</EM3_$3WOL/X$:/T:B^IQWA0^XJ
M3Y-#]1/9:Z^<[A\MJ?XB>]]A_ C1^C47U..\*'W%2?)H?J)[+77SG</EM3_$
M3WOL/X$:/T:B^IQWA0^XJ3Y-#]1/9:Z^<[A\MJ?XB>]]A_ C1^C47U..\*'W
M%2?)H?J)[+77SG</EM3_ !%K2P*;C<K3!=H^G30NQF3TE\+L".IB6I_8'L@
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M;$C@H2O*1KJ7@9V.W_':J")Q .V#[^_M2X;>^ 3\6ZQ]^Z3RJ'6#7"ZU+#[
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M*,*U0&:,:ML,+$BD_LK4RPZ.M36!P<+>#<'LW)WR3_QC'Q]JR&3+7#D7<(
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MGCCU)YC[G_\ =_I3[L3L:51^,5S>--B>>X\75F\ZZN^EM^^VIXX]2>8^Y_\
MW?Z4^[$[&E4?C%<WC38GGN/%U9O.NKOI;?OMJ>./4GF/N?\ ]W^E/NQ.QI5'
MXQ7-XTV)Y[CQ=6;SKJ[Z6W[[:GCCU)YC[G_]W^E/NQ.QI5'XQ7-XTV)Y[CQ=
M6;SKJ[Z6W[[:GCCU)YC[G_\ =_I3[L3L:51^,5S>--B>>X\75F\ZZN^EM^^V
MIXX]2>8^Y_\ W?Z4^[$[&E4?C%<WC38GGN/%U9O.NKOI;?OMJ>./4GF/N?\
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M:GCCU)YC[G_]W^E/NQ.QI5'XQ7-XTV)Y[CQ=6;SKJ[Z6W[[:GCCU)YC[G_\
M=_I3[L3L:51^,5S>--B>>X\75F\ZZN^EM^^VIXX]2>8^Y_\ W?Z4^[$[&E4?
MC%<WC38GGN/%U9O.NKOI;?OMJ>./4GF/N?\ ]W^E/NQ.QI5'XQ7-XTV)Y[CQ
M=6;SKJ[Z6W[[:GCCU)YC[G_]W^E/NQ.QI5'XQ7-XTV)Y[CQ=6;SKJ[Z6W[[:
MGCCU)YC[G_\ =_I3[L68P3C!35?R!/+FR.+GR7H@B WRB;R20S=Z:PCUU;VT
M*).Y.130;L.Q VI;"$BH98QEC/$6+8<W[7H;3EJK67..EJ*ZYQ MAN-XN%==
MZNG!SGO:2X5%0VF=@D%].R*0M):7$$A>3?>ZEK*_6V6RS5]);++.0ZIM&G;3
M:]/4%6X>[8K124CJUN<'HJM\T0<UKFQAP!4@<EZYZF$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(J=^EC^\%^=/^'&
M9(^OXOWK7G_(_M?Y59'QS^3W1'Y&JP_8ACS&L[>0^ ?H6Y<*J81,(F$3")A$
MPB81,(F$3")A$PBC]>B^Q43Q0X(""1#1+KOC2*?[8&Y0O)!!#&>0#=!R 9"5
M2%O8M+"V[2I<H$F(*/VF )0 1@ BAVK)KU%4Z2%G%:8I=54,5X[S@?,T6AU-
M6F<UA9&_H:3I1!TDSS&QKN %XX@#T;0%/IJ>B[H+M0NMK9X-!W2?3OLC4Q4[
MSJ!M=;!2BW-DEB-1<#3NJNBIXQ+(]G2EL;@TD2!R8KG*81,(F$3")A$PB81,
M(F$3")A$PB81,(F$6EJ8M-=:.[9TN:$K3]SFZIS5B/V50<H]TT,2 T#3NZGU
MP >H5+?=(?K4Y7I$E:+!Z Q=>]Y%M+Z@FOYU&)::.F]A-4W;3\71R.D[XAMS
M:9S*E_$!P22]\'BC;EK>$8)R5.=<:2I])C1_05DM9X3:&L&K9NEC9'WK47@U
M@DHXN!SNDB@[U 9(_#W%SN)HP%NG)2H,F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(J=^EC^\%^=/\ AQF2/K^+]ZUY_P C^U_E5D?'/Y/=$?D:K#]B&/,:SMY#
MX!^A;EPJIA$PB81,(F$3")A$PB81,(F$3"*/MZ1^P'UXH@Z#!=1(V&[XT]SO
M;8[ :RPPA,T2 ER$Z%C7(]NC;I8H;]'-@ +!G&;*,TD,T5L0(=JRCO%74Z2=
M:14&*DU50U=WZ"H%.T6IE+6LG-0TRQ=\0=*^'B@ E+G<+NC=PDCHV@;CIVWT
M7=!9?S1B>X:#NE!I_OJC=5N-^EKK8^E%(YL$_>E48(ZK@JG.@:QG&PS-X^%T
M@LF*YRF$3")A$PB81,(F$3")A$PB81,(F$3")A%&_CI*12<^_BA1Z+1_WL\C
M[&B^MQ=E+9MO@6]#&5(9#)-EF&>ZTI<=+_1=7H?JS%I:=($10-$:ZX1HJX&O
M?K &BM]'WCK>]V\=X4K:4U8@AH'BMKN%SN^;A/TN*BJ=PNE#(P6C@!/3NZ7:
M1:H^YV\7*[7$77N9:9NQ]EJYU:* U-1=8C;;8'-;WG::;O?-'1-XFP&24ASC
M(5)#)NN8IA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*G?I8_O!?G3_AQF2/K^+]
MZUY_R/[7^561\<_D]T1^1JL/V(8\QK.WD/@'Z%N7"JF$3")A$PB81,(F$3")
MA$PB81,(HV<A(BME+YQW4HW)@;@Q6_HK)U@'QY2-!SBD1,DD3F-[$4J$$3N]
MG"5@&F:4OI*3R2U!H ["2/J@^LK=+<*K1;XIZ.$6_6%OKY6U=5'3/GBBI*]C
MH:1LA!J:HF0.93QYD>QKW 885U#N<7B"TT'=*BFI;C4F[]SN[VJ%U!0S5D=+
M-/<+5*VIN#X@114+&P.9+62XBC>^-CB#(%)/)PN7IA$PB81,(F$3")A$PB81
M,(F$3")A$PB811ZH"1S.0JKX!,=':+8.0D[CL1]<QH637O,0-46.:-DB0MS?
MMY)VH5N'H/BW:]<MWZ11SB>%,4 J&:.K;I6/U<+GQXH]9W>BMO'214G_ .UP
MT]O=3<)B@A[Z9QR38JY>FEE.6NG>(VAO2>Z+;+';8>YZZR='QW'N;Z?N=YX*
M^HK_ /\ ?*BLNS*SC$]34BA?T4-/F@@%/3P;/CIHS*XOD+DS7-DPB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A%3OTL?W@OSI_P .,R1]?Q?O6O/^1_:_RJR/CG\G
MNB/R-5A^Q#'F-9V\A\ _0MRX54PB81,(F$3")A$PB81,(F$3")A%&OD)'FU^
M?..YSA*F6,C8;^BKXW)W<*T1LG<$K))"2HVS^QISP!=E@%!AY E@DZ3124[U
MAX1[ $4'UE105=7HMTUPI:$T>L+?5PLJ1*75\T=)7M;0TW1L>!42A[GL,I9'
MPQOR\' /4.YQ<JJWT'=*936BNNC;AW.KM05,E&8 RU4TMPM4C[I6]/+&31PN
MB9%((!)-QS1\,9:'$24R<+EZ81,(F$3")A$PB81,(F$3")A$PB81,(F$4?J(
M!8H7*]ON@;D6THKUEHH![OB4B*U -M,=]QM,&E&^H+!I7[I:1A3ZTG]=I5L&
MMBV/>X;I(7L5&K?9@UIC.K;B;/WX7EOL/WM1=["CX^5&).GZ(,\CCZ0C<N)Z
M-W03IDTO<_\ !P6P2CN?V<:B]CA$'^$7?ES[]-Q,>YN)A[U,QD)D#.B#L -
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MS86(0MIT!/I"Z]N;7NJ' 1T=Q]AZ1FT-!9(8;71P-ZF1QTK&/< -@Z:260@
M.><+4A[GVE&DR5MM]F:R0?A[A?)Y[I6U#^M\DM4][&N/,MACBC!W:P+*_@VN
M GS/N/OAG&O]%FOX;ZP]);S\OG^NMCP#T9Z,V;Y##]5/@VN GS/N/OAG&O\
M18\-]8>DMY^7S_73P#T9Z,V;Y##]5/@VN GS/N/OAG&O]%CPWUAZ2WGY?/\
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M)S6N=Q$@.8]F0,XXFD XVR >>-\<E6);?!_F;>-E4E:\SI?C_')EZ^$K$:J
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M&[6@O&R(.D29XI,9)64_LMX)A\<A&U3*6M=*[(/5G@0N*+9C44@1:,VJ3!(
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M,$[464>YDI$Z(2F.25UF:M2[R"90A;%9E)?6 1R!_<T25&G36NB8X@D<NH8
MYY[-CGK&">M7LGD8"UKN?6=SRX<9ZP!R!R!V<U,&25_ YDOC[K+X3$94Z1-:
M)SBKE)(VS/B^,N0_5>FX1]8YHE2AF6C]03Z2MN,3'B]25UF;]6#JO(!Y@''+
M(!PL8)&0"0#L0"1D=A[5[3*QLL;:D3%'6AK8&1L)TF;6=E;TC4U-Z?0A#T0B
M;T))"1(3H8Q"T4026#0A"%Z/7O>]U  V P.P*A))R223S)W)^->IA%7HU_WL
M\H_Y=D&_ZE;#R55O\W%+^>U9^PJ)1&B_G,JOS%H_]X*U6,&FEDEF''& *)*
M,TTTT82RRBRP[$,PP8MZ"   ZV(8Q;T$(=;WO>M:WO.>.<UK7.<X-:T%SG.(
M#6M R7.)P   223@#<KI#6N>YK&-<][W!K&-!<YSG$!K6M )<YQ(  !))  R
MHMT')JL<I]R"20A>I$]J[2&MD87!_9'$A[= Q=BT:ZQ-,W: I!'P)=)TX]J!
M*S KBE.Q*- V$L$ T?7Z?GO&LH[5,\U4E_,M;TU92SLJIQ;Z,.J;='!AXHA'
MT<9+S(1*UY+P"&CK/=$M6K:73W<XFOU/$*&'238+8::WU]-)04ANUQ+*.\2U
M.8C<G3=+*!&(6F!\0$9(+CHRO?[T'E+_ )3^+W[=7KGT'+_-_8/SCU!^J6=?
M+D/\XNH_S;T[^M7=6%9%%,% _I(ZKL*WN+#K'JQARNQ)3&[=XX6F.OVU:QH7
M::1RH.05:6;+X\S&2=S98ZH>ED6BKN)H;WIV;D+FXE)F\2LDU24+,<K2YNPR
M0YKL=9 ()QU966!S6R9<< MD;Q'.&ES'-!. 3C)&<#(&>:ITY;<5^;G*UGB;
MU3_#VO\ C@CK$[E%RGB$.E\F9$,@?[R>K;ACY2;TM10%UD; U\DI.SP)[E+X
ME4OAD#:3K(/0/4U X!4@3X'L>_DP, XW ;9+LC!VR XXSC.-^:V8Y(HR0Z1S
M^+@C) . SA(?[8 E@+L#\HAO);AXW<0>3#9S^:>1%L5]+@TL_<FN;EBQZ!*S
M*Q)*IZ26[45:LL0MA_<FD*F7S.,6#&2K'JIRB*EX6HHU+T44E!+(D3'+5^5:
MQ_2\1:>$N><;;9:!D]9!R1CWLX[;'R,Z(L:1QAD0+O*/$&N=EHR, M/"X.P"
M6Y&<'"E7Q'X_\NZKX/536<4=(#2\W9!<GSK%A\Q@"J83-_/F%LV/(*K%"I_%
M+;BL<KIR(;GA(Z'/3[&[/3F)W5J![DLYK.M(<,C6O#&@8:?*X@1N22<;@C'P
M[\U9*^-TKG'+@>CX2'8 PUH=EI:2[D0 "WKYY54<8X;<TB((#V^BN3A;),%M
M');<AAUY-^[.GTJCO1V6W43G*GB4[O;2QR@[)RS=8I(U[2XSE$D$WFMSZ")C
M:D(T:/#P/Q[5_P"3GRMR1&03G/+C]_'K6<RQ9.'1Y'&6G@\EH,['8QP<S&'#
M9I^'<%=2ONCZYFF\@8CZZG[';&E 70CFI=)C(*=3<=H^D8NBNC7&.:2@1S+(
MA7DLO*+6IM1#HPWMJ1XK7;:G<GUQ:S1)T;V&@CDX_:G?&^0&C\'C//.<[#;'
M/D<*KYHBPCB!R7\@[CWJ3(!RX. MPYV=^0Y[+;A_"N\>1O$:L>-$SX0FT:HA
MT3Z/SCY:%G/[O60[!L<BG&>81>VI0E+@\RDJ1?5%5;<R)+7\B7.2.4OJV6/)
MS9'2341N@W=&Y[0TLX<!C2>LX!!.Q(P#OV[_  JSI&LD<\2\63*]K0'<(XN$
MM&X&'. PX8P, 96K8EP3Z0E_BML"G].L;E;O.(WA<OY).4QD31]SIOW6O)WE
M+9D_C,P5L#L[R!7&V^E8Q0-82(3"A=UKDCGA:9G*5 (<]-=."0YRW=_!Q$\M
MG.)SN3R#0<<QRV5QEA!;PN(;%TP8![8\<<36N&1@'C+W#/+AW[%?7T<,!M^H
MN&U.TO>;$%AL"DDLIIW84SD6\-#U"ZUF<AB57R:/.7K1JU,?D-9-<1<VKW6(
M;WD@@_29U;4"TDU.#9C#@P-<,%N1V[#D1[V,?OW6K.YKI7O8<M>0[?8@N +@
M??#B0<9'83S4X<O6)5\='U_\Q](5_P Q.W_W24+DDUU[31GYDVS]IWE1C0?_
M #FMOSYN?[+LJL7R!J?IA%7#T=__ &9S._YB7+K]M46=(U?_ /2OYDZ:_5'+
MF6B^6KOS[U1^N-5AV0]35,(F$5?C'TD-'.O(9]X\.<5M>'*V>T[%I--;,M8H
MDAIA\M&JJL275-HF@D[?.71_;#VJL57OJ"YRV)QIB5)4RI*G=!N!/L@L?2MX
MBTAPPXMXB!PY R1G.>6^2 %EZ%_!Q@M/DM?P@DNX7.X <8_I;$ D[@XQNMSH
MN:O#URCT3EJ#E+Q]61>=S$^O89($]O0(UGE$Z2A0C4Q%C< ONTSE(B"W1I--
M:4IABPLEW:#A%:*=6\:FO2,P#QMP3@;C<CGZML_".U6]%)DCHWY R1PG8;[G
M;8;'?EL>Q>B+E_Q1"98I0N2E%!-J% Z.=J%BM6$:'7*!DDZN%/*J:@V]^E&B
MVJ8(5,6<?=?202.0@ SJ EKSR"#:\;-_*;MSW&V^-_CV^'X0G1R;>0_RL</D
MG?(R,;;Y&_P;\EQ)>8W$M:IKI$CY,4.J66\0QJ:L1I[7@YRNQ2)-(G"(1\V%
MI@/8CI(!XEK2YQ9OVT@5>TR1O6,1?6Z)C4H*=(S;RAY7M=^>3C;XP1\*&.0<
M68W^3D.\EWDX&3DXVP-SGJWY+IJN:O#Y#%Y/-UG*3CZFA\*F)5>2Z3G6] P,
M4;G2@"LTB(/+GM]]D;Y$>0WN*DEI4&@6&I&UR5@*$F;UAI#I(\$\;< X.XY]
MB=%)D#@?DCB X3N.T;;CW^W;FMAV1?5(4["&ZS+7MZM:XKMX4-:1GG,VFT<C
M43=U+VD.<&@AJ?W9Q2MCD:Y-R=2Y(@(E)XE#:E5.)>A(DQYY=Q<UHRX@#M)Y
M_!VJC6.<>%K7.=OL 2=N>PW_ /OLL:/Y6\84TT-KA1R(I(B?D,RF1'PPVT(6
M7)B(^C@Z>S5+X<RB>M+RF<FN51$]&Y&$!1>\XSWR:.VSA&L#3C9GAXFYQG&>
MK&<_!C?X$Z-^.+@=CMX3CGPXSC&>(8QV[+H<>>5-.<I?NK*Z5D)4QCM2V$AK
M=TF34M8G:'REW7UQ K/*<X0^L#T\)WMA*8[$9VY2L4A;%9$@0O3<-O\ 5(BE
M:HU[7YX=^$XSM@Y .1ORP?>57QOCX>,8X@2 >> XMW'4<M/Q84C<N5B81,(J
M]:)_O)>>OY%^%?\ _6OK)1J#\1]&_P!::J_]5F43T[^/FMOZKTE_Z+TK&LY^
MNB)A%6[T3G]WGQH_PS*?WC3+.E]T+\<KY_V]/^I4RY?W-OQ(L'^SU'Z]5*PQ
M2$0TYX ZZQ#)-"'7Q?&(0!:UKX_B^/>]:^/XLABG"^6\FGN<"_@-Q&H%)Q=Y
M=0I^XZ55:%<S./0ZTZYKE?*+F?:5D[1Q\LV./D Y%,B]YKRM+5VB<'\V3N+,
M:TJG!I>C88^I$2@UNU<2=&QO \<(((! R>$\+MG#(#MR,C&QW*W^*(32OZ2-
MPD<' ECG ,X\O:6N8=RW88!SN,C)7#R6J3G!44/Y(7Q,IE=<3TW-'+ A_GK7
M=#J"-!A[AQ#XN,]:FL,<U8K.RQQ-)>0#):2%L?8XSLTQ:G0U:^$:":7'@'T>
MU[0YQX@?*R<G&.!O5G R[B&1@[_ J,="YS&@,.>CP.'?BZ1Y=D\.3AF.9X3V
M]:W754*=^6/0V\WJYJ=QF5DVE.WSD.RH8..R+1? 1"5B4-<MKBBH39UKO34Y
M3*'0F"*X#$274M2U1&4[ [L;VV:-/DK<9<T<<+P,EQ+MLG8^V#02=P 0/?Y%
M6N<(ZF%S@&M;T9R6@$CDY[FM&Q)XCC<C;WEK2=\:>D+>YUR]D$'*Y7LK=+>/
M=X-=%L[Q905J4Z+2;C#6\:HVO7N9O?)M_<2+=A]J(GP:G9-:D/[1.&V7S>07
M/)TDZ Y+K2R3RL!^X(;D[XX6\()X^8/8,@Y)=@JYLD.(@[HSPO;Q^1OD/<7.
M $8!:YI'Y6,8' "T8RGD1PCY=+K7LHFK$O(\^N/<>0LD*&BY.66 I4AWT<5M
M(VS1ASG;Q;JM5K^9)-9A<7%Y$:O=9$4@.>%2F( 7F:J8W9P [&.?$?\ 1NZ\
M_P!/'O\ Q#:C)8\#BX,[$_@VY_YYF>3?]%Q;#;'(<6%]"=3II,BJRM$<TVM%
M,4E?PU-+!.2H*UQ%)B(ZVE/VUZT)R@*M;MT JVJ5!//"H/\ 6&Z.,T/TQ;+<
MAK<\^$9^'"TW8XCCEDXZML[+4?-GY&?+C_+'??[JI7GO:7_&;3O]>VC]H4ZC
MVK?Q5U-^;]Y_9U2LVXM_)EXZ?D)J+]W\>SPM0_R_?/ZXN?Z[.O>TW^+M@_J6
MU?J,"KMZ6/[P7YT_X<9Y<?7\7[UZ4_Y']K_*K(^.?R>Z(_(U6'[$,>8UG;R'
MP#]"B)T8GR<)7_FBY=?]1UCYTK77\LTOYOZ:_8="N9Z"_D6L_./4_P"W:]6(
M9#5-4PBJDM#I/RZNL;DC73O0+Z%VI!5 &B%HG>Q(W%I/;[I9EF5!44.?6F(/
MS8E=$=4O<VN-I2$6M%3+$86DB.R-+,$L5DQD:C4BPF7#G-+=QC&X!.2&@X.-
MCD;C/(YQUYVP<080\>7G. 2&X#G$$C;BPW/">$[C&1DCIV5TG4GIPE]^Z;Q2
ME<=7UWQJLODC;[<DM6"OIT.:8#.9S6C2PQXYM3#33?<^E\:C1D><R36(]MB\
MP]V90RL;LP+HTIH9BW.6'R6ESAQ#;!Q@=N3C!VY[@856P!V.&0'+VL;Y)&2Y
MH=DYQCA!.>>XP"005J.1]-(BC$;KI8NXFV^NF<M>+E ^0EFU*5:LN)4H[U<V
MODJK;VNLF^26'J2DVW'E4/2/L/K=K6GM4E;7B1,:Q$UA>AG QY)))/;R&,D;
M9//88&>65<*8DN\MH #<';VSPX@.PX@8X3D@NZMMSCN69TK2_97(:*-E5RNO
M#JN2WN;%;'99C"I&Z2,7&WF)7W%6<C)BTDA+FSL1;XY3MI>F@3P4^F;;A/B(
M29$K0-+RX#,3Q8:1C.#D;\+VM.V#CGU@_O1M/[0\0=G@RTAPQTD3I&[@@G9I
M!QUKW9'TOB",2"Z&=QX].I2*M5]RLD3?#K18$K=-'>F>9U=<+'E5(C%$< 56
M\2.F-I1>9+I.XGOON%$D,L4+&H[3*@/?*]-@N' =N( Y&_"\,/P#)SOR *M[
MW)X</!+@PD<)R ^(R@#?RCAI&!S. -SM8'Q&Y"J.4]%QF[QPC4 12MSE*!J9
M-2I%,@GIHC)72'+W9.^MS8UH%K6Y/["\FQY8C*/3O$;TSOY9I.G?:!%D8[C;
MQ8QN1C.>1QZLC;M&ZQ2,Z-Y;G. ,G&.8!Q@[@@$9S@@Y'4I+Y<K$PBK1Y>RR
M.03FIT<TQF#PBCT78%_+(YY>W$S92%N*<:8;61$-29H(M@"I=G1O0%;T'?I*
M%9(/BT+KUZTM_LVG=!ZUJ[W<::V4U1-IBC@FJGED<E4ZY3U+8&D ^68*:HE
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M1T"8GUS 2YS@1EQ>#D9\ES0!\8.2MH5.&-9PG#>C(&<9='(7')YX<T@8.<$
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M.9MY$KB-P([OK]MEH+G12<NL8191M;1I1$WJ*LB,J*67)$:*A@<<^4.>0/*
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MBQ7-US\Y*'$^1"4>@,%1&P# ;L06G<G()R<Y/;OGG[Z&:0D$N.0X/!P!AS0
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M;'9"M2$(U V!2PK7%M1/*E<1BFSP##N'RAU\)//R0>HG_'&.O*S0!I>>)I<
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MU5G'63>^IBE$=.7O)#V9?1IR8ID3SM_D2IJVVO+\L=65R7#) ;1T(<" 3Y7
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MG"D_C)VA:"[\:?\ $N%^=X]AKQYJN7R&J_A)[.67SQ:_G"D_C)VA:"[\:?\
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M3TU\Q6S[*G8)X,?,QXH_1XJ+^4,>&>L/2K4?SW<OM*>!.C?1/37S%;/LJWU
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M+4D(X*W0-^;./;>QU99KA2GJXHZ@U],XM/,!\,;P#AS&G9<W;>N+_AQ<U_\
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J>S>W>Y_NPN6>Q^V>QH_:O9O5^T>RIO7>GZ@KT*Y(Y$A4._/?X=_TK__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g129231g34h85.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g34h85.jpg
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M 0$! 0$! 0'_P  1" $_ =D# 1$  A$! Q$!_\0 'P !  $#!0$!
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M_P#WF^_#M6L6@TA%7013JM?,S*5S,S-57.9F1YS,_EF<^?W$]VX'$>^ +=D
M';[ 1$7M$1&+38B!&#B(B(\T1$<HRS_HV_\ NT?^E/\ [<F>Z5/@U?Z%?ZN0
M??[WPVWZ2[]?'HV_^[1_Z4_^W'=*GP:O]"O]7'?[WPVWZ2[]?'HV_P#NT?\
MI3_[<=TJ?!J_T*_U<=_O?#;?I+OU\>C;_P"[1_Z4_P#MQW2I\&K_ $*_U<=_
MO?#;?I+OU\R!U1I6KWG7^R=G778S&NJGKFQZXJ<EUJG$;B2+&MEP]@3Q#<6
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M)CI)P1EPMYBPP(9%,1^5%3.C12+3,M,:3(CXD(<PR^\WA+BIO4TSU^JUE!I
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MO&BI"-BYQV->Y%L"U<T.\ - V]K';!LJQT^]'4:SJGO*:@QU96JGTQH1BMO
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MMDH>2Y,8YCT+)0SYN==Q!=I;&C>:960J7]'=97F5I[Q&@@%T%=M"CE79UAE
ML@"\Q=HP&G$9$;)V&VW:HT\>2L0R$()U"91)8"KTNBTBLJK1*TA;L5C,5FF5
MH  AD3%IK@(P:L$,:Q83,@5";*%9<9E+/+E&GU]<@,$L)@61MBY]JW:?#PKM
MJ@4OLO<X@77<U2TD<I6+#Z%C)3.6S]SL; F#'+!;*Q5"37JU*B.P.PJVP115
M0E(&RPA+6N !<V5C#&$,<LK ?M/O<$HFX/N[69!-(%3<TA4Z29(U^?6:="H
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M+F;F4IW.%[]IFS1+"E=MV\LU;A71%2&;?77*80RF%&;#6([UW:0*Y*)J)38
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MXQCC&.,8XQCC&>3MV%_G_P!Z?EEVC^W)[F_W#?XO:/YIU_YJK/GKQ3^,N_\
MGC8_G;<M!R:R!QQC'&,<8QQC+J5W=FT*K)J$D+:GFTT6KGZ17!\\:%-@V:;:
MC-@L%EJ92O&QI$%9*X=,6JP3BH2RCBXV:X3>0_&6TVPVU8.U=&P-@6UXGO3T
MVG&!M4V;-=24HL+<HP<ERE5T@MJ#68PN.11,S,R"=KL*Y5I58*(J5W5$ 8*:
MJ*MAKG/K,2T#2]#FV'&Q3P8LY9,$,Q$1$IB=H=[PIY(JS?I"BA.ZUG8>2<D%
M5II$3;J=&CCZV3JTZ:#D2J:P,#1(=;2'J3H4)*J<.)4IHZ36HS IN@6BU) "
MYJ#"PJOI=F+7@#*UJ9-Z[ "V!M2QI$_M+,-:-@BL@8O*63<#O]N)L9%R>T9:
MKW>T)-<S59JQ H96,U$56%K$40JM*5%6$:Q 5<17%)MW87<-YC3(%CN*WA4V
MC-ZSR#%A*W7*]"UZSL 9M1BFAJ]6PPD( KL?88<?;(XL' '18Y5E:V6T,R93
M3W>OI];5(336B&#;F]VK&O<XKDTSUY6FN>QC7/*FPZY,:9D2YY3,R(S%.SNM
MG;$@?:F5G4BAV*U(0@*475[&*JDH4M241=4%F%J !AD3,1$$43,.O^P.S,#!
M77G7EBR&Y,Z8U>Y8.KT$/>#(DA7HCHYJ[BY,RMG2]0FA(I-4?%I"R@SX_P"%
MM9S/:=4PK%OMZ>C.5W-Q*%" S4%MBXRJI@.*#FJP1>I5D&DOGW=HM%G3,=$Q
MSC+G37-\':4M*+W$9Q;)->FNVU9H&5Q;7)(<RL:A9(]X42B#JC\.)Y9NJ[;>
MV62MMZ_@8FS2MUL)38>;+0G*5)L.V8Q8\#>3N!J&Z1 D=E5:3:*R%DL[8C Y
MHCY4U\7(CWAHD+B.MHZNK\/]%?<.*BNLE=+L+<6A3KR6EL3K9* <%&P-=[1+
M7$T6=W<R"J2MA1,]DV>(NTLZ=(WV6G,O=O3FH3]B+'*F-G RQ)WJY6$**-B*
MB5-A*R&W!K&8BC.]K]^O31,YR^(RZ*P>R_'34Z0@9:WK4,BA;1-V0&;K:1&U
M25D$0H@T^4V7"MA$S"C,QR,J2VVE.*GW/ZCI8'=/,R4\B[Q:[2O%<R;7&BWM
M^TUZT,,C2NB=<%D4R Q.4IXBW$DLYN>=?;=0]WJPNQ-E8JL'>5"(5L66%"*W
MLOA98X8B&$41FJ![:]A*T9('PVQ'HY:<='V>/+?K=/(8K9\4('UT>4H<<E7I
M<77,F-6!(BIHS0F*VA51$BJFXA==&PAC'#N'M.]0);2@EBHT$,.LAVZ6,-QA
M;D'"5V">QEB>]R^8LL98B8>PV%RGB/=5VFY5V1:;@L"4HK'V#EK! ,IBQ)#1
M(4+76_N.$1-9:ZTQ*%@L<<N360F.,8XQCC&.,9.]6_SFZY_S[J/[0#^1FZ_B
M;;?-E_\ -6Y+\/\ \>Z7YUU_YVK/6MY\^L^B..,8XQCC&><+WWZ/]U;?WA[?
MVNI=/NTMJJUF[+[N/5RS5KKYML]7K "+[&L4\49!FA50EC"PHE!?8F0","5(
MB2XSS3\=YQI:59W&X+XPX5I<)\/U+?$.HK6:^JJ*>AUZN#5,%<00,"3B1,9\
MQ#,1,3YIB)S3'CC@KBV_Q?Q%=I<.[:S5L[2RQ%A5-I*<N2_!-90/(@+E^"4>
M:8\\3,3$YB7]S\[Z^Q!W _5FW5]".9/]W7!ORGTGUA6_7S%?#_C;Y+;KT%WZ
MN/N?G?7V(.X'ZLVZOH1Q]W7!ORGTGUA6_7QX?\;?);=>@N_5Q]S\[Z^Q!W _
M5FW5]"./NZX-^4^D^L*WZ^/#_C;Y+;KT%WZN/N?G?7V(.X'ZLVZOH1Q]W7!O
MRGTGUA6_7QX?\;?);=>@N_5R4T;I?XBVN+M3]A5'I;V^&VNB6@!<JR07U>W'
M+1!L%8*Q#0:8N)*HKL64B,1A1WEQI+3L=]*,M/-K;6I.:%KC'@>[5LT['$ND
M.O;KNK/"-D@9-+UDIHP0L@AD@,HZAF)CGSB8G+BIP3Q[1MUKM;AG=!8IV$VJ
MYSKV% .KL%JBD2&1*!8 STE$C/+E,3$\LNL9Z]=_) R^@JAX96Z-8 -D4!O7
MME$4CJOVC?2[ 1M77VWE&&"]X>NECR858-9U@4Q'F&IE;&5U)*('KPXD3E%E
M1Z^(^"X94=9XVJ7G4KDW$,M;/61R.=?<UW92NI7JH[+L;UADR*A>;I FO8M8
MKB1;POQQ*[B:W UF@F]2BD]537;&8D(V-/9]J++=JT_M9=0KKB#:: 1!BI ,
M83)D#.K/$U;BGF5] >QKLTH-ZULAC2>K_96&5I5@ZI:Z:U?J:ZU=P;&A1%V6
M/6<2EG6;-#LE8*%2$B>U6X/H!S,&C.ZX!ZE3'%FM@%GNY:J=EKR7:3Q!=F_L
M*MB#410@G],*E!H>M8"$O+F<G6C0^4.!='W(["38O1"IO<+PLJ.X=I1K];;K
MRMX#VXH@I=%@7UV,,CA <@@/FUZ=\1"Q)N>!'AG[GH2MAUJTUNYNU#JQVG6Z
M:^6%GIML+%4KMTNU_$TADI2!B! .OX$TH+$G&6QE5C/3\2&>:^]X(1W;M.-J
MMN*;Z[ZT6=GJ^2N[5[59:_[GK5^U&5VV2QKNTM-(52RP4!RE9X>X[?WKL^![
M-/OJ+"+,UM=LIEG>;%6RQD39MV>R*&5%PM*>SJ*$VPNL)'U1(J;2_$SJ0_(J
M3X<^\[>+;@Z+9AC[-U<[3LQ8A7KI LP_6=@=;J<JK_'<J&BVEY)@#9LG*,<G
MI&S9U26^*'JCT;.UX"L'V@\94JS)+;21HV6KDB7NC0=Y,38K6.R$N[K%3D=C
M;4$F 6(%C(*M5T_E"K!V9<%V[2X#40(6-?L8$6:0'KH.F*UNOVI#%ELM38[:
MHX^@SKR2UR-E]F=0.[NPF ,]KP[^U "W.$KW8;Y8A?6;?36;2;N5S*6&(S\&
MF5TFAH;6Q<B*,%+3\'E*;<D,3OABXS1"5)4>+N$:<M">,-0ZO 5$U$LV%.>P
M56K+24]0]',WL$F,]L><#(=,3(#%W^"^,K@I..#=JFSUVW6WKHV8FPVU:8X8
MZ3-D0"%D*US'27*2@^N1@RE\K2WB=R%''6NB_9>)).U/K]3WI+?4W=TOX(/Z
MV5*J4W7\N+$+58B->G3!=.%/VA)."1&E9SLY<0<,B/MPV+<=]P /91/%.L(4
MV-Q9@9VM8>H]W8L6;@D2Y!D +++(K]F8&L(#J-A1)3<GPYY0REI?<ILA)M;3
M5I*-8\ND-%6K5:9"#)-<F:ZJRL=H!@PY.1!8S 1&[%UO\2ZZN 6KYT<[,6\*
M"/03RJY(Z=;-JPXPJ'E2'AA8CKS7E,M&19&*[(A36QEA&3$LOJ?@38)!F+-C
MUT\3<!U8=-7BC65VM4:NVC<C8-75[3%A==91V@%$&$FDQYQR,#"2 J#^%/*#
M;E,6^%ME94EP.["=1%<&]/MK8=)=6QV9C,@< X"B"F0,#@3':;LZJ>(!N_9%
MBV<2\/#LC23%JDY(&A5'ZT=F?B*25=6M<HHAJZQKH6CR9F5(P]'8+MC6\,M_
M!($;.7<N\ZOBK@O5TDT0XPUMI=<8!3+6PUW:BN(B!7,U555D(\O,4KED\YZC
M+S<NNUX0XXVMY]\^#=C4;8+K:NI1O]B3)F9)D1:?:8)'^48;"XY1T@/GYVH^
MY^=]?8@[@?JS;J^A')#[NN#?E/I/K"M^OD=X?\;?);=>@N_5Q]S\[Z^Q!W _
M5FW5]"./NZX-^4^D^L*WZ^/#_C;Y+;KT%WZN/N?G?7V(.X'ZLVZOH1Q]W7!O
MRGTGUA6_7QX?\;?);=>@N_5Q]S\[Z^Q!W _5FW5]"./NZX-^4^D^L*WZ^/#_
M (V^2VZ]!=^KC[GYWU]B#N!^K-NKZ$<?=UP;\I])]85OU\>'_&WR6W7H+OU<
MAGW.OQ _88[A_JS[H^A7,3^ZKAGY0:;ZRJ?:YGWW+<2_$&X^KK?V6>K#S3[-
MNL<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8SR=NPO\ /_O3\LNT
M?VY/<W^X;_%[1_-.O_-59\]>*?QEW_SQL?SMN6@Y-9 XXQCC&.,8XQCC&376
MK0A_8U 8/X@J O76JM&TDU,H&J$.'8""6""Y"DL(@YAJ>Q+4^I+*8_I,N*PC
M"L\MKLLBG;E/7VT5;$J[.)D^TA1R'1$<YD^KETQ'GY\N7GRZHPJ;M.'='8S:
MKPWM)B%]E+@AG7)<A@.GGU3/FZ>?/S9G]?Y/7FZY $K3'T13XPW?W;:DL-UM
M@KKP2G5U3@=>YVF&R>-$ZRV/:SK.)MFV8U7+K9*P6)6IMHK$,7>>FO0F8N(4
MQW-7M@1.VLD>GX=LSV\A<9[(6#W ;.0]EK]*NHNA%&7U4O6%>962ZH2XI+,;
MLZ6UV+'QJ*T+W/$E0>P%E)?L?6#2GJX9&HH7;#HZ[%^$6WUV,L1#!;;/L0@:
M'5-4:RNEBN8O7&T*N.U/!H DKLVJZ^VM81A[;$Z/<XC]:UV#E=CJ!I"*@@X5
MB#[$2-/ [16*0&#/6K,2S6B*#HYNL_87ZR*QW*#SV!W&+HV+FO2:=>!52%]U
MPZ6YM2Z(43$ J'5WVVMBOU(KDVVFC6UU&T^TNEL*X:X*2F7J]+8.6[8F-H91
M226\J:H>TE@@]C258KU%)FQTV+(IINR#ZZ[CUT+[$X,[0N$336W;3MS45')-
M#((RZ46H=<-9UZBQJE1A>SX=X<@X?L.*_5A=\MA%^41R&U]&C3"DUN]78;B'
MW.LNGII50K%LM>C7[&T':$RM;L[J\ZV5FV= JD%R3+K#*E<($.UN$0+":E0Y
MFM+M**]UVM^S&KV5C9:VHR%@NU3K:.@FH->HN^-N1YO[&NNW9,B.54A$V'%R
MT$<.YF.-B%RD4,2=,B(Q"8P++OP%"GB@]F0XW#(.C%R):QSDR.EN0N"N5)5%
M4YEA3[V49<5Z.N3):R:$+80#+%B?:0LYB)((9TCUP)<Q@^D>KESY1SY9YFT5
MBQ@J.6J$RA;"#LY8$%,"<KZCZ)(>12'473SY=4\N>4WG?.F.,8XQCC&.,8XQ
MD[U;_.;KG_/NH_M /Y&;K^)MM\V7_P U;DOP_P#Q[I?G77_G:L]:WGSZSZ(X
MXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC
M&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQG3<V9]C+;\O6R=
MA7>%V:U!!AW*]6ZV1(4JJ7-<F'&L=@(F6(DA;6<M+?C-34,NK:SZ-3B%*1_)
MSCFQ.L\N%+7ZZA1G06FS3IUZLLBZD(9*% J3@924C!=//EU3RY^WFN.U\A5O
M9;/8;".(:R8O7;-N%31:<KBPXVP$EVX]4CU<N?3'/ESY1D(]5M["^U)IG]$;
MOR^\>Z/R=M^GI^PRP^]\N?*6M]7M]9QZK;V%]J33/Z(W?CQ[H_)VWZ>G[#'W
MOESY2UOJ]OK./5;>POM2:9_1&[\>/='Y.V_3T_88^]\N?*6M]7M]9QZK;V%]
MJ33/Z(W?CQ[H_)VWZ>G[#'WOESY2UOJ]OK./5;>POM2:9_1&[\>/='Y.V_3T
M_88^]\N?*6M]7M]9QZK;V%]J33/Z(W?CQ[H_)VWZ>G[#'WOESY2UOJ]OK./5
M;>POM2:9_1&[\>/='Y.V_3T_88^]\N?*6M]7M]9QZK;V%]J33/Z(W?CQ[H_)
MVWZ>G[#'WOESY2UOJ]OK.09W[&FWTULN%K3/97469\VC%+RDGBJW/X(B(+/B
M #D%37_ULR77B[<A#F/_ (26F5I5_+4GEW'EQI30.][ 6ND+:ZG9]]3SF6):
MZ#ZNQY<HA4C(\N<S,3S\W++.?(1;C8!0^Z*OU'39<AG<&<HA;U)D.GO'/G,M
M@H+GRY1,<ORY.?5;>POM2:9_1&[\M/'NC\G;?IZ?L,O/O?+GREK?5[?6<>JV
M]A?:DTS^B-WX\>Z/R=M^GI^PQ][Y<^4M;ZO;ZSCU6WL+[4FF?T1N_'CW1^3M
MOT]/V&/O?+GREK?5[?6<>JV]A?:DTS^B-WX\>Z/R=M^GI^PQ][Y<^4M;ZO;Z
MSCU6WL+[4FF?T1N_'CW1^3MOT]/V&/O?+GREK?5[?6<>JV]A?:DTS^B-WX\>
MZ/R=M^GI^PQ][Y<^4M;ZO;ZSCU6WL+[4FF?T1N_'CW1^3MOT]/V&/O?+GREK
M?5[?6<>JV]A?:DTS^B-WX\>Z/R=M^GI^PQ][Y<^4M;ZO;ZSDBJ'V,-O^N6VK
MV&1V>T[(C@;$$-/QV:G=4O/LBR<6<ZRRI><(2ZZVPIMM2\X1A:L95][&>6M[
MRYT;E*Y4CA^VN;56Q7@YNI* [=1JZI'L8ZNGJY\N<<^7+GEYK_(/<HWZ5W[H
MJS.Z6Z]GL^X-'M.P:#>CJ[<NGJZ>75TSRY\^4^UG<XYKEFR..,8XQCC&.,8X
MQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&
M<8=T\9CPTM>7*W:_N79\2%M]$L]@IEK#+UQN6:L19JL6E@SPM<P;KJ8/E+'E
M8$N&N3 ERH;RF<N1I#[*D.JS*KY/N,KM9%RKH;;ZUI*WUW =;I:EHP:S'F^)
MB"&8GE,1,>U,1/.,PVUY0N"Z-FQ3M\04D6JKF(L)9#X-3E%(, N29CF)1,3,
M3,3[<3,<IR,_=R/"O]K$/[K]X_5CROX:\=?)R[_IU?6,M_$S@/Y3:_\ V_V.
M/NY'A7^UB']U^\?JQX\->.ODY=_TZOK&/$S@/Y3:_P#V_P!CC[N1X5_M8A_=
M?O'ZL>/#7CKY.7?].KZQCQ,X#^4VO_V_V./NY'A7^UB']U^\?JQX\->.ODY=
M_P!.KZQCQ,X#^4VO_P!O]CC[N1X5_M8A_=?O'ZL>/#7CKY.7?].KZQCQ,X#^
M4VO_ -O]CC[N1X5_M8A_=?O'ZL>/#7CKY.7?].KZQCQ,X#^4VO\ ]O\ 8X^[
MD>%?[6(?W7[Q^K'CPUXZ^3EW_3J^L8\3. _E-K_]O]CC[N1X5_M8A_=?O'ZL
M>/#7CKY.7?\ 3J^L8\3. _E-K_\ ;_8Y8';WC#^&7L2Z:G'9[@60?0!\B[3[
MNY0V^T^KY3DO(&/&J;9(IKZNU*RDH?PYZ<IL:B9*&XDI:ESHN'(\1YN8UO '
M&M*KL61PS)W"BJ%6+E357Q@>U(K$K5=[P@"Z8#FSH$^GF(ER(HF&V?E X(NV
M]:N>*0"F)6SM33O;.A,EV,#7AK:15G&/61<ER9!U<B(>8C,:/W2WP9_;5W9[
MY_$>_P"-<Y^Y+RC_ "5I_P!7^%/4\X^Z[R:_*VU_63BGU['W2WP9_;5W9[Y_
M$>_XUQ]R7E'^2M/^K_"GJ>/NN\FORMM?UDXI]>Q]TM\&?VU=V>^?Q'O^-<?<
MEY1_DK3_ *O\*>IX^Z[R:_*VU_63BGU['W2WP9_;5W9[Y_$>_P"-<?<EY1_D
MK3_J_P *>IX^Z[R:_*VU_63BGU['W2WP9_;5W9[Y_$>_XUQ]R7E'^2M/^K_"
MGJ>/NN\FORMM?UDXI]>Q]TM\&?VU=V>^?Q'O^-<?<EY1_DK3_J_PIZGC[KO)
MK\K;7]9.*?7L?=+?!G]M7=GOG\1[_C7'W)>4?Y*T_P"K_"GJ>/NN\FORMM?U
MDXI]>Q]TM\&?VU=V>^?Q'O\ C7'W)>4?Y*T_ZO\ "GJ>/NN\FORMM?UDXI]>
MQ]TM\&?VU=V>^?Q'O^-<?<EY1_DK3_J_PIZGC[KO)K\K;7]9.*?7LY,=>:BT
M3M:A4O9^O[[V L5%V)50%VII]GM;V[@M&ZO:!<4T!*MPBFWH).(@@,FQI28Q
M"%$FL)=PW*C,/)6VG#;.UVE.P^I9J:=5BLYE=ZBX=X=F5N29+8$R.L(9D3&1
MF1F1GESB9CSYF=;4ZJY71;K6]RVO92NPAH\2<1P+$N"&+.(+9P408%!1!1$Q
MS\\1/FR8_P#)DUQ^,G83];?M;]='*'L[>]XTW]7.'OV7E?V H^_[K^LG$7[4
MQ_R9-<?C)V$_6W[6_71Q[.WO>--_5SA[]EX]@*/O^Z_K)Q%^U,IV>IFHE%FS
MZB.]%'6ASPAHSGM7VDR5;$R)+$U\8V0SN3X6@>_,C1I;T)+V(SDF.R^MO+K2
M%)[_ '1;+LY5T:GLI.&2K[G]!V<L$9$62'L9TR<"1#!<NJ!*8B>4S&=/N<UO
M:0[KV_;0$JAOW1<0=I"R*")<'[*=4!)")2'/IDAB9CG$3E1_Y,FN/QD["?K;
M]K?KHYT]G;WO&F_JYP]^R\[^P%'W_=?UDXB_:F/^3)KC\9.PGZV_:WZZ./9V
M][QIOZN</?LO'L!1]_W7]9.(OVIC_DR:X_&3L)^MOVM^NCCV=O>\:;^KG#W[
M+Q[ 4??]U_63B+]J99S?03JSUAUD9W'O7:^_:#K:O2PT$Q9I/:'N8;:AR[ 6
MB P[.1U8VD:,O*FE9T2(E48<\AI3V'7U-,(<=1?ZRUO=Q<5K]9K]3;N.@Y4A
M?#W#8F<+ F'REFN ?P0$BY243,1YN<Y8;*GHM/3;L-GL-O4I(Z.VL,XCXED%
M]H8K#JZ-F1<I,A'GRY1S\_*//F 'W2WP9_;5W9[Y_$>_XUS*ON2\H_R5I_U?
MX4]3S%/NN\FORMM?UDXI]>Q]TM\&?VU=V>^?Q'O^-<?<EY1_DK3_ *O\*>IX
M^Z[R:_*VU_63BGU['W2WP9_;5W9[Y_$>_P"-<?<EY1_DK3_J_P *>IX^Z[R:
M_*VU_63BGU['W2WP9_;5W9[Y_$>_XUQ]R7E'^2M/^K_"GJ>/NN\FORMM?UDX
MI]>Q]TM\&?VU=V>^?Q'O^-<?<EY1_DK3_J_PIZGC[KO)K\K;7]9.*?7L?=+?
M!G]M7=GOG\1[_C7'W)>4?Y*T_P"K_"GJ>/NN\FORMM?UDXI]>Q]TM\&?VU=V
M>^?Q'O\ C7'W)>4?Y*T_ZO\ "GJ>/NN\FORMM?UDXI]>Q]TM\&?VU=V>^?Q'
MO^-<?<EY1_DK3_J_PIZGC[KO)K\K;7]9.*?7L?=+?!G]M7=GOG\1[_C7'W)>
M4?Y*T_ZO\*>IX^Z[R:_*VU_63BGU[)!H7QI?#9J6O'*[<.W,J60&;#W.V&D6
MRL=A;J?<H;VY;[*UCF?:#E)/&RV$ZW?JB8;IHO,,,04Q8A1;<Z/(8:H[CR=\
M96+L.K<-.$&4M7+8K+HUDQ;]BZ<7^A"6*4N>^Q8ZQ4L%]?5(1TS$S5TWE&X+
MKT939XGK$:[VU%16GW+3YI^RMV:'6]XM<V.XS7Z":PV=GTP<]43$7D^[D>%?
M[6(?W7[Q^K'D9X:\=?)R[_IU?6,E?$S@/Y3:_P#V_P!CC[N1X5_M8A_=?O'Z
ML>/#7CKY.7?].KZQCQ,X#^4VO_V_V./NY'A7^UB']U^\?JQX\->.ODY=_P!.
MKZQCQ,X#^4VO_P!O]CC[N1X5_M8A_=?O'ZL>/#7CKY.7?].KZQCQ,X#^4VO_
M -O]CC[N1X5_M8A_=?O'ZL>/#7CKY.7?].KZQCQ,X#^4VO\ ]O\ 8X^[D>%?
M[6(?W7[Q^K'CPUXZ^3EW_3J^L8\3. _E-K_]O]CC[N1X5_M8A_=?O'ZL>/#7
MCKY.7?\ 3J^L8\3. _E-K_\ ;_8X^[D>%?[6(?W7[Q^K'CPUXZ^3EW_3J^L8
M\3. _E-K_P#;_8Y?WKAXD_27MQ?Y>KNO&\Q^Q[Y K)&XRZ_&IFR:\ZU6A) 0
M+(D_AMNIH 8M$:>=$QU1VYJYB\S$K:CK::?6U%;?A#B305@M[C4V*%9CA0#7
M$B1)Q"9B$0MIESD5G//ERCEYYB9CG+:?B_AKB"R=33;>ML+*TR]BD0WJ!(D
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M-DK4J4T>'3EV'35=W=QUV0,%VJD#9<( 4$V$)/FL[!J@P1+ : .(#-#Q&4G
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M-NY:7<=L&\N7.]VJ4 %@>F10D41'9&X&IW9R\KF:.)U^OT.EENOHET#0B5;
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M3L3;3U.<J-AJFKCKD:-;!=8L\[7H)H]0J[>+,7N5EK%'BCFX%3 @WK/8K&:
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M6JYKZC]KHFNM*7:OZ\IH [2+38^YE;U0,U96380,$E6".4T<7VE8@^O#1*9
MDSM;P#41 ]8LA,?\RJ6RTFAX6VE,WON6^'RN[.J^[:<JTA'#+]BR^]36M%1!
MM5:]#;J@$A&\:RD^T 8]0N5!WG$'%NJN+0FG4XB&CJK::59+JEA_%*-<O7(:
MI2I=#-2W8/52:P@(Z ,#L^S,IQ>I6ANJUKKM:V.87L778.\#K:#JE#ONU!XN
M/*N5.O%7#R)T[=HOKX=!5X38ZS9)4.KXMNNZ_6%7^I6QLQ?1XT?% 39^SM=^
MA[Z2AIW'5#K-LVZFO,Y&M9JV&0 :MFY2YS46$B3^[W76.Z6*_9TS89.''ZNH
MX>L)KWF]]I)MKL*KT[>Q!<%:K6ZZB,]JO2N2A3T/(4=YI(K]\K689<  %);?
M;'4S4.HM1%6;?;#83L+"U[.OS50<+6 [ADP+W<1UF;H! &!TK(I[4"MA I]!
MG8J=WIAHV%7YM<^3C+$EA+7:AQ!L=CL0FM74W3%<&I-J%I5S4S5!>5<!K=I%
MF2>UJ953G5=<TW@_MID9Y\;'AS6ZW6,[U9:G=#2.W%66N=R:O;'0;3-2=5-7
MLT*4Z&WHVW3%U)H["(F.47U%UUT78.OXW8VS-@3P=OOY?>5?I$47,M;OQ68U
M31:P> 0L52N:5V"S<YMAL=H'Q[+!FW_7"JS4I0TXP[/S/4]"K;'<[9.W.E1I
M@VM47JG6C8->.T5L+=A+B[=VTIS6%*:YD@AIW>WL":I@.CD5OK=)J':8+U^\
M2;-MFV34!9V)E;==4KN2/=T:JZ-HW/L+AX%=HRBL2VQ)]?,;AE>K&A' A#9%
M+^7MTU=K>D6LS?%#MDBH%\/7,,"J[X^@F*18]*UZPZ;L$(@5L=GM,A0_;%1D
M4:HGH]0N!:8#FV65:!OMM#0I6NYU;]VU774ZZ3#J*JM:^#MKMIVCT;-1@M"*
MP]6NLQ;L**S64+@KC>,X?T\J.]5[Y:U]&I9;<Z+RPN.M*57D*;*C]4AVK<!G
M8L6"D-C6*I6<-6RTTF\MAI#JOIS;4V:\8%[)UO7=@GB-:TU(N]]ALVA1L5J*
MN[+,"X-2J^D;7-V4V#;N54.NW$T]H^B$M?&0<Q1L.:M+7R;[;3?;+7@,+.E=
M?34#]G%6F<UX4S8OHJ85BQM:XT9;-:PF*RXVUL+BVC"FJKSV_74\/:S9&7:K
MOT4W7&C5E;N -CMEZU%]JQK5]39*_"HM5W%:;.HIG2:DY:IMF.[SJF];]7[7
MN&J<;"@R*Y3"6K^F^O\ Y1!+DQ1F\7_<5;,?!(S 8)I_<EKO=VL,2M&IPB)
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MTBT8K?Q=]V>U .1'@;UN$URQ18D\.4A.DVW0)1$&/-/#C+B=?.MI/L4PBNJ
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MIM/E83=!B[DB':=(S;6UJ[,Q$=N#&"WK$RB=S)W1N&8.IP>9MC94H1KS*54
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MNQ@JB6A.SV1(-6NOM5-0KSRJ=D=?BS4J[.*TJ@!&@CH"(&>TF)8<HN.P]-;
MU@,(F4:'CZ_!]2:S0( EB%Z/L;"[&4.BPJK7'H*GLRK;%$%+V+8M!=0J:WI2
M;J\T;>,(D;CDS,+H5Z6QIWV J=L5QO$3[A,DIG2EI;=LK#Q.(Z:Y,739-=7:
M#.T"^I0JD=6(SES:NZNY06QOL0-)7#B*8J$8C>!O*=,*Z"'GU614RXH;#>S.
M-4>O<Z61.T,LXM>9WGG^.,8XQCC&=V?[%P_HS=F?R]B?W<UWFJWEU_&35_-
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MR-CK*1\USIZ.IDJ6"V'.TZ]!!5(JL/:PW8VKR^YJ5LHRC4U(NVV:Q5*AJTZ
M8K<YO>$\8=)Q&;T1(%FAJ: &$K36I!.D_'>P'+ !ABZ<?[[AAVK!Z]E.\O66
MJ*_9"U5U[[%F^ETO"=4!J64U%@N63<:R)>*[794H0XSM(ZZ5*ZE<-BN[KV;2
MK>;['5;>QKUJVO<D4'&V-;F#%MAL@(IJ7/8$RIVMV7I%=5V!KV5J==4ZYZ5U
M3B\N.Y7Z3+B\JSE;F7/+GTGGJ\JO/\N?/\OG>7/E\O,KCER\T<H_)$1RB(]S
MEYN7]'Y,Q&>?.><\YYSSGGSYS[O/\O/W?RYI\9QCC&.,9<G3/\\&J/RET/\
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M/'G=_$FL^FM?IQX :#X\VWT=3[/'JLFI?:\V-[KZQ])^/'G=_$FL^FM?IQX
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MA&.,8XQCC&<X?V/#_6;Z[_)IM_\ 8^1SR/RU_B67SI1__-GL?D-_':?FB_\
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M)I,&)6)S,#(#!TW0+>K=>U9>R8.Z]6#>P@:]E8FNF;]&V[BM:L@@8X>2)W*
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M^!/@NQ^LG?HS)WJ'X+G4'I1NL1OO3Q7<LR\!0E@ PF;K= !H%\"LH]0TBIZ
M.I@22Y(3&6KX,YB>E#3F?/4VYY,8Y!<1>4?B3BC73J]J=(JLN4_DBI"60Q75
MT3!PR?-^%,3$Q,3S]W)[ASR;<,<+;&-IJ$W%V^P;7F77#>$J=T]<2!QRY\P&
M8*)B8F/<F8GENY@>9[CC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC
M&.,8XQCC&<'7C>"11JA=:(1@8/+0\[=M+N8A.'&GQLNMZTL?HW,L2FW6LN(\
MN?,7YGG)\N?-SCRYY[]^YW6MO&&P!JP8'L*Z>E@"8\XLU^4])1,<X_)/+S9J
MO^ZZM6:?DTH.J6'U7?=+0'M:[F(9TE5N]0]:B$NF>4<XY\IY1SC. /[7>O\
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MIK#(B103S")$2GGRB9S7AZ&@D2+H<?IB).+L%5 WQ</73,HBR;0S-D+#NP6
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MB+<,C2ZG?/\ 8ENXO14H;C6U=H@[4)@B3"4VUK>PQA(N$X!AA F5NOM=Z_\
MQ%IWZ,!/\#R:[C2^!U?1U?J9C7L_O?CK;?6-S[;'VN]?_B+3OT8"?X'CN-+X
M'5]'5^ICV?WOQUMOK&Y]MC[7>O\ \1:=^C 3_ \=QI? ZOHZOU,>S^]^.MM]
M8W/MLY<?!?KX$#V2W"@&$$!42=(#%24"1L,<F0IJ^1,-J?3#99PZIO"UX1ES
M"LHPM6$YQA6?+J_^Z30E-7A7L4J5U/V75V2P7U<EU>7/IB.?+G/+G[7.?=S>
M?]QC>O7BX\F[<M7)6.CA<VK#K$K@IV$E 2TSD8*1CJ@>7/E'/GRC.RAS5'-Z
M\PH\1QII_HQV>8?;;>9>U4<:>9=0EQIUIQR*AQMQM>,H<;<1G*5H5C*5)SE*
ML9QG..97P+$3QEPQ$Q$Q.[UT3$QSB8FRN)B8GS3$QYIB?;S"O*01!Y/^,S B
M PX:W! 8S(D)#1=(D)1,2)#,1,3$Q,3$3$\\ZBOVN]?_ (BT[]& G^!Y](^X
MTO@=7T=7ZF?&+V?WOQUMOK&Y]MC[7>O_ ,1:=^C 3_ \=QI? ZOHZOU,>S^]
M^.MM]8W/MLE=$T;3+_=JC1AM/H4$C<;*$K$&:1K0Q,")+.$8XV/)FYB"I4K$
M1AV2AR1F/&D/X:2O+3+J_-0J.V[-;I]5L=L_7I:G6T;5YJDUZ\N8NJDW&"H9
MT!VA"$B'68#U3'40QSF)CAYO$G$>^TW#]7?WZ]G=;.CJJ[[.RV$5TNOV5UEM
M?*2:V% ;()G9J8?3$] $7(9N-5NJ%$OMIBUB@Q=>75S *SV,Y.K^K[3(17A5
M7$NEGG)<!^B1R<R05RS\5AF!L.5B29D08#[L54UA:H78;NAJ*#+^XT*]7'>Z
M-*HJY8T 3<L7[ UQA;AO&A05^KO%DWL7V=8&N 60HXC)=3H]_P 0[96JX=XT
MN[THH;79W[&N5Q@8ZVIJJ9VS)U=FM7;>RYT=TI+JI=VMUB*["5+UE-,L_58+
M4*_6SIZAUJ'FSTV9>(,%S69%O+(=@[""1/A)!^KLC$N3D362?IVY;L"##DC&
M9\R.0+CX;U>AN='LKEVI4J4&Q1V:M4UHOU)05DZC;3.S2#R?,*E1(Z"6+FM6
M\DJ--9S!M=KIN,=-KM9L-AN=ZB=KHW[]""#B,9"DN^FBCM;!UQJP5@7KM=H#
MCK5TNJA8>NQ<KI.*.==%M300UW1*FR-HCKEUF YK#*)MBB-L)DKD@HJ@>'R\
M=$9:)"WA[<AM+"DNY5AM6%9D8N\,DJV\;>B)- X7>=#]?*J3".5BNVR#Z*QD
M<2$ Z0*3B1B.<3&0Y5_*"#]?5-'&06=LN7:NN2]V+]DD0AI-UZ9&&7%BHA9)
MUA8,!,',],Q.?".O*7%V)MO1N''*@E2[:VC6>%KJZ$-/OK58DI"94$2EB-)>
M4HGB-A+4=]S.<(:<RGF;?#0Q2*;6C@=E,1KIEU"(OS) $12F2Y6IDV ,0CM.
M9& QYRB)X%7'QELA%?&!%IHF=P(ANI+51 &R9V41$S1B 6PYFU"H@%F4^8"F
M*)*T_6H*)KLW5H*&V-D0(9%R52($=$"65CR9@R+-6\,0F+((Q(4R5 8?RV[,
MCQ)+\=+C3#JD72PU#94*@UK2>#F)%8U3ERZYK588J!B98"&M4MQAS%1L6!R)
M&,38-O\ %:!>;[O$*0JLKILDVSLEC7=;4UU13R,QA++24/;76R1)RDM8N"%9
MS%5CZ!BRQ(X]%THQ)!&)Z10@U'UPV\)*%%N/LI&CB+894.=/4[%DM)AQGG9&
M7([Z,-Y4RYA-N=CAU=A]1C]*%NLF;%FJ;*(V*Z($"E[TD4,4F!8!2Q@B$"83
MU<BB9O%QQVZG6V"8XM;0NV(J4[RXW!T[=N28$5JUD>:7V)-31A*C-DDM@P/,
M"B/T'U_CV?*,5K2;-AR[#>(MX!ZW06RX/CR\CY$Y&( :1Y\-B>E4)Z4GRL-2
M\9C+6E[&4<6[/#M#JF\_2TX%HI*;;:-?I<:X<"B[8@Y--,PT5S^$2Y@XB1GG
MB@/'FUZ?8L>+MEUI.R'<(W-SJKK=-=CQ[OVG4E=B)0;8Y@+HE1%!QTYJDM"5
MH<!KMAQ0*=-A6$&3L/F0:E ?=#C!5IFU"0^9S\4I:AMK+PT-MO>E7'_Y[!:6
MZB2_AC'5#M0ZW=I]UJJ;3MHI<VJJ@-E]B@K9 %:/.3)BLV2D>F#_ 'II0,K#
MKGO9^ZRMK]9LHV^VL(V5"WLN5>]LF'2JT]L_3-9>_"@$#-Q(B+.LE_OZ (Q:
MR%YIP^OS!".6EP-)-3HH"''(G9,/6R),<*/EP<E(LXL\R%6V-AR1B5$8\F8I
MEEZ#C,MM:H^,N<Y;9X<2==;K&D4RXTTU :V@L[3ENBNQ5<3*">T'S"#6J"(7
M3"RB#_!SJD./+"[CJX\7/5KDKL;!J1W+5T:[J_>U/N&$$-9+:L396U\@!UX[
M82E?X62$_P!7XU=;KDZ=JROYK]G'TZ:-M;=#;36%.W4&/.CQN33P-J$X3B1I
M_H)T6.Z\I$F)+2QE]MKTF;.GM>';LW5*'7]\H.V:GZ\NXS?@=5;=3<^*HF31
M0PT]:6&(Q*V*D^B2Z8DMAJ^.M:.K>^[OYUVVK:1];;B[<1JNO>T:]^M5F\8@
M@K256.BPI9G(L4Z%]H(=4TTYUQA!';<YG4H<F#I-B*5@]:Q= :DU>(3%$,#7
M4/&OB5$.+Z9]<?+#<Q<:0I,N+A3*%OH1FM4O</6QUL<]8BUM:5>_3U]B:*[[
M$6$]N,C5ZI8SI"#ZR5!A$K9R*8"9BUV%7CF@>Z*;'$=JAH=G;U.PV]1FX;J4
MVJEGNIB=[D*5=;"7*Q>2F3#D\P@F#$P3[7>O_P 1:=^C 3_ \E^XTO@=7T=7
MZF8_[/[WXZVWUC<^VQ]KO7_XBT[]& G^!X[C2^!U?1U?J8]G][\=;;ZQN?;9
MD+U!IU1#]O.KLX35JX+G-[KJZ6Y@X&,A2FTN12J'$HD1HK3R4N(5E"\)7C"T
MYRE6,XSG'/,O+%5JJ\G/$9KK(6<)J\C!*P*.=ZM$\B$8F.<3,3Y_/'FSW3]S
M=MMK;\L/"J+6SV%E)3LY)-BY9<HI'66R&26QA!,B41,3,>:8B8\^=SSGS^SZ
MO8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQ
MG"5XU7_V7UH_*S:_W:6+FP/[G/\ '+8?,C_SFOFJ'[L/_!A0_P"\^O\ S6[G
M!)S=?/F-CC&.,9E3 VGKF+1<5DR8V/<@ZQ=4BB:%8Q8*3C7IN"?KQ*U&Z-L9
M1E90/#GP8-B8%"0U;",256)$6P-2OBC!,GY^[0;MFVF_6K:3668L;!EG;TK%
MM<[FHVI=3KZFVTL58KV6):ZD=BS9O6C7%&64R#O,H1ZY7XMX83H/8NY<XFW5
M,JFH33X>V56@W[F[U?8ZZUMK^AXFFZ5NDFPBOLEU*=+5T5MG9PK8@SN<6K5;
MM.[-=.L"1U?9*NPQT;LBTGX/20]4981M[6@.GU6-G"+;9#%@DP20U^39+':#
M)"P/-/X\V66;C16L6FOX6W8G8?<*N+''P04]>UL[$SGAS>7-EL#CGKJ-:F#4
M6 "C1H54TA(/.NN1L*;_ &W'?#)JJ5=<%LTUE>4X![+14]0"QXRX9U^GU"IZ
M=QL[NQ8BU5:W9[/:WK.Q,6<H;;%21RI1.Q%.CDM;G4HGQ$A+#H A:ZR.H=>8
M?<8TU&#0)$F/=%654TMA484^JM#G HA<=DO(%D"+<<=B4:HMX+V;$;RI,I9-
MJGQ@G7WG;>Z0"?$YV7 !ZN*,*K3VE@8O.BU9@RK#82DC?(5;E/E*TB[7#&P@
M;"8H[+R=6=QJZW#^N!A+X(72KL:K=EM)=;YIJ,G5UIHTY6NZRI8LBNM#;L.D
MV@-7^OA,&S*22,E[,1JM%-//C8I69JLH4$6>WXFUZ,2*$ZZD==J,%:$XGN,,
MDX]VN341\@RW*PQ)!0M7.,D6R7**M:BG8;:J(/977Q!719H:WLKK$(1=E^JV
MUHK/8P9(/5ZPF DB7UPKMK1UODYM4%NBU>N[2SJ-!>,ZJ;;^$K=JEM=U#]:J
MU;MZV*V]T-(*?>"6NTO>[L4G9 7=EM==;AKM9UQ#K,M3HFP5XUL$N.GQZ,"M
MBC$>]U4#7GX+1$J?$N5J7A(18\E-^ &X\P(00M,3X2'1!,5-UPU=O[MMY<#8
MIW:NFK/2>UMZZ*QZC86[@--%>G8B^KG;[9"NVJFNTDAEG9V9;6H\-<:ZW5<,
MHU;Y.IL=;>XCN5;"]#1W$W5<0ZBAK65PLV]C3G5NY49K6K'=[ZW4+(R*>UI"
MBY)E[MUL8S26BXP\TMNLGB%ZEOC6B4"?M*;3*Y01Y:2(A68&];*TH;4&;%/A
MDR8[#MCN5F:F"S 5IP88L8X5WE;V4*M8IS!7JB=2L'$AR= K9WMPZNNRVC;#
M7WH?LBHI970[II:RB2GUK1"^M*%QWPO=G1!=JWPD=5L+._<=4;5>QQ8_2:SA
MZO;;23LZ![?5S5TR]C81:M5Q+9;O:B^K<H@56[O)_8"C.74*=CQK"^,&WS0)
M]]:*U7*\^\(U?J>+0+*[$KH<PL&*ERB3+DT$!@2T"D0<MQE3X&$82FDG@[;#
MJ[-0F4@>[3\84P@KUVZ V=_Q">XHBR[9K#:L+6@H5;MM7-B7=1PEW/G-Q8\H
MW#\[RC?4K9,JU>(O)YLF$.KUNM,Z?"O!ZN'=F:=;2NS0J.;: GT-?7<-2$2*
MIL5XB(BAC=BZ>&#@ +X79R>*UK:56(%@,T$06'Y/RMJF[Q,?=U_)OK88W#2&
M*-Q Z[00)#FS$?$N=6FW%0YX>[?I>)7NN6X701-[>!?=3K;>S7=W1?#U34J
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M("99$LD;%U3+V&>MLTWL R-MQ;8]I4%. F7@M5L%SC)S S/#P+U#Q>,H?6Y
M.NKE@(!."/#O3Q9F$J;66XT-+Q"O34]<JKIJK]=7TNOBU4MD-K84]8R>UA-E
MVI9[%<P@751A=QJ'/LBE]5HJO%,,XEX0=Q'L-P^_Q'=K;FYQ-MBHW]>ME#4;
M'=JB:\V*5??IC?3#)*M?,FZZO:KUJ1V*EU$OU8U+8&XM>WO,1+)R^5?-5E!2
MH:?7ZC7 DNS2&-+ZKUJ1ANC0EIA"J+B*6UM(?"_%>3X^&#M1)+4-EV @87H:
M;AK<ZB&2534W_9!=FO:3=V5VVNB!\3\0;Q+1?:U[;&V[2OO "UWCN;FV]>B9
M80ME]>ZXBXTX:W_8PO8<0:F=2ZC;HV-;IM90=M&!P/PEPQ905:CM45-!V5WA
MAC*7=)V%9-#;6H!(G7&K<C.Y+=&D:[U55O,C-7"2$'FMFO02@TI'GO5: NA:
MJ8E*&2)3<,B'U\.5)DQ)#WPSTME=E26VG)?HTW_#.M8&ZXAV',RUJ[3JNB%M
M=Z#2.P=&WX@-</!<L19W#X & ,+Z:(K B%<3D5QMN5,X:X1U$BL-TRA7O<4F
MBW6MKL'J:\\/<(@Z:K&BBS2X<K2QJ6,E_5LR:T0)O3%=7O\ '#ZA7WZP^Z"N
M@6KZWKBA[5%!NM/2];VBN6* 2S>E6#!5(Z;+JX\^[!9KK4W!^1/@*E9%..39
MMG'!SG;*X%X1MZNU?W=Z'%MK8D*]Y0O4G(C4Q3[O+U+ONJ"TKI*[H"70N+ B
MI4A/E%JUM+KF:IAZ_>4M3PQK)K#H*!@QW#&UUFRKVIWY;'O457.U-;8F@-8%
MCV0;8K2V:9&]\H8W=I6+<94X.(LH:J55_7R-8Q"E4"7!T6#$%+9;+Q!DUN?:
MQU7Q825QMLEVLV,DR>0$"_&68\&(2F,J;L#X5XI9K%JLV:-K8[ =S.^:C86M
M:+[=E&NUVJ:N\K7/O]R1K-< WZ*"IS:L]AUM8A104LOCS@96[=8I4]I1U&I9
MPY'"J;>HH[HJM"E:W&XWU=NLL;>MJO9*UN]PT]5L[0;$:-+O4A73:<$C"IFW
M*&;22#3E604*-4F_U604C!!Y*2.D6'=3FT0TEH4H^/1-CJ'QH8N>CXQB.0Y<
MIYUC$UB(GX3*KX<VU;N]E44;%BIM=/L0KLM.0MP4^%QT%E96(IOE1PXVV%3V
M#(:M8B<J)D]G!-XQX>O#8HV"V=.I=T7$>H;;50KV6UF;+C<^*Z+0ISL*XO7-
M9::E@>\I)+FF80]:8[6=A-Z:>%V-5C2Q:?A4,B)99DDJ2"L$TC71FKZA28T<
M;$(W7(.D%5%PYR8:-0(1H[,%R04447'*@2VI$1;X3XEL4HIR6OZ&HL$:T;2W
M34FZ_?[':F;VIU?>MK7BM9JKJ57-JU%6 MLL5G=LL@R"AQ_P74VD[. VW:IM
M4P!MK14-B^SK:O"FFT2EU4V=Y-'0W)NTK[[UZNB[L'56:]-2[6[NX&0"5M6A
MMC))")-MTXZ8U=J36DROS 0Z*%$*H!'714L<BF46::^29><HCC0>!D(+>5*-
M29<M^*W!PT7F%\/;>7@EBM:JI6W_ !'O57%VWLM68W"=W7KU659HJ!!@.W@K
M+N]/&%U5K6#";)5L>;Q?P\%5EE+]Q8OW.$^#>%GZUVOK)I4YX=M<-7+FP5=C
M:/.T!EH""E7[C4.6WF.<Q0U^BY)+%OVHFPE@3 3-"%LL;D##FW*'7S,LX'V=
M9;:<C2)%EE6-AZMRO@EM=#G&&!!E4>,%%2P\Q^:[YXJQH\'[&I:I2Z56J\%P
MQ9>4;>Y674LZ&CKJC "BND87E]IKALU#.Q5@V6K"[*Q4/*Q);/RB::_1V7=H
M?1N2'&U&L!</ZZZZ_1XJVFXV"F,VC=FL]8WL=P=*^L*5Z5+HU'4G&\^=3#CG
MIF>)XXQE]^J7]++K!^6VJ?\ ZY3GE_EF_P &_$G_ %-3\_K9[U^YF_PS<)__
M #3_ .E7,[C//GOGUNQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQ
MC'&,<8QQC'&,<8QQC.$KQJO_ ++ZT?E9M?[M+%S8']SG^.6P^9'_ )S7S5#]
MV'_@PH?]Y]?^:W<X).;KY\QL<8QQC'&,<8QQC+L:YU9F_P ">2>MH*JQ8=OH
MU'CY,1#TQTB?V"S:W0;49L(*)8:B1_DE/65E3%QDQHRT.14SI7HX3V.[OB"-
M.Y*!UUO8,;K=MMC[LRHL4T],6O&V1E:L(ZF'[(I&NM4'+&1(LE2^;1S#AGA+
M[HJ]BTS<Z_4)1N=!H5S=3L'G9V/$8;<J *"A3M0*5^P]@K;7DJ%*D22-AO2@
MZ<C5=H6R^_\ #Z"PF.].8=CD-JZP$$D.CY+\60AP*7M\ TRYZ:.YZ%I\>T](
M;RVZPVXV\TI=>>(*$& =CN#DQ40FGA[?642+@!@3%JMK752'I,>L@>0!/4)D
M)"41:CPEM2!C.\</+A1O6:[/%W"M.T)UFL2T2HW=S7O 76LN@&5@-@])K$A,
M)*<-@*#.U@=.YJQ2OL"@()BO7HJ6DX*779RR==3:JR-!?"%!)U:%AR%@F-+&
M1&"06,-!3[&>1,/0Z].BBN;=6^J5(OU[AV+=L[NIKU@[#5:&$79U]Y]OHBTF
M]8LII**+##1:-UQ-&F2Z;;JI^-=PZ_A2_L/8FWKEU-?07KN(+EQO>][Q45K6
MQMM55U_:E0?JZE*QL7C-5*[-%5:A8V6Q%]]&ML?-\ T1N@8L@>JDJ2_+M(R'
MKMLP9E3;!?Z'B!8T6"W6,5(=?APW8!>!7(L(K7V0U<F2RAL.-C&WP1">,:BY
MMRW$T;.P1M07KWMW4UJJU4M/MNUI33UU*P @U@NKNO,;7N':NJ57JV7G5&VE
M3^.(-?P^/#D;2EJ+6B8[;54<-#=O-?L>(N'X1LQV6XV=1AFE!5[E?6)1;URZ
M>M>^U?I5EWF4+-BK8+F89YWCC&.,8XQCC&.,9RK^#K_24VW^0X?^WL'FK7[I
MC^]N%/\ K]G_ ,.KF^?[B?V^/_Z-#_OV6=CGFIF;ZYA9XB_]!WLU^2XS_KHG
M,LX$_'/A?Y\UWYRO,(\I?^#WC7_NQNOS!^=4+GTLSXG8XQCC&.,8XQCC&3&A
MT]Z]V+%?9+# 6$@K=8918PDBL="'4VI'+B5=D($P29)S.1H&6VRW#@2GG)"V
MD)95YV?)&;?9CJ:4W"KOMS-O74EUJTIAS7[/8U=97$"L-0@?W^VN3)CEC 04
MR7FR:X?TI\0;.-:%RK0B*&XV3;EV+)5D5=)I[^ZMFP:=>U9+^Y=>X0%-=IDR
M0B F)F8E933QF,0:CB;#228Z8"!6,:5+7.JT-,\8?CONQ<L0+^:K4YV1%>BR
MXA!J*S+:BOLH5E]<>5#>D1U?B:J:2.S2VJ'JMVZ3Z]?5[#;RE],P%D&[35;R
M1!@L6Q),)9,$IB @UM$)BWP7=59!5/9:&W6=K]?LZMRWO-3P_%BKL5&:9"OQ
M%>U=@VJ-34V02#@2P(F62MJ39NJI4 V!VWQ5D'0B1^KT1-B!F MK@%Q0V;'L
M=6A.X8DUJ:1!'42H)QUEQ:24IB&ZA;66L3&U^@Z;'96NVX:L47M13V&WFE;K
M6M<ZM8>HZ6P:/6N^I-NI*VU!(8E"S8)04%*ICKK:?2T>[<:5-G61:V.IX>]D
MZ%VCMZ]VI6L+V6H079MU;[-"_#47S BBTU:3$@D(<,]G=:@Z=KEOJE7;A5[!
M-NPT"_6*Q[*Q:,0_D/=JS\LY 6IK%JE-"&8[\"OUZ5-#EH$RRV"%87B5=G0H
MJ(R6L>V_$UW6[&^3;O832W&GI4M%-#M/9757O8U=K8C8A<V2,77+@*LUW+HT
MVT@1=4QA,DLMX>X*UFYU&J%&M[V&RX=XAV6SXH]ENP]@=[JXWC:6GFI+@I L
MZ^NUSGTKE=^TV*-BRUK7H2*H#$/GI&>-8XQCC&.,8XQCC&7WZI?TLNL'Y;:I
M_P#KE.>7^6;_  ;\2?\ 4U/S^MGO7[F;_#-PG_\ -/\ Z5<SN,\^>^?6['&,
M<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,X2O&
MJ_\ LOK1^5FU_NTL7-@?W.?XY;#YD?\ G-?-4/W8?^#"A_WGU_YK=S@DYNOG
MS&SZRE6/.QE*L93_ /-C.,_R?OXQ_*_[/OYQC[_D^_G&/\O..<>:><<I]KS^
MWYN?F]WS>?\ HSGE,<^<3YO;\T^;S\O/[GG\WG_+GYY,^3R^3/D\OD\OD^]Y
M?\OD\O\ D\OD_P"KG.<<IY<^4\N?+G^3G[G/W<_.,9^^3/DQGR9\F<YQC/D^
M]G./)Y<8S_DSG'EQY?\ L\N/^WCG'/ES\_M\OR\IY\I_R\I_S3CE/*)Y3RGG
MRG\D\O;Y3_-SCG_3CR9\F,^3/DSG.,9\GWLYQY,YQC/^3.<8SC.<?]7EQY?\
MN./[?V_S3CE/+GR\WGCG^3G'+G'^3G'/^F,F=<O1VJC\C1B87P9RYTJ^>65'
M6ZYDW0F;1&!82M+S>,P5(MA;$YCS<KD+3%RAYGT*\.Q=[4U-@[MWRWM!UFTU
M'[V<#$5=N5!EOG$B7[]$Z^M*CY\@B3YB77'3.:S?[#45IJU81V1;O1<0_ORB
M,IO</!M5:_D4&$=WD=Q<[=?+FR85TL#LY@JMC;VQVF9$:+9Y\&#*?GR,P(J6
M40V_C*5(ERVV4.-.+PRM^2_G"5.+SCSLXRK.<>7EO]S>D(@-E!+FK!(=LR2E
MA=@L%K(Y$AB2@ #SP,1/+GRC+S[LN)@!BU;2PBNYEAG8*%8I'O+6.<(00$4!
M+&G/*2*8ZN7/-[8]IIM(D*.*:_H_PNOU\%6A!J,_?V)<$8!2PEM,<1\NU5!A
MTHM$J6<4Q66T$RA4N9>;P8(/S\TJ/#\Z^S:?7W.V[.[<MWK-5@:<UM?;DYF3
ML^Q$;(AKQ*UU(*^4H17K51*:R13E?9\6QMJ=&M;X=T,NUNNH:NE>6SB('(JZ
M^ @872^Z"=,!VR%KK\AJQ&U:MW+IAWRP;YV^Q=F8V1-F%R%'IX,]/G,RY9P#
M*O>92V&(ZXK B.//W<_7QH6-'Q&8@#A0:"R+B0((\5\"&L9AK[Z713HU*K)V
MVSMTTI)2JEQ>H[,3,X85DW4]53N/M&?6;76+32L,<UUCM7GVL4N)>*?NF>ZY
M9T.EH;"P\'.OZ]O$$ME:URI=-5;8[[8:ZK14OLEUZU2B@*B:Z*]3L*R^QFV'
M)[,5QQC'&,_<XSC_ "XSCRXQG'EQY/O9QY<9^_\ ]6<9QG&?^O'W\<<XGVIY
M_D_R^YB8F/;B8\T3Y_<GVI_HG\F?G&,_<XSC.<9QG&<9SC.,X\F<9Q][.,XS
M]_&<9_RXX]OVL3$Q,Q,<ICS3$^W$^Y.<JW@Z_P!)3;?Y#A_[>P>:M?NF/[VX
M4_Z_9_\ #JYOG^XG]OC_ /HT/^_99V.>:F9OKF%GB+_T'>S7Y+C/^NB<RS@3
M\<^%_GS7?G*\PCRE_P"#WC7_ +L;K\P?G5"Y]+,^)V?N,9SY?)C.?)C.<^3&
M<^3&,>7.<^3_ *L8^_G/^3&/\O'.(]N>7Y/\ON8B)GVHF?-,^;W(]N?Z(_+G
MYQC'&,_<XSCR>7&<>7'EQY<>3RX_[<?]N/\ \\8F)CVXF.<<XY_ECW?Z,9QG
M'D\N,X\N/+CRX\GEQ_VX_P"W'_YXQ,3'MQ,<XYQS_+'N_P!&2"M60E4B4DF,
M3'^%2J_;*T[B6TIUO ZYU4S3S&4H2XUE,C @[-5#=RK*69>&'EMNH;4TNSO4
M4;%"T/D^S7<UUX>S*!+M]7L*NRK<YF"B0[S45#!Y<S7UA$C,P426KV=K3VFV
MJL+[9NNW&K.'!)CW;>:B[I;LP,$$PV*6P?*3YS"W=FR1.!D"E;>W+_"2/;%F
MW0J1X -74)&M(9^$#@GPQ0Y4OTV'\NR$8(2<J=1Z-*\.8\C>/)CD=/#FG;+B
M?5&U+KEJ[,O*2Z'VNSA\+Z9#I"92'X,]4Q(^WDN/&/$2(KA5O%1BMKZ6M&*P
M"':5J$.[M+NTAG4P8L,YF/3!04?@QGV"VF5%/W286!@+B0O89L"9(69=E3*:
M&H?B2G&H.:Y8ZZRAQ^2-$O.O2V9CJ,BXS4=3$=\BS.XM\/U[ ZM=>W<UB=1:
M*Y510&CV9/D&+@G=]HW3F!!]D8%9J&>\,(X,P22NVOXMN4V;UUNAKMU9X@HC
MKKUG:3LX<%6&):05_8S9ZU8DQM6F9,<MQQ-10+E:V60?3@5_DUH'.&!*Y6H)
MHB,+@Y-W2T;>M?Q&?8?A&!4;X2<>K<)L@,E2P\@A#KC!I0F7+@8*)8DOI<K6
M].%ZVI]J[>;50^M;7JI*J&O[W3,&UK!]G4&\V4V%KL@EMTZL65K=W>36$C;4
M.(VZO7V*E'6:I%ZS5NT&[Z O,V_<-BMB+M17:WSUB!LU6NI,LHUB[TTW.KQ;
MA;604!Y,9CN.,8XQG[G&<9SC.,XSC.<9QG'DSC./O9QG&?OXSC/^7''M^UB8
MF)F)CE,>:8GVXGW)QC&<Y\F,9SG[_P![&/+G[V/+G[V/^S'W\_\ XXF8CVYY
M?TXB)GVHY_T9^<8R^_5+^EEU@_+;5/\ ]<ISR_RS?X-^)/\ J:GY_6SWK]S-
M_AFX3_\ FG_TJYG<9Y\]\^MV.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8X
MQCC&.,8XQCC&.,8XQCC&.,9PE>-5_P#9?6C\K-K_ ':6+FP/[G/\<MA\R/\
MSFOFJ'[L/_!A0_[SZ_\ -;N<.VD(, EN#6D$E&CSHTJZ &DCYB$.PB<S)!G(
MT5-;=QEIR$3(XBP)B'/(VJ-)=PO*4YRK&W'%37(X:WC4&:F+U=PI<J9%J%=B
M?;V%2/(H:A':.7(_A08#,1,\HGYY<!UZ]KC3A>O:4JPIN\UP16>(DBTZ;*^[
M5'B7X)(M6>RKN$OP26PHGS3D[HD^]V#7/93X3)M1<?/JX:QGD*65ECY-HQMS
M7DF8:)LX\^(LVW <)O/3I"/AC4)<Y:G$1U2,YB=LG44]UP/T!KZSDW[-&H41
M76X*$\.[E:JJ"GDR*I.&N(J">R)L)B!DX#,@X?L<0;+AGRG]JW;7:]C5T=GL
M!F;;J[=K]V'#C'WK01U)*\-<K1L>P>V!$OF2%<LRZS+EDQ#BB&U&/M#+ZMDR
M[D7_ )W\@UV].IR3RBLA./*(S9T=C4M#(\]S'QO@ZW!$8=Q'PU&YCIC1[1EF
M>[?=='']>N)_O?LO&MGB- 17">46>X%P5)O-,?W-W0G6)B3ZCS+UEL^Q33&;
MOA]/DEMW35^_?<^6YC@^TSO;8Y=SG:CY2X7578GG=B^->G#.S@%Y;+2FO %K
M%C)1"H3[N\?VC6]?%TP)Q:&NBUPS#<D/6AM0EYIEHM.5\-4&(6-$ZL0&JR8^
M,@Y+#Z7($]Q3NKFOL/6G9)U04]!>W-:6JKMC;7:K1 =?,6 (BK*B51:32E-]
MI7ZO864]$B[%>!.&]=MZM5MG2V-\>QXLU?#ER*]BXB=!K+R"8>U&:9@L+CY[
M<J5C90_5UPU5WO5*S#(*O3]U&F7Z5U_KD")$BB@FMSTF.[ GV!V(2E3-J["&
MS"WQ<5,$1\.24R":)27QT2$^^]-7%?6X.'A8(RMPM5,=IQC><QC+%K>5%F+D
MTQ:A:N'].Y=?MZ]9+FK1WHDK!S&@ KZPB'.LM?0X[O+9H_)WJZR5*J4.&+[5
MG7L[$TVFOXLXBK.M]VMW;-9+;<T!M-964DV&^5&15:])%7Z/-7(KU_TNJ9&L
M1B'!VOM\57&Y[).? 8A3*[HM8X2*0]A;#4&>424^#0864,RIOQCEEM<CX3GG
M%,]97XQXHA3*59K>'N&[%TE&A+B:J[Q9#[%B1Y&3DU^[]HUL22U=AU3 =G&-
M@&[M^3K@8G)V5U-?B_C.IK1L+M6*ZZ[]9P!-6G4@X)85[%N+?9(1(K<_O,@)
M-[6<D^]BM['5IVF[%E6"S6EV[1CI0I.@SF:;KN5 %G![FN-<R9#:!_P-_P",
ML*LK-<:AU1"ZC6X%9P6&"$%GK#A*OJ'7AV6D72H:\=4RI7KI<HMGNENL5'#N
M]VL"EW:AV'*B5XF[&8V-YM_N]BS-<97R@6^(*VK/2<2MV.TVQ[Y6PMVWU[ :
M/AMU>I?K%PSPTU@#6[$XM1[)AK 1J!+3ZROJ^^5*8W#V@&K5=5!"66PC9UF0
M&TM;+?#"3[ 9C"$F8F]H]2B-(;@RF)$(.N$3D/DQHF0.7/D.R93<R$1D?&#5
M6YL+\;>S1IO50FUQ3K]8VTFG599FJSA,]BPI)RS!MF&H $/L ^$@*UDIJ0[$
MJ&OU&JGA[7[38U;&TBEP/N=RFC8V-U5.+J./EZA("-=JV(I$FRQEJM396*PP
MW-!Z++.\A1T:WJ)'L/6:!GTX6IV6=0Y3D-J7(>?C-6ZK@;([7QLZ0B=-SEZ:
M66!#292"4YM+L-R3\8RDN*D7);O9(X,O[>.BUL:*MLN&DH !A:W86Z(W'I E
M*CI57BW9 "0F9%@AV"YCHLXX8TUCRDZOAV>TI:?:6.'FD@'--BAW.IU^S/75
M7M&R_P##L7)H4FM&U8&#239LM@I9>@-I36=AL'HI-7,B(^*:/.M,16[E50A^
M_P >YG 0#6575LAWX_<1M:'&:!HENR"Q():@IDJ->P!@%QT'%[7%.]ITNI=^
MM9/V2?4(V3K-C:J:<]94MV]]?C21%.)X>896I6"ZZ+5"U5KO";CJSFYQ2X$X
M7V6QZ&:F]35["5]@ *#=ZFCL>(5;N_0U_"VJGB4XV!1Q<E0:^'$RW9H;:C=N
M5CC7U[E:O!V-2@Y]+KJ/D!/&/F]1$;XO8L@B>BQ8]PA7P[6Q]=4HC)Q5& QA
M4(55LQ7XJC$>PEH1#XX0PAX7)EF<16D[2Y/LPEX5>(T:F-(":;&'K6ZBI>?=
MB$A[(':K0VQ?A@,BJ=.NU/=B.1>$"O@ZA8T>M'[G;-5E_@RSQ"7$K+.Q4I6Z
M1O[^LKZV9LL]B I7"14U,J8F;J]C<18[Z*Q.HV>6O2>O:TP,,3J<\VL?&["0
MR02+)OHH$6FZFK%,)@9#9BU_ [ <S@S8"H^R&@PRI!3&1ZH@,&#<C/37HC7<
M4;J^5BNK9C,.9P:U%IB]/8MUU<17]G7MK*MKNUIU/[EIUW4JMFQL;5;MH9:M
MVQ,5#D&WX$X;U:ZMVQI&"597E'1:HJ;Q!4U]Q_!^KTEO7M&[M^QV-Z>^[&W6
MVEVE4T]&[W:5:^C0)9O.APM0T@XZ='!:6^T;/US6IJO.$U7]5,#2[II<'?"(
M,';0RC+(0W%L1AZ0/^V:P: *K$=MDJ<%N1IQ]RZ;Q)M:@U'VMF!5:=W>UKHH
MC3QM+*M7Q1<U";=K76HK%:JLI51!T:(ZUR+YR2*M@333BP3P9HKY;"M1T9C?
MV.LX7O:XK4\1SI*3MYP10X@LZ^AMZ)70HWE;&XQM;[J0O:XM4L0MWZA*?L"^
M!VL !*4#DO5,_LJ649ZU5>6.R;L3TNL!;[JH>7)FH;P^5B1'DIELI&T[XTS,
MJ-=B#I$&8!)1ECV(?9^^N(7; -C4T:T%QQL%/[K2%5^UJ.('5D5& Y?082LN
MWV7=^RV5UCP:JVDX<3.M7A376FZ]IZ?8\4.N!Y,-2VK-_9&[54N(>$T7+5Y#
M*S>T6V'+BMIN]]OI]:FLVN[7V5S7!$5,:^UY!I<F$.$(GF&-0']BM7M!@NJ1
M.)A=]&M>P$P12)B03(,C5H#:Y3+T"9.7/6Q-ADH2&WXTN^J[K<NV:VOL2FL?
M$M32%J)K5NA2+/"-;<MEMB53;.VF^V860N6F%0:F(;) :HN]PUPW7TC45:<6
M+J^"MAQ.'$ W;DM?:H^4&]PY7A%07QKUT+.IK@30.N^Q-B5O1:2(L6ZV&\<Y
M=N\,A)__ -R;H6K[#9LYQ_\ $?LQ[759+&B,I6?Y2R1N7+4=+J7Y'/C<G.PX
ME"\*0F?X3Y#JF)7/.K5V^^I4/Y(4*>ZOUJJ%Q[4(JK7%2M$?@]V0F1F8F)G$
MN/?P]\BRW^_KW#W"FQVL_P#]F;78<-:JW>LNGVRM7G.F_=DOP^^6K$' E$C&
M>_@Z_P!)3;?Y#A_[>P>:_P#[IC^]N%/^OV?_  ZN;?\ [B?V^/\ ^C0_[]EG
M8YYJ9F^N86>(O_0=[-?DN,_ZZ)S+.!/QSX7^?-=^<KS"/*7_ (/>-?\ NQNO
MS!^=4+GTLSXG9>&E95%U7N0@-S__ #:L4$)-4C_Z\>C%C1*18Y*,X_ELLNV4
M50A,I]'F^>P64/<7E@@ZR]C6TB&<0<,I?_>L>S%I43_ /;5JJ I!,3YB(:-C
M;V5C//D=:'#'6D2#--%S5PEQM9J\^_3'#M%Y#_#7H;EZRS9,B?;6![2GP_4:
MP>74%N:Q%V=DP.<;.OMY:U+2*#;;G;+,8N,N/M>Q,66Q%SF1 C,2:)UH'9:*
M3968#TH/,/767\'\UHH*MM1==QEX6WYD5H=3JBXCVNWUVLU]"KK%GP]2*C2K
M5(LV88JQO;)%74OM@7974U:^OF5>QKMD(STO+G/\5\0;\.#M!P]N=YN-K=W;
M5\7[)>TV5V_-*E*7TN%Z0!;<WN[&TF[#>.E?(+=3<:8BCKJ#FZK.N:Q*H $C
M*J4DDR9UGLO8)K8JIQQN%5;-1BUOB@J*ZF%*8KS42PIKE6'SXY)A=C>F;*"/
MBB ]&!S!&G?W5\-Q<0O8K057?:+35M+":A-V%#;5M:RWMAEJRNDRG-Z^Y)H.
M*0KT=H+"7S+B15U?#6I;P[KK+M.VT%WA;BCB.]Q++[XHU.TT%S<IU_#YBAR]
M:"=E&LU->PNTN=F;N**+*EBO$5EV8OV4.9-[5()3!:&Q H&I@QH^//-SHD(=
M#K@YZ+%AI.%"KL&)'3*RRQ @NQA[*&\.-1$/O277I#@>IW3A],RTGLLW-C:>
MXTU4L:YMYXL8WNE>N+6'*^HW-$W%,\B9(B C$^4_83L.+K,0@:J:.OU%"K77
M9OV$HK(UM8U*1%^W<.NE<-D%UT&NLN!Z@2+#:9W&LT+;1G8/7Z6/BF".PB>K
MP^!!2VL2);J)@J9;5NF)$P\AU*?DD)2R9^'OJ<2"CP(9#R(;C,<A*+>':NFX
MQ6YE9&F1OK/>4:XP6,KL*UT#66JI(S,[&S)5NQ"([V;F)_"EAYD^U1QA>XC\
MG+JRKMGB.UPG1BG;W"V.(75';B3NM?L!.(C3TX"[WADE&O5738Y"*EY;7>1P
MH0D5$*8E6JQD*P'GCY>P+I!,PS-SD2S$LBZY ^4*$G,U0,J1B!7$F%8*.MJF
M$ID,*HFBO")OA.HA(;*W67KZ2=A:2Y>GU;:S:NL!=921%W<Y[K&QM0';7IK1
MW<2[)"V6H1-RSB_'U^W9;IJ-UNWV=G54K-9W$>\1>3=WC'76V3*O[)#%^=11
MEG=]9%V>]F$NLO31FT.MIW<B4>C8GXEV0!,N#TDKTQJ$3XZL]B0D>-VOI(H<
ML[C;D A%FO+@NA($>JQ7)F!@"-%B0DP98F/D6[CK-KMI5V=*XO6BNOY3]DWN
MM"E,N?P]Q2BI0@A<EBAAHVVGL&"KM[C#8V6KL'VXYBK0Z"+';;/7/W1MN>1#
M3)[]M=F,5ZO%_ MN_M9$Z]E3SFN="NO4J)\5M<I*40AU-<U3M;JS7M9.7W8(
M@UYI"-2:]:# 4/-:L$I%BFA3PL3B-.BTY+=GF1AP:<3M))BO+AS%PP$I2I<"
M"F7*9G^(-S>J:C36:O[R>TNT*UJRHJ:YI*M5'V.T2S9S-!3'V5(UZ#NPU4-N
M+B%.;*UGB?"7#FKO\0\1T[W*RK1:W:W:-)P;%P[)]'8U*?96$Z6!VKE5J+[6
MVM+UQ)=*->V9=7KPYH70+Z<U^BL[8/#Z]8XI.J-?"J."*.%1#]L^,J;53=TQ
M%%',0K'D9I%@J_<&7E1,D#]:-!)5D;;API[CT!6XFW,WN'JC[E)E?8%V>UN5
MQKV0UTHV>PJ:N&6*DLI18XJ.N&M,89V-.]5M+HD36I$<LN\$\.QJ^+]A6UNT
M3;U =KH=?;*Y29N.]:347]YV52_"-G-3@1=MFZ ^Q[SL-7>H.V8"A%DSKA?1
M5<DV@Z!@ZYD5IJI[#"!PTDP:N,6-?JO(IMWN-BD$75Q#A":X+@52&5'?:_"L
MSY(4A@*U$*V L!)+M*O%MX-?4N-W87BV.EM6;*ZU76&S3[ -GJM;26D8942H
M7MV+*[O9FR25VD]Z)E>G6MHB0N^3_6,VNPU]?AINL#3\24*5)UV]NE*XBU3=
M+O=ULF63)-ZP\JE;4*N5_N<I!8;0?W($V]C<H6BI=RUKK>DPYUJ<HSA/$FOZ
MH*PJR6?NU7#0I5P-WX*9=;&RSCETP*EQ*I%)!62EDS/;?ELS7I"H&5AG+G6;
MS>;1B=?&VA$A<XAKMO5PU5^RU>MJZ>U5$GKJ#JYL+9L&(M'7HPD@62@"'1%D
M;/=<+\,:)+]L6@*U#=;PC;1J[C-[JJ5=VZV'$-&Z8U7; MYW1J=0FS27;VDV
M!8X'L9->2HEH6K3%3%@KQ$K5?)-E*-9[CB58K.FY#)I -6=L/U"*0IYZ$P]K
MHT)8#9@BRXDHS7[2FWXGR0Y8@PB* 5VU_$^P?<U3+]Q!5]M0UG12H3K'J3:O
M\/!LC3LJ;3'=5;!V>VL5K"#N:^=;*0LUTG++D=-KP1IJU#>IU>MM!;T.VW7;
M;+:^S=5]BCK.,#TR;.EV"%'PU>IKH]A3N5+8:[;1N>\-I7;"Q3KIWUHU/5OC
MBZQUU\R>8GE.R90ILN:9/S9-+*:QE6J17 <V7F4H3,FDU" DZT/VA@F9.Q[L
M*9"OBR:F))"CK^(MAW;5G%RK4-5?@=%?1*K4U+VE??*H!=M*7V<65*3WFTJ@
M% T5:AZJP5H;".M::VUX/U/?MZL]==V"[-KRGVK7%+[NQ<W1V^%7;=FMHO=+
MIIO?:FG0?M6;4+5V^O>U I'4M2MMFAV2M!*B2)E-95AP1;M8[BT]6JY):*ES
M$VT2+M6[P??:,Q"$E\<O+1NFPHHF**'#D*%DYH\Q\=O9:F)NZ-^UL4(K[V_%
MG6[[AKB6]= J]:LK7AJKVJIB55B5@^(*KLVLL,L.>46$*=6[J,$J;#9ZNAIK
M5JWPKJCI;GA3C;@O5ZQP7+EU^V9O=9O]BP;J;+&5ID+VD0FHJI6K#-6T^O=B
M\?2Z,=-GCP0G96PQ576VY6AEYMH^NK:<]*TL%"/D(PE;;OESZ1M4!N/E#GES
MYZ<X5Y<^7R\S70NMV='I;%^"&\_4ZYUT2CI(;;::3LP0_P#]2AQ'$Q^2><9Y
MIQ76U]/BCB2IJ9$M75W^XK:T@+K M>C8V54Y ^<]0S7%<B7.>J.4\_/D^ZI?
MTLNL'Y;:I_\ KE.8+Y9O\&_$G_4U/S^MGK?[F;_#-PG_ /-/_I5S.XSSY[Y]
M;L<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8
MS@]\;HF-$T/K1+*D((R)C;EI;S*(2V(<?#B]:6/S&\O27&V\+7Y,^:GSO.5Y
M,^3&?)GGO_[G9@+XQV!,,%C[".CJ,H$><V:_*.93$<Y_)FJW[KRO8M>32@JL
MAUAOW34"[-"C:SIBM=YET+$BY1SCG/+E'..><!;6P*:PZV^Q=JRR\RXAUEYJ
MR"FW6G6U86VXVXB;A;;C:\84A:<X4E6,*3G&<8SS= K-,Q(#L5B$HD2$FJ(2
M$HY2)1)3$Q,3,3$Q,3$\ISYJ!J=TLQ8O6;0# A,#"E;$P,9@A(2%<2)#,1(E
M$Q,3$3$\XRKO[@%2)!:4[LT4I\[*ESC2TW""W\:RYZW')LB>EL@A$IV4MYU3
MZGDJ])Z1>%>7"LXY:@&H *ZQC7P%1:U58F:Y=W6F!A0)DIF5BN!& @9CIZ8Y
M>UEZQ?%367'&G?2S8.=8O$*;X=[=8(B>RP( (M)I&<LDXGJZBB?-,YL<;,K.
M(&16-@ L#,R,2\CL6L?\ S+PCT>)68?P_P"#YD8;_D8>RWZ3"/Y/G>;][E;M
M-=VW>.TI=XZ.R[?J1VW9\^KL^UY]?1S\_1U=//S\N>6_<.(>[S4[EN>Z2SMI
MJ]VO=WEW+I[64]'9]IT_@]IT]7+S<^6?,7956@IDIA7X!#3-C+AS$Q;4.CIE
MQ'<IRY%DX:GHP_&<RE.5L.^>TO*4Y4G.<8YRQNO;(2UM-DJ.&+EAH.5L'G L
M#JF>@XB9Y&/(HYSRGSYPK7;^O#811W"8>HDOA5:ZN')+E)*;  ,,44Q$DL^8
MSRCG$\LVZ[_3'$MI<NM86EE&6F4KL@I26F\N..Y;;PJ;G#:,NNNN90GR)](X
MXOR><M6<]XLTQDI&Q6B3GJ*8:J)(NF!ZBF"\\](B/.><](Q'M1&4RU.Z* @M
M9M"A8] 05*W, '41](1*Y@1ZS,NF.4=1$7+F4S.^SM*OJB,0%;&#*@QEH=C0
MLV^%F)'<;4I:'&(V2'H6EH6M2D+;0E25*4K&<9SG.:/5K(8;H*A#61(FWG7[
M0QF(B1,_X11,1$3$S,3$1$^UEQ-3B64KKS6WDUU$)J1*;_8J,)DA):NGH A*
M9D2$8F)F9B8F<U)VUP91I+!/90HBPAS#J&9UQB2VD.X2I&'4MR"+B$N80M:,
M+QC"L)6I.,^16<9X3[%5RDT>QZ3D>F23W992,S$R,D'3,C,Q$\IGESB)]N(S
MM8K<3VPA=NOOK2Q*#$+"M@X!.(D8.!8)#!0)%$%$<^13'/E,YL<;$J6&_18O
M5<PUZ%4?T6+.,PWZ!;V)"V/,^'>;Z%4C&'U-^3S%/8P[E.5X\[E7O%'JZNVJ
M=75!]7:)ZNN!Z(+GU<^J _ @O;@?P>?+S9;^QF]@>B-=MH#HE?1W2YT]F1PV
M5]/9\NB61#)'ETR<0<QU>?/AS8%->7Z1V[5EUSS4)](Y9!2U^:TA+;2?/5-R
MKS6VT(0C'E\B$)2E/D2G&,=ALTQCI&Q5$><SR%JHCF4S)3R@N7.9F9GW9F9G
MSSG4M3NS+K/6;0RY#'45.V1<@&!".<KF>0B(B,<_P1B(CE$1F]E[2KT]Y<B=
ML8--?<7&=6_+M\&0\MR$VMF&XMQX@M:EQ&G'&HR\JRIAM:T-90E2L9HK+6)&
M 45!0C#!$5S7 8%I031@1Y1$,(1)D1'(RB)+G,1.5W4^)+!RQ]7>/81*,C<B
M^TY-(D"2DC$BDD@1"HIGFL2(0F(F8FLG-W"[".""2>PJVZ. "VA4&(BRC6V'
M&621<JW)F,_&&6I9#$HX0Q\-=1E_T+J6?.\U/W[:K7T]-]JR@Z@OMO*PULM3
M)B1(K5Y!1<^I:9743^]#/1U#)<N<Y?;!G%>SK4*=JGMBK:ZH%-"1IW168!:N
M6Q:\.B1=9[:]8_?SB6=!0'/E&4:3M*OS5Y<F;&#2W,MY:RN3;X3Z\M*8;BY;
MRIT@M66\QF68^49SYN6&FV<X]&A*<7(%K%1R5-!<=4%R":X1U09,@N0\HZH8
M1'$^WUD1<^J9F;)M3B1\R3JN\=,C(3+4WV3(2L52,R8S/3*@!<C[4K 0F.D8
MB/QG:-=CHE-L;$"L-SHK4&:AFW06D3(3*$-,PY24$$ID16FVT-M1W<+9;0A"
M$(PE.,8Y(]:<KDRHE*F$Y4D5<I4TYDB:N9F9!A$121CR*9*9F9F9S@*7$:X:
M*ZF[6+TC7>((O##D (B"&P(1#$@(B(K/F B(Q Q$1GXQL^MQ5/+C;#"1UR(>
M1TA;%M@-*?'Y;0UF \IL@G+L/+3;;>8J\J8RVVA'F>:A.,#/6L@8,Z)P#>W"
M#*N4 _G)=L,3,]+>HB+M(Y'SF9Y\YG.%T>(E29*I[I1,1W9DKKW@EE;I$.[G
M(A$FCH 1[(N:^D1'IY1$1H8V+4L)PC%ZKGF88S%PCY3#/,Q&R]F2J-YF9OF_
M!U2%*?4SY/1Y>5EW*<KSE7._;T><SVU3G)]I,]HGGVD# 0?/JY]<!$!!?PH&
M('GR\V4XUF]B(CV.VW*%RJ![I<Z>RDY9*N79\NSEDR<KY=$G,E,<YF<URNSZ
MT<)3C!C8%?)E2<IZ:0(3;.+D2YDN0O+CTB0\Y-4MQQQ:LJ4I6<_Y?)CR8QC'
M.E<]=40JM693170L5)2IB06I81R$  2B!&(CE$1&5+='B&_:L7;M';VK=IIO
MLV7U+;'.<PI(V,,ER1$13,S,S_-'FSE>\&(V%-=DMP+#EQ99,?1XQ+ZAD^)/
M2PIR^P\MI>S%==PWE>$+RC"\IRK"593Y?-SY-9/W2C5-K<*]DU;.E^RZNS,3
MY<UU>7/IF>7/E/+G[?*?<S>']Q?3MU"X\BW5LUI,='(180U,G SL>J0A@CU0
M/..?+GRYQS]N,[)O-4,WMS"GQ''6V>C/9YYYQ#3+6JS;KKKJTMMM-MN15K<<
M6K.$H0A.,J6M6<)2G&<YSC&,YYE? LQ'&?"\S,1$;O73,S/*(B+*YF9F?-$1
M'MSF$^4D2/R?\9@ D1EPSN1$1B2(B*BZ!$1CG,E,S$1$1,S,\H\^=1OY=4C\
M<:K^D(C_ !G/I+WNI\)K_3+_ %L^+_L-N/BK9>@VOLLW\'9]:&((-C[_ %Z&
MV5@."B;<>SBVVR UU^/)<@S&TS<(D1LRHD25AEU*D(E18TE&$OQVG$46GKGR
MDG,J,*NX;""-BI)+Q$UPU<R7,#[-C%R0S$RMC GF!E$W%>CQ#4BR-:CMT#<K
M'4M"NI;$;%4S6TJ[AA72Q4M2EL <3$-4IHQ#%@0[1W8%.?7Z1^[5EYS"&FL+
M=L@MQ>&V&D,LM^<N;E7F,LMMLM(\OFMM(0VC&$)3C%0;-((Z0L51CF1<A:H8
MZB*2*>4%$<R*9(I]N2F9GG,S.43U.[9/4S6;0RZ0'J.G;*>E8" #S)<ST@ B
M 1[0@(C$1$1&:Z-E59N$\.;OP! ^0\W)?@(M0Y,)^0RG*6GWHN)^&''FDJ4E
MMU;:EH3G.$JQC.>=9;KR:+R93EP"0 Z31+0 IB2 63/6(E,1)#$Q$S$<XGEE
M0==Q *#JC1W UF&+65QK780Q@1, PTP'9D81,P)D,D,3,1,9MW+_ $QY:G'K
MK6'7%>3SG'+(*6M7FXPE/G*5-RK/D3C"<>7/WL8QC'WL8YW&S3&($;%81CVH
M%JHB.<\YY1!1$<Y\_P#3E,]3NF%)'K-H93RYD=*V13RB(CG,KF9Y1$1'G\T1
M$1YHRJN;;#NOQ)+NS1KDB!AS$&0Y=(JWX>'D8;>Q$=42RY'PZVE+;F&5(PM"
M<)5Y4XQCEN,:D08L8UP@[I[4!BM -Z9DA[08\Q],S,CU1/*9F8\^79(XI-B6
MFG?DVO!1782]B3$08P)PDYB25!C$"71(]0Q$3SB,VT_9];*K;<)[#"$7&DY0
MTN?;8$Q;:%9\Y2&U2"#BD)RK[^4ISC&<_?SCR\[I/6UX*$'11!3$E"2KJ@IC
MS1)0$C$S$>:)G*5BEQ'<(2MU-U:((D0*Q7O/(!F><P,M I&)GSS$<HF?/FC]
ML>J9\GEOE>^\J(O'_P#:!OWEP&E,05X_Y]_\T)A2F8BO\L=I2FV<H1G*<]NV
MH>^T_:9'_2)]IQ0;H]OVFG$$R/:,H@BYS'/.GL;OO@&W_A)+^];O\*N$KKE_
MT?\ "0N9!,^VH)D0Z1F8Q'V-4XDIJ=%OE>C367</LS(]H&LRFG\*\[#S4AN<
MEYMW"OY6'$KPO"OOX5Y><F^@Q9*8ZHQ1#T$HV))9!,<I$@*9&1F/-TS$QR\W
M+"];ODN&PJAMU/ ^T!ZZMP' SGSZQ8*X,3Y^?J@H+GY^>?:]EUAQW+[FP +C
MV5RG,O+M8];N5S<*Q,7EQ4_*\KEX6K$I7E\LC"E>EROSL^7K#=<(] LI"/)<
M=,&B!Y*Y=E'*)Y<E\H[..7(.4=/+EG8J'$)'VA4MR3.IQ=95KTGU6.</+JD)
MGJ?$S#IY\V<YZY+G.2&R[S'VRP/V4ML:OY*.D)!1A46T#XS Z9)?Q)>=%,((
MY2.\^0G#^?@N6\Y>QAS.<KQYW+.A4TNNI!0K33BN*0KG#&(8;U+"5B-@Y\[^
M03(?OG5^#^#[7FR2VKN+=QLF;6Y5V\VSLLMA*:EY2ZSVLAIE46(\JW-D0R>R
MZ9Z_PIF2\^1Y_9=8E96J3L #(4ZOTCN7[6/>RXOTS\CSUY<GJRM?PB3)?\Y7
MESZ:0^[Y?/=<4J\!FN7$0ME((&.40!H&(B1 )B.F8Y1(+ .4>;I !]H8B(UE
M#B%LE+:6Y;)SU'+*UXY,NT-O,NH)ZI[5K&<YYSVC#/\ A&4SJ*VC751GX2MB
M!50Y4O!"3$5;H.8TB?CR^2:^QDAZ)V7CRY\DEQ"GOOY_E_?YQ!:R& V"HPU:
M^Q6R)KPP$^] ?/J%?FC\ 9@?-[6=II<1RIB)J;N4-=WEJ91?E3;'O[%]'0;O
M_P#4HD__ /K/G[9U:Q'F1<;"!XBD7D2"$;Y60/@\Z0TM3C;\QGXP]'*>;<4I
M:'7TK6A:E*2K"LYSGGM-=UJ9UTNT0) D^I'6D"B!(%%SZEB0Q$$(3$3$1$QR
MB,X[CQ%V;U=SW7963%ME7=[W9V&"4D+'AT=+3$IDA-D$4%,S$\YG-R.VR#$$
M(Y87L@+ )Q)L8C%GQK8/:EQR,+#F(4]E],_#C<V%Z5S,.6E6)$52U+CN-JSY
M>4WQJK*3KOFBY#%,0Q+"02S2V8EJ2"9Z24WI'M5S'0R(B#@HRK5K\3TK*[M2
MMNZ]M+U65655[HN791!0BP#(#J%Z(,^P=$PQ,E)+(2\^4CY=4C\<JK^D(C_&
M<N>]U/A-?Z9?ZV67L-N/BK9>@VOLLR#ZAVJL%.W75V&,L8$C,<W95U-Q(!@?
M,DK2W%*+<4AB/(<=4E",94O.$9PE.,J5Y,8SGGF/ECL5V>3GB,5O292FKR$&
M@13RO5IGE$%,SRB)F?-YH\^>Z_N;=;L:WEBX4;8H74*&=G!-=5>I<26KMP,2
M9K$8F9F(B)GSS/*//G<WY\_<^L..,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.
M,8XQCC&.,8XQCC&.,8XQCC&.,93"84.;:;8,B1A=AESTK3).!%GM-.^;E'I6
MVY;3J$.>8I2//3C"O-5E/E\F<XYW!AKF9 S"9CE,@4C,Q[DS$QSC.I !Q$&
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$C&?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g129231g34n66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g34n66.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1[N4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'M*^>) X0DE-! 0      $(< 5H  QLE1QP"   "!' < E  "')R,CDS
M-S0Y' (% "%-:6-R;W-O9G0@5V]R9" M($%#3%@@3F]V(#$W+F1O8W@X0DE-
M!"4      !!_*&8"1;MX#E <MQ[$\<?/.$))300Z      #E    $     $
M      MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP
M<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P
M  P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M    0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-
M!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M    0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N
M0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M     $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M    4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!O
MX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M            0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL
M0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G
M4',     4&=00P    !,969T56YT1B-2;'0               !4;W @56YT
M1B-2;'0               !38VP@56YT1B-0<F- 60           !!C<F]P
M5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M  QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M       +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU  (
M @.__C4  @ ".$))300F       .             #^    X0DE-! T
M  0   !X.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      ,U    !@             $)0  !V0          0
M                       !              =D   $)0
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   $)0    !29VAT;&]N
M9P  !V0    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P  !"4     4F=H=&QO;F<   =D     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    %.$))300,
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MI[?'_]H # ,!  (1 Q$ /P#"Z[E90Z]U1K;[0T9N2 !8\  6V: !RI?:\O\
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M *O=-LC?348B/T58B!M;]%@^BWZ"L8MN9DT-N#A5NG]';2X
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M ?_$ !\  0 " 04! 0$            '" 8! P0%"0(*"__$ %\0  $$ @(
M 00-" 8&!0<*!P4#! 8' 0( "!$)&%B8$A,4%19789&7T=76UQ<9&B$Q45:4
M0966T]38"B(C-W%X@;&VN/ D*#4Y4G>A)28G.$=(=(B2P<=HA:?&X?'_Q  <
M 0$  @,! 0$              0(#! 4&!PC_Q !;$0 ! P("! <-! <$!P8%
M! ,!  (#!!$%$A,5(54Q49*4E=+3!A0B05-489'1U-7A\!87<:$C,F2!H['!
M!S1ULR0S0E)TM?$U-D1%8K0E0V5RA6-S@X2DP\3_V@ , P$  A$#$0 _ /3G
M_2,N[?:SJ?:768+UUN^9U,+F, GI23,HNN/30,/Q<B!M&#EWJ]8/-LJMF[E=
M)/*>VF/8J;8VUSGPSCZQ_9Q@>%8M38F_$J&&K=%/ V(RAUV-=&\N#2US?UC8
MG\ OEW]H.,XGA=3AK</K9Z5LL$[I!$YH#W"1@:79FNVM%P/Q*_-]^>/\IWZ9
M=N?S0+[$Y])^QG<ON6D_B]HOGGVN[H][UG+C[)/SQ_E._3+MS^:!?8G'V,[E
M]RTG\7M$^UW='O>LY<?9)^>/\IWZ9=N?S0+[$X^QG<ON6D_B]HGVN[H][UG+
MC[)/SQ_E._3+MS^:!?8G'V,[E]RTG\7M$^UW='O>LY<?9)^>/\IWZ9=N?S0+
M[$X^QG<ON6D_B]HGVN[H][UG+C[)/SQ_E._3+MS^:!?8G'V,[E]RTG\7M$^U
MW='O>LY<?9)^>/\ *=^F7;G\T"^Q./L9W+[EI/XO:)]KNZ/>]9RX^R3\\?Y3
MOTR[<_F@7V)Q]C.Y?<M)_%[1/M=W1[WK.7'V2?GC_*=^F7;G\T"^Q./L9W+[
MEI/XO:)]KNZ/>]9RX^R3\\?Y3OTR[<_F@7V)Q]C.Y?<M)_%[1/M=W1[WK.7'
MV2?GC_*=^F7;G\T"^Q./L9W+[EI/XO:)]KNZ/>]9RX^R3\\?Y3OTR[<_F@7V
M)Q]C.Y?<M)_%[1/M=W1[WK.7'V2?GC_*=^F7;G\T"^Q./L9W+[EI/XO:)]KN
MZ/>]9RX^R3\\?Y3OTR[<_F@7V)Q]C.Y?<M)_%[1/M=W1[WK.7'V2?GC_ "G?
MIEVY_- OL3C[&=R^Y:3^+VB?:[NCWO6<N/LD_/'^4[],NW/YH%]B<?8SN7W+
M2?Q>T3[7=T>]ZSEQ]DGYX_RG?IEVY_- OL3C[&=R^Y:3^+VB?:[NCWO6<N/L
MD_/'^4[],NW/YH%]B<?8SN7W+2?Q>T3[7=T>]ZSEQ]DGYX_RG?IEVY_- OL3
MC[&=R^Y:3^+VB?:[NCWO6<N/LD_/'^4[],NW/YH%]B<?8SN7W+2?Q>T3[7=T
M>]ZSEQ]DGYX_RG?IEVY_- OL3C[&=R^Y:3^+VB?:[NCWO6<N/LD_/'^4[],N
MW/YH%]B<?8SN7W+2?Q>T3[7=T>]ZSEQ]DGYX_P IWZ9=N?S0+[$X^QG<ON6D
M_B]HGVN[H][UG+C[)/SQ_E._3+MS^:!?8G'V,[E]RTG\7M$^UW='O>LY<?9)
M^>/\IWZ9=N?S0+[$X^QG<ON6D_B]HGVN[H][UG+C[)/SQ_E._3+MS^:!?8G'
MV,[E]RTG\7M$^UW='O>LY<?9*P%-^5E\HW(:\[4EC/;>U'Y&$41'Y/%':SL/
MA4*>=]E>O</<$VGL!&FF7"L:E4A$;>W:JI^YBKGPTPI[6IIS*_N3[G(:K"61
MX12M9/72QS-M(1)&W#JZ8--WDVTD<;]A!NP;;7OU*'NGQ^6CQ:1^*U3GP4<3
MX7%S;QO-;2L+FV8!<L>]AN#L<;6*K_\ GC_*=^F7;G\T"^Q.=(=QG<N0#J6D
MV@>5[1<L]UW=&"1K>LV&WZ\?9I^>/\IWZ9=N?S0+[$Y/V,[E]RTG\7M$^UW=
M'O>LY<?9)^>/\IWZ9=N?S0+[$X^QG<ON6D_B]HGVN[H][UG+C[)/SQ_E._3*
MMS^:!?8G'V,[EA_Y-2?Q>T3[7=T>]ZSEQ]FM<^6.\IYC]O<JW/YL%]B__'D#
MN-[ECP8-2>J7M$^UW=)O>LY<?9K3\\?Y3OTR[<_F@7V)R?L9W+[EI/XO:)]K
MNZ/>]9RX^R3\\?Y3OTR[<_F@7V)Q]C.Y?<M)_%[1/M=W1[WK.7'V2?GCO*>>
M'CYY5N>'_P"*!?8G(^QO<M>VIJ2_#;]+Z?\ ]3T%/M=W2;WK.7'V:?GC_*=^
MF7;G\T"^Q.3]C.Y?<M)_%[1/M=W1[WK.7'V2?GC_ "G?IEVY_- OL3C[&=R^
MY:3^+VB?:[NCWO6<N/LEK^>.\IY^K_SRK<_7^S_RH%]B<C['=RMR-3T=V\(_
M27%^"XTBG[6]TFS_ .+5GA<'AQ[=MO)\>Q,^6.\IWC]O<NW/YL%G_J"\#N-[
MECP8-2&W_P"[VB@]UW=(#8XO67_^^/LEI^>/\IWZ9=N?S0+[$Y/V,[E]RTG\
M7M$^UW='O>LY<?9)^>/\IWZ9=N?S0+[$X^QG<ON6D_B]HGVN[H][UG+C[)/S
MQ_E._3+MS^:!?8G'V,[E]RTG\7M$^UW='O>LY<?9*>Z@\K-Y1N05YVA+&.V]
MJOR,*I(!)(LZ5>!\*!CCKL10\2<$6V$Q&FFRRL<E!\3MA;55/W.37VUTPMA)
M33F5O<GW.15.&1QX32M9-7.BE: \YV=X5DH:27DV$D;'V%KEH%[7!Z-%W4=T
M$E/B<C\5JW.@HF2Q$N9=CS6TT1<+, OD>X;01MX% GYX_P IWZ9=N?S0+[$Y
MT_L9W+[EI/XO:+G?:[NCWO6<N/LD_/'^4[],NW/YH%]B<?8SN7W+2?Q>T3[7
M=T>]ZSEQ]DGYX_RG?IEVY_- OL3C[&=R^Y:3^+VB?:[NCWO6<N/LD_/'^4[]
M,JW/YH%]B<@]QO<L.'!J0;+W.EM_F</H]*G[7=TG#K>LXOUX_P _T>S\>!/S
MQ_E.\?\ WR[<_F@7V)_X_P"' [C>Y8\&#4G#;_YO:*/M=W2;WK.5'V2?GC_*
M=^F7;G\T"^Q.3]C.Y?<M)_%[1/M=W1[WK.7'V2?GC_*=^F7;G\T"^Q./L9W+
M[EI/XO:)]KNZ/>]9RX^R6N?+'>4\Q^WN5;GZ_P!G_E0+[$^7D#N-[EC>V#4F
MSA_UO#M__4]"?:[NCWO6<N/LEI^>/\IWZ9=N?S0+[$Y/V,[E]RTG\7M$^UW=
M'O>LY<?9)^>/\IWZ9=N?S0+[$X^QG<L/_)J3^+VB?:[NCWO6<N/LUKGRQOE/
M,9\//*MSQ_\ Q8+P_=^WWEY4=QW<J07:FI+?_P G:J3W6]TH-CBU:#LV%T8.
MVUMFB\8((XQMX%I^>/\ *=^F5;G\T"^Q.6'<9W+'@P:C/X:4_P#^Q1]KNZ/>
M]9RX^S]?$GYX_P IWZ9=N?S0+[$X^QG<ON6D_B]HGVN[H][UG+C[)/SQ_E._
M3+MS^:!?8G'V,[E]RTG\7M$^UW='O>LY<?9)^>/\IWZ9=N?S0+[$X^QG<ON6
MD_B]HGVN[H][UG+C[)3_ 'OY63RC<7840J![;VJ-4E%!1&4GMD'8?.2<@?R.
M9LWA1Q[8(4QAPX;#V2.^$O:TL:-]/8IXS[+.W-P_N4[G)GX@V3"*1PBKY8HQ
ME>,L8BB<UHL\&P)=X_\ :VE;];W4]T$;:,LQ6J:9*&&5^5S?">Y[P7&[7#:
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M3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X16@H'_ '6=T_\
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M^U/W28E!2USVUU!5PT5?!$_$Z=L#=/3/H.^IVTL$M6RGJ:JFE+1)&VH)=$2
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M)\+;=>1//9KQR<(G"*S=$?[J^Y/_ "[1C_O5=:><?$?[Y@_^)._Y;7KKX?\
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MJ>#OKOJF9)55,)FJV5!RRN>VGCAI90[1.9([.YPCPNP+!SA<F(P]]NTK:Z6
ML$T^@,$\C8*>7)3NA_U;6F9TLL9M,U^4,:-+F5BUE?-C>6OM6&]9P<+UFGO#
M7C\G(9E6$7M&-5I!F5%U,[F$_P!H;)HW*AK@@*99V:BL,8^_/$"I9L& )>_!
MAIMS#3U-!3=Q=--B4DPBTU2V.**JEI9*F=]94-B@$T4D;P'N_6S2-C:T.?*1
M&PN&:IIJV;NO?'A\4)>*:D=(Z6FCJ8X8&TD!FE,+XY 2UEPW(PR.>YK8P7N
M/FUY3-^$,=W[\.Q:C9)UVBAN4LW\8K.65\_JLVW#>\0MFA*W-?D1XM6+XGZS
M-Q-M!2;%!!I@[E%/&^VBBF_I^Y4/;@E R2NCQ"5D);)4Q5 JHR[.XF(3ASA)
MWN"(,]SFT9.R]EYCNG<QV-USHZ-]#&Z1I9 ^'0.+<@M*8BUN33?ZW*!89P 2
M "J'<]&N G")PBM!V6_]&=:?^6."_P#:V?\ .-A7^MQ/_$Y?\B)=3$?U,/\
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M;/J-8Z'%*B3OD08J8'8.QE-/6F"*FIJG#FR5U;&Z*:%SWB9K6R.<]S8LQ<X
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M2_1__+%W;+ >2.VVVVV=MLYVVVSG.<YSXYSG/[<YS_3G/].?Z>>T  %@+ <
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M0T,+X72/!='$P6 N9GNS-L>C?]I>J%F>3TF_6"NU;?BMG)!NGL(K6I2#"+.
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M_9FN^?GO^T[_ +QQ_P"&TW^?5K[O_9K_ -WYO\3J?\BD7EO_ *5Q_OFZ@?\
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MTL\=-%"&YI"YSG_I73- <XNN8W#,X@D^.O/;KQJ<(G")PB<(K-T1_NK[D_\
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M;^S@4\%;!K<N%9 R$GO.V3)403YA_I)O?0Y2"0/"OXK.C#]$[8>G ]]7]O\
MC#S<']K+P -2-V?MQ]U6F?[+023KD[3?^XCWI/T3MAZ<#WU?V_XP\?>R_<C>
M?'W5/NM&^3S$>])^B=L/3@>^K^W_ !AX^]E^Y&\^/NJ?=:-\GF(]Z3]$[8>G
M ]]7]O\ C#Q][+]R-Y\?=4^ZT;Y/,1[TGZ)VP].![ZO[?\8>/O9?N1O/C[JG
MW6C?)YB/>DQ_HGC#'Z\=X'N,_OQU_;_C#P?[67'8<#:1Q&N/NJ?=:-]'F(]Z
M6N?]$\89_;W@?9_X]?V^?_XP\?>RX<&!M'_]X^ZI]UHWT>8CWI:?HG;#TX'O
MJ_M_QAX^]E^Y&\^/NJ?=:-\GF(]Z3]$[8>G ]]7]O^,/'WLOW(WGQ]U3[K1O
MD\Q'O2U_1/&.<8QGO"^SC'[,>;^AX8_X8_+#R/O8=>^HV7X^_C?_ -JGW7#?
M3MG!_H7!_P#Y2T_1.V'IP/?5_;_C#R?O9?N1O/C[JGW6C?)YB/>D_1.V'IP/
M?5_;_C#Q][+]R-Y\?=4^ZT;Y/,1[TGZ)VP].![ZO[?\ &'C[V7[D;SX^ZI]U
MHWR>8CWI/T3MAZ<#WU?V_P",/'WLOW(WGQ]U3[K1OD\Q'O2?HG;#TX'OJ_M_
MQAX^]E^Y&\^/NJ?=:-\GF(]Z4F07_1@64)BMQQG7N2\(XMNNQD!V>9HMNVR"
MP.M6M+-]]-4/RL+>^&5<UW@-[DRJT]A@ME][HVRSPT=:=1_:>Z>:CEU,&]Z5
M)J+"MN)+TM13AE^]AE'Z?-<WVML!8DC;I_[-VP0UD6MB[OJG;!F[S R9:B*?
M-;O@YO\ 59;7'#>^RQC/]$[8>G ]]7]O^,/-S[V7[D;SX^ZK4^ZT;Y/,1[TG
MZ)VP].![ZO[?\8>/O9?N1O/C[JGW6C?)YB/>D_1.V'IP/?5_;_C#Q][+]R-Y
M\?=4^ZT;Y/,1[TGZ)VP].![ZO[?\8>/O9?N1O/C[JGW6C?)YB/>D_1.V'IP/
M?5_;_C#Q][+]R-Y\?=4^ZT;Y/,1[TGZ)XP].![ZO[?\ &'C[V7[D;SX^ZI]U
MHWT>8CWI:Y_T3UCG]O>%]G_CU_0S_P#QAY _M7(X,#8/%LK2-G%LI4^ZT'AQ
MHGQ?W+Q<7]Z6GZ)VP].![ZO[?\8>3][+]R-Y\?=4^ZT;Y/,1[TM<?Z)XQQ^S
MO"^Q_P .OZ&/_P",/'WL./#@;/%_XX^+@_\ "^+Q*1_9<!P8TX?A16__ .I:
M?HG;#TX'OJ_M_P 8>/O9?N1O/C[JH^ZT;Z/,1[TGZ)VP].![ZO[?\8>/O9?N
M1O/C[JGW6C?)YB/>D_1.V'IP/?5_;_C#Q][+]R-Y\?=4^ZT;Y/,1[TGZ)VP]
M.![ZO[?\8>/O9?N1O/C[JGW6C?)YB/>D_1.V'IP/?5_;_C#Q][+]R-Y\?=4^
MZT;Y/,1[TGZ)VP].![ZO[?\ &'C[V7[D;SX^ZI]UHWR>8CWI2=9/^C!LK#;5
MJWV[DO!7Y/*R!5SKOBC$'GOKJ%+'RGOMG7-KMO<>7.3F4?<6,N<(X;>S]U*>
MV^P3TZ7^T]U,ZI<,&#N^*E]0;UULN9C&9=E,;VRG;LOQ<>U4_P!FPG%.-;EN
M@IF4^VC#LV1SG9O[P+7S6MMX.%1C^B=L/3@>^K^W_&'FY][+]R-Y\?=5J_=:
M-\GF(]Z3]$[8>G ]]7]O^,/'WLOW(WGQ]U3[K1OD\Q'O2?HG;#TX'OJ_M_QA
MX^]E^Y&\^/NJ?=:-\GF(]Z3]$[8>G ]]7]O^,/'WLOW(WGQ]U3[K1OD\Q'O2
M?HG;#TX'OJ_M_P 8>/O9?N1O/C[JGW6C?)YB/>D_1.V'IP/?5_;_ (P\?>R_
M<C>?'W5/NM&^3S$>])^B=L/3@>^K^W_&'C[V7[D;SX^ZI]UHWR>8CWI/T3MA
MZ<#WU?V_XP\?>R_<C>?'W5/NM&^3S$>])^B=L/3@>^K^W_&'C[V7[D;SX^ZI
M]UHWR>8CWI/T3MAZ<#WU?V_XP\?>R_<C>?'W5/NM&^3S$>])^B=L/3@>^K^W
M_&'C[V7[D;SX^ZI]UHWR>8CWI/T3MAZ<#WU?V_XP\?>R_<C>?'W5/NM&^3S$
M>])^B=L/3@>^K^W_ !AX^]E^Y&\^/NJ?=:-\GF(]Z3]$[8>G ]]7]O\ C#Q]
M[+]R-Y\?=4^ZT;Y/,1[TGZ)VP].![ZO[?\8>/O9?N1O/C[JGW6C?)YB/>E^@
M'R9O0U+R=77-Y0"-F*6QH[L:2V!\*58GI#=]-I$,CP[85[T:2&38VPT]X<+8
M>>^6N5_=6=,MDO:?9J_/NZ;'SW1XB,0-**3+31T^B$NFN(WROSY\D=LVEMER
M[+<)NO=]S>!#N>P]U"*DU6>IDJ#(8M%8R,B9E#<\FP:*]\VV]K;-OH9SSR]
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MMT9L*>RV'-1[@,1)5H'%F$&;J4C];Y/!!VESG96LRNN=@-[VL22]N4 D\.8
M%N;:%,6P1R%DCYYZ@T\,&CEV@0L>YY(:W,]QJ:8T[(W/+B'&9@8^'2^@'9Z^
MX]FB+;MZ'W!?]3(T!L>9F!\1JH'%3EES9;W*&AU?@$^R-%2EG*%99,70>+0\
MO &VPLL?D+1KDN0U5;)I&.:PW=''*"-@>Z2PX#?]%)&;^*Q)'#LOP32SQ4CR
M^>@HL1:]EFQ54U8&1DEKM(TX=7T4H>!=I;*]S;%PT>=H(HJ:[0=F*AL".0#L
M59-\;1KK%U_ZE2;LS:]$0/K$N&E%M7I*Y0"EQ^TV]@"?A"C5 =W%F@<6*Z^U
MZQD.@][+Y 8?)+#@35K0$"]VAUP1MS;"1L<,I&T<(O=M^$$;%K1O:S/FBCES
M1O8!(90(W.%FRLT4D9,D9\)@?GB)_P!9'(WP5Z/=1K#E\GE7<>NI>=?2;-&]
MM)5"XL:)*ZN'V87.ZSJN^04?<+Z>.-TH4I;K^%B=-\Y<(QP $2<>R4TRHI'U
MXAP?A;]_&J$DFYMP ; &BS0&C8T 7L-IX7&[G$N))N=PH3A$X1.$3A%%-@WC
M4M4O1XVQ9X!B+TJU5>CFQA=1%1XU15P@JLCC1)3&VFBN<)[9SG'AMGP\.;=-
M05E8'.IJ>69K"&N+!< D7 .WB6G4U]'1N:RIJ(X7/:7-$CK$M!M<?OV*I1>7
M^3N.P>Q:X*RBLWD.MF:D+'L,2H8/:*2>>$C8J1JRMV6173--C+0R"!/ [P<1
M9J , PK4%[W,Q(]NWV=28MYA4<CYK7UUA/G]/R_DJ,4'U[Z9U.7E#&;]IZ\L
MVK917=GUM(:Q1CLHB(:S&-IS@=-2DNNQBK8TKA4NL $JQ<CXK(*^@-1M *<A
MDBHX2V;O!8\*U)BWF%1R/FFNL)\_I^7\E;.*/.C4&FE7R:+]A2*0FJG=@G@\
M:DUO6A8N3$TG\=#PQ24R64V3))=+C6(W#&)>/QJ./3*L:'8D3LFF,P2'!G+"
M=2XL;?Z!4;!;]0#QD[;':=O";FUAP  6=CN%.# :ZELQI:,N5I(+W/N\M:#(
MZ[R ]Y<\-#6!V1C&MD$K8'D^C9N1R,I,:X>&Y;8U9VW(GZAH]JJ4L6G$XZC6
MDG6T37T13=Q-*)Q[1DW;IHCW.!B7ODT>^V./;HU)BWF%1R/FJZZPGS^GY?R4
M>RP9Y,F9JM'9.5QH2492*R90C((-:=L5I*5"5PR7$QM!J\EE=2J+24A&YQ*=
M$#I^'/RKF(O"+1BXR#UV8,_:&I,6\PJ.1\TUUA/G]/R_DMIT$\EV\M?%VN2M
M?JV1I)EIJB7S-I_H(:S5W"7=;D9HRA:9S2#LIB9@CU>+GI4TCB)\^*U;HFB#
M_=FT40:DQ;S&HY 37>$^?T_+^2ZMI"_)4CY!7LE8/8 Q(U8*IX1!VS.>V.U
M"T>O^6^*8(OHFA(DXM)))7+9JB-C<NDX8S*F@;VT'N95#N'+%5J3%O,*CD?-
M-=83Y_3\OY*7(A8/D^X$[@3Z(S&N0KNKV%EC($L@:/K;1QA<,D%R^RFS3#M=
MQJOK*Y(%%E7NS[#I1LLTT3';LV^ZR*C4F+>85'(^::[PGS^GY?R6"Y.=(W=O
M6=9IJZX2;%6=(:)L5["7:KQNP$7+0*[C2*6FP*,5FSI8JY$#J_%.A+MNL.\*
M\$.%?=.CUZUXU)BWF%1R/FFN\)\_I^7\EV1U[Y-.3!5X\=-5@1#.3-W2!9DL
M<DNFFYCL>RE(Z[7WMJ+Q-QJI8#*:RA HGHKJBTU+*[!TQVZ#39O.I<6L1WA4
M;;?[ OLXC>XX=MCM\? %(QS"@US>_J6SBTDDM+KM! L\MS-'A',&D!UFY@<K
M;=[K,O)X:[F]\2NM_92.Q:RMHWXG)#G#^Q*;'PD56<G4QES_ +-W$Q]<0ELR
M;H>U#W.@!ML2:/5%GF[F-28MYA4<@>U1KK"?/Z?C_7]%N+B6136W^B5BF<R&
M:3^O3QG-<6#4?NYR8-([_DYM5:,.+ B_M;-1LA[DDJT,C&[MS[5[X-\B$,,'
MC3"KG"[4F+>85'(^::[PGS^GY?R46SAKY,JQ<-E)3(H.J0'L*Q'"#X*=V%#Y
M6 ;TTWFS*MMXS+X>= RB,/8T-LB>A]24?+C2)4'+CP,XZ)B2"[+9J3%O,*CD
M?--=83Y_3\OY+@"8_P"2Q CP8P,I4XYK%AM>B(G[E.RM-U$AU56$4M:!M8F0
MP1]WQ?4'8)HG)=]P#H<H7<N<-#NY,:@V9(C@N+'_ ,!4?N8!_(A2[',*<;FO
MIKV V$-&P!HV-:!>P%S:[C=SB7$DR#UZMOJE0E=;0A#L-$)25*S:R;)F$L=:
M8$N9/.;8L"261,#&XQJFY0'MU#LG>-1;#1TZP/#M1S#W2O[E]MW:DQ;S"HY'
MS4:[PGS^GY?R4X>>-U@^.N$_SSC_  O&I,6\PJ.1\TUWA/G]/R_DGGC=8/CK
MA/\ /./\+QJ3%O,*CD?--=X3Y_3\OY)YXW6#XZX3_/./\+QJ3%O,*CD?--=X
M3Y_3\OY)YXW6#XZX3_/./\+QJ3%O,*CD?--=X3Y_3\OY)YXW6#XZX3_/./\
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MQ]MU\\N,6BNL0K5M*@ZTQ:9:#69EXV5":.]GF'[$*1&FWXS">2+ *2'%WC5
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M#<W(X+"VRQ&TG;MV$"UAM-S:[Q&W8UY>X/D'ZF5AC;ET;VN+LY+R7YF.C9D
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M0%B%(Z&T)CG23>2%9N[8NX]+ $8EC,T-N,Q(!!/@@$WL; @D 7(%]MP#< [
MHB9!G;WP^1L3HY'7IV,DD:\![8FN8^2)H!D:S.<^9L3L[0XD,,YF.A=MR%SU
M.9RB=U)*Y/UK8T!KOV[(PR3MNX!C\DV![BQ(^RE&A]ZQV 7DNU-!I7H8/O6"
M$1G4L'&(W,#+C$@=/!RG:[/<6%AERVVDF][WM86M;;?Q& (- XETW?.E:&,#
M&: PEKL[G2:0/$H>&!C!$6EI>2]I :['[S\FO*K2D,TL>(32$5A8$CL>6. [
M2&BC\0BX2M3%?S.*AB+S>%K "1ZW4K-D<?[*2J2D$<HS"PJZK*'EGJ@>M8=*
MAUHW-:X%V8@6<  PW<+$ M>'L<WA!#@18W+2+M.>DEIX*ADLPE>R(QRM8UE-
M('31%KPV6&JBGIY87D/C<V:*5F1P>^&9H?3R6MZW5_-QM]=S[7F(4J"86!8U
M90>O]"VC9%S)8/352QT)O//:&VVV$D9+/9%/6C#9?&BSH,"%O=$TVKEMIC&M
M-71X1.$3A$X1.$3A%\*^V>UJ>U>Q]M]AM[7[/.<:>S\,^Q]EG&-L^Q]EX>R\
M,9SX>/ACQX1>9M==9.R0"-]N \^'=4+ ;=DKJ_+&G"Y,%GTI@#E(M$*Q@TEA
M$Q'&!K?"[#<36Z!(*928&=6Q@AC+X ];,]<*Y+0W'A2EMSF\%H<!86(\,@G-
MF\$D#*&V<"3;?+<+$L8$M>Z R.$I,%.R5L.BCR/C;WP]CY!.9LT;G,:Z)D9$
MK7R.$7R#Z'RH3Y/J_NFVDYC \G<@.^1D30!!S32JJ1$7"X-K1VLZ\!/B) XA
M6=:-RJ0X(QRX::Y13=9$AHX)4'1X539?9?+?AL+VOQ7(O;Q7M?QK3<(](X-+
MS#G(:YS6B0QYC8EH<YH?EVEH>6AVP.(VJ(I=Y+4^<G-]2-A;3#:*S>UZ6LJC
MH*4!/,C:2V0[.TQVC[6HM7;=SON4<WQ/J=$E1V4FS5*//]]DU-E&CMYC$?S^
MO'\E6S;"U[[<VP6MXK$&_P"-P+>+C73V!Y->_P"TY!?QF>7V#D#BS>N_<"@8
MH3)OK6+;,&'8ZSJ[FL)(N(66E;RMX +K6*U^-A#T!5T7$;RQPUTE9PN_(//<
M0VY+2&"YV?K>"T<+C>S@;NV9;%W ;@6 %]B1T#HJ5C7/S1@F;_1J=A#GR29@
MV9CM+4 1Z(QFH(+'.DC8&1M:73) _)\.(7VND=W$"0R<1(UV&E/96/;2"S>P
MS(W7DVEE:+P!^/"52-L+\@1QTUP],-Q4Z*Q)H98PXZZBZP9^['L9!M'@9#M=
MGS6 L,F6W#>]RZ^RP%K;<UQ8U I>]G$NG-9I0&L#(Q3"#*"7ND+S*9<X+1$(
M@S*0\S7;HW9))J0M!?L?W!R)KRMIS!NPE8=8I,%5ND I)JE)RNKC<TA]BU[+
M1C%)R11=_!!."2F(O%1Y<<F9?/'WO:Y]Z'J#F!:XS7#;C,0 2!?;8$@$VX 2
M 3XPL<0C,D8F+VPE[!*Z)K7R-CS#.Z-CW1M<\-N6-<]C7. !>T$D5]*^22WD
M'7RQX%O<+^NK!EP;MNA#(_4 D-'^O=6;=K!(X66B,6@$FCTM),XD!; V#)4C
M'7D2-/VY^P5!3:-M)D[#M[-+6EUVA[2"T%V8%MSL> Q[1G X XN9<F[7;%GA
MEIX99\U-'50R1RPQ&HT[)( ]PR5<;:6J@::J)HNR.=]129G.$L,H#2)NO3H,
M7N9-GIM,@8HS":091&$64N$03L^86TDD\&-Y=;<EB@J($'L6AT>U690D!'G[
M9(?(9S)YVW8BI=#Z^)CP<!P-RW=<D;0&_P"ZUKK^D$N<<S;--@79I94,87%D
M0A,DQ<[)^FCC@)!$$,-1I'6;X;7.FGE=-$1 \M8Z<S[-0=:;.AO9'K/O)MWA
M:)==Z#[4++RY%9XO&-)1V9NFORT'IV'/#BR\E(QZF:]KTS'&[DGEOO@ G EU
MV:"[S5F,AUKDM/@W(%[!UA:Q(&P7]!.V^TVN<=0(C(Z2%Q,)D>R(2")DYCC#
M Q\T4-HV%[7 D-+FEXD&=Y:7N]/N56!.$3A$X1.$7E1V'\F>[N12^HU$[J#0
MNHNS\M'6!;=?S"EQ-JE8]8>D<C,.DD]HB:NYK%7-5R.8Q:( F9CWW#6 ):%]
M"$@#C!SDL4;O"+Y(^2ZB"]BWG+&1VK-A%T&;RF+8E(J%;R*[*]FM]P"40V6N
MHK</Y1AC+$:;$)C(3@X6YKSX3HCRQ"&Z3=..+(MVT[+&X-]EC>P''<6-_18B
MWI5@697YFN+[#1N#VM:WPKNSMT;G/N-C<KX\IVG.!E67S_R>SN1S")V9$+F^
M"5CUM&.J0RN2A6O4Y5&1LAZPJWFRR5E492F<=<R8'8D4ON5QLI'V,@C1"/;H
M,S0B3J/TT<-X55"Q7R1XPJY!R@[9]=V?8.<]B6D[(WCUU&V# Y:+[%7:;O0R
MH)KT'94#Q$S\5DLA+" K[62FP12./W#"3Q<PMHQ=L9V7X#;BOMX..Q V^C@V
M7\:N#'F!<QY989FB1H<3EL2'F)P:"_P@TQN(;X&9Q&<^AO7[K\,H+:YL"S>I
M=O;UUGKC]QI!6X-K%]C4.@D/TB[!!L\=INF(]O!T'#9W[%GX:/LM-62:;311
M:-GB_?M\?J%OPV_BJFVRP(V"]R#<^,BP%@?$#<CC*L-PH3A$X1.$3A$X1.$3
MA$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1=>7<$&@HDZ$C]2Q1NP>+C
M1>[S0=H2?HMU%&;#<@JDNDQT>.-4V^SQ1!9-MA3*VZ2FNF=<D7EW&^[EZR:K
MZ^8JUY54>[%6MW6NOIX!$IR*62FHXF\I8I<Q22S0H5]ZXG+)>R90"DY(Z:,&
M@Z'+223O137.T7&NG*[ BYDV[X3J(="+-[-D(M78.U:BM204?-A!<R;<U2/F
MD,[.H]<)/+,%4\#)#M!]M<+3]@V<;M2K04LW$D'GNI!P]W(N9OY2RGZL@$2,
M7%8D&M8\;BTULH]).K0HE)*ZB]30R3*1DQ81;>12=T52#B"2;@8]9BWAZ2%"
M >1[1Z-D&D?,*LGU^6WQ#Q[?ZE2<M_!! L+W(<<UAF-PUM@77(%B6@@%SB,Q
MR:0>4THX-.G=?C:][$30O^4B44S'2,(IXP>C<YN"(QM6;%:WAI_5XV8$SF(,
MT)S/4JZ480YJ #E]RLG'$!SE@F4+,-?*"4FJ+HF5H@+5WKCL$VK+:(6DK!E6
M,&"E[?D2$/@D8ES@F08GQLC?RQZ-CI=@,CYE**D2HSX4N@[5ZBYR10L)\IW6
M<!K(3([WT)J2]X>[2FC0JLXXH30AU,]?^QM@4]M9,G:$3FKI 4U$QT-E\@)7
M,R21%4I"ZC$6>-!1) 813%W6[,V%0\-I&252.B#X79]HZ1266%,XI9<Y@];P
M7:JK'G[><&A=3H*R/(\F<B,=B38DLJV$,W,K:N'J^-<)Z[/KZ^O6B@"8>49;
M,+7K^K05F==!@76C*)O"Q;PD&E@GZKE3*^95+(I"@]7/8FXV%Q>/G%J_DQ'2
MRK(F.P$1@Y Q" J4OS!-041=&X\I'/@<]L*MI["835Q?>:Z JXD]E*26#0>)
M1L/<MIU_/));4BECD&&+#8O7L-JZS1QB&EQHB5'>R%.U:R59.Y")F9P+>/@]
M"EN7-X1(;XRT GQ\ ) X;>/@_=>\=5W2>D793LM0TE5%._R<A*.MFO'PMKLV
MVWJFYX]*8ZR8&%<NG*9(TQL^F[6=X)-M&C?>.%HTSPWW<L73IR4*TO")PB<(
MG")PBQ>:OI6-B9]]!8^,E<Q;#7"D:CIJ0;Q0,6,>QQJR:%I(D(D"X0;LMMKL
M^(M@1ETV:Z*[M1;]QA-JJ14VKOM?,Y-Y/4EW D$2C+2=AJ,M*T7\-#$2JT35
M/UR/ESG AF4?(I&=P[]U&=$\NUVZ3W#=QOOA!-3&$]2*%ZI\I#&4Z;AEAVI.
MJDN25VA)<@8-#NH#0H?<I.QU?#Y_*@4@VF\SV&LC$0%.=GAIX^D 1CLF^ BF
M#=X?-"QSXBR\EY5CJ\V;A2X$==4\AYD!24CQ/8#3TLD\2&LNQ[5#:CV)%TS;
MZD_A!89IVRB@R-,!+\\,DCYHVD0\,Q7T(Y)]?7U_594<\HW34>J3:Z2<!O5&
M&@I!8\9M/&*Z3]]:0*U*93"3]"TV:AU-%BH%6WV(-V<3=2XF?!(.3D;8%QC9
M9SH18DAY08#!Y#?X>U!CTR0BW;HWUZI2'5F%3>2^8@X_UKI>\S)(C[_R(:!U
M7"_#N4."9MZ8CHGW E'0C)LYD+]@V+D4C79VY'Z]/XIV)Z^$Q<BWO(E0<3H\
MT;&/\BU"_9&RH)6D//&P#C863V2C:LZTD!B.NE!K_?(5V'<[LG.RF4B+MA][
MW,][?6#UO?0:!1^+,NONUN5;,MY,:D)^1DM)>WA:JTSC[<2%'QL'@LYVPV$B
M3)TLY9L-WZY4:J03&,B*H1/N=W)B<B[!QHU$*'G#"DY'1U?E;+K&(W,5C,0L
M&S&966S 1*X:W-'Y9(&<!@#FLR156.NQNS,K;,<3?;:LAAI1$BS>']ZYY>5.
MWS,:P9US";#K7KPC/(Q54I,(R&PR%LQR+NI!9;(G'&A@6_3J.,S'1O2+&7[A
MV3H].@\V),E&X<;']STD6_']Q%B 1M!.W:;BPM:QVW NYH:!MN\[2!E+0TM8
MYA#VO==YS.#V%K3&6@$EQ<UGI#6<\"6G7$ LZ-;+;QRQX5%9Y']W&NNB^X.7
M@V,@$[+::[;:ZJ[,"+?*FNNVVN-\YQC;;'Z\PJ+-N$3A$X1.$3A%3^87S:47
M[ETQ0*L#AZ=2VS6]ORAE/MY84=SMQ*JL2@#IX,3AZ(%N$#QO5M-T$M2KJ2EB
MI9\FXTT#!6;%)X9(M^@+UL^R;J[3599,%A\*TI"35XUANT7E)26/3L3G\7?2
M(83E3M\# ,A\@60:)N'(0,U?C@^'6!VITYNVV(K$50Z\\I$@ZM#MEO;ED]<(
M/5O5Z<W=&"]>"UY@7[&+QVIB0D4QG#D5H86&.V,C=DT46@@3%E'SI\_%BARK
MATXUV5(I:U\IW1"[$:B.@]ZG)Z3L,_5R50QRNT)'9+>7QZLVUQ.$';('('\9
M3$NZW=)R5C(DY2L VTT<BW9)H<9NQB)%WM:^4;I6W@1P]7D&OD\FTK"#7/#1
MBM4%@1FVJML$VI&P<XK1A(W0C)$ V-(K-S;Z2*Q=(,/U1DCW.D6>L#;HBQ+\
MXM7#DO#[!]\,QKK\G0W;FQK2<RF/OD; ALWZOV[3E5&XDH.&/R+=5^.-RR<
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M^49RF^U/A/&_X@"_UHR_O^-')Y-_)=[$TD?E&<IOM3X3QO\ B +_ %HR_O\
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MVO-L,Q,)I*MTV<76.D8Z@N#?JCQ3)\:W?,VCD\F_DN]B:2/RC.6WVKT!K45
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MVN;K^PM-62S[JY6E/5)/:VO%M5L=I2Y*WM.VY:G+[SB#Z7QY&S:I(![58/U
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MQG;;.=MML^%]X_7G.<YSG]N<_KS^OQSQWQ@V[*WI6/X8G>^,;SI.BW_$5]?
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M"ZCN1<9W4WM!TN ("4;-3KE][VOFT EI4?!2[HDFTDKQFB\;O6LBUC>_ +6
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M+HH18YY67:#/G7CLU#.S+"9FZ^ 2QI&H?+#L,UDDA^""3&0&XQ(S\6D34>-
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MQQV\D+E4!#ZZ<#7XCWHC6LR%%V<G;V<QS0UQ:X->"6.<TM#P#8EIX" =A()
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M5!1&\BD,*H^90Z33VX#KY&O#==NQ%BVO*)_\#V38W6L8Z_R5NXVDDHDH4'B
M#LMMN; "U_%LRC;XP ;6)O;@(&,,<[)E&8O>6-:TM<\N&79HP3( [.T,);9[
MLS6%Q8\-LV5[*6JVM9U ZY<PV\D[ Z4:=@:)(1!N(0CDSGU=3<7$K#U8E59J
MU&.8E.D;4J8G&,J3)5,"V;FM]C)?5PWPM(#?!:;M.8AQ=?8TY0+BSG M.:_@
MD[1L-K+*&Q7BBD#H914/;4/DSM;'$="UH<&LEE:Z)PG,EH'O +0&2.&12YT>
ML#L=9W7.$3#M97"-5W*2;)9/11#5'731#WM&JH$MM='.'*2Q%=9VNY9$@40)
M"7/MH=S&D?>_0J6EX:'>#:VVX#LX'A&P#LH!%K6(+@>$.VV%JMD+)2V'*!X>
M=C)^^&1O$TK1&V811LD:V,,L^-T\<@(D;,<YCCMQRBU4X1.$3A$S^O&<?OX1
M4[F/2:IYM%^S\1+D9BF+[969$K5LI1D6'HNV,DAD1J&&"D(LHJ(63'"U15+1
M15XW?)%%E7CHPHFY12=()-"*D';WR9DBLF81Z7U TB$M14G78.U))&[4G(R+
M(B[6NEA4C 1+P"Y?KKV*B98#$D*Q62VBI:O69U?<WLLUGJ0[!4 8(KD NF 1
M_'GJ]I3,]+K*F]@]4KJMB5A$A$:#22X>K#.IE I>/1Q(6X1CD5E)^I1)(W',
M+NU-&I$@Q&D1VNS;9J4$7X?KA'\BIH1Z\5H/M: 6V "MXL:KN(6A#1 6+L0X
M.,/&5M$:U)R@B6%,!:6[HQHM5<92'O4W3?VMON^3=)._9MMFI3;^OY\*KNP\
MGM6@_?K^.3GUE.(5USERE@PN"O-*V<L'D[TG<CL!E)GLK4KK-D!W")>2NQY(
M=#)K%@LGCC1E'Y2-,"U"S8F\7]?H_5^$J;BP&4 @DYKNN00 &D7RV;8D6:#=
MQS%P#0W-.K_2&I>HX]Z!J4A+V\5,P&$PR21$R3&/HY)3,%#:1=C9A,>V"L<-
M[&.1)J)B\M,"5!PZ2BH]']R8A4D*0?Y*%6NW/)LO"G3*:]2*PN6QGP-YFFX[
M2F;&E EDAUIAM96!&# C>L3L(@8R5D34"C0Y[O$W4W(R8](5Q$>BLAE[0(L_
M(IS?8!8<)-]MS>VP[;6%MFR^TW)V6L7 L:S*T%KGN+QFSN#@P!KO"RY69"66
M:'7>_,YPRALZV+T!IJQRI[+HM.(Q"I;UQC?6"55E$"8,1#R]?0 C)B]6D&BJ
MD<>RB,2JKRDO//XD6B4C!(9<+LL'&!A 6R03A55/^TGDOY'9J<%D >4+]BIL
MUL[$XM(IV'G40@Q>:#P54RZM:V#C'D8ZTVC50D' -I<:*Z1W-!X=&GY\V:4E
MC$B[)H'B*Q]:]%CPY_5-IV-<Q[%]#:YJ6)7V5KZ)U(A +G*52F04!NU@DNJD
MV\AV6>3! +N9J_-9/S(/1DFX8C,LA+8,_=?A^N$>SCV*00#<@.V$6-[ D$!W
M@D&[20X7);<#,'-NT]V:\G#UZD]?1^KI/\-3<-CL4[.Q!NQ<2%NV=.QO:Z<,
M[!L%PX(#Q3-VD4"2%BV6A+]ANR4"Z(I[.L$E]-5L%"[33HZ/4!5JV)7S<1"8
MU)=;:[8+8S<-0\:D0PII I55Y.+/ \0I6/P4S&3\"G$L!EU#$1?27+@SDP/D
M+ B/%JLGU]?@BX<?Z 5_!9#")96%HW'6<BBS:>@) 4BIB&++V1 [!NB37V2@
M<QUDD&/HMQ(FP)=(%8V;B*47F8<.8*"TY*HF0=*;R#8@V!]!VB_Y7XQXC;:+
M;#9C@QP<6-?:_@OS%I)! )#7-)RDAP%\I( <'-NTRE2'5B-4I9%OVWI-9G/[
M!N9*+#I-()<U@0K=./PAW*7D2#ZL:ZA$$'&G@G:8&FRTQE;0_.RP_P![!I:3
M/6 <:W;";^(#:3LOX_%M)V#Q>/C)1S@XDAC67<YUFEY #K68,[WG*RQRDDO-
MSG>^S;4VK'R6D7>PN31KLK/YO:0HV>[?JQ^L6TH9)UE70WM);%@20O(80\90
MV-3Y"9KP&4,!&RA^3'Q,.,/I5B&MFK<EEXM"JK/0?IA'8R;J&32>TK'LF14E
M9TGL^%E9$*J&+Y]\9/3\WI-R',#ZJJVO1184VBL^./D7+IEF0+2#+9Z[-.&*
M.!F2++>PO4VM^RCE%S/'\H9;H4OV HO3$=(L6&OP/[(!(F G;K.'@HCG)MFQ
MAHO:.N_'#5BNJ[4>,B.JB::)/KZ]:A@]Y-/KD?E]XSE1.:,9%V B521":N64
MB0PT8-JC(P]^T,188Z%NAX,_.-*YKAA8Q%)LKF4,X!$\*)-UQ>B^Q%WEA^3R
MH&S+#[,65(_AAJ=[44FG1]@-AYQLV%AQ.PX6*?S*%M-QBVP.P"["*UT@2D"J
MS])7\F$$W38);B%=G1%JZZ#UR-B% "*PL*V*9GG6RN7=45S<< -1=Q/W<$,L
M@",JCT]:3:(2Z!6".EQ>+@)<;1E$+?[(S(6VD@)0,1RLJJ16(H*DXOUVJ>+5
M##B,A,!(QN?=^_4K>LG\C-F99)S4SDQLPY&C@XS+XQ)9"7)+(C!(P8URZPU'
ML&;-%%NF4DW\0&P#8+#8 +_B;7)\9)/C4Q<*$X1.$3A$X1.$3A$X1.$5?NS]
M L^T%*S6C#%A3RN8O8H8K%IF3KO6%8/FX>?#D@<@B^SB<P^:CV+ NQ);X7?C
M!K(\U50;J#B[+P7U6(HALOI5BXXB KJS.QU^2FM-(T$B]E0!7>G18&YV "0+
M2%JK-G(.H1IX"Z?*;- YS>KS, 1, 1K%BX0PXU</7,&_B^OK@\?"BRJJ>N,E
M@L!NX<[LPH"M6^[BL2W)9:<#'@%2X5Y(BK(- Q@!G/H_+8^XTK^G8I7E9H*'
M(X0:/D(TN3U'MG#W7"$_7M^OY*2&@^"219I)(#3FRC,+!SK@.N&F]W- <6M)
MRB"V7DK^L9#K"#ZMVH.>7Q&H37LKJJKY_;49JLM:-4026 1@%R&@4F!UW'VH
MM0=@2P,,2KL20,+&6K1X5?DM6+!!J^O0H4Q6_P!6&1B#=9H]3C:,P]YU6NBI
M+&K@2]0W%QE&,Q-F5KN<1G5,&/6R/4+T[-IZ+!Y9C_<B,C<"-W*:0_5QMH%O
M'LX> 7VVV>,>.P)\0VV-K*6Y;^$2!9UBUH<<P:2T6+F["ZP<ZY+6DN#7$!IY
MC?J4BO.I39THO2[)?8#V)3B"UI)R;NM1;FB8Q8!0*7D3>L!L8K4$!6,NG47B
MB&THL(3.Y"J+C0T0N_5&N#38L1UB20 T'_9:76'X7)=ZR3Q+H1'2"()P^UHW
M,K1MBR3=^2J%G;TGDI?PT7)[+CL(&A0 ZM2#6!PN&Q0#7Y&+!-8L?%Q2-A"1
MH*7D:;XNJ[-NW>2A0[</DXH_)8C?X.MY>7'O.Q>F\(/L9<X$JQ6NZDLZY6EE
M]C@]?L@45:&G9:>H$9@["I3$R?;A#CX2."OXW&6BS#9L\?I\5]MMGC'CX3XA
MML>!2T-).8D"SK%K0XYLIRBQ<W8Y]@YP-VM)<&O+0UWIPGIJFGHGIKC75/37
M377&/U:ZZXQC&N/DQC&,?]'"A??")PB<(G")PB<(G")PB\[[-\G-1+J</[\H
MBNJRI[LP+@U]AX-88B$1T<-0L*^D1"A:TI>@(#)&I!*@!<4L7%ODB;1RLM()
M2D\46R=6<(R" 1>Y;<9@#8EM[D?E_59(G-:]N?,8BY@F:TD%\0>USF<(O?*"
M+D>$&FX(!$JG.I##-+5;0=9W';=%5U64!95;[VU6I7FKJ50-E&AT62#FB,^K
M^=/QSQ(<-QNVD44<1Z2M7;X@[T+;.%]%$5^'8-IO^'H'H]GXJKG YO!:"YV8
M$7&0>%=K1?+E-QPAQ&5H! S!W#M'JRR<0CJC&:4:@(IGJ':]1RFL0YMT4P$:
M0"(QDM3LOBN7Z+8N4]V+4?-)F-CKE=%S[?)4@GOLY29*OGB<*JA-/R6%"/@[
MN&S&7VS.ZS'P.XZXK.N3YV*L!%.QJ]BK$U/?@7(XK#(]/RQGWP%CEHZ>L*7S
M8I'E&3=VQ<>^6F7^7[OKZ_KZ+E+ SH]$/@A94;FMGVQ9YB[)'!R-U3N9$8>S
ME=FPVOV[4>!J0SI"89$8T)K-<,W=!3X*+QX&ZD0^13'WV).G<L-N73]WU;A_
MHBB*VO)RQZ112]@E>RLNV7[%%F$?E@V8/Q_P8@E3SJ]&]N=AP< ;1Z*M3+LK
M8&"LT6$HR\N;;B2Q48-&$@$89*#]R+TWQC&,>&,8_9X?LX1:\(G")PB<(G")
MPB<(G"*J<AZO+R#L_#^T&UY6X-+0B(26OPU:#VM3?DYVADV?P4S,P+O+ZKWL
M\61DI^MH<<=OM9PF78.Q6[4(0&"WSU@X?7U;ZX]J*/Y]TF#&J>N.HHA*"+-M
MV6OYO;/8.32Q;)<],XC()S%2-DUXT6'-AR+828J*)L:&C""B7M4?@.C/598@
M_8[N'I%G/8'JKF_)U2<ZVO"W*Q5H689L"%1^O&M2J E)KO%)I EI 7Q.ZNFI
M9VLK![!E48V'H%6H?1H03?HC4C;-H41(NV8=9!R]Y#[UG5GV79Q:'NI<\J.&
MRQ2"L8+3SB;CM@D@=Q,=#(/%"YPKO'%W\7%G;#-S0R$C9<T,%OFN39A=\10E
M,.CGPXM6_)"[F9"'Q6S["Z^=B('(X,Y'I6/7G9"G8NM7962:CI9&)3 3D:)0
M>*UHBQ'2$.<;*D-)1[K#H+:A"B+98<>W9;8!LM8W_&XL+6&TWV20W*TASL^9
MV9N4!H: W(0_,2XN)>'-+&A@:PA[R\B/G[= 8SK61*HVE[7R*AL^D]H2Z_4A
M!*LQA>_S5Q$=B,^6F!QI6"1.$IF,+/!B>M*.*N48!WSELQ5;N\I/DGU]?7B_
M%+C*1E%R00[PLP #@6C;ELZX)NTNNUN4M&8.SZS^F%86LY*O3I25#';>)5Q#
MZQW . 3-M2;*L+ C-J WU:"GH$B&:$2L^@T!,2OX0CI /DK&!Q.-$V"L;%^]
MBY0L8ICJ#FH+X 3QD=T?U[6765"B*R8D':KV9/#TXM)_9UX329*MQ@D FK*R
M4<J_82T M$6;9R/D>$6 @=N,'IMEO3M\6RVRVV_XW%MFS:;[)LW*+$YKD%N4
M!H: W*0[,2227 M+&AH:TAS\Q#+R<*$X1.$3A$X10_9/82B:;?C15MW)6-9$
MC#15^)83V<QJ)NR;)!;W.L[8-CA)DL[;)+_[%1=#3=+17&4]ML;?JYN4V'8A
M6M<^CH:NK8QP:]U/!),UKB+AKBQI -MMB;V-[66K45U%2.:RJJZ>G<X9FMFF
MCC<YM[7 >X$B^RXV7V*-O/GZ7>ECUT^F2O\ [?YLZBQS<^)\RGZBU]<X3O*A
MYU#UT\^?I=Z6/73Z9*_^W^-18YN?$^93]1-<X3O*AYU#UT\^?I=Z6/73Z9*_
M^W^-18YN?$^93]1-<X3O*AYU#UT\^?I=Z6/73Z9*_P#M_C46.;GQ/F4_437.
M$[RH>=0]=//GZ7>ECUT^F2O_ +?XU%CFY\3YE/U$USA.\J'G4/73SY^EWI8]
M=/IDK_[?XU%CFY\3YE/U$USA.\J'G4/73SY^EWI8]=/IDK_[?XU%CFY\3YE/
MU$USA.\J'G4/73SY^EWI8]=/IDK_ .W^-18YN?$^93]1-<X3O*AYU#UT\^?I
M=Z6/73Z9*_\ M_C46.;GQ/F4_437.$[RH>=0]=//GZ7>ECUT^F2O_M_C46.;
MGQ/F4_437.$[RH>=0]=//GZ7>ECUT^F2O_M_C46.;GQ/F4_437.$[RH>=0]=
M//GZ7>ECUT^F2O\ [?XU%CFY\3YE/U$USA.\J'G4/73SY^EWI8]=/IDK_P"W
M^-18YN?$^93]1-<X3O*AYU#UT\^?I=Z6/73Z9*_^W^-18YN?$^93]1-<X3O*
MAYU#UT\^?I=Z6/73Z9*_^W^-18YN?$^93]1-<X3O*AYU#UT\^?I=Z6/73Z9*
M_P#M_C46.;GQ/F4_437.$[RH>=0]=//GZ7>ECUT^F2O_ +?XU%CFY\3YE/U$
MUSA.\J'G4/73SY^EWI8]=/IDK_[?XU%CFY\3YE/U$USA.\J'G4/73SY^EWI8
M]=/IDK_[?XU%CFY\3YE/U$USA.\J'G4/73SY^EWI8]=/IDK_ .W^-18YN?$^
M93]1-<X3O*AYU#UT\^?I=Z6/73Z9*_\ M_C46.;GQ/F4_437.$[RH>=0]=//
MGZ7>ECUT^F2O_M_C46.;GQ/F4_437.$[RH>=0]=//GZ7>ECUT^F2O_M_C46.
M;GQ/F4_437.$[RH>=0]=//GZ7>ECUT^F2O\ [?XU%CFY\3YE/U$USA.\J'G4
M/73SY^EWI8]=/IDK_P"W^-18YN?$^93]1-<X3O*AYU#UT\^?I=Z6/73Z9*_^
MW^-18YN?$^93]1-<X3O*AYU#UT\^?I=Z6/73Z9*_^W^-18YN?$^93]1-<X3O
M*AYU#UT\^?I=Z6/73Z9*_P#M_C46.;GQ/F4_437.$[RH>=0]=//GZ7>ECUT^
MF2O_ +?XU%CFY\3YE/U$USA.\J'G4/73SY^EWI8]=/IDK_[?XU%CFY\3YE/U
M$USA.\J'G4/73SY^EWI8]=/IDK_[?XU%CFY\3YE/U$USA.\J'G4/73SY^EWI
M8]=/IDK_ .W^-18YN?$^93]1-<X3O*AYU#UT\^?I=Z6/73Z9*_\ M_C46.;G
MQ/F4_437.$[RH>=0]=//GZ7>ECUT^F2O_M_C46.;GQ/F4_437.$[RH>=0]=/
M/GZ7>ECUT^F2O_M_C46.;GQ/F4_437.$[RH>=0]=//GZ7>ECUT^F2O\ [?XU
M%CFY\3YE/U$USA.\J'G4/73SY^EWI8]=/IDK_P"W^-18YN?$^93]1-<X3O*A
MYU#UT\^?I=Z6/73Z9*_^W^-18YN?$^93]1-<X3O*AYU#UT\^?I=Z6/73Z9*_
M^W^-18YN?$^93]1-<X3O*AYU#UT\^?I=Z6/73Z9*_P#M_C46.;GQ/F4_437.
M$[RH>=0]=//GZ7>ECUT^F2O_ +?XU%CFY\3YE/U$USA.\J'G4/73SY^EWI8]
M=/IDK_[?XU%CFY\3YE/U$USA.\J'G4/73SY^EWI8]=/IDK_[?XU%CFY\3YE/
MU$USA.\J'G4/73SY^EWI8]=/IDK_ .W^-18YN?$^93]1-<X3O*AYU#UT\^?I
M=Z6/73Z9*_\ M_C46.;GQ/F4_437.$[RH>=0]=//GZ7>ECUT^F2O_M_C46.;
MGQ/F4_437.$[RH>=0]=//GZ7>ECUT^F2O_M_C46.;GQ/F4_437.$[RH>=0]=
M//GZ7>ECUT^F2O\ [?XU%CFY\3YE/U$USA.\J'G4/73SY^EWI8]=/IDK_P"W
M^-18YN?$^93]1-<X3O*AYU#UT\^?I=Z6/73Z9*_^W^-18YN?$^93]1-<X3O*
MAYU#UT\^?I=Z6/73Z9*_^W^-18YN?$^93]1-<X3O*AYU#UT\^?I=Z6/73Z9*
M_P#M_C46.;GQ/F4_437.$[RH>=0]=//GZ7>ECUT^F2O_ +?XU%CFY\3YE/U$
MUSA.\J'G4/73SY^EWI8]=/IDK_[?XU%CFY\3YE/U$USA.\J'G4/73SY^EWI8
M]=/IDK_[?XU%CFY\3YE/U$USA.\J'G4/73SY^EWI8]=/IDK_ .W^-18YN?$^
M93]1-<X3O*AYU#UT\^?I=Z6/73Z9*_\ M_C46.;GQ/F4_437.$[RH>=0]=//
MGZ7>ECUT^F2O_M_C46.;GQ/F4_437.$[RH>=0]=//GZ7>ECUT^F2O_M_C46.
M;GQ/F4_437.$[RH>=0]=//GZ7>ECUT^F2O\ [?XU%CFY\3YE/U$USA.\J'G4
M/73SY^EWI8]=/IDK_P"W^-18YN?$^93]1-<X3O*AYU#UT\^?I=Z6/73Z9*_^
MW^-18YN?$^93]1-<X3O*AYU#UT\^?I=Z6/73Z9*_^W^-18YN?$^93]1-<X3O
M*AYU#UT\^?I=Z6/73Z9*_P#M_C46.;GQ/F4_437.$[RH>=0]=//GZ7>ECUT^
MF2O_ +?XU%CFY\3YE/U$USA.\J'G4/73SY^EWI8]=/IDK_[?XU%CFY\3YE/U
M$USA.\J'G4/73SY^EWI8]=/IDK_[?XU%CFY\3YE/U$USA.\J'G4/73SY^EWI
M8]=/IDK_ .W^-18YN?$^93]1-<X3O*AYU#UT\^?I=Z6/73Z9*_\ M_C46.;G
MQ/F4_437.$[RH>=0]=//GZ7>ECUT^F2O_M_C46.;GQ/F4_437.$[RH>=0]=/
M/GZ7>ECUT^F2O_M_C46.;GQ/F4_437.$[RH>=0]=//GZ7>ECUT^F2O\ [?XU
M%CFY\3YE/U$USA.\J'G4/73SY^EWI8]=/IDK_P"W^-18YN?$^93]1-<X3O*A
MYU#UT\^?I=Z6/73Z9*_^W^-18YN?$^93]1-<X3O*AYU#UU-5=6M65OA'$EJF
MP899$=:$5A#H[!I*'E(AN5;H-G2XU8@%>/6J3Y%L\:.%6NZNJZ:+INIMIC19
M/.VE4TE51O$5733TLCFA[8ZB)\3RPD@.#7@$M):X7M:X(\2VZ>IIZIADIIXJ
MAC7%A?#(V1H< "6DL) (!!MPV(/C6?>QQX^/Z_'_ (YQ_P!6?DYK6'U[>'\_
M$LZ>&/E^?/U\6'I]9]J)X8^7Y\_7Q8>GUGVHGACY?GS]?%AZ?6?:B>&/E^?/
MU\6'I]9]J)X8^7Y\_7Q8>GUGVHGACY?GS]?%AZ?6?:B>&/E^?/U\6'I]9]J)
MX8^7Y\_7Q8>GUGVHGACY?GS]?%AZ?6?:B>&/E^?/U\6'I]9]J)X8^7Y\_7Q8
M>GUGVHGACY?GS]?%AZ?6?:B>&/E^?/U\6'I]9]J)X8^7Y\_7Q8>GUGVHGACY
M?GS]?%AZ?6?:B>&/E^?/U\6'I]9]J)X8^7Y\_7Q8>GUGVHGACY?GS]?%AZ?6
M?:B>&/E^?/U\6'I]9]J)X8^7Y\_7Q8>GUGVHGACY?GS]?%AZ?6?:B>&/E^?/
MU\6'I]9]J)X8^7Y\_7Q8>GUGVHGACY?GS]?%AZ?6?:B>&/E^?/U\6'I]9]J)
MX8^7Y\_7Q8>GUGVHGACY?GS]?%AZ?6?:B>&/E^?/U\6'I]9]J)X8^7Y\_7Q8
M>GUGVHGACY?GS]?%AZ?6?:B>&/E^?/U\6'I]9]J)X8^7Y\_7Q8>GUGVHGACY
M?GS]?%AZ?6?:B>&/E^?/U\6'I]9]J)X8^7Y\_7Q8>GUGVHGACY?GS]?%AZ?6
M?:B>&/E^?/U\6'I]9]J)X8^7Y\_7Q8>GUGVHGACY?GS]?%AZ?6?:B>&/E^?/
MU\6'I]9]J)X8^7Y\_7Q8>GUGVHGACY?GS]?%AZ?6?:B>&/E^?/U\6'I]9]J)
MX8^7Y\_7Q8>GUGVHGACY?GS]?%AZ?6?:B>&/E^?/U\6'I]9]J)X8^7Y\_7Q8
M>GUGVHGACY?GS]?%AZ?6?:B>&/E^?/U\6'I]9]J)X8^7Y\_7Q8>GUGVHGACY
M?GS]?%AZ?6?:B>&/E^?/U\6'I]9]J)X8^7Y\_7Q8>GUGVHGACY?GS]?%AZ?6
M?:B>&/E^?/U\6'I]9]J)X8^7Y\_7Q8>GUGVHGACY?GS]?%AZ?6?:B>&/E^?/
MU\6'I]9]J)X8^7Y\_7Q8>GUGVHGACY?GS]?%AZ?6?:B>&/E^?/U\6'I]9]J)
MX8^7Y\_7Q8>GUGVHGACY?GS]?%AZ?6?:B>&/E^?/U\6'I]9]J)X8^7Y\_7Q8
M>GUGVHGACY?GS]?%AZ?6?:B>&/E^?/U\6'I]9]J)X8^7Y\_7Q8>GUGVHGACY
M?GS]?%AZ?6?:B>&/E^?/U\6'I]9]J)X8^7Y\_7Q8>GUGVHGACY?GS]?%AZ?6
M?:B>&/E^?/U\6'I]9]J)X8^7Y\_7Q8>GUGVHF-<8SG./VY_;^O.?W_OSG]^>
M3]?7C1:\(O.$CY0? ;L3):@*4D=TKJ-]G*^ZAN+?93>..GF;ELNFX7<L:PI6
M:[5B;WA.1DX% B$C%&3!,:1T=$GL;0CK,@78D4MP[O!0=GO:]?578<%FM?3=
M*P7*EA9D;X"'29U[#QLQ+$8LH6CJ8B;BV# CJG*"HZ0,AL24:OVQ%TN5&DQ3
M$=GRM_/@^MBEP+7%IL2TD$M<'"X-MCFDM<.)S2018@D&ZUQW\Z?_  3)S96]
M(DSC@@G#Q#MR11/#'ZKNQ</\URH+!$0[4\<'6/N+(H5X9"C'XB=.V:[**/B[
MO3*&"A9S+NQ<>C%C=8H"V"$S*?: A-6L8/Z9W%( 6L/JPS:F'Q845:-RN??8
M8(][D62B#-ZQ=N<;/D4LHJ(Y(L(*]VJ,A*\N0M*<PZ%+ [=F%11Q@/.%9D=E
MQV%1&-30T/:QT)&-36DN8@Y#[ZDH8(9R)ZP!M<&\/W+7=WH/<7Y^C:?7LL?W
MJ2&V;8DDB[@1;*[,X6!N<PRAKKV&UQ;;P;G+5>X'6E,O  FEPP]XZL\/!)#"
M'8QVY+ BP2TWF1M7$W,G&-'<;!-+,*:[BJ[4D)85\.2VFXN+8*D--FV"A9U5
M=XU==K0V1JV5)2\4 ?8'NC+$8;; W^^V[E))]'#9,8Q%2X&X69/$&LDBKLS'
MW:[-V@V)JK-EM-"*M%N^48ZQ5E75\S,5/Q4\.T56EHV,^AL>T,[.Y>C4RV0T
MM'0PQH$<B92G'IDL-ADT,15:0#:^-D4D9DH(RBMKJ1=%;'<FT:>Z5(]O75'Q
MNQ$H[7)ZU+0BL6L\W%&L=AP(01.K.HJ_L.J@$BDQ)5DT00P(-P^'+Z/%EL87
MV:HI.'!%U2/E"X_7UU*4QVH 1#KL;4IJO;8;.%;%<6 +UQ/[5L>LVK0B:&PH
M&Q#1X?O#HX\)S,WJ+CXHK-1<?*.VSE4>N2>O\-GHV_S^?BGP;#:<US<91E#;
M#*0[,223FS-+0&@-(<[,0VQAGN'UIC\KE\*-6]%ADB@8Z7$I4@[V))#1N(!&
M<S.=BDI#D?F.E)1"XCKM*)7#Q!5_*X]']=BY4,U8ZY7P4+I6'>+JT31A+MC;
M0M<58A 6-A\@]XI>G%BZTADFL/BKK:5JQ[2-C1$UDZB(2!GBQ5@#G3]RU1B!
M$UETVRJ1< AWYZ?"BTS"DKZA#)]7N;(2F6SA4HFP!OJ><.T;4#+%\C/>AS(Z
M\08NB\PC+%\ZD("-I8E1$8A&E4BNY%8T!8,,E$DE\0C\B&%I) <Q[68B6"_N
MAQ'E)6*]_8\B2V3UR@@Y*A=DBS9MA79?(UTR>J)Z-WS119XOG]']]MO[BIL<
MH=LL20/";FNT-)NV^8#PA9Q :XY@TDM<! 5B]Y.IM23@O6]CWE"HC-8^1$!C
MP(LN0T6"F)'&DY=%0Q9VB/6'C3,S J>Z(.)>.T2,V>IN T4;&#39P/2*%J2[
MQ=4A$2BDZ(W3%6\5F;.5$PY7VLTK[D#P,YI&)\>E3%$4H2@L=@$F52C<]D,V
M9Q\+"9 JD$E3X034T:[$4:6]Y0.G:_N.I:+B1R-SZP9W=)6HY@(;G'XM"O\
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MM!Y>)]K&RZ*D I]FDV1(ZH)$5:F?E%HXUHR\;GG%.SBNGM.]AF76UO6<GDD
MUEDBG<DVK%O"M21IG(5X##FY=Y:H+,B<D)<0$PL8Q-%2IA=(<NEJ12+$>V)8
MD=ZO,)C$(.&'=F7=KQ@$8KVUV%O1AM.(/''4_B@\-,@T> B)&%E]?1*RBKDF
MFU'K!C4:8!-&I#!%1ZW(KK\(G")PB<(G")PB<(G")PB<(OG?;V&NVV<>/ACQ
M\,?^/_\ G"*C71_N4\[H0UY8S" 1&&0Q9JS= />FZXU94QUV=/2;?89/X>
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MNLXRXU^%60F-=4@&'F,M2A2$IT4RL0L)ZI8:>Z<\[<=;>T&Z6L7W24'M^O\
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MLQ'R&FF^69-?.F^-6N<6WE7<ZFZZ:EPC==!S2#J*)"DG\D\ CH*62.'];XZ
MDSJPM0A$Q4X=NB["5;-7E?S6=K^UQA;(NL!$F::M]K0,8'P%9F_$DTI#L/+#
MW#AKG%MY5W.INNFI<(W70<T@ZBSI6/>3*;VMK2+J ]9V=GJZD\-XT]K>,L]'
MCL+'-9B:$#SKJ/HQLA(@L0VQ*S$98F'$A%QG&Q]^,;B=-G>&N<6WE7<ZFZZ:
MEPC==!S2#J+6&QWR9EA"HJ:A->=;I*QF\VQ744P+K"/K/C<SVB^9UJ%:"<QO
M4MC;:"93GFKY9DD,V@J[29X>YC#QJ56:YQ;>5=SJ;KIJ7"-UT'-(.HI#KN@>
MC]J 'LDA?7VDR(T9+9Q!B>'-2QL:]&RNN9@;@LO#OQ[\&W>-7(N21\FTQE5'
M5)XV3;D66[@>\:.5FN<6WE7<ZFZZ:EPC==!S2#J+._,XZF^C91_T8P_[)XUS
MBV\J[G4W734N$;KH.:0=1/,XZF^C91_T8P_[)XUSBV\J[G4W734N$;KH.:0=
M1/,XZF^C91_T8P_[)XUSBV\J[G4W734N$;KH.:0=1/,XZF^C91_T8P_[)XUS
MBV\J[G4W734N$;KH.:0=1/,XZF^C91_T8P_[)XUSBV\J[G4W734N$;KH.:0=
M1/,XZF^C91_T8P_[)XUSBV\J[G4W734N$;KH.:0=1/,XZF^C91_T8P_[)XUS
MBV\J[G4W734N$;KH.:0=1/,XZF^C91_T8P_[)XUSBV\J[G4W734N$;KH.:0=
M11-<%6>3VH./,I3;E/4##@I(ED0-7<U.#)NR)'0>^+N&[ 2#C1,N]]PAQA,P
M26:L54!8<<_*D56H]FY<IM<XMO*NYU-UTU+A&ZZ#FD'44?257R4\16KM$^ Z
MFM-+6C\8ET#?MX9"R@8U#YL19AX7,ECHH,]"A(=,3)!B%BDK/OQ<>D9ITB(#
M$GI'?#7C7.+;RKN=3==-2X1NN@YI#U%W=E13R=513#>%V!2E( 2+2N7-HEG>
M]11MX."1?X;1NNP6I)1@$<N]3<VF,F0!00"T9.RDM?B9 V$-EW E=+9KG%MY
M5W.INNFI<(W70<T@ZBXK\;Y+H51+[LT4B/5<;0PO=9$K9C^"P]G'A+YK(_@>
M\$%<N B;X:?8RW&T8?QYZS0.,)#HH&>#T2*2C;5KG%MY5W.INNFI<(W70<T@
MZBDF>4/T;K<1'34IZ^TJW:2V90J QM)A44<*OC$HGYYC'HZP8L!P)P[63W<O
M\$";O5+W*& LBI\FJU$BG[M"1C&+G@Q*NX"?[U-P $G_ &^(?OX!M5F8%A4A
M+6870$ADCR.]:<>#&QTCS<M V,8XVX3:S07$ Q2*U\EB;-S:/#(EU><%*\#3
M.12K3:NHTV9-@5<&$(]89827=1Y 1*6$"D+IK'IHXBKXTG%S[QF$.98E7;9H
MK&N<6WE7<ZFZZKJ7"-UT'-(.HNL0+>2B7A:=@_!;K(VBN9F3KUV\(U<&%OPL
MR!AL24^"D\?)19I(HHYCD7VTE4D5DPD2TCL542DQMPP!*ID-FN<6WE7<ZFZZ
M:EPC==!S2#J+.9/!O)U1'23*F:<HC5"%6-6M3S)XSJ($^'Q6?6X7BH2#1XZ3
M:QU0:Q=D'TXB&2&-G>V(^TDH1^?][69)FLLUQBQ_\RKO&=M5,. 7\;_4.$G8
M-JEN!X0XV&&8>+!SO"IJ=HLUI<=KF@$D AK0<SW68P.<X SAYG'4W/\ ]VRC
M_HQA_P!D\:YQ;>5=SJ;KJ-2X1NN@YI!U$\SCJ;Z-E'_1C#_LGC7.+;RKN=3=
M=-2X1NN@YI!U$\SCJ;Z-E'_1C#_LGC7.+;RKN=3==-2X1NN@YI!U$\SCJ;Z-
ME'_1C#_LGC7.+;RKN=3==-2X1NN@YI!U%+D#K:OJN$+Q^MX5%H("<OU2C@/$
M@0V/C5B2Z+=LL^59BVS9!1VJW:MD5'&^F5=TFZ.FVV=4]<8TYZFHJGZ2IGEJ
M),H:'S2.D<&BY#0YQ)R@DD"]KDGQK<IZ:GI6&.F@BIXR[,60QMC87$ %V5@
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M^%=-81[ZFO:+R.*]"8Q[BL@B$JZ=5].(!-8%3O8N$IU;!;!@,!A<2Z1]GH[
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M'@TU535;,I) !DI99HP[P22PN#P""6@.%^A2U<59&9(FU#&M<6$5-+4TCR0
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MPXO%?;?Q</BVG@&R_"%-C8NV6!:#M -W!Q%FDYB/!.8@$-):'$%S;Y$_[_\
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MX26D9%8\6;NB6VWN?'^'J]'\]JQHY45PXUDQ2,2.0M3\C?70F]P[LB2>]NX
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MFR; @H,;0\SN@H]UPAMN47X?1XK_ ,[\'LVKE%>U.H&8RD,2 B'(6'N7'O\
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ME:H$LE$%%EJZTM=%NG(-FN&6SA6 Y5D&$_98RF@W4;KY1>J-6SDBR"$W= +
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g129231g35f55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g35f55.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $C =,# 1$  A$! Q$!_\0
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M(C[.V560D5(=A9J^^ETCKIJQ;.9CG,BDHU$Q7)%&*+D[DAVYB&!<ID@,B)3
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M:A2;A;$&J;U:L5:P6%-FJH9%-VI"Q+R2(V45*4YDB+F; D90I#F(4XF IA
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MR@9<LG_!H8</HCL]KOFT=\G@2V]J5\&W@52-EH1LS,ZR9U2+R%>.W!!#*%O
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M.+J=<\/$ #MP[@',-M]MMN7I';O[NS;7J,JYOF^=BQ.1TS )+W#::_G,M*D
M)#*((20P)TL-7N'>S@V=X@:BO !U#" [[B C\(]X=@;]O8 \Q ?3;JN;?=<G
M1O<W&_$ZYG*[X93;H==P7)< FYRZGR<DFPR>(1(R1U3F*0W"!1V,;L .?8._
M>'(?9V=H#JUSIR)8<J;-L[G( =]SD;=49+3TLVK6TL,@=;'MM\-<FC$WI*N@
M" KQ2J"<PR[D3"(CRV9F#D(\^\0#EN&X;=VVO]LJHS:2D !2!4+8DWO+/;F
M69SK&\>B3"Q3XIB>?UR@E[UR0Z*A#9Y@[Y-M =,YWX*-5VKX1OHCI,5T$'9\
MKLBH+.43N4$SC#R_-5!-=N=0O#N'"5=,=Q >+<-M:2VPF?L;QB[O2+N;Y+EE
MQ?6SL=<Q>)?]%\K=V\V7(  &)HN?Y.8V1SZN8R#1]'[Q.\_O]6_N;D/TBU&R
M)_L>)\/A#Q.\?O\ 5O[FY#](M(,>)\/A'D1:7,%4A7FZ\=$%""L1.O/DU#I
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M@=6N\?G.*?239<L. &R8D ,"W)RD=I878P2;=]2EU91VX@X0Y=O+D'+;ERW
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MY[.5PX7]=P[7G$(/E])*NA?!P"!_R@8*[_B;:)K:QS#2RO&KP?\ ?<_0&P[
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MY43+^3LDIQ+:>W]XX:.0'K%5UN=<^YX[!-KU^ZJ?][,?T]:=B54-KU^ZJ?\
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M<<+!AQ; 24<[?N?]B#L ;;#L&W<(!S^ -8!M3,)IZ;5YY+V!'T"_T3=R.+^
MC=71I*!K\2('VM)+3U[TW+GEDW=D;L>")=NE/"7]#LC S?QPV760-O'!5%N*
MGD6:VZ[J?V7JP#]P B [>W6IMJEE6 XF"+&EF. Y/VZ&=LB6+CAP,2?Z-Y1&
MVNSJN&(RR7Y2IMLN>7%KF/IG;7K]U4_[V8_IZC_$X(;7K]U4_P"]F/Z>D(\B
M7GKUJ?7C5Q1ZPG7=466!7JN(.LZL3F$G6<&_!Q!P\6W%RWTA$HTA#2$-(1@W
MF+[(UB_@C\11FD(R\I'UF5/[6X3\6MM(1*-(0TA%F<HY%N./WM9-%4VLV>(L
MUHJ-.9$7O4I"6QS.6>;!@["+K:./YR-D&-=@RO+=*NEK3'J)0$+/NE&R*<:5
M5R\^?9UQ0EFYEN^(&]Z2#J-;+V%UCQ^ZI<H]RO!4&0A9L)6U6ZS8EC+G+R$2
MO42PK9&(1ML;CNXR%*>L[#/JR#..9>66$ ^E&[ M6Y\.J_/EKWP!?JNQ?-C[
MQ?L/7$VQ5F,N4%.H9P**'B#"5<6"5C)ORW6D'*%D>0-="M39HJ*&U15L:1$Y
M8(^528QBC6':Q3I[')I6**55I!WR8]L7LTBL1>1FGBKQ6&K[<KJ23 @/7SDI
MPBH8JA0.4SI0O"9V\%,Q5$8UL;K3E,0[A5JB<JID(]R(@F\695THJK(RSH \
M>EGG"9VXVY@DF!0!-FR(;<46+4J;=+??A,H)U#(H WGSXN><5S2*QS4>%U-P
M=)J'$?\ >EK @/?_ -G[=R_7T=FIS_)N+; 5@S?::O+#CZCA@/Q>V4>-7R^4
M_P#+GA"F?_D]P)+'GC6TOQ$:=9=7<Q@#T[;=^P;\_E$!]'+T]F_#J=&(&8SM
MQX<M" +/$*)WTURT#53V#@;CJ!;+]XE.F;WRB/+'!-,1W#L'O[=PY]H#MRV#
MX! >6K5/4ZCUGF6#M[[=CQDU!*"4NSA(!<D,3QUOHWL>(B^=[ IS$ $A]MN?
M, $>8;[]_,?P]FNHHLDY$[I!)NQ;+5S;6V6EH[Z"3,0!?Z0WB- ]]7=GL3UG
M.-3+@1%PKZ 5/OZ.1Q[]@W_41[]:'F*.^M\MYSEG9VX=99KZ1->5+W0BW[U#
MD\@"0#?7AKRCZ$G@+QW\&3T??^%Y1Y>C_55N7+4:.D$OM7B)XHH_R.1'H-T'
M)W>C3 !_UF*V)=GQ6M/ <7RUC;EK"XVU#2$-(1HK\-$8"EP 8>Y/).WIYC2@
MY>GGL&W;S^'4L_DOEOJSX'YB>[:XH.UG?EVQYD?JBP)7T0L'=>V@[T[-:WX/
MEF&UCGLE5!.J)=^TV^_HY[!\&VPA[>7PZE<I0"5'@,].+<<W;-\N!CS,;TL^
M6@*40+DMEDDW_P!(V<\.$1>37ZI$VPASW^3;WW9OV?M@^'OW'>SS5;RB[<P^
MFESE<@<KM<1E=.GT<EV8DMULV>09R"_7<YF J*"H<RAAY;CMS'8 #N';T[>P
M?@[ M\^>)>1N7?)[<&( )\EXO>'4/I7F*2Y5]J.1.>0N]]!EE=]:N1E=[U;@
MWY><,J("&W[7QM7L$>WEO\NV_+6D\763B=<07^RIMRV962]K<7T=CG$P-E9(
M3L]@H  (PVC U=I$L!SF+: V<F.S/ZF6-OT0<X ', Z1;\ 'T[XWH _E^00'
MEJ/O2?\ NO0:GYN#GGZS4!GUL!V$1./Y.X"=E\;'_;ZW T/S=0^?SQTB:UI$
M@8:0AI"-5/A@3</1>KX]G^JY6@W]&];N//6__DX$?5Y6Z_L<K_RS#CXL1$(_
ME[_VF,(X?5_@Q?JP;:(QRR/C<3@W,?>\QW^4/9W^D.\-]QWU-Z>=V6>T7O;0
M#+4'2V;1X[T:!,JE*<D!DAR+ %R==" /XK!GBW\ZX$RW  B  (B/9W 'H]/+
MY/B"Q3YFXA:N(/*[L-'=P]^8 C-:*3Z6IE2_X.Z^0-K=C%^) .D6MF)#8YRE
M$>WEMW@ <@#?O'O'L .0>G6/J(+D\7//GXZO?LC-"E1W*>62X !(&7G4]=](
MP*S8Y,-[D!,;M9QO>.X!XHF ;^W8 $>WV;<QUJ_:=0.+3CH),CA_ ;1]7\BT
MDNCF096R](@@%7K%8HG._IU$W.O'] CI,^I:%@4RCTP ]%$Q2'_M!<>P/E^3
MO[=:,Z3%$TV$AK>L5/7]SE7YN_G68WR>T[N([2&]Z+#WX?=ZG+BW'F8[+-:B
MB4<-(0TA&$/A'1VZ%^;A]$37!^2Z5P=;1Z&/[9FR^CU-6._#:P>^(Z?*S_\
MP^](O\RPC_\ V'"(XY7)A%98V^VP&VY[]@=_P?>Y:]!ZHD2VU/B]P2>WNYWC
MPLPH;\Y9)N%V?]\&2"[\2">SE%K)Q80.Y,(_M0X0'EWB(\N?H'?Y-N6L<Q!7
MT4I?[90L^3#JXOV\XV'@2 9LV:69(MHS)OIW]7$-%FY%R!3++";O$ $>?9OO
MZ._?;LY?!K&ZN8Q">'=>][>SWQGF%20)1F*!>8HJ+L;.=T6X=>8TM&$_2'?]
M9,0([\.T:Z*([B(CLZW#O$ VW^3ER#?6NMJ5CUBF)<O*60!D^^/+DD7XB-]=
M&LLJH,1( !];ECL]"DN_-[Y9 =6UCZF[< IX36O$#_>7RR/;N/)A%;[_ !@&
MWP:T_MXLKP*9>WK=-;M5?7W9CG$I^A>7N[:22V6'5][?P$<GN';JZX^A?K2<
M2^AI"&D(M1GD=L&YF'L_U*,B<_\ ^D)C5_V4^^G9K\?X/_Q&FC!^DX%71MTA
M)2"5'8?:P) #DDX#B   U)-@-8X7WBJ8N%!ZQ,=B_NR[#N'/GO[?O:]/*FTL
M@)/4!>X)\,GY7:/SO8=33C4J7Z&: X'W-9&Z[NY3D-YKN(M9/KIBHY,"A/VH
ME#WX;=H[@ [[=F_LVUC5>E00D,K[9R&S8,YS>_/,OI&P,$D3?69RO13 P+?6
MU-8#5N+!HL9,N *FL8#E QC#L(&#NY .X=VWZAMK&*T+=@E1W0S-R?LYO?@\
M;#PFFF^K@IE32HE1($M8(=1S&Z",L_(PYSR=R]80;9L0ZRRDHOP)EW'8 ;"'
M$;N*4-]S&,(% .8CMVX)M'(J:A%-)E2U+)G%F20!] NI2B&2'9R6T&; R/Z$
M]CL=VHQN;A& X755^(UE-+*9<N60F4CTH>?43EE,JFIY6^/23IRT2T/])8W@
M#EIX'NMIQWA(.A^[=&!=^&6H\0$N_5-^**E2B">X )S[#PBJ8 [1 A2[B)L1
MVGPB51[)8],F 39_S?,)60Z)9"D6E ETEW&^0Y < !1$>J&Q/0'@G1]LYB&,
MXP9.-[6_-TU8JMPJH,(4I(WI>&2E@%4YB4KKYR!-4/HR)=.DK$SZ9^HLQUH:
M0AI"&D(:0AI",&\Q?9&L7\$?B*,TA&7E(^LRI_:W"?BUMI")1I"&D(@TQ1FL
MY>Z;=9!^X63HL=9R0< *28QZ=ALR+",4MBJAA%49B*KB4Y7(D4P330C+?9B+
M=>9ZAXL]_GSU"*-<'AY\]<6^K>$#0-F@7KBVK2=/I-MO=[H52&%0:.X2T9#&
MT)R[B5L1'RHS<9"1]WN$-48U"(AAC(J<,E,.[$\81SYM5^K3P^.L&\//AYO%
M*4Z.T>M?87(2]J?+3C6:+89ITK%LE)%W*-Y=Y)-PK4LHJ=Y3V+Z*7C:':&K4
M9)6TXWJ]5J4@Z33B!?.3\O+>2.;]AK^/-W?/AD&Y#6,C]4BL?@  ;[  ;CN.
MP=H[ &X^D=@ -_0 :0BF2TPRAD"*NS*&46/U+1FV3,X?/G AN5NS:I[J+JCV
MFV $TB 958Z:13G*A%#"1NR@ <E9A4B']\1-S9ERN"%'F4JY6\"Y0*J ; H5
M%PNF4VX$54* &%".</PM*\HKTCX@\LR9L708JK!2HLGRL@B*7EZV"4XKJLF!
M@.(B<#)]2( !0$%!$P@6<_R<+; 59 )/U28@>&5%AF6?!B&CQN^7JYZ<L+<
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M&K7PNCJR*]&*#++Q,4Q;!E>N&*LRF7$@J*P5VW@1,4%8A@4"&*)A%0%A$HE
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MSF0<,EY2OM9DVOG3XB*.'9P_CY\ZQ#7_ $EX2);R4[)TNUHTP%LI1U7L[=2
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M1EQ.K#2[VM'D-@Z?ME9.5J!%LV /6]KY.3%H9U82I+F$.9CGY^PH#L(_)OR
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MX 19+-1?ZZ0G+GY/6#Y7(_%VZ[E+>6KCOD?_ +4'X1;*P_1ED'[92^[Z([+
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M*;4.HC3?@._\QAY8LWJ>K\^Q7]+2%^ [S\(\B,M8CJI$5J:B*9U"%46&:C%
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M[5[5')QKC'%LN?*,8LD1#&/ND@9LB!3K-6 J*F$RBI@!L38O&<3"4H"/(A1
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MV5^!%CW=DQUFQS\-&?F;G3]-RHQ+F'+O /@WV#?GZ.8]_(=_1JU32P-WZAF
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M*9^QA.)8?4 S:>NI)\J=.3329LFIDS9<VH2)A] A<M:DKG!*5*,M)*PE*E$
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M0H9*2SK*6XWSROU<] \6T>J]6B8!';<IM^?=P]OIY]W</Q:Q^I6"I>;,2XY
MY,#KYX9O2R]U"$\ D.X%P.P"S!^OMUA.E]E3AON/6& .78'$(!W?J/=SUIZ8
M2HK L'4Y(^D3?49 B)5R4C=EE[[B<\@]];:W\8^C;X! >+P6G1T-Z7F51_\
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MA$NVX]H=H]^_/4F*A;D@Y7SSO8:%NQ[<HD5,-B_[Z[\ 389$GMR)>YO%QXQ
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MVY^@.?+OWVV[]M;GJ2TPFS@OS9\AV'/.W=$RB#4PNWVJ1Q  8V\>6464LIQ
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M[NAY&]\^EG96&^(K<^[CGE>.7B$9<)2F$/?#S'X1[^?H >7/X?9O:HF78:?
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M$C^B@A.S$]2B$CYTJSO%@ D2*4DDE@PS/#J>-6[3 &:(^VQF/WF(,GL[Y,,
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MOI!)1OI=2"H#>2Y%A'&G<5-6A*DE4M0])+2H;R=YRDK2'*7%T@LX#AVMWY^
MYM$-%^#3P*R=J/2KI2&41."$/,.T_P!DRG<#E$%VC!9 PB4P;@10PE'WIMC
M(!$SI2#;;XM=_H8?_P /IA$?>D(-M37#A)H/R*1&VSSWKW]UD_N>L'T7K7L8
M5#SWKW]UD_N>L'T7I"'GO7O[K)_<]8/HO2$<XGAX,DUFN9*Z#UR?4J$R9"U6
M3R^^FZ'>(N8:5VTQJWN<(.XA^*B+)T0CAL*_4/69E%8YX5L]!-0R)$E=U=$M
M-,JZ+:JFE54ZBFSY>&RY=73%(GTZP:Y29B-X%)90&\E09:=Y+AW&X>BZG754
M6TU-+J9]',G(P],NJIV]+(6/7"F8C>^B2% .E5EI=)(!>-6:/3]K:]=;8C_J
M?2FZ.),1O<3N<:O,NV9_>W+9WE5EF-&;+F!: !^@M%V^/;(Q<,%34A&T =]%
M'9JG=B\2SY6R<],]6(?.[XR<13B":U&'2$4@*:!6&F7\W"<4$3*=:E+F^L":
M9P3,"AN[ISKZE9R9QQ#YV/SQZ^FO36)P^2FE24T*L.,KYO\ 2E!])(4HKF>G
M$PS F:%#=W3^,^G0@7/[KI(J83@39(D+?-J.W:%YMK5J7$4KALN%6V,6*:0F
M5CYN)@>LFF>44%?.4]@.5PNR.S3%D<O94_-"<%&*3?4D4\IDFFIRHXA+Q(XD
MJN639<J9-:4J@(]")5DK"V4*G9@JPL8.,1FBC13RPD&EIU*.(2\1^<EUJGLN
M7,F@2E41'H!*!2E04=X1#(?2DB;[D7#5I1Q2U94W U(;4Z@4>PW&1NSQZ:*E
MK-;(1_>[=,Q*3FW,V=RL17[VOA$1$4^K4>6I-21:+I:3+S4>!3*6CQ*0:]2J
MG%JI535U4FFETJ4"9+D4\U%+32IA33J532=Q$[TDR8B<KUA6^4A$=NCP-=+1
MXA(-<I51BE4:BKJ9-.BF2-]$B1-12T\N84TY732=Q,WTDR8F<LSU;Y2)<8S=
M)OISW+-^'X[ EEJP=?7;;7)>7N+ZXV&=:R#ZC-\@1S.6JU(DN*#H-DNPY!E9
M?+UBAUG3W)5A81,S(%8*H.DGF18!LE389B2\7DU!"9U-.ERZ9-/)E*2FJ52+
M4B?5(^NU<BE%'+EX?)F@(H9*YDI&\%)*6'[.2,/Q2=B4F<R)J)TJ73ID2Y90
MF>JF)ES9Z/KE3)D>K(10R9@":26I:$;P*2GHG^IM[!%P_12S>@^4=E44Z0+M
M4@-XR3?%$GN=T4FYE&+-PF0W$4?>'.4^VQN'A$!'3'3@ -HL) %OF5/Y=6=L
M:MZ6/W7PL,Q&%W'^MU-^W\VD=%/GO7O[K)_<]8/HO6EHU5#SWKW]UD_N>L'T
M7I"'GO7O[K)_<]8/HO2$:1?#X6*)F.AI3&K([PRQ<_TU80<14JR)P$IF1"F$
M%7K)ND)MSEV(!Q.8-Q HE*80VCT2.-IJ@C3"*I[\:BD Z[D999QLWHJ?ZH:M
MOP3/_*:3WM'(NS2VX0]',?E_  [_ !=^I$*+DF-^+59V&3]SZOQMV#JBOH%[
M_D#Y0#\OWM<2[/SL.H,?;YRCY%@/'KUBII%V[>[O^^;]=NSX]<<5C%W+(;7-
MW_P*/^/9N4-_O:R?"F]32<_IS.;_ $LO;[(YDCZ(<9/8CF;\7\\(Z*/J:298
M0V3NE4=^9R0KBB8S(EXNP?OC"9.PV<Q^,K%LX,F  8-C* 4IAW !$0$ TQT[
M ^H[.6#"LQ ]\BF;L-VZC>-2]+8^P,&/^>5+?^"A_P W48ZZO/>O?W63^YZP
M?1>HWQHN'GO7O[K)_<]8/HO2$//>O?W63^YZP?1>D(UR>%JM4+(^#ZZ0S)JJ
M_%PXBZ85(%H:9;)B8N1Z><0,NZ8(H$]Z4=A44* CL4!$P@ YGT>_?A@W*;4D
M]7J=1&9='_WVX3_&JN65%4'P9XX?&:8>]#]R ??#\.P:E,2Y)XEXDNLD/Q?(
M<389L^A?F8KJ)=MQ[QV /P_+S^#7"LG+F[<A8$==W\O06 '"*DD7\@!\ =OY
M-?!\^3WP\^6[HL'FT!\I0/M8.O\ W@@_@'5_P,%4NH(_PJ1V;I#\["\<R X8
M7OXL'[C&T#P L@TB?"&UQV],L5$,4903$4&KMXIQGC6 % $6:*ZPAL [FZOA
M+_;&#EK!^F0-L7- TQ*@"LM53"/-VC ^DT ;*S]2*NC?@/KMN&ACNK\]Z]_=
M9/[GK!]%ZB1$;8>>]>_NLG]SU@^B](0\]Z]_=9/[GK!]%Z0BR'2:N<"OT;^D
M"@FK(BHOA'*Z) /!3J11.I0Y\A0%12-*F0.(0W.H8I"AN)C%* B%SP3]VL';
M/YUP]N'[:E"_+SR-TP2^-80..*8>.^KDCJ[[#6T?/,9I[<(>CF/PCR[/AW'\
MNIC*+DF);++#QUR 8"_;[>45]$O:/Z]X?SZXE*S&CMW7/M UR,? L!U"*FF'
MM[-@_P ^N(Y'3AUG*/H9Y/QZA<^SNBTV:R[PD+MV^5%=_P"2J]OP;?KOJ[X+
M]*HG@9>C3V,L#VD]<<DL$DCJ\7+^>0B^7@KW*##PAG1.=N!.5%OE1@HJ9-%9
MPH!0BI4!X$6Z:JR@[B'O4TS&'T#KI](@'U$[1@-;#U$\?NDMNWAX:18-LP$[
M*XXS$^HS 2>93W>7TCZ*_GQ7O[M)_<_8/HO4)8BC#SWKW]UD_N>L'T7I"/(C
M<H%=5)%-62%190B28&@9Y,HG4,!"@912-*0A1,(;G.8I"AS,8  1TA$ITA#2
M$-(1@WF+[(UB_@C\11FD(R\I'UF5/[6X3\6MM(1*-(0TA% >VNK1L_#520LD
M"QM%C2?.*_6WDQ'MIZ=0C$#NI)>'AUG!)"21CVR:CA\JS;K$:(D.JN9,A1,"
M$4E/)6.EIJ=KB5^I:EAJS%W)V:"3M,&>8KL;'D;J/Y"<C"OA>Q+)BF\:*/73
M]%N@U([:G7.F5PB)T(J,)<:C9D(MS7+37+ VG&<G(PKF$FXR6;R["$?-8R9?
M1:S!RX3?LXF2?,H^3<M3*HL7SQJT='27<))G0B2:0BFRDLQAVX.'RPD YP2;
MH)D,LZ>+F_:-F;5,#+.7!_[5)(AC  "<W"0IC A$>)%2%C.1S8TQ:193%4:U
MDBA3@KL/$1:?72,*;M3?8P1B1C,43 '7'>' !30B9%*4A2D(4"E* %*4H 4I
M2E#8"E -@          #8-(1R$^&,:7E?PK. U,9V&"J&0T\=X9/2K=9WD+'
MUZKV5'(M[6B+#,OK"V>PS./A7I4I)RYD&;M%%-L*A6KA4I$3R)Z-UTJ=@,8%
M=*FU%&:W$A54\A,U<Z?3FBHQ,DRDR5)FJ7,3O( 0I))4Q4D%XW[L JF&PV)B
MLE39](:O$O6)$A$U<V?)-+3)FRI:9)3,4N8ET)"5)-_MD@[T2^<IF9)?*.,^
MCQ$=(=K6L=4;$V8$LD=)"1S7AJ<R9G>-M]\I%QRU&8_/[H$FK1F=CM;"GP>*
M:K9+!4GY8M*7L5G?H,W=HC&_4EU6&RZ"MQA>#*GUE5B&'&BP5&&8E*H<)F4]
M+54N'S*L^IRQ5+DTZZB;7U$B34)WS+DR$J4F0L]:54X=+HJW%IF$F?65-?AY
MH\(1AN(RJ/"UR*6IIZ&95?8B!5*DTZJB;6SY,F>G?W)4E)4F0LX"]*7W8[AT
MA,@YX32AL<2[K(]+Q3#L:[F>EV2WQ"I\7P\=3U7=GI]JD%I]21H46Q\]K]'O
M%8%2SOY6,E7S.0<*QJ>68#\VTV$4>$GTE;+30U6(3%3L,J9%-, KYBZD)D5-
M.@2?1U<Q7JM(M FB0B6M"5( 6<JP/YNI\*I,+)FU<I-'4U\Q<W#JF33S0*V8
MNH"9-1(0F4$54Q7JU(I/I?0H0M"5(2%G+.S=*>U4?IA+8UQQ.4W(%8H]<PGA
M"(O][MEO+"-Y+  HV24RO(VVHVROR<S7VN1U[]=+!$.I&3KMLA')V[R(D5TX
MTR..R<!D56S@KJV74T<^JG8GBDRDI:>G](48N\A&'HIY]/.ERYRJ(4E-)FIE
MHG4\T;R)B$[[V.1@=/4[/"MK)=323JJ=B6)S*2ED4_I5(Q9Y"*!%/42)R)<U
M5&*2FDS$H1-IY@!1,0"M]:_3#QS@NV8)IO2!Q[EOKA8H5*BX[QHYE,:$12J:
MT_DP)V!2HM>L;G(E6R!"R44EE?+$U8:S&T>?MF89 :DHRCE*]Y;SO9JJQ:1B
MU3@]9AS!1J*NMK4RZXGU@2:+T,WUN?)31U%'-1,.'X?+DSYE5)I\.1ZP%+$_
MT5UP&=B$G$I^'5-"V\J=45-4$5:FFB72^BF&IFRDTL^F6E9HZ.7*FKJ)<FA3
MZ8%8F^CZQ/ 8 (>#,P$ _OAE(?ERI<-1_P"E0-MSC(9K4%O_ (?2QJ#I%^^S
M$.4F@'=0TX,;<]:\C!X:0AI".8'ZHT3ZQUT1PVWV3S/V^TV,@_4?O\];QZ&B
MPVB.5L,]M=VY</=&Z>B(LC'NO#CGP%;'-DS1V -PY%]/W_R;^@>S6Z"7)/&-
MOK(&3.6L,@2X&G"^6;B*ZB0>WO'L#\/;W^GY-<*CU7]EF'('-NJ M%31+_-\
M0<Q'X_P_#KX]\//G\T8<7(!\[+$'?Y8??_\ <_\ GUE]$":6G:_UI'LSUCF2
MD,&%VZSQ]^D=E?U-.7AZ)F<N>^_2%=]W_DYHG\WX=1IZ<3^R3"0/P&@]OKU9
M[W\.W0_2U^[&%_BO_P"[J8Z-]:6C5,-(0TA&COP_1>+H8TH-M_\ J@J:/R4K
M(XA]_;X];/Z)RVTM3^**K\HI(V9T5_?!5_BJ>S<?6:1HY &J>P;]X[;>T-A
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M$I3MX],P 1HFL)>L7%(H*KG']F4.0J9"(151$  1$0   1$1'8  .8B(CR
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M"=*0)V3G$V K:.W_ 'AN_EFYQW4^?5/]88W^._R=1+B,KCB.\0\^J?ZPQO\
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MO,^]NDNNO5J_!T/&DBO(%3R5*L9:)KI+[67M$I\1$I7:HRZSD[^>[GP&K7,
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M&C5@U;LF+9!FR:()-FC1JDFW;-6R!"I(-VZ"12)(((I%*FDBD0J:9"E(0H%
M UT22I2E*)4I2BI2E$J4I1+DDDDDDW).9BWJ4I:E*6I2U*)4I2B5*4HERI2B
M25$FY)))-R8]C5(I#2$-(0TA$.MF.Z!?/$?/FC4^Y^3/&/)OG7686P^3_&^I
M\:\1\KLGGBGC/B[?QCQ?J^NZA+K.+JR;=B15U5+O^K5-13^D;?\ 03IDG?W7
MW=_T:D[V[O*9W9RV9CLR*RKI=_U6JJ:;TC;_ *"?-D[^Z^[O^C4G>W7+.[.6
MS,1 .CU@(.S!^'__ %:4OZ%UV/G;%?PGB']-J?ZR.Q\[XM^%,1_IM3_6Q_7]
M3Y@3_>0Q#_ZM:9]"Z?.V*9_.6(/Q]<J?ZR'SQBWX4Q'^FU/];'[_ %/V!@[,
M)8B#X,;4T/P0NJ?.N*?A*O\ Z94?UD/GC%OPIB/]-J?ZV+CPD#!UF,:PM<AH
MJ AF)3$91,+'M(N,9D.H=4Y&K!BD@U;E.JH=4Y44B 90YCF 3&$1Z<R;,G+5
M,G3%S9BKJF3%J6M1 8%2U$J+  7)L&CI39LV?,5-G39DZ:JZIDU:IDQ1 8%2
MUDJ-K7)M%6U\1QPTA#2$-(1'+13JC=X].)NE6KENBDG2;Y*,L\)&S\<F]135
M22>)LI5L[;$=))+KI)N"I J1-94A3@50X#S2*BHIEF933YU/,*2DKD35REE)
M()252U)44D@$AV) +6$<TBIJ*59F4U1.IYA24%<B;,DK*"02DJEJ2HI)2"4D
ML2 6<"(%_4]8"#LP=A\/^32E_0NNU\[8H,L2Q ?ZY4_UD=OYWQ;\*8C_ $VI
M_K8_K^I\P('9A#$(?\FM,^A=/G;%?PGB']-J?ZR'SQBWX4Q'^FU/];'Z'1^P
M*'9A'$0?!C:F!_\ LNJ?.N*?A*O_ *94?UD/GC%OPIB/]-J?ZV)W6JA4Z6Q4
MC*=6*]4XQ5P=VK'5J%CH)@HZ4(FFHY.SBVS5L9PH1)(AUA2%0Y4R%,80(4 Z
MLZHGU"Q,J)TV>L )"YTQ<U82"2$A2U*+ DD!V!)XQU)]3452Q,J9\ZHF!(2%
MSYJYJPD$D)"IBE$)!)(#LY/&)%KBCAAI"&D(:0BDSL!!6B*=P5EA8FPPC\I"
M/H><CF<M%/2)*D72*[CWZ+AHX*FNDFLF"R)P(JF10H <A1#[ES9LF8F;)F3)
M4U!=$R4M4N8DD$$I6@I4'!(+&X)&4<DJ=-D3$S9$V9)FI?=F2EJES$N"D[JT
M$*#I)!8AP2#8Q;4.CS@$.S!V'_\ U:4OZ%UW?G;%?PGB'],J?ZR.[\[XM^%,
M1_IM3_6Q_7]3Y@,.S"&( _Y-:9]"Z?.V*?A+$/Z94_UD/GC%OPIB/]-J?ZV/
MW^I]P*'9A'$0?\FU,^A=4^=<4.>)5Y_URH_K(?/&+?A3$?Z;4_UL2VK8]H-&
M%X:E4BH4\9#JO'QJ];AJ^+WJ!4%#QOR2R:>,]2*JO4]=Q]5UBG!P\9M^O/JJ
MJIW?6:FHJ-Q]ST\Z9-W'9]WTBE;KL'9G:\=>HK*NKW?6JJIJ=Q]SUB?-G;F\
MS[OI%*W78.S.P?*)AK@CK0TA#2$-(1ZSQFSD6;J/D&K9\P?-EV;UD\02<M'C
M1RD9%RU=-EBG1<-W")SI+H*D.FJF<R:A3%,(#5*E)4E:5%*D*"DJ22E25)+I
M4D@@@I(!!%P0"+@1])4I"DK0I2%H4%(6DE*DJ204J2H$%*DD @@@@@$%XM0'
M1YP"'9@[#X;?^32E_0NN_P#.V*9_.6(/Q]<J?ZR._P#.^+?A3$?Z;4_UL?O]
M3Y@,.S"&( _Y-:9]"Z?.V*_A/$/Z;4_UD/GC%OPIB/\ 3:G^MC^OZGW H=F$
M<0A_R:TSZ%U3YUQ3\)5_],J/ZR'SQBWX4Q'^FU/];$AK6+,8TR0/+4_'-$J<
MHHV49GDJU4:_ OSLU3I*JM#O(N/:N#ME%$$5%$#*"D<Z*1S$$R91#BG5M94H
M$NHJZJ?+"@H(G5$V:@* ("@E:U * ) +. 2QN8X9]?752!+J:VKJ)84%A$^I
MG34!8! 4$S%J2% *4 IG )#L3$\UU8ZD-(0TA#2$-(0TA#2$8-YB^R-8OX(_
M$49I",O*1]9E3^UN$_%K;2$2C2$-(0TA#2$-(0TA#2$-(1:YEF&COLJV;#1'
MSIO=ZG4(R\R;=XR6;1BM=DW(M#.X^54V:/%(M8['RR@0Q3QI):)47]X]3$&C
M^?)TZC%'N1P\_!^L1^XDS!2,V8[@,HT=Z\4J5F>3C"(<33!>$?+N:_9I>I/D
ME(]]U;E YYF$?)M4U2E671!)4$RBJ! 16+EBN@54B)EDBK*"<$TA4("IQ3(5
M0X$3$>(PD(8IS@4!X2&*8=@$!%"+9,<RX^DUZXA'S1G1;3;LBT:,<@S=-VI+
M'BEY:8^[M'JKQ)N+1"+?TRP-D7RA!92/BB3F/7<LG;5RJA%S5EB((*N# J=-
M%)18Q4$57*QR)D$X@BW;D47<*F* @FB@FHJJ<0(F0YS%**$0?&V1(/*56"VU
M]I.,&'G!<*RLQL<4K"3+27HUNFZ5/MWL6X.==H*4Y7Y B)%^!8[<$E%4D3G,
MD0;?F@+_ )XGND(:0AI"+8I9=I:V87N"P=O29!98\:90.R4CUR1R]2=V!Q61
M<-940\56>M)5%,CU@ @X00>,W&QDUA$E6L_-O/GW11P[:^?S>7CQ8FS)1<U4
M9ED:BR#EQ5)*5F(B/?RC-6(.]7AIEU"*.&R#P2J*,I!TU%:)<; $@R7:N42\
M*Y T(8L8 @W'%HN<9P@10B)UDBJJF$B21E"%44.5,53%(03 8YBI%,H)2@(@
MF G$.$!'5(K%LT<R8_=+5M)I,G<A:<BW3%<:N1DZ103N>/HJ_2]K8OE'23<6
MK2.;8TMI$Y,Q3,'JK-N+)=PW?-ESF^/GOBCY<RWM^$3J>GX:L0$S:9^1;1=>
MKT/(S\U+.3"#2.AHEDM(R,BN<A3F!LT8MUG*IB%./5)F$I3#L HK%O:%F*OW
MV9>UQ.#N=2L+:!CK8V@[U6W%<DI6IRSIRQ8V&/045<!XN+QJJUD8I\=E98!P
MHT2L4'$GD& .1\^?A:* OQ[?/MB[.D5AI"&D(MC:\NTJEY#QAC"?=O6UIRZ%
MQ&FD2CUUXY<:/'QDC-EDY(@>+11C)3$<WC?&S$"1?N4F#83.E4DU*L;GAGVP
M?3C'CI68Z+D"QY.K-<?NEGV(Y]O6K@Z=LE646E*+,CNUBQLBOPH23>/60>Q<
MDY0$$F<O&R#!0W6M5!U3AS^)'NAQY? 'WQ<P[ENF4AE%T4RJ"D5,QU2%*H98
MY4T2D$Q@ PJJ'(1("[BH<Q2EW,8 %"+;S.8*'!+V!H\E5E'E6N6-:%/-6S!X
MJJPL>69VJUZEMA$R*:3AN]?W.!%V\:*N$(Y!PL=V=-1JLD5"+E)+)+IE6053
M62.&Y%4CE43. "(")3D$Q3  @(;@(\P$.T-(19^L9OK%FM[&F>0;Y7'\[&3\
MS47UPJ$G6XVY1E6>1K*?<0@R $D6BC$\O'.4F%DCH"2E8QR,O"LI**;NWJ%6
MU\WR\\KQ1],LV?5O+]47DU2*PTA#2$6QR7EVE8D/CXMT=O69<FY(K^*:NJT8
M+ODC6ZS,I=]$I2)T 'R='*(PCTJ\FN'BS4_4^,&33.*A'NA'Y#9>I4_E.ZX>
MBW;U>YX^@Z_/6A,8]<D4R;V5(7,<R)*F &SB4(Q492#U@F(JM&,K%N%1 KU,
M-5;(\?/GJBCW(X>?/7%QO'6?BX._&VWBADQ6*ZZ]+Q<R0!Q"J"W'U8I@7WPG
M W" <Q';5(K%NKEF"A41'()Y^6537QAC1;+EN9-6#QTZ9T=)*TJA)->!$&[]
MRJ%,L)4XYJX4?%,T2,L@DD\:*+//GO@_?FVL7*3626 XI*IJ@FH=%04SE.!%
M4QX5$C\(CPJ)F]Z<AMC%'D8 '2$6SD<P4>,RQ7L*K/G:U^L=:DK:V8-(]TX8
MQ\+'J+)(JS4H0GB<8XF#,I<8)HNIXQ)D@II1%,$V"AQ0BZ&D(:0AI"+8Y8R[
M2L*UIE;KZ[>L(%[9(&K^.LF"\@#-[8'@,V[U^1N F:Q# H*OI>2.'41L<V<O
M%_V)$V@OY\]D#;\T R]2C9C]PDCMZ?((8Y<93.T)'KFBTJJVL;"KJF4EP#Q0
MLJ$G)L3C$\0NRL7*#XY"-UT#*H1<8KMJ9'Q@KEN9O^R_LY5DQ1_8>LZ[]E P
MD_8NJ5ZWWW['U:G'MP&V0B(S61*C 31*[(R@$FEJ99+^W8(MW*YG%6J3B%:3
MD@BX32,S$[9Q8(E-%H=R1V[!R95JBLBV=*(//GNAY\]\5FLV2)MU?AK+".!<
M1<[$Q<TQ,<O5N"LYB.:RK('3<1$[9P=D\;JG;J[*)@H&X;" BR@"^405'+<:
M]O<Y0XFIWF9<5B?C*S9;''0K,]4@YF5K->MZ+5]).95LZ,"%>M,$_=JM(]TF
MB5^1(IE%DUDTZM;,=6OP[XH]V8]=F]K^$77U2*PTA#2$-(0TA#2$-(1@WF+[
M(UB_@C\11FD(R\I'UF5/[6X3\6MM(1*-(0TA#2$-(0TA#2$-(0TA&NS/>",N
MVS)-WMV/8PC9>W*T;%KZ<\L1L>Z]Q_(E3L%&S#)1AC/"N49&BOW-*R(S:K(I
M.)=W24&$4FZ<N""3Z!#7S#D==F]D?+%SP+=H8@\Q\>3Q17>";%$1<6TL^!C9
M:J+1_P!-2/A<=,W./UTJ[*98Z14S=<76U-K:;)$0;%I.8]5/'IV%@\4LU#1E
M"L31S1*9L01_S%6OY[_/8UWJL!T;;M'J/[-9*O$V;+#+./12EV^3C&@U;'*5
M*AX\Z/=6RO/1LZ\72F8^->NJ[DM"3BE5&,E/,U'Z(1K]"4:D=ULY[?86BA!L
MUV(?J[7^,?E Z-;(KJ@5F;P/7HRIT_I-=**[6-E(P5 /5IJMW6:RY(XJLS>(
M8/GJ<PS1@K+3(J,;2$8G*UQ9DU9'C6",(DJW$EW?0#F./D<>N*L.'EF_->,L
M>C]6K!1,$8MJ=FC%F5AJ="@H20AB.6+M5FXAXY-HG%H.6SM6.4!ND@DT;=2]
M%F0A$R$6*D4!*+.6R>W5%?/EXCO1H:VV-IEKCKC0;/07Z^7\W6UBTLKNGO%)
M"#R)F*^7V!<ME*?:[4W342A+#')R3=XLT6;2 K-T2N4DO&#4[7[_ '@0[&[O
M<3&16D(:0AI"->_2*PKF6S9+NF0L3QY&UA=4_#U KTZ:6BX\XPMF4Z0% RF[
M*9=V5RF3&T9E*G9?*S711\X9*C145#C(2'6,PJX9CQ)\ WL(U9X^&+J+9L-,
MF8_%K.T49/ DE5$ZRTGL#FROBZMV+I41['$S,^/Y1-L;(5]K4AB.Y(Q5ULD-
M6_%FM'AK95"OC2/G%6D;X!%&#>.=6)S'B7\+]0OXQ5((?@Y;P;V'/WQZ4!T8
M[ZRB&DO:ZG$VG+4%9>@<5MD19S"2%@<,L43&&R9MEX>R2CA*:9-%(^"NJLN1
M0\?(VQ@+AH5G*G?(-%Q.8&3Y?&/KGKY\\XK%8Z-[91_2JS*8*@659K?3*S7E
M"W ]A*$-8LE(M-.Z21<=V(K!F_<GG6\6ZO5$AT(Z3BR2D&^61*G&I,8AR\:5
M)YZ#CG9^^[Z%^,4X69CRR8M[>N,C,61%VQ1T<FT6A2%YNYTFN74]:QRQEX./
M4ECQLI87=)IT;+KO?-Z&;OXTL+#QJKAXE&0C55NFX!L@S.BG0L3W.?;XO% X
M3E>]K<3V13\#Q=J5E[#<,F4Z_,LGS\/$M)VU6I.@L:PWC&#IZZ947',%3K_=
M'4'6(9[)2#T%)L5IV=6<@_L5AEW*$<VC1ZW%^/O BH?7/P[+^V_L&36J16&D
M(:0C#GI,8MOUWMU0M]$@RRTKCK$^6)FKG4DXV-1<95B<G=&K)>,ZJX7>.4EV
MK*[.<63T%*21$%(YG#GD4)9=%)\W0>5!;O'<Q!]OYC'R0Y'('O<-J.''KBQ<
M'T=\C5IBR=6N@^Z'%&N&(<A9:IC-W5GB>4YUQ3<I/LG'9QE@F6,-()US.5_A
M\FHQ=@>,TI1.L$)$'DI,C%!P>Y[AR&6G*T5:P?2Y;4B_+6\4]_T6[38Z;<6\
MSB6)64-@3I/1&)JK,J4V25QQ/9$R=9+-BBDQ!O*;V&KTW7JE(0\6T>0+TU<I
MH(*5R"L7D6/:KKG#C06?L9\N8>#/G?Q\^<XFEPP!(S=GS.T##3%ZIDC)O1%M
MSZV"QI";&ST^DY'PI(Y6AY>0/*)3CITU:U*SV"4BI!B*$V@UZUBK)2CUHU<.
M%_;;SRBOGK\\XR@PA0'>.?==AV]<CZO69'+DQ/T&$BR1C&$2K4C3J2556,C(
M@3MH5H\M;:S.7#,6;1P>05?22C,POBKN5K=5^MS[FBE[]=NIA[WBT=0J=VFN
MD!4LHJXQR/CY^VK-V@\HJW[)4;D.C&;3"<,M'P^'F(WBT+UTSVRP\7,+2=8J
MF-HN7K$<9M=84+$G!1$*LV;\,W[?TF^6L [Y$<7]USQ]VC1FEJD5AI"&D(Q>
MZ3^()G-+#%E9C$E$F#.]7=Y/SJ*[1)>HLYKHWYYHL%:VJ;E=)=P]B+Q<*D9@
M2.2=/6SY5O(=01HS=NFU06?JMW@^Z!R/OR[8Q7BL#YVF*_;K?=Z,V&^94J=-
MMN5JBPL-?<-K"\:9];6ZUX-2D%Y5&,>BZP'"Q>(4Y*0=-:I*)]6F^EFT>L[.
MA5PPY;WB Q[[Q\L7)X[N1X$OX=XM$\J_1[6L5_@9:P85BH+#YLO9 ND-BZT,
M*,\C:9$2.%*/3VSYY3XJ3FZQ'JVC(\):;8WAX0\EXHYF4[-+IQECE)5%G1\^
M)#=KO[.,&RR9W[-UO;%KPZ-]Z:XSMD&MAI-]D:V^#D@\(1UF0\PU7L;E*OTG
M)]?D:E*V5Q.(R#5Q*M[#48-E+MU7<"];,TV[N708Q13IU)&G\(GK&F>>N?&*
MC1QIR[O-HS;Q;BY#&^4<NK5JH1%/Q[8X3%JL SK[6)BXA]8HAK<&-J?!#Q9D
MSHR?B1ZLV?R3QFBM)HMV"97+LK 0;_+P 9^NW</>^=XLG'8)SK7L\TB]FMV/
M;5#/K_E*X7F?]SZ9BY]K$V2)BX2N5M5POEERBX+#5"*B:15G47  TC?(X3\[
M%R;V2DU'M;-J_7;N;WP[N=OS_&,[M4BL-(0TA&/G2-QBOENK5&G&AQFX)UD:
MN*7-GXRT; 6E+,YF,L:QA=KH@L4K&1%,R#8%W:@*_L+=7A, (H0X[1[0\871
M'1ZZ1\M"S%DN3!$<M7/!'28I%LDVMDCF[5:P.'/1AH6,XIG+MGQGT4VRC2\*
M6"Z&>,R*I4Z6M,SY2<,Y8R17E?9Y\Y<VB@%L@"P\-'S[;MSB=L, .+5?JE)$
MP,QH6%29KJUFD,1V!CCM*-9$KG1TSK3YF_OJA5YR>JB2$W;+7C2II1L>N^DW
MBM41L#N.)$G)(#5\[W9GO=R"WMZX-<68."UM ;VYM;MU,>I6L 3U=LF/W[S#
MC-T^C,4=++'438&+2BKJ40MERHA.8AC1?*RR$C%0;G'WE>'KB< F\;UYI)KP
M+U"%0?N43+,0.7'A?Q;NY"*M<=1]S<^/?SB\?1SPF[Q)96RK.CQ%+A7O1PP3
M69\(1*"9HR>3*I)9'6MAI5&'7,I*3;5"?CCO+$Z3<ED_'-D91Z=)<$A(/>6Z
MK-V9VTB@>W#=OE]MK$8R#BAZ_P GS\M2<+VB%R38<NXHNB6?D;C KUUM6:TG
MCB+N!^!Q;&UL@FK^AT^1HTQC>+ISF%N;U5B\D7#EA*2<Y TTSXV':SV8W[1I
M!@[M?-\]>M\NP9=>=&J1]0TA#2$-(0TA#2$-(1@WF+[(UB_@C\11FD(R\I'U
MF5/[6X3\6MM(1*-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#
M2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(
M0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$8-YB^R-8OX(_$4
M9I",O*1]9E3^UN$_%K;2$2C2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0
MTA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2
M$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA#2$-(0TA&#>8OL
MC6+^"/Q%&:0C+RD?694_M;A/Q:VTA$HTA#2$-(0TA#2$-(0TA#2$-(0TA#2$
M-(0TA#2$-(1@%X1WII3/02P57<PP>-V647DYE*O8[/7G]F7JB#5O.5RX3IY@
M))O"3ZBJC4]72:E9^)$*J#TRHN$Q0 BN7[%[,RMJ\5GX=.KET").'SJWTR)
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M?,FCCUPG5UK-87[YFLX=97J3N'B3)R3-BZZINWD*L+6SN3K8E]> X11RYOU
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77[$V311+P((I$]XF7BX>(VYQ,84(_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g129231g36a20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g36a20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1S04&AO=&]S:&]P(#,N,  X0DE-! 0
M    '+2^<T@X0DE-! 0      $(< 5H  QLE1QP"   "&  < E  "')R,CDS
M-S0X' (% "%-:6-R;W-O9G0@5V]R9" M($%#3%@@3F]V(#$W+F1O8W@X0DE-
M!"4      ! 00;859CNK4%3/IR8'E ]0.$))300Z      #E    $     $
M      MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP
M<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P
M  P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M    0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-
M!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M    0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N
M0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M     $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M    4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!O
MX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M            0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL
M0'6$S-         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G
M4',     4&=00P    !,969T56YT1B-2;'0               !4;W @56YT
M1B-2;'0               !38VP@56YT1B-0<F- 60           !!C<F]P
M5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M  QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M       +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU  (
M @.__C4  @ ".$))300F       .             #^    X0DE-! T
M  0   !X.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      ,U    !@             $60  "'L          0
M                       !              A[   $60
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   $60    !29VAT;&]N
M9P  "'L    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P  !%D     4F=H=&QO;F<   A[     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    $.$))300,
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MV.^RES6^P>H_VVU[+&O]G_%6I7RW;_IJK+>__1;5G^,'+@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MDU_7,R2D[<@T(^WJ07N*Q)4IUUA2#H = %@5-_?4K3_*!#?](QO5*I?S=/\
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M=X8?E3O!^?I05_\ S<B]R=/H[Z:_A^9WXW'#VFH.LF/@[PP_*G>#\_2@K_\
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ML/@LOQ.,[[/6J6J#G**_*SK:I;;)X@7? P47P&O*.D.LGP=!O?9L JZMCQ/
MMB2U#"*,0?&,+$SS&.,0;H:A%=W@Z2*$233RB/DD6A8<AEVH2:--QI-)FORL
MZVJ6VR>(%WP,%%\!KRC8JNJ5XS6-7T$L)AQZJ@<QG<-C$R9#WE=P[=VQ:2@(
MQ-MF;K=(5E+9RV1?:(K[)YRGLKIMG3]SG'2_*SK:I;=)XH7? P47P&O*)E\6
M/CCW#4_[.8E[IZ7Y6=;5+;I/%"[X&"B^ UY0^+'QQ[AJ?]G,2]T]+\K.MJEM
MTGBA=\#!1? :\H?%CXX]PU/^SF)>Z>E^5G6U2VZ3Q0N^!@HO@->4/BQ\<>X:
MG_9S$O=/2_*SK:I;=)XH7? P47P&O*'Q8^./<-3_ +.8E[IZ7Y6=;5+;I/%"
M[X&"B^ UY0^+'QQ[AJ?]G,2]T]+\K.MJEMTGBA=\#!1? :\H?%CXX]PU/^SF
M)>Z>E^5G6U2VZ3Q0N^!@HO@->4/BQ\<>X:G_ &<Q+W3TORLZVJ6W2>*%WP,%
M%\!KRA\6/CCW#4_[.8E[IZ7Y6=;5+;I/%"[X&"B^ UY0^+'QQ[AJ?]G,2]T]
M+\K.MJEMTGBA=\#!1? :\H?%CXX]PU/^SF)>Z>E^5K6U2VZ3Q0NZ!@HNSM>4
M<9XQ\<<8SGU"U!GLQG/9BN8EVY[/X,?[T_GS_!TORLZVJ6W2>*%WP,%%\!KR
MC6""+\49P;AX=7B7'(9I,SMD1(>1F-65X@,3FM83FR(-((3N6CWI&"5E6Z]7
M2*0,Q:)C;9S&]VCYNHNXU(,V*_*SK:I;=)XH7? P47P&O**6>7[P9%10O)RG
M%R*:[" $8D'FD95</(O3+.4Q.MYZEB,;;"6>DA]'XA;E?/ICL/QOM&7I[5)\
MGYG0W/;+\K.MJEMTGBA=\#!1? :\HN2UEN+M8L-GK?B/"YKMM6"ELI-XQ ZQ
M?J)Q9E((@&*KD4VF'KD:BS:R[!A$NLUWCSUE'Y)OH72;BE765^5G6U2VZ3Q0
MN^!@HO@->42&G!?$FZ"[P;'N/-1MD4X2 G;%PM!X6X<+BI#*YU'&K4BQ1"8V
M#E$&<1&FW+!RLHLFA)V;?LSLS5777Y6M;5+;I/$"[X&"B^ UY1L4WXU\>&CA
M!TUHRI&SILLDX;.$*]BJ*Z"Z.^JB*R*J8K7=-5)377=/?3;&VFVN-M<XSC&>
ML'6JPHC2JJU$TF1D9'-DF1D96&1D;EAD9=1D?49 5/@$9&4.*1EUD>8:M(_O
M+ZO4?Y_8(_RFHZK.0M/E*RN(,4.P4@6 DG@T,:>Q]\H]#OTW@U1,D/42<IZ(
MN--=E$M=\:+:X\3?&=?DZDHE<J'1ZH(J=,<;:EMMNM)6XTAY&0\DT+(T.$:3
M,TGU'9:1]9':$^!&J49424E2F5J2HR2HT*M0>4FQ2>LNOW_>0^7?Y(OP=7=9
M8WM9E?[=U[7Z7.FN,A[OC>4<#V+H/8/[2[\P_)%^#J[K+&]K,K_;NGTN=-<9
M#W?&\H>Q=![!_:7?F'Y(OP=7=98WM9E?[=T^ESIKC(>[XWE#V+H/8/[2[\P_
M)%^#J[K+&]K,K_;NGTN=-<9#W?&\H>Q=![!_:7?F'Y(OP=7=98WM9E?[=T^E
MSIKC(>[XWE#V+H/8/[2[\P_)%^#J[K+&]K,K_;NGTN=-<9#W?&\H>Q=![!_:
M7?F'Y(OP=7=98WM9E?[=T^ESIKC(>[XWE#V+H/8/[2[\P_)%^#J[K+&]K,K_
M &[I]+G37&0]WQO*'L70>P?VEWYA^2+\'5W66-[697^W=/I<Z:XR'N^-Y0]B
MZ#V#^TN_,/R1?@ZNZRQO:S*_V[I]+G37&0]WQO*'L70>P?VEWYA^2+\'5W66
M-[697^W=/I<Z:XR'N^-Y0]BZ#V#^TN_,/R1?@ZNZRQO:S*_V[I]+G37&0]WQ
MO*'L70>P?VEWYA^2+\'5W66-[697^W=/I<Z:XR'N^-Y0]BZ#V#^TN_,/R1?@
MZNZRQO:S*_V[I]+G37&0]WQO*'L70>P?VEWYA^2+\'5W66-[697^W=/I<Z:X
MR'N^-Y0]BZ#V#^TN_,/R1?@ZNZRQO:S*_P!NZ?2YTUQD/=\;RA[%T'L']I=^
M8?DB_!U=UEC>UF5_MW3Z7.FN,A[OC>4/8N@]@_M+OS'@KX/G@)QR3VNB/U/8
MJY>$XPJS2S:4A<XWR<SB,K?O#UVHU4[&YI7;]]USC7L\?3L4UTSU&[^Z3TPK
M"#IK\V(34FPEF4&.@[&C)\K%)22B^LTGW=9^[W&8W1T5HL)126V7\MJTTVR'
M#_A$:#ZC.SW*/_$>6/!%>#JQC&,578V,8_@Q;,LS_P"7+[MZD^EOIKC(>[XW
ME&I]#*$9VFP_M+OS'/Y(OP=7=98WM9E?[=T^ESIKC(>[XWE&/8N@]@_M+OS#
M\D7X.KNLL;VLRO\ ;NGTN=-<9#W?&\H>Q=![!_:7?F'Y(OP=7=98WM9E?[=T
M^ESIKC(>[XWE#V+H/8/[2[\P_)%^#J[K+&]K,K_;NGTN=-<9#W?&\H>Q=![!
M_:7?F.?R17@Z^SM]5=C]G;V8SZV)7V9S_@_W=_!_#\W3Z7.FN,A[OC>4/8N@
M]@_M+OS''Y(OP=7=98WM9E?[=T^ESIKC(>[XWE#V+H/8/[2[\Q#2'@N_!R#Y
M]%('M3UEJ.)5%IQ*$2.MORC5%HC""<#&.&BJ&7>5%57^\[;*HJZ;ZZ(Z#U]=
M]=]ED_$F3^ZMTV5'=?TZ$1-.L-&B[HQFHWT2%DJW)ZB3HYD9?;E%]QC0^AU!
M)Q#>COF:T.+)6DNV$39MD9>_K,S<+X&)E^2+\'5W66-[697^W=0_2YTUQD/=
M\;RC?V+H/8/[2[\P_)%^#J[K+&]K,K_;NGTN=-<9#W?&\H>Q=![!_:7?F'Y(
MOP=7=98WM9E?[=T^ESIKC(>[XWE#V+H/8/[2[\P_)%^#J[K+&]K,K_;NGTN=
M-<9#W?&\H>Q=![!_:7?F'Y(OP=7=98WM9E?[=T^ESIKC(>[XWE#V+H/8/[2[
M\P_)%^#J[K+&]K,K_;NGTM]-<9#W?&\H>Q=![!_:7?F&?!V\ K-V4AA.J+%T
M9\?-DZA [XM.1)?#"B[5O>2BF=T'>JKCQ2]S%$<K/=E'.,I91UVPT1:ZZQH_
M=+Z80E.24389JJR[P>_>$<['6TIIA6$9'DEFJ<UU%85MJK+5&9[JZ*T5]*&E
ML/9,,CCMV2'"^HLSE&?4?7]>0LNOK*RRS)(@_)%^#J[K+&]K,K_;NI/I<Z:X
MR'N^-Y1I[%T'L']I=^8?DB_!U]UEC>UF5_MW3Z7.FN,A[OC>4/8N@]@_M+OS
M'&?!&>#IQCMS5MBXQ\^;9E>,8_@^7.7W9CI]+G37&0]WQO*'L70>P?VEWYCG
M\D7X.KNLL;VLRO\ ;NGTN=-<9#W?&\H>Q=![!_:7?F'Y(OP=?=98WM9E?[=T
M^ESIKC(>[XWE#V+H/8/[2[\QUVW@EO!P/$]EF=:SYTEHNY;;JMK?DZZ>KEFX
M5:.V^VZ1#?75=JZ16;.4LYPH@X2515UU43VUP^ESIKC(>[XWE#V+H/8/[2[\
MQV/R1?@ZNZRQO:S*_P!NZ?2YTUQD/=\;RA[%T'L']I=^8B0#P6_@Y3T@G8#2
MG[+;*P4Z)!N'.]O2A1,@J5B,>EFBZ*>KO79#1%"0),]M%-M]MU6RBNN<:;ZZ
MXF<_=5Z;-ML.'.AF4AM;B2NZ-]4D/.,F5N3UF9MFK]AD0T3T.H*E.))B06;4
M23/27+#M0E9?;U=2K+#^ZWW"6_DB_!U=UEC>UF5_MW4/TN=-<9#W?&\HW]BZ
M#V#^TN_,/R1?@Z^ZRQO:S*_V[I]+G37&0]WQO*'L70>P?VEWYA^2,\'5V]GJ
MLL7M[.WL];,K[>S&<8SGL\N[>S&<XQG/YL9SC&?SXZ?2YTUQD/=\;RA[%T'L
M']I=^8?DB_!U]UEC>UF5_MW3Z7.FN,A[OC>4/8N@]@_M+OS#\D7X.KNLL;VL
MRO\ ;NGTN=-<9#W?&\H>Q=![!_:7?F/KS1E<PRHZD@=;5VP>BX1#P2(>-#B)
M!P6?-!B2JRB2+DDZW4</%<;JJ9V66WVWSC.,9S\G7@:G4957GRJE.6A<N8Z;
MSZFVTM(4LTI29I;3]5)6)+J21%_?:9^CBQFH<=F*P2B9803;9*4:C))&=A&H
M^L_?[SZQZ9IFRB#M<6/K*KY?%T7H<DQ7E]C&P[I0B'>L30UZJ!0I^7,6CL*>
M8M2 EVF8=+H/&#(FALT=IIZH98;IBFTG(F367>O*;9IS#[9=9V&EU=3CJ5:F
MPS(V49)VD641$H\.+F)69,QX[B.JQ3DIQI7YVH3$=(NOJ_AG:1$?49F14[I4
MA'1D\&I\4.+&@TCE3+\>G-%]&#[964.INIL[::\;L-W&^\R?/99MNJGOMF2/
M'1O.<DEU7.TN9HVL*ENB-ZR(\Y4,)$VYWT\=C2KS:;%R,2XL<8$AKW4=H[8)
MSIVFS<:!UQKH3JJVTXX81VP,=!Q+H?C.G8R=#&#AM\$LT0W39FC:PJ6Z(WK(
M9RH82)MSOIXP8&D',<3+)C>+'&C.318V8)K/+%)/G+AR?WDV'S?9PZXYJK8&
MI,YE* X\9C?#$:".$@C)!$:\7;*,S1M85+=$;UD,Y4,)$VYWT\2E."2Q)HT'
MH\:.-:3$>5:'F+-&PR";9D;8@&D49&&J&G'+"2!-K%Q[&-MWR6FKE("S:B$U
M-1[=)OHS-&UA4MT1O60SE0PD3;G?3QADZ?=I[L-T^)?%/104FHB-WUF*N-QZ
M2R11!5-GMCC9XS;7= V:0VU1SICX$P51_P#@R#S59F:-K"I;HC>LAG*AA(FW
M.^GC.^@\Q\WF1&.-?'# J1/1Y(^,Q8Q/ \V1$NTGPL@69XXZ8;D'PYZ@@[8O
M'::KAJY;H+(*:*();:,S1M8U+=$;UD,Y4,)$VYWT\8IK519BR;C6/%3BXR'-
M%6Z[0>TG#ILQ:K-!J@9JHV:(\;]&Z&[<0JJ+2RDGIG0>HHSU[&^^R>69HVL*
MENB-ZR&<J&$B;<[Z>/>4K,^;556,\7.,1998L./K;DIZ]?;*'1 [80*,[^5<
M<5?&*CA6VPQB0SVNVS#.&:*NC?&$\,S1M85+=$;UD,Y4,)$VYWT\=;2IRB3=
MXS3XI<6TVA%-)(@VTF[G5!^F@<4DZ&KU'7C?A-U\#)%53Z65]5,IFE5">F=7
MN^RV69HVL*ENB-ZR&<J&$B;<[Z>+(%.[M!C!P0+3U,"0X=@T%B10VY90Q'#!
M@]NFT8#Q[)KQ^2;,V3)JBDV:-6Z2:#=!)-%%/1/377#,T;6%2W1&]9#.5#"1
M-N=]/'?\_P#(#NNJ7VWR_P# +IF:-K"I;HC>LAG*AA(FW.^GAY_Y =UU2^V^
M7_@%TS-&UA4MT1O60SE0PD3;G?3P\_\ (#NNJ7VWR_\  +IF:-K"I;HC>LAG
M*AA(FW.^GAY_Y =UU2^V^7_@%TS-&UA4MT1O60SE0PD3;G?3P\_\@.ZZI?;?
M+_P"Z9FC:PJ6Z(WK(9RH82)MSOIX>?\ D!W75+[;Y?\ @%TS-&UA4MT1O60S
ME0PD3;G?3P\_\@.ZZI?;?+_P"Z9FC:PJ6Z(WK(9RH82)MSOIX>?^0'==4OMO
ME_X!=,S1M85+=$;UD,Y4,)$VYWT\//\ R [KJE]M\O\ P"Z9FC:PJ6Z(WK(9
MRH82)MSOIX>?^0'==4OMOE_X!=,S1M85+=$;UD,Y4,)$VYWT\//]_P#==4W;
M\WKNEW9_#_#Z@NWYOX/_ /K,T;6-2L_](C?XWU_T#.5#"1+?[<[_ (Z!_P!
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M.L@6L5KUI&!3=K9A5M7[F#3*+J(R8X*,U3@4_.,Y?K(";<YVJO2,<?X<1Y0
MC5_61:-"\K+=N\+6E_3&NP7#&8#6.-2A$K3AZ]6!F/22MXS&HTI+'#4(5D^C
M)2%N#@:&MG+N4'_)"CMPV5P[0 *SKCCW9M1<E.%,%%Q2_P!A%:5J]\6NZ[XU
M,)"3JZ\[7L4!-$Y7%)% =[ 0AP2/)6'*I+<<TF3V#O),3F+F$B@?:V:%2S8
M^TO0!3M>?WQ^0G^4"'?^IJN.KTK^2TW^SO\ ^MDB%K^'*_KF_P#3MC07PC4,
MY)GY%"#E5P6R+5@86I+=;CH%7,]E<,8_&$=&:\>5N:M%A ;GHB;GX<ZAPZPH
MQ'BH6;/&->S$TREQR.$D$6>[>B)AJ[<9OPP$:BCPY5;.TR,G7N$T.!0EDSXZ
M'8G$JSAD)KA]%QY-260PW8<W:V')#MD#CDR>V>D7:HP4:FD[3+&&SHX 1:P
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M",%)B3Y 1.F@D3<Q"(PAE)JKNH"?:PUB7;/-T "(<HN?O-$'3EV5_F)PNOK
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MHYR/+60EKI'O'=1;!77<8R\EU6./UTUG30*J*06()K_KFN*IM\KBA=\#!1?
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M!LSS6,9A6LPR/;9D>D1V+8.[QK0ME/RS0*H:UT*JCM5<-E7Z2+E1/95%/;4
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MVY_TX/2#D;W44U[>9G_9WZ9FB:QJNYHGKH9=0PT/;G_3@](.1O=137MYF?\
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M/#VQ_D0\]\A>[6G/;9-/P#Z9JBXZJ;JB>LAEU##P]L?Y$//?(7NUISVV33\
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M+0ZUF@4ZWBA&-P^.RZ9L)()W9B2["'@-Y(PBVL_<H-VKB7.!@AX&%IG@CQ^
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MFGI%7TVAYYX.4:^,%*$7X/RHCJ-U(NP"VNS'S8^K'0 [,?-CZL= %#5!C'K
MY1_)CY+S ?ZM_'_/_7G/5V5_$4W^Q.?[C/$#/\9*_KT_Z:.+Y[,?-CZL=4A.
M/'?*:>FV^^=----<[;;;YUUUUUUQG.=MMMNS&NN,8[<[9SC&,?+GY.@#3&#<
MS(]8M7<H[5BU=R]T'XX%Y2Q%CU<LO.=OB0=.0ZYH]*84W:>6*MP5A1^:B=H9
ML^2V?D![A@759(:$4F:0!-XUR?@3BF1-Q3 A'&; G)58:F,JDT5OM1W+<R!S
M'FD3CJ=>Q162RF5;.F^^I2."(DH7!KH$T2+71$2^=I@%;P/GU11Z(U$:GA$K
M6A^WXG'I4 $&(=8R\>43DCYJR;#V4^<089%GY!AH\2)GV&7;0I& 38O()*/$
M! )H@P +Q@?(RGK.F9J P*2O9+(XXU,.CF6$0F>(^,U!S&0P-ZW=S%Q'D8@D
M_6DL5D#<4,V.><3HT:M( C4A']T"BH!01+FZ)$;U([>PH>H$N7D#+:(B.&]A
MQM"8$]X_<3JFVDNCL$*-QQJ7C-7[-:<S) %NKB$5QKO(G3PHX2W&] $YF/+R
MN(U><+HD>1B!*020;%#I<J7L"/1D<+$3N62&#0QI'DW.KYQ-99(I5$Y$+91H
M=JQUT6'H-'!5$N;CHHP >N;<PZUB5P!J@9-9#)BB3Z7L[ (@(78AEC#%HI5Z
M]HJAQST#"#(6;394.L W=U[&C+J:#1TE$EEPNZ+ELBY /6GSPXGJ1=],=K7;
M-@@M1VD4\OB4Z'EQB@\%9\B)Z$8V^B[>1,LBAU+6RF6\I%)^;"U>2P"^^ .!
MW8[0 LBNKN'6)8<LA#( 3&,Q%;U9:<=+F6!T 3.QFSB5B DD"L/E  !(HF:!
M&JU,)/A95MNXV8D@SK?5JNNNT0 +T[,?-CZL= #LQ\V/JQT ,8QC\V.SY>W_
M )\] %2W?7"UN5T0@3<PD$\YR.OR3U\JT8$=?-45L*+2TTP\WE6)02]V+" ;
MT4FT,"R0=QN]T2+#WPW=TU5 -1SO%"ZWL[$RL?>)+*<8EIEU$\O)(_%L(U%2
M^"[8:E'H9%8N$$!W47!DA4=(Q1R7-PFQT8:&*D6<27+&&/0!T2'$*[,J!"8N
M_"S,\V"KB9*=&2 L%F4FR:@E%QV0.4Y\1#3%\)6S,JN+SUGLN!.-ET5@\(48
ML8ZY>[, "RK6H6]Y?)Y0;AU^R&*A3CY/*4;&2<U'U$P2 ZE$&XH471&R$?#R
M."D,M$LO(@\5?O'>)\D,?-G;##A-L 0Z0<9.0$BE&IM[>[O#<,WF@6**M97,
MA10>QE[ZU'OI,Z\R)C!^\D'#9;!HDV'IM]V2#"%I'1I4:[39"- #HF:%Y7XM
M(*\"7>03@3DE(73_ 'VF<F43 X;3[$DCQQ8(^55R;(/(:53KW%>[9<0/5&%:
MR8H4R0EKY@WQU_E\?_\ 0#Q'<5N0^P=HQ/<CCIY7S)#Q9-K)I*9E@I\[$(6[
MZ8$O(M@L=8+)RTO)JPD#!J6%%BD4VA;D QD3P7HS5<9 ;24'#K4A$8D+*WIL
M)F<@+3!X<&*!7,D=B0 1R"CS+8$/=3!^4D6[/>0#SY]LU(DR.1"!Y,(V?.F@
MQ!;< O+Q]/XVO^=C^OH >/I_&U_SL?U] #Q]/XVO^=C^OH >/I_&U_SL?U]
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M*FF,=N=]<8^?QL?U] '.=M<?+G.,8S^;.<XQT <>/I_&U_SL?U]8M+\_@?R
M/'T_C:_YV/Z^EI?G\#^0!X^G\;7_ #L?U]+2_/X'\@&N\ZXLTA9,_$V9,HRL
M6EX.95E/1C[S\8:(-Y-4"4Q3@CO9BS?(-'#49M.C[AT+<I+#2KO(UT2:.5Q
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MHVFN[66E%+VM"042D,4P>3(M"H4FF[AL',MI*BH]>ZX!/&6$-%BV";!:7Y_
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MW.ZTOS^!_(!)X[Q5I2*6JK;X *5'R38N1DC,.E*#OH0'E)B$A:V+R<)"LO\
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MW=AWJ&=M5$LZY ))T .@!T .@!T .@"BN2_]X^=_\@"_TI!]7Z9_+H_[7/\
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M&'5M 8X16CP&->;:^K"OA(6'PL6Z:1YJ4-Z#6>[D_)GI8\1<;KO=4D #;KH
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M.52>7<C; G,:CHD[)1P$U(RE;0(2P3DY;T5B0')2;Z[1>+1H*\;1P0 ?4;H
M= #H = #H = %!<HD57%#6$@B[<#U5F09)-\TU:;NV>ZDF"ZZ.6VC]J^8[KH
M;9PHEJ\9.VN=]<87;+)^,GMT*49%4(QF1*(E+,TJML41-+ZCR32JP_MR5)/[
MC(5Y1&<=PB,TG85AE9:7UBZRMM*W]I&7WD8DGJYF7Z05P_J;C_\ @5U%I+.
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M$;[I>[:ER@>L@3]%+F_H]7Y^&O2Y)W:4O?U!]2"\(WW2]VU+E ]9 GZ*7/\
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MH = #H UUY8_\7ZP?^1CW^EH'KHTG^<(W[7/\EP5IG\G7^UO_,0-BNN<+(=
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MM#$A-HGP,(F\X-,$(L=E0R)R 7%LMH-)I 07+QJ1O9-$HLAHP,&0#Z"] #H
M= #H = #H H&T0#P3@I."W(VSZQC&K@,QP* ":<>!6;XJ^'QX4R'XD].3&3O
M2)XX_8LFC')4@X>%B*+(<AK\,W:Z]*/.C,-);<H]-EK2:C-^0Y54NKM,S(E%
M&J<9DB21DDLAE/41&K*5:HZCL=YQ9J1-E,I.RQMLHF0FPK.K.PW5G;[SREGU
MF=EA6$5=QT:/ER7ED?YK6<42VUPLDX00XQ^([10CP:5Y>,%%J 3P09-XW)@I
ME0@QRX:(,"K9;=?3"FV,37G#]_L]1[?OSM=]:&AQ)&LIWY6E Y QDTH\JX.B
MHTVYG6R[-G(R\F0D>T;<9W:SV*,%AZ#F0HY;T JEYGPJ58:(/]U-&[S*VV6F
MZ^&[C*2\X?X?H_BUWUH8T1_64VW_ .F!_CH'_0>HL&2!ABLA*<V+/:!@@5K(
MRI#?XL&Z#,$0U4W'%5<I4*IOED4PDIJ*63TWU**Z_ L/*5<XTRO.'^'Z/XM=
M]:#1)&LIOP@>GCW,8XY?B=SJ?,>XVPI-4BDH\*#.-X;1+(H@J+>J*Z%^/C%9
M)NF]1VT2=*)ZMG:.[=VT679NVJZR\X?X?H_BUWUH-$?^RI3>[ +_ /0,>D^$
MQ&(VZEYSFE:[&,LW"S-<UNWXS*L</6ZJJ#A@BHWH%;+D@BLW7248-M5GFJB"
M^F4/&14QJO.'^'Z/XM=]:#1'_MJ4WNP#_P#T"'>5B;A!/"J_-*T$4MMBFFJJ
MN_%M-/.X-PFT-:XWWHC&N=A#M5)J4UQGM'N%$T7>$5-]=<KSA_A^C^+7?6@T
M21K*;\('IX]F8<]QG;&>9UIXVTW+I;ZYSQ=QMJI'T\*GD]L9H?MUW")9PJ7T
MSC&PU//CO,(Z_+TO.'^'Z/XM=]:#1)&LIOP@>GC$GQ2$7%O#!WFO:; >P=C&
M#M?=+C(KLB_-(I.1#'*#>@EG&SPFT72>L6NB6R[IEMY8BGNUUV6U7G#_  _1
M_%KOK0:)(UE-^$#T\3O%-SW.,9^-'>_RX[?^XG'#^S]TO.'^'Z/XM=]:#1)&
MLIOP@>GAZFY[^E'>_P"I..']G[I></\ #]'\6N^M!HDC64WX0/3P]3<]_2CO
M?]2<</[/W2\X?X?H_BUWUH-$D:RF_"!Z>'J;GOZ4=[_J3CA_9^Z7G#_#]'\6
MN^M!HDC64WX0/3P]3<]_2CO?]2<</[/W2\X?X?H_BUWUH-$D:RF_"!Z>'J;G
MOZ4=[_J3CA_9^Z7G#_#]'\6N^M!HDC64WX0/3P]3<]_2CO?]2<</[/W2\X?X
M?H_BUWUH-$D:RF_"!Z>'J;GOZ4=[_J3CA_9^Z7G#_#]'\6N^M!HDC64WX0/3
MP]3<]_2CO?\ 4G'#^S]TO.'^'Z/XM=]:#1)&LIOP@>GAZFY[^E'>_P"I..']
MG[I></\ #]'\6N^M!HDC64WX0/3P]3<]_2CO?]2<</[/W2\X?X?H_BUWUH-$
MD:RF_"!Z>'J;GOZ4=[_J3CA_9^Z7G#_#]'\6N^M!HDC64WX0/3P]3<]_2CO?
M_'YDXX=O^K[^;I></\/T?Q:[ZT&B2-93?A ]/#U-SW]*.]_U)QP_L_=+SA_A
M^C^+7?6@T21K*;\('IXBQ6&DQ!\#$B_+RZ6)^6[/4(Z+>!N.:6YQPQ'/BSQ@
MP5WX]>3.2.@@85*:C-5LOEQ@DL_0;*LQ9!9NO.'^'Z/XM=]: HDC64WNP#_^
MUWB(1<@ F*CU"/\ .&UGBXT"I*'Z"H_CB/59QQ!F')KFW&A+CTSV2'-A,CC1
MEVYWQA-F%E$7+NLI#9($=/UYP_P_1_%KOK0:)(UE-^$#T\8)M-(2_<-6@KG1
M;AQT0CPV5!VX #0)U4^!+1M68L7L<T$\;WF9%OM%$M)(Y9A/+WS &\%E'[9J
MR+BUWB\X?X?H_BUWUH9T1_64[NT_D!<8:KY2<$##83E==S\.:8-"XM^S#<;M
MVC\>30T?-'S=37C[C51%X@NFY35QC]\T5QO\OC=+SA_A^C^+7?6AC1)&LIOP
M@>GC+MZ@G:#A!;?DW>#O1%9)7=HY"\=]6[G1/?7?=NOLUH1LZPBMKC*2N6SE
MNOC3;;**Z2F-=]<*J4-25)*@4A)J29$I+M<RDF9=2DY594G*3[RRDJ3;_"29
M6D,E$?(R,ZC-,B.VPTP#(_R/]X$=A_D9']QBUY&0/"A6SF/1_$I)ZJ)::#-B
MS0'A1/??&JJV7SM%9#3X'3.=_$RGVJ=GBZYQG/;USF$,N.$E]XX[9DHS=)I3
MUAD5I%D)-)GE'U6V]7O/J%MQ2TI,VT$XJTK$&LD6E;UGE&1EU%UV6=?N%=^F
MEO\ <FE[3([[NZO:+3-:JV![BBOGI>#+:$>0/32W^Y-+VF1WW=TT6F:U5L#W
M%#/2\&6T(\@>FEO]R:7M,CON[IHM,UJK8'N*&>EX,MH1Y ]-+?[DTO:9'?=W
M31:9K56P/<4,]+P9;0CR!Z:6_P!R:7M,CON[IHM,UJK8'N*&>EX,MH1Y ]-+
M?[DTO:9'?=W31:9K56P/<4,]+P9;0CR!Z:6_W)I>TR.^[NFBTS6JM@>XH9Z7
M@RVA'D#TTM_N32]ID=]W=-%IFM5; ]Q0STO!EM"/('II;_<FE[3([[NZ:+3-
M:JV![BAGI>#+:$>0/32W^Y-+VF1WW=TT6F:U5L#W%#/2\&6T(\@>FEO]R:7M
M,CON[IHM,UJK8'N*&>EX,MH1Y ]-+?[DTO:9'?=W31:9K56P/<4,]+P9;0CR
M!Z:6_P!R:7M,CON[IHM,UJK8'N*&>EX,MH1Y ]-+?[DTO:9'?=W31:9K56P/
M<4,]+P9;0CR!Z:6_W)I>TR.^[NFBTS6JM@>XH9Z7@RVA'D#TTM_N32]ID=]W
M=-%IFM5; ]Q0STO!EM"/('II;_<FE[3([[NZ:+3-:JV![BAGI>#+:$>04!RC
ME]JKT1/4GM/),&VZ(#X1WZPP+O*/9*@>VN?)TF&FZGC[XU3^3;'B^/X^?DUS
MCJ_3(U.*<P::HI2B-RPM!>*W]$Y]N</W%U^[K]PKRW96CKMB$16H_P#Y"#Z\
MXFS_ (?M/J%_^FEO]R:7M+CON[JAHM,UJK8'N*+&>EX,MI1Y ]-+?[DTO:9'
M?=W31:9K56P/<4,]+P9;0CR!Z:6_W)I>TR.^[NFBTS6JM@>XH9Z7@RVA'D#T
MTM_N32]ID=]W=-%IFM5; ]Q0STO!EM"/('II;_<FE[3([[NZ:+3-:JV![BAG
MI>#+:$>08AD5L,:3-&AW'H,P,215BO(2K.>1-L1.KC&*0P:L8>HB='))0>.1
M18,MWBBVS5FGHV0SHCKC3IHM,UJK8'N*&>EX,MH1Y >E;#)$PQHCQZ#/C$=4
M>K1\J[GL4<$0:I)FH.(JB'JHG=R.4?L%5&3W=FHCLZ:;[-U\J)9\3IHM,UJK
M8'N*&>EX,MH1Y!E_32W^Y-+VF1WW=TT6F:U5L#W%#/2\&6T(\@>FEO\ <FE[
M3([[NZ:+3-:JV![BAGI>#+:$>08@^4L*5AB,<D_'D+(H^8;;LBP,Y/(D5$%&
M:F<94:$!SX2NS>-E.S'PB#A%1+?&.S;3..FBTS6JM@>XH9Z7@RVA'D'D6,6*
M>39(G./@<PD-*#C@](I/HH_38FA#K1Z)+M-'0E75L3%O4DG8Y\CC1TR=)IN&
MRJ2NFN^&BTS6JM@>XH9Z7@RVA'D&5]-+?Q_X$TO:9'?=W31:9K56P/<4,]+P
M9;0CR!Z:6_W)I>TR.^[NFBTS6JM@>XH9Z7@RVA'D#TTM_N32]ID=]W=-%IFM
M5; ]Q0STO!EM"/(*0JB7VLG.^2NZ%.IN%5[J!JO4<V( 1\A<XX]42CJUPIL/
MSJYQLT2;//AT\:Z:^5^3YQE1#?;-R5%IF9IUM441%#78>@/':5X3CM_C.JPS
M,K/RM]QB!EZ5G)/[S+^/3;^^$=7[WCV?\/VE8?\ ?9]@N_TTM_N32]ID=]W=
M4]%IFM5; ]Q1/GI>#+:$>0/32W^Y-+VF1WW=TT6F:U5L#W%#/2\&6T(\@>FE
MO]R:7M,CON[IHM,UJK8'N*&>EX,MH1Y ]-+?[DTO:9'?=W31:9K56P/<4,]+
MP9;0CR!Z:6_W)I>TR.^[NFBTS6JM@>XH9Z7@RVA'D#TTM_N32]ID=]W=-%IF
MM5; ]Q0STO!EM"/(.L]E%J$6CH>0HED^8/6ZS1ZR>6+&7+1XU<)[(N&KILL,
MW1<-UTM]TED%=-TE4]MM%-=M=LXRT6F:U5L#W%#/2\&6T(\@[&LSM[7&-=:2
M1QKC'9C&++CN,8QC\V,8\W?)C'\&.FBTS6JM@>XH9Z7@RVA'D'/II;_<FE[3
M([[NZ:+3-:JV![BAGI>#+:$>0/32W^Y-+VF1WW=TT6F:U5L#W%#/2\&6T(\@
M>FEO]R:7M,CON[IHM,UJK8'N*&>EX,MH1Y ]-+?[DTO:9'?=W31:9K56P/<4
M,]+P9;0CR!Z:6_W)I>TR.^[NFBTS6JM@>XH9Z7@RVA'D%HA79-\+9NC K ,F
MLEC=X*P_0)X9*]N>U'#]MHF@YQC'9GX1/377/;V8Q\G7/=2VEQ:6G,ZV1V(<
M-!MY9?K9!F9I_89F+*#4:2-:<A1EUIRB5DG]V45A'^T:]WV2KF;Q\Q4\U8W!
MHVW+0LZN1A%'V3-V6'T1E4?GH3#<JTJZ<0@PUV*@1Z!<>X1*-UFFST8[117V
MW^"ML4V1(:2ZVY 2E5I$3]5I<5TLDS(\IF3,9>3UEU&ILB45BDVI,C.!R6TT
MLT*1)496&9MPY;J.OK*QQIE;9_F25&9'U'88T[;<=N+S1NJU;[\MM6SF/1J.
MNDE*%MYQLNE#*\-5K%'V%W/']9RV<B DB-N5F3)9L!/O'V&<H#&X\T9 V\US
M2^VI6_:'ZB(]/9[*;N^=RXED.JCCC"SLL/LFW)HLO-@EHBI(PD/&FS"PD@]N
M72&IV";RP5X\::(Y,Z0./:IQ-+;2N6&J;U-G"TDW[C39<TOMJ5OVB>HAI[/9
M3=WSN7$'=\;>,[\6Y&OC',<@JX$EQ6"I>A[4/%=<2:$1&O)8]=K'N.A-N=>2
M*+0@"S5Q)VQMH#=)."$3:Q]ZO\-JN:7VU*W[0_40T]GLIN[YW+B3Z4KQLUD
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M5]")]84<);-Z\ECYI$FT?DN,!6N"1;<.]%RYO%0"8C/"=1F3Q<@:AE.34\9
M0F(V/,8UL\VR]A<%LQC5,FJZ4FT8Z%E1P@+F$!LHS+\ZQ*.R8B-Q5%GADAY-
M]&UM]@"Y[AY..8/)*T. M'\A@Q'C?='(-X#AK%K(RUC*1-]24;@<2C[])F]U
M2'F2%QX)K'66S)LW48!'Q0FTC'GKX4 IFJ.9%N6/Q85E8@ -F/(9.<6C%W:T
M/JBT4*<0$5SR8D53G38\M(W0H&XD0FM RTS!UP>LZ-RJP#K1J#&)C5SC=NU
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M#(H_/O2S5I!#Q-JP-CT SJ+.R<\:IN <>07UU+M&PI_HR5(.-\[^6+;>2-L
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M'[;]C=F?=GI=#N-I&]Z?S ::C#SMAE<(/C/5]]'[;]C=F?=GI=#N-I&]Z?S
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M!OCT .@!T .@!T .@!T .@!T .@!T .@!T .@!T .@!T .@!T .@!T .@!T
M.@!T .@!T .@!T .@!T .@!T .@!T ;.0_\ N9#?^)Z_^?OT 4=?+ZO9S'S-
M3S<';3H>L4AYIT\A].329CMWL4DX"=!=4G^*_F$-,M<%@0](L->LRK)RV\L&
M/FV,[JZZ="/37I+274/T]"5&HB3(J<",Z629I/*9?D-NI(S*U)J01**Q16D9
M&=9R4AM9H-N2HRL.UN+(<0=O7U+;;4D_S(CM(_>-1VO'SC*R;N&;01RM19O
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M;[R>*XB&1,:A69X:%N7DMF4P7C,8 !ALG -H*'E=URN4VPO:P!2-!6!$(QA
MG$;<A6;3#=]+&QU%H7?O7KN9]B+< LI*V^!H,MJNBX"!1J"BVBH!LMT .@!T
M .@!T .@!T .@!T .@!T .@"DI;(IV.NRJ@8O!1:OCT?GVDN29P@J2'M33)
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M<OFP!K@N^'IIY>#V#P6Z?HMDBXS=TO.-J2D_&J^J!HSN.E_"'R@N(%7I.2A
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ML7[A=D]2;K[K.M:AM;_G"[X&"B^ UY1:/Q;^/W<K5_V(CWN_I?=9UK4-K?\
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M84<L2P8[,2L?GA#6,2*<D*\-;Q1R"2'E6(4B0&LH'(4D71$ LP%PSY2QN46
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M)E>(CAAZJ5.\ZU_M0Q]R=+Q_H%,V5?'#1CQ,KQ$<,/52IWG6O]J&/N3I>/\
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M#ZD2^EFJZIQ41+9J)+#S14##A8*?D)/!7]:RILQFR+@.-E(]V3 EUVX< ^>
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M".'V>7TZNX- 'K9 P!J&/ 7L<A+05+=FLB>GY DL[,CMTQ8P^ 5#Q0Y?\L&
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M?[_Z786LJ7M2^"&EGA)GA(X@>N!?NEN3[(C_ '_TNPM94O:E\$-+/"3/"1Q
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MC%DAKDOH/SEAJ2SCRS5EG+7"V$,Y3R 0";<=*@G4!F58OHBRC\(L9VNXL0+
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M;CWBJS3;&^<[XRCG&V<[=O0!(^@!T .@!T .@!T .@!T .@!T .@!T .@!T
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M/Y0T).(F;4[Y@]3@[Z?6_P"T^4_MG2]5X*E[OC^4-"3B)FU.^8/4X.^GUO\
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M$,8UQG"#5!)+7;.VV-<9VSG/39JKS+2&DQ:8LD%82WJ9!>=47WK=<84M9_\
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M5-L8[=U-]MM]]LYVVSG.<YZY)G:9G816G;81$1%^1$741?<1=1?8+I%9]_\
M>=H]O6!D.@!T .@!T .@!T .@!T .@!T .@!T .@!T .@!T .@!T .@!T .@
M!T .@!T .@!T .@!T .@!T .@!T .@!T .@!T .@!T .@!T .@!T .@!T .@
%!T ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g129231g37a20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g37a20.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1=F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %TJ^66(X0DE-! 0      $(< 5H  QLE1QP"   "&  < E  "')R,CDS
M-S0X' (% "%-:6-R;W-O9G0@5V]R9" M($%#3%@@3F]V(#$W+F1O8W@X0DE-
M!"4      ! 00;859CNK4%3/IR8'E ]0.$))300Z      #E    $     $
M      MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP
M<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P
M  P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M    0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-
M!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M    0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N
M0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M     $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M    4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!O
MX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M            0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL
M0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G
M4',     4&=00P    !,969T56YT1B-2;'0               !4;W @56YT
M1B-2;'0               !38VP@56YT1B-0<F- 60           !!C<F]P
M5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M  QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M       +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU  (
M @.__C4  @ ".$))300F       .             #^    X0DE-! T
M  0   !X.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      ,U    !@             #;   !4(          0
M                       !              5"   #;
M       !                         !     !        ;G5L;     (
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
M        3&5F=&QO;F<          $)T;VUL;VYG   #;     !29VAT;&]N
M9P  !4(    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E
M$@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R
M:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960
M5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,
M   !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M          !"=&]M;&]N9P   VP     4F=H=&QO;F<   5"     W5R;%1%
M6%0    !        ;G5L;%1%6%0    !        37-G951%6%0    !
M   &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;VP!
M"&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T53;&EC
M94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L
M:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M
M$453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P
M       *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&QO;F<
M        "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,     C_P
M        .$))3001       ! 0 X0DE-!!0       0    $.$))300,
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M/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MV+9#G?;'5R=@K:X-\RYPE
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MM<%69&=XMM;Q_\0 ' $!  (# 0$!              ,$ 0(%!@<(_\0 5!$
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M):VE7NSB\*MX"_G*R+:+JKZ\]JW4V"M+41W1H+9^0MPLCCP%Y2RQ34]@HO\
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ML?&T"06DR=^%?$]^T,UR]H5(%'<E*K<4G0MFP,OV?"FY8W<-WR>Q]51]S4S
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M$:AXPYPI$:AXPYPI$:AXPYPI$:AXPYPI$:AXPYPI$CON#?Z?C#VJK^E1A_\
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M&/L&O?E<MZU*3];&IS:+0@[8UT6OUXHQ%>WWNS=?<]C']2BEU)_8&903].V
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M3.6'7NS$='V+L]A'\*]EGD[9+J"212(I$4B*1, ,OZ4N2?V"86_B#GFD3/\
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MO1Y_:=G+\I97:SY6Y'4^9?MJGHJ_HT.*FZ\7.:JE&9E%C!!ZA+"1T)X4U J
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MO(^9X73C)/DS<3R3BL%NPW5')4[W9$]F6LZU<D=-?T04SX7K]+U<>WM;4.R
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MTTJR\P@;C,W$&")-]UQ8C>03>(VZW%%W:V!Y!^&XE791\6\*P5F4-\I\0#R
M) ;H<,P'D.CT&8#OV8_4]$7W$?Q.\?J]3+[?J_C _D'[)5^&G*W]DO-?QMV<
MO]\ZU_)'%?WU\+_FOQ#_ $+'KW?W'?\ Y>7^<26[,V5-_%7^Q-S4%P)#[0L[
MK=G+40N.3"-P?SZ=X!M !XN_<'OT_)'%_P!]?"]?XK\0_P!"?L^_[_V1Z]O]
MQZ._^WEZ_?\ ,2K\-.5O[)>:_C;LY?[YT_)'%?WU\+_FOQ#_ $+'KW?W'?\
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M 88EV9%D <H'%W3$L6CD1D,EBJ2:(^$EKUBC:.PBR,;G.V,G-#0>T+8%E$Q
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M:64]L0/SNE4&+M\!=;-0]B47UV.Q:XY5%585,E=>$7I3>*0I8\A=5>*]6GU
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MTAPJOB$PO+<%BZ&L2IR(%KTU V7Y[*/%!5AKQDL@-8\,^:IB,=YU5MDM?/\
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K67=_4BP%OME@,]UB8BD12(I$4B*1%(BD12(I$4B*1%(BD12(I$4B*1/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g129231g39b76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g39b76.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1M\4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &V"^< @X0DE-! 0      $(< 5H  QLE1QP"   "   < E  "')R,CDT
M,38U' (% "%-:6-R;W-O9G0@5V]R9" M($%#3%@@3F]V(#$W+F1O8W@X0DE-
M!"4      !"(I_Q8^.6%LSJ+P9N2=X]_.$))300Z      #E    $     $
M      MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP
M<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P
M  P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M    0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-
M!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M    0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N
M0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M     $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M    4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!O
MX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M            0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL
M0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G
M4',     4&=00P    !,969T56YT1B-2;'0               !4;W @56YT
M1B-2;'0               !38VP@56YT1B-0<F- 60           !!C<F]P
M5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M  QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M       +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU  (
M 0.__C4  @ !.$))300F       .             #^    X0DE-! T
M  0   !:.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@             "<   !      & &< ,P Y
M &( -P V     0                         !              0    "
M<                      !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   "
M<     !29VAT;&]N9P  !      &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   G      4F=H=&QO;F<
M  0      W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
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MQLNS)LJ]"VC]-D+HNK_7+I'2[<9CWB]N12_*-E3V$"AM5N15<R7_ *?[5]D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M_5U$L@^J_;^!B3!Y,1B(Q$8B,1&(C$1B(Q$8B,1&(C?GQOQ]=^/I_?B)K_\
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M92DUH:TK>8H++&(0RRSA)]F@ (0A "+01;WO6]YZ/PL<XN'B8K,';&Q:,=G
M(#FFI*RP!)(#%>0"20#P3/8&GXQPL#"PRXL.)B8V,7 Z0YHI2HN 22 Q3D D
M\<\<RIL[4[<8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B01]Y\4\X
M1=XN2Q;!Z<[;K&4>HO?7*-,MB"@IZD2.S/9<:+41V!1VL$A<9%]V&&1H$+@[
M6&LD#DO0%(6Y6K(4(?ZM(>B124/"^#^=?4XKNE$'>?J^6;,JIZ!B]5*YA8,[
M32KCITZ%7)SE;+SU/Y6E8$2I7(WLTM0U*&7[-(;E#@F5MXW@K294<2B;F^(C
M$1B)#XZ?K\(?_A+37_5U$L@^J_;^!B3!Y,1B(Q$8B,1&(C$1B(Q$8B,1&(E@
MNHK5U2]"69899X"'%GC2M,PB'O\ WI(\[ S,&@A\^3/8ZKTIY@0_71))H]^
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MQH(0!UH(0ZUXUK6M:^FLM%5"J%4 *H"@    #@  =@ .P [2X@ H"J %4
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M'()_1V9R3_5C_=\_G\9X0NV7O#VJTG;^N6'SWYM_1>4 YZS^T'[+@!C[X'H
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M%F]+3GI,)'N426UYX6B+))*0R*9E$-P2""PE%)BR65J;%9"8H( Z**)7@T4
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M?$JEV.AJ9X;^F$#^W6\H$ZRM#]_&^,2J615I*4$[=$9[+I"UDC;@C8BF8U0
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MJX+V6$$\ DA5"J"SN[*B("[LJ@D<]MM=%;W7.*ZJU+N[>BJ/4]N2?J !)/
M)($L+1<Q],OO.45LV0!EU)IMRFV-IU4,<D.L2)/<3C4?7L06Q\8T1KXC)D[2
MC<6MB+..=QO"],8!(!X3)P+PZ5;-N;8>Y=I4X^1K.$E>-DL*TR<>^O)I2\JS
M^SVO43Y=W2K, PZ' ;RW?H8#I86JX.H,Z8MW6]?=D971NGD#K4.!U+R0.1SP
M2 P'(YD)CO/5.Q.Y)MT#'X6G;K?L9E01V:3(#L_GJ'MF;"VDI"A,:E3J>PI
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MPD4D/\]:U[&RL;LZE(G-_=433$FQ>H2I?B$(@[*<$H$REP3K5 QIDQI1FZ;
M\2M0W/N7%T?5<#;F)C9%.2ZFC MKOOOJJ+UT5/;EVHK-PS]ZV++6R+PS C&:
MOHE6#@79./=G665E.S7DJJE@&=@$!(4>O<<<\D\ R.CTS.?-]F7^[UG8DPN-
M%#FJO7N4KGZ"RT;<J9W-$YLB)J"Y*GAL?T.T;C\\K2EI=)R%1RCV'D';+2J"
MQ6#XD[@.SM IU+3\32'R[=0HQ:Z,[$%BW5O7<]OE+3;CV==?0K%^ID5>58<L
MIF&T'$.IY5E-]N5Y24M87JN92K!D502P8>]U'MQSVY'8&3Y"]#OG'6M[_+?U
M3]-;W_\ 4F-?L_\ X/**_77N+^A=K_V=D_CGS;/HSA_SG/\ X@?]DU<;M>8Y
M!^@9U$X6]7&HJV$3USBVD4GG^P3EX;XT[&M+PI.=T+0G:6E<Z&HU1[>7]@+2
MFLLU,6J+<1E';.]-:+5E9N@8.5F4Z.NJ9N!5E"S%P <&JS)J%U*K2]K77)6'
M1;#[0AM(<H:^5Z=&S+:Z<ZVJILLXU-IJ*OD,+G"-TNP8* A8@E04/ XYY/IL
MVQ#T7>9YA$XQ+45T=9)44HCS-(D:9;8T9+6)TKVW)G).0K+U!-Z I*)4@+/!
MK>]!-"(.M[\>=^;<OQCW+B963BV:/M5GQLB['=DT[**,]-C5,4/MXY4LI*]A
MVX[3=TVWA.JN,G4 '56 .0.0& /!]SU[]YT)KZ"G.TE:#B6V[N@4[^44(+.Z
MRI]BLP;F\PP98C?C-'W78U*DDT)>M&%)GEO$(6BQ[-W\/0=_>'XY[AQ[E-NC
M: V.2/.JQ:,K$LL !Z>F[VJ]592206IL[$C@<DSXMVIA6IQ[3F!QSTL]BV!>
M>.?=9!R#P.>&4G@=^T[,1]!GG&.-"=,JNSHD;P845MX<(W)8I%FYQ5%^_P '
M$M (BZ&I20!,$$DE0ZN!A>MB\J1[&+>_G+\<MQ9%S,FC;>%()\FO(QLO*LK0
M\=FN.94'8GN66JL'MP@X$FO:N#6H R,WJ_E,EJH&/SZ5K[?UEOMG4L;T0ZG2
M0";*JTN3I)PL--%) H@S?(+)8-,2Z7$M2LV.HWC:>&(SPMBIV"D(6B*5I3-)
MS#-A4$[_ *P/WI_C3JS9^$NHZ1MRO3VRL=<ZS'TW(-Z8C6H,EZ0V98IM2DNR
M HP+ >Z?0K=LX_E6>3DYOF^6_E=>1[ILZ3T!O='NEN.KN#QSP1ZR #E?C7H:
MXNGXY4K]"K?AA'WK3)[ED.T;U&7*+1!&X%FRE8N?W-":A(<S4I)I+&%<!<6X
MO!J )"98$>O-[[IWCM_1]LY.K8^=I.:WLK'1L?KIR:\K,>LC%2NBJP6-6&*M
M>:RAKI#]3+Q-2T_2\_(STHMJRJE#CVJP]=92L'EOVC=BQ X3][EB" 1-C+^@
M[YQ_XW]4_P#4F,_]AYY\_75N+^A=K_V=E?W^;C]&</\ G.?_ !'^"/Z#OG'_
M (W]4_\ 4F,_]AX_75N+^A=K_P!G97]_CZ,X?\YS_P"(_P $M?8GH!T7)2DJ
MB)7U=+*]A4E_/N4W^[-@%*VT !!^4(3IFV'JTB@ MAV2I&Y*R  ]Y8D0]B",
M&3T_QWUS&+KEZ%HU]'0?+JPADX!2TGGJ9FMRU=3W!45JW/!#C@@]>_:6';P4
MRLI7Y'4UC)=RHY[ %4(/R/40/E*^:/0GYG9T!"%)<W324)8="."VSJ)MB0U2
M((=*%!:)/ ]ED?&&'W^S0S!!UX"(TS8?=OH6^-^Y;G9WT?;3$GMYF#EV,%Y/
M2I=L\%ND=N2!S\AZ3F7:^"BA5R,X ? 7JHY^)X6L <GOZ??*0M7T)JF>:_E"
M"N;QO/4Z-;1#BH;(F+2^P8QY3G%*$I,D;6N'(G(;>?LK9 U*$\2E 886O*3+
M!)?DS^WIGCAJU.?C6:CHNB'!%H&5^CL.VC.%+ JYQK;<RRL6+SU!77IL -99
M.OK7XR-KXSTV+5DY?FE3Y?FW==74.XZTZ.2O/KP01V/PX-'>EQZ55W\N7POO
M&\7F*MVV&-O\8B<9A[XI?#GE6_ED)%;R\J](421.SIF\*C2!N'L]<I<#B%:D
ME!IN*"L[GB;XH:+N;0Z]$T2G*L]HR:,K+RLRA:!2E!9TII3K=VN:PJ;+!TUK
M6&12_6>GAT'0,G3LI\K)LKY%;U5I4Q;JZBO+N2JCIX7LO<\D$\<385R@IMT8
MB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1(G>K>'^L+#[)A_8_)W4M;T!+V'FQPYM
M>VFQ:(-N5&\QUSLS5EJG)'XGL1(;5 G!&SI0:$G4F@ D4[T=[56P%(E,?FZ>
MM5^\JY<_@0_G;B(_-T]:K]Y5RY_ A_.W$1^;IZU7[RKES^!#^=N(C\W3UJOW
ME7+G\"'\[<1,->@)/ZWM']%<=T,B['H6?HNJY?8T6=+#9>'%"=CI\J Q%+*"
M'>4)RK.="5B:1FJ=M*$"AU8 E*2A# >K%Y("B9E?FZ>M5^\JY<_@0_G;B(_-
MT]:K]Y5RY_ A_.W$2W[]PYZJTJ<SWJ3]O\.2-Y4A) H=G[TWHZ\.9X$Y0""
M'+W"W%"HT!!( %$A&:()90 E@T$(=:UWZ-5U3%K%.+J6?CTJ6*U49F354I8E
MF*UUV*@+,220!R3R9QM32YZGJK=CZLR*Q[>G<@GM*L9>6/6/C;8E9([ZB7)#
M S(0F 1-++P D:VQ& TXQ0:!*@0W.0E3A,/--.&$DH&A&F&&"UL8Q;WU;K[L
MFU[LBZV^ZP@O;=8]MKD *"]CEG8A0%')/   [ 3[554!54*H] H  Y/)X X
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<@DM$EIQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g129231g40f82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g40f82.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[3>F4&AO=&]S:&]P(#,N,  X0DE-! 0
M    -XJ^%"&#A"24T$!       .AP"   "   < E  "')R,CDT,38U' (% "
M%-:6-R;W-O9G0@5V]R9" M($%#3%@@3F]V(#$W+F1O8W@X0DE-!"4      !
M!QWY2?J=.\NT&]+>(F.T.[.$))300Z      #E    $     $       MP<F
MEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&
M4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F
M%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &
M\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F
M5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      B
MT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F
M)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP
M   $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$
M1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P
M    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M   $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M  0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'*P
M     *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&
M=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M))3009       $    'CA"24T#\P      "0           0 X0DE-)Q
M    H  0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "
M]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4    ! "T
M &       !.$))30/X      !P  #_____________________________ ^
M@     _____________________________P/H     /________________
M____________\#Z     #_____________________________ ^@  #A"24
MT$"       $     $   )    "0      X0DE-!!X       0     .$))30
M0:      -!    !@             $K0  !50    & &< -  P &8 .  R
M   0                         !              54   $K0
M             !                         !     !        ;G5L;
M    (    &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&
M]N9P          3&5F=&QO;F<          $)T;VUL;VYG   $K0    !29V
MAT;&]N9P  !50    &<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6
M-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO;F<
M  !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T96
M0     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T
M]B:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G
M1L;VYG          !"=&]M;&]N9P  !*T     4F=H=&QO;F<   54     W
M5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G951%6%0
M !       &86QT5&%G5$585     $       YC96QL5&5X=$ES2%1-3&)O;V
MP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE;G5M    #T
M53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG;F5N=6T
M /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G
M5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P3W5T<V5T;&
M]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O;4]U='-E=&
MQO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H       ,
M   C_P        .$))3001       ! 0 X0DE-!!0       0    $.$))30
M0,     "TD     0   *    ",   !X  !!H   "T( !@  ?_8_^T #$%D;V
M)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#P
MP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,#
MP, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,#
MP,# P,# P,# P,# P,# P,# P,# S_P  1" ", * # 2(  A$! Q$!_]T !
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MTG<8VO]5MMGT?W-JTB]@>&%PWN!(;.I @.='\G>U9?7::KWX-5K&V,=<_VO
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MD.NAK0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &
M ;8# 1$  A$! Q$!_\0 'P   00# 0$! 0            <("0H%!@L$ P(!
M_\0 81   00" 0,# @,#!0@,"041 P$"! 4&!P@ $1()$R$*%!4B,19!41<8
M(UAA&B0R<9:7UM<E)B<Y0E5X@9&4M=49*#,V-SAVM_ I-$-%A:&QP49'4E-B
M9FBGX3565V>E_\0 '@$!  $$ P$!              $$!08' @,("0K_Q !%
M$0 " 0,# 08#!@8" @(  @L! @,$!1$ $B$&!Q,Q05'P(F%Q"!2!D:'!%2,R
ML='A0O$)%B0S%T-28B4F-#53<H*3HO_:  P# 0 "$0,1 #\ O\=--'331TTT
M=--'331TTT=--'331TTT=--'331TTT=--'334:O*/U<>!/$;9.&Z8VKO?%R[
M?S7,\6PN/KK%9U??7F+2,JN8-.&^V/+;.C4.N,;JFSFVMM89G;TYV5(),N!"
ML%%[3FFG#_SXN%?];[B]_G^U1_I8O331_/BX5_UON+W^?[5/^EG331_/BX5_
MUON+W^?[5/\ I9TTT?SXN%?];[B]_G^U3_I9TTT?SXN%?];[B]_G^U3_ *6=
M--'\^+A7_6^XO?Y_M4_Z6=--'\^+A7_6^XO?Y_M4_P"EG331_/BX5_UON+W^
M?[5/^EG331_/BX5_UON+W^?[5/\ I9TTT?SXN%?];[B]_G^U3_I9TTT?SXN%
M?];[B]_G^U3_ *6=--*QK?=&GMR1[69J':^MMJ0Z(\:-=2]<9UB^<1:B3-&4
ML./:'QFTM!5YY0@&)'#+<$AQB(\37M8]4::8-ZG'J%7' .DX^S*;%=17<C>N
MT;K7#\@WIN9=%:SPEE/@=_FR7.19S^Q^:#B#G+1?@L,):P;#64^$!#>9FITT
MTX#'>6F/X]PVB<O=YR,*J<5J=?R-B9[8Z"R6XY$8'68]%F'9)N<.RG$\6A6^
M<T<.L:*SL;*MQ8/V A6;B@6-6FE.::W70O+30O)R?GL/1>;MV'$UL3"H^49%
M34]TW$63<_PVLS_'ZVHRN77QZ'(+-N)W5-;74"DGSI6/-MJZ-=B@2Y8@.:::
MEK[U"\CR'G!R%XH['T-9Z;Q+1_'@O(FOV/E&:T-S=YCA<78%M@Y+PN'XN*UA
M8U168J*TR*B;.RB5D1J1D UQ14TV>^OAQYX^7]O'^XQ^.GEGZ?KG_&F$Q_7#
MVQ+PG'-AVG#HN)X'R9X^\I-R\&\D!LV+G=]L2SXX8)?9VW&]MX%48Y42,$DY
MI0T_XW1AHLCR=Q(A&5IC"G$*^).FI!_3 Y,YQR8TOGMUL?+8^P,LP3:9\/LL
MZH#:ZL]>7[)^OL SR.FNLEUC%AXY?8[3BS+\'G.DLD7U%D<.ZQBZM+>53+92
MFFDLX1>JQ Y?\HMX: EZG)KS&L=I<JSOC5LB1E"6\?DCJS -NYAI3-LXJ*E:
M>O;2 K<RQ<)8<,%C=/F4UM'L7D")&.,TTVOB3ZVF?;SV!QKKML<:\&UQJSEI
MD?(+%M69IA._(FP,TQF?QW3*Y&56VU=9S\&Q.RQK%)T3$+)\7(ZRSNH<12PW
MV"1V2A(Y[\/?OGPTT\SB)SCY)<L+C"-FU?#L>*\--NRLJ75NZI6YJ*9LPN,4
MK+EV+;%SK3)L=KUQ_#MBNID%CXJ;,<CR*O6ZI)-K4#K9!IXFFM7]0KG/RVX<
MYQIV)K;B_J#;VL]Y;:U;H'"<LR?D#=Z^R9NW]H2;T-?7W.*0]1Y9$@8E!;3L
M>;(PY!.E.]]R)3(H^RM-/,RODI3\>N-8M_<SY.&Z*=CU)4R-EPL=R"ZV+C>/
MY+<6(*BOQK$[:+BU/D><3;6UF5]92Q:[$ 6MI8S!Q8M8]W9RM--_O_5DX28S
MK[ MB7.=;#C1ME6.:5N)X2/0>])>W92ZX)$'GEE8:>B:\/LFDH,22QK37617
M&,P:2,"SKRMGD;,!YM-,,YB>KWGNN,BW;;\99>HMC:AQOTKA\ZM2YE9TV0VK
M<FS*?O2!KFL98&AY)0J7#WXY+>:31+ J[Z-=#>V5:1G -7HTU)%K[U$N-V7;
MAQ/C0[,KBRWW94F+)D]9CFM-EV6 8SF>0:\!LEF&7NSX>,3=<XYD\G&'$NX&
M-767@MB0"10J-\TX@D::?-965=35\ZWMYT.KJJN'*L;.SL90(-?75\(!)4V?
M/FRB"C0X42,(LB5*D%&". ;RE>P;'.1IIM/\^+A7_6^XO?Y_M4_Z6=--'\^+
MA7_6^XO?Y_M4_P"EG331_/BX5_UON+W^?[5/^EG331_/BX5_UON+W^?[5/\
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MLSP_!<OT1KVNR;TNB<&J_'<7JMD5V&8]LN?OM-T6F55$+(+#.<DCZ]*IYT4
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M_J08)_ESN/\ UC]--']S[^CM_4@P3_+G<?\ K'Z::/[GW]';^I!@G^7.X_\
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M331TTT=--'331TTT=--0][I^/45VIV54[\->+R+\KV5%W1S"3LJ?HOQTUV(
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MS*M'Z?R8>?LVLW(=9X/=ILX46#"%L%;7&ZV<[,Q0JRHQ^OABR1QUMQQ8E'4
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MNKM9K'=.H*P4%II7JJ@HSL%PL<2*I.^>9L10HV-JM*RAY"L:[G=5/-$9R0,
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M$N(1L)C$9IZ,O<LN:\+?A+WNKGB1K4:G=/+Y3Y^.J%59V5$5G=R%1%4LS,Q
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M-/1>ZO8X+1>2)>_IY$5OPJ>7;Y_=W 9( \R!P"?$^@!)^@!/H"<:C\_P&3^
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M>KTG=F01"10[O5F$K,J(JH7!@R6!=N0DI34R4/>__-CB64ID&,[@6[L,""9
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M%4K!/!&E*Y)V*LSS N&#;HHI%VD-E>7>)"DLSJ6$*-*%'B[*5"IY$ L1DC)
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M5%0S;X):FAHH0$*<Q1&>I8@E]Q5NXC!5 8WD9>\##%SODLD%GK&B4F:933Q
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M0P,KJ=H.UO!<_P#$!?4:8URSTU38+,A9EB]$"%0Y/(E0+9P9#GCC9*][K49
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M6XVN%8<C5@Z/F0)*)7"A@X3+8 W*0/ZB%QN(^GY:CSXS8D6[V]06LA%#!Q"
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M:A'9+];H\1J[+45"4S*K $?_ 'F-2RYPRJ69&RK@$:ZJFQ4\G=M%/ ^,,_\
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MB1N&03P05X!R!LV=Y]CF(XEG%T*=!LK+!*0-K-JHYED&AGGR$K*-M@*)YEC
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MRRS2MC=)+(\LC8&!F1R7;:,!03P  O@!KH=V<Y=BQQXL23P !DG)X  QX #
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MQO+#-*J00N)G@9V'>]XCY$F\I+MVF2-41B0HU!G;N^ZVH4]&17R,GQWAL$Y
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MPOEKV29%'BT0PW1J/'()Y18MBUHW3;V4!"SR,",8$O\ 9^K>H["HBMEUJ8(
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MG(GRB=XJ+:E+%(YN5NEE0(4IX6JGDF2384>&3[JM.4VOE@TRNC))&P$JE">
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M,#!SK/(KL076LHS2E8YS/>*@XOM!\844;&^V/Q9U8& V,P<*P. "K$\JWQ^
M4A3@$;LG=G&%.J,;?$\G_P#1\/+@Y],^(X^7GJF/ZN]*8GJ-8KKJT*5<.GR<
M"NBXZ,[)-;7GOLI;69$E<KE:\:6<*C DH(R,$<X4*HT*KR.K+?0SW.NI+?3&
M(5%9/%3Q-,_=Q"25PBEW(;:HW<X!)QA020-<XHVE=47Q9E7@,3\3!?  DYW>
M !)QX>ML#C-QWTC98I@^U3%S;#<HPFH,!Q<>D.I(5_C4NI#(@XIEF*'2;7GA
M C6(YD%I P[.L,1ZQI,7W3,)VW2V5%HJVHZEHI)%#9D@8O"VV62(['(7<-\3
M@$ @^1.N=73/23=R[(QVAE920&4YP0& 88(PP(!4Y!'&J8WK'W-19<N+C'\?
ME'EU&*XJV$-)#(Y#Q9-K96=H^%]R-C9!1Q028@ACDO)[3O<4:-8546W:Z/+'
MKS\\^'^<#CQSJWEIW6>2ZPX.<?\ +-?'KM:GQ;&]66.RIECCMU=2LDQS[",2
M?C]/38U&/</ER1!A"FMB!4KH!K'S+$&LB4+*>DC;Y:^JHJZD>L-=130T<:RT
MT CK%1GCFDFJBL*+&F]E+L$[T1DAF51JOMI4S-&\0E$B$*H1&8, 26#.R[,+
MNY&_G'PDXQ5C]<#;%EG?,JVI?O; $*APZ@2QI6']FL#<236L\"K6,8#VYD&!
M/^S<28!DX;'/"Y!C5K.L:G79-+&'[SNY&C#\ ,$)3<-OPD':2"N5/!4D8.J)
ME"LRC@*67GGE3@@8R/D#X'Q!\,=&7AJO?B)Q;7_]W?2_^-/]SG&_U_MZZ]<-
M1&X3SEY<T,J+O+,]B8!G&H+_ -478W R9I$NM*_&\@Q_"DWADVIL%SG#-BU5
M^*=:9/C2UU7<955Y+1V==<8^.\,$M/)B"FHTTJ&#>MWI?,<@R*N-J_(J_&<3
MV#Q_QO)-B5F<X3E>"4>#<CL\R[5V%[(GY/12C44JLI<_QB)1Y:/'K2^H(4;(
M:ZVI,OOX<>=[#33GG\HM@\@N$T+DIH2CV+@!\NM[F7AD3'M7T.]-D9'KRJSN
M\Q2CRS$L&L<PP?'7KG]/6UN;T\BXMI\>JQ.V:0]=.F/&4#36Y^F[R$SOE)PO
MTGNG:<O%96SLDJ\DK-AAQ"IM<?KJO,,/S7),.NJ2QQVY(:?CN64YZ)*_-J!3
MR(=/E\>[@54F55 A2"--:)ZOW^]A<Y?^3KL'Y_A_L6[Y_1?\7_/TTUS!>+V(
M8]EVRX:7\AS7T$7]I*:O'(6,2SN*N9#)%"A&I[CVQ$]R<0(580K8_;R\$>U=
ME]E5AM%^ZF,5W8-'1TAK*6F9]B5%3'/"H,F&4R1PHQ=H<[7R"X:)9 >$\TM-
M25%5! *F:G42+$06!&>6*C)8)YCPY!(.,:ND^G+KUE+J3:7+K,;V9"R0UW,Q
M+&;"\FO;5W?>"Q]TRQ/*DOBS+&;DUKCK*ITP'XE'MJ]CJUZI)DN;F/:O<9#5
MTG2=JIN^B6D-3)%3+MF@V[WAD@*("BI34]09%1Q&R2CO""BYNL4]1+0Q[X]]
M36Q/+)RRM&HV%"I! .PI.I4KX$@#& U2O6MEG_(;U%,#FW]K-=GF;<AX$FRG
M &YYHC*LMB^3#&)JL[1H=36+7.:G9&1!O5R*B.[Z#5V#I*K$.I$BR*2&5P59
M74C!!!&X$8((\M6_)\5+#!X(.,>GAC!SSD$<_/71TR+CQ09[K'&,4GVMC1PL
M ATD2#"QB#55=;&/ R&AR0LJN#70X<R-*GDJW*3VIK8['%4C@&59 95]MW4-
M902U$[*M5/4B5:BHJFEGJ)@]--3H'>64JXC[X,"R,^U=@8':RUE-7-3%_@60
M2(RN6+ER-KA/BS@!"_(VY9?AR  5I]R] 9S8>OM<5,0C[&UB'C;+9,9&=',V
M(_%V8_&.-C?\ JSI33,*WLC?-7]NS7+U81@?GGUQN/'/G]3R?'5%@^GX^7XG
MPU<SL<?KB89<!\[G'EP['I\BUBQV_;Q2_<0);A09Q$CE:62XBK.;&CGCR!F6
MODG\A'$TG<%>.+>R1E:@%(F?^M!$Z,\D2Y##?S%WC HP$B)ED9EY%65<LH 8
MX7(^+CDE<'P(!&2",Y'CD:I1^FE=Y#D?KNY]9(\\5L_,-QNR)D #D;(J(GX3
M$<.2%J(Q!FD!BO,KFHU2N56^*N3MULS,=SLSM@#<[,[$*,*-S$L0JC"C/
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MS%?Q,3W^Z=T-\&RANK!B(]"#C"?9'BA<-SP,>AW-&KSJP;\Q[0IJ&CZ2O*U
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MS5%3&D1F>.)W0PJB8",Y$JO(DF48C5(?NM,JQTJAR#*TLS>$CRJJ,$7<<Q;
M5&[EMS'"XQJTSQUX>Z3XD:SV9$JI@+7),LR"Q+87]N>6V8/$F6$A,2Q@R>^D
M))53 GR8QID*-&_%+&0DDPVM4(Q8KU5UE=.J:JADJ=Z0TM.BK2PJF&JUA5ZF
MI!&7".\ DVLY,,2'!XRT/."L<,$8AB4!V1%4DS<LSAN20IXC!9L*">26S5(]
M2SC/K[4?J&<4L-U3"?%M]SXE<.2EL;Y)"?BN16\VMQ.$PTUZ-KQV$Z<>' :<
MB"<1XAD,B,4C,@Z?Z^J#U?9KY?W5HZ.DDM/>TT*IW=/-'5(DTXW_ !B*:I+R
MN/C$>_8C' UPG*5Y,=2%19,J3&"BAF.X.^6. '4%L8P,E0!D:VMO%/=W\G5U
ML<F"VT>AQZS!66R2QI!FP%+ !8(4T.<Z-)*-X)0',=%8=!-8=9?VRNBI)WW+
MUOT[#7PTDEUI8VGA:HBE:5/N[H)#'N$H)CV[@PRS+N)!C#*KE*\VB..F6)JB
M$3.BLB&08[H_"0)6'=]YN\%+@!0V,M@:A,YQV+HN=T^#2HSX]IB,$IK<)58D
MB'/OVADLA2!]U<$P8$2)(>)ZH]B2V-5C7+UIOM?ZDM]XJ[/14$\-4M!!5333
MP2)+"&K'@18@Z$_&JTA=QG;MF0YRI&K8*5*&,P*ZR-([3.RLKXW!50%E)&5"
MN"/'X@2>!GJ-\-/_ %0^+7_)VTM_[N<<ZTWKAIR?331TTT=--'334;_J_KV]
M,+G+^GSQTV%\_P#V8OZ?X^FFN:IPVWE><9V;-W7B.3LK<NJ(&(8U3XHZ0$8\
MIC7F2"G6SYD5Y&GEPJR!2%%YQF.=%D60#/<Q$;Y--6,.2/KXWF#'Q?7>O\+G
M0(&9:1Q6ZO,\D%!87F-V>P,:CW->['Z4CXD2:*J#- 66.39 625J!8J-'W>_
MW[]_IICW[^O/G]>-0N<9,BR;0G+#'>6,'/<?S3 *"[J\HR_-\GLOP61DD+,(
MMQ"R/'35*/M+<V=1&3IDPE+!'-<-\:OF&(ROG >^/EX\$'\1@@_4'GU'CJ?]
M^O(/!^6/$'ZXYU9UQOUV=33N(VT]FX307=EG>'9548E P68QT(DV=E=Y(K<)
ML),WQ<Z)36P!+,F/\'%C/%,BJCC(WRG4>_?O]-0<\I^7N88[R3V=NS;F(8/F
MN0;1QO'L%Q[64@]C(K\2H<.M*LEEFBV0)8)5?<VIQY+5U$2,='O'8.GS"H(8
M!%NMFO5RL-<E=;*J2GDPL<RH1MG@[V.5H9 RL&5C$ "5+#<VTKDL.Z&5H7#C
M!&""K*K*V<<$,",@X.1@C'!U)97^ICIC1E%Q:Q+B!I>G-E/(;'PWF8WV0QF1
M[(59"N+J*F/6UM'(.7;S8N1QI=<P1)7A"@1?N'(^24+G=][ZDO'4,HDNE9+,
MB'=%3[B*>!MBHSQ19VH[A<LP Y) P !KG45+SD@A$C!4K&BJJKA2N>!N).22
M6).>/ 8U!AA&^G:[V?N+<?)"V@9WD7(FDOK^PP/&O<F9)6Y9)N&3<5G&NRJE
M=B@*QL8\ D)[K22:B,R,:.R0-$&Z>ZBN/3=<*VWR>(VS4TA?[O,I(/QHKJI<
M8.V099 6 \3GE2U<E*S%0KQNK))$^>[<'!!(4A@RD HP((.1R#Q(;G?-[CIQ
MND\;]UZ(P"QRO+=D0CYHJY*0U?287"'.L<7N( ZE9$V-.L*JX:4, ;U&/V8
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M(ZK[K$E1&#)C<5D0EV4!#(S[,J-S9[4! RA&+A8XT!P1@*NT#GT 'AP#N'(
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MR9/DL/V5HFF;,N;:HQQJ.&Q1/C"FJ9?<4/=II&2?2J<MWN<J\F^-2=VHB?\
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M55#6Q&2"JHJVED=)H=\<U/)N$<L533SQ,HV;FR5#+N;J>0,C([N' @A'*L9
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MXXUSNDE8J@QC R%9LMX *I/CP "1]]Z9#N;6.:W..-VQL)@!#@SH;(N>Y28
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M!5 C>=C)A<,P8G:"PV@@ $\@<G./ZO,G U4Q]2SBWK?CYRBG:TUQ/M_N<BE
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M ). =4SN&5!W2(47874MER"2"P)*[L$Y(QY<<<OF^F1U_</T_G^6 G+")<;
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M\.\ F66$RA/NZ!#N40N7E65U)9048[L+W;::>GEI:AYHEE96$T&TR(5W?#L
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M &1[1U!+;)KI1S(1_,CG>TTF 3\*]Z /YI.G+\'J\D;G+J*W'#;#@9*NR[
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M/=*KU:SQ5B(N\NJ+O+8'L24/3M9?'O-\I;14"DE5/X733Q2RS7*?<A!AIQ$
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M$CJ>1)><$:2UY;7V?]64O2MUJ:FX+/)1U% :<K31))*)8YQ/"0&>/Q+2H<N
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MZCV&(EA)J=CP)AFQ0FQEA9)(T,IRD9'&1XA>97-:-KGK/OW[/[!I.HG'SG;
MPF9@L#C1R'A5$N_CY$(\?3&S66=?:!@2JU7UU@/&QFA E1)9AS@!\$E_D]Y5
M1B-Z::T!>'7+YL@14XM<C6JT14\_Y%MD^2/]Z*]A$[XT[L_R;W[HJ(JI^G=$
MZ>GR.1\CZCT/SU()'@2#\CC3D]]\=>:6/<D<FV5@W'/D VQM'8YDT.TK]-Y[
M9QW/RG"*0ES$>X>.2(Y'#-86$"9&*BN$891&8TK%1( QP.!C\1X?[SG/.F<^
M/)SG)\3]3I3\IXU<LZCTW>-D&@X];Y#GF,\VN0V5+4Q]0YT;(:B!*U5HR/3W
MTBG7'C2X\"5/KIH*Z?(C)%D2H,D82/+%,UDZC34]&\9>9.-;VU9G5AQGY()(
MI]GX??V-E+TULE7*(.1P#V<F4<N-]U:^*LA2O(O@C5<YWPG3_(/XCP/U'D=2
M3D8/(YX(!'(QY^HSKXYIPZY@4.RLQ?1<:^1?G39YD)*:XK-/;'5CD@9#,2%.
M@S 8YXD$5@F'CR N5CVN81CG-7OU 'Z'(QQR3G)'AD<<\G(SP="21C.0?$>7
MG[_ZTN4WCYS+USKC7=-AN@>2DK(<B.38V63$U'L:6.MD)-GP:?$XP&XZ](48
M@ FL\CBR$4MA*E1%<T<:.'WLDMO5W4MH@6FM]XJZ>G202) 2DL8(78% F20B
M(J%_DC^4"H.S)8GO%5,JJBOE%.0'2.3'() [Q'*KZJI )RWCSK:.06B^8E?R
M7G[1P?C)O>53W=9@%]&I*_3>>%I/V?ML$HB6.&38@\8-"0,*2:PK9L"4(IHY
M_?<7RE(YW5FK:VKN-5+6UU1+554Q)DFE<LQ] ,G"J/!54!0/  :ZY)9)6+R,
M68X&>  !X   *H X    X  TD&8Z5YH;$V]'V18<0-^4K/Q['30ZB!IS8@X%
M/44!8$>L@1F-Q5C4%#AP@L1[6#]QZ/(K&*YW5)SS^GO/[<>AUUZV#<''7F1"
MW1R$-2<6][6E1L#)\YJI,M--[%F1951<9-^+,EUY(V/)'>1'QA)&D.<<;6$<
M1B>?B]DZ:QN,\<>:&=[TUAD&1<8]^538F<ZXA 46G-CP:C'J&CR"I9%!'-)H
M4;#@0(87%>0AD8/R*]7(Q$[, > QJ<GU/IX^7IKTYKI'FKCO*#9.U:/C)R%M
M22MEYM8*T^FMCS*[(*6SR2Z:>LEJW'#!EU=E5D;&5$0HE X9 _*#<V/#]3\O
MG[\>!Y#3)]^_E^?/CI*,OT)S=R7'Z;$HW%/D1C^$T8B+ Q2FTKLT-<^7(.65
M*L[)5QWW;2Q.<SE0\QY4C#:P$-D<#&C1CG]QP0?+'TY_Z)T!P?/P(X\P?$>(
MX(R#X_32E9_Q^YHX9G6@\MQGC%OZUG:^U3K*0",_36R9U:EP&'*DVL*P%&H$
M>A#J=L:T"I0RO;1HBN8YC/&MJKC7UT=-#6UE15Q42&.D2HE>44\;;<QQ%R2%
M.U?$DX51G" #F\LC@*[LP7^D$D@?N3P "2<  > &'^<9>.G)(?HW^J3B][Q_
MW)49WG.Z>,UUCN'2=69M7Y!D (>9P9UQ(QW'ST@[*SA5;'$),)7QI X(&^1W
M#:WOU1^^<D_F=</'WX?E^VH6 <+^83.W?BMR-3_'I+9*?P3Y1<:3^W]%^/XI
MTT\/#Y_KQYZ<CCW$3E@WCCGM1(XQ<@$GGW!KNSA5[].;$9-<"-B6>Q9DP$5<
M=0Q(XUD1@2#L8X8WF"U[VN(-KHP,YQS^I^7/T'IX:$Y.?T]X\^?KK3\(XT\V
M\$OXF28_QAY#@L8 )PHZR-(;(/&5;&MFU$EQ(S\<01'K!GG&Q[T[L54<BJJ(
MWIP<^H!\/$9_?CZZ9Q\\X)SY_(_C^>E2IN)7+"1QLRB@D<:>089U-N;"LFKZ
MTNGMAI)DCN,&RVAM9(8[L>]\P8BU54TYA#<T3Y(4*YKBC1>6"06R,+MSD^(.
M0 ,^/)\LX_'4@$J3GA?+TSSQ]<'\M)18\5N:MI!IJJ=QSY,'JZ 4P-)!+IG8
MY8U6&=(69-%#$N,*@6RI3E.;Q^7O[=^Z,;VXX]^N/K]/']=<=+)2\3>5T+C-
ML6J;QPY!MM,CW)K)KZ]-.; ;/)546*;$GNELAKC2&?"#82X@BG:%P1R#B$\B
M/>-JO#_)^I]CU_NT@<CB'S$/$A5TGC5R7D0:\\B3!AGTYLI\2(:4X+Y#P 7&
M48%\AP1*=1(BE<)CB>7@B=/'GQ]^_P M-+%Q_P"*/*N+F.18S=<8=_Q\>V7@
MV58';%F:;V-&@@DSZ<]CCDV08F.C$)*_+*NBDM.1S6B1KNZM155)T]^?[>_Q
MQIO!^&',!R#5>*W(O\@GM5$TILE?%_M-:J(B8W\]U14:J?'[_P!_S'!_3]#_
M */ZZDY^?X_0?Z_#&NK)Q&KK"GXJ<::BW@3:NVJM!Z@KK2LL8IX5A76$+7^/
MQID&=#E,%)B3(D@9 28QQL, PWB*QKVN:DZC3ANFFCIIHZ::.FFFA<^]W9GQ
MLX7\E=]Z[93ESC4VI<KS;%AY!"+94C[FFA+(AI:0 R819<-2)_2A'+CN>WNB
M$;TTU1:7ZICU,(Z"]RAXY%0I/%#?R;WHVL:[R5/)K,U=_@HWY=W^>_?_ !M/
M3WYGWSK=G?4R^I\W!(><-H^-;H\VRD0!Q7:UOT]M(H$,\JO_ &]:XJ$[JC?!
MJ(-6+YHON-7IJ<>0\?#V??U.DY+]5-ZFB231FX]QH8HFD<K_ .33)'?^3AMD
MHB>6>=NSE56*JHO\?E.FHTL=Q]1[ZI-9JFAVAX\7GQKF[LZ1]4W6=\LV%(@1
MVR1E>B9T\9 2 D'V<YS#--[@W#5C/<6 <Y\>#Y\?/]]/3Y_Y(_;2+F^J:]3P
M1BA6OXV(01I@G)_)=>+\QU@HGYDSKLB>4IZ*J=_AJ?O5.ITTN>=?48^J7A>L
M]?[%>?BY81\XCY*1T6-J[)VDJI./W<RI2(<I\T'%E/F1P L@NA',C(\M@S(P
M["C8]^_?[:>_?Z:05?JG_4\:<@UK^-;D:66-.^K;Q%58YPC1>_[=+V[H1R]^
MZ_"=^W=._33Z_/P_3]=+5D?U%_JV8UJ/"-RS:/C3^R><7.64=>;^2W(6N!.Q
M/\%?*8?SSA&N8<%[%, C.[%1'HBJK7(D8^9_3_&GOW^FD=;]5#ZG#9)8ZTO&
MHJC+(&W_ ',,@8KO8EBC(OY<[_5Z$\NRKV3LB=OW=3J?W_M^7]O34\?&3U9.
M:FY-3Z"V-E</5]6/.-=7659W(J\'FB@K;0]K[)PRN@4C).1F( DFGQBI,0'O
M2_$Z2CN5C901IB-N3K3JSM8LW9[TJ+8M/+;J>_7VLK89)'MUDAK'CKZ@2(^U
M9:@+%04$;(2]74*WQ)%+MS3M O/9+V9?9CJ^T*^?Q.X]K74?5EVZ6Z$LM+<H
MXZ%$H*.WU51?+G0=R'DM]M2ID$K&JB%34S4T*LL25#Q/$M/4#Y$QH85A0\(=
M,L/<%5NF5)DC&E-'[C126022Y<?]48Y61Y"M?^K>R_%-V_=:W_L>"%^S.*AI
MZF>6*DK[AUG2W1Y4A :69:&DIZ)-NP[T[ZNIUP "P+!->.NRWM,N'6MQH*:^
M]94UNM]3,D59<+5T5)<IJ,29^(6][U1O4&,C:Z15.X\E-V,%-+#U!^=< ZC-
MB.HXU<:P6) N939[@68OM%F?=UX@C9+%$&%6L,2QKAF8;NUP6J,OAY#LWVE>
MJNHKFM!;KA9X:US3F2VR610M ]76BABIZFK-WDBD/?\ @:>ID4Q /WAW1A_H
M-U!8/LT]$=#63J&]]J/:EU9<;Y!6"->E.@K1;#05M#1+6RTUQM]_KT2F>2)T
M>+9=*E63+F14#,%)KN>_)<OM E1\*4[G! ^1'QDQ(;I"QRF.\+W6S7/CL< C
M&N5&O<JL7P:U>OI-T;V5==7SI>AO=YZD[/J:HK:(50AMU!?J^.F9)5@E6:<W
MBGBF*RL4+0(D>_ C9U.[7S"ZB^T9<Z*_W*AL='5U-M@N%1!;Y+G245+<9Z3O
M)&I#4T]/]XIXJIZ55GFCBJIX5V3;92%4-FB<W^1J$>-UQKT7BP3WHW$CJ0*&
M\FL4GG</;X^XC&(J(JO5WPB(U5ZPNX]&]7QW"\T/_O\ T+;DME/2SB5.FKO5
M5#"KK'I8B\$O49CB21E'=2R.PD(<=VI0[KI!VZ=3-#23_P +6;[RS*R;8(EB
MVP&4Y<(Q<JWPLJKGD')'(;]LOU'>8&+P,EOZ2\U(VMQT<<AJJTPB:D\X7R8U
M>DB'*;>>U)?(DG'*^W>,"ACR0M&X_@]_7CF[]NW5W3_4K=,35%EO+&[7JUTU
MVI+=)!'*UHK*FG)GI?O;=PTD<#2J%DE 1"78-A3],OLAT/91VZ24'2?6'0/7
M\'5*O1Q5W45@ZBHY+"1<Z.^W:FJJZWS6Z&HM%)%16J.C$D51<_O-9/&VV%)
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M(<0VE*U'=7>@L-XNE'65]NMU364E  :N6! _=Y4.0L>>]F<(0[1PI(Z1_&P
M(UW)"\BLR -M) 7<N]R!DK''DO(P'+! Q QIMTCZJ'U.@G4+:_C<Y1D4+W)J
MR[5%<V>R,JM[9RB=D&O?OW7OW\E^/CJT9S_L$?W_ %]#P>==1!'CQ]>#XXQC
MU\\>FGI9!]1)Z@-5P7U!R)# T,[8&=<F=SZFN!.UY<K0MQ3 <"U?D=(Z+7)E
MZ&!:NLLOMTFRUF$&>*R(,<<+@O>1J--%+]4EZF;9+0-K>.+O>6.,+6ZMO7/0
MIC.8J+_MX17+V:Y&M1._?MW[_"(]1@DG 7&/'(R,>))'"X\_+P.N0 /G@G
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ME1^ ECEC9IA..N<&SC@;[%J.PMSQ75,IZ/<]&Q(XBSXI'=F!17!8JJ9[6:1
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M&9MK1+'[=V&2J_\ #YA@294PL*+$M8SE>I*Z=. :N:^*203\.KX##L"Q6/\
M0ER[)>FA;Y32RU5)4(FX5!D,ZJ5*NQ='!(7:I7(?$6YW W<ZKH#3U,QIEH>Z
M4Y59C(=__$@YD.QFXQM &X,0B[R-0L^I)L?%=T^L+D%]AS(*50+O J [JX*I
M&F6N*X37K8O8)6,:CQE$.*=6C;V+&<]/T1>M1=(4;6OKJR4MS(IY(:F.0[B
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M*J-16_X7DU$5R6?J>JFH+!=:ZG@EJI:*DDJQ3PX,LRT_\V1(]Q4;C&K$<^6
M&)P=$_:AZ%N?:1V#]HG2%GD:.X7"UT=3 JG'?K:+O;[Q/3-\2@I4T]!+"03@
M[P"".-)GR!G5,G(<_/6&(6LG9E9?A!7#]IYP-NRR(Y'C?\C1\:.XKF._,Q$[
M?+DZ]'?8SH+[7=K/9C+#3PFNH*.>Y7A)G+14M)_ JJ"XL'3EY$^]]S3E<JU2
M\.[^66.M/]O]';>@OL25_3'4$SPR4?9_T;TK2K2%6>>^P-9HJ*!"05: U=)W
ME41S]SCJ&3XPNM,PIJ-QV&Y%56D?*>U%3MX]Y14<B+_PFN(CRM=^]I$3]W5W
M^U75TE9V[]<O20]R(9K32SMWJ2BHJ::R6Z*6H!C=U0/M5>[W!U*'O$CD+HN=
M?8OH+C;?LU=F<%RJ._DEH;M64Z=S- U+15E_NE134CI/%#(SP))M:388Y,[H
M9)8>[D;QYXIV544H#D"H[ 2N]HKA.7N$_@Y',5KE<,B-<U$5%:O]*BI[?=,D
M^QY2=/W7M8J+'U%8Z&^T=ZZ2OE%'3W&BBKZ6*2-J.KD>2">*6)1+2T]13]ZP
M4J91&C;I0K8K]NZX]4V'L,_]GZ1ZCN/3-SZ:ZSZ9N;UEJKY;=6S02255M2GC
MGAFBE<+5U]+4O O>+(E.W>1F-6(SV/S"3Z:!*-Y*5X5&][E15*\#W@<553M\
MD<)7N^$[.541%3LJZG[;>C:+H#M4ZSZ4MKA[=;;HLM OG3T=SI*:ZTU&QVKE
MJ*&N2D)Q\7<[B22=;E^SQV@7+M1[&.@>N+S&L=WO-G=;F4C,4<U=;*ZKM-35
MHADDVI62T+58 ;;_ #CM5%PBR9^F[F1 [YK<3EML3K<5&8S8DN,)93 $KM>W
MX2!L?(C7 @DC1H@Q2D]Q 'CQPJ-6G\QX[V6S5EL[1>GWM\L,-/=!76JYP/.:
M?OZ=Z6MKHS$JJRU$R5:=Z86VELF4/NC*OY7^WQV)4?5W3W2O:S#<Z.VUG9>]
M?%/;YX4!O='U%5TD*PTL^]"E925CRU(B*N)X9ZM@4=,O3RXPUX+'>N N._P?
M76LR[AO\E:Y+*E@3;2O>-43NTPID8)PJBL[$$UR+W3L[Z,]F]MHKKU=;Z6X1
MQSTRQ5<Y@E4/'-)#3NT2NC*RNJM_-*-A2(SDD#:WRUA<1LTNT,T:.Z!@&&X*
M<$J<[B"=P&#D@9&,ZL/X9S!Y!X-C]SA%#LO)4Q6YJA5=G26*BO*X<".I'1_M
M4L@2S4RQSE9(:>M+#<0H0?<O,,3&)ZBJ^A;%6RQ5S6RF^\PR&:.>$=Q(7.%;
M>8RHER@*X</A20FW.=6W_P!R@BK4CKEA$CD+%),OQ+(V%SD%2SGPPY;( R"5
M U!KNO"+79?-%<:1L\L_:>S,3DN))1QI!GYK<52V,D2M(=[XJ2YDY8G=ZN9%
M$P95:\3NWDCK"TBR=2W>W*28XZII8LL6(AJD2JC4N>2468(2WQ$J3C&#JZ5(
M3O6:/_ZY-LL?F-DJ[QX\XR2!X_TGD\$WW:7TW-&;BP.9?7F,WW[:CU]CN.P;
MFMMG0(Y+7$: 88E@^N:4 9$BQ8") G2I)/(PXK48:.BF<^ZV'K^_V6"@M\-1
M$;?22OE)(1(XBE?)0/\ $0D:%MBJAP225<@:[Z>O>+8DD<<L6!&Y;O!*(PX8
M,'1U;,7_ .6HXQA3D 8J*\Q^)^XM"<L>)/\ *51BQFRSW(L+;5=Y<2R6*M;L
MBK*^):%@/DPTF1PV##NB@E2%8$K54G=?%*_M/ZCL_4=WM\MH=Y4HJ TD]1W;
M)%,W?O*@B#@-B,F1F8HF>\ _XG;T2)W:LIJA5,TTTN_XAL25E*1 D#)C(<M@
MD?'C+ 9-[_6>,2*'6^0W-D-TJGJL<G6,-1H8LF.%T$MF:*@A,(0HAA51B8$+
MRJG8;&O[]EUQ&G?30P!E5ZB5((RQ"C?*=B\L57Q/F0/7C.NJ.-I9$C4[=[*A
M8C(4,<;C],Y//@.,'G5"C/L'A;.]1#CYD&32_P '78^YX,G+9M@L>$R!6X[F
ME??RIEF=XPQXR0HDPT22>0T8HP(K?-&"%^3<_:M8J:C@Z*2U0F6I>US6MHZ9
M))'J%MZ49IBBIN=I-M3-M9,NZE5)(4 <W6JDJ:R.2)@D=68*)%')ITC3NT"G
M!<Y#MGGXB6\\:NJ8!ZHG";$Y5MA]9E%T]M'0R[9<J'BUH#&;4\4 1$JJ81(H
M[4MD"*AS.?+K8<24\)6ULN=(D@";%SV8]8_=8:J:CB$\SI!]W:KADJ8]PVQO
M,^[N^[R F1)(ZY4R(@#;:Q:%IR1]Z@:15W."SG8JJ68NY7&5X&U2S$L-HQJB
M3ZL>P:[;6_2Y]#CGBOOGV\N*(PPH85&:W4-2*25B>;Y8U'*<9'HC6^Y\?F5Z
M=5_:'9*3INU]'VB-F>K@IKH]1)E"KFHG@F=O_P"IAIS)W8Y14^$$G7&L"*D<
M2Y"1911MP7?;&T[G(RI,Q8*#X+QMR!K3,U=Y>DYQH3^'.+DVBHO95^-0:#3]
M47M_C^/UZU?[^>J ^/'A[]-*)P\PME)KUN25T9UA>YQ((0JC;V,"%761Z:NK
M1HKNY5=,0IW>#?)SI36?/MIV]:]D'3E-2]*0W(LAGN\KU4[[,,(X9)8::#.<
MD1(LD@)('>3R  J%U8>H.I4L4<,..[[R.:::<MM0(H<X8D8V(D;,S,< ;FXX
M&I5@:+I8FO-D4>1)%R7;LK%*^QB8JD.4J8M7A=#M+@;93T6).L)-/*8TK0^8
M2L5\,*E0JN?K"U?:N[+;_P!H\'9_;[C5T=";M<+#'U#64]&O3W4EZ1I;=%::
M6H>5JN.,U\<T5/4R000U<\"1HYAF5GQ?J/H'MSH[%T)VWW'I&ZVGLAN-RB^[
M]0QU-+4"KI*MIX:*Y7*WT\KUMKM\TE,S0RUT,:=U,*B0I,(8M1=<7<"N-6BV
M9%NHRQ?VAR:-60?,:^,JLQE\Y8\R*][6$6+(/9$]M[AC0WM,<U/%O==D= =G
M[=/SWROGC'?-<:F&@(YQ:T8_=W&X;M\H=PS?#\"+\/)+;%J[E2VR1("?YEP#
M;,$_!"A5U&<D#>6!RW.%4+@$AI=9_,W965:)L^.&;!H;C6\MV,K1J&K% M<.
M#B\.)# *C/%:K"MF"KX;I+IXI1_?6<81VK8RD?<3T514MZ3J.W255/=(TJUE
MS*9(:MZIG?=.C8 ,32N4VX7&P,K=VF+Q3U]'/4AJJ*,!XPF]&9-P8[AO3)W_
M ! '*E'4DD$C: ]CZ:>'$F<?MPU-Q08[*+C6U,YJ<:OI5=#-E$**>/CTNQK6
MV+Q+-% GH,+SQAE&%711=VN3Q5OE.X3W.+O[;65%4(:>JG5J66601+.M1-OS
M'N*,PJ'F)!#;79P0,D:H9)JE"R&64*)&. [;-PD9B54':OQ,3@ #//IJ/[UB
M-3WMWNCF/#H,)LYM?1AAWDF/75S;./6CB89CN0"LS/JHOL5P#M;]_'=(:THF
M$6/)E298Y)';_MU7;W[)/NM=5TP>>QW*.G[^7N!)44\U7W$4?>N'>6*6)$41
MDDN@9%5"H'.2GJ)7AJ@1W"P*DK,P&\?=5)4LS#XLA26SXKQDC&HU>"N)YUCF
M*R;O7D'(0YOD\J=:^Y2"/]\3&:X#!0VR$5/;6O<L>3,"QZ>,ET@3AM(]XD6\
M=F73%LH>C$J>HZ*W?=;S6PUT\5[BIY:<M'4PPV@F.M#(K]_'#4T19>\6IJ5:
M,]XR :O[2JSI<VJ.W=1O3")*@5$:U#-&(ZB=&BC4.N'W"G9RY1@%ADE9R(@Y
MT\Z7K/>60'O<DNL/R:?.$206ZM;AX02#/ -Q3MB,G'"^8\ 6N>*+ 85!C1C!
M#1OBWK/[A>^C>FQ9+557NPV&*ZU*6GIRVFHI*&.LJVW"*BM].A1&+.O=JD2[
M=Y$6 [JK818.NNBK)!24%JGHWB'=O**-9*J*&-W&9:N2".98-^YF>:L=&=MT
MKN<.X;IQSGR<4P_:#)"BOKC/[3]D;V_R)IK2_AQ-<Y[E,FM6JFF,J5I)HI[0
M3TBM4!H3!QAL&)/'JP6VPPU%=%>YI:XW.C>YVJ1I:AW2HIJ2[W&.F,R.,.R*
MS-$%*QHC((E557'HN6XP4T:N SM4P%%<L%3NI%+*1&@7!&XD$Y)4@8(!RN%Q
MG&1GT_FNI:NP6#7YJ.6"4=ZH7[9LR%]F]L<*HG;WT1OW"/>\;F=U8(9>Y5CJ
M#HJU]33PRW*)V,$,L<;1LZ%6=6 D;# -L;8RJ5Y*!22I(UP2YT'W9(*G^84D
M<Q'<59.]VJ0OC@ @2!1M!.2>,Y2'C+3R<=]%#U;**6U4DTV]N+%8?NQPT4D+
M.:^.]W@Y55K5<)51.Z_"HO=4[=>1KM0/:KI<+;(=TE!63TCML*;S#(RAPC%B
MJR+AU&XC:PP<>-+,G=RO'D$(Q4$< @>!&?(CGQ^>3J,;AM7Y5'WI@N=8S]N)
M-<WM?E-G+F,&^..,%Q!-A(-RJY3VJ*2$![&/^W5[I3VN&!6NR/HGHZJZQN$E
M/%*U/24:++6U(4.8PW>=S%''O0O),\;#(9>Y16E)#*BM >&)1-4RF& 21H[K
M_7EW4!8^1EV&=N< $<YR,3<"3*=J9G-%@&)Q(]BI3W#(-(\%;&JF&EN+[QK2
M9("YOC*D-:!QI+?!RBCQF#8P V>J9/X/TI8A7=2WRGH;52+34<UPO%1'%"6E
M:*D@1GD98M\\KQQ <F21OB)8L3CO6/:5:[ L/>!HF<K' T$,M14SS)&S@E*:
M"2>239&\TA52%5-[  9TT:DUS!C;TV9LO*(Q#YR2YKI$&QLEG2ID>7,J8M3?
M*IGF.$EH>RK[!\B:=%.)@S-]UJ3&M=T6WHRU4/4%^NZ4\)GJTA>@D2,HM-1_
M<:2"6.(*_<'OYX)I"\<:RHDIC5N[=@]0.I)IZ&P7JE1:E+M41K/,A/\ +B[K
M D.< A]J.&4%G[S##:I(<CEEQ32Z^M+5U,F#;J"0N0RGS&&C6=C)DN<R17P1
MQP#JXS ^*K&8XC?>(1!^T!@F)?+92S+/(LTPD@5E^[J5(:.-%QL>0L3*Q(QN
M/D,G<2=77J2XQM2":")5GF7$@C&%9Y,#<J@MM 8DC^G ^' QS]O2=AXI*YT\
ME8FR@42:_D:SMR7TS(5CK"B6=(M!?U<T:RE<K94,-58V@WA:KA?9J]B(_P!M
MJ^:^M*:]'K[J.[V2&8K1U]FH&-.["1I[E04T<$(C7EXIT22*5O\ ZXMT?>;0
MX.NVUI6+34;IO,\--3JY4G+LT:J1SC(8$;RQ&%(;YBQ-ZD/*311N,--@V%9%
M2YQ-VI@=]BM*[#SQI5=3!A0'XY-F6\ION1X+*PDH(Q5(H[3S'L5@$!%"XZ6;
MI_L_ZCZ@KZVFJ1+:(Z=A)635D32.TE06FC2.#?$U06&YVF,@56.68NQ353)
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MJG]P3WQ UIC6-9&M9(L,;N<;9CMW "S[4\<]/+<T3HSY B*K(\R,(S7L1PY
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M-82C1&9("LL:*DZ01J\6-JH&6+NP[!HIZC#+%( 8G<[SL#.J.%$BH20"&"X
M<-_^J.6SI6Y^0.3[,@P\;*)*NAK2JZ5$$=#%N)X"%:R;/*@(Z> D<OL0F#0#
M'?TJH\B,5E5UCVCU_5M-'0)3"W4"2B6:%)S-)5R1D]TTLHBA41)P_<*A5I0K
MLS=W&%X2R0C>M/ L*O@.0V68*3A<!5V)D!MIW$GQ)QJ3KB0JKZ''JL]OU_EE
MXF_/;^.95??O^O\ 8J+_  ;\?V:YU3Y.<^?[YSJ'C5EYBN,9E5WF:8T++Z*
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MXW%@PHV6AEE%X-FI(L!->1QB$)**YY?)8/AY_7Z>?L?AC33=R;:^E*^X8PF
M;Q<20@RJ]T7D._NZ2TQ/Z1[LL[^:H$JD[]U[JBJJ^2JDZ9\OV']_'2Y4>4_3
M0&TEF%O4Z[W0[5LS),2E9*/[7?SSDNJV-=?@<IBKDSSQQ006$\4KPDA8YTV(
MP[#*\"->_P"WY_KYZ>_?^](0NVOI17.:W^3_ 'C^9T=GS#Y#=O[Z"\POTRU.
MR*UCD7OW1'*B)W[KU&/#D_Y^N<ZG.?3\@/[:7Q)OTUF9:"AYJ#4^];33NNLN
MMZ898L/?S35%UE$%F2VLN4,64LF%A205@6+/.4@(YQ!@,4;BB&YC\<>_IJ#[
MXQINZ;,^D\>5HVZ\WE[CV>:=H_(OQ5C0.F)V7]KT_0?EV^._FOAW_?U.-/IJ
MQ+P\X8^F1R3XS:6VCQTP#+R:190Y-C^LOQ?*ME45K'IJ[8N8R;H$V#:9"ZS<
M_P#;.9DL@)K$ACO 8*"(D5D<8\SL'7W4_3-";;:*R&GHS/)4F-Z2FG/>RJBR
M'?-$[ $1IA<X'. ,\XQ>NC[%?Z@U5SIGGF,:1$B9XUV1A@@VH0 0&(R,$C&<
M\Y>,+T].+@'TA!8;=H_'3S)-0Y^:Y:58IIP#QI!%<2W>IW*"2=@O?4B!\^X4
M&J-5,;OMRJ.I.K^GNN;RM-6]1]+03T]FJI*:'N*:.H+-(9*()]TJ7#-NC>>%
MWC;#*P*KBEM?0G3EFZ>ZRZ7MM-4TEGZ^IK=1]3P05U5%+74MJN5%=J2!*F.5
M)Z6,5]NHJB9:9XQ.].G>AL:VT?"S0(?D>-W"+V\?S95D#T[?KW1'3U3OW_?\
MK_;UEDO:1U7,")*FAP6W?#:K?&PX (W1P*=N!_3X9YP?/#(NP7LU@.8[7<1\
M.W#7V\.,#D9#UC D8X8@M\]?.?PGX_644\*7C-L^/*"2.=C,IR +G!*U&O:A
M SV$:JHG9'-<U[>ZJUR+UCM_O]SZFL5VZ;N\L4]HO=+-17&GB@CI9)J>H!6:
M-:BG$<\7>*2&,;KG)SGD&_6/LHZ(Z>OMGZCMMLE6Z6*X4=SMTE375E93I5T,
M\=13F>DJ9I::IB66)"\-1')'(NY'5E8@^H7#+0@1M$+&;)@V-:QC$R*[5K&-
M3LUC?*:J^+4^$[JJ]OU5>N^AZFNMNM=#9J-Z:"VVVBI;?14RTD&V&DHX(Z>G
MBW%"S;(HT7<Q+-@EB22=4]3V/]"5=955]1;:J2JK*F>KJ)#=+A\<]3*\TS;?
MO&U0TDC$  !1@+@ #6IY+Z?G%_+OPU,@PBPGI468+> U<IR(+!SHS"L$0@P6
M(V2&-:5RJ&0TH7.1KG#56_.#=4]/VCK)Z-^H**.J-#*\T(C:2E5F<ID3+3/$
MLR$1A=D@9 K.N,.=9_T';:?LU_\ :CT<9K5)UETG=.B;Y/WTE34R=.WEZ9[E
M24=14-)+;Y:K[I"CU=&T-3W0:)90CN&S N#?'0*)[>(SVJG9>Z9%=KV_L3O-
M7X_=V_@B=^JNBMELMYS26V@B((((IHV(P> -P.%(X*@ 8X.1K"7[+.CI!AZ*
ML(QC_P#F5:/QXF\?F>=9)G##0(V^ \7GL;_!N0W*?O[_ *I,[_K_ &]9;2]2
M7*B01TJT,2#_ (B@I2,>./BB.0#X ZHI.QOH.4YDMU8Q]?XK<1\O^-0/\ZUZ
M!P(XTUMW?9%#Q&V%;Y*^$^WE_M;DKG2%KXZ18C1L?9.'&&,"(U11FB&]WYWM
M<[MVLUHE%BZFO75]N@I8K_U!#3P7*KEIHJE)(J50L:PTU0)*>E!"IWGW>./O
M"B%\E%(S'J3IBT]5]&=#]G]YCJ).ENSL7X=+6^FJZBB>D;J6Y+=KQ-555*\5
M3<)ZJL5#WM;+.\<,<5/&RPQHB['"XI:&P6:N;1,>M@R\?K[B3]P_(\@F-%#/
M43H5DOVA)[Q'<ZMDRAL1PW.:]S7C5I&,<F87#M"ZGN=LJK15U=*:"L1$J(HK
M?10%UCD250)(H5D4;T4G#>7SUAMC[&>@.G;U1]06NUU45TH&D>EGGNUSJUC:
M6)X7/=5-5+$28Y'']/GZ#&J;QLV^DYBL\WZWWKXJJHY6"Y&N\5\N_9R?MAW3
MY7]4^/C]>L)UM/2QXMG/TQ5GJ?8L+'-;[U+KF@RC#+C.@#KN0KGANWBOZ/&)
MI3)DKY+8PG/M8JM20..LJ6!SQO(1CFM-),_:/TH0"!"[7>\V.,K%9Y0^0_=/
M.22+\K^UO=$4K'JY.R]T1J_/Z=1^?Z<^'I^7YZGU^O\ G\M+U49#]-1FFCK#
M(:K5>^K#4NJ\P<V0X-9R#8E?D.>PD25+8]N2H6:)\7%8K9;GR'-KD=&>C&,F
M%>@'/@#CUP0#ZX)P&QGG&0/#QXTP1@D?3\,9_+//Y:0P^U/I1P*#W=?;S:L@
M0BB1(O(=4\#2CPQN7MEOY7>\$O=/U1J([Y14ZG4:5_7.=_3'5==:;:P? =TQ
MF862+!E2"Q^0!)3!Y=#NJ%RBA2LF+%DQRQ63HDI#/:\:R0/"(OYR"Y*N5D8L
MJB-5;#,=TA9@NU% .YAG<1P @)R. 9 R"<@8QP>"?+CC'UY^9TCO\K7THCB,
M8NO=Y-<[VD1/L^0Z-;[TI\1J+VRSLB>XU>_Q_@*B_P!B<=1I5<4SKZ96SUML
M0V+ZFW_/U^V5BLK.3 J>0)Q1Y$.;/'CI_<)E3Y07AD6$QA70>WB*3VF=@O8O
M3\?[?EX?[^>FD?=LKZ3SW C=KS>2N,@RL[!Y&(B*0Y1-1W^V[NUR/&]%;W5$
M3Q[+V7X::>0S:WTVV-<.];VMSJ+-[_C;9[[VD# *W)\<W9=VD/;L;"==FS^:
M(1<I;>1H4O&#86$3Y,LM80T<K8@!R&27N::0L7)GZ3MJN1G'ZS8K?%KD)KG?
M7?N[NK6IWRM4[JHW(BHY4_*[YZCQ]?P)'CP1P0<8\1X$''.GCD>HQ^?I\];C
MF?)[Z7"MM!U&7<?LA+84-:"J -^O-X24BUD )2@B@,#,'#($ U(YOB]_9%=W
M=WZKJZXUMS:F>OJ7JGHZ.&W4[R!=T='3%^Y@RJ@L(R[X9]SG)RQX YO(\A#.
M<D #. "<>;$#+-R26;+9)R=:U Y8?2G?=1EA<?KT4ELP0HQ/Y-MY)[<D;AO&
M]'+ERHWVU<QZ.5$[?"JG;JFAEDIY8IX&[N:&2.:)\ [98G$D;88%3M=0V""#
MCD'7%6*D,IP000?F#D?(\^1XUNVR^1?TO>)YWE^/9YQZR$F84MY<0\C*FN]X
MRT/8U9BCGRV2AY:T4J.50N,"4-/9D@<,XU5A&JO95U=37U516UDIGJJJ5IZB
M9@H:25SEW(1549/DJJ!Y :EF9R68Y)P"> #M  &!@<    <:T:+RK^E,FE&&
M/QWOWE.1PAM36N\T\WL:)ST[IEWQXM,QRN5$1&KW541%[4^N.M\V+RM^F%IY
M\/",^X_Y.V3KJ'.QFNK3:TW6\=17AFS+<\.'(BY:@Y<,TJ9)GQY'O262&26%
MCF?'>%4::U[%^:/TLV+VH[C%]%9)5VR1K.J#,!K'=Q"I'N*HM;9QA--E1F(L
MJKLSQGO1B$:P[E$]A$:]&FOUF&^/I;L$OK#&<SXLYCC>04_DVPI[C4^_($Z(
MB1V2D4L:3E@7M:^,X9Q/1JL((C",<YCVNZC _/\  _F-->3$^8/TK^-9'29)
MB>A,BK<BI[,4^EGQM9;R*>+:1WB((H1%RTXB%&0S%\'A(CNZHK7HBIU/O@X_
MMI[]^_WUA[?DE]*/!FS(]IQPOPS0&(DP3]:;Z$41T,@BL*%V7#()[3/\'#<U
MBM>OAV;^B--/ITYN;Z?^SX)<L<IUCIFRKN(5+FNHP<C<:+ANV(I[W*9US%9K
M:2.LG9(;(9K8-HZ.1SZ>;$ !&JZ8,K.Z*TTQ%W)+Z4$#AM3CG>*I%1!JS7.]
MU:Y51>R(O[8*J+V3M\_IV[]TZ::5R7OGZ8J'I;&,G+Q\N%U;?YQE(::./76\
M.ZY?C]3CH[J1*9^U##*]M7=58HRDDF'[:2U$(2L,I&FDL7E/]*0,GL.X\7B$
M1KW*G\FN\OT9&9+7Y_:_NO\ 0$:K4^?GNW]W332VY/N_Z:+$M.:[O+OCKD =
M4[(L<BS+#V#UONX@#WE%-/A%Y*,JY,R1%GB;4L Z.IW!)"=#E-;YE[M::1@O
M*CZ4T!C!)Q[O&F"^6,K5UOO)7-?"<Q#M[IEZHOBXC4;V5?)47]/%.FFECNMZ
M_3489J&FO++C;E<'5.SK5UW$>FLMWEA6-Q@Q[.C#)E=\I61#E0OQ2Q'$[$$*
M9'E/>BG0:^RTTC"\JOI2E(47\WN\5XE.CD_DVWG\K&4?N]O]MWSV]UOC^]WY
MOT[?+32IW?(#Z9RHT]BMK;\:<N!J/*,KR2SQPY-7;N6O-E5/7U55>R1F_:I)
M8"K72*L'9Q60Y3&(X3"%"]S6FDB?R@^E"5YF.X[W3GA<<).VM]ZJBJ(@1E1.
MV9*BKYF8UJM[]T7NG;LB]-/G[.KDFDIV!6>F]466JH3Z[6$_7&$S==0" EQG
MP<&E8W6GQ.(Z-/(:='=&H7P N#,*24)S%9(>\K7N5II3^FFCIIHZ::.FFHY/
M5Y[_ /@QN</;]?YN^P.WZ?K^%N_C\=--<IBIIKC*[.FQ:AA$L;S(K2#3T]>%
MS?>F3YLD8(L9BD<C$4YWC&BN>C45RN541.GO_?KJ?'Q_W]?G^?Z:L*\>O3(O
M\1XN;7H=CTHS[LVMB5L/$*MY3S8%-,QTH[VK%!;')'0]T:7'9%)(5IXP'36]
MB.:WVWO?O.H]Y]_M_C5=R/A.6S<\J,-BUIRY1:W4+':^I/WBRB7+9#XC83ED
M>#1N2>5\57N<@FN&]RN\6KV::M+X1Z2>\]->GWM3%-A6.'QLUV]CV.9$W%0_
M<V5[72L/O8][5-'/!/CPHA#?_-RFDQ7Q7AD2%C/.CFE:]_7358VNTOL63MA-
M6.QJR?ED"S^TM*N%').FPP5@I1;.9[(D[2!QH9BG&X+U9)\1M XCS#:YJ?['
M\_?XX_+5QO7?I7%U]PCOM'W>44;2;2PV'9NR*QPV>MS3$-+2;7DLO9MQC28P
MY(B% .(Z0H1C1'!]MR)'Y?[\?#]=/#WY>'I^N-4Y<TTUDV![GN-+WDB%&R&@
MS>JPN1.D_<1X'W+);:\-@;^B)(9#*"0*:KV#(J@=Y#:1%:CIU&K5UAQ8_FO>
MG W0=A6T&;@VQ(D0KG/:H$MPY5U;,)=0;>O@.FJ*4^C'41Z]QT1Q C(#WH@W
MR&.7)>E^F*KJJMEHZ:KI:/N(&J9I:H2,HC5UC4((U(WL[ IWC1J527#$I@U5
M/3B?<=^T+MXVEV8L0N J\D[F &.<$GP4ZJ@[.U?D.HL\F89D#$295L"@92 D
M1XUE ?'?!#91$DC$9P)(^QVJX;517.&J(K5ZL%13S4E144M0FR:FFD@E3QP\
M3%6P<D,#C*L, @@C@ZZ71HW9#XHS*V",;D)!QZCT/.0<^' Z:_T]J(WTC^*C
M.ZJK ;6&JJO?NK-T;"1514[)V5>ZI\=^W;OUTZZ]31]--'331TTT=--'331T
MTT=--'336KYO_P"9>7_^R]__ -DR^H/@?I]?T\]-<9 @I,Y4KH,8\N7-(\0(
MX&.*0CO)5[-&Q%<[\J*J]FKV3NJ_E:O:=3^WB?T_+P^?C]-6U^$/IKY=JOT_
M]S6FZM?T);G=6+%O*:]C96)P:>';M:_%PV<=*62&1)<9R#\(\]Y(R&]R,YAG
MJ1&H\-53=B:JSK!=DSM<9#5*#+,?OHF,G TS'1)-BR=)E+]E-<C0GC$%( X4
MA%1CAD83NC7(O33W[SJU_P"GOPYR%/3TSS7T[%,"S*SVQAMTU+\.3V,5*6;D
M90V%::;#94N#,/4_AZ13302QM8-""$]S"]W/#\R?Q.F<_P!M53MA:5SO!-NW
M&F)T$-OF5!DD+%W1J=Y9X["8RQDS6/BH(2F]L@3M>K7#1PV(YST:J+V?IX^G
MY^?OQ&I_U[]D:G]U)Z8FQM(\5-EDW!1U[[S:F& AP35UHV=$IHQ["JOL>E/&
MY(Q630&"-C_RC<(DHZ*\[!N&C3/OU]_N?75<O(,/R#%LDG8[;54F'?4TT<*5
M F+[1"20WSB"[HX3&B9(808Q^3R,>WL9I%81K6]K!&C5XU=3&@%02QD5I'E<
M*ZXC7ND*F.)8V:0EU9N\^(1IR8 X(& !SD^/)QQY9&/[^>=7 /3S]/',\?X&
M[6Q+(\/PW(<KV[1W-C,LAW-C-;34DV-#L:Q!K5C+&E%A,@"*JL>X,LA%"TC@
MC5Q>K7#52G=&G<OT;LJQP'*Q@2?1%5&D![C S(@;225AF>^,96=T4H'(K?%"
M#56N>Q6/<TT_#/W_ /R3W&,+E5WVO-KDR)7+V5J_[D6A7JJ(BKV;V5.W?Y55
M5>R=_ED>OLG'/IR1X^HTTR'6.IL]W5FM5A^N\7L<BM9T^ (SH<$I8<(*))0L
MJQE-8H8X J9BO<5Z*YJJC>Z]-/K[]^?KI\OJ4\<IV@LEU5+L%L)$[--6QF7D
MF6.$X+\GQ[&J>CM!U[H+R/)&?,(WVC2?Z<C%:=ZO5Q%:T]^_?^V%:5PG(<_V
M/CF*8[7OG6=I=F0*,$\C0,:.,PISO:BM"R.QCW*YWBB+X]W)W1>GZZGT\N?'
MS'AY>\_AI['J;8)<8]OZVRLL>8.)L6I?;A;)8(AXT\-'6U5M7R902/!)DCL&
MN.XXT'[L:6 [ C0GML:C31>.6KK[:NX<0PFDA3#2+6WE.D/A,<^0*N^RB/DD
M UB.<XS1 ,C$1%17J)ORKNFI\#P?GG/XCR'/[^FGI^I/Q+V1I;*8.:RZ#(Y6
M)9#30/Q&\G1C'6+D1L=''E,L9; #"%TR2$A H=[CJU%:<\@J>Z1[]_73Q]_M
M_KSY\M-^X2<8=D\G=L4]+AF+S+FBQV\K+#,9P3QH?VM7+!% ./'=),Q#SI!8
MKV"CA7W$&CB.<-O9RO'Z:C/GZ?MJ0SUEN.NP,<RC#-H QO)28\'$:W%<EL)W
MLFAU,^HQ^!C=1$1\<QA@$"NK(%>@GD<^*"+$$5R_T:N:>7O/OV//4=' _4MC
MN?DCK+$ 49[BMC7SLFR4+?!@P8_6 @2),B01SV]@_= ''>UG]*YQ6,$USGHB
M-3^7KG]OUY'YXT^CU=^'6;:<W<?9V-X/=NU#DM+0(_)(M2QM7$R./44C;99I
M8CBN"MA,BRIJEFJA'/,1Q2/(]>SW[]_MH.<#\-*=Q(,T_H<^JR]._C_+/Q0[
M_E1%3_;A5_'9O?X[?V_"?K_%6A!'C_?/TU"SAN(Y'L?+,6U_AT)+')<LNH5+
M305(T*&L)Q/MX[7D=V:P:$)YD)\JT;57LO;MTT\OH?[_ /6K2=YZ9^4XEZ9;
M]%6>L)4'DA.MX=M2R)MY3@QJ=DD4LPMG'B6)G#.LF9$DQP@,H6#,0 H!2@&U
M%5J/3W^?KJKM1:FV%EVU*K5=50N'F]Y9?@\>JL)$:$H)4N%"AB?,D'*T$>.U
M'L.IB/;_ $2M5$4CVL7M@@FJ7,=/#+/(%9S'#'))(409=@B*Q*H/B<XPJ@DG
M US5'D+;$9V R512Q_J"\ 9)Y(&?4C/CG5A;E;P,S#!_3^P#7/[$$;L3"Y5]
MF3+1]E!E19()$2#+OH%3)81"D=)CU]A8OC(-@GR7HT2-<]JDZB"A*NK(X."C
M@JP;)R"& .<@\>(QC QK@,^88'T*E6& /$$9SR/$#.<>.3JO)J[5.;[IV91:
MTP6NCS\IS*;<Q*T<VPC0(P$.4)BSYLR4]@61HD<+Y)G^3G*Q.S&/>K6.8.#@
M$[5+$ 9. .< ?V&IP3P.3\OG@ _B3CY'QU:RY'\-\AMO3JK] P<,HJ_,=>1E
MO'YH?(#DJQVM;7(EE65$%E<B'98O"^0T[9"* I)!7>ZTJJLD$$ @@E0P!!!V
MG_E@X.#D<XT967A@1Z9!&><<>O(QJI>##<H+EH,2_!RAR&]MCTL"!)5(ZK+N
M7P@P">Z=HVI&,_P(R0OBQX"M*CO;7RZXG]QX_7Y^OE^8U'O\O?XZMJ<F>&>7
M2_2DUSI>IPVC6UP@-+DDC*A9"DIL7+UJ_9R!@XC:L95C&1AV/7[]PQC5DCV7
ML:CDG350V76651=VM581W1IT.?-ARX[G(K@24/'<1B_HCD8^*Y&JB?*^+D54
M^>FN0!SD8&#DGQP/U!QY>?UUV'>&:(G$+BTC45&_S=M+]D5.RHG\G..?JG=>
MR_V?N_3IKCKX5_-#B?:;;G:&A<A=4$W)79-*PN7KDF854;*&9C"B,GRL2% E
M'"Z3DP()&3'T,9QK7[55D)$437/1IIS/FW^/_P!_IIK2]A;)P'4^(VV>[+S#
M'\&PVC8%UKDF364:JJH:R9 XD0+Y,I[&ODS)9@Q(407N29DLP8L4)3E8-S32
M0BYD<4CX?J[/P<A]0FPS=N1P\/U%D0<ZH2UVQ\JG7H<8!CV($9,<^[N&9'(!
M12X$)A9$"V*.!/'&DN0:M--V]7I4_P#!B<XE_5/YNVP5_P#^6[IIKFL>G98T
MT#FIQP!>T-5=UMGL[&*^0^R@DLB4\<MI%)(MZZ(D@$4D\ !E8)\X<H 4>\J1
MG&8-S6I'@>?'RY_T/[_373;'J+0^SVT=A'K&-FZXF!L<>M6M^V(UPW1W2!ND
MB^'Q2."QD@#41A5:U>[O!JM9\O3W[^FN/K^GY>_#5.7<'$+2>T?J$,1U!C'V
M-!K*DKZ#8N8012XPHD*RJL9EY'9A@ 55]U\N:Z';2(H!H]7R),@CAL\S(U.K
M?^QJ_"L_J:Z.-%'C>+T3PR_M%&V99P P_LXJ6 @JQK8[&"8YXVC<HP*[MX^*
M.; /U'ED^)QG\/IY>/XM4NJ["L6'ZY9<?P)5L*Z7BT-YAO<4<2'9'P8!)@ E
M]XHW1HX$![B$=[3G.)Y#]U$8LZ:M^I:8D&GO:7*JF9>0:^,UMC;SGB]B)%?'
M(&004=&L:^"SW7(Q@F-(OM^X@R^/9(Y_S_K\?737/>]0LM)B'._)]L:XNFSL
M99G5+*HI$1[#R:>SU],@55C5R"O9VD2(B0P>!R"5#"D,:J+[3^IT]^_?EJ^U
MJ?$^/&\=::OS>HJ(LO6%)95NQL8?"M;"+ ^VL<>CQ4 7[68P,Y\Y;*PA2 &0
MH4CI[9O<(BN;<;;=:VTFJ:AD6,UL'W><M&LA,:L)$VE@2C1R .K+@@\9P<:[
MX:F6G$@B('>J$;*@Y .?/S\?]X&J@?U'.B(.KN4^!YOB&.#J-?[ QFZ?4RX
M5%4K8QI\:<> !B=V!*QLDQG!1>R$26C45K%[4#.\C,\CL[L2S.QRS$DDDD^)
MYY/GKJ+%VW,<YSD_AC/ ^GEQQC@ :MU_3V.\O20XK.^/S#VT[X_@NZMA]O\
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MR58?;J]>YVQA0XDL<?Q<&6:-[*%*XOD)I[_Q^N--5^FLT;1YYMK8VTI\BO\
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MZ]_E8_M_UC]_QT^?_6JD?#33O[+>NAO/%LBL6W%I Q>^M\>ER!M>_P ):4+
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M7Q]XIG)^JIU.N0\1CU_?4R/T\KD?Z17%%4__ $&V/G^U-U[$14[_ +^WZ_\
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M6*IB:)VBD!V.H8<J<$<'*L"C8964<Y(GB;;(NTD9&"K9!\^"1P<@C.58$'#
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MEQH;BB"1Z&K@JT0MM#O!(LBJ6VM@%E&>.1D<9SKFC=VZOM#;2?A)X/!!&<'
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M#L?*@9PVHW_3FUQA&G/6)W+KC(<OK/VBI]?1*^*6)*5*^TR5^.XY+R"# <=
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M?OZ::U;ECS>R_<?(+<-3N>DI]C:MK]F9954^+G$>+.H*NDG2ZFOD8O;@E,?
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M%Y0T%O9R)*JC5BY--C2J^D)%>IHK FL2/1?8'TX_+V./[?34_F><#]<_CX<
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M04'[AE5(PWL<-J-&R=-:WGOTQ6T]GSZNQS?U!<"OI5-20,=K7R]/V!?M:RM
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M&4Y;Z?N:;X9E>3/S7'\L%?UQG9K<1;$^(M#74<V ,!++O8^4P\BV031-="%
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M9%5Q(+'1A/#8IB3 3"-0GR1[62K)!N$3Q8B,>]J*J=TD#)&2 ,@$GP )&3^
MR?33CZ9_''ZY]^>I_P#U+K;<LSA%R!D5<VTGVUIJJ]!%@!D.CD;3&@L)((V,
M-[6->&O',>QJ.3W%1R#:KFIW;2$1L@[LAMH8A) JNR,Q& =K*X&<A67<%) U
M)1EP?$'.",XX)'CX9XSP3@8SK+^D'B%-J+@+I1,9$QEQL:CMM@S[<B*DYALA
MS>\B*.,H_!_MN^P>C'*U48 7EW5"(Y>(]\>.?/\ SP-<3^?OC&?WTG/K;5,_
M+>$6WE+*.GV% R;'(1J-=*-53(E@1GN$3Q>A @.-[6.\U5&JG97*BAQ[/O\
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MYJ>/9'?_ *R)W_MZ::CG]7WLGIA<Y$__ '==@]OC^%8OZ=D_A\=/?YZ:H_\
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MJ/<K1_E<Q%6./\?I^GAIJ+'Z>; )$'B5R9HK*-X?:[YV74.B/16C:7'R@ 0
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M$2H0[9 ?_)"GS$&%%&QKNITU=2^GI_WHSBDBIV5 ;71?[53=.PT_7]_PG?\
MY_X]^FA]_OZ^_34T_331TTT=--'331TTT=--'331TTUJ^<+VPO+U_P#V7O\
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M<XR>MB4MQ.R2[J'U,%"LB5\+&B#I:R,)#O(]O>+6 <_N[LXI7.8GBJ=/?O\
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M>].8M&XF<C9$Y^9[6R^VK@Z=SLLBM=8)AU#6_?!92.)%)*CT<DT=IVL<4/\
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A5V 8_$GU\^'(8.1$F0Y0BQY,8XV% 8;QD8U[51)U&O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g129231g41x63.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g41x63.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1IP4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M  !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$
M8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,
M   #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M  !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RP
M    "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G
M4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M            4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN
M=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E
M8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R
M;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU  (
M 3A"24T$)@      #@             _@   .$))300-       $    6CA"
M24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M   *  $          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O
M9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M!@       3A"24T#^       <   _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H   X0DE-
M! @      !     !   "0    D      .$))300>       $     #A"24T$
M&@     #00    8              T8   3(    !@!G #0 ,0!X #8 ,P
M  $                          0             $R    T8
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   T8     4F=H
M=&QO;F<   3(    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   -&     %)G:'1L;VYG   $R     -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
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M# P,# P,# P,# P,# P,# P,# P,_\  $0@ ;@"@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MT]37(D&V,K4E87&!&"-#L21"4B8G-3949&61H?_$ !P! 0 # 0$! 0$
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M62M5BG(>U/8ES;XHK>6=K*/HF!EF2,UV<K9X1<5!,'U7-<FCZQ?*/69_HL'
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M:,VZ-0WN)W3Q=%LBF'8E.KUEW!R)E$1\12B?F(B % 1'.5X4NOKEXSKKT_\
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M"P:.Z2&#X;)S8M%I,7X([GL<;*G5I.Y@.5TVCTU*:HBX"4K+$?!^4=+I"L5
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MBAS%(0A3&,(  CGAC%J V-,5K ;(S.Z$0$:ZV17?W55>]ST &PP6L"-AD(
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M%Y;"52V]HD7EF?;5WTJ;N-82]^8A6QUDSR?+4=J<5:!)!>0VO=6@1;99V_\
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M?;BK^L="+ L!Z78E9X&ZS3^(2O;JK]K9L8"M1#-JPI9=?5DUH"591!X<%AW
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MC$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B03!?*9N'Z]1/\5-D?C?\ :O\
M)1)!3\HGZY?>#)B%/**>N;WAQ$HQ$8B,1&(C$1B)&>Y?DON/U%C_ +W%XB9
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MVK+93MEZO@J!9Z"YN,'39&.V"2"@[)#36NK(I(HO(>%?KEC'HHS!FO<%491
M3EI;D3]#XWMS;CW!XD\6K7BL'AIY3-S"./Q,7ELQ\SR=QT=<?R..Q%1B]V5P
MT.BZNS.PZWX\7&K6_87#Y/I1RB.EY=>#6S?PK&UG.O,=QN$6,V<>\2(TL6G6
M@NJAET<*NX5=;;]B="6*D0ZUDM=>A&@SDIL>*';-9K+*$/)5:%1U G IR7P<
MM611=3%W:3+:+3LLBY8C&%*P0 N["X=H\ADM9)TX6ZU\AHS*/1GT[^&RY5L^
MDM)-(\2E9'*XW@S>W7])-S:-"R$MED7!>L,>;B=86UJMHI7B%XWG&LG*:]+1
MT<?7:*MFM^@3W\VC,G)7&YVY5-#KF(1ZG9--Z5--:X/9O9^HE]6=]GRQ8Q%O
M7^^(5U69 (-N(DIR3L%T0/'=U_\ CQ4 4S=U66_J[I^4IQ_*J/+6;^3X4N*]
M2^Z2((\WTUVSR NQQ"?=5>71_P!7K5=;LK^Z_P"S^0YSYFQ>#J1Q_A'QJ'C#
MZ*X\"UFWE;S?285F]>S[7/&BUL*M/9TRT'0A[%KZ#V=R6@=-: !U=R:1 .0<
MN;2L<_\ ORUX(?%YO%G*O!\L_7WYC@Z_LO/T_P#;CK_]_>?6_6/YAWX>!_'O
M3_E_,_\ MT\3W[?W]YSX =-?Z9=(?8ZQ_'>1Z#Y9OSGA/A(_;8^L?S#_ -$>
M//C\U_)X\ .FO],ND/L=8_CO'H/EF_.>$^$C]MCZQ_,/_1'CSX_-?R>/ #IK
M_3+I#['6/X[QZ#Y9OSGA/A(_;8^L?S#_ -$>//C\U_)X\ .FO],ND/L=8_CO
M'H/EF_.>$^$C]MCZQ_,/_1'CSX_-?R>/ #IK_3+I#['6/X[QZ#Y9OSGA/A(_
M;8^L?S#_ -$>//C\U_)X\ .FO],ND/L=8_CO'H/EF_.>$^$C]MCZQ_,/_1'C
MSX_-?R>/ #IK_3+I#['6/X[QZ#Y9OSGA/A(_;8^L?S#_ -$>//C\U_)X\ .F
MO],ND/L=8_CO'H/EF_.>$^$C]MCZQ_,/_1'CSX_-?R>/ #IK_3+I#['6/X[Q
MZ#Y9OSGA/A(_;8^L?S#_ -$>//C\U_)X\ .FO],ND/L=8_CO'H/EF_.>$^$C
M]MCZQ_,/_1'CSX_-?R>/ #IK_3+I#['6/X[QZ#Y9OSGA/A(_;8^L?S#_ -$>
M//C\U_)X\ .FO],ND/L=8_CO'H/EF_.>$^$C]MCZQ_,/_1'CSX_-?R>/ #IK
M_3+I#['6/X[QZ#Y9OSGA/A(_;8^L?S#_ -$>//C\U_)X\ .FO],ND/L=8_CO
M'H/EF_.>$^$C]MCZQ_,/_1'CSX_-?R>/ #IK_3+I#['6/X[QZ#Y9OSGA/A(_
M;8^L?S#_ -$>//C\U_)X\ .FO],ND/L=8_CO'H/EF_.>$^$C]MCZQ_,/_1'C
MSX_-?R>/ #IK_3+I#['6/X[QZ#Y9OSGA/A(_;8^L?S#_ -$>//C\U_)X\ .F
MO],ND/L=8_CO'H/EF_.>$^$C]MCZQ_,/_1'CSX_-?R>/ #IK_3+I#['6/X[Q
MZ#Y9OSGA/A(_;8^L?S#_ -$>//C\U_)X\ .FO],ND/L=8_CO'H/EF_.>$^$C
M]MCZQ_,/_1'CSX_-?R>/ #IK_3+I#['6/X[QZ#Y9OSGA/A(_;8^L?S#_ -$>
M//C\U_)X\ .FO],ND/L=8_CO'H/EF_.>$^$C]MCZQ_,/_1'CSX_-?R>/ #IK
M_3+I#['6/X[QZ#Y9OSGA/A(_;8^L?S#_ -$>//C\U_)X\ .FO],ND/L=8_CO
M'H/EF_.>$^$C]MCZQ_,/_1'CSX_-?R>/ #IK_3+I#['6/X[QZ#Y9OSGA/A(_
M;8^L?S#_ -$>//C\U_)X\ .FO],ND/L=8_CO'H/EF_.>$^$C]MCZQ_,/_1'C
MSX_-?R>/ #IK_3+I#['6/X[QZ#Y9OSGA/A(_;8^L?S#_ -$>//C\U_)X\ .F
MO],ND/L=8_CO'H/EF_.>$^$C]MCZQ_,/_1'CSX_-?R>/ #IK_3+I#['6/X[Q
MZ#Y9OSGA/A(_;8^L?S#_ -$>//C\U_)X\ .FO],ND/L=8_CO'H/EF_.>$^$C
M]MCZQ_,/_1'CSX_-?R>/ #IK_3+I#['6/X[QZ#Y9OSGA/A(_;8^L?S#_ -$>
M//C\U_)X\ .FO],ND/L=8_CO'H/EF_.>$^$C]MCZQ_,/_1'CSX_-?R>/ #IK
M_3+I#['6/X[QZ#Y9OSGA/A(_;8^L?S#_ -$>//C\U_)X\ .FO],ND/L=8_CO
M'H/EF_.>$^$C]MCZQ_,/_1'CSX_-?R>/ #IK_3+I#['6/X[QZ#Y9OSGA/A(_
M;8^L?S#_ -$>//C\U_)X\ .FO],ND/L=8_CO'H/EF_.>$^$C]MCZQ_,/_1'C
MSX_-?R>/ #IK_3+I#['6/X[QZ#Y9OSGA/A(_;8^L?S#_ -$>//C\U_)X\ .F
MO],ND/L=8_CO'H/EF_.>$^$C]MCZQ_,/_1'CSX_-?R>9=\(L9Q!Q#':#+B=G
MJY9-L%L]?4?2E63:)1)X)2N$&$0 K&+AV_:44^T L(,4SB4R?7.H/]6?I'AI
M7B!/%+#Q-HRZ>5IS[-N2@%/D656D>BU)#OJN[NZ+J_\ >[OWO^6/E8U_)IN\
M9:='R2\=RG%>#;P8!1DY@GELKD1!GT@SNT:]S?)85J\JKT$-=I=HA5])F&GY
M1/UR^\&=^?FT*>44]<WO#B)1B(Q$8NJNKJZZU?M=7]UU_M<3\I&+%)J9BDQ9
M),3D53.Q3:-TV1TW G,X(=H1,K<Y%S**"N0R8E6%0XJ 83FYP=4RK%E4P;JA
ML3KOJQJJJANBZU8U5555?M5=*KVJJGKO/N[^XN^[ZV?=??=U72KLNO=UJJJJ
MOKUJJJNO2JGX6==KT=%!!1U?@H^#+UN4(QAXYI#AUU 5,(1;=LFQYF5 JAA[
MAS%0I3C_ %% 0]]YW8%9E9+H165E=VL0_P!%+O[PH>M]M#TH>M].G6YY#^E9
M$O\ ID1$16'V+(BJJ(BL>EV15545WUNZJJN[JI].\<)WV"P=Y8?O^#7L)9T8
MMB,T5ES$>QEENS]\"M.8B/9@< CXQ_H\8YY'J-'0W8TWIYM#=U3>V^H^95>S
M.V_<>_KTOWKI<%?=2Z+[5)LK35^]*L_8[55^R[*O8NSIUK[^LL?<OR7W'ZBQ
M_P![B\1,@4_)I^H7W0Q$KQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B)U4[.0]8A9>QV&38PD! 1C^9FYF4=(LHR(B(MJL^DI.1>N#I
MMVC!@S06=.W2ZA$6[=)154Y2$,8$31UPG<=\CL7BPO6QKIONOR&@]T\)VR^(
M[7VIVE@K$FRX>]:<.^QZ;6&4Y9V\,9:8A[GM/76RHS;-X8V)0CZ&5>)4XC4@
M4DZRZ)E<'&]NJ)U35MRW'AGKT'7-W*:\@^&:F--WJ/\ :MYONW[)#Q.L:9L^
MO.M51=9U>>6KLNI?;A,PERV4VH%>@+,@^:RLA%MTY!$ZW;/'KL+1\_0]0[-U
MII&M\0.P&MXM\5!FX@K:ZU.UU51R55D>V+WA'A^\/W]PLMKMC>HU/6$)J"3F
M)QY#V*71ETH>)4641.G=](#O:7;5Z'I'" 9KL%/@\B>+G;->V_MMYJ^%TXQF
MY6U14'K>R2K?5-OL:]OLRM$N*M=2=4J$4[)!R#BS,JNJQ<- 1.@I_'5N&W[N
ML.PG57UY3>"K6? SI[B@VE)6*^2R6R*L3=E?O.Q&\F\KC;3[Y)W9*'7=63L-
M(TM&^1,0O!62-N2LR\EW;6J0R)]9;I(MKZ\"2E]V<,4#0*N'!?O3C@CC1&\_
M"VX0VO=,H4P6]'V+6#ZK@&-8V);'-\@6Z"%?LESK;%RWL;)M.R[F! )%$N4W
M2'WRC*;43WSPVK:^D*9H#3>\ZC4JALYIL&Z3TIO;95CT_K32UP8NZ;3("E;5
MN&Q81G 036,LMVJJJ\@_!Y9VA8)99ZB?KVIQX;4T/)Z[UQN?4^BJ9NK<+FQR
MFO81+B3LLGK5"@4B(@'-XL]TO*W#U%VB-FX:RVNL4FO4VJZVN+Z\S<\Q=1+Y
MG%-+"Z@42?8GBDDTN".P<76T-:36GGM6TOL;;EIUU95GXR4 SH,199<X'7FH
M"JS/89R-@$IJ&-.U:MSG>F6CPF:]#RG:HULB0X%UO^O.&KH^]8[1GM@V_=F]
M;CP\ZSNMKA[D-)N"]TBM>2^\]KV.6E&D+*J.(,L7JFXMK)6&Z$66?@WB]9"9
MB2/P=%1(O@^DAW3<974"U&X1FDW2M_[PWWH;3LP_W@E$6.QR.F'6TSM=O3M=
M1UA*Q]6T1-PNKG4E+6A:Q25YB5)=LW@-;W$JM?6LZ)WE'XRK)OY;AN8&H+VB
M[*FK5QL6>4K-?W<_8:W4:\%-QL&@I=W9;BVUGWVNNH;]L6T4UY'D=T^OOXPC
MZ.L:\+.+5<T+*HD[='=MGB'WKPLZVW%Q%UVD0%BVG$%V74C4VT/IXSO7>PG3
MVXT1K.1;G7- ;UF1KU1FH&N$9M5K0O*M8I*=EYA.8DGS)%$FZ"^4S</UZB?X
MJ;(_&_[5_DHD@I^43]<OO!DQ"GE%/7-[PXB48B,1&(C$1B(Q$C/<OR7W'ZBQ
M_P![B\1,@4_)I^H7W0Q$KQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B)$F\M,53B"UI.ZCO;J<3H]L<P9+A%P;Y".-;*W%3L;-2U&FW
M"S)Z=6GW9K'GJ]UCFG9'<S5)28ATI!D5^=8J)%>P^"KAXV39(2RR]#C(=:(U
MON;4;N/J#.+JD?9=>[XK\'7-@URR##1K:1>M'3.NQ#F-%K(,58Z09I/"'4.4
MI2HD>J\!%9D-75;6=@W]Q)V=SKFWZPNVI-B3EPH9[UJF;U V?,*4I5"1VLXV
MCR1"Q4K+1%E7O-*N$C=8V15;6Y]-=EC3L42XI?@QC7UJI.QH??\ Q#U7:]2U
M_8M7RVT8FPZXEK3L2DV:W(7EY$7>/NFKK72BC&V=([VM/*=4J@[J[1RYA8%6
M/@U"QJ:)!<KP"SFW]Z\6=_W!M7:]=UYN=KJS3K+7VNK]',83:?#GK_6<1V^M
M[-![59&=K[R=VC<]U(/GFN;!2[.[J=@5:.+"+:6.V11)WL/ UJ&S37$:O)2E
MW)2.*C3C+2>W-2,).!8:[?5N-I"FMHR6KQ&U83N58GHZBKNJ\S)$7%O6DDG*
MLCX.&F2HR22)'0]&MIV63V(XV%LC>VVK%M+5.OM(W"V["NT"[F7.K]=W8;NR
MJ,2QKM-KE6KL9970)1-V2@:Y'^$T<DH^>=6T2,O8I!$E;;'!=JO<3C=<C9YF
M^L)S=S+0S61L%<L#&*F:*ZX:;D_V1IR7UTY-".DX>2JNQ9-Y=P&90L+&0FUC
MIOV2\08\69$Z25X+&<E8J#L-+B*XC8W<E"@=AU!/<S2<U8\N%FI>SI2GS=FI
M]AKD[J.8U.C DEJ#4)&#1J^MZT\@7D0HYC'B"TS8#RR),>\M!U?B"T#?.'6]
M3]P2J&R*.XH%IGX22BVMR=PKULDSDURR$A"RD.9_+-DU$9,SJ!<L7:;MXD=B
M"2_4*B6#5^$]A%V/6EOO.ZMV;ILVHK%>;-0YC9[_ %F16'D;Y10UX_#L>NM7
MZ^BW*4177,ZG G78G=LW%HGC.G3YNJP;1Z)]-9\'>I]4EX:4ZRYMJR'"GJNY
M:HUDUEYEJ]0=Q][:T9E8+;;.I%ME9F\K-J,FDA--U(YHD6T6_K1:@RZ L$2V
M=?<!VDM<-8!I#NKQ($KG#_L'AR8JS%A;*N#TS:UU1V#L>=7<1T3&K>'%QM#5
MB_E[ V.V3$8]H+6.;*D.J=$GK1FI6FB=3T?449<+C>8;7U?CJK 3U\5K*UF&
MNPC9..@(MZM4:Q4(19*$AV[*(9KI02#UPT9(KRCJ1DU'<@Y1.B@OE,W#]>HG
M^*FR/QO^U?Y*)(*?E$_7+[P9,0IY13US>\.(E&(C$2V;K:XRB4ZUW>9'E$5"
MN35FDO\ S4D!%E"1[B1<E!9<Q$$1.DW,0%5CE23$P'4,!0$<Q[]B\&-^QEA0
M)$;NV%V!W&8*#O/H78'>8]Y]I=@]2[2Z=+TX\]Z]2,U%8><T0(Z FV =>K#I
M859LL HC[ JS/M[1J[NIJ_TMQVW[:^I]\[*BIBF66V5_6Z&R]7Z5A-)[@A[3
M$PLFD0T4Z=3$RZY[YB"BX;D=SNJH!C%+R!5(MBX65.BLI[YD.0XOP[NV95CR
M')XN11A8^L^E&537&'>EW%W3.375*)SL>EMJ#=GSWH!2UD5!XXVL^WGLV%[D
M9\6K-N?G$-:G^I7EM@JTHY6P7A[7W6?SLQ*MN)NH4N+N65W\8_C%W@[X57>S
M(:Y478>QFVP4*E9Y6K<*N_&!M5%5:(NB15QX<7%C?[F?23E<Q6B4BFXB&:;5
MZWF%&W8$E!4LY(F(=PXX%ULS:V\G3=JW*:C6W )WGXH341+XG;L;VYG-W$P>
M/(A;I58FNKJXKIL'DKU5:-&1. [PLZY7Y%:JKU/(V>FAKD\F0+)RE8UB?(4I
MBLKK-;.W,?AYW5<MT+*24I%P4! Q59B8R29&3=-[!+;*[F@ZLRL0T=/.[-:I
M#(JILA1<,W#H)195J=\"D>Y3'<0)M+M(75HU.4WBZ7H7H(,(JM>N];5AY3+'
MD*;ERN405H#(Y]J$&)LLB6N(<JV 5/%#+W&2R0'J"=?I4I0PK>II8Q#9K3H^
MWFO4A%=Y"PJNC<.Q*"MKRX1B-UJRLCW!LV%BG-L#NP<(3<?W=$4 6[H"J/<E
M.ZD$O6)U#=8 Y#F::I-A-P:J A '8M,Y@4H#_P#:*+^,  /_ -3B)5\,&JO2
M+3/Q%%_N<1'PP:J](M,_$47^YQ$?#!JKTBTS\11?[G$3@-Q:H'GRV/2AY#U1
MY62*'D;_ .D>3H>1OBYE'D/(0'EXPQ$Y^&#57I%IGXBB_P!SB(^&#57I%IGX
MBB_W.(CX8-5>D6F?B*+_ '.(G'PQ:HY]7X1Z5UA#K=7PDBNMU0'EUNKVKK=7
MGXNMRY<_%SYXB<_#!JKTBTS\11?[G$1\,&JO2+3/Q%%_N<1'PP:J](M,_$47
M^YQ$X'<6J2AS-L:E% /C$UDBBE#_ *B9T !_W'$3GX8-5>D6F?B*+_<XB/A@
MU5Z1:9^(HO\ <XB/A@U5Z1:9^(HO]SB(^&#57I%IGXBB_P!SB)P&XM4& !+L
M>E& ?B,6R11BC_T$KH0'D/B'Q^(>8#XPQ$Y^&#57I%IGXBB_W.(CX8-5>D6F
M?B*+_<XB/A@U5Z1:9^(HO]SB)Q\,6J>?5^$>E=;ESZOA)%=;J_%UNKVKK=7G
MXN?+ES\7/GXL1.?A@U5Z1:9^(HO]SB(^&#57I%IGXBB_W.(CX8-5>D6F?B*+
M_<XB<#N+5!0$3;'I10#XS&LD44H?]1,Z  YCX@\?C'D >,<1.?A@U5Z1:9^(
MHO\ <XB/A@U5Z1:9^(HO]SB(^&#57I%IGXBB_P!SB(^&#57I%IGXBB_W.(G
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M45]%1GW>S_1Q$=ZHKZ*C/N]G^CB([U17T5&?=[/]'$2R JA/A,-.]XX[O,-
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M^8WM#B([&CYC>T.(CL:/F-[0XB.QH^8WM#B([&CYC>T.(CL:/F-[0XB<@T1
00, &Y@("']7]P^+^V(G_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g129231g42b83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g42b83.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1EB4&AO=&]S:&]P(#,N,  X0DE-! 0
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M;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M  !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$
M8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,
M   #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M  !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!RL
M    "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G
M4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M            4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN
M=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E
M8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R
M;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  $#O_XU  (
M 3A"24T$)@      #@             _@   .$))300-       $    6CA"
M24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M   *  $          3A"24T#]0      2  O9F8  0!L9F8 !@       0 O
M9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M!@       3A"24T#^       <   _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H   X0DE-
M! @      !     !   "0    D      .$))300>       $     #A"24T$
M&@     #00    8              VX   41    !@!G #0 ,@!B #@ ,P
M  $                          0             %$0   VX
M             0                         0     0       &YU;&P
M   "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   VX     4F=H
M=&QO;F<   41    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC
M90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M  9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/
M8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T
M;&]N9P          0G1O;6QO;F<   -N     %)G:'1L;VYG   %$0    -U
M<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M 0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L
M 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%
M4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M#T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU
M;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO
M;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L
M;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
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M# P,# P,# P,# P,# P,# P,# P,_\  $0@ ; "@ P$B  (1 0,1 ?_=  0
M"O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04! 0$! 0$
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M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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ME+'4%B(V0517D;8W88&T"B.A&"0E)C-#4F)"\&/!X?_$ !P! 0 " P$! 0
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MO:];!T;H2#T920>A!!Z'T((/J)]W7K^.5\H?TYA,Y$57   BJL &\ BH?O\
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MLY@];AM;;R.O;8EV?Q+XKIX3B:TU6BM>&\,79:SX;X;DMI"YZ_$OC(\>_/\
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M1O,GQP7.Q*TV!W%4:W8)#NA#Z^4.](G:94X)EB$8E($%E%T3I))JIN%0'VW
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M.AJTSJ_LSK51YE3&L36KL:CB,G$YB<S8:.1R9.2J/3D:,?,J!RV=;3W(PWV
MW76-6;A<SNEB=Q$I'BN[#]PQ<4FTX+>S2S;JX<=XPT(WK#G:_#9L%]KFWV&M
M,FO:;&&GG223QNZ3:MP!$'B;=*071(DW=.ED$4DRZ-.:S-NY#;FU:*!R[WW\
MMEK<+FY#7H>AVU7IT[O-!H7T1TJ8_/LK>P*ZV/<EG'\?Q]V>BVOB$KIXFZQ
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M(8"B7H[RO*<?RO'\C6FP<M517;KN+G=E?/;7=5IPZ^[S<VE&J15N5NY44*I
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M(X<R*)G*<AP\',IR")1#_,!Q$F8B,1/E</F30Z*;IVU;*.#]6W(NX21.N?\
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M9H"1 YBBB;/\1&(C$1B)*670;E ZZR2)#&*0#*J$3*)SCR*4#',4!,81 "E
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M?</X#^DNJV]\)?3#$F2C^[-](WXCB)QQ$8B,1&(C$1B($0 !$1   .8B(@
M >$1$>\ !^\1[P8B4%2ED%]R[%40717)^A6O""=!5-8@&*XM',.FD8Y>8<^^
M'/F " _O#$2^N(C$1B(Q$\^__$#<9?'GP<Z,U+9."2FOY!:T7IS&;%O$935;
MT[JK%LW;+04=W*3;NDV"-B?'4:J23AN<IP2%DD9-9<I\1-I' +L_>>YN#[0N
MSN).E#K[=EPHD;*WRKF9*1AVDHH*I$WBD4J *Q*LLS(VE5(L_P"LP.\%L/\
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MJ;VM1UAET(U[<)DM?KB"I3F-)2YD3."LR"0!!(PI%$P**B1/]W2Y][$2J?\
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M=+$D<M>VV(U3MEP=XNH,9T#(R 3Y"-B%(4Q3L772.8.0!Y.W\K.>OCLO(?\
MAOER-6G7F%0*=Z'*F9B[$IT[7&@!/3WH_6?:LO\ ]%O(Z?$O,>'?E5\&*W$\
M7PW)G::+_*T#E[N3I6A$&OJMF8\:7M))ZKHJZ*.GK5/MUL'\E;<?WQEZIS0^
M6?-]E^9^*O\ MSO_ *"/)?O>\$_RVC_-CVZV#^2MN/[XR]4X^6?-]E^9^*O^
MW'Z"/)?O>\$_RVC_ #8]NM@_DK;C^^,O5./EGS?9?F?BK_MQ^@CR7[WO!/\
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MR2=Z>(]"Z_"^<:%U/>-E>,<'JS5HS"G\RZ<FC9HRDK9QE><VFI/,4-W6[Z1
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M_>\/+GX.]X?!WL=!]'_'_3T]/_@?<(D!,(AR$>]SY_N\/+EWQ\(][X<?]_\
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MUCBK>#%UB*2.(O&47<:%Z!!D<8<BFH+VA:$5>BCI-*I130,M0[*!NHY,5KU
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M[4O$3,;]ME2X>M:F;0-HA*[4>'TNP7K*<=W*6:2,Q9+8]V$8#0SIJC&,FL9
M5%NT@R"X?JJI"8R($OXZZO!PNCCP+6OTKCH[2Y.?)FR!V?R;6=M.FS7:Z!UU
M%EHKR4FD]]U\U>4<[>1>^OM;._(7<C;IU4H_)Z]"K=5B-EBDU9Q77JUVZS0
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*! H (?Z\L1/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g129231g43n80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g43n80.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1T,4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '/"^= @X0DE-! 0      $(< 5H  QLE1QP"   "   < E  "')R,CDT
M,38U' (% "%-:6-R;W-O9G0@5V]R9" M($%#3%@@3F]V(#$W+F1O8W@X0DE-
M!"4      !"(I_Q8^.6%LSJ+P9N2=X]_.$))300Z      #E    $     $
M      MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP
M<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P
M  P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M    0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-
M!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M    0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N
M0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M     $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M    4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!O
MX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M            0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL
M0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G
M4',     4&=00P    !,969T56YT1B-2;'0               !4;W @56YT
M1B-2;'0               !38VP@56YT1B-0<F- 60           !!C<F]P
M5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M  QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M       +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU  (
M 0.__C4  @ !.$))300F       .             #^    X0DE-! T
M  0   !:.$))3009       $    'CA"24T#\P      "0           0 X
M0DE-)Q        H  0         !.$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      -!    !@             #0P  !,0    & &< -  S
M &X .  P     0                         !              3$   #
M0P                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   #
M0P    !29VAT;&]N9P  !,0    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   T,     4F=H=&QO;F<
M  3$     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
M A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46
MHK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A
M,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8U
MPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:V
MQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#T]+55<J[+KRL>NH#T[B07
MFLO:TM]WZ:X6U>@VS^;I_1V_IE7RNC?:<FR]UK&>H^MP+:HL:&-+)]7U-OVE
MKC^@R_3WTU[Z4E.EJE*S>G=&& ZUXM;-C8BFOT0-=^T>^W]!7M_5*?\ M.RR
M[^<]5:%5.^ICC99+F@GW=R$E,E2ZSDYF)TO)R\)@MOQF>N*2"?4;6?5NQV;=
MSO5OI:^JE_YEJN_9Q_I+/\XI?9Q_I+/\Y)3R>3]9?K!B.NP'8GK9C&O(RQ6]
MM.YE-%SFT8[6N^U;;K;/\/2_TOH>K^DKK+1]9NJ7TYE[L<8E;,S$QJ3:RS]$
MRY[*<E^0Z]N/ZMU+G;/T7ZO1=_A\FO\ 2+I_LX_TEG^<4OLP.A>\@]BZ4DV\
MH?K9UNW&<\=(=B6%C'UF;+]7'">ZNVIV-C;?T74??ML_G<;)K_P?J*.+];.L
ML<UN7T]]QM>RMNVNRH>Y][-E?Z/(WY#ZZZWU-O\ 0Q?T=OJY5'Z/U.M^SC_2
M6?YQ2^SC_26?YQ258[//],^L^=F]0Q,._ICL490<]UF^QX8P4TYE1.[&H^G]
MH]"[U/3KIOJ]+U+;$/IGUCZQU/J6'4W!^QXA?D#+-@L<\^E76ZJAKK:L=E%]
M=]_IY/\ .4^I3^JY-WO72?9Q_I+/\XI?9Q_I+/\ .*2GDS];^K7UUMHZ8ZFR
MQC;7.>+7[/UAN+?C^B^C&]2_'9[<O:_]!;;795]HQ_TJ/T?ZS=1SLK$Q<G'%
M%CG>CD M>"_]5&<[+JWM9Z+:+V_9K\?=D>E]JI]:RNST_4Z7[./])9_G%+[,
M)G>^?'=JDJU))?9Q_I+/\Y+[./\ 26?YR2%2E*7V<?Z2S_.2^SC_ $EG^<4E
M*E)+[./])9_G*+6EESF;G.&UI&XS!)<$E/\ _]#M.I5,/U@P\F*YH])MKRYW
MJ 6NOJQPRE\8SJWW>W>WU+V?Z/\ PBNY#.IFYQJM<RH6;F;65N'IBK^;<U_Z
M1_ZTWV[7TV_I/]&EEW4-ZEB-<QCGL)FQU+WN8+0:JO1RF,-.,ZVWVV>H]-E=
M6;C6.:^EQ97;Z;[ YL &K[0Q^W_A'_H/?_QMGZ- I##I[^KDN^UM,>BS^<#&
M@O@;G-]#W[W_ *5V36]OITO]&NC_ $BU,?\ F*_ZC?R+-P>KLRW/9Z1865[C
MM<+?<#LL;%0W;-SF^A;_ -J:_P!*Q:6/_,5_U&_D10D22224I))))2DDDDE*
M22224I)),"" 09!X*2ETE3/48P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $+ 88# 1$  A$! Q$!_\0
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MD YM^BO_ (\SR,*4PO<=D-5\]=<B9"6:14:]F))\1G%QS%>3?/UE# W:Q[5
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MJ!N^V[=!15DFL3KC?O9H;KP<QH(3\0YN(KB-G,!7ELY!?E>G8YB+LUK9ISB
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MC$QA4(Z[83I%:&.*A5NA 3"8!'(VLI2F-L&,I:S98*"V-.@&R[%KKWFPNG0
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M,L8 1-XU4"6+5:N6?<HO9XM<@RSCQNH19N[F"Q;4LFZ;K)@":R#AZ"ZR2I
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MTC /2 #[H .(G.(GXN'+=FW6=.UT6K5LDHNX<N%2(H((I%$ZBRRRABII))D
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MD<EDSXB,1&(C$3YK^8W=OMX\;.ZNZGX#U?BV:[:YM[Z@1LM;#%G_ !XL 7D
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MD<HD-V0.A.)\1-[D:@B6(CVW@_O%N$8S;^"EC X[R0!HFGX-6,8RA5^]4_\
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MOU-#N9Q[238P[%CS;!'7CN,9[%&F@Q=BAXN+RRJ#<K/PN#;PX#=0'IFG9E3
M4>^ Q$SSX$$Y,I\0-"$YB"@;D>6@0X;0%,S0[KPX"70 3!V F8'G^] ;^'3L
MC&:&E>^C(&$@@.(F7V(C$1B(Q$8B>=VT:/VZK1\V;O&JY0*LV=(IN&ZI0$#
M51%4ITS@!@ P 8H@ @ ^V 8B?L4I2% A"@4A0 I2E "E*4 Z *4H     '0
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ML<^EYF091,3&-5GTE*23I!C'Q[)L057#QZ\<G2;M6J"93*++KJ$23(43',
M(Y&URD+-SF I05U-C"$ &KNJJR(KH:ZW=576Z]]U4[!9M.EK F&77M !(B+I
M5E?01JROI57=]*OI57?S5(KJ'(CC_L!*;7H>\=0W1&LQJDS9%:KL>HSZ=?AT
M1$%96:/%R[HL7')" @H]>BBV(("!E 'S9(SJG,>UM6K&LQ6S4SY&<&'74%FX
MNBP,J]X@141?^VKG("3&@A=6;F=WEI"NYIT%=3L KY14%>\NE7TKYYRWY#Z!
M=TQ;8[7>&HW&O6\HG!N+TAL6HJT]":6,4B,0M8TY8T0G)JG.0J;$SL')S'*!
M4AZ<]NK$LPE5B6PR7D&ZZ%I,.M$"*O\ ]8ANKJQ7W77^W2>#\OU'E_+]*%,T
M]GRK0N_F8ZJ]Z@+K70C[1N[JNO62TV=-GK9N]9.4'C-V@BZ:.VJR;ALZ;.$R
MJH.&ZZ1CI+(+I'(JDJF8R:B9BG(82B YZ8&LR6P2 P*P,#JQ("&[HA(;JK$A
MNKJZNJNKKI<Y P8 L68FLQH@,"HA,2KJ)"57=$-U?6KJ[JZ]]2UZ#^$K;7YE
M!_XZMG,ZDSXB,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(
MQ$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(D&$_#1>?U"H/\ %[EB))L7]\'_
M $)OIIXB>!3_ !%/SS?2'$33_P L-[\FZ1LNWZY9[IU%HFM%>J7_ %_>)ZUZ
MB9V:V5]M7TTJUJ"$I]\D6;MS,3]T26\;;)(%*W;5M0"0+DK\"E%$VO5-Y*R%
M4J\A/$9)SK^N0;V;3C52KQQ)=U&-5Y(D>N4QRK,BO%%@:JE.<IT.S,4YBB!A
M1*PZ9M)%LNP?M6KYB\2.V=LWS=%TS=-UBB15!TV<$40704((E526(=,Y1$IR
MB B&1M%9+.G"!*[;LZ8-$';7ONR&ZNKJNG7WU?S=?GJ= 1@5$LB$ZOY)!=B5
M7?N]UU=75WUZ?/7SS5Y3]-:/V3K3ECMI9U0-+TS<:4QK",V! 0-,KL73]5Z]
M?C%)RKLDI'M*Z/A"S(2;N90F2K1CLR"":Y1)]P-'=E7K\*9L&]EXO;VK/S^\
M7+!;*96H*X7$]+B)+"S9,RZ0SM[FKV7==2*KFHH]63Q-V+P6YWA_-HX1&>@O
MS7%JRWJY;0+LU XU/]4!(J[\S,.<A[NR[J8=T"WZDB=C4&!WW==*[)XK:XL&
MT:I0MZ&IE!HVH=A6V3UZ@X%&P1U7:,]7/;/ LB.Z]&3<:V!K+/E!;QACRJ*Q
M"W#?Z[%X@W;U#GU;/#?-8<6+IIO1J+C_ !(FW<APZG]VH=?)\>XC<."^QRT7
M>7OJSZX(+WXG9<?%MTLXS)RO":>5UB[&*%)U\,X>/P<F:2&G9N-YC.NT>I[G
MH>\2VT "HZV:\,F6SFW$K3+=JI",)(K&>4:)W1E-+ 2EK6:<5IB35NP<-';?
MJU]2+%J5UTE)'=@0" 8 '-KE_+]3GI?6K'BN&!M7148O#BL@M%M'T93Q*NU]
M,JFTX3IE>9W2P9<8>KD#X4;'ACY#6?&5TL1],3+(R776Z\D]-Z#38_@R40VJ
M[7V3)+4A;"2];9"SK0B\KVE'$RE>0D&T=WN-?5[W*5*37<.NV .MVIA4[,W2
M7JD*(&#,N)/^(C$1B(Q$8B,1&(G B!0$3"  'G$1$   #SB(B/F]K$3@BA%"
M@9,Y#E'IZ#$,!BCT#T#T"41 >@?,/0/F'$3MB(Q$8B,1+:BKG49R9FJ["VBO
M2\_6SH)V&$C)F/?2T&HY*)VY)>/;.%7<<=8I1,D5VDD*@!TDZ?/T(ERXB,1&
M(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1,6:'S;XH;/WI<^-% WM0+5
MO;7J;E2X:UB985Y^&[Q5!"02.!D2,W;F.6,"<DU8.G3B//TE>)("!NA$RFQ$
M8B,1&(D&$_#1>?U"H/\ %[EB))L7]\'_ $)OIIXB>!3_ !%/SS?2'$30OR)N
MB&H.8^W';>_\/90U\=ZXD9YCNOC'OC<5@U>@=D6(C&E@V92W+BEU".E5 .]8
M1S\T8C$ ?OYTFF@L=<SK_G^?^?\ ;\<?Y_G^?\3>Q&B)HV.,91@J86#,QE8H
M.K%JF%LD(J1A>L<21R@CUF11.<2MA2 3F$.L*)[<\NJNKJZJZNNEU?OJZOYZ
MNOQU<2DN("!=Q+B =0<,Y@7::J+J#<13!:&<HKG%5=)Q%*-S,%TEU3&5635;
MF(JH8RB@&.83"95-_P#5JF=.WIYE=_3LJJ#_ %=?]%55#^355TZ=)V+6 RVB
MPQ;=W=L$RIEV0]MW9U=%UL?DW?7WC[K]WNE)/0:&K -JFK1Z:K56:J:[.L*5
M:"/76BZ*@K)+M8,[ 8MNNDL(JIK)-2*$4$3E,!A$<Z*[,U,.[)B.GD,*[LT]
M*Z5Y17\I?2O=79=>[W?-(J !%@"(B#KNW!0U0MLNG=;!JNAV72NME5]>E=9=
M1"$3(1-,A$TTR%3333*4B::9"@4B:9"@!2$(4 *0A0 I2@!2@   8N[*[(KL
MB*[(B*[LB*[ZV17?6[N[N[N[N[N[N[OK/1$1$1$:$1JA$1JJ$1JNE"-5TJJJ
MJJJJJZ57NJ6E0?PE;:_,H/\ QU;/)[)GQ$8B,1&(C$1B(Q$PV[H-IS=G('AI
MO_3G'6]^3;<U\HSF&H]N&0<Q!6,@9ZS<.F9I=D4[N*)-1J#V&-(MBBJS*_%8
M ZI38B8,=PKX8\RN$/%.RZQYF[)1NUKE-B/K!2:ZWMCZ[HT"J*QS)LK$EL3X
MA3+FE99)W+F9(&4;L>WZA#B=0Y2HF[#$1B(Q$_-8@J)*I@8Q!43.0#E'H,43
ME$H&*/\ D8O3T@/NAB)\U'<Q^XB;[X.]T+WERXV#R92V31KRQO<? 5UL:P>,
M%I&[32,LVD+[X15-'@ZK22/9-0;F=F5=*BJW.U0*9(R)]+>(C$1B(Q$8B,1&
M(C$1B(Q$8B,1&(C$1B(Q$8B,1*.^L,!%R$9$R4W$Q\K-'53AXU[(M&K^540)
MVBZ<<T76(N].BG]VJ5LFH9,GW1@ //B)5S !BB4?:, @/^PAT#[7_C$31SQA
M[A)QQXO=T#V%S_J^P]CSMMMTM?)^ U_,*QA*S4IG9"SE6RNDW[9N26F42)OY
M!O&-I%8Q&Z;L3KBY6005*B;Q\1&(C$1B)!A/PT7G]0J#_%[EB))L7]\'_0F^
MFGB)0)M^>*CI:4)'OY8\<S?/B144F@K*21FB*JY6$:DZ<-&RCYV*?8-$W#IL
MB==0A5%TB")P1-(W)"+VX[V=LJ(U73>9E>UCR)94Z2W?$4;4>@+A%OG3R(9-
MISQ4MEJVK%3U8GW<*"5;MJ*\9*QT8NU<.:^!UP(LHB;JJQ&,(6M5R&BF3F,B
MX>!AXN,C7I^T>Q\?'QS9HR8O%.U6[1VT;))MW)^V6 RR9S JH @842N?[B !
M[HB  '_D1'S 'NB/F#'S?/$Z JD8HG*JD9,.GI4*JF9,O1[?6.!A(7HZ//TB
M'1_GB/GOI7OOYNGX^O3KTZ?\>_\ X]\Y$Z92]<RB94Q !!0RA"IB!O\ M$%#
M& @@;I#J]!ONA$ #I''X^GX^O3I^/K\_3I\_7I[^D?BZ_B_W_%\_3K_QU_'.
MV(EH4'\)6VOS*#_QU;$29\1&(C$1B(Q$_!RL+=NNN"2BXH(J*@BD &55%,@G
M!-(HB4#*'Z.J0HB &,(!TAT].(GS@=R\[N)MKGOSPY <3[KQF+K6J:Y:7*3J
M]I8*3RLU (4ZPIP1HO9Y)/K,$)6=,J"D:,:C'II.$5V@I.2E!<R)](V(C$1B
M(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(C$1B(Q$8B,1&(GS3=U![C#RAY
ML]T$X]<J=4\G4M<:]UZUIC&>@WC^P-9^CGJ%B=3[J5H+:+#P:]<6,JZ:"J;Q
M1J=%X0RSM5TS$C<B)]*35$[=LW045.N=%!)(ZZG1VBQDR%(993H\W:*" G/T
M>;K&'H\V(G[XB,1&(C$1B)!A/PT7G]0J#_%[EB))L7]\'_0F^FGB)&^TV3>2
MUWL"/>(L'#1Y5+ @Z;RD5(3L:NW.P<=LD^A8E1&5EFITP,56.C54GKPH]@V.
M54Y1Q$^;6P\:]5Z[MT1!SNN>+QY0R=;FDUZ_P=Y8R[/O6:3:2#+LY>/NSN.;
M/BH+D!P@NIVD8YZR;Y),Z1TP?^?\^?Y_YSW_ (_[_C_S\7N_[_\ B?39!$(G
M!PB:14R))P\61(B*"S5$B9&*!2$1:N3&<-4BE  3;.#&70( )+&%0AA%/)&^
M^Z!,[5TOLS6]?GH^L3-UJ<E7X^>ED7[B+CEGP$*9620BGT9)*L54BJ-W9&$@
MR=&064!%PD<0,&5S7'ERG&OP P56\\UV96RA[4:D:""_)-;+IE*\NZHZJZ.Z
M+J/4;T>*UKP[TZFK-H+#0-BNPIE6[,Y L"V P*-1,IE60774?_S-/-0J-=KM
M"@.(%UI6IZ+28OEM1==[G6T8ZM4'JC;499JJO8(J'?IV6?F[#&+33UJSB[C
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M/5,4W1T& 11.^(C$1B(Q$@PGX:+S^H5!_B]RQ$DV+^^#_H3?33Q$\"@B"IQ
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M[:OACV]S'Z>_ZQ^&/8!<,_>Z:V^*5O6L??=XG^G.0^VKX8]O<Q^GO^L?ACV
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M,BVB:S<5[LQ7C"R5L,B^5E'%=K)V[I1<RZ1V0,%"D3236!R;MA33P>43Q2-
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M/XB/+E0_<MGR"N_]/XB>9UO[6[%,JSYU9&:)UV[8BSFCW1%,SEVL1NU;E.I
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MATK> -LF4P+(!^1TZ]=Z^<U7IV:B5G,MW/I\1/6Q=FDM2;UWZ:U$146-E;7
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g129231g43p97.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g43p97.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1ZX4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'IR^>#8X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
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M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'0\@Q         *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
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M       $    'CA"24T#\P      "0           0 X0DE-)Q        H
M 0         !.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ !
M *&9F@ &       ! #(    ! %H    &       ! #4    ! "T    &
M   !.$))30/X      !P  #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z     #_____________________________ ^@  #A"24T$"
M    $     $   )    "0      X0DE-!!X       0     .$))300:
M  ,]    !@             "H@  ! $    $ &$ <@!C &@    !
M                  $             ! $   *B
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   *B     %)G:'1L;VYG   $
M 0    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "H@    !29VAT;&]N9P  ! $    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     0X0DE-! P     %%$
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M] MSNG>KTW,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L
M0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M_\  $0@ R $P P$1  (1 0,1 ?_$ !X  0 " @,! 0$            ("08'
M! 4* 0,"_\0 -A   00" @$$ 0,# P,#!0  ! (#!08!!P ($0D2$Q05%B$Q
M%R)1(T%A)"8R8G&1,U)T@;'_Q  = 0$  00# 0              !P0%!@@!
M @,)_\0 0A$  @(" @$# @0#!04&!04  @,!!  %!A$2!Q,A%#$(%2)!(S)1
M%D)A<? D,X&1L1=2H='A\3138G+!0W.2HL+_V@ , P$  A$#$0 _ /?QQC'&
M,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8SJIV/<EX2
M8BF3"8]Z3BSP&3PGG!S 73!71VS!"&5MNL$C+<2\P\TXAQMU"5H6E6,9QV O
M$Q*8@H$A*1F.XGJ8GJ8GXF)ZZF,]4,A+DMD!9"FK9*S&" X X*0(2B1(2Z\2
M$HF)B9B8F,Z#7,\]:*%3Y\E:5F2E=BB9!2//M_)?4:;DDI]V$JQA!Z"$>%)2
MK'M\93C/G'/2P$+>Y8_R@PQ'_P"V"GQG_B/65&RK13V%RL/\B;#07/??:O.9
M5/?^*Y&9_P _WSOV)V%*ECH$:5CWYJ,9&)D8EDQAR0!8+3[Q72Q$+R^PA]'A
M;2G$)PM"D+Q_:M&5><@<")R)0!3,"4Q,"4Q]XB>NIZ_?J<\"KO%*[)):-=I$
M"WDLH4PP_F$&3'B4C\Q,1,_,%'W&>NUYUSQQQC'&,<8QQC'&,<8QQC'&,<8Q
MQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&
M,<8S\4D#K?=&0^RHEAMIUX=+J%/LM/Y=2PXZUA67&VWE,/):6M.$N99=PC*L
MMK\=(8$F2X,)8$"1A!1)@)^7@1#$^0P?B7C,Q$%XEUWU.=Y6R %L@<+,C$&2
M)0!DOQDQ$YCQ(@@PDXB9D?(>XCRCO3'8G<X?7_4EGVD7#KL.8%44.)!MGM1B
MY,V7E@XH<=)S[3[8^$9+42XK++F<M,.)0G*LXY6TJIW;*JP3XRR9[*8[@1$9
M(BF.X^(B,R/B''&\LW]+2*=]-]2-AC+'MRZ5*K5VV#*%P0R4E[<+&/*(B3@I
M^(F,BOUMWA;K_P!/=E;!)AFJ2[1XJ_LU1<9(8DSWD5JL_J',L640+@-9+LP4
M4SEEH3#"&F,M^,J_U.7._26C:UT27N^^2)8,QXP,,9[?A'C,SUX1$Q,3W\YE
M_-N-T-'SG5ZM367HN%K6WAM (K@K5LJ\(  @3@!KK"?UD1S)=]]=1D)_3@V-
MO#LZQV$"LFV)]J7@AJE9:K8LCQ3I$;L&55)- S)SZ8]!Y\7@>JQ<9*U_![<5
M+5]),,6,H5UM+5YWE:AJF:^1JP:SEJWIEC9@JP]>8!YF4 R)>9+;UY SP./F
M)[]?7C0I7QVMK.-D''-GL*]A-':4A,/HF:QU2_0\ZRS75M5)OF++U=ZFS<KG
M9KL,1LM\KA]![CA-Z:TA[Q%+&9D4$2%<N4*._P#.JL7NM%.1-MKCZE80YG,;
M+COX$==;;4;&N@R"$8:+;\XUM->W67#K,\I"06^LR8Z]^J\897=$?;]:YCRB
M)GQ.##OL9S7CA'*ZW,N.4=TB%KL%[M/;4UL]S\MW5%DUMIKR*8@I^FMK8*C(
M1EJ)2^(@6CFYN6[,MQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC
M,6MMR@:5'-2$X2ZE19* (F+!&>D9R?E'4+<9B8&($2X=+23S;3KN!A&EY9&9
M?,)4P$,20U55*;[C?:3 QU'DQK3!2$+B8B6O>R16E<3,1Y&4=E, ,$9",VO;
M;BCI:T6;ILF6'":M6NIEF]>LR)$%2A32)OMV3$".%* O!8,<V5I4Q@:Q&W@0
M"0PY?]4;)U=7C'&61;?;,T22KK#Q*TMC-3S](N]M,JN'W%MM)-L04=%((<:%
M?D6BG6F5W'\EAL$-#9Z_96 $B*I6^M78. B9*:XW*=4+,C$27MH,W2,3(J*(
M*8QH>:G6,#W_ !?D7&=>TP6O;[2=%9URS9(BH;[-)N]L[5BPB@(?L$UZ@LD5
MG9!AK$][)4E:<*2K"DJQYPI.<93G'^<9QYQG'_..63[??,XB8F(F)B8GYB8G
MN)C^L3'WS[QG..,8XQCC&.,8XQCC&.,8XQCC&.,8XQF%6J]PU6<&CE(*F[/)
MI5F$J$&ALRP2RL9]F74#*=:9CXQI>4I-G9=\"$C\*PHV09RI"5T=J\BK(+GR
M;9;_ +FHF(.P[YB.Q#N(!8S,>X]L@E<?+&#&5U37OMP38D4553_'N/F0KI^.
M^I*(DF-F/Y*Z18]D_ +GYF(:[S@=B4[9/7O=[=@7'S4IM&IZKO\ $0;JDP2:
M1>Y\ 6,K[J7&VU3HT6>HQ#LO)CY)=E9A4C',0S+0@X6)[?6S6L4.2L;*=J&Q
MTU%Q5W$A,Z^]M*]"=<T0E8[!(?7M8,7!;U:9-FL"#6F%R!QW:5KNNWO$AK _
M4_D^[W%.;2A99';:S4V;GYFLYDRHO9%-*_"H:PFJF*UB;$,>;:T^_P#V<O4Q
M=.Q.FTOAD:TID[0WHH,D+!IF;6RW").&P62ZM34>Z2N>(:%:^!IDP01*%LLN
M/8<XU?).3U/4A6NU5,=KK#.8M42:M+U5QJ!];9JVGD( :"(FKJL-:;+!"L+D
M$WRF6_2OCFI_)];NB!E7?#1N0N]6(%$2'->*4MKS (>;%BH?J2@W F6F8NZ#
MPAAIS?O9[>U MG6_3TNG5FG-943:^SMRW:+ ^,VS0<:)(&RD=F560DAL23(;
M!J ,/"DB/$DDR)DZ^5%#N!#;4W-3I--K1Y)ME_6[:\Y=/3ZXF1*E,&(B+#A^
M?.%Q/OGY"4!VI4=&SRCYL>H'J5SC\0GXD!X'P?:;;CWI[K'Z^ONN3T#=K=WM
MZE2XJF=JCLZ<HLT(M6I]G3HI.KO-1'>V)-$64T;<Z7:+V-L_K7ONV:;A[;*;
M21;Z+4=>R$!MJ7U8W7C@H^4-L-@DWQY(&$L;,6),1#JXJ2#*)7\RL13X#CCC
MF;"6ZJ4^0H3LW)#6#6]R\'Y95O2TCDY6D%,7,*DQ$)\Q_EB8DP/N(F6/Q5>C
M%?5<0TFK],JO++?-4J=-+8.]3>3UKRHLV:]<MS>L[7>/HW33*+3&H) &XI+Z
M>4L6$A=-T"ZJ37434$]';#N;MHV%L:VO7W8$H3).E1[-CDF!P?@&*)4G[9;J
M&F4R,AG&79(_/GY2$(87G&^7\A5R&[6*M7!-77UHI59%?@;$@4D,F,=^(B/0
MK#^X,?,1,SF ^AWI;?\ 37CENELMI:W6_P"07OSK=F32L)7L65@"R-4I&&,&
M9 V.L,DF-+LB+P$('-ISN/2XG9&MJ@%"&3U1V59WJ,#L:*DPG8N)N"7G1Q(V
M2BUMI)2%(/-_$))()SA;J7DJ%2EI*GL<*H:P[9/@?S,!(S\]#)3$E'Q!?$Q
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MKK$>.QIT-EW/<N?6A%R?ZS-VC-6PPOW[L&^._F1GN8G%%\$IZXX9QS<\AXW
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MOVCDI^1&)%AP4S$Q\A!QY3,?>(B<^UWXO+S+\(O>FKW4#%1JNZ?D5=]@US
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M&-^_:E%5Q#NZ9Z(0I/8)3952M];$R*K!FH+=6C$/956SN#?]/GNQZ+H7U2=
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M3EU<E[&N]JR5>OT:UK8)F1DAOSY(MLZ$BC_:;"66ER,^#$N4U<R#(F<X]/\
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MFZV7&K;4A,<\U%5&+A&$@?&Z]^6M+AN''IHQPJ7>86U<<H<<T],!K-:Y^SW
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M'B%MQECAV18RRF_0+00I@I3QP!0Q:G'EX;K^7;2KR>P86EV-=97+;:I]MB9
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MPPCQ*(B1&)(2893$S/<=SD>]HS]8A-2+!NM>3(5+(E(]%/EX>Y,R$]S)3'E
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MS_((#/W$9^3.9@1F.HF9B8S'O3#T&W&^70Y!OI=JJ=AT%K:AUX*Q8\0E@6K
M--4)7WX'73,$U_8F<*3^LH9]+Z4YV.W'<KA1=/Q=1HQ\ 7"6B]2RXZSU>,D)
M-39#LM1ZG/U8JO/6J19;9;2R6T?'CAD%'I0$M;;QE3NWD8#KB('#(PUQD(DP
M/*"]D9\A,9+KIDC,?R2$S]X[D?U)V6M]/-53J6>27-WLJ]Q;-;KZ1V-.ZX-:
M(!BKNRUNQB_^4(,S$F(=68^PD$@3EP<+LJF>@Y<-[Y'1_8;96G)_"FEX<A8F
MH,5\[+3J'/;,UZHP]'#E5O(;PPLH_)3V$9]ZDO*RZE['A3[1^:"E<0(Q")B"
MJR41'9FF(B9(YC]1 83$? ^/49#2?6Q.R$*_->!<<Y95B6>3[%C:QN5"P3$1
MJ;79W-RRLM,G+ KK6*ID1'H8B)B!7;'0/?!U=>MEPO,S<6:(N2:CK[JJNQ4Q
M)Q,)-KC6Y>2Q76TU^T0TR -%LR0\E!KQ@=S[@JIX(0MUY%<F[5 _*[KR 8&5
M]U7-)#19,P4N^8>J/D9F!!@>(S!%U]Y!X5R#TR.O>U/%QIZ\]S*;#M+S-L((
MKU 6G015O$BYIKR6&YM?PNL18DF)8NH]JX&+*^D.J]-TS7.;5KN_';EM-C]@
MUTVS9B'3+?)&,I;+Q E-FD&'5V- R0V2- **?]WV&Y%\N26^T:OFS_/'BE*5
MR,$J$>)+-9=R!PT9+WHF)^#\RCORZZF2C($Y_NN1;';LJ[NBS2JJ&?TFB )K
MTZ424@;%UP!*)<<A(-<"5S/A"O (7 #-OE/F!8XQCC&.,9C\M#ODEB2\65@&
M7!0MG&7,96%)@N9][D9*-)_O6Q\F,/AEM9P5&E>YUCY1R#PCK?<I$YJ;=9OT
M]VO!BMDCYJ<D^I95M+B1EB#*!8,B0-2T!8LNO<6VMK606#*]E<NJNF"(1+Q:
MAL1T-BN4]C#('L6+*/;>O]!^)BER>@P4_'R$C;[,.#4HN*@"V)R0,FQ7HX@(
M!],@+).DY0,V(%$-*F%J).2(ZEL]SY&?:GW-<U:URQL5,BH(.97^D,*[2L':
M;+Q*LM8"E9LA,R_VB,1.)M,$5=F4BOW==0U+Y=?'Z:LZ;\V+01310KA7.+K7
ML:TE+AHA6ELP9K$:@E+8B.BI9OO:&F;AN%\WD2:Q0M/4'8-7UD/M&TF-5YI_
M70I]=&F;#5VIEC")^7.F+999:/A(M@UX>OQ:96?0R^S&PTE(](Z_!%;2]7U<
M<CY7M3X]J+.NK1+GT*=G:+IU@M>P+"11H,V=W:/DY45EGDL#%2IL(UKN\FGU
MAN:W7,W@<#].^-.Y5MJW*-NQ="EM;5#3S<M6*'YB5=%W<[D==5TFKK+BT&LJ
M+F_<7[]H-7?K4GW6_5![TJ!K[<P#U5T56BR&4H26)B-TU1/)LN:G+V$J#M6V
M)["VV23/$LTB4$>.P5BN/X1,;&-X#Q*2=*V\KY!9^9#VS,]C:B!"%@ S!5]8
MLA$%KCV9; BL8%T1FL-&G'XA?66AK-?)4/33B85ZP':EM>M3XS2<,V+-EK&+
ME-SD-N#-UAY#9779#+!$5%DY8%2JO9_4'MLWI6BF.4;I1U^AY@"1DJVPF/B]
MJ;VD@SR(8&'4A&&WJ)0),P0V'B?C6PBL0\,U(-+;M0/T(PY#35QG5.59,F<I
MW]4ENDRB6Z?7M"0F(.)]P=A9#YL/\A.&R<+G]!&S9;BW+F>K_JS1;HZ*E^A'
MI1MM0%>A]/X4^=6]$:1U^N<,B*3THJK+L,I+&5LJDL[@=;1*:^[?2+G;"ZO?
M='ODSF3O&M3:O47!G1LLN1D*Q9=FR;XR%XQEE2<VF5L"G6VLH^+_ $&_A0PV
M-YBZI2*C0KIDS="V/6+C-C)( D/ 98R2,B'YF9,B/J8B3/J"GZ'>O;Z]_::/
M;ZVG%/6;F@&SD5^$*;=?2UZI;X+@0"9U]>@$1 Q$DMIC$21Q%T//7( QQC'&
M,<8QQC'&,<8QQC(I]UXC-@ZV[#@7I";BHJ8'C K#(U_#69$2N9E1'II>$D.-
M"N#.@LNCF,&.)"*&>=$,S]5][F9\ M#2Y5K;GTR;C:WU#:M9\D*W6XKL&N,2
M D<'#"@UDL98#!$UQ)B.8;SZFS8\6V-$+C: 69KKL6TB)DFK%A9V)D#(%DLU
MC*V"TA40&0MGVY+-:=(-5]1*O%SUXZSS;=PF):)@*M=+619BIZ:P-%8)D8B!
ME!\$9C(SZ3AI;S(P0J/9AU:$ONM)3XO'J'N^<WFTZ'+JDZY"V6+VNI#0745/
MOR*FV%,E<6'P4+$")K"^1^1@^\Q[TUX_PC6A?O\ %=NW?7"%&NVNQ?LHNL"4
M##E5"KUI70I^'G[D+KUUST?<D0S&=YL'6LAOR>BMC5&RUUB1H-AD8>#/ +DP
MCHA<')N8(;,D@3O?DQ3ON*4,_'H&^J5EM.'Q2$$D6FE>I:6NRA;KV3*VE3G0
M0+8MLN4,R +.!B B)\/*#*9F.Y^8\1R&Y5O[:P-VJU !6:Q*I@I6P!4R?U&<
M29213'G R(0,%'7<=%-8M3[ Q3_;2D4/ID[MN]P9.P08+<!(-7*C=:1 ;)CJ
MK%.M2 OM"?BB,CE/LI/C0T--+08P66*2RI4O;'A5\.+;+=<]M:JA:C3LN:FN
MVV#MC9=*QBI69+9ABG@)!$@@WF3(%)"J8.(AC6^H.J;R/3Z'T]J7=A6G?KU^
MT8JN5>I7I Y@W[]:M5 _>IP^.O?LJJUP4;+/NL'VO<]"O-;,V9QQC'&,<8QQ
MC'&,P39U[B=8Z^MU^FRA XVK09DH\^>^@8/#S:/C":((<4E#+1!SHPZG%*3A
M'R^<YQXYW6$L, 'N9(HCXB2GY^\Q$?,]1\]?X9>./Z>QR#=ZO2U5M:_97451
M%(^3? SCW3 >B[E:88S[3'0SW$QGF#'Z);P[53NU]RT6-A(&*+GIN6B(DEQN
M,<F'I(EP\*+A@T_7C02<@$-$DAF'B-1^26V"D-ON_7Y5VU(!J819M F D#68
ME$ 03XD*X*0*4&?E)@0^,E'Z/B9@?HY6]:^%^F6MTO$N3+"WNHJTJY7J\':*
MFE*Q1-[>/$'O8Z/;]JE8JA:-J AL+]KIS+;.AFA6.F.MK5-;MLT+!7N\2Z!R
M(C$L(2M4;!.EL1 T:!'NONS<U+$%EDB!0XQ1:Q'X\5@?[CA+..6&^[(Q D]D
M3,L=XP,3_=&._@%+$(@I\O&(DI\NNLU%]:.;*]2^2U0XO3D]#JZO=6452KKF
MS=!+;KGR:D!76F%IKL-L+4)H<V3D3\YQCM-T2FNZ=I1MT9;&IRP(>/@8> L0
M!")^^Q(!!I29>U.CK?S1#'6B\1T,*]$6&5'CVVW;"",2V/$Q]TU^W#5+*OU-
MF#(C,P+I:BF(B!7$Q_%B)CR,NQ&9B(#N.RFW</\ 457!:4Z-LGN$,:ZRU]1@
M%6UMAH",)J"<#&Q7!C[MDQ?63+9+Z5C!DG.V/W"W94NF?62M:THD !'34_7&
MZ14ZBT9A:H*N,@-BV:;?>%6R2<2,T4H1N0;4E\^?DDRCJG4LF\H:E8MC9>UY
M^0#),<4]C[DE,^(1^XP41/VC](1U'4S&<>FG%[WJ#S*UO-G8:VGKK<;._=E?
M<V[TMDZ%-8,$P$&&L38N1($U%2GH?-6>:KK5MG7%9[,TN7WY2'IK2D))DP<U
M7+*P[)J0\2VH<2YS8+GOS:%QQ[0<B:"4T^&7&(6&"&1G"$/5*=:V]5LV5RJM
M64$#7A<"M#9442*$2,QY+[@NW01>XV8&99VSQW+]1$; >(.TG#;]HN;;0 N%
M;K'[;4+D)FU1$H[&BZR'DE7A*FUB&+#&HB Z]%$-ZF6B8:[1='IM$S'ZC9*3
M&,W>(P'#QX[&,X9;DXFF@1*<9@VU80K^XP.0R'Y=1&I>;0&[U+2V23+B<)/D
M?/VI[*9_K$LF9[+]OMX^7QY=?.::7/2'DY:]NQV>PD]U*I;.NL"Y[ID?U2AU
MUK?A\Q,QU &H6?IEO4D0VBPLU$V*)CIZ"D1):&EPV)",D@'D$!FADMX=8('>
M;SE*VW$*QG&<9\XSY2K&%8SC%E(2 I$HD2&9@HGXF)C[Q.0X]#JSFU["C2])
MDIJF#(,6P)D2 QGJ8(9B8F)SL^=<\LA'<^O1VO=BS.Y]0%6F. LRF/ZBZ[HI
M+$<<00XLA1=]IP9CCM>D["(\H4J0I\Y$%Q4^.J:*"PBRE!X?K*C0 #KL]N5%
M,FH7#)+6R9[./(9@U W[S*I'Q9V<_!L[D,.7QNM12TF^13L6]<!IUVZO";29
M5$5Q6U>R,/&P*5B+$UMDEP6:ZYK5VR5.O'A)_6,C;)6DQ!UU%=$GWG)1*TE
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M,1$F7S,1T,"(!$S #'43,S,S+NRV)W"@/>>\(83F6+/46+5@Q "<T8-@@(+
M4UT"PQ0H>A+LS[V5SPRUXXQCC&.,8XQCC&.,8XQCC&5D]ZHBN]>-.73L%"0+
M<@J!EZJV12XLC%7B)%,U8HJO!/EF!CF/)5$DRI$@VAMA+#CCOQ(:&QA2URAP
MFX_D.XI:"T<^5M=B)V#I*S8[4EU@H(2E?F)P$!$DSR"(\I,_B(@KUCV"_3C@
M^ZYO0HJLCI9H^WIDF.OK$%F]4H+D& FQ"I05B6]!7D3Z@!%?R>8ITSV-J_U
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M<8R-.Q.X?6K5-KE:5>]K0L18ZX."9;Q!8^PSXE!"DQTFQYNR)FN0\M":W",
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$&,__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g129231g48w84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g48w84.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2A.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    *#*^$"D#A"24T$!       #QP!6@ #&R5'' (   (    X0DE-!"4
M   !#-S_I]J,>^"05P=JZO!<-..$))300Z      $+    $     $
MMP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $
MEN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&
M5R3F%M951%6%0    4 $, 80!N &\ ;@ @ %0 4P U #$ ,  P "  <P!E '
M( :0!E ',       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &
M8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N96YU;0
M    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !
M     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;
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M0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
MIV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !09U!#
M   $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F
M$ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0    8
M    $X0DE- _@      '   /____________________________\#Z
M#_____________________________ ^@     ______________________
M_______P/H     /____________________________\#Z   .$))300(
M     0     0   D    )      #A"24T$'@      !      X0DE-!!H
M   S4    &              /;   '           !
M        $             !P    /;                      $
M                  $     $       !N=6QL     @    9B;W5N9'-/8F
MIC     0       %)C=#$    $     %1O<"!L;VYG          !,969T;&
M]N9P          0G1O;6QO;F<   /;     %)G:'1L;VYG   '      9S;&
MEC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L:6-E24
M1L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0
MQ%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0
MI%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $       !28W
M0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;V
MUL;VYG   #VP    !29VAT;&]N9P  !P     #=7)L5$585     $
M!N=6QL5$585     $       !-<V=E5$585     $       9A;'1486=415
MA4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415
MA4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N
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M$       $! #A"24T$%       !     4X0DE-! P     ':4    !    H
M   %@   '@  "E    '8D &  !_]C_X@Q824-#7U!23T9)3$4  0$   Q(3&
MEN;P(0  !M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14
M,@<U)'0@               0  ]M8  0    #3+4A0("
M                                               !%C<')T   !4
M   #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:
M "&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;6
M1D   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !
M1M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/
M  " QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97
M=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3
MDV-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                      6%E:(
M       /-1  $    !%LQ865H@                     %A96B
M!OH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*
M^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M      %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                    !D97-C         "Y)14,@-C
M$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M       "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92
M M('-21T(                             9&5S8P         L4F5F97
M)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
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M0)N@G/">4)^PH1"B<*/0I4"FH*@0J8"JX*Q0K<"O,+"PLB"SD+40MI"X +F
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MN]%;V/O@J^A+[_OWJ_]<!PP.S!8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M971VA(6BL[2UX0D8<G.#I<4X8H*RP\3C9I:VPAEWAO_:  P# 0 "$0,1 #\
M^_C2E>;_ "I6Z_*FSK;3%Y2PVPIDA=YK+N/\=-27R.E92OMV=N-+D<NE6D-+
M0STRZ1V" )G!V8B:9UC"W6/T8!N.!L/P,27M4"Y.2FXK<"9,68:VVWU*CH24
MH2IQ"T#2*N(@9D :0SK3\<7Z;AVRHG6]$9<IVXPH2-UI<6RE,E:@I2DM+0X2
M G5HDY9DY'*L*4?>;O"P3NOPYM?WWTC![R)W&L;,3$.:MOKBZ-JZE:JHQ+(2
M%5ML#=A6D$EUT3M447++H"(N):(,7M@V6D58C)2L-X>NF'[A?<+2KFERRK8Z
MI6R[B,73'D*T$28[\8A"D@Z1*%C2(;65:)"0K&,8DO\ :K_;K'B>+;%-WE$C
MJ=<K2909V^,D+<8DLR=):%%*D@*2=$*6C(K!5HYHQWRK6T/)V0:_CFO2N4F$
MM>8JQ3&,)6UX8R34ZYEEI5H=W/2Y,<2L[7V8V%V6+9++,6O8[1647,VCX\KF
M1>LVCC&S,"X@A079[K<%;49;#<YIBYP7Y%N5(6&VC/9;?4J.G3("U*)#62BZ
M4!"RG)Q,=6";-9@-+N"'I3;SD%<BUSX[%P3';4ZZ(3KK"4OJ"$$I2,BYFD-A
M16C2OJ,Y1O:G-8DP7FJ(NTI)4O<;E)EAG%1&-5GW=CF<@O9>5@QAGM908J3,
M05F_AG9'[R0:HM6J2K!=13HI%D=:V<P=B!JXW6UN1$(E66 NYW#2D,I9:AH;
M:=+J'BH-N:27D:"4**E'23D"@BKA&,;"Y;[5<VY2UQKU/1;8&C'>4\Y,4XZV
M6E,I07$:"FEZ:E)T4C143DH&JAMXW_[?-T=X?4O#QLE3;9-C9)*!R#)XIO<!
MBN[LJC,-(&QJ4G(,Q"M*]/*1<H]0;JMR.4'*P=*JU2<)(JG)3N^%+O8HK4FY
M"$RIQ3"7(:+A$>N$4R65OQ]UPFW"^P'6D%:2I)&B4DD:0JI:,56F^R7(]MW<
MZA*7UMS5V^4U;I0C.H8?W).<;$>1M3JTI.@O,G2T0=%67YSQR@6WK;SD]KAV
MX*Y(LE_"K-+U8H7%^*KUDTU$HSZ05BVMOO"E.AI0L#"JO43I<\_3O"%,W759
MD0>,U7"UX4N]V@+N4<0F(8?7%9=GW") $N4AL.+CQ=TNM[<ZE"DE03[D9@%6
MEF!%TQ9:;3/;MC^[9$Q3"93S4"!+GF)%6X6D299C-.;2TM84 5>Z.B2$D9$Z
M^FWX0^'<W\H#(9XS97I+">V$^WXJ5-K&*[:E;<6ERTU91[8T_/DCC-[R%BG)
M:-51&!7EPB&QE5'@Q1$E&QLN,*O7*V821:K5(1<[YU7)DOW"*8UPW I2R&&=
M(+B%AM"DJ#VAMJM:-/,&L0<5LVZYXK7=;HRJVV06D[F9M\D2(.[T9 NOZ.C+
M#SBDD%H*VH$Z91HD5E_ _*<;.]Q=KR'4,>9%D&\AC:DOLG3+RZ5.QT6'D\81
MJC=.0R-7Y*T1\:C)5!IV6T56DU :*=B.D'Y&QV!^R0Q]UP5B.S1X4F9"0I$Z
M2F$TF+(8EN(FJ!*8;R(ZW"U)5D=%LYYD:)(40FLA:\;8=O$B;&AS%!R#&,YU
M4EAV*VY!20%36%O)1MD89I)=  *5!0!!SJWL8<J[LMRNRR%-05\LT%5L<4*>
MRC)W*\8YO-.JD[CVLSD969JTTZ7F8-!*S-6EBFHB$+&L"#/.Y22:,F42Y74Y
MA:MPP)B6VKA-/Q&')$Z2W"1%BSHDF4S,=;<>;C26&G5+86IIIUPJ7DVE"%*4
ML '*E QWARX(FNLRGVHT&*Y.<ERH4J-&>B-.(:<D1GGFDI>0''6T )^V+4M(
M0@YUD?;5O_V[;J+C+8\QR_O,)?(RGLLBMJCDS'5NQQ-V/'$F\081V0*HVM$8
MQ)8*D\=.VB2,FQ5.<O9;4ZK=)-=,YK2]82O-@CM2IR(CD5R0N&9$"=%GLLS6
MDZ;D-]<9Q89DH3[HMKR5D".,$5>67%EGOLAR)#7*:E-QFY@C3H4F"\]#=5HM
MRV$2&T%Z.M6H.(S&L'B(-:Z;O]X^XYCNHQGL6V757&DAFZXX\?9=O61,PGG'
M% QGCUJ_D(MHLXB:VHE*OY:2?QQD2G 7"3960@VQ8]UVU6>1>7P[AVSKL,[%
M>)7YR+7%FMVV+!MH:$R?-6A#JDAU[-MMIMM1).04K:W2%#:PES$8@Q%=TWR#
MA;#;,)5TDPUW&5,N!<,6#!0M;05M3/NW7G'$Y)3GD I&:2%*4B3FC=3NLVC[
M#LJY=W*P.&'NY*MV-*BXK98N5L<ACW)<W;9*!A<?RB4),.F-D0<B\EY5[/5O
MLQJX.PK#YPS501=(B3Q:[#8\18J@6ZRNW-%E?:,J>N:&DS(+$=MUV8G;60ZR
MI*4-MI;?T"--X!23D2?5SOU\P]A:=<;RU;7+PPZ(L%N"7E19STA;+4->UO%#
MJ%J4XM3K 7J2THI7D<AC#!G**9LN?)];O<RY'JM(KF[#9VMFVIY#I*+&1)4D
M;KCR,=3%><+0P3KJ1[3.DC$C'78UB52DGL+++L'Z**J9&]_=,'6V/BW#MLA2
M93U@Q(+7(A2U%&Z3$FK2AU.V;4&P\@9K&;>:$N-Z22>.PMF,;C(PEB&Y3(\=
MJ^X;-S8FQ4A>Y]U0D+6WDC3+A:6!HYA?NUMK*2!J&M>#>4SWR6;(>UC'5S2V
MA7R1WL8EM=KQ>3%R]Z1LV&;0UH;NSUISFFKKS4PL6LIR0-F]@1C3(N#QK*QN
MHV5!Q!F9OLS<\$X8:A7^=$7B**WABXL1IW5 1"Q<V3,$=Y-M?#:$A\MA2V]L
MTO=K826U)<4MO#6S&V)GIN'H4E.'Y2\3VZ1)A[A5*#]N>3#,AHW".IUQ2F Y
MHH<*-K.@E]06DMI2Y>N*]T7*U7S>3E?:&\DMC2%AP1!8[NN0IQ*L9B2A):K7
MAK79<K2I.QF%WQYQ"+GDTC%EHEBR(\24 KA9("G/9S[)@&+AN!B%",4*;NKL
MZ+$95(MVV-R(FVH"Y"0V$):4XV#]K6I922,@=9O(-]QW)Q)/P^M6&0NUM0I,
MMT,W$(<CR]J7HQSMBE%U*'"/=H"<QQZ]7KMNAW982V?8^:9(S?9'<+#2U@CZ
ME7(R&AY"QV>U6B43<+LH&N0$2BN]D7RC9F[<J&$$6C9!N8[ERD)TBJ:'8[#<
M\133!M;*'74,KDON.NMQX\:.V4A;[[[I2VVVDJ UG24HA*$J)RK?;Y?K;AZ&
MF;<WE--+>1'90TTX_(D/N9Z#+##25..+(22<@$I2"I2@!G7EWM<Y5&MWS+/*
M092R=E-2/VB;=VV!9+'!I^B*U>>IY+?#S\3;8&0B"U]E>)2RR%]C$H%O"2Z4
MB_": K"(+T#A/I-XOV!'H=OP7"@P"O$-Z-V1,2U*W0S*5'?:7&>:<VU<5N.F
M&L.EQO03H%2W,U Y:18L=QY<_&<V;.T,/V86IR&7HICNQDOLN-R67&RTB2MY
M4Q&U);<"EASW"/<D9VQ5.57D\X[R+["X$LLPO@^B\G]DS-3G'^0<;.*E+(YI
MJ,\>1AW\JI,1<?;%H>0ITA7'3=*)G5*](Q<HFY;'+(].=O6DX!3:\-PG;JRV
MFZRL81+4F7$G"2RJVR(^BXEO:G5Q]L;DI>2I2V0\E:""='(&A%QXJZ8CF,VI
MYQ5KB80F71467"5'>3<H\G-M:RZVA_:W(RV5!*'"TI"PI.1SK'FT;E4MW&1\
MF[,H?)@;5,FU;=ZZM+)Y2L&+VYOFG"3>M]DE5LF1(!_/V%A&0A00%^<7*92.
M8MO(*)O&JS8HJW=_P'8(4+$RX2K]"D8<$=8DW1,=5LNFWJ2$M0WD-,N*<5GH
M)R!&V%(R*#FFTL&.[],F88;FIL4UC$9D)7&M:I";E:]SI45NS&G'GD!I&6FL
MDI.UA1!*@-+-]=WC<H=O#R?GQYL6K&VBNX(V\9+F<2HSN>3WIY/9FNU5*FK/
MH0:M5,FVKT0=%=HNS5>-T3(-9*)67D5U7+YK%XU_#F$,-P;2G%,B^/W6\P6K
MBIJTHBI:M<61I;27$R5)7(>&@I*P%)2I:7$H1DE+CF29Q%B[$4Z[KPNQ96;5
M9ISMM#MU5*4[<Y<?1VY+9CYHCM>[&@LI40E3:E**E+;:L3)G*NY^PURCD%MO
MR-1L:1>WQG,;>Z)DRQ-$)QW9Z7=\\XS;3[%R%F">+#KP,7=#2#([I6N DI 1
MQA,L1^Y17&Z@8!M5RP8[>H<R8N\*1=Y4*.LLH8E1;5,+;B=JVLN!]48MJ"4O
M'[<X !HI(%M.QY=;;C)FRS(D--G"K3&FR$!U3\:7=8I6@[:'- M-R04DED L
M@G/2*<[QW)\J+EZB\H]B':;B&K428P_Z;6 \,9QN<Y'S,A.,+[FU](2Q*_6I
M!A.Q\6S<Q-&9D>CV3'RAT)DKQN^(4J)$#6UEP-;YF#KA?[A)E-7#J;>+I;(K
M);2TN):4-M*=?"VE+5MLQU*$A*D9M#223F2FO>\<SXF,+=8;='BO6\W*SVNZ
M274NJ=;EW5;CB6F5(<0VDMQ6RO-27/MA*%!.6N+O\Y5'+NU_=A#8YQC3*?;,
M%8=B,16/>%9Y./DGL]28[+MZ3K\/'1#YE-LFT1(DKB\;,,S/8B5!TXFV95$2
M($_39PG@2!?;"[-G2I,:ZW%RXLX<CH6VEF8Y;8FWO%P+;4M:2\"T=%:-%*5*
M.9R26*\=3[%?FX<.(Q(M5N;MS^(I*T.*=B-W&9N=L-J2XE*%):*'LE(7IZ:$
MC(:93[*9<M;BN89R5>*_88V#=06,[A:H:U/8]>P0T.K&5>0EV%@=Q,?SW,Y&
MQYD$I%:/9<]>2;)&;MBG46( \Y@L!ZX0XSK+CJ79D=AUA#B677 MY#:F4..>
MX:<7F4!:\DMDZ2B ,ZZ-.?+5OER6G4-*;AOOMOK;4\VV4,J6AU33?NW4)R"R
MA'NE@9#6:\VJ'RI6#<4[>=LMAW,Y>4N>2<XXRE[M!3N.,17I-ED9>%L/:)RU
MK529P(RC"56>NVD>SBWC".4>F;.Y0R$?'@84MSDX&NTZ\7MBS6[<T*U7!$-]
MN;<8A5!VQI2P7Y1<2VMH;6M2GDDI3IMM@K6:TR+CBUP;19'[S<#*F76 Y,8<
MAVZ6D3MJ=0V4L14MJ<0Z=M;2&2 HZ+BR$I!(UEWX<L)5R[8,'WG9ID:9AIO/
M.9VF/5\@.L23%F?XTKE>553R*56JSD,XAW60H]P[KA(>GO2N7UAAI-W*UU-R
MBFA)(YO"VQW(-^NL+$D)"V[1;')HAHN3,=,YYU(,'1DMNI6F&YHO;9*00TPM
M"4/J"B6E83%.R&P+%:IF')KC:[O=&X6[%VY]]4)ELY3"J,XT4F8V5L[5%6"N
M0A2U,@I&V)]"\';W\/O:?>*A:,IV?(60]M6 <?9BSM;Y;$TUCM](5FW8Z:Y"
M86L:<1D#:.FI>NK$DY&FQ/2N8-^L>(,@FNB9%/3[GAFXHD1)#%O:B0[W=IEO
MM,=NX-S@EZ-,,-;&Z-(J6TV_DTW)7[A\#;$J4#G6WVS$EO5'E1I$]V7,LEJA
M7"[2'(*X:E,R8>ZT2#& T6W'&07'(S>:F5':R H952[/RIFTZN1F)G[.0RA>
M'F9,9I9GJ]<QMA_(%[M4;B=607BO1_:X&OPCM[7*\E)-7;)59Z7LLJS5?F-%
M$R <U9C U_>7<4*1!BIMDXVV0].N,2&PNX !6Y(SKSB4OOE!2L)0<M%225#,
M"J3V.;"RW;EI7.E*N<%-RCL0K=+F246]1R$N0PPVMQED*!22H:6D% ).B<K?
MJ>\EC![H][4;E+/M#;X,V]8TPW?2U-;']EK4]BV,NU*C;*ZEK-<W\<FSMIK$
M1\@XBX:%5E95-Q),X8L?'R;<S%[[?PXXY8\,NP;3+5<[S.N45,@3&'F9ZXKZ
MF4M1XC:BXQM)0K;77=!LA*G 2G6FDQB-MN^XE:FW:(FVV>#;I1C*B/L/04R8
MZ7E.R);B0V_MVD-K:;TEI*DMD!?N57-@_E2MHF?K5(4FH6:ZP-I1HLKD^OP^
M0\<7"B.;[CV&9.9%];: ,_&-DK1&$8,W;Y%%DH$DY9-'KUNP5:Q[]9K2NN!\
M0VAA$F0Q%>8,IN"\["G1IB(DQU00F-,+"U&.X%J2A6F @+4E!7I*0%5[5CC#
M]WDJB1GI34@1G)K+<V%)AF7$:!4J3#V]M(D-:*5*&@=-2$J6E!2A93;&)N5^
MV-9KR9C?%="R'97<]E=<L72Y65Q[<(*IR-K,S2?>@@UEE8IK&DMA$'+,BL>1
M15NB^?L8I5Z25=H,CU[AL?8HM<&=/F0F$,V[)4MMN;$>D-,G1 E%AMU3AC'2
M.3F0S"%JT=%)-4+?L@X7N<R%!B3'U.W#-,5QR%*9C./#/.-NAUI+6Z$D %L*
M.2EH3GI* J1RHVXC*6#L0XDIV"; -3S5N2W$XJP+1;6G'1,PO4T[1+G?V*QH
MQ$\PDX=\*,3%'AA*^8N$T#3A'1"E602,# UF@W2XW&3=61(M=DLUPNTN.7'&
MA(+#6@PRIQE:'$!3RTN$H4"0TI).BHTQS>)]KM]OCVMTL7*]7FWVF+(2VTZJ
M.)#A6\Z&WD.-*(:;4V--) +H4/=)%7'G'E-MK&VJ\3N-LG3&45G^/E*Q'9-N
M<!A[(%EH>/7MIBH>6@ N]UA:\:OL7DQ&3L/(%;1:C\Z?;-N@*"2YNQR4+3@F
M^WR*W+@(@ 2@^N#$>N41B;-1'6XA[<D5YX/N!I33B"I02"6U'2.1RKW7&MBL
MDER)/<GDQ5,-S93-MFR(<-;Z&UL[KE,LJ9;4XEQM02DJ5DM/N1F*NG)/*);:
M\9Y;C<*NY#(%UNKF!J=JG1Q9C"ZY*@:+6+TLDC4;#>IZIQ,C'5V*G2N&SIHN
MJJL=-@\8OW:3=F_9+N*$'"-YGVY=S0B'&C)=?8:$^?%@O2WXJ2J0S#9DN-N2
M'&0"%I0-2P4 E0(%>;BZS09Z+:I4R3)+4=]W<$"7.:B,2E!,=Z6[':6B.V[I
M!22LYZ!"R D@G8'/FX#$NV/%T_F/-=M:TR@USL-)[*+MGL@Z<OI%P1I&1,1$
MQ;9Y*2\O(NE"HM(^/:+KG %5SE3:MW"Z6)M5JN%[G,VZV1E2I;^D4-I*4I2A
M TG'''%E+;3;:<U+6M24@:L\R <M=;M LL%VXW.0F-$9T0MPA2B5K.BAMM"
M7''%J]RA"$E2CKRR!(T"L?*Y;;);!>Y.\XY>WMKDW ^.U;0[Q?>\57JNW9NZ
ML2:,70)UY5'46F^=TM]9): +.3K)8[2OP\BA*3RL4Q=M'*^UM;']Z;NMEB2Q
M#5!N\P1T7&'<8;\-0:)7+:1*#FU)EHCH=4VPO)QQ8"&T.*.C6J.X_LSEKO<N
M&98FVB&9#EOE0)3,M)=2$Q'5QBC;%15O+;#CR,VVV])QU2$>ZJK<D5G;+&Y'
M:N&7LQYDE\N6NP6Q9)X$KA]CB-K0W9:]7Y1Y3:ZI',HYED&MLRR[9XPO39IT
M#QRZ?Q2;EP:*4Z.EL@6J!9<0.6ZWVU%NCL,Y(T;BNX*EI#SR$RG@M2E0GEZ!
M0J&I04V$)4I(*B34V/[I/O-@3<+C<7+A(?>))7;1;DQ<V65*BLZ*4":R@JTD
M2PG)96I UH(&M%-Y4G,.5.4EQ?@?'U6HI]GV1KKFC%]8R*\CY5Y;LA67!% 7
MGK[:JE+H3C>&)3T;B\CZ["/4HB4:3#.-DG"3XKHZJ$?FY.!8$#!DZ[3),H8B
MA,6R:_"2ML1HD:[2PU#8D(+9=W4J,AR0ZG;$;7MC0T2G(UA8N.;A.QG M,2-
M&.'9TBZP8\Y0<5)ER+-$V^9(CK2X&MRB0M$=I>BX'-K=)((R&PW*R;T,][,<
M9X8GMN]0J%WO&2\N!1E(&VQ,O,D?1R%1L-B4:0[2'G8%QVV=KQ***!A<.3')
MST$&BKA9+ABL 89M6)IUS:O$J1#BP;<96W,+;1HK,AEK2=4XT\ TA+BEJR2"
M<AF<JRV/<2W3#4*V/6B*Q,E3KB(FTOI<7IIW.\]HM);=:)<6IM*4YJ(UG5GD
M1:N-^4KD<X9ZY.ZOXP:U7TH]W>(<W7;(";]-V_MM.N6*ZJX?NJHRE6\HVCV9
MX&T1\A#S(/HAV:0;H Z:G;)+(JFK3,$BV6K&3T];XN&'+C:XD4(T4L2(\^0$
MB0M!0M:@\PM"VPEQ.@3D=(Y@6\3&RKC=<%LPD,&WXEM]UDRRO24_%D6Z*751
MTJ"DH26GT+:=*D*T@ 1HC(UE2"Y7;8[8\G1.,XO(EB42L-Z5QA6\GKX_N#;"
M]BR$DL1N-3A<G+11*X]?J+J(D;O"KEAG2;AJZ;RBC-TW<*V#NQ_BAF [/7#8
MS8B)GOP$S8RKHQ"4-(27;>'#(2WH^Z(T"XGB4@*! R#6R!AAV>W!1,>R>EJ@
M,3E1)";:_-20DQFIQ;VA3FEFD'2""1FE9203?0<I=M+' =DW(C<YY/'%2RL;
M",XDK2K,G<6V42R$?'C4$Z4:."Q+RO&4:/>@38B8(T57I@!-!7F6F\W$'59F
MR[D;W:_;A=6ONE@QU6\M+>W3ND++(1HH*=:OTS) S*AG=;\[#U*>O.Z7=Q,7
M#J6[]S/"0F=MJ6MHW,4!XKTEI.6C]YFOB!K,>Y][NK)CV*;;08G$;G)DQ9F+
M&2F,WO["TIU1J1XN6=R$^>.K2*DS-2I9%M$13.+0X%*,FJ\<E,@S5*&-LHL6
MZUJQ"NXI@ML+6AJUH95)D2 M"4-;8^I+;+)2I;BW=%2@$!*4YKS3D;TJ^;D0
MG#Z+>9KKR$K<N:W4QXT<H<4M[:V$J<>="TH0AH:*25E2E ((/G)L=W[[OL]X
M<W=,[#AG'66=Q.V#+0XB@&V,K02D8SRK-'F%H1^[;62V.WS2.CZIV$\LDI((
MJE/,5M:.)&Q#:6=)(.-SQ3A3#UIN6'E,7.; M%\MPN+QG1Q)G6]O0VU*"PQD
M7') *6FD$ )>TM-PMC-.FX7Q7B"ZV[$"'K=$GW>QW(VUG<3VYH,]W3#:EAZ0
M5!MME06ZXL9E;.CH-A:@DUS9UNFW3;S]AVZ>\S<M4<8[AJ-?<YXQH<UC" !>
M'@YR@5"N3%<5)'7-Q:VTPH:P2;F/=N7J!DGD:9(Y&+=R7I!H8BL5CPUBFQQD
M)DSK/*BVJ?*;G.Z+KC$UYQ#P*HP9+?VE*5I2A7N%Y@N* SJOAV^WS$F%KY*6
MJ-!N\:7=H$1R$WIM-/PFFRRK0D[<ES)Y2D**TD*2 = $ZMQN3QW#R>ZK9?M_
MSE8%T7-LMU**SNSA%)LV*YN]2E9*FVY^#)H!&[ DK/P#^608I)HI-FKY!-%)
M-$$RA@,7V=NP8DN]J9SW/&DZ48%164Q9+;<J,A2SF5J0P\VA:B22I)).>=;#
MA&\+O^&[1=7""_)BA,D@!(,J.XN-)4$I 2D+?9<6E(  2H9:LJW/UK=;'32E
M-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4T
MI32E>6_*\;<\U;G-JT)0\"4]M>[[!9MQI?PK;FRUVIE>0U5/-*2(DF+1(Q<2
MDH4[QL4$U'8+'(<YD4EC)BF.\['MXMEDOSDN[251(CMLG1"^EAZ24N2$MI1]
MJ82MPC42<AEJR)&8-:/L@6>Y7RPMQ+5'3*E-W.#+VE3[4<*;C+6M?VUY24 Z
MTCC)UD@'+*M?G.W[?MO%W486W#;@\8X[VJ4O:Q 9%F,/XY:Y+ALQV>SY=N$#
MVKAY^S3=78IP3.MQ+YM"2;E$I1="G"&CB1CTLTN^C<J+OA;#M@NEFM$^9?9-
M_=A-W*883EM8CVZ,\5N,,-/J4ZM]Q*G4)7F$@.Z9(4@).*5:,4XAO]LO%WAP
M[%%L+4URW0T3$7%^1<)36UH>?=92EI,=O1:64:.EI-E.BL+*DZ?X)V2<HQ,[
MF]EN6-QE"RG+RN$<IW6>S/DW(>[*EY/JTZUL3250BYO$^(HZ:*TQW7F3!M%1
ML@PBVA)Z4<.68+0B4?'&4;[#=<2X-:LN)H%EDPFFKM B,VR##L$B%(84PXVI
MQJX7)Q 7,><6IQQ*EJ6P@-ZEE;A!UZU8:QB[><-3[S%FN.VF?+=N4Z9B!B;'
MD)?9<0AVWVQM9;AL)&UH*4)0^I1UMZ"210MIFUJ6;\L!E_"<9+M)K;;LRO62
M=T-"J+4P*P5;R7N,JE*:P%.<JD*<&2U:345=1;0XJ=@*T]VZ!,RLD] *V(+Z
MTO8[MES<:6U>L2Q85ADR2,EO0;+)DK>D(RR*R\HA#JB<G$2$IXFTD6UAL3J=
MD.Y6UMQ#MEPY*FWZ(P,BTS/O4>,EJ.X2"4E@:2VDC/:U1R<AMBQ6V7)^;4]V
MV$=V+BQQN%K/M&VDO:/:3WW!$[N3JF?L?SF4)5^LO&3&&82"66DZ'&IN%4)!
MRXGD6;]1B@ZBC<Y)TBU;Z_BV^V"Z6!#3MSCXAQ$B5'$6[-661:9C5N;;4E3-
MT>="43'<@$C:ML 44*TR4*6K8L)V*_VR_K>1;7[#A]<61NJU/7IBZQ7+@MW3
M2_;6FBI<5HZ2E';-K64E04G6EMN3RD.U?=5E3<)%Y.VCX(M=/S5&5ZBP%4WA
MT;<]5,<0K>";6(\C8J=F3#TR7MS<H"*04>*,Q@FDDI*$=L$WY9%G%! +><&7
MRQ0+2["Q#=(\FUNO2G9&')5DD3'5.ED(8EVRYM9MQ9"U!(4'5-I0$*.I3FF/
M6,['?9UV:G8>M<B/=$-16F,11;TQ#:#*']L>BW.W.D+E,)!44;6EQ2RI()"4
M:!Q)N=Y/S=UDDO*]&KV/H^PO=UC+9(3#+M*Y46(0O;[#TA4762E^@E+(U-54
MHL8N16;I6H(7M@5,B42+XQT^?DK#C##\ ;'@>DNM)P^O$IN:=S2'%1F[B'DP
MDA3:/NA2PM(4IDKVL E>1X\9?<'X@GJV02S&:<-_1AL6U6Z8[>Z%VY32IA4%
MK^YPV4$HVT(T\@$9\F>]QVP7-N:=T-OFX"$B:OC6Y\E?<=J1+T:9KY&<-EJ:
MLSQS$0+VNLI'T3+PJ,>JV5=2;"(7B"L 5:(O!=%3;FP]FQ9;;98X[3JG'YL7
M'D7$&Y=J62];V64A;B7U)+27"M)"6E*"RM06H:()&8O&$[G<KY(>:2TQ#DX"
ME8?W27&\F;B\\HMMEA*MM4VE!"BXE)0$IT K2.58@2VU<H/G3D[K9R?V1MM%
M P8A1=O]/I='RHIFRH6Y/*EZQ?D/'D_6H]I7:AV>XID%::Y4I8L_)6-P=4L\
MZC7(-TFPNTD\GU:PC:<91\70[W-NQEWF1+E0>IDB.J!$G1IK;RUR)"D;J?CO
M2$%IM@!)92M(<TLL\=U$Q9=L'2<)3K+$M.Y+3'B19PN<>0FX28,B(XR$,Q@H
MQF)#3"]N6^=+;BDEL)!K,')X;4,I4?/,5E?-^U'+N*;A4<'OL?M,L92WQLMR
MZ4BY=2]=,M3Z=2&4C..ZY5794YR>:J2DJBA"J)IQ[>/7=/3/B8S%U^A2;4NW
M6R_6ZX1)%T3-5;X&&%V7:]%IU*9$F2MMD/2 "AI8;0YMF>F7 E.B<CA&Q38]
MU1<+GA^X6Z5&MBX2;A.Q.+UMNDXT2Q'BI>?VEA1VQT*6I.UD: 0HKTA>>[7;
MKNVQYOOQQO\ =H>.ZSG9V.''6"<P83G+Y XVEYJMA,NYV/F:];+0HA -C [/
M%*."KJJ.&KBO-2IQ\BVEG9H^AAZ\6&7A2=A'$,U^U)-Q1=;==&HKLUIJ1M;;
M3C3\=A*WE@H0L)T4I!#RB7$% #E?$%FOT3%4+%N'X;-U4FVKM=QM;LMJ$XZS
MIK=;=COOY,I6%J3GI*S&UA(0I*R48DW%[?>4-Y0&>VI5C,.-8+:9CZDY=NF:
M+G/T/)%#RI.X_DJC6VK7!S=TU>/096ZY!8E+.N^<0L(ZJ3&*GHX[H1>L':"E
M_:+OA'"3-_?MLQ[$$V7;XELC-S(4J"Q*;DOJ-V4-#)R/&VA+ 0''D2%N-* !
M0NK&[VC%V+'K"S<H;5AA1KA*N4IR)-B3GXCD9E*;4"%YHD2=OVY2RVTN.AMU
M&E[M!%8ED>3AWEXDNV_^I4Z;G=R>.MYNT6T-7^2[;/XUI4^\W*H)2D=6XN8K
M99F$13"0B'LHW4LK:,1B5#SC)27DT5&#LX7Z<98<N$7"$B4PU9IN&<1,%,.(
MS-D,IL2BVZ\XVZM+Q*D/MH462\7"$J2TV$E %@K!F(H$K%S$:0[>(6)<//)5
M+EO1([YOB0XVRVXVA;02%L+4@/H:#>:DEU94DDW#MPY-O->T#,')\9XPAB:(
MC)E?$$?AK?Y3&=MIY4FZ\I$182.2FCJ5L:C"9EHJP'/)32=!<.G4KZ%F*,>V
M>I3<D+BC>L:6[$5MQ;:[K.?<0FYKN>$9*F'U'12\X$P%A* MIER.=%H2AH-%
MY940IMLIK6;!=QP[<L)72U06&U]346S%L=+["0HJ:;TIJ%+64NO-OC3=,8Z;
MH90E.DEQ>EMU3]G>4I/E%M_F6[Q#2U=P-N0P#C3%]2O=5O$7$6MV^CZ34ZU9
M^TA826/<*E+1"L;)'C9US', 2<I-GD:Y6-T9M:[(Q#"3A#"ENC+0[=+->)T^
M1%D15.QPE;[CL;;-M;W/(;<"\G&=)>:24K XAL$?#LU6,,4W*2A;5KO%HAV^
M/(8DI:D%2&&FI!0IIP2([B"E1;<T4$* 4@G*L+[J>3CR3CBO[9KQL_9WS<3;
M-O.Z&)SM*8QSYG)Q.25PC#0\9$O6%<NV2I D1 +1IH".78MG3EL@V6D9.9;=
MEOVZ4<]RMAQA"F/7R+B$Q+/&O5A<M")UHM2641G-N4Z''XT!(=?2XEQQ#A 6
M5Z+:% )]VG&7_!TV(S8Y6'A,O$BS7YJ[.0;M=G'W)36U!I:&),]PM-*;+:%(
M2I2$Y+=6"5Y(7J1>^3PWV;A*CRGUFO&'*5B7(&Z::VM9%Q70V63ZA:X&5>XC
ME):2L%&E;%'/D$FTXC%&8MG\U,,(FN2UP6.XCGHP@GDV^P1,886L\C [$6XS
M+A$L+-^A7"6J"\P\VFYMMMHE,,.#,ME1<VMM"UO(C)2%I0\="L!*P?BF[QL;
M2),");IM^>L,V!$1/9D-*5;5+4[#>?2  O1"--U24M+D**D*+0"AL-7=O6_'
M-V[+(NY#,VV.H8(C;-R>N4]LE?J\)F"@7MZ6[2#U)Y DG7L)((M4 L3^2EC1
M:L>B]B8*!CV#29E4G_Z%;#OW;"EKL$*S6R]2;LXQC&%?7GW;=*AH,5*"ATLI
M="E9M(0TEP. ..O*6MM"F\JR\>T8INE^FWFZ66-:6W\'3+$RPW<8TQ>ZENMN
M-[:6E)2 ZM3I04DH;90A#BPX=>I&WSDSMWG3[(*RYVA8SVEVK;5DJ)NV5MW$
M)F#'T_D;+-=CIE])/ZJ:M8U*YD'BLLP=)1/"TRLLU%)HDW/(L8QS(-7>P7C&
MU@4,4O)Q#<+_ ![W!>BV_#SUMDLPK<^ZA*6Y(>F+T$[0H%P%AM"\R2$J<2A:
M=?M&"<0)5A=E6'[?8I-EG-2[AB%FXQGYEP8;<4IR*68B=L5MR%!HA]QQO13K
M4$*6VK<'">'.4:Y/6^[E,<[?-LE"W0X*S-F6S9GQI<9#.%/Q=(X\E;H1HV>Q
M5UA[(<)F>:1C.-BFSA&OM.+@T:>092722RL?'Z]<KC@[&$2QS+Q?)=BNELMD
M>USXZ;7)GIFM12HH<BN1_M3*W"M9TGEY)"@E3?N-)6PVRVXOPA*O<.T62)?+
M7<[G)ND&0JZ1X"X3DH)*V9+;X+CR$:"$G:DC2*2I*QIZ**'GKDY=P^XG*'*0
M6.XTRO18;@-NFVU/#UBB[5!&C'6>\.UFK2[V-BDEI12RUR)1NM><5Y.;L+"-
M3<04@JL5PX167$:MJQG:+/!P6S'?><ZCWJ]*N3"V' OJ3<W7V0I9"-H?=,5T
M/%II:@'4!.BDZSXNV#;K>)V,7WV6&^J]FLZ+<\A]&B+K;FVG5)2-(/,M;I:V
MH.N $LJ)]T,Q5CXOY.'=M#4#9A=\B5M"T;AW/*20F[[=M(N+=1C.:W7&+AQ$
MHK)R3><)%6).+@HYE(I0E05DSM7T\^9QC%1) YBW,[&=@<FXEC0G%L648(?P
MWAYL1Y"0\^L-K]T@MJ<9VUU3B5./Z (;2M:P5:-64/!F($0L-R);2'[R<:Q\
M28A<,B.HMLMK* 4N;8E#P:92@I:8TLBM2$).14?PUY)K=7N)K6];(N;LSVK
MU[W6Y&M,Q)8)@28SO%3L=0IB_9>"HRYVUHM-*HDA714FZ!(24;K1<>U:/%")
M2AETR0K']ELTC#$2TVR+=8F'H<=#=TD)G1I+4J3^%5QF=-E(VSC!=97I+4I.
M:V\B?8P#>[PQB:7=+I+M4K$$M]:[6P8,B.[&C@BUMRGPEXY-G40RZ@I0$G)+
MFD*].\"XXW).^3+9X3S;3QA=P[/;E?<..:^M:ZO/]M9"/K-BI%#?+6F'FI*
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MII2FE*:4II2FE*:4II2FE*:4II2FE*:4JF.6LDJL8[:3!JD(% J(LD5^ @'
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MW;-T$S*KKKKJKD21113*91550Q4TR%,<Y@* B$AF2HA*9*E*40$I##9*E$Y
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M.Z&F7T\9%*< 'O@'N:9#V)]N[U^6HRX^W[>W6H  'K?U][[>F0]O;C[?'4T
MH!W@_GU-*< \ ?\ ;P_L#2E<\/S_ #_/O>#2E-*4U&0]B>OG^6E4&SU6L7:
MEJK<JY!6VKSS-6.G*W9HAA.P,U'K!P682T/*-W4?(LE@[BK5XW604#N'3,&J
MK+SL=UM^.Z['?96EQIYAQ;+S3B3FE;;C:DK0M)UI4E0(.L'.J3S#,EIQB0RU
M(8=2I#K+[:76G4*!"D.-N!2%H4"04J!21J(RKO@(""JL)$UJL0L57*Y 1S.'
M@H""CVD3"PL1'-TVD?%Q,6P1;L8Z.8-4DFS)BS01:M6Z::*"2:9"E"'77'G'
M'GG''GG5J<===6IQQQQ:BI:W%K)4M:E$J4I1)))).=2TTTPVVRPVVRRTA+;3
M32$MMMMH 2A#;: $H0E("4I2 E(    JKZ\54II2FE*:4II2FE*Q3D[$,%E)
M6K.Y.<MM;DJ<]FGD++TV82A91(+#7W]8F6QG:K%\9-)[#23MN#AH#619J&(Z
MCWS1RF14%*UFM')^8:?UJ[0=/5F:>O;JM!TIBZ2=F=DIU;A)V@3#1O6G+88R
MRE=Q(8[@BU=>5LLFE6ETN;'($BS+Q2ZE9^KF JA3WN2Y*J2=BK<CD]" :R;J
M#4@(L()"KDE4X(*\R95]&,!TQ1EW#,\K8&-@F)"*:P\'*2#V"@82-CU*L)EL
MSPLQ:J-B-K(H+BLS]6>KGFB)*/&EI#,Q[ ]41:,6S%L_DG6>\C/1+'-&4:Q6
M?QJ,9',6$2S9E4KJL&S3$]ECRQ$H\M3J&87F>R)6H607K-@A*E9;>M;G5S7A
M86TU:=B7+:UO;S9'\DWL3.=!B]=MEZZ>$&,C :*5E">P50+'>X#(DBVD@L5:
MBXB(BA:/NQ8Y)E",;W',$SL$D02,)&N1;(0W-$A3"HR$I"@S(!E#K^3Y#G6*
M'&RG#IZD%,8N[S"Q9T@9.G$39P;R3Z'4P_1\'/X)T[6CW!1BY6B8ZJB,@5%%
M%Z:48JR+9ZU.Z63,I4Q[LXQ)(2]DL#IQ;0G;)-R5D/)LI6,B#Q,\^LV/[@VF
M(IC#PC")[;Q5CQC4))"7E(^4E9=2/,E:WMB04!(BE7=6MM6-:O)1,RR"PNYB
M+L+.W'DI*9,Y<REH;R.5YEW.2@$;HH*NYB:S3?I641:HM&)G4BT38LV+./;-
M2J5L!I2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4
MII2FE*:4II2FE*:4II2FE*:4KSJY3[">YW/FVYA1=IMTL-$R63)U4FY*8J^3
MK+B685IS&,LC:59M[95)VM2HE"3?PD@K%#-,VC\D>/9!'@(E8NE*T5C\0\NC
M(EF*U;,_TME#RPWBLD5H[3%L6VKL+)5"ZQ5-LU>R?-U>=R8_=P2SRC/G!9C'
MR%FD+U$S+E6;:UR00DFBE7IG';%RBN19#"4C5<@7>+FXK!>VF <6@VYRPT4F
M*<PT3*3VT[E+3D;'N+XRNXZW&JYHQ:I%8Z@QDX):&@Y>.>.V+&JMY1:P@I[=
M:M;-MG)_<JYC7+FVFPY/W,WJY47$%TKLQDB,=;G,QSJ&1H&PFQ7Z*8Y.(M%S
MGVSMK4S%O!IF*R2&1V]L)$V4V/E\:!>JFA1E*]%N4HP-O+S6]VV.]H-_D:(^
MQ_D-Y8[THAE>X8RA))JC+T:1AD;<TJ$M'JW.KG:PEEB9F"D(ZSH"QG'!$*V]
M7= Z8J5I,CASEW['0G<%D#/L4K87%9KTB]=X]/@W%CB/N=7R9B^SSD?3;7&4
MVVR,['7"OPN1*S74[1 TF*1JDY&DO"2\EV?$N5.7E^4_+Q#N5=>YK9[RH]\W
M/Y>M^&-QTU4=O61LQX*OB%/)F2VP<Q 57!-(PZR)4:*UC@[#I,%ER\S.8)O+
MT1$*,&-MC\;U9A*-WJ5YD"I*5K5MZY/KE=L>.,91V1MP-_N<M#'HLN.0W^\[
M-CNN4:Q+'V@2^0']BQU,S=H4S$S2:8ZW(4_T&6YS-T6RRV0 LD#%XRB;(:-J
MJGM[?#7U%Z4II2FE*L?)3RW,*-8GE%:'>VE!HD:,010:.G7-,[;DD%V#-\NV
M9/9-I&&>NXMB\73:O9%!LU7$4EC%%2N_'KFV/*+4'5[:ILKFXKD0M:&B9&Z1
M6\XHQ1-(I&29N'C-!4KD5.F09NW;1!;GI-G3A B:QU*O'2E-*4TI32E-*4TI
M6E^2KCNA:3=U8XUJ[R52CK ]]"*SRM0C:(DXXT'C4[5@Y?R,ZW579("OEM\G
M*D/'K.K)$52)75;1LBFSDE*V7QLZMCVF1#F[HK(6)525Z8KIJS8OU8U.9D$Z
M\[E6,>HJQ8S+ZO$BWLRQ:&*V9RKAXV11032*@FI5\Z4II2FE*:4II2K<N#V1
MCJG99"(;2[V5904JZCF< TCGTXZ?(,EE6K:'9RZS>*=2:ZQ2)L4))=)@HY,F
M5VH1N*@@I6D%7N6]9Q/UMO/54@PRJF.$YU\G6Z\Q9F>N0B MY$NRIY.90KZL
M0I89.5D5XIE*0UD8P\-$L5VCQ=N=2O0+2E-*4TI32E-*4TI6!,_369H2!@5L
M(P@3]H6F^B=1SE&.-%*QO8BQE1DUW_0 @F0X%.B*<M B8Y1.61=N$6U>G5*M
MG"<_G^5MM@;90AWK*IH)SWH<>R$/7HIT^B$W=7&C2CT(>2<K(VB::.+N%PAC
M-6S*&-#5T4&,0I(J)R*E;0Z4II2FE*:4II2FE*TJRS;=WT?D.R,L:42.>TI%
M&FEI3TQ:X]0EY,65M6GD[.Z?3S"3A8>0E@K\=*NFC!5U Q+-M(1G9KN9=ILW
MM\GTZZ5L+AU_?I.B1[O)+1RTLRCV7*8C]A'14HK&$DW)(I>4BXAT^C(]ZHR!
M+B@S=K$,@5!PL#=TNNU04K*&E*:4II2FE*:4JG3!WQ(B4/&#PDB1ST\>/0 Y
MX/2ME1:CV,*B0.."X)_I JI]+]#Z0G.YP*5H2:[;TU!BNQ:4]33,670?&=QM
M/>"JFVKZ1Z%+]-TU?5;C=+T1_'7J+6AVCRD452+>%;QLR5W*N5*]!]*4TI32
ME-*4TI32E8.SO.9A@8.HN<-5=.URSF\Q[.T1YGL;'*HU0T'87!ET7LJU?-6A
M%[*WK4;(.NP72K:)D)!9,6!B=MXY2L7X*LVYV8N*;;+E=7C*IZ'91=-VZAJW
M%*K.P=1':Q9]VEG)91I8#/5++'GA6_2Q(5J/@YE1\,I(+)JJ5N#I2FE*:4II
M2FE*:4K5G-$GN(C+*X7Q,V=2%?0K:0&8K1%7?)N[7(M;,I IQ:KUQ'R2,>SG
MX"N1=[7D'*R"%<OO;.$4CG4 _D&2E7]@F4RO+TM5WF*+[46D9-$I&IFD8Q4(
MB:O0"TPB5")D))J9A'W):U1,"[,Y,YD:W'P\BY.Z6=F?NU*S1I2FE*:4II2M
M?+I.Y%E\RP>-Z?;(RG1"./75\F7JE6;V*6E5DK4P@DHMNM(23=C%M ;*.%%5
M@CWCHZJI!(=(J7-4V"&Q;V;*_<Y<1V8\JXIM[*!*5&99"HCC^W*#;2G'5Z82
M DN(0 D@@Z68QC[LI<]N(P\AAL13)6HM!U;A2\EO:P5*"4)R.9.@I1)&13D<
M_,[E >5$R;L]SNUQ-5,;4:VQ3BA5ZVC*6)Y/-WY7<P_G6:S0"1CM!N*")(E(
MZ9N9T@G6.!A$H%$.G;'NQ9;,8V!=WFW.?%=3/DQ-JC(C%O08;CJ2LEU"U:2E
M/'/(Y #[VM0Q1C.58;DF"S#COH5&:?TW%N)5I.*<!2 DY9 -\HSU\=:0]?=G
M'V#L3^4[A\8ZWG@#L//EW\'"\S6N<)EPYNB>$=IU]V<?8.Q/Y3N'QCIP!V'G
MR[^#A>9IPF7#FZ)X1VG7W9Q]@_$_E.X?UR/_ %>'3@#L//EW\'#\S3A,N'-T
M3PKOT5FK)G+.Y?H@8[[$Q%CA\-TQ52<@NP<R%E(#)]:6CAPYCVW1/2\]HU.@
M ('5YRQ@,/2'$>'#XUV2;T_@C&5YPS"9:FQK8_M+<F45!]P99Z3@94AL'/5[
MA.7+W.-;)?V36(,"XA8LT/#5GGM.V:VW,OR9,UMP.3D+6MH):5HZ"- :)/NB
M#[HD\>)G?+TY;C^QNS\0XC8]FNT(]EV9.V1MV6_<B)6S%MTTD3LAXX,42H-D
MN<LJ(#S"&X#PT=&R%=7-+:[9&<T$*<7M8DKT&TZU.+T5G10G5FI60&8UZZT>
M-]E_C>;NC<> K1*W)&=F2MSNW=_<T1C+;I,C:@O:8[6D"Z^YHM-@@K4 :I[3
ME_\ (S](B['&F$WB"DH>$36:VF<<)'F4RG,>(*HC+'(:43*FH91@41=D*0QC
M(E* CJHK'E[0K079FD*#1?*5MRDJ#&K[<0I0(:.8 <(T"2 %9ZJO9'V5NR/%
M4XW)V-(<=UJ"+HXT^B^M.-VU603<7$+;"D0%%20F8H".=(9.:Q5;Z]G-7L)X
MO\IVO^+_ /C]41LBW$_M"%\9_P Y6(_ZYN*NAN'_ !RY?6KZ%=O^1Y'+V$<5
M93F6#&)DL@T.LVY]&QQUCL&#J>BF\BLT:'<F.X.@@=<4TC+',H8I0$QA$1UT
M^V2U3K?"F+2E"Y,5A]:$9E*5.MA1"223H@D@9G/(:Z^Y<%7Y[%&$<-8CD,-1
M7[Y9+;=78["EJ98<G16Y"FFU.$K4A!<T4E?NLAKUUF#B'A#W0];OZOJV>G.+
M_C%]T/#P_G[GV^YI2NIPL"#==?@!@1145X<> #T9#'X<> \ 'AP$> \._P .
MYJ"<M=/D[NH?">2M>@W?[3@  5W/;>$50#@HBIFK&Q%$E [ATU"'LI3%.0W$
MIBF*!@, @( /<UL8P?BU0!&%L1D$ @BR7,@@ZQD1&(.?)EQ\E8LWRR))2;Q:
MP02"#<(@((.1!!>!!!XP1F.6N?5?[2_&BVZ^>S&GRFU.\[%W1;$?D.Y^BU'5
MVR<\VKRC$\]3U7^TOQHMNOGLQI\IM-YV+NBV(_(=S]%IU=LG/-J\HQ//4]5_
MM+\:+;KY[,:?*;3>=B[HMB/R'<_1:=7;)SS:O*,3SU/5?[2_&BVZ^>S&GRFT
MWG8NZ+8C\AW/T6G5VR<\VKRC$\]3U7^TOQHMNOGLQI\IM-YV+NBV(_(=S]%I
MU=LG/-J\HQ//4]5_M+\:+;KY[,:?*;3>=B[HMB/R'<_1:=7;)SS:O*,3SU1U
MMXNTY-1J0FYW;NJ5PN=)4Y<V8VX-R%;.%P5/PLA@YIE$4T YPD#GK$X&$W-*
M9O/Q=T6Q'Y#N?HM.KMDYYM7E&)YZI'JO]I?C1;=?/9C3Y3:;SL7=%L1^0[GZ
M+3J[9.>;5Y1B>>IZK_:7XT6W7SV8T^4VF\[%W1;$?D.Y^BTZNV3GFU>48GGJ
M>J_VE^-%MU\]F-/E-IO.Q=T6Q'Y#N?HM.KMDYYM7E&)YZGJO]I?C1;=?/9C3
MY3:;SL7=%L1^0[GZ+3J[9.>;5Y1B>>IZK_:7XT6W7SV8T^4VF\[%W1;$?D.Y
M^BTZNV3GFU>48GGJ>J_VE^-%MU\]F-/E-IO.Q=T6Q'Y#N?HM.KMDYYM7E&)Y
MZGJO]I?C1;=?/9C3Y3:;SL7=%L1^0[GZ+3J[9.>;5Y1B>>KJ3WA[33J+D-N>
MV[$*D8A2''-F->"H&3*<QB\;* <"F,)!X";NE'B(#W ;S\7=%L1^0[GZ+3J[
M9.>;5Y1B>>KM]5_M+\:+;KY[,:?*;3>=B[HMB/R'<_1:=7;)SS:O*,3SU/5?
M[2_&BVZ^>S&GRFTWG8NZ+8C\AW/T6G5VR<\VKRC$\]3U7^TOQHMNOGLQI\IM
M-YV+NBV(_(=S]%IU=LG/-J\HQ//4]5_M+\:+;KY[,:?*;3>=B[HMB/R'<_1:
M=7;)SS:O*,3SU/5?[2_&BVZ^>S&GRFTWG8NZ+8C\AW/T6G5VR<\VKRC$\]3U
M7^TOQHMNOGLQI\IM-YV+NBV(_(=S]%IU=LG/-J\HQ//4]5_M+\:+;KY[,:?*
M;3>=B[HMB/R'<_1:=7;)SS:O*,3SU=#7>)M.7;-UU-SNW=!19!)51 ^;,;<]
M$ZB93F2/SK(4W.3,(D-SBE'B4>)0'N WG8NZ+8C\AW/T6G5VR<\VKRC$\]7?
MZK_:7XT6W7SV8T^4VF\[%W1;$?D.Y^BTZNV3GFU>48GGJ>J_VE^-%MU\]F-/
ME-IO.Q=T6Q'Y#N?HM.KMDYYM7E&)YZGJO]I?C1;=?/9C3Y3:;SL7=%L1^0[G
MZ+3J[9.>;5Y1B>>IZK_:7XT6W7SV8T^4VF\[%W1;$?D.Y^BTZNV3GFU>48GG
MJ>J_VE^-%MU\]F-/E-IO.Q=T6Q'Y#N?HM.KMDYYM7E&)YZGJO]I?C1;=?/9C
M3Y3:;SL7=%L1^0[GZ+3J[9.>;5Y1B>>KJ5WA[32"D!=S^W8X**@F<0S9C7]+
M()3F%0W"RCW $H%[O .)@[O'@ MY^+NBV(_(=S]%IU=LG/%J\H1//5V^J_VE
M^-%MU\]F-/E-IO.Q=T6Q'Y#N?HM.KMDYYM7E&)YZGJO]I?C1;=?/9C3Y3:;S
ML7=%L1^0[GZ+3J[9.>;5Y1B>>IZK_:7XT6W7SV8T^4VF\[%W1;$?D.Y^BTZN
MV3GFU>48GGJ>J_VE^-%MU\]F-/E-IO.Q=T6Q'Y#N?HM.KMDYYM7E&)YZGJO]
MI?C1;=?/9C3Y3:;SL7=%L1^0[GZ+3J[9.>;5Y1B>>IZK_:7XT6W7SV8T^4VF
M\[%W1;$?D.Y^BTZNV3GFU>48GGJ>J_VE^-%MU\]F-/E-IO.Q=T6Q'Y#N?HM.
MKMDYYM7E&)YZN@N\3:<+E5 =SNW<$TT&ZI5QS9C7F*'64=$42+_PE .<B5!,
MYN!A'@N3B4H<!,WGXNXMZV(_(=S_ "[ERIU=LG/-J\H1//5W^J_VE^-%MU\]
MF-/E-IO.Q=T6Q'Y#N?HM.KMDYYM7E&)YZGJO]I?C1;=?/9C3Y3:;SL7=%L1^
M0[GZ+3J[9.>;5Y1B>>IZK_:7XT6W7SV8T^4VF\[%W1;$?D.Y^BTZNV3GFU>4
M8GGJ>J_VE^-%MU\]F-/E-IO.Q=T6Q'Y#N?HM.KMDYYM7E&)YZGJO]I?C1;=?
M/9C3Y3:;SL7=%L1^0[GZ+3J[9.>;5Y1B>>IZK_:7XT6W7SV8T^4VF\[%W1;$
M?D.Y^BTZNV3GFU>48GGJ>J_VE^-%MU\]F-/E-IO.Q=T6Q'Y#N?HM.KMDYYM7
ME&)YZNI'>'M-43YY]S^W=(W/4+S#9LQKQX$4.0IN[92CP.4H'#N<.!@X"(<!
M%O.Q=T6Q'Y#N?HM.KMDYYM7E&)YZNWU7^TOQHMNOGLQI\IM-YV+NBV(_(=S]
M%IU=LG/-J\HQ//4]5_M+\:+;KY[,:?*;3>=B[HMB/5_@.Y^BTZNV/GFU>48G
MGJZ,$;K<+[C)K)M=QC<82PS.*K2O7; WBIB,EVSUB<I58>V0,A%N73.8J\VB
M8Z3649JJ(I2+1_&KB5=L4RU&\X;N]A;@.7.%(BIN$</LA]AUA;:P<G8S[;J4
M+:DM>Y6II:4KVIQIS1T7$DVMFQ+:+[)ND.WRV7I-HEF++:0ZVX<BE*FI#90H
MAR.Z%%*74YI#J'6B=-M0K9'6"K/TTI32E=+A;H$RGYO.YR[9'AQX<.R'*3?G
M<> _L.EY_#A^BYO-XAQX@I7=I2FE*:4II2FE*U_/^^H;_P#-^>?ZQF'K?GP_
MCUL']B:O\HFO^'.5C#^&4_O8Y_O3=?.)RT6-LBVS>!'RE6H-TLL87#U+:FD:
M_5IV98E<I35N.JW,[CF#EN"Z154C*(BITA"JIB8H <HC](;"UUMD/!SK,NXP
M(KO5>:K:I,R.PYHJ:A9*T'7$JT3D<CED<CD=1KDVR!"F2+\AQB))?0(,=)6R
MPZXC2"Y&8TD(4,QF,QGF,QUZT"P+@ DE9;,EG7'67X*LHT*Q.Z^\CL?Y#6<J
MW5L>//!L",X:IR2KTS]#MBT13>N86+:.E4).0DET&!H27WS$.(]JBQ3A^YV5
M^4JX1D24.7*V)"8!VS;UZ<B8TE 0K:E*+:'W5("FVVTJ<VYK6[7:=-]X7.'/
M::3%>4R4PYBB9/N0V-%MA95I)*T@*4VD*4E17[G([DW7&V$!JN=(V-PVJ_F9
MKT1&P(YI^$L]Q*E;KK6*L+VEQ5U>6.EM'PWI-0D5&R,G'O)6)D+"I%%G9:0K
MAYR39:7!NM\W98'7KXEIA@Q1B%$R_8=>$J2MZ,B<]"1&FN($#+;74-.(:>;C
MAXQX[<@LM.;#(@V\1;HA%N4X\Z'^I98M=T;VAG:WEQT/J?CMY20H(0IQ"E)6
M\6PZ\4:2T^8XX0S3Q']:'*'?'_Q MGQ2.NI=7[%SU:?*,/SU:9U,N7-\X]L1
M)&1[F;8U? *VYSQA'-$NGA!6)Q%D^42:;=L4Q[I2.H-K>IMG[2.?%=,7!VT2
MJ5%XV,8I7#902K(B8 4(41#7Y?;.C#\[90Q1)A,NS(SDS-N1%;7(8<&1S*'6
M4K;4 ?[51RKY>V=\(XLN>-(<FVX8Q#<(XPO86B_"LMRELAUMET.-%UB,X@.(
M) 6C2TDDC2 SK4+(NT3<+>65>:M<290AUH"X5NVINWF&+I-J'4K<FA*(M&@%
M2B3QYW:S=-!P](JL?L([AN5#BN"J?,8#,^$N0I5KN#P?B2(I2AM]@ 2$%LK5
M]SNAS0!*DI( "PE7&!6D8-M&,\+2KP_)V.\<7)J[8?NUA5'C6^\6Q*4W:,J*
MX^^399R926&UK6U'4VA(?VMTN?:]!>/<<\GIE6CQK!K)X<S'9W\-/5V<A9,<
M67F#.P/4ZE#TR"*HW9-5B/'':B&14F'*YP1EWKARHHR;M3)LT\C/GWR6MPM6
MV7&;>8D,OM[E=>TQ*DNRGBE:XZ5(2''5!I SVI(3K4H%1W#%F)=E?$,B8NWX
M Q198=RM-TM=RAKP_<[KNE-[N\V^7(H?DV=M<9E,V<XW;F&4A<"*TRA+[CR2
M^=A/4]Y\]@_+_FTNGQ+K =3;CV!-XR?U(_RG/WNN/;P<=]"L6_\ [<O')_F5
M?7YAS#DCD/8SM_QO-JJU*4:8LQP$DQLE:5E$F[MA64&CJ-L%5?/859=9F=<[
MIHW<NVJD78&$7)G26/'=B+=\L2%MV:UH<0I"T0(J5H6DI4E26AFE25 $*!XP
M1F#QC.OUMV*XTB'L:X$B2X[T65&PI8F9$:2TXQ(8>;M["'&7F74I<:=;4"E;
M:TI6A0(4 015V8[VJ.L=R[:2C,C 4Q(:WP#V694UHUNC]E9FN-&X22]E?3DP
MQ5L[A?&;*3MD\]K;XUIEIN8D4VD&[%DJUR];]6*D-@#5,K8#9(CD10/-&,2-
MQNA'MS%GJA'4Q8$$/1>X*V&"3BDKS31*8X5[*TM9KR8)$9PT0U4]O;V[M;D4
M&CN*!1G]7<R$1()A,7F;:F@Z\K6(YDUMMFG+6$6A%*S<^)"1BTTNR17(^(1=
MNBB?L5 X' S7R:CR=VA (R.L'4>X>.M ^IVV*//[K<8]MAUW7]T+'#)%R)SE
M5_TQ0W,)* 4O$YA'FE  #O &NI(V9,>(2E(N$/)*4I'Z&P]02 !^Q\@''Q\I
MUUIRL!X:45$PWLU*4H_=<G+-1).K;.4DTZF[8?['=L\Y5T^-=>N&;'G.$/R9
M#\U[=^HWA89[#>\<D^<IU-VP_N?K>6SSE73N_;_574\,^/<LNJ,/D'X,AZ\N
M+/[5VZC>#AGL-[E_;DGEX_V2G4W;#_8[MGG*NGQKJ.&;'G.$/R9#\W4[PL,]
MAO>.2?.4ZF[8?['=L\Y5T'^>5TX9L>']T(?DV'YNHW@X9XMQO#N3)(_(Y3J;
MMA_L=VSSE73XUU/#-CWBZH0_)L/\S7MF>N:;P<,]AO>.2?.>V0ZPIU-VP_V.
M[9YRKI\:Z#9FQX/W0A^3(9_*U0X!PR?VF]XY)'Y'*@N^1UV)I.(Q,F/+6!73
MU5%8!R3<QYR98Y^Y  $97B4>E03'B' > "7O".HX9L>YC]$(?+^YD/7GU_M7
MMQ4W@X9[#>\<D^<U?!4[J;MA_L=VSSE73XUTX9L><X0_)D/M_P!R[=3O"PSV
M&]XY)\YVJ=3=L/\ 8[MGG*NGQKH-F;'HXKC$'^C8?FZ@X!PR>.&\?\[D^<IU
M-VP_V.[9YRKI\:Z<,V/.<(?DV'YNIW@X9X]QO9_XY)\Y3J;MA_L=VSSE73XU
MU/#-CWG"'Q9?@R'Q>#J-X.&>PWN//]62N/PO>ZW)3J;MA_L=VSSE73XUU'#-
MCSG"'Y-A^;IO!PSV&]XY)Y#G[Y[?#3J;MA_L=VSSE73XUTX9L>\X0_)L/S?:
M'>%3O!PSV&]XW)\YVSWZ=3=L/]CNV><JZ?&NG#-CWCZH0\^OU-A^;IO!PSQ;
MC>RZVZY/G*BH\CGL2.X>)FQY;!*BHD5,/3)N8<TIVZ:A@XA*\1XG,8>[QX<>
M'>TX9L><X0_)D/S7Y>7.H& <,CBAO>.2?.>VH<@J5U-VP_V.[9YRKI\:ZGAF
MQYSA#\F0_-<>OCXZ;P<,]AO>.2?.<6KBXJ=3=L/]CRV><JZ?&NHX9L><X0_)
ML/S?:IO!PSQ[C>\<DZ^[]LU_#3J;MA_L=VSSE73XUU/#/CWG"'J_P9#\U['7
MQTW@X9[#>\<E>=]AJXJ=3=L/]CRV><JZ?&NHX9L><X0_)L/S=3O!PSV&]XW)
M\Y3J;MA_L=VSSE73XUU/#-CWG"'Y,A^;J-X.&>PWO')/G*=3=L/]CNV><JZ?
M&NG#-CWG"'Y,A]K^Y]H4W@X9'[3>\<D]O^Z=LTZF[8?['=L\Y5T^-=.&?'O.
M$/K?@V'V_P"Y]LTW@X9[#>\<D\F7]T[0[U0HWD=-B3F.8.%<>6L57#)JLH(9
M)N90%15!-0X@4)7@ "8PB !W [P:CAFQ[JSN$,Y=>VP_-T& <,C]IO=O[KDZ
M^[]LJ;U-VP_V.[9YRKI\:Z<,V/.<(?DV'YNIW@X9[#>\;D^<IU-VP_V.[9YR
MKI\:Z<,V/<LNJ,3R;#\W4;P<,]AO>-R?.4ZF[8?['=L\Y5T^-=3PSX]'[H0^
MM^#8?FZ' .&3^TWNO^K)/G*=3=L/]CNV><JZ?&NHX9L><X0_)D/NZOM>KX*G
M>#AGL-[QR3W-?VS7\-.INV'^QW;/.5=/C74\,V/><(?'G^#(?'X.HW@X9[#>
MZWZLD_EVS.G4W;#_ &.[9YRKI\:Z#9GQZ.*X0Q_HR'YOV^"AP#AD\<-X_P">
M2?.>WPU%<\CGL22,U F/;8 +.BI'_7)N8\2"BL<0#]5>Y^B(4>/?];O#J.&;
M'O.$/R;#\U\-3O"PSV&]XY)\Y4KJ;MA_L=VSSE73XUT.S-CT_NA#\F0^]^E<
M7:Y.3*H& <,CBAO>.2?.<?;XS3J;MA_L=VSSE73XUU/#/CT?NA#\FP^3_P /
M53>#AD_M-[E_;DGE_P#$UTZF[8?['=L\Y5T^-=.&;'O.$/R;#R[VUTW@X9[#
M>\<DY]_;*=3=L/\ 8[MGG*NGQK^?KZ<,V/3^Z$/R;#\UVO;(9!@'#(_:;WCD
MD_E<[9[YZ].INV'^QW;/.5=/C73AGQ[SA#ZWX,A]SWKVX^.F\'#/8;W7_5DG
MN^^>W%Q4ZF[8?['=L\Y5T^-=.&;'O.$/CS_!D/C\%[:Z;P<,]AO<67ZLE<7A
M?;X*=3=L/[WI>6SSE73['^=?L!IPS8]YPA^38?FZ;P<,=AN\G[;D\G%^R5#)
MR.FQ,S]TW''ML%))FQ6(7TR;GQ!1=:1(H/.[:\X0$K=+@ B( ("(<!,.HX9L
M><X0^YU,AZNY]JY:G>%AGL-[QR3YRIG4W;#_ &.[9YRKI\:ZGAFQ[J'5"'JX
MOT,A\O\ X=1O!PSF3N-[7Q_=DGD_\2G4W;#_ &.[9YRKI\:ZCAFQYQ=4(?DV
M'YNF\'#/8;WCDGSE.INV'^QW;/.5=/C74\,V/><(?DR'YOO]?EIO!PSV&]XY
M)\YWNMR4ZF[8?['=L\Y5T^-?S]W4<,V/><(?DV'JX^+[7GRTW@X9[#>\<DZ^
M[]LU_#3J;MA_L=VSSE73XUTX9L>\X0]7%^AL/S=3O!PSV&]KX_NN3YRG4W;#
M_8[MGG*NGQKJ>&;'O.$/R;#\W4;P<,]AO>.2?.4ZF[8?['=L\Y5T]?\ ]JZC
MAFQYSA#Z_P"#8?FZ;P<,]AO<67ZLD\7A._U^6HS3D<]B*J **8\M8FZ5P7CZ
M9-S .";A5,G<"5 .X4I0'PCW1[^G#-CSG"&?]&P_-4WA89[$>U_WY)''_P")
M\ Y:D]3=L/'A^MY;/.5=.]Y5_CTX9L>\X0]?'^AL/7\WUZ;P<,]AO=?]62>Y
M[YUM5.INV'^QW;/.5=/ZY70[,V/=?Z(1,_WMAY_*W^6F\'#/8;PRZTR2.7/W
MSKU=.S#DY,7;0LE9?RA7RJN9J\2\A"TAHI(R$DA2,7@X9.&L)V5('%S(SLT_
M8IR<U).A5%!%)A%,3$30?.9'"XMQY=,5QK=%F%($=M+TQQ+;;>[+@0I*GM!L
M!+3339#;3: G2)6XO,E ;LL*8 MN&+Q?+RSI+DW-]3<9)6XI$*W?:E!A)6<W
M77G6]M><7I% 2VTWH@.*=](=:+70*:4II2H3_P"@)_=L;_2+72E3=*4TI32E
M87S_ )<)A+%\_?$HD]BEV1 ;UVLIBZ25LLV=)=VA"(/$&CELQ=O6C-Z#%S+K
M1<*9Z1NUDYJ(;N1?H*50-KN5[QFC$43?,AU2!IEFD)2;:KPM:EI.9B$FK)^H
MBU%L^F(R'D5CHEYS!==Q',PD%V2DJ@S8-GZ,>T4KO/\ OIV__-_>_;[F16']
MOV/X_6V#^Q-7^437_#G*QA_#*?WL<_WINOF2Y<!10N\Z. ISE+Z2]'[A3&*'
M'MW<N(\ $ [H#PX]_N<.]KZ>V#D@X+=.0SZLSM>0]YA#K=NN/[(JB,0(R.6=
MOC#YR0?S<>OK5Y,UVLW"XNG;&I5^R6EZPCG$N^9UV*E)MTRB69T2.Y-VWC&[
MI5M'-3KH%</5R$:HF62*HJ4RA 'K,F7"A(0Y,DQ8B''$LMKDO-,(<>6%%#2%
M.J2E3JPE12VDE2LB0,@<M)9:DOJ4EAIY]2$*<6EEI3BDMI("EJ"$DA"=(9J(
MR&8S.9&><YG:;GZ!A[G./ZY"G98[2=*79*.R7C>8E*VYCT'[J8B9*$B;@]F4
M[! MHM^YL5=38*3D"W:J.)>/9H\TYM?9QAA^1(@1FWY(<N:DB"MVUW-EF4EQ
M2$L/-OO1$,F-)4XA,63IAB0I02TXLUDW+'=6FI+RFV5(B F0E$N$XXRI 67&
MUMH>4X'F@A9>:R*V@DE:4UK9TZP?_?*__F'_ +?7UM&0_M1WJP^DKK]<<0^C
MO$&OMQV)#SMFVVPPB)C#B>N"(CW>/Z6MQ[_V^ ][CX=?"VR"G+&^*!UKO) &
MHZO<G7JU9YDY#+4>N2:^B\,*5O>LYS.N"T3D3K)SS[XU=RI^\O/5LVR[=;GF
M.AXX3R[=(2=Q=6*IC56Q!42V^?R?EFC8LBXLMB/&3*<4KV9=$G2"RL:X147;
MIMW H(K'<HZ<H  D =X=KM?#W:SR2HD#25EKY3W:TEV-\J8AO>SA)8^K&/8.
MHT,N.;'D>N3\Y;':%[L46PSIF'$D(B-"DH**?Q;Q6*Q<ULEB9KJN%:^^FGD(
MY.*D6DM(>02HZ\LCQZA\''GG\M>E9@9Z:R=7*>37\FL\>JO7OAWP[X>L AW.
M/>\'KCW1X</PZJ9#BZW(0,N+N#KYZN7K53TE=<Y=;,UQD+),9BJCMK1*1TA*
MI =LR181RL>W765%D[?K"=Y+/8^-:D181[Q8%'CU$JZR:+-$QW3I!,]$\9[I
M]N7\M5AQ#N"L;4?=12;L8JZ<#9X2(5K\U9D9J53AU6YXV,9XSDFB*L=%2TC.
M-9:4C\IP"Y8MS%I.(Y9K)M9/L59-IV7%3[>WME6- WXX^ $.EI%W3,X&T 0$
MW-,<E_X&8^A<J6#@JWM2B"O14>PQ3J/%NJL20GC/:X0Z3V/<* I6T-,O;7(5
M+>V=C&NXUL+RSQ*";IQ'/$WG:&3D(8TC'OHIV]8OXJ069'<1SYLX.B[:G(NB
M)T3IJJ.MKRS(!/6!.6>O5JX]>KKD#74'/(D#,Y$@<6>K/*O%-7E,>4#;*JMT
M.3ER(Y0;J*((N"X_S68JZ*1Q326*8E1$@@J0I3@)!$H@;B41#@.N\M[&. 5(
M0H[)=J25("E),RS9IS&92<YX/N3[DDC/,:\M=<V5B_$Z5*2,(S%!*E *#,W)
M0!R!'W/Q$:^/6.6NOK-^4(]K>R-YOLV_)'7O@PP ,\]DVTCK?=EF]8:_DXJ\
M[\,4=$)G@9VKN_<^OX*=9ORA'M;^1O-]F[Y(]S\.G!AL?Z_Z9MI\=LVKN_=]
M-^&*.B$WP,WK?XOU_DU=NG6;\H1[6_D;S?9M^2.G!?@#EV3;3XY9O6';'L:;
M\,4=$)G@9WH].LWY0CVM_(WF]S=\D=."_ '+LFVGM_=EFZ_[X:N7X>]3?ABC
MHA,\!.\Q3K-^4(]K>R-YOLV_)'3@OP!^,VT\F7W99O6&O/DIOPQ1T0F> G>8
MIUF_*$>UO9&\WV;ODCIP8;'^O^F;:>+LVS<O%^Z'T9YC*IWX8HZ(3.7]AG?!
M^U_;M<L1QRF/*"*+,#J<G'D4AT'9U4"#C_-8"NJ9D\0%(H&J/.,((JJK<"<3
M<$A,(<T#"#@OP!^,VT^.6;M:_P (>V8^&-^&*.B$SP$[T<^W>,OK-^4(]K?R
M-YO<W?)'3@OV/_QFVGQVS<0X_P!OTWX8HZ(3? S?1Z=9ORA'M;^1O-]FWY(Z
M#8OP!^,VTGN3+-Z?VC["F_#%'1";X&;Z/3K-^4(]K>R-YOLV_)'3@PP!J_IF
MVGD_;EFZV?.'+JRX_AJ=^&*.B$SP,[7U_P!K^W;IUF_*$>UO9&\WV;?DCIP8
M;'^K^F;:?'+-K[GZ(?34;\,4=$)G@9OH].LWY0CVM[(WF^S;\D=."_ 'XS;3
MW-V6;UA]--^&*.B$SP,[T>G6;\H1[6]D;S?9M^2.G!?@#\9MIX^S+-V]7X0X
M_H/P-^&*.B$SP,[T>G6;\H1[6]D;S?9M^2.AV+\ <?"=:0.3.99O6%-^&*.B
M$SP$[S%1TN4SY04BSDY>3BR*8ZITS*$#'^;!%,2HID* @%1XASB%*<.< <>/
M$.YH=C#8_P"39-M.?;F68_\ J IOPQ1T0F>!F^C]SVXI'6;\H1[6_D;S?9M^
M2.G!?@#EV3;3XY9N3C_= TWX8HZ(3/ SO1Z=9ORA'M;V1O-]FWY(Z<%^ /QF
MVGC[,LW>_"''3?ABCHA,\#.]'IUF_*$>UOY&\WV;?DCIP7X Y=DVT]O[LLWI
M]-^&*.B$WP,WT>G6;\H1[6]D;S?9M^2.G!?@#/\ JFVGN;LLV?\ Q#N4WX8H
MZ(3/ SO1Z=9ORA'M;^1O-]FWY(Z<&& .+A.M.?\ CEF]84WX8HZ(3/ SO1Z=
M9ORA'M;V1O-]F[Y(Z<%^ /QFVGQRS?#^Z'=]A3?ABCHA,\!.\Q3K-^4)[W5O
MY& ?LX^S;^'_ ((AIP7['_XS;3X[9N7B_;_<IOPQ1T0F^!F^CU%8\IER@B#)
MF@ER<>15DD6K=))8N/\ -9@5331(4B@&)4A*('* &XE'AW>YIP7X Y-DVT\>
M7ZLLQY=0_5XU\G=ZW%3?ABCHA,\#.]'J5UF_*$>UOY&\WV;?DCH-B_8__&;:
M3W)MFX_'ZG?ABCHA-\#-^']K_P W;IUF_*$>UOY&\WV;?DCIP7X Y=DVT^.6
M<=S]T*C?ABCHA,\!.\Q3K-^4(]K?R-YOLV_)'0;&& /QG6D]R99NU_A#VS'P
MM^&*.B$SP,[T>G6;\H1[6_D;S?9M^2.G!?L?\?";:<N3[LLWI^OY*;\,4=$)
MG@9OH_7^CMTZS?E"/:W\C>;[-OR1TX+\ ?C-M/:^[+-ZP[8IOPQ1T0F> G>8
MIUF_*$>UOY&\WV;?DCIP7X S_JFVGN;LLV?_ !#\U-^&*.B$SP$[S%1UN4SY
M050S<3\G%D4@IN 43 <?YL+TAP35*! YU1[HB4QC<"\3#S>(=SCIP7X S/\
M3-M/<W99LQW?T0^BF_#%'1"9X"=YBI'6;\H1[6_D;S?9M^2.@V+\ ?C-M)[D
MRS<HU?NA_.._3?ABCHA,\#.]'IUF_*$>UO9&\WV;?DCIP7['_P",VTZ_[\LV
MO^']WVXV_#%'1";X&;Z/3K-^4(]K>R-YOLV_)'3@OP!R;)MIXNS+-U^/\(<7
MYZ;\,4<F$)G@9I_^W%.LWY0CVM_(WF^S;\D=."_ 'XS;3XY9NW_A#VR/P-^&
M*.B$SP$[S%.LWY0CVM_(WF^S;\D=."_8_P#QFVGM?=EFZ^O]O_S&IWX8HZ(3
M? S?1Z=9ORA'M;V1O-]FWY(Z<%^Q_GEPFVGN;LLV?;_;_P":HWX8HZ(3/ SO
M1Z=9ORA'M;V1O-]FWY(Z<%^ /QFVGQRS>L.V/8TWX8HZ(3/ S?1ZC%Y3+E!"
MO'"Q>3CR(*RC5FD='TO\UB*::2KTZ2HE"I<\ 5,LL0!, %$41 O$2G#0;&&Q
M_P NR;:?'+-VO\('K^W*WX8HZ(3/ 3O1ZD]9ORA'M;^1O-]FWY(Z'8OP!^,V
MT_#,LWIXIOPQ1T0F>!G>CTZS?E"/:WLC>;[-WR1TX+]C_EV3;3XY9N+Q_P"7
MY*;\,4=$)G@9OH].LWY0CU^3>R-YOLW?)'\_L:<&&Q_R;)UI\<LQ_P#4!QTW
MX8HZ(3/ SO1Z=9ORA'M;^1O-[F[Y(Z<%^ /QFVGQRS=K_"';^44WX8HZ(3/
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M4"K>'PC8>(^MZ_V-;?G>O[2U^%E^:K"96W+[Z=GVDQ_DS77OW2^4RH&UG#V
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M%"-TU*Q2SEXJ4W5F3C)./D#L,!ND7R;%XW='9K'R*SYB3LB"AS-U3]&KS2+
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MY29&;N+Q@X)+24XLWKLG*OI"#CG4E+&5?.%XMFY+'D,HZ= +5LV$BB!3 Q:
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M*B+ ZKE A' G63 SJC<=6<^;R?MN1GJ[>V9Y<G<U<6JFY(IS^YH^O^X-C/\
MU,N[WZR)VCA?J/%^3VGXG7H7*XY@;OF:R <Y+QU9ZQGIYTW)%[%C^ :^K7SA
M\L3FZ_8?W#RSJO7V^UFJ5;!%'L:\%4+/+PS4$F$!)R#\S*,92<?'@[<)MS
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M J6T'*KS?V'$6\JLT_8)V-H"VKP[9Y5QD[#.%A:(SR9N-("'EW%NP.,K9,C
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MHDS$N6_;0TA^(EK=Q9;<6IR,-N6MQA8;6M"T)44H2I1TD-J)\S^\/VOS]?\
MKUU&M-[E;=[B?\!'_-JQ#_1C_7Y1[/W]5;%?6W9^8U\E_9"?KZA?Y)X>_P!@
M]6E.327,S*K*4E"<=/6]ZJ;J8;PKJOM$UZNWED%;&E*GGGK 5F"D25R0K6,<
M%?.'HM$Q*9J+CARRVJAA<L3#'2A<"4AE3Z'UE,E3>3!:#+;F3FV$>Z6G)*-,
MCW60.AX&7AY,J^HQ&[:V(\C"]\C6]^YQKI)+-Y>AK1:W80MD:7M,EN86E&1+
M9,=J.'BDA\M9XLQE5<\K1<:>^VUW%.HZY5^7DV#\["6>3C%I4X=M:V3>2@I(
M$&5=E;B,Y)5^,6("K)D#('35LT L,3*7"78TN.B'#;?2[#D,MN-A;2&%KD.J
MBN%I]KW4IJ*&6I#P!)<TR%+/VP[_ (QQ%L5,RI[>',/1+DB;AR[6^#-A-R(+
M%JE/WF<NQONPKE$TI%V@V,6^/=9R"=ODB08\AQ]1GG9[P^OW1^QK6AJ '6 ]
MO;/NGCKA%?:3@Z7R+"[!MN;W%\>K(6;TI,7I 5M%H3CQNT4K+3].:0[EXP0?
MBL_*P8/.E>(%81;U_*](46 #KZ'P_P#@2U?O=$X^/]*''7[*;$?]2[8]_P C
M\/\ _#8]7KCN_P"YE>::MKU2!.9]#W0XQ1*\I#Q+*TL4,:N(Z-/=F[V79A76
M;]UD^*@)1Y&-G%K91,4^.<!=,',CF:Z)6)VV1]\1RMN;2%E@4/*E4.\HT4P5
M*!*PP>T\RB);0<B(3^3CV"BV@"*K^A_'\7!W=4T.:7-,JJ5M[B64R%,XS,MD
MQDJVMJ"LXR</%698I*;0;J*@UFF<*=A&OH-@Z QDFD7*M!D6Z38#K.Y5)5"5
M?-6K/BS&=#Q'DKQL5V7\KXJJJJSWM5Q!FJH=1J@.0;\446ZAA.@D)0QN<"BF
MF)2"4#& .' #" <1[VC&NQ $("L"/*4$I"E=3[:=)02 3F;AKS.O7W>.N9JL
M&/"I1&(F,B21G(D9Y$\N4/*OQZBOEA?'?KGG"O\ \VNO>_;8>Z!O>3K;ZPJ.
MH&/>D3'C$CT.N/45\L-X[];\X5_^;;3?ML/= WO)UM]85/4#'G2-G/\ QB1^
M7<?YJ>HKY8;QWZWYPK_\VNF_;8>Z!O>3K;W></;BXJCJ!CWI$QXQ(]#IZBOE
MAO'?K?G!R!\VVF_;8>Z!O^3K;ULN</8Z^.G4#'O2)CQB1Z'7/J*^6%\=^M^<
M*_\ S:Z;]MA[H&]Y.MOK"G4#'G2)CQB1Z'3U%?+"^MO?K?G"O_S;:;]MA[H&
M]Y.MO<YP]N/CIU Q[TB8\8D>AU#<;+^5_(NP*KO;KAU%72A&Q@R#?AZ)8&3M
M4QQ$<;@)0%LFNES@ P\5 +PYIC"5OVV'N@;VK_!UMU_^89=_X*GJ!CSI&SXQ
M(]#Z^7L*E^HKY8;QWZWYPK_\VNF_;8>Z!O>3K;ZPJ.H&/.D3'C$CT.GJ*^6&
M\=^M^<'('S;:;]MA[H&_K_P=;?6&KX*GJ!CSI&SXQ(^#]I^W;KGU%?+"^._7
M/L_K@W_O>M_@V[GX=-^VP]T#>\G6WUA3J!CSI&SXQ(]#KCU%?+#>._6_.#D#
MYMM1OVV'N/>&_P"3[;^3JAE3J!CSI&SE_C$C\FX_SUSZBOEA?'?KGG"OX_\
MTU#U_7_!J=^VP]T#>\G6WUA4=0,>](F/&9'H5/45\L+X[];^S^N%?P_^FPZ;
M]MA[H&]Y.MOK"G4#'G2)CQB1Z'7'J*^6&\=^M^<'('S;:;]MA[H&]U_P=;?6
M'R<5.H&/>D3'C,CT*NA+9=RP!EG12;W*X50ATP6-Z8-^ #F%$AB#Q]+81-S4
MQ*7N\WAPX 'KBW[;#W0-[R=;?6&1_+3J!CSI$QXQ(]#J1ZBOEA?'?KGG"O\
M\VNHW[;#W0-_R?;?6-.H&/.D3'C$CB\3^3Y:>HKY87QWZYYPK_\ -KX?[/LZ
MG?ML/= W_)UM]84Z@8\Z1,>,2/0ZX]17RPWK[WZWYP;_ /-MIOVV'N@;WDZV
M^L/;X33J!CSI$QXQ(]#KGU%?+"^MO?KGG"OX_P#TU#3?ML/= W_)UM]84Z@8
M\Z1,=O[HD>A_13U%?+"^._7/.%?_ )M=-^VP]T#>\G6WUA3J!CWI$QXQ(]#K
MCU%?+#>._6_.%?\ YM?#_9]G3?ML/= WO)UM]85/4#'G2-GQB1Z'3U%?+#>/
M!6_.#?\ ^;TM@_GTW[;#W0-[R=;?6%1U QYTB8\8D>AU&8[+N5_49,U&V]RN
M)-E&J!VZ8Y OQ.C1.D0R1!*7&Y@#F)B4H@!A !#@ B <1'&VP_T$?.OCZG6W
MUAQ=H]ZG4#'G2)CQB1Z'4GU%?+#>._6_.%?^]YM?P_@TW[;#W0-_R=;?6%.H
M&/>D3'C$CT.GJ*^6&\=^M^<*_P#S:^'^S[.HW[;#W0-_R?;>3_2'\_+3J!CS
MI$QXQ(]#IZBOEAO'?K?G"O\ \VOA_L^SJ=^VP]T#>\G6WUA[?":=0,><F(F/
M&) _^S-/45\L-X[];\X.0/FVTW[[#_0-[R=;/6%.H&/.D3'C$CT.GJ*^6&\>
M"M^<'('S;:C?ML/= W_)]M]8TZ@8\Z1,>,2/0ZY]17RPOK;WZWYPK^/_ --0
MU._;8>Z!O>3K;ZPIU Q[TB8\8D>AU'7V7<L 4S<%=[E<.)W!2I#Z8-^'F*]&
MH8#]W&P<W@4IPXAQ$./#@("(@W[;#Q_L#>\G6W\UP_+4]0,>\F(V?&) U>)]
MSV&OO]17RPW#]^_6^/\ I!O_  X>;;3?ML/= W_)UM]85'4#'O2)CQB1Z'3U
M%?+#>._6_.#?^]ZW^#;3?ML/= WO)UM]84Z@8\Z1,>,2/0ZY#97RPOK[WZY_
M%D*_][S:Z;]MA[H&]Y.MOK"G4#'O2)CQB1Z'3U%?+"^._6_.%?\ YM=-^VP]
MT#?Y?W.MO+_I#^;DIU Q[TB8\8D>AUQZBOEAO'?K?G"O_P VVHW[;#W0-_R?
M;?6-.H&/>D3'C$CT.GJ*^6&\=^M_8_7"O_S:]W\&IW[;#W0-[R=;?6%3U QY
MTC9\8D>AUAO<+LPY5Y+"N11N>Z)EE*L*5Y5M+X[@;=>9J9N*#MRW:IP,;$N:
M"P0?NWSA9!-%NL]:IF-W3+$ .(7]LQIL4+N$5,+")MDHN@L7%Z%;F6H3@!*9
M+CJ)KBD(:RTU$(6<AEHG/*M?Q5AS';N';NTJ\)G!R$Z@PV''W7I.EDD,-MF*
M@*6X3HITE)&9S) S(]J]EM!S9C' N/J3N"N25WR9"4Z";2TB4I5G$8TZ:5&+
MK,A, X<&LTC7&71Q3RRG$JDNJ@*YSNQ+V>[XCB>9:I]]N$NRQ##MSSZE,,DZ
ME',Z;Z6\AM"'U9N)CC,- Z((^]'1L'P+S;<-VJ%?YHG71B,A#[H!)0G1&U1U
MO%:U2G(Z,F5REG3?*-L45*45';76 K9J:4II2FE*:4II2FE*A1_[6#^'>?#%
M]*5-TI32E-*4TI32E-*5"?\ T!/[MC?Z1:Z4J;I2FE*:4K2#?_1+G?\ !L9'
MT"'EG=GALETRQLK/!5&-R9,8T3CADT761([#LTNC#9B<0J#P[ *%(E=E.G+G
ML[!@_F*S'-%E/;N^WPUQR>\',5S;JC$61%V-E;Y(RHK8I63@X6ER]HEWEWEW
MCBVS.,*Z<T/B*3LI'"4LOC-L1LM6R.4AD&C22>/&Z:E9?/\ OJ&W_-^>_P"L
M9AK8/[$U?Y1-?\.<K&'\,I_>QS_>FZUKW2X0P[D+)J,_>\84:WS9*S%1Y):Q
M5N+E9 K%NZDE$&@.GC=58&Z*CA<Z:0&YA#+*"4 $P\8MF*L1V:.8EJO5Q@12
MZMXQXLA;31=6E*5.%(.6DI* %'ET4\67NHFV6TW!T/S;?&DO! ;VUUM*EZ"2
M2E.EEGHI*E'+KGK#(Z[M]L.W5J*PML(XP;"X04:KBWIL,B*S98 !5NMT;8O2
M(*\TO2)'XIG H 8H\ X7Z\?8R7EIXENR@E06G3E+.BL<2AGGDH9G)0R(SU&K
M5.&,/IST;5$3F"E6BWEI)/&#D1F#RCB/**D*;;-OZP%(MAK'"I2(]CIE4JL4
M<"MP04;= 4IT# "(-E56_1E "= HHES>C.8H^!CK%X.8Q%<P2K2)$@@E6F'-
M+4/OM-(7GQZ8"L\P#7HX:L1X[;&XLOO2=6CHY:SQ!.K+BR.7%JJG^I6VU=S]
M8C%/<[W_  (@OR/P=SC_ -FJO"!C;I/>/''*\;UL/9Y]2(7@AE5]W;;?@*3-
M5.V6',<ONUU(KD4P[*JD0L#*,9(+$9Q[8#MA!%FU(8Q$$"<$TBB($* #PUHM
MUA1+Y.?N=XCLW&X23I/RY;8>?=5_;..*S4L]LG/4-?+6#NVQAL>WV4F;>,(6
M.Y2T,-1D29<%AYU,=@$,LA:T$Z#040A(( !R&5:Z9MH^R;;MC"SYCR_B_&%4
MQU3@AC6.P!CDLUVN)/V"*J\6<8V!AI.5<$7FIN-:G%JQ7Z BYG*_1MD5E4\=
MO<L7-, ]K<Z,SW]7L>O6,X%MB?H!AGR9&\W6.,:SW)[9?R?+8AQOC>B6JXP<
M5.S4N:.PW+^AA@PKM[MN-I!5>Z*UE.J<Y:W4>S1\6D28,>90C@DHL'<<Z9NE
MXWMV+FF!GU]S(UGV&?<ZVNG ML4<N ,,Y<GZ&1ORZ'YJV<]2YMP]@[%_O.AO
MR74[V[%S3 XLOU.C+D[6?)Q9];K4X%MB?\7^&?)D;S=>IU"&HX\Q-34CK0%,
MJ$!6*_'- <N&,% P[,&[5C'LDU7*K=DT1Z11!FT1%0A3*'202 3G*4<NTTTP
MTVRRVEIEI"6VVT#)"$( "4I'( !D*Z' @0K7"BVZW1F84"#':BPXD= ;8C1V
M$!MIAE U(:;0D(0D?>I ')5U,+O2Y62&&B[?5Y*8*M(-S13"?B7DD5Q$&(25
M0%BW=J.@6C#J$+()"ESV1CD*Y*D)@ :E7=4Q+*6,ERD.AD6B+$4Z#HSI6ZOJ
M%4[)>*QS;F&)("!NR)!!9@AS1'I7B*K5/G+IG("E5QM.PM@@7$O 2\7.12R$
M@FC)0[]I*,%56AEVCI-)XR66;J*-72*S9P0BHF1<)*HJ 51,Q0'/DXR0!GVS
MEVOE('7(%-7+Q#C]M?Y*T*+RK>P)J -G&X%JDX;AV.NF..LO&%-9']+4()BT
M Q3<TY3%YQ3&*(AQ*8P" CT-.Q/L@K2E2</*R4E*A^B-HXE $99W <AZW= R
M-:LK&N&4E23<QFDD'*'/(!!R.L12#D1Q@D5SUL7)^^,(T\W&7_F_UZX)=D,<
M>'E>4;1V_P#"/:U]8ZJC?MACG/\ @=P]$[8IUL/)^^,(T\W&7_F_T.Q)LA]'
ME<>7X1L_>_"7'4;]\+\Z#BS_ %'<.+K_ *DXJ=;%R?OC"-/-QE_YO]."79#U
M98>5KS'X1L_&/])>W)G3?OA?G0>)W#T2G6Q<G[XPC3S<9?\ F_U/!)LB='E<
MG[I6<\?)^$AVLNOUJ;]\+\Z#Q.X>B4ZV+D_?&$:>;C+_ ,W^HX)=D/+];QXL
M_P (V?UEG\E3OVPQSGVOU'<.7_-/;X:=;%R?OC"-/-QE_P";[3@EV0^CQ\I6
M?X/W2R_F(UY&F_;#'.?\#N'HG;%0'G*N; 57,4HGN!:&(W?*K+#Z7.7@YB9H
MR00*80&@ (\55DB<"@)@YW$0 H&$'!+LAY9[WE:N/*XV<CK<X]?BXN+K4W[8
M8YS_ ('</1*G];%R?OC"-/-QE_YO]!L2[(9_L>5VLKC9^MGK_1+5R]ZF_;#
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MD34 1 QD5 #NE'5G:L*8DO<4S;599\^*'5,E^,SMC8=0E*EMJ(.I: M)4/\
MWAEGKRKS+W:;>Z&)L^-&>* Z&W7 E1;)("P.L2" >4@UHKGS.>W7+>#LPXLA
M=Q6*(>8R-C.\4>+EG]A048QK^TUN1A&CYXF5F]%1JU7>D773[#=<](ABBV7
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M/Y--Z^'N9X/@13J^=D_#AZF?$_#P>AM+A_\ Y-.$/&_2:Z^,?R:;U\/<SP?
MBG5\[)P[VV?$X?\ NVE^,TX1,;])KKXQ_)IO7P]S/!\"*XZOC9/XLV)_>VE^
M,TX1,;])KKXQ_)IO7P]S/!\"FHC?D_-E1G+XAMM&*!*FJB4A?0VCP*!FR1Q
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M**P)0JVYF(.8@335>BBQTPP:S<<XC'2\>[*<X(.TD')U&RITE2HN")J]&82
M&O;.R-C5M^,^K$-PD;FDL2DLOO%;#BX[J'D)=0 --M2D!*TYC205)SR4<[:=
M@S#,^%+@O6B(EJ9&>BN+;:2EU"'D%!6TYD2AQ&86VL9E+B4JUE(JV=L?)Z83
MVL7B2R#2Y*XV2R/H-: :.KD\A'Q(9F[<(KOUHHD9!Q(MWCTK9%JLY.990&?3
MMDNC3=.04RF,ME/$6-;<Q:K@S;XD)J2)2V[>W);,AU"%(:2^7Y+^DVWIK6E
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MRA3_ .O<)^#^/3J)L&=*KWX.9_%ZG5+9%YCM_A&/6E/3KY<CQ5\*_P OI_\
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M#L5QW?\ U1_Z]0>(\O:XZ5CM#,N("H(E-E;&Q3%23*8IKS6"F*8I  Q3%&4
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M95:T;I/W2D/_ $:B_A,CK)V49PC_ -^YGJSU:"->7:SY.+CK#7G]6#_N4?\
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M>/<NEER[S_YIP^CK94ZHC<%W/^Z.9CXA_F>Z_P 7^&GUO[/!J>%O#WXL\/\
M+_7PO4O)_/G3>/<^EMSY/ZU_DZWW=[<F5.J(W!>V.9B\CW7^K-(?@TX6\/?B
MTP_Q9??PN_\ @7C]A3>-<^EES[6:7SEVOU=E\G=IU1&X+VQS,?<X_P!Y[KZ_
M?_PTZ<+>'OQ9X?\ CPO4M-X]SZ6W/XK^KK@?=W$>6@\D1N"X<.L<S'Y(NO\
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M0;.!6%,$E.;AF'\"R'F8T=6&'GY#JF6&FF[:M;SR-'2;:"4';%C23J1I9E0
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M@$%P,7GD(<"B @!RE,'= !"-\-_XQ?+OGQ$]4YO>_3Z=2K7JSMMOSU_M./\
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M-=4K3.+5UO;DKZGL!?O<MNO=X_K*TKX.X[G\7>U_(9_TJ_\ [96.>3]!L/\
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M][ *7G*R_P ?=]'_ !_Z^[W].%K9!Z0J\F6;U=3>/ACFS^%SO2:=4SR?P_X
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MBG\82_&;=Z+3?'C/BWL)[S_Y=M_+^6N!WR\JEP'_ +GXF'?#NPEW /XQ[?\
M>^SIO$V*?QA+\8MQ_P#M:;X\9]&$]?BD'\CI[W(,]66=5;DPLZ;Q<GYYW10V
M8L<*UW&#>XR$W(HRR\BR'%V3Y#L)5[CVI)R17SJ6CY!BH$U,0QWA$:PY%&2Z
M=%>Q"UD\%LB63"=KMMB59;DB7-,=+*%LAM8N5N;TPU<)1:T&VG0=%I#H3G)
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M8'5',E8*5)(]R4D+!T2"<T>HMVJ^PS'>_G+/S@:Y^?LZ]FA*LE6S ((X_P!
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M-7\JBOR+3@1F]*\/_&=IPC1^9KA\9'U:=>'3O7VLYJ_E<7^1!J>!&9TKP_\
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M=?RGOUBG/D'7Y&\IKRC>75<A!1Z93,91HS1Z,J[T2@**\,_/SP$3<3]/P$.
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MFYI#E#G#W.(\.(\ \ :O[,VA4,J4E*B7W!K2"<M%O5F0>Z!U^+6=6(O*UB6
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ML\@JI"4#$<.) YS.BB4ATZRNFBJB=ZQ3$V^N84*;&G)'Z)H)DK.9]T-#W44
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MZ(&D:J?5*-_&#6'N</W)T_6\'ZY(>#A^8ZI<&[O.Z/$N7QCK^V>JK#_J6/\
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M*VF_0BF23A* D9 DM(PZ1R(E%*.D9--)_(-$^:B]=HH+NB*J()&(I[=^JB>
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MIIHLY)*(>H+F7!(4'["2709R,:J!'T<NY:)OF[<SMJ"RIJL*VFL( (K6."2
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,2E-*4TI32E-*5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g129231g50a54.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g50a54.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2"P4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ()2^@T X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0&B\_@         *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,W    !@             "M@
M!&X    ! #<    !                          $             !&X
M  *V                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  *V     %)G:'1L;VYG   $;@    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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M]1MJ;:!)+7-,M<TP0>%4Z)@OPNGL9?535EVEUV9Z$['WV'??;NL_2/WN_?\
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M!GT_T3O3M]W^"_X94JADBTU8[@7MD&UKM@#/H_2T_E_\8D,
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MP?J "ID*<]M8@1M8$CZ1@;0 2#D8!]-8KJ&-&,B;48N&W#TA@#DE0 <XP-N
M%]F&WQ8=ME\7;6U(&0[ORZ>.)>651&S+)ZRLKY=H&HA1H]<:7!J80(421+#
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M#CC1(<2.-Q9$F3(,Y@@  )CB%*5[1C8USG.1J*O/2JSLJ(I9V(554$LS$X
M'))/  Y)KR[I&C22,J(BEG=B%5549+,3P !R2?%<[74!L/H(ZH/JN:4U9G]=
MMD.U]="Q*OQ[,C$D5&N[W+*:TC[+Q77TO&[U4FMJ9XC6L.7< I8!K2[NP0 2
MT!&#.6PZE\&[K5.G(.NKMXI(["6.9;**X#N;.UN)$:60(&B(6X;=+$),F!"6
MYRHZ%T=\2^J>FNGM7TK0+FU31]<@U".Z$MH!=K/<V_R$US%,ZI-#+!!$>R'!
M&_8X'&'Z+^5RN?TXI3BE0#ZW>M;+ND^9JK&=?=-&S>I/.]OFRV/CE!@+R18E
M<3$8U/*FONIT>FOY(&DCVZ2FJVN;'%$@S#R9<=C$=RY])=*6O4BZE<7VOZ?H
M%GI8M6GFO1O>07+3*HAC,L*L08MIS)DLZ*JL2162-%<MN?;M /@'.<^264+C
M'D^<\9/%1CQ[ZE^':J@Z=VYUBZSS#INRKJDC,PRKPZTIKZ7(P,&M,ER>$:]S
M<]W!Q^96T]TN31)]:.+32+18#FS719,+O)!6?B!J&@=&7*Z;'JQU>QAN\1W]
MG"LL3K=06SR3$0/*-EH5*3]N25RV>W$6#BK;T-\+^INO=7UL].1Z?,]KIMLX
M2ZOXK62YE@:X>&Q@[AV-=W9ED$&[M6H,0$]U$TBK6X>HN*K(*JNO**R@W%+;
MPHUC56M9*#.KK&!,$T\6;"F1GD!)BR O84)PD>,C'-<URHJ+R.AFBN(HYX)8
MYH9D62*6)U>.2-P&5T=2596!!# D$'(JKWEG=Z==W-A?VT]G>V<TEM=VEU$\
M%Q;7$+E)89X9%62*6-U*NCJ&5@00#51YDK6IQ2G%*PSO#?FL>GG#I6:;,R*-
M40V#.E75L>,MYD,P(U)]OI*WS::9(=W8A"?HC16O:26< U1R[5I9W%[)VX(R
MV,%W/"1J2!ND;PHR??D^P-9H();B01PH7<^P\ #DDGP  "23["N3;J]Z@,CZ
MQ=Q5NS;VL'B]#C%-(QO",>%)DRRU>/S)CI<HTUSC_#DWEG(<%]A,BPP>M@HL
M-KO3&8K^BZ7HT6GH"I,DP =V)*Y)P" H8IVPP"Y/.0>>#CH6A:0(E Y97<+*
MY3(DDVD;8MP5E"AL^<L,G!XJ)=[AX&D=:Q8[$^0^.*63U.9(>QC%1CO-&HC_
M (SF-&UAR,=XN>YB]Q/:W9@O[^'J6WL3H ;3[O2VN)^IC=VD9AN8;@);:4UF
M0;N<S+/+.EPI6WB(<,"SY'0_P#3VZ:N+W\<9+ZVU..*+IL6MT>_!- O>U5;D
ME;2$QF)+<P%3.X1<$#MJUC3(8QC>U7*YS/)K5(J(C>Z.[HUB*USD1?SXJJ_I
M3OV5O=.7=RS)&Q!4MN?#$D%L \;20<^D9Y)/+$J<"JBVB0D'+$D!B%RP* E@
MREE)SNS]0.[&5)'&.[2$Z.(Z">7Q1O94\F>IJE1@_-?8YK%&KE=^C]'Z6H_L
MY.ST\]A)H]LJ%P3].0C-CCAB""?[S  #$%F;&WTZLMJK[VB(3ME"VX+G<VT*
M 2R\%R RD'  8!\<8O??SZ>82858$AX%:)D(D)WML$4JH9&28S?7$4(&J522
M/6,JJT#/(B>*5K55O8M4TS3[72;VXL;Q+UKS51=016^DFWA62T2XAF=+B87S
MYC3Y=9!&ZYD"*01G@TRSDTO5-1GU:TM]0LI+:.STB2WN9I]5$\A2[,$R1M;P
M?)K^:3,RAP2L9WD!MHW0)]0[+NG3.:P=;D5E<:AFVU>S8.O[5Q2-B5]@Y@)=
MO2 D=UKKFH\G2AFC/&.?ZDKYGNCE"Z-6-6TU;F+<8XNYM)AND=6$N#QZXF,1
M3)(R2<@AOL:KMYIL%ZMTC[XKZ'E8W21)87 (,4JRA9"C,NTAU!C).WP%/:S3
MV];?U-9>TTV/8U%S AVE7812--&FU\^..5#EQRL56D#(CE&4;VJJ.8Y%3^><
M_92I*L"&4D$'@@C@@U1""I*L"""00>""#@@CV(/!JH\^5\IQ2G%*<4IQ2G%*
M<4K#FTEN[&UUUCM71'D1)&>8S>6F2>3D#10L;LF7!1QAACR'DFVGPV5!DD$K
MXPZNSG'23)>)T$TI810&"_N);E(Y(K65(;8KEKAI5$?+%E"*@<R*5$C-)&JE
M4#!JKVLW5REYH]C#8W,L5U?0237\6TQ6:VT@FVN,,Q,W;[+[NVHCE9E9RK1U
MF/D75AK"G4/U!:PZ7=19=NS;]XZBPC#X@S33  Z78V,Z45L6KI*>"QS73K>V
MFD%#@QO,8U(12R#1XHCG%*Z+HU_K^I6VE:;$);JY8A=S!(XT4%I)I7/"11("
M[MR<#"AF(4_0,D#(&?<G X&?]!X&2? !-4;IBZH-.]7>IJ'<>E<F#?8U<#:*
M?7F='#D.)W;!,?.QG*ZL)Y#JF\KW/:A@.*6/)"X,ZNDS*Z3%EFR:[H.H].:C
M-IFIP]J>(DHZY:"XB)(2>WD( DB?'!P&4Y1U5U90((.#_O\ :I"<AJ^4XI7G
MERXT"+)G3##C1(<<TJ5(,Y&"!'CC<4YBO=V1@Q#8Y[W*J(UK55?PG/H!) ')
M)P!]R:^JI9@J@EF(50.223@ #[D\"M5P<JAGW5GF^G5MV:+F^#NK:F(VBGQ9
M&.T]6D:/CQ;:1(&..]V65M*6[BD"15"*RCQ#+WC.5+!+%OL(+))T(BE4M^9&
MP=I03+V@A9OR7?8P;RREE(' ZQI&CJNF6T"M%WA<QW$A>5&-P0K=U;=%8NHM
MWD6)]RG<R-(OI88UI]1N> R[,;6TE13CL2.&YEO'/ZA3H[PM.*,>&_\ 0-(;
M52.-S3O*C(XT(\GBQ6V_0XGM84C<J5 ?,/.]&SA<-GS*"I.5 R<*!M*FR1VS
MVL>S(502 2< 8\J 0!R0<G>#[Y .!"+,9,.0I6E8CG.16L\V^1$:C!_EWK7R
M\G/1'-_SJBD:Y?P[Q2TVY8X2.-\-D8)#G#,&W8!898 J3Z<8(Q@YK')(N"'
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M_&Y\ON3M'KX;5L:LDUR.;"C36D,HX8#&'3.IK4RPP/DF=#@;R2\@;@(&\%B
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MCWB];%:B(O?LYWD[Q;W7Q8BN8WL-$1B(YR*Q%<WO9XGB<!C,BCRA&',C!7(
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M<ZM<V5WJ=]<Z=9C3[&>YEDM;(.9/EX6;T1[VSSCDJ/2A.Q/2JUC8AF)  !/
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M.:]OQVE\F/;W8[8M03, #AF294.,XD,,@C( (.[>5V\CU8K;L-OSEN&(53(
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M$8:1&/(DD:U\9'.1\=PT:ODKA\WZX^)>D]"WVC6.H6EW=R:R91%\GL=X1$R
M&2-L<2 OVB70.\90$DDKW?X.? ;7/C';ZS<Z9K%CHD&D316W?U*TOI;6ZN9;
M:>Y["W-I'*L#HD*%S*I 24.,E0C\\^3_ % ^LO:=-=VY]ZGP>AB;$LB0:3$X
MM7C^3U4,L(<NLK)-G2Q**6?&ZM$,,;[0\]]JY6I/1QQ$0EPM)-0O6<H\4:",
M.B.@WL2%+;FR5] ;A1DA@5)=BM7QN@>@]$GMX'T:?4I9;/LRW+7$LMF\D<LE
MO)/%%.78SRNJL=AA5.6B"QMA</;7O=M[/Q_'LXVCNC*LAR.=4T\;'Z>5+R6]
M2[JI-G+6W\X9IR4]:1H(U=+2OC1'-E$4<HXR3XQ7\HL.@ZW==:RZZ_4UW%I=
MJD;II1,L\ (58IX%@65(4CE;,HE"DA@A8$*=W9--ZDZ+Z?Z"DZ(TGX?:-+JE
MS<W*774)@TNTG@<9-A<K<I;2:C=3*99;=FFN<K'NC5T@D5%KVK^K?8'33@>5
MXQ2V#*[$,X@NC6<F54CEL(67#DUBDI&B IH"GA2&"DA&C7%)'#YO48Q.;^A=
M#TN[UFZ@L+&S^>GAB>Y21Y1 B!&C.]B[)'L&Z+T.^XON"E=QQP77+71GFCO]
M0,!FL[N*6)FEEDC2170;9%A9GG8R0!E9D4("6[.TEFE'T\?6]DX/A%%IF^P)
MN:Y+4Q24>)Y5+GR<7'5T,&.@*I<DKC54U+PE4-C&#6NE5#YT*.&-)?&.Y; V
MQKG0G4FD03:UJEI:0:8LB&>6&_@FD3N$DYBCR 6(V)M=MTSH@'JR.?ZQT?HN
MM7<DO3VLS/JEX7D.EOIMPT;WDT@&8KMS"L5N'<S7#2JX@@624,^T15 3?6T]
MO;Q.^%?YF/,::IN;S(J^@B1XE'&/?V\5H;;(2PHB /?WY_4K(4RS//L QD#5
M0"#![(I:=>W(#K).Q9MEN5MX4#"VC>)-D2!?K"DELXVJSE@<*2MM^'G1FF:)
M8R6=K:"TN;BXO%OM6NY29=1DAO[AGDG>4D6ZRA5@=!(K2)$H91E,1ED;+W-!
MIZ/7>7;#S65@^/EFW^,8)=Y)=V5!6SG1W*^+ I94LL:ID*-#C"\,5H1D/*[H
M-"D>NG(9K(K+,R.LY51&NTM"7X5MIY<JV-_ P20H\DV6.RL+K4KA-'L6M;N&
M%VN-4>W"?B4<+*SPB6-!L0I@Q'?*9-@>38 $C_L?:^1,F5\NPE6B3*4\8V,1
MBV4OWTA8J_)$6G\T<RLB,LT?8-6*T RG[O15>\CUSO!W@X= S2;I448#1I'M
M0R A2$#2$D%1N)!!.!S+6;QVUI(JQ@%\PWDORZNL\EP"=DH+9G80 1L)&95!
M!7!.T]=G0A]1;"^IK$L8QG8;X^#;R,CZZ10FBSXU)F)(H4(&YQ>RD!=!]MD!
MA"FH33EL(\D4AL9DF*H2+X9'"J[1R(K\*74C)QGABH# @9!'!'@G!K\X]6=&
MW.@7ER;9UO-/CQ+W(WC::VCD/I6YA5C(@4D+W=FPC&XJ>*V/PLDQVRGRZJNO
MZ6?:5Y7@GUL*T@RI\(PO^H*7# <DB,4?=/,9AL<S_N1.>/?'OP<>^#R#_,>/
MO5.>WGCC29X)DBDYCE>-UC<?='*A6_\ :35:XK#3BE:4_K.0L5EX/I$<T7EF
M!\QOAX\9I?4HH :N*>P<;LU5*%)_V@?K[HC6&.]/U(B+:>F>Z9+I5;$06)W!
M( +*S%?/!]&\$8)(_A;&#-:&KM<R '$9CV2^XPS84^",@Y/\.1D;AFM1^).0
M=%5NF 4;@5#T02$5GC)_<>!4>Y'N[,1XW*Q47V(U454:U&DFY9V24M&V"TIQ
ME=WI?*D 8'Z# &%P"%]U[!IP(MX%.5,<<8+<?4 <<GQD#Q@GR 1G-?6R:8(T
MD^E4(6/['(J>)9 F]W@1J]AKV=W[C:YZA;W5556]T7,)(0\DPB7O%<2.B1]Q
MMN"$9E[9D(W-LRQVDD  >)Y))'6&,W#&%78HKR.T*+(5#,J$E5R55G*^=BY!
MP!6/Z_()4Z&]T^M= ,XIF+%,5Y$5C%(/Y*J\3'=R(1%8BA7V,8UPGN1[7+KZ
M!J>I:CIUM=WNES:%</)<"72[R6&Y>)8IVBB=Y+=MK">%5E0(=T:R>HEAFI;J
M#3M-TW59;/3=7MM;LT6V*:I:0S6\=P9H%ED41SDLO:D=HG; #;$8*-Q6L/YB
M2"K#D?):B>:D5ODY._9&HU/%[FJCOY<CD[HBJWQ9Y*BNG83+$2P;@D$^DJ@8
M9*^G(RV<@;EW8+$C&!5;EV[3(&*L@])+$-Z@.,[@JG;@D*2O S]C&[)3Q8K!
M-BD,20U\A9 R"&@QO<K&1Q@412OD_MMD$/[6C4:O:,7=WFYORQO==GU?5K>_
ML=/@T2WBLAH=[!>F34KJ1HF_$?GK5H EM';RQP_+/'*Y=)&;:I#%?M[#H,6C
M:5+IUYJ$NN3O>#5[2XM(XK&W19E^0:TG#;[B26$RM.)8PJL5& P57PS;!@V,
M.V69<PZE]=63)T9LQLE$M)$96>F!'>!AT]\A".:-#JP?9KO8Y%[]M;J/6[S1
METOY#0]0UW\2U.#3KHV,D$9TBUN#F35;IIGR;6W&%F6'![;'&&&3JZ-I=AJJ
MZH]_KUCH1TW3+J_MA>13M^)W<"CMZ?;M$Q(N+DMZ-RD.2!M;+;,)XV(QLE"<
MB^'L(]ZM1RD'[01S*U&*[\]U:PC&#[$:U'H)R_CQYBOYP5"KA0JL8R6)!SD(
M-K$%2V0&+L<%MY52 E4O#RS.QVG?PP4<# 5@3ER">.21M4$H"!C'5?\ 12Z;
M+>ROZ/=\TC(.+8+C/IA1@C*+[UE^2PYL=Q7M]JQW.A4\@DFQD,&UQ)18#$9X
M^;F<R%@NG7FO3G4M7U"36+Y;D0:G=_,0:6J(O]FTR((JVMJ=W$.6.>3XYD>N
MNIS=]-=+:*FE:-ICVM@T4\VEV0MKC4HXY5"W>K3%W:[O7>-1W25'HD( W #I
MKYXKD-.*4XI3BE?E[&D8]CN_B]KF.\7.8[Q<BHO9S%:YJ]E_#FN1S5_+5141
M>?0<$$>001D CC[@Y!_8C!]Z^$!@5.<$$'!(.",'!!!!_4$$>0<U%T(<JT-E
MV5S0XWE6=Z<RF-'OQ&Q:([)LQU[D]?';"LZTV+Q&ID65XYD4,4.=7SJ,%YD5
M=<@L(UE!DP)L6="F;BY&JQ6_=>""\MP8<L!##<0LQ=7,I/;CEC9F5E;MQ%"N
MPKM*FL:9I2]-R7RVL=W<Z=>R_.M^8;FXM+@1I$\2Q$"66"2.-&5U,L_=#F7?
MOWB/O4ZN7]<.@]F=/^BKS)=.Y3EM$P<O)LZ?_05U'I/EL;-KI^!2(TW8[L?R
M%B.I+5\JFQ9J@E/$EB<?OKY<-K6A_,:9=6LFHFV>YC,<4MBOS*[R,E)+@%(1
M&PXE$,KR%-P7&<U>^@^M8= ZLTK63H4>J1:9<+<2VFJN+5POA;FVMCW)OFK<
MGNVKW4"0)<(A?+*,8K^EM]+7!^AK"8.<9S5TN1=4N2UT^-FN;0+"?:U6/5L\
MP5;B>'.F#B!# 8"( ME:MKH\^RF2)@5-]N;' E8Z;Z=BT.VQ)VIKYR_=N44@
M",L=D4>X!@JH%WG"EWW$C& .D_%7XHW?7^JL+/YFRZ>B2V^7T^5EW37,<0[]
MW<!"PW/,S]J/>RQQ+&2.X6-;>N6:N1TXI7Y\&_Z+_P"RJB__ "BHJ<5\P/U_
MJ?\ K7Y5B_\ :][?_*^:?^_GW7_X<B_[\?RS_O\ W]_VKY@^S$?O@_ZC/^=?
MGV.&G[R-1O\ _%;W\$__ ,T7\C3_ '57,3^[T543GW&?')^WO_+[_P"OZ5\W
M%3ZA@?XQ]/\ ,>5_GD>Y:J;D-+"R2@N\>L@CD5][4V-/. 5J/&:)90S0Y WM
M5%16O$9[514_A>?4<HZ.."C*PQ]U(/\ RK("5(*G!!!!!P01R#GVP?>N3JWS
M2QTU8OTYEJ2C6BY3E429=6RD))J[N'9RJ9H72%\'%K)@XQH=BDIY6N0X)SW#
M BD-;VM1([W,+,B!(A&B ;9(F192V6P@>+G&-A"C:<Y%=7Z?U$E+4S28AEB5
M5;)V12[WSO&,+F1E5CP1N#GE<BV26&0U$N=,IK.PH[*5"FU<[X,R3%.>NL&N
MCSJXY!/$0D4['.')CD5S'+[D5'*YO;=AO5C14*AD&U@'56P8\'N+D>AQM+ C
ME3M(('FZ,N]20JLRLN<A3MD5A@KG.UT?U1D$;3Z@V<;HDY!5!M,AB44N?"IW
M6-K%KWV5D1PJRM%.E)'?832L&16Q(@BO/*<-KR-8-Y?U^IR<M-K=*$#[BZ[2
MRA6VNWT[E4A<9(!VAF7+>3MW9C6PS&-RP)(!?EN#RQ/!#-M'K^DAGW%L9QB^
M[SW*.FS;>3?\MLRJ+"XHTO\ #0Y;0Q0W%#?P+>))I[.;7);0O7(@38YC?!E+
M%<83W>Z(3OV*LC)<6UU#'#<6\A2402""4X>.52DJJ_;=3NB==K(KD[LJV &6
MHRZE%L[F,@EDCD,;^D%LI*5EVEL&&0 E%=@)(PK;U8@PSM9:R'%(Y_\ B7JK
MU,]O=5]C4<Y'L$Y$5SNR(G=G@UG^9&*QCV_;BZ5PQ+*@4 ]P<%UVXV9&0=IV
MY!!( /*E<#04[F8D*LO#;3M+,0,YR1E0#M;T >E.3D<?:JNKF' LJ.';6L*D
MO/BI<T\.PEBK[DD-[SQG6,5AD#+)",UA!-(![@%=((!PGJGG&BY]6&*'"'D'
M\S)C!=E9AD<  A<;VWD,/ V4=MKQ1R2*I4DA<8?! SE2S8)RV1P20Q8 U+G%
MV97JO5JIC&6ZZN:/J(Q2349/CT,-??Y;C%;C61]QQ;I+&$DW%;6?)$DV!*KI
M*&E5A43VHY$;'U[@H0& D7LG$<C%E24R198J1(JRK&DK*ZR-A7##!R&K+*S6
MT(='!$F I177B2-E)+(P,N!(T9$N1'.N0@VJPD-TTXUE>)Y1C1ZV'/#:Y$>O
MJ:2O;'5Y;?Y\P$,0GQ2*C9(91B=FC*Y&.5O9.Q&#<S5%I;7D%PLQ+1JBDD87
MMA$RTC/N"E@%9P20<<,> 3J1W4FC2"^;<CM)O/!.Y O ,?/IVYW9RH/E,8-=
MJ>KL;+AVO,0Q8\0,$M!21*M8X58Y$2(U1,*51D,+Y<EC6R9R"*423#'012#1
MKW<QN9%EGED7Z7<LO&  ?"@8!VK]*Y . ,\YKF.HS)<7UU/'(\JS3/+W'&&=
MI#N<X*J=N\L$RJG8%RJG(%^\P5I4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE6!;
M;,Q*LFOJH\R1D%VQ51U)C$*3?V3')_+9+*]A8\#M^.[K"1$:WOW5R)S;CL;A
MU[A588O/=G984(_X2Y!?_P!@:H*ZZCTJVF:V2:2^O%\V>FPR7]PI^TBVZND'
M[W$D2CW-4@E_M2Y7M1X54XU&=_DG9G=-D2E8[^'I2X]\I1O1%[J.19C<B_I<
MC5[HF7LZ?%_>W4D[#REM$57]N[-MS^ZH1]B:U6ONIKLXLM'M=.C/B?6+L228
M/@_)V!E((\E7N5/L<'BOXF(;'L4[W6T"PFN[J^-B>-5=:UG?_L'-M%N)2HG\
M(148Y?Y[-7CYFR3^[L _V:XGD?[^5C[:^X]_(KY^$]07'_Q?4KP@XS'I>G6U
MN /<":Y-W+^F[TDX' Y%?(FH*Z7_ /FV9['ME7_,DC,)T4;O]?V:UD(34_V:
MU$3^WX[<#477^[MK*/[;;921_-RQ_P!_J:\GI.WEYNM7ZANB?(DU::-3_P"R
MV6!!R3P *^"Z'UR__KP;N6O]W2LIR,SE_P#/E9]E_P#C_7MVYZ_%;S^%HE_]
M,$(__A7@]$=/M_>0WLI]S+JFHN3^^;GFOP[0.KW?Q23F+_ZF9#D#5_\ /=++
M^W]N_?C\6O\ _P U3_\ Z8?_ /G7D]"]-'_]'./U74+\'^OS-?!V@L&9^84S
M,*QR=_%T#+[L:M_\>V29/Q_XYZ_%KK^);9__ %V\9S^^ *\?]QM%4YAFU>V/
MW@U:]7_[I''^7[UYY.G[6O 4V/[3V;$*(9""BFMXEPPKF-5PP##8B -7/5$8
MWW21C[JGF1C>[F_5U&-R!-86+ GEA$T1&3RQ*$G]3@9X.!SBL<G2=U;H[V'4
MW4D3JI*Q/=Q7@8@9"!;A$4DGA=TBJ,^I@,FL0X%KWJ,Q>VLK6'9T42-:3Y$^
M?4Y#/9*BSCR3N*622'3 E1X4LW=7&+ D _4Y6HKV(U$D+N[T>=$1DE8QJ$5X
M8]K*H  4-(5+*,<;U/G@"JKH>@_$#3;JXNH;BRACN9Y)YK34+@21322.6>1H
M;..2.&5\Y9H)(QGC+#%2^I2W98 G9!$KH=FGX..JFR)T)RHB?N"+*APCL1R]
M_P!IXGJSMV]I._?E>E$0<]EG9/8R*%;]B%9@?W!'[5U:S:\>!3?0P0W/AUMI
MGGA)Q]2/)%"X!.?2R$C_ !-YJJ\QUM5AW>&]-?=/>#R\_P!C3Y42EBO](X]=
M''+LIQT&\SA1 &/$C]QA&\CRR948#?T#4ON, 1?+,JE0<Y=@B@*S$L<D !03
MX!)XP "3P*D=+TJ]UBZ%I8QB24J7.Y@BJH(&23SR2  H9B3P, D1MK_J-].M
MTW$G4;=D6K,PJ!W$0\?7MXV/41B*@>UZX[0DCH*:2/!*>"*QB)(D"]4DH?,S
M/ GA8E1*I8$@KZ@W )/!7/M@CR#Y%3<O1>N0&Y$\=K#\J_;<O>0$2-NP!$59
M@Q*Y<!RA*J1C=A3J,ZDMSY)OC>F&:LW;G57BFH[*6I[^V'CF,'#K\MF6Q@Q5
MI+27"+9,6+$&!)\LMA)193)$TK'Q& &+%!HNG]3(?Q728+D6,SS6J721G=)'
M$"BH958AY&+8*JJE0,<L*[CT"FI]&:?J&J])WMZFKW%J8DLK2_O+674C 5D,
M<I@FB@*NW"(49V#%(P&WYU6YOA^N\9VQL?$-<9>_:^)P;B1#J;AX"0(MQ"@.
M&V-903C;$:95DO.(ZM&-IF,(>/+)&\2/V+W3K:WO"EK)/')%$CW-L09! [)&
M3 )XV578N1E3ZANP0&1JZ)-?ZK<:3I5QJ&FQ:0US%%,81/W9EN)4)E2XB;>"
M(Q$KJ0-H# /M8MLSU/Q25AU!"I+FYF2[B5+KYV*W<25(+3I"CPY$6TC1 /9(
M+$<XI?BOA@\ARVCBD[C(=XF8H;)6N!<B!5B6/MRQONC<LSY$S(H]*CR,M@;7
M;!.:IS:P\I:%(I@6[DC((UD8AB.WN<]LME48X(! 8C=A0:MW#TQUF3X/)SR@
M/=T^)Y=17?VFRA-LJZ:&H,R2"OFBCD V3%E"1Q)$,\E62(3U84CU57)?](U*
M73FGDMKB6V,]G+ISSH R]N=02%EVDI)E$D5P_<]()R2=T1-;K=BXWP(BSD.>
MW,8&BN-K*LZ*4:)&5F!]E,JD;0/JN+JWGZYVEO&YV]B&LH.$PF8W6T\1^-5S
MQ M$BP6L):E@J$8&33D>R*]Y*]TB* 80OD&"@GNQ:MK6IP].MHDE]+>Z6'-T
MX017+RSABZ0(V9'"Q.%=8B45I=SD#&*E^D=%C@GTZ!;A)M6DE:.:_P!2N);-
M4C>4%5D>(8[4<.Y#<H\F01E  *AO!GWN'Y")]?)E+ R<3ZZ&UX3NE1RN5KED
MU;YOF>.]3(1K0^:F$%[F,>0?QI"_D'3NL>H]$ZED;68=4GM]2NS82VLK3&26
M&"9+>WNM-B=66)84DA#01@ H=N=KPR#]]Z[\*NB>IND+:'1+K0(+K0XI-4M[
MFT-DD,,]S#/?RP:S=6LA-S#>B.:4W4X+K/$;CM>B>!LR@TSFM\1;B5$QF)71
M<>G>=EE1V-E+YB=,DFB!CN0SRS4$R%#&KY3R$.U!->KU[]IU1]2:[MA&%,+R
M*J&10<3$J<S&/!B7C.,$*I)8Y85^5.GO^Z8LK])GO?GF[F4LUD,AC96C1;99
M]L,TP#8+#MK)(0%./4N%<YUJ/$.H4.$7E?9R658JB/"I#1Y,-\TUC0Q\DG'G
M2QA9+#CT**\BQY37,^Y))@'CJZ-)D/%W[2^B]/C^'4.O:@B7.NP"ZNY[DWIB
M@AB2\:.#352-NW(639W59'<R+. R.T2MPSJ3J^8]82Z3HLS:7TY/+&!,EL+J
M^EECL8XC%8B<EOQ+4=2S96I<&"UB#RSG?"K/MUKNI2-!H<GI9>D,:QNSL,?H
MXVJ,LK3 BS<'CTE644G(@7Q),J<Z;<2C!M(A&O$:+.:_R0 !J6)PBQZZZCON
MJ=6TR]Z4O8>G LL.DZM)<:<XDD6*1;E[J-<O&F6@DLDA'=CW-'*0ROB\]:_!
MCI^YZ;Z0U_3_ (DQOU#ITEKJ_5FB33ZK=_B)O;^WD@T:UAC:WA1;&)9K&]GO
M$:UU*W5KE(E8H#';56XK[66S*K:U8&5]^IK@UA%DS[DCX]A;G[C("TE*&4Z9
M#M8DF6"Q&U6.FL,KEF@*O=LA>2%[F,PL]L@<,ZSA1E-C2$;RP!,C)(,!MN-N
M5+;:PP].0:GH%UIVH1IJ!FMFA@^05E:!A<)"K)&%.'M3+"RJT;N"C\[-X/3U
MTY=6VK.HJCKUH[:-39RL9SKK!+$KPVT*5':]93J_Y HZ6L!6C?)#(BM<5D54
M=+#'>U[4RQW$4I 1B&*ANW(K1RA3X)C<!B/^( J<C!YK\V]3=%:WTQ)(]W;&
M;3N\T,.IVS1W%G(ZMM,;S0/(D,Z-Z'BD8'?]!92K&4W,U5&M:OU/M#"VOHL&
M=UZB%E.FK N2P"%*HTE45@L6)D%:Q._@\YO373(Z*GF\D'T#<U3KWW[+6[30
M4N[W4)A!I\=M))=S,KN(HXE+=PK&K2-@%AA%)R00"0*L/2UE?ZIKFGZ/ID'S
M-]JMU#9VT'<CB$D\C@1YDF=(D YW/(ZHJDEF !K0!5V\(\*%#D2@BL8X!#.)
M7=ORQ'-57-;V<Q'/14:Y58QR>QS55R)WMT<L,A7LRHX[<<ZA&!D6";<(I656
M+QQR@8C<KAF3 9ML@KKL"36R;;J&6)EFEMI&DB*QFYMRHFA23;VVDA)!DB1\
MJ'!VC<N:W=S$6"$L@C7JP"C$KG*G80T1K6L[-_1W5R_V7S17=O%/TKE>$#Z6
M W8WX&Y> N"#P.6& ?IR/2Q'!DTF5AD 98L4&]?JP"0RY)&0>,KD@9]B#B^3
M) 8Q5:C7*[\-1/8Q.[G(C?\ M>B*Y$:WLWNY55J_E4=VSIGTG+Y]0!)8^-Q8
M>K.#XP #P3M  R=@#<W!4J55@I."FX>E ?5G<H'!\L !@9SA+*8D9D\:OER0
M <XC9+XPDD/&)4<B^"%,'\N[^#F/(B^#G._+FJ/D;JMUJL>F7WX/!:WFIK"S
MV-O?320V<MUN4QBYDA!ECB())*!F&T>Q./5A#I4VJ6<>M2W=OI7> U":R2.>
MXC@VL<VZ2>@N64+ZCM3>3M](%1UMXPVC<QSGJ1Y7KXJK&N[/>B,>K7.541J(
MYZM1J_A&HB?J:YTQ9W5R+*WEO^Q'>M:Q&\6V=GM5NRB=Y(I'P[0"4,(F=5EV
MJI(RV#"7R67S=U%8O,]HMS(EJ]T$BN6M!(_8:=$)B6;L]MY$0E0=V&.!G N8
M5MA(:-XXQFP7/>$,EXW- 65X>Q1-E/\ 2-YE14<0;'>;6JBN:B(KEQC6K>YN
MSIKW<!NXX1<?)B:%;SL%RB73VNX3"!G CCE*[,C;DL#43J]E<6UE%JBVM^-.
MDG-LM\;6=[*2[$6^2V6]"]@W B_-DB1\E0#M$8R?5K76607V4P1-CL"T!VR#
M*\K/5':J.\G'<SNP;"L<U"(_L17*K4:]_BCM>X)??@E0Q<N0,' )89494*K%
M3SC!!P"0A,'8-NDWA26SR>1LWX4AB0<LR!R5P6\DLN#CO0^FIJI=4](VM81Q
M.#.RF&_+I(GM<U0QK)@H].)/)$5R+30X$A7JUOF^0]Z-1'(G*1?%_F9%D=9'
M0E'D1=BNX/J*K_"H/I4')"J,DG)-2ZGO(;S5I?ED:.UMDCM;:-W$CQQ1@L5>
M0!0[]QWWLJJI?.U0N!4]>:=5ZG%*<4IQ2G%*<4KE3_XA3.,_P3?W1A,Q_;6=
MZKQNUJLHA6%YB&0WU.M(0.7XPVXR(<>DLJTLB9$JI\9Y&C.(TD4,$=3,:C'-
M_0/P<M-/N]&ZD%SIMEJ$\5Q;M&EU!#(TBM:S[+</)'(4221"N=I ,A8@@&LL
M2QED9D5G1B48J"RA@%8 D' 8$@@?5C!R!74U2F!(IZD\6Q;<1CUD T>W:096
MVH"Q1/#8M*)5$1LX;FR4(-5&]"HYBJU47G I05ED5D,3+(X:,@@QD,04(.""
MA])! ((YYK%52YCI3BE.*4XI3^?YXI7F9^R1HE_Z1._I5?\ L<U%5P>__I\4
M5XD_/9K7L_#6#3GH\C/N//ZCP#_H#]S@\DDUC'H8)_"V=G_"0,E?VQROV&1P
M *U+?4$^GY*W<^RVMJL48F8MB/EY-AANX$R:7"BM"&\QR6-6)&R9\0 8-A62
MGI6Y#'!&?Y1;<##RYS3-56!%MKC<8PP[;Y)55)RT<B_X#DE7&3&6.593Z9S2
M=2-G((Y23;/D$ X[;MXD7@G().? )(+9 Q6A.-DF2Q(4BLS*(ZBR&@E-JI )
M\65#-,!' X9)+R26-;[XTJ.Z#*:Y12'/:!I!J=I".DKC'=W(@6-U,@ 8'8Q(
MW*HPH&Y5+J0I'MN!//7=/O))(T9F,R"-0L_M(GI$6YL>ID!7=(2.XGJ8 YSA
MG/"1K<YYL.4Q\AO?S$)RHK_4%_@\CD8UO9JIW:YB.[/:Q"-\_8WF_:WCP1]G
MD)@,C,#B,D^1C).%X8C#8&<':,99DCF.]9%,H.W"L5SC+ ^G)&S!VG=P23QN
M"B)&6UQ(\E%=V53.\4<K$\%1[E*KO-K&JJL52-5Q$(URHSNC?PJR O'P,N=Q
M(\\J"<<DD[552P&U0QW>>2<Q%Q"P8$ D$%< L<DD-XQABHW KD@##$ X-8Y=
M3DD-3LTK7(1B^+T1&F<BB&J,1C/P7];T_P SD145RH[LUO,RW1;.0@.2KX+'
M.XJ,,F$D7"LRY_,+ DD9(!P+& 8RT>(VE4AF&=Q! ]+',8*K@A2<$;2 2=M5
M^AQ.RLY:!CM)V"J(GK<KG.8B(Y4>J)_F&-'-&1JK^GLQB]FE8H3;V1#L"[2K
M#U,R(,KE_4#M\!4QZ1@(!EMV3+(74+(,N"6W D\*H\\Y$3!5V^L@852RD/*_
M'];NQ:KKYMQ'E2!V$9\RN58D@;)X1R"1R$C%D*,;Q?)&\2R(ZE&(@7L(5KVD
M&FP;=G:-$E,Q=>X""1@_4P8-_=Y&&P<,4 8G&*P:EFV$3[D-NP+)(-X;<"N2
MR2 #^)6!)X0;B/4<[_OI>ZE!M'-"[ERC'WSL:UC4 I,#E68?  \N-,25\V&-
MB("66H@+(,TI7RG1I=A$E-49DC/;7^H;C\.L(K""0I+>;GG P3V!E&!;<Q03
M,JA@H 95*$D!EJH=0:I)>+"F\HH!5(0P+"(>&E(QC=G:B#@J'+$DD5OT:YKN
M_BYKO%RM=XJB^+D_EJ]OX<G]T7\I_?E"JJU_>*4XI7R.\@P&($?M*P1'B%W\
M?:1K'.8/R_MYN1&]_P"W?OSZH!903@$@$^< GDX]\#FO+DA6*C<P4E5_Q$ D
M#^9XK _34<-KJJFRK[M/LK++Y%A>Y)'G,A@2BRLLZ1&R7' 18D:.Z*/'K>/*
MH_5,)+G(VM9\N7(/YE?.=1.?Q*2W[<:1V:I;V\B;R9[5%4V]PS.S;C/&1-E
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MCF+4<B3&2*R**&Z."1,DP(L59%S/(20;YSU>V()4 Z(E?4)UWVZ.T2R[HG5
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MZ^/NO858& /]J4C%?L&#1)4D-CE<T^66(7-*!EBQ@J. 5%[HZMH1=X0E8O\
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MA&]_TN3F6&>>W;?!+)"W^*-V0D?8[2,@^X.0?>O:LR'<C,K#P5)4CG/D$'R
M?W%:[]D_2$Z-M@SBSX>/YC@"F>I"5V$Y9(!2^Q[D4CPU=]%OA0D>B(WT5[X<
M5B?@<=B*Y%EH]?OU39+VK@ $*TJ,'7VR&B>//'!R"2"<G/-;D.I7T#!X[A@>
M<[@'W9]FW YYYYR<^_)S>N#?3 Z3L!QY^/UN*6MNV5%FP;*SR6PBW-A-@V(5
M#*$-AJX=;5RT3LZ+=5%?!OH:J_X]HQ2/<[$-:OE8LCJF=I"J& !7./XB67!(
M*,3&W\2')S(Q=1ZE'+),6BD=X^WZD*A<8PP$;(6&!AHV)B?.&0@ "5VG-!Z@
MT!0R,;U#@M1A=7-.R38?"=,F6%G(&U6"+9W%I)G6U@X+%<P"2YIF1VN<T#1M
M<J+HW-U<7<AEN96ED( W-@8    "@*   , #@ >U15U>7-[)W;F4R/C ]*(H
M'V5(U5%^YPHR<DY))K+_ #7K5J._5=JW9>ZM [&U=J39$;5&;YG3MIH69RZL
MUL")729(&WM<0461&F0TNJ;YU3]T@O=,K?E_,CA*02,6-U>SN=0TZZL[6\:P
MFN(^V+E$$C(C$=Q0"05,B;DWJ0Z;MR$, :M/16MZ9TYU/I.N:OHZ:[8Z;<_,
MOIKR]I)I8T8V\C$JR/V)^W/VI!VY#&$? ->3IXZ9,(Z>M 8/H*C-.MZC$HL6
M3)NIY7OL+/*DLV7\[) ^]\AM:9^0HZQK8L9?35,9&!&_Z"$=L:):+H5G:6=I
M))(EI 8 ]PQD:5'1DE$F3C;('<&-=J*K;54* *U.N]?N>O\ 7M8U[58H()]6
MNTNC%9QK EMV'C:U$10 F6 0Q$SOF6213(Y);%22:GBUK>ZN\41.[E[N7LG;
MNY?[JO\ *K_=>;1Y)]OT'BH #  R3@ 9)R3CW)]S]S7]XK[5H9%K_!<NN,5R
M#*L.QG([W!;&1;X7<7E)76EEBEI+C_%DV./S9L<TBIF'CHT19$$@2O:P?DY5
M&-6[4%]>6L5S!;75Q;PWL:Q7<4,TD<=S$K%ECG1&"RHK$D*X(!)P.33[\GGS
MSC/(.#]QD X_2KOYJTK^=D[J[LG=41%7LG=43OV15_E43NO9/[=UXI7]XI5J
M2LH:62:MQV$_(+(#U%)<$R1Z>M*B?EEI<*,P0E;W17P88I]FUJHY8+1K[$V%
M@(4/,W90X*Y&9'!]XX\@D?9V*1GP&)XJ,EU(-(]O80F_N$.V38XCM+=OM=7>
M'5&'O#$D]R!@F$+ZJ\PL3?8E9,R^:E^=KVE!5L$Z+C4!['>;%!4J0OSSC<C5
M2;<&G&:1OLB#@-<H4^FXV K;IV0<@R$AIW!X.9,#8"/*1!![,7\UB32S<,)=
M5F%^X8,EL%,>G0%3E2EJ6?OR*>>]=M,X8;HE@!V5>:(B(B(B(B(B(B)V1$3\
M(B(GX1$3\(B?QS6J8  & , < #P!]J_O%*<4IQ2G%*<4IQ2G%*<4IQ2OP4;#
M#((C4<,K'C(U>_9S'M5KFKV_/96JJ?C\_GGT$@@@X(((/V(Y!KXRAE*L,A@5
M(^X(P1_,5!G/NH6MZ3M&[ NR8E8Y_A^C&TU)4S<<O*XB2Z*9*K8-5#NI+Q%+
M62\?%-)4SY,:%;L,^E<:2D.5-9$9DZMOSI^EWW4C0F>Z%M)?S:8<VLL\P;$G
MR\KJ\>R9OSAO"LHDVJLBJ7K?^%724W4O5NA?#IKI=*M+BZ33;77YD-Y!:6?R
MS7%N;RT62"<R10K\ON1VBE[7>DF@[BH<']'?U1Z'JYW&/4=?I?),'))P^YR^
M'D,W("7,4D6GDP@>,B*_%*)H(<U911Q;(<Z2)\L+(K0O4ZD%R_I/X@W74NJ?
MAT_3-YI4;6LEQ'>27B743=L@;&5+:$(K<A9!(_Y@"%><C])?%W_LY6/PNZ4/
M4MM\2M'ZIGCU6STVXT>VTB33;F,7<<SB9)7U6^[C1]N-FA:"(F*1I1)B,*^Q
MS:&/Y=E6OLMQW!,J9A.77%-*@T64O@K8MJ)AD1/=\9IXQ&N*+V1FRPF21 <9
M)T=A3QQB?=M<L[_4-(U"RTO43I&H75K+#::DL"7#6<KC F6%RJLP&0"3E"=Z
M@LH!X#TEJ6C:/U+HVI]0Z.=?T6QOH;C4-(6X%J;V!"3V^Z8Y5(1]LIAD0Q7(
MC-O*R1RLZ\<&;0LOH\PM<=#?4%I=-RO)A$SY)SSP!6)"SH=A95$B\;'MF0T.
MR81MH>'%D(\OW*/":,H7DY[KMMU1HGPENK?J+78[C5=-A>2\U>",![J")ML5
MLH(MVFFFC:.)F1$9YV4-',W<>;]Z?#_5_A]JOQ@T[5]!Z5U+_NY?648AZ>N(
MHVN(KN.V6YEOQ:6;7-M#MEA#QV FDB2 R!+B/T0P>+I^=7ZZSZ1D<A\G)Q!A
M38,Q!C&P$HDZ:R"ZQC%D&E,D :9%6NF3 Q%^80C)"#*Q&<YM\(=-B=;CJ<:A
MJMJEY:O96UC):2VCW-RT\+3R32"2:">UB\%I9XI5GC8K 60&3NO_ &D]?;J+
M0;#HY=,TZSQ=6FLW%Y=7%I/-I-K#9WDD-JEFO;U"WU6XVB.6.VMKJV^2.1<&
M-Y&3Q[GRT.9Y7-=67=Q*Q]R,GP2.RB,2OF26O1DU@*2IK(=:U8'L^$Z:AY!V
M")7/^:Z4K7&_3^V2'2;<B:9"<R.([]Q;LQD0*&M2LBF1E9FD*2(RRR1 +NRK
M?C?IY5BN?PVX;:DUQ+:;;BU*L@5"\<Y+GO1Q,R.RJ6=7168(H%4:'B%1=506
M1<HNY$><&,R2!%A29KV>2$:&.8L%L@9O;X$1?,CU(CGM<XA%5=OMPR6Z.EY,
M4=(RX;89#&!N&&:,,IR 200QP3DGSY?YB.\DM6TNW:6*:40O&93"93N1MRQR
MLK(P+ >%VDC:HPPN#7%2L7+R06QQR(YB12JZU60R!"Q* 0<>982[(H1QD#&4
M<9+%K'&5)*FCN81Q5[<_T?X@]+=2ZOJ?3^CZA\Y=Z?*\<XA1G18H#%$62;:R
M2LSO$-G#$EV4,@R>A=5_#GJ3I[I>QZBU6&VAMG/;D2&XB-Y#JM]#+<06MQ9(
M>]"PACE>+N#:5:'<X8&-)G8ANGIZQ_5&S\9O<$D7>T[^QM!8WET1&L+!C2 -
MAA(I22'RHGPE[M+6A2+4V4>1(-,>0@1C9U>W@M$^7)9$1(A#<P-%W)YL>07*
M=M6(/!:3=&R;D4 UQ<VVL7%QI\T>H"'38(Y&O=/:-BT\F7D 0$*A64,")B7D
MAD55C*;VS$*B6 F=4 A,!*I1+%GFCPX0(Q6-C'&<J,4(F.,Z4)%;YG(K6#[*
MTKFQE8NC?0EO3#)'VY(F RH)W<J"2$8@$,& +* 5VYV\U(13L;:\DF2Y2[BF
M81,UVP18V)&WM,ZQY5U*EPI)#;R,8!EGO"<W9%$(\>YJ<>Q2CQ^*R%21HOL2
MQLZM\P+(\./&(!L..!LOP66QK"^P8QR4.5T-!Q%G!V+I8^VCF5FBDDD)';0@
M!7 )9E?/J&./88%1-O(EHKSRFY,H/>7Y=U9F&T-*KR-Q*CG?N0@^6!V^H&,V
M/UPX,&XJ(/PWFEJT4.4HO%#G5\8[3-)),,$=)?DL0T@@5$%JO>X;_+V/F3$\
M-LRP.8YHIU98U(5W1"$(=5W=P/@RKA06R4)P I^->Q7FIPW%W;K)9W5M)%,[
M!F2%I@TZ%"VQK=XO3!)ZG"Y64*&8D84S+';2=+1KIQ8-\9S01@1D]XODM(0;
MHL02$*Z2PJ-<9#(]GL$9"-1K1>/(+68S)&9VE9'D6&2-77 13X0('9LG<S\$
M<[<D8Q71.CYX(6%I%:1SP1RW4$LJR R2;%+=^23MHGH]$0RA "O_ (V>LK83
MB>7UD$&,PWQ)$RU7QE@K2ED3X!!(^68IQ%&YA_ +AJ26 A@L1O9)#D$_Q@&@
MF!=1NC=XBI>9SVV1E;UR JP1@QQNSN"L5V-E<7\:AIT*)<(I>"WD/:,5NJRQ
MNK#\B&16+/N(#H.VI9HS(Q0AA4D*Z2#!L-M,5KKV/4W;ZRY'<@G8A"2'9@FC
M&4D&?;/F3WR9)'O<*')*"+(CB[C]@'G3M[%D3*S-;[(HXD6.19RO9!0*)-FU
M0 6(=T8,"<X]P*W<ZN)Y%9KFYF[]T)( H<-</')ME0*I#]QHR8E;+1NS!7C8
M*"8]91C5WD!ED8[8R&U]1&BV""CA4420=0,*=\%R?I.6)$$43(JM1(X42.-J
MD\6KM)#/+;VW;,4I"RQ=A,B1V8NPVAF.6V1%U;!#<EOX=OB9K6VGNGF2X!GG
M@N#<8,BP0Q)!&W>V(BH@DE"-@E@0<#ZR<9&V3L+%(665^O[P,?(LAP3)L"2Y
ME5<6WCPZW,(1:NZK8R6*%D5MA952RH3+"$H9,84B0&,JN.B+(=.]81=-ZA9'
M4;0W^GB[MKR>U7\NZ9K.3=$\15HU<)*0S1S'MOLRQ!!-;UWTI9]4:+?V8589
M9);:6WN@SQP1W-LTDD+3NI#S1 D-VF)3NLCA20I&VGZ+.SX_3_TTYGJR\I]B
M;.O3;DR#,01]:8S"RU:J!DF/XQ#2$RF@7/\ 5,>,*90S9LR=8TL:N!*G.CCF
ME5$5W0^I==M^O;Z+7K2)=*A-G%;.NIR/$TLB37$N]9>P(& 641HJRR2!(AO(
M)"#\9_$/1).E=96PFEBOG6#:6L628@Q,00\:N94]+( 77#8)1G0*YWW8+M#$
M]A/LH=,2WKKZD%!->XGE5#<8GEM(&S:9U=)L<>OX<&Q9 G_&E,@V@!2*J<6)
M+'#FG?%.T=.GM9;?:7V/&Y81S1.LL,A7&X)(A*EER"R$AUR-RC(JD1RI)D*2
M& !9'!610<X+*>0#@X/@D$ Y!K(?->LM.*5C[)]3:NS5SWY?KK",G(5JM(:]
MQ:EM#O:J]U1QYD(IE15_/^?^?SS8AN[JW_N+F>'](Y70?T5@/8>U#SP>1]CX
M_?'C/Z_]*M#&^F?IZP^W%?XOI365'=@7R!:5^&T09T=W?R\HTA(:DCN1?RC@
MJQR?V5.99-1OY4V27EPZ<Y5I7P<YR#SR#DY!XKUN8 KN;:?*[C@X\<9QQ@8'
MM6;T:UJ(UJ(U$_"(B(B(G^B(GX3FE7FO[Q2L+;5ZB]&Z00";7VCB&$R)3$)&
MK[BU$EM($O?L8-1&^19D"O9>QFQ%$OBJ>?=%YMVUA>W@)MK:691P753L!'D%
MSA ?TW9K/#;7%QGLPR28\E5) _0MX!_3-80@_48Z+;&YBT47?.,_/F$"(#CU
MV2Q("N.Y&"4EK*I U@1N<YJ*4TL8F=T4CVI^>;GX#JVTO\E(0 20&C+\>?0'
M+$@<X SC&!R*V6TG444NUI*%'GZ21[X*ABP..<8SCFI;T678IE D-C634&0!
M5J/]E)<5]HSP7^'*Z#(.B(O;\*O9%Y&20S0DK+%)$PX(D1D/]& K0((\@CDC
MD$<CR/W'N*N'F.OE.*4XI3BE.*4XI3BE.*4XI3BE:D/K/[FWUH3I(A;'T1?5
M>/2H&TL,@YM-L*>OMC,QV2^;)K"P4L@R8H##R^!CHS><4S9,<Y(ST]1'L?6.
MK-6U+1-,%_IDBQ2K.L,LAA28K#<1R1$JKY4$LRKN(.-W&#@CL'P3Z1Z7ZWZQ
M;0.JK1KVUDTRYO+. 7D]FCWEC+;W 61[=HY9%$"S.(UD3+("<J"*FST<;AE[
M^Z6="[@LY@I]YG.L\8M,EE &$(RY4*O' RAR C-8".O]01+'O'",8@K^V-C&
M-:U)?2;PW^F6%Z2"US:02R8  [K1CNC P!B0,, <8Q5(ZWT->FNK^HM"C0I#
MINK7D%JK%F(L^ZSVGJ<EFS;/$=S$EO))))J2W)"JM3BE>)P"!<XL/Q3S<KR1
MGJK0D<OY<\;D15CE<OY<J-<(CNZO&A'N*GH$$ -[<!AY ^Q'N/Z$>QQQ6$HR
M$M%@Y.6B8X5B3RRG^!CR3P58^0"=U?04L17>I?()^RJL<R>!>R?RYB=U:9B?
MW(%Q!HJHGGW_ !P5(&?*_P"(<C]C]C^AP?TKZDJLVPY23&>V_#8'DCV8#[J2
M/UKT\\UEIQ2G%*<4IQ2G%*<4IQ2G%*<4JWY.11&D+%K GO)XG>LD6L1A!QR]
M^RLG3R/' @JS^7B/(23X_D<<J]FKF6!L!I"(D/(:3()'_"@!=_T(7;]V'FM"
M34(@S16RO>SJ=K1VVUEC;[33L5@A(]U>3N8Y6-O%>-U)9W2=\CFH*(Y>ZT-.
M4H83V+_ [*Q5HI]EV7\/&%*Z$1O<9HDAOZE]"5(O[E,M_P"=( 6!^Z)RB?SW
ML,\,*Q&SN;L9OY0L1SFQM6986'&%N+@A9K@><J@MX6!VR12#.;EC18T( HL.
M.&+& Q!ACQQ," 3$_A@Q#:UC&I_9K6HG^W,#,S$LS%F)R68DDG[DG))_>I&.
M..%%BB1(XT&U(XU"(BCP%50%4?H !7WY\KW3BE.*4XI3BE.*4XI3BE.*4XI3
MBE0D^H*7J@;TT9A'Z3*H=KLBQ("MLF0Y"@RZ)B,X4B/=3,#1Y 1B90)SXK!.
M,=AX]<2QE5;27 (#>6[H@=._]X+5NII3%I\8:1"Z[K5KI"K1+>X#,+<@,3A2
MK2"-92(F<UZ7'.?MQ[C/ZCW_ $YQGSD<58'TWNBZ\Z0M(S*#.\XO,RS#91ZS
M,<VQJQ+'D8CA^0GKFLGT^.Q%20\YD5XXUY;'E%;<2H #!!'")GLW>O\ JJWZ
MKU82VME!;V=@LMI:3*I^8N[=9"4EN"<*%/+PQ! 8UD8,22<>B^&!3TL.2X.'
M9L %BPP?; SR!]LXK8H.. 2M40 B5HVA:HQL8K0M55:)JM:G8;555:-.S455
M5$1>42O!9CG))R<G))R?N<^3^OFH1_4"Z@<IZ>=#MO,(CN3+,WRVJUW2VZ-:
M1,<-=P+:PD7; D$0,B8"'42(U<$RL&D^5'.Y2H#XYLD0#2Q*5W!W"X]N<XS^
MA.!^Y'GP9WIW38-2OI$N7"PVMK+>.G@S"%HU[6<@J#W-S$9)52HP6##E4RC%
M<PO74,?$ZMPHL><599;F;&_JBUFRCC"DV3)&%L9$>Q2.DP5<+U/$SQ)*<K2I
ML)H\A#W%V4D$@+/$ZC:@)W2*RY"N!MY)521@$'&*[MHNIBSNW4SR1H4C6*:W
M=ECBC5<KV#EG1HSM96&5XR,'E=CU]JK4&K*N#2T&R/ZFJ]N:UGMS2Q#4M/D-
M9>TS8LT^.U%N2''C JCQXUDCQRW&*&9"),,\03C0,;K=A##:K>6$%O#\K<C9
M;QM$UM)%*C.;@V\3#&Z3:Y"KM9W4@L_)RQZYKNHWD;ZBUS+<V6H!()+^_P#G
M6OK8(D$3S.TK,0D915#85(=J GMFM,=R:DL,CN_Z,K5QZFK"_!H S)BSI$B*
M+V!--F#E&E##86!!+,DQF*^($RN9&5!L$[E7EN+B P12.+EXFCED!*E&:0DR
M 0RJ0'A$H"N(P7"9P6#-7?-.TRVU#3Q)=S0BXFL;AS=QQ2)+#<A#)'$;B%@D
ML"N#;,LC;^"I;AUK(@,\E#D4SHK9D^6Z$6'7U#%D-K8\4"QP&DS)@VME+*:R
M.OK[2'('NB=R^0@.M*7<LX$JE2J1,D40<!!&H1FD=V7=O_A!)V\X&">:/-I
MLB\6TK-/.LL]P$*R22R,ZPQ(C,(^T1DE%7=MY;Z2PS?E$JCUT^L &%-G6LPB
M R2_--(6/6Q1R'DE5<&"0LDT65,FJ-):QWC8U1*QPB-C>X=>Z=Z&Z>Z3UN?J
MBRTF""^U?,]W<O*TS=RYG>26:,/N:'YAV:,[=P8;"HC6([Y3J#XE=4];].2]
M,W.H6YL-/;;%:VVGQ6KZB;"U@CMS=31A1>BT5#,G=4,&WEF=I!&M@6MW3FME
M6#(7WEAG,4X#KXDE>PKQN>QK6L:P /$3^[^[D5"(SLBN2^->03W!VS88@LS
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M$I:V7M2;)5=T:/=M9)<D."L@#2*[ QF"V98K=4MA*9,$0C84N5$*(#V,D1)
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MBIVY!((W#(R"",9SP:UY;>>$XFAEB/'UHR^?'D#[$?N"/(K,/,%8:LG8FML
MVYB5G@6S\-QS/L*N70GVN+974Q+NCL'UTV/90'RZZ<(T8SHD^+&EQW/8JBD
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M2!=T1<*RB[Q^RKX\8Y)GM;93X8CQ72'1CM&X$;VP7O(UTH;@V"H*.54=FO\
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MJO*B,+N5-ISN9BH.<@'^*IO4.J=/^1$87N7J0=DKE>RS'U,[289N"" H)X)
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MR32/<ZA>RM&\85A(8M@7B&2/**HQN+22NL6-M5:BV%E46F@XA5ULD=_DS5!
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MQRJJKRKZPRWD>JVGY;K&KPR.CJ^QNTI:&4*S=J0=Z-L8(&X+R,@1EQ:)-!-
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M0IACFECC=XXF<.ZJQ4$ U<W,M:=.*5\R"$9JL*,96+_+2,:]J_\ EKD5/_\
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M?(M*$DJ;;1X\0\UZ%.1Q5804=S0-@0V^36.,@%(3V&4BJ\9$&ODR.-7=)W+
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MTMU)V.B\ES^?D\1_3;D]MK>]N\PF:HPO*K=,BK<E/A8L>C/OXUOF,2JA7ES
M#6?TQ4#*L@MNZ7&"R5TOIK1=6N-1O_Q..RU?3](E-B;]A;6^H0K/'-<VBNUP
M8+>9(T,L18/)</B-3&H;,W::_K9Z?N.F));>'1Y]4AUIK1$C=_Q""VDLTG>\
M:&.8I\O(5$ Q$I_,Y8$UL'Y#U$4XI3BE.*4XI3BE.*4XI6LR)KSJQT5UB[1V
MTNV8&P>D?:..%O[O&=G96.OL-:9Q#:>'08WK^.D=8T&I:]8@!EC@$*RII+X=
MO&L,BJJZWFWR?5.DM0Z2L+*YLUTGJ+3+E+>.]M8E$&H6<K*9I[^61U#3'+8#
M.66908BD,KQI[E%U+"4L+&:_NUC8QVUNKM(W;0L3B*.61D;&2$C=U;<V,'!V
M%4@\Q:9A+ZPQJ;#.!I4'45-E /%,YC5]#9,J[M V &N54;*0$%[VHB_';Y?I
MILQLBN+>.Z5PQ&Z::*1'3V;:D$31L?\ !ND S]9QS&6RZJL@^<EL)(BA+);V
MUQ#+%+_@#R74ZRH/!<I"Q()V#.!=/-6I"G%*\4^MKK4#(UI7PK*,R1&ELCSX
MH)@&2X9F28DE@I R#;(BR!C/&,C4( PV%$YKVM<GQE5AAE##(.& (R#D'!]P
M>0?(/(K)'++"Q:*22)F1XRT;LC%)%*NA*D$HZDJZGAE)!!!Q7MY]K'3BE.*4
MXI3BE.*53J^J@5:S%@QT L^86?+7S(132C=O855(]ZM[^*(C&>+&HG9K4YED
MFDEV=QMW;18TX PB^!P!X^_DUKV]K!:]XP1[#/*T\IRS%Y7QN8[B<9P.!A1[
M 54>8JV*<4IQ2J'*R?&H-F"DFY!21+F3Z_C5,FU@@LC^Y>P?3!*=LDGM7\#\
M!+YK^&]^;"6EU)"UPEM.\"9W3+#(T2XY.9 I08')R>!R<5H2ZKID%U'8SZC8
MPWLNWMVDMW!'<R;SA-D#R"5MYX7:IW'@9JN<UZWZ<4J,^QMLYS;YQ,TEH.LI
M++8E;75MIL#8.7 ES=;Z6J+QI"TWWVMJYU;:9ML.]AC)9XWK.JM:)5IFCR/+
MLHQ2GL,:_JA_O_?^_P"1I5BYST8U>TM?9;BFTMU[XV!D>5XU=T9<CE;.RK ,
M?@R+>!)B#+&UCIFUUI@$FMKR'100;BEM9\F*)L>UN;([SS#>D(5U9EW!6!*Y
M(R/<9'(R,C/^OBLD4C0RQRJ2&C=74JS(<J01AE(93QPRD$>17+ON+4N5=,-A
ML'65-M.Q)<X#=CQ*Z)?91D>Q,*OZBZA >"&6GR9)F3T(BPIRNL#87E&-74>4
M*?&4\H4-R/A>I^I>G^G;>V.JW-S9VTRNP>& W.WMF+:KQH=P.Z2(':K@*4PK
M,XQ^F?A=\-.J_BM<2W'2")WK*U6XE@U&X!C:?9.%437;R B5[>4Q@W-L%9D)
M<< V+&ZAV6EH_&K;&L?Q"ZP^+$R"1 :*3=@F5@!(M#.QF7+%7Q[.JR(\A\:L
ME2:V,:CKH$\-U7)=A<X_UKM);.R72FC-KJ,*W_SL";3-;RHDD;&9R'0&.3<(
MPH=I#B3MG 69M>FYK2]U>UZD6\M->T6<Z--HQN \<%R)9UN+B$PX%U91+;.'
MG5]K3JT60L;2&VL0RJ5F^<9K,RWSD!F"N+1L*O>>)&C2QM:"-""-Q9+Q5T-9
M$<;HS2E<R/$49"O5I"NS:/<SSW%S9F5YHR6CD9-I(92FYFX4!MK8;:,AB>&P
M34_U%H%II6AZ;>6D*0S*D,\+79S,\;!\=M@!ZIU1G1G1=P /I;:M5;%\HLEA
M6U#)F )#]K@Q94E2#?# @6QBRB0VB9W]4-K8P_#LG9K2=VJCD6W6-HUP#&9H
MUAMW*1/(<.%9.2$*-G8 JD@@G"L>3N%%U"XM866[MH726YB$MS$H&9)49C@3
M]Q3AGW.P97V;F0';R;BC5U7B\4)9)C%/=#>^N64AV 2L/$,QQQ%\D8V9[E&H
M'/"<('D'V<0C/)=N4);21B79+"Z94LY9D(*%<Y/CG)4X (VME<BO,5Q<:E;/
M/%B![:0B5-B.TI4AB&1\L,A0&*L&=3Z1XQ(CIQZJ6=*A\WM)&$5>?X_EM3!C
M73+:*C9L&7&2P2J ,[A^<A5)/&:7%86*R0YG896(QB\BY[ZUA=H)S<+VW$B2
MVV&?'Y8975G"'<&&WU!D8GAEQ4L>DFZLL+66.]DTRYAG:9%20Q93TF0J@1UV
MLJ.L;NOIR>"3@1(-.O,^D9+D%#\:G@%MGO%\@C@&C29L@Y7Q(X1+'=ZB>QXQ
M@5TM!,:+U(-Z/4D??7T]_+<21%T&6V[PP=1G)5S&5 )!& Y<#/@'U&WII%EI
M\\(N"K23*7E"M&T<SL2J/&)E8$CD,4"%I%\\U?6/:GNYU7:W-M/^21D)+",\
M_B,WR RHH2( S?6KE9[7()[T$@RM&1?6CC/6-L(Y'EFCR>V8S.XP-RNN\E]X
M)+,QYR2=P^S$"ONO7=I:Q6C^HRB?Y7)#@&+:I"+&<C;&I 5$?CE5W;,FSLI#
M;')26$);&_I8$@,RQ&=H7N02/2-'B&<T;B$"Q[FH$;Y)R"<YKW-&YXVOR:D+
MCMPM$TDENI,DB808. 02Q"EG!)&W+$$9(R!6+IN.P6YU#YA+>TOY<00R-)(C
MR+')AA$C95(V9 &:.*-7V\, QJ3>KX<]N,9)88Z.''C6A&-/2V8VHU(K1C*V
M9&+)C-4QGD'\98Y7,"_U/:%HG,(I/%@6FN3<QJJJFU#"P 9T">K9GD2*C.2
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M/9(\@V^QJ^+GM&U&E0ODTCB-1?:UPG*U%[M0?@3NC4>)414E;A(@QW(R.RE
M!@84GD.#M!5=OJ+[L>_&:HJM-P H(3DC ) ]39&2AW 8*_PR*<90J2?M2EG2
MIBME&8_^7R6.>CWH1%8U._DKF^2JC>[W/16M[(C555\-0QL""&WKA-VP[LA6
M8@#W]*GP1]\YR6&$R%L1N-KL"&WD!@6P=KG:$)7);(Y $94@EEK8=T9=3.4=
M-.UL=RF@,:9C,J0.JS"C8Y"@M<</(8L\!&_P*7'8))5=*3P4,R.!2>0'$&33
MO%CE@:)^8G)",WU12AL)(#S@+]#KQE?2><,*UJ^C?B"N@5?FXD+Q.I&^4XXC
M;.2R,?!&""00!R#V;T=W5Y+2U&14<T-C37M9!N*F?'<CP3:VRC"F0I07I^'#
M/&,,K%_]+D[]EY3W5D9D8896*L/L0<$?U%<R965F5@592592,$,#@@CV((P1
M55YYKY3BE.*4XI7S*40!$.<@PA"QQ"E*]HQ"&Q%<\A'O5&L8QJ*YSG*C6HBJ
MJHB<5] +$*H)8D   DDDX  '))/  Y)J&=_UR:6E0X\?4>3XUM?*I=_#HPT4
M/(/Z=@!&224%C;3\ALZTL")5U;0%4\I&&&YZC1'-$YQF: U33S=)9+=PM=R,
MJK;B1>Z0QP7"$AF1/XV0-M)48W,H/3[#X0];30O?ZGHU_I.D1033R:C+:FZ7
M="D<@MH[>VD:9[J595,,!"/)SMS@U'GJ9^IK1Z(RS%<:H\2J<MD2*UMEF,8N
M1J/[8DT@_M<>GNJJ)9T]@T\)261)C7& @'A Y@9/N8*5GC%NL+NX,<Y';90<
MLA.-^&QA<A@,G)(XX8&LVB?"S4M6@OY)))[9H'[=IOM6B,IC[@G$]M<&*ZA>
M.1.TT10.K*[>I0N:AA'U5]%7VG,IV5DD.=4Y5B\VX NKZ(S\@R:X@5R1BQ[F
MN(:)518]7)CRD>>?:/@PXBQY*+(+X,1^K//!"K.)-Z D # D8Y( V%A@MC*Y
M.&!&&(YK3G^%G4\>IP6"6Y:"6**23471A:6YD!W1RM%WF:16 7MQ*\A+*"@)
MJR+;ZS_3 ;#?O6#U.:Y)ESG5K6X/=P 8C*$E@QQ"&-;22V4,X(B,<PKZL=BY
MQ%9^E@E<9FM%J%K-)'%%*&DE8HG#;-P4MAI%5D!X(QDG<",5+P?!/JY9)GU,
M6MA8VZ222W*RI<2E48HHBLR\$Q+G8<R=H+&ZN<_36:NFOZC&MNH/9MOJR?C<
MW5N0MJ*RTQ$&7WU4LC,WR .+:5]9&$P+6SH#$;,B %(EELJMSIK61W!*!NV2
MRR%'3;C(5MP(=AC<%QY*D^Q.1S4!U'\/KS0=+MM4AOX=6B=Y%NULX)@;% V(
M992Q8E)/I<E4[4F$]:D.=B?/5<]J'G79TT7'5ITZ9)IK'KNCQV^L[S%+RINL
MB#92*J#(Q^\BV!GG%4N;,>\L)DH 6L\AJ4K$*B#5SFUSJK0Y>H='ETR&Y6TD
MDGM9EG>,2!1;SI*R[2#RZJR9'(W9!!Y'3OA%U];?#7K:SZJO--EU:VM['5+.
M6QAF6!Y?G[*6WC;N-@8AF:.8@GG8.&'I:5&,UDJEQO'Z:;)',FU-'4UDN8)C
MABERH$"/%D21C>YSQC.43RL8]SG-:Y&N<JHJK/Q*4BC1CN9(T4MXW%5 )Q^I
M&:YW>SI=7MW<QQF*.XNKB=(B=QC265Y%C+  $HK!<@#.,X%5OF2M6G%*<4IQ
M2G%*<4IQ2G%*<4IQ2G%*<4JR,PV7KO7P4D9UG.)X@)S?)BY%?UE0XC?S^1#F
MR0D*GX7MZV.[K^$_/-^RTK4M1;;86%Y>'./[-;RS '[%D4J#^Y'O]JTKO4M/
ML!F]O;6U&,_GSQQ$C[A78$C]0*U3W^8:MV)U0OR"QS6I/KJ=DM6-F45EL%*X
MCH=-#97#;:"0PP#/: C1GD56>MI%_<!W]K.Q6^F:UIG2HMHM,N%U-+&:1K.>
M!Q)L:60RR=HE2VR)G;@D$K@JV-M?D'6=0Z;UGXORR:GJT":*^L6=L;R&Y54^
M8CLK=;2W[ZJ_;,UVD,)'I*A^'3(<;AXDN+.CAEP9,>9$.Q" E13#D1S#=_E>
M(XG/&1B_V<QSD7^R\X@Z/&S)(C(ZG#(ZE64_9E8 @_H0#7[)1T=0Z,KHPRK(
MP96'W# D$?J#5O9SEM;@.$YAG5SY)485BV09;:^"HC_MN.5,NXG>*K^$=\6&
M7Q5?PB]E7\<\UZJ(.)9('IBZ9,?RW)(XKS;&S"BV#F;2D<*5ENW=DH#(<KD2
M3]GR646+LD?9*<)'/;183C..XQ!<./ K8[9SI_19==OA;(QC@C0S75P%W"&$
M<#&>#)*Y6.)2>6;<?2K$4KKSK*UZ)T*34Y46XO9Y5M=+L2Q4W=V_)W%?4MO;
MQ!Y[F0?3&FT'N21JV;M';G+M?%;6\NL=/B<JB*)EB\[B_:),<T19S)\"5)&%
M_H;&3VG83S0(WA*ARC,UR>]?T5=&NHX8KE+J.96:,C E0JVQDE525R&X## 8
MAAM!4YP= =93]9Z;/<W.E3Z7=6DL44JD.UM<":,2QRVDDBH[*4(+(0VT,C!W
M5P:Y?_J(7VK-C;GRK.]563XV([!RBCMK6RL1R QLJR2IQ>+33+W&8(QO-]K6
M",#Y!K1D$DFQDJK.R.48.&_$7HG6^M#I;Z;<V4-C!,MI,;B22.0D2GYJ>!-G
M:G,49@!5F0R- D:,V0R_T_\ ^RK\6.E_A9IFOZ'U#8ZK/U++:W&IP?)6\4UM
M!9RI&VGZ9?W/=$]I/=W=K</;I';7"1))//)M5LG7-M0$>-AF)YA'CR(Q<9R^
MHKHUE]NA_P"-QK++B-17L%TW]UQPPB%B780D0PX\RF@H#Q1J=K'H.AZ?T]T[
M::!;WL]\=.:5)KUXC\P-\TLPDV=R1!M&8TC0L"0A&/4IB^N>L-1ZHZYCZON[
M&UL9+J;3X8=-^=66(P7,5GI<UO<RQQ6\K@R/;ZA)+(D;,8W5O3DF_:^VH<;O
M,8D4GW>:WYOE*<,(B%E!+)(20WN=G=QEDG&%YW#4DAKO/P]KVL2R6@M+6<1V
M\5Q';*&VS.J[[@,7,L@#XDD!9L,[%6=CP-NVH_5$U/5+&2;4);.2\D+!H(MQ
MALNP@BM$Q'^3$$1&>.WB9DA10=X96(R=F63QKW+,E?D5(N-64FZCE5M,QS@U
M$)AI<:SK9$>,QQHQ2ED /'42?'<09_8!WK1BV2*X6,B$$HC0@QRI&=Y+8&6"
MC@D8\X /U<C%<Y@M)DM(Y8A',8=T<B7.!NP%9)8Y)"%E3A@S ;V0 JW/-HS\
M^D#NX$"RLILR"\SA0'$$HVD@.D_ID" 90%$-7M$\)7! LI1#*)J(]C4\O=,6
M1)V<=P&0 [5;E@!G:2%!.W<5 1CADPF!7V*V4":6RAB+QNJNZ.S(7"[9=S,@
M$C*BLJ)D.JDJP9U(JJ9F*;;I7%K31XP8$JLDC'\-)+"HT@OD2Y36O]:.'(.Y
MR#(QW<0"*0B_Y>1E^KN/2RHMN\;A& <NJ'8TK;6 (R2S(58E0O*U=>FY[>!-
MMQ%+*]]'.DLR2O$L+2 &&V7*912H$:R*Z8;. 5&3EK2>ELOSN;;CH'#FDA)*
MMIKP5HS-%$I1N=,GNC"&H'*4QFQP>Q'J-P1H[R< 2<Q6^GW=Y/)';3E#-M$J
M[%"NV4!*AF!7*E%"J59B=I/@UYZAZMZ>Z:TZVO=>2-(8R1;3W-VZE))6D5(G
M< ]P 0RS.61EC178!59R,^5>-P9&+)2K;,,L6">>;[@Y!RA":1D5CV,<@D=W
MED]KVL60H6P"=AE]KDYEM[8Z;?F!E9=Y2,NR^H2*')]3%@,D,HW9'Y@R,K41
MJNHIKEE'=XC>+NN=MO(6B[$HC9"J*H=]BM$Q9"!F)MK[6 ,7,A8:(-E/! *9
M(F^!V*%_^9$>5.RC1KGM H'^X;W(GFU_DQGEZDYFNG"1M&FS&TJN,>F1BP8-
M@E<@@'TC.0=V3P<VFH9KU9YGE)CD];,I#&*-8V61&.TJ" RX;&!AA@D%;UPO
M80J*NL\9RP"O/&HY980XK"L20L8J2AAE@5[3N>!Y7$&C/:)_B C&(WW>=>@E
M[-TT,\9BGD[DB,#DLQ#?2%.68E<'=C(R.2O%SU739+ZPBO\ 3[E+JV1H8;B,
MA=JJ"H/=9^$)&#G/(V!=H;->B%G>8WF88=;U:P:F_IXS88!$8&:"RC6 QO:Q
MZD"AHPVC;,$CF(5'L.X)E&/^,;3WEQ=P136T4]NL4DC1 DNX7<69E;'"B,HF
M #W &W-N 'I='TBQT>_NHM0NH+B>:.WBN-BQQVSN\2PPH5+!C+)<I+([?5"&
M4(NV1Q./(\AHJC&G["%B4B-D\><TM:*:L1U=8VDXSXBS&P? [RDC((TESS,$
MH7" Y'R!HI$^64:/,(UF6&%%E2Y1LH8(HE$@)D.T 9*J"'<$ @X (JOWOSD<
M1C*R79+6ZVO; G:>XF"QI#%M;)=MPRC1YQAE.57. ,DQ^LNYEF6RS ]C;1G0
M"%F!0T5S[6PK8Z6<5@W)'([TR2$B^!&.9)8UY8KTBJGLGK&TT>]:2[$GKNFV
MQG.Y4AB 2(=MO2JA4$F'4-NR>?>$O]9ZPT2TL]/_  OM1VB-)-$ZC=<33S2R
MR2&ZB+.\K&40[HWPB;495*XK^EQRZ;(@T]:698V$TL&"E>@(S3TU='AF$,Q%
M9&6)65WD< I R@:]9LV AE7Y#'.B-9O=-TM^UI\HO0S8G,3]T(78%V8@J RJ
MGI;<^UFQ[YJW=)0:QKUF][KEJFAQ0QR/;"9# MSLCW0P1AS+*X>0NS*H1^S;
M22@-L93.7I*H,*Q/.,?VELC*HT6NUX[*9<F^EC[XC%BGJ*N@%>I>2/AQ PGV
MEQ)AQ+,+9<*2UJ_&=[3&E.B-#@N=?U=&M[29DMGE-M;Q)W,R.">651W99F,I
M 4,WY6$RB%JT/BG->:/T->Z!8]B2YZ@@TE]0G>:."^>2*::ZDL$M@\KQ0VMI
M8P.;69K>2+NO)<+O<1G9-TI]<_3YUF$V/'TC?V]E-U9=QJ?*(%[2FI)?HLGV
M Z:^K1E*9LRCN755BD*0KPS!NBO9/@PWO"TO4^HNDM:Z6^1.K0Q1KJ$)FMVA
MF69<J$,D,A &R:+>F]<%?4-KL,X_&EQ:2VP0R%&60':R-N&1C(.0.1D<C*G^
M%C@U,'E9K5IQ2G%*<4JW\KQ3'<YQNYQ'+:B'>XWD, ]9<5$\?LBSH4A.SQ$1
M%:]KFJC2!,)[# ,P9P$&8;'MR12R02)+$Y22-@R.IP01[_\ (CP1D'@U]!*D
M%25(\$'!!^X/L:YK>NWZ;V4Z-L).U]%/O<CU7+=VR'%NTRWO<2,17]BO6.$K
MY^/N151;0XDDP41H[.21GC)-T#1]<AU!/EKSMQ78W;9,[$F4X^CV27<!E!D2
M+](!XJTZ1K1C#0S9$I4+%*6"H<'E74D#./IQQG)&" K:>9A; S?)))X%@AV#
M<-!G:]BJK'@>Y!(KQM3U.3V-8B(Y$1&>*N[61;-U53%*"V"P+K@>20%VDX^Y
MW X( &< FZ#4'2-9%<$,(RNR4+R "P&#D;2JX(V8P"0#D5A[(,5R(]BZ&D1R
MFE%=X*Y_QQ&<Y7?N,DF>UCF$1S&O5ST55[(Y%_#4VT-P<(<9+@<#*ALMX++@
M+@L"6!.,[?TPBZ,Q[:EBSG'J;9@NS80OEBHSE26(R0N2< "O:ET#E.S,_P <
MQ&GQJ1D%K<VL2OAT4(9)TF4<I6QWH]D=7+Z8S7O)(F$(,$6(PY#E9':KF^C.
MMK&9YC'#!&"7>8J=H5?4!ZL%L$%7&TE<A<X .,WL,0+R[(HHCOD,QR,!2NQ%
M)R[')V! . %<$#CK%Z;/I5:[TYG%;DUY8/MJ?%+>MR/&L:# C1 R+Z(($F+*
MR*>$I'V0:BS:29$@ 8R(:2T!I1C*(P"\TU;J5]01DC@6%I$[<C*20$&01&",
MKO3;N.<D[L^1BKZOKEO<P%+*,HUR6[[,<E$'I$:>G.'P6+,VX9("@-N.W;E5
MJIUJW^IMN?-]>XAB>)X8&0!F1Q,CNKVZ%%D&6NCU;ZFHK$"82H&/*'+OC6D4
MYE58TZL@R@I[@L>S=LXH96VRM@LZJB98=S +,AV@G#853D@$$JQ(;!MO2-A#
M=7S33@-';A"%W*/4Q8EMIY8!5*X \ODD &M=^ O9CVG\:IXUD"QGY,K[RQ.K
M)P7@,DH!'!;[^Q#+&6.(1IG<D="CD?%7UD4YIF%B+U9A&C+:($=,JQ8LA(9A
M@,I96# 'U*NS.2%4=<L(TEBN&$Y#.W;MQE?2%WKLR&,:J%"D!% R23P<C%6Q
M\E#40\F/&21)L)$.!'FB$4J0P!"U/9/+5M*H7,"_S8$H%8@''&]7F8Q['[5K
MI\,VIIJ+6Z)<RQ&WWN"&DA60NEOD<$I([>HJ^TJP(&<K)WVIW$-K;Z>\W]GC
MFDGBB8)DSO"B22H  [;UA!^H@ $(/4<P9LLVDCE2&'=&*AT*(99*$%(C.<J=
MY(G#(H/:-/X9(11N&1RJQ2H+U7RRL4N'CMY&2V.[SSZ]I8&,H1_%DY8.,! I
M(!8-5[R[GC7>"^ X(52&! W$_4$QG'U %QR=IP!6#K3,YM7+EM--]_J(5S55
M"*ACR93R-DF 8A1 $ (XX(@(S(PE1ARJTIY#7CA=,Z6UG1M=ZEO+WJ;4-9L]
M4O;>?3=+NXK:*UT*%(VCE@TZ4$R217([1<R$!,+N#R,SM,:MU/IFJ:1H%O9=
M/V6E7>E6<D&H:A;R2/<:U+(ZNEU=Q! D;0L'"J9)&9Y&VLL8CC3%]OF)I3C%
M[@3XHWS'(>1'CJ1!$ SP TRL]Q?,W<8&>9B#816C([LPGSJ+JA.G)-%C_#=5
MOI-3U:WTV*;3K%KR*R=@S+<:A(77L62OQ),0ZH=K $8(S]/]//U'#K-U'J6C
MZ?\ @NE2:F\>IWJVDU[#$?5:V"[ 9;I@I,5OE)'( )W8%8DL+M#/?(81ZH,Q
M$<P:,5YD:X:HQRN<K41BM5SW"4K^Y'*]$5%Y)['D!F]4A=VRI .PGG<^YG:1
MCGA@F0 V""JFJS+*S%\[F"9#+$3D@'!&"2J#A6!R0S [B &+>VD0]J>/%A%"
M%9(S(8DV0L2%%>T39'K^4=RH(C^Q6B08D>I1@16KW<5U)ZRUZ#IG3#JDECJ6
MJ"%X(I;?2K9KJZ*RRJ#(0IVK&I8B5R"L:(Y8DYJZ=$]+2=8:M#HT&HZ5I<DD
M$\PN=3N/E[13&AD$0D<-OE=F[:K&,Y.!G)=KW@H=GJB=VQC&(\)&^#2(Q[WJ
MPKT>QRL(K"-(P:H42N]*$:U7N:Q,D&HI>6%O<1(Z)<PQSJMQ T%P@=5D(E1L
M,C)D!MVTCD%67),-J&DSV%]>:?<30M<6MW+;7#P2Q741>W=H@\$\19)D8Q[B
MZR .H15R1M7,^O!E):$AP&E(C"O[-8]KU&]0E(XC41%8SQ_RIX]NSW_ERL:J
MO]1O$\4JS$%-AY.<<C9Z0O &["H,9R<X 0BHFZMY([D2Q#^[VNGJR3)O#)G/
ML0"[X8X4<L2<MUZ_2\V%89WTE8M"MG%)8Z^R'),"*4JJYQ(E;)%;536O5$\A
MQ:NZB0!(GY&.&T:HU6^*5K4E5;I]H !   \#9Z,8\YPH)S@DDD^:Y;U/:_+:
MO.0,+=*EV!@ 9FSW,   #NJ_I_A\'D5L/YH57Z<4IQ2L8[AVOC>E, N-@Y2*
M=*KJM\&*"MJV +:6]I:3 U]955PI)XP'RYLR0(3%*<0QM\RD>U@W+SX2 "QS
M@<D@%L#.,X4$^_VJ2TG2[G6;Z'3[4QK+-O;?,Q2*..-&DDDD<!B%1%).%))P
M ,FM,W61URYELFMR;2N 8E98= F.BT]I,L;:-&RJ]ER)3(SZ8-8)O<%3)>56
MJ>%)*:66,-R2/@G<,T+K5U?16,,ND06][+<,P:.>4PIVC&_*RA6CW[A@JS@C
M:X(#!0WZ3^$?PHT5]136NKM5N+>SLDFN5DT^P>]@MC"T06>=R#MV&12V^,"-
M74L 1O6"&RM&YC48959!#Q\M6>LQN+'KF8W(]]5%'>!L!SVVGB\KF7< +TAF
M\PDBDD2I!GD]S(ZDYYJ?PPL>K+^6_P!2NKV"^BTJZTJ)8)@J1]R3N-*(I 69
MU,DV75T[N(PR Q1E>]])?&F+II9-'@M['5+*XU1+UY-0C99YH;=HFBAC:,J8
MHIVBBD4Y:2)(HXO4CL%M+INQ'2>8#S2AZC+C)Z>]HL9<FN%JT..,68P4Q&LG
M^^!(23%646N%$:\\" -%D?(E 8)C2]0Z7TBWT/2K'1)YI+F+3-MM%-JER>\]
ML)24595[2.+=&5$C56,<:*%5MC,M:^(G4NNZ]K:]4]-6>DO'K%W;OJEJ@*+%
M#'!%!+)$IN6*32".:2>0-)-++EEBR[$6'"Q=FNH]'>-?'<L^PDK'6>V/+#>D
M;+2,VJM:2/,%82*]$+'9((!30V2##&1_9@S2*=U1UITUH%[IF@ZDUZEWU!=2
MQ64MK:/<J)$>%")G4 QI(LZ)$0I9@),(I0U9>G.D]=ZKEU'4=/>T,6D6Z"2U
MGDGMU[*VS74LEO="VFMH+@-$[!;J6*5PH>-W5&:/"%S6VV5'O Q:<(\S#<!8
M.ZKHL@D$$ C*N%'@1J^-%'#@QHT>-";YSI2D.[Y3_<%Y%8^JZ]J/4/3VMZ-:
MZ3H&HZO;W=XL<MS90R3V6GAYHQ\Q<LF^0OBZ<JKB*(,XS(Q4A>H]+:'H&O:#
MK%UJ>I6^GPFV=)&NY((;G=%;27#1AYY$VVA-DL7<M1<7"K#(\D:HP9_=:-";
M[/[3$/GE3815?<B5L#T2F>41:^)/69'8,+9A2*:6]Q)!1C$QDD86?CJ=W=$V
MP[_-S"%9F$8*%P2KJ@+*%(DV[CAL,0%!PU<"TW1434YC8/VM-O))"D1G.\JY
MWB:9!#(6!A5HXH=R J&:2,N<5T3_ $\^LW(,T@U>E=N3I^19P&P'2XG=PJAH
M52@@8Z6<)F3D),6<8\9E<^,:Y='D*69*CBE&>TB2E]V5\94B66.1&D)2-RK!
M)&52Q&2 P.T$AL%& X?=D#@_Q4^&,>CS7^M:*]M'9VT2W6I63W,?=C:XN%B2
M>T5 8C'*TJDVP=)(L-MC(4XV\\DZX'3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5
M3K:XJ*&">TO+2NIJR,U'2;"UFQJ^"!JKV1QI4L@0"15_"*\C4[\R10S3R+%!
M%)-*WTQQ(TDC?^E$#,?Y"L<LT4"&2:6.&->6>5UC0?NS$ ?S-1TW'NJ)CF*W
M%O67@:/'X$0KIN7M]!"O<HG*T./CD#*"0?\ ],IXRA:Y%>B>#/)]KT+0^_=H
MES;]^<'<+21F2&)5/JDO&0APBX_NE8%CA#DMM%"ZCZFF6W9=*G6& GMMJ"@2
M22NPXBL$8;&8_P 4YRJ ,P(VY;E)W]UF:U?FUQ+IZ6YSZU?,*Y]O=VTB<[Q<
M0G<Q;FP9-,>0KFJY0P8T2,C%1 ,&!$5G=K?4DT^&.""","-0I$,2Q1 #/**H
M*!#Z@HWL1@;CSSS-.GKS4=]Q=W;1L_K9II-\S%PK MG#$CTY+ $D@XR35A0N
MJ:YMJFE9]KB5E/(D./*IPME&.3Y90181%F%8V/X^]RO&B-<=%&QXG"&B^=A@
MOU>W%R\31LZF**X8^OM%F)C0 X*,Y(X#%E)&20!7)[[I:Q'7D4,=PERP@-[>
M631QM ES"GY5YO8;TN!&D)!PNQD! )D!$VM!]4V=XB98VN<WN,?66)'&I02(
MDNL]R]D<9]3/8>I>X:*BJ9T13HC"-<JKW8D!JVBZ/JX!U&VM9P 2MPP>*8D8
M)C6:,+*K;F.$("$Y 8@%AUC2=5U?2SLL[FZ3)P85,<\8&TE97BE<(8]JEF=2
M"J@-M8\',&Q^MKK"GXCL+6.40L+V+B&T,%S3!@7#JVIQ6T@1\LQN?1*=[X\V
MHAODQELE>,HOE )ZD<\+7*H>4N^^'^A2Q/\ )I/;2E6[;)<NX#@>D2)*)R!G
MAAZ"PVE64$D6NUZVUFWEA^?D@>%B"Y>VX>/=C?"\)B!R.=V9%!##!*;#*?"M
MB?\ UWXOIK+L321A5U$UW40)F'Y][8-4MS&E@CWZX]/C1I+)DYL]I*VX@3AP
M)3EHHX8;)CA&4<9IL Z4TAIIA\[:7Y6Z-U8JIN[<& Q]B_MRX:+Y=XY CHTD
M<;S2=SM-Z:YWUK!-\2.L(M-L)1INI:! ;+Y#6>['I=\'N8K@WNC7D<,D=RUU
M!/ +F&5+>5X[2(0"X5&99N]45[>Z-Z?<YS:'F"18L/$:S&+"H+41VUWS;D\#
M&/NF.RX(6V6/2 #L"F1\@>01 18H?"N]P$,[F;7MK+([3V;/B666)H[AHYFW
M,72*=G2=) 6P"RQQ,&9F+$$K7Z1TCI[69+FRM--UJ"U=K>&&=+C2HKRQBDMH
M.;FSMHKK3Y82-F!!+=7$3(L<>P%=S<LG5+/Q.1B([O *JO<3$0P*&<TSSG+6
MX]#D,##G58%FF$4423*:XKUC",=TZ;/D,>>.8[^B?#K3]%U/69+#6M/MI'EM
MM^F0.6GMT,:;Y+8J^(6D9)&9/R@=T,DG,TC..MVMAK_2]E%<IK^HW-Q<W4ES
M?W0CMK07=S<#!EE5(I+AF9H%5>Y>2B"%;>VMC!8Q0VPM?>N6:;R'56K).D R
M)$G+8NHL;VC73XS87AFF/FK+G/APDD"*QD-U5CEM>@EQ5/&1(Y7J+PD.&2I=
M8]-2Z'>ZCIXLX;,2RS26W;E!C>TFED^288)=1''&Z2KE0-H'I?<QZ%I^JR:Q
M#ISZG<F:ZGU2)+54B<[HEO8)[@R!PNV>*!)FD9F=<+&5#U5\/Q -582IV0U:
M M,C1;6%7B&QC:84PQ)\.$(2G.5 , >&9KW/0@FD8A?85RF6GVEN%C[/>[LZ
M]I$?=O8E1A@ JC+ A?&4.TLIYP>AZQJ<DP1K$QQVL#SK<E JHY;"G!*@OPW;
MC/\ &1]2Y<"A9'K6YB'EY*7Y=5"LY1/B%KG!>$+I4B0QK;!DH:O>XKT;_@Y+
MBF1R^;"-_85DK+97&?GT$L*EC CQHIB+D;B6+#$FXX 4JY)'UY %0]EJ6F-;
MMHMPMM=2 I<217#,MP(4&<1/#*3$P1LEE95C4D&/!8-9$7'R3 QKV9*9.M8T
MY/N)VQB$(QT<CVO 44<B_$A@01AJ( G*CFO4*HI!M)AM=SJ6N'WSH6/=7(W(
MNY!&P#< %6](^IN02W->]3B,$T<5C$+>S:,&*#"*PDRLKR1,4];O&T8+N0V4
M='505 N2PQ3*+BCG2L:!*CR10#"I0R)KZHEBKY/L*#[D\SQ,8\:O2O=):P;2
M,!\@HE5',GNF;?3(];TZ;6P[Z6DCFZ'9EG1D*.$[B([-+ DPB+PCDJK!@^-M
M8M8OI38316)@2_:-?EA)VE973:Q95:-0)Y(S(2Y!RS+M +8J\>G_ &#U%:FN
MUJ:6SM\)_J(]17YC+L9^/Y.*/0&.0UK''/EN/(B*83WD?,IQ2I,E0K$.U@O=
MSK&M7/P[&GWKZ>VFB[2VG-F+2SGLW:[D0"W=D6)$.V4*V)G"H<LI)"UQW5^G
MM=ZHU'13U%%=WFDV+S2O M\MNJGN0LDHCBSW<01O UM(JQ&.YD64.DK@VCMJ
M7;7>3PUK<B(P,2O+$4A9[HJ-<Z464@)'V^%&"QSV>!Q,D-51-*T*D[HQJ?B[
MXK=+]5=1:K8S=/WR6\-M9/%<*=3NK1I)1,\JN55.TI*N#N,@!! X5"S?T%_[
M/?Q%^'G1?2=[I_55GJ$VI3:O<7D-Q)H-G>JUG/9V44<,'RT2W#"-K>16#P9+
M-P3O*K;6*AS)DLI*ZQ6;8Q)*E/-;(DVH&18[8;D<Z2PJ"^.+TN*I6D>-J 8U
MCE(]&)J]%:9U)T[INH6VO78OKB2X22$-?27ZQPH@!B29R0&>3U%$)X#$,-S$
M;OQ2U?HOK;5M%O.E;,Z99PV4\=Y,FEQZ5-/<329B9[7LJ[F.'>-UPHSO3(PJ
M;I*XGCM=DT"/;3RRG7:"^)-5PG]R(PLB4<!',17A819$9H3R7_XH?L8I503!
M<Z5"8YR)I\)<=I753Z.U+D^E5DW%D!5G7:,$,"0P((_/VJ3:AI7<T^R+26#S
M/$TB@.)K8XW.TD:@"8LT<3J[ (58J%92#^FQSX$=V21*0EY81>T)T,[U -($
MH;XS)$<K K):8!7%$TT=CR,<KBM;YH!P\VHV\T,;:A:KF1(6C8(0"8C(#(JY
MQMW+A@V2P' X9Q7SI_4(-: Z<U*?LQ3W<4J9#,6N(HPL3MC<K[2"-DBA&=49
MF&U%.7Z.LRG+<8R>L+)6IRRR..\]96*- 0Z\4TW9JO>X=>P,AL1PO<-DN=*.
M.2UQB$\N0ZW%E<VL(#2?-3 1R;XP%=MT;*BC=DH$#ASD@DLS ?W8G);?4=)U
MGN21QRZ19#-L\<@+1DQS1/+(%38)R[HT6!M"((VVA2X\\ U# )0UE+'K:]E.
M9[[FR0LA\R^O&'4))ICF/(DJY@6,)#K2#"R&0DF0K'>T0QX0+F]D>-7:*)F6
M-(40QY126DC550+D'\MI$;U@9?=A -^=AI]JT\T7S5U+&9%EE*3) D@3Y=Y7
M>9 $E5F<JR[H\JL;1#NUB+9NZ,VH\ZM<;Q# C7!83H:4\:'&FE;D$\U>*05T
MR/2PPS[5LM'^E(@)H2JP2^X:JJQA<CZJZLU33]<GT&RZ>DDAADA2*0FYF,DD
MB1R&62.&(%RBN%2(2A5Y8G!K]#_#KX8=/WO1-MU=JG5R"ZN[:[NKMU%A;6]E
M%;RS1+;6\]^T\=L@F3?+>-!OFRO;V@!GV;;-Z9\@ZW>A32D.XP_+.E[8E3'G
M6QY5)KBWO<0OFH.?2I77F.T%O>[&I()V5M+<0K;(JKUU*#DNC@E0Y@)8?U%\
M'NJ'Z>LK+5+G2;42W]HJ7FGN[V-S:313,HFC>^CP#+&K?EM(SLDJ9?T#?_-+
MXR:D-#^)'6&E6VNW?5FCP7UO\G?R7T-_'*'MH;MHQ+IJ&S/8FN[BWD:&V15D
MCW,IDC=3L/\ IW].73IT\:22HT) ?(L+&>V#M',;B7#M<OR?-\?%\::E_:P"
M&@NC072B&I*ZJ>RIB5]@V1'$LF=,.??ZPZ@UKJ#4S/J\HVQJ38VT2LEM;6TI
M!"PQOALMM E>3,CNAW'"J!QTWQO_ ,[<"H9D"*<I&0WJ5<<$9YW?Q#!^P$^>
M5.O-.*4XI3BE.*5_%1'(K7(CFN14<U4145%3LJ*B_A45/PJ+^%3BE0?V_P#3
MKZ4]S39]Q=Z^=C.16"D(>^P2TEXQ(=)*]2/EDK(ZEQZ5(>5SB$)+ICJ9[G/+
MYN7R2<L^HM5LU1$G$T:>([A1*,?X=_$H'V <8]L5N0WUS -L<GI_PLJL.<>Y
M&X< 8PPQY&#S6$]>?2*Z8<(R-,AMY^?[!]"=Z^GRVXK$J(94>CFF4-)3U)Y2
MM:BC0!Y"Q',>]KXSNZ>,A-UEJTD8CA%O:GG,D*,9/?P9'=5/.00N00""#G.Z
MNNZ@C(RN@*/O V#DC. 223CG/GD@$\  3EU#T\Z:T1 F0-68'2XM]QE%F6$\
M RS+><<JKW^3;V!95D\#$56 B))2+'9^@(1M546!O=3OM1</>7#S%0 J^E$
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MMU!)FQS@R,X9,Q2C>"O.^. *@PWM]#+I-DUC-%<1ZCFZ$]N1(DEDI 5TGC+
MB0%RBKE60AR<%<]KZ7T2^T>WMM)U2V.FWFH7,DMY:RZ?"=2,&ZW$44D\NVZ@
MR@9C9AXT99$>2,NQ!U?=.>U]@TVP\ZP;/B4EO@%S:MV7MBWGU<"VLH),-(VQ
MK$H; \J.HW761OJX+F1H\XA62U;$"%2/.S<M=1$$4$,5KW)KC,-KF0Q+"DT2
MQNKHL;BX54WR;28@K;V+-N"5U;J/3-$?2++4K-KNVU+2XI]/TV.*66*.Y:^!
MBN#=0+O!,,7<97<H,(BNQ505I5'U%YAE5ME6O!O<7&3U5Q\:]R!J3EB55;-)
M-^_9!(B0I$VQR2($K*^K:Q"+-0D&(OD(86/TI(UL[B&.4.\Z3.ZM;MLRXX$2
MAWXA(5BQ)W8RX*YJ/?I^#\/CU92EO(DUO'+:[W ,DRD*EJ05[8<A9'0C\MMX
MR1P,2;3KA$R.=/J;Y<A@5CH=,.WKZ^9"D3I,&(.%(5(IRN##.QRNCD:-KQ3F
M..@6.0:*^7CLEN;-5:T=68M*T8<3L)&.Y6WE0-VUQ@!#A<CZEK+I&K3Q7:1-
M);V\LY9W5D6(!&+,F[8^Z2(D ENY"P<!F&URPJ6S<"S_  _$]>;!SC';2#29
M-5/EX/)0L-]6Q[HT<YI D5RRH,Q6%#*L)4UJ&*_U!8]4B$8W3OM#T]A:75W!
M;74^FRAX7G@66>RF8EXS%)*H:!SVPYDC*[2@!4N<U;-$ZENYKG7-%T+5A;AF
M2TUZUMYY[=I;<B6(QW$,8:*XC*N\%M"C2'\YF9TWASC_ !7.[VV^;!C5T=::
MF@5,=8K6#AP(D@8V?)LIIF&"V;,(1A2..0IT\CO,\/N1CQRFEZNV^2W^7$MJ
ML<0" +LC4H1/(Y9F5S(P)/J  #;BK2 +9[H:%IEG%+=33PS7,[I$S'%V\?84
M-;QJ\<Y[8D*K'$BP&5<*).WW>Y8$'7DR%)+>-R"'.LI<FQGUOQS,GQZYP;$X
M40L-1_F4(S4(-RO>] GCD5[E=ZTJ[V+2WE]'AQ/N:6)2,VX@E9@>TQ8QL\3A
M@5W$H K;<8(UKO7X3:VEY;VL<5@9FM6W'L7!G"I+M[0Q-##-"RJDC JQ[L.]
MPF3FK2?4%F&B,[Q?94 CYUE33)@KJ')C+)A6X)4:3!G0BL!($0BR:V3Y1)"N
M1\.<T)!^31."3':RO'&5+B1+.6:-TC9)&61F0RAP@W*Q9]Q+DG!4E00JU7>L
MM T[7;">QNDELUUBVMIX9B&ME7Y93\FZ/-O1UCDA"LD:!)1O&X[RZ]2?3_OG
M#.HW74+8^$"MHE:>8>LG5UY"=!LJRUB BR),(X_)XBHP4R.0<@!""(PJ(JL(
MT@V2\;[U#%60D#*L,$9 /^A'/^AXK\:]0:%==.ZD^G7<D$S!%FBGMW+130NS
MJDBY 922C!D8 J5/E2&.;>>ZA*<4IQ2G%*<4IQ2G%*<4IQ2G%*C3U&;^=IVD
MB5V+TO\ 5^R<E*VOQ3&1N?Z_EG[L%.LU"BE9#$Y?/U-4;CHUWD8 D<9+5TUT
MVVLO)<W4IM-+M?5<W!(4R;>6BB9O2#MY>0AA&/"LQ"U4NI>J8=$V6D"BYU.=
M-T< )80H<JDLRIEV+MZ88%P\Q!P0H).NW+R%I2.R??M])W)M2S*T\+&S&+_0
M&OCE<UL>OJ:",KX 3P5+XRK)D1LQ%1B%D#>A"+U#2;%K@+%HD$>D:5$Q8W7:
MC^?U!4R3(9I@7$3 ?EAV8L265"IV#DFJZC+<2LVK32W]ZZ]LVPGD%I8&5@.V
MZ6[A&GQ@RQQ!(X@,22N06J//U MXS<NTCB^O\&K_ +<Z_A#LLGDB.0KH4^$]
M(;J.#Y-5T5LB9&+82D0B/D121?8]6R",3>Z?Z7N;.YU2[DD>5VD-O9JJ#=)
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MXRNYMZJ"XDF?* ]:J5 ;9OE0X(U:\=?AO+B"874,\EO=0?F6EQ"QBD@FB.^
MJR@D890I/@J6W Y)KOFF=<B\OK6PN],MDTZZ98+F,">\FFDF7M,<,PW!F?=%
M&D7<1Q$%D8+@Z;]%8D#/<;#M"WM)\*O 2:?"==5PXSX$:,,D,=C/O">\K5S"
MY1(]7+CLA*E+#&*F^89\JS4D=->:IKFLF?4)9[R1XBT][<2O-+*L)WI!&'W
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MRN_[?$?\HY'*KN?))(AM[;S'<@#[F(!Y)VC!P5Q@C/V_;!99W+-<1Q84GM%
M7D4!2#NR,JX.5.W@ \#)YN^'B$ 'F8(@L&5K7M\_)!B<V.C&)ZE0:L WT,,9
M%(CG/<5SD:JJY?I9"8D[8#QDQL(E4EUWYW%\MNE;<44A=HP@&>16L)'19Y>\
M1%,O?C>X9B(F*_3VML3);H$5V4N'!9^4 %9 '$C,K8T)E5&<\+BE?)&1R2)!
M$4;XZ$17JQC0D$GJ<+L5CE17*Y?SS4"H7<O,X!*@(5!5%7.=F &WG.?4-O&<
MKC%>YIK@K%VH4?8KG>'V.S.04W;BR]I0""5.\;@ K!B1\)M7-2.,XX89<=5
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M_"S3^IS:_BU]>0K:7$TMN;":#<RNT;.KLXG"JSJKE BJ^ 6##@52[_[5=_\
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M9GB.XM)#'&"TAYPC9*98G< :3ZOI.GS/=ZQ>M+?QN9CIEO'EQ,C*4AFD8E5
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M1:C+^'-:M)WWCFDE9UG7=DK'($W!G13)E4 1FJ]\YUCJBPB4D75D6^;B)<5
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M?T*ZACO]-N[6_LS$;>;N!&193&C20D%]\+1B15:.98;A6+#8HP7@-U#V6O\
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M'+!E%=$Z#F7\-+]V&)5NXR)9HLKMWM$X0EXPLLA81I+O906QLDR09U5[O89
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M%A&)6^4BBWNE]8S];Z;J%IK4%MT?%9=N_P!,.?F)KPK=@2J!$VY,O;[LS1@
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MUAKZ ZE-"RAY06-M?#9 \-8TN0N!:C,L0+[AN.CD16C:YUO&)D+V8^.33)8
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M+X*U4>Q'+*6#LFQU8@X  !QG!&<XSR3@'C&"1SYK=TL=R:,-LVLJQ.C!61@
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M%M P6AC/B)),Q9$@8F$&C6KX/%[6NVK#7Y!.EK>J,2L$6=5VD,W"AU7((;.
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M9&$&IPNE3%:O<3P/8Y%['T[T%:6,Z7&KW"W-U"\;"W@)6&UEP''=<\S.N58
MJJ?=7KC_ %3U;<:UIE[I^E*UI:WUK/;B](#SS)*K1[XD!Q$A.?6&9V!X:,\U
MAS$NHK=6(RB7([R->3/L<&@^'=QW'C!@0$?\:/&;#:#UEC/>]63FQ7R#HUB2
M?D-142PWG2'3M\H@:WDM4-Q)<]V!\-OE(WLV\^I6 4=LLH')4KC-5BRUK7=*
M$MW:79O+[\(MM,C6\9GMU6S1E@=8D4!'WL7EE"EGP%/N#L<Z8]PX[GN'5M 2
MTL%S>KAEDWD"_L$FV=@4DDCYEM7G>]5D5KI1'(V.-@WU3'AB& %J"5_).KM
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MDLEN7^9BMV;![KIN565I(D4DC89$EQ9\6-.@R03(4P I427&*P\:3&.-I02
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MO5M7OA;:3<(C'\T"$@<D(V#(1Y(SAA[?5C.[%=]Z%TV/5NI+>Z4KV;,&Z8(
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M?N#YX(&1QC*^3FO6MZ596]RULD@DA8.K-A>%"X]1]@PXR,@L3XXQW?\ TO\
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MIQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2K7S'+Z?!Z*1?7+I#Q,+'AP:^
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M=(I4*-W:^BE*4QW^7O;4^3X#6O;,1_WJD7<\3PQAOEB#D*S)EERP[FT^I"<
M@G' W#P1)_!6ST.SDAU*<HVL;E,3R*DNR.4A7["R*>W.$W8=5+EF.Q\^=N>?
MZJTO-S7!J>!)&^FW!#R7![Z/76(Q-DBLZ.9.!.CN&B>JP]\9K&JK%>K'%&[Q
M:_Q7ED&H:G';W,\\02XL)(I8BZ,NX*2)$89&\;,\@^X(SCC]:WNB]/75Y96-
MO+\QI^L6UQ;7*1R*YBSL,,D1.3$>Z0"A&, J!@L#)O1&@-:].F$BP;6M.L"
M^0Z=;6<M[95W?V;V^#K"XG^ W23-&B!CB8P<:(!J!C!$SR1U>U75KS6+DW-X
MX) VQ1("L4*9SLC3)P">68DLQY8DU>NG^G=*Z9L%T_2;<0Q;NY+(QW37$N O
M=GDP"[!0%48"HH"J *Q?UL:9P'<>A\RKL^<*/7TM//M 32M8J * "O:U5?\
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M@A5<9[R/CPA.(]7>;B\EN%2,A(H(R3%;0KL@C)&"P7+,\C  --*TDS@ -(0
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MVRQLC-DL2LOIOPUT3XH]):M=:CJ]]?=;WLBSSZQ>S-MA==QM(K6U0+'#I4B
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M&2$^2>N<95(2&]ZJO,L4\L6=C$ Y!4\J<_=3Q_/S6-XHY,%EY'AAPP_F.?\
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M+]L:)Y/($H.N*23_ %'+:S]<2]M<-.QR/"=$DS\P"4N5"NNW(!!(R,^W !#
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M8V.Y3(F" 4(P59BI]6X?&]EBNT;:A/'K3V41",!ZW/0@A/)V^,#T1P^XI41
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M*-(U'-3.[W,0M>UI(\:*[\("*/U\>2?;QQXX_P"M:^H]3:KJ*]IYNQ;@%1!
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MZD<@L\FLUR/9R[*9%R"KQBQN)L-IH.,4]SD]$&GJK>:'[0.5)>V/_P _Z_\
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,XI3BE.*4XI3BE?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g129231g67w08.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g67w08.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1QD4&AO=&]S:&]P(#,N,  X0DE-! 0
M    '$B^<D X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0&L\           *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  0.__C4  @ !.$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         !.$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,W    !@             "D
M!(H    ! #4    !                          $             !(H
M  *0                      $                         $     $
M      !N=6QL     @    9B;W5N9'-/8FIC     0       %)C=#$    $
M     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<
M  *0     %)G:'1L;VYG   $B@    9S;&EC97-6;$QS     4]B:F,    !
M       %<VQI8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$
M;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T
M;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R
M   &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @;&]N9P
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M!"@       P    "/_         X0DE-!!$       $! #A"24T$%
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MU/49_P +^C5 FWHK1U'IE6^QK"?L[;'M90
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MS;$! +;5!8@9YP#QS75P-AF+:J9=55[5V%<6L9<B/'GQ40E:4"20RU^8POA
M4+F$8:0HA>U[7.>UB^[GN2VGAE,$L;QRK(8V5E/I<':5](.2"""%R>" ":_+
M>[MKN"*YMYDE@FB2:.0' :*10R/AL,H92"-P!Q[5HW]'7K<]>WK!]=&V+4]2
MAZS]&G6Q;K$[//[NG; O:ZQCCDDH[,.C47W+GL:SF"!+E4E&^9E*?-2!@G*I
M)=5I+'KO5/2?1G3'2%D&U,ZCU1J"QW=M<V4Q>%U+*LT7T^=L5A&I95GF"W,L
MZDIPLEO'(%8>R'#Y=LX&//@[@0?RXR.?C(_-QOMYQNL%.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE
M.*4XI3BE.*4XI3BE.*52KUW^M#/^A/IVD[FU&$T78%'8=BYK"V57EY(8]K60
M[V'<SI5^-),8\>6VMCTQ4; ,6 R88X0K81E7W+9^E.FGZJU&;3H[Z"PDCL9[
MM);A2T<CQ/$BP>EE93(TH.\!RJJQ[;>WZ ">3C]L^X'/QYJ%>A_U.>K?6=UW
MZ@;3TGPI[MYU10G3(P^Z:U,EG=AJYE!=VM-&8.HM["X)6A/4*VVC_P#E]JR,
M<11"&-[SADM5Z)N>F;O1!U%<1?1:G-_O3:5*+FYM+:.:%)F(EC2,2E)=T1_F
M1DJ1EB-I\LRH0'8#S[XR%&6VY&20.?'CG&*AK],;J;U[V'9W>7JM]9>JG8=.
MZRL@UGINCE=+S]06B."OK=3&A3+2^_TM#@U<%U/GX5?:2)E[4R?W*ZE21,K"
MGF^O]3Z.73]'Z=Z6MDNAI2EWUQ@%GD$VZ1X'D2.#ZF221Q+.[QJD,BB.%%/<
MQGD:(QHJX)(&[ (51CQR 69N2Y(P, #/MU7ZU71NXM/2#7RO39UEK;O>U?=&
M)N+*OZH@: FB!E6UVJ_=31H.4,*VCU2W1J)]C^R"$\9/K2BHP4=YP_GX5ZI8
M6_4TIURZMDM9=)NX8WU!X1";DR6VSUW(,7<[*S!#)G(W* Q;!P6EI:)*I[$*
MA>0I 1,[@2!C&W(R/3R<^*VJ^G4&GC] =(#W#+UNX3J'K7_6JZH;A:HFM;BJ
M,>A)IVD<\O\ J%;1DE+A3/>9)[3M(]SD5>4#6S;-K.K&S[/T?\3O_I/ISFW%
MJ;N8P"WQQV.T5[6 !LVXKV^-[[<;=S8QXQDXQ]L>*Q79^H%N9[LH>E86;JY-
MI:468TA;/3;JDQ'[I7:;0W] ^)UW66T:0?L2^S#<Y)M=A3U\BL?2U]MF$9(F
MR[^-%'%UYKE9_P!4O2FJ24[/WVGLV!BZ>7"*#J_M1 Z0>+NAY[6!Q)2XL8]Y
M.S]R1L&TK<8Z^L(ST(5T7X!%*Q2N%-]4?7,NOK1X0.H[!V6AI>Q+G*]?U6-V
ME5H[=.J;:/0[JNM$O,W!B86PJ+Z7#SXV]@FRT67?6-56BE(ZQCF52LNZ5[KS
M7?6=G[K!1;"1UXZS?5Y37S@O@!VCZ\(PZ*;554H8;2'74&B2PR$@MJ"'*DZ"
M@O6QX:UL:#8V2E3'Q2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2OA)BQI@7QY<<$J.1/!
M 20C.%Z?]'B*US')_P!G-7GZ&92"I*D>""01^A'-*Q)G777T>NN:R/BLI KK
M]XSWD:OH:NM%9G QS02YSH,:.X\N*U56+,(Y9,1?#XYA.1')G:ZN9&C9[B>1
MX^(R\CR% ?Z5W%L ^ZC@^"#7EU5T99 &0CD-XQ\\^,8\\$8R",5U751XJ9@M
M16VA+VDR]Q99>AO"RTL"V-13/''CC+/]Y'SY%&139B5/.0DJ?*HS399"29!7
MN]7D,T,P%Q$T$TD<<SQ.C1LO>42(Q1@"HE1EF48QMD7'&*T]/N;>ZMR]I/'=
M6\<LMO'/%(LR/V',3@2J65S%(KP.P8G?&VX[LU)/-6MZL>O]=E,HZE9J--09
MQ^DNH>;SS+VXKZAU[H;!"+ HJ=L^1'6SN)J!*L2MAH:9(01%$%Z,=XS0VUQ<
M"4V\$TX@B:><PQ/*(84(#32E%;MQ*2 TCX121DC(I46]J]$UG;\Z FEW6\B9
M./*S<ZSZ\JDPKLI>S\K?#T55/DS+S#7>VH9Z3@QQ29V'V&3EGBQ@,4S3#0_,
M-*@/*>ANF'A(&0[#[2[&UK*DVKEYFM%,R0\SA+#4[]NZF3LS!F8@TZ^:<L6)
M43*/M";V#E2YZ5>Y%M F2O;*EE*5(63]('76+SDW.T.DWT#]RI.SZ"9<UEAF
M,Y;?0[?VU3NMNM8W)9+/T^<D2K.I'!JS9BHI5H:N5);3-A6(X%E"4J8.M^H\
M7U(W0P>OH)<WF+^PAVP\1 6.#'YRS!6QZN?+R=.*,/\ 8&: <*'.OJZ'(2HF
MWHYFC'7QK^^TEE<J5)O%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4I
MQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2N)/GP*J')L;.;$K:^$
M%\B9/GR0PX<0 T\D/)E2'C  +$_+R%>QC4_+G(G/2(\CK'&C2.Y"HB*6=F/A
M5502Q/L "32OU#FP[&)'GU\N-/@RPLD1)L,XI424 K4<,\>0![PF"1JHYA!O
M<Q[516N5%\\,K(S(ZLCJ2K(P*LK X*LI ((/!! (/FGCS7W>QA&/&1K7C>US
M'L>B.8]CD5KFN:J*CFN:JHY%145%5%3QS\!((()!!!!!P01R"".00?!K\(#
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MTM=,IZ>/3ETGT@Z4"?*ZQZVRF2M)\5YB1)]Y6U4=M_/AOD" =8<VZ=/E1$*
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M4YUW;0"E>",62@1ESTL<@-@4"OF0V-C,*DA8I/O8QRF %2&;:&)!'A0WO_U
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M)M="2SS\IHIME:05($"C6M4]G750897D,&/%))E-DIYW5M5VQ2%LHS+N.=H
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MN(Y@AC:GM$(8Q#8QNH[EV+' ).<#P/L,D\#]35?FFDGD:65BSMC)/P!@ #V
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MJ+#-K-BFAU]B^0USI$2<*9%*XB+"=++"/'5_UG$E1BC$]) 2QF%&[?T2VO\
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MP\T @_CLG>Z-,L?8]48"M<5JO;'?[G(6:C5_V_+!,<XC2,D(H@"6R/8$>V"
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M'O>1?6S04@J.)($V5(GR;"?+MK"?)5OR2YTYZ/*1HQHT0(XAM#&B1A)[ 1
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MQ;[G(Y'L\M5J^YS6JJM5')Y_.8(5"DX)X)R1XQY\_P"OVYBY"&]^.?L1]_\
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M)UMTGJ-FG2\C2QZW)+;6\VEV3PMJ=I87L[P2ZM=V2.TD=O<=F5+4.@6YN.W
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M7?7")YB$5&%(HU(WRKE8S:M-.EU.ZM-/M(EDO+ZYAMH0[=N,//($4LW.!N<
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M))9"4$S-W9HXU"*C3%G]*#A8R=P0#@ 8XQBOE+K#I*]Z9O=SH7TR]FN/X=>
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M]IK>-7Q:VA?F$-\KF6!ID&(A -CHD0GS3543D"I("[D=',:Y?&?OY^W/.?[
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M\C3,CY/&><D>/8^,X]LYX'R!6U:R:=+$LD(PQ/K20C<"@V!]N.-VT9(])*\
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MZ1* ]C!-=SCP2"@_N%H]\ 8"M'63'S2K.@M!*;[1E8G+1K/4*]5:G=:\-/\
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M6X!R!S@X.",G:V1DXJT:#JZ:]H^GZQ';S6B:A;K.MO< "6+)92K$8##*DHX
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M#8Q;EDX(8>D><6#N@9"GS6TP <X2[%?P RLRVNF1HDJIU@H)8LDTXTD!)%C
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M0!8GY5?"*]Y'N5HPA$UYCE<P(1D*]C'9;>WGNYH[>VB>:>5@L<:#+,?/Z!0
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MSFC,MG]$IN)TA8%]D]O"K-N0<--$HC8 G$?BNU:!U*->B@@D9=-V,INC=S)
MJ.^.V\-Q,RYA;(&7QAC@EL;JQ)>HIMYOWZX?9"R4O="CY^?L,U%?)$U8,I:\
M0;26?[3*ERQ8ZEAJ0< CHXSD#&_VVICL^ONEY-,BT]^C8(-5L+-8K6YV0I U
MPO\ Q)[B$PPSNS N^'ED&]LG) (E-1Z6ZETVYGU!=>2_MG<;[=IC*Q11M6".
M8!TV A=K*1$&VXQFNRQ76'7775Q;7LW0ZZZL(UK,MJ^)?7MN>#%CV@TF5E,Z
MGK58<JEE2"DDRY4Z2U6' ,;@((AB5G6NI4DMX[*/3[/3W@B E[)E=[F2;$O<
M7>62*)5("1(#M.]F9@RJN]T_93ZQ;QZK;74U[9W]Q=Q1B:"&%M.33]1N[&59
M3(6E,F;<F4,Q8,=H!(R9RJ=#=MH#0(<\D*%-F#)8(Y6$D3H[&L<"&.>T C,A
M!*LB6<!G$84OU?(T6*)ZUZ*=W4.<C&?@DY_?X)\^!G]:L$FD:>MT$D'U4A4
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M-I(QA+%E@B&(00:@YKH3T8<0H[&K+# VMO/!+%=.IB[$L<J*\7<=WC<,H$#
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M.15:7ZST5IPO(Q\YT_9:3J>OZ?8:HT4=CW&=NZQ1965&*1/(/R+(RJF[/.[
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M">1U=:3+ LM&J-TEJ*4J>X-$%XXCO=1U2Z7&6"W7T0*Y *A=-2R# _\ \4R
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MV3&AM+(-/D:0ZFU^P-G::?<DV6^1I+)E!)RI]#L&#-#EF9$)S&?4N -HW?\
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MU\J!8M5WX\A.)$<BJC3A*0)/<(KVK!=33"+3)G(21?1%)$WY9H9G6.: @?\
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M1;WM/0U,6??3IU71S^Z=+%V?9#*J"9ZM#$T.MC$T"QCODLKIDV8"L6'7.!"
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M^"S=XED8?G .#X (_,",@^?;/L0,'CXXO;=8YY4C.55W53@\!6Q@Y&00P(Y
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M'6OP8O)>G.DI[3J:Z:XM;Z;,6GRDLVEHR@#MLP8I)*X#21 K&G&1W QJR?\
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MKJP_>>TYN,G4&HV=]#H:@)HE5UQO0RH$<\OYK60^;"EQ1C5L:OG*Y%12H/\
M7WZ;M=ZC.A8<O'A%4]W=</'L\>.IL7G4EFD%K=%DZN[/&JBF98HP?[7//!KG
M2Y]96J>-!').P5BZ:U6/3;XK<,19W2B*<\E8V!S%,P )(0EE;']#L>< &O\
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M'BP82$62IG.D1E,5Y)#W/YHW%_=W\\TUW$D;M(66&)!'%'N/(12SX4>.68X
M&> !T6#2;-8;)EAC]$ !+N[]LX& BLQ R<XR!PQP0,BNSQ/;&UJC'A+)E742
MQI79V37SII'185",;@@@,62Q1QV>UK"J@!.>_P"L 1W$:U%7Q%-VI ^P-M(X
M)^/[CSD_.?>LEQH%E<6Y<2?2R(>YW$4D,W/)"^1[>?!.!48=W]:ZJT#9SZD
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M ,&8S58NGVU=I(V.U5:>/H%H%^']X;)<IYM>LQM2=MC\0"6(9\J.R;,4ZF0
MNV]<:LW46C:/U-:Z1=VD4,(TVZU?-O#;74ZS/"ZI'&3<-%!(DT*R2QP11RR"
M*$OM1JXA?]*?53:IH<VH6MY)<0/?6FG[7D^E2,?4VY7NR*HGN9)+=YG7>_T]
MF\;")+F59?=!UU:=?Z//!UO6]C4V^<U:1[H%E2S?N0)/S0XXA*$:%(.!\<<0
MAOKQCBI&*TC21A'4OGE\MQ+<"/NR=SM1]M"0N=FYGY8 %VW,<NY9B, M@ #B
MBZ4FD375M](UG,]PTES"X=2)@B1'".2$4)&H58PL6!N4>HDY[S#62G%*<4IQ
M2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*P;LGL/.=5XN\W.I,
M9E72QVN9#A!=*MKJSE%9$I\]10!_[UG?W]F>+4TM9'1QYUC+CQQM\O\ *2&E
MZ;=:O?V^GVBJ99WP7<A(8(D!>:YN)#Z8K>WB5YIY6PJ1HS'QBM2]O(+"UENK
M@D1Q+PJC=)+(QVQPQ)Y>:9RL<:#EG8#@<B,/3_UYHZ*)J.S^RPB;V_W#.A:#
M811F9*#C*.  H<7U=5RV(C#5F$JI1H\N2%&AMM18:2^:UJ6C6LE>H]2M;A[3
M2M+9CHNBQO;63E=C7UQ(RM?ZM,G],NH3(&1228;2.V@S_*K1TBRFB6>_O0/X
MCJ3)-<J#N%M$BD6UC&?^2UC8AB.'G>:3G>*L1RM5,TXI3BE.*4XI3BE.*5PY
M\"+9PSP9HOEC2&HU[?<YCVN:YI!&"5BM("1',P9XT@3F&C2!B.%["C8]N2*5
MX9%EC;:Z'(. 0000RLIR&1U)5T8%70LK J2#XDC65&1QE6QGD@@@@JRD8*LK
M ,K AE8!E((!K'*ZWDU<\&<T)O?)D*1E#=O:T4?0,&PAUAF]C6!C:*)&&]\F
M"U49:1HYKBM8T++&!4;4L"31/=VJX1,&YMQDM:EB%$BY)9[5W("2'F%W6"8E
MC%+/KQRO&ZV]P<LQ(@FX"S@ ML;  6X502R#B15:6, "2.++^:-;=.*4XI3B
ME.*4XI3BE.*4XI3BE.*4XI3BE?Q51$555$1/[55\(G_NJ\4JNG=?JHZ?Z"K8
M]CV#;6\1LZ8RNK1P\Y=R!6$\C2/'$C6;X0:9Q2,$0C4=8M]PV.(WRQJN22LM
M*O+\L($4A%+L6=1M5<9)4$OQG_EQGC.>*TI[^VM\!V9F8[0J*3D_&>%_QJ _
M5%O+;;]8&KX.3MXCH,J/H1A-(C0P79X<:8R+2#DWI\S&F@D&D#*6US\C00A*
M%CXI)+_C5TIT_=QZ3J'U##O%XGMP<;1$9'3=*.)"2%0KM*H2K$$C.#3NNNGS
MU?HJ:8]P]G#'>07TI0"0W"6Z2@6[?S(E0.T@82!I=K(I$;,.-7W7_P"K;VU!
M2)U-8]78*NB@AMPU385^AO0:+/R?A_984V6EI(G@GRJDJC.<'Q0_E)'<)' ;
MX]EXM>BK+5K];SZBXVRW'U,J%(WCD7<9GC556-@L@!7(8E0?!/-4G7NLK[HW
MHZ\AMX83_"M':SLI9)'66-XX%M;:9I)I2DC0NR2%2!NV;1C@'9KZ#>Q.I[:C
MT%'1=BNG[V=9$E7N+M;",'XB1I4YR7N6BN?[KF%;@E@-96T0LIY9(F?;:!/A
M^2!Z\M;Z.]A,EBD5I#$JPW,2,6962/,5UD#LO"ZLJ1E54*<J6R<>OP,%B.G)
M[J/4+^2]U&ZE:\L;\[(HI[:>X1KC3T<!IX[I75IKK<[321@G"JN=BG.?UW*L
M5J]QD+N^M\Q4:.IL=!0^U;>IBS!EF0O<J-=\@VK_ #^%[FBD_$I/J'<T$GXC
M.1B[<UC>6\$-S-;2Q6]QGLRNA"R8YX]QN'*[@-ZY9,J,U$VFNZ/?:A>Z59ZE
M:7.HZ?CZRSBF5IH,X!W*/.QB$EV%NS(1'+L<A:RKFI4M3BE:0OUBHO;$SJS"
MXB/?46:ZCTW9]7=;+M2_+3#-UZRDD@F5#H19TB#9Q)\9\B7/@)G2DNK5M,^!
M"E@)/DU\OK/X:/I:7.I7SPS7&J6FF31VNF0),ZWZRHR3;TC22.16(19%F':4
M2%V1MBNN?IE+VWUV)9)'FMI[@M!,'57MG9BZQN<)LBVJ8UD+%4D6++ S$)IT
MQW;E%?.E09-? V%U0UMC-":]CO<34:.UE09,:4V00+9IOF,X<JY#.<UUI[01
MC'8C6,;S#4D-WJMW*[8<R*N(U"(D0& L2+@)$!@*!PH. <Y)[0]G?6L0N9G8
MK/<2*SC!P [!0WL-H  &!@+QQBH O;VP-7R+"9#;!::8^?;!A@9%CF,3VJX[
MP1AQHQG$0A!&1!_AJL][W-+Y61ED[5M'&6D>&)1L0R.RH3C\H).W)YQQS4MI
MUK)<W MU?<6!VY]P/(^3C]"#BN!E=J*]L8E8?YPUH6-C!.R2D!'QUE%.@6!5
M4:Y3FF%'Y5AF^QK'M:Y1/1\5!<!9R0A 8G#'@?Y '[Y^/GBIK4-"CBMGE$L<
MDJ\R1J-Y4@>[#/D#D#YYXP*FF)+S@\GO4)G(]MI)<>EE9R?,G2F3LV"!8-=<
ML!3QVNB6G[G"(..4I6M/":(DL"O:A$;/F2-K64LN9 A*>#G!!/@? /@>./(K
MEUW]=:=1=-'ZY[/2IK^ZM=0!6-8)3-I]S+8=^Y?!@7ZR!(4+,(Y9IX8B1(R!
MZ=V?=\+ 63VW3YV@.572RU-1"&>7 $92@::8\_\ LC%]=??[2>)!&J)WL:CG
M$2=Z2Z"ZDUZ$ZM#]-::21-LN;R0QB9XF*,(DC1Y#&KJ4>4A$0@C)VL!TCJ/5
M-%MXX[%!F]!A3%OZP=ZAR<J0I.""H!)/L,5S/454WG8O7V9#F<JD^[C[BAU(
M-!*OB5<.AI8]1:I(@?M"@:"R+;G)#D-/(*R96$J71@@>RR.B>^F]:TS1CK/\
M3B;-U936D?;03B.1F7>5DC?PH1E 4F*7N!F8!$W1MQIL]P;**RD2.6"YBDFR
MVQY8U8')_P#P\$A?DD\[.)0J]I%KA_9KGF9YC/9.A$>C1,*K4\$ U$_BGN1R
MJW_]WE6HOA5\<Y2Y22,*0 5497QR,# /OX^WQS5ON[!XI@T8W!VPA&<?W&0,
M'^P'.14<:^='.6/<"/"DDE>3.&9[6$4J->)J#:O^X01%]B>UJ(Y[T5C7HUR^
MV.NID7#C:QR>&Q^G.?'/MYYJ5TZUED=D/<4QJ&WKE,-D9"D?/G@GX!]JBN$E
M)2;BR[C[)V$6,*)6P*@4 U4L8<"29E751SEE0R?[K"0P_3-_M/60^2XA$8C2
MJO1Y>L;GJ'HC1NAK'1'%W:W$;&2"97CN%MQ=3LZ0M"K1R2M,&EW7#H#&6&6<
MA:_-HEMI74VI]37.HJ(9[95:.1,+"&$$(!E[C9"K$$4"-<;L?KZ4/T8+*-([
M [>O(5@-^<T>?I*^"^/-=)K)5T&<>PA0 D&58SY,2C0SX[GC^3ZQ/B8\;G?"
M2HQ6-VMJ\SP,G88I.#M#Q,K!"'3=N&&(##;E/ZL"N4_BGK&CK<Z9IB7T+WMS
M,;BTC".S2V[6G<)2X[?:==NQE FPX*E%;;D>B#F"N6TXI3BE.*4XI3BE.*4X
MI3BE.*4XI3BE.*4XI72U^CH;:QN*BLN*ZPM,^6."[@0Y89$JJ-*80D<4\(WN
M?&(5@B*UA$:[_;>BHBM5$S26\\4<,TD,D<5P&,$CH564(0&*$@!@I(R1\CYK
M2M]1L+NXO+2UO+:XNM/:-+V"&5));5Y59HTG123&SJK%5;!])XXI,TF=KY3(
M,^^I8,TJM:.',M(,:41S_P#E1D<QV&>KO_VHUBJ[_'GA+:XD0R1P3/&/+I$[
M(/U8*5'[FL[W%NCB)YX4D;\L;RHKMCSA"P8_L*[=A!E:CAO81J_E',<U[53_
M *HK55%_^%YB((."""/((P1^QK,"#R#D?(K]\_*4XI747]_29:DM=)I+6#1T
M%' DVEQ;V<D42OKJ^&)QI4N7),YHPA")CGO<YR?UX1%<J(N:WMY[N>&UM89)
M[BXD2*&&)2\DLCD*B(HR2S$X']SQ6*::*WBDGGD2*&)&>221@J(B@EF8G@
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MV3#0E6KF+#&*%,.CB%'']SGD>+_U0B4RN^-?X^!E>)GA/8C:UV8C&Z@ !@,
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MIBR"S7&NY2S"_(15,UQ&-CO?_)'(1Y4<B+X]RJY?'=7T*ZFM1!!!':1[0J1
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M??.-POI\UV:["-:U>SU&8T.1A9IE8^TCZ8UK42JFQG0X]6*PLG40ARW64'1
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MI4NVDK5W(!?[0*:2]HHP!0AC0ZEC(\S%"ON(XGAC?8C/),0,;0JICV.4 X'
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MWV+MP2V/ !P!YQQ6T>J+7YO%"^TUX8]1#C).>C&N7X(CQ$)-:QJ*Y51@W/\
M#45[?\>7(CN0]M*]S<,Y8 L6* DA02"%!)XQD\GQCG[5V**SBMH88'"ND:HD
MC,H8L@QOR"#Y&1M&2!P0:] OH+RDW+^F'KZ3: -'M=BVWW,QDA561]?2VDF7
M1(='*JL*S--IF/$OA1*U1N1'M<G/GC\1+];_ *KU$QOOBM!!8(W(!:VB59R
M?8W)F(/OG-=^Z*TZ'3M ME@@CMUNGEO.U&JHJB9L1 *N ,0I&,8X\> !5Q>4
MBK93BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI7QD1H\P!8TL 948['
M#-'D"8<!AN3PX91%:X9&.3\.:]JM5/PJ+STK,C*Z,R.I!5E)5E(\%6!!!'L0
M<BOQE5@58!E(P58 @@^00>"/L:A.R].74LF22PHJ"=UW;%<XA+7JC1Z'JZ5(
M.[\J>P#AK.CKKHBK_P R7D&S$3^B#>GXY/1=3ZRBB.XN8]3A  $.L6MMJR*H
M\+&VH17$L 'MV)(B/8BHJ31-.9B\,3V4A.3)IT\U@Q/RPM7BCD)\'NHX8<,"
M*ZYW5';-,Q4R'J-UY4;_ .C#[+QN$W< 3?/X8LBCJ<!HSM3^O?*T4@ZIX]Q7
M.\N7)_&-'G/^^],60/N^EWVH:?(3QSMGFU&U7CV2V5<G@ <5X_A^HQ?^SZW<
MD>RWUM:7:@<\;HH[28^W+3,W'))K@/B^KRJ54CW/IUW T5/:LZA['ZTD/;^?
M*$)$O>T0-=_7\F1?:OY_VT_I<H?HN89:#J:P8^1'<:7JB#] ]OI+$?JW[UX*
M]1QG"RZ+=#V+Q7MDQ_7;+?*/;P/G]*^*Z[U<0G>V3T=T=<-__DI?4-KHCE_[
M_!<^GZ.B*OY\-^PJ)_\ >O/WZ+HV3\FOZ] ?BXZ;LW__ ,H.H6_?TT-SU$@.
M=*TR8^QBU>=!_:72Q_G_ .GP?V7ZHA>4=Z7LP=4\>%A^H6F>QW_5469U[!>B
M>?Z\C153^T3^N>AI721Q_P#K;=+]GZ:G!'_P:E(/UY_O7GZ[7N<Z!"?_  ZQ
M"<__ !6B_P"O\8%[N[[]<^5CXHG7/I.I)]K::\%9-ID[*B;@5I3$@S#2UE&J
M:/-!QK(I @(W46]PZGBO>D.1 G&F1T#8="Z=Z!NS?C4>KYUBALS+'.=,?3C#
M.)$5-@GN+HWI<,X^DA@[SA2Z21A&W16IZOU3!]+])H$6^2XV-&+Q;T21[&)W
M"**#Z8*0O\^27MJ2%97W#$V;.U[DV?ID[E?N^MJCK?;3>J-V"MSE#O6;XJSR
MY2U:,9+"+G*&( SCJP8A12V**YRI\Z^UKGU<PZ+9:[IXTS4Y]5LTO[9GN)]/
M.G#8L\9]*/<SR,,9)9TBQQZ>2!-"34;G3;OZVRBL9VMIE6**[%V<F)ADLL,:
M+[8"O)[C.,$^0[HSNC1S^Q[*E3&UV&G5D;ZX;0(2_N\NNEB;\4PMHCUDN98
M:V4H O\ KL:3V!8-C$$'N^IMINJ6R6ZVMQ%+%(#NF=6C(7)';1 HQ[[FRP(&
M3N!KEJP/IT<D\4N\."0P;/.3D#_EQRK#.220< U7[O\ U!IW<MA(U*$G5T E
M6"1&@?"!QJ]@ E^*.]J,8QTAA$^1Z^?*N]RO=[6N7L'3L?T_2L8MB/J6@F2.
M9R7<9D8KESE]J,=P49 X   XX;KXMVUZ5YH8XX3+#)*EO&D/<PB@G"A09' 4
M%R2Q'EMQ!K ]7KLRS;4>PPI)L-8T2)\M?9^\T6%+A!<%!154GN2OE@0:+$08
MQQ2.,-KBC<CUU+1)9])OM-UUE!F9PMS;MM+I(JLCR*!D2I(N"ZLY8$2$+MQ6
M*ZO+.WU"TO=*[RK$JM(EX>Z5F4D,JD')@8$*B[5$2DQX8+DQ?/LDM)]E-6#$
MAI92#R1QH(FQHL13'4KAQ@_GX@L:]S1C1?:-GM:WPC43D7)JK06K6LBB9A (
M$N)"#,>W@=UR.)'9!M8D>IB'!!!!@+N<2322JBQ%I'<QQAA&F]MVQ%+-M13Z
M57.%7C'@'B@AN\HJ^?\ OY_I$3Q_V1%_S^5_^?'YY3;N\#9&3SD8)_7'QG'C
MGCGEESA=-Y<\GS[ 9!QS]_/O[CG]JO=Z.X5O%L-39 &_]E6/"A&;X7XCV*%>
M8"(J(K46/&(5Q5;_ $V0Q/\ E=YYI6CM(7X](('G^H$Y W>< XY\G[<&V]&2
M3]V^D ?M!(D)P=IDW,>#S@A<EOMC[U>2LW-*?6 QDP#XEC*"I8IO'R@*C/'D
M1%<J/$16_ECG>YK_ .E=[OPDU#$C8R.?^V,@'YYSX_;YJXMJT7U7T8XE R."
M1CDX)\ _ .,GP:C3U*U[(U'3QV.;Y/<)-:W\(JMKH9Q/1$\HO_-8L<J)Y158
MU?'N1$=-Z>FQE[8VDG!('@L,?!]AP?\ ,9KV^[N+-D\*5P"<88JQ/Z^G /MD
MX\\[K_T9]]9Z'T[Z[#V3CD'U]O9*TKR.(\0:751&VB0@.>GM8T5U&NI:A8OA
MGWVN\(CT\\$_%[2!IW4%M=KM'\3L^XZC&>[;OVV9A\F-X1G)R5(SD$#NW0>H
M?6:.8B6+6DHC);/"R*'4#)/@ASCC@@^];?\ G)ZNU?A1"5ZD48U(YGQ*16-]
MZC\J[XU?X]RL]RJOL5?;Y55\>>?N3C&3C.<9XSXSCQG'O2M"/K7]!M)U#H:7
MNKT_=3/N: TRX?N<W!N=)*E5>COKADRMN*6%"=,M*NIG3Y/TK U/Y%3B9'<\
M,>N:]PXC4K4O&9HPSNAW%<DEA[@#/MGC&, 8\>._?AS^(-Q<S#1->U**-)1%
M#:RRQQP[U2'MJCW("H'78I)E*]PMG<SYK2MWY5;3IOK>B['N@9MUIK;>P82C
MK9X[*USP 3PPSQ;JF=5E=5EGLFOD!]KGO?!= 897.4T3G4?PTZ=L-7U+38+^
MY%LLD%W=$Q7,4$ZFVCC,:QLQWH[-)O;M;9$2-B64FH'JC5[O4]=U[3+%+Y[/
M0H[.'-U9WZ66I7=_-.TS$Q75M;W5G;16BI&ER)8IY9G>*,B,2F)[VM)38Z).
MS]78QJ M5%M+"OIZ=\&NJK2S@19%K[@ "04,8K$\F/$>9XS%C-CD=\<A?A9"
M]87,U_JVJ-;WNH:O;VLSVPO)VDNG[,+M!"9+@J 4.W$;<+)GTELY:]:&(+ 6
M0N!96-Q<Q@QP//%&TDZQ]VXCM878/*T>6>18U?8N6<@9D-,^Q9YZ^OJD%.DU
M$2VNXU?:+'BGE.K**6) R[([816S7R$897#AQPNDS !>J_&,**^R_@YI^F6W
M4%SJFK+;-<65BTNEQ75P(HXKIG53*59&3O&$R")V8F L'6)MZR1Z'7/54][I
ML.EZ>9VANKIK>]NH(2^Y(L=V*-P^^2%&*).X7Z<2%;=YN^6B$^6H:VA(2AQ>
MFMMKEZALR!2Z236R*K]\J!$^.MN"U,Z6>54+9B^.:2KDR"D@/,D1SR?"Y_*U
MUAJ<NMZ]JFHLD$1FE4/#;!>S&%1$"JZ_\9@5(:X('?8&4*JE5&WHJ0V%A86B
MDO(D:%>Z^6+9W2 ,P (0L0JJ %0*!M4"L?AQZ"JDU<JTT+ 3Y!BI+AU\:?.L
M:Y&>U4EE:&(D=K'G0J-<,Y&B:WW$<BN1B4A[J"RV=TJ-SE6R 3@^,?)R?/\
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M!>1G;.?8DDY^^?8']-B7ITK)Y>J[JVL='%MHRG^M!K%FR#V56\3?881!2&>
M@*YPR!:$KF_'Y5J-7^^?:BMO+K4$JPE75-TCJF(9"Q"YW*P!<#!*A ,\@Y&*
MNW1NLZA=1ZA826]V4BP]M=L%>W!5581F1B0K.2#&N"/2^X#@GU4>AO-V>?\
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M-/Z<U.^EL>H-T1N[9[?3KP2]B*UNW/I,\JKW41_R(Z,%5R-X(8,EJZ6ZEO-
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M&][+?7BF/^'H(IBT?<PJ*%"(#N.7<A<^0+S4/266J*$>TUMK4190K8@JW)V
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MH4[U(8I#2"&D'*1R_P BG,1_M:P:.08V-;S6\O;K4+A[J\F:>XDQOD?:"<#
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M$0VHP8A#8C6#&-B(UC&-1K6HC6HB(B<YB2222222223DDGDDD\DD^37<@
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..XI3BE.*4XI3BE.*5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g129231g69b02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g69b02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1ZN4&AO=&]S:&]P(#,N,  X0DE-! 0
M    'I*^>"8X0DE-! 0       \< 5H  QLE1QP"   "    .$))300E
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M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0'0\@Q         *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M      !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG
M8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE
M9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E
M8W14;W!L;VYG       X0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))
M300F       .             #^    X0DE- _(       H  /_______P
M.$))300-       $    'CA"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          3A"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #-0    8              N8   1I
M          $                          0             $:0   N8
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   N8
M    4F=H=&QO;F<   1I    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$$0       0$ .$))3004       $
M!#A"24T$#      40     $   "@    :0   >   ,3@   4)  8  '_V/_M
M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0 # @(" D(# D)#!$+
M"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ :0"@ P$B  (1 0,1
M ?_=  0 "O_$ 3\   $% 0$! 0$!          ,  0($!08'" D*"P$  04!
M 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&" 4###,!  (1
M P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.'Q8W,U%J*R
M@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<75Y?569G:&
MEJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0$  A$#(3$2
M!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J*R@P<F-<+2
M1)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6
MYO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]5246/98W<PAS3(D>(,%*Q[*
MV.L>=K& N<X]@-24E7U9)*LVS)R&A](%-9 +3:W<YP.O\VU[/3;_ %W>I_P=
M:#3U?&<!ZQ%0W!OJD@5DNGTW5N<6O=5=L=Z-NSTK/WT>$K>.(J]+V;Z28$$2
M.$Z"Y22222E))*+WMK8ZQYAK 7./@!J4E,E4ORJ*\_&QW61=<'AM>I) &\N]
MO[NS\] ZCZEV&XV/^SO?M^S-!AWJR'4N>X?ROI5U_P#"?SJYKJ&3GNZWBDVO
MK;F9-N+1<T#<RH6.HL].6^U_[CG?0]1*!XI\-;A?48PE.1^4'0=9?H1O^\]-
MT[K6/U"36US6>J^AKG "7U@/<S1SOI,WO;_46BN.Z)1A.Q\&W(N<+WW/R*<,
M6 %VX[<.W(:X[G;:V>HW]_U%T'3<_)S[K;FL:S"8Y]+2=7.?6[;ZU3A[7T6>
M[^W6G2C6R.&1EET CC-:2XOHZ*222:M4DDDDI22222G_T/3WXE+GFP378[E]
M9+23_+V^VS_KBR.J9]^%F-Q>H@OZ/E5&I^9&TLM<7-VWOK]K&;-OZ3TZO^K6
MZHO8U[2QX#F.!#FD2"#R"$Z,J.NO\NBR<+'I/"?P/]Z+SW4>IYMO4,+HF*/4
M-[-^5>TP/2^BVUKA[=CF_I'_ -BC>M'JF)3D5MIH=6S,8UWH5.C:]D#U<>VK
M\[&L;LW_ .C_ $5O\Y6Q8W5L$]/R;:^G-.(S+JVT^F;&[K9L>ZJBQA;5CNJC
MU:L??3Z^]_\ +47X?3^H8>/E85U5?6*60*_Y@OL9[+&^C8?4JL;<';+/^W%+
MP@\)OA'>OTOZS4,YCW(F/'/3T\7#Z!TQ?U_TV>);U=FQG3"^MC"ZO[!F,/L,
M%\,OAOVBFOT_T3_69_PO\ZK)ZQUI@-66RG!NT%;[:['4N)TUOJ>ZJG^T^Q4\
M#KM&=7;7U)W[/ZKAM+K7/!8VQM8ESBWZ3+6?N-_2?GT^I5^C1;OK!3;4W&O-
MUM!&Z^W&;N.W1PQ[7-^CZK?YWTOTOI_Z+^<1,23K$7U[_P!X?OK(SC&(K+(
MZ1U]'[O#*/SXI1_Q'9Z7F9]X?3U#&^SY-7TG,.ZIP/T75OD[?^+<KZSL/J.%
M5AU.R+JZ-PF7EK 1RV7SZ+K?3_G?3>K0SL;27EK7?1>YKFM,\;;'M:SW*&0-
M[-W'("(!GQ'^M7%_A)T#)R<6JNP7N&UK"ZQL%Q#(]SG-9N=M1T X>.=X+218
M27MW.AQ/TMS=VUR:R=^_1Q.K=59CTM;B_KF5L:,8UGV[2YEHMNR7_J]?\W7^
M?^E6 T9MO5VNQ=N5UIC@6"HSBXE7NWUVV'VVO][O4_X;_"77[T;ZR5UNZGE=
M.>UF55:[$=CL9)=C>^JA^.UC8;5]HJ^A7^>KN/7TW%_:3LMWV3I_3+0#@T^U
MM@+&OJ?E63ZV99;N]/T7O]#?_I4[#DQ^N@;'IE?FLRX.8D8:B0^>/!TXN&(,
MHRC^]+AC+]9_J\3E]"P[:G6OQ*G=0R+F-H;9&T>FPL&9D3<ZIOTOU;#:VUC_
M &6?
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! ?_  !$( -P!3P,!$0 "$0$#$0'_Q  >  $  @,! 0$! 0
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M;K  #*(EF\2R7RUQH]J)0#\+XJ6GL(+0RDMIEUN[ZS303:M[QEGB>2&8L4=
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M'5D=3TRNI5E(_(*D @C_  1DIPSPV8HYZ\T4\$J+)%-#(DL4J,.U>.1"R.C
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M&,<8QQC'&,<8QQC'&,<8QQC'&,<8R)7:?I5HOMS6G8C9E;;9L+ V68.^PC;
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M>---^V7WSTIVTP_:K;;(#9, (TI),W(#3D#:JJ>2D@F3DV6,9KQU>FGA,X<
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M0Z#3&FD$%(84\\IE+[CF&LNNY1A.7%>>1=V549V95[\5+$JO?Y\5)Z'?0[Z
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M<=>>DW_YU.N7[\ 1IE_=\1N#=M%UK8:8<_0]G5# (ACXJ%1GY<W6=QFKQ1;
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M/5B7O_<)(O#HB14YB^I>BD^H/V^VUM':]@.J%:K8FQMY72\)>0TS5I Y\O\
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M7:LT#9G8C,"XVLF'IC*?IUBAX?"=6PP[8Y%F0DYQF/4D1_.9A#:28^P(?=V
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M_K%RG;?7>J%^Y7WO+(2M6*+6S::OMZO'.-T8((NDAU-B_6LWYW?O9VY=C?\
MQ+%'!U'C##A##AB,-#"B,-###,(2TR..PVEIEAEM&,(;::;0EMM"<82A"<)3
MC&,8QRFR%'=Y'>21F=W9G=V)9G=B69F8]DLQ)))^222<_?C...,8XQCC&.,8
MXQCC&.,9_*DI6E25XPI*DY2K&?\ 64YQG&<9_P"V<9SC/_;GT$@@CX(/8/\
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M1L'6141PD,60%^R1!GOLY'->PM$D0DQ1+Z#WG<&+>>P[E5N:-*\AC3Q9$8?
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M6&<2JX'V.']R!RA,L:JA4%)I!D=6->='RS<\ADJ&Q1W=+40S3"0$I-KQ;C:
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&8QQC/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g129231g77g82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g77g82.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[4:(4&AO=&]S:&]P(#,N,  X0DE-! 0
M    1FR^& *#A"24T$)0      $                      X0DE-!#H
M   0L    0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O;
M$     26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D
M)I=&)O;VP     "W!R:6YT97).86UE5$585    !0 0P!A &X ;P!N "  5
M!3 #4 ,0 P #  ( !S &4 <@!I &4 <P      #W!R:6YT4')O;V93971U<$
M]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7
M     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64
ML .$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G
M,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP
M   $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP      $YG='
M9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC
M   0       %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&
M1O=6) ;^            !";" @9&]U8D!OX            $)R9%15;G1&(U
M)L=                $)L9"!5;G1&(U)L=                %)S;'15;G
M1&(U!X;$!BGC5         "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0
M    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&
M]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M 08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&
MQO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 )
M3QJ@ !  $ E/&J  $  3A"24T$)@      #@             _@   .$))30
M0-       $    'CA"24T$&0      !    !XX0DE- _,       D
M    $ .$))32<0       *  $          3A"24T#]0      2  O9F8  0
M!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:    !@
M   0 U     0 M    !@       3A"24T#^       <   ______________
M_______________P/H     /____________________________\#Z
M#_____________________________ ^@     ______________________
M_______P/H   X0DE-! @      !     !   "0    D      .$))300>
M     $     #A"24T$&@     #-0    8              CT   'H
M    $                          0             !Z    CT
M               0                         0     0       &YU;&
MP    "    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&
MQO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   CT     4F
M=H=&QO;F<   'H    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&
MEC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M    9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&
M5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'
M-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,96
M9T;&]N9P          0G1O;6QO;F<   (]     %)G:'1L;VYG   !Z
M-U<FQ415A4     0       &YU;&Q415A4     0       $US9V5415A4
M   0      !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V
M]L 0    AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0
M]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M
M  #T53;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96
MYU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&
MQO;F<         "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S97
M1L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #
M    (_\        #A"24T$$0       0$ .$))3004       $    !#A"24
MT$#      \3     $   "(    H    9@  /\    \,  8  '_V/_B#%A)0T
M-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:( ?.  ( "0 & #
M$  &%C<W!-4T94     $E%0R!S4D="               !  #VU@ !     -
M,M2% @(
M          $6-P<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&
M)K<'0   ($    %')865H   (8    %&=865H   (L    %&)865H   )
M  %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,    AG9I97<
M/4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@   0P    #')44D
M,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7
M)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C
M       !)S4D="($E%0S8Q.38V+3(N,0              $G-21T(@245#-C
M$Y-C8M,BXQ
M                !865H@        \U$  0    $6S%A96B
M          6%E:(        &^B   X]0   Y!865H@        8ID  +>%
M 8VEA96B         DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R
M]W=W<N:65C+F-H               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                                           &
M1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('
M-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR+C$@1&5F875L="
M!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M!D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@24
M5#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&
MET:6]N(&EN($E%0S8Q.38V+3(N,0
M  =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(
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M^$?^6 1X"H@0J!:X'-@C""DH+T@U>#NH0=A("$XX5'A:N&#H9RAM>'.X>?B
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M[<_VW____M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0 # @("
MD(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,# P,#
MP,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,# P1$0
MP,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@ H "( P
M$B  (1 0,1 ?_=  0 "?_$ 3\   $% 0$! 0$!          ,  0($!08'"
MD*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"!0<&"
M4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,')9)3\.
M'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34Y/2EM<
M75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'!P8%-0
M$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T\24&%J
M*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%U>7U5F
M9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]522224I9G4;+V
M]0PV5N>UCS#FM)AT.8YW];]'O_ .MJ[ETV7XMM-5IHLL86LN DL)$!XU;]'^
MLLNNBW"ZGA_;,AV<ZQCZV66!K32[G>QM8:W9D?S.^S?=ZGI_I/TJ9*4@0!&P
M:]7F5\81(),@"+]/4T/\5VDDDD]8I86!FVV?6KJ6)9EO(I:TTX19[-AKQG.R
M!;M^EZS[&;-_\ A%I=1HS[ZJVX.0,6P6!S[',]260X.9L,?G%BI]*M97U3,P
M\C(;D=0:VM[[ 0":M=E?V<%WH?9W6>_P#\,UW?X=1RD>*,:(%_-^CMLSX@!C
MRG21,*X?TL?KA^L]4>'_NW72224C BR7N9C6O88<UCBT^! *SOJSEVYG2V7W
M9)RK71ZA+ S8XLK<^C0-]3TW._G$3-HZT[)?9B9E6/C"J RRO>=XW;G[I9L;
MMV_P"D_P"+4^AV8UG2Z/LP+&-&US"[<X/!_2[W_GN<_P!_J?X3^<47%>4"B*
M$M_P!+Y?E72QT!,3!Z& O]+][_ !?Z[?0LNUU.+=<R"ZNMSV@\2T%VJ*LS.?
MUPWVUXN-CVXIJT-SB"YYW;V;&A^]O]?TO^-3YRH;$_W1Q)QQXI;@5KZCPK_5
M[/RNH=*IS,MU#K;0'1C$EK0X->VNS>7;;F;OTK%9ZC<:,*VUMS,8M$^M8-S&
MZCW/8"W=_G*KTFO&Q.AUGIU)M8VHV,J:&5OL?&YS#N+*:[GV>SWO\ 38J_U?
MZKE]5Z$[,ZSAG"<3:RRMP :ZMCG,WM9OML:W8-GZ3Z;_TE?Z'TD ;A=[B[_M
M3GX3EGP#AB9'A%?*/[K<Z%F7YW2<?+R"#;:'%VT0-'.;QK^ZDJ?2Z^M>CA&J
MRD=/ !-;P?7]*/T3++&[JGW?0]3:RI)1^X?:OAE\N_^#?$KV->#W(W5<6N_P
M G^,__T/54DED=?ZAU?!;2_IN,,EI%CKQZ;[' !H93Z8I<WW-OL9;95].[&J
MO]#],DIUU1S,&W(S,>]CFAM)EP,S])C_;_ )BRZ/K7DV]2JZ<_ISJ+[A<ZME
MMH:\MJ%GH[6^GL]2]]%GL]78QGZ:JW)J4,7ZQ=9+<>IW3W9-U];7.L%=V,RN
MQ[C4^FQMU>2[TL-P_6<C?ZOZ2KTL2VOUK*DIZ5)<ZSZQ]8%+[;.E.T)AOZ8.
M:'$>A78QN):]]FS^<]#U65V>A_W9^R:%.9U%_1;LIU0JS0V\U56L> "QUHQA
M=73ZUSO8VKU/0]3U/\ DITED8?3,NCZP9V>]F.<;+#37:).0"&8]/I?1V-H=
MZ#WN]_^B6?1];<\@M=TK(N?6::["QCPX/L;3;9ZM+:[:Z/T61ZM3/M5W\W^L
M?9?5H]4]?6^M'[0^W <P-Q1=14VNU[G7N%7ZD;7>DS=1ZM?JV^G57;]I]&O_
MDG.ML!%UX&U\,DH"8'Z<>"7]VXR_[AZ!)5.E9&5D]/IMS:C1EP6Y%9;M L83
M5::VEUGZ%]C-]'Z2S?3Z?Z1Z75;,JKIV19AEHR6L)J+F/L&[M-6.VR]_\ UN
MNS_BWHK$^36ZS'MK;&Y['-$\21"H?5W"R,'IC,;)IJHL9 /HF0_:QC/6L=#?
MTUFSWK,J^L_57P&=)ON#;64O(!W-D.%_K[:_0;95M;9^KVY./_ (!]U5Z5G5
M?K1Z&:YV(*GUMH.+LJLLW&QU8SNV]_V'?8RK]7_6?Z1]GL_FT*U![:(X=0>P
M(^UZ9 SF.LPLBMGTGU/:V3&I:1R5'IUV3?T_&NRZ_1R;*F.OKC;M>6@V-VR_
M;[_P"4A=;PZ<WI63C7O974]DOLMG8T-(LWO].S'=[=O^E2(L4N!H@]FO\ 5?
M!LP.CTXUV/]EM;_.-]3U=SX;ZEX<"_;ZS_ '^G^8KN?3]HP[:157D%X@4VN+
M6.@CVO<UKW?]!8-/U<ZX^N1UI];76![36'.#JV^H*B/TU=-/JUV^^G%IJQ?9
M5^C]2O[0E9]7L*JGJ37]2;5CYXK9D.?!+*JG^CD5>MD66?TQF^O,??ZGJ9MN
M3D_P"&])(1TI=EF<DYSEO,F1_PO[W$['0\*[ Z51B7[3;4'!Q89&KG/YAO[R
M2;#Z=E4V8MUN?;?Z&-]GLKAHKM=[?UNQD/?Z_L_P!*DEPCAX>E<+'PCAX>E<
M+_ /_1]5226';]7^HOZY9U-G6\RJBRDU##:*BQCMS7[ZO5JMHV[6[??C?:O^
M[?I_HDE.WM;N#H&X @'O!Y_P"I3K,_9&;_ .7.;_FXG_O"F_8V9_Y<YWW8W_
MO$DIU$EE?L7*_\N,[_ -E__>-7<+%?BTFM^1;E$N+O4O+"[7\S]#72S:W^HD
MIGCY.+DL-F+;7>P.+7/K<'C<W1S2YD^]J9V9AL=M=?6UWJ"F"]H/JEOJMHY_
MGG5GU/2^GL62/JS&-7CMRC4RK+&7774TMK:UK0QN%74ZVS9A6;=V31ZGZ7U;
MOYG?[&ROJN,G*ON?>T5Y-QL?4VH":WMQ67U%Y>?TMG[/Q_UG;[/T_L]]?I)3
MK?;L(5LL.14*[6&RMY>V',:-[[&.GWUM9[]ZBSJ73K',97E4O=:PVU-;8TEU
M8^E<P!WOJ;_I%F=1^JN/FNK].]V/7CTNHQZFM:YK1:+*\QSO4W6/\ M%-OI_
MSC/YOU%/!^KIPKWNIRG>C<0ZQNW]*7-LLNJ_7-_J_0M]/)]7U7Y/Z2[U/4R,
MCU4IT\7,P\VKUL.^O)JG;ZE+VO;(Y;OK+FIVY..ZYV.VUAO:)=4' O ]NKF?
M2_PE?^>LO(^KOK8]-#<I]7HNR';F@ C[0;'>K3M+?1R\7U?U3)]_I?I/T7Z1
M5F?5$5FIS,MS75&MTALC]&ZE^U@LLL]GZ#;77=Z]5'^#K_ $&/Z24]$JO4\%
MG4,"[#?MBX 2]I< 00]KMK7U/W-<W<Q]=M=E;_ -)78GSL%F;6VM]MU(:[=N
MHL=4XZ%NUSZBUSF>[Z*I_\W<?_ +F9_P#[&7_^E$E.?_S2RWESK.JWL>;O4W
M5_2<UOJMK=:_\ [D.KOV7/H;13Z7Z#T/T;+$1WU/QQ3FU4WFL9KL=[@6DAIQ
M'LLQVM<U]=^UU=3*[OT_JOL]3)9;5=8KG_ #=Q?^Y6=_[&9'_I9/\ \WL/_N
M1G'_T-RO\ TNDINX.*W#PL?#8XO;C5,I:]T D,:*]SM@:S\W\QJ2S^C_5K"Z
M1FYF;CW9-EF<[?8RZY]E8,-;[:WGW6;:V?I[_5R/\ A=B22G__TO3KL["Q[!
M5?D556%CK Q[VM=L8-UENUQ_FZ_P ]Z\L_QF6WV_7+"QJ<QV-3=AU$V"UU=8
M'J93O4<ZH_NL^DO0>L?5;IW6,G[1E/M:[TVU[:RT#V&UU%OOK>[?0_(M>WW>
MC9_P!J*KZUYK_C&Q,;"^M'3\1KBS%Q.E55M<XS#*W953-_YSO[*="N*-Z"Q?
MDD-4](ZM_SJMZ4S+M#O1=?MLNL:&;VPWU&ML>YC?=ZO[[*[*]ZCC=,M9;U#&
MRNLW5BC>&O-EDO90WUK6,E^S[5N]'\[T%&[JEV5EY&9;>Q^<WI[<9UK9J>U[
M+JO:7Z?:,YM3?S/YRJS_NO8Q3S<QK\^W)-C=EMMUCRP;FO;?52W-;4]_ZO9[
M[/L]M?^ R+?]%^D4PQQ%DR@-<D0?$1]*YJ9&-GT_5S'S7=2?NR&V97HBYYN
M!-%.^K=[:7^GMW^I_._OHEUF7E==PZ79[\:L=-P;GV666"L;<2BRQ]@KW?UO
MY;U6ZINMPI<:W-JQJ::_3)/]';4W:6GWMLK<6_;-_\WZG_ !:EE 'JE0)#0_
MI.!5+N"7XF-LJ_XRUS=M7YG^D33&(GC%QVCQ'2M]>)'4.A@]$RK\WJ&,.L/:
M*2\5 VVG=2U@R,BRKZ3?5QFV5-9ZCV>K^D57$Z?U&[ZJV=7=U1S!N?9Z1R'^
MJ64#T_T-6_W_I;?UAGJ?HV6T*UB]5J;U!O4+LN+Z7;GWLJWML8,5M=E==;MC
M+W>GC/IL]3T:LC]);ZJC2_%/0J,0VC=7C9=#\1H+G_ &C*L]?%KI:R/4^T4U
MUW8W_$I&,+%2C\L[\_57_H*J:O5L+JN%]7<'/OS[&MN98]@9<]SW>HX^E-3G
ML?Z.VO^=_]*5>I<ZV<S(^N/4J_M5M>/06.L:+7MAKJZ*YK8U[=[F[]_M6?];
M,^W-I;ZEM+ZL:JK&PV8\BL4M9ZK'L:\;V>HW]*_P!?]8W_ *+T_8K/U@G_ )
MW=6V_3!J+/&0S'^A_+WN9[/ST@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M'2Y/5K_Y/7DG_'_@I5__ %GH_P#U?OUJ7./_ -FK_P#XZ?\ _&0== _A7_\
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M1^$X2IQ&ZF)PHMRXW-->S5V2UJ1:UYEB'Y6O)'!#&D2':A6[W/;HL2IZ[/\
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M +\]5UWCOOFW6\4=$8Y=BYF4F]8W%_=&P\(V=;;7Y1:TM,PGP-Q[%BZ,H;G
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MVO%U[#\BXGM+,<-%CF!;0@"M[:CDV>O9Q+>5<S8L6PIY*&#D5'C5BL8L.<&
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ME9-C<$Y(LW(*2'*$J(6-*M8$<XE5J.1"!-(81BJUR.1'-15:J*GV5.CHT3\
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M,<CD61W:Y"*ODB_='=NZ)WZC!E*L58%64E64C1!!T00?((/@@_!Z;?.R"3\
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M/\QQ:NIMB(.1EJ1)0H<FNCADO@6-%9(BU\P1O*3"AGCA&]S&KJ7J#ELIR'D
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MOR#L:V-#JZU)R*ON&>K/35PRVJX]GAP<!7)-A3+&3/?;7\#,)E&/(+%8#9\
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MKR/K"D]R,5Y!!.[F>_6DQ&=R,=B)F6GG)%F#;E17%C;+O2^^(FVP!51.L8#
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M8![ME8EW\M/11SVP2=P9C_VR*_<Q!/P=%3KQXT=GIE7JDZ#T-2\)^,NZ>/\
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M')NV>>I4G[E"LPDU(H#>>Y22P9E!V"5[AX'ZMGX/5?;/%=>XUMJSJRYU66F
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M'<G<"4;>P>TCXV1L;ZCR5L2NQ/'JN#9X-;2^0NN\CGTD+.+A&3:NMJJRQE%
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M!WJ D*P/T7B^Y[R"&Q$XRZH\B.*KT:B-;0K]U5BHB)W7NO;MW_>@!)T!LMX
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M8T,L*TSZM8:2&6-''>("3H[Y;RN<K0B.ODY6"]Q>:^7EYN7\I"*TS_\ ,.:
M" R-(5OV#M.U1W+V_P .E!*^=#X&.W!_U4L4:Z[GTJC9(T2#X \ !?CIL=1Z
M6O(7#,TP_64?1>P*''9_PDNLBF5SLAC->2 LK);^7.JRGA_3IJ1II:0JGC0)
M,0+0,*TP);8_2G#>2<1XYZ:6J\>1IV;8HVK%JBE@136;=N,@UA^9C5S(C2)
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M+_=6"8_;]QP%G0+MNY03ACQEZO49[TYE>*0J)7)9I 69M=Y/<Q76@6&P#V_
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MADE7IK->F?I[QGCC6<S/E+"61$\]Y9=O&[01?KKH \,??,@=%D+M(9#$K-M
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MV"&DEF,C'?9I44%4&P"2=D[!*CX!V#UC/,;<&69WK[46I+RG<3(JFM:F,_$
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M=HK-'(6DK@JXT-D D*3X\?4'7<?*C7U/J7^GRO?@?PQ_Z+.A?^[5^,)URL/
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MS39!H)KTU>2O8K008Y/:KB0O-.TKA.V);WI+C<CR:7-W9GDQ$Q2PN,[==]Q
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M/Q2"JGJT9VJHBHFH=0JB*OV7M2RU5.R?=47LB+]T^W?I&#H@ZV =Z.]'R-[
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MD>:<BBX]QSA64YKRMJ64RPQF'AE>XF+PU>6UDK5IXY(B:M9-DI*SJ['M"ER
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MVDRRM8OT\\_)<@D_(M",@L/(&*-%&*-$BO5Y#.&QZ/(1$:]W%7JWZEWO6#U
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M_'B'J7_Z?D_V_P"O]O\ [OO'0!/@#9V /'W\:_J?_G[TC^#X_K]/Y?[WK?\
MC*'#DNO>.W$/1,['+"UV)'R:TSB3O2IQ6B)83(5EE^/UT&PP[(:QI1E+ ;C%
MN_L=Q1F5(S2!48EF>S+G"^'YO&YR6OE(:V-MV:=*]1%^9(66)9I'KVZE@,VK
M"6(5C:,*\9$I20K)[(?9<?%[<;[]MMHC ,%?3=Y)(\C15P%==[UX/G0ZL#^)
M:TQIS67$_@;0:5P:NPC$; ]M?U=35U\6&8WYDIZ4MA9VTN*$8IEY9FMH#9<F
M0OOE2*)CO$4)@QQYR&UELGF<CD,K:>W8BF_)S322AB#$\RQQ1([L_LHJ,5"
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M 'E#D0/BD"L*0AR^_%4)O)4?W5>\@E8R!(T[M$K&@C0$  Z1?"[(VP  !)T
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MNDW <D?%>G?+,'%+.N1S-Z@E6&*&Q[BUE9#D)&D5#&BO%"(-=XD/>XT  >E
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M(^H/U&@2WWW]P!X\C2CQ9;EKW_?)\D\%E2QKY75HG9R%CKV1?E)XKX]_LO\
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M0IVV4*9R7[G_ (@J^?TZ4$$>=?)/T^?C>_"MP?RZD:79\GS^L$#?@GY^X/P
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MO((( 6FE,DCDJI5EW$I2)$\",D]K[[7(.NEDI':V]DE1Y+$DG0/_ -H&@/\
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M1/>W]5%,:J-5K53R[*J(OV5'=ONB)WZRQ/V,"#H$,KDCN\%6'Z0!L,1L*?\
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MG=!?AO\ O2::)I$,6XCQI\K(2*PB"5',E$/4,<B(U8\$)&.<BH]WI9PG@\/
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M3.M=Y9AE$NQ;(GM-+R<PQM"CEE9-\@)PF8C/%K0-FO>C6M:]OO1G*_R7N_T
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MQ!<^Q^7QYQL%&KQ^O@8W!!LX2ACDQU>W&^RLL5C\NELE /9DN- X!5=^K?\
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M\7YQSBOE;-86>,T)9DK\@Q<TL4587Y9K]6Y2Q_Y.N'03Q?F2JQ-8?J>G^/\
MY'FOPUY;(9_%R5_53E65Y)POC5[CM*#'08B&;"4\C2Y/GJ.0O.V.DQ]7)O#[
M=$VVLWZ2R15X%=_;^7ILRW3/40X=23E24>=R*UU+DD?Y/,<QLDB'<?Q:J(Y7
MO+[I'.14:CFO[?=O7I)SXUH>$9FI6CACK0X.S'7KPKVI!!%56.".&)"%6**/
MM4+HK&BKH#0Z\SGKQUJLB)LZK]G<S,SG0\,S-MG9@26=R6))+$D[-=?7I?2#
M]9/EX_(P6,FC9G^*OLP5)0 L3Q&Z^Q1Q Q#R6O"$I>R,0KV/0;7.>C'N:C5X
M/&P00 2#O1WHZ._.M'6OG1&OH>FA"NT[@2!K>OGXV1O8(V/\1O75)].;!#EN
M4SJNPIP46N<2P[)<IL0Q)<RQMZ^JQR"^6$3;>X/(=)F6,TD.EBH0"!;(G1D%
M&:QG@LR\4]:^1<;K5\=9BK9#'5H)(:Z2";\TKG9K@V'F<O#$WZ>QEV(R0'70
M(4,E.X52Y61HXT8ADV)=@?IV[%NX'^$@_?>QKKNL=D/S;&I.W[7)H.%XM@.0
M6<29C#'O/:Y/!E08A*VLKQN48+*U.<C(DLY6CBP1D2Q9':HE85-D?6GEU[-8
MK,"6M5_LTS]F-JB;\G.DS#O2[&\_?.KQ@1J_=_=%1)&J.VV!!5:N(Q#%'7[B
M)8E7N:70_26)\]PV=-K]).P =;[N/N2UL-$6N0R9]FL''-A0**CP0]E-E4#+
MC(JFSLW7P N(V.Q05U*2/8>V(4@AR1_;<@SO\-]?\0BG'R6H^.P1\BD)KK*3
MNH:JR]\:R3#MM-VQL2(@>QI@S@HNE+76X[@*]B;*)2/Y^0K &9(_,4;&2-)9
M@HE=4WL(=@GX_:&X\A+2]+MT.65M37A:"OF5%NUYK.-+,-&OQZ'7P>QK.&2,
MA)<:R&D5JC&59+!R!D1=!I<]MGET?.[>;K5KTB2P28I*ENP5JQK'&N/9 R**
MD\99DMK.[).@:2(.0.G>:I5LJQ9HXXB ?8*$F-P? 70\D:[U<'7T(7SJ?,$R
M'&\VC9[.C7!*2CP+#?SAD,ZQ%(&*9&991*H%; C1F'*>PEV]A5Q((I"A$4TM
M'O*%H".ZFEOQ$<65)O\ ]795I4AC:N/:A46;# B2(;F)A2(Z/NR#]2$E4)7M
M9H/'<8\@<V)@D:*Q!B3N9B"&$;'^#Z DD'3>!\]8Y@&5XQFV30;(]_&Q^OJJ
M]T*ZQBY1L.1)CVLR-%)>T-JTQ(5G+J9)($DU/*#!DGKQ3DB/(1SD2,\QZ\9F
M;/XO+8JF(ZM6G)7FQ5H]R226)()+)$\+_K=A L5>;V5,*,VX7+L>G:*OCXE$
M4=56B:,+-'* &?S\K(K']2_.RORQ/:=@"2]LQ:S <ZU)KZ(0GUC8%973<B6]
M"R #%)4[);3%_A!EP95@*T LNI/*!8M: 981 %=&:XJH/9*_XD9'EJ^_QL0P
MK.@R#+=-AUA\>Y^5B,%?NE79T)75?^WZ["2QB<4_9"L,L!)'?(&#-&-A=("
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M/:MM))VLT]IPRZ13TZVO4"IEL9QW!P2XY:_'Z^4]N.*Z)&MW<QD7NWLE,O<
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M5<6>580/C*M::..^U),C4NV[3=EBY-6I02QV66+WI))@ %'75'XCO^'IR/T
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M#'QS*YBG)C<C%-+F^.YO(5H(,HKWK$L\ML9'%FEJ<3S1M3]F&)U6,Q1I?4/
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MWS))7'7Y;FH]$1O;!(K)8"L._N(*%B=^3\C7@ $'9^=?O\W2'OA[E.@J[95
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M+1O!"9\)<YC@4SF/MR3$)(E2K[N:Q:'ND&5HQ5X0!=F#8ZJ]U5?YJJ_]O6K
M: 'V&NNO@- #>] #?WT/G^O4&;QQ2&4--F("R1S+:<#'K6,82K#,^KB1B1YL
M64,C'^X^ UL6P 56)'5(<@3R,.08?2K\'WJ)?Y+Q',>FUVB@BX57KW<;E8I'
M(EQ^9R%U_P"SKD "F*2O.EHU["3%):[%7CC:OW2^#7XX_1VIZ8^M4W)L7D:T
MV+]75S'*SAE1H[N&S56S17/2N%7V9,=EK=Y;M>78F%R3(),.Q(G:^/XCS7EU
MM'U2N-6$T,(DV59\9M-.,-C%>P,"+>9(:9(.J(O@ 8FHA'JG9OFG?]^RQS<9
M4EL$D=HEE&_V[V'CKAV%2TG:/@,#]AH'SY^WP.MT[TX,4'KSBAKVD;'9(D8]
M$'2D<-6H7V8[ @>A6E<WV&@]I)*M_3Y1WJ1$<O9$0U#N-G(&VD.R-;\Z_P!/
MD[\Z\^>K;)W,3\  :'\P=?T/G7CSL:T.M&W\1K=-V#ZG&K-91;&1?2::MJ8L
MJN1A75X2YEGLT@0PPJ5[5:6NC10&4;6(\482N17HYRD/Z188G8[V.Q\:"C6O
MKXWKSY^.LJ@$0CS\>0/KY(^1Y\Z/\O'D#XWN.(>/&K.-5=5F&.<:3C,BO?WC
ML8XK!52P0QFL&T*-:IV."C$1J*YJ^*,^W5E4;@D^I/=_/X/^/U^_6*<_WV_@
M @'Q_G\;^=$_Y_'7G*>OQ@4O".;%0^P"L:QR'3N*W<J.G=/;4TVZ8Q'(YK5:
M5.SAF:O=6O&J?LB*MU/?M$'?AOZ>0#_L???[GI1*0Y4CSI2/\"?(^GU/U)\_
MOKIYGX6W "SM1667SZ\!X47>TVKK22%>C6OLL*:LZ4J(Y/<<R375\8*,^Z(,
MW?L[[K9,H:U&?D#0(UX\]Q^^_)'G7U&B=]6N>V KO7<"P\@_!'SO^OG7CYV0
M#TPW\03IBYSWA3MJ%)44B?A.+Q\SIYKA$<68*FN(A4JH?MC>Z4<D0ZF[&5"1
M&A*QCE$UOE0]T=F/N('C1)V-@G0'[G9^/D?;75("&1P-_J7X 'R 6&_L/&O'
M^.^OM^'2RR5MKT\,+Q_(EFSV8H%V$Q2R!.\64N,V$Z#$A (]W@V-!,**UCVH
MU$4I5?W:B.2[LW-.I!\]K??0(V3^WG[??[]6S;41$ ?PD$$_4?R^NMZ_P_?I
M#GXE_6UH#-L7S@6/S:W&JFV?3U,F<Q/,T.PHW]GCDC;[1_</%9[K4<KQ.*/]
MT<J]4K%5EE0 @'RN_J!Y^/V_;?G]M$YG\P ^&*D]VMC6PW]0-@>=>?']-YWT
M^4[<#^&*?_)9T)_X7XQ_>O2_I"WR?YG_ %ZM_P!'5.CHZ.CHZ.O-<Y 1IA?4
MBYB$CQ&$CNW-NJMEV;B@:^A2VS*RCCM!QW%27*:OME@RDKPGDQX4R3(4?B-4
M6>?7V&.U^&:M3;*RXR>:AQ^S5BCJW[,>9DQ< R;X6Q)1KV%IQWHJS^U9O>S1
M-J*O!//&)M]2[Z$YFK@/7/THS-O"T^1U\%GH,U9P]_*8/#1R5HH9J;7ZMSD=
MNCB)LAAIKL&7HT);<5BW9I11UNV74L>!O:K'.:[[*QRM=_<J+V7[_P"E.O*5
M2&"L-Z8 C[Z(V/'WZ^F^&:*S%'/!(DT,R+)%+$RR1R(PVKHZ$JRD'8*D@CX/
M7,'F-1D018-6C.ZUPFKMLEMYQ),?Z=\2QG112@*\B!;#)7C95D8%YBNEEGRD
M&QA1>V27W]!^8U_32AZJP4LI<ASF=.+;!08^Y/<AQRP(F,S=>K#$\SU[=E+L
M-N=8B@@7'3EQ CN//*M^+'TUX?\ C ]1^%\FSO$<;QKDG&>$8?%\Y2Y42JO+
M.-5<M;L\=S&6B[X)#)'G;4-=I[*0XVYCI*3D372L?XAPY,^0V+$$I3/88B,\
MFL1!QHYI<DCG$<UK61XL<\D[E5$$ )3/[#&]R197Q]^YW"G1NW"DU6NXJU9[
M!2>]9CI4XG]I'[)+5R:*K75^TRV)$B3;L >TN<^JOIOZ:8ROF.>\WXUQ3'W5
MD>A/F<K4JG("*%K##'0M(9[S>TO<JU8Y2Y:-$[I)8U>/)>QX<*'"GY!DE5,H
M;*7*BX8* =ME<0:R%*/%LFV\2(-TVN@NM6%G50;". [HTXI(Z2!/:@NP<_\
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M;<,DTDFWQC$;*3\*3.;-CL/"-:#(>>Q21V^#""1X^_FU%00_EY Q&W[F.CL
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M2VE7T*-[=161Z:CCRBP/E/&Q9,Z4VSKRO9'5XQB+YD>U2-8ZRMW/(9" %"D
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MV[S5L5C6+8S%U'L32-5Q51V[ZV/B*UHM?IB VIBU/24]1A51$XC;<;]T3O\
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M95GDK21RZ=)-Z;P1TZXVQ&V,QID05IA3KF6)M1M'+[2>ZI0 !6[NX,&'=L_
M.]MA_$&<"N?.]^;>H=L<7>/6W,[IJ'C#K_$I&6834H<59>A)DT>YHY!GF&X<
MP<"R0,R.07V')[*G=>Z<@R]KO(?D,[,-_8L2/Z_'QTD1NTL0VCLZ/U\^-[^3
M\_T^?KTEC=_I >I_D&:PP5'"C>-CC^,83@^'4AHF.L=%;&HL5K 2O85TM45O
MUHEF8J-:U"&>5R*GEY=8ZY50WO1L_<LN@'*ZD?8C<DH_<J'19/'</T]ZD[7,
M[IW_ ,2L H4'?CP/DZ\'SO>OD>.L,7TD?5Y*^@*7AYR'=*Q5OMX[/?1(MA4
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g129231g91e20.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g91e20.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %* 0T# 1$  A$! Q$!_\0
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M  (1 Q$ /P#[</(3J%MHX_.*3S4:%(ZEVB^LT&FDV,<LZ K8PL%-6VWW:8C
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M5[MM?=X@:GC?Z*EG7MO<"=!PM]5/F%8DXNOQ0]DFF)N7CH@-J=L*(YJ$&EI
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MY;<A*=^>/BH,:GV.<W>T$\!XJ!^R59<CH<T&Q69YT93+]5%?=E&!Y6.,)#;
MD6B%18FUN UO:V9S2X!=?C8 :WR%_;<*V^-?)IRG]>\: >@P"]VWF_@:'7U%
M&-+-359\B[UP,^"'D=Z<%3*1D/MR 6ZPZIY<>R8VPXH(I[Y9)%C8ZNOY6^%T
M:""+\&^S,_)::F8,&"CO)CCG9.[=SHSE^ZIVF39Y%3.6<VLSG7:7U>?DYBN%
M\SEI3C=IM%CD9:#EPZR2D*Y;.IU@B'A%O5J/CH]YAGD0 <AF;Y6&=\["WOZJ
M,A<$FY)RL,^1&1U\<BMJ=HFZ]RBW=(L_/.M]*Y/V*1K%8-EN:WGF9/0.=^0\
MO!42+BZVW%Q*(,@V8LD@"!'4&P'\QN4=("G1BT2402@=@HZ!G:X!&>?$#K\1
M?R2]M"0;#4?F/AKT.:H.I7(6E3=VZ+7NAWW@OD#;*13+)<N+6;FQW1.5]KMX
MG/(<>.@ZY&NP#DI.3#:1A>:2TCS>W14LP_"ZU+0K^V6B39 OP!&8OH1GQ^.?
M/R4DVXD.-C:UP3;AXZ7NLXOE=Z-TZ]]I#$@2JO?>B?3DA:^(#MQ:1H/H=FF^
MM-[KR9=>FQ_NHF7E&1G'OF0XTWILM7L0I*\#(#/1_P .*9D]2SWKTZZ!4NS;
M\0.?\NBID>X<TZ)2;C>( BKSL&5Q6LT7GUF@[3"W!R0C0V*^>:]),T".AE.[
M=G%2CA$:T7$#/FHBUMZ_$99C.]K$<^=_FE[[H' B^1%K Y=.5EBDQ!R?]Q3R
M6 ;AS_R1_>?(@UD)$>1]\:@CRIL9(9;8R6?N"4/ )8(&(2A>G!$LNM+4SI"L
MEOYQX#_]5!_*[EO&WA<:+IM903Y.N3\;%%_CY21A)4&-/]RD?9'E@OCAE^Y&
MMK3]L0XV][D:VK7L]4ZWO6LHKD7!',67+:&L\+;/'SQA\9JO!S49W>A7#QLC
M[335UJ9#DN5%\4N%0FNEW2>.=CVHT*">B:K8F86P[.V+=566.:AGY)R9VG=[
M9EU\C>QOK>]AS_HJ@@AHX@C*VECFM@&PQ_\ =W^IB.F*,^[F[?Y,+CV- O?<
MRZ">%5D4)8;>FOE/20\A0PJF$NZ=<2IEK:E)VG0ZL\&_%!H_Q=\%/>@H6W1:
M6VZE:'$5*N(<0XG:5H6F'#2M*TJUI25I5K>E)5K6];UO6]>NLJ=3XGXJPT'@
M%'&T@FK\Y.-R* REQ['C;W(1\Y([J@V2B.@<7='&=)TC;#9#[0[[C+*UZ<=0
MRZM"5);7M+@?$?!R<1X'XA2OD FI$ V/?VI+)XA(3VT;]%Z:*96PYM&_3?HK
M2%[VG?IOTWZ;],A3JN<7"O(6K^/'"ZWPSJ,7;0NU\8@7>> \ZC*9:I*8Z@JL
M*(BZ9+\U>CH<R/LT5>8QB)(%D!"]CPY9A0T\N.T 0[JY;<DC0YWN,KZW\%0.
M %CJ.&?EGG]]%C%U*O\ 5NZQ?4NQ]1N/C4QT?QRY=!OV"@UFB7BEPW0*K/7>
M;NO,IBPWSFO1$0K[3EOCI*LE#_@!;=L69:6]*EQ,<P,X$ 7L2;9WMD ;"U^O
M).(N;7&N6H.F=^?/-7ZL56*AH3P<'ICG2IVLH\J.L6IN=Z-60ZU9#Q;7SGR5
MG"[*37HB$KP==K,Y-3SAE5'=K]>UJ$DH=.XL)1+3&X-_6OK8>XM\4RNRVGK?
M?TZ*17  RQNM>9+Y(I([)_?*P2"\^PZTT8,CQWXD*L@1QQ*4$,))'?'4ZSM;
M:7V'F=JTXTM*8.C?#YE6&KO'Y!2GR%*81,(F$3")A$PB81,(F$3")A$PB81,
M(F$6NZ-S6%H$QTZ;B3)0HGJU_P!]%GFY%T1Q@&9W3:?2/M(A(P8KC,9^+I48
M3\1KAQ7WY)[GW?V[@XPSET^I/S46S)YV]RV)A2F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PBUOU^TSU'YG=;I6VH@B3J-<E[-H:<9
M->!+%@@"),L/: "@R$OEL"K&'?\ GTV,ZZDAUHA#6QW9&9 YY*#EGRS*TIVO
MR&DN7WC]F!TP#;8]6J5B!#DHBP2K]Q/LUQEJH[7W;)#FC0')& 70XC8=NZ P
M5!39,^^V$VVS59]YN0+_ 'IUMQXY#/+JGT/R^]#]?RP^0EAJ,.=T:9AX4OG>
M[1VFI!0L<V>S;Q'^-PW4)-Z<,F7SWHB0%M+W)9L46&'@HY^%1.0I!$M([%D6
M=+<!K8'VVR]_-+BU^&?N^_%7.1ZMTNO6Z$Y9-BTA^^7=57<JLW&@SK=6B42@
M%^F;4+,Q)$T[*3+E2B.>2)$8<+,5]%R+E0 U@U-(Q1*UAKG;/QRMTZCWJ+G(
M&USID>&O'3DJ4'L72+$?8JG7HRELW#G,;;I"Z/2K$TY!3S\'8#8:K1M<:&DV
M"Z^BZ QQDO(2LB59?V'<^"*_%7';BY%N+#7.W#Y^-O*_"RG/+W\LK?'[NI&5
M2PAVZKUNUQ[;S0%G@(>P@M$:TE]L.:CAI(9M]*=[3IY#)*$N:3O>M+TK6M[U
M^N0<B1R4C, \U=!7%K69I:MJTV6IM'K_ /51IEA6DZ_\GN4K?_GWO"*KPB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(L.O],%
MZ%3Y^E2$M,0T998TJ'EBH)44B1=BCV7!9$%IV8BID5ALX1UT5Y]L/1C+;FW
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M#CXX0<$$,=&FV!0Q&4#C#,-I_P +;+##:&FT:_1*$)3K]-9"E> 7\9_\\O\
MIQL(J[")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+
M2-L[#+1ECD:A1.2=&Z?.POVJ9PN'8K]4I\(\:$/)#"DW*_SE8BY@U8)@C[P5
M-1:BX_[EE$JS'K4K29MQN!]\A<^U03P )^'M.2\JCU^6E;''5"\\DZ-S"?F$
ME_@R9H>OVFH3;H(1$D4*)<Z!.6B)B36P!"B&@+CJJG'I&?U%#2&V]^HCD0?<
M?8?E= 3Q%KZ<0MV9"E,(F$3")A$PBH0OXS_YY?\ 3C815V$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6CN_*8_9"*:2)V4Z9(LX;
M58$X9,?A+F]/IB)M]G1)9TQ"5)< B/9D79!B_E.4Q3Z 79 9T]F,4B0+\AX_
M?P4'3CY:K1E&G/,JF-ERW0XZF76HM&12HNE%GC2'D0Y77I,"-G)B4E.=5F!Y
M7(2<$P>W(Z@("LNAG)94,]<0G2F76Y.[POXZ"_GGYDY'HJW<. /3^+EP%NNB
MG)E5=,(F$3")A$PBH0OXS_YY?].-A%781,(F$7R0V+ZS?FW ?5<7XYGU^L1G
M&F?)R/X CD,C4HX29+JLI>Q:3&7C5S)2W8DV.9BC!+I%$(E?V.?9-#0U&$Q+
MB2WOTA!V7;*3=G0QQDU1)BAP!^,G$V5+W1-J(Z1U7)2>BMO"8(I&NI9 8O2@
M6.)>V0%HWQFSN&OP/TL/D=4&C-7Z0'DM#VQ&0Q=V#N;C7 QN%N\N#ZP=DOK>
MS\WK0TPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB810H\@:/%6:T5
M^]&V/RBC-\VOP;28#D\/9),.0+DN6VZ*3,U8"+C"'1QFQ+HZ%-7,))XB#!I"
MH$-,DR#KXMFGAZN?$\,]#[-/-4<./K:Z#PU'U\0KQP>'J9-].LK#?E!(66-J
M,E!@R_?XFX@14?!34S 'S,=77)Z*BXY4A*R$! $FH;2^:L:(:4VIMAM_2SM/
MX?\ P_/WHW71U[:N^"V?Y)FL1?">IRSL\?6BH>DV.6B)B,LTG5#19V.B3"X;
MX92)DHLIQ2Y%H=.HY9#@LEOT$*%*9<4PN!J/$*SM#X%:1[#T64B>F3<H^8 ?
M2:5R^@WRKP0O5[/1Y2]'S5GN;4XS38RI:9$Z!-FC0M6C(:+G#CHW<D;$08X(
MS5]+E&Y R\203:]A8<]/'QY!0>.NG.USR%N)M]-2L,M=TML9%2E@IEKL$GVU
MSH'E#"GTO5EEIEMBMTZK=N,YXQOFA$B3!PP(+E>Y";#S8E=CRIEZ8B7'9 G=
M_,W,AUM;+/Q(OGEURX6/)#?47OG\#;+,<CU\397&2L,.%=Z]6:CTZR2_%)S^
MRAWH5K7U*S3:H9Z<"ZP]!+9Z 1829BNKZ%8(3GT1.A1LU&C.C%1R6A E6HIV
M4G/B!?.V7APMG87Y^Y..1/"^>G+7B="->.1UH [.$>3:8ZY=/M,)SFN5SKQW
M*+4STBQPI=@W WDZ.DI)RRC3HQ]W?Y\RS$1%>U-&S;9D<9LTQJ7>*V:MGR%[
MBXL.5QEUSO;EP2X''+,CUCG;K;RMGY\)S48R>D:33I"TC;#LYU6KQEC$VU\&
MQ9XJ)$?EQML:UK3.V)!9#6VM:U\?M]GIKTRIU-M+FRD:#P\%>POXS_YY?].-
MD*5781,(F$4#//GP+Y?YO\4MU,DXF!K76TBBS'+^PCQ(S%KIUWKJ2'ZP\_/A
MCZFR*TZ^\]&3D2DAQ"HH\HF/:8F!8PT3;]CMK\0V3Q6FJHY)I\-WG18AAAD<
M::JI)R!4-$+B8A. !)%(6@B1C0\F)TC'93"\4GPVICD:Y[Z>Y;/3EQ[N2-V3
MQN$[H>!FUUOS  DM+@=)?2R\T;AWNDW#QU\C6'JWYF>+!_[!=GK\LIMJ3M\;
M&/?C(7J "=;^*28F4-LC6(^-4_'NS#@L\+L>&MU>:<RW:#LM2X/5TN-X&1/L
MOM"STS"IH[F.FDD'>2X>_C&Z(DNA8^SQ$'0NWI::<CZ<<PZ.EECJZ.S\.KAW
MM,]N;8W$;SX#_*6W)8UV8;=ANZ-]NL&<Z6"3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3"+1_<2NB1H%"FZ# 6FW"0'01)B\U*DRU>AK39:J+5K8F/
MC(XNSS->B7 TWYVDG6$%V9!</K0<N-K[YI;T4?(MGX97\O'A=0;Y6OKG;S^=
MEJ[@_.NL4VZ1<I=9.VR!5BY.N?[$;-7>1L]2D>RV:U"R0$/SZ#/FCQJQ&\[B
M!K57BM0$-7863@).CI2W)%1KRH\;9^.7A^N7OYYP ;B]],\^-[Z?>62EP6&(
M>RH8X48P=>TJ4P6PT0RI2-Z4C:FGDK1O:5:TI.]IWM.]:WKTWK(5EZU1L<O8
M.UQX2]QF];C=J%85N/WIKX-;!WMO?VF],_\ !UL?X_1K_A_P?IA%YI""06Z>
M@05!S[38[YJ1VDEO,-;VIIETG2-/.--*4I3;:U[0C:M[2G6][PB]2(J+0,4$
MB- 0&<LAPT1 8Z1C'"__ )4X4QIO31"R?_O"WD+4]_\ :;5A%^N1D:\T&.['
M@NL1[C#P#+@@ZV@7A4^P9T-M3>T#.#I_PL+92A3*?\+>TZ_3"*NPBH0OXS_Y
MY?\ 3C815V$3")A$PBX=?5(\=^D<GO5+^J3XF1FU]V\>@TM=PI0276A.W\$&
M;^.PAS8PB%JD)"KPNB$%$*9</_95")$,C4K1*J-G6>S_ !NAQ&CJNS[:.2V#
MXT^^$U;MTNPG&'&\#X7/([ME1+NEK00STDECF]U65+CLN"5<,\4F"5[O[K5G
M^[2G,TU4?R%M] ]]K"X;WA(/JRR%=4/&GR(YOY6<2H/>.52?Y"H7R&;/:'>4
MU^3@)9E2A9VK3S#2UI%G:Y+-%14FRE2V5OC?<AND@$"E/<]QW!*[9W%JS!\1
MCW*FCE+"X7[N:,C>AJ(7$#>AGC+9(S8$!VZX->US1A*RDFH:F6EG;NR1.M<?
ME>TYM>PG5CVV<TZYV(!! WKF(7RIA$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3"*-'D_39NY5FAMQG/U=7B8'I4?.7+F[T_!5V(M54U4[C#DHFRK%*Q44
M8)!2LQ#VD"+*4:P=/0<.A\5EA+LK&2..=LLC]Z>(57"]LKV-[:<"K1X_TRM5
MNPS)D'XL0_!G2H%E*['&S/,I-<X(^<PZQ%J;H\Y*')'=4PHYI\MIL%S82DH=
M4]I"=C?^:_M^80:_E \+?)2NR%9,(F$3")A$PBH0OXS_ .>7_3C815V$3")A
M$PB\'&VWFW&7FT.M.H6VZTXA*VW&UIVE;;B%:VE:%IWM*T*UM*D[WK>MZWO6
M2"0002""""#8@C,$$9@@Z%--%\Y@NW_HQ>;_ -@YMR/^F]YO6_:PG%;4F \;
M>]%HUK;"E;_YI$52290AOW+^S2[26V7-N&*Y42J2[<ZW:CLGOY/VYV4IK. M
MWV.X.TWN!^:6IC))RWB*HD -_$6B/;C;:+#;ZXQAL=C8>O64H][I&FYRN1)<
M #OQ;Z-$+0XE*T*2M"TI6A:%:4E:%:UM*DJUO>E)5K>MI5K>];UO6];],X@0
M02"+$9$'4'D5J*\L(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB811P\E*F
MJX0G.XU4-6;P"+TH:3D^0VJ<CX2/[("%1[RM=,&3+H=AIN3A7E,],#KTTP["
MR7[ .[E'(\1AR7CI''.V6O+,?T\U5U\K9YZ'C]ZK3WBW0[O4Y?FC%^J<#RR:
MIGC;$<I354VVN3ELZ/JHR-1T7;C(^L$FQ@]2YX2Y^)J[R9.2.:=Z5+HDAH'1
M0+$E+K9V-[F^AROP\_#@C;W%Q:PMKF=,_+W7ZJ9]IM=<I4*78[7+AP<(#I.R
MY$Y:D#L:5OTUM7L2M>]:UZK5[4*]C2''5^UIM:TU5E^S]KK55_"ZL<W&PN['
M/QM5@4R!+8ZI>QRZG4QD+'I7O2B9 W;+VV!V]*6I+3B_32$*5HEU9V.E4,BP
MFU5JTQ.YT#9Z"@U/[;;2_%#MERX31[J$1Q,C#B.MES$:,6\?$BK21(C#,[]^
M38\BBM@G8^8G0\A.B7*)>C(QR';)=ULE+Z]V-[8]9<! 6.F0E&+01I3%6)C!
M3![*\A;4&[(+0M*5CR^_TX\N*BX]B'=CYA&Q43-FW6%8BIIF7)!+V\XXG0==
M*; LIQ[;32WHF/JY[K<?:9"6;""K)[B IU^/*4EK<6^B7 U6RDJ2I*5)5I25
M:TI*D[UM*D[UZZ4G>O76];UO6];UOTWK]=84JB"_C/\ YY?].-A%781,(F$3
M")A%H+R?\;^;^6G#;]P7JD?]Y5KS$+$0>PVTJ5K,Z-O1-?ML \ZE21IRN2K8
MTD"M6ML$;9<CSVB8TPT5_,X!CE=LYB]'C&'/W:BCE#BQQ/=U$+O5FII@""Z&
M>,NC>!9S;A["V1K'-^JBK)J"IBJH#9\3KV/Y7M.3XW\VO;=IXB]P0X CE_\
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MNE"-:*6(^ZD9]QQ:!WMH=4P^E.VE0#8@\E8Y@CFL0G.86>9N=;NCEY =*K<
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MECYX\V^KER:'D'_'OLQ\'PWZAM&@!G71TQ\V2%'57L[,4,E36Y9IP2/VX7I
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M<R1ZJ%:M=*BR>;"<513==$FKJ'6;:4J+B3+Z 55HV/\ V2:M4A8C9<Z"CEP
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M2,^VME]EQ;3J%(4I.[QR/B>R6-[HY(WMDCD8XM>Q["',>QS2'-<UP#FN!!!
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M'0[9SB'CVHX-T)0XC,@\TV[(,LMH:.=;0X6AY:$JTN>9]JBPRZ:??WPY+/\
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MZV4@_IF>=-5^H3XET+O$4T+#7IA+E([71V=K0]1.O5H<5JUPJA7UK)&BY+9
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MPBD'U2ZPFG=I2F9JE@&CYH-"EH8-^U<C3M.QQIC#N2PC$ZC!\1I<1I3^]II
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M,]$H7!%N!&>MK#ROG[_TEI/$@],KCV??SG3E59,(F$3")A$PBH0OXS_YY?\
M3C815V$3")A%Q&F_KK>+]=\USO#V8K%MCQ(F\$<UF>S''1(=/BKD(6J--2;'
M$[;(8JP,BAQHVT/2+;+ C3T@H'8Z/174(^RK'I=EV[2QSTSR^E%;'AK6R.J9
M*5PWVEKV@M,SF$%L :7%Q#-ZYN,.-I=G';6Q[!-KZM^UDM-'41TC,.<_#G32
MX<,6BPT8BVH,IQ22@<V1D+:!U(9G-HS7"J)B'7J4A^:=FJ:6)!BJ]$I\HC;@
MQ(Y $[%N[VG:=%QDJ \\E@E"5;^(Z.+:)9]?5I]&]^N<Y8^LP^>[3/25##9S
M7-=&\<=U['@7'-KVD'B%EJRA:\/I:ZE-Q^>&HC<Q[#SW7AKV.Y.&ZX<"HFE>
M/O8N%$D3GC+=')BM?,LLSC=]*V;$O:4K;CK4!)ONCMC/NJWK2=N$0QJD-IV7
M.R&]:87FABE!B+1'B],(YK -KZ4;L@X RL )( URD;GZL3-5KCL+K\-)DP>H
M,D-RYV'U)WF'B1$\D $GK&_+UI7WLL]YSY<4RPR^J3TR+D.-=(84A@FNW/2P
MHTPA6_8A43.E-"#K02KTV*W(-@K)^1"(]<BGT>5\U7@=1$STBC>ROI#<B6"S
MGM'^O&"XY9@EA<!8EP;HOJI,<IY7^CU;'T%6" 8JB[6.)_DD(:+'AOAM[C=+
M]5+/6];UK>MZWK>M;UO6_76];_76];U^F];U^NMZ_?F$6;4;^]^*'%?(P'VW
M^L(9LH[*6XB^UY3</=8=37ZC[8F&F7-'CC*]5,QTT/)QK2U*=:$;?VEY.[[(
M]H6U&Q4M\'KRZA>XNJ<(K0ZIPNI#LG[],YS>Z>\9.FIGP3N #72%OJGC7:KV
M"]FO;#2@;68&V/&H6!N'[58.YF';2X>YF<1BQ&.-WI4,)NZ.CQ**MHF.)D93
MLEM((>_DO-'PP_PS3)OEUX_@:_\ G8-+S78*9%-:_B,:4H\V7%!8TMQQQ]5A
M$4P.GY9:JB[2RCI/<=F':=G2NB[.-L)O_EY2UVS6)U#N$;@(HJ:25]FM#!1O
M#GG=IZ^2[C^>/3?VD?V;A;$HJG]H+LFI,A7TXDC[1-G*!I_-4QN-74XC!2Q;
MSGNE=BT!BA;OU^!4]HVS4X7Y.\8\BHG\AS.W"G20["7Y:HR>DQ=P@O7>DKU)
MP3[BGU,-N*TS^3CEGP[SNMMC2+RDJUKE^UFPFT^Q=3W..X;)% ]Y;38C!>HP
MVKM<@P5;!N!Y:-[N)A#4M;8OA8"%^E.R[MM[..V##S6;%;00559#$),0V?K@
MVAVBPNY#7"MPJ5YE,3'D1^FTCJO#I)+LAK)2"!O_ #3UUA,(F$3")A$PB81,
M(F$3")A$PB81,(HYWEKIL1;)>4%XKS_L=2D=A.1BXJ4A*OTF%4Q'""E 2PUW
M8W5K4*X8R06#,CVVKDA!OCP[E=,V%N9+L#_K$>VQ]FGL/R53K^4'XV\_JJF@
M;ZG(V<.0)X_1.,TQEHM,NP7,15FZ-8]K$>0#'CCTIEFI5< 214)(DR3]IN)$
M@T*Y%MP48LA$R/!\23YV'MS]P\<D /\ *&_'W*0>0K**G;_( 6@W&J4Z(M5*
MA"P['S,_H2[1)1S#[=1O/0X:D#P\0(7( N)E3@C+!9RYAO1C%;AZKK<D&VFS
M1)K4@$B]B>&7O^^O103]_+J3R^&5\6MG<KW3:P=U=XB/F()ZY^05/8H&XQD5
ML /C4#VB1A9,6<:6J6?FI@SC_P#X0LF*>CAP[$2W'@A/022).; Y<;--_&W#
MEGX]4N=?'+PO;V@=>G%7R8O73ZST"M\>,MT=+RE^W471+TBLQX;U649%]0G+
M@P-#MO.1CPI8?.6@*#N71(DQ\C,$.3Y%J;CVQR5A:_*^5_"W7CG;W)?/+/CY
M9_H!YG.RHXOH_4;1+V^D@6B&@Y?E\3=SC[.[7!2A+H?%6>0BJ<@T!XI(X$2/
M%QCO]H3,*L$XR9*:W7I*K"-;$>6 SM<&P\,@3RYY</%1GYWOPS%]/9[+C/-2
M>I5B_:^FU*V?:+ _:BLP-B^P<5[W OS<4))?:.+VE&U+&^Y^%2O:GW*1O?MU
MZ^FH(L2.1LK*\!?QG_SR_P"G&R$5=A$PB81<UKC](_P0O_D%/^2EMX[J6Z#:
M7Y&0L(2K#-"5.6GI9AT>1LA$& 4*I$X9I]U]\@8U@9PMQ9BA-DK6ZK=:;M"V
MLI,'BP.GQ,QT4 8V$]S$ZHCBC<',@;,]KCW+2  US20T;H=NY*L$&'TV.0;4
M0X5AC-J*6G92P;0^BAV)QP10"DC:'.<ZF,T=&!1,K'4SJYM&!2-J13@1C IS
MZ17'J_)DV3QK[!W;Q>LSJO>RYS^^2TG7DJUZ[1HR/DS&;(<TC?HGX%W-IA;.
MUM.-J2K6T_3%V@8C,QL.-8=A6.0@6/I=)&R;Q:]C3"TZFXIB0<P19="B[0\1
MFC;!C>'85CL %CZ921LFX7+7QM,+">8IKWL0<E:?V&^KOPC]:CU+B7E[6 _^
M&/#]!AT4.]OCH_?I!HS]=!V2XG^ J9OTVM#V_1UIYI/INYJNS[%/\8H,3V>G
M=F9*.3TNE!/$M<)7[H.K8J6*XT(.GIZ5V>8K_C%!BFSL[LS)1R^F4C3U:X3/
MW1Q;'217&A!6O.B>=L>N*U6O/GP+[/S 4;2AT7ZNQJ;Q5HXA6])=/B[BRU6E
M1C.EZTXZ-"3=B4M.FD$-FLK]N_KI=E'%YFV5VJPRN<[/T29_HM0\<&/IR9P\
M\ Z6.$:ENZ5\E7V;X9CK-W!L?P?& <XZ>H>:*O8#<@,:TRRAQM_$V!KOXA86
M7MY3Y8T>LJ'<\9/)ND]DHWJGV<2ZY+N4/HT:SK?JN/J3=R8KI,J^.C2]-M5U
M#@[CBM*'KLLK_CJ\:_9^M>#^,X)58?4<<1H(Q54CS_/4&F,S8PX\9CO "QE9
MH-#K]AMN-E]Y\6'5=?01FYAW15=VP?\ =STIE:UMAD"8\R!W+G+I+R/RHYCU
M8A$ LDFD7Q"DL%4>WI3&2NR_37N8BR'M-"R^][]=ML,[9E-M)^9^+&1O6:?6
MX-648[T-%13&Y;40>NS='%X%W1]2;LOD'DA8RBQBDJW&%Q=2U33NOI:D=W('
M@V+6[U@\@Y;N3^;&J2N8E990K[IX,\HZ[+ZOM6?D^,]B#?5(1G3^<+5#R*I3
MT5[#)V,">!'EW=J5O;YS#\7//)]&E3?P:VRKJ&R?:MM#LY3'"*]D&T^S4C!#
M/@.-@5, I^,=)/*V5],T >I$YD](TW<*7?.\OS9VH_LP;!]H.(?VJP.6N[..
MT6GE-50[;[&N.'5AKL]VHQ6BII*6'$7DDF6JCEH<5D%F'$Q$#&8:=!\OO+OP
MUV#SSN-6H/6R99@@B@=3$EB(7<_%1#XC,FB>B  D/$RHC9T>T[M8<$XRZ1IY
MPRQ:5LM>Z_V/[,]LZ5VT.S-7C>!MCJ(J;%=G#3QU'HE55132POI:R>5S(J9X
MIYW, ?6=X&;C8J*Q8WCH[6/VB^R#$8]@NT?"]CMM)9Z&HK]F.T$5U1A_XKAV
M'5%)35<6(X50TS):G$8?3J)DI=!A)A,AFDJ<8+FS2=+_ !R[2)Y!\=J/5A(5
M^NJL*),<Z%?(^]U'RD)+G0DDT,?I@9)P*S(]UX(KX&''!G&DD,,$H>8;XYM7
M@!V9QRJPCTD5D<4=)44]3W?<OEIJZDAK*<RP[\G<S-BG:R6,22,$C7&.22,L
M>[];=F.W+>T78S#=J?P\X5/4SXG05U )S5Q4^(8-B=7A-<*6K,-.:JCDJ:.2
M6EG=!#*Z"1C9X(*ALL+-X9KJW],(F$3")A$PB81,(F$3")A$PBT5=.V25/LA
M]>'X9W6YM I$4FQTNLU61K9_W80YBD@&2=WAC75"*?V&7IV.8TV:.0VWMUI"
M'G)MU'O^B@FW GP%U>.=]6.O\D='%<CZ[SQ 0/WJ9+HD#78F-.5]PTQ]B"]#
M6RP/NG>CNR/B=&8:^W:=5\_O2EM:W4'V_,! ;\"/$66W<A2K'.5N"LHS(DY&
M#2(X\I!S3*'M+3M$G6IH"PPA6G&EMN;V!,Q@)J&E+VPZH?31#3PZW6EOOVHL
M41R3GR)TRPJK_P!P8:_-&.@FRLV?669"R"D V*4 IQLD148N7GQ#)$>;EXV$
M$DY5J6FDGED?FI7[R;G[U]NOWT46'+G[]5;AN(<U%C3HMN%DW&SEU]2I RX7
M0^Q IJ;Y)-78A+4=82;-71*Z0=(/0@4#+QH<6Y)RJPF&=RDALE<_8%L^FBE#
M>'\R/BXZ'(KYB0HT:P!I4)9[;'R$F%;9!,M; ;++@3HTM;0;5*HU*68*TFS
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-$3")A$PB81,(F$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g129231g94t84.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g94t84.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[18>4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %@*^5C0X0DE-!"4      !                      .$))300Z
M  $+    $     $       MP<FEN=$]U='!U=     4     4'-T4V)O;VP!
M     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y"
M:71B;V]L      MP<FEN=&5R3F%M951%6%0    4 $, 80!N &\ ;@ @ %0
M4P U #$ ,  P "  <P!E '( :0!E ',       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q ;9AZX         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O
M<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M        #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ ._
M_C4  @ ! [_^-0 "  $X0DE-!"8       X             /X   #A"24T$
M#0      !    !XX0DE-!!D       0    >.$))30/S       )
M   ! #A"24TG$       "@ !          $X0DE- _4      $@ +V9F  $
M;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M  $ -0    $ +0    8       $X0DE- _@      '   /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H     /______________________
M______\#Z   .$))300(       0     0   D    )      #A"24T$'@
M    !      X0DE-!!H      S4    &              )O   $Q
M   !                          $             !,0   )O
M              $                         $     $       !N=6QL
M     @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   )O     %)G
M:'1L;VYG   $Q     9S;&EC97-6;$QS     4]B:F,    !       %<VQI
M8V4    2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P
M   &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E
M9     !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG   ";P    !29VAT;&]N9P  !,0    #
M=7)L5$585     $       !N=6QL5$585     $       !-<V=E5$585
M  $       9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O
M; $    (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /
M15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0
M  ]%4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N
M=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L
M;VYG          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T
M;&]N9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P
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MMO>T^]V]WN:?]?YQ_P"F_2*3.A8S7N<;\JQKFEGIV9$
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M P$! 0            @%!@<) P0* @$+_\0 /A   @(" @$$ 0," P8$! <
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MU1%H=G:2Z%9V^Q(;H7,MW%<7Z*[B)X9740M/M,4>9&_?J5=E,@(]-U#;^/\
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MZ>4UE;0^N!]7:GEW=,:HEJ,-H.O?[&QK6NI:QJXK).\!5TR&&(MM5&MBC%7
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M%*<4IQ2G%*<4IQ2G%*<4IQ2NNXXI7J-/OM+I(HKG<=<;,-=51184C,-,L&E
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MP8PK%B2F&XBP01&8&ROD(A"G-PLOL8D",H*YA,D)>V>8^DLV @=L ,F\KO\
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MY]0]JRUC9>,>AR^;%]-U;8-+&KJMY;W7F[O2AADF-KJ*D@@#8LL:G!:-@,U
M+M?QQ[1Z6%U[;]K=J47:/C.$U^_U[1$[ $1>R45P%YY,-#7W-R32\VZ@$CW<
M:)^V#% R2HG5-B/%4,CZJKO=7%@8H&>';.885FA.[";]^U 61G8>8^ _I4^8
M.1N+I;5.F^I8[G2[;0]4T#KH3VL&IW<FGO$4>8NELR7=S;VYN_*972&"\@A/
MG":=#)9QLQW%=0]C=@]]=3=5]?Z0EJ^G])5/7E0GM6_,7S'78 V"*/XKM/+7
M--6%FE2!$Q5/UR9,!-!)F&R;2LZRVB"RCNK:.5KB'?<W<CAD51OCB8D$F1CZ
MC<%ADK&&\M_<84G1O4W2>@=*ZIKT_47U6I:W=W]S';]/)9P:VL]I.Y23]IQW
M,:VZ)>1N)$FN%]23#Z339X DK9!2WCH#I[J0:_6/9-7WSO6@JYL-,Z]5W6*^
MJW&\VEB2".\V-"Q=20@C.Z=C;V.Q.VCE A:R/>4G[7;LA8AD)KK6KUY#+;QP
M37,?E7%XMKBX:W551XC(JM*5$?H=8]L\T68IY)$+&M-:9X0V5UU/:S7^D:ST
MUTL-4DU--+GN+N?2M*D5S=RII]F\6R74%?+Z797$,L5A<F*>SM()(@]=3I7S
M1\E4^Y=6ZF\KNCJ;KY;L,8L:9MNJ',Q4D;;-!=&,G!7NSU%NBRT99-@Z%J!B
MK*XB9Q>0' RSC9-.0VTEU:7:W2PD>=&8C#(BDX#A2Y)7W(*C@,0QQBMJ=0]
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MU&WT+H3RB[2V[N7<>R-I\F=R9WBQU77:I&,]"2ZLLSCEJE0G3TA\KE^C7:R
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M_N>B/$>Z[$6+J#Q_Y6E:B_Z_^9_0S7 ?XK,WGC3^'C3!R&UN%]N1_P#N>I]
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MQ2G%*<4IQ2G%*?S_ #Q3O6CO]);_ ,N]O^9^A2EF.:G<JKV!SG'MC^R[1O\
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ML7;$&,PSC$4R3&QB>8"+F'LC_;'&5O26,YG*?IDD\9%C&(1CF<O3/I>H03R
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M*> UPV-99]6)P/!9PK,_? .<@KV)_8PE&'IY=Y\Z=G3!*B--C$9P"QDR!QW
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MSR)RP:+.4/\ F-$AL^WX\8A4&!QG)'R<GGD?ZDX]N> *H8.!P<<G[=^2/MP
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M>Q5UK]J?-+V$(:$:S5GG3-Y)+)#3^S6RA'YLDGF3!"YSF/OS* . ,^R@<'@
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MJ]F**XL5W6_=7W>OUD0A*7Y13]'%QL)R%G.<_#AUU,T,XQ$?N^+TQ+,,^R;
M9AN&> PR>Q8!?OWWG/ [GN*AD@-MS@Y5N<9'#C/ZD ]N" :H%]L44X1%!CTP
M^@(&<Q8ED$7%OH'A&$8RQCV#@ZX.,LR_MAB8\Y]28CR#$D  ]^#R?8 C_P#M
MC('/;]8CCDC.#_O\\'X'_N:RD3L?69FVQ5D;*4-A-6"$B5E5@*EVO,4F499
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MG[2C;ALYR1Z?@'*\G[%=V.Y!Q5/L-\%)VV#!TRHBS8&U3%<%+(XF1K\V"\E
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MDGXXE((!''<$')S@<8^.Y')^!V Q7TOO94WK <#D(#&%EZY6<Y,1KA&Q%7+
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M,Y8'X/8FJM8=BU!2^]$JCM8F:5HJQG,(S"M%I&Q0'F4YQS\1TGF Q#C$H8C
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MB4;-F<>,+)6$%G3P $C4985*8<_7&5XYG[HQ .6*Y*]N_&3P?\W''!/;(J'
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M@8QF1U3$6#N;!W@Y&UMY4*#SD;%5@?8L>!C%4B\WEVQPZV_:RPVG1*(C:EZ
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M)-6<W4', 3"F)LRA<0%%]@DYX&7X1!'++%@(,Q0"L"3)H0@4LB7RKD$ M]B
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M->QE&(>2+U+R-UJ0 1MVR@D*?S9)C ) _+@ ?/S4YZ;.!MN^=K;MT1 +?X,
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M_A(TE_T]U]82N\AETX>7O9W)>YLM3B8+G=DLRIGW).<Y%<+?BY1-)\0OP_\
M4$**@L>IG,AC15PEAK?3%XI9E ("KYF >XW#MFMX).R.M\S^L7?=(S,F?C^
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M(4O?\DE_A.$L20*7U,?)??(Y\R,:4RRE/-JTTK.TC2.9&8L6W$$DYYR,8[X
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MX?3:!*<"*&^+J.+3NB-'$J0P:?9L!Y4D:R;G+")9Q&T*LTCL(9%E5 A<(X.
MKC/)5UKG5_53V<FJ6BZRMN1<V4UWI\<D<+/*+8SQ3RQ"*#-Q!Y;R*1'YD;+N
M!C]-K=I7GD'4*H6/85CM-4A<,V2:(&KH$O\ B:=HB3JSR%?8&92- X2X7_<P
M )8!%)E++*L<FY<Z=-TI+OBTRTT^26%(WD:.U (651(CQF6-4<;2-WE/A"X5
MRK$K6/UO6.N$6.35;W4H8II98D07*J-T$KHZ2QV[AE96W*OGHGF*-R%E!8>Z
M3])3<WM[_3Q\9[VSL&+.Q#J=U0MN-G*RQ.6L[ELFOA&4QIS)+X5:Y<,,9EG$
M!P@./I",<8X,\4+9+3KWJ6**)88VOQ.D:J$55N+>&?A0 !DR$G [D]Z^A_A#
M?RZGX;=)7=Q*\TYTSR9I9&9Y&DM;B>V8NS>HD>5@D_''&*V,\\%6R*<4IQ2G
M%*<4IQ2G%*<4IQ2G%*<4KPZ^6GZL/F32^1G=VC#['MJS7]+[2WK4:FDU]QO6
MDD:O7MGLZA!>&:0BA6<P45%B;+DV&S$S*9C%EG/IVWT9X2]"WW36BW]Q9&2Y
MO=-L[J>:0B4F2:VCDD)+DA5,A8 *%"\ #V'"?6OC?UOIG5/4&EP2Q_3:;JM]
M90QH7AV);W$D46/+*[]T8!#$EBQPS$C @Y4^6/D SV!LO;&NCW$'8%B+Z^P;
MC5DVBTM9_;DK3P';V$&(,"RV5).OA@YL?(R&"^!S-B,.>[GZ*Z.33;;1KEXG
MT^-O,@M)98(4!0/*7B 7UA1*\GI4J%.XE16I;7J;5(>J=0Z]L-,GAZHO87M[
MS4HFO;HLLPM[/;+$\@CC#BU@BW+ZF=!@$DYD'T1^IGYQZ9Y"]7U6P]O[R!#_
M 'D:A1;5I6U_<*BS56MXA7VM=;TMW@A0S+7MEC"4XC:5G(;*I L#$6/DNIO#
M?P]?IG5;BPTBV,ZZ?<SVE]#,S.LL4$CQ/')$^TJ)$&1^63E6!4D5[KIGQC\1
M4ZLT6RU'5)T@EU:SM;ZQN+<1IY4UQ'',DD4J^8KF-^ 2K+PZX."/?5SA:OH9
M3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.
M*4XI3BE.*5UG2_ FV?.?3 5CESG/XQCXQ3GZYS_T].3*-S*ORP'\SBI7.$<_
M"L?Y FOYA^IVW6;O:.\7/:O[Q.A;7[%L*A>K1F^)K<' V<]:#<9!<T;J]6-\
MT6I-),,RS8@KP.(FJ6+&8?H(MQJD>E64.F,@E7Z".0NX1EM59#<>5F&9&D*#
M85?@QLS(ZR+&*^6<3:7/J]_<ZH)?(D&IRPQHGFAKN43-:"8+/;R1Q"5]V^-F
MS(L:RQM"\C"6G7NL>%^STNO$N[&DI+8[RTK96>QWRK< 8UG]NLU2'V3L#5JK
M(%+P,=B#+(:B;96S"K[FV&NOI;-E<ZMUK;S7"VXFEB$96)A;PLF/J0T;A;?3
M[F0-)"3;_P#FA @+0QLS7B^G@T[H::TM3=R0QRO(IF_ZB>)\"TV2*[7-_:Q;
M([A/JAQ"SDE8YI0JV1O;](VI@7]37QR2![2J+['ME@H2!)%C)9'0MK>7+F<A
M G+,A!AF4Y@!G,_7U"/U]F,?XNWKR>'NM%BVYXK19%Q@*[7MNCC:&90-S'LS
M#X)[U?>!5NB^*&A*F6427TRL&+@1_LZX:,DE$R2H4$A  >#M/ _H'\X6KZ,T
MXI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5YM/]I)U!RUZ,\=]N4KV&1ZYV?LE2
MZX$)"#4'L.N+G7@<D(YB+#!J//Q^^4<SR*6(8EG&<<WSX"7:Q:[K5LT@4W&F
MQ.B$CUF"Y7=@=R0LA[<8)!P#D<R_B@LI)^D]$NXX9)#::RZR.B.PCCN+*93O
MV [0S(H!; R.]>76E\B>UM3SI:JJ=)G.ATL-;HX?L)*=J5/#:Z#<H+.O:PSK
M]LT>-OKPO9;Q=%=C'97!@60K![#P>EY= L+OZQF>?_KIO/F/FB51,;:>S)1+
MA)HT7RI^8C&T!*0AD$:[6Y)TSJ34[0V<1BA4Z9:BWMU>V-NQA^KMKY5=[9K:
M9W$MN'6?S!,!+.1*'<2FO[GV9WOY))TFK/ZZ[?0JK6VMJU&BJ]DL&IV-Y8V;
MQXAA96=V:)RL6[46CH0!9[$7Z;NU,;#;IIV 9;73=&Z=,]R+A+;S8HHI&GEM
MT BACC12PCCAX"Q*460,D WK;K!$[QFGJ>H]2]4M#8K9S7(M;F:>%+:"YE;S
M9YY),(TTDO+/.P;R@LMXPC>ZDN9ECD7VW_HW=9]G=2> O56F=L:G;Z3LH+C>
MK537;]4E?=)T%[M=E;51+*M/$;5:=N+1FQJ-B$U%8P"E'#)<8YQKXJ:AIVI]
M;:K=Z7<Q7EJZVB&X@;?"\L5M%%)Y4@XD52H7>N5+ @$@5] /!?2]6T?PZT&P
MUJTEL;Z/ZZ1K6=/+GCBGO9YHO-B[QNZR>84<!U##> V16T?FNZVI3BE.*4XI
M3BE.*4XI3BE.*4XI3BE?SD/.Z!- _4)\F; 54A9RUWR+WG9!U%VNX:GLXQW9
MRZ"K9+IM5[9ZQS!!89@%U23"TYQ$S"4H3QW]T"7ON@NGXC+-&MQH=O;>;#@2
MQ VPA9HV9&02!5."RN!A6(;!Q\SO%-DTWQ,ZBD$$,C0:_/?&&=)##*3,LN)@
MCQL8I2<-M93M+*' 88ZU!YNWE-L.R7[FBK6;%QLEMLM0D;82,IZ_.XO-XO6*
MU=C8J79+W"7VM_O3_-5W5-:,OE(9RQ91=M:JPKS]%I)!;P+J#H(;:*"4BW"2
M3"&"TMTD*PSV\!D*V,"[9(98U1?1&'2.1+>VZYDC-W>O8I*9;F:>!#<,\=N9
M[F^N'C$EQ!<7&S=J$[%HIH)F=BTDKHTD;8<=WHW9'?&K;PG1?LN);#UFFI3J
MY29*NMJ*NN:\CC/[/3:Y4R.=:D"20JJ@J$1E)[%:\,8Q]UW=::UATW>V;S&9
MA:ZG(TS%E1VN7N+B3)FFGF4*9656EGE? W-(Q.:\Y::J=6ZPTF^CM_IU;4-'
MACMXS'(R16HL[6,#R(+:/<T< 8B*W@49(6-!P?Z:P99F$4\XSC,Q#EG&?QG&
M90QG.,XS^<9_/Y]>?/ C!(^"17U;7L/T'^U<O(5&G%*<4IQ2G%*<4IQ2G%*<
M4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*XRB&<1 &A$@C#
MF(HY8]8S&2.83A+'^<91SF.<?Z9Y$$@@C@@@@_<=J@0""",@@@CY!X(K0%VY
M_L[WB3N]U:WO7N]]E=59LW&G\THIUFW4%?-HLS37K5WX5EJ),4YYPN%NY=((
M?H/!\PC&,=SZ1XW=2:?#'!>65AJ2QHJ;V#VTSA1M!D>/S$+D#EEC7)Y(R3GG
MO7/PY=':C/-=:;>ZCHKRR/+Y,?EWEK&SL6*Q12F.18P2=L9G8*,*I"C;6G3P
M#_2/TSS%V#NM5_MNXTBNZFL];KU#IZH&]-L,=@9VL4#&Q/9*C]ORJ+6Q%Q&,
MG,&^Y*.90^&,I[CZY\3[WH^#1C%ID%[)JL,\C!YW@6W$"VQV#]S+YA+7!'.W
M:$&.#@<P>"O1-KXQW'5L<]W)HMKTQ=6%O&T49OOV@;]]20NW[VS$!B&GHX"&
M4-Y[*VW;ZO0KX9_HW^/7A[VI7=WH;=O78_9='7O5^O/7\JVGUVAC9UIJA]M"
M@K $9,Z6N994$6SNK 0!,EE &6/C./0G5WBMKW5NG-I,UM96.GR2))+' LDL
M\S1OYB"2>1@-H?#,(XHRQ5<G (/8/0O@ITQT-JHURVN+[4=52%H()KEDCM[:
M.2,12>3;QAF+,F5W332D G&"<UMWYJ^MQTXI3BE.*4XI3BE.*4XI3BE.*4XI
M3BE.*51=@US7=KJ6Z+:J*EV6B>AB#U-L%6C<5+D(Y]V(MUUB!E-B$<X]V(F#
M/&,X]?3UY5AGFMY%FMYI8)D.4EAD>*1#VRKH593CC@BJ4\$%S$\%S#%<0R##
MPSQI+$X[X>.161AGV(-:3_U5^K/#_7/$GL86F:7XY:CV<E<:2]5AU77.M:+>
M2CAN5,O;"3A4)+7OQYKF6R.C'B(Y+C+D_J.$N;>\,=6ZEEZKTT7M]K=SISQW
MD;BZNK^6R!:SF,982NT.3(J;3WW$$<]^6OQ,:1TK9>$_4EQH]IH&G:Y:W.BS
M0RZ=;Z?:ZGM;6;*&X19+5([H*\$TGF@, R!MP*@BLH>!_EEX@:)XI]%5%UV/
MUCI>Y5^@UE3LB,5@(VN+*I,Q63):G1KO4K;$5ALS*P:928/@DY9S/.>8OKG0
MNH;WJO79(+6_O+5]0EEMVWM+'LF"R@1AG.$7<5    7'M7I? [JWI6V\*.AV
MN]0TVSOUT*""]W!5N'FM)9K1GN'1"SROY 9F=F<D^KU9%;0.ONS^N^UZ3.R=
M:[KK6\4<&)IFLM:ME+4"S@XQG--SZI9D3;C"<"95:@$^!S@3X_9.,LZ\O=/O
MM-E$%_:7%G,5#B.XB>)F0]F7< &7VW*2,@C.0:WMIVJ:=JT!N=,OK:^@#F-I
M+69)520 $QR;23'( 02CA6 (.,$5?7+.K^G%*<4IQ2G%*<4IQ2G%*<4IQ2G%
M*AAW5^GGX:>0FU/;UVOT1J>P;K:#&.UVM,USKEY:X" :P9VSFMV=3FU,( @A
M@>RBT:(@B%\GQCC''KM&Z[ZMT"W2STK6[NWM(R3':L(KB",L23Y4=Q'*(@2Q
M)$>T$DDC)KQ6O>'71?4MR][K/3]C=WLB;)+L+)!<R*%"@2RV[Q-+A0 #)O(
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M')9G=*:<%%\%R9B<\Q%$V<^F-K_V7T2TM);<&.&!U>22%IA%&R(/WC%=W9
M9'((4@$X!Q7.MY=:IJ^MVO4,LMY-J]H;>*UO$4R2Q2 R^3%&?*9O6\L@2/<2
MV\KA@2#?%9Y-^6/6=K66M+V1V5H#A1YLJ=P1[>@,X!1]BO*RI@^0X:3'8(O(
M,>S!E\M)MHFQ,@&!1L).B^DKR*9/V98W@0E)4W).(RT0F ?;G#%)(W&&!V.C
MKP5QZ9.NNO-,D@GCUO5]/E9 \$JAH&D1)'A+H6C"RQB:-XG(5D+QO&P]+(/Z
M&/0FX6?871G3&_71ALW.[]4==[=;L!%  CVFQZA3W%@801^@PC(XX:<!#QB
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M\/K*\V+J/6;4FY;&A*JN-VVRXE>;(Q4S96<)5@F)>OJJU$S:BS)PUE4GE@@
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(%*<4IQ2O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g129231g96c25.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g96c25.jpg
M_]C_X0FD17AI9@  34T *@    @ # $   ,    !)*X   $!  ,    !!UD
M  $"  ,    #    G@$&  ,    !  (   $2  ,    !  $   $5  ,    !
M  ,   $:  4    !    I $;  4    !    K $H  ,    !  (   $Q  (
M   >    M $R  (    4    TH=I  0    !    Z    2  "  (  @ *_(
M   G$  K\@   "<0061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C R
M,3HQ,3HQ." Q-#HU.3HR,0     $D   !P    0P,C(QH $  P    '__P
MH ( !     $   %HH , !     $   !(          8! P #     0 &   !
M&@ %     0   6X!&P %     0   78!*  #     0 "   " 0 $     0
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M_\0!/P   04! 0$! 0$          P ! @0%!@<("0H+ 0 !!0$! 0$! 0
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MQJ=S9;[/W8T+8^C_ -MKU;H?4AU/I6/F?X1[8N TBQOLN'_;C?9_(4?Q/EN
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M&0   !     !       +<')I;G1/=71P=70    %     %!S=%-B;V]L 0
M  !);G1E96YU;0    !);G1E     $-L<FT    /<')I;G13:7AT965N0FET
M8F]O;      +<')I;G1E<DYA;65415A4    &P!" '( ;P!T &@ 90!R "
M30!& $, +0!, #( -P U #  1 !7 "  <P!E '( :0!E ',       ]P<FEN
M=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M  IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8
M   )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I;G1/
M=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B
M;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M  !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!OX
M         $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M  !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M      !2<VQT56YT1B-0>&Q <@            IV96-T;W)$871A8F]O; $
M    4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M             %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R
M8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C
M=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R
M;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"
M24T#[0      $ $@     0 ! 2     !  $X0DE-!"8       X
M    /X   #A"24T$#0      !    !XX0DE-!!D       0    >.$))30/S
M       )           ! #A"24TG$       "@ !          $X0DE- _4
M     $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@
M  $ 6@    8       $ -0    $ +0    8       $X0DE- _@      '
M /____________________________\#Z     #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z   .$))300(       0     0   D    )
M     #A"24T$'@      !      X0DE-!!H      W4    &
M  !(   !:    "  00!R &, 90!L &P > !? %  <@!I &T 80!R 'D 7P!,
M &\ 9P!O %\ 4@!' $( 7P!- #  ,0!? %8 ,  Q     0
M           !              %H    2                      !
M                     !     !        ;G5L;     (    &8F]U;F1S
M3V)J8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F
M=&QO;F<          $)T;VUL;VYG    2     !29VAT;&]N9P   6@    &
M<VQI8V5S5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC
M94E$;&]N9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T
M   ,15-L:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T
M   *15-L:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   $@     4F=H=&QO;F<   %H     W5R;%1%6%0    !
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M3001       ! 0 X0DE-!!0       0    ".$))300,      @Z     0
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M?\.'R/KRXSZX,=U_K_3/JG3:ZJMH=U+J-M<%S*ZIKQ&^_=6[U,AWT+*W_P"
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MC^;?:\O_ %;,V[]S_P#"?Z*NJVV[MTDN+2NBG__9.$))300A      !5
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-! 8
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MP  1" !( 6@# 1$  A$! Q$!_]T !  M_\0!H@    8" P$
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ME0'U$#Y LM:^H4 UH.K1BLD8I@D@XK4%2:?($@?;2G6QM_)SW1O+>?\ *N^
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M5"::/'X:B)(Q^'HZ: EY%DEDAGF?F&ZYFW:?<;@D15I&A-=" X7[?-B,%B:
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M)H=1-1QRQ-,J?S^SHS'^RW_\+(/^?N;U_P#2@/AO_P#6'V7?O'V7_P"4=/\
MG%<?YNM:1_OUO^,_] =>_P!EO_X60?\ /W-Z_P#I0'PW_P#K#[]^\?9?_E'3
M_G%<?YNO:1_OUO\ C/\ T!UN+?R^,'\G]M_"SXYX+YI5];D_E1C.N<?3=WU^
M1S6U]Q5U3O85E<]6]5F]EO+M7)3+2-"IDH7> VL&8@L83WMMO;=;QMK(-AJ&
M@@$ B@J0"J')J<HO^E7@*BH U&K=:I_\S?\ EA_SA_YO7\PC:-;V7U;0?'OX
M*;&W=5===59K(=R]3;GS?674\V2T=A=ZU/76V-WY3)9?MWMS&XB*2AHT4-C(
M&QN/JI$CIZRH:6>5^9^4N3^7YS:W0GY@==3424!FT]J!FC50$8E34D?$ZDZO
M#-A5264C7P!]/4C'Q>7R'KD'<3^//075?Q9Z1ZR^/'26V*;9_5?4>T\;L[9N
M!ICY'@QV/5GGK\C5E5ER>>S>0FFKLC6RWGKJ^IFJ)2TDK,8=W"_NMTO;G<+V
M37=2L68_X !Y "@4<   ,#JH    H.G7NOIGK3Y$=2]B=&]Q[4QN]^K^U-IY
MC9>]MKY:(2TN4P>:I7IJ@1R?YZAR-&[+44=7"R5-%5Q15$#I-&CK2SO+BPNK
M>]M)"EQ$P93\QZ^H/ @X()!P>O$ @@C'6E_\ ?Y57\X'^3[_ #%]U;M^/'5^
M.^2OPFW1N3']?=E9(]T=2[0W+V[T149-:K:F^*C8^[-T8&IQ_=_2%/EI9?*T
M<295H,A14\OVV11TFGF'FOE/G/EV"+<KOZ7?$!9!HE94>F1J"-59"*4U4H5=
MB&4*+&K:"6%1@Y.1Y>1[AZUSFOE3_];?X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M12_G-\<J7Y6?%CMWI?1"NX,[MN7+["KY8XW;$]B[8D3<&R:^)Y658 <]00P3
M/<?Y--(O()!E7V2]PY?:[W/Y3YQJ3807 CNE!/?:3#PKA33C^DS,H_C53Y=2
M1[1\\2>W?N'RUS34_10SA+A03WVTOZ<ZFG']-BRC^)5/EUH 1?<A3'6TDN/K
MZ>6>CR6.G!%1C<G1324F2QM0K!2M3CJ^"2&0$"SQD>^\K>&2&@E$D# ,CC@Z
M, R./DZD,/D1UV8;PR0T4@>%@&5AP9&%58?)E(8?(]9/=>J]63_RE_D8/CK\
MU=A)EZ\46Q.]((^D]YF:1(Z.FR6;K5K.MLW4R3NE/3#';S5:%I205ARTES;C
MWCG]ZOV\/N%[-;X;2#7OFR,=QMZ"K%(UTWD8 !+:[>L@7S:!>H*^\AR/_7?V
MJW@VT.O>-H)OH*"K%8UTW48IDZH*R4\VA7K>(]\4^N2W7O?NO=>]^Z]U[W[K
MW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]
M^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW
M7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^
MZ]U__]??X]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=:0W\W7XX_[+U\T]Z9/
M#T#4>PN_J9^Y=IF..U'2[AKZE<?V=@X/'''3TYIMUA<FL*BZQ9=?J!?WVE^Z
M=[A_U_\ 9O9K:[GU[[L+?N^>I[FB4:[.0U))K!6$L>)@/76/[M7//]=?:O:H
M+J;5O&S,+*:I[C&HU6LAJ236']+5ZPGJLGWDGU/?6*9)GC/VU3+15<;1U%%7
M0$BHQ]?2RI4T&0IF!!6IH*R*.:(@W61 ?Q[LA0-^I&'B((93P96%&0_)E)4_
M(GJRE0>] T9!#*>#*11E/R925/R/6_G\"_DA!\K?BEU%W%++%_>C([?3;O8M
M%'*DKXSLC:3G;^]*:41I&L2U.8H7JX5M_P !:F(W(-SP@]]/;M_:WW2YLY11
M3^[([CQ;1B*:[2?]6W(K6M(V$;'^-&'EUQL]X>1G]NO<7F7EA5/[OCG\2V8B
MFJUF_4@(XUHC!&_IJW1P?<2=1EU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]
MU[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?
MNO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
@[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g129231g99g99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g129231g99g99.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1L@4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &P2^:18X0DE-! 0      $(< 5H  QLE1QP"   " /\< E  "')R,CDT
M,38U' (% "%-:6-R;W-O9G0@5V]R9" M($%#3%@@3F]V(#$W+F1O8W@X0DE-
M!"4      !!V_2-9"[EW#5SS%U\GI@;R.$))300Z      #E    $     $
M      MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M     $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP
M<FEN=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P
M  P 4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M    0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-
M!#L      BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M    0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N
M0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M     $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M    4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!O
MX            $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M            0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL
M0'+            *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G
M4',     4&=00P    !,969T56YT1B-2;'0               !4;W @56YT
M1B-2;'0               !38VP@56YT1B-0<F- 60           !!C<F]P
M5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG
M  QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M       +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #O_XU  (
M 0.__C4  @ !.$))300F       .             #^    X0DE- _(
M  H  /_______P  .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          CA"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #00    8
M         TL   =D    !@!G #D .0!G #D .0    $
M         0             '9    TL                      0
M                   0     0       &YU;&P    "    !F)O=6YD<T]B
M:F,    !        4F-T,0    0     5&]P(&QO;F<          $QE9G1L
M;VYG          !"=&]M;&]N9P   TL     4F=H=&QO;F<   =D    !G-L
M:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)
M1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE;G5M
M#$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M
M"D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   -+     %)G:'1L;VYG   '9     -U<FQ415A4     0
M &YU;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%
M6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%
M6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX
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M+$M]++SJJ+"SU +,E[99);N#MNW\UR[''K&+4VC'QPRJJ0Q@)@:[OSOY3@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0'_P  1" $. ET# 1$  A$! Q$!_\0 '@ !   ' 0$!
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MT'SC3S_U./Y#Y#_4_'N-.R3;;GAY,^BF/?X0T^YI[AOQ=QOM/$/YS3WT\?\
MG&GU6-_!U&GNDFV]=OK;G@U=2VE;KMT3Q[7@VTK2E:UW1#HI2M:4K6O1OK2G
M;KI]S7W"_B]C?:>(?SFI]]'N@^<:_E^!Q^[\O]1^[4.R3;;GAY,^BF/?X0T^
MYK[AOQ>QOM/$/YS4>^GC_P XT^JQOX.G9)MMSP\F?13'O\(:?<U]PWXO8WVG
MB'\YI[Z>/_.-/JL;^#KU;[I)MOW<+@YX-W<&VM]W!B>/:\&RW=PK[MT0KNMI
MOIONKT4WTWUZ::?<U]POXO8WVGB'\YI[Z?=!\XT^JQOX/_G?YM2^R4;;7"X/
M/V7X7P>M7'G"[6_M=:._M=/]6GW-/<-^+N-]IXA_.:>^GC_=_P#$:=_D^!Q^
M_P#1\#WZ]=DFVW/#R9]%,>_PAI]S7W#?B]C?:>(?SFGOIX_\XT^JQOX.G9)M
MMSP\F?13'O\ "&GW-?<-^+V-]IXA_.:>^GC_ ,XT^JQOX.G9)MMSP\F?13'O
M\(:?<U]PWXO8WVGB'\YI[Z>/_.-/JL;^#IV2;;<\/)GT4Q[_  AI]S7W#?B]
MC?:>(?SFGOIX_P#.-/J<?^#IV2;;<\/)GT4Q[_"&GW-?<-^+V-]IXA_.:>^G
MC_SC3ZG'_@Z=DFVW/#R9]%,>_P (:?<U]PWXO8WVGB'\YI[Z>/\ SC3ZK&_@
MZ=DFVW/#R9]%,>_PAI]S7W#?B]C?:>(?SFGOIX_\XT^JQOX.G9)MMSP\F?13
M'O\ "&GW-?<-^+V-]IXA_.:>^GC_ ,XT^JQOX.G9)MMSP\F?13'O\(:?<U]P
MWXO8WVGB'\YI[Z>/_.-/JL;^#IV2;;<\/)GT4Q[_  AI]S7W#?B]C?:>(?SF
MGOIX_P#.-/JL;^#IV2;;<\/)GT4Q[_"&GW-?<-^+V-]IXA_.:>^GC_SC3ZK&
M_@Z=DFVW/#R9]%,>_P (:?<U]PWXO8WVGB'\YI[Z>/\ SC3ZK&_@Z=DFVW/#
MR9]%,>_PAI]S7W#?B]C?:>(?SFGOIX_\XT^JQOX.G9)MMSP\F?13'O\ "&GW
M-?<-^+V-]IXA_.:>^GC_ ,XT^JQOX.G9)MMSP\F?13'O\(:?<U]PWXO8WVGB
M'\YI[Z>/_.-/JL;^#IV2;;<\/)GT4Q[_  AI]S7W#?B]C?:>(?SFGOIX_P#.
M-/JL;^#IV2;;<\/)GT4Q[_"&GW-?<-^+V-]IXA_.:>^GC_SC3ZK&_@Z=DFVW
M/#R9]%,>_P (:?<U]PWXO8WVGB'\YI[Z>/\ SC3ZK&_@Z=DFVW/#R9]%,>_P
MAI]S7W#?B]C?:>(?SFGOIX_\XT^JQOX.G9)MMSP\F?13'O\ "&GW-?<-^+V-
M]IXA_.:>^GC_ ,XT^JQOX.G9)MMSP\F?13'O\(:?<U]PWXO8WVGB'\YI[Z>/
M_.-/JL;^#IV2;;<\/)GT4Q[_  AI]S7W#?B]C?:>(?SFGOIX_P#.-/JL;^#I
MV2;;<\/)GT4Q[_"&GW-?<-^+V-]IXA_.:>^GC_SC3ZK&_@Z=DFVW/#R9]%,>
M_P (:?<U]PWXO8WVGB'\YI[Z>/\ SC3ZK&_@Z=DFVW/#R9]%,>_PAI]S7W#?
MB]C?:>(?SFGOIX_\XT^JQOX.G9)MMSP\F?13'O\ "&GW-?<-^+V-]IXA_.:>
M^GC_ ,XT^JQOX.G9)MMSP\F?13'O\(:?<U]PWXO8WVGB'\YI[Z>/_.-/JL;^
M#IV2;;<\/)GT4Q[_  AI]S7W#?B]C?:>(?SFGOIX_P#.-/JL;^#IV2;;<\/)
MGT4Q[_"&GW-?<-^+V-]IXA_.:>^GC_SC3ZK&_@Z=DFVW/#R9]%,>_P (:?<U
M]PWXO8WVGB'\YI[Z>/\ SC3ZK&_@Z=DFVW/#R9]%,>_PAI]S7W#?B]C?:>(?
MSFGOIX_\XT^JQOX.G9)MMSP\F?13'O\ "&GW-?<-^+V-]IXA_.:>^GC_ ,XT
M^JQOX.G9)MMSP\F?13'O\(:?<U]PWXO8WVGB'\YI[Z>/_.-/JL;^#IV2;;<\
M/)GT4Q[_  AI]S7W#?B]C?:>(?SFGOIX_P#.-/JL;^#IV2;;<\/)GT4Q[_"&
MGW-?<-^+V-]IXA_.:>^GC_SC3ZK&_@Z=DFVW/#R9]%,>_P (:?<U]PWXO8WV
MGB'\YI[Z>/\ SC3ZK&_@Z=DFVW/#R9]%,>_PAI]S7W#?B]C?:>(?SFGOIX_\
MXT^JQOX.G9)MMSP\F?13'O\ "&GW-?<-^+V-]IXA_.:>^GC_ ,XT^JQOX.G9
M)MMSP\F?13'O\(:?<U]PWXO8WVGB'\YI[Z>/_.-/JL;^#IV2;;<\/)GT4Q[_
M  AI]S7W#?B]C?:>(?SFGOIX_P#.-/JL;^#IV2;;<\/)GT4Q[_"&GW-?<-^+
MV-]IXA_.:>^GC_SC3ZK&_@Z=DFVW/#R9]%,>_P (:?<U]PWXO8WVGB'\YI[Z
M>/\ SC3ZK&_@Z=DFVW/#R9]%,>_PAI]S7W#?B]C?:>(?SFGOIX_\XT^JQOX.
MG9)MMSP\F?13'O\ "&GW-?<-^+V-]IXA_.:>^GC_ ,XT^JQOX.G9)MMSP\F?
M13'O\(:?<U]PWXO8WVGB'\YI[Z>/_.-/JL;^#IV2;;<\/)GT4Q[_  AI]S7W
M#?B]C?:>(?SFGOIX_P#.-/JL;^#IV2;;<\/)GT4Q[_"&GW-?<-^+V-]IXA_.
M:>^GC_SC3ZK&_@Z=DFVW/#R9]%,>_P (:?<U]PWXO8WVGB'\YI[Z>/\ SC3Z
MK&_@Z=DFVW/#R9]%,>_PAI]S7W#?B]C?:>(?SFGOIX_\XT^JQOX.G9)MMSP\
MF?13'O\ "&GW-?<-^+V-]IXA_.:>^GC_ ,XT^JQOX.G9)MMSP\F?13'O\(:?
M<U]PWXO8WVGB'\YI[Z>/_.-/JL;^#IV2;;<\/)GT4Q[_  AI]S7W#?B]C?:>
M(?SFGOIX_P#.-/JL;^#IV2;;<\/)GT4Q[_"&GW-?<-^+V-]IXA_.:>^GC_SC
M3ZK&_@Z=DFVW/#R9]%,>_P (:?<U]PWXO8WVGB'\YI[Z>/\ SC3ZK&_@Z=DF
MVW/#R9]%,>_PAI]S7W#?B]C?:>(?SFGOIX_\XT^JQOX.G9)MMSP\F?13'O\
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M7!WQ\14I1AV9*7ZU:XU@T?Z0N2M,=\5^2<\M,:,9TW:8M2'HATHM'ZGD0L@
MR0"E,*IN:&^H3V/9/S(S;#%DK6#NP8MDF4O1SAPY;N'UM+4T$OT#W(9O%\[A
MN1;C!9JKGVGBO3'KC7?#6&,RF\Z\.X5S47(?)FM)X$)O))[!V#4?YSCV+A8N
M1CIA@+SXW/=4HE9BAR,A9E&3+S2-\=8ET>_/S'J%)B@FNE]?5:\+33333333
M333333333333333333333333333333333333333333333333333333333333
M333333333333333333333333333333333333333333333333333333333333
M33333333333333333333333333333337Z$?<2O\ H;M _P#UI@G_ .#R#7\[
M_P"W+_YOW.?_ ,/Q+_\ .8>OTWW ?U/$O]_%_=DZP?.ON6,_R3FC*F06.6H2
M+9S2>R>3-AKP)(5G3%$R6<OTVCA5"G$J+(6+VIJ7I5JG==;6MO16FN[@/^UC
MAO#."\*X?7A&?6F%@8N*])WQ@E&A)9,ZACS!6*D@, 0" =9<0]QF5EYV7DC-
MQT6^1:RJ4KNJTHSJ&(4@L VQV[M_)W=YU3V'O)/AH@'H_)O5UZWW9N$_,G$O
MK\3UZY?>)E_.&/\ 0MYMOD>;N_1IV'O)/AH@'H_)O5T^[-PKYEXE]HQ?7J/>
M)E_.&-Y-OO+>3S?>>34.P]9(\-&/_1^3>K^FOCT^[-PGYEXE]?B>O4CW"98\
MG$,8?']Y;V-1[#WDGPT0#T?DWJZ?=FX3\R\2^OQ/7J/>)E?W_&_6EC^]-0[#
MUDCPT8_[G_1^3=KN?@Z?=FX5\R\2\_\ \QB^7S^74^\3+^<,;Z%O8U'L/>2/
M#1C_ *.U_P GY-T?_=T^[-PGYDXE]?B>O3WBY8W(XACC?R[)8?E^)//IV'O)
M/AH@'3V_^3\F]73[LW"?F7B7U^)Z]0?<)E'_ /?\;Z%O8_\ .X?%IV'O)/AH
M@'H_)O5T^[-PGYEXE]?B>O3WB97?_3\;O_,K['[-.P]Y)\-$ ]'Y-ZNGW9N%
M?,O$OM&+Z]/>)E=__P 0QN_R^);O[MN_Q._N[OT:AV'K)'AHQ_Z/R;U=/NS<
M)^9>)?7XGKU/O$R_G#&^A;S[_(\_?J/8>\D>&C'_ &MW_1^3=KN?@]K3[LW"
M?F7B7U^)Z]/>)E_.&-]"WL?K_3L?*!J93W'?)/%7*\]4 WT4MLK;UOR;^E;?
M=OK7=V_M-V[=VO?][4?=GX5S;>!.);;;_P!?B[[[_IU'O#RMO_G\;R[?>5\P
M[_O?3W=_GU+[#WDGPT0#T?DWJZG[LW"OF7B7VC%]>GO#RO[_ (WT+>QJ'8>L
MD>&C'_H_)O5T^[-PGYEXE]?B>O4^\3+^<,;Z%OT_(\_?^GOU'L/>2?#1 .Y_
MT?DW:[GX.GW9N%?,O$OM&+Z]![A,L>3/QO+O_5U\OT-0[#UDCI_]=&/^GHK_
M ,GY-TT[E?M>G3[LW"?F7B7U^)Z]/>+E_.&./T)8;_IV3O\ TG5P?^Y(9>*T
M'4*Y]B9.P,+1!ADR+"9/D0X5N[>OT1 E%TJJD,&)OB1%]:P8V(-:/'[QUQ7'
MN5E+^>/^US@&/3)M#W.YD:YE%ME4D^%-\FJ32*5NR[&M%DB3#N2PFBIORJ!K
M1_<5Q"DY2?B<6E .(S87*2%&YZ":E2$#OX[@=S/NQW/?JW]AZR1X:,?^C\F]
M7]%-='W9N$_,O$OK\3UZS]XF6?+Q#&/Z4M^7\S\IT[#UDCPT8_Z.U_R?DW1_
M]W3[LW"OF7B7VC%]>H]XF5_?\;Z%O8U'L/>2?#1 /1^3>KI]V;A/S)Q+Z_$]
M>GO#RO[_ (WT+>QIV'O)/AI@'H_)O5T^[-PGYDXE]?B>O3WAY7]_QOH6]C7M
M/W'G)-]]EG/3 *<.^VW?UOR:N[A5I3?NW4[O=IJ#_MFX4 2."<2[@3_7XOKT
M]X>5_?\ &^A8_P#Z UYK[CWDFE:TYZ8!7=6M-_6_)O>K6G<_1J?NS<*[M^"<
M2WV'_KXGQC?SZ>\/*_O^-]"WL'4.P]Y)\-, ]'Y-ZNGW9N$_,G$OK\3UZ>\/
M*_O^-]"WL:\T]Q^R/6ZMM,U8_K=2F^MO4"3;Z4[M:<'?2F_HWUZ-^GW9N$_,
MO$M_-VC$W]&^GO#RO[_C?0M[&O78>\D[JUYZ(!6E*;ZUI'Y-7=3HZ:[K>UTT
M\=-3]V7A6X'@3B6Y\F^1B#]Y_)I[P\K^_P"-]"WL:=A[R3X:8!_\ DWJZC[L
MW"?F3B7U^)Z]/>'E?W_&^A;V-6YW[DG,F#P:.?9]Q<R(&5G#<.Q=C3K9X6<-
M&][MT@,:K7V+D%FS6R]TX2:)K7H-K+EU;;$;:WT?=FX3S!? O$>8JSA>T8G,
M47E#.%YMRJEE#-MLI8 D$C0^X/+"\W;L?EYE0MR6"AWWY%+% .9^5N1=^9]C
MR@[':NI[C_D:ZM:6YKQ_6MM=UU* )-7@UZ>BOVO1VJ]O=VJZ?=GX3\R\2^T8
MGKT]X>5_?\;Z%O8U[K[CYDFG_MI@'H_)O5T'^V7A1_\ Z)Q+[1B>O3WAY7]_
MQOH6]C3L/>2?#1 *?UQ^34K_ +Z<'HT^[-PGYEXE]?B>O3WAY7]_QOH6]C3L
M/>2?#3 /1^3>KI]V;A/S)Q+Z_$]>GO#RO[_C?0M[&O=?<><D43L4YZH!OO45
M3X/6])MU.+L1OW[]W3OHKTTW4I3=3=6[?6EL#_;-PK<CP)Q+8!3OVC$^,L/)
MOYU_+I[P\K;?M^-Y2/O*_%M^;^7_ ,^+QV'O)/AI@'H_)O5U/W9N$_,G$OK\
M3UZ>\/*_O^-]"WL:=A[R3X:8!Z/R;U=/NS<)^9.)?7XGKT]X>5_?\;Z%O8T[
M#WDGPTP#T?DWJZ?=FX3\R<2^OQ/7I[P\K^_XWT+>QIV'O)/AI@'H_)O5T^[-
MPGYDXE]?B>O3WAY7]_QOH6]C3L/>2?#3 /1^3>KI]V;A/S)Q+Z_$]>GO#RO[
M_C?0M[&G8>\D^&F >C\F]73[LW"?F3B7U^)Z]/>'E?W_ !OH6]C3L/>2?#3
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M:]T]QYR15.^^N:H!2MMZ=F[K?DVZO&44KOW[NC=Q?<KOWUWUINIOC[L_"N8
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MCIRU<HI.&SEN$D:S=PW73M517063X2:R*R5]BB2J=UR:B=UM]EUUMU*UL?\
M;+PI25;@?$U92593?%!# [$$$[@@@@@]X(V.JK[A<EE#+Q#%*L RD+4@J1N"
M"%(((((()!!W&IW8?,D^&F =/:_] 2;]VH^[+PKYDXEW>7X?%]>I]X>5_?\
M&^A;V-.P]Y)\-, _^ 2;U=/NS<)^9.)?7XGKT]X>5_?\;Z%O8U"ON/F2:4WU
MS3 *4I[_ %OR;=OW;]V_@[M^[IW=O3[LW"=M_ O$OM&)Z_VZ>\/*_O\ C?0M
M[&HT]Q\R37IYZ8!Z/R;U=/NS<)^9.)?:,3UZ>\/*_O\ C?0M[&G8?,D^&F ?
M_ )-^[3[LO"OF3B7U^+Z]/>'E?W_ !OH6]C7U%]SSV2)%LK <GBY!,@,N4F)
MF-$&RH-@28V,;!# HV43<6D:4N4O6N>VWIU2WVVTLNI?NK6FORS_ &B^[#&]
MUM^%4QL+(PQA2RT89%).:=>D2I7I$[!1(@\WE)[N[7UGN:X'7@J9:5O._:&B
M5,U<<O3%=]^<#<GG[MAW;:ZY,?\ .Q+^^K_XZZ^+E_52_P!P?O.OH7^^/ZOW
M#5NU?5=---41(@T$CGY4@K1NP&,G1!\O6Q12B#-D@HY=+531L454HD@DHIP$
MDU%+^#P4[+KZTMKG:LX2K>S<DHSI:K[%N6<T+NVR@D[*I.P!)^(:O.;VI.4U
MYJ5=)S7<#F=V"JN[$ ;L0-R0!Y20-<X84VR-FS:$"D#^+LGL7[$6[C3-XC+
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MH4#Y*8N/FOCR:A5;V7%RL>QG$T?EH-EYN[4U1H32M=EF\!E!MPW+CG(MBBU
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MRC=B.<TP<?.OATI4?!F9YUS0A6,CHTRLZB-$]3C&9G</%EH<625X-Q>>"]I
M$HT\[(Q)9(DK#QF4"F)U@<F;8]]U+=)M2["99P""HC>3D&-XI*IAL^$9?)1U
M-IF IQR(;01 .T) Y$=0P XR0_)W10NR'*M+0;!](B,G8MT5NC'.0M\2F04<
M"G )Y**K#&;%?B_'%XO4KRK4Y,."OP=:O-E6F4KTC.M$9ER80I"TT=Y,4XR\
MJTYNNMI\(X.>&S!F'GTK\9GQ40!0F<&FN32,:-S9=M,XQ]T(R9F3.T4BCW*#
M3#DM Y)C<:6 3'"PC$3[#AC9<-"@D99AB%+LL--H$EM-.&:BLH?)MHFV@:EZ
M*AE =QC2GFY&/F9&#Q6%%+TKC\8 FQ4BQ%,1N"1PRNPG-I=HGQ,9+2Z@.2@+
M"F(T>J-<>&9P^J-RHK\+)HG.#!A7('%K9@;<NRSZ3<.&*'"4[/5U!CDK;Z:[
M,&,[L-;.F$,5+-G+-W L70J.$FCV\2J[:F&(!C:9;.%@+9H'74;E;GB-7 Y"
MC9>EE%;%7%;ZN%?IN(5G;-R:28O$V=(,006QY,908@A2&:2(S#E0!F("( $7
MQ\5:+CP%N;J])#4,W,5H5!= W?NLR2B;EB$5068CF.]=<>M]3*?B%?[9K_A<
MZ@??C_<I_P#HZL/O6_\ ;^_7RWSULIY.R?MX1':  ",?]0,5;,2@^"GLA8^B
M.0$>>AOD:2&@PN-.2QQI(<:&&[5R)*/)X%#ON,&\,78K<O6Y.SB*9<:\;RL0
MA,NO#<''X:W<K-DC%]T<Z$6V8I&-<O!.1!@)Y245&)6;\O7U(/'A4*LW1GGY
M]<X+S$=EJW P%,P5ZCWCCYJ39&9H\C$@=10W#U^SY[H?E:-1%'+D;R;)K(\K
M,'BC#+<VP,3E@_(TPV%MIK%N33,8>8V*,P37$$FR_.L? L; 7RZA\0@\)$B
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MT)=O(TK8TC[D$K)S2S^\XY<JJ7[242&"J@+/A_N@GQB4TV2;8T_=$O'TQ>F
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MKXNP[-5H%PZ)1CS*_6V+L_\ N:8_$>7L>9MD1K$9*41"99IFCB-XXP<RQQ
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M23A:DE&#39W3ABHPK.N/X\W7'%8"M+2%]QRD@6&XSCZ>:<8NU<5*REP B1#
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M=.R]ES+DHRS',JI3.@Q22XIVA\W87>$ [.\>.-#H#,W2,5+)LE'+RK5XXAY
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MSY^E['K;P57\,OU?_<U3M)_ GZP>QISBL_S0Y\_2]CT\%5_#+]7_ -S3M)_
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M?UJ>O39OD-Z!Z]7&U@]ZDJV\B>;^J+:N[DJV_H;.]]=W![73361M/KJ>>?\
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MQXE-M@"LWGA"T@&92M*-)=YT>@M^6]GC,NT1AW,!^.C65[S+<NR"=3@<W&'
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MGRY_6IZ]-F^0WH'KTZG/N\GOFBWJZ==/ES^M3UZ;-\AO0/7KBK:CQ/F^3S.
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M/?[WDA6+4+CEY583<T(2U9F4^*,^_4X;G/AF:[,M%3CT^!M4T/+RD-5*A K
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MME9B"5KB5SEQJSV)-YT5NF59%[8HLM6E*U54Z?U[OWZU*KN=@-OB[AZM5_\
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MAZMZ]*#GE*6,WBE=ZZ':L;J5K3\#WZ=%.CHKTUZ-5;AM0!\*GW\U[T8;<S
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M97=V[?TTUA5T\4\R[&T=CS#O\8#S^?4 $EMOC0_N;5OY*Y[W7\BIZNM^I/\
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MH9>$8&"95S(VFT_+!HW#)++RG $1I+(8V,F.&SC86'91)'GJ\&IRY)&(O.&
M9OW%;V95<=N)4FT+8G#ZKCID-O+KT$<G*N54+0#IQ'#?@VV++Q255=N@95IC
M*UY\/!%)Y.:#7H <[RD6A&:MN4V:MJ7".H(YN'Y$64&@I*I@FTC+)C,-GT _
MQ82B(7.^!S68.JQN76VFXG(0:$#>/\>NXG:%L=.E632=-KWDC?/P=+'"*35L
M#=**O:C=W 3-R\-P%[/AOEJS(H=Q++P,2R54%D@TWSUW K8]2-D[D6=JXEF[
M/C64K47S>Q'IL3,;XO$,J=8N0&O*J\/8S)G+>=8T/C%IIA@;:EGBC: 3 A%X
MF3QKF#,)V$XZ=#)<;89 <PAH_E30/-&,.NCID7+!J\;AC[*I8BG+(O5AC\S;
M?8(4? +ZG^3M23EB5O,JN1P[+XG1DGS-#'GAYO%\=K18 R7P>O#,.S%W8<6S
M1$I/><CU-!S7,23;]ERL;" 9MNKD-?$X=DR2@)5W3B+Y[2 "JV'B&O,=G=;
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MW-3\3#IB36F47:0V,B)4H&E$.(QZX<(8)O) ,QPI*$)P417F=6+J@AHR,K-
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M9@V0CWP&K=JBCBO:.)7XA>N37O.[7M?/&(7W:21*1HS8QJ(.6%6W++DEESE
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M!F#W; _VO/JPR4Y6/(X&Z[@D;_&=_(>[N_3^K5+SA"^\"7RFGKZOX-MYY_\
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M^!WOX7D# %V>\?KBYQ>XF+H4Y4Q</CX><1-S%V0V$)RF0Y0:Q\*>0ETG9JO
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M4<\DR[LQ$(X^.I$,>,TS-YDR(FZ",(XTE10J)""=.4E0,%5%'-0JH :];Y#
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M@=&<ECFC.&9/&%\IGQ0-F),9A,BCTO(#=J_+31PD0"L& <=?'+T\$_\ )E)
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MU4#F^.,72-^2C18OC"$&7D=&1,,YH1VF,KWL9@*Q]*GTWQX/G8EO@UL)EC2
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M/!U?//Z#>K4]I3Y%/HCVM5JF3L]T'M5JXTPWP;WC].W=FB=</>BW%W75N_\
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M)XD)N>5L?*(JK\K7L6NX2-M]EG K:DE2VG!OKOI6E=]=U=^N+*S+9C(UN3=
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ML[\8,3[#;^8T]_\ C_-U?M"_P=.S=P+P"S#TP"?5FGW#L[\8,3[#;^8T]_\
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MOYC3W_X_S=7[0O\ !T[-W O +,/3 )]6:?<.SOQ@Q/L-OYC3W_X_S=7[0O\
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MSV#PXPO8ED$W*9UK<\<DF-HTH@RML316/+NZ)WL6%..GN^NV4Q[)V3AL>/\
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MD0HVY5V[+Y'NCR19;3SV2^-V2B#'HLSC]IGF&803Y0&RI)9N4 M0%B22=&L
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MCE_9Z^QIS#9Q\#65?F]EOU1IX=X)\\\*_P"(XG\;3P;Q#^XY?V>OL:<PV<?
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M)XUQS-AH(^HP2&VOVLB=44$M$2)%P_%-7SH@D%=MZ#U6&YS,5LOD:*$1K%:
MAK8UZ9$I63FY223C\[3 /*E9[.S+99,@+"TXAA4L>5V0$B5>SRR>G0#<K\'3
M8,Q +H?%"M-J?3B$UKQ1'I_TK?\ RU-<V7Y9_P"ZW_5JR?'^K_/6(F/^=B7]
M]7_QUUTR_JI?[@_>=5?[X_J_<-6[5]5TTTUC,U0?.89+FPNQPH3<1>0(#4VE
M;[7=Y!80\396-;K+K;Z.;G-R5J%;+K;Z*ULK;6EVZNN+B25?AW$$@'-WP<M8
MB>_.:MCT$PA4A@Q<CE(((.Q'?KJP6FN=A-8J)+EXS5+@%!(60T+@@@J$!Y@0
M=QN-?G&88J]U V3ME.#G\,TR$?RUE(5CHR<QE%+2V46N,34%P99:0;Y!'9I
MY&D"DGS//;*I9$;PBN/(O'C8UHU:REJL[H\(=.2UHYRX\N2V&<[+S T_&Q)8
M[7X1CIPV%"RWZ*0'$>)K6E9%V;(E*1LT17'&25L=JU+1KV?'Q%!8)D/0MQ+(
M.?5#-H+04KAX3S$JJDYRK2J3%0G1:XCW06-2>=/(ZVS-D^9!]JS:)F>/F.4A
MD:NQ>P@)O9'R80PF/B\A&,8ZFG"'.8'49B1421.7,XZ63'#+K0SPB7?/^0]K
MAB$09ZY4,#W58_7KTVR*7\/P;AM H"QL;\)89>-S3"&W7Q9=/$QXXV/T)V?(
MK)L@+&-\GW-5I&7.LI3\'5\**".>\NSY@$K<QHQ03N_7M1[6PT3,/=>">'$7
MUQS(S2:#HYM'3!JY5P'CYI+#YZ&8PQM(,0XUD8<_  K!-C*\I*3B-#B8.&QP
MD=C]SP4/+DW+(5.+MKM:91X$626.])HP8]K/O@X1C27)\:=I9'@>_%+NJKAD
M)C3NV-(AEIECB-55;\T7KD8Z596&^&AX3QBV09[AY5D,^/"Y*2V1RTNTQ=PQ
M5=S&8;M=O\"[?L8,%-HF59"-[0L+DF$V!5N,;,6.,#$FQ)(+A^'#\6%AB*H8
M2T0F R21]4JZLCS4/1)9HV?E#;HSO!.FO!9LQJ<7W5XXR\BI^&?A\/=BMEM;
MEY)4PZ<%Z60]"G*%?)Q5$\7'EC0H[AQFT"++M'N:RS*4^8*N??W+UB8*K-1Y
MY$^*EI2!V=J%+N]:.+-9]EG&F= ^T_'S3> [0D,689SVTR^T9-<C&9@VQ'D7
M$,KG,^<[.X6'!9-*'H22'62SV"F(V6AD:9IQ2*BS8\H403*I,'G/P=7G@X0K
M\&B\!Z&;+(//D4XUV_#>-9H2U9M/%7.Z^066#SH( 4JZ">W%&G3)RC(J[-Q>
M-<1X^+.?#!PUTRDH5*H5KF&/1CRO1:JU>6:*SG[<4[5-_<UUGRG].N734:::
M::J*?DE_]X2_RUM5_M_^W_/4_$/TG]RZI]6U&FFFFFFOC[[H3C_($LSA"2(C
M&.TED2.6[+.>XY"E\ &YC'>M;:1,3'&+C$L@-R*.RJ*!HJY8L64E6:2B7/J@
M1;.U]5]2]%6J*GF6GE-?BO9"9YU.&\-7A.36BIC1RYY'%C9G:O-'9%?$>Z--
MWI(+-4HS+-O1D^*(<.[04,9\2S:<0D$+VIA-AX@FB">U6+T6R1*NG)4ER\PI
MH.<RN9O=4\9G\ZF9PS/CL=X-P!9D%8W)(UCI?'LWE^%EL%R>8#XC.4($$7:L
MLX0Z[-X-)$K*)>3!%+&Q%)_%2 M)CKIR\U8OQ'.>3=CQ^*"\\8 1I;AYXSEX
M5L6:;!]_!;XW$\/D4.UNR8IR+E<W'?EABM6?#\1'';,C $*5+FDY9M.$=HAD
M6;9QO+BLNQYI-600>]C) ^)D)M_. K:@ROLT;'TOR'$LT9"LE=,HS[.V.L%N
MW,4F@0EDK$T_,;/D>>L(68AQ8G'L3S"0P^-DW"3^^C8Z(%3.67ND!S\@EEQ/
M$R\>@Q>=[9V-P+,PH94',HI[J@.%KVYSNLH1(EQF>-:NT("T58AW'-?"RL>D
MVRE43Q;\7Q,KH43J5?@ ?-;H)XCNU'0\-M>:,*UVHJDR!4?57 @K((+!V' F
M6B%Q;*8C%>/AF22E[FQZH1GC")B6LM>JOD[KTWRSD\D_56>IJ*)NU;[W-E]U
MBM+J^SFM%LO),.7HF]3/D7D0H7.Q1-E*(?*B%%*J0NPVY1YF(*KC1%RW5Z:\
M_.W.X.WD=]SS.!L';<\S G<[\QVUKEUTZ:::FH?CT?[5/_';J&\A_0?W::EW
M?A7_ .W?_CKJQ\OZE_<--0[>H\FFN;9[B;98QY()CM9SO$N*1LVAL8+RF79M
M=8X#%<@#8W&8PLV*$+Y"R!OY<ZJ/B;)8=8@/N<OE1274MHBJE=:VNYJOBX,,
MO(IR0BZNV6RH3U4H%2@HJ*S4%%"I12&YUV5@P.VMYKD9E<>"<UJAISQD9AXC
M([/(3+D!.1V9T((Y'/,"&[]:"P"V]S<R1"")?"^,L&1Z(PK*L6/%A9S!Z6%'
ML6S U!-34$D[Z'9(@\%D F6K1J2MB$*DRH9%P0"E^& (.6BZENNE)+(8W(H1
MI9.3#%0$+266L9X^9CHBMU)9(@D4O JMNBL6=.3D.LC1W:Y8NQR(1M=F5N7(
MQ:4:L+%RH2^.]C1IU5GD:AP&YU8#?H;#FR/ A>4(H!QML^P\-.K[>>6-CHOC
MX$.E-QI%XJBGD40BS;-R=A-N[(JMD9"W53<I.GJK>RZBZUUV7)!<5<0K+L<W
M(3'/+V=*(@8A9GQ%><\=6  #32 (Y5EW6#U6_: SC)*\W6W/6*T<KS<_WQ%'
MKREMR'>FQ)+=][@V.]FO&"D)'8WB.&8"J'B\F0QVQAXF&QQ5C#92^&228=:+
M<2BT4MCT@)! YV1*BK*L"3L4P(D;UE&B*MFNZJ]"2JT3&G.I+;.N)&E*22G?
MNN/.MJO,-M-:5HR^.[$Y*-T15&\VR*5F!WHV55%E6B;>*UWDJ2=EWH9JB$\H
M4:GH1C9RK'PHQL(P[=%P^07YR/,D$8A>#'92DBQDF1)"$4][%O.CB\K/OW2S
M2EITBI(2CE2JM2;B];,PDRQ@9H4C&F'"14;3@V/;"KC20_>S.+6V+22@+T7>
M+#E)76G6H&M?JN&=Y7R+!R"]$M+)C:M =V9;QA:=')/4E-U/,BD4(O!^S$[E
MH P&Q9A1Y.<015MC:-DA\1A;N48TAEPY^P90<6X08JDXE'ZB"95FT (W,674
MX@101;<G=NK5+<J5Z]BJT&2K8V33[X755$Z0LVY%-DY4>;DD+LK#E &HW=!.
M9+*(N+R7O7INSBJUF.XHQH!577;QP'!YMCK:<'@D*QG%0T%QW$X[!H7'6U[,
M!$XF'8 (Z%:JN5WBC84'%H-F#!!1TY<.+TFR":=RRRJE;>'?=6NA9FY>9BW*
MB(NY)V2:+.:#<G941511\2@ =P&J; %B  69G;8 ;LY+,QV\I9B23\9.LKU7
M4ZFW_DZ']Y=_Y#+4C^U_N3_ZZ:GXA^D_N77PWVB\9Y\-[868C6-8#M"WSPI(
M=BYWL]99CYF7!,&PR.10JNXVCTIF]K*1<!=!"<4Y:,/1,D%-%I6^>,F0L>J^
MX#AORX0:>19A,BB^Z2N1E&Y ED<!\!>Y^1QY+0E:M7+AQ*4$DH>.8PR6>81J
MIT9G3?&FH92W@&D8B8/5GQ8\6XN\*,T^1DZ4:X-K/1PCXJ&*\[%9OJV$R;W4
M?(,K"ELKM=IC'<&A>U?AP^H,B,/QK66N<5R<%FN.9%BY.X7C  *R1CZ&28?B
M]=XHVCAFQH+DKR5WGY*T8@3H6N"V0? U[[M5JY\LF=CR1<7X#B6PVS4!5XI/
MBQR^'M?DATR:71488>1/3,[.M.)SQPI0+-X$'F*''XM23KB4YASM;AU(Y?3-
M[I4Q2)HRG,QZ[SP?/_=4'L'VQ#&28Q:YR4)@<F>8&@1>! 0<>%94:FYBD#!0
M646,XN-G\.=QM&-.6EY2039%8DFU4(SYG>8>@V%9ME>!EHS.V:S\+ZAY$[7-
M:(IXV%QV98N<,[GA_P  LZ,I1;\00]1((QFXJ9KLN"&X@L]W82HLZ<O"F>Q4
MTFN2HYLMBPI-6YC'&*<KXYBK&>UEF3:9V7<C9R5S<3Q7AS(FT:8A#[*V,,1P
MN4.PZN*L.-X5)<L1&.PM%G$I.[R$5R_%X,3#M(G(%(<!8.FUC10L4*R'HQ59
M<ZF38+N.$<9Q\<\^XY:<=Q(X3%@0Z9V9PDOD94T*#DQ(@RQTIQ#$OQT8TPE@
M">_B'"<BZ\A0]:?#,JN4BJW,M,/#SEDF-5NH>KE79;Y!3#MCXFPV==NZ%R7:
M5V@<>2^50B1R'-V4(5!H6/ME60)-,H5/]KV#.1^5)!"LC/2^+10/&>%V,MYN
M$XK&KG#F-24D0+$&J;!JP5RP96G#!E2Q1<[)PHY: <_8I+[H^+4S,^C5)Y,N
MW#KXT=E!BF'*5#U&"B?3E4C6V2RH-L/%R+8]-V':LCWN8"0PDG)4ZF.O$94H
MS,_4?,9YJ%4.[VO:9VA_=%-GM/:'E]Q&=6PC&J,_$L91,\:8F:XG1Q[:UQC'
M<(90B,\"1JI0_F29RLY)W600C\89AD4MH^7NQ:(&!!;,YD<BH0-91C]HR92J
M"QF<:V1[J</$QL? :@OS8M?<W2^17(R99C2RPO-45'97T$$IDHD_'184NJS4
MN+1AP'-R<I\D\X,KSXU*,(8RO!ZXOC#JSWR3.PQF;W0K+N#CN6L/Y5E&8%Q^
MS%,I)!K7N-,9,8I.MH>_-^6(<I"%9&ZQ)C1S)%L78V'19\.6C06'A,@RD<-/
M436CAEQ''VEAE)"C^. <7W-"5%D12J965Q$^Z'B$,=C6@MC2QY3Q,>B6"R:+
M=GR:U2EL8G'>BJ2!RY7'A69H7Z?9L7AS<%Q*V59S*93WK2]I\C"AK/J22!6>
M6P7(_NHK1U@2DH8Y/EK F3R<TEM&^%(1%WS@*HXK?#9+E%<_$HZA8XBS=%^S
M;Q%DQV:R,QM5!EA!>2+\L"/;T:ZEP.7F;@N0R,GCSEQ +QML:K3#%LBKI/@Z
MMCSR%,[NSTQ%2]H84()%)L3N!Q*(JA)2KXA\&+6:T*\DT5GXB_5Z%>::E!E3
MI&+Y& #IE[IZZ$XEEAN'9TL+#@>0XAE*?,<8XZ?Y(MASO,NSY1><8]Q<\A,0
M HRAW$D\DKPF%2['A(^Q"#23E9M/;AHT_(*<SC*4JM(XML/ GE4FXO<-')]U
M;*5+H%8UHG 5RBF-)Y8>6:O&%@S2OTPV%4\\:Y<,S+?&FYZ$G2N)PC^QUE95
MDAXET13)NM,N"HEZ)2*MN[%$K]T[?SG%!K(E9LRB ]]L[#);#76+,:-4)A&I
M[/LZ!<FRN=EA AV3B\SA>-1&&Y7*PL).!@47EQEXU487#7-X=#7';(-<0Y2S
M1K5,LV<B3#%(]QRYKOCOU'=Y^^=3A3>E+S;FK!6NKPK/&HD9W..U6$XO;%HX
M"6R/_P"8^SRE>#27INW V.0Z*LZ +.AZ=$LM/M2AVU/[LX[OQ"G=Z?'TZU;_
M #'[QJFI.ITUQK[H-%LG3?8USU$L--9"]R:?BHX=$FT5O*)GE7JTI U=T95"
M$1!>ZRP7:^O>ICB@]TH/M=)I/&];^-MY\F36&'->78\5X,;%P[37&3BV"^2]
ME1YNT$QQ9KJM$+Q#KS#?<=.,Z3;(>G>!P_B@0#;F:[<-RUQUF65PM6NTUBQ1
MN6I1N4[;:XS*B=N_#N5<58;Q^P)E,9!!F'VZ+G&.,6E^!)DWD619XOM+N\FR
MO+,^ROF+')"&X^K%W^+ S')MRIR3.[[$%)*T<*1\+G8WL<F3*QD$IC+-PG3.
M O +'M6/6,Y.^;3CPZ"0J:">+V<4G45OF)4B45Q:2(#N!6C;M2OA!>(8B+&R
MD\L\)N']2[66:[/U9K<5BD[<DX9@6W3@."QFD5Q_G"#L#>)MC&&91/X_QS$)
M_ED$AC_ >;T28V%PW(+0W'W[IGEMUCN,Y!<J 3+P$"-.G=J8^RJQP9#/E3PV
MG(-SF^5D24!"*9L_<9[B</ EDER#+"MG87$X6JK3/7Q#)KP5GIK:W0ID&O,I
M4($8DOXF+;W7^Z;(RJQ1>5K9:X.5B7E':A,+B@C0HDVV?*LH>[1!'@,&RQU8
M9>.XO#7\I/A(9"'(4-)\X8<A4-2$ 5TK7S5\VV9\_B\@9'G%RBA&UY!S@1DZ
M<G0R3:Y/7X=\ZN.66&,>*#AZ9*@NJ8N5:7$VXG/J+NV-@XLLO@4NH":TR,7)
MNIR$HU,%,%QIV(>M5P#FG'<%'K;&;(P.P5*;<M^(-3"XLPF9]$1RXR,XLDQT
MWM)98VV,>9?DX"!1V?$L6-5(#+!V2!T$A)2#A,?A<(9FNRLG)9 X:U=LSR^6
M16-R5!MK!P];L7**HVC6.N":=>3-R,B<N)6']'7&]\62G.I*#%G[ETMP6<G(
M8NR<=3(WZAYGY%ED,TZXZ4Z,*$7OP^-#USD+P7'<KXK'+?W1='B;T52H1*<&
MI#E"^(K,](\KQNZ\]0J7;<>T-[G)M5DY:VRY*I;.\(8W,8'(NH1&,:92D<HF
M&)XU(,F#8&)QAU)2?04?,'BR&,I'6G5XJP</TEC9E-HW>U[^)0::UDR4^ ]U
M,$Z:\QNW!<7B7"&HV4DW8)7NXK*B(5#8TIMRT5EO?DX5='I*KLIE;@5*,SC:
M0XC?%XJJK%GFC,AGX.=2Z!ER:."(D&,M;9-?>Z#XBB.2BFQ#B;:3C6.)1D\>
M3Q!!<@,FLZF$=LC&)+5Y:B:@^4AF59Q&,6Y.R*B@Q!A+C$">#RH\X8M,Q]G*
M!"9')6R9TQ)T5:1/$<VXV*,$X6:\!E'%O:?(5IXW'<^2-;JSQT$"6N\,>>R3
MQF2A+]-^P</QZ.I*D\19>+-;(@E%>?)-?!6/D.<=I/;>NZ12UGS/(1'W4& !
M\MC,7F<\F"1K;#R&25D\DQ]#,@V0_!YJ#KG<5(X<'ML?2-8S"GTPO;@)L.3"
M'5X;8-:#$5X+<3-R*[)>U3G@21N<H_'I4I8*U<C+EQ9SPI,QEZ*#!R>%U.4,
MA:84VR!V1<O%QHX^&@F#&UG3D-9\&=828K.$Z\.4\2,@W4HM\;.08YE3KN9'
MM)CD7>]W^Z<%6E#B$P]Q.$6C>:+Q:/+2]!@AR5BA*%!#.^0(LFW+25&[1,M5
MW8W0M(D+44J6)T>NZ6\>IZN5T1DY QSO 7J(DDMO(4;IGF*HS[IL0S(C$=Y1
M3W#A@:&,C7^M,T-#R\N[E1S'EW/+XV^Z_$=P.X:RF[M5_JK_ ,-8:UU/<?E"
MO^U3_!9J%^\7]!_ZFU9_OC^K]PURUF7;)V=-GZ<QW'67)V^B<GDP9A(V5*0+
M(\@CPN.DY4VA#"03"91>(&X= @;J6O&8%,O-SL?'4?NVR:CFRU=*Z^LZ)7*[
M&A+9&^&O+MRKU.(4R)84A1RLS;+KC7ECQY^I6DRB*25#2\Z3@,EE/1/:CS*#
M1N7"E&V6YE,-7IXT;RK:G)TYS;F+;*Y7-\K1G9^R[&#\(S6(Q-D2(1H@)+2F
M*Y%1BDD 1XJWONO!D3XD_P J9"'R*BU]XMT11;K6W*W7-;]]]:UJZ0L)T=9T
M$;-TJ-LPED=.D7",?O:].M).!LX5V0C9B#*M5.HB%UZT@**O,.I$.EEY@/OI
MBDDH"=UYD5QWJ#K#G.!-CXX[@ )UB/9X*/\ #@[A8R#*0S'CMYC(2S=B3W&0
MP=R"]:)L6CZP(9JJ)19(H.JCB-;K554%K]#LN0V42%R8I-7OS;6E/%8])6IN
M'1(.6$U)"R8NJ!26&L]RT1'RPLU'6>V\ZMDIM1U7[UVO/[YP":( 22 #JF,8
M<V,Y:/QPJ>QULY207#2A4AB9<I'L=%6,<,&).S)FG<"7<MUT1Q C,E&#\BJ!
MO37<R51FX<5N)WH7UI.<I4QGBB3K#'Q,?$:8"TEBXH5<*4"NS+&"Q"XR)XB!
M&68 ##5Z5I1,@5HSSM>]\D48LE,B_.V32W-NK5J*.UF;QG#[ON"-5K[#VR(B
MVG;HGCK9]39$2TU1R6N0CN/[6;H[E.X'3("4VO<MJ-[BN0% 4<K*4S>YW)%1
M0>XC:[4:-*V5Z4!)9\DA%@<5)[*),!DIF''FOWIY<I9Y(FNY6R)4 .JL+BU^
MKS"E.M/IW)YCU4VA3&E5O[8!QZ6@CMW&3UF"49P<7<0#8Y@LCAN"D\/8C"*E
ML8S"0@HZ-QQ%F45"XKQ[.(5+3[DHLB-0#@HZCD<[$9&S1=531(2M&PVC9>\%
M.7C:X:?6LNX%<.7#LNK-N.CV;*NG"R6/DK&],VN&I[Y\F;2>Q5RV81DE,J")
MY-\O'FJ[D4IDXR4SME&^ZWA''GE,!LX.+.G,&F-442MV*<V3&6Y;'PS"YK(C
MHODC 1V?22(0]M-I8A#*.8I/(PPD!5I0U*XE<-N<#EEF3IX))QY6Y/>H+5K;
M7,)C/CNYG(0XA/*.0CJJ#(EC95L/(;)1MN9!;AK$F@(*8\W/BHO+=S9;2!9S
M7">!QW4ENC3(A/+AV>BD[.T\T%0A#![40#F9N;I9A(L>Q\<""C3\.#BTF4>%
MQH6U+A6#*T<0:WH10>%:)N$D:M'[)@HC'V[).J3MLR4L'6*IM[Z6=3N]:NU&
M9[4JQH6):CV;:C\VY+-5N<.X/C'FYCY=8!5G->4!)(B\FP"S68/(O+Y%" CE
M&WB[C8>35!C/*$0RW'W\DA;QRZ8")=-8&81?L7 PB)EN/945ALL"D&#NRQ=N
MY''0SY&VZM*I.VO)G[519F[;K7YS84AC9"[]/*A/(EN-FY'+*RNI[TI*J4A:
M; -.\Z28<R'5W4SK>+??X]3*FQW7?D2J,C#N:=8TE:3CN>5$<=S:V/3\0K_;
M-?\ "YT'WX_W*?\ Z.I'WK?^W]^L64AD15D[B:J1D$I,'<:MAKJ3WBF5YYQ$
MK"*I>V,KE;D*O%0-I5=8E03>M<QY:JHYXCC5+[JQR)\-NBD9 DMP1N*K 66(
MH/(XFN3D*@;<*+U VYVW<[_!^,WP+4:7>?@VKTNJT^_Q#3H1YRNQ;I3WWY%V
MU/'ME/9DB0FX#%=GS#$;"7FC<CN$ L:0\2.N/R2+E(0?,W,V(A!"I(Q#3AJ*
M$7E;./=1TL1#*WW#WB[>^IC)I"!FIB(WQA,C=!CY*S3)CR^3IW6,5LFVU!*0
M;<37:PK1:M9:.M7M+(>@8AVO!VI"Q8$'J1=W>3^6;.Y0@NV^'2W'6R7B6;0^
M3E<,8M%Y$S(]%;.D=.A\8QE:6R<<1B1.ML'=DV@FTA6&CX%#253"#QS0.RBP
M#D;BRYH@V:W*=*M:X] M'XN,Y\M'!9,I98]<[-KF;[K1:+#X1ZAA7(>$VYJU
MF-0O.DYW4\B<+7%7&<'E;%-,F6)BSQ2/&FXKD 361#3EUJ#EE.I%LQD2V-(U
M+\HP3&4>P[""D,C&)L>3]P"CL2BL>(14D)D[+%\!M.-4&@F1#@HL=)10^+)+
MN$@%E[D98S0Y2HC4ACE0R#LE<?(S7PKI0 KE94N&\/H=T/=D+X/SL**U\8-,
MF(W66VI;J8]8;\Z4CC=IBZD@XT&SLL'9AMT&[=CY%63Q2*L*GQZ;ZPN2;$ON
M?SGK&<$\.[/@*(XV+SB0C82UC6-PN,2!XF)!P:1')7$[A:8(V7C2 L(+;$7=
MJ;J//TF3==6U2J+?4H)*Z6!4E<>B2)(812^9@7?(CWDSJ]^&XLNL@!9129+%
M]A!YW0R(/*UY5?;<,[8^-Q&:RIW#GFL>)95C-CL&Y:[ )OK<*HG9LV@)M+8W
M(<?0>=3/!2:\&(63*$"";L!'LQX_&OWS>,/2S%S1Q"\A0DI:')+"5:"3:3$J
M#>V+5&N4;(")D#(R'GS.;7X;DM5"*FF,89=(6+ ,P':,;+0$LIZJ4'CE@ =H
M=&4Z<J]&&?!9..F)T?)QHVGR'E5E?%R);C9D,R.X<I.8O=G? I%,JD_PUC%X
MD<1ES<RFZA$<7L*H3]( A.42%J@ZZCQ*8(16,HR6Q?C+324?#6$*.+1K2B5R
MJL2S %BW.2>\\WA <5#?I'$P.( _%F?TC^M\;4*S*%56*JH4*JD@ +A'AJ@
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M-G^\0?U;^7GH?D]VWD[_ "G?;R:DCN'Z3\8\PU(Y-=W6WGC/VC4\Q\S^7?\
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M])OYXS]HTW_-?ZM_9TU#D]]??;>>,O:-3S$?$_=OMXC]V_\ [=-.2WT]]O\
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MR8!W +8#9<L9K9"N&22#AG+N\1&E.-UDPZT3GK+#WVT[.&V/9BHRVB[SQQ_
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M0M&67*05@[2B*9?((,E W"[N7:)<K[;[0>14\.8OR<GFH'2+2C:O@T4CY>6
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MR)T1 17"R,0"C*Z?#I#(MB2JP%9!JI"QV9TUDM"LHWF1T[J92HA8@+DRR&"
MJ28O64<ATYC-_$-$V95.I(C/^S_)I/'^.9MV,@,2*9Q2&2600<^W#F2<"(S@
M>70 9)H.=0Y!1=+'LU, 12\I8'3$=#N3K$/>-6275Q2T"@R.N$%,5LP4ITYL
MV*9"PJKNJBH?!:><PDU&3 H,BH2:6Z=VE1&,>D6Z5YXW*@:BI9FG,(RKWQ*Y
M;=B!HDP<]#C3+4,N>T+;16RR\AAF1K)LGT."/FQ4W3F?R4]L8(&P+V4,Y\\C
M]D)6)VP@Q'!Y$TURM47=!" ]D[<(RI:Q!7@68S55ZC&:SH^.W65)+BTF,=Z2
MR#5$7"Y%R\5Z+DF'*+S9@ P.@5RQ5!SNZ+51)S5LA':TT;'$V8YA=L>Z(,?K
M,S2=5!*D:V**S#A1UDFV AWX*^?*M[@J%[,">3'/5!8-E+E(>PG=@ZR(DCXR
M+$64K5@S"1N9$QCBU) H#2$IJO4]5'/6ZJU"ZBM+$H%9QC9$L/(?QD!J,;*O
M/&LZ\RQNW1HRT#(,SLLXMRITV$EB5(956TJW@/%8],7C*EHAN7K244F&0JQW
M3QR?>J'RG/M&G*?EMZ$]G3<>8?M]>IJ*J=5D?O9"GW5/M7.?AT_:/^.^G=IJ
M"" ?';R'RA/9_=WZD$#RJ#^L^O\ ?J7<LGPK_O5#\._MW.=_X5>FOWQ2G3V^
MBE*=RFIY2-O'8]P^)?,/S3J-QYA^W_(C4..3[U0^4Y]HTY3\MO0GLZ;CS#]O
MKUJB2S[#PW)L$Q])UHG7*<P9F",#"O1SE_('3&--'1@F\:.K4'- [9HW8OW;
M5=Z['IOEF#ZP9<Z=LW2:55Y6I55H36&/VFVP7>>,:KCBC,%^]:MEF$WYFYG(
M4JKZEMUG-G4=.MC"0))%+],V**I;O*SGSLVVR[3YB"R;ZE=Y-V9+1$IS*@!;
MIN=GRI0P40K!YC"96&)R:+J-FSH?$92PB3LX1F( RY"PH[</=L#E#A$;'#-U
M7Y:VM$<!%M$NYM1.%HDU3J&V7D<-HN&9%0T;UL>%N4HLJB;X[-M&@YM.0O3I
M5Y%Y0<XTHS=,2A+/FV4++S"D)S[>&>9>99*D[TD"EV(YYV98^&RR>D2L>B8_
M'HMF7RQUTP&51I[8$-$S# 674'F(\S?3L$>.A#@T(:BR$G#2(T-?,@KXB^2O
M3U!I%,<VZW]'ZJ3!"@ OTUO(]%IK50T:BTFI)-Y&E!L)UY85:O5$$W%GF[ $
MG<J&$ZKU%=IL\W"RNBT8S<S1]C2?-72&880QL720<Q1R2=YS1>30BUC\7E$[
M7+"('&(;'$CCJ*#*&3745@S<8_BHH1&X\\KU>/B>*#6+D"Y).[HL:7QFYE=#
M7,R5"+0M=LK"P&+%$=J9%'I%4W[ABX5FYDCB;"JTZLH9*,IFRPQ,=^;I@1:&
M=Q!  >0+%53)H03OU\A4 :E@#3L-H+9GMKCNT:5C2:<C;CW,+690Z5)M8ZC+
MI(ZA(OK@=(@;6N*%9-,V9&%,6T[6A[HS,!Q6*((N3XU^-;RA5Z35*]1J1QVD
M\^G2=(Y4'R<59W56E09$)-2$YNYLH7IJW.G-#[I.C.A1)UN*(P9'2F-1)Y+-
M%BM%[-1T&15D"PYE:KH"#JG3S?LTH#)1:FP8-J-3X..GHIS29!;2X\9,M")J
M-6B\<W0Y.:3QH5'ASAH&:C<</AWHZ/R,LP(*LH\:<L,A2/1G57;I/2B3'3 9
M:PQ$SJJ\NGSQ>.%6>5045&G"DW8!7&M.2O4<%0'$T=V-/%:5<EL1&%2_)1*9
M:MC)RLP?(!F-Z'8[]BDKC,SC0&6Q%X+.Q>2B!YR/F!JSI5@3#DVJ;L<]9W\?
M;6J#AJJFI92ZRR^RE> I99?;=9;TNCJQYJ$D[-S S<,& 975U!5U=6#*ZDJZ
MD,K,I!UB&4CN78*2G*P=60H2K(R-RLC(P*.C*K(P*LH((&0<<GWJA\IS[1JO
M*?EMZ$]G4[CS#]OKU-N53Y.C]ZH]+EUV[W.ZE>)9UWT^^-_32NZM*UK3HINI
M3IW@K;MX[?>)\2?*<;?>_DWW_*?+OJ=QL.[XS\9_)^7S=VWZ]2N.3[U0^4Y]
MHTY3\MO0GLZC<>8?M]>G')]ZH?*<^T:<I^6WH3V=-QYA^WUZIGB \BU69$!8
M]\R<V52<M'B2KEJX2N_"37;K+7I+)W>_8I9=;7WZ5U!3F!!8D';N(0CN(8'8
MIY00"#\1 .@;8[@ 'O[P6![P0?C^,$@^<$C6,-H-"F<@+RAO%1%AHY%H]"2;
MFM'JB+B)Q5Y(7X$ F/5>7C6@U@[E9];D[)FWHZN(5H]JYL:LK6SD[J+S$BSI
M2NZH31IH4GSDH2RS4MTT)Y)M2SHJO:K//-_5[C^I%!'8D"76*&Q0 ^*:F4NH
MPV:@E)7)$IA:5ACF "Y)26C(8"'G;(X\B23EBDZ:-D8\2),RY0<@+0=)BD*%
M"(X:Y*NDF5KTG04)0?.5VXM@DW":KU=B=[I!+;JAYTQCE-!.]3LB'-RCRKRA
MC9BP8\NTER0@_!O6B=Y!#V6"T8D$%BRXT0"Q/($V3EYGY[PC%H>V:7L&\.BZ
M#%1XD149(AVR310@A6VJ+Z]LG2U&]XC6VVJ3FZRJR=;;:V7VUI3=/*?%\9O$
M;F3N3Q&\G,OB>*VP W&Q[O+JI._,"-PRA6[V\90=PK=_> >\ ]P/>-35(Y%5
M7CPBK$XVH0(MU6A!_>+1O>OFJ]E$UVSUU=6J[INLG2EBR*ZBB:ME*6WVW4IN
MU 38, Q ;[X )LWC<_C#D[_&\;O_ +7?Y>_4\QW4_&IW4[MNIVY?%/-N/%\4
M;;;+W>3NU7#6 @.VHS$!!(IG12]6C0:UJQ;454KO44HW:J))444KNK??2SA7
MUI2MU:[J:MLVP'.^R@A1XO<"=R!XO<"23^DD^4G4;C<GE&YVW/?W[#8?'\0
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MZSIL\#JY;85+Q95;'AV- LLBQ,>.EW*4JR \M#1D X&!A;US,Y/)RJEH!H$
MMI 9=F[Z %&G56O(=44S>*NA9XMF/B($D'#YDQ"E$2:S)8S%XO2BKR(.:C.!
M&C((*59"!.J8B9;\SF;)BOUDG1V+*%5Q"R(K,&(V0*>J@?:4"F4.G$5%2.#\
ME=1ES1\P'\$::!J,E0))V *!G@(NB++ 20$N+?A"@(J-'D@Q(>Z&OF+5TV51
MLWV8I-Q0LE92O-E,V5YWFM9.K!2"'DZL#O\ 'RG8J0* C=EY>4H])NI#*5>;
MM-U()!!5U(\Q&S*2I!.8<<GWJA\IS[1JO*?EMZ$]G4[CS#]OKTXY/O5#Y3GV
MC3E/RV]">SIN/,/V^O3CD^]4/E.?:-.4_+;T)[.FX\P_;Z]3*+)\0K]ZH_CF
MW]-SNZ;7&ZM?N^_HW=&ZM*=-=]*]&Z.4\X\=OO'[]E_-[OO=M6!'*W=YN[<[
M>7T_MU+XY/O5#Y3GVC4\I^6WH3V=5W'F'[?7IQR?>J'RG/M&G*?EMZ$]G3<>
M8?M]>H563W5WM4.U\)U_X.- I^6W^#_-1IN/,/V^O6GF>2</N9S+(#1JP'3&
MT&5/21 Y#)5&F4CC<>78"CY9G*9 %%QJ=B8XX/"Q\@= 39]L 4+LFQ:YE5ZA
M8KB&BT<EC0".-O3)%!- BE[J;O-U5C(OC7'7Y#(F9(<[@G3EH'@ I+V(G H6
M8L_))Q%61B%KR4F1$D4Y3]YXIVP^/YNV<)H,Q<1BM@>7LINV(N\9I1S',TD;
MM(0%D*4>*'J"A49>DH/%14EM;#GLJD+./1IF0JUXXHG6]O?=J-S95#N+&.-?
MQ@B-..1/J8IL[JH@U$#=&562A,KHJ<T+*F9V6;G93);7B0A+K2T7,\D25">O
MTV(%7D' %)DGELA;I*BR?O-D/E.?:-6*MOWNWH3V=-QYA^WUZ<<GWJA\IS[1
MJ.4_+;T)[.FX\P_;Z]..3[U0^4Y]HTY3\MO0GLZ;CS#]OKUGD,OMN3([DDT]
MRK?HLJK7?]HIV^,4OKT?HW?IUR90(,]V+;JWEV[N_P G<!^G6B$=^PV\GG_S
MUB99NK<4(W4HGNN>+UIO<-K:[N'7MVW+4K2O1TTK2E:=JM*5UU2(Z4^_;9 /
MO6\Y\RD:JP/,>X^C\FK?R9;N)><M?IM7[O/_ (7]G5=CYCZ#IR9;N)><M?IM
M.[S_ .%_9TV/F/H.J=V-O>-7+12MEJ;I!9NI5-VULOI8LG<G?6R_CJ\"^EMU
M>#=2E:VW;KJ4Z-8Y$DR(7QV9@MXUBQ4,&"U1IL5)7;<!B1OW;^4'R:O)GE6=
M57=I42BAEW!*,& (((()&Q'QC7S=C6P_E&,2/".0T,BP,A.MF^'P'&..&BX<
MLTBDJ@\)A&6H X(3JQ$ZX*#Y6=$Y6N)6T!7O!04E%T$$K2+0^[J,%L@VR<PF
M/:\^*X^:1*O0$TD])MBISAU<<2H^2RT<JV&PP04HO;B*S,Y8_+;L^+6UL4E_
MAN:^3 NF0Y1EJHP<=,=2%![43FLK*J8J[%QULG3G'$DPJV&S0&YA.*MF^88&
M>E&Z[L//RA&;&8#)RLU"\74@#!W,SD"1H+$JJD*MV9A2Y1\HJ*2L(UG"<Z6"
M-6>/X/X1PW% W:\\?@TJPQFO7E1:5K.OPS)-5YD+*HZO),[O19,ZJ;'.XKQ#
M(\0](VXO<9%TDI8NLXN/@N=W8@@.S<O,V#Y9V"#N5662($_RC:AC/)DMNR07
M*OV_5?*#::6;/%-GYNTM*5),@+P'<DR#3AV[58H$5WK4G&J-K&)1(L-Q?%+!
M=G57Q,CB&9P\B3%%R,_$IB_TN98&TI'+SZE)O)JFN,@:0QJ')Z4R.4]\V=;1
MPL?+!8AFCA\1GQ '&< ]&M.SXD0Y5NCRY%E#ULG1J36QWF(Y,IYEM7(>-V>3
MLI0::XHE;1( 9<P4)!IA!\<16TM'6BDC2,/Y8'+XZ3DUB)5PW%DFD@<Q=55G
M:);2%Y6V#*T^)0)JD.-'+;/ /-61RDX?B?T5^0(QGPW $=ZIL^97M>R2F,-Z
MPR:1;AU B/7A0PABDJZ3LN&_$LG;("LS+U<SB'..FS=/&B<==Z6?)7IG&>"U
M8'.Y3-'YE W56%8YQ5CYM=5!->*8SQZ&NOM&O%[W5R3X](YD5D!\\4:(,4';
M%**C;FE;P%'*_IM5JUS[U_KN(<0IFU(5@BS"<N-C(-BW2QGKFW7G+-UL_)/-
MR=-5Y%DLXX&/(4Z6#@)B#G.YI<T)R,K90 K7C+ @RGG(&"CAAU&1=]\F6[B7
MG+7Z;5.[S_X7]G4['S'T'3DRW<2\Y:_3:=WG_P +^SIL?,?0=.3+=Q+SEK]-
MIW>?_"_LZ;'S'T'511NKR6^FY+?5PG7\I;=JB:OO\=N]_M;]_P"C5=QS^7^S
MY>5O/_N[_LU.QV'<?*>[;O\ (._]&J?DRW<2\Y:_3:MW>?\ PO[.HV/F/H.O
M%[5Q6V[@40X>ZO!X3EMP>%NKP=]:+5K2F_=OK2E:TIOK2E:[M"=@2NQ;;Q00
MX4GXN;9=^7S[ G\A\FI [QN&VW&^P[]OCVWV&^WDW(&_E.N#"&S+F\AA3(6-
M;Y%BI.03G:&=9JM*VK22\./%/LR,,TK@%$*V6OG1!(L+;QQ)]2])LH/76+WM
MTW**8Y7FFC2CPI  QX;Q%,YO%8"G3XY3C220!6*<S6?&9SS%41:!69F19<&C
M\2)Y@N?A/AKW>-/J<'EP9J/N=F"SBF2JJ1S49I$JJK1KH<P?G:91G.+MF;CD
M"FV:,GM1AIPY+W+/6.S_  L2C#!T5B<FCKI\XC)2:MV1V8,#5S)X3BB62SUM
M@X7+4$'@JC01\><".>5\O+S.)0J'':.J#BXV/S3"\LVP,+A,<Y4)ZJSSHPM-
MLA,M-ULRW:R@I7'Q,7'P;3"T$Z(5R[W*.@#O/-R^)#&+@A2N%6TZRDV,]!D[
M9_S%:6BF1,;,L;BI%AN$2$;C2,Q1X38N"[@IB,QC\1C<@I*)*TA(B#!I<78S
M=22LA;.0NQD/CL;2%ME;'[\E?)%K6SK"S+?B$ZX9N$8,J9N5@O3.R!M0_P!"
M[.<DPQQS9%9R9&7D.-?/'$)3Q)/+>.(T;F;,S$MBKDGH0;9/&RY4.&*Y)HLE
MO9WW+K6%>7V2)$_<XJ@M#<8=8&Q3B=:"1N-*/" ^5CYH6A4AQR<RHN\0H\&R
M20H0LZ\&15F_J,9!7L@F!Q_0R6) W$<C,@F;X00CHQRL+)X?AK-.;P=C7QVA
MM%'786"<F)U10%.'K3%F%7)RNM.+:V-V1^8UM++CFYS/S;<0R)9*99:C#FVF
MV0'R^D4(;-$<AV)QX!,-*[)&="D9-#W60<:K$YI$<-8;R*V&M)'&A4HPAA\3
M.;7 ,:10+&2\7DF2S\Z))RY\W3)HBH)>YBD>62.KHSAGMD%\FMJU6;)F\2MQ
M3-QBKF+T:&+..'N037#6N.]LA756RIT7$IM%*G(S@HQ9P6#5G3!P98&%D; T
MFJ7M1\H@[!<KHO.<'4[8]4?*7F=I3CL:-[+$G%Y1C\E?R:+VP.*9JE^T*  "
M62R,@0G,WP\4Q(0BKH@N0ZEJPD,E*9<>$NFH]F5<4<QT&LT:-@;Q^;143H&=
MWIT$XK/&<A@]/"W%Z<5K?))+[UDV1E8ZHGB.M(V+*\"ECCFGRI-9]5N&-9%#
M,D_!G#IX$Y8W<FTZ]GQJEG7>?):81NNKQ[.Y,M_U7G+7Z;6FX\_^%_9U78^8
M^@ZFH-EN.1Z$OQJ?^LM:_P!.G<6U#$;'O^(_V7\W^[IRGS'T'4NYLM2Z_P#%
M?AWU_*6OOW5K[ZU*ZG<'8[D;@=Q5M_(/,I'[=.4^8^@ZAR9;N)><M?IM.[S_
M .%_9TV/F/H.N?LG8LR!,,M8$G  C#6D;Q'))3(C+ PY(5-FKY5!9+ 7#09>
MRX8]I:Q82&I5)=W<I5RZ:<AO3;HK<K2R0,F6]^[D;AN5@* K<W/D9G#,X5)V
M'B)3A<IA .8K>C\RF2K2SCFQTD P9<Z&6Q(.Q6&+GXG3'=]\Z\0JY8]P,D79
M@[%-"A]G?-2I<$SR2M"9A=.\[A,O9OG,?**M6[T%BT0[,XM@HR,'G/*PT=#S
MH+C5J# BECK6P0$F)>3%G,BDSPF8KC)TCB<Q(.+VW/LZAB,WBE\?'P$HXVYE
M9$JV9C=P3%GP7AF*'K111[6?G&7W;BZ8^!CJ>YL7ARY%\NJ>0(ZU5'Q,CQC3
M(IQ;+OR)!!*5_(;.V9ST;VH[)'(L:%9_GV-F((!EU%SJ ^*8_5;R4'$8?0#1
M*]5J*AH64F#BG)BQ!Y*IX<DIA\\%C2K 8#YK8SWX9D83N!7++-DVY&96>L1)
MV1205E%4E/$QMPDTZM:TKDVR+WZ)7$<^&4J,8XI'9Y'N9%6BT\<A=GID,.;+
MOL&?EA.<TA",936>'\_.GF3)(/*0R%9+&XCQW@W$$I>JHR:*L&#!%*49$GPP
M0D^M)LU9 <+M +1@=;6*]4\8 "Q(25!7MDB/7=GR#Q&B\V/3B'$9/0H2*+P_
M&7F2<:&=$ED#(SN-&-N2H5+8E:Q+S:"\N.BX\^'XYVO+"P*JH96"'.L3+FLB
MLCTB(8'"6HBNA).9&-IES76$4V))-1DSCK"1Q,!#I+#\%1')(I-R;DIZE,"Y
MAEV7&!V,2HJ]8JE)!DEY,2K2<DY0,Y0V,++REI>4=KKL%IFJRM/D1%QH9G#.
M(X\)HZ".1PJ&+''Q5W9_Z"G@WABHI)L(PRD=WIE)7&BO4K.Q=J-D9&+Q7"O6
MFS"LN*M8UR2JJJKE@9G$&/*JR9K8RJLXXAC>\,-F#-2DB:93D$MQF4S.%S-7
M*C,_7KANBY\-7'.1\2#\<NP]5TG\1BT.A60WCN)I"2,@54EO5N0&[GKV4F7"
MO/.592ARNIL%S1EET=DO7/QL5*Y*=ZF;3M@8$XRY2J\-PYXAHV0],UMZ.M:7
M!1Q!NRC% V#PEB9E<B<6V7:AHF1E-:I.[9N1UQ-<?'Q\1.HL(8JOPUB6 8OM
M+6'[X9'&8AR;NM:#Z%B%*J.BA!(=:]=4'MG9%RZ69L.5.[F32]%K>[=7(U74
MZU2,IX\(\XCBXF'A1%-VH88.)'#@:,J*K5,8(:,%530L555V&L&-*4O:B@4R
M,K+RZ!%8(M<W*MF55 Q9A-:W=9\S,W(%YB6WUM3DRW<2\Y:_3:GN\_\ A?V=
M1L?,?0=3;FRU6Z/0ET.'5:_?+;WT6=*=/';M_17?3?OI3=6M*4K;O!ANPW/W
MJ#[UOB:A\VIV.P[CY3\7Z-2N3+=Q+SEK]-IW>?\ PO[.HV/F/H.G)ENXEYRU
M^FT[O/\ X7]G38^8^@Z<F6[B7G+7Z;3N\_\ A?V=-CYCZ#IR9;N)><M?IM.[
MS_X7]G38^8^@Z<F6[B7G+7Z;3N\_^%_9TV/F/H.G)ENXEYRU^FT[O/\ X7]G
M38^8^@Z<F6[B7G+7Z;3N\_\ A?V=-CYCZ#IR9;N)><M?IM.[S_X7]G38^8^@
MZ<F6[B7G+7Z;3N\_^%_9TV/F/H.G)ENXEYRU^FT[O/\ X7]G38^8^@ZG(-EN
M$IT)?B'%/REM7MHWTIVEJ^_7IKVJ>_JK$ >7XQ_9;S[_ "?R:<I\WI[OWZD\
MF6[B7G+7Z;5N[S_X7]G38^8^@Z<F6[B7G+7Z;3N\_P#A?V=-CYCZ#JF>-R5K
M1S<.M87$;6ZUS"UZ\239U>T3NJUHZ4;WJKIMJK4LHO>BDHK:GPKD[+KZ4MK5
MRP5N38L1W!@X7?R>-LN^W?\ $/./CU*KXPY@P7?O(&Y ^,@'8$_DWUPP,V:,
MUC<.8EQO;(<6*EL=9V:Y=(D[EI$F+*#AN3B.3609JWMLO=MGRSLR^"NGJURJ
M"+=NU((H+*N%F2'/"(@>  LSIP?"EB4V0BF09>Y[*]SH>8.ZH&AD',*L6VJG
M9]^0]<:6=K+Q?=.1^)YE,M?DPZG'(\>:;$C=]K07&# *#-C4J& F<<E^Q=(\
MX8DG2,PF4EQ?D[(\SS3/7"(EYCR2AA).?1QUBB MI,R+A)<R+N('A<='(RDO
M&2XM5N_<R1T,+VJO6SAM5(GH8# ].\YSMD*4Y]LK)S\?BV;RMR*>MCNIX5#)
M4@-@R6;K2-:*^C5/5RU'PD7<1D5+*&QL3%?"QN[O'0O0GBU(.A*9E5?9+Q1U
MRDS@3.4OAF9T4)"#B\JS+E90?)WAXFUJ<=[/4+%IX_ QH1(X3=>VBQO(88*X
MF;TB/%J7Q>F2Y<S%C 4GHT?!1EU(1DX4SOEYF?Q+%=:]*SY!,\?$YB2W13 Q
M>%8F<H+]H&-E2E8)<9(JE#.S4GSBN/BX6+@Y(Y6=#';(ODLG*$ZO;<KB=,4[
M#I<V+5T<1[,?%FR?D(9*NJ\9DV.0<?'Y.2S[&X]403=)!,HL-G=' P:'\)L9
M&(JXJ%*MVTKMN:(#I$LU1I%4$F"%;2Z=Z3HU'J+&EX6XS?!K5&)ZW&FRFO3.
M )ZIEX1XBR)(H*-;$YG08M>TQ-IA)Q>++"D^$0S91<@]'A5L>BKAM1")FJX.
M$G-:=.4IE4*.^2HQXTV9\P(X@B$)2.XW=3IGG>&YQR%,RI(ZZID"116>QO(I
M(HZL:#A]6!.3E =P-%BU:I@X?&D@PL&U78"&H^S4*B6X69AEQ^''**HY+U;M
M.-Q#'=C0*BTM5N)9&=E6Z<A;+9^2494 GBXI6.>M2#;-&,.=%=9(,:N#5%23
M,[3C-,".)"74HRP I6M;AWKW7:V7I;3A41W[J;]SIK6F_P#1O6I7_NIK3=?B
M)V_*K;_I[E/E\NWQ:;-\8/H.H\F6[B7G+7Z;3N\_^%_9TV/F/H.H5;+5I6FY
M+M5_UIKW/[?3<>?_  O[.FQ\Q]!U/<ME>/5K]RK2MU/]9;?!MIVJK4K3II7M
MZJA!5>\C8$=ZM\HGX@?/J6!)) /Q?%^0:D\F6[B7G+7Z;5N[S_X7]G4;'S'T
M'3DRW<2\Y:_3:=WG_P +^SIL?,?0=.3+=Q+SEK]-IW>?_"_LZ;'S'T'7,^TM
M@R79TC+"'!BT1CX^YT@^4D92IYQ)(B<&F0A8'+8FS#R(:!-%0J@U=TQ$2QJL
M(H9L$D7"CEFS?!R>>Q[5C6)V7&OC9"E5;J,<?)GD5B0X:?)E+)("O+SXRFE%
MG=F1)Z;CH7F4YS:5I%'YA,BL*11SR<M-X-0U,U=>MLJ=2)'4UJ3+.RADG*IW
M:%4?R''S.*YDMP.@S#\9(KG]1.$9D[D2H,R6'OA9()=-!1)Z-LE$.(,Y'!B:
M(\\ 7>O&]EJ>"1*RY6\=AQL\7"J:R#[X'#L%)FJ?"SI"G"\;.2B$K:N^-=#C
M\_6EF)N:+S*K<(\%DE%=EWR>)9+TZ9'2=*CB5L9YD K%>K-UL5$^B=GK$)3"
MN)HUC=^::G+X^YDJK59NNI<V&C#DI-2$5'&[\L0?'3J,8'E&X"V32-Z[DDHN
M'72 ^O<5).K;>P-\%CS)),,7%QV?D""AQX)$,)33EDH5%2<UW"310S.Y=VQY
M6-+TY2HM>M@F[/R=5B[#G?QF+N7J['^W1@H681%W5R9;N)><M?IM1W>?_"_L
MZG8^8^@Z<F6[B7G+7Z;3N\_^%_9TV/F/H.G)ENXEYRU^FT[O/_A?V=-CYCZ#
MJ;1JM5!7\5^.;5_*6WO6N-_3QVZG;IVZTW^]JO,!1>\]ZN/O6^/E_)^3O_\
MN-6 /*W<?B^+\NI7)ENXEYRU^FU;N\_^%_9U78^8^@Z<F6[B7G+7Z;3N\_\
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M&#:[.$5$E@!,022(& 0%J)'S)H6G@IL(E;R13% >OU7B[(>\Y9$\:JY>1.F
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M5R=-D9\B;/!S11RW+R3G2B-0=-IL6"TESXL $QBR.JNMTQA0,C(N/03O,39
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MFE^HL7##88TK%'6=*&,W<A Q:B!\>LR+L:K1N(M%XSCY@"D66KL91R*&\/&
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M:=7\;L^?A9^--694086/Q+$EAD$/MC"'$KOW;T.87RJ-2EZDY?B79DR!B:6
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M;QK#)7Z=V5X5M+J5I=2M-]*TK2M*TKTTK2M.CQ:V/<?)M\1'F/Q_&?CU0$$
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M#/>G*9PF"]F1._5$AFO!<K.3:(JF #U_%@DF=2^T^"/L@#B.PTG<)G"K&22
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M?U<F8"8S&=B+PK1&<@P) M*D4\43JIZ2QY(D.$&5XRX1B%SC++5J9)AQ!II
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1]SO\1.KJO+OW^7;_ #U__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
